PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Hannon, B; Zimmermann, C; Bryson, JR				Hannon, Breffni; Zimmermann, Camilla; Bryson, John Robert			The Role of Fentanyl in Refractory Opioid-Related Acute Colonic Pseudo-Obstruction	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							MORPHINE		[Hannon, Breffni] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Psychosocial Oncol & Palliat Care, Toronto, ON, Canada; [Zimmermann, Camilla] Univ Toronto, Campbell Family Canc Res Ctr, Princess Margaret Canc Ctr, Dept Psychosocial Oncol & Palliat Care, Toronto, ON, Canada; [Zimmermann, Camilla] Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada; [Zimmermann, Camilla; Bryson, John Robert] Univ Toronto, Dept Med, Toronto, ON, Canada; [Bryson, John Robert] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Psychosocial Oncol & Palliat Care, Toronto, ON, Canada	Hannon, B (reprint author), Univ Hlth Network, Princess Margaret Canc Ctr, Dept Psychosocial Oncol & Palliat Care, Toronto, ON, Canada.			Zimmermann, Camilla/0000-0003-4889-0244			[Anonymous], 2002, GASTROINTEST ENDOSC, V56, P789; Branford R, 2012, CLIN GENET, V82, P301, DOI 10.1111/j.1399-0004.2012.01923.x; De Giorgio R, 2009, BRIT J SURG, V96, P229, DOI 10.1002/bjs.6480; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; KAUFMAN PN, 1988, GASTROENTEROLOGY, V94, P1351, DOI 10.1016/0016-5085(88)90673-7; Nakamura Atsushi, 2011, J Pain Palliat Care Pharmacother, V25, P318, DOI 10.3109/15360288.2011.620689; Saunders MD, 2005, ALIMENT PHARM THER, V22, P917, DOI 10.1111/j.1365-2036.2005.02668.x; Tamayo AC, 2004, SUPPORT CARE CANCER, V12, P613, DOI 10.1007/s00520-004-0649-7; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Twycross R, 2010, PALLIATIVE CARE FORM; Weinstock LB, 2011, J CLIN GASTROENTEROL, V45, P883, DOI 10.1097/MCG.0b013e31821100ab	11	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAR	2013	45	3					E1	E3		10.1016/j.jpainsymman.2012.11.002			3	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	123SV	WOS:000317412000001	23369542	Bronze			2020-06-30	J	Galvez, R; Schafer, M; Hans, G; Falke, D; Steigerwald, I				Galvez, Rafael; Schaefer, Michael; Hans, Guy; Falke, Dietmar; Steigerwald, Ilona			Tapentadol Prolonged Release Versus Strong Opioids for Severe, Chronic Low Back Pain: Results of an Open-Label, Phase 3b Study	ADVANCES IN THERAPY			English	Article						Chronic pain; Equianalgesic; Equipotency; Low back pain; Neuropathic pain; Opioid; Severe pain; Tapentadol	CHRONIC NONMALIGNANT PAIN; EXTENDED-RELEASE; NEUROPATHIC COMPONENTS; DOUBLE-BLIND; SAFETY; MANAGEMENT; EFFICACY; OSTEOARTHRITIS; QUESTIONNAIRE; ANALGESICS	This open-label, phase 3b study evaluated the effectiveness and tolerability of oral tapentadol prolonged release (PR; 50-250 mg twice daily [b.i.d.]) for managing severe, chronic low back pain in patients responding to World Health Organization (WHO) step III opioids but tolerating treatment poorly. Equianalgesic ratios for tapentadol to prior strong opioids were calculated. Patients rotated directly from prior WHO step III opioids to tapentadol. Patients received tapentadol PR (50-250 mg b.i.d.) during 5-week titration and 7-week maintenance periods. Tapentadol immediate release (IR) 50 mg (a parts per thousand currency signtwice/day, a parts per thousand yen4 h apart) was allowed (total daily dose of tapentadol PR and IR a parts per thousand currency sign500 mg/day). The primary endpoint was responder rate 1 at week 6 (percentage of patients with the same or less pain intensity [11-point numerical rating scale (NRS; 3-day average)] vs week -1). Responder rate 1 at week 6 (last observation carried forward [LOCF]) was 80.9% (76/94; P < 0.0001 vs. the null responder hypothesis rate [< 60%]), resulting in a positive trial despite premature termination (136 recruited of 180 planned). Significant improvements from baseline in pain intensity and neuropathic pain symptoms were observed at weeks 6 and 12 with tapentadol PR (P < 0.05). Equianalgesic ratios were calculated for PR formulations alone and for PR and IR formulations combined for tapentadol to oxycodone, buprenorphine, fentanyl, morphine, and hydromorphone. The prevalences of adverse events reported as the reason for switching to tapentadol (most commonly constipation and nausea) decreased over time. Tapentadol PR (50-250 mg b.i.d.) provided at least comparable pain relief and improved tolerability versus prior strong opioids in patients with severe, chronic low back pain responding to WHO step III therapy. Conversion from strong opioids to tapentadol PR, with its two mechanisms of action, went smoothly considering overall effectiveness and tolerability outcomes. Equianalgesic ratios of tapentadol to oxycodone and other strong opioids were in line with other phase 3/3b studies.	[Galvez, Rafael] Hosp Univ Virgen Nieves, Unit Pain & Palliat Care, Granada, Spain; [Schaefer, Michael] Charite, Campus Virchow Klinikum, Dept Anaesthesiol & Intens Care Med, D-13353 Berlin, Germany; [Hans, Guy] Univ Antwerp, Multidisciplinary Pain Ctr PCT, Antwerp, Belgium; [Falke, Dietmar; Steigerwald, Ilona] Med Affairs Europe & Australia Grunenthal GmbH, D-52078 Aachen, Germany	Steigerwald, I (reprint author), Med Affairs Europe & Australia Grunenthal GmbH, Zieglerstr 6, D-52078 Aachen, Germany.	ilona.steigerwald@grunenthal.com	Hans, Guy H./B-8507-2008; Schafer, Michael/AAB-1395-2020	Hans, Guy H./0000-0003-4522-9055; 	Medical Affairs; Grunenthal Europe Australia; Grunenthal GmbH, Aachen, Germany	This study and page charges were sponsored by Medical Affairs, Grunenthal Europe & Australia, Grunenthal GmbH, Aachen, Germany. Editorial support for the writing of this manuscript was provided by Megan Knagge, PhD, of MedErgy, and was funded by Medical Affairs, Grunenthal GmbH, Aachen, Germany. The authors retained full editorial control over the content of the manuscript.	Afilalo M, 2010, CLIN DRUG INVEST, V30, P489, DOI 10.2165/11533440-000000000-00000; Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x; Ballantyne JC, 2006, SOUTH MED J, V99, P1245, DOI 10.1097/01.smj.0000223946.19256.17; Bartleson JD, 2002, PAIN MED, V3, P260, DOI 10.1046/j.1526-4637.2002.02043.x; Bell TJ, 2009, PAIN MED, V10, P35, DOI 10.1111/j.1526-4637.2008.00495.x; Biondi DM, 2012, PAIN PHYS IN PRESS; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024; Buynak R, 2010, EXPERT OPIN PHARMACO, V11, P1787, DOI 10.1517/14656566.2010.497720; Chaparro LE, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008943.pub2; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chou R, 2007, ANN INTERN MED, V147, P505, DOI 10.7326/0003-4819-147-7-200710020-00008; Christo Paul J, 2003, Anesthesiol Clin North Am, V21, P699, DOI 10.1016/S0889-8537(03)00087-7; Duensing L, 2010, CURR MED RES OPIN, V26, P1579, DOI 10.1185/03007991003783747; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Freynhagen R, 2006, CURR MED RES OPIN, V22, P1911, DOI 10.1185/030079906X132488; Freynhagen R, 2009, CURR PAIN HEADACHE R, V13, P185, DOI 10.1007/s11916-009-0032-y; Gregorian RS, 2010, J PAIN, V11, P1095, DOI 10.1016/j.jpain.2010.02.007; Lange B, 2010, ADV THER, V27, P381, DOI 10.1007/s12325-010-0036-3; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Moore RA, 2005, ARTHRITIS RES THER, V7, pR1046, DOI 10.1186/ar1782; Porreca F, 2009, PAIN MED, V10, P654, DOI 10.1111/j.1526-4637.2009.00583.x; QUIGLEY C, 2004, [No title captured], DOI DOI 10.1002/14651858.CD004847; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; Schroder W, 2011, J PHARMACOL EXP THER, V337, P312, DOI 10.1124/jpet.110.175042; Schwartz S, 2011, CURR MED RES OPIN, V27, P151, DOI 10.1185/03007995.2010.537589; Selai CE, 2005, CURR MED RES OPIN, V21, P733, DOI 10.1185/030079905X43695; Slatkin NE, 2009, CURR MED RES OPIN, V25, P2133, DOI 10.1185/03007990903120158; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Steigerwald I, 2012, CURR MED RES OPIN, V28, P911, DOI 10.1185/03007995.2012.679254; Taruilli AW, 2007, NEUROL CLIN, V25, P387, DOI 10.1016/j.ncl.2007.01.008; Thomsen AB, 1999, ACTA ANAESTH SCAND, V43, P918, DOI 10.1034/j.1399-6576.1999.430909.x; Tolle TR, 2013, 4 INT C NEU IN PRESS; Tzschentke TM, 2006, DRUG FUTURE, V31, P1053, DOI 10.1358/dof.2006.031.12.1047744; Tzschentke TM, 2007, J PHARMACOL EXP THER, V323, P323; Varrassi G, 2012, CURR MED RES OPIN, V28, P823, DOI 10.1185/03007995.2012.674499; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wild JE, 2010, PAIN PRACT, V10, P416, DOI 10.1111/j.1533-2500.2010.00397.x	39	31	32	1	24	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0741-238X	1865-8652		ADV THER	Adv. Ther.	MAR	2013	30	3					229	259		10.1007/s12325-013-0015-6			31	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	109PM	WOS:000316380500003	23475406	Bronze			2020-06-30	J	Fernandez-Carrion, F; Gaboli, M; Gonzalez-Celador, R; de Quero-Masia, PG; Fernandez-de Miguel, S; Murga-Herrera, V; Serrano-Ayestaran, O; Sanchez-Granados, JM; Payo-Perez, R				Fernandez-Carrion, F.; Gaboli, M.; Gonzalez-Celador, R.; Gomez de Quero-Masia, P.; Fernandez-de Miguel, S.; Murga-Herrera, V.; Serrano-Ayestaran, O.; Sanchez-Granados, J. M.; Payo-Perez, R.			Withdrawal syndrome in the pediatric intensive care unit. incidence and risk factors	MEDICINA INTENSIVA			Spanish	Article						latrogenic withdrawal syndrome; Opioids; Benzodiazepines; Fentanyl; Midazolam; Intensive Care Units; Pediatric	NEONATAL ABSTINENCE SYNDROME; OPIOID WITHDRAWAL; FENTANYL; SEDATION; CHILDREN; TOLERANCE; MIDAZOLAM; CLONIDINE; METHADONE	Objective: To determine the incidence of withdrawal syndrome after prolonged infusion of fentanyl and midazolam in children, and the associated risk factors. Design: Historic or retrospective cohort study. Setting: Pediatric Intensive Care Unit in an academic center. Patients: Forty-eight pediatric patients who received sedation and analgesia only with fentanyl and midazolam through continuous infusion for at least 48 hours. Interventions: None. Main variables of interest: Collected data included demographic and clinical parameters, dose and duration of sedation received, and incidence, severity and treatment of withdrawal syndrome. Results: Fifty percent of the patients developed withdrawal syndrome. There were significant differences between the patients who developed withdrawal syndrome and those who did not, in terms of the duration of infusion and the cumulative doses of both drugs. A cumulative fentanyl dose of 0.48 mg/kg, a cumulative midazolam dose of 40 mg/kg, and a duration of infusion of both drugs of 5.75 days were risk factors for the development of withdrawal syndrome. Most children developed mild or moderate disease, beginning about 12-36 hours after weaning from infusion. Methadone was used in most cases for treating withdrawal. Conclusions: There is a high incidence of withdrawal syndrome in children following the continuous infusion of midazolam and fentanyl. The duration of infusion of both drugs and higher cumulative doses are associated with the development of withdrawal syndrome. (C) 2011 Elsevier Espana, S.L. and SEMICYUC. All rights reserved.	[Fernandez-Carrion, F.; Gaboli, M.; Gomez de Quero-Masia, P.; Fernandez-de Miguel, S.; Murga-Herrera, V.; Serrano-Ayestaran, O.; Sanchez-Granados, J. M.; Payo-Perez, R.] Hosp Univ Salamanca, Unidad Cuidados Intens Pediat, Salamanca, Spain; [Gonzalez-Celador, R.] Hosp Univ Salamanca, Unidad Epidemiol, Salamanca, Spain	Fernandez-Carrion, F (reprint author), Hosp Univ Salamanca, Unidad Cuidados Intens Pediat, Salamanca, Spain.	pacojum@gmail.com	Fernandez-Carrion, Francisco/AAQ-3302-2020	Fernandez-Carrion, Francisco/0000-0002-0582-4995			Agthe AG, 2009, PEDIATRICS, V123, pE849, DOI 10.1542/peds.2008-0978; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Berens RJ, 2006, ANESTH ANALG, V102, P1045, DOI 10.1213/01.ane.0000202395.94542.3e; BERGMAN I, 1991, J PEDIATR-US, V119, P644, DOI 10.1016/S0022-3476(05)82420-5; Bicudo J N, 1999, Rev Assoc Med Bras (1992), V45, P15, DOI 10.1590/S0104-42301999000100004; Birchley G, 2009, NURS CRIT CARE, V14, P26, DOI 10.1111/j.1478-5153.2008.00311.x; Cammarano WB, 1998, CRIT CARE MED, V26, P676, DOI 10.1097/00003246-199804000-00015; Cunliffe M, 2004, PEDIATR ANESTH, V14, P293, DOI 10.1046/j.1460-9592.2003.01219.x; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; Esmaeili A, 2010, ACTA PAEDIATR, V99, P209, DOI 10.1111/j.1651-2227.2009.01547.x; Estebanez-Montiel M B, 2008, Med Intensiva, V32 Spec No. 1, P19; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Fonsmark L, 1999, CRIT CARE MED, V27, P196, DOI 10.1097/00003246-199901000-00052; Franck L S, 1998, Am J Crit Care, V7, P364; Franck LS, 2008, PEDIATR CRIT CARE ME, V9, P573, DOI 10.1097/PCC.0b013e31818c8328; Franck Linda S, 2004, Intensive Crit Care Nurs, V20, P344, DOI 10.1016/j.iccn.2004.07.008; French J P, 1994, J Pediatr Nurs, V9, P107; HUGHES J, 1994, ACTA PAEDIATR, V83, P1194; Ista E, 2009, INTENS CARE MED, V35, P1075, DOI 10.1007/s00134-009-1487-3; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Liatsi D, 2009, INTENS CARE MED, V35, P275, DOI 10.1007/s00134-008-1251-0; Lugo RA, 2001, PHARMACOTHERAPY, V21, P1566, DOI 10.1592/phco.21.20.1566.34471; Mencia S, 2011, AN PEDIATR, V74, P396, DOI 10.1016/j.anpedi.2010.12.002; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; Robertson R C, 2000, Pediatr Crit Care Med, V1, P119, DOI 10.1097/00130478-200010000-00005; Sfoggia Ana, 2003, J. Pediatr. (Rio J.), V79, P343, DOI 10.1590/S0021-75572003000400013; Siddappa R, 2003, PAEDIATR ANAESTH, V13, P805, DOI 10.1046/j.1460-9592.2003.01153.x; SURY MRJ, 1989, CRIT CARE MED, V17, P301, DOI 10.1097/00003246-198903000-00027; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; Valdivielso-Serna A, 2008, Med Intensiva, V32 Spec No. 1, P115	32	19	20	0	10	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	0210-5691	1578-6749		MED INTENSIVA	Med. Intensiv.	MAR	2013	37	2					67	74		10.1016/j.medin.2012.02.009			8	Critical Care Medicine	General & Internal Medicine	107QT	WOS:000316236500002	22608303				2020-06-30	J	Hasani, A; Gecaj-Gashi, A; Llullaku, S; Jashari, H				Hasani, Antigona; Gecaj-Gashi, Agreta; Llullaku, Sadik; Jashari, Hysni			Postoperative Analgesia in Children After Propofol Versus Sevoflurane Anesthesia	PAIN MEDICINE			English	Article						Propofol; Sevoflurane; Postoperative Analgesia; Children	PAIN; ISOFLURANE; TRANSMISSION; RECEPTOR; MATTERS; NEURONS; RATS	Objective. Postoperative analgesia remains a problem, especially in pediatric patients. We hypothesize that patients anesthetized with sevoflurane have more postoperative pain than with propofol. Design. Randomized, prospective, double-blind study. Setting. University teaching hospital. Subjects. The subjects were 88 premedicated children, aged 36 years, and American Society of Anesthesiologists (ASA) Physical Status I or II. Interventions. Subjectsunderwent hernia repair surgery. Methods. Anesthesia was maintained with propofol (group P, N=46) or sevoflurane (group S, N=42) and fentanyl was administered during surgery. All children before surgical incision received 40mg/kg paracetamol, rectally. Prior to wound closure, the margins were infiltrated with 0.5% bupivacaine. Outcome Measures. The primary outcome was pain score assessed by Faces Pain Scale (FPS) 2 hours postoperatively. The secondary outcomes included recovery time and adverse events within the first 2 hours. Results. Group S had a significantly higher proportion of patients who exhibited postoperative pain than group P (24.3% vs 4.5%, respectively; P<0.05). FPS score in group P was 1.2 +/- 0.6, compared with 3.4 +/- 1.5 in group S (P<0.001). Mean recovery time in group S was significantly shorter than the corresponding mean for group P (10.1 +/- 1.3 vs 16.5 +/- 5.4 minutes, respectively; P<0.001). Conclusion. In children, anesthesia maintenance with propofol was associated with a significantly lower incidence of postoperative pain than with sevoflurane.			antigona.hasani@gmail.com		Hasani, Antigona/0000-0002-1088-3404			ANKERMOLLER E, 1991, BRIT J ANAESTH, V66, P185, DOI 10.1093/bja/66.2.185; Bandschapp O, 2010, ANESTHESIOLOGY, V113, P421, DOI 10.1097/ALN.0b013e3181e33ac8; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Cheng SS, 2008, ANESTH ANALG, V106, P264, DOI 10.1213/01.ane.0000287653.77372.d9; COLLINS GGS, 1988, BRIT J PHARMACOL, V95, P939, DOI 10.1111/j.1476-5381.1988.tb11724.x; Hasani A, 2012, PAIN MANAGEMENT CURR, V012, P223; Howard R, 2008, PEDIATR ANESTH, V18, P1, DOI 10.1111/j.1155-5645.2008.02423.x; Hunter M, 2000, J PAIN SYMPTOM MANAG, V20, P122, DOI 10.1016/S0885-3924(00)00171-8; JEWETT BA, 1992, ANESTHESIOLOGY, V77, P1148, DOI 10.1097/00000542-199212000-00016; Kingston S, 2006, ANESTHESIOLOGY, V104, P763, DOI 10.1097/00000542-200604000-00021; McFarlan CS, 1999, PAEDIATR ANAESTH, V9, P209; ORSER BA, 1995, BRIT J PHARMACOL, V116, P1761, DOI 10.1111/j.1476-5381.1995.tb16660.x; Rony RYZ, 2010, PEDIATRICS, V125, pE1372, DOI 10.1542/peds.2009-2632; Rowley TJ, 2005, ANESTH ANALG, V100, P991, DOI 10.1213/01.ANE.0000147708.73945.B3; Shafer SL, 2008, ANESTH ANALG, V106, P3, DOI 10.1213/01.ane.0000299045.22629.86; Shin SW, 2010, BRIT J ANAESTH, V105, P661, DOI 10.1093/bja/aeq257; Sun YY, 2005, BRAIN RES, V1043, P231, DOI 10.1016/j.brainres.2005.02.048; Tan T, 2010, ANESTH ANALG, V111, P83, DOI 10.1213/ANE.0b013e3181c0ee9e; Wang JP, 2009, EUR J ANAESTH, V26, P60, DOI 10.1097/EJA.0b013e328318c76a; Wong J, 2002, CAN J ANAESTH, V49, P13, DOI 10.1007/BF03020413; Yamakura T, 2000, ANESTHESIOLOGY, V93, P1095, DOI 10.1097/00000542-200010000-00034; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044	22	9	11	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAR	2013	14	3					442	446		10.1111/pme.12031			5	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	107IV	WOS:000316210600024	23294622	Bronze			2020-06-30	J	Hisada, T; Katoh, M; Hitoshi, K; Kondo, Y; Fujioka, M; Toyama, Y; Ieda, H; Gocho, S; Nadai, M				Hisada, Tatsuya; Katoh, Miki; Hitoshi, Kotaro; Kondo, Yuya; Fujioka, Miho; Toyama, Yukio; Ieda, Hideaki; Gocho, Saori; Nadai, Masayuki			A Simple Liquid Chromatography-Tandem Mass Spectrometry Method for Determination of Plasma Fentanyl Concentration in Rats and Patients with Cancer Pain	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						fentanyl; liquid chromatography-tandem mass spectrometry; plasma concentration; pharmacokinetics; rat; human	SOLID-PHASE EXTRACTION; TRANSDERMAL FENTANYL; ORAL MORPHINE; PHARMACOKINETICS; ABSORPTION; EFFICACY; ASSAY; NORFENTANYL; ALFENTANIL; MIDAZOLAM	A fentanyl patch is widely used for the treatment of cancer pain. Its few adverse effects include constipation and drowsiness. The absorption volume of transdermally applied fentanyl may differ according to its site of application and variability in patch adhesion. Since fentanyl is predominantly metabolized by the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 in the liver, its concentration may vary in cases of physiologically reduced CYP3A4 activity in the liver (liver disease and aging) or on co-administration of drugs. The clinical significance of measuring plasma concentration of fentanyl is high, but conventional methods require complicated processes such as solid-phase extraction and liquid liquid extraction before the sample is injected into an HPLC system. In this study, a simple liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed for determining plasma fentanyl concentrations by deproteinization with acetonitrile. A recovery test was conducted using an absolute calibration curve to confirm the method's linearity and inter- and intra-day reproducibility. The required plasma volume for detection was reduced from I mL in the conventional method to 20 mu L in the present study, and a good calibration curve was obtained in the concentration range from 0.05 to 5 ng/mL. These findings suggest that the method for sample preparation and quantification developed in this study are appropriate for measuring fentanyl concentration in human plasma in clinical settings.	[Hisada, Tatsuya; Katoh, Miki; Hitoshi, Kotaro; Kondo, Yuya; Fujioka, Miho; Nadai, Masayuki] Meijo Univ, Fac Pharm, Dept Pharmaceut, Tenpaku Ku, Nagoya, Aichi 4688503, Japan; [Hisada, Tatsuya; Toyama, Yukio] Toyota Mem Hosp, Dept Pharm, Toyota, Aichi 4718513, Japan; [Toyama, Yukio] Aichi Med Univ, Sch Med, Dept Hosp Pharm, Nagakute, Aichi 4801195, Japan; [Ieda, Hideaki] Nagoya Ekisaikai Hosp, Dept Palliat Med, Nakagawa Ku, Nagoya, Aichi 4548502, Japan; [Gocho, Saori] Nagoya Ekisaikai Hosp, Dept Pharm, Nakagawa Ku, Nagoya, Aichi 4548502, Japan	Nadai, M (reprint author), Meijo Univ, Fac Pharm, Dept Pharmaceut, Tenpaku Ku, 150 Yagotoyama, Nagoya, Aichi 4688503, Japan.	nadai@meijo-u.ac.jp					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Almousa AA, 2011, J CHROMATOGR B, V879, P2941, DOI 10.1016/j.jchromb.2011.08.029; Boleda MR, 2007, J CHROMATOGR A, V1175, P38, DOI 10.1016/j.chroma.2007.10.029; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Ebrahimzadeh H, 2008, ANAL CHIM ACTA, V626, P193, DOI 10.1016/j.aca.2008.07.047; Holmquist GL, 2009, PAIN MED, V10, pS20, DOI 10.1111/j.1526-4637.2009.00596.x; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kaestli LZ, 2008, DRUG AGING, V25, P269, DOI 10.2165/00002512-200825040-00001; Kokubun H, 2008, YAKUGAKU ZASSHI, V128, P447, DOI 10.1248/yakushi.128.447; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Lambropoulos J, 2000, J PHARMACEUT BIOMED, V23, P421, DOI 10.1016/S0731-7085(00)00312-5; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Malkin J.D., 2001, PAIN MED, V2, P246; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Nitsun M, 2006, CLIN PHARMACOL THER, V79, P549, DOI 10.1016/j.clpt.2006.02.010; Nugent M, 2001, J PAIN SYMPTOM MANAG, V21, P385, DOI 10.1016/S0885-3924(01)00257-3; Numata C., 2005, JPN J PHARM HLTH CAR, V31, P599; Ohtsuka H, 2007, ARZNEIMITTEL-FORSCH, V57, P260; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Solassol I, 2005, ONCOL REP, V14, P1029; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	27	9	9	0	11	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	MAR	2013	36	3					412	416		10.1248/bpb.b12-00825			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	097KH	WOS:000315472500013	23257955	Bronze			2020-06-30	J	Ince, IE; Iyilikci, L; Yilmaz, S; Gunes, D; Akkus, M; Isguven, D				Ince, Icten E.; Iyilikci, Leyla; Yilmaz, Sebnem; Gunes, Dilek; Akkus, Muhammed; Isguven, Duyguhan			Sedation for Short Hemato-Oncologic Invasive Procedures in Children: Comparison of Propofol-Remifentanil and Propofol-Fentanyl	JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY			English	Article						children; short oncologic procedures; sedation; propofol; remifentanil; fentanyl; bolus	BONE-MARROW ASPIRATION; PAINFUL PROCEDURES; LUMBAR PUNCTURE; ANESTHESIA; MIDAZOLAM; COMBINATIONS; ALFENTANIL; ANALGESIA; SAFE	Introduction: Short hemato-oncologic procedures are often painful in children, and sedation should be performed outside the operating room. Aim: The study aims to compare the effects of remifentanil with those of fentanyl administered during short hemato-oncologic interventions in children. Materials and Methods: A prospective, randomized study was planned for 29 ASA I to III children (aged, 2 to 18 y) to undergo a total of 60 short oncologic interventions. The patients were placed into 2 groups: propofol-remifentanil (group PR) and propofol-fentanyl (group PF). Group PR was first administered propofol (2 mg/kg) and then remifentanil bolus (0.5 mu g/kg). Group PF was first administered propofol (2 mg/kg) and then fentanyl bolus (0.5 mu g/kg). Systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, respiratory rate, peripheral oxygen saturation, and heart rate were recorded every 3 minutes during the intervention and every 5 minutes after the operation. Postanesthetic recovery scores, eye-opening time to speech, and recovery time were recorded. Results: Comparison of diastolic arterial pressure in groups at minute 3 of the procedure showed significant difference (P<0.05). Eye-opening to speech (P=0.043) and recovery times (P=0.002) were shorter in group PR. Conclusions: During short hemato-oncologic interventions in children, the PR combination is a suitable one for early recovery.	[Ince, Icten E.; Iyilikci, Leyla; Akkus, Muhammed; Isguven, Duyguhan] Dokuz Eylul Univ, Sch Med, Dept Anesthesiol & Intens Care, TR-35340 Izmir, Turkey; [Yilmaz, Sebnem] Dokuz Eylul Univ, Sch Med, Dept Pediat Hematol, TR-35340 Izmir, Turkey; [Gunes, Dilek] Dokuz Eylul Univ, Sch Med, Dept Pediat Oncol, TR-35340 Izmir, Turkey	Iyilikci, L (reprint author), Dokuz Eylul Univ, Sch Med, Dept Anesthesiol & Intens Care, TR-35340 Izmir, Turkey.	leyla.iyilikci@deu.edu.tr	INCE, Dilek/Q-2705-2019; iyilikci, leyla/Q-1633-2019	INCE, Dilek/0000-0002-7914-7886; 	Department of Anesthesiology and Reanimation	Supported by the Department of Anesthesiology and Reanimation and I.E.I.	[Anonymous], 2005, GUID REM LOC AN, P1; Antmen B, 2005, PEDIATR ANESTH, V15, P214, DOI 10.1111/j.1460-9592.2004.01411.x; Bailey P.L., 1994, BASICS ANESTHESIA, V291; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bell C, 2005, CURR OPIN ANESTHESIO, V18, P271, DOI 10.1097/01.aco.0000169234.06433.48; Cechvala MM, 2008, J PEDIAT HEMATOL ONC, V30, P142, DOI 10.1097/MPH.0b013e31815d8953; Cote CJ, 2008, PEDIATR ANESTH, V18, P9, DOI 10.1111/j.1460-9592.2007.02404.x; Eck JB, 1998, PAEDIATR ANAESTH, V8, P437, DOI 10.1046/j.1460-9592.1998.00296.x; Foubert L, 2002, ACTA ANAESTH SCAND, V46, P355, DOI 10.1034/j.1399-6576.2002.460404.x; Glaisyer HR, 2005, ANESTH ANALG, V100, P959, DOI 10.1213/01.ANE.0000147667.06156.DF; Gozal D, 2008, CURR OPIN ANESTHESIO, V21, P494, DOI 10.1097/ACO.0b013e3283079b6c; Hayes JA, 2008, ANESTHESIOLOGY, V109, P613, DOI 10.1097/ALN.0b013e31818629f3; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Hollman GA, 2008, PEDIATR CRIT CARE ME, V9, P616, DOI 10.1097/PCC.0b013e31818e3ad3; Iyilikci L, 2006, TURK ANEST REAN DER, V34, P169; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Keidan I, 2001, PAEDIATR ANAESTH, V11, P297, DOI 10.1046/j.1460-9592.2001.00662.x; Litman RS, 1999, ARCH PEDIAT ADOL MED, V153, P1085, DOI 10.1001/archpedi.153.10.1085; Marx CM, 1997, J CLIN ONCOL, V15, P94, DOI 10.1200/JCO.1997.15.1.94; MAUNUKSELA EL, 1986, ACTA ANAESTH SCAND, V30, P409, DOI 10.1111/j.1399-6576.1986.tb02440.x; Morton NS, 1998, PAEDIATR ANAESTH, V8, P65, DOI 10.1046/j.1460-9592.1998.00688.x; Peacock JE, 1998, BRIT J ANAESTH, V80, P509, DOI 10.1093/bja/80.4.509; Reeves JG, 2002, CLIN ANAESTHESIOL, P173; Toklu S, 2009, EUR J ANAESTH, V26, P370, DOI 10.1097/EJA.0b013e328318c666; Von Heijne M, 2004, PEDIATR ANESTH, V14, P670	25	4	4	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1077-4114			J PEDIAT HEMATOL ONC	J. Pediatr. Hematol. Oncol.	MAR	2013	35	2					112	117		10.1097/MPH.0b013e318279cbda			6	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	095TH	WOS:000315357100019	23412587				2020-06-30	J	Truesdale, CM; Soulen, MC; Clark, TWI; Mondschein, JI; Wehrenberg-Klee, E; Malkowicz, SB; Wein, AJ; Guzzo, TJ; Stavropoulos, SW				Truesdale, Carl M.; Soulen, Michael C.; Clark, Timothy W. I.; Mondschein, Jeffrey I.; Wehrenberg-Klee, Eric; Malkowicz, S. Bruce; Wein, Alan J.; Guzzo, Thomas J.; Stavropoulos, S. William			Percutaneous Computed Tomography-guided Renal Mass Radiofrequency Ablation versus Cryoablation: Doses of Sedation Medication Used	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							NEPHRON-SPARING SURGERY; CELL CARCINOMA; IMPACT; TUMORS	Purpose: To compare the amount of sedation medication administered during radiofrequency (RF) ablation versus cryoablation of small renal masses. Materials and Methods: Records were retrospectively reviewed in patients who underwent percutaneous computed tomography-guided RF ablation and cryoablation of small renal masses from January 2002 to June 2011 for patient and tumor characteristics, amount of medications used for moderate sedation, and complications. Sedation was performed by giving patients titrated doses of midazolam and fentanyl. Additional medications, were given if the desired level of sedation was not achieved. Results: There were 116 patients Who underwent 136 ablation procedures; 71, patients underwent RF ablation, and 65 patients underwent cryoablation. RF ablation was associated with a significantly higher mean dose of fentanyl (mean dote for RF ablation, 236.43 mu g; mean dose for cryoablation, 172.27 mu g; P < .001). RF ablation was also associated With a higher mean dose of midazolam (mean dose for RI ablation, 4.5 mg; mean-dose for cryoablation, 3.27 mg; P < .001). In the RF ablation group, two patients required additional sedation with droperidol. As a result of oversedation, two patients in the RF ablation cohort required sedation reversal with naloxone and flumazenil. None of the patients'. who underwent cryoablation required sedation reversal. No other sedation-related complications occurred. Conclusions: Cryoablation of small renal masses was performed with less sedation medication than RF ablation. This finding suggests renal cryoablation is less painful than RF ablation; however, prospective studies with validated pain scales are needed to confirm these results.	[Truesdale, Carl M.; Soulen, Michael C.; Clark, Timothy W. I.; Mondschein, Jeffrey I.; Stavropoulos, S. William] Univ Penn, Hosp Univ Penn, Div Intervent Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Malkowicz, S. Bruce; Wein, Alan J.; Guzzo, Thomas J.] Univ Penn, Hosp Univ Penn, Div Urol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wehrenberg-Klee, Eric] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Stavropoulos, SW (reprint author), Univ Penn, Hosp Univ Penn, Div Intervent Radiol, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	stav@uphs.upenn.edu			Nicolo Fund for Kidney Cancer Research; Bard and B. Braun	Research for the present study was funded by the Nicolo Fund for Kidney Cancer Research.; S.W.S. has research funded by Bard and B. Braun. None of the other authors have identified a conflict of interest.	Allaf ME, 2005, RADIOLOGY, V237, P366, DOI 10.1148/radiol.2371040829; Campbell SC, 2009, J UROLOGY, V182, P1271, DOI 10.1016/j.juro.2009.07.004; Chan NY, 2011, PACE, V34, P2, DOI 10.1111/j.1540-8159.2010.02858.x; Clark TWI, 2006, J VASC INTERV RADIOL, V17, P1563, DOI 10.1097/01.RVI.0000236718.12560.47; Goldberg SN, 2003, RADIOLOGY, V228, P335, DOI 10.1148/radiol.2282021787; Hafez KS, 1999, J UROLOGY, V162, P1930, DOI 10.1016/S0022-5347(05)68071-8; Johnson DB, 2004, J UROLOGY, V172, P874, DOI 10.1097/01.ju.0000135833.67906.ec; Kunkle DA, 2008, CANCER, V113, P2671, DOI 10.1002/cncr.23896; LI CL, 1958, AM J PHYSIOL, V194, P200; LLOYD JW, 1976, LANCET, V2, P932; Luo Gao-quan, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P579; Pandharipande PV, 2008, RADIOLOGY, V248, P169, DOI 10.1148/radiol.2481071448; Pirasteh A, 2011, ACAD RADIOL, V18, P97, DOI 10.1016/j.acra.2010.08.006; Sacks David, 2003, J Vasc Interv Radiol, V14, pS199; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Trescot Andrea M, 2003, Pain Physician, V6, P345	16	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	MAR	2013	24	3					347	350		10.1016/j.jvir.2012.11.022			4	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	098IU	WOS:000315543600007	23433410				2020-06-30	J	Liao, Q; Chen, DJ; Zhang, F; Li, L; Hu, R; Tang, YZ; Ou-Yang, W; Huang, D				Liao, Qin; Chen, Dao-Jin; Zhang, Fan; Li, Li; Hu, Rong; Tang, Yong-Zhong; Ou-Yang, Wen; Huang, Dong			Effect of CYP3A4*18B polymorphisms and interactions with OPRM1 A118G on postoperative fentanyl requirements in patients undergoing radical gastrectomy	MOLECULAR MEDICINE REPORTS			English	Article						analgesia; mu opioid receptor; cytochrome P450 3A4; fentanyl; single nucleotide polymorphism	GENETIC-VARIABILITY; CANCER PAIN; ASSOCIATION; ANALGESIA; CYP3A4; PHARMACOKINETICS; CYCLOSPORINE; DISPOSITION; METABOLISM; EFFICACY	The present study aimed to investigate the effect of cytochrome P450 3A4 (CYP3A4)*18B polymorphisms and the interaction of the mu opioid receptor gene (OPRMI) A118G and CYP3A4*18B polymorphisms on postoperative fentanyl analgesia in Chinese Han patients undergoing radical gastrectomy. In total, 97 patients scheduled to undergo radical gastrectomy under general anesthesia were enrolled in this study. Post-operative patient-controlled intravenous analgesia of fentanyl was administered as analgesia up to 48 h following surgery. Venous blood (2 ml) was obtained from each patient to measure the OPRM1 A118G and CYP3A4*18B genotypes. The differences in fentanyl consumption and adverse effects were compared among the genotypes at 24 and 48 h following surgery. In the first 48 h following surgery, patients in the CYP3A4*18B/*18B group consumed significantly less fentanyl compared with patients in the *1/*1 group (P=0.032). With regards to the joint genetic effect, during the 48-h period, patients with AA and *1*18B polymorphisms received fewer fentanyl doses compared with those with AG and *1*1 (P=0.049), while patients with AG and *1*18B polymorphisms received significantly fewer fentanyl doses compared with those with AG and *1*1 (P=0.010), and patients with *18B*18B polymorphisms received significantly fewer fentanyl doses compared with those with AA and *1*1 (P=0.024) or those with AG and *1*1 polymorphisms (P=0.006). No correlation between OPRM1 A118G and CYP3A4*18B and postoperative nausea, vomiting and dizziness was found. Results demonstrated that 48 h following surgery, patients with the CYP3A4*18B/*18B genotype required less fentanyl than patients with the CYP3A4*1/*1 genotype to control pain. Additionally, the combined genotype of CYP3A4*18B and OPRMI A118G may affect fentanyl doses administered for pain control, but not postoperative nausea, vomiting and dizziness.	[Liao, Qin; Zhang, Fan; Li, Li; Hu, Rong; Tang, Yong-Zhong; Ou-Yang, Wen; Huang, Dong] Cent S Univ, Dept Anesthesiol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China; [Chen, Dao-Jin] Cent S Univ, Dept Gen Surg, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Chen, DJ (reprint author), Cent S Univ, Dept Gen Surg, Xiangya Hosp 3, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	daojinchen@126.com	tang, yongzhong/AAP-3125-2020				Agrawal V, 2010, PHARMACOGENET GENOM, V20, P611, DOI 10.1097/FPC.0b013e32833e0cb5; Dong ZL, 2012, J CLIN PHARM THER, V37, P153, DOI 10.1111/j.1365-2710.2011.01268.x; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Fukushima-Uesaka Hiromi, 2004, Hum Mutat, V23, P100, DOI 10.1002/humu.9210; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; Hu YF, 2007, XENOBIOTICA, V37, P315, DOI 10.1080/00498250601149206; Hu YF, 2006, CLIN EXP PHARMACOL P, V33, P1093, DOI 10.1111/j.1440-1681.2006.04492.x; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Spielberger C., 1983, MANUAL STATE TRAIT A; Tan PCS, 2012, J CLIN PHARM THER, V37, P100, DOI 10.1111/j.1365-2710.2010.01232.x; Tateishi T., 1996, Anesthesia and Analgesia, V82, P167, DOI 10.1097/00000539-199601000-00031; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Wong CA, 2010, INT J OBSTET ANESTH, V19, P246, DOI 10.1016/j.ijoa.2009.09.005; Yuan RM, 2011, CLIN CHIM ACTA, V412, P755, DOI 10.1016/j.cca.2010.12.038; Zhang W, 2010, ANAESTHESIA, V65, P130, DOI 10.1111/j.1365-2044.2009.06193.x; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	25	12	15	0	6	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	MAR	2013	7	3					901	908		10.3892/mmr.2013.1270			8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	096SC	WOS:000315423600030	23313934	Bronze			2020-06-30	J	Giannopoulos, P; Papatheodoropoulos, C				Giannopoulos, Panagiotis; Papatheodoropoulos, Costas			Effects of -opioid receptor modulation on the hippocampal network activity of sharp wave and ripples	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						hippocampus; sharp wave; ripple oscillation; -opioid receptor; opiate; memory; recurrent inhibition; network excitability; CA1; slices	POST-TRIAL MORPHINE; FREQUENCY OSCILLATIONS; MEMORY CONSOLIDATION; PYRAMIDAL NEURONS; IN-VITRO; RAT; ENKEPHALIN; CA1; INTERNEURONS; INVOLVEMENT	Background and Purpose Hippocampus-dependent memory involves the activity of sharp wave ripples (SWRs), which are thought to participate in the process of memory consolidation. The hippocampus contains high levels of endogenous opioids and of -opioid receptors (MORs). Here, we have assessed the role of MOR agonists in the modulation of SWRs. Experimental Approach Using recordings of extracellular potentials from the CA1 field of rat hippocampal slices, we examined the pharmacological actions of morphine, DAMGO and fentanyl on SWRs and on network excitability and paired-pulse inhibition. Key Results All three MOR agonists (1nM10M) significantly increased the amplitude of sharp waves and the occurrence of SWR sequences, but reduced the initiation of episodes of SWRs. Fentanyl was most potent in producing these effects and morphine the least. Interestingly, although SWRs were reduced by relatively high concentrations (100nM) of all agonists, they were significantly enhanced by very low concentrations of morphine (510nM). Morphine and DAMGO at moderate-to-high concentrations increased network excitability and reduced inhibition. Furthermore, DAMGO suppressed inhibition more readily than it increased excitation, whereas morphine suppressed inhibition only at high concentrations. These drug effects were reversed by the MOR antagonists naloxone and CTOP. Conclusions and Implications We found that the SWRs were significantly modulated by three MOR agonists and that the SWRs were very sensitive to subtle changes in the excitation/inhibition balance induced by MOR agonists. Such modulation might underlie the effects of these agonists on hippocampus-dependent memory.	[Giannopoulos, Panagiotis; Papatheodoropoulos, Costas] Univ Patras, Sch Med, Physiol Lab, Patras 26504, Greece	Papatheodoropoulos, C (reprint author), Univ Patras, Sch Med, Physiol Lab, Patras 26504, Greece.	panos.giannopoulos@oxfordhealth.nhs.uk; cepapath@med.upatras.gr		Papatheodoropoulos, Costas/0000-0002-7860-9583	Research Committee of the University of Patras [C176]	This work was supported by a 'Karathodori' grant (No. C176) from the Research Committee of the University of Patras. We would like to thank the reviewers for their constructive suggestions.	Alexander SPH, 2011, BRIT J PHARMACOL, V164, pS1, DOI 10.1111/j.1476-5381.2011.01649_1.x; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P7041, DOI 10.1073/pnas.91.15.7041; Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; Battaglia FP, 2011, TRENDS COGN SCI, V15, P310, DOI 10.1016/j.tics.2011.05.008; Behrens CJ, 2005, NAT NEUROSCI, V8, P1560, DOI 10.1038/nn1571; Bernards CM, 2003, ANESTHESIOLOGY, V99, P466, DOI 10.1097/00000542-200308000-00030; Blasco-Ibanez JM, 1998, EUR J NEUROSCI, V10, P1784, DOI 10.1046/j.1460-9568.1998.00190.x; Bodnar RJ, 2010, PEPTIDES, V31, P2325, DOI 10.1016/j.peptides.2010.09.016; Bouw R, 2001, ACTA ANAESTH SCAND, V45, P390, DOI 10.1034/j.1399-6576.2001.045003390.x; Bragin A, 1999, HIPPOCAMPUS, V9, P137; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; CASTELLANO C, 1975, PSYCHOPHARMACOLOGIA, V42, P235, DOI 10.1007/BF00421262; Chaturvedi K, 2000, MOL BRAIN RES, V76, P64, DOI 10.1016/S0169-328X(99)00332-0; CHAVKIN C, 1985, J NEUROSCI, V5, P808; CHROBAK JJ, 1994, J NEUROSCI, V14, P6160; Colgin LL, 2004, J PHYSIOL-LONDON, V558, P953, DOI 10.1113/jphysiol.2004.068080; Crooks PA, 2006, BIOORG MED CHEM LETT, V16, P4291, DOI 10.1016/j.bmcl.2006.05.060; Csicsvari J, 2000, NEURON, V28, P585, DOI 10.1016/S0896-6273(00)00135-5; Dacher M, 2011, NEUROPHARMACOLOGY, V61, P1088, DOI 10.1016/j.neuropharm.2011.01.028; Davidson TJ, 2009, NEURON, V63, P497, DOI 10.1016/j.neuron.2009.07.027; DINGLEDINE R, 1981, J NEUROSCI, V1, P1022; Drake CT, 2002, HIPPOCAMPUS, V12, P119, DOI 10.1002/hipo.1107; Drolet G, 2001, PROG NEURO-PSYCHOPH, V25, P729, DOI 10.1016/S0278-5846(01)00161-0; Ego-Stengel V, 2010, HIPPOCAMPUS, V20, P1, DOI 10.1002/hipo.20707; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; Ellender TJ, 2010, J NEUROSCI, V30, P5979, DOI 10.1523/JNEUROSCI.3962-09.2010; Faulkner HJ, 1999, BRIT J PHARMACOL, V128, P1813, DOI 10.1038/sj.bjp.0702948; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Fuentealba P, 2008, J NEUROSCI, V28, P10017, DOI 10.1523/JNEUROSCI.2052-08.2008; Fuentealba P, 2008, NEURON, V57, P917, DOI 10.1016/j.neuron.2008.01.034; GALL C, 1981, J COMP NEUROL, V198, P335, DOI 10.1002/cne.901980211; Girardeau G, 2009, NAT NEUROSCI, V12, P1222, DOI 10.1038/nn.2384; Gunnar T, 2004, J CHROMATOGR B, V806, P205, DOI 10.1016/j.jchromb.2004.04.005; Hadjiconstantinou M, 2011, NEUROPHARMACOLOGY, V60, P1209, DOI 10.1016/j.neuropharm.2010.11.010; Hasselmo ME, 2005, HIPPOCAMPUS, V15, P936, DOI 10.1002/hipo.20116; Hunsaker MR, 2007, BEHAV NEUROSCI, V121, P742, DOI 10.1037/0735-7044.121.4.742; IZQUIERDO I, 1979, PSYCHOPHARMACOLOGY, V66, P199, DOI 10.1007/BF00427631; Jamot L, 2003, GENES BRAIN BEHAV, V2, P80, DOI 10.1034/j.1601-183X.2003.00013.x; Kesner RP, 2010, HIPPOCAMPUS, V20, P550, DOI 10.1002/hipo.20676; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Klausberger T, 2004, NAT NEUROSCI, V7, P41, DOI 10.1038/nn1159; Klepstad P, 2003, ACTA ANAESTH SCAND, V47, P725, DOI 10.1034/j.1399-6576.2003.00138.x; Koniaris E, 2011, NEUROSCIENCE, V175, P224, DOI 10.1016/j.neuroscience.2010.11.027; Krook-Magnuson E, 2011, J NEUROSCI, V31, P14861, DOI 10.1523/JNEUROSCI.2269-11.2011; Lam M, 2008, PSYCHOPHARMACOLOGY, V201, P261, DOI 10.1007/s00213-008-1267-8; LUPICA CR, 1995, J NEUROSCI, V15, P737; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; Maier N, 2003, J PHYSIOL-LONDON, V550, P873, DOI 10.1113/jphysiol.2003.044602; Maier N, 2011, NEURON, V72, P137, DOI 10.1016/j.neuron.2011.08.016; MANSOUR A, 1987, J NEUROSCI, V7, P2445; Martinez CO, 2011, NEUROBIOL LEARN MEM, V96, P207, DOI 10.1016/j.nlm.2011.04.014; MASUKAWA LM, 1982, BRAIN RES, V249, P271, DOI 10.1016/0006-8993(82)90061-0; McGaugh JL, 2002, TRENDS NEUROSCI, V25, P456, DOI 10.1016/S0166-2236(02)02211-7; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; McQuiston AR, 2008, NEUROSCIENCE, V151, P209, DOI 10.1016/j.neuroscience.2007.09.077; McQuiston AR, 2011, NEUROPHARMACOLOGY, V60, P472, DOI 10.1016/j.neuropharm.2010.10.029; Meilandt WJ, 2004, J NEUROSCI, V24, P2953, DOI 10.1523/JNEUROSCI.5569-03.2004; MONDADORI C, 1979, PSYCHOPHARMACOLOGY, V63, P297, DOI 10.1007/BF00433566; MORRIS BJ, 1995, TRENDS NEUROSCI, V18, P350, DOI 10.1016/0166-2236(95)93927-P; NICOLL RA, 1980, NATURE, V287, P22, DOI 10.1038/287022a0; O'Neill J, 2010, TRENDS NEUROSCI, V33, P220, DOI 10.1016/j.tins.2010.01.006; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; Pan ZZ, 1998, TRENDS PHARMACOL SCI, V19, P94, DOI 10.1016/S0165-6147(98)01169-9; Papatheodoropoulos C, 2002, NEUROSCI LETT, V319, P17, DOI 10.1016/S0304-3940(01)02505-8; Papatheodoropoulos C, 2010, NEUROSCIENCE, V168, P429, DOI 10.1016/j.neuroscience.2010.03.058; Papatheodoropoulos C, 2011, NEUROPHARMACOLOGY, V60, P662, DOI 10.1016/j.neuropharm.2010.11.022; Pasternak GW, 2001, LIFE SCI, V68, P2213, DOI 10.1016/S0024-3205(01)01008-6; Petrides T, 2007, EXP BRAIN RES, V177, P370, DOI 10.1007/s00221-006-0681-6; Racz A, 2009, J NEUROSCI, V29, P2563, DOI 10.1523/JNEUROSCI.5036-08.2009; Ramadan W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006697; Robbe D, 2006, NAT NEUROSCI, V9, P1526, DOI 10.1038/nn1801; Schnell SA, 2008, J COMP NEUROL, V508, P542, DOI 10.1002/cne.21712; Singer AC, 2009, NEURON, V64, P910, DOI 10.1016/j.neuron.2009.11.016; Skaggs WE, 2007, J NEUROPHYSIOL, V98, P898, DOI 10.1152/jn.00401.2007; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; STAUBLI U, 1980, BEHAV NEURAL BIOL, V28, P487, DOI 10.1016/S0163-1047(80)91860-9; Sutherland GR, 2000, CURR OPIN NEUROBIOL, V10, P180, DOI 10.1016/S0959-4388(00)00079-9; SWEARENGEN E, 1987, NEUROSCI LETT, V78, P80, DOI 10.1016/0304-3940(87)90565-9; VESELIS RA, 1994, ANESTH ANALG, V79, P952; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; WATSON GB, 1993, BRAIN RES, V601, P129, DOI 10.1016/0006-8993(93)91703-U; WHITE N, 1978, LIFE SCI, V23, P1967, DOI 10.1016/0024-3205(78)90564-7; Whittington MA, 1998, P NATL ACAD SCI USA, V95, P5807, DOI 10.1073/pnas.95.10.5807; Wierzynski CM, 2009, NEURON, V61, P587, DOI 10.1016/j.neuron.2009.01.011; WISE RA, 1989, NEUROSCI BIOBEHAV R, V13, P129, DOI 10.1016/S0149-7634(89)80021-1; Wu CP, 2002, J PHYSIOL-LONDON, V540, P509, DOI 10.1113/jphysiol.2001.013441; YLINEN A, 1995, J NEUROSCI, V15, P30; ZASTAWNY RL, 1994, J NEUROCHEM, V62, P2099; ZERNIG G, 1995, LIFE SCI, V57, P2113, DOI 10.1016/0024-3205(95)02204-V; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	94	12	12	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	MAR	2013	168	5					1146	1164		10.1111/j.1476-5381.2012.02240.x			19	Pharmacology & Pharmacy	Pharmacology & Pharmacy	094XV	WOS:000315299700011	23043226	Green Published			2020-06-30	J	Sia, AT; Leo, S; Ocampo, CE				Sia, A. T.; Leo, S.; Ocampo, C. E.			A randomised comparison of variable-frequency automated mandatory boluses with a basal infusion for patient-controlled epidural analgesia during labour and delivery	ANAESTHESIA			English	Article							BACKGROUND INFUSION; PAIN RELIEF; INTERMITTENT; ROPIVACAINE; SUFENTANIL; FENTANYL; PCEA	This trial was conducted to compare the analgesic efficacy of administering variable-frequency automated boluses at a rate proportional to the patient's needs with fixed continuous basal infusion in patient-controlled epidural analgesia (PCEA) during labour and delivery. We recruited a total of 102 parturients in labour who were randomly assigned to receive either a novel PCEA with automated mandatory boluses of 5 ml administered once, twice, three or four times per hour depending on the history of the parturient's analgesic demands over the past hour (Automated bolus group), or a conventional PCEA with a basal infusion of 5 ml.h(-1) (Infusion group). The incidence of breakthrough pain requiring supplementation by an anaesthetist was significantly lower in the Automated bolus group, three out of 51 (5.9%) compared with the Infusion group, 12 out of 51 (23.5%, p = 0.023). The time-weighted mean (SD) hourly consumption of ropivacaine was similar in both groups, 10.0 (3.0) mg in the Automated bolus group vs 11.1 (3.2) mg in the Infusion group (p = 0.06). Parturients from the Automated bolus group reported higher satisfaction scores compared with those in the Infusion group, 96.5 (5.0) vs 89.2 (9.4), respectively (p < 0.001). There was no difference in the incidence of maternal side-effects and obstetric and neonatal outcomes.	[Sia, A. T.; Leo, S.; Ocampo, C. E.] KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore, Singapore	Leo, S (reprint author), KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore, Singapore.	danxer159@yahoo.com.sg					Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Boutros A, 1999, INT J OBSTET ANESTH, V8, P236, DOI 10.1016/S0959-289X(99)80103-4; Bremerich DH, 2005, INT J OBSTET ANESTH, V14, P114, DOI 10.1016/j.ijoa.2004.12.005; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; D'Angelo R, 2003, CLIN OBSTET GYNECOL, V46, P623, DOI 10.1097/00003081-200309000-00015; FERRANTE FM, 1994, ANESTH ANALG, V79, P80; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Lim Y, 2006, ANAESTHESIA, V61, P339, DOI 10.1111/j.1365-2044.2006.04535.x; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; Missant C, 2005, ANAESTH INTENS CARE, V33, P452, DOI 10.1177/0310057X0503300405; Petry J, 2000, Acta Anaesthesiol Belg, V51, P163; Sia A. T., 2006, SMJ Singapore Medical Journal, V47, P951; Sia AT, 2007, ANESTH ANALG, V104, P673, DOI 10.1213/01.ane.0000253236.89376.60; Sng BL, 2009, ANAESTH INTENS CARE, V37, P46, DOI 10.1177/0310057X0903700119; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a	18	25	26	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409			ANAESTHESIA	Anaesthesia	MAR	2013	68	3					267	275		10.1111/anae.12093			9	Anesthesiology	Anesthesiology	085UW	WOS:000314640800007	23278328				2020-06-30	J	Xiang, Q; Huang, DY; Zhao, YL; Wang, GH; Liu, YX; Zhong, L; Luo, T				Xiang, Q.; Huang, D. Y.; Zhao, Y. L.; Wang, G. H.; Liu, Y. X.; Zhong, L.; Luo, T.			Caudal dexmedetomidine combined with bupivacaine inhibit the response to hernial sac traction in children undergoing inguinal hernia repair	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia; caudal; analgesia; dexmedetomidine; hernia; inguinal; sympathetic nervous system	HYPOSPADIAS REPAIR; BLOCK; CLONIDINE; ANESTHESIA; ANALGESIA; AGONISTS	Caudal bupivacaine is widely used for inguinal hernia repair in children, but often cannot totally eliminate responses to hernial sac traction. The current study examined whether supplementation of caudal bupivacaine with dexmedetomidine could achieve better results. Sixty children aged 1272 months undergoing unilateral inguinal hernia repair received standardized premedication with midazolam, i.v. ketamine anaesthesia, and then were randomly assigned to receive either bupivacaine 0.25 (1 ml kg(1); Group B) or bupivacaine plus dexmedetomidine (1 g kg(1); Group BD). The response to hernial sac traction was defined as an increase in heart rate or systolic arterial pressure by 20, and was treated with ketamine rescue (2 mg kg(1)). After the surgery, fentanyl was administered as needed with a nurse-controlled analgesia pump. Only one subject in Group BD (3.33) needed ketamine rescue, as opposed to 13 subjects in Group B (43.33; P0.001). The first fentanyl injection occurred at a much later time point in Group BD (median: 860 vs 320 min in Group B; P0.001). Total fentanyl consumption of fentanyl was significantly lower in Group BD [2.5 (1.2) vs 6.9 (1.6) g kg(1) 24 h(1) in Group B; P0.008]. The addition of dexmedetomidine to caudal bupivacaine could reduce the response to hernial sac traction, and prolong the duration of postoperative analgesia in children undergoing inguinal hernia repair.	[Xiang, Q.; Huang, D. Y.; Wang, G. H.; Liu, Y. X.; Zhong, L.; Luo, T.] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Dept Anesthesiol, Wuhan 430074, Peoples R China; [Zhao, Y. L.] Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China	Huang, DY (reprint author), Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Dept Anesthesiol, Wuhan 430074, Peoples R China.	whetyymzk@gmail.com					Axelsson K, 2009, CURR OPIN ANESTHESIO, V22, P649, DOI 10.1097/ACO.0b013e32832ee847; BUTTERWORTH JF, 1993, ANESTH ANALG, V76, P295; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; De Mey JC, 2000, EUR J ANAESTH, V17, P379, DOI 10.1046/j.1365-2346.2000.00690.x; Duman A, 2010, PEDIATR ANESTH, V20, P530, DOI 10.1111/j.1460-9592.2010.03315.x; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159; Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Hansen TG, 2004, BRIT J ANAESTH, V92, P223, DOI 10.1093/bja/aeh028; Hunter JC, 1997, BRIT J PHARMACOL, V122, P1339, DOI 10.1038/sj.bjp.0701520; Konakci S, 2008, EUR J ANAESTH, V25, P403, DOI 10.1017/S0265021507003079; LLOYDTHOMAS AR, 1990, BRIT J ANAESTH, V64, P85, DOI 10.1093/bja/64.1.85; Lonnqvist PA, 2005, BRIT J ANAESTH, V95, P431, DOI 10.1093/bja/aei221; Lundblad M, 2012, BRIT J ANAESTH, V108, P675, DOI 10.1093/bja/aer513; Ma DQ, 2004, BRIT MED BULL, V71, P77, DOI 10.1093/bmb/ldh036; NAGUIB M, 1994, ANESTHESIOLOGY, V80, P1338, DOI 10.1097/00000542-199406000-00022; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Sanders JC, 2002, BRIT J ANAESTH, V89, P707, DOI 10.1093/bja/aef263; Sasaoka N, 2005, BRIT J ANAESTH, V94, P243, DOI 10.1093/bja/aei031; Sharpe P, 2001, PAEDIATR ANAESTH, V11, P695, DOI 10.1046/j.1460-9592.2001.00748.x; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Silvani P, 2006, MINERVA ANESTESIOL, V72, P453; Walker SM, 2009, ACTA ANAESTH SCAND, V53, P1097, DOI 10.1111/j.1399-6576.2009.02013.x	24	29	31	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAR	2013	110	3					420	424		10.1093/bja/aes385			5	Anesthesiology	Anesthesiology	092LR	WOS:000315123800013	23161357	Bronze			2020-06-30	J	Chen, YK; Lei, J; Jin, L; Tan, YX; You, HJ				Chen, Y. -K.; Lei, J.; Jin, L.; Tan, Y. -X.; You, H. -J.			Dynamic variations of c-Fos expression in the spinal cord exposed to intramuscular hypertonic saline-induced muscle nociception	EUROPEAN JOURNAL OF PAIN			English	Article							DORSAL-HORN NEURONS; GASTROCNEMIUS-MUSCLE; SPATIAL-DISTRIBUTION; FORMALIN INJECTION; PROJECTION NEURONS; DESCENDING CONTROL; WITHDRAWAL REFLEX; EXPERIMENTAL PAIN; RAT; STIMULATION	Background Numerous studies focus on intramuscular (i.m.) injection of hypertonic saline-induced muscle pain and nociception. The spatio-temporal characteristics and dynamic variation of spinal neuronal activities elicited by i.m. hypertonic saline remain unknown. Methods The spatio-temporal variations of c-Fos expression in the lumbar spinal cord exposed to i.m. injection of 5.8% saline were investigated in male rats. Results After a unilateral i.m. 5.8% saline injection, c-Fos expression in dorsal horn of spinal L4-6 segments was significantly enhanced bilaterally (p<0.05 and p<0.001). These 5.8% saline-induced bilateral spinal Fos expression occurred rapidly 0.5h following the i.m. injection, and reached the peak levels within 1h, which declined gradually and returned to the control levels within 8h. Compared with intact rats without i.m. insults, no significant influence of the spinalization on spinal c-Fos expression was found. However, the 5.8% saline-induced increases in Fos expression in intact and spinalized rats differed significantly. During muscle nociception, the c-Fos expression within the superficial layer (laminae III) and the deep layer (laminae VVI) in spinalized rats were significantly lower and higher than that of in intact rats (p<0.05 and p<0.001). Fentanyl (20g/kg, intraperitoneal) completely attenuated the 5.8% saline intramuscularly induced increases in c-Fos expression in laminae IIIVI (p<0.001), but not laminae III. Conclusions It is suggested that spinal nociceptive neuronal activities in superficial and deep layers may differently be modulated by endogenous descending facilitation and inhibition, respectively.	[Chen, Y. -K.; Lei, J.; Tan, Y. -X.; You, H. -J.] Xi An Jiao Tong Univ, Coll Med, CBRP, Xian, Peoples R China; [Jin, L.] Xian Med Coll, Hosp 1, Dept Neurosurg, Xian, Peoples R China	You, HJ (reprint author), Xi An Jiao Tong Univ, Coll Med, CBRP, Xian, Peoples R China.	yhj@mail.xjtu.edu.cn			National Natural Science Foundation of P.R. ChinaNational Natural Science Foundation of China [30971424, 30770699]; Chinese Education MinistryMinistry of Education, China [NCET-07-0684]	This study received support from the National Natural Science Foundation of P.R. China (30971424,30770699) and Chinese Education Ministry (NCET-07-0684).	ASHTONMILLER JA, 1990, SPINE, V15, P1006, DOI 10.1097/00007632-199015100-00005; BASBAUM A, 1994, APS J, V3, P49; BETT K, 1995, NEUROSCIENCE, V67, P497, DOI 10.1016/0306-4522(95)00017-D; Bileviciute-Ljungar I, 2000, NEUROREPORT, V11, P291, DOI 10.1097/00001756-200002070-00014; BROWN AG, 1982, Q J EXP PHYSIOL CMS, V67, P193; BULLITT E, 1992, BRAIN RES, V580, P172, DOI 10.1016/0006-8993(92)90941-2; Casale R, 2009, J REHABIL MED, V41, P418, DOI 10.2340/16501977-0353; CERVERO F, 1991, EXP BRAIN RES, V83, P675; Coggeshall RE, 2005, PROG NEUROBIOL, V77, P299, DOI 10.1016/j.pneurobio.2005.11.002; DUGGAN AW, 1988, [No title captured], V77, P193; FIELDS HL, 1977, BRAIN RES, V120, P49, DOI 10.1016/0006-8993(77)90497-8; GIESLER GJ, 1981, J NEUROPHYSIOL, V46, P1285; Harris JA, 1998, BRAIN RES BULL, V45, P1, DOI 10.1016/S0361-9230(97)00277-3; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; HERDEGEN T, 1994, MOL BRAIN RES, V22, P245, DOI 10.1016/0169-328X(94)90053-1; Honore P, 1995, PAIN, V63, P365, DOI 10.1016/0304-3959(95)00065-8; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JASMIN L, 1994, NEUROSCIENCE, V58, P275, DOI 10.1016/0306-4522(94)90034-5; JENSEN K, 1992, CEPHALALGIA, V12, P101, DOI 10.1046/j.1468-2982.1992.1202101.x; Ji RR, 1997, J NEUROSCI, V17, P1776; LEAH JD, 1992, NEUROSCIENCE, V48, P525, DOI 10.1016/0306-4522(92)90399-M; Leffler AS, 2000, EUR J PAIN, V4, P73, DOI 10.1053/eujp.1999.0160; Lei J, 2008, BRAIN RES, V1232, P85, DOI 10.1016/j.brainres.2008.07.056; Lei J, 2012, BRAIN RES BULL, V87, P564, DOI 10.1016/j.brainresbull.2011.11.003; Lei J, 2011, EXP NEUROL, V228, P206, DOI 10.1016/j.expneurol.2011.01.004; Li HS, 1998, J PHYSIOL-LONDON, V506, P459, DOI 10.1111/j.1469-7793.1998.459bw.x; Li XQ, 2004, J NEUROSCI RES, V78, P533, DOI 10.1002/jnr.20274; Lima D, 1998, EUR J PAIN, V2, P195, DOI 10.1016/S1090-3801(98)90015-5; Ling LJ, 2003, J COMP NEUROL, V461, P140, DOI 10.1002/cne.10619; MCMAHON SB, 1988, J NEUROPHYSIOL, V59, P1204; MENETREY D, 1989, J COMP NEUROL, V285, P177, DOI 10.1002/cne.902850203; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Panneton WM, 2005, NEUROSCIENCE, V134, P175, DOI 10.1016/j.neuroscience.2005.02.032; Paxinos G., 1998, RAT BRAIN STEREOTAXI; Petko M, 2000, J COMP NEUROL, V422, P312, DOI 10.1002/(SICI)1096-9861(20000626)422:2<312::AID-CNE11>3.0.CO;2-A; PRESLEY RW, 1990, J NEUROSCI, V10, P323; Ro JY, 2007, EUR J PAIN, V11, P398, DOI 10.1016/j.ejpain.2006.05.008; Sandkuhler J, 1996, NEUROSCIENCE, V73, P657, DOI 10.1016/0306-4522(96)00073-5; Schadrack J, 1998, J NEUROSCI RES, V53, P203, DOI 10.1002/(SICI)1097-4547(19980715)53:2<203::AID-JNR9>3.3.CO;2-T; Shenker N, 2003, RHEUMATOLOGY, V42, P1279, DOI 10.1093/rheumatology/keg397; Stohler CS, 1996, PAIN, V66, P215, DOI 10.1016/0304-3959(96)03026-6; Sun XH, 2004, ANESTH ANALG, V98, P1093, DOI 10.1213/01.ANE.0000104580.89717.A2; Suzuki R, 2004, TRENDS PHARMACOL SCI, V25, P613, DOI 10.1016/j.tips.2004.10.002; Svendsen O, 2005, BASIC CLIN PHARMACOL, V97, P52, DOI 10.1111/j.1742-7843.2005.pto_97108.x; Taguchi T, 2007, NEUROSCI LETT, V427, P22, DOI 10.1016/j.neulet.2007.08.021; TODD AJ, 1989, J COMP NEUROL, V289, P676, DOI 10.1002/cne.902890411; Yamazaki Y, 2001, BRAIN RES, V914, P106, DOI 10.1016/S0006-8993(01)02783-4; You HJ, 2009, NEUROSCIENCE, V164, P1845, DOI 10.1016/j.neuroscience.2009.09.047; You HJ, 2006, BRAIN RES, V1090, P116, DOI 10.1016/j.brainres.2006.03.065; You HJ, 2010, J PHYSIOL-LONDON, V588, P4177, DOI 10.1113/jphysiol.2010.196923; You HJ, 2005, EXP NEUROL, V195, P148, DOI 10.1016/j.expneurol.2005.04.009; YU XM, 1990, NEUROSCIENCE, V39, P823; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	53	5	8	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAR	2013	17	3					336	346		10.1002/j.1532-2149.2012.00207.x			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	087ZS	WOS:000314804200005	22893527				2020-06-30	J	Gallagher, R				Gallagher, Romayne			The management of wound-related procedural pain (volitional incident pain) in advanced illness	CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE			English	Review						advanced illness; breakthrough pain; incident pain; wound-related procedural pain; wounds	BREAKTHROUGH PAIN; INTRANASAL SUFENTANIL; OLDER-ADULTS; FENTANYL; FORMULATIONS; ANALGESIA; DEMENTIA; SEDATION; SYMPTOM; OPIOIDS	Purpose of review The prevention and treatment of wound-related procedural pain is one of the greatest areas of unmet need within wound management. Also referred to as 'Volitional Incident Pain', it is the most prevalent subtype of breakthrough pain experienced by patients afflicted with wounds. Novel formulations of existing analgesics are now available to address this challenge. Recent findings This review focuses on the principles of breakthrough pain assessment including those patients with cognitive impairment. Current management principles are discussed with an emphasis on the novel formulations of fentanyl citrate that may be delivered through the sublingual, buccal, and nasal mucosal routes. Summary Novel formulations of fentanyl citrate, delivered through an array of noninvasive routes, allow for rapid-onset and short-acting effects that better match the onset and duration of wound-related procedural pain.	[Gallagher, Romayne] Providence Healthcare, Div Palliat Care, Dept Family & Community Med, Vancouver, BC, Canada; [Gallagher, Romayne] Providence Healthcare, Div Residential Care, Dept Family & Community Med, Vancouver, BC, Canada	Gallagher, R (reprint author), Univ British Columbia, Providence Healthcare, Dept Family & Community Med, Div Palliat Care, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	rgallagher@providencehealth.bc.ca					[Anonymous], 2004, PRINC BEST PRACT MIN, VMedical Education Partnership Ltd; Bahn EL, 2005, EMERG MED CLIN N AM, V23, P503, DOI 10.1016/j.emc.2004.12.013; Bell RF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004603.pub2; British Pain Society & British Geriatrics Society, 2007, ASS PAIN OLD PEOPL N; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Dworkin RH, 2007, J PAIN, V8, P118, DOI 10.1016/j.jpain.2006.06.005; Elsner F, 2011, CLIN DRUG INVEST, V31, P605, DOI 10.2165/11592910-000000000-00000; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Fulop T, 2010, BIOGERONTOLOGY, V11, P547, DOI 10.1007/s10522-010-9287-2; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; Girouard K, 2008, OSTOMY WOUND MANAG, V54, P30; Good P, 2009, PALLIATIVE MED, V23, P54, DOI 10.1177/0269216308100249; Gorecki C, 2011, J PAIN SYMPTOM MANAG, V42, P443, DOI 10.1016/j.jpainsymman.2010.11.016; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hagen NA, 2007, J PALLIAT MED, V10, P331, DOI 10.1089/jpm.2006.0163; Herr K, 2006, J PAIN SYMPTOM MANAG, V31, P170, DOI 10.1016/j.jpainsymman.2005.07.001; Hopkins A, 2006, J ADV NURS, V56, P345, DOI 10.1111/j.1365-2648.2006.04007.x; Horgas AL, 2009, J AM GERIATR SOC, V57, P126, DOI 10.1111/j.1532-5415.2008.02071.x; Jackson K, 2002, J PAIN SYMPTOM MANAG, V23, P450, DOI 10.1016/S0885-3924(02)00406-2; Karp JF, 2008, BRIT J ANAESTH, V101, P111, DOI 10.1093/bja/aen090; KUNZ KM, 1993, J PAIN SYMPTOM MANAG, V8, P189, DOI 10.1016/0885-3924(93)90125-F; Logsdon RG, 2002, PSYCHOSOM MED, V64, P510, DOI 10.1097/00006842-200205000-00016; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V28, P505, DOI 10.1016/j.jpainsymman.2004.02.024; Mustoe TA, 2006, PLAST RECONSTR SURG, V117, p35S, DOI 10.1097/01.prs.0000225431.63010.1b; Okon Tomasz, 2007, Pain Physician, V10, P493; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; Passik SD, 2007, PAIN MED, V8, P130, DOI 10.1111/j.1526-4637.2006.00295.x; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Payne R, 2007, PAIN MED, V8, pS3; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2004, OXFORD TXB PALLIATIV, P438; Quirino J, 2003, WOUNDS, V15, P381; Rastinehad D, 2006, J WOUND OSTOMY CONT, V33, P252, DOI 10.1097/00152192-200605000-00005; Reisfield GM, 2007, J PALLIAT MED, V10, P465, DOI 10.1089/jpm.2006.0150; Smally AJ, 2011, CURR OPIN CRIT CARE, V17, P317, DOI 10.1097/MCC.0b013e328348bf43; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Taylor DR, 2012, FUTURE ONCOL, V8, P121, DOI [10.2217/FON.11.146, 10.2217/fon.11.146]; van Herk R, 2009, J CLIN NURS, V18, P2478, DOI 10.1111/j.1365-2702.2008.02776.x	42	2	3	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1751-4258	1751-4266		CURR OPIN SUPPORT PA	Curr. Opin Support Palliat. Car.	MAR	2013	7	1					80	85		10.1097/SPC.0b013e32835ac704			6	Health Care Sciences & Services	Health Care Sciences & Services	AJ2IC	WOS:000337478100014	23150425				2020-06-30	J	Deftereos, S; Giannopoulos, G; Raisakis, K; Hahalis, G; Kaoukis, A; Kossyvakis, C; Avramides, D; Pappas, L; Panagopoulou, V; Pyrgakis, V; Alexopoulos, D; Stefanadis, C; Cleman, MW				Deftereos, Spyridon; Giannopoulos, Georgios; Raisakis, Konstantinos; Hahalis, Georgios; Kaoukis, Andreas; Kossyvakis, Charalambos; Avramides, Dimitrios; Pappas, Loukas; Panagopoulou, Vasiliki; Pyrgakis, Vlasios; Alexopoulos, Dimitrios; Stefanadis, Christodoulos; Cleman, Michael W.			Moderate Procedural Sedation and Opioid Analgesia During Transradial Coronary Interventions to Prevent Spasm A Prospective Randomized Study	JACC-CARDIOVASCULAR INTERVENTIONS			English	Article						fentanyl; midazolam; percutaneous coronary intervention; radial artery; spasm	RADIAL ARTERY SPASM; FEMORAL ACCESS; ANGIOGRAPHY; MECHANISMS; MIDAZOLAM; ENDOTHELIUM; EXPERIENCE; IMPACT; SHEATH	Objectives The aim of this study was to test the hypothesis that moderate procedural sedation can reduce the incidence of radial artery spasm. Background Transradial access for left heart catheterization and percutaneous coronary intervention is increasingly used for emergent and elective procedures, in lieu of the femoral approach. However, increased rates of access site crossover have been reported, with radial artery spasm being a major contributor to this effect. Methods Patients undergoing elective transradial percutaneous coronary intervention were prospectively randomized to receive fentanyl and midazolam during the procedure or no treatment (control subjects). The primary endpoint was angiographically confirmed radial artery spasm. Patient discomfort was quantified with a visual analogue scale. Results Two thousand thirteen patients (age 64.5 +/- 8.4 years) were randomized. Spasm occurred in 2.6% of the treatment group versus 8.3% of control subjects (p < 0.001; odds ratio [OR]: 0.29). The number needed to treat to avoid 1 case of spasm was 18 (95% confidence interval [CI]: 12.9 to 26.6). The access site crossover rate was 34% lower in the treatment group: 9.9% versus 15.0% (OR: 0.62; 95% CI: 0.48 to 0.82). Patient discomfort visual analogue scale score was 18.8 +/- 12.5 in the treatment group versus 27.4 +/- 17.4 in control subjects (p < 0.001). No significant differences were observed in the 30-day rate of death or repeat hospital stay for any cause: 4.6% versus 4.5% (OR: 1.02; 95% CI: 0.67 to 1.56). Conclusions Routine administration of relatively low doses of an opioid/benzodiazepine combination during transradial interventional procedures is associated with a substantial reduction in the rate of spasm, the need for access site crossover, and the procedure-related level of patient discomfort. (J Am Coll Cardiol Intv 2013; 6: 267-73) (C) 2013 by the American College of Cardiology Foundation	[Deftereos, Spyridon; Giannopoulos, Georgios; Raisakis, Konstantinos; Kaoukis, Andreas; Kossyvakis, Charalambos; Avramides, Dimitrios; Pappas, Loukas; Panagopoulou, Vasiliki; Pyrgakis, Vlasios; Cleman, Michael W.] Athens Gen Hosp G Gennimatas, Dept Cardiol, Athens 11527, Greece; [Deftereos, Spyridon; Giannopoulos, Georgios; Raisakis, Konstantinos; Kaoukis, Andreas; Kossyvakis, Charalambos; Avramides, Dimitrios; Pappas, Loukas; Panagopoulou, Vasiliki; Pyrgakis, Vlasios; Cleman, Michael W.] Athens Gen Hosp G Gennimatas, Cardiac Catheterizat Lab, Athens 11527, Greece; [Giannopoulos, Georgios; Cleman, Michael W.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Hahalis, Georgios; Alexopoulos, Dimitrios] Univ Patras, Sch Med, Dept Cardiol, GR-26110 Patras, Greece; [Stefanadis, Christodoulos] Univ Athens, Sch Med, Hippokrate Hosp, Dept Cardiol 1, GR-11527 Athens, Greece	Giannopoulos, G (reprint author), Athens Gen Hosp G Gennimatas, Dept Cardiol, Cardiac Catheterizat Lab, 154 Mesoge Ave, Athens 11527, Greece.	ggiann@med.uoa.gr	Giannopoulos, Georgios/AAL-1228-2020; Stefanadis, Christodoulos/AAA-4102-2020	Giannopoulos, Georgios/0000-0002-7287-3850; 			Bertrand OF, 2010, JACC-CARDIOVASC INTE, V3, P1022, DOI 10.1016/j.jcin.2010.07.013; Biondi-Zoccai GGL, 2011, ACTA CARDIOL, V66, P9, DOI 10.1080/AC.66.1.2064961; Borges AAFR, 2003, MOL CELL BIOCHEM, V246, P13, DOI 10.1023/A:1023439508821; Caussin C, 2010, CATHETER CARDIO INTE, V76, P668, DOI 10.1002/ccd.22552; Chen CW, 2006, CARDIOLOGY, V105, P43, DOI 10.1159/000089246; Colussi GL, 2011, HYPERTENS RES, V34, P929, DOI 10.1038/hr.2011.62; Coppola John, 2006, J Invasive Cardiol, V18, P155; Deftereos S, 2011, CATHETER CARDIO INTE, V77, P649, DOI 10.1002/ccd.22688; Defteres S, 2011, HELL J CARDIOL, V52, P111; Eichhoefer J, 2008, AM HEART J, V156, P864, DOI 10.1016/j.ahj.2008.06.044; Gursoy S, 2006, EUR J ANAESTH, V23, P496, DOI 10.1017/S0265021506000172; Hahalis G, 2012, ANN M AM COLL CARD M; Hetherington SL, 2009, HEART, V95, P1612, DOI 10.1136/hrt.2009.170233; Ho HH, 2012, CARDIOVASC REVASCULA, V13, P193, DOI 10.1016/j.carrev.2011.11.003; Jolly SS, 2011, LANCET, V377, P1409, DOI 10.1016/S0140-6736(11)60404-2; Jolly SS, 2009, AM HEART J, V157, P132, DOI 10.1016/j.ahj.2008.08.023; Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P1269, DOI 10.1016/S0735-1097(97)00064-8; Kim SH, 2007, INT J CARDIOL, V120, P325, DOI 10.1016/j.ijcard.2006.10.008; Klockgether-Radke AP, 2005, EUR J ANAESTH, V22, P135, DOI 10.1017/S0265021505000256; Rao SV, 2010, J AM COLL CARDIOL, V55, P2187, DOI 10.1016/j.jacc.2010.01.039; Rathore S, 2010, JACC-CARDIOVASC INTE, V3, P475, DOI 10.1016/j.jcin.2010.03.009; Sahin AE, 2005, J CARDIOTHOR VASC AN, V19, P197, DOI 10.1053/j.jvca.2005.01.031; Varenne O, 2006, CATHETER CARDIO INTE, V68, P231, DOI 10.1002/ccd.20812	23	42	45	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1936-8798			JACC-CARDIOVASC INTE	JACC-Cardiovasc. Interv.	MAR	2013	6	3					267	273		10.1016/j.jcin.2012.11.005			7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	124SE	WOS:000317485300012	23517838	Bronze			2020-06-30	J	Dannals, RF				Dannals, Robert F.			Positron emission tomography radioligands for the opioid system	JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS			English	Review						fluorine-18; receptor; opiate; neuroreceptor	C-11 LABELED DIPRENORPHINE; OPIATE-RECEPTOR-BINDING; IN-VIVO EVALUATION; BIOLOGICAL EVALUATION; SELECTIVE AGONIST; HUMAN-BRAIN; MU; POTENT; PET; KINETICS	Opiate receptors are found in the brain, the spinal cord, some peripheral sensory neurons, and the gastrointestinal tract. Naturally occurring and synthetic opiate ligands exert their influence on a wide variety of processes including analgesia, euphoria, dysphoria, sedation, respiratory depression, and miosis and are frequently topics for discussions on addiction and physical dependence. This review looks at the history of positron emission tomography radioligands for probing this receptor system.	Johns Hopkins Univ, Sch Med, Div Nucl Med, Dept Radiol, Baltimore, MD 21287 USA	Dannals, RF (reprint author), Johns Hopkins Univ, Sch Med, Div Nucl Med, Dept Radiol, Baltimore, MD 21287 USA.	rfd@jhu.edu					Akgun E, 2006, J LABELLED COMPD RAD, V49, P857, DOI 10.1002/jlcr.1095; BAI LQ, 1990, NUCL MED BIOL, V17, P217; BURNS HD, 1984, J LABELLED COMPD RAD, V21, P1167; CHANNING MA, 1985, INT J APPL RADIAT IS, V36, P429, DOI 10.1016/0020-708X(85)90204-2; CHESIS PL, 1990, J MED CHEM, V33, P1482, DOI 10.1021/jm00167a031; COSTELLO GF, 1988, EUR J PHARMACOL, V151, P475, DOI 10.1016/0014-2999(88)90546-8; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; DEVOS V, 1978, VET REC, V103, P64, DOI 10.1136/vr.103.4.64; FELIU AL, 1992, APPL RADIAT ISOTOPES, V43, P1159; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; FROST JJ, 1984, BRAIN RES, V305, P1, DOI 10.1016/0006-8993(84)91113-2; Frost JJ, 2001, NUCL MED BIOL, V28, P509, DOI 10.1016/S0969-8051(01)00221-9; FROST JJ, 1984, ANN NEUROL, V15, pS85; GAIL R, 1992, APPL RADIAT ISOTOPES, V43, P1129; GOLDSTEIN A, 1971, P NATL ACAD SCI USA, V68, P1742, DOI 10.1073/pnas.68.8.1742; HAIGH JC, 1983, J WILDLIFE DIS, V19, P140, DOI 10.7589/0090-3558-19.2.140; HARTVIG P, 1990, PHARMACOL TOXICOL, V66, P37, DOI 10.1111/j.1600-0773.1990.tb00698.x; HARTVIG P, 1986, REGUL PEPTIDES, V16, P1, DOI 10.1016/0167-0115(86)90190-4; HARTVIG P, 1984, J PHARMACOL EXP THER, V230, P250; HARTVIG P, 1989, PHARMACOL TOXICOL, V65, P214, DOI 10.1111/j.1600-0773.1989.tb01159.x; Henriksen G, 2005, J MED CHEM, V48, P7720, DOI 10.1021/jm0507274; Henriksen G, 2005, J LABELLED COMPD RAD, V48, P771, DOI 10.1002/jlcr.995; Henriksen G, 2005, BIOORG MED CHEM LETT, V15, P1773, DOI 10.1016/j.bmcl.2005.02.049; Henriksen G, 2006, DRUG DEVELOP RES, V67, P890, DOI 10.1002/ddr.20161; HUNTER JC, 1990, BRIT J PHARMACOL, V101, P183, DOI 10.1111/j.1476-5381.1990.tb12110.x; HWANG DR, 1986, J LABELLED COMPD RAD, V23, P277, DOI 10.1002/jlcr.2580230306; Jewett DM, 2004, NUCL MED BIOL, V31, P321, DOI 10.1016/j.nucmedbio.2003.10.009; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; JONES AKP, 1988, J NEUROSCI METH, V23, P121, DOI 10.1016/0165-0270(88)90184-7; KLOSTER G, 1979, J LABELLED COMPD RAD, V16, P441, DOI 10.1002/jlcr.2580160310; LADURON PM, 1985, NEUROPHARMACOLOGY, V24, P617, DOI 10.1016/0028-3908(85)90102-9; LANGSTROM B, 1982, CHEM SCRIPTA, V20, P46; Larsen P, 1997, APPL RADIAT ISOTOPES, V48, P153, DOI 10.1016/S0969-8043(96)00177-7; Lever JR, 2007, CURR PHARM DESIGN, V13, P33, DOI 10.2174/138161207779313821; LEVER JR, 1987, TETRAHEDRON LETT, V28, P4015, DOI 10.1016/S0040-4039(01)83849-1; LEVER JR, 1990, APPL RADIAT ISOTOPES, V41, P745; LEVER JR, 1995, J LABELLED COMPD RAD, V36, P137, DOI 10.1002/jlcr.2580360206; LUTHRA SK, 1985, J CHEM SOC CHEM COMM, P1423, DOI 10.1039/c39850001423; LUTHRA SK, 1994, APPL RADIAT ISOTOPES, V45, P857, DOI 10.1016/0969-8043(94)90217-8; Madar I, 1996, SYNAPSE, V24, P19, DOI 10.1002/(SICI)1098-2396(199609)24:1<19::AID-SYN3>3.0.CO;2-J; Mathews W. B., 1995, Journal of Labelled Compounds and Radiopharmaceuticals, V37, P404; Mathews WB, 1999, J LABELLED COMPD RAD, V42, P43, DOI 10.1002/(SICI)1099-1344(199901)42:1<43::AID-JLCR165>3.0.CO;2-2; MAZIERE M, 1981, J RADIOANAL CHEM, V62, P279, DOI 10.1007/BF02517357; MCLEAN S, 1987, NEUROPEPTIDES, V10, P235, DOI 10.1016/0143-4179(87)90073-4; MCPHERSON DW, 1986, J LABELLED COMPD RAD, V23, P505, DOI 10.1002/jlcr.2580230507; Nabulsi NB, 2011, NUCL MED BIOL, V38, P215, DOI 10.1016/j.nucmedbio.2010.08.014; NAGREN K, 1986, APPL RADIAT ISOTOPES, V37, P537; NAYLOR A, 1993, J MED CHEM, V36, P2075, DOI 10.1021/jm00067a004; NOBLE GD, 1992, J LABELLED COMPD RAD, V31, P81, DOI 10.1002/jlcr.2580310202; Ogawa M, 2003, NUCL MED BIOL, V30, P1, DOI 10.1016/S0969-8051(02)00387-6; Ogawa M, 2001, NUCL MED BIOL, V28, P941, DOI 10.1016/S0969-8051(01)00260-8; PERT CB, 1984, FEBS LETT, V177, P281, DOI 10.1016/0014-5793(84)81300-9; PERT CB, 1973, P NATL ACAD SCI USA, V70, P2243, DOI 10.1073/pnas.70.8.2243; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PERT CB, 1976, P NATL ACAD SCI USA, V73, P3729, DOI 10.1073/pnas.73.10.3729; Poisnel G, 2008, NUCL MED BIOL, V35, P561, DOI 10.1016/j.nucmedbio.2008.02.010; PORTOGHESE PS, 1990, J MED CHEM, V33, P1714, DOI 10.1021/jm00168a028; PORTOGHESE PS, 1988, EUR J PHARMACOL, V146, P185, DOI 10.1016/0014-2999(88)90502-X; RAVERT HT, 1995, J LABELLED COMPD RAD, V36, P365, DOI 10.1002/jlcr.2580360409; Ravert HT, 1999, NUCL MED BIOL, V26, P737, DOI 10.1016/S0969-8051(99)00043-8; Ravert HT, 2002, NUCL MED BIOL, V29, P47, DOI 10.1016/S0969-8051(01)00285-2; RIMLAND A, 1987, APPL RADIAT ISOTOPES, V38, P949; SADZOT B, 1991, J CEREBR BLOOD F MET, V11, P204, DOI 10.1038/jcbfm.1991.52; SAJI H, 1992, NUCL MED BIOL, V19, P455; Sajjad M., 1995, Journal of Labelled Compounds and Radiopharmaceuticals, V37, P401; SHIUE CY, 1991, NUCL MED BIOL, V18, P281; Studenov AR, 2003, J LABELLED COMPD RAD, V46, P837, DOI 10.1002/jlcr.722; Talbot PS, 2005, J NUCL MED, V46, P484; Tomasi G, 2010, J NUCL MED, V51; TURTON DR, 1987, J LABELLED COMPD RAD, V24, P1051, DOI 10.1002/jlcr.2580240906; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; Wadsak W, 2007, RADIOCHIM ACTA, V95, P33, DOI 10.1524/ract.2007.95.1.33; WAGNER HN, 1983, SCIENCE, V221, P1264, DOI 10.1126/science.6604315; Wester HJ, 2000, J NUCL MED, V41, P1279; Wilson AA, 2005, J LABELLED COMPD RAD, V48, pS142; Zaveri N, 2005, AAPS J, V7, DOI 10.1208/aapsj070234; ZHU YC, 1992, J LABELLED COMPD RAD, V31, P853, DOI 10.1002/jlcr.2580311103; Zoghbi SS, 2008, J NUCL MED, V49, P649, DOI 10.2967/jnumed.107.047308	79	9	9	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0362-4803	1099-1344		J LABELLED COMPD RAD	J. Label. Compd. Radiopharm.	MAR-APR	2013	56	3-4			SI		187	195		10.1002/jlcr.3005			9	Biochemical Research Methods; Chemistry, Medicinal; Chemistry, Analytical	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	133XN	WOS:000318174300016	24285325				2020-06-30	J	Gil, AG; Silvan, G; Martinez-Fernandez, L; Illera, JC				Gonzalez Gil, A.; Silvan, G.; Martinez-Fernandez, L.; Illera, J. C.			Effects of different fentanyl anaesthetic mixtures on cortico-adrenal function in rabbits	VETERINARY RECORD			English	Article							DIAZEPAM; XYLAZINE; REVERSAL; SURGERY; CATS		[Gonzalez Gil, A.; Silvan, G.; Martinez-Fernandez, L.; Illera, J. C.] Univ Complutense Madrid, Fac Vet, Dept Fisiol Anim, E-28040 Madrid, Spain	Gil, AG (reprint author), Univ Complutense Madrid, Fac Vet, Dept Fisiol Anim, Ciudad Univ S-N, E-28040 Madrid, Spain.	aggil@vet.ucm.es		GONZALEZ GIL, ALFREDO/0000-0002-5802-8028			Baumgartner C, 2011, LAB ANIM-UK, V45, P38, DOI 10.1258/la.2010.010091; Baumgartner C, 2010, CAN J VET RES, V74, P286; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Gil AG, 2001, VET REC, V148, P784, DOI 10.1136/vr.148.25.784; HALL GM, 1990, BRIT J ANAESTH, V65, P251, DOI 10.1093/bja/65.2.251; ILLERA JC, 1993, CHRONOBIOLOGIA, V20, P219; Kalman BA, 1997, PSYCHONEUROENDOCRINO, V22, P349, DOI 10.1016/S0306-4530(97)00026-7; Kanda T, 2008, CAN J VET RES, V72, P278; Kim MS, 2004, EXP ANIM TOKYO, V53, P423, DOI 10.1538/expanim.53.423; Wang Chen, 2004, Chinese Medical Sciences Journal, V19, P282; Zhao YN, 2012, BEHAV BRAIN RES, V228, P339, DOI 10.1016/j.bbr.2011.12.013	11	0	0	0	4	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND	0042-4900			VET REC	Vet. Rec.	FEB 23	2013	172	8					213	U52		10.1136/vr.101350			2	Veterinary Sciences	Veterinary Sciences	110RF	WOS:000316462300016	23362181				2020-06-30	J	Kang, H; Ha, YC; Kim, JY; Woo, YC; Lee, JS; Fang, EC				Kang, Hyun; Ha, Yong-Chan; Kim, Jin-Yun; Woo, Young-Cheol; Lee, Jae-Sung; Fang, Eui-Chan			Effectiveness of Multimodal Pain Management After Bipolar Hemiarthroplasty for Hip Fracture A Randomized, Controlled Study	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							LOCAL INFILTRATION ANALGESIA; TOTAL JOINT ARTHROPLASTY; POSTOPERATIVE PAIN; ELDERLY PATIENTS; HOSPITAL STAY; DELIRIUM; CONSUMPTION; DEMENTIA; KNEE; PUMP	Background: Appropriate pain management affects outcome after hip fracture surgery. Although multimodal pain management is commonly used for pain control for patients undergoing elective surgery, few studies have evaluated its use in those undergoing hip fracture surgery. This prospective randomized study was designed to determine the clinical value of multimodal pain management with preemptive pain medication and intraoperative periarticular multimodal drug injections in patients undergoing bipolar hip hemiarthroplasty. Methods: Of eighty-two cognitively intact elderly patients about to undergo bipolar hemiarthroplasty after a hip fracture, forty-three were randomly assigned to receive preemptive pain medication and intraoperative periarticular injections (Group I) and thirty-nine were assigned to not receive preemptive medication and injections (Group II). These two groups were compared with regard to the pain level on postoperative days one, four, and seven; at discharge; and when they started walking and standing exercises. Total amounts of fentanyl used, the frequency of use of patient-controlled analgesia, patient satisfaction at discharge, and perioperative complications were recorded. Results: Group I had a lower pain level than Group II on postoperative days one and four, but no intergroup difference in pain level was observed on postoperative day seven. The total amount of fentanyl used and the frequency of use of patient-controlled analgesia were also lower in Group I. Patient satisfaction at discharge was higher in Group I. No significant intergroup differences were found in the times until the patients walked or performed standing exercises or in the complications. Conclusions: Multimodal pain management provides additional pain relief until the fourth postoperative day, improves patient satisfaction at discharge, and reduces total narcotic consumption for postoperative pain management after hip hemiarthroplasty for hip fractures. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.	[Kang, Hyun] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 156755, South Korea; Chung Ang Univ, Coll Med, Dept Orthopaed Surg, Seoul 156755, South Korea	Kang, H (reprint author), Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 224-1 Heukseok Dong, Seoul 156755, South Korea.	hayongch@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880			Abou-Setta AM, 2011, ANN INTERN MED, V155, P234, DOI 10.7326/0003-4819-155-4-201108160-00346; Andersen KV, 2007, ACTA ORTHOP, V78, P180, DOI 10.1080/17453670710013654; Busch CA, 2010, CLIN ORTHOP RELAT R, V468, P2152, DOI 10.1007/s11999-009-1198-7; Busfield BT, 2009, ARTHROSCOPY, V25, P647, DOI 10.1016/j.arthro.2009.01.019; Dragoo JL, 2008, AM J SPORT MED, V36, P1484, DOI 10.1177/0363546508318190; Edlund A, 1999, DEMENT GERIATR COGN, V10, P325, DOI 10.1159/000017163; Feldt K S, 2000, Orthop Nurs, V19, P35, DOI 10.1097/00006416-200019060-00008; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; Gomoll AH, 2009, AM J SPORT MED, V37, P72, DOI 10.1177/0363546508323748; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; JITAPUNKUL S, 1992, Q J MED, V83, P307; Johanson NA, 2009, J AM ACAD ORTHOP SUR, V17, P183, DOI 10.5435/00124635-200903000-00007; Kehlet H, 2011, ACTA ANAESTH SCAND, V55, P778, DOI 10.1111/j.1399-6576.2011.02429.x; Kerr DR, 2008, ACTA ORTHOP, V79, P174, DOI 10.1080/17453670710014950; KOLBEINSSON H, 1993, ACTA PSYCHIAT SCAND, V87, P123, DOI 10.1111/j.1600-0447.1993.tb03342.x; Koval KJ, 1998, CLIN ORTHOP RELAT R, P37; LERESCHE L, 1988, J DENT RES, V67, P33, DOI 10.1177/00220345880670010601; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Morrison RS, 2000, J PAIN SYMPTOM MANAG, V19, P240, DOI 10.1016/S0885-3924(00)00113-5; Murphy TP, 2012, CLIN ORTHOP RELAT R, V470, P1151, DOI 10.1007/s11999-011-2108-3; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Parker MJ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000521.PUB2; Parvizi J, 2011, J BONE JOINT SURG AM, V93A, P1075, DOI 10.2106/JBJS.J.01095; Peters CL, 2006, J ARTHROPLASTY, V21, P132, DOI 10.1016/j.arth.2006.04.017; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Van Balen R, 2003, DISABIL REHABIL, V25, P507, DOI 10.1080/0963828031000090443	28	40	40	0	12	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	FEB 20	2013	95A	4					291	296		10.2106/JBJS.K.01708			6	Orthopedics; Surgery	Orthopedics; Surgery	AF7LR	WOS:000334897100002	23302898				2020-06-30	J	He, XY; Cao, JP; Shi, XY; Zhang, H				He, Xing-Ying; Cao, Jian-Ping; Shi, Xue-Yin; Zhang, Hao			Dexmedetomidine Versus Morphine or Fentanyl in the Management of Children After Tonsillectomy and Adenoidectomy: A Meta-analysis of Randomized Controlled Trials	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						dexmedetomidine; fentanyl; meta-analysis; morphine	OBSTRUCTIVE SLEEP-APNEA; EMERGENCE AGITATION; RECURRENT HYPOXEMIA; OPIOID REQUIREMENT; SEDATION; ANALGESIA; BEHAVIOR; CARE	Objectives: The primary objective of this review was to evaluate and compare the efficacy and safety of dexmedetomidine hydrochloride with the efficacy and safety of opioids for postoperative management of children after tonsillectomy and adenoidectomy. Methods: We searched the Cochrane Central Register of Controlled Trials (Central) in the Cochrane Library (most recent issue), Medline (1966 to date) through Ovid, Embase (1980 to date), and Web of Science (1945 to date). The number of patients who required rescue analgesics (morphine or fentanyl) in the postanesthesia care unit, the number of patients with emergence agitation, the number of patients with postoperative nausea and vomiting, the time to eye-opening in response to verbal stimuli, and the time to extubation were analyzed. Results: We included 5 trials, consisting of 482 patients in total. There were no significant differences in the number of patients who required rescue analgesics in the postanesthesia care unit, the number of patients with emergence agitation, the number of patients with postoperative nausea and vomiting, or the time to extubation between patients who received dexmedetomidine and those who received opioids. Compared with opioids, dexmedetomidine was associated with a significantly decreased time to eye-opening in response to verbal stimuli (mean difference, -2.11 minutes; 95% confidence interval, -3.32 to -0.91 minutes; p = 0.0006). Conclusions: Intraoperative use of dexmedetomidine was as effective as opioids in preventing postoperative pain and emergence agitation in children who had undergone tonsillectomy and adenoidectomy.	[He, Xing-Ying; Shi, Xue-Yin; Zhang, Hao] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai, Peoples R China; [Cao, Jian-Ping] PLA 455 Hosp, Dept Anesthesiol, Shanghai, Peoples R China	Shi, XY (reprint author), Changzheng Hosp, Dept Anesthesiol, Fengyang Rd 415, Shanghai 200003, Peoples R China.		Zhang, Hao/AAK-8111-2020		National Natural and Scientific Foundation of ChinaNational Natural Science Foundation of China [81100049]	This research was funded by the National Natural and Scientific Foundation of China (81100049).	Brown KA, 2004, ANESTHESIOLOGY, V100, P806, DOI 10.1097/00000542-200404000-00009; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Juni P, 2001, BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Lubisch N, 2009, PEDIATR NEUROL, V41, P88, DOI 10.1016/j.pediatrneurol.2009.02.006; Mason KP, 2008, PEDIATR ANESTH, V18, P393, DOI 10.1111/j.1460-9592.2008.02451.x; Moiniche S, 2003, ANESTH ANALG, V96, P68, DOI 10.1213/01.ANE.0000040583.65135.57; Olutoye O, 2007, PEDIATR ANESTH, V17, P1007, DOI 10.1111/j.1460-9592.2007.02234.x; Olutoye OA, 2010, ANESTH ANALG, V111, P490, DOI 10.1213/ANE.0b013e3181e33429; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Pestieau SR, 2011, CAN J ANESTH, V58, P540, DOI 10.1007/s12630-011-9493-7; Petroz GC, 2006, ANESTHESIOLOGY, V105, P1098, DOI 10.1097/00000542-200612000-00009; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Zhuang PJ, 2011, ANAESTHESIA, V66, P989, DOI 10.1111/j.1365-2044.2011.06817.x	22	10	11	1	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	FEB	2013	122	2					114	120		10.1177/000348941312200207			7	Otorhinolaryngology	Otorhinolaryngology	200TP	WOS:000323094100007	23534126				2020-06-30	J	Pecina, M; Stohler, CS; Zubieta, JK				Pecina, M.; Stohler, C. S.; Zubieta, J-K			Role of mu-opioid system in the formation of memory of placebo responses	MOLECULAR PSYCHIATRY			English	Letter							RATS		[Pecina, M.; Zubieta, J-K] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Stohler, C. S.] Univ Maryland, Sch Dent, Baltimore, MD 21201 USA; [Zubieta, J-K] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA; [Zubieta, J-K] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI USA	Pecina, M (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.	zubieta@umich.edu	STOHLER, CHRISTIAN/AAQ-7539-2020; Pecina, Marta/W-7135-2019		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA027494, R01 DA022520]		Adcock RA, 2006, NEURON, V50, P507, DOI 10.1016/j.neuron.2006.03.036; Alreja M, 2000, J NEUROSCI, V20, P1179, DOI 10.1523/JNEUROSCI.20-03-01179.2000; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; BOSTOCK E, 1988, BEHAV NEUROSCI, V102, P643, DOI 10.1037/0735-7044.102.5.643; Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398; de la Fuente-Fernandez Raul, 2009, Parkinsonism Relat Disord, V15 Suppl 3, pS72, DOI 10.1016/S1353-8020(09)70785-0; Liu MG, 2009, NEUROSCI BULL, V25, P237, DOI 10.1007/s12264-009-0905-4; RIGTER H, 1978, SCIENCE, V200, P83, DOI 10.1126/science.635578; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Simmons ML, 1996, INT REV NEUROBIOL, V39, P145, DOI 10.1016/S0074-7742(08)60666-2	10	11	11	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	FEB	2013	18	2					135	137		10.1038/mp.2012.16			4	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	112BW	WOS:000316567800003	22430673	Green Accepted, Bronze			2020-06-30	J	Mankes, RF; Silver, CD				Mankes, Russell F.; Silver, Charles D.			Quantitative study of controlled substance bedside wasting, disposal and evaluation of potential ecologic effects	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article						Controlled substances; Narcotics; Hazardous waste; Hospitals; Wastewater	PERSONAL CARE PRODUCTS; PHARMACEUTICALLY ACTIVE COMPOUNDS; ENVIRONMENTAL RISK-ASSESSMENT; PROMOTING HUMAN HEALTH; WATER TREATMENT PLANTS; TO-CRADLE STEWARDSHIP; URINARY-EXCRETION; PRIORITY PHARMACEUTICALS; HOSPITAL EFFLUENTS; HAZARD ASSESSMENT	Drugs in wastewater arise from many sources. For health care, these include excretion and direct disposal (bedside wasting). The present study reports on the dispensing and wasting of 15 controlled substances (CS) at two health care facilities in Albany, NY over a nearly two year period. The study considered measures of ecotoxicity, drug metabolism, excretion and disposal of these CS. Potential alternatives to flushing of CS into wastewaters from healthcare facilities are discussed. Drug medication and waste collection records (12,345) included: numbers of drugs dispensed, returned and wasted. Overall, 8528 g of 15 CS were wasted. Three (midazolam, acetaminophen-codeine and fentanyl) accounted for 87.5% of the total wasted. Wasting varied by hospital, 14 CS at the academic medical center hospital and 8 at the surgical care center were wasted. Liquids were more frequently wasted than tablets or pills. Some combination drugs (acetaminophen (APAP)-codeine) were frequently (50% of drug dispensed) wasted while others were less wasted (APAP-hydrocodone-6.3%; APAP-oxycodone-1.3%). The 8 CS judged more hazardous to aquatic life were: APAP-codeine, APAP-hydrocodone, APAP-oxycodone, alprazolam, diazepam, fentanyl, midazolam, and testosterone. Ketamine, morphine, oxycodone and zolpidem were of lesser acute toxicity based on available LC50 values. These CS might provide a therapeutically equivalent alternative to the more environmentally harmful drugs. In health care facilities, professionals dispose of CS by bedside wasting into water or other receptacles. This can be avoided by returning CS to the hospital's pharmacy department, thence to a licensed distributor. Study of this process of drug wasting can identify opportunities for process improvements. We found 3 CS (APAP-codeine, midazolam and testosterone) where 1/2 to 1/3 of the drug was wasted and 5 others with 30 to 13% wasted. Knowledge of the adverse impacts from the release of highly toxic drugs into the environment might influence CS selection and disposal alternatives. (c) 2012 Elsevier B.V. All rights reserved.	[Mankes, Russell F.] Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; [Mankes, Russell F.] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; [Silver, Charles D.] Environm Protect Bur, New York State Off Attorney Gen, Albany, NY 12224 USA	Mankes, RF (reprint author), 141 Mohawk Dr, Schenectady, NY 12303 USA.	RMankes@NYCAP.RR.COM			US EPAUnited States Environmental Protection Agency [X9-97256506-0]	The technical assistance of Laurie DeWeerdt, BS and Peter Gorman, BS and the assistance of Union College interns Lindsey Walaski and Kelsey Powers in review of the literature is gratefully acknowledged. Supported in part by a US EPA grant X9-97256506-0 to RF Mankes.	Aiello SE, 2012, MERCK VET MANUAL; Aley KO, 1997, J NEUROSCI, V17, P3907; Ankley GT, 2007, ENVIRON TOXICOL CHEM, V26, P1214, DOI 10.1897/06-428R.1; [Anonymous], 2009, Can J Hosp Pharm, V62, P516; [Anonymous], 2005, FED REGISTER, V70, P25462; Armstrong SC, 2003, PSYCHOSOMATICS, V44, P515, DOI 10.1176/appi.psy.44.6.515; ASCALONE V, 1992, J CHROMATOGR-BIOMED, V581, P237, DOI 10.1016/0378-4347(92)80277-W; Ashton D, 2004, SCI TOTAL ENVIRON, V333, P167, DOI 10.1016/j.scitotenv.2004.04.062; Baldacci A, 2006, ELECTROPHORESIS, V27, P2444, DOI 10.1002/elps.200500867; Barakat NH, 2012, J ANAL TOXICOL, V36, P257, DOI 10.1093/jat/bks019; Barnes KK, 2008, SCI TOTAL ENVIRON, V402, P192, DOI 10.1016/j.scitotenv.2008.04.028; Becker Julie, 2010, Nurs Adm Q, V34, P297, DOI 10.1097/NAQ.0b013e3181f5640a; Besse JP, 2012, ENVIRON INT, V39, P73, DOI 10.1016/j.envint.2011.10.002; Boxall ABA, 2003, REV ENVIRON CONTAM T, V180, P2; Boxall ABA, 2012, ENVIRON HEALTH PERSP, V120, P1221, DOI 10.1289/ehp.1104477; Brain RA, 2004, AQUAT TOXICOL, V70, P23, DOI 10.1016/j.aquatox.2004.06.011; Brown KD, 2006, SCI TOTAL ENVIRON, V366, P772, DOI 10.1016/j.scitotenv.2005.10.007; Bruce GM, 2010, ENVIRON SCI TECHNOL, V44, P5619, DOI 10.1021/es1004895; Bruchet A, 2005, WATER SCI TECHNOL, V52, P53; Brun GL, 2006, ENVIRON TOXICOL CHEM, V25, P2163, DOI 10.1897/05-426R.1; Bunch AR, 2011, ECOTOXICOLOGY, V20, P97, DOI 10.1007/s10646-010-0560-6; Butterfield S, 2009, DUMPING DRUGS PUT TR; Cavenati S, 2012, WATER SCI TECHNOL, V66, P603, DOI 10.2166/wst.2012.218; Cleuvers M, 2003, TOXICOL LETT, V142, P185, DOI 10.1016/S0378-4274(03)00068-7; CONE EJ, 1977, J PHARM SCI, V66, P1709, DOI 10.1002/jps.2600661213; Crane M, 2006, SCI TOTAL ENVIRON, V367, P23, DOI 10.1016/j.scitotenv.2006.04.010; Daneshvar A, 2012, CHEMOSPHERE, V88, P131, DOI 10.1016/j.chemosphere.2012.03.016; Daughton CG, 2003, ENVIRON HEALTH PERSP, V111, P757, DOI 10.1289/ehp.5947; Daughton CG, 2003, ENVIRON HEALTH PERSP, V111, P775, DOI 10.1289/ehp.5948; Daughton CG, 2009, ENVIRON TOXICOL CHEM, V28, P12; DePriest A, 2010, J ANAL TOXICOL, V34, P444, DOI 10.1093/jat/34.8.444; Dixit V, 2007, DRUG METAB DISPOS, V35, P1853, DOI 10.1124/dmd.107.016089; Dorfman RI, 1939, J CLIN INVEST, V18, P67, DOI 10.1172/JCI101027; Escher BI, 2011, WATER RES, V45, P75, DOI 10.1016/j.watres.2010.08.019; Esteban S, 2012, GAC SANIT, V26, P457, DOI 10.1016/j.gaceta.2012.01.018; Fasola G, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-70; Fent K, 2006, AQUAT TOXICOL, V76, P122, DOI 10.1016/j.aquatox.2005.09.009; Fernandez C, 2012, APPL TOXICOL    0621; Ferrari F, 2011, J TOXICOL, DOI 10.1155/2011/989270; Ferrer I, 2010, J CHROMATOGR A, V1217, P5674, DOI 10.1016/j.chroma.2010.07.002; Flaherty CM, 2005, CHEMOSPHERE, V61, P200, DOI 10.1016/j.chemosphere.2005.02.016; Fram MS, 2011, SCI TOTAL ENVIRON, V409, P3409, DOI 10.1016/j.scitotenv.2011.05.053; Giglio J, 2001, LETT NURSING HOMES R; Giglio J, 2001, LETT HOSP CLASS 3 FA; Glassmeyer ST, 2009, ENVIRON INT, V35, P566, DOI 10.1016/j.envint.2008.10.007; Grung M, 2008, ECOTOX ENVIRON SAFE, V71, P328, DOI 10.1016/j.ecoenv.2007.10.015; Hall W, 2012, ADDICTION, V107, P1767, DOI 10.1111/j.1360-0443.2012.03887.x; Hedgespeth ML, 2012, SCI TOTAL ENVIRON, V437, P1, DOI 10.1016/j.scitotenv.2012.07.076; Herring ME, 2008, J AM OSTEOPATH ASSOC, V108, P338; Hope Bruce K., 2010, Integrated Environmental Assessment and Management, V6, P735, DOI 10.1002/ieam.94; Houlihan KPG, 1999, J ACCID EMERG MED, V16, P29; Huggett DB, 2002, ARCH ENVIRON CON TOX, V43, P229, DOI 10.1007/s00244-002-1182-7; Hyland R, 2009, BRIT J CLIN PHARMACO, V67, P445, DOI 10.1111/j.1365-2125.2009.03386.x; Jean J, 2012, J ENVIRON MANAGE, V103, P113, DOI 10.1016/j.jenvman.2012.03.005; Jelic A, 2012, EMERGING PRIORITY PU; Johnson K, 2004, DELMARS FUNDAMENTAL; Jones OAH, 2002, WATER RES, V36, P5013, DOI 10.1016/S0043-1354(02)00227-0; Kaplan HL, 1997, J PHARMACOL EXP THER, V281, P103; Kar S, 2010, CHEMOSPHERE, V81, P738, DOI 10.1016/j.chemosphere.2010.07.019; Khandelwal N, 2011, AM J MANAG CARE, V17, pE169; Kidd KA, 2007, P NATL ACAD SCI USA, V104, P8897, DOI 10.1073/pnas.0609568104; Kim Y, 2007, ENVIRON INT, V33, P370, DOI 10.1016/j.envint.2006.11.017; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Kostich MS, 2008, SCI TOTAL ENVIRON, V389, P329, DOI 10.1016/j.scitotenv.2007.09.008; Kummerer K, 2001, CHEMOSPHERE, V45, P957, DOI 10.1016/S0045-6535(01)00144-8; Lacey C, 2012, ENVIRON MONIT ASSESS, V184, P1049, DOI 10.1007/s10661-011-2020-z; Lai FY, 2011, WATER RES, V45, P4437, DOI 10.1016/j.watres.2011.05.042; Langford KH, 2009, ENVIRON INT, V35, P766, DOI 10.1016/j.envint.2009.02.007; Le Corre KS, 2012, ENVIRON INT, V45, P99, DOI 10.1016/j.envint.2012.03.008; Leonhart M, 2012, PHARM MANUAL INFORM; Lewis JH, 2007, J ANAL TOXICOL, V31, P195, DOI 10.1093/jat/31.4.195; Li AC, 2012, XENOBIOTICA; Lienert J, 2011, ENVIRON SCI TECHNOL, V45, P3848, DOI 10.1021/es1031294; Lin AYC, 2010, CHEMOSPHERE, V81, P562, DOI 10.1016/j.chemosphere.2010.08.051; LO MW, 1987, J CLIN PHARMACOL, V27, P866, DOI 10.1002/j.1552-4604.1987.tb05581.x; Lorenzini KI, 2012, BASIC CLIN PHARMACOL, V110, P219, DOI 10.1111/j.1742-7843.2011.00814.x; Madadi P, 2010, PEDIATRICS, V126, pE986, DOI 10.1542/peds.2009-1907; Madden JC, 2009, TOXICOL LETT, V185, P85, DOI 10.1016/j.toxlet.2008.12.005; Mankes RF, 2012, ANESTH ANALG, V114, P1091, DOI 10.1213/ANE.0b013e31824ea491; Moldovan Z, 2009, ENVIRON SCI POLLUT R, V16, P46, DOI 10.1007/s11356-008-0047-7; Nava-Ocampo AA, 2004, FUND CLIN PHARMACOL, V18, P107, DOI 10.1046/j.0767-3981.2003.00214.x; OECD, 2012, EC CAT RES CAN DOM S; ONDCP Office of National Drug Control Policy, PROP DISP PRESCR DRU; Ort C, 2010, WATER RES, V44, P605, DOI 10.1016/j.watres.2009.08.002; Page Alfred N., 1971, TRANSLATION MANUALE; Pal R., 2012, SCI TOTAL ENV; Parrott JL, 2009, J TOXICOL ENV HEAL A, V72, P633, DOI 10.1080/15287390902769428; Phillips PJ, 2010, ENVIRON SCI TECHNOL, V44, P4910, DOI 10.1021/es100356f; Postigo C, 2010, ENVIRON INT, V36, P75, DOI 10.1016/j.envint.2009.10.004; Quinn B, 2008, SCI TOTAL ENVIRON, V389, P306, DOI 10.1016/j.scitotenv.2007.08.038; Radjenovic J, 2007, ANAL BIOANAL CHEM, V387, P1365, DOI 10.1007/s00216-006-0883-6; Ramirez J, 2004, DRUG METAB DISPOS, V32, P930; Rannazzisi JT, 2006, PRACTITIONERS MANUAL; Reidy L, 2011, J ANAL TOXICOL, V35, P294, DOI 10.1093/anatox/35.5.294; Richards SM, 2006, ECOTOXICOLOGY, V15, P647, DOI 10.1007/s10646-006-0102-4; Robbins Julie, 2012, Qual Manag Health Care, V21, P188, DOI 10.1097/QMH.0b013e31825e88f6; Rodriguez-Mozaz S, 2010, ENVIRON HEALTH PERSP, V118, P1016, DOI 10.1289/ehp.0901532; Boleda MR, 2009, WATER RES, V43, P1126, DOI 10.1016/j.watres.2008.11.056; Roy K, 2009, WASTAGE SUPPLIES DRU; Ruhoy IS, 2007, SCI TOTAL ENVIRON, V388, P137, DOI 10.1016/j.scitotenv.2007.08.013; Sailaukhanuly Y, 2013, CHEMOSPHERE, V90, P112, DOI 10.1016/j.chemosphere.2012.08.015; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Sanchez W, 2011, ENVIRON INT, V37, P1342, DOI 10.1016/j.envint.2011.06.002; Sanderson H, 2003, TOXICOL LETT, V144, P383, DOI 10.1016/S0378-4274(03)00257-1; Santos JL, 2009, J HAZARD MATER, V164, P1509, DOI 10.1016/j.jhazmat.2008.09.073; Sellin MK, 2009, AQUAT TOXICOL, V92, P221, DOI 10.1016/j.aquatox.2009.02.004; Sellin MK, 2009, ENVIRON TOXICOL CHEM, V28, P2443, DOI 10.1897/09-135.1; Seo KA, 2010, DRUG METAB DISPOS, V38, P2007, DOI 10.1124/dmd.110.035295; Sim WJ, 2011, CHEMOSPHERE, V82, P179, DOI 10.1016/j.chemosphere.2010.10.026; SMITH ML, 1995, J ANAL TOXICOL, V19, P18, DOI 10.1093/jat/19.1.18; Smolen A, 2011, US PHARM, V36, P52; Soliman MA, 2007, WATER ENVIRON RES, V79, P156, DOI 10.2175/106143006X111961; Stackelberg PE, 2007, SCI TOTAL ENVIRON, V377, P255, DOI 10.1016/j.scitotenv.2007.01.095; Stackelberg PE, 2004, SCI TOTAL ENVIRON, V329, P99, DOI 10.1016/j.scitotenv.2004.03.015; STAMBAUGH JE, 1976, J CLIN PHARMACOL, V16, P245, DOI 10.1002/j.1552-4604.1976.tb02401.x; Stonemetz Jerry, 2011, Anesthesiol Clin, V29, P145, DOI 10.1016/j.anclin.2010.11.007; Stoner S, 2009, CONSERVATIONIST, P14; Straub JO, 2002, TOXICOL LETT, V135, P229, DOI 10.1016/S0378-4274(02)00209-6; Straub JO, 2012, ENVIRON TOXICOL CHEM, V31, P681, DOI 10.1002/etc.1733; Strempel S, 2012, ENVIRON SCI TECHNOL, V46, P5680, DOI 10.1021/es3002713; Stuer-Lauridsen F, 2000, CHEMOSPHERE, V40, P783, DOI 10.1016/S0045-6535(99)00453-1; Subedi B, 2012, ENVIRON SCI TECHNOL, V46, P9047, DOI 10.1021/es301359t; Tamtam F, 2008, SCI TOTAL ENVIRON, V393, P84, DOI 10.1016/j.scitotenv.2007.12.009; Terzic S, 2010, ENVIRON POLLUT, V158, P2686, DOI 10.1016/j.envpol.2010.04.020; Thomaidis NS, 2012, GLOBAL NEST J, V14, P72; Toxnet: Hazardous Substances Data Bank (HSDB), DAT NAT LIB MED TOXN; US Food and Drug Administration, DISP UN MED WHAT YOU; US Office of National Drug Control Policy, 2007, PROP DISP PRESCR DRU; Valtier S, 2012, J ANAL TOXICOL, V36, P507, DOI 10.1093/jat/bks058; Verlicchi P, 2012, SCI TOTAL ENVIRON, V429, P123, DOI 10.1016/j.scitotenv.2012.04.028; von der Ohe PC, 2011, SCI TOTAL ENVIRON, V409, P2064, DOI 10.1016/j.scitotenv.2011.01.054; Weinger MB, 2001, J CLIN ANESTH, V13, P491, DOI 10.1016/S0952-8180(01)00317-8; Winker M, 2008, SCI TOTAL ENVIRON, V399, P96, DOI 10.1016/j.scitotenv.2008.03.027; Yeh BT, 2010, C RES SERV      1019; YOO YC, 1995, J ANAL TOXICOL, V19, P120, DOI 10.1093/jat/19.2.120; Zarfl C, 2012, ENVIRON SCI POLLUT R, V19, P3152, DOI 10.1007/s11356-012-1046-2; Zuccato E, 2008, ENVIRON HEALTH PERSP, V116, P1027, DOI 10.1289/ehp.11022	137	11	11	2	84	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697	1879-1026		SCI TOTAL ENVIRON	Sci. Total Environ.	FEB 1	2013	444						298	310		10.1016/j.scitotenv.2012.11.096			13	Environmental Sciences	Environmental Sciences & Ecology	107SD	WOS:000316240200032	23274246				2020-06-30	J	Lai, HC; Hu, MH; Liaw, WJ; Lu, CH; Huang, GS				Lai, Hou-Chuan; Hu, Mei-Hua; Liaw, Wen-Jinn; Lu, Chueng-He; Huang, Go-Shine			Atypical involuntary movements following fentanyl anesthesia	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Anesthesia; Complications; Fentanyl; Involuntary movements	DYSTONIC REACTION; GENERAL-ANESTHESIA; DISORDERS; PROPOFOL; INFANT	Postanesthetic involuntary movements are triggered by a variety of drugs, including propofol, sevoflurane, anti-emetics, and anti-psychotics. A case of acute involuntary movements in a healthy man after fentanyl exposure is presented. The movements consisted of large-amplitude motions of the upper limbs of the elbow joint for flexion and extension, and shaking of the head from side to side. (c) 2013 Elsevier Inc. All rights reserved.	[Lai, Hou-Chuan; Liaw, Wen-Jinn; Lu, Chueng-He; Huang, Go-Shine] Natl Def Med Ctr, Triserv Gen Hosp, Dept Anesthesiol, Taipei 114, Taiwan; [Hu, Mei-Hua] Chang Gung Univ, Coll Med, Chang Gung Childrens Hosp, Div Gen Pediat, Tao Yuan 333, Taiwan	Huang, GS (reprint author), Triserv Gen Hosp, Dept Anesthesiol, 325,Sec 2,Chenggung Rd, Taipei 114, Taiwan.	goshine@seed.net.tw					Bragonier R, 2000, BRIT J ANAESTH, V84, P828; Harris MK, 2009, MED CLIN N AM, V93, P371, DOI 10.1016/j.mcna.2008.09.002; Iselin-Chaves IA, 2009, ANAESTHESIA, V64, P1359, DOI 10.1111/j.1365-2044.2009.06068.x; Jankovic J, 2009, LANCET NEUROL, V8, P844, DOI 10.1016/S1474-4422(09)70183-8; Kawana S, 2007, PEDIATR ANESTH, V17, P901, DOI 10.1111/j.1460-9592.2007.02250.x; Martinez L P, 1997, AANA J, V65, P150; Michailidou M, 2004, ANAESTHESIA, V59, P413, DOI 10.1111/j.1365-2044.2004.03730.x; Saneto RP, 1996, PEDIATR NEUROL, V14, P339, DOI 10.1016/0887-8994(96)00062-8; Schramm BM, 2002, ANESTH ANALG, V94, P1237, DOI 10.1097/00000539-200205000-00034; Sinclair RCF, 2004, ANAESTHESIA, V59, P727, DOI 10.1111/j.1365-2044.2004.03855.x; STEMP LI, 1991, ANESTHESIOLOGY, V75, P365, DOI 10.1097/00000542-199108000-00029; Zesiewicz TA, 2009, CLIN NEUROPHARMACOL, V32, P48, DOI 10.1097/WNF.0b013e31817e23e3	12	2	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	FEB	2013	25	1					58	61		10.1016/j.jclinane.2012.06.007			4	Anesthesiology	Anesthesiology	091RM	WOS:000315067500013	23246981				2020-06-30	J	Aissaoui, Y; Serghini, I; Qamous, Y; Seddiki, R; Zoubir, M; Boughalem, M				Aissaoui, Younes; Serghini, Issam; Qamous, Youssef; Seddiki, Rachid; Zoubir, Mohammed; Boughalem, Mohammed			The parasacral sciatic nerve block does not induce anesthesia of the obturator nerve	JOURNAL OF ANESTHESIA			English	Article						Lower extremity nerve blocks; Regional anesthesia; Parasacral sciatic nerve block; Obturator nerve block; Knee surgery	TOTAL KNEE REPLACEMENT; POSTOPERATIVE ANALGESIA; SINGLE-INJECTION; REHABILITATION	The ability of the parasacral sciatic nerve block (PSNB) to induce anesthesia of the obturator nerve remains controversial. Our objective was to evaluate the anesthesia of the obturator nerve after a PSNB. Forty patients scheduled to undergo knee surgery (anterior cruciate ligament reconstruction) were included in this prospective, randomized, controlled study. Patients were randomized to receive PSNB alone (control group, n = 20) or PSNB in combination with an obturator nerve block (obturator group, n = 20). After evaluation for 30 min, the two groups received a femoral nerve block, and patients were taken to surgery. The obturator nerve blockade was assessed by measurement of adductor strength at baseline (T0) and every 10 min during the 30-min evaluation (T10, T20, and T30). Pain scores after tourniquet inflation and during surgery were compared between the two groups. The requirement for additional intravenous analgesia and/or sedation was also recorded. The two groups had comparable demographic and surgical characteristics. Four patients were excluded from the study because of PSNB or femoral nerve block failure. The adductor strength values were similar between groups at T0 but were significantly lower in the obturator group at T10, T20, and T30 (p < 0.0001). Patients in the obturator group reported less pain than those in the control group (p < 0.05). They also required less additional intravenous sedation and/or analgesia (p < 0.05). This clinical study demonstrated that the PSNB is an unreliable means of inducing anesthesia of the obturator nerve and emphasizes the need to block this nerve separately to induce adequate analgesia during knee surgery.	[Aissaoui, Younes; Serghini, Issam; Qamous, Youssef; Seddiki, Rachid; Zoubir, Mohammed; Boughalem, Mohammed] Cadi Ayyad Univ, Dept Anesthesiol, Avicenna Mil Hosp, Fac Med, Marrakech 40000, Morocco	Aissaoui, Y (reprint author), Cadi Ayyad Univ, Dept Anesthesiol, Avicenna Mil Hosp, Fac Med, Marrakech 40000, Morocco.	younes.aissaoui@live.fr					Akkaya T, 2009, ANESTH ANALG, V108, P1037, DOI 10.1213/ane.0b013e3181966f03; Albrect A, 1996, REGIONAL ANESTHESIA, P548; Bouaziz H, 2002, ANESTH ANALG, V94, P445, DOI 10.1097/00000539-200202000-00041; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Choquet O, 2005, ANESTHESIOLOGY, V103, P1238, DOI 10.1097/00000542-200512010-00020; Cuvillon P, 2003, ANESTHESIOLOGY, V98, P1436, DOI 10.1097/00000542-200306000-00021; Enneking FK, 2005, REGION ANESTH PAIN M, V30, P4, DOI 10.1016/j.rapm.2004.10.002; Hagon BS, 2007, ANESTH ANALG, V105, P263, DOI 10.1213/01.ane.0000266437.41544.b3; Jochum D, 2005, ANAESTHESIA, V60, P974, DOI 10.1111/j.1365-2044.2005.04329.x; Jochum D, 2004, ANESTH ANALG, V99, P1544, DOI 10.1213/01.ANE.0000136464.86801.EE; LANG SA, 1993, J CLIN ANESTH, V5, P292, DOI 10.1016/0952-8180(93)90121-T; Macalou D, 2004, ANESTH ANALG, V99, P251, DOI 10.1213/01.ANE.0000121350.09915.84; MANSOUR NY, 1993, REGION ANESTH, V18, P322; McNamee DA, 2002, ACTA ANAESTH SCAND, V46, P95, DOI 10.1034/j.1399-6576.2002.460117.x; Morris GF, 1997, REGION ANESTH, V22, P223, DOI 10.1016/S1098-7339(06)80005-2; Ripart J, 2005, REGION ANESTH PAIN M, V30, P193, DOI 10.1016/j.rapm.2004.08.026; Sakura S, 2010, J ANESTH, V24, P411, DOI 10.1007/s00540-010-0916-3; Soong J, 2007, REGION ANESTH PAIN M, V32, P146, DOI 10.1016/j.rapm.2006.10.012; Muniz MT, 2008, ANESTH ANALG, V107, P2085, DOI 10.1213/ane.0b013e318186641d; Tran DQH, 2007, CAN J ANAESTH, V54, P922, DOI 10.1007/BF03026798; Valade N, 2008, ANESTH ANALG, V106, P664, DOI 10.1213/ane.0b013e3181607205; Von Lanz T, 1938, PRAKTISCHE ANATOMIE, P45; Wang H, 2002, REGION ANESTH PAIN M, V27, P139, DOI 10.1053/rapm.2002.29253; WINNIE AP, 1973, ANESTH ANALG, V52, P989	24	3	6	1	2	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2013	27	1					66	71		10.1007/s00540-012-1463-x			6	Anesthesiology	Anesthesiology	091IG	WOS:000315042200012	22868407				2020-06-30	J	Scharnagel, R; Kaiser, U; Schutze, A; Heineck, R; Gossrau, G; Sabatowski, R				Scharnagel, R.; Kaiser, U.; Schuetze, A.; Heineck, R.; Gossrau, G.; Sabatowski, R.			Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency	SCHMERZ			German	Review						Fentanyl; Oxycodone; Tilidine; Prescription drug misuse; Opioid dependency	CHRONIC NONCANCER PAIN; FENTANYL BUCCAL TABLET; DRUG-RELATED BEHAVIORS; BREAKTHROUGH PAIN; TOLERANT PATIENTS; AMERICAN ACADEMY; NEUROPATHIC PAIN; NONMEDICAL USE; UNITED-STATES; DOUBLE-BLIND	Annually published data show a continual increase in the volume of opioid prescriptions in Germany, thus indicating an intensification of opioid therapy. The majority of opioids are prescribed to treat chronic non-cancer-related pain. On the basis of current guidelines, as well as in terms of the lack of data regarding long-term use of opioids and their effectiveness beyond a period of 3 months, this development must be viewed critically. With reference to four case reports, we discuss and evaluate opioid therapy in relation to medication misuse and the development of drug dependency. Particular emphasis is placed on the administration of rapid-release and short-acting opioid preparations, which we consider to be particularly problematic. A full-text English version of the article is available. The English full-text version of this article is available at SpringerLink (under"Supplemental").	[Scharnagel, R.; Kaiser, U.; Schuetze, A.; Heineck, R.; Gossrau, G.; Sabatowski, R.] Univ Klinikum Carl Gustav Carus, Univ SchmerzCtr, D-01307 Dresden, Germany; [Scharnagel, R.; Heineck, R.; Sabatowski, R.] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Anesthesiol & Intensivtherapie, D-01307 Dresden, Germany	Scharnagel, R (reprint author), Univ Klinikum Carl Gustav Carus, Univ SchmerzCtr, Fetscherstr 74, D-01307 Dresden, Germany.	ruediger.scharnagel@uniklinikum-dresden.de	Sabatowski, Rainer/K-3475-2019	Sabatowski, Rainer/0000-0003-2228-3147			Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), 2010, MED SED HYPN AN PSYC; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), 2012, LANGZ OP BEI NICHT T; Arzneimittelkommission der deutschen Arzteschaft, 2012, ABH PREG LYR AUS UAW; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Ballantyne JC, 2007, PAIN, V129, P235, DOI 10.1016/j.pain.2007.03.028; Bell J, 2010, ADDICTION, V105, P1531, DOI 10.1111/j.1360-0443.2010.03014.x; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bradshaw DH, 2008, J PAIN, V9, P1077, DOI 10.1016/j.jpain.2008.09.008; Bundesarztekammer in Zusammenarbeit mit der Arzneimittelkommission der deutschen Arzteschaft, MED SCHADL GEBR ABH; Bundesinstitut fur Arzneimittel und Medizinprodukte, 2012, SACHV BET; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Caraceni A, 2011, PALLIATIVE MED, V25, P402, DOI 10.1177/0269216310392102; Chapman CR, 2010, J PAIN, V11, P807, DOI 10.1016/j.jpain.2010.02.019; Chou R, 2003, J PAIN SYMPTOM MANAG, V26, P1026, DOI 10.1016/j.jpainsymman.2003.03.003; Chou R, 2010, CAN MED ASSOC J, V182, P881, DOI 10.1503/cmaj.100548; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Cicero TJ, 2008, PAIN, V139, P127, DOI 10.1016/j.pain.2008.03.021; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deutsche Hauptstelle fur Suchtfragen e. V, 2012, JB SUCHT 2012; Dhalla IA, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5142; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Dilling H, 2008, TASCHENFUHRER ICD 10; DIMDI, 2012, ICD 10 GM 2012 SYST; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2007, PAIN MED, V8, P647, DOI 10.1111/j.1526-4637.2006.00200.x; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Fine PG, 2009, PAIN MED, V10, pS79, DOI 10.1111/j.1526-4637.2009.00666.x; Fishbain DA, 2008, PAIN MED, V9, P444, DOI 10.1111/j.1526-4637.2007.00370.x; Fleming MF, 2007, J PAIN, V8, P573, DOI 10.1016/j.jpain.2007.02.432; Furlan AD, 2010, CAN MED ASSOC J, V182, P923, DOI 10.1503/cmaj.100187; Gilson AM, 2009, PAIN MED, V10, pS89, DOI 10.1111/j.1526-4637.2009.00668.x; Gomes Tara, 2011, Open Med, V5, pe13; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Ives TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-46; Jage J, 2005, EUR J PAIN, V9, P157, DOI 10.1016/j.ejpain.2004.11.009; Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007; Maier C, 2008, SCHMERZ, V22, P639, DOI 10.1007/s00482-008-0716-y; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P57; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401; Markman JD, 2008, PAIN, V136, P227, DOI 10.1016/j.pain.2008.03.011; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; McLellan AT, 2010, ANN INTERN MED, V152, P123, DOI 10.7326/0003-4819-152-2-201001190-00012; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Michna E, 2004, J PAIN SYMPTOM MANAG, V28, P250, DOI 10.1016/j.jpainsymman.2004.04.007; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Pabst A., 2010, SUCHT, V56, P327, DOI DOI 10.1024/0939-5911/A000044; Passik Steven D, 2006, J Pain Palliat Care Pharmacother, V20, P5; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9; Porada Stephen, 2011, J Fam Pract, V60, pS55; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Reinecke H, 2009, SCHMERZ, V23, P440, DOI 10.1007/s00482-009-0839-9; Roset PN, 2001, DRUG ALCOHOL DEPEN, V64, P285, DOI 10.1016/S0376-8716(01)00127-2; Sabatowski R, 2012, PAIN MANAG, V2, P201, DOI [10.2217/PMT.12.17, 10.2217/pmt.12.17]; Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007; Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7; Schubert I, 2012, DTSCH ARZTE IN PRESS; Schwabe U, 2011, ARZNEIVERORDNUNGSREP; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Soyka M, 2005, NERVENARZT, V76, P72, DOI 10.1007/s00115-004-1828-y; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; Sullivan MD, 2012, ARCH INTERN MED, V172, P433, DOI 10.1001/archinternmed.2011.2156; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401; Webster Lynn R, 2011, J Opioid Manag, V7, P297; Weisner CM, 2009, PAIN, V145, P287, DOI 10.1016/j.pain.2009.05.006; Zeppetella G, 2011, PALLIATIVE MED, V25, P516, DOI 10.1177/0269216310385601	77	10	11	1	19	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-433X	1432-2129		SCHMERZ	Schmerz	FEB	2013	27	1					7	19		10.1007/s00482-012-1278-6			13	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	091FQ	WOS:000315035200002	23340881				2020-06-30	J	Wirz, S; Wiese, CHR; Zimmermann, M; Junker, U; Heuser-Grannemann, E; Schenk, M				Wirz, S.; Wiese, C. H. R.; Zimmermann, M.; Junker, U.; Heuser-Grannemann, E.; Schenk, M.			Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society	SCHMERZ			German	Article						Breakthrough pain; Pain management; Opioid dependence; Fentanyl; Analgesics, short-acting	BREAKTHROUGH CANCER PAIN; DOUBLE-BLIND; OPEN-LABEL; MU-G; PREVALENCE; SPRAY; CROSSOVER; CITRATE; DEFINITION; MANAGEMENT	The spectrum of indications for rapid release fentanyl preparations is controversial. For this reason the Working Group on Tumor Pain will formulate comments on how to deal with these substances. Breakthrough pain should receive individualized therapy; therefore, the use of opioids of various galenic formulations seems to be advisable. New rapid release fentanyl preparations are suitable for alleviating spontaneous breakthrough pain in tumor patients due to a rapid but short-acting effect. However, a prior optimization of the analgesic basis medication is absolutely necessary. Uncontrolled prescription for non-cancer pain must be criticized due to the problem of addiction. The medical profession should be informed about the benefits of rapid release fentanyl preparations but must also be made aware of the risk of a rapid development of addiction and tolerance. A self-commitment of the pharmaceutical industry to waive advertising for the dangerous off-label use would be desirable. In the opinion of the Working Group on Tumor Pain the use of fentanyl should be openly discussed and further scientific investigations are imperative with the aim of formulating clear recommendations.	[Wirz, S.] CURA Kath Krankenhaus Siebengebirge, Abt Anasthesie, D-53604 Bad Honnef, Germany; [Wiese, C. H. R.] Univ Klinikum Regensburg, Klin Anasthesiol, Regensburg, Germany; [Zimmermann, M.] Univ Frankfurt Klinikum, Klin Anasthesiol, Frankfurt, Germany; [Schenk, M.] Gemeinschaftskrankenhaus Havelhohe, Abt Anasthesiol Palliativmed & Schmerztherapie, Berlin, Germany	Wirz, S (reprint author), CURA Kath Krankenhaus Siebengebirge, Abt Anasthesie, Schulgenstr 15, D-53604 Bad Honnef, Germany.	stefan.wirz@cura.org					[Anonymous], 2010, SCHMERZNACHRICHTEN, P1; Bertram L, 2010, SCHMERZ, V24, P605, DOI 10.1007/s00482-010-0989-9; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Cain DM, 2001, PAIN MED, V2, P15, DOI 10.1046/j.1526-4637.2001.002001015.x; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; DAVIES A, 2006, [No title captured]; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Gorman E, 2006, J ADDICT DIS, V25, P139, DOI 10.1300/J069v25n04_16; IMS Health GmbH & Co. OHG, IMS DPM; Kessler J, 2011, ANAESTHESIST, V60, P674, DOI 10.1007/s00101-011-1868-1; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Markman JD, 2008, PAIN, V136, P227, DOI 10.1016/j.pain.2008.03.011; MERCADANTE S, 1991, PAIN, V45, P107, DOI 10.1016/0304-3959(91)90172-T; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Nauck F, 2007, SCHMERZ, V21, P359, DOI 10.1007/s00482-007-0572-1; Nauck F, 2008, Z PALLIATMEDIZIN, V9, P221, DOI 10.1055/s-0028-1090095; O'Connor AB, 2008, PAIN MED, V9, P258, DOI 10.1111/j.1526-4637.2008.00413.x; Petzke F, 1999, J PAIN SYMPTOM MANAG, V17, P391, DOI 10.1016/S0885-3924(99)00023-8; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Sabatowski R, 2001, SCHMERZ, V15, P241, DOI 10.1007/s004820100054; Saunders CM, 1978, MANAGEMENT TERMINAL, P210; Soyka M, 2004, PHARMACOPSYCHIATRY, V37, P191, DOI 10.1055/s-2004-827177; Striebel H W, 1993, Schmerz, V7, P174, DOI 10.1007/BF02530425; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; TROJAN A, 1978, DRUG ALCOHOL DEPEN, V3, P383, DOI 10.1016/0376-8716(78)90010-8; U.S. Food and Drug Administration, 2008, J PAIN PALLIAT CARE, V22, P47; Vainio A, 1996, J PAIN SYMPTOM MANAG, V12, P3, DOI 10.1016/0885-3924(96)00042-5; Zarth R, 2007, SCHMERZ, V21, P545, DOI 10.1007/s00482-007-0590-z; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	36	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-433X	1432-2129		SCHMERZ	Schmerz	FEB	2013	27	1					76	+		10.1007/s00482-013-1292-3			4	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	091FQ	WOS:000315035200010	23377349				2020-06-30	J	Wu, QF; Hwang, CK; Zheng, H; Wagley, Y; Lin, HY; Kim, DK; Law, PY; Loh, HH; Wei, LN				Wu, Qifang; Hwang, Cheol Kyu; Zheng, Hui; Wagley, Yadav; Lin, Hong-Yiou; Kim, Do Kyung; Law, Ping-Yee; Loh, Horace H.; Wei, Li-Na			MicroRNA 339 down-regulates mu-opioid receptor at the post-transcriptional level in response to opioid treatment	FASEB JOURNAL			English	Article						fentanyl; morphine; promoter; UTR	ACTIVATED PROTEIN-KINASE; MESSENGER-RNA; UP-REGULATION; PROMOTER; GENE; TRANSCRIPTION; IDENTIFICATION; INVOLVEMENT; FENTANYL; EXPRESSION	mu-Opioid receptor (MOR) level is directly related to the function of opioid drugs, such as morphine and fentanyl. Although agonist treatment generally does not affect transcription of mor, previous studies suggest that morphine can affect the translation efficiency of MOR transcript via microRNAs (miRNAs). On the basis of miRNA microarray analyses of the hippocampal total RNA isolated from mice chronically treated with mu-opioid agonists, we found a miRNA (miR-339-3p) that was consistently and specifically increased by morphine (2-fold) and by fentanyl (3.8-fold). miR-339-3p bound to the MOR 3'-UTR and specifically suppressed reporter activity. Suppression was blunted by adding miR-339-3p inhibitor or mutating the miR-339-3p target site. In cells endogenously expressing MOR, miR-339-3p inhibited the production of MOR protein by destabilizing MOR mRNA. Up-regulation of miR-339-3p by fentanyl (EC50=0.75 nM) resulted from an increase in primary miRNA transcript. Mapping of the miR-339-3p primary RNA and its promoter revealed that the primary miR-339-3p was embedded in a noncoding 3'-UTR region of an unknown host gene and was coregulated by the host promoter. The identified promoter was activated by opioid agonist treatment (10 nM fentanyl or 10 mu M morphine), a specific effect blocked by the opioid antagonist naloxone (10 mu M). Taken together, these results suggest that miR-339-3p may serve as a negative feedback modulator of MOR signals by regulating intracellular MOR biosynthesis.-Wu, Q., Hwang, C. K., Zheng, H., Wagley, Y., Lin, H.-Y., Kim, D. K., Law, P.-Y., Loh, H. H., Wei, L.-N. MicroRNA 339 downregulates mu opioid receptor at the post-transcriptional level in response to opioid treatment. FASEB J. 27, 522-535 (2013). www.fasebj.org	[Wu, Qifang; Hwang, Cheol Kyu; Zheng, Hui; Wagley, Yadav; Lin, Hong-Yiou; Kim, Do Kyung; Law, Ping-Yee; Loh, Horace H.; Wei, Li-Na] Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA	Hwang, CK (reprint author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	hwang025@umn.edu		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	U.S. National Institutes of Health, National Institute of Drug Abuse [DA000564, DA001583, DA011806, DA011190, DA013926]; A&F Stark Fund of the Minnesota Medical Foundation	The authors thank Dr. Tracy Kuhlman and Mr. Bradley J. Stish for editorial assistance with the manuscript. This work was supported by the U.S. National Institutes of Health, National Institute of Drug Abuse (grants DA000564, DA001583, DA011806, DA011190, and DA013926); and by the A&F Stark Fund of the Minnesota Medical Foundation. The authors declare no conflicts of interest.	Afify EA, 2002, MOL BRAIN RES, V106, P83, DOI 10.1016/S0169-328X(02)00414-X; Akan P, 2008, GENE, V410, P165, DOI 10.1016/j.gene.2007.12.011; Binyaminy B, 2008, LIFE SCI, V82, P831, DOI 10.1016/j.lfs.2008.01.015; BRODSKY M, 1995, NEUROREPORT, V6, P725, DOI 10.1097/00001756-199503270-00005; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; Chen HC, 1999, NEUROSCIENCE, V92, P1143, DOI 10.1016/S0306-4522(99)00030-5; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; He Y, 2010, J NEUROSCI, V30, P10251, DOI 10.1523/JNEUROSCI.2419-10.2010; Huang HY, 2006, NUCLEIC ACIDS RES, V34, pW429, DOI 10.1093/nar/gkl333; Hwang CK, 2007, MOL CELL BIOL, V27, P4720, DOI 10.1128/MCB.00073-07; Hwang CK, 2011, NEUROMETHODS, V60, P49, DOI 10.1007/978-1-61779-179-6_4; Hwang CK, 2010, MOL PHARMACOL, V78, P58, DOI 10.1124/mol.110.064311; Hwang CK, 2009, J CELL MOL MED, V13, P3591, DOI 10.1111/j.1582-4934.2008.00535.x; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Im HJ, 2001, MOL PHARMACOL, V59, P1486; Jalali A, 2011, J NEUROSCI RES, V89, P299, DOI 10.1002/jnr.22562; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Karaji AG, 2005, INT IMMUNOPHARMACOL, V5, P1019, DOI 10.1016/j.intimp.2005.01.012; Kelkar YD, 2010, GENOME BIOL EVOL, V2, P620, DOI 10.1093/gbe/evq046; Kim CS, 2008, BBA-MOL CELL RES, V1783, P1835, DOI 10.1016/j.bbamcr.2008.06.019; Kim DK, 2011, J NEUROCHEM, V116, P1077, DOI 10.1111/j.1471-4159.2010.07163.x; Koch T, 1997, J NEUROCHEM, V69, P1767; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Law P.-Y., 2011, OPIATE RECEPTORS, V23; Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910; Pan YX, 2001, P NATL ACAD SCI USA, V98, P14084, DOI 10.1073/pnas.241296098; Pan YX, 2002, GENE, V295, P97, DOI 10.1016/S0378-1119(02)00825-9; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Reese MG, 2001, COMPUT CHEM, V26, P51, DOI 10.1016/S0097-8485(01)00099-7; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Solovyev VV, 2010, METHODS MOL BIOL, V674, P57, DOI 10.1007/978-1-60761-854-6_5; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; UNTERWALD EM, 1995, MOL BRAIN RES, V33, P351, DOI 10.1016/0169-328X(95)00143-G; van Rooij E, 2011, CIRC RES, V108, P219, DOI 10.1161/CIRCRESAHA.110.227496; Wagley Y, 2007, BIOCHEM BIOPH RES CO, V354, P985, DOI 10.1016/j.bbrc.2007.01.083; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wei LN, 2011, ANNU REV PHARMACOL, V51, P75, DOI 10.1146/annurev-pharmtox-010510-100605; Wu H, 2010, BIOSTATISTICS, V11, P499, DOI 10.1093/biostatistics/kxq005; Wu QF, 2005, MOL PHARMACOL, V68, P279, DOI 10.1124/mol.105.012567; Wu QF, 2009, MOL PHARMACOL, V75, P744, DOI 10.1124/mol.108.053462; Wu QF, 2008, FASEB J, V22, P4085, DOI 10.1096/fj.08-108175; Xiong HP, 2009, BIOCHEM BIOPH RES CO, V378, P883, DOI 10.1016/j.bbrc.2008.12.010; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	61	36	42	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2013	27	2					522	535		10.1096/fj.12-213439			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	081YG	WOS:000314358000012	23085997	Green Published			2020-06-30	J	Shlamovitz, GZ; Elsayem, A; Todd, KH				Shlamovitz, Gil Z.; Elsayem, Ahmed; Todd, Knox H.			KETAMINE FOR PALLIATIVE SEDATION IN THE EMERGENCY DEPARTMENT	JOURNAL OF EMERGENCY MEDICINE			English	Article						palliative sedation; ketamine; angioedema; palliative care; end of life care	CARE; LIFE	Background: Palliative sedation to treat severely distressing symptoms in those with a poor prognosis is well-accepted. Objective: We discuss palliative sedation in the Emergency Department and the use of ketamine. Case Report: We present the case of a patient with angioedema of the tongue and severe respiratory distress. The patient's nursing home was unable to control her symptoms and she was transferred to the Emergency Department. The patient received fentanyl 50 mu g i.v. and ketamine 50 mg i.v. every 5 min until adequate palliative sedation was achieved. Conclusion: Ketamine can be considered for Emergency Department palliative sedation in selected patients. Identifying and caring for unmet palliative care needs is an important skill for Emergency Medicine. (c) 2013 Elsevier Inc.	[Shlamovitz, Gil Z.] Ben Taub Gen Hosp, Baylor Coll Med, Sect Emergency Med, Dept Med, Houston, TX 77030 USA; [Elsayem, Ahmed; Todd, Knox H.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA	Shlamovitz, GZ (reprint author), Ben Taub Gen Hosp, Emergency Ctr, Baylor Coll Med, Sect Emergency Med, 1504 Taub Loop, Houston, TX 77030 USA.						Baumann Antoine, 2011, Philos Ethics Humanit Med, V6, P4, DOI 10.1186/1747-5341-6-4; Broeckaert B, 2011, AM J BIOETHICS, V11, P62, DOI 10.1080/15265161.2011.577518; Carter MJ, 2008, J PAIN SYMPTOM MANAG, V36, P1; Cherny N I, 1994, J Palliat Care, V10, P31; Cherny NI, 2006, NAT CLIN PRACT ONCOL, V3, P492, DOI 10.1038/ncponc0583; Claseem A, 2008, ANN INTERN MED, V148, P141, DOI 10.7326/0003-4819-148-2-200801150-00009; De Graeff A, 2007, J PALLIAT MED, V10, P67, DOI 10.1089/jpm.2006.0139; Elsayem A, 2009, SUPPORT CARE CANCER, V17, P53, DOI 10.1007/s00520-008-0459-4; Engstrom J, 2007, EUR J ONCOL NURS, V11, P26, DOI 10.1016/j.ejon.2006.02.007; Green SM, 2010, PEDIATR EMERG CARE, V26, P798, DOI 10.1097/PEC.0b013e3181fa8737; Kirk TW, 2010, J PAIN SYMPTOM MANAG, V39, P914, DOI 10.1016/j.jpainsymman.2010.01.009; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V41, P754, DOI 10.1016/j.jpainsymman.2010.07.013; Smally AJ, 2011, CURR OPIN CRIT CARE, V17, P317, DOI 10.1097/MCC.0b013e328348bf43; Vissers KCP, 2007, CURR OPIN ANESTHESIO, V20, P137, DOI 10.1097/ACO.0b013e328049557b	14	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	FEB	2013	44	2					355	357		10.1016/j.jemermed.2012.08.026			3	Emergency Medicine	Emergency Medicine	086EC	WOS:000314665400052	23047198				2020-06-30	J	Landau, R; Liu, SK; Blouin, JL; Carvalho, B				Landau, Ruth; Liu, Shih-Kai; Blouin, Jean-Louis; Carvalho, Brendan			The Effect of OPRM1 and COMT Genotypes on the Analgesic Response to Intravenous Fentanyl Labor Analgesia	ANESTHESIA AND ANALGESIA			English	Article							CATECHOL-O-METHYLTRANSFERASE; INTRATHECAL FENTANYL; CANCER PAIN; MORPHINE; GENE; REQUIREMENTS; POLYMORPHISM	BACKGROUND: IV fentanyl is used as a labor analgesic; however, few studies have reported the effects of IV fentanyl for early labor analgesia. We evaluated the analgesic response to IV fentanyl according to the combined effect of the single-nucleotide polymorphisms rs1799971 (c.118A/G, p. 40Asn/Asp) of the mu-opioid receptor gene (OPRM1) and rs4680 (c.472G/A, p.158Val/Met) of the catechol-O-methyltransferase (COMT) gene in women requesting labor analgesia. METHODS: Labor analgesia was initiated with IV fentanyl 1.5 mu g/kg. The primary outcome was analgesic success, defined as Numerical Verbal Pain Scale score <= 10/100 15 minutes after the dose of fentanyl. Analgesic and side effect outcomes were compared according to OPRM1 and COMT genotypes. RESULTS: One hundred six women were enrolled and received IV fentanyl. IV analgesic success was 6% in women with the combination Asn/Asn-Met/Met (n = 17) versus 20% in all other women combined (not Asn/Asn-Met/Met; P = 0.30; difference = 14%; 95% confidence interval [CI], -10% to 26%). IV analgesic success was 20% in women 118A/A (Asn/Asn) versus 21% for A/G and G/G of OPRM1 (P = 0.82; difference = 2%; 95% CI, -17% to 19%), and 10% in women 472A (Met/Met) versus 22% for A/G (Met/Val) and GIG (Val/Val) of COMT (P = 0.24; difference = 12%; 95% CI, -6% to 26%). Met/Met158 (n = 31) versus Met/Val or Val/Val of COMT was associated with a smaller decrease in Numerical Verbal Pain Scale (24 +/- 18 vs 37 +/- 23; P = 0.005; mean difference = -13; 99% Cl, -25 to -1). CONCLUSION: This study was underpowered to draw firm conclusions on the influence of OPRM1 and COMT genotypes on labor analgesia with IV fentanyl. Further larger studies are needed to evaluate whether genotyping COMT alone or in combination with OPRM1 may have potentially useful clinical implications, such as not offering IV fentanyl in early labor to women who will most likely not benefit from it. (Anesth Analg 2013;116:386-91)	[Landau, Ruth] Univ Washington, Dept Anesthesiol & Pain Med, Med Ctr, Seattle, WA 98195 USA; [Liu, Shih-Kai] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Liu, Shih-Kai] China Med Univ Hosp, Dept Anesthesia Pain Serv & Crit Care Med, Taichung, Taiwan; [Blouin, Jean-Louis] Univ Hosp Geneva, Geneva, Switzerland; [Carvalho, Brendan] Stanford Univ, Med Ctr, Dept Anesthesiol, Palo Alto, CA 94304 USA	Landau, R (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, Med Ctr, 1959 NE Pacific St,Suite BB 1415B, Seattle, WA 98195 USA.	rulandau@u.washington.edu			Swiss National Foundation (SNF)Swiss National Science Foundation (SNSF) [3200B0-114129]	Supported by Swiss National Foundation Grant (SNF #3200B0-114129).	Capogna G, 2010, INT J OBSTET ANESTH, V19, P167, DOI 10.1016/j.ijoa.2009.05.013; Evron S, 2007, CURR OPIN ANESTHESIO, V20, P181, DOI 10.1097/ACO.0b013e328136c1d1; Jensen KB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006016; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Landau R, 2011, ANESTH ANALG, V113, P432, DOI 10.1213/ANE.0b013e31821f154f; Landau R, 2010, CURR OPIN ANESTHESIO, V23, P323, DOI 10.1097/ACO.0b013e328339802c; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Rakvag TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Wong CA, 2010, INT J OBSTET ANESTH, V19, P246, DOI 10.1016/j.ijoa.2009.09.005; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	12	23	23	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2013	116	2					386	391		10.1213/ANE.0b013e318273f2c7			6	Anesthesiology	Anesthesiology	078DJ	WOS:000314078300019	23302985				2020-06-30	J	Lee, A; OLoughlin, E; Roberts, LJ				Lee, A.; OLoughlin, E.; Roberts, L. J.			A double-blinded randomized evaluation of alfentanil and morphine vs fentanyl: analgesia and sleep trial (DREAMFAST)	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia; patient-controlled; analgesics; opioid; pain; postoperative; sleep disorder; environmental	PATIENT-CONTROLLED ANALGESIA; PAIN; SURGERY; QUALITY; ADULTS; DISTURBANCES; DYSFUNCTION	Patients using fentanyl patient-controlled analgesia (PCA), the standard first-line choice in our hospitals, commonly complain of postoperative sleep disruption due to pain. The aim of this study was to determine whether the PCA combination of alfentanil and morphine, which provides longer analgesia without compromising onset speed, would improve postoperative pain-related sleep interference. Two hundred and twelve adults undergoing major surgery where PCA was the planned principal postoperative analgesic modality were randomized to either the combination of alfentanil and morphine (Group AM) or fentanyl (Group F). The primary outcome was pain-related awakenings during the second postoperative night as measured by the study questionnaire, based on the St Marys Hospital Sleep Questionnaire. Analgesic efficacy, other sleep measures, and opioid-related side-effects were also assessed. There was no difference in pain-related sleep disturbance between the groups, with 41 of Group AM and 53 of Group F waking due to pain (P0.10). Group AM had better rest and dynamic analgesia in the first 24 h with fewer requiring rescue ketamine infusion during the 2 day study period (2 vs 14, P0.001). Those in Group AM experienced less nausea and vomiting in the second 24 h (18 vs 35, P0.028) but more pruritus (40 vs 23, P0.013). Despite better early postoperative analgesia, pain-related sleep interference was not improved by the PCA combination of alfentanil and morphine. Ref: ACTRN12608000118303.	[Lee, A.; Roberts, L. J.] Sir Charles Gairdner Hosp, Dept Anaesthesia, Nedlands, WA 6009, Australia; [Roberts, L. J.] Sir Charles Gairdner Hosp, Dept Pain Management, Nedlands, WA 6009, Australia; [OLoughlin, E.] Fremantle Hosp, Dept Anaesthesia, Fremantle, WA 6160, Australia; [OLoughlin, E.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia	Lee, A (reprint author), Sir Charles Gairdner Hosp, Dept Anaesthesia, Hosp Ave, Nedlands, WA 6009, Australia.	alee@meddent.uwa.edu.au			Fremantle Hospital Medical Research Foundation	This work was supported by a project grant from the Fremantle Hospital Medical Research Foundation.	Alamili M, 2010, DAN MED BULL, V57; Buyukyilmaz FE, 2011, CLIN NURS RES, V20, P326, DOI 10.1177/1054773811406110; Cremeans-Smith JK, 2006, J BEHAV MED, V29, P215, DOI 10.1007/s10865-005-9045-0; Dawson L, 1999, J ADV NURS, V30, P875, DOI 10.1046/j.1365-2648.1999.01161.x; Devine EB, 2005, PHARMACOECONOMICS, V23, P889, DOI 10.2165/00019053-200523090-00003; Dogan O, 2005, J CLIN NURS, V14, P107, DOI 10.1111/j.1365-2702.2004.01011.x; ELLIS BW, 1981, SLEEP, V4, P93, DOI 10.1093/sleep/4.1.93; Friedman Zeev, 2008, Pain Pract, V8, P248, DOI 10.1111/j.1533-2500.2008.00212.x; George Jessica A, 2010, J Opioid Manag, V6, P47; Gogenur I, 2009, SURG ENDOSC, V23, P1026, DOI 10.1007/s00464-008-0112-9; Hedges C, 2008, AM J CRIT CARE, V17, P133; Kain ZN, 2003, J CLIN ANESTH, V15, P505, DOI 10.1016/j.jclinane.2003.02.002; Kee WDN, 1999, ANAESTHESIA, V54, P629, DOI 10.1046/j.1365-2044.1999.00844.x; Krenk L, 2010, ACTA ANAESTH SCAND, V54, P951, DOI 10.1111/j.1399-6576.2010.02268.x; Lautenbacher S, 2006, SLEEP MED REV, V10, P357, DOI 10.1016/j.smrv.2005.08.001; Lavigne GJ, 2010, PAIN, V148, P6, DOI 10.1016/j.pain.2009.10.013; Ludbrook GL, 2001, ANAESTHESIA, V56, P739, DOI 10.1046/j.1365-2044.2001.02132.x; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; Moore JT, 2009, ANESTHESIOLOGY, V111, P1175, DOI 10.1097/ALN.0b013e3181bdfa2e; PARKER RK, 1992, ANESTHESIOLOGY, V76, P362, DOI 10.1097/00000542-199203000-00007; Raymond I, 2004, SLEEP MED, V5, P551, DOI 10.1016/j.sleep.2004.07.007; Raymond I, 2001, PAIN, V92, P381, DOI 10.1016/S0304-3959(01)00282-2; Smith MT, 2008, CURR OPIN ANESTHESIO, V21, P596, DOI 10.1097/ACO.0b013e32830a4c4a; Spence J, 2011, J NURS CARE QUAL, V26, P88, DOI 10.1097/NCQ.0b013e3181ed939a; Tiede W, 2010, PAIN, V148, P36, DOI 10.1016/j.pain.2009.08.029; Tranmer Joan E, 2003, Clin Nurs Res, V12, P159, DOI 10.1177/1054773803012002004; Wylde V, 2011, ORTHOP TRAUMATOL-SUR, V97, P139, DOI 10.1016/j.otsr.2010.12.003	27	4	4	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2013	110	2					293	298		10.1093/bja/aes362			6	Anesthesiology	Anesthesiology	074QC	WOS:000313826500019	23075634	Green Published, Bronze			2020-06-30	J	Weerts, EM; McCaul, ME; Kuwabara, H; Yang, XJ; Xu, XQ; Dannals, RF; Frost, JJ; Wong, DF; Wand, GS				Weerts, Elise M.; McCaul, Mary E.; Kuwabara, Hiroto; Yang, Xiaoju; Xu, Xiaoqiang; Dannals, Robert F.; Frost, J. James; Wong, Dean F.; Wand, Gary S.			Influence of OPRM1 Asn(40)Asp variant (A118G) on [C-11]carfentanil binding potential: preliminary findings in human subjects	INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY			English	Article						Alcohol use disorders; genetics; imaging; mu opioid receptors; naltrexone	OPIOID-RECEPTOR OPRM1; SINGLE-NUCLEOTIDE POLYMORPHISM; POSITRON-EMISSION-TOMOGRAPHY; ALCOHOL DEPENDENCE; HEAVY DRINKERS; NALTREXONE; PHARMACOGENETICS; 6-BETA-NALTREXOL; RESPONSES; GENOTYPE	The Asn40Asp variant (A118G) of the mu opioid receptor (OPRM1) gene is thought to contribute to the development and treatment of alcohol dependence. Employing positron emission tomography (PET), we first examined whether the single nucleotide polymorphism (SNP) modifies binding potential (BPND) of the mu-selective ligand [C-11] carfentanil in healthy control (Con) and 5-d abstinent alcohol-dependent (AD) subjects (unblocked basal scan). Second, we examined whether the allelic variants were associated with differences in OPRM1 occupancy by naltrexone (50 mg) in AD subjects. Con and AD carriers of the G allele (AG) had lower global BPND at the basal scan than subjects homozygous for the A allele (AA). In AD subjects, naltrexone occupancy was slightly higher in AG subjects (98.9%) compared to AA subjects (93.1%), but this was not significant. We are the first to demonstrate using PET in healthy normal and AD subjects that the A118G SNP alters OPRM1 availability.	[Weerts, Elise M.; McCaul, Mary E.; Wong, Dean F.; Wand, Gary S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [McCaul, Mary E.; Yang, Xiaoju; Xu, Xiaoqiang; Wand, Gary S.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Kuwabara, Hiroto; Dannals, Robert F.; Frost, J. James; Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Environm Hlth Sci, Baltimore, MD USA	Wand, GS (reprint author), 720 Rutland Ave,Ross 863, Baltimore, MD 21205 USA.	gwand@jhmi.edu		Weerts, Elise/0000-0002-8234-0919	National Institute of Alcohol Abuse and Alcoholism (NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Kenneth Lattman Foundation; Acadia; AmgenAmgen; Avid; Biotie; Bristol Myers SquibbBristol-Myers Squibb; GE; Intracellular; J J; LillyEli Lilly; Luhdeck; Merk; Orexigen; Otuska; RocheRoche Holding; Sanofi-Aventi; Sepracor; Lilly Research LaboratoriesEli Lilly;  [R01AA11872];  [R01AA11855];  [R37AA12303]	The National Institute of Alcohol Abuse and Alcoholism (NIAAA) provided financial support for research related to the subject matter of this manuscript from the grants R01AA11872 (PI : J.J. Frost), R01AA11855 (PI : M. E. McCaul) and R37AA12303 (PI : G. S. Wand). The authors acknowledge the technical support of Dr Hayden T. Ravert, Mr Robert Smoot and Mr Daniel Holt for their radiochemistry expertise and Ms Karen Edmonds and Mr David Clough for their PET acquisition and reconstruction expertise.; Dr Wand is the recipient of a gift fund from the Kenneth Lattman Foundation. He is an investigator in a post marketing study for Eli Lilly & Company, entitled The Global Hypopituitary Control and Complications Study (HypoCCS). He is an investigator in a post marketing study for Ipsen entitled Somatuline Depot (lanreotide) Injection for Acromegaly (SODA). Dr Wong is a consultant for Amgen. Between 2009 and the present, Dr Wong has received funding from the following companies: Acadia; Amgen; Avid; Biotie; Bristol Myers Squibb; GE; Intracellular; J& J; Lilly; Luhdeck; Merk; Orexigen; Otuska; Roche; Sanofi-Aventi; Sepracor. Dr McCaul was principal investigator on a contract (A Phase 2 Study of LY2196044 Compared with Naltrexone and Placebo in the Treatment of Alcohol Dependence) funded by Lilly Research Laboratories; Drs Weerts and Wand were co-investigators on this project.	Anton RF, 2008, ARCH GEN PSYCHIAT, V65, P135, DOI 10.1001/archpsyc.65.2.135; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Chong RY, 2006, NEUROPSYCHOPHARMACOL, V31, P204, DOI 10.1038/sj.npp.1300856; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Huang P, 2012, BIOCHEM J, V441, P379, DOI 10.1042/BJ20111050; Huang W, 1997, J ANAL TOXICOL, V21, P252, DOI 10.1093/jat/21.4.252; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; Kranzler HR, 2010, CURR PHARM DESIGN, V16, P2141; Lotsch J, 2011, BRIT J PHARMACOL, V163, P447, DOI 10.1111/j.1476-5381.2010.01074.x; McCaul ME, 2000, ALCOHOL CLIN EXP RES, V24, P1385, DOI 10.1111/j.1530-0277.2000.tb02107.x; Oslin DW, 2006, ADDICT BIOL, V11, P397, DOI 10.1111/j.1369-1600.2006.00036.x; Pritchard JK, 2000, GENETICS, V155, P945; Ray LA, 2012, ALCOHOL CLIN EXP RES, V36, P385, DOI 10.1111/j.1530-0277.2011.01633.x; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Setiawan E, 2011, ALCOHOL CLIN EXP RES, V35, P1134, DOI 10.1111/j.1530-0277.2011.01446.x; Smith MW, 2001, AM J HUM GENET, V69, P1080, DOI 10.1086/323922; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41; Tidey JW, 2008, ALCOHOL CLIN EXP RES, V32, P58, DOI 10.1111/j.1530-0277.2007.00545.x; Uhart M, 2009, ADDICT BIOL, V14, P43, DOI 10.1111/j.1369-1600.2008.00131.x; van den Wildenberg E, 2007, ALCOHOL CLIN EXP RES, V31, P1, DOI 10.1111/j.1530-0277.2006.00258.x; Weerts EM, 2008, NEUROPSYCHOPHARMACOL, V33, P653, DOI 10.1038/sj.npp.1301440; Weerts EM, 2011, ALCOHOL CLIN EXP RES, V35, P2162, DOI 10.1111/j.1530-0277.2011.01565.x; Yang BZ, 2005, GENET EPIDEMIOL, V28, P302, DOI 10.1002/gepi.20070; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	24	35	35	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1461-1457			INT J NEUROPSYCHOPH	Int. J. Neuropsychopharmacol.	FEB	2013	16	1					47	53		10.1017/S146114571200017X			7	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	058TX	WOS:000312658300005	22397905	Bronze			2020-06-30	J	Failey, C; Aburto, J; de la Portilla, HG; Romero, JF; Lapuerta, L; Barrera, A				Failey, Colin; Aburto, Jaime; Garza de la Portilla, Hector; Francisco Romero, Jorge; Lapuerta, Leo; Barrera, Alfonso			Office-Based Outpatient Plastic Surgery Utilizing Total Intravenous Anesthesia	AESTHETIC SURGERY JOURNAL			English	Article						anesthesia; office-based; outpatient surgery; TIVA; sedation; intravenous; research	ABDOMINOPLASTY; COMPLICATIONS	Background: Office-based plastic surgery procedures continue to increase in popularity and a range of anesthetic techniques can be utilized, from light conscious sedation to general anesthesia requiring intubation. Total intravenous anesthesia (TIVA) is well suited for the office environment because it allows for moderate to deep sedation without the need for intubation. Objective: The authors review plastic surgery procedures performed in an outpatient office-based operating room under TIVA to assess patient outcomes and complications. Methods: A retrospective chart review was conducted of patients who underwent surgical procedures performed by 2 senior surgeons at American Association for Accreditation of Ambulatory Surgery Facilities certified outpatient operating rooms between 2003 and 2011. TIVA was always administered by a board-certified anesthesiologist because it required the use of propofol. Conscious sedation with midazolam and fentanyl was always administered by the plastic surgeon. Patient outcomes and complications were analyzed to assess the safety of TIVA in an office operating room. Results: A total of 2611 procedures were performed on 2006 patients. No deaths, cardiac events, or transfers to the hospital occurred in any patients, regardless of the type of sedation utilized. Six hundred forty-two patients were given TIVA, which included propofol and/or ketamine, in addition to midazolam and fentanyl. The remaining 1364 patients received conscious sedation. There was 1 documented case (0.05%; 1/2006) of deep vein thrombosis/pulmonary embolism in a patient who had an implant exchange under TIVA; this patient was taking oral contraceptive pills at the time of surgery. Conclusions: Office-based surgery is an attractive option for many patients. This review suggests that a variety of procedures can be performed in a safe manner under TIVA. Although patient selection for outpatient surgery is paramount, TIVA offsets the risks of general anesthesia and is associated with minimal postoperative complications.	[Failey, Colin] Methodist Hosp, Plast Surg Program, Houston, TX 77030 USA; [Aburto, Jaime] Wright State Univ, Boonshoft Sch Med, Dayton, OH 45435 USA; [Garza de la Portilla, Hector] Univ Autonoma Tamaulipas, Fac Med Tampico, Tampico, Mexico; [Francisco Romero, Jorge] Univ Autonoma Estado Puebla, Puebla, Mexico; [Barrera, Alfonso] Baylor Coll Med, Houston, TX 77030 USA	Barrera, A (reprint author), 915 Gessner 825, Houston, TX 77024 USA.	abarrera@lookinggood.com					Alderman AK, 2009, PLAST RECONSTR SURG, V124, P2127, DOI 10.1097/PRS.0b013e3181bf8378; *AM SOC AN, CONT DEPTH SED DEF G; American Society for Aesthetic Plastic Surgery. National Cosmetic Surgery Data Bank Statistics, 2011, NAT COSM SURG DAT BA; Ascherman JA, 2008, PLAST RECONSTR SURG, V121, P1, DOI [10.1097/01.prs.0000295378.43033.c4, 10.1097/PRS.0b013e31818338cb]; Bitar G, 2003, PLAST RECONSTR SURG, V111, P150, DOI 10.1097/01.PRS.0000037756.88297.BC; Blake Douglas R, 2008, Aesthet Surg J, V28, P564, DOI 10.1016/j.asj.2008.07.012; Byrd HS, 2003, PLAST RECONSTR SURG, V112, P636, DOI 10.1097/01.PRS.0000070976.80666.50; GRAZER FM, 1977, PLAST RECONSTR SURG, V59, P513, DOI 10.1097/00006534-197759040-00006; Hatef DA, 2010, PLAST RECONSTR SURG, V125, P352, DOI 10.1097/PRS.0b013e3181c2a3b4; Hoefflin SM, 2001, PLAST RECONSTR SURG, V107, P243, DOI 10.1097/00006534-200101000-00040; Kryger ZB, 2004, PLAST RECONSTR SURG, V113, P1807, DOI 10.1097/01.PRS.0000117303.63028.7D; Matarasso A, 2006, PLAST RECONSTR SURG, V117, P1797, DOI 10.1097/01.prs.0000209918.55752.f3; Most D, 2005, PLAST RECONSTR SURG, V115, P588, DOI 10.1097/01.PRS.0000150147.31475.BB; Mustoe Thomas A, 2007, Aesthet Surg J, V27, P442, DOI 10.1016/j.asj.2007.05.003	14	13	14	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1090-820X	1527-330X		AESTHET SURG J	Aesthet. Surg. J.	FEB	2013	33	2					270	274		10.1177/1090820X12472694			5	Surgery	Surgery	088SB	WOS:000314856300011	23335648	Bronze			2020-06-30	J	Kim, MS; Moon, BE; Kim, H; Lee, JR				Kim, M. -S.; Moon, B. -E.; Kim, H.; Lee, J. -R.			Comparison of propofol and fentanyl administered at the end of anaesthesia for prevention of emergence agitation after sevoflurane anaesthesia in children	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i; v; propofol; anaesthetics volatile; sevoflurane; analgesics opioid; fentanyl; recovery; postoperative	GENERAL-ANESTHESIA; PEDIATRIC-PATIENTS; DESFLURANE ANESTHESIA; GYNECOLOGICAL SURGERY; DOSE FENTANYL; HALOTHANE; MIDAZOLAM; DELIRIUM; ADENOTONSILLECTOMY; METAANALYSIS	Propofol and fentanyl can be administered at the end of sevoflurane anaesthesia to decrease the incidence and severity of emergence agitation (EA), although it has not been determined which agent has superior efficacy. The purpose of this study was to compare the effects of propofol and fentanyl on EA. In this prospective, randomized, double-blind study, 222 children, 1872 months of age, undergoing sevoflurane anaesthesia were randomly assigned to one of the three groups receiving either propofol 1 mg kg(1) (Group P), fentanyl 1 g kg(1) (Group F), or saline (Group S) at the end of anaesthesia. The incidence and severity of EA were evaluated with the paediatric anaesthesia emergence delirium (PAED) scale. Time to recovery and incidence of nausea/vomiting were assessed. The mean PAED score was 4.3 in Group P and 4.9 in Group F (P0.682), which were lower than 9.0 in Group S (P0.001). Nausea and vomiting were significantly more frequent in Group F than Groups P and S (adjusted P0.003 and adjusted P0.001). Group F had also longer stay in the post-anaesthesia care unit (PACU) than Group S (P0.001), while Group P did not. However, the differences in PACU stays between the P and F groups were considered clinically insignificant. Small doses of propofol or fentanyl at the end of sevoflurane anaesthesia comparably reduced EA. Propofol was better than fentanyl due to a lower incidence of nausea and vomiting.	[Kim, M. -S.; Moon, B. -E.; Kim, H.; Lee, J. -R.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Anaesthesia & Pain Res Inst, Seoul 120752, South Korea	Lee, JR (reprint author), Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Anaesthesia & Pain Res Inst, 50 Yonsei Ro, Seoul 120752, South Korea.	leejeongrim@gmail.com		Lee, Jeong-Rim/0000-0002-7425-0462; Kim, Min-Soo/0000-0001-8760-4568			Abu-Shahwan I, 2008, PEDIATR ANESTH, V18, P55, DOI 10.1111/j.1460-9592.2007.02376.x; Abu-Shahwan I, 2007, PEDIATR ANESTH, V17, P846, DOI 10.1111/j.1460-9592.2007.02298.x; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Bajwa SA, 2010, PEDIATR ANESTH, V20, P704, DOI 10.1111/j.1460-9592.2010.03328.x; Chen JY, 2010, PEDIATR ANESTH, V20, P873, DOI 10.1111/j.1460-9592.2010.03375.x; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2002, PAEDIATR ANAESTH, V12, P604, DOI 10.1046/j.1460-9592.2002.00903.x; Cohen IT, 2001, ANESTH ANALG, V93, P88; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; De Oliveira GS, 2011, BRIT J ANAESTH, V107, P362, DOI 10.1093/bja/aer156; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Hung WT, 2005, J CLIN ANESTH, V17, P494, DOI 10.1016/j.jclinane.2004.09.014; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kim JY, 2009, ACTA ANAESTH SCAND, V53, P678, DOI 10.1111/j.1399-6576.2009.01943.x; Kim YH, 2011, ANAESTH INTENS CARE, V39, P904, DOI 10.1177/0310057X1103900516; Koner O, 2011, EUR J ANAESTH, V28, P640, DOI 10.1097/EJA.0b013e328344db1a; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Roberts F L, 1988, Anaesthesia, V43 Suppl, P14, DOI 10.1111/j.1365-2044.1988.tb09061.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; Varveris DA, 2002, PAEDIATR ANAESTH, V12, P589, DOI 10.1046/j.1460-9592.2002.00921.x; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08; White H, 2007, BRIT J ANAESTH, V98, P470, DOI 10.1093/bja/aem001; Yasui Y, 2007, ANESTHESIOLOGY, V107, P992, DOI 10.1097/01.anes.0000291453.78823.f4	29	52	59	0	38	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2013	110	2					274	280		10.1093/bja/aes382			7	Anesthesiology	Anesthesiology	074QC	WOS:000313826500016	23103775	Bronze			2020-06-30	J	Wildschut, ED; de Wildt, SN; Mathot, RAA; Reiss, IKM; Tibboel, D; Van den Anker, J				Wildschut, Enno D.; de Wildt, Saskia N.; Mathot, Ron A. A.; Reiss, I. K. M.; Tibboel, Dick; Van den Anker, John			Effect of hypothermia and extracorporeal life support on drug disposition in neonates	SEMINARS IN FETAL & NEONATAL MEDICINE			English	Article						Analgesia; Extracorporeal membrane oxygenation; Hypothermia; Infant; Pharmacodynamics; Pharmacokinetics	MEMBRANE-OXYGENATION; MILD HYPOTHERMIA; MORPHINE PHARMACOKINETICS; POPULATION PHARMACOKINETICS; THERAPEUTIC HYPOTHERMIA; INFANTS; GENTAMICIN; MIDAZOLAM; PHARMACODYNAMICS; FENTANYL	Extracorporeal membrane oxygenation (ECMO) is a valuable treatment modality in neonates with reversible cardiopulmonary failure in therapy-resistant pulmonary hypertension after perinatal asphyxia, septic shock or ECMO cardiopulmonary resuscitation. Neonates with severe perinatal asphyxia are currently treated with therapeutic hypothermia to improve neurological outcome. Consequently, therapeutic hypothermia may be indicated in the neonatal ECMO population. Both ECMO and hypothermia have been associated with changes in drug disposition. However, little is known about the combined effects of these treatment modalities. This review will explore the available literature, identify possible changes in pharmacokinetics and make suggestions for future research directions. (c) 2012 Elsevier Ltd. All rights reserved.	[Wildschut, Enno D.; de Wildt, Saskia N.; Reiss, I. K. M.; Tibboel, Dick; Van den Anker, John] Sophia Childrens Univ Hosp, Erasmus MC, NL-3000 CB Rotterdam, Netherlands; [Wildschut, Enno D.; de Wildt, Saskia N.; Reiss, I. K. M.; Tibboel, Dick; Van den Anker, John] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Surg, NL-3000 CB Rotterdam, Netherlands; [Mathot, Ron A. A.] Univ Amsterdam, Amsterdam Med Ctr, Dept Hosp Pharm, Clin Pharmacol Unit, Amsterdam, Netherlands; [Reiss, I. K. M.] Sophia Childrens Univ Hosp, Erasmus MC, Div Neonatol, NL-3000 CB Rotterdam, Netherlands; [Van den Anker, John] Childrens Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA; [Van den Anker, John] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA; [Van den Anker, John] George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Pharmacol, Washington, DC 20052 USA	Wildschut, ED (reprint author), Sophia Childrens Univ Hosp, Intens Care Erasmus MC, Dr Molewaterplein 60, NL-3000 CB Rotterdam, Netherlands.	e.wildschut@erasmusmc.nl	de Wildt, Saskia/A-9589-2008	de Wildt, Saskia/0000-0002-0502-0647			Ahsman MJ, 2010, CLIN PHARMACOKINET, V49, P407, DOI 10.2165/11319970-000000000-00000; Ahsman MJ, 2010, ANTIMICROB AGENTS CH, V54, P1734, DOI 10.1128/AAC.01696-09; ALCARAZ C, 1989, ARCH INT PHARMACOD T, V297, P133; ARNOLD JH, 1991, J PEDIATR-US, V119, P639, DOI 10.1016/S0022-3476(05)82419-9; Arpino PA, 2008, PHARMACOTHERAPY, V28, P102, DOI 10.1592/phco.28.1.102; BANSINATH M, 1988, J CLIN PHARMACOL, V28, P860, DOI 10.1002/j.1552-4604.1988.tb03229.x; BHATTMEHTA V, 1992, PHARMACOTHERAPY, V12, P28; Blijdorp K, 2009, CRIT CARE, V13, DOI 10.1186/cc7771; Bouman CSC, 2008, CURR OPIN CRIT CARE, V14, P654, DOI 10.1097/MCC.0b013e32830f937c; Buck ML, 2003, CLIN PHARMACOKINET, V42, P403, DOI 10.2165/00003088-200342050-00001; Carcillo JA, 2003, INTENS CARE MED, V29, P980, DOI 10.1007/s00134-003-1758-3; DAGAN O, 1993, THER DRUG MONIT, V15, P263, DOI 10.1097/00007691-199308000-00001; DAGAN O, 1994, CRIT CARE MED, V22, P1099, DOI 10.1097/00003246-199407000-00008; De Cock RFW, 2012, CLIN PHARMACOKINET, V51, P105, DOI 10.2165/11595640-000000000-00000; de Haan TR, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-45; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; Field D, 1996, LANCET, V348, P75; Field DJ, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-24; Franck L S, 1998, Am J Crit Care, V7, P364; Geiduschek JM, 1997, CRIT CARE MED, V25, P360, DOI 10.1097/00003246-199702000-00027; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Hervey-Jumper SL, 2011, J NEUROSURG-PEDIATR, V7, P338, DOI 10.3171/2011.1.PEDS10443; Hines RN, 2008, PHARMACOL THERAPEUT, V118, P250, DOI 10.1016/j.pharmthera.2008.02.005; Horan MR, 2004, J PEDIATR-US, V144, P301, DOI 10.1016/j.jpeds.2003.11.034; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; Ista Erwin, 2010, J Opioid Manag, V6, P55; Karimova A, 2009, ARCH DIS CHILD-FETAL, V94, pF129, DOI 10.1136/adc.2008.141051; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; KOREN G, 1985, CRIT CARE MED, V13, P844, DOI 10.1097/00003246-198510000-00014; Lawson Scott, 2011, J Extra Corpor Technol, V43, P236; LEUSCHEN MP, 1993, J THORAC CARDIOV SUR, V105, P885; Liu X, 2009, PEDIATRICS, V124, P310, DOI 10.1542/peds.2008-2942; MARTINANCEL A, 1995, J PEDIATR-US, V127, P786, DOI 10.1016/S0022-3476(95)70174-5; Mellon RD, 2007, ANESTH ANALG, V104, P509, DOI 10.1213/01.ane.0000255729.96438.b0; MILLER RD, 1978, J PHARMACOL EXP THER, V207, P532; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; Mulla H, 2005, BRIT J CLIN PHARMACO, V60, P265, DOI 10.1111/j.1365-2125.2005.02432.x; Mulla H, 2003, ASAIO J, V49, P41, DOI 10.1097/00002480-200301000-00007; Mulla H, 2000, PERFUSION-UK, V15, P21, DOI 10.1177/026765910001500104; Peek GJ, 1999, ASAIO J, V45, P250, DOI 10.1097/00002480-199907000-00003; Peters JWB, 2005, INTENS CARE MED, V31, P257, DOI 10.1007/s00134-004-2545-5; Pokoma P, CURR PHARM IN PRESS; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Rosen D A, 1990, J Cardiothorac Anesth, V4, P332, DOI 10.1016/0888-6296(90)90041-D; Satas S, 2000, BIOL NEONATE, V77, P50; Shah PS, 2010, SEMIN FETAL NEONAT M, V15, P238, DOI 10.1016/j.siny.2010.02.003; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shekar K, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.02.013; Steiner CK, 2001, J PEDIATR SURG, V36, P487, DOI 10.1053/jpsu.2001.21609; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; van den Anker JN, 2012, CURR PHARM DESIGN, V18, P3114; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000; Van der Vorst MMJ, 2007, CRIT CARE, V11, DOI 10.1186/cc6146; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; van Saet A, CURR CLIN P IN PRESS; Vet NJ, 2012, PEDIATR CRIT CARE ME, V13, pE48, DOI 10.1097/PCC.0b013e3181fe406d; Wildschut ED, 2012, CURR DRUG METAB, V13, P767; Wildschut ED, 2010, INTENS CARE MED, V36, P2109, DOI 10.1007/s00134-010-2041-z; Wildschut ED, 2010, INTENS CARE MED, V36, P1587, DOI 10.1007/s00134-010-1931-4; Wildschut ED, 2010, THESIS ERASMUS MC; Zanelli S, 2011, J PERINATOL, V31, P377, DOI 10.1038/jp.2010.146; Zhou JQ, 2011, DRUG METAB DISPOS, V39, P2209, DOI 10.1124/dmd.111.040642; ZWISCHENBERGER JB, 1994, J THORAC CARDIOV SUR, V107, P838	63	13	16	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1744-165X	1878-0946		SEMIN FETAL NEONAT M	Semin. Fetal Neonatal Med.	FEB	2013	18	1					23	27		10.1016/j.siny.2012.10.002			5	Pediatrics	Pediatrics	081NJ	WOS:000314328600005	23158109				2020-06-30	J	Stucki, C; Sautter, AM; Wolff, A; Fleury-Souverain, S; Bonnabry, P				Stucki, Cyril; Sautter, Anna-Maria; Wolff, Adriana; Fleury-Souverain, Sandrine; Bonnabry, Pascal			Accuracy of preparation of i.v. medication syringes for anesthesiology	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article							ERRORS; INFUSIONS	Purpose. The results of a study of the accuracy of i.v. medication preparation by anesthesiologists are presented. Methods. The accuracy of syringe preparation was assessed by analyzing the contents of 500 unused syringes collected after adult and pediatric surgery procedures. The collected syringes contained various i.v. medication formulations representative of different preparation techniques: atracurium 1, 2.5, and 5 mg/mL and fentanyl 10, 20, 25, and 50 mu g/mL, which required serial dilution,after withdrawal of the drugs from ampuls; thiopental 5, 25, and 50 mg/mL, prepared by diluting reconstituted powdered drug from vials; and lidocaine 10-mg/mL solution, which was withdrawn directly from the ampul into a syringe. Variances between actual and labeled drug concentrations were determined via a validated ultraviolet-visible light spectrophotometry method. Results. Overall, 29% of the evaluated syringes were found to contain drug concentrations outside the designated range of acceptability (+/- 10% of the targeted concentration); 18% of preparations deviated from the declared dose by +/- 20%, 8% deviated by +/- 50%, and 4% deviated by +/- 100%. In one instance, the actual drug concentration was at variance with the labeled concentration by >100%. In 4% of cases (n = 20), discrepancies exceeded 100%, suggesting not just imprecision but errors in the preparation process, such as incorrect dilution calculations and selection of the wrong medication vial by the syringe preparer. Conclusion. Analysis of different i.v. formulations of four medications prepared in syringes by anesthesiologists revealed a high rate of discrepancies between ordered and actual drug concentrations, suggesting a need for increased institutional efforts to prevent errors during the preparation process. Am J Health-Syst Pharm. 2013; 70:137-42	[Stucki, Cyril; Bonnabry, Pascal] Univ Hosp Geneva, Pharm Cytotox Unit, CH-1211 Geneva 14, Switzerland; [Stucki, Cyril; Bonnabry, Pascal] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland; [Stucki, Cyril; Bonnabry, Pascal] Univ Lausanne, Geneva, Switzerland; [Sautter, Anna-Maria; Fleury-Souverain, Sandrine] Univ Hosp Geneva, Pharm Qual Control Unit, CH-1211 Geneva 14, Switzerland; [Wolff, Adriana] Univ Hosp Geneva, Serv Anaesthesiol, CH-1211 Geneva 14, Switzerland	Bonnabry, P (reprint author), Univ Hosp Geneva, Pharm Cytotox Unit, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland.	pascal.bonnabry@hcuge.ch					Abeysekera A, 2005, ANAESTHESIA, V60, P220, DOI 10.1111/j.1365-2044.2005.04123.x; [Anonymous], 1998, AM J HEALTH-SYST PH, V55, P165; Breckenridge A, 1976, REPORT WORKING PARTY, P9; Caporal-Gautier J, 1992, STP PHARM PRATIQUES, V2, P227; Ferner RE, 2001, BRIT J CLIN PHARMACO, V52, P573, DOI 10.1046/j.0306-5251.2001.01490.x; Gad SC, 2008, PHARM MANUFACTURING, P35; Garnerin P, 2007, EUR J CLIN PHARMACOL, V63, P769, DOI 10.1007/s00228-007-0319-z; Griffiths W, 2005, EJHP SCI, V11, P107; International Organization for Standardisation, 268252008 ISO; Kohn L., 2000, ERR IS HUMAN BUILDIN, P26; Parshuram CS, 2008, CAN MED ASSOC J, V178, P42, DOI 10.1503/cmaj.061743; Parshuram CS, 2006, ANN PHARMACOTHER, V40, P805, DOI 10.1345/aph.1G334; Parshuram CS, 2003, CRIT CARE MED, V31, P2483, DOI 10.1097/01.CCM.0000089638.83803.B2; STUCKI MC, 2008, [No title captured], V14, P14; Wheeler SJ, 2005, ANAESTHESIA, V60, P257, DOI 10.1111/j.1365-2044.2004.04062.x	15	14	14	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	JAN 15	2013	70	2					137	142		10.2146/ajhp110654			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	070AU	WOS:000313479000010	23292267				2020-06-30	J	Hudec, R; Tisonova, J; Foltan, V; Kristova, V				Hudec, R.; Tisonova, J.; Foltan, V; Kristova, V			Consumption of three strong opioids (morphine, oxycodone and fentanyl) in seven European countries during seven years (2003-2009)	BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY			English	Article						morphine; fentanyl; oxycodone; consumption; pain treatment	ANALGESICS; TRENDS; SPAIN	Purpose: The aim was to analyse the consumption of selected strong opioid analgesics during a seven-year period of 2003-2009 in order to compare Slovak consumption with that in six other European countries and to determine our position. Methods: Drug consumption data from the State Institute for Drug Control in Slovak Republic were used. As to the data from other countries, annual health statistics published on websites were used in comparison. Results: Obviously the consumption of one of studied opioid drugs with transdermal aplication route, particularly fentanyl, tended to increase in all countries during the observed period. Oxycodone tends to yield a rapid increase in consumption as well. As opposed to the latter drugs, the consumption of morphine was decreasing throughout the observed period. The consumption of these drugs in Slovakia remains low (except for that of fentanyl). Conclusion: Our analysis confirmed a clear shift from oral to transdermal therapy as well as usage of newer drugs. Drug consumption data are a relatively new source of information for health research. Our analysis showed increasing trends in fentanyl (patch opioid) consumption in all compared countries as well as an increasing consumption of oxycodone and decreasing consumption of morphine (Fig. 3, Ref. 17). Full Text in PDF www.elis.sk.	[Hudec, R.; Tisonova, J.; Kristova, V] Comenius Univ, Dept Pharmacol & Clin Pharmacol, Fac Med, SK-81372 Bratislava, Slovakia; [Foltan, V] Comenius Univ, Dept Org & Management Pharm, Fac Pharm, SK-81372 Bratislava, Slovakia	Hudec, R (reprint author), Comenius Univ, Dept Pharmacol & Clin Pharmacol, Fac Med, Spitalska 24, SK-81372 Bratislava, Slovakia.	dr.hudec@gmail.com					Chinellato A, 2011, EUR J PAIN, V15, P220, DOI 10.1016/j.ejpain.2010.11.005; Czech State Institute for Drug Control, SPOTR LEC CESK REP J; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Fredheim OMS, 2010, EUR J PAIN, V14, P289, DOI 10.1016/j.ejpain.2009.05.006; Geppetti P, 2009, CLIN DRUG INVEST, V29, P3, DOI 10.2165/0044011-200929001-00002; Hamunen K, 2008, EUR J PAIN, V12, P705, DOI 10.1016/j.ejpain.2007.10.012; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Hudec R, 2004, EUR J CLIN PHARMACOL, V60, P445, DOI 10.1007/s00228-004-0793-5; Hudec R, 2009, BRATISL MED J, V110, P316; International Narcotic Control Board, ANN REP DRUG CONS; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS63; Norwegian Institute of Public Health, DURG CONS NORW; Rosenquist RW, 2010, ANESTHESIOLOGY, V112, P810, DOI 10.1097/ALN.0b013e3181c43103; The Agency for Medicinal Products and Medical Devices of Croatia, ANN REP DRUG CONS; The Danish Medicines Agency, MED PROD STAT DENM	16	2	2	0	2	COMENIUS UNIV	BRATISLAVA I	SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA	0006-9248	1336-0345		BRATISL MED J	Bratisl. Med. J.		2013	114	10					581	583		10.4149/BLL_2013_124			3	Medicine, General & Internal	General & Internal Medicine	AA4JY	WOS:000331063100007	24156682	Bronze			2020-06-30	J	de Kort, EHM; Reiss, IKM; Simons, SHP				de Kort, Ellen H. M.; Reiss, Irwin K. M.; Simons, Sinno H. P.			Sedation of Newborn Infants for the INSURE Procedure, Are We Sure?	BIOMED RESEARCH INTERNATIONAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; POSITIVE AIRWAY PRESSURE; RESPIRATORY-DISTRESS-SYNDROME; SIGNIFICANT ARTERIAL-HYPOTENSION; UK NEONATAL UNITS; PRETERM INFANTS; ENDOTRACHEAL INTUBATION; INTERINDIVIDUAL VARIABILITY; SURFACTANT TREATMENT; ELECTIVE INTUBATION	Background. Neonatal intubation is a stressful procedure that requires premedication to improve intubation conditions and reduce stress and adverse physiological responses. Premedication used during the INSURE (INtubation, SURfactant therapy, Extubation) procedure should have a very short duration of action with restoration of spontaneous breathing within a few minutes. Aims. To determine the best sedative for intubation during the INSURE procedure by systematic review of the literature. Methods. We reviewed all relevant studies reporting on premedication, distress, and time to restoration of spontaneous breathing during the INSURE procedure. Results. This review included 12 studies: two relatively small studies explicitly evaluated the effect of premedication (propofol and remifentanil) during the INSURE procedure, both showing good intubation conditions and an average extubation time of about 20 minutes. Ten studies reporting on fentanyl or morphine provided insufficient information about these items. Conclusions. Too little is known in the literature to draw a solid conclusion on which premedication could be best used during the INSURE procedure. Both remifentanil and propofol are suitable candidates but dose-finding studies to detect effective nontoxic doses in newborns with different gestational ages are necessary.	[de Kort, Ellen H. M.; Reiss, Irwin K. M.; Simons, Sinno H. P.] Erasmus MC Sophia Childrens Hosp, Dept Pediat, Div Neonatol, NL-3015 GJ Rotterdam, Netherlands; [de Kort, Ellen H. M.] Maxima Med Ctr, Veldhoven, Netherlands	de Kort, EHM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat, Div Neonatol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.	e.dekort@telfort.nl	simons, sinno/AAC-7442-2019		Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [ZonMw 90713494]	The authors declare that there is no conflict of interests regarding the publication of this paper. Sinno H. P. Simons received a personal Grant from The Netherlands Organisation for Health Research and Development (ZonMw 90713494).	Allegaert K, 2007, BRIT J ANAESTH, V99, P864, DOI 10.1093/bja/aem294; Allegaert K, 2011, PEDIATR ANESTH, V21, P174, DOI 10.1111/j.1460-9592.2010.03482.x; Ancora G, 2010, ACTA PAEDIATR, V99, P1807, DOI 10.1111/j.1651-2227.2010.01910.x; Bohlin K, 2007, J PERINATOL, V27, P422, DOI 10.1038/sj.jp.7211754; Byrne E, 2006, ARCH DIS CHILD, V91, P79, DOI 10.1136/adc.2005.087635; Carbajal R, 2007, SEMIN PERINATOL, V31, P309, DOI 10.1053/j.semperi.2007.07.006; Chaudhary R, 2009, PEDIATR ANESTH, V19, P653, DOI 10.1111/j.1460-9592.2008.02829.x; Cherif A, 2008, AM J PERINAT, V25, P647, DOI 10.1055/s-0028-1090590; Choong K, 2010, ARCH DIS CHILD-FETAL, V95, pF80, DOI 10.1136/adc.2009.167338; Davis PJ, 2005, CLIN PHARMACOKINET, V44, P787, DOI 10.2165/00003088-200544080-00002; Deshpande G, 2009, EUR J PEDIATR, V168, P115, DOI 10.1007/s00431-008-0720-3; Flor-de-Lima F., 2012, CRITICAL CARE RES PR, V2012; Ghanta S, 2007, PEDIATRICS, V119, pE1248, DOI 10.1542/peds.2006-2708; Giannantonio C, 2009, ACTA PAEDIATR, V98, P1111, DOI 10.1111/j.1651-2227.2009.01318.x; Gizzi C., 2012, CRITICAL CARE RES PR, V2012; Kelleher J, 2009, ARCH DIS CHILD-FETAL, V94, pF332, DOI 10.1136/adc.2008.154518; Kumar P, 2010, PEDIATRICS, V125, P608, DOI 10.1542/peds.2009-2863; Lago P, 2008, PEDIATR ANESTH, V18, P736, DOI 10.1111/j.1460-9592.2008.02636.x; Lemyre B, 2009, ARCH DIS CHILD-FETAL, V94, pF439, DOI 10.1136/adc.2008.146068; Lemyre B., 2004, BMC PEDIAT, V4; Leone F, 2013, MINERVA PEDIATR, V65, P187; Nauta M, 2011, PEDIATR ANESTH, V21, P712, DOI 10.1111/j.1460-9592.2011.03552.x; Norman E, 2011, J PEDIATR-US, V159, P893, DOI 10.1016/j.jpeds.2011.06.003; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; Papoff P, 2008, PEDIATRICS, V121, P448, DOI 10.1542/peds.2007-3132; Penido MG, 2011, J PERINATOL, V31, P356, DOI 10.1038/jp.2010.135; Penido MG, 2010, ACTA PAEDIATR, V99, P1454, DOI 10.1111/j.1651-2227.2010.01868.x; Sammartino M, 2003, PAEDIATR ANAESTH, V13, P596, DOI 10.1046/j.1460-9592.2003.01101.x; Sammartino M, 2011, PEDIATR NEONATOL, V52, P176, DOI 10.1016/j.pedneo.2011.03.013; Sandri F, 2004, ARCH DIS CHILD-FETAL, V89, pF394, DOI 10.1136/adc.2003.037010; Sarkar S, 2006, J PERINATOL, V26, P286, DOI 10.1038/sj.jp.7211499; Silva YPE, 2008, PEDIATR ANESTH, V18, P176, DOI 10.1111/j.1460-9592.2007.02378.x; Silva YPE, 2007, ARCH DIS CHILD-FETAL, V92, P293, DOI 10.1136/adc.2006.105262; Silva YPE, 2005, PEDIATR ANESTH, V15, P993, DOI 10.1111/j.1460-9592.2005.01666.x; Simon L, 2004, CRIT CARE MED, V32, P565, DOI 10.1097/01.CCM.0000108883.58081.E3; Simons SHP, 2013, ACTA PAEDIATR, V102, pE487, DOI 10.1111/apa.12367; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Stevens TP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003063.pub3; Sweet DG, 2013, NEONATOLOGY, V103, P353, DOI 10.1159/000349928; Thewissen L, 2011, ARCH DIS CHILDHOOD-E, V96, P112, DOI 10.1136/adc.2008.145565; van den Berg E, 2010, ARCH DIS CHILD-FETAL, V95, pF53, DOI 10.1136/adc.2008.156414; Vanderhaegen J, 2010, NEONATOLOGY, V98, P57, DOI 10.1159/000271224; Venkatesh V, 2011, EUR J PEDIATR, V170, P223, DOI 10.1007/s00431-010-1290-8; Verder H, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.2.e24; VERDER H, 1994, NEW ENGL J MED, V331, P1051, DOI 10.1056/NEJM199410203311603; Veyckemans F, 2001, PAEDIATR ANAESTH, V11, P630, DOI 10.1046/j.1460-9592.2001.0750c.x; Welzing L, 2009, ACTA PAEDIATR, V98, P1416, DOI [10.1111/j.1651-2227.2009.01364.x, 10.1111/j.0803-5253.2009.01364.x]; Welzing L, 2006, DRUGS, V66, P1339, DOI 10.2165/00003495-200666100-00003; Welzing L, 2010, PEDIATR ANESTH, V20, P605, DOI 10.1111/j.1460-9592.2010.03330.x; Whyte S, 2000, ARCH DIS CHILD-FETAL, V82, pF38, DOI 10.1136/fn.82.1.F38	50	11	11	0	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2013									892974	10.1155/2013/892974			9	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	289QO	WOS:000329697300001		DOAJ Gold, Green Published			2020-06-30	J	Singh, GD; Kinjavdekar, P; Amarpal; Aithal, HP; Pawde, AM; Zama, MMS; Singh, J; Tiwary, R				Singh, Gyan D.; Kinjavdekar, Prakash; Amarpal; Aithal, Hari P.; Pawde, Abhijeet M.; Zama, Malik M. S.; Singh, Jasmeet; Tiwary, Ramesh			Clinicophysiological and haemodynamic effects of fentanyl with xylazine, medetomidine and dexmedetomidine in isoflurane-anaesthetised water buffaloes (Bubalus bubalis)	JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION			English	Article							DETOMIDINE; ANESTHESIA; CARDIOPULMONARY; PROPOFOL; HYPERGLYCEMIA; SEVOFLURANE; HALOTHANE; CLONIDINE; SEDATION	The present study was undertaken to investigate the sedative, analgesic and clinical effects of xylazine, medetomidine and dexmedetomidine with fentanyl as pre-anaesthetics in water buffaloes and to compare the dose-sparing effect of xylazine, medetomidine and dexmedetomidine on thiopental for induction and isoflurane for maintenance of anaesthesia in water buffaloes. Six male water buffaloes randomly received intravenous fentanyl (5.0 mu g/kg body weight) and xylazine (0.05 mg/kg body weight), fentanyl (5.0 mu g/kg body weight) and medetomidine (2.5 mu g/kg body weight), fentanyl (5.0 mu g/kg body weight) and dexmedetomidine (5.0 mu g/kg body weight) at weekly intervals in groups I1, I2 and I3, respectively. After 15 min, the animals were restrained in right lateral recumbency and anaesthesia was induced by 5% thiopental sodium administered intravenously. The intubated animal was connected to the large animal anaesthesia machine and isoflurane in 100% oxygen (5 L/min) was insufflated for 60 min. The treatments were compared by clinicophysiological, haematobiochemical and haemodynamic parameters. Fentanyl-medetomidine and fentanyl-dexmedetomidine produced more cardiovascular depression during the pre-anaesthetic period but less depression of cardio-respiratory dynamics in the post induction and maintenance period. Quicker recovery was recorded in I2 and I3 groups. A lower dose of thiopental was required in group I3 (4.33 mg/kg +/- 0.66 mg/kg) than in groups I2 (4.41 mg/kg +/- 0.98 mg/kg) and I1 (4.83 mg/kg +/- 0.79 mg/kg). The dose of isoflurane was less in group I3 (45.50 mL +/- 5.45 mL) than in group I1 and I2 (48.66 mL +/- 5.10 mL and 48.00 mL +/- 6.38 mL). Better anaesthesia was recorded with fentanyl-dexmedetomidine-thiopental-isoflurane (group I3) than with fentanyl-medetomidine-thiopental-isoflurane (group I2) and fentanyl-xylazine-thiopental-isoflurane (group I1). Fentanyl-medetomidine and fentanyl-dexmedetomidine were better pre-anaesthetic agents in comparison to fentanyl-xylazine for thiopental and isoflurane anaesthesia. Fentanyl-dexmedetomidine-thiopental-isoflurane and fentanyl-medetomidine-thiopental-isoflurane produced effective surgical anaesthesia and were found to be safe, as cardio-pulmonary functions were well preserved during maintenance anaesthesia with no deleterious effect on vital organ functions in water buffaloes.	[Singh, Gyan D.; Kinjavdekar, Prakash; Amarpal; Aithal, Hari P.; Pawde, Abhijeet M.; Zama, Malik M. S.; Singh, Jasmeet; Tiwary, Ramesh] Indian Vet Res Inst, Div Surg, Bareilly 243122, UP, India	Kinjavdekar, P (reprint author), Indian Vet Res Inst, Div Surg, Bareilly 243122, UP, India.	pk@ivri.res.in					Amarpal, 1998, INDIAN VET J, V75, P150; Ambrisko TD, 2002, CAN J VET RES, V66, P42; Branson K R, 2001, VET PHARM THERAPEUTI, P274; BROCKMAN RP, 1981, RES VET SCI, V30, P383, DOI 10.1016/S0034-5288(18)32565-7; Carroll GL, 1998, VET SURG, V27, P75, DOI 10.1111/j.1532-950X.1998.tb00101.x; Celly CS, 1997, J VET PHARMACOL THER, V20, P464, DOI 10.1046/j.1365-2885.1997.00097.x; Cullen LK, 1996, BRIT VET J, V152, P519, DOI 10.1016/S0007-1935(96)80005-4; CULLEN LK, 1993, VET REC, V132, P378, DOI 10.1136/vr.132.15.378; De Moor A., 1971, VET MED REV, V2, P163; EICHNER RD, 1979, AM J VET RES, V40, P127; GASTHUYS F, 1987, J VET MED A, V34, P641, DOI 10.1111/j.1439-0442.1987.tb00326.x; Hikasa Y, 2002, SMALL RUMINANT RES, V43, P167, DOI 10.1016/S0921-4488(02)00002-0; Hugar B, 1998, INDIAN VET MED J, V22, P139; Kastner SB, 2006, VET ANAESTH ANALG, V33, P8, DOI 10.1111/j.1467-2995.2005.00230.x; Kastner SBR, 2001, DEUT TIERARZTL WOCH, V108, P409; Kinjavdekar P., 2003, Buffalo Journal, V19, P349; KNIGHT AP, 1980, J AM VET MED ASSOC, V176, P454; KOKKONEN UM, 1987, J VET PHARMACOL THER, V10, P11, DOI 10.1111/j.1365-2885.1987.tb00070.x; KUMAR A, 1979, LAB ANIM SCI, V29, P486; Kuusela E, 2000, J VET PHARMACOL THER, V23, P15, DOI 10.1046/j.1365-2885.2000.00245.x; Kuusela E, 2003, J VET PHARMACOL THER, V26, P199, DOI 10.1046/j.1365-2885.2003.00465.x; MacDonald E., 1992, ANIMAL PAIN, P181; Malik V., 2008, THESIS DEEMED U; MASALA A, 1985, PHARMACOL RES COMMUN, V17, P293, DOI 10.1016/0031-6989(85)90104-3; MIRAKHUR KK, 1984, INDIAN J VET SURG, V3, P86; Mitchell MA, 1999, RES VET SCI, V67, P59, DOI 10.1053/rvsc.1998.0279; MUGE DK, 1994, VET REC, V135, P43, DOI 10.1136/vr.135.2.43; Pawde AM, 1996, SMALL RUMINANT RES, V20, P95, DOI 10.1016/0921-4488(95)00784-9; PESHIN PK, 1979, INDIAN VET J, V56, P864; PONDER S W, 1980, Journal of Veterinary Pharmacology and Therapeutics, V3, P203, DOI 10.1111/j.1365-2885.1980.tb00483.x; Raekallio M., 1991, Journal of Veterinary Anaesthesia, V18, P45; Ranheim B, 1999, J VET PHARMACOL THER, V22, P368, DOI 10.1046/j.1365-2885.1999.00231.x; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pa.33.040193.001331; RUGH KS, 1985, LAB ANIM SCI, V35, P178; RUSKOAHO H, 1986, ACTA VET SCAND, P17; SCHEININ H, 1989, PROG NEURO-PSYCHOPH, V13, P635, DOI 10.1016/0278-5846(89)90051-1; SCHEININ M, 1989, ACTA VET SCAND, P11; SERTEYN D, 1993, J VET PHARMACOL THER, V16, P199, DOI 10.1111/j.1365-2885.1993.tb00164.x; Siegel S, 1988, NONPARAMETERIC STAT; Sinclair MD, 2003, CAN VET J, V44, P885; Singh GD, 2010, INDIAN J ANIM SCI, V80, P613; SKARDA RT, 1992, [No title captured], P292; SNEDECOR GW, 1980, STAT METHODS; STENBERG D, 1989, ACTA VET SCAND, P21; Thurmon J., 1996, LUMB JONES VET ANAES; TIBIRICA E, 1991, J PHARMACOL EXP THER, V256, P606; Tilley L P, 1985, ESSENTIALS CANINE FE; Tranquilli W, 1993, ANAESTH PHARM REV, V1, P297; VENUGOPALAN CS, 1994, AM J VET RES, V55, P1148; WAGNER AE, 1991, AM J VET RES, V52, P651; Wilson DV, 2000, VET SURG, V29, P106, DOI 10.1111/j.1532-950X.2000.00106.x	51	10	10	0	8	AOSIS	CAPE TOWN	POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA	1019-9128	2224-9435		J S AFR VET ASSOC	J. S. Afr. Vet. Assoc.		2013	84	1							67	10.4102/jsava.v84i1.67			11	Veterinary Sciences	Veterinary Sciences	265FE	WOS:000327934500001	23718913	DOAJ Gold			2020-06-30	J	Ficklscherer, A; Kreuz, PC; Sievers, B; Gulecyuz, MF; Jansson, V; Muller, PE				Ficklscherer, Andreas; Kreuz, Peter C.; Sievers, Birte; Guelecyuez, Mehmet F.; Jansson, Volkmar; Mueller, Peter E.			Fentanyl is less toxic on adult human mesenchymal stem cells compared to ropivacaine when used intraarticularly. A controlled in vitro study	CONNECTIVE TISSUE RESEARCH			English	Article						Cell toxicity; human mesenchymal stem cells; intraarticular analgesia; local anesthetics and opioids	LOCAL-ANESTHETICS; PAIN RELIEF; BUPIVACAINE; CHONDROLYSIS; MORPHINE; SUFENTANIL; CARTILAGE; INFUSION; EXPOSURE; MODEL	The purpose of this study was to evaluate the toxicity of ropivacaine and fentanyl on adult human mesenchymal stem cells (hMSC). hMSC's were seeded in monolayer triple-flasks and then plated into 96-well plates at a density of 5000 cells per well. After fully aspirating the culture medium, ropivacaine or fentanyl in its corresponding concentration (0.5%, 0.25%, 0.125% for ropivacaine and 0.05%, 0.025%, 0.0125% for fentanyl) or culture medium only was added to each well. After 30 min, the anaesthetic was removed and fresh culture medium was added. hMSCs mitochondrial activity as a marker of cell proliferation and apoptosis marker was evaluated after 1, 24 h and 7 days. Proliferation was significantly decreased after a 30 min exposure to 0.5% and 0.125% ropivacaine, respectively compared to the control group after 24 h (p<0.001). Simultaneously, apoptosis was significantly induced. Proliferation of hMSC's was decreased after 24 h when exposed to 0.05%, 0.025% and 0.0125% fentanyl (p<0.001). Apoptosis was only induced 24 h after an exposure to 0.05% fentanyl. Our data suggest that both drugs have a concentration-dependent effect on proliferation in adult hMSC's in vitro. This effect was more distinct with ropivacaine compared to fentanyl. Translating these results into clinical practice, this in vitro study suggests fentanyl as a potentially less toxic analgetic drug for intraarticular application after arthroscopic bone marrow stimulation or rotator cuff repair with comparable to prolonged pain reduction.	[Ficklscherer, Andreas; Sievers, Birte; Guelecyuez, Mehmet F.; Jansson, Volkmar; Mueller, Peter E.] Univ Hosp Munich LMU, Dept Orthopaed Surg, D-81377 Munich, Germany; [Kreuz, Peter C.] Univ Hosp Rostock, Dept Orthopaed Surg, Rostock, Germany	Ficklscherer, A (reprint author), Univ Hosp Munich LMU, Dept Orthopaed Surg, Marchioninistr 15, D-81377 Munich, Germany.	andreas.ficklscherer@med.uni-muenchen.de					Anderson SL, 2010, ARTHROSCOPY, V26, P451, DOI 10.1016/j.arthro.2010.01.022; Anz A, 2009, ARTHROSCOPY, V25, P225, DOI 10.1016/j.arthro.2008.12.003; BRUN A, 1959, Acta Anaesthesiol Scand, V3, P59, DOI 10.1111/j.1399-6576.1959.tb00008.x; Cela O, 2010, MITOCHONDRION, V10, P487, DOI 10.1016/j.mito.2010.05.005; Chu CR, 2006, ARTHROSCOPY, V22, P693, DOI 10.1016/j.arthro.2006.05.006; Dogan N, 2004, J INT MED RES, V32, P513, DOI 10.1177/147323000403200509; Fedder C, 2010, CLIN EXP IMMUNOL, V162, P280, DOI 10.1111/j.1365-2249.2010.04252.x; FOSTER AH, 1980, ANESTH ANALG, V59, P727; Gomez-Arnau JI, 2003, BRIT J ANAESTH, V90, P189, DOI 10.1093/bja/aeg029; Gomoll AH, 2006, ARTHROSCOPY, V22, P813, DOI 10.1016/j.arthro.2006.06.006; Haasters F, 2011, KNEE SURG SPORT TR A; Hansen BP, 2007, AM J SPORT MED, V35, P1628, DOI 10.1177/0363546507304136; Jacobs TF, 2011, KNEE SURG SPORT TR A, V19, P1206, DOI 10.1007/s00167-011-1420-5; Kalso E, 1997, PAIN, V71, P127, DOI 10.1016/S0304-3959(97)03344-7; Karpie JC, 2007, AM J SPORT MED, V35, P1621, DOI 10.1177/0363546507304719; Kazemi Asif Perviz, 2004, Middle East Journal of Anesthesiology, V17, P1099; Kizilkaya M, 2004, ANESTH ANALG, V98, P1062, DOI 10.1213/01.ANE.0000103185.18333.68; Mayer-Wagner S, 2011, BIOELECTROMAGNETICS, V32, P283, DOI 10.1002/bem.20633; Moiniche S, 1999, REGION ANESTH PAIN M, V24, P430, DOI 10.1016/S1098-7339(99)90010-X; Nole R, 1985, Arthroscopy, V1, P123, DOI 10.1016/S0749-8063(85)80042-6; Petty DH, 2004, AM J SPORT MED, V32, P509, DOI 10.1177/0363546503262176; Piper SL, 2008, J BONE JOINT SURG AM, V90A, P986, DOI 10.2106/JBJS.G.01033; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; Unami Akira, 2003, J Toxicol Sci, V28, P77, DOI 10.2131/jts.28.77; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; Vranken JH, 2001, ANESTH ANALG, V92, P625, DOI 10.1213/00000539-200103000-00013; Wiater BP, 2011, J BONE JOINT SURG AM	29	3	3	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0300-8207	1607-8438		CONNECT TISSUE RES	Connect. Tissue Res.		2013	54	6					403	407		10.3109/03008207.2013.824431			5	Cell Biology; Orthopedics	Cell Biology; Orthopedics	249BT	WOS:000326752400009	23869613				2020-06-30	J	Guitart, J; Vargas, I; De Sanctis, V; Ferreras, J; Fuentes, J; Salazar, R; Vazquez, JM; Folch, J; Moya, J; Ribera, H; Rodelas, F; Tomas, A; Arilla, M; Coma, J; Aberasturi, T; Sintes, D; Lomban, E				Guitart, Jordi; Vargas, Isabel; De Sanctis, Vicente; Ferreras, Julia; Fuentes, Jose; Salazar, Rafael; Vazquez, Juan M.; Folch, Jordi; Moya, Jordi; Ribera, Hermann; Rodelas, Francisco; Tomas, Albert; Arilla, Maria; Coma, Joan; Aberasturi, Teresa; Sintes, Dolores; Lomban, Ester			Efficacy and Safety of Sublingual Fentanyl Orally Disintegrating Tablets in Patients with Breakthrough Pain: Multicentre Prospective Study	CLINICAL DRUG INVESTIGATION			English	Article							OPIOID-TOLERANT PATIENTS; CHRONIC NONCANCER PAIN; CANCER PAIN; BUCCAL TABLET; DOUBLE-BLIND; RELIEF; TOLERABILITY; PREVALENCE; MANAGEMENT; THERAPY	Background and Objectives The aim of this study was to evaluate the effectiveness and safety of sublingual fentanyl oral disintegrating tablets (sublingual fentanyl ODT) for the treatment of breakthrough pain (BTP), cancer or non-cancer related, in terms of relief of pain intensity, adverse events (AEs) and patient satisfaction, and to further examine the clinical and epidemiological profile of patients with BTP in a clinical setting. Methods A multicentre, prospective, open-label study was conducted in 19 pain units from Catalonia hospitals (Spain) over a 1-month period. Opioid-tolerant adult patients experiencing episodes of BTP intensity > 5 on a visual analogue scale (VAS) during the 12-24 h before screening or AEs related to their previous rescue medication for BTP received sublingual fentanyl ODT in the course of routine clinical practice and completed a 30-day study period consisting of five assessment points: days 0 (baseline), 3, 7, 15 and 30. The efficacy was assessed by collecting pain intensity and pain relief data at baseline and at each assessment. AEs were recorded by investigators throughout the study during clinic visits and telephone follow-ups. For all patients, titration was begun with an initial dose of 100 mu g. No more than two doses were allowed to treat an episode and patients might wait at least 4 h before treating another BTP episode with sublingual fentanyl ODT. The dose was increased by 100 mu g multiples up to 400 mu g as needed; and by 200 mu g multiples up from 400 to 800 mu g, the maximum titration step. Results A total of 182 patients were enrolled and 177 (97.2 %) completed the study: 37 had breakthrough cancer pain (BTcP) and 145 had breakthrough non-cancer pain (BTncP). The mean pain intensity showed a statistically significant improvement at the first assessment point and at all assessments thereafter (p < 0.0001). At the end of the study, the time lag between administration and first effect of sublingual fentanyl ODT was <= 10 min in 69.0 % (60 % BTcP and 71.2 % BTncP). The number of daily BTP episodes decreased in both groups, but it was statistically significant in BTcP. 114 patients (62.64 %) experienced AEs during the study. AEs recorded included nausea, vomiting, somnolence and constipation, and seven (4.49 %) were considered severe. No death or discontinuation was considered related to AEs. Conclusion Sublingual fentanyl ODT provided rapid and consistent relief from BTP, both in cancer and non-cancer patients. It was well-tolerated and well-accepted by patients in routine clinical practice.	[Guitart, Jordi; Vazquez, Juan M.; Folch, Jordi] Hosp Plato, Dept Anesthesiol, Barcelona 08006, Spain; [Vargas, Isabel] Hosp St Boi, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [De Sanctis, Vicente] Hosp Univ Capio Sagrat Cor, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Ferreras, Julia; Rodelas, Francisco] Hosp Residencia St Camil, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Fuentes, Jose] Pius Hosp de Valls, Dept Anesthesiol, Tarragona, Spain; [Salazar, Rafael] Hosp Comarcal dInca, Dept Anesthesiol, Palma De Mallorca, Spain; [Moya, Jordi] Hosp Mateu Orfila, Dept Anesthesiol, Pain Unit, Menorca, Spain; [Ribera, Hermann] Hosp Son Dureta, Dept Anesthesiol, Pain Unit, Palma De Mallorca, Spain; [Tomas, Albert] Fundacio Hosp St Bernabe, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Arilla, Maria] Hosp Esperanza, Dept Anesthesiol, Barcelona, Spain; [Coma, Joan] Hosp Gen Hosp, Dept Anesthesiol, Barcelona, Spain; [Aberasturi, Teresa] Hosp Comarcal de lAlt Penedes, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Sintes, Dolores] Hosp Municipal Badalona, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Lomban, Ester] Consorci Sanitari Terrassa, Dept Anesthesiol, Pain Unit, Barcelona, Spain	Guitart, J (reprint author), Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain.	jordi.guitart@hospitalplato.com					[Anonymous], 2011, P & T 3, V36, P2; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Darwish M, 2012, PAIN PRACT, V12, P307, DOI 10.1111/j.1533-2500.2011.00491.x; De Sanctis Briggs V, 2011, DOLOR, V26, P29; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Gatti A, 2010, CLIN DRUG INVEST, V30, P39, DOI 10.2165/1158413-S0-000000000-00000; Gatti A, 2009, CLIN DRUG INVEST, V29, P17, DOI 10.2165/0044011-200929001-00003; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE103; MERCADANTE S, 1992, PAIN, V50, P151, DOI 10.1016/0304-3959(92)90155-5; Nalamachu SR, 2011, CURR MED RES OPIN, V27, P751, DOI 10.1185/03007995.2011.554808; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Trinidad J. M., 2011, Rev. Soc. Esp. Dolor, V18, P207; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Webster Lynn R, 2011, J Opioid Manag, V7, P297; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	31	6	7	1	10	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.		2013	33	9					675	683		10.1007/s40261-013-0111-z			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	207YA	WOS:000323639500007	23881567				2020-06-30	J	Welzing, L; Link, F; Junghaenel, S; Oberthuer, A; Harnischmacher, U; Stuetzer, H; Roth, B				Welzing, Lars; Link, Florian; Junghaenel, Shino; Oberthuer, Andre; Harnischmacher, Urs; Stuetzer, Hartmut; Roth, Bernhard			Remifentanil-Induced Tolerance, Withdrawal or Hyperalgesia in Infants: A Randomized Controlled Trial. RAPIP Trial: Remifentanil-Based Analgesia and Sedation of Paediatric Intensive Care Patients	NEONATOLOGY			English	Article						Remifentanil; Infants; Tolerance; Withdrawal; Opioid-induced hyperalgesia	OPIOID-INDUCED HYPERALGESIA; YOUNG INFANTS; NEONATAL-RAT; CHILDREN; INFUSION; FENTANYL; SURGERY; UNIT; PHARMACOKINETICS; ANESTHESIA	Background: Short-acting opioids like remifentanil are suspected of an increased risk for tolerance, withdrawal and opioid-induced hyperalgesia (OIH). These potential adverse effects have never been investigated in neonates. Objectives: To compare remifentanil and fentanyl concerning the incidence of tolerance, withdrawal and OIH. Methods: 23 mechanically ventilated infants received up to 96 h either a remifentanil-or fentanyl-based analgesia and sedation regimen with low-dose midazolam. We compared the required opioid doses and the number of opioid dose adjustments. Following extubation, withdrawal symptoms were assessed by a modification of the Finnegan score. OIH was evaluated by the CHIPPS scale and by testing the threshold of the flexion withdrawal reflex with calibrated von Frey filaments. Results: Remifentanil had to be increased by 24% and fentanyl by 47% to keep the infants adequately sedated during mechanical ventilation. Following extubation, infants revealed no pronounced opioid withdrawal and low average Finnegan scores in both groups. Only 1 infant of the fentanyl group and 1 infant of the remifentanil group required methadone for treatment of withdrawal symptoms. Infants also revealed no signs of OIH and low CHIPPS scores in both groups. The median threshold of the flexion withdrawal reflex was 4.5 g (IQR = 2.3) in the fentanyl group and 2.7 g (IQR = 3.3) in the remifentanil group (p = 0.312), which is within the physiologic range of healthy infants. Conclusions: Remifentanil does not seem to be associated with an increased risk for tolerance, withdrawal or OIH. Copyright (c) 2013 S. Karger AG, Basel	[Welzing, Lars] Univ Hosp Bonn, Dept Neonatol, Childrens Hosp, DE-53105 Bonn, Germany; [Link, Florian; Junghaenel, Shino; Oberthuer, Andre; Roth, Bernhard] Univ Hosp Cologne, Dept Neonatol & Paediat Intens Care, Childrens Hosp, Cologne, Germany; [Harnischmacher, Urs] Univ Cologne, Clin Trials Ctr Cologne, D-50931 Cologne, Germany; [Stuetzer, Hartmut] Univ Hosp Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany	Welzing, L (reprint author), Univ Hosp Bonn, Dept Neonatol, Childrens Hosp, Sigmund Freud Str 25, DE-53105 Bonn, Germany.	lars.welzing@ukb.uni-bonn.de			GlaxoSmithKline (Munich, Germany)GlaxoSmithKline	This study was supported by a grant from GlaxoSmithKline (Munich, Germany) and by departmental sources. GSK had no influence on study design, data analysis or writing of the manuscript. Sponsor of the clinical trial according to GCP was the University of Cologne.	Abdulkader HM, 2008, EARLY HUM DEV, V84, P351, DOI 10.1016/j.earlhumdev.2007.09.018; Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Ceger P, 2000, PSYCHOPHARMACOLOGY, V150, P253, DOI 10.1007/s002130000413; Cortinez LI, 2001, BRIT J ANAESTH, V87, P866, DOI 10.1093/bja/87.6.866; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; Delvaux B, 2005, ANESTHESIOLOGY, V102, P1281, DOI 10.1097/00000542-200506000-00030; Duhrsen L, 2013, NEONATOLOGY, V103, P35, DOI 10.1159/000341769; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Fishbain DA, 2009, PAIN MED, V10, P829, DOI 10.1111/j.1526-4637.2009.00653.x; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Hunseler C, 2010, EUR J PEDIAT; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Osborn DA, 2010, COCHRANE DB SYST REV, V10; Ross AK, 2001, ANESTH ANALG, V93, P1393, DOI 10.1097/00000539-200112000-00008; Roulleau P, 2003, PAEDIATR ANAESTH, V13, P701, DOI 10.1046/j.1460-9592.2003.01102.x; Sammartino M, 2010, PEDIATR ANESTH, V20, P246, DOI 10.1111/j.1460-9592.2009.03241.x; Steinmetz J, 2007, PEDIATR ANESTH, V17, P32, DOI 10.1111/j.1460-9592.2006.01999.x; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Welzing L, 2012, INTENS CARE MED, V38, P1017, DOI 10.1007/s00134-012-2532-1	28	8	9	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1661-7800			NEONATOLOGY	Neonatology		2013	104	1					34	41		10.1159/000348790			8	Pediatrics	Pediatrics	178IU	WOS:000321442100007	23635551				2020-06-30	J	Holmgaard, R; Benfeldt, E; Sorensen, JA; Nielsen, JB				Holmgaard, R.; Benfeldt, E.; Sorensen, J. A.; Nielsen, J. B.			Chronological Age Affects the Permeation of Fentanyl through Human Skin in vitro	SKIN PHARMACOLOGY AND PHYSIOLOGY			English	Article						Human skin; Penetration; Age; Fentanyl; Static diffusion cells	PERCUTANEOUS-ABSORPTION; TRANSDERMAL FENTANYL; BARRIER FUNCTION; CLINICAL-PHARMACOLOGY; STRATUM-CORNEUM; OLDER-PEOPLE; PAIN; PHARMACOKINETICS; PENETRATION; VARIABILITY	Aim: To study the influence of chronological age on fentanyl permeation through human skin in vitro using static diffusion cells. Elderly individuals are known to be more sensitive to opioids and obtain higher plasma concentrations following dermal application of fentanyl compared to younger individuals. The influence of age - as an isolated pharmacokinetic term - on the absorption of fentanyl has not been previously studied. Method: Human skin from 30 female donors was mounted in static diffusion cells, and samples were collected during 48 h. Donors were divided into three age groups: <30 years of age (n = 6), = >= 30 and <60 years of age (n = 18) and = >= 60 years of age (n = 6). Results: The youngest group had a significantly higher mean absorption (3,100 ng/cm(2)) than the two other groups (2,000 and 1,475 ng/cm(2), respectively) and a significant larger AUC (young age group: 9,393 ng; middle and old age groups: 5,922 and 4,050 ng, respectively). Furthermore, the lag time and absorption rate were different between the three groups, with a significantly higher rate in the young participants versus the oldest participants. Conclusion: We demonstrate that fentanyl permeates the skin of young individuals in greater amounts and at a higher absorption rate than in middle-aged and old individuals in vitro. Copyright (c) 2013 S. Karger AG, Basel	[Holmgaard, R.] Univ Copenhagen, Roskilde Sygehus, Dept Plast Surg, Roskilde, Denmark; [Benfeldt, E.] Univ Copenhagen, Dept Dermatol, Roskilde Sygehus, Roskilde, Denmark; [Sorensen, J. A.] Odense Univ Hosp, Dept Plast & Reconstruct Surg, Odense, Denmark; [Holmgaard, R.; Nielsen, J. B.] Univ Southern Denmark, Inst Publ Hlth, Odense, Denmark	Holmgaard, R (reprint author), Univ Copenhagen, Dept Plast Surg, Koegevej 7-9, DK-4000 Roskilde, Denmark.	rikkeholmgaard@gmail.com	sorensen, jens/D-6279-2014	Sorensen, Jens Ahm/0000-0003-4903-0094			Bayer A, 2000, BRIT MED J, V321, P992, DOI 10.1136/bmj.321.7267.992; BRONAUGH RL, 1986, J PHARM SCI, V75, P1094, DOI 10.1002/jps.2600751115; Cepeda MS, 2003, CLIN PHARMACOL THER, V74, P102, DOI 10.1016/S0009-9236(03)00152-8; Christophers E, 1964, PERCUTANEOUS ABSORPT; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Crome P, 2011, DRUG AGING, V28, P667, DOI 10.2165/11591990-000000000-00000; DrugBank, 2012, OP DAT DRUG DRUG TAR; Farahmand S, 2009, INT J PHARMACEUT, V367, P1, DOI 10.1016/j.ijpharm.2008.11.020; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gloth FM, 2001, J AM GERIATR SOC, V49, P188, DOI 10.1046/j.1532-5415.2001.49041.x; Gniadecka M, 1998, BRIT J DERMATOL, V139, P815; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Hilmer SN, 2007, FUND CLIN PHARMACOL, V21, P217, DOI 10.1111/j.1472-8206.2007.00473.x; HOLDSWORTH MT, 1994, GERONTOLOGY, V40, P32; Kaestli LZ, 2008, DRUG AGING, V25, P269, DOI 10.2165/00002512-200825040-00001; KLIGMAN AM, 1979, J INVEST DERMATOL, V73, P39, DOI 10.1111/1523-1747.ep12532758; Kobayashi H, 2004, BRIT J DERMATOL, V150, P563, DOI 10.1046/j.1365-2133.2003.05741.x; Konda S, 2012, Skin Therapy Lett, V17, P5; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; Li L, 2006, ARCH DERMATOL RES, V297, P412, DOI 10.1007/s00403-005-0628-y; LOGKOW, 2012, DAT EV OCTN WAT PART; McLachlan AJ, 2011, BRIT J CLIN PHARMACO, V71, P351, DOI 10.1111/j.1365-2125.2010.03847.x; Meidan VM, 2008, TOXICOL IN VITRO, V22, P1062, DOI 10.1016/j.tiv.2008.01.009; Mercadante S, 2007, DRUG AGING, V24, P761, DOI 10.2165/00002512-200724090-00004; Neerken S, 2004, J BIOMED OPT, V9, P274, DOI 10.1117/1.1645795; Nielsen JB, 2011, SKIN PHARMACOL PHYS, V24, P93, DOI 10.1159/000322304; Nielsen JB, 2005, ARCH DERMATOL RES, V296, P560, DOI 10.1007/s00403-005-0555-y; Rogers J, 1996, ARCH DERMATOL RES, V288, P765, DOI 10.1007/s004030050138; ROSKOS KV, 1989, PHARMACEUT RES, V6, P949, DOI 10.1023/A:1015941412620; ROSKOS KV, 1986, DERMATOL CLIN, V4, P455, DOI 10.1016/S0733-8635(18)30808-8; ROSKOS KV, 1992, DRUG AGING, V2, P432, DOI 10.2165/00002512-199202050-00007; ROSKOS KV, 1989, J PHARMACOKINET BIOP, V17, P617, DOI 10.1007/BF01062121; Seyfarth F, 2011, CLIN DERMATOL, V29, P31, DOI 10.1016/j.clindermatol.2010.07.004; Tagami H, 2008, ARCH DERMATOL RES, V300, pS1, DOI 10.1007/s00403-007-0799-9; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Wilder-Smith OHG, 2005, EUR J PAIN, V9, P137, DOI 10.1016/j.ejpain.2004.07.011	37	10	10	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1660-5527			SKIN PHARMACOL PHYS	Skin Pharmacol. Physiol.		2013	26	3					155	159		10.1159/000348876			5	Dermatology; Pharmacology & Pharmacy	Dermatology; Pharmacology & Pharmacy	161BF	WOS:000320164700005	23736084				2020-06-30	J	Encinas, E; Calvo, R; Lukas, JC; Vozmediano, V; Rodriguez, M; Suarez, E				Encinas, Esther; Calvo, Rosario; Lukas, John C.; Vozmediano, Valvanera; Rodriguez, Monica; Suarez, Elena			A Predictive Pharmacokinetic/Pharmacodynamic Model of Fentanyl for Analgesia/Sedation in Neonates Based on a Semi-Physiologic Approach	PEDIATRIC DRUGS			English	Article							SYSTEMIC CLEARANCE PATHWAYS; CRITICALLY-ILL; COMPARATIVE PHARMACODYNAMICS; DRUG DISPOSITION; IN-VITRO; CHILDREN; PHARMACOKINETICS; INFANTS; SEDATION; AGE	Background and Objectives Fentanyl is a synthetic opioid commonly used as an anesthetic and also increasingly popular as a sedative agent in neonates. Initial dosage regimens in this population are often empirically derived from adults on a body weight basis. However, ontogenic maturation processes related to drug disposition are not necessarily always body weight correlates. We developed a predictive pharmacokinetic/pharmacodynamic model that includes growth and maturation physiologic changes for fentanyl in neonatal care. Methods Key pharmacokinetic variables and principles (protein binding, clearance, distribution) as related to fentanyl pharmacokinetic/pharmacodynamic behavior in adults (tricompartmental model) and to neonatal physiologic data (organ weights and blood flows, body composition, renal and hepatic function, etc.) were used to guide the building of a semi-physiologic ontogenic model. The model applies to a normal-term neonate without any other intervention. Then, extension to a pharmacokinetic/pharmacodynamic link model for fentanyl was made. The final model was evaluated by predicting the time course of plasma concentrations and the effect of a standard regimen of 10.5 mu g/kg over a 1-h period followed by 1.5 mu g/kg/h for 48 h. Results Hepatic clearance was linked to ontogeny of unbound fraction and of alpha(1)-acid glycoprotein. All parameters were reduced in the neonate compared to adults but in a differing proportion due to qualitative changes in physiology that are analyzed and accounted for. Systemic clearance (CLS), volume of the central compartment (V-1) and steady-state volume of distribution predicted by the model were 0.028 L/min, 1.26 L, and 22.04 L, respectively. Weight-corrected parameters generally decreased in adults compared with neonates, but differentially, e.g., CLS = 0.0093 versus 0.0088 L/min/kg, while V-1 = 0.42 versus 0.18 L/kg (neonates vs. adults). Under such complexity a pharmacokinetic/pharmacodynamic model is the appropriate method for rational efficacy targeting. Fentanyl pharmacodynamics in neonates were considered to be similar to those in adults except for the equilibrium rate constant, which was also scaled on an ontogenic basis. The model adequately predicted the reported mean expected concentration time profiles for the standard regimen. Conclusions Integrated pharmacokinetic/pharmacodynamic modeling showed that the usually prescribed dosage regimens of fentanyl in neonates may not always provide the optimum degree of sedation. The model could be used in optimal design of clinical trials for this vulnerable population. Prospective clinical testing is the reasonable next step.	[Encinas, Esther; Lukas, John C.; Suarez, Elena] Univ Basque Country, Sch Med, Dept Pharmacol, Leioa, Spain; [Calvo, Rosario; Lukas, John C.; Vozmediano, Valvanera; Rodriguez, Monica] Dynakin SL, Derio 48160, Vizcaya, Spain	Calvo, R (reprint author), Dynakin SL, PTB Suite 801, Derio 48160, Vizcaya, Spain.	rcalvo@dynakin.com		Suarez, Elena/0000-0002-6683-4847	Basque Country GovernmentBasque Government; Spanish Ministry of Science and Innovation-MICINNSpanish Government [ITP-09000-2010-002]; Ikerbasque Visiting Professor Grant	At the time of preparation of this study, Rosario Calvo was employed at the Department of Pharmacology, School of Medicine, University of the Basque Country, Leioa, Spain. This study was supported by a predoctoral grant to one of the authors (Esther Encinas) from the Research Staff Training Program (Basque Country Government) and by an INNPACTO project of the Spanish Ministry of Science and Innovation-MICINN (ITP-09000-2010-002). One of the investigators (John C. Lukas) was supported by an Ikerbasque Visiting Professor Grant. Esther Encinas, Rosario Calvo, John C. Lukas, Valvanera Vozmediano, Monica Rodriguez, and Elena Suarez have no conflicts of interest that are directly relevant to the content of this study.	Alcorn J, 2002, CLIN PHARMACOKINET, V41, P1077, DOI 10.2165/00003088-200241130-00005; Alcorn J, 2002, CLIN PHARMACOKINET, V41, P959, DOI 10.2165/00003088-200241120-00003; Allegaert K, 2007, PEDIATR ANESTH, V17, P1028, DOI 10.1111/j.1460-9592.2007.02285.x; Anderson BJ, 2010, BEST PRACT RES-CLIN, V24, P419, DOI 10.1016/j.bpa.2010.02.019; Anderson BJ, 2010, PEDIATR ANESTH, V20, P223, DOI 10.1111/j.1460-9592.2009.03072.x; Anderson BJ, 2009, DRUG METAB PHARMACOK, V24, P25, DOI 10.2133/dmpk.24.25; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; Baber N, 2003, BRIT J CLIN PHARMACO, V56, P489, DOI 10.1046/j.1365-2125.2003.01901.x; Bellanti F, 2011, EUR J CLIN PHARMACOL, V67, pS75, DOI 10.1007/s00228-010-0974-3; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; Bjorkman S, 2006, CLIN PHARMACOKINET, V45, P1; Bjorkman S, 2005, BRIT J CLIN PHARMACO, V59, P691, DOI 10.1111/j.1365-2125.2004.02225.x; BLAIN PG, 1985, BRIT J CLIN PHARMACO, V20, P500, DOI 10.1111/j.1365-2125.1985.tb05107.x; Booker PD, 1996, BRIT J ANAESTH, V76, P365; Bouillon-Pichault M, 2011, J PHARMACOKINET PHAR, V38, P25, DOI 10.1007/s10928-010-9173-1; Bouzom F, 2008, FUND CLIN PHARMACOL, V22, P579, DOI 10.1111/j.1472-8206.2008.00648.x; CHAY PCW, 1992, CLIN PHARMACOL THER, V51, P334, DOI 10.1038/clpt.1992.30; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; Edginton AN, 2006, CLIN PHARMACOKINET, V45, P1013, DOI 10.2165/00003088-200645100-00005; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Franck LS, 1998, J PAIN SYMPTOM MANAG, V15, P41, DOI 10.1016/S0885-3924(97)00272-8; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; Hayton WL, 2000, AAPS PHARMSCI, V2, part. no.; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; *ICRP, 2002, [No title captured], V32, P5; JacqzAigrain E, 1996, CLIN PHARMACOKINET, V31, P423, DOI 10.2165/00003088-199631060-00003; JOHNSON K L, 1984, Anesthesiology (Hagerstown), V61, pA441, DOI 10.1097/00000542-198409001-00441; Johnson TN, 2006, CLIN PHARMACOKINET, V45, P931, DOI 10.2165/00003088-200645090-00005; Kalvass JC, 2007, J PHARMACOL EXP THER, V323, P346, DOI 10.1124/jpet.107.119560; Knibbe CAJ, 2011, INT J PHARMACEUT, V415, P9, DOI 10.1016/j.ijpharm.2011.02.056; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; KOREN G, 1984, ANESTH ANALG, V63, P577; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Manolis E, 2011, PEDIATR ANESTH, V21, P214, DOI 10.1111/j.1460-9592.2011.03523.x; McNamara PJ, 2002, AAPS PHARMSCI, V4; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Reed MD, 1996, CRIT CARE MED, V24, P175, DOI 10.1097/00003246-199601000-00030; Rigby-Jones AE, 2002, ANESTHESIOLOGY, V97, P1393, DOI 10.1097/00000542-200212000-00010; Rostami-Hodjegan A, 2007, NAT REV DRUG DISCOV, V6, P140, DOI 10.1038/nrd2173; ROTH B, 1991, DEV PHARMACOL THERAP, V17, P121, DOI 10.1159/000457510; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Santeiro M L, 1997, J Perinatol, V17, P135; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SHAFER SL, 1993, SEMIN ANESTH, V12, P222; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; Tobias J D, 1999, Paediatr Drugs, V1, P109, DOI 10.2165/00128072-199901020-00004; Tod M, 2008, CLIN PHARMACOKINET, V47, P231, DOI 10.2165/00003088-200847040-00002; VEROTTA D, 1989, AM J PHYSL, V256; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; Yassen A, 2006, J PHARMACOL EXP THER, V319, P682, DOI 10.1124/jpet.106.107953	56	13	14	0	8	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1174-5878	1179-2019		PEDIATR DRUGS	Pediatr. Drugs		2013	15	3					247	257		10.1007/s40272-013-0029-1			11	Pediatrics; Pharmacology & Pharmacy	Pediatrics; Pharmacology & Pharmacy	164RB	WOS:000320426100008	23657896				2020-06-30	J	Parikh, N; Goskonda, V; Chavan, A; Dillaha, L				Parikh, Neha; Goskonda, Venkat; Chavan, Ashok; Dillaha, Larry			Pharmacokinetics and Dose Proportionality of Fentanyl Sublingual Spray: a Single-Dose 5-Way Crossover Study	CLINICAL DRUG INVESTIGATION			English	Article							BREAKTHROUGH PAIN; CANCER-PATIENTS; DRUG-DELIVERY; PREVALENCE	Fentanyl sublingual spray is a novel formulation of fentanyl for sublingual delivery that was designed to enhance the rate and extent of absorption of fentanyl for management of breakthrough cancer pain (BTCP). The primary objective of this study was to determine the pharmacokinetics and dose proportionality of 5 different doses (100, 200, 400, 600, and 800 mu g) of fentanyl sublingual spray in healthy subjects under fasted conditions (part A); the secondary objective was to assess the effects of temperature and pH in the oral cavity on relative bioavailability of fentanyl (part B). Analyses were performed on venous blood samples drawn 5 min to 36 h after administration of fentanyl sublingual spray (Subsys(A (R)), Insys Therapeutics, Inc., Chandler, AZ, USA). Part A of this phase I study was a 5-treatment, 5-sequence, 5-period crossover study in which subjects received a single treatment of each of the 5 fentanyl sublingual spray doses. Dose proportionality was assessed using analysis of variance and linear regression techniques. Part B was a 5-treatment, 2-sequence, 5-period crossover study in which subjects received a single assigned dose of fentanyl sublingual spray 200 mu g under the following 5 conditions: no pretreatment, pretreatment with cold or hot beverage, and pretreatment with low- or high-pH beverage. Naltrexone was administered to block potential opioid effects associated with fentanyl. Adverse events (AEs) were monitored and recorded throughout the study. Fifty-three subjects (15 men, 38 women; mean age, 31 years) were enrolled in part A. Fourteen subjects (11 men, 3 women; mean age, 32 years) were enrolled in part B. The first quantifiable mean plasma concentrations of fentanyl were observed at the first sample time (5 min) for all doses. Mean maximum plasma concentration (C (max)) increased with increases in dose, whereas median time to reach C (max) (t (max)) tended to decrease with increases in dose. The dose-normalized C (max), area under the plasma concentration-time curve from time zero to infinity (AUC(a)), and AUC from time zero to time of last measurable concentration (AUC(last)) values were linear and consistent with dose proportionality across the 100-800 mu g dose range. Pretreatment of the oral cavity with a cold or hot beverage, or low- or high-pH beverage, did not appreciably alter fentanyl absorption (C (max) and AUC(a) values). The most commonly reported AEs were nausea and vomiting. In healthy subjects, administration of fentanyl sublingual spray produced a rapid rise in fentanyl plasma concentrations. Dose-dependent parameters (C (max) and AUC) showed dose proportionality across the range of 100-800 mu g. Altering the local environment of the oral cavity (temperature and pH) showed no effects on the bioavailability of fentanyl. The rapid and predictable rise in plasma fentanyl concentrations following administration of fentanyl sublingual spray corresponds with the rapid onset and duration of many BTCP episodes.	[Parikh, Neha; Goskonda, Venkat; Chavan, Ashok; Dillaha, Larry] INSYS Therapeut Inc, Chandler, AZ 85224 USA	Parikh, N (reprint author), INSYS Therapeut Inc, 444 South Ellis Rd, Chandler, AZ 85224 USA.	nparikh@insysrx.com			Insys Therapeutics, Inc., Chandler, AZ, USA	This study was funded by Insys Therapeutics, Inc., Chandler, AZ, USA. Technical editorial and medical writing support was provided by Michael Shaw, PhD, for Synchrony Medical Communications, LLC, West Chester, PA, USA. Funding for this support was provided by Insys Therapeutics, Inc., Chandler, AZ, USA. All authors are full-time employees of Insys Therapeutics, Inc., Chandler, AZ, USA.	Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; HARRIS D, 1992, J PHARM SCI-US, V81, P1, DOI 10.1002/jps.2600810102; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; *INSY THER INC, 2012, SUBSYS FENT SUBL SPR; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Narang N, 2011, INT J PHARM PHARM S2, V3, P18; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Nicholson Bruce, 2011, J Opioid Manag, V7, P69; PARIKH N, 2012, J PAIN S4, V13, pS78; Pather SI, 2001, DRUG DELIV TECH, V1, P54; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Shojaei AH, 1999, INT J PHARMACEUT, V192, P139, DOI 10.1016/S0378-5173(99)00301-4; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Venkatalakshmi R, 2012, INT J PHARM SCI RES, V3, P35, DOI 10.13040/IJPSR.0975-8232.3(1).35-41; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	27	11	11	0	8	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.		2013	33	6					391	400		10.1007/s40261-013-0079-8			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	151RS	WOS:000319478500001	23605506				2020-06-30	J	Lotsch, J; Walter, C; Parnham, MJ; Oertel, BG; Geisslinger, G				Loetsch, Joern; Walter, Carmen; Parnham, Michael J.; Oertel, Bruno G.; Geisslinger, Gerd			Pharmacokinetics of Non-Intravenous Formulations of Fentanyl	CLINICAL PHARMACOKINETICS			English	Review							POSTOPERATIVE PAIN MANAGEMENT; OLFACTORY VECTOR HYPOTHESIS; TRANSDERMAL FENTANYL; BREAKTHROUGH PAIN; DOUBLE-BLIND; CANCER PAIN; BUCCAL TABLET; MU-G; COMPARATIVE PHARMACODYNAMICS; RELATIVE BIOAVAILABILITY	Fentanyl was structurally designed by Paul Janssen in the early 1960s as a potent opioid analgesic (100-fold more potent than morphine). It is a full agonist at mu-opioid receptors and possesses physicochemical properties, in particular a high lipophilicity (octanol: water partition coefficient >700), which allow it to cross quickly between plasma and central nervous target sites (transfer half-life of 4.7-6.6 min). It undergoes first-pass metabolism via cytochrome P450 3A (bioavailability similar to 30 % after rapid swallowing), which can be circumvented by non-intravenous formulations (bioavailability 50-90 % for oral transmucosal or intranasal formulations). Non-intravenous preparations deliver fentanyl orally-transmucosally, intranasally or transdermally. Passive transdermal patches release fentanyl at a constant zero-order rate for 2-3 days, making them suitable for chronic pain management, as are iontophoretic transdermal systems. Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively. Intranasal formulations partly bypass the blood-brain barrier and deliver a fraction of the dose directly to relevant brain target sites, providing ultra-fast analgesia for breakthrough pain. Thanks to the development of non-intravenous pharmaceutical formulations, fentanyl has become one of the most successful opioid analgesics, and can be regarded as an example of a successful reformulation strategy of an existing drug based on pharmacokinetic research and pharmaceutical technology. This development broadened the indications for fentanyl beyond the initial restriction to intra-or perioperative clinical uses. The clinical utility of fentanyl could be expanded further by more comprehensive mathematical characterizations of its parametric pharmacokinetic input functions as a basis for the rational selection of fentanyl formulations for individualized pain therapy.	[Loetsch, Joern; Walter, Carmen; Geisslinger, Gerd] JW Goethe Univ Hosp, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, D-60590 Frankfurt, Germany; [Parnham, Michael J.; Oertel, Bruno G.] Fraunhofer IME Project Grp Translat Med & Pharmac, Frankfurt, Germany	Lotsch, J (reprint author), JW Goethe Univ Hosp, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	j.loetsch@em.uni-frankfurt.de	Parnham, Michael J/D-8733-2014	Parnham, Michael J/0000-0002-7098-8451; Lotsch, Jorn/0000-0002-5818-6958	"Landesoffensive zur Entwicklung wissenschaftlich-okonomischer Exzellenz'': "LOEWE-Schwerpunkt: Anwendungsorientierte Arzneimittelforschung''	"Landesoffensive zur Entwicklung wissenschaftlich-okonomischer Exzellenz'': "LOEWE-Schwerpunkt: Anwendungsorientierte Arzneimittelforschung'' (JL and GG) for supporting the pharmacological research environment for human pharmacokinetics in a comprehensive drug development facility located at the bridge between pharmacological research in academia and in the pharmaceutical industry, hosted in the "Fraunhofer Project Group Translational Medicine and Pharmacology (IME-TMP)'' at Frankfurt am Main, Germany. The authors have declared that no competing interests exist. This paper was written using Free Software programs on an office and home PC running Ubuntu GNU/Linux.	Andresen T, 2011, BASIC CLIN PHARMACOL, V108, P274, DOI 10.1111/j.1742-7843.2010.00649.x; [Anonymous], 2006, INTERNATIONAL NARCOT; Archimedes Pharma Germany GmbH, 2010, PECFENT FACHINFORMAT; Archimedes Pharma US Inc, 2012, LAZANDA FULL PRESCRI; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; BENDE M, 1983, ACTA OTO-LARYNGOL, V96, P277, DOI 10.3109/00016488309132900; BENTLEY JB, 1983, CLIN PHARMACOL THER, V34, P703, DOI 10.1038/clpt.1983.235; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; BOWER S, 1981, J PHARM PHARMACOL, V33, P507, DOI 10.1111/j.2042-7158.1981.tb13849.x; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; Cephalon Europe, 2011, EFFENTORA FACHINFORM; Cephalon Inc, 2011, ACTIQ FULL PRESCRIBI; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Curtiss Carol P, 2011, Evid Based Nurs, V14, P90, DOI 10.1136/ebn1150; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Darwish M, 2012, PAIN PRACT, V12, P307, DOI 10.1111/j.1533-2500.2011.00491.x; Darwish M, 2010, PERSPECT MED CHEM, V4, P11; de Lange ECM, 1998, PHARM RES-DORDR, V15, P1657, DOI 10.1023/A:1011988024295; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Djupesland PG, 2006, LARYNGOSCOPE, V116, P466, DOI 10.1097/01.MLG.0000199741.08517.99; Doty RL, 2008, ANN NEUROL, V63, P7, DOI 10.1002/ana.21327; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Finn Andrew L, 2011, J Pain Res, V4, P245, DOI 10.2147/JPR.S22641; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Flockhart DA, 2007, DRUG INTERACTIONS CY; Forsgren J, 2010, J PHARM SCI-US, V99, P219, DOI 10.1002/jps.21814; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gharagozlou Parham, 2006, BMC Pharmacol, V6, P3, DOI 10.1186/1471-2210-6-3; Gharagozlou Parham, 2003, BMC Pharmacol, V3, P1, DOI 10.1186/1471-2210-3-1; Gharagozlou P, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-19; GmbH Janssen-Cilag, 2011, DUROGESIC SMAT FACHI; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Graff CL, 2005, J PHARM SCI-US, V94, P1187, DOI 10.1002/jps.20318; GUERTNER T, 1964, Anaesthesist, V13, P183; HABERER JP, 1982, BRIT J ANAESTH, V54, P1267, DOI 10.1093/bja/54.12.1267; Hermann DJ, 1999, CLIN PHARMACOL THER, V65, P511, DOI 10.1016/S0009-9236(99)70070-6; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1; HULL CJ, 1978, BRIT J ANAESTH, V50, P1113, DOI 10.1093/bja/50.11.1113; Illum L, 1996, BIOPHARM DRUG DISPOS, V17, P717, DOI 10.1002/(SICI)1099-081X(199611)17:8<717::AID-BDD985>3.0.CO;2-I; Insys Therapeutics Inc, 2012, SUBSYS FULL PRESCRIB; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; Janssen Pharmaceuticals Inc, 2011, DURAGESIC FULL PRESC; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Kern S, 2007, ANESTHESIOLOGY, V107, pA1085; Kesimci E, 2012, GENE, V493, P273, DOI 10.1016/j.gene.2011.11.040; Koehntop DE, 1997, PHARMACOTHERAPY, V17, P746; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; LEHMANN KA, 1983, ANAESTHESIST, V32, P165; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Levin TT, 2010, GEN HOSP PSYCHIAT, V32; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lotsch J, 2010, PHARMACOGENET GENOM, V20, P291, DOI 10.1097/FPC.0b013e3283386bda; Lotsch J, 2009, PHARMACOGENET GENOM, V19, P429, DOI 10.1097/FPC.0b013e32832b89da; LOO JCK, 1968, J PHARM SCI, V57, P918, DOI 10.1002/jps.2600570602; Lotsch J, 2001, ANESTHESIOLOGY, V95, P1329; Lotsch J, 1999, ANESTHESIOLOGY, V90, P1026, DOI 10.1097/00000542-199904000-00016; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Meda Pharmaceuticals Inc, 2011, ONSOLIS FULL PRESCRI; MEERT TF, 1988, EUR J ANAESTH, V5, P313; Mibe GmbH Arzneimittel, 2010, FENTADOLON FACHINFOR; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; NHS Information Centre, 2007, PRESCRIPTION COST AN; Nugroho AK, 2005, PHARM RES-DORDR, V22, P335, DOI 10.1007/s11095-004-1870-2; Nycomed Danmark ApS, 2011, INSTANYL FACHINFORMA; Oda Y, 1999, BRIT J ANAESTH, V82, P900; Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Prediger RDS, 2012, NEUROTOX RES, V21, P90, DOI 10.1007/s12640-011-9281-8; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; ProStrakan Ltd, 2010, ABSTRAL SUMMARY OF P; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; SANDLER A, 1992, J PAIN SYMPTOM MANAG, V7, pS27, DOI 10.1016/0885-3924(92)90050-R; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; SCHNEIDER E, 1986, N-S ARCH PHARMACOL, V334, P267, DOI 10.1007/BF00508781; Schroder B, 2012, J PHARM SCI-US, V101, P2262, DOI 10.1002/jps.23108; Schroder B, 2012, J PHARM SCI-US, V101, P245, DOI 10.1002/jps.22765; Schwabe U, 2008, ARZNEIVERORDNUNGS RE, P232; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Sevarino FB, 1997, J CLIN ANESTH, V9, P173, DOI 10.1016/S0952-8180(97)00043-3; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Skarke C, 2003, CLIN PHARMACOL THER, V73, P107, DOI 10.1067/mcp.2003.5; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; STANSKI DR, 1979, ANESTHESIOLOGY, V51, P235, DOI 10.1097/00000542-197909000-00011; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; TAEGER K, 1988, BRIT J ANAESTH, V61, P425, DOI 10.1093/bja/61.4.425; Takashina Y, DRUG METAB PHARMACOK; Thurlkill RL, 2005, J CARDIOTHOR VASC AN, V19, P759, DOI 10.1053/j.jvca.2004.11.039; Twycross R, 2007, PALLIATIVE CARE FORM, P269; UNADKAT JD, 1986, CLIN PHARMACOL THER, V40, P86, DOI 10.1038/clpt.1986.143; Upton RN, 2004, BRIT J ANAESTH, V93, P687, DOI 10.1093/bja/aeh261; Uysalel A, 1995, ARTHROSCOPY, V11, P660, DOI 10.1016/0749-8063(95)90105-1; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Walter C, 2009, CLIN PHARMACOKINET, V48, P625, DOI 10.2165/11317200-000000000-00000; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Wang F, 2008, J CLIN PHARMACOL, V48, P719, DOI 10.1177/0091270008315956; Waters CM, 2000, ANESTHESIOLOGY, V93, P825, DOI 10.1097/00000542-200009000-00033; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; Wu WD, 2009, MOL DIAGN THER, V13, P331, DOI 10.2165/11317320-000000000-00000; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025; Zaveri N, 2001, EUR J PHARMACOL, V428, P29, DOI 10.1016/S0014-2999(01)01282-1; Zhang W, 2010, ANAESTHESIA, V65, P130, DOI 10.1111/j.1365-2044.2009.06193.x; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	139	49	52	1	44	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0312-5963	1179-1926		CLIN PHARMACOKINET	Clin. Pharmacokinet.	JAN	2013	52	1					23	36		10.1007/s40262-012-0016-7			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	138QA	WOS:000318522200003	23100195				2020-06-30	J	Moriyama, A; Nishizawa, D; Kasai, S; Hasegawa, J; Fukuda, K; Nagashima, M; Katoh, R; Ikeda, K				Moriyama, Ayako; Nishizawa, Daisuke; Kasai, Shinya; Hasegawa, Junko; Fukuda, Ken-ichi; Nagashima, Makoto; Katoh, Ryoji; Ikeda, Kazutaka			Association Between Genetic Polymorphisms of the beta(1)-Adrenergic Receptor and Sensitivity to Pain and Fentanyl in Patients Undergoing Painful Cosmetic Surgery	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						beta(1)-adrenergic receptor; gene polymorphism; opioid; pain; individual difference	INDIVIDUAL SENSITIVITY; BETA-BLOCKADE; BED NUCLEUS; PROTEIN; INJECTION; HAPLOTYPE; OPIATES; HUMANS; RATS	Individual differences in the sensitivity to fentanyl, a widely used opioid analgesic, can hamper effective pain treatment. The adrenergic system is reportedly involved in the mechanisms of pain and analgesia. Here, we focused on one of the adrenergic receptor genes, ADRB1, and analyzed the influence of single-nucleotide polymorphisms (SNPs) in the ADRB1 gene on individual differences in pain and analgesic sensitivity. We examined associations between pain and fentanyl sensitivity and the two SNPs, A145G and G1165C, in the human ADRB1 gene in 216 Japanese patients who underwent painful orofacial cosmetic surgery, including bone dissection. The patients who carried the A-allele of the A145G SNP were more sensitive to cold pressor -induced pain than those who did not carry this allele, especially in male patients. The analgesic effect was significantly less in females who carried the G-allele of the G1165C SNP than the females who did not carry the G-allele. The haplotype analysis revealed a significant decrease in 24-h postoperative fentanyl use in female 145A/1165C haplotype carriers. These results suggest that SNPs in the ADRB1 gene are associated with individual differences in pain and analgesic sensitivity, and analyzing these SNPs may promote personalized pain treatment in the future.	[Moriyama, Ayako; Nishizawa, Daisuke; Kasai, Shinya; Hasegawa, Junko; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Substance Project, Setagaya Ku, Tokyo 1568506, Japan; [Moriyama, Ayako; Nagashima, Makoto; Katoh, Ryoji] Toho Univ, Sakura Med Ctr, Dept Surg, Sakura, Chiba 2858741, Japan; [Fukuda, Ken-ichi] Tokyo Dent Coll, Div Dent Anesthesiol, Dept Oral Hlth & Clin Sci, Suidoubashi Hosp,Orofacial Pain Ctr,Chiyoda Ku, Tokyo 1010061, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Substance Project, Setagaya Ku, 2-1-6 Kamimitazawa, Tokyo 1568506, Japan.	ikeda-kz@igakuken.or.jp	Nishizawa, Daisuke/G-6933-2013; Ikeda, Kazutaka/I-4694-2013	Ikeda, Kazutaka/0000-0001-8342-0278	MEXT of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20390162, 23390377]; MHLW of Japan [H21-3jigan-ippan-011]; Smoking Research Foundation	We acknowledge Mr. Michael Arends for his assistance with editing the manuscript. The authors are grateful to the volunteers for their participation in the study and the anesthesiologists and surgeons at Tokyo Dental College Suidoubashi Hospital for collecting clinical data. This work was supported by Grants-in-Aid from the MEXT of Japan (20390162, 23390377), MHLW of Japan (H21-3jigan-ippan-011), and Smoking Research Foundation. The authors declare no conflict of interest.	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Brodde OE, 2008, PHARMACOL THERAPEUT, V117, P1, DOI 10.1016/j.pharmthera.2007.07.002; Cairns BE, 2001, J NEUROPHYSIOL, V86, P782; CHAUVIN M, 1986, ANESTH ANALG, V65, P999; Chia YY, 2004, BRIT J ANAESTH, V93, P799, DOI 10.1093/bja/aeh268; Davidson EM, 2001, CAN J ANAESTH, V48, P59, DOI 10.1007/BF03019816; Delfs JM, 2000, NATURE, V403, P430, DOI 10.1038/35000212; Deyama S, 2008, J NEUROSCI, V28, P7728, DOI 10.1523/JNEUROSCI.1480-08.2008; HAGELUKEN A, 1994, BIOCHEM PHARMACOL, V47, P1789, DOI 10.1016/0006-2952(94)90307-7; Hagiwara H, 2009, EUR J NEUROSCI, V30, P2379, DOI 10.1111/j.1460-9568.2009.07002.x; Hayashida M, 2008, PHARMACOGENOMICS, V9, P1605, DOI 10.2217/14622416.9.11.1605; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Kasai S, 2008, N-S ARCH PHARMACOL, V377, P269, DOI 10.1007/s00210-007-0205-3; KINOSHITA G, 1995, J VET MED SCI, V57, P293, DOI 10.1292/jvms.57.293; LaCroix-Fralish ML, 2009, ANNU REV PHARMACOL, V49, P97, DOI 10.1146/annurev-pharmtox-061008-103222; Leineweber K, 2004, N-S ARCH PHARMACOL, V369, P1, DOI 10.1007/s00210-003-0824-2; Levin MC, 2002, J BIOL CHEM, V277, P30429, DOI 10.1074/jbc.M200681200; Liu J, 2003, CLIN PHARMACOL THER, V74, P372, DOI 10.1016/S0009-9236(03)00224-8; Martikainen IK, 2004, NEUROSCI LETT, V361, P140, DOI 10.1016/j.neulet.2003.12.060; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; MOGIL JS, 2006, WALL MELZACKS TXB PA, P159; Nagashima Makoto, 2007, Curr Pain Headache Rep, V11, P115, DOI 10.1007/s11916-007-0008-8; Neil MJE, 2011, CURR CLIN PHARMACOL, V6, P280, DOI 10.2174/157488411798375886; Nonen S, 2008, BIOL PHARM BULL, V31, P295, DOI 10.1248/bpb.31.295; Perez JM, 2003, NAT MED, V9, P1300, DOI 10.1038/nm930; Philipp M, 2004, PHARMACOL THERAPEUT, V101, P65, DOI 10.1016/j.pharmthera.2003.10.004; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Sofowora GG, 2003, CLIN PHARMACOL THER, V73, P366, DOI 10.1016/S0009-9236(02)17734-4; Terra Steven G, 2005, Pharmacogenet Genomics, V15, P227, DOI 10.1097/01213011-200504000-00006; VELDHUIS JD, 1984, J CLIN INVEST, V74, P47, DOI 10.1172/JCI111417; *WHO, 1990, [No title captured], V804, P1; WOULFE JM, 1990, EXP NEUROL, V109, P308, DOI 10.1016/S0014-4886(05)80022-6; ZHOU JN, 1995, NATURE, V378, P68, DOI 10.1038/378068a0	34	18	18	0	3	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613			J PHARMACOL SCI	J. Pharmacol. Sci.	JAN	2013	121	1					48	57		10.1254/jphs.12159FP			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	134HD	WOS:000318200100006	23257656	Bronze			2020-06-30	J	Moadebi, S; Kwan, F; Stackhouse, S; Reddekopp, L				Moadebi, Susanne; Kwan, Fiona; Stackhouse, Sherry; Reddekopp, Lisa			The impact of interprofessional collaboration on nurses' satisfaction and comfort with intranasal fentanyl	INTERNATIONAL EMERGENCY NURSING			English	Article						Interprofessional education; Pharmacist; Intranasal; Fentanyl	PROCEDURAL SEDATION; EMERGENCY; PAIN; PHARMACISTS; ANALGESIA; CHILDREN	Background: Healthcare providers' beliefs and comfort with analgesics can impact medication decisions. Interprofessional educational interventions (IPE) improve medication delivery processes ultimately resulting in better patient care. The purpose of this study was to determine the impact on nurses' satisfaction and comfort with administering intranasal fentanyl for pediatric pain management in the Emergency Department (ED) before and following IPE. Methods: A protocol for administering intranasal fentanyl for children age 1-15 years with acute pain was introduced to the ED Nursing staff by an educational session conducted by a clinical pharmacist. Nurses' level of satisfaction and comfort was surveyed prior to and following IPE. Compliance with patient monitoring was determined by chart review. Results: Eighty percentage of the nurses were very satisfied with the analgesic effect of intranasal fentanyl but barriers for its use included personal comfort, nurse monitoring time and age appropriateness. Most nurses felt comfortable administering intranasal fentanyl but showed increased comfort with intravenous morphine (83% versus 98%, p < 0.05). Benefits cited by nurses included having a pharmacist available in the ED to assist in the delivery of intranasal fentanyl. Conclusion: The use of IPE facilitated knowledge sharing to improve nurses' comfort with administering analgesic medication and the quality of patient care services. (C) 2012 Elsevier Ltd. All rights reserved.	[Moadebi, Susanne] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada; [Moadebi, Susanne; Kwan, Fiona] Lions Gate Hosp, Dept Pharm, N Vancouver, BC V7L 2L2, Canada; [Moadebi, Susanne; Stackhouse, Sherry; Reddekopp, Lisa] Lions Gate Hosp, Emergency Dept, N Vancouver, BC V7L 2L2, Canada	Moadebi, S (reprint author), Lions Gate Hosp, Emergency Dept, N Vancouver, BC V7L 2L2, Canada.	susanne.moadebi@vch.ca					Amer Coll Clinical Pharm, 2009, PHARMACOTHERAPY, V29, P880, DOI 10.1592/phco.29.7.880; Andolfatto G, 2010, ACAD EMERG MED, V17, P194, DOI 10.1111/j.1553-2712.2009.00646.x; [Anonymous], PROF PRACT EM NURS C; [Anonymous], MAD300 MAD NAS DEV; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Canadian Nurses Association (CNA), 2011, POS STAT INT COLL; Canadian Pharmacists Association (CPA), 2008, BLUEPR PHARM INT CON; Crellin D., 2010, AENJ, V13, P157; Fairbanks RJ, 2007, EMERG MED J, V24, P716, DOI 10.1136/emj.2006.044313; Grindrod KA, 2008, CAN J HOSP PHARM, V61, P49; Grymonpre R., 2010, J RES INTERPROF PRAC, V1, P127, DOI DOI 10.22230/jripe.2010v1n2a13; Le May S, 2009, PEDIATR EMERG CARE, V25, P498, DOI 10.1097/PEC.0b013e3181b0a0af; Moadebi S, 2005, CAN J HOSP PHARM, V58, P136; Pepper E, 2009, J OBSTET GYNAECOL CA, V31, P504, DOI 10.1016/S1701-2163(16)34212-8; Ratnapalan S, 2010, INT J PEDIAT, DOI 10.1155/2010/454731; Santos JRA, 1999, J EXTENSION, V37; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Zempsky WT, 2004, PEDIATRICS, V114, P1348, DOI 10.1542/peds.2004-1752	18	4	4	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1755-599X	1878-013X		INT EMERG NURS	Int. Emerg. Nurs.	JAN	2013	21	1					58	63		10.1016/j.ienj.2012.02.004			6	Nursing	Nursing	118JQ	WOS:000317022200009	23273805				2020-06-30	J	Yu, AL; Cai, XZ; Gao, XJ; Zhang, ZW; Ma, ZS; Ma, LL; Wang, LX				Yu, Ai-Lan; Cai, Xing-Zhi; Gao, Xiu-Juan; Zhang, Zong-Wang; Ma, Zeng-Shan; Ma, Long-Le; Wang, Le-Xin			Determinants of Immediate Extubation in the Operating Room after Total Thoracoscopic Closure of Congenital Heart Defects	MEDICAL PRINCIPLES AND PRACTICE			English	Article						Thoracoscopy; Atrial septal defect; Ventricular septal defect; Ultra-fast-track anesthesia; Extubation	ARTERY-BYPASS SURGERY; CARDIAC-SURGERY; SEPTAL-DEFECT; FAST-TRACK; REPAIR; ANESTHESIA; ROUTINE	Objective: This study was designed to assess the factors that influence immediate extubation following totally thoracoscopic closure of congenital heart defects. Subjects and Methods: Clinical and operational data of 216 patients (87 males, average age 13.6 +/- 10.9 years) were retrospectively analyzed. Atrial (ASD, n = 90) or ventricular septal defects (VSD, n = 126) were closed via a totally thoracoscopic approach. Ultra-fast-track anesthesia (UFTA) was used in all patients. Results: Immediate extubation in the operating room was successfully performed in 156 (72.2%) patients. A delayed extubation was completed in the intensive care unit in the remaining 60 (27.8%) patients. There was no significant difference in the age, sex, body weight, or type of congenital heart defect between the immediate and delayed extubation groups (p > 0.05). However, more patients in the delayed extubation group had severe preoperational pulmonary hypertension [8 (13.3%) vs. 4 (2.3%), p < 0.05]. The cardiopulmonary bypass time, aortic clamp time, and total duration of the surgery in the immediate extubation group were shorter than in the delayed extubation group ( p < 0.05). Multivariate logistic regression analysis showed that preoperational pulmonary hypertension, duration of the surgery or cardiopulmonary bypass, and dosage of fentanyl used during the surgery were independent predictors for immediate extubation. Conclusions: UFTA and immediate extubation in the operating room was feasible and safe in the majority of patients undergoing totally thoracoscopic closure of ASD or VSD. Preoperational pulmonary hypertension, duration of the surgery, and the dosage of fentanyl used for UFTA were the determining factors for immediate extubation. Copyright (c) 2012 S. Karger AG, Basel	[Yu, Ai-Lan; Cai, Xing-Zhi; Gao, Xiu-Juan; Zhang, Zong-Wang] Shandong Univ, Liaocheng Peoples Hosp, Dept Anesthesiol, Liaocheng, Peoples R China; [Ma, Zeng-Shan] Shandong Univ, Liaocheng Peoples Hosp, Dept Cardiac Surg, Liaocheng, Peoples R China; [Ma, Long-Le; Wang, Le-Xin] Shandong Univ, Liaocheng Peoples Hosp, Dept Cardiol, Liaocheng, Peoples R China; [Ma, Long-Le; Wang, Le-Xin] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2678, Australia	Wang, LX (reprint author), Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2678, Australia.	lwang@csu.edu.au					Argenziano M, 2003, CIRCULATION, V108, P191, DOI 10.1161/01.cir.0000089043.82199.2f; Davis Steve, 2004, Pediatr Crit Care Med, V5, P63, DOI 10.1097/01.PCC.0000102386.96434.46; Djaiani GN, 2001, J CARDIOTHOR VASC AN, V15, P152, DOI 10.1053/jcan.2001.21936; Hawkes CA, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003587; Horswell JL, 2005, J CARDIOTHOR VASC AN, V19, P282, DOI 10.1053/j.jvca.2005.03.002; Kurihara Yuka, 2009, Interact Cardiovasc Thorac Surg, V8, P624, DOI 10.1510/icvts.2008.189431; Ma ZS, 2011, J THORAC CARDIOV SUR, V142, P850, DOI 10.1016/j.jtcvs.2011.03.001; Ma ZS, 2011, J THORAC CARDIOV SUR, V141, P1380, DOI 10.1016/j.jtcvs.2010.10.028; Mittnacht AJC, 2008, J THORAC CARDIOV SUR, V136, P88, DOI 10.1016/j.jtcvs.2007.11.042; Morgan JA, 2004, ANN THORAC SURG, V77, P1328, DOI 10.1016/j.athoracsur.2003.09.044; Oxelbark S, 2001, EUR J CARDIO-THORAC, V19, P460, DOI 10.1016/S1010-7940(01)00612-1; Silbert BS, 1998, CHEST, V113, P1481, DOI 10.1378/chest.113.6.1481; Svircevic V, 2009, ANESTH ANALG, V108, P727, DOI 10.1213/ane.0b013e318193c423; Szekely A, 2006, PEDIATR ANESTH, V16, P1166, DOI 10.1111/j.1460-9592.2006.01957.x; Vistarini N, 2010, J THORAC CARDIOV SUR, V139, P139, DOI 10.1016/j.jtcvs.2009.07.022; Wimmer-Greinecker G, 2003, J THORAC CARDIOV SUR, V126, P465, DOI 10.1016/S0022-5223(03)00053-9; Zhang ZW, 2012, J CARDIOTHOR VASC AN, V26, P270, DOI 10.1053/j.jvca.2011.07.033	17	1	1	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1011-7571			MED PRIN PRACT	Med. Princ. Pract.		2013	22	3					234	238		10.1159/000345844			5	Medicine, General & Internal	General & Internal Medicine	118CM	WOS:000317000100005	23296121	DOAJ Gold, Green Published			2020-06-30	J	Russell, T; Mitchell, C; Paech, MJ; Pavy, T				Russell, T.; Mitchell, C.; Paech, M. J.; Pavy, T.			Efficacy and safety of intraoperative intravenous methadone during general anaesthesia for caesarean delivery: a retrospective case-control study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Caesarean delivery; General anaesthesia; Methadone; Patient-controlled analgesia	POSTOPERATIVE PAIN; MORPHINE; ANALGESIA	Background: Most patients undergoing caesarean delivery with general anaesthesia require systemic opioid administration. Due to its rapid onset and long duration of action, intravenous methadone may make it suitable for analgesia after caesarean delivery. Intraoperative methadone combined with postoperative intravenous patient-controlled analgesia with fentanyl or morphine has recently been introduced in our unit. Methods: A retrospective case-control study of 25 patients who had received methadone was performed. Fifty control patients undergoing elective or emergency caesarean delivery were matched for the use of postoperative intravenous patient-controlled analgesia, transversus abdominis plane (TAP) block and regular non-steroidal anti-inflammatory drugs. Exclusion criteria included preoperative neuraxial analgesia or pre-delivery opioid consumption greater than 10 mg of intravenous morphine equivalents. Results: Patients in the methadone group had lower pain scores and were less likely to require intravenous opioid supplementation in the post-anaesthetic care unit (P < 0.001). Opioid consumption over 48 h was significantly lower in the methadone group. Delayed discharge from the post-anaesthesia care unit was due to sedation in one patient in the methadone group compared to three control patients in whom it was due to sedation and inadequate analgesia. Conclusion: A single intraoperative bolus of intravenous methadone appeared to provide effective analgesia with an acceptable side-effect profile. (C) 2012 Published by Elsevier Ltd.	[Russell, T.; Mitchell, C.; Paech, M. J.; Pavy, T.] King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Subiaco, WA 6008, Australia; [Russell, T.] Sir Charles Gairdner Hosp, Dept Anaesthesia, Nedlands, WA 6009, Australia; [Paech, M. J.; Pavy, T.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia	Russell, T (reprint author), King Edward Mem Hosp Women, 374 Bagot Rd, Subiaco, WA 6008, Australia.	twain.russell@health.wa.gov.au		PAECH, MICHAEL/0000-0001-9023-6575	Pfizer AustraliaPfizerPfizer Australia	Michael Paech is a recipient of a Pfizer Australia investigator-initiated research grant and on a clinical advisory panel of Schering-Plough (MSD).	American Academy of Pediatrics Committee on Drugs, 2001, Pediatrics, V108, P776; BERDE CB, 1991, J PEDIATR-US, V119, P136, DOI 10.1016/S0022-3476(05)81054-6; Bogen DL, 2011, BREASTFEED MED, V6, P377, DOI 10.1089/bfm.2010.0060; Carvalho B, 2010, INT J OBSTET ANESTH, V19, P10, DOI 10.1016/j.ijoa.2009.02.012; Fishman SM, 2002, PAIN MED, V3, P339, DOI 10.1046/j.1526-4637.2002.02047.x; Gottschalk A, 2011, ANESTH ANALG, V112, P218, DOI 10.1213/ANE.0b013e3181d8a095; GOURLAY GK, 1982, BRIT MED J, V284, P630, DOI 10.1136/bmj.284.6316.630; GOURLAY GK, 1986, ANESTHESIOLOGY, V64, P322; Group AE, 2007, THER GUID AN; Jansson LM, 2007, J HUM LACT, V23, P184, DOI 10.1177/0890334407300336; Kharasch ED, 2011, ANESTH ANALG, V112, P13, DOI 10.1213/ANE.0b013e3181fec9a3; Krantz MJ, 2002, ANN INTERN MED, V137, P501, DOI 10.7326/0003-4819-137-6-200209170-00010; Larijani GE, 2005, PHARMACOTHERAPY, V25, P1168, DOI 10.1592/phco.2005.25.9.1168; Loane H, 2012, INT J OBSTET ANESTH, V21, P112, DOI 10.1016/j.ijoa.2012.02.005; Meyer M, 2007, OBSTET GYNECOL, V110, P261, DOI 10.1097/01.AOG.0000275288.47258.e0; Nagele P, 2012, ANESTHESIOLOGY, V117, P321, DOI 10.1097/ALN.0b013e31825e6eb3; Richlin D M, 1991, J Clin Anesth, V3, P112, DOI 10.1016/0952-8180(91)90007-A; Rossi S, 2012, AUSTR MED HDB, P43	18	8	8	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2013	22	1					47	51		10.1016/j.ijoa.2012.10.007			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	102FG	WOS:000315829600009	23219678				2020-06-30	J	McGregor, C; Katz, S; Harpham, M				McGregor, C.; Katz, S.; Harpham, M.			Management of a parturient with an anterior sacral meningocele	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Anterior sacral meningocele; Pregnancy; Caesarean section; Combined spinal-epidural anaesthesia	CESAREAN-SECTION; OVARIAN-CYST; SPINA-BIFIDA; ANESTHESIA; PATIENT; ANALGESIA; PREGNANCY; LABOR	Anterior sacral meningoceles are rare disorders featuring anterior herniation of the meninges through a sacral defect or foramen. They are frequently misdiagnosed as ovarian or abdominal cysts and surgical exploration has resulted in meningitis. In pregnancy it represents an obstacle to delivery of the fetus and rupture of the meningocele during vaginal delivery is a significant risk. The successful multidisciplinary management of a primiparous patient with an anterior sacral meningocele and previous abdominal surgery is presented. (C) 2012 Elsevier Ltd. All rights reserved.	[McGregor, C.; Katz, S.] Royal Hosp Women, Dept Anaesthesia, Sydney, NSW 2031, Australia; [Harpham, M.] Royal Hosp Women, Dept Obstet, Sydney, NSW 2031, Australia	McGregor, C (reprint author), Royal Hosp Women, Dept Anaesthesia, Sydney, NSW 2031, Australia.	cathy_gary.mcgregor@bigpond.com					Altamimi Y, 2006, ANAESTH INTENS CARE, V34, P816, DOI 10.1177/0310057X0603400609; Benes V, 2008, EUR J OBSTET GYN R B, V138, P249, DOI 10.1016/j.ejogrb.2007.04.006; BROOME IJ, 1989, ANAESTH INTENS CARE, V17, P377, DOI 10.1177/0310057X8901700328; Fitzpatrick MO, 1999, J NEUROSURG, V91, P124, DOI 10.3171/spi.1999.91.1.0124; Hanna AS, 2001, J NEUROSURG, V94, P162, DOI 10.3171/spi.2001.94.1.0162; Kontopoulos EV, 2005, J MATERN-FETAL NEO M, V17, P423, DOI 10.1080/14767050500123616; Kreeger RN, 2005, INT ANESTHESIOL CLIN, V43, P65, DOI 10.1097/01.aia.0000182636.47314.90; Krivokapic Z, 2004, DIS COLON RECTUM, V47, P1965, DOI 10.1007/s10350-004-0664-2; Kuczkowski KM, 2007, ANAESTH INTENS CARE, V35, P298; Manson F, 2007, ULTRASOUND OBST GYN, V30, P893, DOI 10.1002/uog.4061; May AE, 2008, INT J OBSTET ANESTH, V17, P31, DOI 10.1016/j.ijoa.2007.03.016; Nel MR, 1998, BRIT J ANAESTH, V80, P512, DOI 10.1093/bja/80.4.512; Tidmarsh MD, 1998, INT J OBSTET ANESTH, V7, P111, DOI 10.1016/S0959-289X(98)90007-3; Tortori-Donati P, 2000, NEURORADIOLOGY, V42, P471, DOI 10.1007/s002340000325; Vamsi KY, 2010, PEDIATR NEUROSURG, V46, P245, DOI 10.1159/000321923	15	2	3	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2013	22	1					64	67		10.1016/j.ijoa.2012.08.007			4	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	102FG	WOS:000315829600011	23122279				2020-06-30	J	Valap, S; Millns, P; Bulchandani, S				Valap, S.; Millns, P.; Bulchandani, S.			Management of a parturient with mast cell activation syndrome	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							MASTOCYTOSIS; CLASSIFICATION		[Valap, S.; Millns, P.; Bulchandani, S.] Birmingham Womens Hosp, Dept Anaesthet, Birmingham, W Midlands, England	Valap, S (reprint author), Birmingham Womens Hosp, Dept Anaesthet, Birmingham, W Midlands, England.	sachin.valap@yahoo.com					Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Auvray L, 2001, ANN FR ANESTH, V20, P635; Blunk JA, 2004, ANESTH ANALG, V98, P364, DOI 10.1213/01.ANE.0000097168.32472.0D; Hamilton MJ, 2010, GASTROENTEROLOGY, V138, pS89; Hepner DL, 2003, ANESTH ANALG, V97, P1381, DOI 10.1213/01.ANE.0000082993.84883.7D; Koppert W, 2001, ANESTHESIOLOGY, V95, P659, DOI 10.1097/00000542-200109000-00019; LERNO G, 1990, BRIT J ANAESTH, V65, P254, DOI 10.1093/bja/65.2.254; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; Molderings GJ, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-10; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8	10	3	3	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2013	22	1					83	84		10.1016/j.ijoa.2012.10.006			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	102FG	WOS:000315829600018	23218498				2020-06-30	J	Mitra, F; Chowdhury, S; Shelley, M; Williams, G				Mitra, Farzana; Chowdhury, Shahead; Shelley, Mike; Williams, Gary			A Feasibility Study of Transdermal Buprenorphine Versus Transdermal Fentanyl in the Long-Term Management of Persistent Non-Cancer Pain	PAIN MEDICINE			English	Article						Persistent Pain; Fentanyl; Buprenorphine; Transdermal	CANCER PAIN; OPIOID THERAPY; PHARMACOLOGY; ANALGESICS; EFFICACY; MORPHINE; SAFETY; UPDATE	Objective Buprenorphine and fentanyl transdermal patches are used widely for the management of persistent malignant and nonmalignant pain. Buprenorphine and fentanyl transdermal patches, both potent opioids, are considered to be equally efficacious in managing persistent pain. Various retrospective studies comparing dosage changes of buprenorphine and fentanyl patches in persistent pain patients have been completed; however, no long-term prospective, randomized, clinical study has compared the effectiveness of these patches. The objective of the present study was to satisfy this need. Aims This study aims to compare prospectively the long-term efficacy, acceptability, and side effects of both of these patches in patients with persistent pain. This study would examine the feasibility and lay the groundwork for a larger, multicenter study where such efficacy and safety outcomes of the two medications can be adequately assessed. Design The participants were 46 adults (range 2280 years.) with nonmalignant persistent pain (mean = 11 years), predominantly with lower back pain. Data were obtained monthly for 12 months. Participants recruited were opioid-naive patients, having pain for the greater part of the day and night, and appropriate for treatment with transdermal patches. After initial assessment, participants were randomly allocated to either buprenorphine or fentanyl patch treatment. Participants were then titrated to optimal doses of medication. Patients with adverse effects or unsatisfactory pain relief were treated alternatively and discontinued from the study. Results Nearly one-third of all patients, 41% (8 of 22) of the transdermal buprenorphine (TDB) group and 37.5% (8 of 24) of the transdermal fentanyl (TDF) group stopped treatment due to unacceptable side effects or inadequate pain relief. The remaining participants showed a similar trend in the improvement of pain intensity, physical activity, sleep, and mood throughout the study. Significant relief in the intensity of pain was achieved for the initial 6 months and the effects stabilized in the remainder of the study in both groups. There were no significant group differences over time. However, a higher equipotent dose of fentanyl was required for comparable pain relief. Compared with TDF group, the TDB group initially experienced relatively less side effects. However, a greater number of buprenorphine users suffered from local skin reactions. Buprenorphine users had significant improvement in mood. Thirty-one percent (5 of 16) of the buprenorphine group and 57% (8 of 14) of the fentanyl users needed additional pain relief medications by the end of 3 months. By the end of 12 months, a significant number 78% (7 of 9) of buprenorphine users but comparatively fewer 44% (4 of 9) of the fentanyl group used rescue medicines. Both had more doctor visits in the latter half of the study. Conclusion Thirty percent of the total number of patients discontinued treatment because of side effects or unsatisfactory pain relief. For those continuing treatment, clinical improvements were seen in the initial 6 months in both groups. Fifty percent of the TDB and 43% of TDF groups had significant relief in 3 months, which persisted up to 6 months. Only 11% and 13% of patients, respectively, had sustained relief after 6 months. Twenty percent more patients in the TDB group benefited significantly in symptoms of depression from TDB compared with the TDF group. Interestingly, switching of patches seemed to increase acceptability by preventing adverse effects and tolerance. Confirmation of these effects should be studied in future with a multicenter study and larger sample.	[Mitra, Farzana; Chowdhury, Shahead] Townsville Hosp, Townsville Pain Management Clin, Townsville, Qld, Australia; [Shelley, Mike] Persistent Pain Unit, Gold Coast, Qld, Australia; [Williams, Gary] James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, Townsville, Qld 4811, Australia	Mitra, F (reprint author), Pain Management Clin, Level 2 Medilink Retail Ctr,Townsville Hosp Campu, Townsville, Qld 4814, Australia.	farzana_mitra@health.qld.gov.au			Private Practice Research Fund of Townsville	We are deeply indebted to A/Prof Dr. Milton Cohen-Pain and Rheumatology, Pain Clinic, St Vincent's Hospital Sydney-for his time and valuable suggestions for this study. This study was funded by the Private Practice Research Fund of Townsville. The authors thank Ms Helen Karami and Dana Corden for the collection of data. None of the authors have any conflicting financial interests.	AHMEDZAI S, 1995, EUR J CANCER, V31A, pS2, DOI 10.1016/0959-8049(95)00496-6; Aurilio C, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-61; Aurilio C, 2009, PAIN PRACT, V9, P105, DOI 10.1111/j.1533-2500.2008.00237.x; Buettner P, 2011, PRACT PAIN MANAGE, V1, P24; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Dupen A, 2007, PAIN MANAG NURS, V8, P113, DOI 10.1016/j.pmn.2007.02.004; Gianni W, 2011, J PAIN SYMPTOM MANAG, V41, P707, DOI 10.1016/j.jpainsymman.2010.06.015; Glajchen M, 2001, J Am Board Fam Pract, V14, P211; Griessinger N, 2005, CURR MED RES OPIN, V21, P1147, DOI 10.1185/030079905X53315; Hans G, 2009, J PAIN RES, V15, P117; Hulst KV, 2008, CONTACT DERMATITIS, V59, P366, DOI 10.1111/j.1600-0536.2008.01472.x; Kim JG, 2005, TRANSPL P, V37, P4488, DOI 10.1016/j.transproceed.2005.11.038; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; Landau CJ, 2007, CLIN THER, V29, P2179, DOI 10.1016/j.clinthera.2007.10.010; Lewis John W., 1995, P151; Mercadante, 1999, Cancer Control, V6, P191; Mordarski S, 2009, J PHYSIOL PHARMACOL, V60, P31; Mundipharma Pty Ltd, 2005, PROD INF; Narcotics Anonymous (NA), 1996, BUPR BUPR IN SUB TAB; Niscola P, 2010, CURR DRUG TARGETS, V11, P752, DOI 10.2174/138945010791170879; Pace MC, 2007, FRONT BIOSCI-LANDMRK, V12, P1291, DOI 10.2741/2147; Perez-Perez L, 2008, CONTACT DERMATITIS, V58, P310, DOI 10.1111/j.1600-0536.2007.01206.x; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Pharmaceutical Society of Australia, 2011, PRESCR GUID; Purdue Pharma LP, 2010, BUTR PROD INF; Schmid-Grendelmeier P, 2006, CURR MED RES OPIN, V22, P501, DOI 10.1185/030079906X89829; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; Sittl R, 2006, PALLIATIVE MED, V20, pS25, DOI 10.1191/0269216306pm1125oa; Sittl R, 2006, CLIN THER, V28, P1144, DOI 10.1016/j.clinthera.2006.08.002; Stannard C, 2007, OPIOIDS NONCANCER PA, P31; Sullivan MD, 2010, PAIN, V149, P345, DOI 10.1016/j.pain.2010.02.037; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Weinstein SM, 2000, SOUTHERN MED J, V93, P472; Wirz S, 2009, EUR J PAIN, V13, P737, DOI 10.1016/j.ejpain.2008.09.005	35	20	21	1	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	JAN	2013	14	1					75	83		10.1111/pme.12011			9	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	073FF	WOS:000313728200009	23320402	Bronze			2020-06-30	J	Ohashi, Y; Terui, K; Tamura, K; Tanaka, M; Baba, K				Ohashi, Yuki; Terui, Katsuo; Tamura, Kazumi; Tanaka, Motoshi; Baba, Kazunori			Success rate and challenges of fetal anesthesia for ultrasound guided fetal intervention by maternal opioid and benzodiazepine administration	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE			English	Article						Cordocentesis; diazepam; fetal cardiac arrest; fetal anesthesia; fentanyl; thoracoamniotic shunt	PAIN	Objective: The safe and effective methods of fetal anesthesia/analgesia during ultrasound guided direct fetal procedure are yet to be determined. The authors investigated whether maternal diazepam/fentanyl administration meets this purpose. Methods: The medical/anesthesia records were retrospectively reviewed in cases between 2001 and 2010 at a tertiary perinatal center. Success rate as well as maternal and fetal complications were analysed. Results: Among the 150 procedures in 118 fetuses, diazepam 10 mg and fentanyl 200 mu g sufficiently prevented fetal movement upon the procedure in 56% of the procedures. Supplemental anesthetic agents such as nitrous oxide and propofol were needed in other cases. No serious maternal complication was noted, while fetal cardiac arrest/severe bradycardia was noted in three fetuses, one of which was successfully resuscitated by intracardiac adrenalin injection. Conclusions: Maternal diiazepam/fentanyl administration offered adequate fetal condition without significant maternal complications. Since these procedures are performed to treat severe fetal conditions, preparation for fetal resuscitation is also important.	[Ohashi, Yuki] Kyorin Univ, Sch Med, Dept Anesthesiol, Mitaka, Tokyo 181, Japan; [Terui, Katsuo; Tamura, Kazumi] Saitama Med Univ, Saitama Med Ctr, Div Obstet Anesthesia, Ctr Maternal Fetal & Neonatal Med, Kawagoe, Saitama 3508550, Japan; [Tanaka, Motoshi] Natl Def Med Acad, Dept Anesthesiol, Tokorozawa, Saitama, Japan; [Baba, Kazunori] Saitama Med Univ, Saitama Med Ctr, Dept Obstet, Ctr Maternal Fetal & Neonatal Med, Kawagoe, Saitama 3508550, Japan	Terui, K (reprint author), Saitama Med Univ, Saitama Med Ctr, Div Obstet Anesthesia, Ctr Maternal Fetal & Neonatal Med, 1981 Kamoda, Kawagoe, Saitama 3508550, Japan.	terui@saitama-med.ac.jp					ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ELLIOTT JP, 1994, FETAL DIAGN THER, V9, P226, DOI 10.1159/000263937; Fisk NM, 2001, ANESTHESIOLOGY, V95, P828, DOI 10.1097/00000542-200110000-00008; Lee SJ, 2005, JAMA-J AM MED ASSOC, V294, P947, DOI 10.1001/jama.294.8.947; Myers LB, 2005, ANESTHESIA FETAL INT; Strumper D, 2003, ANESTHESIOLOGY, V98, P1400, DOI 10.1097/00000542-200306000-00015	6	2	3	0	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1476-7058			J MATERN-FETAL NEO M	J. Matern.-Fetal Neonatal Med.	JAN	2013	26	2					158	160		10.3109/14767058.2012.722733			3	Obstetrics & Gynecology	Obstetrics & Gynecology	072NH	WOS:000313678100011	22928538				2020-06-30	J	Anand, KJS; Clark, AE; Willson, DF; Berger, J; Meert, KL; Zimmerman, JJ; Harrison, R; Carcillo, JA; Newth, CJL; Bisping, S; Holubkov, R; Dean, JM; Nicholson, CE				Anand, Kanwaljeet J. S.; Clark, Amy E.; Willson, Douglas F.; Berger, John; Meert, Kathleen L.; Zimmerman, Jerry J.; Harrison, Rick; Carcillo, Joseph A.; Newth, Christopher J. L.; Bisping, Stephanie; Holubkov, Richard; Dean, J. Michael; Nicholson, Carol E.		Eunice Kennedy Shriver Natl Inst	Opioid Analgesia in Mechanically Ventilated Children: Results From the Multicenter Measuring Opioid Tolerance Induced by Fentanyl Study	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						agitation; anxiolysis; child; clinical practices; infant; intensive care; pain; variability	INTENSIVE-CARE-UNIT; CLINICAL-PRACTICE GUIDELINES; CONSENSUS GUIDELINES; PROLONGED SEDATION; PAIN-CONTROL; WITHDRAWAL; MIDAZOLAM; MORPHINE; DEPENDENCY; PREVENTION	Objective: To examine the clinical factors associated with increased opioid dose among mechanically ventilated children in the pediatric intensive care unit. Design: Prospective, observational study with 100% accrual of eligible patients. Setting: Seven pediatric intensive care units from tertiary-care children's hospitals in the Collaborative Pediatric Critical Care Research Network. Patients: Four hundred nineteen children treated with morphine or fentanyl infusions. Interventions: None. Measurements and Main Results: Data on opioid use, concomitant therapy, demographic and explanatory variables were collected. Significant variability occurred in clinical practices, with up to 100-fold differences in baseline opioid doses, average daily or total doses, or peak infusion rates. Opioid exposure for 7 or 14 days required doubling of the daily opioid dose in 16% patients (95% confidence interval 12%-19%) and 20% patients (95% confidence interval 16%-24%), respectively. Among patients receiving opioids for longer than 3 days (n = 225), this occurred in 28% (95% confidence interval 22%-33%) and 35% (95% confidence interval 29%-41%) by 7 or 14 days, respectively. Doubling of the opioid dose was more likely to occur following opioid infusions for 7 days or longer (odds ratio 7.9, 95% confidence interval 4.3-14.3; p < 0.001) or co-therapy with midazolam (odds ratio 5.6, 95% confidence interval 2.4-12.9; p < 0.001), and it was less likely to occur if morphine was used as the primary opioid (vs. fentanyl) (odds ratio 0.48, 95% confidence interval 0.25-0.92; p = 0.03), for patients receiving higher initial doses (odds ratio 0.96, 95% confidence interval 0.95-0.98; p < 0.001), or if patients had prior pediatric intensive care unit admissions (odds ratio 0.37, 95% confidence interval 0.15-0.89; p = 0.03). Conclusions: Mechanically ventilated children require increasing opioid doses, often associated with prolonged opioid exposure or the need for additional sedation. Efforts to reduce prolonged opioid exposure and clinical practice variation may prevent the complications of opioid therapy. (Pediatr Crit Care Med 2013; 14:28-36)	[Anand, Kanwaljeet J. S.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Le Bonheur Childrens Hosp, Memphis, TN 38163 USA; [Anand, Kanwaljeet J. S.] Univ Tennessee, Ctr Hlth Sci, Dept Anesthesiol, Le Bonheur Childrens Hosp, Memphis, TN 38163 USA; [Anand, Kanwaljeet J. S.] Univ Tennessee, Ctr Hlth Sci, Dept Neurobiol, Le Bonheur Childrens Hosp, Memphis, TN 38163 USA; [Clark, Amy E.; Bisping, Stephanie; Holubkov, Richard; Dean, J. Michael] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; [Willson, Douglas F.] Univ Virginia, Dept Pediat, Childrens Hosp, Charlottesville, VA USA; [Berger, John] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; [Meert, Kathleen L.] Childrens Hosp Michigan, Dept Pediat, Detroit, MI 48201 USA; [Zimmerman, Jerry J.] Univ Washington, Sch Med, Dept Pediat, Seattle Childrens Hosp, Seattle, WA 98195 USA; [Harrison, Rick] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Carcillo, Joseph A.] Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Newth, Christopher J. L.] Childrens Hosp Los Angeles, Dept Anesthesiol & Crit Care Med, Los Angeles, CA 90027 USA; [Nicholson, Carol E.] Eunice Kennedy Shriver Natl Inst Child Hlth & Dev, Bethesda, MD USA	Anand, KJS (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Le Bonheur Childrens Hosp, Memphis, TN 38163 USA.	kanand@uthsc.edu	; Anand, Kanwaljeet/B-3287-2014	Holubkov, Richard/0000-0003-0431-3381; Anand, Kanwaljeet/0000-0001-6498-1483	Eunice Kennedy Shriver National Institute of Child Health and Human Development, Department of Health and Human ServicesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, U01HD049934]	This work was supported, in part, by cooperative agreements (U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, and U01HD049934) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Department of Health and Human Services.	Anand K J, 1996, Crit Care Nurse, V16, P87; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; ANAND KJS, 1993, CRIT CARE MED, V21, P1817, DOI 10.1097/00003246-199312000-00003; Anand KJS, 2006, PEDIATRICS, V117, pS9, DOI 10.1542/peds.2005-0620C; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Baba H, 2000, J NEUROPHYSIOL, V83, P955; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; BERGMAN I, 1991, J PEDIATR-US, V119, P644, DOI 10.1016/S0022-3476(05)82420-5; Birchley G, 2009, NURS CRIT CARE, V14, P26, DOI 10.1111/j.1478-5153.2008.00311.x; Blumer JL, 1998, CLIN PHARMACOKINET, V35, P37, DOI 10.2165/00003088-199835010-00003; Chahal H, 1998, ARCH DIS CHILD-FETAL, V78, pF116, DOI 10.1136/fn.78.2.F116; Curley MAQ, 2009, SEDATION MANAGEMENT; Dahan A, 2008, ANESTH ANALG, V107, P83, DOI 10.1213/ane.0b013e31816a66a4; Deeter KH, 2011, CRIT CARE MED, V39, P683, DOI 10.1097/CCM.0b013e318206cebf; Ebert B, 1998, BIOCHEM PHARMACOL, V56, P553, DOI 10.1016/S0006-2952(98)00088-4; Fonsmark L, 1999, CRIT CARE MED, V27, P196, DOI 10.1097/00003246-199901000-00052; Franck L S, 1998, Am J Crit Care, V7, P364; Horn S D, 2001, Manag Care Q, V9, P10; Horn SD, 1997, J CLIN PSYCHIAT, V58, P15; Horn SD, 1999, J CLIN OUTCOMES MANA, V6, P26; Iliadis EA, 1999, J AM COLL CARDIOL, V34, P1689, DOI 10.1016/S0735-1097(99)00405-2; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JacqzAigrain E, 1996, CLIN PHARMACOKINET, V31, P423, DOI 10.2165/00003088-199631060-00003; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Koch SC, 2008, ANESTHESIOLOGY, V108, P122, DOI 10.1097/01.anes.0000296079.45446.15; Krantz MJ, 2004, ARCH INTERN MED, V164, P277, DOI 10.1001/archinte.164.3.277; LANE JC, 1991, J PEDIATR-US, V119, P649, DOI 10.1016/S0022-3476(05)82421-7; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Loyd DR, 2008, EUR J NEUROSCI, V27, P1517, DOI 10.1111/j.1460-9568.2008.06100.x; Malviya S, 1999, REGION ANESTH PAIN M, V24, P438, DOI 10.1016/S1098-7339(99)90011-1; Matthews AJ, 1993, PAEDIATR ANAESTH, V3, P107; McPhie AA, 2009, DEV PSYCHOBIOL, V51, P544, DOI 10.1002/dev.20392; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Playfor S, 2007, PEDIATR ANESTH, V17, P881, DOI 10.1111/j.1460-9592.2007.02313.x; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Rahman W, 1998, DEV BRAIN RES, V108, P239, DOI 10.1016/S0165-3806(98)00054-6; Robertson R C, 2000, Pediatr Crit Care Med, V1, P119, DOI 10.1097/00130478-200010000-00005; SCHWIEGER IM, 1989, ANESTHESIOLOGY, V70, P667, DOI 10.1097/00000542-198904000-00021; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Siddappa R, 2003, PAEDIATR ANAESTH, V13, P805, DOI 10.1046/j.1460-9592.2003.01153.x; Simons SHP, 2006, SEMIN FETAL NEONAT M, V11, P260, DOI 10.1016/j.siny.2006.02.008; Simpson RJ, 1997, AM J CARDIOL, V80, pH53, DOI 10.1016/S0002-9149(97)00821-7; Stoller DC, 2004, PEDIATR ANESTH, V14, P642, DOI 10.1111/j.1460-9592.2004.01264.x; Suresh S, 2001, PAEDIATR ANAESTH, V11, P511, DOI 10.1046/j.1460-9592.2001.00764.x; TOBIAS JD, 1994, INTENS CARE MED, V20, P504, DOI 10.1007/BF01711905; Tobias JD, 2005, PEDIATR ANN, V34, P636, DOI 10.3928/0090-4481-20050801-12; Tobias JD, 2001, J CLIN ANESTH, V13, P122, DOI 10.1016/S0952-8180(00)00232-4; TOBIAS JD, 1990, CRIT CARE MED, V18, P1292, DOI 10.1097/00003246-199011000-00024; Tobias JD, 1999, CRIT CARE MED, V27, P2262, DOI 10.1097/00003246-199910000-00033; Trafton JA, 2007, J BEHAV HEALTH SER R, V34, P260, DOI 10.1007/s11414-007-9074-2; Wiesenfeld-Hallin Zsuzsanna, 2005, Gend Med, V2, P137, DOI 10.1016/S1550-8579(05)80042-7; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	53	43	44	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2013	14	1					27	36		10.1097/PCC.0b013e318253c80e			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	068FS	WOS:000313352200010	23132396	Green Accepted			2020-06-30	J	Parker, MM				Parker, Margaret M.			Analgesia in Mechanically Ventilated Children: To Each His Own?	PEDIATRIC CRITICAL CARE MEDICINE			English	Editorial Material						analgesia; children; mechanical ventilation; pain; sedation	IMPLEMENTED SEDATION PROTOCOL; GUIDELINES; DURATION		SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA	Parker, MM (reprint author), SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA.						Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Bucknall TK, 2008, CRIT CARE MED, V36, P1444, DOI 10.1097/CCM.0b013e318168f82d; Cannon ML, 2011, CRIT CARE MED, V39, P887, DOI 10.1097/CCM.0b013e31820a4dd8; Curley MAQ, 2009, SEDATION MANAGEMENT; Deeter KH, 2011, CRIT CARE MED, V39, P683, DOI 10.1097/CCM.0b013e318206cebf; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; Marshall J, 2008, CRIT CARE MED, V36, P427, DOI 10.1097/01.CCM.0000300275.63811.B3; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Quenot JP, 2007, CRIT CARE MED, V35, P2031, DOI 10.1097/01.ccm.0000282733.83089.4d	12	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2013	14	1					101	102		10.1097/PCC.0b013e31825b87d8			3	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	068FS	WOS:000313352200022	23295838				2020-06-30	J	Engelman, E; Marsala, C				Engelman, E.; Marsala, C.			Efficacy of adding clonidine to intrathecal morphine in acute postoperative pain: meta-analysis	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia; spinal; analysis; meta-analysis; intrathecal clonidine; intrathecal morphine; pain, postoperative	LOCAL-ANESTHETICS; ORAL CLONIDINE; ANALGESIA; SURGERY; PREMEDICATION; ADJUVANT	Clonidine may be used along with intrathecal morphine for single-dose postoperative analgesia in adults. The efficacy of this is not clear. A meta-analysis was performed for two endpoints of efficacy: the time to first postoperative analgesia request and the amount of systemic morphine used during the first 24 h after operation. A Bayesian inference supporting direct statements about the probability of the magnitude of an effect was also used. The frequency of the five adverse events (postoperative nausea or vomiting, sedation, respiratory depression, pruritus, and hypotension) was analysed. Clonidine increased the duration of analgesia by 1.63 h [95 confidence interval (CI): 0.932.33]. There is a 90 probability that clonidine increases the duration of postoperative analgesia by more than 75 min compared with morphine alone. Clonidine reduced the amount of postoperative morphine by a mean of 4.45 mg (95 CI: 1.407.49 mg). There is a probability of 90 to obtain a decrease 2.3 mg but only 35 to obtain a decrease 5 mg. The incidence of hypotension was the only adverse event increased by clonidine (odds ratio 1.78; 95 CI: 1.023.12). The addition of clonidine to intrathecal morphine extends the time to first analgesia and decreases the amount of morphine used. However, as the effects are small, and the results heavily influenced by a study in which intrathecal fentanyl was also given, this must be balanced with the increased frequency of hypotension.	[Engelman, E.; Marsala, C.] CUB Hop Erasme, Dept Anaesthesia, B-1070 Brussels, Belgium	Engelman, E (reprint author), CUB Hop Erasme, Dept Anaesthesia, Route Lennik 808, B-1070 Brussels, Belgium.	eengelma@ulb.ac.be					Andrieu G, 2009, ANESTH ANALG, V108, P1954, DOI 10.1213/ane.0b013e3181a30182; Breitfeld C, 2003, BRIT J ANAESTH, V91, P218, DOI 10.1093/bja/aeg165; Dopfmer UR, 2001, EUR J ANAESTH, V18, P389, DOI 10.1046/j.0265-0215.2001.00862.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elia N, 2008, REGION ANESTH PAIN M, V33, P159, DOI 10.1016/j.rapm.2007.10.008; Engelman E, 2011, ACTA ANAESTH SCAND, V55, P927, DOI 10.1111/j.1399-6576.2011.02471.x; Gehling M, 2003, ANAESTHESIST, V52, P204, DOI 10.1007/s00101-003-0459-1; Giovannelli M, 2008, EUR J ANAESTH, V25, P118, DOI 10.1017/S0265021507001305; Goyagi T, 1996, ANESTH ANALG, V82, P1192, DOI 10.1097/00000539-199606000-00016; GRACE D, 1995, ANESTH ANALG, V80, P86, DOI 10.1097/00000539-199501000-00015; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Lena P, 2003, BRIT J ANAESTH, V90, P300, DOI 10.1093/bja/aeg070; Mayson KV, 2000, CAN J ANAESTH, V47, P752, DOI 10.1007/BF03019477; McQuay HJ, 2008, BRIT J ANAESTH, V101, P69, DOI 10.1093/bja/aen108; Meylan N, 2009, BRIT J ANAESTH, V102, P156, DOI 10.1093/bja/aen368; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Nader ND, 2009, CLIN J PAIN, V25, P101, DOI 10.1097/AJP.0b013e3181817add; Paech MJ, 2004, ANESTH ANALG, V98, P1460, DOI 10.1213/01.ANE.0000111208.08867.3C; Popping DM, 2012, PAIN, V153, P784, DOI 10.1016/j.pain.2011.11.028; Rawal N, 1998, EUR J ANAESTH, V15, P354, DOI 10.1097/00003643-199805000-00019; Sites BD, 2003, ANESTH ANALG, V96, P1083, DOI 10.1213/01.ANE.0000055651.24073.59; Wijeysundera DN, 2009, J CLIN EPIDEMIOL, V62, P13, DOI 10.1016/j.jclinepi.2008.07.006	23	47	48	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JAN	2013	110	1					21	27		10.1093/bja/aes344			7	Anesthesiology	Anesthesiology	058MW	WOS:000312639000006	23002167	Bronze			2020-06-30	J	Albrecht, E; Taffe, P; Yersin, B; Schoettker, P; Decosterd, I; Hugli, O				Albrecht, E.; Taffe, P.; Yersin, B.; Schoettker, P.; Decosterd, I.; Hugli, O.			Undertreatment of acute pain (oligoanalgesia) and medical practice variation in prehospital analgesia of adult trauma patients: a 10 yr retrospective study	BRITISH JOURNAL OF ANAESTHESIA			English	Article						clinical practice variation; emergency medical services; physicians practice patterns; prehospital emergency care; wounds and injuries	FENTANYL; MANAGEMENT; PERFORMANCE; REGRESSION; JUDGMENTS; MORPHINE; SCORE	Prehospital oligoanalgesia is prevalent among trauma victims, even when the emergency medical services team includes a physician. We investigated if not only patients characteristics but physicians practice variations contributed to prehospital oligoanalgesia. Patient records of conscious adult trauma victims transported by our air rescue helicopter service over 10 yr were reviewed retrospectively. Oligoanalgesia was defined as a numeric rating scale (NRS) 3 at hospital admission. Multilevel logistic regression analysis was used to predict oligoanalgesia, accounting first for patient case-mix, and then physician-level clustering. The intraclass correlation was expressed as the median odds ratio (MOR). A total of 1202 patients and 77 physicians were included in the study. NRS at the scene was 6.9 (1.9). The prevalence of oligoanalgesia was 43. Physicians had a median of 5.7 yr (inter-quartile range: 4.27.5) of post-graduate training and 27 were female. In our multilevel analysis, significant predictors of oligoanalgesia were: no analgesia [odds ratio (OR) 8.8], National Advisory Committee for Aeronautics V on site (OR 4.4), NRS on site (OR 1.5 per additional NRS unit 4), female physician (OR 2.0), and years of post-graduate experience [4.0 to 5.0 (OR 1.3), 3.0 to 4.0 (OR 1.6), 2.0 to 3.0 (OR 2.6), and 2.0 yr (OR 16.7)]. The MOR was 2.6, and was statistically significant. Physicians practice variations contributed to oligoanalgesia, a factor often overlooked in analyses of prehospital pain management. Further exploration of the sources of these variations may provide innovative targets for quality improvement programmes to achieve consistent pain relief for trauma victims.	[Yersin, B.; Hugli, O.] Univ Lausanne Hosp, Emergency Dept, CH-1011 Lausanne, Switzerland; [Albrecht, E.; Schoettker, P.; Decosterd, I.] Univ Lausanne Hosp, Dept Anaesthesiol, CH-1011 Lausanne, Switzerland; [Taffe, P.] Univ Lausanne Hosp, Inst Social & Prevent Med, CH-1011 Lausanne, Switzerland	Hugli, O (reprint author), Univ Lausanne Hosp, Emergency Dept, Bugnon 46, CH-1011 Lausanne, Switzerland.	olivier.hugli@chuv.ch	Schoettker, Patrick/AAE-4462-2020; Hugli, Olivier/AAA-7057-2020	Schoettker, Patrick/0000-0001-5370-048X; Hugli, Olivier/0000-0003-2312-1625; Albrecht, Eric/0000-0001-6432-1311			Aubrun F, 2003, ANESTHESIOLOGY, V98, P1415, DOI 10.1097/00000542-200306000-00017; Austin PC, 2008, J APPL STAT, V35, P1355, DOI 10.1080/02664760802382434; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; CHAMBERS JA, 1993, ARCH EMERG MED, V10, P187; Cintron A, 2006, J PALLIAT MED, V9, P1454, DOI 10.1089/jpm.2006.9.1454; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Eisenberg JM, 2002, MED CARE, V40, P1016, DOI 10.1097/00005650-200211000-00004; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Frakes MA, 2009, AM J EMERG MED, V27, P49, DOI 10.1016/j.ajem.2008.01.005; Fung V, 2010, MED CARE, V48, P140, DOI 10.1097/MLR.0b013e3181bd4dc3; Guo G, 2000, ANNU REV SOCIOL, V26, P441, DOI 10.1146/annurev.soc.26.1.441; HAUSMAN JA, 1981, ECONOMETRICA, V49, P1377, DOI 10.2307/1911406; Heins JK, 2006, J EMERG NURS, V32, P219, DOI 10.1016/j.jen.2006.01.010; HOSMER D. W., 2000, APPL LOGISTIC REGRES; Jennings PA, 2011, EMERG MED J, V28, P530, DOI 10.1136/emj.2010.098954; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Krauss WC, 2011, J EMERG MED, V40, P182, DOI 10.1016/j.jemermed.2009.02.009; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Lord B, 2009, AM J EMERG MED, V27, P525, DOI 10.1016/j.ajem.2008.04.003; Marquie L, 2007, QUAL LIFE RES, V16, P1267, DOI 10.1007/s11136-007-9228-y; Mikkelsen ME, 2010, CHEST, V138, P551, DOI 10.1378/chest.09-2210; Moerbeek M, 2003, J CLIN EPIDEMIOL, V56, P341, DOI 10.1016/S0895-4356(03)00007-6; Neighbor ML, 2004, ACAD EMERG MED, V11, P1290, DOI 10.1197/j.aem.2004.07.014; Park C L, 2010, J R Army Med Corps, V156, P295; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; Schoettker P, 2001, RESUSCITATION, V49, P169, DOI 10.1016/S0300-9572(00)00356-7; Smith MD, 2012, J EMERG MED, V43, P69, DOI 10.1016/j.jemermed.2011.05.018; Sullivan LM, 1999, STAT MED, V18, P855, DOI 10.1002/(SICI)1097-0258(19990415)18:7<855::AID-SIM117>3.0.CO;2-7; Tait RC, 2009, PAIN MED, V10, P11, DOI 10.1111/j.1526-4637.2008.00527.x; Tamayo-Sarver JH, 2004, ANN EMERG MED, V43, P483, DOI 10.1016/j.annemergmed.2003.10.043; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; Thomas SH, 2008, J EMERG MED, V35, P47, DOI 10.1016/j.jemermed.2007.05.041; Veldman A, 2001, J TRAVEL MED, V8, P154; Weisse CS, 2003, J PAIN, V4, P505, DOI 10.1016/j.jpain.2003.08.002; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6	38	61	64	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JAN	2013	110	1					96	106		10.1093/bja/aes355			11	Anesthesiology	Anesthesiology	058MW	WOS:000312639000017	23059961	Green Published, Bronze			2020-06-30	J	Wiebe, ER; Byczko, B; Kaczorowski, J; McLane, AL				Wiebe, Ellen R.; Byczko, Beata; Kaczorowski, Janusz; McLane, Amanda Lea			Can we safely avoid fasting before abortions with low-dose procedural sedation? A retrospective cohort chart review of anesthesia-related complications in 47,748 abortions	CONTRACEPTION			English	Article						Fentanyl; Midazolam; Preprocedure fasting; Abortion; Minimal sedation; Conscious sedation; Moderate sedation; Aspiration; Anxiolysis	ADVERSE EVENTS; ASPIRATION; ANALGESIA	Background: Some licensing authorities require fasting before abortions under intravenous sedation to avoid aspiration of gastric contents. This study was conducted to estimate the incidence of anesthesia-related complications in women undergoing abortions without preprocedure fasting. Study Design: This is a retrospective cohort chart review of patients having abortions with both fentanyl and midazolam at two urban freestanding abortion clinics with routine policy of advising women to eat a light meal before the procedure. Results: There were no reports of anesthesia-related complications in the 47,748 charts reviewed from 1998 to 2010. Applying Hanley's formula for rare events that have not occurred, the upper 95% confidence interval for the true incidence of anesthesia-related complications for women having abortion under low-dose procedural sedation without fasting was estimated to be 0.00006%. Conclusions: This large retrospective cohort chart review identified no complications related to low-dose procedural sedation in over 47,000 consecutive nonfasting patients having abortions through 18 weeks' gestation. Eliminating the requirement to fast would decrease unnecessary stress and unpleasant symptoms without increase in the anesthesia-related complications for women having abortions. (c) 2013 Elsevier Inc. All rights reserved.	[Wiebe, Ellen R.; Byczko, Beata] Univ British Columbia, Dept Family Med, Vancouver, BC V5Z 1H9, Canada; [Kaczorowski, Janusz] Univ Montreal, Dept Med Familial & Urgence, Montreal, PQ, Canada; [McLane, Amanda Lea] Thompson Rivers Univ, Kamloops, BC, Canada	Wiebe, ER (reprint author), Univ British Columbia, Dept Family Med, Vancouver, BC V5Z 1H9, Canada.	ellenwiebe@gmail.com			Willow Women's Clinic	This study was funded by Willow Women's Clinic.	Cheung KW, 2007, ANN EMERG MED, V49, P462, DOI 10.1016/j.annemergmed.2006.09.004; Engelhardt T, 1999, BRIT J ANAESTH, V83, P453; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Machin D, 1997, SAMPLE SIZE TABLES C, P134; McKenna Gerald, 2010, Prim Dent Care, V17, P5, DOI 10.1308/135576110790307681; Molina JAD, 2010, INT J EVID-BASED HEA, V8, P75, DOI 10.1111/j.1744-1609.2010.00163.x; Nygren J, 2007, CURR OPIN ANESTHESIO, V20, P540, DOI 10.1097/ACO.0b013e3282f15493; Racek CM, 2010, CONTRACEPTION, V82, P286, DOI 10.1016/j.contraception.2010.01.024; Roback MG, 2004, ANN EMERG MED, V44, P454, DOI 10.1016/j.annemergmed.2004.03.015; SIMKIN P, 1986, BIRTH-ISS PERINAT C, V13, P234, DOI 10.1111/j.1523-536X.1986.tb01054.x; Wilson LC, 2009, CONTRACEPTION, V79, P122, DOI 10.1016/j.contraception.2008.08.005	12	12	12	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0010-7824			CONTRACEPTION	Contraception	JAN	2013	87	1					51	54		10.1016/j.contraception.2012.06.012			4	Obstetrics & Gynecology	Obstetrics & Gynecology	060AT	WOS:000312748400009	22840276				2020-06-30	J	Bekker, A; Haile, M; Kline, R; Didehvar, S; Babu, R; Martiniuk, F; Urban, M				Bekker, Alex; Haile, Michael; Kline, Richard; Didehvar, Sorosch; Babu, Ramesh; Martiniuk, Frank; Urban, Michael			The Effect of Intraoperative Infusion of Dexmedetomidine on the Quality of Recovery After Major Spinal Surgery	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						postoperative recovery; dexmedetomidine; spine surgery; cytokines; cortisol; C-reactive protein	PERIOPERATIVE CYTOKINE RESPONSE; SYSTEMIC INFLAMMATORY RESPONSE; POSTOPERATIVE PAIN; IMMUNE-RESPONSES; BOWEL FUNCTION; ANESTHESIA; CLONIDINE; FATIGUE; HYSTERECTOMY; PRETREATMENT	Background: Surgery induces a variety of metabolic, endocrine, and immune changes collectively known as the "stress response," which may often lead to prolonged postoperative convalescence. Anesthetic management may modulate this physiological response, thus affecting the postoperative course. We hypothesized that the intraoperative administration of dexmedetomidine (DEX), a sympatholytic agent, would reduce the stress response and improve the quality of recovery in patients undergoing major surgery. Methods: We conducted a prospective randomized double-blinded study of 54 patients undergoing multilevel spinal fusion. Anesthesia was maintained using either propofol/fentanyl/dexmedetomidine (PFD) or propofol/fentanyl/placebo-saline (PFS). The quality of recovery (a primary endpoint) was assessed using a 40-item quality of recovery questionnaire and a 9-question Fatigue Severity Scores. The tests were carried out preoperatively on postoperative days (POD) 1, 2, 3, and 30. Blood samples were collected at baseline, in the postanesthesia care unit, and at POD 1 and were analyzed for levels of cortisol, C-reactive proteins (CRP), and cytokines interleukin (IL)-1 alpha, IL-1 beta, IL-1ra, IL-2, IL-6, IL-8, IL-10, and tumor necrosis factor-alpha. Data were analyzed using SPSS software (version 18) using a multivariate and mixed model approach to test for the effect of surgery and drug group. Pairwise comparisons were assessed by means of the t test or rank tests after correcting for multiple comparisons. Results: The global 40-item quality of recovery questionnaire scores showed a significant effect of time (F-4,F-114 = 22.63, P < 0.001) and drug (F-1,F-51 = 4.368, P = 0.042), with average scores decreasing to lower values on POD 1 (163.63 +/- 2.47) and POD 2 (170.94 +/- 2.38) compared with baseline (180.56 +/- 1.588, mean +/- SE, 2-tailed t tests, P < 0.001). By POD 3, scores were significantly lower ( -13.74 point difference, P = 0.005) in the PFS group (169.3 +/- 3.87) than in the PFD group (183.04 +/- 2.76). All patients reported significantly higher levels of fatigue postoperatively, but intergroup difference in Fatigue Severity Scores was detected on POD 3 only, with scores in the PFS group higher than in the PFD group (50.0 +/- 4.0 vs. 36.3 +/- 4.9, P = 0.035). In both groups, plasma cortisol levels were highest in the postanesthesia care unit, whereas CRP levels were elevated on POD 1. DEX significantly reduced the levels of cortisol, but not those of CRP. Levels of cytokines IL-6, IL-8, and IL-10 were significantly higher immediately after surgery and at POD 1. Plasma levels of other cytokines were not affected by surgery. DEX delayed postoperative rise in IL-10 but not in IL-6 or IL-8. Conclusions: DEX infusion during multilevel spinal fusions moderately improved the quality of recovery and possibly reduced fatigue in the early postoperative period. Moreover, it reduced plasma levels of cortisol and IL-10 in comparison with the control group. Our sample size was not sufficient to detect differences either in the incidence of complications or in clinically relevant outcomes.	[Bekker, Alex] UMDNJ New Jersey Med Sch, Dept Anesthesiol, Newark, NJ 07101 USA; [Haile, Michael; Kline, Richard; Didehvar, Sorosch] NYU, Sch Med, Dept Anesthesiol, New York, NY 10003 USA; [Babu, Ramesh] NYU, Sch Med, Dept Neurosurg, New York, NY 10003 USA; [Martiniuk, Frank; Urban, Michael] NYU, Sch Med, Dept Med, New York, NY 10003 USA; [Urban, Michael] Hosp Special Surg, Dept Anesthesiol, New York, NY 10021 USA	Bekker, A (reprint author), UMDNJ New Jersey Med Sch, Dept Anesthesiol, 185 S Orange Ave, Newark, NJ 07101 USA.	alex.bekker@nyumc.org			Hospira (Chicago IL); Clinical and Translational Science Institute [NCRR-NIH 1UL1RR 029893]; Department of Anesthesiology, New York University Medical Center; Foundation for Perioperative Research and Education; Hospira	Supported by Hospira (Chicago IL); a grant from the Clinical and Translational Science Institute (Grant: NCRR-NIH 1UL1RR 029893); Department of Anesthesiology, New York University Medical Center; Foundation for Perioperative Research and Education (http://www.fpre.org).; A. B. received honoraria for presentations and research funding from Hospira. The other authors have no conflicts of interest to disclose.	Anselmi A, 2009, ANN THORAC SURG, V88, P326, DOI 10.1016/j.athoracsur.2009.01.031; Borsook D, 2010, PROG NEUROBIOL, V92, P601, DOI 10.1016/j.pneurobio.2010.08.006; Chambrier C, 1996, ANN SURG, V224, P178, DOI 10.1097/00000658-199608000-00010; CHRISTENSEN T, 1993, WORLD J SURG, V17, P220, DOI 10.1007/BF01658930; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; De Oliveira GS, 2011, ANESTHESIOLOGY, V115, P575, DOI 10.1097/ALN.0b013e31822a24c2; Genser B, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-27; Goldfarb Y, 2011, ANN SURG, V253, P798, DOI 10.1097/SLA.0b013e318211d7b5; Hjollund NH, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-12; Homburger JA, 2006, CURR OPIN ANESTHESIO, V19, P423, DOI 10.1097/01.aco.0000236143.61593.14; Kehlet H, 2006, REGION ANESTH PAIN M, V31, P47, DOI 10.1016/j.rapm.2005.10.005; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kehlet H, 2011, LANGENBECK ARCH SURG, V396, P585, DOI 10.1007/s00423-011-0790-y; Kennedy B C, 1999, Acta Anaesthesiol Belg, V50, P205; Kim MH, 2000, ANESTH ANALG, V90, P1441, DOI 10.1097/00000539-200006000-00035; Kohl BA, 2006, CURR OPIN CRIT CARE, V12, P325, DOI 10.1097/01.ccx.0000235210.85073.fc; Kolsen-Petersen JA, 2008, BRIT J ANAESTH, V100, P478, DOI 10.1093/bja/aen015; Kurosawa S, 2008, J ANESTH, V22, P263, DOI 10.1007/s00540-008-0626-2; Kyrou I, 2009, CURR OPIN PHARMACOL, V9, P787, DOI 10.1016/j.coph.2009.08.007; Leslie K, 2003, ANESTHESIOLOGY, V99, P1158, DOI 10.1097/00000542-200311000-00024; Lu CH, 2004, ANESTH ANALG, V99, P1465, DOI 10.1213/01.ANE.0000132974.32249.C8; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; Myles PS, 2012, BRIT J ANAESTH, V108, P423, DOI 10.1093/bja/aer505; Myles PS, 2001, ANESTH ANALG, V92, P281; Myles PS, 2000, BRIT J ANAESTH, V84, P11; Nader ND, 2001, ANESTH ANALG, V93, P363, DOI 10.1097/00000539-200108000-00026; Offner PJ, 1999, ARCH SURG-CHICAGO, V134, P935, DOI 10.1001/archsurg.134.9.935; Offner PJ, 1999, ARCH SURG-CHICAGO, V134, P938; Schilling T, 2011, ANESTHESIOLOGY, V115, P65, DOI 10.1097/ALN.0b013e318214b9de; Schneemilch CE, 2005, J CLIN ANESTH, V17, P517, DOI 10.1016/j.jclinane.2004.12.017; Taniguchi T, 2004, CRIT CARE MED, V32, P1322, DOI 10.1097/01.CCM.0000128579.84228.2A; Tasdogan M, 2009, J CLIN ANESTH, V21, P394, DOI 10.1016/j.jclinane.2008.10.010; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; van Munster BC, 2008, J AM GERIATR SOC, V56, P1704, DOI 10.1111/j.1532-5415.2008.01851.x; Westaby S, 2001, ANN THORAC SURG, V71, P667, DOI 10.1016/S0003-4975(00)02405-X; Wichmann MW, 2003, LANGENBECK ARCH SURG, V387, P397, DOI 10.1007/s00423-002-0346-2; Wu CT, 2004, ANESTH ANALG, V99, P502, DOI 10.1213/01.ANE.0000117146.46373.51; Zlotnik A, 2012, J NEUROSURG ANESTH, V24, P30, DOI 10.1097/ANA.0b013e318232deaa	38	81	95	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2013	25	1					16	24		10.1097/ANA.0b013e31826318af			9	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	057KJ	WOS:000312561800003	22824921	Green Accepted			2020-06-30	J	Anghelescu, DL; Burgoyne, LL; Faughnan, LG; Hankins, GM; Smeltzer, MP; Pui, CH				Anghelescu, Doralina L.; Burgoyne, Laura L.; Faughnan, Lane G.; Hankins, Gisele M.; Smeltzer, Matthew P.; Pui, Ching-Hon			Prospective Randomized Crossover Evaluation of Three Anesthetic Regimens for Painful Procedures in Children with Cancer	JOURNAL OF PEDIATRICS			English	Article							INTENSIVE-CARE-UNIT; INTRAVENOUS ANESTHESIA; HOSPITALIZED CHILDREN; PROPOFOL ANESTHESIA; PEDIATRIC ONCOLOGY; LUMBAR PUNCTURES; ADVERSE EVENTS; SEDATION; LEUKEMIA; FENTANYL	Objective To identify the most effective sedation regimen for bone marrow aspiration and lumbar puncture procedures with a prospective trial of 3 combinations of sedation/analgesia. Study design In this double-blind crossover study, we randomly assigned 162 children with acute lymphoblastic leukemia or lymphoblastic lymphoma to receive fentanyl 1 mcg/kg, fentanyl 0.5 mcg/kg, or placebo, in addition to propofol and topical anesthetic for 355 procedures. Results We found no significant differences among the 3 regimens in the frequency of pain (pain score >0) or severe pain (pain score >= 5) during recovery, or a >20% increase in hemodynamic/respiratory variables during anesthesia. Treatment with fentanyl 1 mcg/kg was associated with a lower frequency of movement during procedure compared with treatment with fentanyl 0.5 mcg/kg (P = .0476) or treatment with placebo (P = .0545). The placebo group required longer time to recover (median, 18 minutes) compared with the fentanyl 0.5 mcg/kg group (median, 9 minutes) (median difference 2.0, P = .007) and the fentanyl 1 mcg/kg (median 8 minutes), (median difference 2.0, P = .15). The placebo group also required larger total dose of propofol (median 5 mg/kg) compared with that of the fentanyl 1 mcg/kg group (median, 3.5 mg/kg) and the fentanyl 0.5 mcg/kg group (median 3.5 mg/kg) (median differences 1.5, P < .00005, in both comparisons). Conclusion The addition of fentanyl 1 mcg/kg to propofol for brief painful procedures reduces movement, propofol dose, and recovery time. (J Pediatr 2013;162:137-41).	[Anghelescu, Doralina L.; Burgoyne, Laura L.; Faughnan, Lane G.] St Jude Childrens Res Hosp, Div Anesthesia, Memphis, TN 38105 USA; [Anghelescu, Doralina L.; Burgoyne, Laura L.; Faughnan, Lane G.] St Jude Childrens Res Hosp, Pain Management Serv, Memphis, TN 38105 USA; [Hankins, Gisele M.] St Jude Childrens Res Hosp, Canc Ctr Adm, Memphis, TN 38105 USA; [Smeltzer, Matthew P.] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Pui, Ching-Hon] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Pui, Ching-Hon] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA	Anghelescu, DL (reprint author), St Jude Childrens Res Hosp, Div Anesthesia, Mail Stop 130,262 Danny Thomas Pl, Memphis, TN 38105 USA.	doralina.anghelescu@stjude.org	Anghelescu, Doralina L./N-8082-2018; Pui, Ching-Hon/N-8076-2018	Anghelescu, Doralina L./0000-0002-8521-2744; Pui, Ching-Hon/0000-0003-0303-5658; Smeltzer, Matthew/0000-0003-1366-9267; Faughnan, Lane/0000-0002-8463-8217; Burgoyne, Laura/0000-0003-1088-1641	Cancer Center Support grant [5P30CA021765-32]; American Lebanese Syrian Associated CharitiesAmerican Lebanese Syrian Associated Charities (ALSAC)	Supported by the Cancer Center Support grant (5P30CA021765-32) and the American Lebanese Syrian Associated Charities, neither of which had any involvement in the planning or conduct of this study. The authors declare no conflicts of interest.	[Anonymous], 1999, CONT DEPTH SED DEF G; Cechvala MM, 2008, J PEDIAT HEMATOL ONC, V30, P142, DOI 10.1097/MPH.0b013e31815d8953; Cravero JP, 2009, ANESTH ANALG, V108, P795, DOI 10.1213/ane.0b013e31818fc334; Gottschling S, 2005, J PEDIAT HEMATOL ONC, V27, P471, DOI 10.1097/01.mph.0000179238.37647.91; Hertzog JH, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e30; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Hockenberry MJ, 2011, J PEDIAT HEMATOL ONC, V33, P119, DOI 10.1097/MPH.0b013e3181f46a65; Hockenberry MJ, 2009, WONGS ESSENTIALS PED; Holdsworth MT, 2003, ANN PHARMACOTHER, V37, P17; Hollman GA, 2008, PEDIATR CRIT CARE ME, V9, P616, DOI 10.1097/PCC.0b013e31818e3ad3; Jayabose S, 2001, J PEDIAT HEMATOL ONC, V23, P290, DOI 10.1097/00043426-200106000-00011; Keidan I, 2001, PAEDIATR ANAESTH, V11, P297, DOI 10.1046/j.1460-9592.2001.00662.x; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; MCDOWALL RH, 1995, J CLIN ANESTH, V7, P273, DOI 10.1016/0952-8180(95)00017-C; Merkel S I, 1997, Pediatr Nurs, V23, P293; POWERS SW, 1993, J PEDIATR PSYCHOL, V18, P681, DOI 10.1093/jpepsy/18.6.681; von Baeyer Carl L, 2006, Pain Res Manag, V11, P157; Von Heijne M, 2004, PEDIATR ANESTH, V14, P670	18	14	14	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JAN	2013	162	1					137	141		10.1016/j.jpeds.2012.06.056			5	Pediatrics	Pediatrics	062JK	WOS:000312915900031	22883421	Green Accepted			2020-06-30	J	Wuethrich, PY; Metzger, T; Mordasini, L; Kessler, TM; Curatolo, M; Burkhard, FC				Wuethrich, Patrick Y.; Metzger, Tobias; Mordasini, Livio; Kessler, Thomas M.; Curatolo, Michele; Burkhard, Fiona C.			Influence of Epidural Mixture and Surgery on Bladder Function after Open Renal Surgery A Randomized Clinical Trial	ANESTHESIOLOGY			English	Article							URINARY-TRACT-INFECTION; SURGICAL-PATIENTS; ANALGESIA; FENTANYL; RETENTION; LUMBAR; BUPIVACAINE; MORBIDITY; PRESSURE; INFUSION	Background: In a previous observational study, thoracic epidural analgesia (TEA) after open renal surgery resulted in clinically relevant postvoid residuals (PVRs). This study aimed to investigate the individual contribution of epidurally administrated drugs and surgery in bladder dysfunction. Methods: In this single-center, parallel-group, randomized (computer-generated list), double-blind superiority trial, 40 patients undergoing open renal surgery were equally allocated to receive epidural bupivacaine (0.125%) alone or with fentanyl (2 mu g/ml). Patients underwent urodynamic investigations before TEA and during TEA preoperatively and postoperatively. Primary outcome was the difference (Delta) in PVR between before TEA and postoperatively during TEA. Secondary outcomes were changes in detrusor pressure at maximum flow rate, bladder compliance, and Delta PVR between different time points. Results: Median Delta PVR (ml) from baseline to postoperatively was 180 (range, -85 to 645; P = 0.001) in the bupivacaine group and 235 (range, 0-580; P value less than 0.001) in the bupivacaine/fentanyl group, with no difference between groups (95% confidence interval, -167 to 103; P = 0.634). Detrusor pressure at maximum flow rate (cm H2O) from baseline was more pronounced in the bupivacaine/fentanyl than that in the bupivacaine group preoperatively (-10; range, -64 to -2; P value less than 0.001 vs. -3; range, -35 to 13; P = 0.397) (P = 0.045) and postoperatively (-18; range, -64 to 0; P value less than 0.001 vs. -12; range, -34 to 22; P = 0.006) (P = 0.135). Surgery did not affect PVRs, but a decreased bladder compliance was observed in both groups. No adverse events occurred. Conclusions: Thoracic epidurally administrated bupivacaine resulted in clinically relevant PVRs based on impaired detrusor function. The addition of fentanyl enhanced this effect without generating greater PVRs. After surgery, the voiding phase was not further impaired; however, bladder compliance was decreased.	[Wuethrich, Patrick Y.; Metzger, Tobias; Mordasini, Livio; Kessler, Thomas M.; Curatolo, Michele; Burkhard, Fiona C.] Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, CH-3010 Bern, Switzerland	Wuethrich, PY (reprint author), Univ Hosp Bern, Dept Anesthesiol & Pain Therapy, CH-3010 Bern, Switzerland.	patrick.wuethrich@insel.ch	Burkhard, Fiona/AAE-4524-2020; Curatolo, Michele/A-5859-2011	Curatolo, Michele/0000-0003-4130-6826; , Livio/0000-0002-4087-6555; Mordasini, Livio/0000-0001-9146-2793	Bangerter Rhyner Foundation, Berne, Switzerland; Department of Anesthesiology and Pain Therapy; Department of Urology, University Hospital Bern	Received from the Department of Anesthesiology and Pain Therapy, University Hospital Bern, Berne, Switzerland. Submitted for publication March 27, 2012. Accepted for publication July 30, 2012. This study was supported by a grant from the Bangerter Rhyner Foundation, Berne, Switzerland, and by the institutional research funds of the Department of Anesthesiology and Pain Therapy and of the Department of Urology, University Hospital Bern. The sponsors did not influence any aspect of the study.	Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Baldini G, 2009, ANESTHESIOLOGY, V110, P1139, DOI 10.1097/ALN.0b013e31819f7aea; Basse L, 2000, REGION ANESTH PAIN M, V25, P498, DOI 10.1053/rapm.2000.9537; Cho SY, 2009, NEUROUROL URODYNAM, V28, P1010, DOI 10.1002/nau.20713; Curatolo M, 2000, ANESTHESIOLOGY, V93, P1517, DOI 10.1097/00000542-200012000-00025; DURANT PAC, 1988, ANESTHESIOLOGY, V68, P325, DOI 10.1097/00000542-198803000-00002; Eichenberger U, 2003, BRIT J ANAESTH, V90, P467, DOI 10.1093/bja/aeg100; Foxman B, 2002, AM J MED, V113, p5S; Freise H, 2008, ANESTHESIOLOGY, V109, P1107, DOI 10.1097/ALN.0b013e31818db16c; Gasser HS, 1929, AM J PHYSIOL, V88, P581; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GIVENS CD, 1980, J UROLOGY, V124, P646, DOI 10.1016/S0022-5347(17)55596-2; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Gupta A, 2006, ANESTHESIOLOGY, V105, P784, DOI 10.1097/00000542-200610000-00025; HAMPSON SJ, 1992, BRIT J UROL, V70, P506; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Madersbacher S, 1999, NEUROUROL URODYNAM, V18, P173, DOI 10.1002/(SICI)1520-6777(1999)18:3<173::AID-NAU3>3.3.CO;2-D; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; Panicker Jalesh N, 2010, Pract Neurol, V10, P178, DOI 10.1136/jnnp.2010.213892; Rosseland Leiv Arne, 2002, Tidsskr Nor Laegeforen, V122, P902; Saito M, 2001, J UROLOGY, V165, P1745, DOI 10.1016/S0022-5347(05)66406-3; Schafer W, 2002, NEUROUROL URODYNAM, V21, P261, DOI 10.1002/nau.10066; TAMMELA T, 1986, SCAND J UROL NEPHROL, V20, P197, DOI 10.3109/00365598609024494; Truzzi JCI, 2008, J UROLOGY, V180, P182, DOI 10.1016/j.juro.2008.03.044; Visser WA, 2008, ANESTH ANALG, V107, P708, DOI 10.1213/ane.0b013e31817e7065; Wuethrich PY, 2011, NEUROUROL URODYNAM, V30, P121, DOI 10.1002/nau.20950; Wuethrich PY, 2010, ANESTHESIOLOGY, V112, P1345, DOI 10.1097/ALN.0b013e3181d4f4fe; Zaouter C, 2009, REGION ANESTH PAIN M, V34, P542, DOI 10.1097/AAP.0b013e3181ae9fac	28	11	11	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JAN	2013	118	1					70	77		10.1097/ALN.0b013e318271606a			8	Anesthesiology	Anesthesiology	057BM	WOS:000312536800012	23208521	Green Accepted, Bronze			2020-06-30	J	Kairaluoma, P; Bachmann, M; Kallio, H; Rosenberg, P; Pere, P				Kairaluoma, P.; Bachmann, M.; Kallio, H.; Rosenberg, P.; Pere, P.			Hyperbaric articaine with or without fentanyl in spinal anaesthesia: patient and observer blinded comparison	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							INGUINAL-HERNIA REPAIR; LOW-DOSE BUPIVACAINE; INTRATHECAL FENTANYL; CESAREAN DELIVERY; PROLONGING RECOVERY; PLAIN ARTICAINE; LIDOCAINE; HERNIORRHAPHY; TRIAL	Background The rapid and short-acting local anaesthetic articaine is a feasible spinal anaesthetic for day-case open inguinal herniorrhaphy (OIH). We hypothesised that similarly to other spinal local anaesthetics, the addition of fentanyl may prolong articaine spinal analgesia without prolonging motor block. Methods We performed a randomised, controlled study in 100 adult patients undergoing OIH. Spinal anaesthesia was induced by injecting hyperbaric articaine 72?mg with (Group A?+?F) or without (Group A) fentanyl 10 mu g with the patient in lateral decubitus position. The distribution of sensory block was tested using pinprick and controlled by tilting the operating table 10 up or down. Motor block testing was based on the patient's ability to flex knees and ankles. Rescue analgesic was intravenous (i.v.) fentanyl. Pain scores were registered, and i.v. paracetamol 1?g was given as the first post-operative analgesic. Results There were no differences (A?+?F vs. A) in the maximum median extension of the sensory block (T5 vs. T5), mean duration of sensory block =?T10 (76?min vs. 73?min), or total duration of sensory (146?min vs. 146?min) or motor block (99?min vs. 107?min). Fewer patients in Group A?+?F needed fentanyl (5 vs. 14, P?<?0.05) perioperatively or paracetamol (3 vs. 18, P?<?0.001) post-operatively. Conclusion Fentanyl 10 mu g added to spinal hyperbaric articaine improved analgesia and reduced analgesic consumption during and after OIH. Fentanyl did not prolong motor block or delay recovery.	[Kairaluoma, P.; Bachmann, M.; Kallio, H.; Pere, P.] Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Helsinki, Finland; [Rosenberg, P.] Univ Helsinki, Dept Anaesthesiol & Intens Care Med, Helsinki, Finland	Kairaluoma, P (reprint author), Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, POB 263, FI-00029 Hus Helsinki, Finland.	pekka.kairaluoma@hus.fi			Helsinki University Hospital (EVO); Finska Lakaresallskapet, Finland	The study was supported by grants from Helsinki University Hospital (EVO) and Finska Lakaresallskapet, Finland. We are grateful for the assistance by Paivi Turunen, RN, and the cooperation of the staff of the day-surgery unit of Surgical Hospital, Helsinki University Hospital.	Atallah MM, 2006, ACTA ANAESTH SCAND, V50, P798, DOI 10.1111/j.1399-6576.2006.01063.x; Atallah Mohamed M., 2003, Middle East Journal of Anesthesiology, V17, P415; Bachmann M, 2008, BRIT J ANAESTH, V101, P848, DOI 10.1093/bja/aen294; Bachmann M, 2012, EUR J ANAESTH, V29, P22, DOI 10.1097/EJA.0b013e32834a11be; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Callesen T, 2001, ANESTH ANALG, V93, P1373, DOI 10.1097/00000539-200112000-00004; Callesen T, 2003, DAN MED BULL, V50, P203; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Dijkstra T, 2008, BRIT J ANAESTH, V100, P104, DOI 10.1093/bja/aem332; Duman A, 2010, PEDIATR ANESTH, V20, P530, DOI 10.1111/j.1460-9592.2010.03315.x; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; Hendriks MP, 2009, BRIT J ANAESTH, V102, P259, DOI 10.1093/bja/aen357; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Jensen P, 2002, REGION ANESTH PAIN M, V27, P612, DOI 10.1053/rapm.2002.37122; Kallio H, 2006, BRIT J ANAESTH, V97, P704, DOI 10.1093/bja/ael222; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Martin R, 1999, ANESTH ANALG, V88, P523, DOI 10.1097/00000539-199903000-00010; O'Donnell D, 2010, CAN J ANAESTH, V57, P32, DOI 10.1007/s12630-009-9207-6; PALMER CM, 1995, REGION ANESTH, V20, P389; Zaric D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003006.pub3	20	9	11	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2013	57	1					118	125		10.1111/j.1399-6576.2012.02794.x			8	Anesthesiology	Anesthesiology	053LA	WOS:000312271800017	23075046				2020-06-30	J	Cevik, E; Bilgic, S; Kilic, E; Cinar, O; Hasman, H; Yahya, A; Eroglu, M				Cevik, Erdem; Bilgic, Serkan; Kilic, Erden; Cinar, Orhan; Hasman, Hakan; Yahya, Ayhan; Eroglu, Murat			Comparison of ketamine-low-dose midozolam with midazolam-fentanyl for orthopedic emergencies: a double-blind randomized trial	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							PROCEDURAL SEDATION; ADVERSE EVENTS; ANALGESIA; KETAMINE/MIDAZOLAM; REDUCTION; ETOMIDATE; CHILDREN	Objective: Most of the fractures and dislocations are reduced in the emergency setting. Many drugs are available for procedural sedation and analgesia in the emergency department (ED); however, the adverse effects are still a common problem. The aim of our study was to compare the 2 drug combinations. Method: We performed a prospective, randomized, double-blinded, placebo-controlled trial of patients presenting to the ED after a traumatic event and required urgent reduction either for a fracture or dislocation. Patients were randomized to midazolam-fentanyl (MF) group or ketamine-low-dose midazolam (KM) group. Hypoxia, duration of hypoxia, need for oxygen, time to onset of sedation, recovery time, pain scores during reduction, and sedation depth were set as primary outcome measures and were recorded. Results: A total of 498 patients who presented to ED with extremity injury and required closed reduction were assessed; 130 of them were approached for eligibility and 69 patients were excluded. The remaining 61 patients were randomized to either KM group (n = 31) or MF group (n = 30). Hypoxia and duration of hypoxia were significantly lower in the KM group compared with the MF group. Patients in the KM group reported significantly lower pain scores during reduction; however, adverse effects were higher compared with MF group. Conclusion: Both drug combinations can be effectively used for procedural sedation and analgesia; however, with lower risk for hypoxia and lower pain scores, KM combination stands as a reasonable choice for orthopedic interventions in the emergency unit. (C) 2013 Elsevier Inc. All rights reserved.		Cevik, E (reprint author), Gulhane Mil Med Acad, Dept Emergency Med, GATA Acil Tip Anabilim Dali, TR-06010 Ankara, Turkey.	cevikerdem@yahoo.com; serbil11@gmail.com.tr; erdenkilic@gmail.com.tr; orhancinar@yahoo.com; hakan_has@yahoo.com; yahya_acar@yahoo.com; drmeroglu@yahoo.com	Cinar, Orhan/A-5305-2011; Kilic, Erden/AAG-9311-2019	Cinar, Orhan/0000-0001-5097-1276; Kilic, Erden/0000-0001-6098-9576			Agrawal D, 2003, ANN EMERG MED, V42, P636, DOI 10.1016/S0196-0644(03)00516-X; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bordo D, 2008, WEST J EMERG MED, V9, P86; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; Chudnofsky CR, 2000, ACAD EMERG MED, V7, P228, DOI 10.1111/j.1553-2712.2000.tb01064.x; Godambe SA, 2003, PEDIATRICS, V112, P116, DOI 10.1542/peds.112.1.116; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Graff KJ, 1996, PEDIATR EMERG CARE, V12, P31, DOI 10.1097/00006565-199602000-00009; Green SM, 2002, ACAD EMERG MED, V9, P35, DOI 10.1197/aemj.9.1.35; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; Hostetler MA, 2002, AM J EMERG MED, V20, P96, DOI 10.1053/ajem.2002.31572; Jamal S M, 2011, Med J Malaysia, V66, P231; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Meredith James R, 2008, J Emerg Trauma Shock, V1, P88, DOI 10.4103/0974-2700.43189; Migita RT, 2006, ARCH PEDIAT ADOL MED, V160, P46, DOI 10.1001/archpedi.160.1.46; Miller MA, 2005, EMERG MED CLIN N AM, V23, P551, DOI 10.1016/j.emc.2004.12.016; Newman DH, 2003, ANN EMERG MED, V42, P627, DOI 10.1016/S0196-0644(03)00446-3; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; Roback MG, 2005, ACAD EMERG MED, V12, P508, DOI 10.1197/j.aem.2004.12.009; Sener S, 2011, ANN EMERG MED, V57, P109, DOI 10.1016/j.annemergmed.2010.09.010; Warner MA, 1999, ANESTHESIOLOGY, V90, P896; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131	22	18	20	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	2013	31	1					108	113		10.1016/j.ajem.2012.06.012			6	Emergency Medicine	Emergency Medicine	062WM	WOS:000312954600017	22944555				2020-06-30	J	Gong, XD; Wang, JY; Liu, F; Yuan, HH; Zhang, WY; Guo, YH; Jiang, B				Gong, Xiao-Di; Wang, Jiong-Yi; Liu, Feng; Yuan, Hai-Hua; Zhang, Wen-Ying; Guo, Yue-Hui; Jiang, Bin			Gene Polymorphisms of OPRM1 A118G and ABCB1 C3435T May Influence Opioid Requirements in Chinese Patients with Cancer Pain	ASIAN PACIFIC JOURNAL OF CANCER PREVENTION			English	Article						SNP; opioids requirements; cancer pain treatment; OPRM1 gene; ABCB1 gene	SINGLE-NUCLEOTIDE POLYMORPHISM; MU-OPIATE RECEPTOR; CANDIDATE GENE; P-GLYCOPROTEIN; MDR1 GENE; INDIVIDUAL SENSITIVITY; SEQUENCE VARIABILITY; MORPHINE; ANALGESIA; ASSOCIATION	Backgrounds: Polymorphisms of OPRM1 A118G and ABCB1 C3435T have been suggested to contribute to inter-individual variability regarding pain sensitivity, opioid usage, tolerance and dependence and incidence of adverse effects in patients with chronic pain. This study aimed to investigate the association of both two polymorphisms with opioid requirements in Chinese patients with cancer pain. Methods: The genotypes of rs1799971 (OPRM1) and rs1045642 (ABCB1) were determined by PCR-RFLP and direct sequencing methods respectively in 112 patients with cancer-related pain. Comparisons between the different genotype or allele groups were performed with t-tests or one-way ANOVA tests, as appropriate. The potential relationship of allele number with opioid response was performed with a trend Jonckheere-Terpstra test. Results: In the 112 subjects, the frequencies of variant 118 G and 3435T allele were 38.4% and 37.9%, respectively. Significant higher 24h-opioid doses were observed in patients with GG (P=0.0004) and AG + GG (P=0.005) genotypes than the AA carriers. The dominant mutant 118G allele tended to be associated with progressively increasing 24h-opioiddoses (P=0.001). Compared with CC/CT, patients with ABCB1 TT genotype received higher 24h- and weight-surface area-adjusted-24h- opioids doses (P=0.057 and 0.028, respectively). Conclusions: The OPRM1 A118G single nucleotide polymorphism (SNP) is a key contributor for the inter-individual variability in opioidrequirements in Chinese cancer pain patients. This may possibly extend to the ABCB1 C3435T SNP.	[Gong, Xiao-Di; Wang, Jiong-Yi; Liu, Feng; Yuan, Hai-Hua; Zhang, Wen-Ying; Guo, Yue-Hui; Jiang, Bin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 3, Dept Oncol, Shanghai, Peoples R China	Jiang, B (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 3, Dept Oncol, Shanghai, Peoples R China.	dr_jiang@yeah.net			Science and Technology Research Foundation of Shanghai [10JC1409200]; Science and Technology Research Foundation of Shanghai Jiao Tong University School of Medicine [11XJ22014]; NO.3 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Foundation [syz2011-05]	This study was supported by the Science and Technology Research Foundation of Shanghai (10JC1409200), the Science and Technology Research Foundation of Shanghai Jiao Tong University School of Medicine (11XJ22014) and the NO.3 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Foundation (syz2011-05).	Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Baldissera VD, 2012, ANN HEPATOL, V11, P899; Bayerer B, 2007, EUR J PAIN, V11, P421, DOI 10.1016/j.ejpain.2006.06.004; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Campa D, 2008, CLIN PHARMACOL THER, V83, P559, DOI 10.1038/sj.clpt.6100385; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Fujita K, 2010, CANCER CHEMOTH PHARM, V65, P251, DOI 10.1007/s00280-009-1029-2; Haerian BS, 2013, PHARMACOGENOMICS, V14, P813, DOI [10.2217/PGS.13.57, 10.2217/pgs.13.57]; Hamabe W, 2006, PHARMACOL BIOCHEM BE, V85, P629, DOI 10.1016/j.pbb.2006.10.018; Hirota T, 2003, DRUG METAB DISPOS, V31, P677, DOI 10.1124/dmd.31.5.677; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Huang P, 2012, BIOCHEM J, V441, P379, DOI 10.1042/BJ20111050; Hung CC, 2008, PHARMACOGENET GENOM, V18, P390, DOI 10.1097/FPC.0b013e3282f85e36; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Kasai S, 2008, N-S ARCH PHARMACOL, V377, P269, DOI 10.1007/s00210-007-0205-3; Kasai S, 2011, PHARMACOGENOMICS, V12, P1305, DOI [10.2217/pgs.11.68, 10.2217/PGS.11.68]; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Kosarac B, 2009, CURR OPIN ANESTHESIO, V22, P476, DOI 10.1097/ACO.0b013e32832e34c9; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Leschziner G, 2006, PHARMACOGENET GENOM, V16, P439, DOI 10.1097/01.fpc.0000197467.21964.67; Li D, 2007, J CLIN PHARM THER, V32, P89, DOI 10.1111/j.1365-2710.2007.00791.x; Linares CL, 2011, OBES SURG, V21, P1257, DOI 10.1007/s11695-010-0143-x; Lotsch J, 2006, PHARMACOGENOMICS J, V6, P200, DOI 10.1038/sj.tpj.6500362; Lotsch J, 2006, CLIN PHARMACOL THER, V79, P72, DOI 10.1016/j.clpt.2005.09.010; Mealey KL, 2008, VET PARASITOL, V158, P215, DOI 10.1016/j.vetpar.2008.09.009; Oertel BG, 2006, PHARMACOGENET GENOM, V16, P625, DOI 10.1097/01.fpc.0000220566.90466.a2; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Robles CRF, 2012, CURR OPIN ANESTHESIO, V25, P444, DOI 10.1097/ACO.0b013e3283556228; Salama NN, 2006, J PHARM SCI-US, V95, P2293, DOI 10.1002/jps.20717; Shabalina SA, 2009, HUM MOL GENET, V18, P1037, DOI 10.1093/hmg/ddn439; Sia AT, 2010, INT J OBSTET ANESTH, V19, P254, DOI 10.1016/j.ijoa.2010.03.001; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Smith K, 2012, J CLIN ONCOL, V19, P2542; Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008; Tan EC, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-32; Tang K, 2004, HUM MOL GENET, V13, P783, DOI 10.1093/hmg/ddh099; Uhl GR, 1999, P NATL ACAD SCI USA, V96, P7752, DOI 10.1073/pnas.96.14.7752; Wang DX, 2005, PHARMACOGENET GENOM, V15, P693, DOI 10.1097/01.fpc.0000178311.02878.83; Wang DX, 2001, J BIOL CHEM, V276, P34624, DOI 10.1074/jbc.M104083200; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Zhou B, 2012, RADIOLOGY, V262, P1014, DOI 10.1148/radiol.11110552; Zhou SF, 2007, DRUG DISCOV TODAY, V12, P664, DOI 10.1016/j.drudis.2007.06.004	47	31	34	0	6	ASIAN PACIFIC ORGANIZATION CANCER PREVENTION	GYEONGGI-DO	APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA	1513-7368			ASIAN PAC J CANCER P	Asian Pac. J. Cancer Prev.		2013	14	5					2937	2943		10.7314/APJCP.2013.14.5.2937			7	Oncology	Oncology	AB0HU	WOS:000331473400042	23803057	DOAJ Gold			2020-06-30	J	Ona, XB; Comas, DR; Urrutia, G				Basurto Ona, Xavier; Rigau Comas, David; Urrutia, Gerard			Opioids for acute pancreatitis pain	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							MORPHINE; BUPRENORPHINE; GUIDELINES; MANAGEMENT; DIAGNOSIS; PROCAINE	Background Acute pancreatitis is an acute inflammatory process of the pancreas that may also involve adjacent tissues and/or remote organ systems. Abdominal pain is the main symptom and is usually accompanied by nausea, vomiting and fever. Opoids are commonly used to manage pain in acute pancreatitis but there are still some uncertainties about their clinical effectiveness and safety. Objectives To assess the effectiveness and safety of opioids for treating acute pancreatitis pain. Search methods The search strategy included the Cochrane Upper Gastrointestinal and Pancreatic Diseases Review Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2013, Issue 6), MEDLINE (from 1950 to June 2013) and EMBASE (from 1980 to June 2013). There were no restrictions by language or publication status. Selection criteria We considered randomised clinical trials (RCTs) assessing the effectiveness of any opioid drug used for treating acute pancreatitis pain. Data collection and analysis Two review authors independently selected studies, assessed risks of bias and extracted data. We estimated risk ratios (RRs) for dichotomous data and calculated a 95% confidence interval (CI) for each RR. We performed an intention-to-treat (ITT) analysis. We undertook meta-analysis for some outcomes. Main results We included five RCTs with a total of 227 participants (age range 23 to 76 years; 65% men) with acute pancreatitis pain. The opioids assessed were intravenous and intramuscular buprenorphine, intramuscular pethidine, intravenous pentazocine, transdermal fentanyl and subcutaneous morphine. One RCT, comparing subcutaneous morphine with intravenous metamizole reported non-significant reduction in the number of participants with improvements in pain intensity (primary outcome) (RR 0.50, 95% CI 0.19 to 1.33). Three studies compared analgesia using opioids with non-opioid treatments. After excluding one study that used opioids through continuous intravenous infusion, there was a decrease in the number of patients requiring supplementary analgesia (RR 0.53, 95% CI 0.30 to 0.93). In a single study, there were no differences in the number of patients requiring supplementary analgesia between buprenorphine and pethidine (RR 0.82, 95% CI 0.61 to 1.10). Pancreatitis complications were not associated with a significant difference between the drugs tested. No clinically serious or life-threatening adverse events occurred related to treatment. No differences for this outcome were found between opioid and non-opioid treatments, or for type of adverse event (nausea-vomiting and somnolence-sedation). One death in the procaine group was reported across all the trials. One RCT comparing pethidine with intramuscular buprenorphine reported non-significant differences of supplementary analgesic, adverse events or deaths. One RCT comparing fentanyl with placebo found no difference in adverse events. The findings of this review are limited by the lack of information to allow full appraisal of the risk of bias, the measurement of relevant outcomes and the small numbers of participants and events covered by the trials. Authors' conclusions Opioids may be an appropriate choice in the treatment of acute pancreatitis pain. Compared with other analgesic options, opioids may decrease the need for supplementary analgesia. There is currently no difference in the risk of pancreatitis complications or clinically serious adverse events between opioids and other analgesia options. Future research should focus on the design of trials with larger samples and the measurement of relevant outcomes for decision-making, such as the number of participants showing reductions in pain intensity. The reporting of these RCTs should also be improved to allow users of the medical literature to appraise their results accurately. Large longitudinal studies are also needed to establish the risk of pancreatitis complications and adverse events related to drugs.	[Basurto Ona, Xavier] Hosp Figueres, Emergency Dept, Fundacio Salut Emporda, Figueres 17600, Girona Cataluny, Spain; [Rigau Comas, David; Urrutia, Gerard] CIBER Epidemiol & Salud Publ CIBERESP, Iberoamer Cochrane Ctr IIB St Pau, Barcelona, Spain	Ona, XB (reprint author), Hosp Figueres, Emergency Dept, Fundacio Salut Emporda, Rda Rector Aroles S-N, Figueres 17600, Girona Cataluny, Spain.	basurto18@gmail.com		Urrutia, Gerard/0000-0002-8850-0960	Iberoamerican Cochrane Centre, Spain; CIBER de Epidemiologi y Salud Publica (CIBERESP), Spain	Internal sources; Iberoamerican Cochrane Centre, Spain.; CIBER de Epidemiologi y Salud Publica (CIBERESP), Spain.	Banks PA, 2002, GASTROINTEST ENDOSC, V56, pS226, DOI 10.1067/mge.2002.129022; Banks PA, 2006, AM J GASTROENTEROL, V101, P2379, DOI 10.1111/j.1572-0241.2006.00856.x; BLAMEY SL, 1984, BMJ-BRIT MED J, V288, P1494, DOI 10.1136/bmj.288.6429.1494-a; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; Carroll JK, 2007, AM FAM PHYSICIAN, V75, P1513; Cebrian JG, 2003, MED INTENSIVA, V27, P116; Frossard JL, 2008, LANCET, V371, P143, DOI 10.1016/S0140-6736(08)60107-5; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JSG, 2011, COCHRANE HANDBOOK FO; HOPTON D, 1971, GUT, V12, P51, DOI 10.1136/gut.12.1.51; Isenhower HL, 1998, AM J HEALTH-SYST PH, V55, P480, DOI 10.1093/ajhp/55.5.480; Jakobs R, 2000, SCAND J GASTROENTERO, V35, P1319; Johnson CD, 2005, GUT, V54, P1, DOI 10.1136/gut.200A.057026; Kahl S, 2004, DIGESTION, V69, P5, DOI 10.1159/000076541; Munoz A, 2000, AM FAM PHYSICIAN, V62, P164; Peiro AM, 2008, PANCREATOLOGY, V8, P25, DOI 10.1159/000114852; SALAZAR JR, 1987, REV ESP ENFERM APAR, V72, P99; SALIM AS, 1991, ARCH SURG-CHICAGO, V126, P1109; Santosh D, 2010, J GASTROEN HEPATOL, V25, pA17; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Spiegel B, 2001, AM FAM PHYSICIAN, V64, P219; Stevens M, 2002, APPL NURS RES, V15, P102, DOI 10.1053/apnr.2002.29532; The Nordic Cochrane Centre The Cochrane Collaboration, 2011, THE COCHRANE COLLABO; Thompson DR, 2001, AM J GASTROENTEROL, V96, P1266, DOI 10.1111/j.1572-0241.2001.03536.x; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Wang GJ, 2009, WORLD J GASTROENTERO, V15, P1427, DOI 10.3748/wjg.15.1427; Whitcomb DC, 2008, PANCREATOLOGY, V8, P520, DOI 10.1159/000152001; Whitcomb DC, 2006, NEW ENGL J MED, V354, P2142, DOI 10.1056/NEJMcp054958; WHO Collaborating Centre for Drug Statistics Methodology, 2009, GUIDELINES FOR ATC C	29	31	31	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2013		7							CD009179	10.1002/14651858.CD009179.pub2			48	Medicine, General & Internal	General & Internal Medicine	193OD	WOS:000322568300033	23888429				2020-06-30	J	Ona, XB; Tuma, SMU; Garcia, LM; Sola, I; Cosp, XB				Basurto Ona, Xavier; Uriona Tuma, Sonia Maria; Martinez Garcia, Laura; Sola, Ivan; Bonfill Cosp, Xavier			Drug therapy for preventing post-dural puncture headache	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							ACCIDENTAL DURAL PUNCTURE; DURATION OUTPATIENT LAPAROSCOPY; FENTANYL SPINAL-ANESTHESIA; POSTOPERATIVE PAIN RELIEF; EPIDURAL BLOOD PATCH; LOW-DOSE BUPIVACAINE; DOUBLE-BLIND; LUMBAR PUNCTURE; INTRATHECAL FENTANYL; TRANSDERMAL NITROGLYCERINE	Background Post-dural (post-lumbar or post-spinal) puncture headache (PDPH) is one of the most common complications of diagnostic, therapeutic or inadvertent lumbar punctures. Many drug options have been used to prevent headache in clinical practice and have also been tested in some clinical studies, but there are still some uncertainties about their clinical effectiveness. Objectives To assess the effectiveness and safety of drugs for preventing PDPH in adults and children. Search methods The search strategy included the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2012, Issue 5), MEDLINE (from 1950 to May 2012), EMBASE (from 1980 to May 2012) and CINAHL (from 1982 to June 2012). There was no language restriction. Selection criteria We considered randomised controlled trials (RCTs) that assessed the effectiveness of any drug used for preventing PDPH. Data collection and analysis Review authors independently selected studies, assessed risks of bias and extracted data. We estimated risk ratios (RR) for dichotomous data and mean differences (MD) for continuous outcomes. We calculated a 95% confidence interval (CI) for each RR and MD. We did not undertake meta-analysis because participants' characteristics or assessed doses of drugs were too different in the included studies. We performed an intention-to-treat (ITT) analysis. Main results We included 10 RCTs (1611 participants) in this review with a majority of women (72%), mostly parturients (women in labour) (913), after a lumbar puncture for regional anaesthesia. Drugs assessed were epidural and spinal morphine, spinal fentanyl, oral caffeine, rectal indomethacin, intravenous cosyntropin, intravenous aminophylline and intravenous dexamethasone. All the included RCTs reported data on the primary outcome, i.e. the number of participants affected by PDPH of any severity after a lumbar puncture. Epidural morphine and intravenous cosyntropin reduced the number of participants affected by PDPH of any severity after a lumbar puncture when compared to placebo. Also, intravenous aminophylline reduced the number of participants affected by PDPH of any severity after a lumbar puncture when compared to no intervention, while intravenous dexamethasone increased it. Spinal morphine increased the number of participants affected by pruritus when compared to placebo, and epidural morphine increased the number of participants affected by nausea and vomiting when compared to placebo. Oral caffeine increased the number of participants affected by insomnia when compared to placebo. The remainder of the interventions analysed did not show any relevant effect for any of the outcomes. None of the included RCTs reported the number of days that patients stayed in hospital. Authors' conclusions Morphine and cosyntropin have shown effectiveness for reducing the number of participants affected by PDPH of any severity after a lumbar puncture, when compared to placebo, especially in patients with high risk of PDPH, such as obstetric patients who have had an inadvertent dural puncture. Aminophylline also reduced the number of participants affected by PDPH of any severity after a lumbar puncture when compared to no intervention in patients undergoing elective caesarean section. Dexamethasone increased the risk of PDPH, after spinal anaesthesia for caesarean section, when compared to placebo. Morphine also increased the number of participants affected by adverse events (pruritus and nausea and vomiting) There is a lack of conclusive evidence for the other drugs assessed (fentanyl, caffeine, indomethacin and dexamethasone). These conclusions should be interpreted with caution, owing to the lack of information, to allow correct appraisal of risk of bias and the small sample sizes of studies.	[Basurto Ona, Xavier] Hosp Figueres, Fundacio Salut Emporda, Emergency Dept, Figueres 17600, Girona Cataluny, Spain; [Uriona Tuma, Sonia Maria] Vall Hebron Univ Hosp, Barcelona, Spain; [Martinez Garcia, Laura; Sola, Ivan] Inst Biomed Res IIB St Pau, Iberoamer Cochrane Ctr, Barcelona, Spain; [Bonfill Cosp, Xavier] Univ Autonoma Barcelona, E-08193 Barcelona, Spain	Ona, XB (reprint author), Hosp Figueres, Fundacio Salut Emporda, Emergency Dept, Rda Rector Aroles S-N, Figueres 17600, Girona Cataluny, Spain.	basurto18@gmail.com		Sola, Ivan/0000-0003-0078-3706; Bonfill Cosp, Xavier/0000-0003-1530-3509	Iberoamerican Cochrane Centre, Spain; CIBER de Epidemiologia y Salud Publica (CIBERESP), Spain; Agencia de Calidad del Sistema Nacional de Salud, Ministerio de Salud y Consumo, Spain	Internal sources; Iberoamerican Cochrane Centre, Spain.; CIBER de Epidemiologia y Salud Publica (CIBERESP), Spain.; External sources; Agencia de Calidad del Sistema Nacional de Salud, Ministerio de Salud y Consumo, Spain.	ABBOUD TK, 1992, REGION ANESTH, V17, P34; Ackerman WE, 1990, ANESTHESIOLOGY REV, V17, P45; Ahmed SV, 2006, POSTGRAD MED J, V82, P713, DOI 10.1136/pgmj.2006.044792; Al-Metwalli RR, 2008, ANAESTHESIA, V63, P847, DOI 10.1111/j.1365-2044.2008.05494.x; Altunkaya H, 2005, ARCH ORTHOP TRAUM SU, V125, P609, DOI 10.1007/s00402-004-0788-9; Angle P, 2005, CAN J ANAESTH, V52, P397, DOI 10.1007/BF03016283; Apfel CC, 2010, BRIT J ANAESTH, V105, P255, DOI 10.1093/bja/aeq191; Arevalo-Rodriguez I, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009199.pub2; AZIZ H, 1968, BRIT MED J, V4, P677, DOI 10.1136/bmj.4.5632.677; Balestrieri PJ, 2003, INT J OBSTET ANESTH, V12, P305, DOI 10.1016/S0959-289X(03)00067-0; Banks S, 2001, INT J OBSTET ANESTH, V10, P172, DOI 10.1054/ijoa.2000.0826; Ona XB, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007887; BAUMGARTEN RK, 1987, ANESTH ANALG, V66, P913; Beilin Y, 2003, ANESTH ANALG, V97, P56, DOI 10.1213/01.ANE.0000068940.36040.54; Berger CW, 1998, CAN J ANAESTH, V45, P110, DOI 10.1007/BF03013247; Bezov D, 2010, HEADACHE, V50, P1482, DOI 10.1111/j.1526-4610.2010.01758.x; Boonmak P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001791.pub2; Breebaart MB, 2003, BRIT J ANAESTH, V90, P309, DOI 10.1093/bja/aeg078; CALDWELL LE, 1994, REGION ANESTH, V19, P2; CAMANN WR, 1993, ANESTHESIOLOGY, V78, P870, DOI 10.1097/00000542-199305000-00010; CAMANN WR, 1992, ANESTHESIOLOGY, V77, P884, DOI 10.1097/00000542-199211000-00008; CAMPBELL DC, 1995, ANESTH ANALG, V81, P305, DOI 10.1097/00000539-199508000-00017; Cesur M, 2009, J ANESTH, V23, P31, DOI 10.1007/s00540-008-0690-7; Chalmers PC, 1988, PAIN CLINIC, V2, P49; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; Cho JE, 2008, ACTA ANAESTH SCAND, V52, P1360, DOI 10.1111/j.1399-6576.2008.01796.x; Choi PT, 2003, CAN J ANAESTH, V50, P460, DOI 10.1007/BF03021057; Clark JW, 1996, J NEUROL NEUROSUR PS, V60, P681, DOI 10.1136/jnnp.60.6.681; Clarke H, 2009, PAIN RES MANAG, V14, P217, DOI 10.1155/2009/930609; COLONNAROMANO P, 1989, ANESTH ANALG, V69, P522; COWAN JMA, 1980, BRIT MED J, V280, P224, DOI 10.1136/bmj.280.6209.224; Danelli G, 2004, REGION ANESTH PAIN M, V29, P221, DOI 10.1016/j.rapm.2004.02.003; DANGELO R, 1994, ANESTHESIOLOGY, V80, P1209, DOI 10.1097/00000542-199406000-00007; Davignon Kristopher R, 2002, Int Anesthesiol Clin, V40, P89; Dayioglu H, 2009, J ANESTH, V23, P19, DOI 10.1007/s00540-008-0677-4; De Pietri L, 2006, ANESTH ANALG, V102, P1157, DOI 10.1213/01.ane.0000198567.85040.ce; Delfino J, 2001, REV BRAS ANESTESIOL, V51, P91; DENNY N, 1987, ANESTH ANALG, V66, P791; DEVCIC A, 1993, REGION ANESTH, V18, P222; Dijkstra T, 2008, BRIT J ANAESTH, V100, P104, DOI 10.1093/bja/aem332; Dilli D, 2008, INDIAN PEDIATR, V45, P899; Dominguez-Hervella F D, 1993, Rev Esp Anestesiol Reanim, V40, P279; Doroudian MR, 2011, ACTA ANAESTH BELG, V62, P143; Edstrom HH, 1986, REGIONAL ANESTHESIA, V11, P139; Elkhodair S, 2010, EMERG MED J, V27, P476, DOI 10.1136/emj.2010.097162; Esmaoglu A, 2005, J CLIN ANESTH, V17, P58, DOI 10.1016/j.jclinane.2004.04.003; FLAATTEN H, 1987, ANAESTHESIA, V42, P202, DOI 10.1111/j.1365-2044.1987.tb03001.x; FOGARTY DJ, 1993, BRIT J ANAESTH, V71, P661, DOI 10.1093/bja/71.5.661; FOGARTY DJ, 1995, ACTA ANAESTH SCAND, V39, P191, DOI 10.1111/j.1399-6576.1995.tb04041.x; Forster JG, 1996, BRIT J ANAESTH, V97, P393; Frey K, 1998, REGION ANESTH PAIN M, V23, P159, DOI 10.1097/00115550-199823020-00008; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; Fu RQ, 2008, CLIN EXP PHARMACOL P, V35, P60, DOI 10.1111/j.1440-1681.2007.04735.x; Fujii Y, 1998, ACTA ANAESTH SCAND, V42, P921, DOI 10.1111/j.1399-6576.1998.tb05350.x; Gangopadhyay S, 2010, J ANAESTH CLIN PHARM, V26, P59; Ganzi F., 1995, Anesthesia and Analgesia, V80, pS143; Garg A, 2010, ANAESTH INTENS CARE, V38, P285, DOI 10.1177/0310057X1003800210; GIELEN MJM, 1986, REGION ANESTH PAIN M, V11, P176; Ginsberg L, 1996, BRIT J NEUROSURG, V10, P285, DOI 10.1080/02688699650040151; Girgin NK, 2008, J INT MED RES, V36, P1287, DOI 10.1177/147323000803600616; Gogarten W, 2004, EUR J ANAESTH, V21, P38, DOI 10.1017/S0265021504001073; Grande PO, 2005, ACTA ANAESTH SCAND, V49, P619, DOI 10.1111/j.1399-6576.2004.00601.x; Gurbet A, 2008, J INT MED RES, V36, P964, DOI 10.1177/147323000803600512; Hafer J, 1997, ANAESTHESIST, V46, P860, DOI 10.1007/s001010050480; Hakim SM, 2010, ANESTHESIOLOGY, V113, P413, DOI 10.1097/ALN.0b013e3181dfd424; HANSEN PE, 1979, ACTA NEUROL SCAND, V60, P183; HANSEN PE, 1980, BRIT MED J, V280, P1146, DOI 10.1136/bmj.280.6223.1146-a; Harrington BE, 2004, REGION ANESTH PAIN M, V29, P136, DOI 10.1016/j.rapm.2003.12.023; Harsten A, 1997, EUR J ANAESTH, V14, P642, DOI 10.1046/j.1365-2346.1994.00212.x; Hein A, 2010, INT J OBSTET ANESTH, V19, P384, DOI 10.1016/j.ijoa.2010.04.003; Hendriks MP, 2009, BRIT J ANAESTH, V102, P259, DOI 10.1093/bja/aen357; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; ILIOFF G, 1990, Regional Anesthesia, V15, P65; Imbelloni LE, 2009, ANAESTH INTENS CARE, V37, P242, DOI 10.1177/0310057X0903700209; Imbelloni LE, 2010, REV BRAS ANESTESIOL, V60, P113, DOI 10.1590/S0034-70942010000200002; Imbelloni Luiz Eduardo, 2003, Rev. Bras. Anestesiol., V53, P322, DOI 10.1590/S0034-70942003000300002; Jacobsohn E, 2005, CAN J ANAESTH, V52, P848; Kallio H, 2005, REGION ANESTH PAIN M, V30, P48, DOI 10.1016/j.rapm.2004.11.002; Kallio H, 2004, ANESTH ANALG, V99, P713, DOI 10.1213/01.ANE.0000129976.26455.32; KAUKINEN S, 1981, ANN CHIR GYNAECOL FE, V70, P107; Kouri ME, 2004, ANESTH ANALG, V98, P75, DOI 10.1213/01.ANE.0000093228.61443.EE; Kuczkowski K M, 2006, Acta Anaesthesiol Belg, V57, P55; LANZ E, 1982, ANESTH ANALG, V61, P236; Lauretti G. R., 1999, Regional Anesthesia and Pain Medicine, V24, P17, DOI 10.1016/S1098-7339(99)90194-3; Lauretti GR, 2000, J CLIN ANESTH, V12, P444, DOI 10.1016/S0952-8180(00)00189-6; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P734, DOI 10.1097/00000542-199903000-00015; Lauretti GR, 2000, ANESTHESIOLOGY, V93, P943, DOI 10.1097/00000542-200010000-00011; Lavi R, 2006, NEUROLOGY, V67, P1492, DOI 10.1212/01.wnl.0000240054.40274.8a; Lee YY, 2005, ACTA ANAESTH SCAND, V49, P1477, DOI 10.1111/j.1399-6576.2005.00864.x; LEWIS RP, 1992, EUR J ANAESTH, V9, P105; Lierz P, 2004, EUR J ANAESTH, V21, P32, DOI 10.1017/S0265021504001061; Lopez-Soriano F, 2002, Rev Esp Anestesiol Reanim, V49, P71; Luck JF, 2008, BRIT J ANAESTH, V101, P705, DOI 10.1093/bja/aen250; LYBECKER H, 1995, ACTA ANAESTH SCAND, V39, P605, DOI 10.1111/j.1399-6576.1995.tb04135.x; Manaa EM, 2005, EGYPTIAN J ANAESTHES, V21, P75; Massou S, 2008, ANN FR ANESTH, V27, P861, DOI 10.1016/j.annfar.2008.09.001; MCQUAY H, 1998, EVIDENCE BASED RESOU; Meininger D, 2003, ANESTH ANALG, V96, P852, DOI 10.1213/01.ANE.0000049685.38809.7E; Michalek-Sauberer A, 2008, REGION ANESTH PAIN M, V33, P4, DOI 10.1016/j.rapm.2007.06.396; MOLLER IW, 1984, BRIT J ANAESTH, V56, P1191, DOI 10.1093/bja/56.11.1191; MOREWOOD GH, 1993, CAN MED ASSOC J, V149, P1087; MORRISON LMM, 1994, BRIT J ANAESTH, V72, P164, DOI 10.1093/bja/72.2.164; MOSAVY SH, 1975, ANAESTHESIA, V30, P807, DOI 10.1111/j.1365-2044.1975.tb00961.x; Murto K, 1999, CAN J ANAESTH, V46, P327, DOI 10.1007/BF03013223; Neilson G, 2008, CANADIAN J ANAESTHES, V55; Newman MJ, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008266, DOI 10.1002/14651858.CD008266]; Ogun CO, 2003, BRIT J ANAESTH, V90, P659, DOI 10.1093/bja/aeg123; PAECH MJ, 1993, ANAESTH INTENS CARE, V21, P79, DOI 10.1177/0310057X9302100119; PALAHNIUK RJ, 1979, CAN ANAESTH SOC J, V26, P132, DOI 10.1007/BF03013783; Pan PH, 2001, J CLIN ANESTH, V13, P430, DOI 10.1016/S0952-8180(01)00294-X; Patra P, 2005, J ANAESTHESIOL CLIN, V21, P147; PHERO JC, 1987, ANESTH ANALG, V66, P549; Phillips TJC, 2009, ANAESTHESIA, V64, P97, DOI [10.1111/j.1365-2044.2008.05803.x, 10.1111/j.1365-2044.2008.05804.x]; Plaja I, 2000, Rev Esp Anestesiol Reanim, V47, P194; Prusinski A, 1974, Neurol Neurochir Pol, V8, P565; Radpay B, 2003, ARCH IRAN MED, V6, P81; REINHART K, 1985, BRIT J ANAESTH, V57, P294, DOI 10.1093/bja/57.3.294; Rivera-Ordonez A, 2005, REV MEXICANA ANESTES, V28, P14; ROUX FX, 1983, SEM HOP PARIS, V59, P319; RUCCI FS, 1985, BRIT J ANAESTH, V57, P275, DOI 10.1093/bja/57.3.275; RYAN DW, 1983, ANN ROY COLL SURG, V65, P40; Sadeghi S, 2012, WORLD J MED SCI, V7, P13; Sakaguchi Y, 2000, ANAESTH INTENS CARE, V28, P522, DOI 10.1177/0310057X0002800506; SANGARLANGKARN S, 1987, ANESTH ANALG, V66, P235; Sanli S, 2005, EUR J ANAESTH, V22, P457, DOI 10.1017/S0265021505000785; Santos DJ, 1986, REGION ANESTH PAIN M, V11, P42; Sawhney S, 2004, J ANAESTHESIOLOGY CL, V20, P401; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; SENGUPTA P, 1989, ANAESTHESIA, V44, P54, DOI 10.1111/j.1365-2044.1989.tb11100.x; Seyhan TO, 2005, REGIONAL ANESTHESIA, V30, P75; Shah ER, 2003, EUR J ANAESTH, V20, P904, DOI 10.1097/00003643-200311000-00008; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Singh V, 2006, J ANAESTH CLIN PHARM, V22, P371; Smith KN, 2004, ANESTH ANALG, V98, P81, DOI 10.1213/01.ANE.0000093361.48458.6E; Soni AK, 2001, CAN J ANAESTH, V48, P677, DOI 10.1007/BF03016202; Strelec S., 1994, Regional Anesthesia, V19, P79; SUDARSHAN G, 1995, BRIT J ANAESTH, V75, P19, DOI 10.1093/bja/75.1.19; Tekin M, 2007, CURR THER RES CLIN E, V68, P313, DOI 10.1016/j.curtheres.2007.10.006; [The Nordic Cochrane Centre The Cochrane Collaboration], 2011, REV MAN REVMAN 5 1; Thew M, 2008, CURR OPIN ANESTHESIO, V21, P288, DOI 10.1097/ACO.0b013e3282f8e21a; Thomas S, 2006, CAN J ANAESTH, V53, P899, DOI 10.1007/BF03022833; TRIVEDI NS, 1993, J CLIN ANESTH, V5, P42, DOI 10.1016/0952-8180(93)90086-T; Tsen LC, 2001, REGION ANESTH PAIN M, V26, P52, DOI 10.1053/rapm.2001.18185; Tucker AP, 2004, ANESTH ANALG, V98, P1521; Tuncer Sema, 2005, Pain Clinic, V17, P95, DOI 10.1163/1568569053421645; Turan A, 2006, BRIT J ANAESTH, V96, P242, DOI 10.1093/bja/aei294; Turker G, 2003, ACTA ANAESTH SCAND, V47, P986, DOI 10.1034/j.1399-6576.2003.00194.x; Turnbull DK, 2003, BRIT J ANAESTH, V91, P718, DOI 10.1093/bja/aeg231; Unlugenc H, 2006, EUR J ANAESTH, V23, P1018, DOI 10.1017/S0265021506000950; Unlugenc H, 2009, ACTA ANAESTH SCAND, V53, P346, DOI 10.1111/j.1399-6576.2008.01864.x; USUBIAGA JE, 1967, ANESTH ANAL CURR RES, V46, P293; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011; Vale NB, 1995, REV BRAS ANESTESIOL, V45, P301; Vallejo MC, 2000, ANESTH ANALG, V91, P916, DOI 10.1097/00000539-200010000-00027; Verma R, 2011, ANAESTHESIA, V66, P417, DOI 10.1111/j.1365-2044.2011.06651.x; Vichitvejpaisal Phongthara, 1992, Journal of the Medical Association of Thailand, V75, P278; Viscusi ER, 2005, ANESTHESIOLOGY, V102, P1014, DOI 10.1097/00000542-200505000-00022; Waxler B, 2004, CAN J ANAESTH, V51, P680, DOI 10.1007/BF03018425; Wells J, 2004, INT J OBSTET ANESTH, V13, P35, DOI 10.1016/j.ijoa.2003.07.001; Whiteside JB, 2003, BRIT J ANAESTH, V90, P304, DOI 10.1093/bja/aeg077; WIDERLOV E, 1979, LANCET, V1, P548; Wilder-Smith CH, 1998, ACTA ANAESTH SCAND, V42, P299, DOI 10.1111/j.1399-6576.1998.tb04920.x; WOOD MB, 1993, ANESTH ANALG, V76, P1274, DOI 10.1213/00000539-199376060-00015; Yanagidate F, 2004, BRIT J ANAESTH, V93, P362, DOI 10.1093/bja/aeh218; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032; Yousefshahi F, 2012, ACTA NEUROLOGIC 0420; Yucel A, 1999, REGION ANESTH PAIN M, V24, P51, DOI 10.1016/S1098-7339(99)90165-7; Zackova M, 2000, Minerva Anestesiol, V66, P643	170	21	22	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2013		2							CD001792	10.1002/14651858.CD001792.pub3			73	Medicine, General & Internal	General & Internal Medicine	097FV	WOS:000315460300002	23450533				2020-06-30	J	Hadley, G; Derry, S; Moore, RA; Wiffen, PJ				Hadley, Gina; Derry, Sheena; Moore, R. Andrew; Wiffen, Philip J.			Transdermal fentanyl for cancer pain	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							RELEASE ORAL MORPHINE; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; CLINICAL-TRIALS; METAANALYSIS; MODERATE; QUALITY; OPIOIDS; SAFETY	Background Opioid drugs have been used for many years to relieve pain. Transdermal fentanyl offers one option for delivering and maintaining pain relief in patients with moderate or severe cancer pain. Objectives To determine the analgesic efficacy of transdermal fentanyl for relief of cancer pain, and to assess the adverse events associated with the use of transdermal fentanyl for relief of cancer pain. Search methods The following databases were searched: Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 4 of 12); MEDLINE (1966 to May 2013); EMBASE (1974 to May 2013; CANCERLIT (PubMED) (November 2012); and ClinicalTrials.gov (May 2013). Selection criteria Published randomised controlled trials (RCTs) using placebo or active comparators reporting on the analgesic effect of transdermal fentanyl in adults and children with cancer pain. Studies with fewer than 10 participants were excluded. Data collection and analysis Data were extracted independently by two review authors. We extracted any available data on the number or proportion of patients with 'no worse than mild pain' or treatment success (very satisfied, or very good or excellent on patient global impression scales), together with information about adverse events and withdrawals. Main results We identified nine studies meeting the inclusion criteria, including a Turkish study that is awaiting formal translation. There were 1244 participants randomised in classically designed RCTs, of whom 1197 had evaluable data, and 138 patients enrolled in an enriched enrolment, randomised withdrawal (EERW) trial. Overall, 600 participants were treated with transdermal fentanyl patches, 382 with various formulations of morphine, 36 with methadone, and 221 with paracetamol plus codeine. There were major sources of potential bias, including lack of blinding, small size, high levels of attrition, and inconsistent reporting. We could not compare data in a meaningful analysis regarding adverse events such as nausea, abdominal pain, gastrointestinal bleeding, and confusion. These events may have been attributable to the underlying disease process. There were insufficient comparable data for meta-analysis to be undertaken or to produce numbers needed to treat (NNT) for the analgesic effect. In seven studies with 461 participants reporting pain intensity results after about two weeks, the mean or median pain scores were on the borderline of mild and moderate pain. Most participants would have had no worse than mild pain on treatment. Another reported that 77% of participants using transdermal fentanyl had an undefined successful outcome. Fewer participants experienced constipation with transdermal fentanyl (28%) than with oral morphine (46%), giving a risk ratio of 0.61 (95% CI 0.47 to 0.78); the NNT to prevent constipation was 5.5 (95% CI 3.8 to 10). Authors' conclusions The randomised trial literature for effectiveness of transdermal fentanyl is limited, but it is an important medicine. Most studies recruited fewer than 100 participants and did not provide data appropriate for meta-analysis. Only a few reported how many patients had good pain relief but, where data were reported, a majority had no worse than mild pain within a reasonably short time period. The evidence pointed to a useful and significant reduction in complaints about constipation for transdermal fentanyl compared with oral morphine.	[Hadley, Gina; Derry, Sheena; Moore, R. Andrew; Wiffen, Philip J.] Univ Oxford, Pain Res & Nuffield Dept Clin Neurosci, Oxford OX3 7LE, England	Hadley, G (reprint author), Univ Oxford, Churchill Hosp, Pain Res & Nuffield Dept Clin Neurosci, Pain Res Unit, Oxford OX3 7LE, England.	glhadley@doctors.org.uk					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Cachia Elaine, 2011, Curr Opin Support Palliat Care, V5, P15, DOI 10.1097/SPC.0b013e3283437a39; Cancer Research UK, CANC INC ALL CANC CO; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Cleary JF, 2007, J PALLIAT MED, V10, P1369, DOI 10.1089/jpm.2007.9842; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Dwan K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000031.pub2; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Ergenoglu P, 2010, J CLIN INVEST, V4, P134; Hadley Gina, 2009, J Pain Palliat Care Pharmacother, V23, P106, DOI 10.1080/15360280902899921; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kongsgaard UE, 1998, EUR J PAIN-LONDON, V2, P53, DOI 10.1016/S1090-3801(98)90046-5; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Koyyalagunta D, 2012, PAIN PHYSICIAN, V15, pES39; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Marinangeli Franco, 2007, Pain Pract, V7, P307, DOI 10.1111/j.1533-2500.2007.00155.x; McQuay H, 1998, EVIDENCE BASED RESOU; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Moore RA, 2010, ANN RHEUM DIS, V69, P374, DOI 10.1136/ard.2009.107805; MOORE RA, 1982, BRIT J ANAESTH, V54, P1117, DOI 10.1093/bja/54.10.1117; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; MORRIS JA, 1995, STAT CONFIDENCE CONF, P50; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou Kyriaki, 2005, J Opioid Manag, V1, P204; Ozturk T, 2008, AGRI, V20, P20; Pistevou-Gompaki K, 2004, CURR MED RES OPIN, V20, P159, DOI 10.1185/030079903125002829; Sarhan T, 2009, 6 C EUR FED IASP CHA, V13, pS199; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Tassinari D, 2011, PALLIATIVE MED, V25, P478, DOI 10.1177/0269216311404274; The Nordic Cochrane Centre, 2011, COCHRANE COLLABORATI; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Wiffen PJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub3; Wirz S, 2009, EUR J PAIN, V13, P737, DOI 10.1016/j.ejpain.2008.09.005; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25	39	45	51	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2013		10							UNSP CD010270	10.1002/14651858.CD010270.pub2			37	Medicine, General & Internal	General & Internal Medicine	244FT	WOS:000326373200039	24096644	Green Published			2020-06-30	J	Zeppetella, G; Davies, AN				Zeppetella, Giovambattista; Davies, Andrew N.			Opioids for the management of breakthrough pain in cancer patients	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review						Administration, Oral; Analgesics, Opioid [administration & dosage; therapeutic use]; Fentanyl [administration& dosage; therapeutic use]; Morphine [therapeutic use]; Neoplasms [complications]; Pain [drug therapy; physiopathology]; Pain Measurement; Randomized Controlled Trials as Topic; Humans	TRANSMUCOSAL FENTANYL CITRATE; CLINICALLY IMPORTANT CHANGES; DOUBLE-BLIND; BUCCAL TABLET; MORPHINE-SULFATE; VIVO EVALUATION; OPEN-LABEL; SPRAY; EFFICACY; TOLERABILITY	Background This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 1, 2006). Breakthrough pain is a transient exacerbation of pain that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger despite relative stable and adequately controlled background pain. Breakthrough pain usually related to background pain and is typically of rapid onset, severe in intensity and generally self limiting with a mean duration of 30 minutes. Breakthrough pain has traditionally been managed by the administration of supplemental oral analgesia (rescue medication) at a dose proportional to the total around-the-clock (ATC) opioid dose. Objectives To determine the efficacy of opioid analgesics given by any route, used for the management of breakthrough pain in patients with cancer, and to identify and quantify, if data permitted, any adverse effects of this treatment. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and trial registries in January 2005 for the original review, and again on 6 February 2013 for this update. Selection criteria We included randomised controlled trials (RCTs) of opioids used as rescue medication against active or placebo comparator in patients with cancer pain. Outcome measures sought were reduction in pain intensity measured by an appropriate scale, adverse effects, attrition, patient satisfaction and quality of life. We applied no language restrictions. Data collection and analysis Two review authors independently selected and examined eligible studies. We retrieved full text if any uncertainty about eligibility remained. We screened non-English texts. We conducted quality assessment and data extraction using standardised data forms. We compared drug and placebo dose, titration, route and formulation and recorded details of all outcome measures (if available). Main results The original review included four studies (393 participants), all concerned with the use of oral transmucosal fentanyl citrate (OTFC) in the management of breakthrough pain. Two studies examined the titration of OTFC, one study compared OTFC versus normalrelease morphine and one study compared OTFC versus placebo. Fifteen studies (1699 participants) met the inclusion criteria for this update. All studies reported on the utility of seven different transmucosal fentanyl formulations, five of which were administered orally and two nasally. Eight studies compared the transmucosal fentanyl formulations versus placebo, four studies compared them with another opioid, one study was a comparison of different doses of the same formulation and two were randomised titration studies. Oral and nasal transmucosal fentanyl formulations were an effective treatment for breakthrough pain. When compared with placebo or oral morphine, participants gave lower pain intensity and higher pain relief scores for transmucosal fentanyl formulations at all time points. Global assessment scores also favoured transmucosal fentanyl preparations. One study compared intravenous with the transmucosal route and both were effective. Authors' conclusions Oral and nasal transmucosal fentanyl is an effective treatment in the management of breakthrough pain. The RCT literature for the management of breakthrough pain is relatively small. Given the importance of this subject, more trials, including head-to-head comparisons of the available transmucosal fentanyl formulations are required.	[Zeppetella, Giovambattista] St Clare Hosp, Hastingwood CM17 9JX, Essex, England; [Davies, Andrew N.] Royal Surrey Cty Hosp, Dept Palliat Med, Guildford, Surrey, England	Zeppetella, G (reprint author), St Clare Hosp, Hastingwood Rd, Hastingwood CM17 9JX, Essex, England.	John.Zeppetella@stclarehospice.org.uk			Arachis; Archimedes; Cephalon; Dompe; Flynn Pharma; Grunenthal; Janssen-CilagJohnson & Johnson USAJanssen Biotech Inc; Napp Pharmaceuticals; Nycomed; PfizerPfizer; ProStrakan; WyethWyeth	GZ has, in the past, received sponsorship for lectures and advisory boards from Arachis, Archimedes, Cephalon, Dompe, Flynn Pharma, Grunenthal, Janssen-Cilag, Napp Pharmaceuticals, Nycomed, Pfizer, ProStrakan and Wyeth.	Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; BENNETT D, 2005, [No title captured], V30, P354; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; CLEARY JF, 1997, [No title captured], V16, pA52; Colleau SM., 1999, WHO CANC PAIN RELEAS, V12, P1; COLUZZI P, 1997, P AN M AM SOC CLIN, V16, pA52; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; COLUZZI PH, 2002, DOULEURS, V3, P26; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; del Consuelo ID, 2007, J CONTROL RELEASE, V122, P135, DOI 10.1016/j.jconrel.2007.05.017; Elsner F, 2011, CLIN DRUG INVEST, V31, P605, DOI 10.2165/11592910-000000000-00000; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Hagen NA, 2010, PALLIATIVE MED, V24, P696, DOI 10.1177/0269216310375999; Hanks G., 2001, EUR J PALLIAT CARE, V8, P6; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; McQuay HJ, 2003, J PAIN SYMPTOM MANAG, V25, P395, DOI 10.1016/S0885-3924(03)00099-X; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; National Institute for Health and Clinical Excellence, 2012, OP PALL CAR SAF EFF; PASQUALUCCI V, 1987, PAIN, V29, P273, DOI 10.1016/0304-3959(87)90042-X; Portenoy R K, 1989, Oncology (Williston Park), V3, P25; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2011, J PAIN S, V4, pP50; Rauck R, 2012, PAIN PRACT, V12, P192; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Reynolds L, 2011, J PAIN S, V12, pP50; Reynolds L, 2012, PAIN PRACT, V12, P193; SAVARESE JJ, 1988, CLIN PHARMACOL THER, V43, P376, DOI 10.1038/clpt.1988.46; Scottish Intercollegiate Guidelines Network, 2008, CONTR PAIN AD CANC P; Shaiova L, 2004, SUPPORT CARE CANCER, V12, P268, DOI 10.1007/s00520-004-0595-4; SIMMONDS MA, 1997, P AN M AM SOC CLIN, V16, pA52; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stanley K., 2011, J PAIN S, V12, pP50; Taylor Donald, 2010, J Support Oncol, V8, P184; The Nordic Cochrane Centre The Cochrane Collaboration, 2012, REV MAN REVMAN 5 2; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2011, CLIN ONCOL-UK, V23, P393, DOI 10.1016/j.clon.2010.12.002; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	63	44	44	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2013		10							CD004311	10.1002/14651858.CD004311.pub3			55	Medicine, General & Internal	General & Internal Medicine	244FR	WOS:000326373000025	24142465				2020-06-30	J	Wu, J; Yao, SL; Wu, ZY; Wu, ZL; Chu, SJ; Xia, GQ; Deng, FT				Wu, Jing; Yao, Shanglong; Wu, Zhouyang; Wu, Zhiling; Chu, Shujuan; Xia, Geqing; Deng, Feitao			A comparison of anesthetic regimens using etomidate and propofol in patients undergoing first-trimester abortions: double-blind, randomized clinical trial of safety and efficacy	CONTRACEPTION			English	Article						Analgesia, obstetrical; Abortion, induced; Propofol; Etomidate; Fentanyl; Midazolam	MYOCLONIC MOVEMENTS; UNITED-STATES; INDUCTION; MIDAZOLAM; MORTALITY; FENTANYL	Background: This prospective study compared the safety, recovery time and side effects of six distinct general anesthesia regimens for first-trimester surgical abortion. Study Design: Two hundred forty women scheduled for surgical abortion at 6 to 8 weeks of gestation were randomized into three groups (n=40) of propofol: group P (2 mg/kg propofol alone), group PF (2 mg/kg propofol+1 mcg/kg fentanyl), group PMF (2 mg/kg propofol+1 mcg/kg fentanyl+0.02 mg/kg midazolam) and three groups (n=40) of etomidate: group E (0.2 mg/kg etomidate alone), group EF (0.2 mg/kg etomidate+1 mcg/kg fentanyl) and group EMF (0.2 mg/kg etomidate+1 mcg/kg fentanyl+0.02 mg/kg midazolam). Vital signs including pulse oxygen saturation (SpO(2)), mean arterial pressure (MAP) and heart rate were recorded as the primary outcomes. The recovery time and side effects were recorded as secondary outcomes. Results: During induction, SpO(2) and MAP decreased significantly in all the three groups of propofol and were significantly lower than those in the groups of etomidate. Mean recovery times to both eye opening and to obeying commands were significantly shorter in group PF than those in groups P and PMF, while there were no significant differences among the three groups of etomidate. Compared with the etomidate groups, the incidence of injection-induced pain was significantly higher, while the scores of myoclonus and postoperative nausea and vomiting were lower, in the three propofol groups. Moreover, myoclonus scores as well as nausea and vomiting scores were lower in group EMF than in groups E and EF. Conclusions: The results of this study suggest that (a) etomidate is much safer than propofol for first-trimester surgical abortions and (b) using a lower dose of etomidate, supplemented with fentanyl and midazolam, is more beneficial than the use of etomidate with or without fentanyl in reducing adverse effects like myoclonus and postoperative nausea and vomiting. (c) 2013 Elsevier Inc. All rights reserved.	[Wu, Jing; Yao, Shanglong; Wu, Zhouyang; Wu, Zhiling; Chu, Shujuan] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Anesthesiol, Wuhan 430022, Peoples R China; [Xia, Geqing; Deng, Feitao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Obstet & Gynecol, Wuhan 430022, Peoples R China	Wu, J (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Anesthesiol, Wuhan 430022, Peoples R China.	dr_wujing@yahoo.com.cn			Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	This work was supported by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.	Bartlett LA, 2004, OBSTET GYNECOL, V103, P729, DOI 10.1097/01.AOG.0000116260.81570.60; Bocian D, 1992, J Foot Surg, V31, P603; Cheney FW, 1999, ANESTHESIOLOGY, V91, P552, DOI 10.1097/00000542-199908000-00030; Forman SA, 2011, ANESTHESIOLOGY, V114, P695, DOI 10.1097/ALN.0b013e3181ff72b5; Fujii Y, 2011, OTOLARYNG HEAD NECK, V144, P206, DOI 10.1177/0194599810391728; HAKIMELAHI E, 1990, OBSTET GYNECOL, V76, P129; Huter L, 2007, ANESTH ANALG, V105, P1298, DOI 10.1213/01.ane.0000287248.25610.c0; Hwang JY, 2008, J INT MED RES, V36, P17, DOI 10.1177/147323000803600103; JAKOBSSON J, 1993, ANAESTHESIA, V48, P1005; LAWSON HW, 1994, AM J OBSTET GYNECOL, V171, P1365, DOI 10.1016/0002-9378(94)90162-7; Matta JA, 2008, P NATL ACAD SCI USA, V105, P8784, DOI 10.1073/pnas.0711038105; Renner RM, 2010, CONTRACEPTION, V81, P372, DOI 10.1016/j.contraception.2009.12.008; Reves J, 2005, MILLERS ANESTHESIA; Schwarzkopf KRG, 2003, ANAESTH INTENS CARE, V31, P18, DOI 10.1177/0310057X0303100103; Steinbacher D M, 2001, Anesth Prog, V48, P66; STOCKHAM RJ, 1988, ANAESTH INTENS CARE, V16, P171, DOI 10.1177/0310057X8801600207; ULSAMER B, 1986, ANAESTHESIST, V35, P535; VANAKEN H, 1988, ANESTHESIOLOGY, V68, P157; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; *WHO, 2004, [No title captured]; ZACHARIAS M, 1979, BRIT J ANAESTH, V51, P127, DOI 10.1093/bja/51.2.127	21	13	15	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0010-7824			CONTRACEPTION	Contraception	JAN	2013	87	1					55	62		10.1016/j.contraception.2012.08.014			8	Obstetrics & Gynecology	Obstetrics & Gynecology	060AT	WOS:000312748400010	22995543				2020-06-30	J	Bjelland, TW; Klepstad, P; Haugen, BO; Nilsen, T; Dale, O				Bjelland, Thor Wilhelm; Klepstad, Pal; Haugen, Bjorn Olav; Nilsen, Turid; Dale, Ola			Effects of Hypothermia on the Disposition of Morphine, Midazolam, Fentanyl, and Propofol in Intensive Care Unit Patients	DRUG METABOLISM AND DISPOSITION			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; MILD THERAPEUTIC HYPOTHERMIA; CRITICALLY-ILL PATIENTS; CARDIAC-ARREST; CARDIOPULMONARY BYPASS; CONTROLLED ANALGESIA; DRUG-METABOLISM; HUMAN SERUM; PHARMACOKINETICS; CLEARANCE	Therapeutic hypothermia (TH) may induce pharmacokinetic changes that may affect the level of sedation. We have compared the disposition of morphine, midazolam, fentanyl, and propofol in TH with normothermia in man. Fourteen patients treated with TH following cardiac arrest (33-34 degrees C) were compared with eight matched critically ill patients (36-38 degrees C). Continuous infusions of morphine and midazolam were stopped and replaced with infusions of fentanyl and propofol to describe elimination and start of infusion pharmacokinetics, respectively. Serial serum and urine samples were collected for 6-8 hours for validated quantification and subsequent pharmacokinetic analysis. During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CLtot) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CLtot, 1201 (283) versus 1687 (200) ml/min, P < 0.01. No significant differences were seen for midazolam. CLtot of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05. Compared with the matched, normothermic intensive care unit patients, t(1/2) of morphine was significantly higher during TH. CLtot was lower during TH for morphine, fentanyl, and propofol but not for midazolam. Reducing the infusion rates of morphine, fentanyl, and propofol during TH is encouraged	[Bjelland, Thor Wilhelm; Klepstad, Pal; Haugen, Bjorn Olav; Nilsen, Turid; Dale, Ola] Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway; [Klepstad, Pal; Dale, Ola] St Olavs Univ Hosp, Dept Anesthesiol & Emergency Med, Trondheim, Norway; [Haugen, Bjorn Olav] St Olavs Univ Hosp, Dept Cardiol, Trondheim, Norway	Bjelland, TW (reprint author), NTNU, Inst Sirkulasjon & Bildediagnostikk, Det Med Fak, Postboks 8905, N-7491 Trondheim, Norway.	thor.w.bjelland@ntnu.no			Norwegian University of Science and Technology, Trondheim, Norway	This work was funded by the Norwegian University of Science and Technology, Trondheim, Norway.	ALCARAZ C, 1989, ARCH INT PHARMACOD T, V297, P133; Arpino PA, 2008, PHARMACOTHERAPY, V28, P102, DOI 10.1592/phco.28.1.102; Asokumar B, 1998, CAN J ANAESTH, V45, P515, DOI 10.1007/BF03012700; BANSINATH M, 1988, J CLIN PHARMACOL, V28, P860, DOI 10.1002/j.1552-4604.1988.tb03229.x; Bauer M, 2004, ANESTHESIOLOGY, V101, P1096, DOI 10.1097/00000542-200411000-00008; BEAUFORT AM, 1995, EUR J ANAESTH, V12, P95; Berkenstadt H, 1999, INTENS CARE MED, V25, P110, DOI 10.1007/s001340050796; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bjelland TW, 2010, RESUSCITATION, V81, P1627, DOI 10.1016/j.resuscitation.2010.07.002; BURNS JW, 1989, ANAESTHESIA, V44, P2, DOI 10.1111/j.1365-2044.1989.tb11086.x; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Court MH, 2003, DRUG METAB DISPOS, V31, P1125, DOI 10.1124/dmd.31.9.1125; DADGAR D, 1995, J PHARMACEUT BIOMED, V13, P89, DOI 10.1016/0731-7085(94)00106-C; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; GIBALDI M, 1982, PHARMACOKINETICS; GRAVES DA, 1983, CLIN PHARMACY, V2, P49; GREENBLATT DJ, 1984, ANESTHESIOLOGY, V61, P27, DOI 10.1097/00000542-198461010-00006; Gustavsson E, 2007, J MASS SPECTROM, V42, P881, DOI 10.1002/jms.1219; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; KADAR D, 1982, CAN ANAESTH SOC J, V29, P16, DOI 10.1007/BF03007942; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Krishna DR, 1990, CLIN PHARMACOKINETIC; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Lovstad RZ, 1996, CLIN INTENSIVE CARE, V7, P282; Macintyre PE, 1996, PAIN, V64, P357, DOI 10.1016/0304-3959(95)00128-X; MACNAB MSP, 1986, INTENS CARE MED, V12, P366, DOI 10.1007/BF00292927; Martens J, 1997, J CHROMATOGR B, V692, P95, DOI 10.1016/S0378-4347(96)00506-3; MILNE RW, 1992, BRIT J CLIN PHARMACO, V34, P53, DOI 10.1111/j.1365-2125.1992.tb04107.x; MORTENSEN B, 1995, ACTA ANAESTH SCAND, V39, P199, DOI 10.1111/j.1399-6576.1995.tb04043.x; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Pedersen Trine Funder, 2007, Tidsskr Nor Laegeforen, V127, P163; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; R Development Core Team, 2008, R LANG ENV STAT COMP; RINK RA, 1956, ANESTHESIOLOGY, V17, P377, DOI 10.1097/00000542-195605000-00001; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; RUSSELL GN, 1989, ANAESTHESIA, V44, P205, DOI 10.1111/j.1365-2044.1989.tb11223.x; SHAH VP, 1991, EUR J DRUG METAB PH, V16, P249; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Tyrefors N, 1996, J CHROMATOGR A, V729, P279, DOI 10.1016/0021-9673(95)01090-4; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000; Zhou JQ, 2011, DRUG METAB DISPOS, V39, P2209, DOI 10.1124/dmd.111.040642; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127	53	51	53	0	5	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0090-9556	1521-009X		DRUG METAB DISPOS	Drug Metab. Dispos.	JAN	2013	41	1					214	223		10.1124/dmd.112.045567			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	062FD	WOS:000312903700024	23115086				2020-06-30	J	Bulloch, MN; Hutchison, AM				Bulloch, Marilyn N.; Hutchison, Amber M.			Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain	EXPERT REVIEW OF CLINICAL PHARMACOLOGY			English	Article						breakthrough cancer pain; fentanyl; intranasal; pectin		Fentanyl pectin nasal spray is a novel intranasal formulation for the management of breakthrough cancer pain in patients taking and tolerant to opioids for persistent cancer pain. The pectin-based delivery modulates the product's transmucosal absorption. Nasal delivery allows fentanyl pectin nasal spray to achieve a greater maximum plasma concentration than oral transmucosal fentanyl products and at a much faster rate. Compared with intranasal fentanyl compounded with aqueous solutions, the pectin-based system decreases the maximum plasma concentration and prolongs exposure to more closely match the time course of a typical breakthrough cancer pain episode. Throughout all phases of clinical studies, it was shown to be safe and effective in doses between 100 and 800 mu g per breakthrough pain episode. Fentanyl pectin nasal spray is the only proprietary intranasal fentanyl formulation in the USA and one of two in Europe. Owing to the medication's delivery system, the pharmacokinetics and subsequent dosing are unique to this product and should not be interchanged with any other proprietary or compounded fentanyl product.	[Bulloch, Marilyn N.] Univ Med Ctr, Tuscaloosa, AL USA; [Bulloch, Marilyn N.; Hutchison, Amber M.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA	Bulloch, MN (reprint author), Univ Med Ctr, Box 870326, Tuscaloosa, AL USA.	mjn0004@auburn.edu					American Cancer Society, 2011, GLOB CANC FACTS FIG; [Anonymous], 2009, PHYS GUID PRESCR INS; [Anonymous], 2011, INST INTR FENT SPRAY; [Anonymous], 2012, PECFENT FENT PECT NA; [Anonymous], OP DRUG DAT DRUG TAR; [Anonymous], 2012, SUBS FENT SUBL SPRAY; [Anonymous], 2011, RED BOOK ON; [Anonymous], 2012, LAZ FENT NAS SPRAY P; [Anonymous], 2011, AWMSG SECR ASS REP; Archimedes Pharma US Inc, 2012, LAZ FENT NAS SPRAY C; Bowie Mark W, 2007, Am J Geriatr Pharmacother, V5, P263, DOI 10.1016/j.amjopharm.2007.10.001; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis G, 2007, P 10 C EUR ASS PALL; Elsner F, 2011, CLIN DRUG INVEST, V31, P605, DOI 10.2165/11592910-000000000-00000; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Leppert Wojciech, 2010, Cancer Manag Res, V2, P225, DOI 10.2147/CMR.S7926; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mystakidou K, 2011, EXPERT OPIN PHARMACO, V12, P1653, DOI 10.1517/14656566.2011.585637; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Swarm R, 2010, J NATL COMPR CANC NE, V8, P1046, DOI 10.6004/jnccn.2010.0076; Taylor Donald, 2010, J Support Oncol, V8, P184; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]	33	6	8	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1751-2433	1751-2441		EXPERT REV CLIN PHAR	Expert Rev. Clin. Pharmacol.	JAN	2013	6	1					9	22		10.1586/ECP.12.69			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	V37SH	WOS:000209295000007	23272789				2020-06-30	J	Wenderoth, BR; Kaneda, ET; Amini, A; Amini, R; Patanwala, AE				Wenderoth, Bradley R.; Kaneda, Elizabeth T.; Amini, Albert; Amini, Richard; Patanwala, Asad E.			Morphine Versus Fentanyl for Pain Due to Traumatic Injury in the Emergency Department	JOURNAL OF TRAUMA NURSING			English	Article						Analgesia; Emergency department; Fentanyl; Morphine; Pain; Trauma		The analgesic response and safety of intravenous morphine versus fentanyl for adult trauma patients who presented to the emergency department (ED) were evaluated. Median pain reduction on the numeric rating scale (0-10; 0 = no pain and 10 = worst possible pain) after opioid administration was similar between the groups (2 vs 2; P = .67). The lowest postdose pain score was recorded sooner in the fentanyl group than in the morphine group (22 vs 47 minutes, respectively; P < .001). There were no significant differences in drug-induced adverse effects between groups. Fentanyl produced a similar but more rapid analgesic response compared with morphine in trauma patients.	[Wenderoth, Bradley R.] Univ So Calif, Sch Pharm, Dept Pharm, Los Angeles, CA USA; [Kaneda, Elizabeth T.; Patanwala, Asad E.] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA; [Amini, Albert] Univ Arizona, Coll Med, Dept Surg, Tucson, AZ USA; [Amini, Richard] Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ USA	Patanwala, AE (reprint author), 1295 N Martin,POB 210202, Tucson, AZ 85721 USA.	patanwala@pharmacy.arizona.edu	Amini, Richard/M-9964-2013	Amini, Richard/0000-0002-9292-8206			[Anonymous], 2008, FENT CITR FENT CITR; Berben SAA, 2008, INJURY, V39, P578, DOI 10.1016/j.injury.2007.04.013; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Chang AK, 2006, ANN EMERG MED, V48, P164, DOI 10.1016/j.annemergmed.2006.03.005; Chang Andrew K, 2009, J Opioid Manag, V5, P75; Chang AK, 2009, AM J GERIATR PHARMAC, V7, P1, DOI 10.1016/j.amjopharm.2009.02.002; Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; Curtis KM, 2007, J TRAUMA, V63, P819, DOI 10.1097/01.ta.0000240979.31046.98; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Patanwala AE, 2010, ANN PHARMACOTHER, V44, P1800, DOI 10.1345/aph.1P438; Patanwala AE, 2010, J EMERG MED, V39, P330, DOI 10.1016/j.jemermed.2009.08.060; Smith MD, J EMERG MED IN PRESS; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X	16	7	8	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1078-7496	1932-3883		J TRAUMA NURS	J. Trauma Nurs.	JAN-FEB	2013	20	1					10	15		10.1097/JTN.0b013e31828660b5			6	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	V37KC	WOS:000209273700004	23459426				2020-06-30	J	Santos, P; Watkinson, AC; Hadgraft, J; Lane, ME				Santos, P.; Watkinson, A. C.; Hadgraft, J.; Lane, M. E.			Influence of penetration enhancer on drug permeation from volatile formulations	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Fentanyl; Saturation; Supersaturation; Propylene glycol; Octyl salicylate; Isopropyl myristate	HUMAN STRATUM-CORNEUM; PROPYLENE-GLYCOL; PERCUTANEOUS-ABSORPTION; TRANSDERMAL DELIVERY; SUNSCREEN AGENTS; OCTYL SALICYLATE; SKIN PERMEATION; MODEL MEMBRANES; IN-VITRO; VEHICLE	Previously we have reported the influence of supersaturation on the permeation of fentanyl across model membranes and skin. The findings indicated that the vehicle and, specifically its residence time in skin, influence the ability of the formulation to enhance membrane drug permeation. The aim of the present study was to probe the role of vehicle components on (trans) dermal drug delivery in more detail. To this end, three commonly used chemical penetration enhancers were selected for investigation namely, propylene glycol (PG), octyl salicylate (OSAL) and isopropyl myristate (IPM). A further objective was to clarify the mechanism of action of OSAL. Model spray formulations were prepared consisting of 10% (v/v) of individual enhancers in ethanol. Saturated and supersaturated systems were evaluated for their ability to promote fentanyl transport across human skin in vitro. Mass balance studies and determination of the extent of uptake of enhancers by skin were also conducted. The results indicated that increasing the degree of drug saturation (DS) does not promote drug permeation for formulations in PG but increasing drug DS did promote drug permeation for IPM and some OSAL systems. This probably reflects faster depletion of PG compared with IPM and OSAL. Non-linear modelling of the permeation data indicated that PG and IPM act to promote drug solubility in the membrane whereas OSAL appears to act as a skin penetration enhancer by increasing drug diffusivity in the skin. (C) 2012 Elsevier B.V. All rights reserved.	[Santos, P.; Hadgraft, J.; Lane, M. E.] Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England; [Watkinson, A. C.] Storith Consulting Ltd, Hythe CT21 5JU, Kent, England	Lane, ME (reprint author), Univ London, Sch Pharm, Dept Pharmaceut, 29-39 Brunswick Sq, London WC1N 1AX, England.	majella.lane@btinternet.com	张, 张鑫月/AAP-1001-2020; Hadgraft, Jonathan/D-6184-2013		Acrux DDS Pty. Ltd. (Australia)	Paulo Santos is grateful for the provision of a studentship from Acrux DDS Pty. Ltd. (Australia).	Alberti I, 2001, J CONTROL RELEASE, V71, P319, DOI 10.1016/S0168-3659(01)00244-9; AUNGST BJ, 1990, PHARMACEUT RES, V7, P712, DOI 10.1023/A:1015859320604; BENDAS B, 1995, [No title captured], P61; CAMPBELL RL, 1981, TOXICOL APPL PHARM, V59, P555, DOI 10.1016/0041-008X(81)90310-0; Finnin BC, 1999, J PHARM SCI-US, V88, P955, DOI 10.1021/js990154g; FUNK JO, 1995, DERMATOL CLIN, V13, P473, DOI 10.1016/S0733-8635(18)30094-9; HADGRAFT J, 1990, PHARMACEUT RES, V7, P1307, DOI 10.1023/A:1015954325514; Hadgraft J, 1999, INT J PHARM, V184, P1, DOI 10.1016/S0378-5173(99)00095-2; Holzner C., 1963, AM PERFUM COSMET, V78, P89; Jiang RY, 1997, J PHARM SCI, V86, P791, DOI 10.1021/js960523y; Lane M. E., 2012, INT J COSMET SCI; Lane ME, 2012, TOPICAL TRANSDERMAL, P23; Lee PJ, 2006, INT J PHARMACEUT, V308, P33, DOI 10.1016/j.ijpharm.2005.10.027; MOLLGAARD B, 1983, ACTA PHARM SUEC, V20, P443; Morgan TM, 1998, J PHARM SCI, V87, P1213, DOI 10.1021/js980025k; Morgan TM, 1998, J PHARM SCI, V87, P1226, DOI 10.1021/js9800275; Nicolazzo JA, 2005, J CONTROL RELEASE, V103, P577, DOI 10.1016/j.jconrel.2004.12.007; Oliveira G, 2012, INT J PHARMACEUT, V435, P38, DOI 10.1016/j.ijpharm.2012.05.037; ONGPIPATTANAKUL B, 1991, PHARMACEUT RES, V8, P350, DOI 10.1023/A:1015845632280; Reed B.L., 1997, PCT/AU97/00091, Patent No. 9700091; Santos P, 2011, INT J PHARMACEUT, V416, P155, DOI 10.1016/j.ijpharm.2011.06.024; Santos P, 2010, INT J PHARMACEUT, V384, P67, DOI 10.1016/j.ijpharm.2009.09.043; Silva CL, 2006, SKIN PHARMACOL PHYS, V19, P132, DOI 10.1159/000092593; Simonsen L, 2004, DRUG DEV IND PHARM, V30, P1095, DOI 10.1081/DDC-200040297; Squillante E, 1998, EUR J PHARM BIOPHARM, V46, P265, DOI 10.1016/S0939-6411(98)00030-7; Traversa B., 2005, ENHANCEMENT PERCUTAN; Trottet L, 2004, INT J PHARMACEUT, V274, P213, DOI 10.1016/j.ijpharm.2004.01.013; TWIST JN, 1986, J SOC COSMET CHEM, V37, P429; Walters KA, 1997, FOOD CHEM TOXICOL, V35, P1219, DOI 10.1016/S0278-6915(97)85471-3; Walters KA, 2002, DRUGS PHARM SCI, V119, P1; Watkinson RM, 2009, SKIN PHARMACOL PHYS, V22, P225, DOI 10.1159/000231528; WOTTON PK, 1985, INT J PHARM, V24, P19, DOI 10.1016/0378-5173(85)90141-3; Zatz J. L., 1991, IN VITRO PERCUTANEOU, P51; ZATZ JL, 1983, J SOC COSMET CHEM, V34, P327	34	40	43	1	62	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173			INT J PHARMACEUT	Int. J. Pharm.	DEC 15	2012	439	1-2					260	268		10.1016/j.ijpharm.2012.09.031			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	038BV	WOS:000311151100032	23000063				2020-06-30	J	Hoffmann, F; Glaeske, G; Windt, R				Hoffmann, F.; Glaeske, G.; Windt, R.			Prescription of high-potency opioids in 2011	SCHMERZ			German	Article						Health services research; Claims data; Pain management; Fentanyl; Regional analysis	CANCER PAIN; TRANSDERMAL FENTANYL; RECOMMENDATIONS; GERMANY; EAPC	Background. The aim of this study was to analyze the prescription of high-potency (WHO step III) opioids with respect to regional differences and to assess the proportion of opioid-naive new users of transdermal fentanyl. Methods. Prescription claims data of the largest single German health fund (BARMER GEK) with 9.1 million insured persons from the year 2011 were used. For new users of transdermal fentanyl who had had no prescription in the preceding 6 months it was studied whether they had received other high-potency or low-potency opioids before. Results. A total of 18.9 million defined daily doses (DDD) of high-potency opioids were included corresponding to a mean of 208.6 DDD per 100 persons. Significant regional differences were found with lower values in the south, ranging from 145.9 DDD in Baden-Wurttemberg to 259.5 DDD per 100 persons in Lower Saxony. Fentanyl was the most frequently used step III opioid (40.8% of DDDs) which is nearly only given transdermally. Of the 11,184 patients with new use of transdermal fentanyl 80.7% had received no other high-potency opioid before and 52.9% had received neither low-potency nor high-potency opioids before. The first prescription exceeded the smallest available dose of 12.5 mu g/h for over half of the patients starting treatment. Conclusions. Although oral morphine, oxycodone and hydromorphone are recommended as first-line step III opioids, transdermal fentanyl seems to be prescribed too often as the first choice and might not be appropriate.	[Hoffmann, F.; Glaeske, G.; Windt, R.] Univ Bremen, Abt Gesundheitsok Gesundheitspolit & Versorgungsf, Zentrum Sozialpolit ZeS, D-28334 Bremen, Germany	Hoffmann, F (reprint author), Univ Bremen, Abt Gesundheitsok Gesundheitspolit & Versorgungsf, Postfach 330440, D-28334 Bremen, Germany.	hoffmann@zes.uni-bremen.de	Hoffmann, Falk/F-5201-2013	Hoffmann, Falk/0000-0003-0182-5373			Ahmedzai SH, 2012, PALLIATIVE MED, V26, P50, DOI 10.1177/0269216311418869; Arzneimittelkommission der Deutschen Arzteschaft (AKdA), 2012, DTSCH ARZTEBL, V109, pA724; Arzneimittelkommission der deutschen Arzteschaft (AkdA), 2007, TUM ARZN PRAX; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; DGSS, 2009, LANGZ OP BEI NICHT T; Dicheva S, 2011, BARMER GEK ARZNEIMIT, P89; Garbe E, 2012, PHARMACOEPIDEM DR S, V21, P904, DOI 10.1002/pds.3314; Garbe E, 2012, PHARMACOEPIDEM DR S, V21, P191, DOI 10.1002/pds.2164; Glaeske G, 2009, GESUNDHEITSWESEN, V71, P685, DOI 10.1055/s-0029-1239517; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hoer A, 2008, SCHMERZ, V22, P156, DOI 10.1007/s00482-007-0575-y; Hoffmann F, 2012, GESUNDHEITSWESEN, V74, P291, DOI 10.1055/s-0031-1275711; Hoffmann F, 2011, ONKOLOGE, V17, P55, DOI 10.1007/s00761-010-1973-9; Hoffmann F, 2012, BARMER GEK ARZNEIMIT, P114; INSIGHT Health, 2009, MARKTTR BTM AN LICHT; Kahan M, 2011, CAN FAM PHYSICIAN, V57, P1257; Librach SL, 2010, J PAIN SYMPTOM MANAG, V40, P761, DOI 10.1016/j.jpainsymman.2010.03.026	17	11	11	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0932-433X	1432-2129		SCHMERZ	Schmerz	DEC	2012	26	6					707	+		10.1007/s00482-012-1240-7			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	083YJ	WOS:000314502200011	23183991				2020-06-30	J	Ter Beest, J; McClean, M; Cushing, A; Bildfell, R				Ter Beest, Julia; McClean, Modesto; Cushing, Andrew; Bildfell, Robert			THIAFENTANIL-DEXMEDETOMIDINE-TELAZOL ANESTHESIA IN GREATER RHEAS (RHEA AMERICANA)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Anesthesia; dexmedetomidine; greater rhea; Rhea americana; thiafentanil; tiletamine-zolazepam	OSTRICHES STRUTHIO-CAMELUS; CHEMICAL IMMOBILIZATION; TILETAMINE-ZOLAZEPAM; MEDETOMIDINE; INDUCTION; XYLAZINE; RATITES	Ratite anesthetic events are often dangerous because these birds use their powerful legs and clawed feet as a defense, and physical restraint can result in self-trauma or injury to handlers. Although various combinations of opioids, alpha-2 adrenergic agonists, and dissociative agents have been employed in ratites, few effective chemical immobilization protocols have been documented for rheas (Rhea spp.). An intramuscular, remote-delivered combination of thiafentanil (0.30 +/- 0.08 mg/kg), dexmedetomidine (7.31 +/- 2.72 mu g/kg), and tiletamine-zolazepam (5.09 +/- 2.31 mg/kg) was utilized in eight adult (four male, four female) greater rheas (Rhea americana). Smooth inductions were observed. During clinical procedures, birds were intubated and maintained on isoflurane gas, and atipamezole was administered to antagonize the dexmedetomidine. At recovery, naltrexone was administered to antagonize the thiafentanil, and midazolam was administered to smooth crate recoveries until release. This low-volume, high-potency, reversible drug combination demonstrated safe inductions and smooth recoveries and proved to be a reliable anesthetic regimen for greater rheas.	[Ter Beest, Julia; Bildfell, Robert] Oregon State Univ, Coll Vet Med, Corvallis, OR 97331 USA; [McClean, Modesto; Cushing, Andrew] Wildlife Safari, Winston, OR 97496 USA	Ter Beest, J (reprint author), VCA Anim Referral & Emergency Ctr Arizona, 1648 N Country Club Dr, Mesa, AZ 85201 USA.	julieterbeest@gmail.com		Cushing, Andrew/0000-0002-5258-1543	Oregon State University, Department of Biomedical Sciences	The authors thank Oregon State University, Department of Biomedical Sciences, for funding, as well as all of the veterinary students and Wildlife Safari staff who provided assistance with the study.	Arnemo J. M., 2007, HDB WILDLIFE CHEM IM, p[33, 263]; Carpenter JW, 2005, EXOTIC ANIMAL FORMUL, P199; CORNICK JL, 1992, J AM VET MED ASSOC, V200, P1661; Cornick-Seahorn Janyce L., 1996, P79; Cushing A, 2010, J ZOO WILDLIFE MED, V41, P234, DOI 10.1638/2009-0143R1.1; Gilsleider EF, 1998, VET CLIN N AM-FOOD A, V14, P503, DOI 10.1016/S0749-0720(15)30233-4; Lin HC, 1997, J AM VET MED ASSOC, V210, P244; OSTROWSKI S, 1995, VET REC, V136, P145, DOI 10.1136/vr.136.6.145; RAATH JP, 1992, J S AFR VET ASSOC, V63, P138; Reissig EC, 2002, J ZOO WILDLIFE MED, V33, P328, DOI 10.1638/1042-7260(2002)033[0328:HASCVO]2.0.CO;2; SAMOUR JH, 1990, VET REC, V127, P575; Santangelo B, 2009, VET RES COMMUN, V33, pS209, DOI 10.1007/s11259-009-9274-8; Schumacher Juergen, 2008, P455, DOI 10.1016/B978-141604047-7.50059-2; Siegal-Willott Jessica, 2007, P325, DOI 10.1002/9780470376478.ch24; Smith D.A., 2003, ZOO WILD ANIMAL MED, P94; Smith KM, 2006, J ZOO WILDLIFE MED, V37, P513, DOI 10.1638/06-027.1; VANHEERDEN J, 1991, J S AFR VET ASSOC, V62, P114; Westcott DA, 2002, AUST VET J, V80, P150, DOI 10.1111/j.1751-0813.2002.tb11380.x	18	4	4	1	13	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2012	43	4					802	807		10.1638/2011-0175R2.1			6	Veterinary Sciences	Veterinary Sciences	059AJ	WOS:000312676500014	23272347				2020-06-30	J	Rajasekhar, PT; Rutter, MD; Bramble, MG; Wilson, DW; East, JE; Greenaway, JR; Saunders, BP; Lee, TJW; Barton, R; Hungin, APS; Rees, CJ				Rajasekhar, P. T.; Rutter, M. D.; Bramble, M. G.; Wilson, D. W.; East, J. E.; Greenaway, J. R.; Saunders, B. P.; Lee, T. J. W.; Barton, R.; Hungin, A. P. S.; Rees, C. J.			Achieving high quality colonoscopy: using graphical representation to measure performance and reset standards	COLORECTAL DISEASE			English	Article						Funnel plots; colonoscopy performance; caecal intubation rate; adenoma detection rate; quality assurance	FUNNEL PLOTS; INSTITUTIONAL PERFORMANCE; COLORECTAL-CANCER; RISK; INDICATORS	Aim Completeness and thoroughness of colonoscopy are measured by the caecal intubation rate (CIR) and the adenoma detection rate (ADR). National standards are >= 90% and >= 10% respectively. Variability in CIR and ADR have been demonstrated but comparison between individuals and units is difficult. We aimed to assess the performance of colonoscopy in endoscopy units in the northeast of England. Method Data on colonoscopy performance and sedation use were collected over 3 months from 12 units. Colonoscopies performed by screening colonoscopists were included for the CIR only. Funnel plots with upper and lower 95% confidence limits for CIR and ADR were created. Results CIR was 92.5% (n = 5720) and ADR 15.9% (n = 4748). All units and 128 (99.2%) colonoscopists were above the lower limit for CIR. All units achieved the ADR standard with 10 above the upper limit. Ninety-nine (76.7%) colonoscopists were above 10%, 16 (12.4%) above the upper limit and 7 (5.4%) below the lower limit. Median medication doses were 2.2 mg midazolam, 29.4 mg pethidine and 83.3 mu g fentanyl. In all, 15.1% of colonoscopies were unsedated. Complications were bleeding (0.10%) and perforation (0.02%). There was one death possibly related to bowel preparation. Conclusion Results indicate that colonoscopies are performed safely and to a high standard. Funnel plots can highlight variability and areas for improvement. Analyses of ADR presented graphically around the global mean suggest that the national standard should be reset at 15%.	[Rajasekhar, P. T.; Rees, C. J.] S Tyneside Fdn Hosp, S Shields, Tyne & Wear, England; [Rajasekhar, P. T.; Rutter, M. D.; Bramble, M. G.; Greenaway, J. R.; Lee, T. J. W.; Barton, R.; Rees, C. J.] No Reg Endoscopy Grp, S Shields, Tyne & Wear, England; [Rajasekhar, P. T.; Rutter, M. D.; Bramble, M. G.; Wilson, D. W.; Hungin, A. P. S.; Rees, C. J.] Univ Durham, Sch Med & Hlth, Stockton On Tees, England; [Rutter, M. D.] Univ Hosp N Tees, Stockton On Tees, England; [East, J. E.] John Radcliffe Hosp, Oxford OX3 9DU, England; [Greenaway, J. R.] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Saunders, B. P.] St Marks Hosp, Harrow, Middx, England; [Lee, T. J. W.; Barton, R.] N Tyneside Gen Hosp, N Shields, Tyne & Wear, England	Rees, CJ (reprint author), S Tyneside Dist Hosp, Dept Gastroenterol, Harton Lane, S Shields NE34 0PL, Tyne & Wear, England.	colin.rees@stft.nhs.uk	Saunders, Brian/AAP-4137-2020	hungin, amritpal Pali/0000-0001-7275-8927	'Good Ideas' grant from the NHS North East Strategic Health Authority	The study was funded by a 'Good Ideas' grant from the NHS North East Strategic Health Authority. They were not involved in data collection, analysis or manuscript development. There are no conflicts of interest to declare.	Barclay RL, 2006, NEW ENGL J MED, V355, P2533, DOI 10.1056/NEJMoa055498; Bowles CJA, 2004, GUT, V53, P277, DOI 10.1136/gut.2003.016436; Chilton A, 2010, NHS BOWEL CANC SCREE; Cotton PB, 2010, GASTROINTEST ENDOSC, V71, P446, DOI 10.1016/j.gie.2009.10.027; Dafnis G, 2005, DIGEST LIVER DIS, V37, P113, DOI 10.1016/j.dld.2004.09.015; Heydtmann M, 2006, GUT, V55, P1672, DOI 10.1136/gut.2006.103903; Iqbal CW, 2005, J GASTROINTEST SURG, V9, P1229, DOI 10.1016/j.gassur.2005.06.023; Kaminski MF, 2010, NEW ENGL J MED, V362, P1795, DOI 10.1056/NEJMoa0907667; Kirkham JJ, 2008, J TRAUMA, V65, P1494, DOI 10.1097/TA.0b013e31815ebabf; Kunadian B, 2008, BRIT MED J, V336, P931, DOI 10.1136/bmj.39512.529120.BE; Lee TJ, 2011, GUT; Marshall T, 2004, INT J QUAL HEALTH C, V16, P309, DOI 10.1093/intqhc/mzh054; Mayer EK, 2011, BJU INT, V108, P844, DOI 10.1111/j.1464-410X.2010.09896.x; Noyez Luc, 2009, Interact Cardiovasc Thorac Surg, V9, P494, DOI 10.1510/icvts.2009.204768; Rabeneck L, 2008, GASTROENTEROLOGY, V135, P1899, DOI 10.1053/j.gastro.2008.08.058; Rees C, 2006, GUIDANCE SUPPORTING; Rex DK, 2002, AM J GASTROENTEROL, V97, P1296, DOI 10.1016/S0002-9270(02)04168-0; Rex DK, 2006, AM J GASTROENTEROL, V101, P873, DOI 10.1111/j.1572-0241.2006.00673.x; ROSEN L, 1993, DIS COLON RECTUM, V36, P1126, DOI 10.1007/BF02052261; Spiegelhalter DJ, 2005, STAT MED, V24, P1185, DOI 10.1002/sim.1970; The Joint Advisory Group for Gastrointestinal Endoscopy, GUID COL CERT CONT P; van Rijn JC, 2006, AM J GASTROENTEROL, V101, P343, DOI 10.1111/j.1572-0241.2006.00390.x	22	17	17	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8910			COLORECTAL DIS	Colorectal Dis.	DEC	2012	14	12					1538	1545		10.1111/j.1463-1318.2012.03057.x			8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	039NJ	WOS:000311253000026	22540766				2020-06-30	J	Orbach-Zinger, S; Ginosar, Y; Elliston, J; Fadon, C; Abu-Lil, M; Raz, A; Goshen-Gottstein, Y; Eidelman, LA				Orbach-Zinger, S.; Ginosar, Y.; Elliston, J.; Fadon, C.; Abu-Lil, M.; Raz, A.; Goshen-Gottstein, Y.; Eidelman, L. A.			Influence of preoperative anxiety on hypotension after spinal anaesthesia in women undergoing Caesarean delivery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia; anxiety; bupivacaine; Caesarean delivery; complications; hypotension; intrathecal; spinal	SALIVARY ALPHA-AMYLASE; HEART-RATE-VARIABILITY; PREDICT HYPOTENSION; BLOOD-PRESSURE; ACID-BASE; SECTION; STRESS; DEFINITIONS; RESPONSES; TIME	We designed a prospective observational study to assess the effect of preoperative anxiety on hypotension after spinal anaesthesia. After IRB approval and signed informed consent, 100 healthy term parturients undergoing elective Caesarean delivery under spinal anaesthesia were enrolled. Direct psychological assessments of preoperative anxiety were verbal analogue scale (VAS) (010) anxiety score and State-Trait Anxiety Inventory questionnaire (STAI-s); salivary amylase was measured as an indirect physical assessment of anxiety. Direct and indirect anxiety data were transformed into ordinal groups for low, medium, and high anxiety (VAS: low 03, medium 46, high 710; STAI-s: low 40, medium 4055, high 55; log(10) salivary amylase: low 3, medium 34, high 4). Spinal anaesthesia was performed using hyperbaric bupivacaine 10 mg and fentanyl 20 g. All patients received i.v. crystalloid 500 ml prehydration and 500 ml cohydration. Hypotension was treated by standardized protocol (fluid bolus and ephedrine or phenylephrine depending on maternal heart rate). Systolic arterial pressure (SAP) was measured at baseline and every minute after spinal anaesthesia. The effect of low, medium, and high anxiety groups on the maximum percentage change in SAP (SAP) was assessed (one-way analysis of variance, Tukeys honestly significant difference). Ninety-three patients were included in analysis. There was a significant effect of direct psychological measures of anxiety on SAP (VAS P0.004; STAI-s P0.048). There was a significant difference between low and high anxiety groups (VAS P0.003; STAI-s P0.038), but not between other anxiety groups. Salivary amylase did not correlate with SAP. Preoperative anxiety assessed by VAS had a significant effect on hypotension after spinal anaesthesia.	[Orbach-Zinger, S.; Elliston, J.; Fadon, C.; Abu-Lil, M.; Raz, A.; Eidelman, L. A.] Rabin Med Ctr, Dept Anesthesiol, Petah Tiqwa, Israel; [Ginosar, Y.] Hadassah Hebrew Univ, Med Ctr, Dept Anesthesiol, Jerusalem, Israel; [Goshen-Gottstein, Y.] Tel Aviv Univ, Dept Psychol, Sch Psychol Sci, IL-69978 Tel Aviv, Israel	Orbach-Zinger, S (reprint author), Rabin Med Ctr, Dept Anesthesiol, Beilinson Campus, Petah Tiqwa, Israel.	sharonorbach@yahoo.com			Department of Anesthesiology, Rabin Medical Center-Beilinson Campus, Petach Tikvah, Israel	This study was supported by the Department of Anesthesiology, Rabin Medical Center-Beilinson Campus, Petach Tikvah, Israel.	Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e; Blasquez JCC, 2009, PSICOTHEMA, V21, P531; Cyna A, 2006, COCHRANE DB SYST REV, V18; Delaney JPA, 2000, PERCEPT MOTOR SKILL, V91, P515, DOI 10.2466/PMS.91.6.515-524; Frolich MA, 2002, CAN J ANAESTH, V49, P185; Fujiwara Y, 2007, ACTA ANAESTH SCAND, V51, P1161, DOI 10.1111/j.1399-6576.2007.01435.x; Guglielminotti J, 2012, INT J OBSTET ANESTH, V21, P35, DOI 10.1016/j.ijoa.2011.09.008; Hanss R, 2007, ACTA ANAESTH SCAND, V51, P1297, DOI 10.1111/j.1399-6576.2007.01455.x; Hanss R, 2005, ANESTHESIOLOGY, V102, P1086, DOI 10.1097/00000542-200506000-00005; Jeon YT, 2010, ANESTH ANALG, V111, P712, DOI 10.1213/ANE.0b013e3181e8137b; Kindler CH, 2000, ANESTH ANALG, V90, P706, DOI 10.1097/00000539-200003000-00036; Klohr S, 2010, ACTA ANAESTH SCAND, V54, P909, DOI 10.1111/j.1399-6576.2010.02239.x; Ledowski T, 2008, ACTA ANAESTH SCAND, V52, P1342, DOI 10.1111/j.1399-6576.2008.01697.x; Ng K, 2004, COCHRANE DB SYST REV, V2; Ng V, 2008, PSYCHOL REP, V103, P455, DOI 10.2466/PR0.103.2.455-458; Nierop A, 2006, J CLIN ENDOCR METAB, V91, P1329, DOI 10.1210/jc.2005-1816; Noto Y, 2005, ANESTH ANALG, V101, P1873, DOI 10.1213/01.ANE.0000184196.60838.8D; PAGANI M, 1991, CIRCULATION, V83, P43; Piccirillo G, 1997, INT J CARDIOL, V60, P121, DOI 10.1016/S0167-5273(97)00088-0; Reynolds F, 2005, ANAESTHESIA, V60, P636, DOI 10.1111/j.1365-2044.2005.04223.x; RILEY ET, 1995, ANESTH ANALG, V80, P709, DOI 10.1097/00000539-199504000-00010; ROCKE DA, 1995, BRIT J ANAESTH, V75, P257, DOI 10.1093/bja/75.3.257; Roth WT, 2008, J PSYCHIATR RES, V42, P205, DOI 10.1016/j.jpsychires.2006.12.003; ROUT CC, 1994, INT ANESTHESIOL CLIN, V32, P117, DOI 10.1097/00004311-199400000-00010; Spielberger CD, 1970, MANUAL STATE TRAIT A; Tonni G, 2007, INT J GYNECOL OBSTET, V97, P143, DOI 10.1016/j.ijgo.2006.11.021; van Stegeren AH, 2008, INT J PSYCHOPHYSIOL, V69, P33, DOI 10.1016/j.ijpsycho.2008.02.008; Vogelsang J, 1988, J Post Anesth Nurs, V3, P235; Watkins LL, 1998, PSYCHOSOM MED, V60, P498, DOI 10.1097/00006842-199807000-00018; Yamaguchi M, 2006, BIOSENS BIOELECTRON, V21, P1007, DOI 10.1016/j.bios.2005.03.014	30	25	27	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2012	109	6					943	949		10.1093/bja/aes313			7	Anesthesiology	Anesthesiology	040EN	WOS:000311304400015	22964265	Bronze			2020-06-30	J	Niesters, M; Mahajan, R; Olofsen, E; Boom, M; del Valle, SG; Aarts, L; Dahan, A				Niesters, M.; Mahajan, R.; Olofsen, E.; Boom, M.; Garcia del Valle, S.; Aarts, L.; Dahan, A.			Validation of a novel respiratory rate monitor based on exhaled humidity	BRITISH JOURNAL OF ANAESTHESIA			English	Article						complications; monitoring; postoperative care; recovery room; respiratory depression; respiratory rate	OXYGEN; PREVENTION; AGREEMENT; ACCURACY; CARE	Postoperative monitoring of ventilation is largely restricted to the measurement of haemoglobin-oxygen saturation (Sp(o2)) and respiratory rate (RR) derived from the ECG. Sp(o2) measurement is inadequate when used with supplemental oxygen and ECG-derived RR is subject to artifacts. A new monitor measures RR by quantifying the humidity of exhaled air (respiR8). The accuracy of the system was tested using a breathing simulator. In healthy volunteers, the respiR8 monitor was compared with two other methods of measuring RR: capnometry and counting of thoracic breathing movements. The ability of the monitor to track changes in RR resulting from the infusion of 2.5 g kg(1) fentanyl was assessed and compared with RR measured from a validated flow measurement system. The RR in 50 postoperative patients measured with the respiR8 was compared with that derived from the ECG. RR values were compared by population-based BlandAltman analyses. The respiR8 monitor was accurate in the range required in clinical practice. There was a close agreement between RR from respiR8, capnometry, and manual counting of respiratory movements without bias (limits of agreement 1 bpm). The respiR8 monitor was well able to accurately track RR changes from fentanyl. In postoperative patients, RR from respiR8 and ECG had a bias of 1.7 (5.7) bpm due to greater RR values observed from the ECG due to artifacts. The respiR8 gives an accurate measurement of RR and is useful in postoperative care.	[Niesters, M.; Olofsen, E.; Boom, M.; Aarts, L.; Dahan, A.] Leiden Univ Med Ctr, Dept Anesthesiol, NL-2300 RC Leiden, Netherlands; [Mahajan, R.] Univ Nottingham, Queens Med Ctr, Div Anaesthesia & Intens Care, Nottingham NG7 2UH, England; [Garcia del Valle, S.] Hosp Univ Fdn Alcorcon, Area Anestesia & Cuidados Crit, Madrid, Spain	Dahan, A (reprint author), Leiden Univ Med Ctr, Dept Anesthesiol, NL-2300 RC Leiden, Netherlands.	a.dahan@lumc.nl	Garcia del Valle, Santiago/H-5388-2018	Garcia del Valle, Santiago/0000-0002-6216-8226	Anaxsys Technology Ltd, Send, Surrey, UK	This study is supported in part by funding from Anaxsys Technology Ltd, Send, Surrey, UK.	[Anonymous], 2002, ANESTHESIOLOGY, V96, P742; BEAL BL, 1989, NONMEM USERS GUIDE; Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204; Breakell A, 2001, EMERG MED J, V18, P366, DOI 10.1136/emj.18.5.366; DAHAN A, 1990, J PHYSIOL-LONDON, V428, P485, DOI 10.1113/jphysiol.1990.sp018223; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dahan A, 2007, PLOS MED, V4, P1195, DOI 10.1371/journal.pmed.0040239; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; DAVIDSON JAH, 1993, BRIT MED J, V307, P372, DOI 10.1136/bmj.307.6900.372; DOWNS JB, 1994, J CLIN ANESTH, V6, P180, DOI 10.1016/0952-8180(94)90055-8; Drummond GB, 2011, BRIT J ANAESTH, V107, P462, DOI 10.1093/bja/aer153; Folke M, 2003, MED BIOL ENG COMPUT, V41, P377, DOI 10.1007/BF02348078; Gaucher A, 2012, BRIT J ANAESTH, V108, P316, DOI 10.1093/bja/aer383; Mimoz O, 2012, BRIT J ANAESTH, V108, P872, DOI 10.1093/bja/aer510; Niesters M, BR J ANAESTH UNPUB; Overdyk FJ, 2007, ANESTH ANALG, V105, P412, DOI 10.1213/01.ane.0000269489.26048.63; Smith I., 2011, BRIT J HEALTHCARE AS, V5, P18, DOI DOI 10.12968/bjha.2011.5.1.18	18	10	10	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	DEC	2012	109	6					981	989		10.1093/bja/aes275			9	Anesthesiology	Anesthesiology	040EN	WOS:000311304400020	22907341	Bronze			2020-06-30	J	Lee, BY; Katon, R; Herzig, D; Fennerty, MB				Lee, Brent Y.; Katon, Ronald; Herzig, Daniel; Fennerty, M. Brian			Warm water infusion during sedated colonoscopy does not decrease amount of sedation medication used	GASTROINTESTINAL ENDOSCOPY			English	Article							IMMERSION; VETERANS; TRIAL	Background: Water infusion versus air insufflation during colonoscope insertion has been suggested to reduce patient discomfort and decrease sedation medication requirements. Warm water is thought to further facilitate colonoscopy perhaps by decreasing colon spasm. Objective: To compare the utility of warm (35 degrees-38 degrees C) versus cool (20 degrees-23 degrees C) water infused during colonoscopic insertion by measuring patient sedation medication use and discomfort scores between the warm and cool water groups. Design: Randomized, controlled, double-blinded study. Setting: Outpatient endoscopy unit at an academic medical center. Patients: A total of 175 adults. Intervention: Elective outpatient sedated screening colonoscopies. Main Outcome Measurements: Sedation medication used, pain scores, cecal intubation rate, endoscopy times, satisfaction scores, and patient willingness to repeat procedures. Results: There was no significant difference in sedation medication requirement during colonoscopy with the use of warm or cool water (fentanyl 83.6 +/- 29.0 mu g vs 87.6 +/- 39.6 mu g; P = .45; midazolam 3.3 +/- 1.2 mg vs 3.3 +/- 1.3 mg; P = .91). There was no significant difference in patient pain scores or satisfaction scores. Cecal intubation rates (100%) were similar. There was no significant difference in cecal intubation times (6 minutes 40 seconds +/- 4 minutes 9 seconds vs 7 minutes 49 seconds +/- 4 minutes 0 seconds; P = .06) between the warm and cool water groups. All patients were willing to repeat the colonoscopy by using the same method in both groups. Limitations: Limited generalizability to patients undergoing screening sedated colonoscopies with good to excellent bowel preparation. Conclusion: Water does not need to be warmed before infusion in patients undergoing sedated colonoscopies. (Clinical Trial registration number NCT01322724.) (Gastrointest Endosc 2012;76:1182-7.)	[Lee, Brent Y.; Katon, Ronald; Fennerty, M. Brian] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97239 USA; [Herzig, Daniel] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97239 USA	Lee, BY (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, 3181 SW Sam Jackson Pk Rd,PV-310, Portland, OR 97239 USA.						Abe K, 1986, YAKURI TO CHIRYOU, V14, P108; Baumann UA, 1999, ENDOSCOPY, V31, P314; Church JM, 2002, GASTROINTEST ENDOSC, V56, P672, DOI 10.1067/mge.2002.128916; FALCHUK ZM, 1984, NEW ENGL J MED, V310, P598; Hamamoto N, 2002, GASTROINTEST ENDOSC, V56, P825, DOI 10.1067/mge.2002.129608; JENSEN MP, 1989, CLIN J PAIN, V5, P153, DOI 10.1097/00002508-198906000-00005; Leung CW, 2010, ENDOSCOPY, V42, P557, DOI 10.1055/s-0029-1244231; Leung FW, 2011, CLIN GASTROENTEROL H, V9, P1012, DOI 10.1016/j.cgh.2011.09.007; Leung FW, 2010, GASTROINTEST ENDOSC, V72, P693, DOI 10.1016/j.gie.2010.05.020; Leung FW, 2009, GASTROINTEST ENDOSC, V69, P546, DOI 10.1016/j.gie.2008.08.014; Leung J, 2011, GASTROINTEST ENDOSC, V73, P103, DOI 10.1016/j.gie.2010.09.020; Leung JW, 2009, GASTROINTEST ENDOSC, V70, P505, DOI 10.1016/j.gie.2008.12.253; Leung JW, 2009, DIGEST DIS SCI, V54, P1997, DOI 10.1007/s10620-008-0576-4; Park SC, 2010, DIGEST DIS SCI, V55, P2940, DOI 10.1007/s10620-009-1096-6; Sakai Y, 1988, GASTROENTEROL END S1, V30, P2925, DOI 10.11280/gee1973b.30.Supplement_2925; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008	16	8	8	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	DEC	2012	76	6					1182	1187		10.1016/j.gie.2012.08.002			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	040TT	WOS:000311347800013	23021168				2020-06-30	J	Orosz, JEB; Braz, MG; Golim, MA; Barreira, MAA; Fecchio, D; Braz, LG; Braz, JRC				Orosz, Jose Eduardo B.; Braz, Mariana G.; Golim, Marjorie A.; Barreira, Marcio Antonio A.; Fecchio, Denise; Braz, Leandro G.; Braz, Jose Reinaldo C.			Cytokine Profile in Patients Undergoing Minimally Invasive Surgery with Balanced Anesthesia	INFLAMMATION			English	Article						balanced anesthesia; sevoflurane; minor surgical procedures; cytokines; flow cytometry	STRESS-RESPONSE; ABDOMINAL-SURGERY; SURGICAL STRESS; PLASMA-LEVELS; CABG SURGERY; BEAD ARRAY; IN-VITRO; SEVOFLURANE; PROPOFOL; REMIFENTANIL	Patients undergoing surgical procedure develop an inflammatory response due to surgical trauma that may be modulated by anesthetics. The aim of this study was to investigate the cytokine profile in the plasma of adult patients who underwent minimally invasive surgery with balanced anesthesia with propofol, fentanyl, and sevoflurane. The study included 15 healthy patients scheduled for tympanoplasty or septoplasty under balanced anesthesia. Blood samples were drawn at four time points: before anesthesia, before surgery, 120 min after anesthesia induction, and on the first postoperative day. Plasma interleukin (IL)-1 beta, -2, -4, -6, -8, -10, -12, TNF-alpha, and INF-gamma levels were assessed by flow cytometry. IL-6 levels were elevated on the day after the surgery (p < 0.001). All other cytokines did not change either during or after balanced anesthesia (p > 0.05). In conclusion, balanced anesthesia with propofol, fentanyl, and sevoflurane anesthesia is not associated with intraoperative changes in the plasma cytokines in healthy patients undergoing minimally invasive otorhinological surgeries. Considering IL-6 results, a postoperative inflammatory response may have occurred due to surgical stress.	[Orosz, Jose Eduardo B.; Braz, Mariana G.; Barreira, Marcio Antonio A.; Fecchio, Denise; Braz, Leandro G.; Braz, Jose Reinaldo C.] Univ Estadual Paulista, UNESP, Botucatu Med Sch, Dept Anesthesiol, BR-18618970 Botucatu, SP, Brazil; [Golim, Marjorie A.] Univ Estadual Paulista, UNESP, Botucatu Med Sch, Ctr Blood, BR-18618970 Botucatu, SP, Brazil	Braz, JRC (reprint author), Univ Estadual Paulista, UNESP, Botucatu Med Sch, Dept Anesthesiol, BR-18618970 Botucatu, SP, Brazil.	jbraz@fmb.unesp.br	Braz, Leandro Gobbo/W-4445-2019; Braz, Mariana G/E-7639-2012	Braz, Leandro Gobbo/0000-0002-1927-8729; Braz, Mariana G/0000-0003-4413-226X; de Assis Golim, Marjorie/0000-0002-4824-9441	Sao Paulo Research Foundation (FAPESP), Sao Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/51110-5]	The authors acknowledge the support of Sao Paulo Research Foundation (FAPESP), Sao Paulo, Brazil (grant number 2009/51110-5).	Braz MG, 2009, EUR J ANAESTH, V26, P654, DOI 10.1097/EJA.0b013e328329b12c; Chen R, 1999, CLIN CHEM, V45, P1693; Cheng C.R., 2005, ADV ANESTHESIA, V23, P107; CROZIER TA, 1994, BRIT J ANAESTH, V72, P280, DOI 10.1093/bja/72.3.280; Delogu G, 2005, EUR J ANAESTH, V22, P462, DOI 10.1017/S0265021505000797; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; El Azab SR, 2002, EUR J ANAESTH, V19, P276, DOI 10.1017/S0265021502000443; Elshal MF, 2006, METHODS, V38, P317, DOI 10.1016/j.ymeth.2005.11.010; Gilliland HE, 1997, ANESTH ANALG, V85, P1394, DOI 10.1097/00000539-199712000-00039; Goto Y, 2000, EUR J ANAESTH, V17, P474, DOI 10.1046/j.1365-2346.2000.00708.x; Haack M, 1999, J PSYCHIATR RES, V33, P407, DOI 10.1016/S0022-3956(99)00021-7; Hofstetter C, 2007, ACTA ANAESTH SCAND, V51, P893, DOI 10.1111/j.1399-6576.2007.01353.x; Kawamura T, 2006, J CARDIOTHOR VASC AN, V20, P503, DOI 10.1053/j.jvca.2006.01.011; Ke JJ, 2008, ANAESTH INTENS CARE, V36, P74, DOI 10.1177/0310057X0803600113; Kehlet H, 1999, WORLD J SURG, V23, P801, DOI 10.1007/s002689900583; KHARASCH ED, 1995, ANESTHESIOLOGY, V82, P1369, DOI 10.1097/00000542-199506000-00008; Kohl BA, 2006, CURR OPIN CRIT CARE, V12, P325, DOI 10.1097/01.ccx.0000235210.85073.fc; Koksal GM, 2005, ACTA ANAESTH SCAND, V49, P835, DOI 10.1111/j.1399-6576.2005.00677.x; Kudoh A, 2001, CYTOKINE, V15, P270, DOI 10.1006/cyto.2001.0927; Kumakura Seiichiro, 2008, Masui, V57, P1200; Kurosawa S, 2008, J ANESTH, V22, P263, DOI 10.1007/s00540-008-0626-2; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; Morgan E, 2004, CLIN IMMUNOL, V110, P252, DOI 10.1016/j.clim.2003.11.017; Sanchez-Conde P, 2008, ANESTH ANALG, V106, P371, DOI 10.1213/ane.0b013e318160580b; Schneemilch CE, 2005, EUR J ANAESTH, V22, P616, DOI 10.1017/S0265021505001031; Schneemilch CE, 2005, J CLIN ANESTH, V17, P517, DOI 10.1016/j.jclinane.2004.12.017; Sheeran P, 1997, BRIT J ANAESTH, V78, P201; Sugasawa Y, 2012, J ANESTH, V26, P62, DOI 10.1007/s00540-011-1244-y; Winterhalter M, 2008, EUR J ANAESTH, V25, P326, DOI 10.1017/S0265021507003043; Wu Y, 2009, MOL BIOL REP, V36, P1113, DOI 10.1007/s11033-008-9286-4; YASUDA N, 1989, ANESTH ANALG, V69, P370	31	10	10	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997			INFLAMMATION	Inflammation	DEC	2012	35	6					1807	1813		10.1007/s10753-012-9501-2			7	Cell Biology; Immunology	Cell Biology; Immunology	042XR	WOS:000311506000008	22777067				2020-06-30	J	Sia, ATH; Tan, HS; Sng, BL				Sia, A. T. H.; Tan, H. S.; Sng, B. L.			Closed-loop double-vasopressor automated system to treat hypotension during spinal anaesthesia for caesarean section: a preliminary study	ANAESTHESIA			English	Article							COMPUTER-CONTROLLED INFUSION; PHENYLEPHRINE INFUSION; BLOOD-PRESSURE; EPHEDRINE; FETAL	Hypotension occurs in most caesarean sections under spinal anaesthesia, necessitating vasopressor administration. However, the optimal dosing regimen remains unclear. We have developed a novel vasopressor delivery system that automatically administers phenylephrine or ephedrine based on continuous non-invasive blood pressure monitoring. This prospective cohort study recruited 55 healthy women under standardised spinal anaesthesia with 2.2 ml hyperbaric bupivacaine 0.5%, 15 mu g fentanyl and 100 mu g morphine. A 50-mu g phenylephrine bolus was given at 1-min intervals when systolic blood pressure fell below 90% of baseline, and a 4-mg ephedrine bolus was given when hypotension developed with bradycardia (heart rate <60 beats.min-1). Systolic blood pressure was within 20% of baseline in 88% of all measurements. Six patients (11%) had one or more measurements above 120% of baseline (1% of all measurements), whereas 36 (65%) had at least one reading below 80% of baseline (11% of total measurements). The system maintained systolic blood pressure at a mean (SD) of -9.1 (7.0)% below baseline, with 5.4 (2.5)% fluctuation. Two patients (4%) experienced pre-delivery nausea. All 5-min Apgar scores were 9.	[Sng, B. L.] KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore, Singapore; [Sia, A. T. H.] KK Womens & Childrens Hosp, Med Board, Singapore, Singapore; [Tan, H. S.] Duke NUS Grad Med Sch, Singapore, Singapore	Sng, BL (reprint author), KK Womens & Childrens Hosp, Dept Womens Anaesthesia, Singapore, Singapore.	sng.ban.leong@kkh.com.sg			National Medical Research Council, SingaporeNational Medical Research Council, Singapore [NMRC/EDG/1003/2011]	This study was funded by National Medical Research Council, Singapore, grant number NMRC/EDG/1003/2011. No competing interests declared.	Allen TK, 2010, ANESTH ANALG, V111, P1221, DOI 10.1213/ANE.0b013e3181e1db21; Cooper D, 2008, BRIT J ANAESTH, V100, P727, DOI 10.1093/bja/aen064; Cooper DW, 2002, ANESTHESIOLOGY, V97, P1582, DOI 10.1097/00000542-200212000-00034; Hanss R, 2010, EUR J ANAESTH, V27, P166, DOI 10.1097/00003643-201006121-00531; Ilies C, 2010, BRIT J ANAESTH, V108, P202; Jeleazcov C, 2010, BRIT J ANAESTH, V105, P264, DOI 10.1093/bja/aeq143; Kee WDN, 2007, ANAESTHESIA, V62, P1251, DOI 10.1111/j.1365-2044.2007.05257.x; Kee WDN, 2006, CURR OPIN ANESTHESIO, V19, P238, DOI 10.1097/01.aco.0000192816.22989.ba; Kee WDN, 2005, ANESTHESIOLOGY, V103, P744, DOI 10.1097/00000542-200510000-00012; Kee WDN, 2004, ANESTH ANALG, V98, P815; Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028; Smiley RM, 2006, ANESTHESIOLOGY, V104, P644, DOI 10.1097/00000542-200604000-00006; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186	13	25	25	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	DEC	2012	67	12					1348	1355		10.1111/anae.12000			8	Anesthesiology	Anesthesiology	033OI	WOS:000310807000010	23020653				2020-06-30	J	Ousley, R; Egan, C; Dowling, K; Cyna, AM				Ousley, R.; Egan, C.; Dowling, K.; Cyna, A. M.			Assessment of block height for satisfactory spinal anaesthesia for caesarean section	ANAESTHESIA			English	Article							REGIONAL ANESTHESIA; PINPRICK; TOUCH; COLD	We investigated block heights that anaesthetists considered adequate for caesarean section to proceed under spinal anaesthesia. During 3 months, 15 obstetric anaesthetists recorded block height to touch, pinprick or cold when spinal anaesthesia was considered satisfactory for caesarean section to proceed. Median (IQR [range]) block height for touch, pinprick, first cold and icy were: T10 (T7T12 [T3L1]); T5 (T4T6 [C7L1]); T5 (T4T6 [C7L1]); and T3 (T2T4 [C7L1]), respectively. Modalities were significantly correlated for: touch and cold, p = 0.0001; touch and icy, p = 0.0007; touch and pinprick, p = 0.0018; cold and icy, p < 0.0001; cold and pinprick, p = 0.0001; icy and pinprick, p < 0.0001. Pairwise comparisons showed differences between all modalities (p < 0.001) apart from pinprick and first cold (p = 0.94). All women had satisfactory anaesthesia despite 76 (81%) having a block to touch below T6. Single modality assessment of block height, particularly using touch, may erroneously indicate inadequate anaesthesia for caesarean section.	[Ousley, R.; Egan, C.; Cyna, A. M.] Womens & Childrens Hosp, Dept Womens Anaesthesia, Adelaide, SA, Australia; [Dowling, K.] Womens & Childrens Hosp, Dept Publ Hlth, Adelaide, SA, Australia; [Cyna, A. M.] Univ Adelaide, Adelaide, SA, Australia	Cyna, AM (reprint author), Womens & Childrens Hosp, Dept Womens Anaesthesia, Adelaide, SA, Australia.	allan.cyna@health.sa.gov.au					Allen JG, 2001, INT J OBSTET ANESTH, V10, P328, DOI 10.1054/ijoa.2001.0892; Bogod D, 2000, REGIONAL ANALGESIA IN OBSTETRICS, P371; Bourne T, 1998, ANAESTHESIA, V53, P718, DOI 10.1046/j.1365-2044.1998.537m-az0584m.x; Bourne TM, 1997, ANAESTHESIA, V52, P901, DOI 10.1111/j.1365-2044.1997.180-az0314.x; Congreve K, 2006, ANAESTHESIA, V61, P453, DOI 10.1111/j.1365-2044.2006.04609.x; Cyna AM, 2010, HDB COMMUNICATION AN, P38; Kinsella SM, 2006, INT J OBSTET ANESTH, V15, P340, DOI 10.1016/j.ijoa.2006.06.003; Kocarev M, 2010, INT J OBSTET ANESTH, V19, P261, DOI 10.1016/j.ijoa.2010.02.002; ROCCO AG, 1985, ANESTH ANALG, V64, P917; Russell IF, 2006, INT J OBSTET ANESTH, V15, P294, DOI 10.1016/j.ijoa.2006.06.006; Russell I F, 1995, Int J Obstet Anesth, V4, P71, DOI 10.1016/0959-289X(95)82995-M; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; Russell IF, 2001, REGION ANESTH PAIN M, V26, P385, DOI 10.1053/rapm.2001.22995; Russell IF, 2001, INT J OBSTET ANESTH, V10, P83, DOI 10.1054/ijoa.2000.0770; Shirgaonkar AT, 2010, INT J OBSTET ANESTH, V19, P61, DOI 10.1016/j.ijoa.2009.06.003; Yentis SM, 2006, INT J OBSTET ANESTH, V15, P2, DOI 10.1016/j.ijoa.2005.06.010; Yentis SM, 2005, INT J OBSTET ANESTH, V14, pS1	17	16	16	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	DEC	2012	67	12					1356	1363		10.1111/anae.12034			8	Anesthesiology	Anesthesiology	033OI	WOS:000310807000011	23061397				2020-06-30	J	Killeen, T; Kamat, A; Walsh, D; Parker, A; Aliashkevich, A				Killeen, T.; Kamat, A.; Walsh, D.; Parker, A.; Aliashkevich, A.			Severe adhesive arachnoiditis resulting in progressive paraplegia following obstetric spinal anaesthesia: a case report and review	ANAESTHESIA			English	Article							EPIDURAL-ANESTHESIA; NEUROLOGICAL COMPLICATIONS; CAUDA-EQUINA; SYRINGOMYELIA; DEFICITS; BLOCK	A 27-year-old woman developed severe adhesive arachnoiditis after an obstetric spinal anaesthetic with bupivacaine and fentanyl, complicated by back pain and headache. No other precipitating cause could be identified. She presented one week postpartum with communicating hydrocephalus and syringomyelia and underwent ventriculoperitoneal shunting and foramen magnum decompression. Two months later, she developed rapid, progressive paraplegia and sphincter dysfunction. Attempted treatments included exploratory laminectomy, external drainage of the syrinx and intravenous steroids, but these were unsuccessful and the patient remains significantly disabled 21 months later. We discuss the pathophysiology of adhesive arachnoiditis following central neuraxial anaesthesia and possible causative factors, including contamination of the injectate, intrathecal blood and local anaesthetic neurotoxicity, with reference to other published cases. In the absence of more conclusive data, practitioners of central neuraxial anaesthesia can only continue to ensure meticulous, aseptic, atraumatic technique and avoid all potential sources of contamination. It seems appropriate to discuss with patients the possibility of delayed, permanent neurological deficit while taking informed consent.	[Killeen, T.; Kamat, A.; Parker, A.; Aliashkevich, A.] Wellington Reg Hosp, Dept Neurosurg, Wellington, New Zealand; [Walsh, D.] Wellington Reg Hosp, Dept Anaesthesia, Wellington, New Zealand	Killeen, T (reprint author), Wellington Reg Hosp, Dept Neurosurg, Wellington, New Zealand.	tim.killeen@doctors.org.uk		Killeen, Tim/0000-0001-8246-4957			Aldrete JA, 2003, ACTA ANAESTH SCAND, V47, P3, DOI 10.1034/j.1399-6576.2003.470102.x; Aldrete JA, 1997, ANESTH ANALG, V84, P233, DOI 10.1097/00000539-199701000-00059; Aromaa U, 1997, ACTA ANAESTH SCAND, V41, P445, DOI 10.1111/j.1399-6576.1997.tb04722.x; Bogod D., 2010, ANAESTHESIA NEWS, V271, P7; BOURNE IHJ, 1990, J ROY SOC MED, V83, P262; BURTON C V, 1978, Spine, V3, P24, DOI 10.1097/00007632-197803000-00006; CAPLAN LR, 1990, J NEUROL NEUROSUR PS, V53, P106, DOI 10.1136/jnnp.53.2.106; Checketts MR, 2012, ANAESTHESIA, V67, P819, DOI 10.1111/j.1365-2044.2012.07263.x; Christie I, 2009, REPORT FINDINGS 3 NA, P71; Cook TM, 2009, BRIT J ANAESTH, V103, P456; COPE R W, 1954, Anaesthesia, V9, P249, DOI 10.1111/j.1365-2044.1954.tb01922.x; DAHLGREN N, 1995, ACTA ANAESTH SCAND, V39, P872, DOI 10.1111/j.1399-6576.1995.tb04190.x; Daily Med Plus, PRESCR MON CHLOR MAX; DENSON JS, 1957, ANESTHESIOLOGY, V18, P143; DOLAN RA, 1993, SURG NEUROL, V39, P479, DOI 10.1016/0090-3019(93)90035-Y; Fischer B, 2009, REPORT FINDINGS 3 NA, P77; GEMMA M, 1994, ACTA ANAESTH SCAND, V38, P742, DOI 10.1111/j.1399-6576.1994.tb03988.x; Gozdemir M, 2009, ACTA ANAESTHESIOLOGI, V54, P59; GUYER DW, 1989, SPINE, V14, P1332, DOI 10.1097/00007632-198912000-00010; Haisa Toshihiko, 1995, Neurologia Medico-Chirurgica, V35, P107, DOI 10.2176/nmc.35.107; HAUGHTON VM, 1993, SPINE, V18, P1193, DOI 10.1097/00007632-199307000-00012; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Hirai T, 2012, SPINE, V37, pE195, DOI 10.1097/BRS.0b013e31822ba817; HOLDCROFT A, 1995, BRIT J ANAESTH, V75, P522, DOI 10.1093/bja/75.5.522; HUTTER CDD, 1990, ANAESTHESIA, V45, P859, DOI 10.1111/j.1365-2044.1990.tb14573.x; KANE RE, 1981, ANESTH ANALG, V60, P150; Kim H, 2008, KOREAN J PAIN, V21, P259; Kitsou MC, 2011, CARDIOVASC INTER RAD, V34, P1288, DOI 10.1007/s00270-011-0159-1; Klekamp J, 1997, J NEUROSURG, V86, P233, DOI 10.3171/jns.1997.86.2.0233; Koerts G, 2008, CLIN NEUROL NEUROSUR, V110, P171, DOI 10.1016/j.clineuro.2007.09.004; Kok AJM, 2000, ACTA NEUROCHIR, V142, P795, DOI 10.1007/s007010070094; Koyanagi I, 2005, SURG NEUROL, V63, P350, DOI 10.1016/j.surneu.2004.05.038; LAMBERT LA, 1994, ANESTHESIOLOGY, V80, P1082, DOI 10.1097/00000542-199405000-00017; Miaki K, 1999, EUR SPINE J, V8, P310, DOI 10.1007/s005860050179; Miller A, 2011, DEFENCE UPDATE   WIN, P14; NGUYEN C, 1991, INVEST RADIOL, V26, P745, DOI 10.1097/00004424-199108000-00010; Petty PG, 2000, J CLIN NEUROSCI, V7, P395, DOI 10.1054/jocn.1999.0223; Quiles M, 1978, SPINE, V3, P45; Rice I, 2004, BRIT J ANAESTH, V92, P109, DOI 10.1093/bja/aeh009; ROSS JS, 1987, AM J ROENTGENOL, V149, P1025, DOI 10.2214/ajr.149.5.1025; SCOTT DB, 1990, BRIT J ANAESTH, V64, P537, DOI 10.1093/bja/64.5.537; SGHIRLANZONI A, 1989, ANAESTHESIA, V44, P317, DOI 10.1111/j.1365-2044.1989.tb11285.x; SMITH RA, 1962, ANESTHESIOLOGY, V23, P5, DOI 10.1097/00000542-196201000-00002; Talbot L, 2004, BRIT J ANAESTH, V92, P902, DOI 10.1093/bja/aeh566; Tatara N, 1992, No To Shinkei, V44, P1115; Tseng SH, 1997, CLIN NEUROL NEUROSUR, V99, P256, DOI 10.1016/S0303-8467(97)00086-3; WINKELMAN NW, 1952, NEUROLOGY, V2, P284, DOI 10.1212/WNL.2.7-8.284	47	42	45	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	DEC	2012	67	12					1386	1394		10.1111/anae.12017			9	Anesthesiology	Anesthesiology	033OI	WOS:000310807000015	23061983				2020-06-30	J	Wedmore, IS; Kotwal, RS; McManus, JG; Pennardt, A; Talbot, TS; Fowler, M; McGhee, L				Wedmore, Ian S.; Kotwal, Russ S.; McManus, John G.; Pennardt, Andre; Talbot, Timothy S.; Fowler, Marcie; McGhee, Laura			Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Acute pain; prehospital analgesia; battlefield; oral transmucosal fentanyl citrate; pain management	BREAKTHROUGH CANCER PAIN; COMBAT CASUALTY CARE; RANDOMIZED CLINICAL-TRIAL; INTRAVENOUS MORPHINE; EMERGENCY-MEDICINE; OPEN-LABEL; POSTOPERATIVE PAIN; LACERATION REPAIR; CASE SERIES; MANAGEMENT	BACKGROUND: Acute pain, resulting from trauma and other causes, is a common condition that imposes a need for prehospital analgesia on and off the battlefield. The narcotic most frequently used for prehospital analgesia on the battlefield during the past century has been morphine. Intramuscular morphine has a delayed onset of pain relief that is suboptimal and difficult to titrate. Although intravenously administered morphine can readily provide rapid and effective prehospital analgesia, oral transmucosal fentanyl citrate (OTFC) is a safe alternative that does not require intravenous access. This study evaluates the safety and efficacy of OTFC in the prehospital battlefield environment. METHODS: Data collected during combat deployments (Afghanistan and Iraq) from March 15, 2003, to March 31, 2010, were analyzed. Patients were US Army Special Operations Command casualties. Patients receiving OTFC for acute pain were evaluated. Pretreatment and posttreatment pain intensities were quantified by the verbal numeric rating scale (NRS) from 0 to 10. OTFC adverse effects and injuries treated were also evaluated. RESULTS: A total of 286 patients were administered OTFC, of whom 197 had NRS pain evaluations conducted before and approximately 15 minutes to 30 minutes following treatment. The difference between NRS pain scores at 0 minutes (NRS, 8.0 [1.4]) and 15 minutes to 30 minutes (NRS, 3.2 [2.1]) was significant (p < 0.001). Only 18.3% (36 of 197) of patients were also administered other types of analgesics. Nausea was the most common adverse effect as reported by 12.7% (25 of 197) of patients. The only major adverse effect occurred in the patient who received the largest opioid dose, 3,200-mu g OTFC and 20-mg morphine. This patient exhibited hypoventilation and saturation of less than 90% requiring low-dose naloxone. CONCLUSION: OTFC is a rapid and noninvasive pain management strategy that provides safe and effective analgesia in the prehospital battlefield setting. OTFC has considerable implications for use in civilian prehospital and austere environments. (J Trauma Acute Care Surg. 2012;73: S490-S495. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Kotwal, Russ S.; Pennardt, Andre; Talbot, Timothy S.] USA, Special Operat Command, Ft Bragg, NC 28310 USA; [Wedmore, Ian S.] Joint Base Lewis McChord, Madigan Army Med Ctr, Washington, DC USA; [McManus, John G.] Army Med Dept Ctr & Sch, Emergency Med Serv, Ft Sam Houston, TX USA; [Fowler, Marcie; McGhee, Laura] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA	Kotwal, RS (reprint author), USA, Special Operat Command, 2929 Desert Storm Dr, Ft Bragg, NC 28310 USA.	russ.kotwal@us.army.mil					ASHBURN MA, 1993, ANESTH ANALG, V76, P377; ASHBURN MA, 1990, CAN J ANAESTH, V37, P857, DOI 10.1007/BF03006621; BEECHER HK, 1946, ANN SURG, V123, P96, DOI 10.1097/00000658-194601000-00008; Bredahl Claus, 2005, Ugeskr Laeger, V167, P2289; Buckenmaier CC, 2009, PAIN MED, V10, P1487, DOI 10.1111/j.1526-4637.2009.00731.x; Butler FK, 1996, MIL MED, V161, P3; Butler FK, 2007, MIL MED, V172, P1; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Curtis KM, 2007, J TRAUMA, V63, P819, DOI 10.1097/01.ta.0000240979.31046.98; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Eastridge Brian J, 2011, US Army Med Dep J, P11; FELD LH, 1989, ANESTHESIOLOGY, V71, P374, DOI 10.1097/00000542-198909000-00010; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; GERWELS JW, 1994, J DERMATOL SURG ONC, V20, P823, DOI 10.1111/j.1524-4725.1994.tb03712.x; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Hennes H, 2006, CLIN PEDIATR EMERG M, V7, P25, DOI 10.1016/j.cpem.2006.01.008; Hillier RJ, 2009, RETINA-J RET VIT DIS, V29, P1506, DOI 10.1097/IAE.0b013e3181ae70d4; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; Kotwal Russ S, 2011, US Army Med Dep J, P15; Landy SH, 2004, HEADACHE, V44, P762, DOI 10.1111/j.1526-4610.2004.04142.x; Lewis RJ, 2002, JAMA-J AM MED ASSOC, V291, P1382; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; LIND GH, 1991, ANN EMERG MED, V20, P1117, DOI 10.1016/S0196-0644(05)81387-3; Macaluso AD, 1996, ANESTH ANALG, V82, P158, DOI 10.1097/00000539-199601000-00029; MacIntyre P A, 2007, J Wound Care, V16, P118; Mahar PJ, 2007, PEDIATR EMERG CARE, V23, P544, DOI 10.1097/PEC.0b013e318128f80b; McManus JG, 2005, EMERG MED CLIN N AM, V23, P415, DOI 10.1016/j.emc.2004.12.009; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Miner JR, 2007, ACAD EMERG MED, V14, P895, DOI 10.1197/j.aem.2007.06.036; National Association of Emergency Medical Technicians, 2011, PREHOSP TRAUM LIF SU; Proudfoot Jeffrey, 1995, Emergency Medicine Clinics of North America, V13, P357; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; Sayre MR, 2002, PREHOSP EMERG CAR S3, V6, P1; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; Schutzman SA, 1996, ANN EMERG MED, V28, P385, DOI 10.1016/S0196-0644(96)70001-X; Shah H, 2009, BURNS, V35, P798, DOI 10.1016/j.burns.2008.09.014; Singer AJ, 2008, ANN EMERG MED, V52, P689, DOI 10.1016/j.annemergmed.2008.04.017; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Wedmore IS, 2005, EMERG MED CLIN N AM, V23, P585, DOI 10.1016/j.emc.2004.12.017; Zarth R, 2007, SCHMERZ, V21, P545, DOI 10.1007/s00482-007-0590-z	50	27	27	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2012	73			5			S490	S495		10.1097/TA.0b013e3182754674			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	056QT	WOS:000312506900019	23192075				2020-06-30	J	Yu, J; Lu, Y; Dong, C; Zhu, H; Xu, R				Yu, J.; Lu, Y.; Dong, C.; Zhu, H.; Xu, R.			Premedication with intravenous dexmedetomidine-midazolam suppresses fentanyl-induced cough	IRISH JOURNAL OF MEDICAL SCIENCE			English	Article						Anesthesia induction; Dexmedetomidine; Midazolam; Fentanyl-induced cough	PROLONGED INJECTION TIME; SMOOTH-MUSCLE; DOUBLE-BLIND; ANESTHESIA; INDUCTION; PROPOFOL; LIDOCAINE; KETAMINE	The incidence of fentanyl-induced cough (FIC) occurs frequently during induction of general anesthesia, and methods to prevent it are needed. In this study, we hypothesized that premedication with intravenous dexmedetomidine-midazolam can suppress FIC effectively. A total of 440 patients of ASA I or II, aged 18-65 years, weighing 41-90 kg, undergoing elective surgery were randomized into four groups of 110 each, using computer-generated random numbers. Group S + S: normal saline 0.15 ml/kg + normal saline 0.06 ml/kg; Group S + M: normal saline 0.15 ml/kg + midazolam 0.06 mg/kg; Group D + S: dexmedetomidine 0.6 mu g/kg + normal saline 0.06 ml/kg; Group D + M: dexmedetomidine 0.6 mu g/kg + midazolam 0.06 mg/kg. After receiving the above-mentioned drugs, all patients received i.v. fentanyl (3 mu g/kg). After fentanyl administration, the onset time and the severity of cough for 1 min were recorded. Severity of coughing was graded as mild (1-2), moderate (3-5) and (> 5) based on the number of cough per minute. Forty-five (40.9%) patients had cough in Group S + S, 70 (63.6%) in Group S + M and 25 (22.7%) in Group D + S. None of the patients in Group D + M had any cough. The total incidence of cough was significantly higher (P < 0.01) in Group S + M in comparison to that in other groups. The onset time of cough was significantly shorter in Group S + M (13.8 +/- A 3.8 s) than in Group S + S (18.7 +/- A 3.9 s, P < 0.01) or Group D + S. (18.2 +/- A 3.2 s, P < 0.01). However, there was no significant difference among groups in cough severity. Pretreatment with dexmedetomidine-midazolam could completely suppress FIC caused by fentanyl 3 mu g/kg injection within 2 s.	[Yu, J.; Lu, Y.; Dong, C.; Zhu, H.; Xu, R.] Anhui Med Univ, Peoples Hosp Hefei 1, Dept Anaesthesiol, Hefei 230061, Peoples R China	Yu, J (reprint author), Anhui Med Univ, Peoples Hosp Hefei 1, Dept Anaesthesiol, Huaihe Rd 390, Hefei 230061, Peoples R China.	majuny163@163.com					Adachi YU, 2000, EUR J ANAESTH, V17, P126, DOI 10.1046/j.1365-2346.2000.00624.x; Agarwal A, 2007, ANAESTHESIA, V62, P1230, DOI 10.1111/j.1365-2044.2007.05249.x; Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ai Q, 2010, PHARMACOL REP, V62, P747, DOI 10.1016/S1734-1140(10)70333-9; Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Bailey PL, 1999, ANESTHESIOLOGY, V90, P335, DOI 10.1097/00000542-199901000-00067; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; Cheng EY, 1996, ANESTH ANALG, V83, P162, DOI 10.1097/00000539-199607000-00028; Groeben H, 2004, ANESTHESIOLOGY, V100, P359, DOI 10.1097/00000542-200402000-00026; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Hung KC, 2009, ACTA ANAESTH SCAND, V53, P1227, DOI 10.1111/j.1399-6576.2009.02027.x; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lin JA, 2007, J FORMOS MED ASSOC, V106, P649, DOI 10.1016/S0929-6646(08)60022-4; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; Sato T, 1998, ANESTH ANALG, V87, P1383, DOI 10.1097/00000539-199812000-00033; SCHEININ B, 1992, BRIT J ANAESTH, V68, P126, DOI 10.1093/bja/68.2.126; SHORT TG, 1991, BRIT J ANAESTH, V67, P539, DOI 10.1093/bja/67.5.539; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	24	18	22	0	5	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0021-1265			IRISH J MED SCI	Irish J. Med. Sci.	DEC	2012	181	4					517	520		10.1007/s11845-012-0807-8			4	Medicine, General & Internal	General & Internal Medicine	025XH	WOS:000310230000011	22373589				2020-06-30	J	Feng, XM; Mi, WL; Xia, F; Mao-Ying, QL; Jiang, JW; Xiao, S; Wang, ZF; Wang, YQ; Wu, GC				Feng, Xiao-Ming; Mi, Wen-Li; Xia, Fang; Mao-Ying, Qi-Liang; Jiang, Jian-Wei; Xiao, Sheng; Wang, Zhi-Fu; Wang, Yan-Qing; Wu, Gen-Cheng			Involvement of spinal orexin A in the electroacupuncture analgesia in a rat model of post-laparotomy pain	BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE			English	Article						Electroacupuncture analgesia; Orexin A; Post-laparotomy pain; OX1R; SB-334867	EXPERIMENTAL DENTAL PAIN; ACUPUNCTURE ANALGESIA; OPIOID RECEPTORS; HYPOCRETIN OREXIN; PHYSICAL-EXERCISE; HIGH-FREQUENCY; DORSAL-HORN; BRAIN; STIMULATION; NALOXONE	Background: Orexin A (OXA, hypocretin/hcrt 1) is a newly discovered potential analgesic substance. However, whether OXA is involved in acupuncture analgesia remains unknown. The present study was designed to investigate the involvement of spinal OXA in electroacupuncture (EA) analgesia. Methods: A modified rat model of post-laparotomy pain was adopted and evaluated. Von Frey filaments were used to measure mechanical allodynia of the hind paw and abdomen. EA at 2/15 Hz or 2/100 Hz was performed once on the bilateral ST36 and SP6 for 30 min perioperatively. SB-334867, a selective orexin 1 receptor (OX1R) antagonist with a higher affinity for OXA than OXB, was intrathecally injected to observe its effect on EA analgesia. Results: OXA at 0.3 nmol and EA at 2/15 Hz produced respective analgesic effects on the model (P<0.05). Pre-surgical intrathecal administered of SB-334867 30 nmol antagonized OXA analgesia and attenuated the analgesic effect of EA (P<0.05). However, SB-334867 did not block fentanyl-induced analgesia (P>0.05). In addition, naloxone, a selective opioid receptor antagonist, failed to antagonize OXA-induced analgesia (P>0.05). Conclusions: The results of the present study indicate the involvement of OXA in EA analgesia via OX1R in an opioid-independent way.	[Feng, Xiao-Ming; Mi, Wen-Li; Xia, Fang; Mao-Ying, Qi-Liang; Jiang, Jian-Wei; Xiao, Sheng; Wang, Zhi-Fu; Wang, Yan-Qing; Wu, Gen-Cheng] Fudan Univ, Dept Integrat Med & Neurobiol, Inst Acupuncture Res,Inst Brain Sci,Shanghai Med, WHO Collaborating Ctr Tradit Med,State Key Lab Me, Shanghai 20032, Peoples R China; [Feng, Xiao-Ming] Shanghai Inst Acupuncture Moxibust & Meridian, Shanghai 200030, Peoples R China	Wu, GC (reprint author), Fudan Univ, Dept Integrat Med & Neurobiol, Inst Acupuncture Res,Inst Brain Sci,Shanghai Med, WHO Collaborating Ctr Tradit Med,State Key Lab Me, Shanghai 20032, Peoples R China.	gcwu@shmu.edu.cn	Mi, Wenli/P-5541-2019; Wan, You/M-5279-2019		National Key Basic Research Program of ChinaNational Basic Research Program of China [2013CB531906, 2007CB512502]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31000495]	We would like to thank the National Key Basic Research Program of China (2013CB531906, 2007CB512502) and National Natural Science Foundation of China (31000495) for kindly providing the funding for this research.	Abramova T V, 2007, Pathophysiology, V14, P79, DOI 10.1016/j.pathophys.2007.05.003; Arihara Z, 2000, PEPTIDES, V21, P565, DOI 10.1016/S0196-9781(00)00184-4; Bartsch T, 2004, PAIN, V109, P367, DOI 10.1016/j.pain.2004.02.005; Bingham S, 2001, PAIN, V92, P81, DOI 10.1016/S0304-3959(00)00470-X; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Bucinskaite V, 1996, EUR J NEUROSCI, V8, P382, DOI 10.1111/j.1460-9568.1996.tb01221.x; BUCINSKAITE V, 1994, BRAIN RES, V666, P128, DOI 10.1016/0006-8993(94)90294-1; Callahan BL, 2008, J PAIN, V9, P174, DOI 10.1016/j.jpain.2007.10.011; CHAPMAN CR, 1983, PAIN, V16, P13; CHAPMAN CR, 1978, ANN ANESTHESIOL FR, V19, P427; CHEN XH, 1992, BEHAV BRAIN RES, V47, P143, DOI 10.1016/S0166-4328(05)80120-2; CHEN XH, 1992, EUR J PHARMACOL, V211, P203; Cheng JK, 2003, J PHARMACOL EXP THER, V307, P1065, DOI 10.1124/jpet.103.056663; CHENG RSS, 1979, LIFE SCI, V25, P1957, DOI 10.1016/0024-3205(79)90598-8; Chiou LC, 2010, CURR PHARM DESIGN, V16, P3089, DOI 10.2174/138161210793292483; Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Date Y, 2000, NEUROSCI LETT, V288, P87, DOI 10.1016/S0304-3940(00)01195-2; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dolan S, 2007, EUR J PAIN, V11, P644, DOI 10.1016/j.ejpain.2006.10.002; ERIKSSON SV, 1991, AM J CHINESE MED, V19, P1, DOI 10.1142/S0192415X91000028; ERNST M, 1987, ACUPUNCTURE ELECTRO, V12, P5, DOI 10.3727/036012987816358940; Feng P, 2008, J PSYCHOPHARMACOL, V22, P784, DOI 10.1177/0269881106082899; Feng PF, 2007, BRAIN RES, V1154, P163, DOI 10.1016/j.brainres.2007.03.077; Ferguson AV, 2003, FRONT NEUROENDOCRIN, V24, P141, DOI 10.1016/S0091-3022(03)00028-1; Guan JL, 2003, BRAIN RES, V987, P86, DOI 10.1016/S0006-8993(03)03257-8; Han J S, 1986, Sheng Li Xue Bao, V38, P475; Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; Han ZR, 1999, CHINESE LITERATURE, P100; Harris GC, 2006, TRENDS NEUROSCI, V29, P571, DOI 10.1016/j.tins.2006.08.002; Holmqvist T, 2002, FEBS LETT, V526, P11, DOI 10.1016/S0014-5793(02)03101-0; Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X; Huang C, 2002, BRAIN RES, V945, P20, DOI 10.1016/S0006-8993(02)02503-9; [姬广臣 Ji Guangchen], 2003, [针刺研究, Acupuncture Research], V28, P111; KITADE T, 1988, ACUPUNCTURE ELECTRO, V13, P87, DOI 10.3727/036012988816358705; Koo ST, 2002, PAIN, V99, P423, DOI 10.1016/S0304-3959(02)00164-1; LASCELLES BDX, 1995, PAIN, V62, P201, DOI 10.1016/0304-3959(94)00266-H; Lee I, 2007, PAIN, V133, P9, DOI 10.1016/j.pain.2007.01.035; Lei J, 2012, BRAIN RES BULL, V87, P564, DOI 10.1016/j.brainresbull.2011.11.003; Lim S, 2003, NEUROSCI LETT, V343, P49, DOI 10.1016/S0304-3940(03)00317-3; Lin L, 2002, PEPTIDES, V23, P2203, DOI 10.1016/S0196-9781(02)00251-6; Mobarakeh JI, 2005, PAIN, V118, P254, DOI 10.1016/j.pain.2005.08.024; Roughan JV, 2001, PAIN, V90, P65, DOI 10.1016/S0304-3959(00)00387-0; Sakurai T, 1998, CELL, V92, pU29; Sakurai Takeshi, 2006, CNS & Neurological Disorders-Drug Targets, V5, P313, DOI 10.2174/187152706777452218; van den Pol AN, 1999, J NEUROSCI, V19, P3171; Wang Y, 2005, EXP NEUROL, V192, P156, DOI 10.1016/j.expneurol.2004.11.003; Watanabe S, 2005, NEUROREPORT, V16, P5, DOI 10.1097/00001756-200501190-00002; Watson C., 2007, RAT BRAIN STEREOTAXI; Yamamoto T, 2002, BRIT J PHARMACOL, V137, P170, DOI 10.1038/sj.bjp.0704851; Yamamoto T, 2003, EUR J PHARMACOL, V481, P175, DOI 10.1016/j.ejphar.2003.09.022; Yamamoto T, 2003, NEUROSCI LETT, V347, P183, DOI 10.1016/S0304-3940(03)00716-X; Yoshida Y, 2003, NEUROSCI LETT, V346, P182, DOI 10.1016/S0304-3940(03)00571-8; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	56	20	21	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1472-6882			BMC COMPLEM ALTERN M	BMC Complement. Altern. Med.	NOV 22	2012	12								225	10.1186/1472-6882-12-225			10	Integrative & Complementary Medicine	Integrative & Complementary Medicine	092CC	WOS:000315095400001	23173601	DOAJ Gold, Green Published			2020-06-30	J	Ho, WM; Yen, CM; Lan, CH; Lin, CY; Yong, SB; Hwang, KL; Chou, MC				Ho, Wai-Meng; Yen, Chia-Ming; Lan, Chin-Hung; Lin, Chung-Yi; Yong, Su-Boon; Hwang, Kai-Lin; Chou, Ming-Chih			Comparison between the recovery time of alfentanil and fentanyl in balanced propofol sedation for gastrointestinal and colonoscopy: a prospective, randomized study	BMC GASTROENTEROLOGY			English	Article						Balanced propofol sedation; Alfentanil; Fentanyl; Deep sedation; Diagnostic endoscopy; Cost benefit	DEPARTMENT PROCEDURAL SEDATION; LOW-DOSE PROPOFOL; OUTPATIENT COLONOSCOPY; ENDOSCOPY; MEPERIDINE; ANALGESIA; MIDAZOLAM; UTILITY; SAFETY; OXYGEN	Background: There is increasing interest in balanced propofol sedation (BPS) titrated to moderate sedation (conscious sedation) for endoscopic procedures. However, few controlled studies on BPS targeted to deep sedation for diagnostic endoscopy were found. Alfentanil, a rapid and short-acting synthetic analog of fentanyl, appears to offer clinically significant advantages over fentanyl during outpatient anesthesia. It is reasonable to hypothesize that low dose of alfentanil used in BPS might also result in more rapid recovery as compared with fentanyl. Methods: A prospective, randomized and double-blinded clinical trial of alfentanil, midazolam and propofol versus fentanyl, midazolam and propofol in 272 outpatients undergoing diagnostic esophagogastroduodenal endoscopy (EGD) and colonoscopy for health examination were enrolled. Randomization was achieved by using the computer-generated random sequence. Each combination regimen was titrated to deep sedation. The recovery time, patient satisfaction, safety and the efficacy and cost benefit between groups were compared. Results: 260 participants were analyzed, 129 in alfentanil group and 131 in fentanyl group. There is no significant difference in sex, age, body weight, BMI and ASA distribution between two groups. Also, there is no significant difference in recovery time, satisfaction score from patients, propofol consumption, awake time from sedation, and sedation-related cardiopulmonary complications between two groups. Though deep sedation was targeted, all cardiopulmonary complications were minor and transient (10.8%, 28/260). No serious adverse events including the use of flumazenil, assisted ventilation, permanent injury or death, and temporary or permanent interruption of procedure were found in both groups. However, fentanyl is New Taiwan Dollar (NT$) 103 (approximate US$ 4) cheaper than alfentanil, leading to a significant difference in total cost between two groups. Conclusions: This randomized, double-blinded clinical trial showed that there is no significant difference in the recovery time, satisfaction score from patients, propofol consumption, awake time from sedation, and sedation-related cardiopulmonary complications between the two most common sedation regimens for EGD and colonoscopy in our hospital. However, fentanyl is NT$ 103 (US$ 4) cheaper than alfentanil in each case.	[Ho, Wai-Meng; Chou, Ming-Chih] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan; [Ho, Wai-Meng; Yen, Chia-Ming] Buddhist Tzu Chi Gen Hosp, Taichung Branch, Dept Anesthesiol, Taichung 427, Taiwan; [Ho, Wai-Meng] Tzu Chi Univ, Sch Med, Dept Anesthesiol, Hualien 970, Taiwan; [Lan, Chin-Hung] Buddhist Tzu Chi Gen Hosp, Dept Anesthesiol, Hualien 970, Taiwan; [Lin, Chung-Yi] Buddhist Tzu Chi Gen Hosp, Taichung Branch, Div Gastroenterol & Hepatol, Taichung 427, Taiwan; [Yong, Su-Boon] Show Chwan Mem Hosp, Dept Pediat, Changhua 500, Taiwan; [Hwang, Kai-Lin] Chung Shan Med Univ, Dept Publ Hlth, Taichung 402, Taiwan; [Chou, Ming-Chih] Chung Shan Med Univ Hosp, Dept Surg, Div Thorac Surg, Taichung 402, Taiwan	Chou, MC (reprint author), Chung Shan Med Univ, Inst Med, 110,Sec 1,Jianguo N Rd, Taichung 402, Taiwan.	9503013@gmail.com			Buddhist Tzu Chi General Hospital, Taichung Branch, Taichung, Taiwan	This study was supported by research funds from Buddhist Tzu Chi General Hospital, Taichung Branch, Taichung, Taiwan. The authors thank the patients who participated in this investigation. We especially thank the reviewers and also the editors for their helpful suggestions.	Agostoni M, 2011, GASTROINTEST ENDOSC, V74, P266, DOI 10.1016/j.gie.2011.04.028; Chan Y. H., 2003, SMJ Singapore Medical Journal, V44, P172; Clarke AC, 2002, MED J AUSTRALIA, V176, P158, DOI 10.5694/j.1326-5377.2002.tb04345.x; CODA BA, 2009, CLIN ANESTH, P465; Cohen LB, 2011, GASTROINTEST ENDOSC, V73, P215, DOI 10.1016/j.gie.2010.10.027; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; Deitch K, 2008, ANN EMERG MED, V52, P1, DOI 10.1016/j.annemergmed.2007.11.040; Deitch K, 2011, ANN EMERG MED, V58, P360, DOI 10.1016/j.annemergmed.2011.05.018; Fanti L, 2009, AM J GASTROENTEROL, V104, P1119, DOI 10.1038/ajg.2009.53; Froehlich F, 2006, ENDOSCOPY, V38, P461, DOI 10.1055/s-2006-925368; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; HOLLOWAY AM, 1990, ANAESTH INTENS CARE, V18, P210, DOI 10.1177/0310057X9001800209; Hsieh YH, 2011, J GASTROEN HEPATOL, V26, P1559, DOI 10.1111/j.1440-1746.2011.06786.x; Hsu CM, 2012, J GASTROEN HEPATOL, V27, P76, DOI 10.1111/j.1440-1746.2011.06795.x; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; Jung M, 2000, ENDOSCOPY, V32, P233, DOI 10.1055/s-2000-96; Lee CK, 2011, GASTROINTEST ENDOSC, V73, P206, DOI 10.1016/j.gie.2010.09.035; MILLIGAN KR, 1988, ANN ROY COLL SURG, V70, P304; Nelson DB, 2001, GASTROINTEST ENDOSC, V53, P876; Paspatis GA, 2011, COLORECTAL DIS, V13, pE137, DOI 10.1111/j.1463-1318.2011.02555.x; Radaelli F, 2008, AM J GASTROENTEROL, V103, P1122, DOI 10.1111/j.1572-0241.2007.01778.x; Regula J, 2008, BEST PRACT RES CL GA, V22, P945, DOI 10.1016/j.bpg.2008.06.002; Sipe BW, 2007, CLIN GASTROENTEROL H, V5, P563, DOI 10.1016/j.cgh.2007.01.013; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Sporea Ioan, 2005, Rom J Gastroenterol, V14, P195; Stanski D R, 1987, Eur J Anaesthesiol Suppl, V1, P3; Usta B, 2011, J CLIN GASTROENTEROL, V45, pE72, DOI 10.1097/MCG.0b013e318201fbce; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Wang A, 2010, DIGEST DIS SCI, V55, P2337, DOI 10.1007/s10620-010-1226-1; Wehrmann T, 1999, GASTROINTEST ENDOSC, V49, P677, DOI 10.1016/S0016-5107(99)70281-6; WHITE PF, 1986, ANESTHESIOLOGY, V64, P99, DOI 10.1097/00000542-198601000-00018	33	18	18	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-230X		BMC GASTROENTEROL	BMC Gastroenterol.	NOV 21	2012	12								164	10.1186/1471-230X-12-164			10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	117RV	WOS:000316971700001	23170921	DOAJ Gold, Green Published			2020-06-30	J	Pang, GSY; Ithnin, F; Wong, YY; Wang, JB; Lim, Y; Tiong, A; Sia, H; Lee, CGL				Pang, Grace Su Yin; Ithnin, Farida; Wong, Yin Yee; Wang, Jing Bo; Lim, Yvonne; Tiong, Alex; Sia, Heng; Lee, Caroline Guat Lay			A Non-Synonymous Single Nucleotide Polymorphism in an OPRM1 Splice Variant Is Associated with Fentanyl-Induced Emesis in Women Undergoing Minor Gynaecological Surgery	PLOS ONE			English	Article							OPIOID RECEPTOR GENE; POSTOPERATIVE NAUSEA; RISK-FACTORS; MORPHINE CONSUMPTION; IDENTIFICATION; ANALGESIA; PROPOFOL; EVENTS	Background: Fentanyl-induced emesis (FIE) is a distressing adverse effect in the postoperative setting. The genetic basis of FIE remains largely unknown, therefore, we examined whether it was associated with specific genetic variants of OPRM1, the gene encoding the main receptor target of fentanyl. Methods: In this prospective case-control study, 193 women undergoing gynaecological surgery under a standardized anaesthetic with a low emetogenic risk were enrolled. Inclusion and exclusion criteria were designed to select extreme phenotypes as well as to ensure that most major confounders for FIE were either excluded or present in all patients. To control for unforeseen intra-and postoperative confounders for FIE, only 161 patients were further analysed, out of which 10 were categorized as having FIE, defined by the presence of at least one of three symptoms: nausea, vomiting or retching that was likely to be fentanyl-related. To identify SNPs relevant to FIE in our population, DNA from 40 controls and 10 cases was sequenced at the following OPRM1 regions: 3 kbp of the promoter, main and alternative exons as well as 2 kbp of the 39 downstream region. The genotype of the significant SNP was further determined in the remaining 111 controls. Results: The incidence of FIE was 6.2%. Initial sequencing of 10 cases and 40 controls identified 25 SNPs. Only rs540825, a non-synonymous SNP in the splice variant, MOR1X, showed a significant association with FIE post-Bonferroni correction. This SNP was further examined in the remaining 111 controls which confirmed its significant association with FIE (p = 0.019 post-Bonferroni, OR: 5.6, 95% CI: 1.42-21.91). Conclusions: This is the first report of an association between the occurrence of FIE in Chinese women undergoing gynaecological surgery and an OPRM1 splice variant SNP, rs540825.	[Pang, Grace Su Yin; Wang, Jing Bo; Lee, Caroline Guat Lay] Natl Canc Ctr Singapore, Liver Canc Funct Genom Lab, Singapore, Singapore; [Pang, Grace Su Yin; Wong, Yin Yee] Natl Canc Ctr Singapore, Dept Palliat Med, Singapore, Singapore; [Pang, Grace Su Yin; Wang, Jing Bo; Lee, Caroline Guat Lay] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore; [Lee, Caroline Guat Lay] DUKE NUS Grad Med Sch, Singapore, Singapore; [Ithnin, Farida; Lim, Yvonne; Sia, Heng] KK Womens & Childrens Hosp, Dept Obstet Anaesthesia, Singapore, Singapore	Lee, CGL (reprint author), Natl Canc Ctr Singapore, Liver Canc Funct Genom Lab, Singapore, Singapore.	bchleec@nus.edu.sg	Lee, Caroline G/M-8918-2019	Lee, Caroline G/0000-0002-4323-3635	Academic Research Fund - Ministry of Education (MOE) [T206B3105]; Academic Research Fund through the National University of Singapore [R-183-000-172-112]; National Medical Research Council (NMRC), Singapore through the National Cancer Centre, Singapore [NMRC/0993/2005]; Singhealth Foundation Start Up Grant, Singapore; Singapore Millennium Foundation; NMRC Fellowship and Cancer Research Endowment Fund; National Cancer Centre Singapore through the National Cancer Centre; National Cancer Centre	This work was supported by grants from the Academic Research Fund - Ministry of Education Tier 2 (MOE T206B3105), the Academic Research Fund Tier 1 (R-183-000-172-112) to CL through the National University of Singapore; the National Medical Research Council (NMRC) (NMRC/0993/2005), Singapore to CL through the National Cancer Centre, Singapore; Singhealth Foundation Start Up Grant, Singapore, Singapore Millennium Foundation, NMRC Fellowship and Cancer Research Endowment Fund, National Cancer Centre Singapore to GP through the National Cancer Centre as well as Singapore Millennium Foundation and block funding to CL through the National Cancer Centre. The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript.	Aihara M, 2011, J DERMATOL, V38, P246, DOI 10.1111/j.1346-8138.2010.01196.x; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Chang TJ, 2011, PHARMACOGENET GENOM, V21, P829, DOI 10.1097/FPC.0b013e32834bfff1; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Daly AK, 2012, DRUG METAB REV, V44, P116, DOI 10.3109/03602532.2011.605790; Daly AK, 2010, NAT REV GENET, V11, P241, DOI 10.1038/nrg2751; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Fahmi S, 2008, HUM MOL GENET, V17, P2101, DOI 10.1093/hmg/ddn108; Freidlin B, 2002, HUM HERED, V53, P146, DOI 10.1159/000064976; Gan TJ, 2007, ANESTH ANALG, V105, P1615, DOI 10.1213/01.ane.0000295230.55439.f4; Garriock HA, 2010, AM J PSYCHIAT, V167, P565, DOI 10.1176/appi.ajp.2009.08081167; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Grimes DA, 2005, LANCET, V365, P1429, DOI 10.1016/S0140-6736(05)66379-9; Guey LT, 2011, GENET EPIDEMIOL; Huang RS, 2008, CANCER RES, V68, P3161, DOI 10.1158/0008-5472.CAN-07-6381; Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064; Johnston KD, 2010, ACTA ANAESTH SCAND, V54, P132, DOI 10.1111/j.1399-6576.2009.02115.x; Kaab S, 2011, CIRC CARDIOVASC GENE; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laugsand EA, 2011, EUR J CANCER, V47, P1682, DOI 10.1016/j.ejca.2011.04.014; Leslie K, 2008, BRIT J ANAESTH, V101, P498, DOI 10.1093/bja/aen230; Margas W, 2007, J NEUROPHYSIOL, V97, P1058, DOI 10.1152/jn.01007.2006; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; Nebert DW, 2000, EUR J PHARMACOL, V410, P107, DOI 10.1016/S0014-2999(00)00809-8; Nelson MR, 2009, PHARMACOGENOMICS J, V9, P23, DOI 10.1038/tpj.2008.4; Oderda GM, 2007, ANN PHARMACOTHER, V41, P400, DOI 10.1345/aph.1H386; Offit K, 2010, J CLIN ONCOL, V28, P4665, DOI 10.1200/JCO.2010.31.2926; Ono T, 2009, J BIOL CHEM, V284, P20175, DOI 10.1074/jbc.M109.019414; Pan YX, 2003, BIOCHEM BIOPH RES CO, V301, P1057, DOI 10.1016/S0006-291X(03)00089-5; Pan YX, 2005, MOL PHARMACOL, V68, P866, DOI 10.1124/mol.105.011858; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reichardt JKV, 2009, P NATL ACAD SCI USA, V106, DOI 10.1073/pnas.0903681106; Ross CJD, 2009, NAT GENET, V41, P1345, DOI 10.1038/ng.478; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; TAYLOR JW, 1977, AM J EPIDEMIOL, V106, P260, DOI 10.1093/oxfordjournals.aje.a112461; van Rijn RM, 2010, CURR OPIN PHARMACOL, V10, P73, DOI 10.1016/j.coph.2009.09.007; Vasileiou I, 2009, EUR J PHARMACOL, V605, P1, DOI 10.1016/j.ejphar.2009.01.007; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wilke RA, 2007, NAT REV DRUG DISCOV, V6, P904, DOI 10.1038/nrd2423; Zhang W, 2011, MINERVA ANESTESIOL, V77, P33	44	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e48416	10.1371/journal.pone.0048416			10	Multidisciplinary Sciences	Science & Technology - Other Topics	048TK	WOS:000311935800057	23144877	DOAJ Gold, Green Published			2020-06-30	J	Pinturaud, M; Pruvost, I; Leteurtre, S; Martinot, A; Gautier, S				Pinturaud, Marine; Pruvost, Isabelle; Leteurtre, Stephane; Martinot, Alain; Gautier, Sophie			Accidental Poisoning with Transdermal Fentanyl Patch in a 8 Months Old Infant	THERAPIE			French	Article						transdermal fentanyl patch; child poisoning	CHILD		[Pinturaud, Marine; Gautier, Sophie] CHRU Lille, Ctr Reg Pharmacovigilance, F-59045 Lille, France; [Pruvost, Isabelle; Leteurtre, Stephane; Martinot, Alain; Gautier, Sophie] Univ Lille Nord France, UDSL, Lille, France; [Pruvost, Isabelle; Martinot, Alain] CHRU Lille, Unite Pediat Gen Urgences & Malad Infect, F-59045 Lille, France; [Leteurtre, Stephane] CHRU Lille, Serv Reanimat Pediat, F-59045 Lille, France	Gautier, S (reprint author), CHRU Lille, Ctr Reg Pharmacovigilance, 1 Pl Verdun, F-59045 Lille, France.	sophie.gautier@chru-lille.fr	Martinot, Alain/M-6780-2016	Martinot, Alain/0000-0002-2146-8273			Behrman A, 2007, J EMERG NURS, V33, P290, DOI 10.1016/j.jen.2007.02.004; GRISSINGER M, 2009, P & T, V34, P343; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; McMorran M, 2009, CANADIAN REACTION NE, V19, P3; Meyer D, 2005, CLIN PEDIATR, V44, P499, DOI 10.1177/000992280504400605; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Vidal, 2011, MONOGRAPHIE DUROGESI; Woolf A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e4	8	3	3	0	1	EDP SCIENCES S A	LES ULIS CEDEX A	17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A, FRANCE	0040-5957			THERAPIE	Therapie	NOV-DEC	2012	67	6					545	546		10.2515/therapie/2012073			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	059VV	WOS:000312734500009	23249583				2020-06-30	J	Moshourab, R; Stein, C				Moshourab, Rabih; Stein, Christoph			Fentanyl decreases discharges of C and A nociceptors to suprathreshold mechanical stimulation in chronic inflammation	JOURNAL OF NEUROPHYSIOLOGY			English	Article						nociceptor; inflammation; opioids; peripheral	PRIMARY AFFERENT NEURONS; RECEPTOR MESSENGER-RNA; DORSAL-ROOT GANGLIA; MU-OPIOID RECEPTOR; PLANTAR RAT HINDPAW; HUMAN SKIN; PERIPHERAL INFLAMMATION; INFLAMED TISSUE; NERVE-FIBERS; SPINAL-CORD	Moshourab R, Stein C. Fentanyl decreases discharges of C and A nociceptors to suprathreshold mechanical stimulation in chronic inflammation. J Neurophysiol 108: 2827-2836, 2012. First published September 5, 2012; doi: 10.1152/jn.00082.2012.-An essential component of mechanical hyperalgesia resulting from tissue injury is an enhanced excitability of nociceptive neurons, termed mechanical sensitization. Local application of opioids to inflamed rat paws attenuates mechanical hyperalgesia and reduces electrical excitability of C-fiber nociceptors in acute injury. Here, we examined the effects of the opioid receptor agonist fentanyl on the mechanical coding properties of not only C-but also A-fiber nociceptors innervating the rat hind paw in a model of chronic pain, i.e., 4 days after Freund's complete adjuvant-induced inflammation. The peripheral mechanosensitive terminals of C-fibers (n = 143), A-fibers (n = 79), and low-threshold mechanoreceptors (n = 25) were characterized using the in vitro skin-nerve preparation from the saphenous nerve. Although mechanical activation thresholds were not changed, discharges to suprathreshold mechanical stimuli were elevated significantly in both A- and C-fiber nociceptors from inflamed tissue. In addition, the proportion of nociceptors as well as the frequency of spontaneous discharges in A (14% vs. 0%)- and C (28% vs. 8%)-fibers were increased in inflamed compared with normal tissue. Fentanyl inhibited responses to suprathreshold stimuli in a significantly higher proportion of not only C (36% vs. 7%)- but also A (41% vs. 8%)-fibers in inflamed tissue in a naloxone-reversible and concentration-dependent manner. Our results demonstrate that mechanical sensitization persists in chronic inflammation, in correlation with behavioral hyperalgesia. Opioid sensitivity of both A- and C-fibers is markedly augmented. This is consistent with an upregulation or enhanced functionality of opioid receptors located at the peripheral terminals of sensitized nociceptors.	[Moshourab, Rabih; Stein, Christoph] Free Univ Berlin, Charite Campus Benjamin Franklin, Dept Anesthesiol & Crit Care Med, D-12203 Berlin, Germany	Moshourab, R (reprint author), Free Univ Berlin, Charite Campus Benjamin Franklin, Dept Anesthesiol & Crit Care Med, Hindenburgdamm 30, D-12203 Berlin, Germany.	rabih.moshourab@charite.de		Stein, Christoph/0000-0001-5240-6836; moshourab, rabih/0000-0002-9180-8472	Forschungsforderung of the Charite-University Hospital	Support for this work was provided by the Forschungsforderung (research support) of the Charite-University Hospital to R. Moshourab.	ANDREEV N, 1994, NEUROSCIENCE, V58, P793, DOI 10.1016/0306-4522(94)90456-1; Andrew D, 1999, J NEUROPHYSIOL, V82, P2649; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Banik RK, 2008, PAIN, V138, P380, DOI 10.1016/j.pain.2008.01.017; BAUMANN TK, 1991, J NEUROPHYSIOL, V66, P212; Brack A, 2004, PAIN, V108, P67, DOI 10.1016/j.pain.2003.12.008; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Busch-Dienstfertig M, 2010, BRAIN BEHAV IMMUN, V24, P683, DOI 10.1016/j.bbi.2009.10.013; Buzas B, 1997, NEUROSCIENCE, V76, P479, DOI 10.1016/S0306-4522(96)00242-4; Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0; Djouhri L, 2006, J NEUROSCI, V26, P1281, DOI 10.1523/JNEUROSCI.3388-05.2006; Djouhri L, 2004, BRAIN RES REV, V46, P131, DOI 10.1016/j.brainresrev.2004.07.015; Du J, 2003, NEUROSCIENCE, V118, P547, DOI 10.1016/S0306-4522(03)00009-5; Fraser GL, 2000, BRIT J PHARMACOL, V129, P1668, DOI 10.1038/sj.bjp.0703248; Garell PC, 1996, J NEUROPHYSIOL, V75, P1177; Gebhart GF, 2000, ANN NY ACAD SCI, V909, P41; Gold MS, 2010, NAT MED, V16, P1248, DOI 10.1038/nm.2235; Grant GJ, 2001, ACTA ANAESTH SCAND, V45, P906, DOI 10.1034/j.1399-6576.2001.045007906.x; Hamalainen MM, 2002, J NEUROPHYSIOL, V87, P712, DOI 10.1152/jn.00207.2001; HANDWERKER HO, 1991, J PHYSIOL-LONDON, V435, P229, DOI 10.1113/jphysiol.1991.sp018507; HANDWERKER HO, 1987, ACTA PHYSIOL HUNG, V69, P333; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; IADAROLA MJ, 1988, PAIN, V35, P313, DOI 10.1016/0304-3959(88)90141-8; Jaffe RA, 1996, ANESTH ANALG, V83, P776, DOI 10.1097/00000539-199610000-00021; KOCHER L, 1987, PAIN, V29, P363, DOI 10.1016/0304-3959(87)90051-0; KRESS M, 1992, J NEUROPHYSIOL, V68, P581; Lechner SG, 2009, J PHYSIOL-LONDON, V587, P3493, DOI 10.1113/jphysiol.2009.175059; LEEM JW, 1993, J NEUROPHYSIOL, V69, P1684; Lewin GR, 2004, J NEUROBIOL, V61, P30, DOI 10.1002/neu.20078; Li JL, 1998, BRAIN RES, V794, P347, DOI 10.1016/S0006-8993(98)00332-1; LYNN B, 1982, BRAIN RES, V238, P29, DOI 10.1016/0006-8993(82)90768-5; MAEKAWA K, 1994, NEUROSCI LETT, V168, P97, DOI 10.1016/0304-3940(94)90425-1; Mantyh PW, 2006, NAT REV NEUROSCI, V7, P797, DOI 10.1038/nrn1914; MEYER RA, 1991, BRAIN RES, V561, P252, DOI 10.1016/0006-8993(91)91601-V; Milenkovic N, 2008, J NEUROPHYSIOL, V100, P2771, DOI 10.1152/jn.90799.2008; Mousa SA, 2002, J NEUROIMMUNOL, V126, P5, DOI 10.1016/S0165-5728(02)00049-8; Mousa SA, 2007, BRAIN, V130, P502, DOI 10.1093/brain/awl330; NEWBOULD BB, 1963, BRIT J PHARM CHEMOTH, V21, P127, DOI 10.1111/j.1476-5381.1963.tb01508.x; Olausson H, 2010, NEUROSCI BIOBEHAV R, V34, P185, DOI 10.1016/j.neubiorev.2008.09.011; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; Pogatzki EM, 2002, J NEUROPHYSIOL, V87, P721, DOI 10.1152/jn.00208.2001; Puehler W, 2006, NEUROSCIENCE, V141, P989, DOI 10.1016/j.neuroscience.2006.03.078; Puehler W, 2004, NEUROSCIENCE, V129, P473, DOI 10.1016/j.neuroscience.2004.06.086; REEH PW, 1987, EXP BRAIN RES, V65, P505; REEH PW, 1986, NEUROSCI LETT, V66, P141, DOI 10.1016/0304-3940(86)90180-1; Rittner HL, 2009, BRAIN BEHAV IMMUN, V23, P548, DOI 10.1016/j.bbi.2009.02.007; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Rukwied R, 2008, EUR J PAIN, V12, P242, DOI 10.1016/j.ejpain.2007.05.007; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Schaible HG, 2009, EXP BRAIN RES, V196, P153, DOI 10.1007/s00221-009-1782-9; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Schmelz M, 2000, BRAIN, V123, P560, DOI 10.1093/brain/123.3.560; SCHMELZ M, 1994, J PHYSIOL-LONDON, V480, P389, DOI 10.1113/jphysiol.1994.sp020368; SCHMIDT R, 1995, J NEUROSCI, V15, P333; Schmidt R, 2000, NEUROSCIENCE, V98, P793, DOI 10.1016/S0306-4522(00)00189-5; SENAMI M, 1986, PAIN, V27, P81, DOI 10.1016/0304-3959(86)90225-3; Silbert SC, 2003, J NEUROSCI, V23, P34; Slugg RM, 2000, J NEUROPHYSIOL, V83, P2179; Steen KH, 1996, PAIN, V66, P163, DOI 10.1016/0304-3959(96)03034-5; STEEN KH, 1992, J NEUROSCI, V12, P86; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1988, PHARMACOL BIOCHEM BE, V31, P445, DOI 10.1016/0091-3057(88)90372-3; STEIN C, 1990, J NEUROSCI, V10, P1292; STEIN C, 1988, NEUROSCI LETT, V84, P225, DOI 10.1016/0304-3940(88)90412-0; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Treede RD, 1998, J NEUROPHYSIOL, V80, P1082; Wang H, 2001, J COMP NEUROL, V429, P590, DOI 10.1002/1096-9861(20010122)429:4<590::AID-CNE6>3.0.CO;2-V; Wang HB, 2010, P NATL ACAD SCI USA, V107, P13117, DOI 10.1073/pnas.1008382107; Wenk HN, 2006, J NEUROPHYSIOL, V95, P2083, DOI 10.1152/jn.00394.2005; Wilder-Smith Oliver Hamilton, 2010, J Pain Palliat Care Pharmacother, V24, P119, DOI 10.3109/15360281003706069; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xiao WH, 2007, ANESTHESIOLOGY, V107, P813, DOI 10.1097/01.anes.0000286983.33184.9c; YUGE O, 1985, ANESTH ANALG, V64, P667; Zimmermann K, 2009, NAT PROTOC, V4, P174, DOI 10.1038/nprot.2008.223	75	12	12	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	NOV	2012	108	10					2827	2836		10.1152/jn.00082.2012			10	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	039EK	WOS:000311226600016	22956796				2020-06-30	J	Moore, N; Darwish, M; Amores, X; Schneid, H				Moore, Nicholas; Darwish, Mona; Amores, Xavier; Schneid, Helene			A review of the pharmacokinetic profile of transmucosal fentanyl formulations	CURRENT MEDICAL RESEARCH AND OPINION			English	Review						Administration, mucosal; Analgesia; Analgesics, opioid; Breakthrough pain; Fentanyl; Pharmacokinetics	BUCCAL SOLUBLE FILM; MULTIPLE-DOSE PHARMACOKINETICS; HEALTHY ADULT VOLUNTEERS; PALLIATIVE CARE-UNIT; 1300 MU-G; BREAKTHROUGH PAIN; OPEN-LABEL; CANCER PAIN; RELATIVE BIOAVAILABILITY; INTRAVENOUS MORPHINE	Background and objectives: Breakthrough pain (BTP) is a transitory flare of moderate-to-severe pain that occurs in patients with stable, controlled persistent pain. Management of BTP episodes is difficult because frequency, time-to-peak intensity, and duration of episodes vary both within and between individuals. Formulations of fentanyl that use a buccal, sublingual, or nasal transmucosal route of administration have been developed for the treatment of BTP in opioid-tolerant patients with cancer. These formulations allow rapid passage into the bloodstream and avoid first-pass metabolism and, therefore, are more likely to match the time-course of BTP episodes than are oral formulations. The purposes of this analysis were to identify and review published data describing the pharmacokinetic properties of rapid-onset fentanyl formulations and to evaluate these properties in view of the temporal dynamic characteristics of BTP in order to help guide medical practice. Methods: Relevant publications were searched in the PubMed database from 1998. The plasma drug concentration-time profile of each formulation obtained from the identified studies was adjusted to a consistent scale for comparison. Results: The data revealed that the various transmucosal formulations resulted in three typical plasma fentanyl concentration profiles: (1) type 1: a very rapid rise and short duration; (2) type 2: a rapid increase and sustained intensity; and (3) type 3: a slower onset and longer duration. Conclusions: Given the substantial variability of BTP episodes experienced by patients, these pharmacokinetic differences may provide useful information for a physician who is selecting a rapid-onset opioid medication for a patient.	[Moore, Nicholas] Univ Bordeaux 2, Dept Pharmacol, F-33076 Bordeaux, France; [Moore, Nicholas] INSERM, U657, Bordeaux, France; [Darwish, Mona; Amores, Xavier; Schneid, Helene] Cephalon Europe, Maisons Alfort, France	Moore, N (reprint author), Univ Bordeaux 2, Dept Pharmacol, Case 41,146 Rue Leo Saignat, F-33076 Bordeaux, France.	nicholas.moore@pharmaco.u-bordeaux2.fr			Teva Pharmaceuticals	Funding for this manuscript was provided by Cephalon France, now a wholly owned subsidiary of Teva Pharmaceuticals.	Archimedes Pharma UK Ltd, 2010, PECFENT SUMM PROD CH; BENNETT D, 2005, [No title captured], V30, P296; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Cephalon Ltd, 2010, EFF SUMM PROD CHAR; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2008, ARCH DRUG INF, V1, P50; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Darwish M, 2010, CLIN DRUG INVEST, V30, P365, DOI 10.2165/11533360-000000000-00000; Davies AN., 2011, BR J NURS, V20, P6; Davies A, 2011, CLIN DRUG INVEST, V31, P317, DOI 10.2165/11533540-000000000-00000; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies Andrew N, 2011, Br J Nurs, V20, P803; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Finn AL, 2012, CLIN DRUG INVEST, V32, P63, DOI 10.2165/11594670-000000000-00000; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Flynn Pharma Itd. Actig Summary of Product Characteristics, 2010, ACT SUMM PROD CHAR; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Meda Pharmaceuticals Inc, 2010, ONS SUMM PROD CHAR; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Nycomed Ltd, 2010, INST SUMM PROD CHAR; Pather SI, 2001, DRUG DELIV TECHNOL, V1, P53; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5; ProStrakan. Abstral Surnmary of Product Characteristics, 2011, ABSTR SUMM PROD CHAR; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Therapeutics Insys Inc., 2012, SUBS SUMM PROD CHAR; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658	55	12	13	0	15	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	NOV	2012	28	11					1781	1790		10.1185/03007995.2012.735227			10	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	035XE	WOS:000310985600005	23020252				2020-06-30	J	Choudhury, M; Malik, M; Singh, P; Kiran, U				Choudhury, Minati; Malik, Madhur; Singh, Pooja; Kiran, Usha			Anesthesia for an infant with Beckwith-Wiedman syndrome who underwent open heart surgery for complete atrioventricular canal defect	PEDIATRIC ANESTHESIA			English	Letter							CARDIOPULMONARY BYPASS		[Choudhury, Minati; Malik, Madhur; Singh, Pooja; Kiran, Usha] All India Inst Med Sci, Dept Cardiac Anaesthesia, Cardiothorac Sci Ctr, New Delhi, India	Choudhury, M (reprint author), All India Inst Med Sci, Dept Cardiac Anaesthesia, Cardiothorac Sci Ctr, New Delhi, India.	minatichoudhury2002@yahoo.co.in					Atkins BZ, 2010, INTERACT CARDIOV TH, V11, P599, DOI 10.1510/icvts.2010.234344; Kaw R, 2012, CHEST, V141, P436, DOI 10.1378/chest.11-0283; Kotoku Rumiko, 2002, Masui, V51, P46; Singh G, 2011, J CARDIOTHOR VASC AN, V25, P203, DOI 10.1053/j.jvca.2009.11.014; Su XWW, 2010, ARTIF ORGANS, V34, pE91, DOI 10.1111/j.1525-1594.2009.00963.x	5	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2012	22	11					1139	1140		10.1111/j.1460-9592.2012.03926.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	033MW	WOS:000310802400017	25631696				2020-06-30	J	Riches, JR; Read, RW; Black, RM; Cooper, NJ; Timperley, CM				Riches, James R.; Read, Robert W.; Black, Robin M.; Cooper, Nicholas J.; Timperley, Christopher M.			Analysis of Clothing and Urine from Moscow Theatre Siege Casualties Reveals Carfentanil and Remifentanil Use	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							TANDEM MASS-SPECTROMETRY; OPIOID RECEPTORS; HUMAN PLASMA; FENTANYL; ANALGESICS; DRUGS; QUANTIFICATION; METABOLISM; EXTRACTION	On October 26, 2002, Russian Special Forces deployed a chemical aerosol against Chechen terrorists to rescue hostages in the Dubrovka theatre. Its use confirmed Russian military interest in chemicals with effects on personnel and caused 125 deaths through a combination of the aerosol and inadequate medical care. This study provides evidence from liquid chromatographytandem mass spectrometry analysis of extracts of clothing from two British survivors, and urine from a third survivor, that the aerosol comprised a mixture of two anaestheticscarfentanil and remifentanilwhose relative proportions this study was unable to identify. Carfentanil and remifentanil were found on a shirt sample and a metabolite called norcarfentanil was found in a urine sample. This metabolite probably originated from carfentanil.	[Riches, James R.; Read, Robert W.; Black, Robin M.; Cooper, Nicholas J.; Timperley, Christopher M.] Dstl, Detect Dept, Salisbury SP4 0JQ, Wilts, England	Timperley, CM (reprint author), Dstl, Detect Dept, Salisbury SP4 0JQ, Wilts, England.	cmtimperley@dstl.gov.uk			UK Ministry of Defence (MoD)	We are grateful to the UK Ministry of Defence (MoD) for funding this study. (c) Crown Copyright 2012. Published with permission of the Defence Science and Technology Laboratory on behalf of the Controller of Her Majesty's Stationary Office.	Antonov N. S., 1994, CHEM WEAPONS TURN CE; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Crowley M., 2009, DANGEROUS AMBIGUITIE, P76; Dosen-Micovic L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI 10.1016/j.bmc.2005.12.010; Drdla-Schutting R, 2012, SCIENCE, V335, P235, DOI 10.1126/science.1211726; Dukhovich FS, 2005, CHEM BIODIVERS, V2, P354, DOI 10.1002/cbdv.200590015; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Godunov A. V., 2007, FORENSIC SCI INT S, V169S, pS29; Janssen A. J., 1964, US Patent, Patent No. [3,141,823, 3141823]; Janssen P.A.J., 1964, NEWS B          1030, Patent No. 3,141,823; Kuzmina NE, 2011, RUSS CHEM REV+, V80, P145, DOI 10.1070/RC2011v080n02ABEH004171; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Liang LL, 2011, J PHARMACEUT BIOMED, V54, P838, DOI 10.1016/j.jpba.2010.11.016; Navapurkar VU, 1998, BRIT J ANAESTH, V81, P881; New Scotland Yard (NSY), 2002, BRIT HOST DEBR REP; Panfilov A V, 2000, PHARM CHEM J, V34, P371; PANFILOV AV, 2000, [No title captured], V34, P76; Rieder J, 2003, LANCET, V361, P1131, DOI 10.1016/S0140-6736(03)12869-3; Said R, 2011, J CHROMATOGR B, V879, P815, DOI 10.1016/j.jchromb.2011.02.002; Schiermeier Q, 2002, NATURE, V420, P7, DOI 10.1038/420007a; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Zlobin V. A., 2000, PHARM CHEM J, V34, P279	29	82	85	4	51	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	NOV-DEC	2012	36	9					647	656		10.1093/jat/bks078			10	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	021ZI	WOS:000309924300008	23002178	Bronze, Green Published			2020-06-30	J	MacLeod, DB; Habib, AS; Ikeda, K; Spyker, DA; Cassella, JV; Ho, KY; Gan, TJ				MacLeod, David B.; Habib, Ashraf S.; Ikeda, Keita; Spyker, Daniel A.; Cassella, James V.; Ho, Kok Yuen; Gan, Tong J.			Inhaled Fentanyl Aerosol in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics	ANESTHESIA AND ANALGESIA			English	Article							THERMALLY GENERATED AEROSOL; PULMONARY DRUG-DELIVERY; BREAKTHROUGH PAIN; THERAPEUTIC EFFECTIVENESS; SINGLE-BREATH; BUCCAL TABLET; BIOAVAILABILITY; MEDICATIONS; MORPHINE; OPIOIDS	BACKGROUND: Rapid delivery of potent opioid to the systemic circulation is an important feature for the effective treatment of acute and acute-on-chronic breakthrough pain. The delivery of different opioids by the pulmonary route has been inconsistent, usually resulting in low bioavailability of the drug. Staccato (R) Fentanyl for Inhalation is a handheld inhaler producing a single metered dose of aerosolized fentanyl during a single inspiration. The aerosol is of high purity (>= 98%) at a particle size (1 to 3.5 microns) shown to be best for pulmonary absorption. METHODS: We conducted the study in healthy volunteers in 2 stages. In the crossover stage, 10 subjects received IV fentanyl 25 mu g and inhaled fentanyl 25 mu g on separate occasions. The dose escalation stage was a multidose, randomized, double-blind, placebo-controlled, single-period dose escalation study of inhaled fentanyl (50 to 300 mu g). Serial blood sampling was performed over an 8-hour period after drug administration to determine the pharmacokinetic profile, and serial pupillometry was performed as a measure of pharmacodynamic effect. RESULTS: In the crossover stage the pharmacokinetic profiles of the inhaled and IV fentanyl showed similar peak arterial concentrations and areas under the curve. The time to maximum concentration was slightly shorter for the inhaled than IV fentanyl, 20.5 and 31.5 seconds, respectively. In the dose escalation stage the administration of repeated doses resulted in predictable, dose-dependent serum concentrations. CONCLUSIONS: This study has demonstrated that the pharmacokinetic profile of single doses of inhaled fentanyl is comparable to IV administration. (Anesth Analg 2012;115:1071-7)	[MacLeod, David B.; Habib, Ashraf S.; Ikeda, Keita; Gan, Tong J.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Ho, Kok Yuen] Raffles Hosp, Pain Management Ctr, Singapore, Singapore; [Spyker, Daniel A.; Cassella, James V.] Alexza Pharmaceut Inc, Mountain View, CA USA	MacLeod, DB (reprint author), Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA.	david.macleod@duke.edu	Habib, Ashraf/K-4889-2019	Habib, Ashraf/0000-0002-6980-1856	Alexza Pharmaceuticals, Inc., Mountain View, CA; Alexza Pharmaceuticals	This work was funded by Alexza Pharmaceuticals, Inc., Mountain View, CA.; Department of Anesthesiology received research funding from Alexza Pharmaceuticals.	Avram MJ, 2009, CLIN PHARMACOL THER, V85, P71, DOI 10.1038/clpt.2008.184; Avram MJ, 2007, DRUG METAB DISPOS, V35, P262, DOI 10.1124/dmd.106.010652; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Dershwitz M, 2000, ANESTHESIOLOGY, V93, P619, DOI 10.1097/00000542-200009000-00009; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; FARR SJ, 1995, THORAX, V50, P639, DOI 10.1136/thx.50.6.639; Farr SJ, 2006, ADV DRUG DELIVER REV, V58, P1076, DOI 10.1016/j.addr.2006.07.013; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P600, DOI 10.1046/j.1365-2125.2003.01893.x; Labiris NR, 2003, BRIT J CLIN PHARMACO, V56, P588, DOI 10.1046/j.1365-2125.2003.01892.x; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Myers DJ, 2011, FUTURE MED CHEM, V3, P1719, DOI [10.4155/FMC.11.122, 10.4155/fmc.11.122]; Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rabinowitz JD, 2004, J PHARMACOL EXP THER, V309, P769, DOI 10.1124/jpet.103.062893; Rabinowitz JD, 2006, J PHARM SCI-US, V95, P2438, DOI 10.1002/jps.20694; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Tansley B, 2008, J PAIN SYMPTOM MANAG, V9, P22; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2	25	26	26	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2012	115	5					1071	1077		10.1213/ANE.0b013e3182691898			7	Anesthesiology	Anesthesiology	032ZO	WOS:000310762100013	22984155				2020-06-30	J	Choi, HS; Kim, KO; Chun, HJ; Keum, B; Seo, YS; Kim, YS; Jeen, YT; Um, SH; Lee, HS; Kim, CD; Ryu, HS				Choi, Hyuk Soon; Kim, Kyoung-Oh; Chun, Hoon Jai; Keum, Bora; Seo, Yeon Seok; Kim, Yong Sik; Jeen, Yoon-Tae; Um, Soon Ho; Lee, Hong Sik; Kim, Chang Duck; Ryu, Ho Sang			The efficacy of transdermal fentanyl for pain relief after endoscopic submucosal dissection: A prospective, randomised controlled trial	DIGESTIVE AND LIVER DISEASE			English	Article						Endoscopic submucosal dissection; Fentanyl patch; Pain	CHRONIC NONCANCER PAIN; EARLY GASTRIC-CANCER; RELEASE ORAL MORPHINE; SAFETY; MANAGEMENT; NEOPLASMS; COST	Objective: Epigastric pain management following endoscopic submucosal dissection is an important consideration. This study aimed to investigate the utility and safety of fentanyl patches for pain relief after the procedure. Methods: Patients who were scheduled to undergo endoscopic submucosal dissection were prospectively randomised to either a transdermal fentanyl patch group or a placebo control group. An additional pethidine was intravenously administered when pain developed and a numerical rating scale was used to evaluate both pre- and post-procedural pain. Results: One hundred and ten patients were randomly assigned to receive either a 12 mcg/h fentanyl patch or a control patch on the night before the procedure. The fentanyl patch group had significantly lower pain scores immediately following the procedure (mean, 5.17 vs. 4.26, p = 0.030). Maximal pain scores during the first 24 h (5.43 vs. 4.46, p = 0.038) and pain scores on the day after the procedure (2.98 vs. 1.20, p<0.001) were also lower in the fentanyl patch group. In addition, the fentanyl patch group required a significantly lower dose of pethidine for pain management (24.54 vs. 11.25, p = 0.004). Conclusions: The application of a transdermal fentanyl patch is an effective, convenient, and safe method to control epigastric pain after endoscopic submucosal dissection. (C) 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.	[Choi, Hyuk Soon; Chun, Hoon Jai; Keum, Bora; Seo, Yeon Seok; Kim, Yong Sik; Jeen, Yoon-Tae; Um, Soon Ho; Lee, Hong Sik; Kim, Chang Duck; Ryu, Ho Sang] Korea Univ, Coll Med, Div Gastroenterol & Hepatol, Inst Digest Dis & Nutr,Dept Internal Med, Seoul 136705, South Korea; [Kim, Kyoung-Oh] Hallym Univ, Coll Med, Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea	Chun, HJ (reprint author), Korea Univ, Coll Med, Korea Univ Anam Hosp, Inst Digest Dis & Nutr,Dept Internal Med,Div Gast, 126-1 Anam Dong,5 Ga, Seoul 136705, South Korea.	drchunhj@chol.com		Choi, Hyuk Soon/0000-0002-4343-6950	Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A111182]; Korea University	Funding for this work was provided by the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111182) and Grant of Korea University.	Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Cachia Elaine, 2011, Curr Opin Support Palliat Care, V5, P15, DOI 10.1097/SPC.0b013e3283437a39; Caldwell JR, 2002, J PAIN SYMPTOM MANAG, V23, P278, DOI 10.1016/S0885-3924(02)00383-4; Chun HJ, 2011, WORLD J GASTROENTERO, V17, P2592, DOI 10.3748/wjg.v17.i21.2592; Chung IK, 2009, GASTROINTEST ENDOSC, V69, P1228, DOI 10.1016/j.gie.2008.09.027; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Fujishiro M, 2006, WORLD J GASTROENTERO, V12, P5108; Gotoda T, 2006, J GASTROENTEROL, V41, P929, DOI 10.1007/s00535-006-1954-3; Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; Kakushima N, 2008, WORLD J GASTROENTERO, V14, P2962, DOI 10.3748/wjg.14.2962; Kiriyama S, 2009, GASTRIC CANCER, V12, P142, DOI 10.1007/s10120-009-0514-y; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V31, P4; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; Takizawa K, 2008, ENDOSCOPY, V40, P179, DOI 10.1055/s-2007-995530; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003; Uesato M, 2010, GASTRIC CANCER, V13, P84, DOI 10.1007/s10120-009-0541-8	22	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1590-8658			DIGEST LIVER DIS	Dig. Liver Dis.	NOV	2012	44	11					925	929		10.1016/j.dld.2012.06.015			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	036HH	WOS:000311016500009	22824834				2020-06-30	J	Deschamps, JY; Gaulier, JM; Podevin, G; Cherel, Y; Ferry, N; Roux, FA				Deschamps, Jack-Yves; Gaulier, Jean-Michel; Podevin, Guillaume; Cherel, Yan; Ferry, Nicolas; Roux, Francoise A.			Fatal overdose after ingestion of a transdermal fentanyl patch in two non-human primates	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						fentanyl patch; opioids non human primate	TRANSMUCOSAL; DOGS	Case history and presentation Two non-human primates (Macaca fascicularis), weight 3.5 kg, enrolled in an experimental protocol received a 25 mu g hour-1 transdermal fentanyl patch for postoperative analgesia. The following day both animals were clinically normal, but after a new induction of anaesthesia with ketamine, they developed severe and prolonged respiratory distress, profound coma and myosis. Management and follow-up Attempted reversal with naloxone was ineffective. After several hours of ventilation, both primates eventually died, 7 and 15 hours after ketamine injection, respectively. In both cases, the patch was discovered in the animals cheek pouch. Subsequent fentanyl serum concentration measurements (8.29 and 14.80 mu g L-1) confirmed fentanyl overdose. Conclusions This report of two fatal intoxications in non-human primates secondary to ingestion of a transdermal fentanyl patch demonstrates that this method of analgesia is inappropriate for non-human primates, because of their tendency to chew almost anything they can reach.	[Deschamps, Jack-Yves] LUNAM Univ, Emergency & Crit Care Unit, ONIRIS, Nantes Atlantic Coll Vet Med Food Sci & Engn La C, F-44307 Nantes, France; [Gaulier, Jean-Michel] Univ Hosp, Dept Pharmacol & Toxicol, Limoges, France; [Podevin, Guillaume] Univ Hosp, Dept Pediat Surg, Angers, France; [Cherel, Yan] LUNAM Univ, Dept Pathol, Oniris, Nantes Atlantic Coll Vet Med Food Sci & Engn La C, F-44307 Nantes, France; [Ferry, Nicolas] CHU Hotel Dieu, INSERM UMR Biotherapies Hepat S948, Nantes, France; [Roux, Francoise A.] Alfort Sch Vet Med, Emergency & Crit Care Unit, Maisons Alfort, France	Deschamps, JY (reprint author), LUNAM Univ, Emergency & Crit Care Unit, ONIRIS, Nantes Atlantic Coll Vet Med Food Sci & Engn La C, BP 40706, F-44307 Nantes, France.	jack.deschamps@oniris-nantes.fr	, Gaulier/D-6510-2017	, Gaulier/0000-0003-1111-4671	AFM (Association Francaise contre les Myopathies)Association Francaise contre les Myopathies	This work was supported by grant from AFM (Association Francaise contre les Myopathies). We thank the staff of the Gene and Cellular Therapy Centre of Boisbonne at Nantes Veterinary School, France.	Dale E, 2009, BMJ CASE REP, P1454; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; HENDERSON GL, 1983, P W PHARMACOL SOC, V26, P287; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Moon JM, 2011, J EMERG MED, V40, P37, DOI 10.1016/j.jemermed.2007.10.075; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Reed F, 2011, VET ANAESTH ANALG, V38, P407, DOI 10.1111/j.1467-2995.2011.00628.x; Schmiedt CW, 2007, VET ANAESTH ANALG, V34, P70, DOI 10.1111/j.1467-2995.2006.00302.x; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; van Rijswijk R, 2006, J AM GERIATR SOC, V54, P1298, DOI 10.1111/j.1532-5415.2006.00832.x	12	7	7	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2012	39	6					653	656		10.1111/j.1467-2995.2012.00749.x			4	Veterinary Sciences	Veterinary Sciences	017TO	WOS:000309614100012	22789128				2020-06-30	J	Hakkinen, M; Launiainen, T; Vuori, E; Ojanpera, I				Hakkinen, Margareeta; Launiainen, Terhi; Vuori, Erkki; Ojanpera, Ilkka			Comparison of fatal poisonings by prescription opioids	FORENSIC SCIENCE INTERNATIONAL			English	Article						Opioids; Benzodiazepines; Poisoning; Post-mortem toxicology; Alcohol	DRUG-RELATED DEATHS; OVERDOSE DEATHS; MORTALITY; TRAMADOL; BLOOD; BENZODIAZEPINES; INTOXICATIONS; ALCOHOL; USERS	There is a rising trend of fatal poisonings due to medicinal opioids in several countries. The present study evaluates the drug and alcohol findings as well as the cause and manner of death in opioid-related postmortem cases in Finland from 2000 to 2008. During this period, fatal poisonings by prescription opioids (buprenorphine, codeine, dextropropoxyphene, fentanyl, methadone, oxycodone, tramadol) increased as a share of all drug poisonings from 9.5% to 32.4%, being 22.3% over the whole period. A detailed study including the most prevalent opioids was carried out for the age group of 14-44 years, which is the most susceptible age for drug abuse in Finland. Poisonings by the weak opioids, codeine and tramadol, were found to be associated with large, often suicidal overdoses resulting in high drug concentrations in blood. Methadone poisonings were associated with accidental overdoses with the drug concentration in blood remaining within a therapeutic range. The manner of death was accidental in 43%, 55% and 94% of cases in codeine, tramadol and methadone poisonings, respectively. The median concentration of codeine and the median codeine/morphine concentration ratio were higher in codeine poisonings (1.4 and 22.5 mg/l, respectively) than in other causes of death (0.09 and 5.9 mg/l, respectively). The median concentrations of tramadol and O-desmethyltramadol were higher in tramadol poisonings (5.3 and 0.8 mg/l, respectively) than in other causes of death (0.6 and 0.2 mg/l, respectively). In methadone poisonings, the median concentration of methadone (0.35 mg/l) was not different from that in other causes of death (0.30 mg/l). Sedative drugs and/or alcohol were very frequently found in fatal poisonings involving these prescription opioids. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Hakkinen, Margareeta; Launiainen, Terhi; Vuori, Erkki; Ojanpera, Ilkka] Univ Helsinki, Hjelt Inst, Dept Forens Med, FI-00014 Helsinki, Finland	Hakkinen, M (reprint author), Univ Helsinki, Hjelt Inst, Dept Forens Med, POB 40,Kytosuontie 11, FI-00014 Helsinki, Finland.	margareeta.hakkinen@helsinki.fi		Ojanpera, Ilkka/0000-0001-5790-1473	Finnish Foundation for Alcohol Studies	Margareeta Hakkinen received a research grant for this study from the Finnish Foundation for Alcohol Studies.	Baselt R.C., 2014, DISPOSITION TOXIC DR; Caplehorn JRM, 2002, AUST NZ J PUBL HEAL, V26, P358, DOI 10.1111/j.1467-842X.2002.tb00185.x; Clarkson JE, 2004, J FORENSIC SCI, V49, P1101; Druid H, 1997, J FORENSIC SCI, V42, P79; Druid H, 2007, FORENSIC SCI INT, V168, P223, DOI 10.1016/j.forsciint.2006.02.047; DRUMMER OH, 2001, FORENSIC PHARM DRUGS; EMCDDA, 2009, DRUG SIT FINL 2009; Evans JL, 2012, AM J EPIDEMIOL, V175, P302, DOI 10.1093/aje/kwr318; Gerostamoulos J, 1996, AM J FOREN MED PATH, V17, P327, DOI 10.1097/00000433-199612000-00011; Goeringer KE, 1997, J ANAL TOXICOL, V21, P529, DOI 10.1093/jat/21.7.529; Green TC, 2011, DRUG ALCOHOL DEPEN, V115, P221, DOI 10.1016/j.drugalcdep.2010.11.007; Hakkinen M, 2012, EUR J CLIN PHARMACOL, V68, P301, DOI 10.1007/s00228-011-1122-4; Hickman M, 2003, J URBAN HEALTH, V80, P274, DOI 10.1093/jurban/jtg030; Jones AW, 2012, J ANAL TOXICOL, V36, P12, DOI 10.1093/jat/bkr013; Jones AW, 2011, FORENSIC SCI INT, V206, P43, DOI 10.1016/j.forsciint.2010.06.015; Jung BF, 2005, CLIN PHARMACOL THER, V77, P324, DOI 10.1016/j.clpt.2004.10.013; Lai SH, 2006, FORENSIC SCI INT, V162, P80, DOI 10.1016/j.forsciint.2006.03.037; Launiainen T, 2009, INT J LEGAL MED, V123, P109, DOI 10.1007/s00414-008-0261-3; Lunetta P, 2007, INJURY PREV, V13, P282, DOI 10.1136/ip.2006.012922; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Pirnay S, 2004, ADDICTION, V99, P978, DOI 10.1111/j.1360-0443.2004.00790.x; Rintoul AC, 2011, INJURY PREV, V17, P254, DOI 10.1136/ip.2010.029611; Schifano F, 2005, HUM PSYCHOPHARM CLIN, V20, P343, DOI 10.1002/hup.698; Shields LBE, 2007, J FORENSIC SCI, V52, P1389, DOI 10.1111/j.1556-4029.2007.00565.x; Simonsen KW, 2011, FORENSIC SCI INT, V207, P170, DOI 10.1016/j.forsciint.2010.10.001; Tjaderborn M, 2007, FORENSIC SCI INT, V173, P107, DOI 10.1016/j.forsciint.2007.02.007; Tremeau F, 2008, AM J ADDICTION, V17, P187, DOI 10.1080/10550490802020160; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x; Zamparutti G, 2011, BRIT J CLIN PHARMACO, V72, P330, DOI 10.1111/j.1365-2125.2011.03908.x	29	61	62	2	51	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	OCT 10	2012	222	1-3					327	331		10.1016/j.forsciint.2012.07.011			5	Medicine, Legal	Legal Medicine	004OI	WOS:000308690600051	22884575				2020-06-30	J	Quintard, H; Tran-Marsalla, L; Esquirole, C; Ichai, C				Quintard, H.; Tran-Marsalla, L.; Esquirole, C.; Ichai, C.			Economic and clinical impact of a controlled sedation procedure in an intensive care unit	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						Sedation; Economic; Protocol; ICU; Cost	CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; DURATION; PROTOCOL; SCALE; PAIN	Objective. - Since the last consensus conducted by Sfar/SRLF, the use of protocol for sedation became the reference in our ICUs. Decrease in length of stay and length of mechanical ventilation with used of these protocols have been already described. We would like to investigate the economic impact associated. Study design. - Using the PMSI data, we studied retrospectively, the economic effect, one year before and one year after protocol implementation in our ICU. Method. - The economic evaluation compared the cost of sedation but also the cost of mechanical ventilation and length of stay in ICU. Results. - Characteristic and number of patients were equivalent during the two years. We described a significant decrease in length of mechanical ventilation (8.8 vs. 8.4; p < 0.05) but not in length of stay (11.4 vs. 11.7; NS) between the two periods. We described a decrease of sedation cost of 11 412 euros and a decrease of mechanical ventilation cost of 27 360 Euros between the two years. Conclusion. - We confirm in this study that use of sedation protocol in ICU is associated with a clinical impact but also with an economic effect. (C) 2012 Societe francaise d'anesthesie et de reanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.	[Quintard, H.; Tran-Marsalla, L.; Esquirole, C.; Ichai, C.] CHU Nice, Hop St Roch, F-06000 Nice, France	Quintard, H (reprint author), CHU Nice, Hop St Roch, 4 Rue Pierre Devoluy, F-06000 Nice, France.	quintard.h@chu-nice.fr					Brattebo G, 2002, BRIT MED J, V324, P1386, DOI 10.1136/bmj.324.7350.1386; Celis-Rodriguez E, 2007, Med Intensiva, V31, P428; Constantin JM, 2011, IMP C CONS 2007 PRAT; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; Dasta JF, 1996, J CLIN ANESTH, V8, pS99, DOI 10.1016/S0952-8180(96)90022-7; De Jonghe B, 2000, INTENS CARE MED, V26, P275, DOI 10.1007/s001340051150; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Muellejans B, 2006, CRIT CARE, V10, DOI 10.1186/cc4939; Payen JF, 2009, ANESTHESIOLOGY, V111, P1308, DOI 10.1097/ALN.0b013e3181c0d4f0; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Quenot JP, 2007, CRIT CARE MED, V35, P2031, DOI 10.1097/01.ccm.0000282733.83089.4d; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Sauder P, 2008, ANN FR ANESTH, V27, P541, DOI 10.1016/j.annfar.2008.04.021; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186	14	3	3	0	3	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0750-7658			ANN FR ANESTH	Ann. Fr. Anest. Reanim.	OCT	2012	31	10					778	782		10.1016/j.annfar.2012.05.004			5	Anesthesiology	Anesthesiology	036WP	WOS:000311063300005	22795773				2020-06-30	J	Nave, R; Connolly, SM; Popper, L; Lahu, G; Schmitt, H				Nave, Ruediger; Connolly, Sandra M.; Popper, Lars; Lahu, Gezim; Schmitt, Holger			Single-dose and multi-dose delivery systems for an intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						breakthrough pain; cancer patients; intranasal administration; fentanyl; dose delivery system	BREAKTHROUGH CANCER PAIN; CROSSOVER TRIAL; DOUBLE-BLIND; OPEN-LABEL; PREVALENCE; MANAGEMENT; EFFICACY; ACCEPTABILITY; TOLERABILITY; ASSOCIATION	Background: Intranasal fentanyl spray (INFS, Instanyl (R)) was developed to treat cancer patients with Breakthrough Pain (BTP). INFS is delivered via a multi-dose delivery system (MDS) that is available in various dose strengths. The aim of this study was to demonstrate the pharmacokinetic bio-equivalence of INFS single dose delivery system (SDS) in relation to the currently marketed MDS device. Methods: In a randomized, single-center, single-dose, open label, comparative, four-period, two-sequence, replicate cross-over study, 48 healthy subjects (24 male and 24 female, mean age of 28.1 years, mean bodyweight 69.8 kg) received 200 mu g/100 mu l fentanyl administered via SDS and via MDS in one of two alternating treatment sequences. Naltrexone was given to all subjects to prevent potential fentanyl adverse drug reactions. Blood samples were frequently taken up to 72 hours post INFS administration and analyzed by liquid chromatography with tandem mass spectrometric detection. Primary pharmacokinetic parameters were area under the curve extrapolated to infinity (AUC(0-infinity)) and peak plasma concentration (C-max). Statistical analyses of the primary pharmacokinetic parameters were performed using a linear mixed effect model applied to the natural log-transformed data. Results: Healthy subjects showed very similar plasma concentration over time profiles for both delivery systems. The mean fentanyl Cmax and AUC(0-infinity) values for SDS and MDS were 948 pg/ml, 949 pg/ml and 4,439 pgxh/ml, 4,489 pgxh/ml. respectively. Point estimates (and 90% confidence intervals) for AUC and C-max were 0.97 (0.93 - 1.02) and 1.00 (0.92 - 1.09) and therefore in the bioequivalence range of 0.80 - 1.25. Conclusions: Results of this study show that SDS and MDS met the pre-defined regulatory criteria for bioequivalence. Safety profiles were consistent between both devices and no safety concerns were identified with INFS administered in combination with oral naltrexone.	[Nave, Ruediger; Lahu, Gezim; Schmitt, Holger] Takeda Co, Nycomed, D-78467 Constance, Germany; [Connolly, Sandra M.] Celerion, Neptune, NJ USA; [Popper, Lars] Takeda Co, Nycomed, Roskilde, Denmark	Nave, R (reprint author), Takeda Co, Nycomed, Byk Gulden Str 2, D-78467 Constance, Germany.	ruediger.nave@takeda.com			Nycomed, a Takeda Company	This study was sponsored by Nycomed, a Takeda Company.	Agu RU, 2008, DRUG ABSORPTION STUD, P216; BENNETT D, 2005, [No title captured], V30, P354; Chaushu G, 2000, CANCER, V88, P984, DOI 10.1002/(SICI)1097-0142(20000301)88:5<984::AID-CNCR6>3.3.CO;2-S; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; EMA, 2008, CPMPEWPQWP140198REV1; FDA, 2001, GUID IND BIOAN METH; *FDA, 2001, GUID IND STAT APPR E; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kaessner N, 2012, INT J CLIN PHARM TH, V50, P665, DOI 10.5414/CP201737; Klepstad P, 2005, PALLIATIVE MED, V19, P477, DOI 10.1191/0269216305pm1054oa; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Nave R, 2009, 6 C EUR FED IASP CHA; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; Patt RB, 1998, ONCOLOGY WILLISTON P, V12, P1049; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	25	3	3	0	6	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	OCT	2012	50	10					751	759		10.5414/CP201729			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	029KO	WOS:000310494600007	22943926				2020-06-30	J	Dietrich, E; Gums, JG				Dietrich, Eric; Gums, John G.			Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain	ANNALS OF PHARMACOTHERAPY			English	Article						breakthrough cancer pain; intranasal fentanyl spray; opioid analgesic	PECTIN NASAL SPRAY; CROSSOVER TRIAL; DOUBLE-BLIND; OPEN-LABEL; EFFICACY; TOLERABILITY; ACCEPTABILITY; PHARMACOLOGY; ASSOCIATION; OPIOIDS	OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse events, dosing, and administration of intranasal fentanyl spray in the treatment of breakthrough cancer pain (BTCP) in adults. DATA SOURCES: Relevant published data were identified using PubMed from inception to April 2012 using the search terms fentanyl nasal spray, intranasal fentanyl, intranasal fentanyl cancer pain, and fentanyl pectin cancer pain. Only articles evaluating the use of intranasal fentanyl spray for cancer pain were selected. STUDY SELECTION AND DATA EXTRACTION: All articles evaluating the pharmacokinetics of intranasal fentanyl or the clinical efficacy of intranasal fentanyl spray for the treatment of BTCP were considered; references of selected articles were manually reviewed to identify further articles. The manufacturer of intranasal fentanyl spray was also contacted to obtain information. DATA SYNTHESIS: Intranasal fentanyl spray gained Food and Drug Administration approval for the treatment of BTCP in adults with cancer receiving stable background opioid therapy for chronic pain. In doses ranging from 100 to 800 jig! spray, intranasal fentanyl spray was found to be more effective than placebo and more effective than oral morphine or oral fentanyl formulations in reducing pain for up to 15-45 minutes; onset of analgesia was also improved with intranasal fentanyl spray. The most commonly observed adverse events included nausea, vomiting, vertigo, and dizziness. CONCLUSIONS: For the treatment of BTCP, intranasal fentanyl spray offers improved onset of analgesia compared to other oral therapies; this improved onset of analgesia may closely mimic the typical time course of a BTCP episode. Nasal administration may overcome problems such as nausea, vomiting, or xerostomia that may complicate oral administration of analgesics. Potential disadvantages include uncertainty in treating more than 4 BTCP episodes per 24 hours and a higher cost compared to generically available oral opioid analgesics.	[Dietrich, Eric] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA; [Dietrich, Eric] Univ Florida, Coll Pharm, Dept Community Hlth & Family Med, Gainesville, FL USA; [Dietrich, Eric] Univ Florida, Coll Med, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA; [Dietrich, Eric] Univ Florida, Coll Med, Dept Community Hlth & Family Med, Gainesville, FL USA	Dietrich, E (reprint author), Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA.	ead1129@ufl.edu					Cadet P, 2004, MED SCI MONITOR, V10, pMS28; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lazanda REMS, 2011, ARCH PHARM; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Package insert, 2009, PACK INS ROX OX; Package insert, 2011, PACK INS LAZ INTR FE; Package insert, 2011, PACK INS FENT OR TAB; Package insert, 2011, PACK INS ACT OR TRAN; Package insert, 2009, PACK INS DIL HYDR; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Ruiz Garcia V, 2008, BRIT MED J, V337, pa3104; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]	24	9	10	0	12	HARVEY WHITNEY BOOKS CO	CINCINNATI	PO BOX 42696, CINCINNATI, OH 45242 USA	1060-0280			ANN PHARMACOTHER	Ann. Pharmacother.	OCT	2012	46	10					1382	1391		10.1345/aph.1R069			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	022HE	WOS:000309947700012	23012382				2020-06-30	J	Billings, F; Hoyt, MR				Billings, F.; Hoyt, M. R.			Epidural lipomatosis causing new debilitating back pain in a patient with human immunodeficiency virus on highly active antiretroviral therapy	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Epidural lipomatosis; Human immunodeficiency virus; HAART; Obstetric anesthesia; Neuraxial analgesia; Patient-controlled analgesia; Fentanyl	HIV-POSITIVE PATIENT; LIPODYSTROPHY; ANALGESIA; SECONDARY; FAT	Spinal epidural lipomatosis is a rare condition of adipose tissue hypertrophy in the epidural space. Through nerve root and spinal canal compression, it may lead to both sensory and motor compromise. Chronic steroid use, obesity and other metabolic derangements are known causes of spinal epidural lipomatosis. Recently, several cases have been attributed to antiretrovirals taken to treat human immunodeficiency virus, given their side effects of lipodystrophy and altered fat metabolism. We report a patient on highly active antiretroviral therapy (HAART) who developed debilitating back, hip and thigh pain during the third trimester of pregnancy that prevented ambulation. Epidural lipomatosis was diagnosed by magnetic resonance imaging. Given her evolving symptoms, neuraxial anesthesia was considered to be contraindicated. We present her management and labor course. (C) 2012 Elsevier Ltd. All rights reserved.	[Billings, F.; Hoyt, M. R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, Boston, MA 02135 USA	Billings, F (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, Boston, MA 02135 USA.	fbillings@partners.org					Cersosimo MG, 2002, CLIN NEUROPHARMACOL, V25, P51, DOI 10.1097/00002826-200201000-00009; Ebright JR, 2001, CLIN INFECT DIS, V32, pE90, DOI 10.1086/319209; Fassett Daniel R, 2004, Neurosurg Focus, V16, pE11; Flisberg Per, 2009, J Med Case Rep, V3, P128, DOI 10.1186/1752-1947-3-128; Fogel Guy R, 2005, Spine J, V5, P202, DOI 10.1016/j.spinee.2004.05.252; GARCIALAZARO M, 2006, CLIN INFECT DIS, V42, P428; GUEGAN Y, 1982, J NEUROSURG, V56, P267, DOI 10.3171/jns.1982.56.2.0267; Heath KV, 2001, AIDS, V15, P231, DOI 10.1097/00002030-200101260-00013; Hooten WM, 2008, PAIN PHYSICIAN, V11, P87; Lang SA, 2002, REGION ANESTH PAIN M, V27, P494, DOI 10.1053/rapm.2002.34323; Lisai P, 2001, SPINE, V26, P307, DOI 10.1097/00007632-200102010-00017; Marwah R, 2012, CAN J ANESTH, V59, P246, DOI 10.1007/s12630-011-9625-0; Miller J, 2003, HIV Med, V4, P293; Palanisamy A, 2009, INT J OBSTET ANESTH, V18, P258, DOI 10.1016/j.ijoa.2008.10.002; Robertson SC, 1997, NEUROSURGERY, V41, P68, DOI 10.1097/00006123-199707000-00015; Schurmann D, 2005, AIDS, V19, P2052, DOI 10.1097/01.aids.0000191924.16561.ca; Vince GH, 2005, SPINE, V30, pE524, DOI 10.1097/01.brs.0000176314.89648.78	17	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2012	21	4					367	370		10.1016/j.ijoa.2012.06.003			4	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	028FU	WOS:000310409000013	22918029				2020-06-30	J	Sadana, N; Houtchens, M; Farber, MK				Sadana, N.; Houtchens, M.; Farber, M. K.			Anesthetic management of a parturient with neuromyelitis optica	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Neuromyelitis optica; Neuraxial anesthesia; General anesthesia; Cesarean delivery; Demyelinating disorders	MULTIPLE-SCLEROSIS; EPIDURAL-ANESTHESIA; TRANSVERSE MYELITIS; SPINAL-ANESTHESIA; PREGNANCY; PATIENT; DISEASE; ANALGESIA	Women with neuromyelitis optica, an acute inflammatory demyelinating condition of the central nervous system, have an unpredictable clinical course in pregnancy. Providing neuraxial anesthesia for these patients is controversial, although relapses may occur after exposure to either general or neuraxial anesthesia and are common. We report the successful obstetric anesthesia management of a parturient with neuromyelitis optica, review the medical literature, and discuss specific considerations for obstetric anesthesia in patients with underlying demyelinating disease. Published by Elsevier Ltd.	[Sadana, N.; Farber, M. K.] Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA; [Houtchens, M.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	Sadana, N (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Anesthesiol, Oklahoma City, OK 73104 USA.	Neeti-Sadana@ouhsc.edu	Farber, Michaela Kristina/M-8146-2019	Farber, Michaela Kristina/0000-0002-8329-2277			Bader A M, 1988, J Clin Anesth, V1, P21, DOI 10.1016/0952-8180(88)90006-2; Beach T P, 1971, Anesth Analg, V50, P431; Berghella V, 1996, OBSTET GYNECOL, V87, P809; Bonnet F, 1999, LUPUS, V8, P244, DOI 10.1191/096120399678847696; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Cornelio DB, 2009, ARCH GYNECOL OBSTET, V280, P475, DOI 10.1007/s00404-008-0918-7; Dalmas AF, 2003, ANN FR ANESTH, V22, P861, DOI 10.1016/j.annfar.2003.08.005; Facco E, 2010, EUR J ANAESTH, V27, P578, DOI 10.1097/EJA.0b013e3283350c54; Gunaydin B, 2001, ANAESTHESIA, V56, P565, DOI 10.1046/j.1365-2044.2001.01968-2.x; GUTOWSKI NJ, 1993, ANAESTHESIA, V48, P44; Hebl JR, 2006, ANESTH ANALG, V103, P223, DOI 10.1213/01.ane.0000220896.56427.53; Hosseini H, 2003, MULT SCLER, V9, P526, DOI 10.1191/1352458503ms942cr; Keeling SO, 2009, CLIN RHEUMATOL, V28, P1, DOI 10.1007/s10067-008-1031-9; KYTTA J, 1984, ANN CHIR GYNAECOL FE, V73, P299; Mata S, 2011, J NEUROL SCI, V303, P13, DOI 10.1016/j.jns.2011.01.002; May AE, 2008, INT J OBSTET ANESTH, V17, P31, DOI 10.1016/j.ijoa.2007.03.016; Mckeon A, 2009, MUSCLE NERVE, V39, P87, DOI 10.1002/mus.21197; Miyazawa I, 2002, J NEUROL, V249, P351, DOI 10.1007/s004150200020; Pellkofer HL, 2009, MULT SCLER J, V15, P1006, DOI 10.1177/1352458509106512; Shang WY, 2011, INT J GYNECOL OBSTET, V115, P66, DOI 10.1016/j.ijgo.2011.05.016; Verduyn W H, 1997, J Spinal Cord Med, V20, P371; Wang A, 1999, ANESTH ANALG, V88, P1083, DOI 10.1097/00000539-199905000-00022; WARREN TM, 1982, ANESTH ANALG, V61, P1022; Weekes G, 2010, INT J OBSTET ANESTH, V19, P333, DOI 10.1016/j.ijoa.2010.03.009; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Wingerchuk DM, 2008, CURR TREAT OPTION NE, V10, P55, DOI 10.1007/s11940-008-0007-z; Zifman E, 2010, J CHILD NEUROL, V25, P746, DOI 10.1177/0883073809343316	27	7	7	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2012	21	4					371	375		10.1016/j.ijoa.2012.06.002			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	028FU	WOS:000310409000014	22922089				2020-06-30	J	Jaime, F; Degani, J; Lam, N; Allen, G				Jaime, F.; Degani, J.; Lam, N.; Allen, G.			Placental abruption occurring soon after labor combined spinal-epidural analgesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Placental abruption; Combined spinal-epidural analgesia; Spinal opioids	HEART-RATE ABNORMALITIES; FETAL BRADYCARDIA; CONTROLLED-TRIAL; FENTANYL	We present a case of placental abruption necessitating emergency cesarean section in an otherwise uncomplicated patient soon after initiation of combined spinal-epidural analgesia in labor. Administration of spinal opioids has the potential to cause fetal bradycardia due to uterine hypertonicity following rapid onset of analgesia. In this case, a previously bloody show before placement of combined spinal-epidural analgesia may have been evidence of a small abruption. We hypothesize that uterine hypertonicity following administration of spinal opioids may have hastened the development of an existing placental abruption. (C) 2012 Elsevier Ltd. All rights reserved.	[Jaime, F.; Degani, J.; Lam, N.; Allen, G.] Univ New Mexico, Dept Anesthesiol & Crit Care Med, Albuquerque, NM 87131 USA	Degani, J (reprint author), Univ New Mexico, Dept Anesthesiol & Crit Care Med, Albuquerque, NM 87131 USA.	JDegani@salud.unm.edu					Abrao KC, 2009, OBSTET GYNECOL, V113, P41, DOI 10.1097/AOG.0b013e31818f5eb6; Albright GA, 1999, REGION ANESTH PAIN M, V24, P117, DOI 10.1016/S1098-7339(99)90071-8; Cascio M, 1997, CAN J ANAESTH, V44, P605, DOI 10.1007/BF03015443; CLARKE VT, 1994, ANESTHESIOLOGY, V81, P1083, DOI 10.1097/00000542-199410000-00041; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Mardirosoff C, 2005, EVIDENCE-BASED OBSTETRIC ANESTHESIA, P68, DOI 10.1002/9780470988343.ch7; NORRIS MC, 1994, ANESTH ANALG, V79, P529; Segal S, 1998, ANESTH ANALG, V87, P864, DOI 10.1097/00000539-199810000-00022; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66	10	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2012	21	4					376	379		10.1016/j.ijoa.2012.07.002			4	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	028FU	WOS:000310409000015	22940265				2020-06-30	J	Maisonneuve, E; Morin, F; Crochetiere, C; Lemyre, E; Bigras, JL; Leduc, L; Girardin, C; Bilodeau, M				Maisonneuve, E.; Morin, F.; Crochetiere, C.; Lemyre, E.; Bigras, J. -L.; Leduc, L.; Girardin, C.; Bilodeau, M.			Multidisciplinary management of a hepatic and renal transplant patient with Alagille syndrome	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							TYPE-1 PRIMARY HYPEROXALURIA; COMBINED LIVER; KIDNEY-TRANSPLANTATION; PREGNANCY; DISEASE; RECIPIENT; IA		[Maisonneuve, E.; Leduc, L.] CHU St Justine, Dept Obstet & Gynecol, Montreal, PQ, Canada; [Girardin, C.] CHUM Notre Dame, Dept Nephrol, Montreal, PQ, Canada; [Bilodeau, M.] CHUM St Luc, Dept Hepatol, Montreal, PQ, Canada	Maisonneuve, E (reprint author), CHU St Justine, Dept Obstet & Gynecol, Montreal, PQ, Canada.	emelinem@yahoo.com	Bilodeau, Marc/L-2822-2017	Maisonneuve, Emeline/0000-0001-5765-4468			ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2; Albayram F, 2002, FETAL DIAGN THER, V17, P182, DOI 10.1159/000048035; Armenti VT, 2000, LIVER TRANSPLANT, V6, P671, DOI 10.1053/jlts.2000.18703; Belingheri M, 2007, LIVER TRANSPLANT, V13, P762, DOI 10.1002/lt.21147; Carvalho Luciana de Souza Cota, 2009, Rev. Bras. Anestesiol., V59, P746, DOI 10.1590/S0034-70942009000600011; Deshpande NA, 2011, AM J TRANSPLANT, V11, P2388, DOI 10.1111/j.1600-6143.2011.03656.x; Duggan T, 2008, INT J OBSTET ANESTH, V17, P194, DOI 10.1016/j.ijoa.2007.09.012; Gosakan R, 2003, J Obstet Gynaecol, V23, P434; Josephson MA, 2011, SEMIN NEPHROL, V31, P100, DOI 10.1016/j.semnephrol.2010.10.009; Kamath BM, 2004, CIRCULATION, V109, P1354, DOI 10.1161/01.CIR.0000121361.01862.A4; Lee PJ, 2004, J INHERIT METAB DIS, V27, P537, DOI 10.1023/B:BOLI.0000037397.39725.57; Lykavieris P, 2001, GUT, V49, P431, DOI 10.1136/gut.49.3.431; McKay DB, 2005, AM J TRANSPLANT, V5, P1592, DOI 10.1111/j.1600-6143.2005.00969.x; Mehrabi A, 2006, CLIN TRANSPLANT, V20, P97, DOI 10.1111/j.1399-0012.2006.00608.x; Priebe HJ, 2007, BRIT J ANAESTH, V99, P102, DOI 10.1093/bja/aem119; Pruvot FR, 1997, TRANSPLANTATION, V63, P615, DOI 10.1097/00007890-199702270-00024; Rahmoune FC, 2011, INT J OBSTET ANESTH, V20, P355, DOI 10.1016/j.ijoa.2011.07.012; Rinella Mary Eugenia, 2006, Ann Hepatol, V5, P212; SKANNAL DG, 1995, OBSTET GYNECOL, V86, P641, DOI 10.1016/0029-7844(95)00216-E; Wang LP, 2008, ANESTH ANALG, V107, P193, DOI 10.1213/ane.0b013e31816c8888	20	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2012	21	4					382	383		10.1016/j.ijoa.2012.08.003			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	028FU	WOS:000310409000020	22959070				2020-06-30	J	Kapoor, S				Kapoor, Shailendra			Emerging Opioid Alternatives to Nebulized Fentanyl for Improving Exercise Capacity in Patients With COPD	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							MORPHINE									BEAUFORD W, 1993, CHEST, V104, P175, DOI 10.1378/chest.104.1.175; Currow DC, 2011, J PAIN SYMPTOM MANAG, V42, P388, DOI 10.1016/j.jpainsymman.2010.11.021; FORESTI V, 1991, Recenti Progressi in Medicina, V82, P230; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; KIRSCH JL, 1989, CHEST, V96, P761, DOI 10.1378/chest.96.4.761; Light RW, 1996, CHEST, V109, P975, DOI 10.1378/chest.109.4.975	6	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	OCT	2012	44	4					E1	E1		10.1016/j.jpainsymman.2012.07.004			1	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	029QY	WOS:000310511800001	23026483	Bronze			2020-06-30	J	McCullagh, N; Pereira, P; Cullen, P; Mulcahy, R; Bonin, R; Little, M; Gray, S; Seymour, J				McCullagh, Nora; Pereira, Peter; Cullen, Paul; Mulcahy, Richard; Bonin, Robert; Little, Mark; Gray, Suzanne; Seymour, Jamie			Randomised trial of magnesium in the treatment of Irukandji syndrome	EMERGENCY MEDICINE AUSTRALASIA			English	Article						Irukandji syndrome; jellyfish; magnesium; toxinology		Objectives Irukandji syndrome is a distressing condition characterised by pain, hypertension and tachycardia. Some develop cardiac failure and there have been two reported deaths. Magnesium sulphate has become the standard of care despite minimal evidence. The aim of this study was to investigate if magnesium would reduce analgesic requirement and length of stay for patients with Irukandji syndrome. Methods This was a double-blind, randomised controlled clinical trial. Patients with Irukandji syndrome who required parenteral opioid analgesia were randomised to receive either 10?mmol of magnesium as a bolus, and then a 5?mmol/h magnesium infusion for 6?h or saline. Fentanyl patient-controlled analgesia was commenced to allow patients to self-regulate their pain relief. The primary outcome measure of the study was comparison of total analgesic requirements between the two groups. The secondary outcome measure was to compare length of stay. Results The study ran from November 2003 to May 2007. Thirty-nine patients were enrolled in the study; 26 were male with a median age of 28. Twenty-two received magnesium. There was no significant difference in the morphine equivalent dose used, peak CK, peak troponin, peak pulse, peak blood pressure, peak mean arterial pressure (MAP), percentage MAP rise and length of stay for those receiving magnesium compared with placebo. Conclusion Our study did not demonstrate a benefit in the use of magnesium in the treatment of Irukandji syndrome. As such the current use of magnesium needs to be reconsidered until there is good evidence to support its use.	[McCullagh, Nora; Pereira, Peter; Cullen, Paul; Mulcahy, Richard; Bonin, Robert; Little, Mark] Cairns Base Hosp, Emergency Dept, Cairns, Qld 4870, Australia; [Pereira, Peter] James Cook Univ, Dept Trop Biol, Cairns, Qld, Australia; [Little, Mark; Seymour, Jamie] James Cook Univ, Sch Publ Hlth & Trop Med, Cairns, Qld, Australia; [Little, Mark; Seymour, Jamie] Queensland Trop Hlth Alliance, Townsville, Qld, Australia; [Gray, Suzanne] Peel Hlth Campus, Mandurah, WA, Australia	Little, M (reprint author), Cairns Base Hosp, Dept Emergency Med, POB 902, Cairns, Qld 4870, Australia.	mark_little@health.qld.gov.au	Little, Mark/J-3849-2019; Seymour, Jamie/C-9748-2013	Seymour, Jamie/0000-0002-4805-3289			Bailey PM, 2003, MED J AUSTRALIA, V178, P34, DOI 10.5694/j.1326-5377.2003.tb05040.x; Corkeron M, 2004, ANAESTH INTENS CARE, V32, P666, DOI 10.1177/0310057X0403200510; Corkeron MA, 2003, MED J AUSTRALIA, V178, P411, DOI 10.5694/j.1326-5377.2003.tb05263.x; Little M, 2005, ANAESTH INTENS CARE, V33, P541; Pereira P., IRUKANDJI TASKFORCE; Queensland Ambulance Service, 2009, MAGN SULPH DRUG THER; Ramasamy S, 2005, TOXICOL LETT, V155, P135, DOI 10.1016/j.toxlet.2004.09.004; Schnorf H, 2002, NEUROLOGY, V58, P873, DOI 10.1212/WNL.58.6.873	8	11	11	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731			EMERG MED AUSTRALAS	Emerg. Med. Australas.	OCT	2012	24	5					560	565		10.1111/j.1742-6723.2012.01602.x			6	Emergency Medicine	Emergency Medicine	017TV	WOS:000309614800014	23039299				2020-06-30	J	Rigler, SK; Wiggins, S; Mahnken, J; Reed, GA				Rigler, Sally K.; Wiggins, Sharee; Mahnken, Jonathan; Reed, Gregory A.			Extent of Variability in Fentanyl Plasma Levels During Steady-State Transdermal Delivery in Older Nursing Home Residents	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY			English	Letter							MATRIX; PAIN		[Rigler, Sally K.] Univ Kansas Med Ctr, Dept Internal Med, Landon Ctr Aging, Kansas City, KS USA; [Wiggins, Sharee] Univ Kansas Med Ctr, Landon Ctr Aging, Kansas City, KS USA; [Mahnken, Jonathan] Univ Kansas Med Ctr, Dept Biostat, Kansas City, KS USA; [Reed, Gregory A.] Univ Kansas Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS USA	Rigler, SK (reprint author), Univ Kansas Med Ctr, Dept Internal Med, Landon Ctr Aging, Kansas City, KS USA.						Flaherty E, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000324375.02027.9f; Guidance for Industry, 2012, GUID IND DRUG INT ST; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Moore Kenneth Todd, 2011, J Opioid Manag, V7, P99; Overholser Brian R, 2011, Am J Manag Care, V17 Suppl 11, pS276; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Rigler Sally K, 2007, Am J Geriatr Pharmacother, V5, P91, DOI 10.1016/j.amjopharm.2007.05.002	10	0	0	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-8614			J AM GERIATR SOC	J. Am. Geriatr. Soc.	OCT	2012	60	10					1986	1988		10.1111/j.1532-5415.2012.04170.x			3	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	019LF	WOS:000309740400036	23057458				2020-06-30	J	Kreeger, TJ; Kellie, KA				Kreeger, Terry J.; Kellie, Kalin A.			Sufentanil Citrate Immobilization of Alaskan Moose Calves	JOURNAL OF WILDLIFE DISEASES			English	Article						Alaska; Alces alces gigas; carfentanil; immobilization; moose; sufentanil; xylazine	ROCKY-MOUNTAIN ELK; POTENT	Free-ranging Alaskan moose calves (Alces alces gigas.) were immobilized with 0.12 mg/kg sufentanil (S; n=16), 0.12 mg/kg sufentanil plus 0.27 mg/kg xylazine (SX; n=11), or 0.007 mg/kg carfentanil plus 0.36 mg/kg xylazine (CX; n=13). Immobilants were antagonized with 1.2 mg/kg naltrexone (S) or :1.2 mg/kg naltrexone plus 2.4 mg/kg tolazoline (SX, CX). There were no differences in induction (P >= 0.29) or processing (P >= 0.44) times between groups. Moose given either S or SX had significantly shorter recovery times than moose given CX (P=0.001) and recovery times from S were shorter than from SX (P=0.02). Oxygen saturation values for all groups averaged 85 +/- 8%, but were significantly higher (P=0.048) for CX (89 +/- 7%) than for S (82 +/- 8%). Based on these data, sufentanil at 0.1 mg/kg or sufentanil at 0.1 mg/kg plus xylazine at 0.25 mg/kg could provide effective remote immobilization for Alaskan moose calves and could be substituted fix carfentanil or thiafentanil should the need arise.	[Kreeger, Terry J.] Wyoming Game & Fish Dept, Wheatland, WY 82201 USA; [Kellie, Kalin A.] Alaska Dept Fish & Game, Div Wildlife Conservat, Fairbanks, AK 99701 USA	Kreeger, TJ (reprint author), Wyoming Game & Fish Dept, 2362 Highway 34, Wheatland, WY 82201 USA.	tkreeger@wildblue.net					Arnemo Jon M., 2003, Alces, V39, P243; Arnemo Jon N., 1995, Rangifer, V15, P19; Franzmann A. W., 1984, ALCES, V20, P259; Kreeger T. J., 2012, HDB WILDLIFE CHEM IM; Kreeger TJ, 2011, J WILDLIFE DIS, V47, P638, DOI 10.7589/0090-3558-47.3.638; Kreeger TJ, 2010, J WILDLIFE MANAGE, V74, P902, DOI 10.2193/2009-286; Kreeger TJ, 2000, WILDLIFE SOC B, V28, P751; KREEGER TJ, 1990, J WILDLIFE DIS, V26, P561, DOI 10.7589/0090-3558-26.4.561; Lacy C. F., 1998, DRUG INFORM HDB, P1166; NIEMEGEERS CJE, 1976, ARZNEIMITTEL-FORSCH, V26, P1551; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548	12	0	1	0	8	WILDLIFE DISEASE ASSOC, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	OCT	2012	48	4					1088	1091		10.7589/2012-04-112			4	Veterinary Sciences	Veterinary Sciences	020VV	WOS:000309845600030	23060515				2020-06-30	J	Gagnon, P; Bussieres, JS; Ribeiro, F; Gagnon, SL; Saey, D; Gagne, N; Provencher, S; Maltais, F				Gagnon, Philippe; Bussieres, Jean S.; Ribeiro, Fernanda; Gagnon, Serge L.; Saey, Didier; Gagne, Nathalie; Provencher, Steeve; Maltais, Francois			Influences of Spinal Anesthesia on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						chronic obstructive pulmonary disease; exercise tolerance; peripheral muscle dysfunction; ventilatory response; group III/IV afferents	IV MUSCLE AFFERENTS; GROUP-III; LOWER-LIMB; CARDIOVASCULAR-RESPONSE; QUADRICEPS FATIGUE; MAJOR LIMITATION; CYCLE EXERCISE; HIGH-INTENSITY; PERFORMANCE; COPD	Rationale Lower limb muscle dysfunction contributes to exercise intolerance in chronic obstructive pulmonary disease (COPD). We hypothesized that signaling from lower limb muscle group III/IV sensory afferents to the central motor command could be involved in premature cycling exercise termination in COPD. Objectives: To evaluate the effects of spinal anesthesia, which presumably inhibited central feedback from the lower limb muscle group III/IV sensory afferents on exercise tolerance and cardiorespiratory response during constant work-rate cycling exercise in patients with COPD. Methods: In a crossover and double-blind randomized design, eight patients with COPD (FEV1, 67 +/- 8% predicted) completed a constant work-rate cycling exercise after sham (NaCl, interspinous L-3-L-4) or active (fentanyl 25 g, intrathecal L-3-L-4) spinal anesthesia. Measurements and Main Results: When compared with placebo, endurance time was significantly prolonged after spinal anesthesia with fentanyl (639 +/- 87 s vs. 423 +/- 38 s [mean +/- SEM]; P = 0.01). Ventilation and respiratory rate were reduced at isotime points under the fentanyl condition, whereas ventilatory efficiency and dead space ventilation were improved. Patients exhibited less dynamic hyperinflation at isotime points with spinal anesthesia. consequently, the rise in dyspnea was significantly flatter during the fentanyl condition than with placebo. Conclusions: Spinal anesthesia enhanced cycling exercise tolerance in patients with COPD, mostly by reducing ventilatory response and dyspnea during exercise; these effects were possibly mediated through the inhibition of group III/IV lower limb sensory muscle afferents. Clinical trial registered with www.clinicaltrials.gov (NCT01522729).	[Gagnon, Philippe; Bussieres, Jean S.; Ribeiro, Fernanda; Saey, Didier; Gagne, Nathalie; Provencher, Steeve; Maltais, Francois] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ G1V 4G5, Canada; [Gagnon, Serge L.] CHUQ, Hotel Dieu Quebec, Quebec City, PQ, Canada	Maltais, F (reprint author), Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, 2725 Chemin Ste Foy, Quebec City, PQ G1V 4G5, Canada.	francois.maltais@med.ulaval.ca			Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec; CIHRCanadian Institutes of Health Research (CIHR) [MOP-115136]	Supported by a research training award of the Fonds de la Recherche en Sante du Quebec (P.G.), by Fonds de la Recherche en Sante du Quebec (S.P.), and by CIHR grant MOP-115136 and local research funds.	Adreani CM, 1997, J APPL PHYSIOL, V82, P1811; Almeida TF, 2004, BRAIN RES, V1000, P40, DOI 10.1016/j.brainres.2003.10.073; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2011, J APPL PHYSIOL, V110, P1500, DOI 10.1152/japplphysiol.00181.2011; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2010, AM J PHYSIOL-REG I, V299, pR314, DOI 10.1152/ajpregu.00183.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; BATES DV, 1989, RESP FUNCTION DIS; Bell HJ, 2006, RESP PHYSIOL NEUROBI, V152, P1, DOI 10.1016/j.resp.2006.02.005; Borghi-Silva A, 2008, THORAX, V63, P910, DOI 10.1136/thx.2007.090167; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Debigare R, 2008, J APPL PHYSIOL, V105, P751, DOI 10.1152/japplphysiol.90336.2008a; Fisher JP, 2004, EXP PHYSIOL, V89, P639, DOI 10.1113/expphysiol.2004.028639; Forster HV, 2012, COMPR PHYSIOL, V2, P743, DOI 10.1002/cphy.c100045; Gagnon P, 2012, AM J RESP CRIT CARE, V185, pA5308; Gagnon P, 2009, J APPL PHYSIOL, V107, P832, DOI 10.1152/japplphysiol.91546.2008; Gandevia SC, 2001, PHYSIOL REV, V81, P1725; HUGHES JMB, 1972, CLIN SCI, V43, P583, DOI 10.1042/cs0430583; Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509; KADOWITZ PJ, 1975, J CLIN INVEST, V56, P354, DOI 10.1172/JCI108100; KNIGHT DR, 1992, J APPL PHYSIOL, V73, P1114; Laviolette L, 2008, THORAX, V63, P115, DOI 10.1136/thx.2006.076844; Mador MJ, 2003, CHEST, V123, P1104, DOI 10.1378/chest.123.4.1104; Maltais F, 2005, CHEST, V128, P1168, DOI 10.1378/chest.128.3.1168; Maltais F, 1998, J APPL PHYSIOL, V84, P1573; Maltais F, 2001, MED SCI SPORT EXER, V33, P916, DOI 10.1097/00005768-200106000-00010; Maltais F, 2011, RESP MED, V105, P580, DOI 10.1016/j.rmed.2010.11.019; Marcora SM, 2011, J APPL PHYSIOL, V110, P1499, DOI 10.1152/japplphysiol.00146.2011; MORIKAWA T, 1989, J APPL PHYSIOL, V67, P2006; Morin D, 2002, J NEUROSCI, V22, P4756, DOI 10.1523/JNEUROSCI.22-11-04756.2002; O'Donnell DE, 2004, EUR RESPIR J, V23, P832, DOI 10.1183/09031936.04.00116004; O'Donnell DE, 2001, MED SCI SPORT EXER, V33, pS647, DOI 10.1097/00005768-200107001-00002; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770, DOI 10.1164/ajrccm.164.5.2012122; O'Donnell DE, 2006, J APPL PHYSIOL, V101, P1025, DOI 10.1152/japplphysiol.01470.2005; O'Donnell DE, 2008, J APPL PHYSIOL, V105, P753, DOI 10.1152/japplphysiol.90336.2008b; Oga T, 2003, AM J RESP CRIT CARE, V167, P544, DOI 10.1164/rccm.200206-583OC; Piepoli M, 1996, CIRCULATION, V93, P940, DOI 10.1161/01.CIR.93.5.940; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Richardson RS, 1999, AM J RESP CRIT CARE, V159, P881, DOI 10.1164/ajrccm.159.3.9803049; ROTTO DM, 1988, J APPL PHYSIOL, V64, P2306; Saey D, 2003, AM J RESP CRIT CARE, V168, P425, DOI 10.1164/rccm.200208-856OC; Saey D, 2011, J APPL PHYSIOL, V110, P116, DOI 10.1152/japplphysiol.00153.2010; Sala E, 1999, AM J RESP CRIT CARE, V159, P1726, DOI 10.1164/ajrccm.159.6.9804136; STRANGE S, 1993, J PHYSIOL-LONDON, V470, P693, DOI 10.1113/jphysiol.1993.sp019883; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; Whipp BJ, 1998, BRIT J SPORT MED, V32, P199, DOI 10.1136/bjsm.32.3.199	48	91	92	0	13	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2012	186	7					606	615		10.1164/rccm.201203-0404OC			10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	014NV	WOS:000309383600011	22822019				2020-06-30	J	Bansal, S; Ramesh, VJ; Umamaheswara, GS				Bansal, Sonia; Ramesh, Venkatapura J.; Umamaheswara, Ganne S.			Fentanyl Co-administration Decreases the Induction Dose Requirement of Propofol in Patients With Supratentorial Tumors and not in Patients With Spinal Lesions	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article; Proceedings Paper	2nd Conference of Asian-Society-for-Neuroanaesthesia-and-Critical-Care / 12th Annual Conference of Indian-Society-of-Neuroanaesthesiology-and-Critical-Care	FEB 25-27, 2011	New Delhi, INDIA	Asian Soc Neuroanaesthesia & Crit Care, Indian Soc Neuroanaesthesiol & Crit Care		supratentorial tumors; anesthesia induction; propofol; fentanyl; Target Controlled Infusion	BRAIN-TUMOR; CELL-LINE; PHARMACOKINETICS; PHARMACODYNAMICS; ALFENTANIL; SURGERY	Background: The requirement of anesthetic drugs in a patient with an intracranial space-occupying lesion is of relevance to the neuroanesthetist. The requirement is often presumed to have reduced or at least altered. However, not much research has focused on this issue. Hence, we conducted this study to examine whether intracranial tumors reduce the induction dose of propofol in patients undergoing craniotomy based on plasma and effect site concentrations (C-e) of propofol and the effect of additional fentanyl. Methods: A total of 80 patients were recruited into the study. The study group included patients with supratentorial tumors undergoing craniotomy, and the control group consisted of patients undergoing spinal surgeries. Patients in each group were randomized further to receive propofol alone or propofol preceded by fentanyl for induction of anesthesia. They were divided into the following groups: patients with supratentorial tumor receiving only propofol (group T1), or fentanyl and propofol (group T2); patients who were undergoing spinal surgery and receiving only propofol (group S1) or fentanyl and propofol (group S2). Anesthesia was induced with infusion of propofol through a Target Controlled Infusion pump. At the point of loss of verbal contact, plasma concentration (C-p) and C-e of propofol, time taken for loss of consciousness, and the total dose of propofol required were noted. Hemodynamic variables were recorded before and after induction of anesthesia. Results: There were 19, 21, 19, and 21 patients in groups T1, T2, S1, and S2, respectively. In group T2 the C-p, C-e, time to loss of verbal contact, and dose required for induction were all significantly lower compared with the other groups. There were no significant differences in the study parameters between T1 and S1, whereas the differences were significant between T2 and S2 (C-p: 3.9 +/- 1.1 vs. 4.9 +/- 1.2 mu g/mL; C-e: 2.6 +/- 1.0 vs. 3.7 +/- 1.2 mu g/mL; P < 0.05). Conclusions: Propofol dose for induction of anesthesia was significantly reduced when administered after fentanyl in patients with supratentorial tumors. Tumors per se without fentanyl coadministration do not decrease the propofol requirement for induction of anesthesia.	[Bansal, Sonia; Ramesh, Venkatapura J.; Umamaheswara, Ganne S.] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuroanaesthesia, Bangalore 560029, Karnataka, India	Ramesh, VJ (reprint author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuroanaesthesia, Bangalore 560029, Karnataka, India.	ramesh@nimhans.kar.nic.in	Ramesh, Venkatapura J/H-1147-2013				BENONI G, 1990, EUR J PHARMACOL, V183, P1457, DOI 10.1016/0014-2999(90)94598-R; Chan MTV, 1999, ANESTHESIOLOGY, V90, P1571, DOI 10.1097/00000542-199906000-00012; Daniel KO, 2001, ANESTHESIA NEUROSURG, P178; GIAGNONI G, 1977, P NATL ACAD SCI USA, V74, P2259, DOI 10.1073/pnas.74.6.2259; GILL SS, 1990, BRIT J ANAESTH, V65, P760, DOI 10.1093/bja/65.6.760; Hans P, 1997, J NEUROSURG ANESTH, V9, P112, DOI 10.1097/00008506-199704000-00002; KAY NH, 1986, BRIT J ANAESTH, V58, P1075, DOI 10.1093/bja/58.10.1075; KIRKPATRICK T, 1988, BRIT J ANAESTH, V60, P146, DOI 10.1093/bja/60.2.146; Lim TA, 1997, J NEUROSURG ANESTH, V9, P242, DOI 10.1097/00008506-199707000-00008; Nieuwenhuijs DJF, 2003, ANESTHESIOLOGY, V98, P312, DOI 10.1097/00000542-200302000-00008; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; Pavlin DJ, 1996, ANESTHESIOLOGY, V84, P23, DOI 10.1097/00000542-199601000-00004; Peter JD, 1999, ANESTH ANALG, V88, P335; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Schubert A, 1996, ANESTHESIOLOGY, V85, P513, DOI 10.1097/00000542-199609000-00010; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; THOMAS GE, 1990, LIFE SCI, V46, P1279, DOI 10.1016/0024-3205(90)90360-4; YU VC, 1986, J BIOL CHEM, V261, P1065	19	7	7	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2012	24	4					345	349		10.1097/ANA.0b013e318262282f			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	013GR	WOS:000309294400010	22828155				2020-06-30	J	Upton, RN; Foster, DJR; Christrup, LL; Dale, O; Moksnes, K; Popper, L				Upton, Richard N.; Foster, David J. R.; Christrup, Lona L.; Dale, Ola; Moksnes, Kristin; Popper, Lars			A physiologically-based recirculatory meta-model for nasal fentanyl in man	JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS			English	Article						Fentanyl; Nasal; Intravenous; PK-PD; PB-PK; Population; Recirculatory; Meta-model	PHARMACOKINETIC MODELS; COMPARATIVE PHARMACODYNAMICS; TISSUE DISTRIBUTION; CARDIAC-OUTPUT; DOUBLE-BLIND; KINETICS; PAIN; BUPRENORPHINE; INTRANASAL; ALFENTANIL	Pharmacokinetic (PK) and pharmacodynamic (PD) data were available from a study of a nasal delivery system for the opioid analgesic fentanyl, together with data on the kinetics of fentanyl in arterial blood in man, and in the lung and brain of sheep. Our aim was to reconcile these data using a physiologically-based population recirculatory PK-PD model, with emphasis on achieving a meta-model that could simultaneously account for the arterial and venous (arm) concentrations of fentanyl, could relate PD effects (pain scores) to the CNS concentrations of fentanyl, and could account for the effect of body size and age on fentanyl kinetics. Data on the concentration gradients of fentanyl across brain, lung and muscle were used to develop sub-models of fentanyl kinetics in these organs. The sub-models were incorporated into a "whole body" recirculatory model by adding additional sub-models for a venous mixing compartment, the liver and gut, the kidney and the "rest of the body" with blood flows and organ volumes based on values for a Standard Man. Inter-individual variability was achieved by allometric scaling of organ size and blood flows, evidence-based assumptions about the effect of weight and age on cardiac output, and inter-individual variability in the free fraction in plasma and hepatic extraction of fentanyl. Post-operative pain scores were found to be temporally related to the predicted brain concentrations of fentanyl. We conclude that a physiologically-based meta-modelling approach was able to describe clinical PK-PD studies of fentanyl whilst providing a mechanistic interpretation of key aspects of its disposition.	[Upton, Richard N.; Foster, David J. R.] Univ S Australia, Australian Ctr Pharmacometr, Adelaide, SA 5001, Australia; [Christrup, Lona L.] Univ Copenhagen, Fac Pharmaceut Sci, Dept Pharmacol & Pharmacotherapy, Copenhagen, Denmark; [Dale, Ola; Moksnes, Kristin] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway; [Popper, Lars] Nycomed, Roskilde, Denmark	Upton, RN (reprint author), Univ S Australia, Australian Ctr Pharmacometr, North Terrace, Adelaide, SA 5001, Australia.	richard.upton@unisa.edu.au	Foster, David J R/D-1172-2011; Upton, Richard N/G-4727-2011	Upton, Richard N/0000-0001-9996-4886; Foster, David/0000-0002-7345-4084; Christrup, Lona/0000-0002-4128-7373			AINSLIE SG, 1979, ANESTHESIOLOGY, V51, P293, DOI 10.1097/00000542-197910000-00003; Anderson BJ, 2008, ANNU REV PHARMACOL, V48, P303, DOI 10.1146/annurev.pharmtox.48.113006.094708; Andresen T, 2011, BASIC CLIN PHARMACOL, V108, P274, DOI 10.1111/j.1742-7843.2010.00649.x; BJORKMAN S, 1994, J PHARMACOKINET BIOP, V22, P381, DOI 10.1007/BF02353862; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Corrigan B, 2007, AAPS NEWSMAG, P26; deSimone G, 1997, CIRCULATION, V95, P1837; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; JACOBS JR, 1995, J PHARM SCI, V84, P370, DOI 10.1002/jps.2600840320; Jamei M, 2009, DRUG METAB PHARMACOK, V24, P53, DOI 10.2133/dmpk.24.53; Kazama T, 2003, ANESTHESIOLOGY, V98, P299, DOI 10.1097/00000542-200302000-00006; Krejcie TC, 1999, ANESTH ANALG, V89, P541, DOI 10.1097/00000539-199909000-00001; KREJCIE TC, 1994, J PHARMACOL EXP THER, V269, P609; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Langdon G, 2007, EUR J CLIN PHARMACOL, V63, P485, DOI 10.1007/s00228-007-0264-x; Levitt David G, 2003, BMC Clin Pharmacol, V3, P3, DOI 10.1186/1472-6904-3-3; Masui K, 2010, ANESTH ANALG, V111, P368, DOI 10.1213/ANE.0b013e3181bdcf5b; MATHER LE, 1981, BRIT J CLIN PHARMACO, V12, P319, DOI 10.1111/j.1365-2125.1981.tb01220.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Nestorov I, 2003, CLIN PHARMACOKINET, V42, P883, DOI 10.2165/00003088-200342100-00002; Nestorov I, 2007, EXPERT OPIN DRUG MET, V3, P235, DOI 10.1517/17425255.3.2.235; Price PS, 2003, CRIT REV TOXICOL, V33, P469, DOI 10.1080/10408440390242324; R Development Core Team, 2008, R LANG ENV STAT COMP; Rodgers T, 2005, J PHARM SCI-US, V94, P1259, DOI 10.1002/jps.20322; ROWLAND M, 1989, CLIN PHARMACOKINETIC; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; STANSKI DR, 1984, J PHARMACOKINET BIOP, V12, P223, DOI 10.1007/BF01059279; Tod M, 2008, PHARM RES, V25, P1431, DOI 10.1007/s11095-008-9546-y; Upton Richard N., 2008, Journal of Pharmacological and Toxicological Methods, V58, P198, DOI 10.1016/j.vascn.2008.08.001; Upton RN, 1996, BRIT J ANAESTH, V77, P764; Upton RN, 1997, CLIN PHARMACOKINET, V33, P225, DOI 10.2165/00003088-199733030-00005; Upton RN, 2005, ANESTHESIOLOGY, V103, P344, DOI 10.1097/00000542-200508000-00018; Upton RN, 2004, BRIT J ANAESTH, V93, P687, DOI 10.1093/bja/aeh261; Upton RN, 2004, BRIT J ANAESTH, V92, P475, DOI 10.1093/bja/aeh089; VEROTTA D, 1989, AM J PHYSIOL, V256, pR1005; Villesen HH, 2006, J PHARM SCI-US, V95, P1666, DOI 10.1002/jps.20632; WATANABE K, 1992, RISK ANAL, V12, P301, DOI 10.1111/j.1539-6924.1992.tb00677.x; Weiss M, 1996, BRIT J CLIN PHARMACO, V41, P261, DOI 10.1046/j.1365-2125.1996.03121.x; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; Yassen A, 2006, J PHARMACOL EXP THER, V319, P682, DOI 10.1124/jpet.106.107953	45	7	7	1	13	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1567-567X			J PHARMACOKINET PHAR	J. Pharmacokinet. Pharmacodyn.	OCT	2012	39	5					561	576		10.1007/s10928-012-9268-y			16	Pharmacology & Pharmacy	Pharmacology & Pharmacy	008MX	WOS:000308962200010	22903816				2020-06-30	J	Bessiere, B; Laboureyras, E; Ben Boujema, M; Laulin, JP; Simonnet, G				Bessiere, Baptiste; Laboureyras, Emilie; Ben Boujema, Meric; Laulin, Jean-Paul; Simonnet, Guy			A high-dose of fentanyl induced delayed anxiety-like behavior in rats. Prevention by a NMDA receptor antagonist and nitrous oxide (N2O)	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Opioid; Anxiety-like behavior; Nitrous oxide; NMDA receptor	ELEVATED PLUS-MAZE; OPIOID-INDUCED HYPERALGESIA; METHYL-D-ASPARTATE; LONG-LASTING HYPERALGESIA; SPONTANEOUS WITHDRAWAL; POSTOPERATIVE PAIN; EXPERIENCED RATS; DORSAL-HORN; MORPHINE; DEPENDENCE	Postoperative negative affects such as anxiety need to be better understood and treated to improve patient recovery. The present study evaluates the effect of a single exposure to a high-dose of opioid (4 x 100 mu g/kg fentanyl injections in 15 min intervals resulting in a total dose of 400 mu g/kg), as used for surgery in humans, on anxiety-like behavior (ALB) in rats. First, the level of anxiety was evaluated 24-h after a high-dose of fentanyl using an elevated plus-maze apparatus. Second, the preventive effect of BN2572, a N-methyl-D-aspartate receptor (NMDA-R) antagonist, and 50% nitrous oxide (N2O), a gas with NMDA-R antagonist properties, was assessed. A significant increase in ALB was observed in fentanyl-treated rats. Interestingly, fentanyl-induced ALB was prevented by BN2572, suggesting a NMDA-dependant pathway. Fentanyl-induced ALB was also prevented by a single 50% N2O exposure. The present study provides evidence that deleterious outcomes of opioid use, referred to as "post-opioid syndrome", include not only pain hypersensitivity as previously described, but also negative affects such as anxiety. Since N2O prevents elements of this post-opioid syndrome, we speculate that N2O could be a good therapeutic agent to facilitate postoperative rehabilitation. (c) 2012 Elsevier Inc. All rights reserved.	[Bessiere, Baptiste] Air Liquide Sante Int, Ctr Rech Claude Delorme, F-78354 Jouy En Josas, France; [Bessiere, Baptiste; Laboureyras, Emilie; Ben Boujema, Meric; Laulin, Jean-Paul; Simonnet, Guy] Univ Bordeaux, INCIA, UMR 5287, F-33000 Bordeaux, France; [Bessiere, Baptiste; Laboureyras, Emilie; Ben Boujema, Meric; Laulin, Jean-Paul; Simonnet, Guy] CNRS, INCIA, UMR 5287, F-33000 Bordeaux, France	Bessiere, B (reprint author), Air Liquide Sante Int, Ctr Rech Claude Delorme, 1 Chemin Porte Loges, F-78354 Jouy En Josas, France.	baptiste.bessiere@airliquide.com			Universite Bordeaux 2; Universite Bordeaux 1; Centre National de la Recherche Scientifique (CNRS), Bordeaux, France; Ministere de l'Education nationale, de l'Enseignement superieur et de la Recherche, Paris, France; Air Liquide, Paris, France	This work was supported by the Universite Bordeaux 2, the Universite Bordeaux 1, the Centre National de la Recherche Scientifique (CNRS), Bordeaux, France; the Ministere de l'Education nationale, de l'Enseignement superieur et de la Recherche, Paris, France; and Air Liquide, Paris, France. BB was a PhD Student employed by Air Liquide with an Industrial Convention for Research Training (CIFRE) delivered by the National Association for Technical Research (ANRT). All this work was performed by the "Homeostasie-Allostasie-Pathologie-Rehabilitation" team under the supervision of Prof. Guy Simonnet in the Unite Mixte de Recherche CNRS 5287.	Adamec RE, 1999, PHYSIOL BEHAV, V65, P723; American Psychiatric Association, 2007, DSM 4 TR DIAGN STAT; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; BECHARA A, 1995, BEHAV NEUROSCI, V109, P91, DOI 10.1037/0735-7044.109.1.91; Bergink V, 2004, EUR NEUROPSYCHOPHARM, V14, P175, DOI 10.1016/S0924-977X(03)00100-7; Bermudo-Soriano CR, 2012, PHARMACOL BIOCHEM BE, V100, P752, DOI 10.1016/j.pbb.2011.04.010; Bessiere B, 2007, NEUROPHARMACOLOGY, V53, P733, DOI 10.1016/j.neuropharm.2007.08.003; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Buse DC, 2012, HEADACHE, V52, P18, DOI 10.1111/j.1526-4610.2011.02050.x; Carr ECJ, 2005, INT J NURS STUD, V42, P521, DOI 10.1016/j.ijnurstu.2004.09.014; Caumo W, 2001, ANAESTHESIA, V56, P720, DOI 10.1046/j.1365-2044.2001.01842.x; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Culley DJ, 2008, ANESTHESIOLOGY, V108, P553, DOI 10.1097/ALN.0b013e318167a7fb; Echevarria G, 2011, BRIT J ANAESTH, V107, P959, DOI 10.1093/bja/aer323; Emmanouil Dimitris E, 2007, Anesth Prog, V54, P9, DOI 10.2344/0003-3006(2007)54[9:AIUTAO]2.0.CO;2; Ersek Mary, 2004, Pain Manag Nurs, V5, P75, DOI 10.1016/j.pmn.2003.11.002; Georgiev SK, 2008, PAIN, V134, P24, DOI 10.1016/j.pain.2007.03.026; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Harris AC, 2005, PSYCHOPHARMACOLOGY, V178, P353, DOI 10.1007/s00213-005-2155-0; Harris AC, 2008, PSYCHOPHARMACOLOGY, V196, P649, DOI 10.1007/s00213-007-0998-2; Hirbec H, 2000, BRAIN RES, V859, P177, DOI 10.1016/S0006-8993(99)02420-8; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Koks S, 1999, NEUROPEPTIDES, V33, P63, DOI 10.1054/npep.1999.0015; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Li S, 2003, PSYCHOPHARMACOLOGY, V166, P366, DOI 10.1007/s00213-002-1363-0; Li S, 2001, PHARMACOL BIOCHEM BE, V68, P789, DOI 10.1016/S0091-3057(01)00487-7; Liu JA, 2004, PHARMACOL BIOCHEM BE, V79, P101, DOI 10.1016/j.pbb.2004.06.006; Macaluso AD, 1996, ANESTH ANALG, V82, P158, DOI 10.1097/00000539-199601000-00029; MAURICE T, 1994, PSYCHOPHARMACOLOGY, V114, P520, DOI 10.1007/BF02249345; McKenzie LH, 2010, PSYCHOL HEALTH MED, V15, P74, DOI 10.1080/13548500903483486; Mennerick S, 1998, J NEUROSCI, V18, P9716; MOTTA V, 1993, PHARMACOL BIOCHEM BE, V44, P119, DOI 10.1016/0091-3057(93)90288-5; Munafo MR, 2001, J PSYCHOSOM RES, V51, P589, DOI 10.1016/S0022-3999(01)00258-6; Nagele P, 2004, P NATL ACAD SCI USA, V101, P8791, DOI 10.1073/pnas.0402825101; Pain L, 2008, BEHAV BRAIN RES, V190, P119, DOI 10.1016/j.bbr.2008.02.010; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Ranft A, 2007, NEUROPHARMACOLOGY, V52, P716, DOI 10.1016/j.neuropharm.2006.09.021; Research and Analysis Section of UNODC, 2007, WORLD DRUG REP; Richebe P, 2005, ANESTHESIOLOGY, V103, P845, DOI 10.1097/00000542-200510000-00024; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Rivat C, 2007, NEUROPSYCHOPHARMACOL, V32, P2217, DOI 10.1038/sj.npp.1301340; Rivot JP, 1999, BRAIN RES, V821, P101, DOI 10.1016/S0006-8993(99)01075-6; Rothwell PE, 2009, NEUROPSYCHOPHARMACOL, V34, P2285, DOI 10.1038/npp.2009.56; Sanders RD, 2008, ANESTHESIOLOGY, V109, P707, DOI 10.1097/ALN.0b013e3181870a17; Sato Y, 2005, ANESTHESIOLOGY, V102, P557, DOI 10.1097/00000542-200503000-00013; Silbert BS, 2006, ANESTHESIOLOGY, V104, P1137, DOI 10.1097/00000542-200606000-00007; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Simonnet G, 2005, PAIN, V118, P8, DOI 10.1016/j.pain.2005.07.021; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Tao YX, 2000, EUR J PHARMACOL, V392, P141, DOI 10.1016/S0014-2999(00)00129-1; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401; White JM, 2004, ADDICT BEHAV, V29, P1311, DOI 10.1016/j.addbeh.2004.06.007; Wiley JL, 1995, EUR J PHARMACOL, V294, P101, DOI 10.1016/0014-2999(95)00506-4; Zhang Z, 2008, PHARMACOL BIOCHEM BE, V89, P392, DOI 10.1016/j.pbb.2008.01.013	59	4	5	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	OCT	2012	102	4					562	568		10.1016/j.pbb.2012.07.002			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	007PI	WOS:000308900200013	22796204				2020-06-30	J	Troster, A; Ihmsen, H; Singler, B; Filitz, J; Koppert, W				Troester, Andreas; Ihmsen, Harald; Singler, Boris; Filitz, Joerg; Koppert, Wolfgang			Interaction of Fentanyl and Buprenorphine in an Experimental Model of Pain and Central Sensitization in Human Volunteers	CLINICAL JOURNAL OF PAIN			English	Article						opioids; analgesia; hyperalgesia; pharmacodynamic model; interaction	TRANSDERMAL BUPRENORPHINE; POSTOPERATIVE PAIN; INDUCED ANALGESIA; RECEPTOR; HYPERALGESIA; MORPHINE; ALFENTANIL; KETAMINE	Objectives: There is controversy about combining opioids with different receptor affinities. We assessed the analgesic and antihyperalgesic effects of the mu-agonist fentanyl and the partial mu-agonist/k-antagonist buprenorphine in a human pain model, when given alone or in combination. Methods: Fifteen healthy male volunteers (22 to 35y) were included in this randomized, double-blind, placebo-controlled, cross-over study. Transcutaneous electrical stimulation induced spontaneous acute pain and stable areas of secondary hyperalgesia. Pain intensities, measured on a numeric rating scale from 0 to 10, and the size of the hyperalgesic areas were assessed before, during, and after an intravenous infusion of 1.5 mu g/kg fentanyl, 1.5 mu g/kg buprenorphine, a combination of 0.75 mu g/kg fentanyl and buprenorphine each, or saline 0.9%. Maximum effects of the treatments were compared by repeated measurement analysis of variance, and pharmacodynamic interaction models were fitted to the data. Results: Starting from a baseline value of numeric rating scale = 6, the maximum reduction of pain intensity after correction for placebo effects was 43.9 +/- 22.2% after fentanyl, 35.0 +/- 23.0% after buprenorphine, and 39.4 +/- 20.8% after the combination (mean +/- SD, P = 0.24). The maximum reduction of the hyperalgesic area was 38.3 +/- 39.0% for fentanyl, 34.4 +/- 32.7% for buprenorphine, and 30.0 +/- 53.8% for the combination (mean +/- SD, P = 0.82). The time courses were best described by pharmacodynamic models assuming an additive interaction. Discussion: For the doses administered in this study, buprenorphine and fentanyl showed an additive interaction.	[Troester, Andreas; Ihmsen, Harald; Singler, Boris] Univ Hosp Erlangen, Dept Anaesthesiol, D-91054 Erlangen, Germany; [Filitz, Joerg; Koppert, Wolfgang] Hannover Med Sch, Dept Anesthesiol & Intens Care, D-3000 Hannover, Germany	Ihmsen, H (reprint author), Univ Hosp Erlangen, Dept Anaesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.	harald.ihmsen@kfa.imed.uni-erlangen.de			Grunenthal GmbH, Aachen, Germany	This work was supported by a grant from Grunenthal GmbH, Aachen, Germany. The authors declare no conflict of interest. Presented, in part, at Euroanaesthesia, Vienna, Austria, May 28-31, 2005. A.T. and H.I. contributed equally.	BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; Bol CJJG, 2000, J PHARMACOL EXP THER, V294, P347; BULLINGHAM RES, 1980, CLIN PHARMACOL THER, V28, P667, DOI 10.1038/clpt.1980.219; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; COOK PJ, 1982, BRIT J ANAESTH, V54, P285, DOI 10.1093/bja/54.3.285; COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/j.1476-5381.1977.tb07532.x; Cowan Alan, 1995, P31; Dahan A, 2006, BRIT J ANAESTH, V96, P627, DOI 10.1093/bja/ael051; Englberger W, 2006, EUR J PHARMACOL, V534, P95, DOI 10.1016/j.ejphar.2006.01.022; Freye Enno, 2005, J Opioid Manag, V1, P162; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; Koppert W, 2005, PAIN, V118, P15, DOI 10.1016/j.pain.2005.06.030; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Koppert W, 2001, ANESTHESIOLOGY, V95, P395, DOI 10.1097/00000542-200108000-00022; Koppert W, 2007, BEST PRACT RES-CLIN, V21, P65, DOI 10.1016/j.bpa.2006.12.004; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; LEANDER JD, 1987, NEUROPHARMACOLOGY, V26, P1445, DOI 10.1016/0028-3908(87)90112-2; Lehmann KA, 1997, SUPPORT CARE CANCER, V5, P439, DOI 10.1007/s005200050111; LEWIS JW, 1985, DRUG ALCOHOL DEPEN, V14, P363, DOI 10.1016/0376-8716(85)90067-5; Lutfy K, 2003, J NEUROSCI, V23, P10331; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; Muller H, 1986, ANAESTHESIST, V25, P125; Pergolizzi J, 2010, PAIN PRACT, V10, P428, DOI 10.1111/j.1533-2500.2010.00378.x; SADEE W, 1982, J PHARMACOL EXP THER, V223, P157; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; Wala EP, 2011, EUR J PHARMACOL, V651, P89, DOI 10.1016/j.ejphar.2010.10.083; Wnendt S, 1999, MOL PHARMACOL, V56, P334; Yassen A, 2006, ANESTHESIOLOGY, V104, P1232, DOI 10.1097/00000542-200606000-00019	32	9	11	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	OCT	2012	28	8					705	711		10.1097/AJP.0b013e318241d948			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	004HL	WOS:000308672100009	22469638				2020-06-30	J	Naguib, AN; Dewhirst, E; Winch, PD; Simsic, J; Galantowicz, M; Tobias, JD				Naguib, Aymen N.; Dewhirst, Elisabeth; Winch, Peter D.; Simsic, Janet; Galantowicz, Mark; Tobias, Joseph D.			Pain Management After Surgery for Single-Ventricle Palliation Using the Hybrid Approach	PEDIATRIC CARDIOLOGY			English	Article							LEFT-HEART SYNDROME; EARLY EXTUBATION; CARDIAC-SURGERY; ANALGESIA	The hybrid pathway for the management of patients with hypoplastic left heart syndrome was pioneered at our institution and is the preferred approach compared with the traditional Norwood pathway. Patients undergoing this surgery are generally < 6 months of age, and pain management in this age group after surgery for complex congenital heart disease (CHD) may be particularly challenging. We retrospectively reviewed our pain-management strategy after stage 1 hybrid procedure (HS1) and evaluated its efficacy, especially in the setting of early tracheal extubation. We retrospectively reviewed the records of patients receiving fentanyl analgesia after HS1 palliation for single-ventricle anatomy between June 2008 and August 2011. In addition to demographic data, we also recorded the mode of analgesia, total fentanyl administered during the first 48 postoperative hours, and total hours of fentanyl use. Other data collected included pain scores, adverse effects, time of tracheal extubation, and use of adjunctive medications, such as dexmedetomidine. Nurse-controlled analgesia (NCA) with fentanyl was used in 21 of the 33 patients in the study cohort, with the remainder receiving a continuous fentanyl infusion. NCA-fentanyl was the method of choice in 12 of the 13 patients whose tracheas were extubated in the operating room versus 9 of 20 patients who received postoperative mechanical ventilation and tracheal intubation (p = 0.0093). During the first and second 24 h after surgery, fentanyl requirements were lower in patients whose tracheas were extubated (11.8 +/- A 7.6 vs. 20.6 +/- A 18.1 and 6.6 +/- A 10.3 vs. 24.3 +/- A 20.4 mu g/kg, respectively). Adverse effects were noted in 3 of the 33 patients (9%) and included one episode each of respiratory depression requiring reintubation of the trachea, pruritus, and excessive sedation. Dexmedetomidine was used as an adjunct medication in 5 patients and resulted in decreased fentanyl use (6.3 +/- A 1.3 vs. 19 +/- A 15.9 mu g/kg in the first 24 postoperative hours and 7.9 +/- A 3.5 vs. 19 +/- A 20.3 mu g/kg in the second 24 postoperative hours). Fentanyl administered by way of continuous infusion or NCA provided effective postoperative analgesia with a limited adverse effect profile after HS1 surgery in neonates with complex CHD. Fentanyl requirements were lower in patients who achieved early tracheal extubation as well as those who received dexmedetomidine.	[Naguib, Aymen N.; Dewhirst, Elisabeth; Winch, Peter D.; Tobias, Joseph D.] Ohio State Univ, Nationwide Childrens Hosp, Dept Anesthesiol, Columbus, OH 43210 USA; [Naguib, Aymen N.; Winch, Peter D.; Simsic, Janet; Galantowicz, Mark; Tobias, Joseph D.] Nationwide Childrens Hosp, Ctr Heart, Columbus, OH USA; [Simsic, Janet; Tobias, Joseph D.] Ohio State Univ, Dept Pediat, Nationwide Childrens Hosp, Columbus, OH 43210 USA	Naguib, AN (reprint author), Ohio State Univ, Nationwide Childrens Hosp, Dept Anesthesiol, Columbus, OH 43210 USA.	aymen.naguib@nationwidechildrens.org					Alghamdi AA, 2010, J CARDIAC SURG, V25, P586, DOI 10.1111/j.1540-8191.2010.01088.x; Galantowicz M, 2005, PEDIATR CARDIOL, V26, P190, DOI 10.1007/s00246-004-0962-4; Galantowicz M, 2008, ANN THORAC SURG, V85, P2063, DOI 10.1016/j.athoracsur.2008.02.009; Howard RF, 2010, PEDIATR ANESTH, V20, P126, DOI 10.1111/j.1460-9592.2009.03242.x; Iodice FG, 2011, EUR J CARDIO-THORAC, V40, P610, DOI 10.1016/j.ejcts.2010.12.032; Morton NS, 2010, PEDIATR ANESTH, V20, P119, DOI 10.1111/j.1460-9592.2009.03187.x; Naguib AN, 2010, PEDIATR ANESTH, V20, P38, DOI 10.1111/j.1460-9592.2009.03205.x; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Winch PD, 2009, HEART LUNG CIRC, V18, P271, DOI 10.1016/j.hlc.2008.11.009	9	6	6	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-0643			PEDIATR CARDIOL	Pediatr. Cardiol.	OCT	2012	33	7					1104	1108		10.1007/s00246-012-0233-8			5	Cardiac & Cardiovascular Systems; Pediatrics	Cardiovascular System & Cardiology; Pediatrics	006OJ	WOS:000308828200015	22349680				2020-06-30	J	Uchida, K; Yasunaga, H; Miyata, H; Sumitani, M; Horiguchi, H; Matsuda, S; Yamada, Y				Uchida, Kanji; Yasunaga, Hideo; Miyata, Hiroaki; Sumitani, Masahiko; Horiguchi, Hiromasa; Matsuda, Shinya; Yamada, Yoshitsugu			Impact of remifentanil use on early postoperative outcomes following brain tumor resection or rectal cancer surgery	JOURNAL OF ANESTHESIA			English	Article						Remifentanil; Brain neoplasm; Neurosurgery; Postoperative outcome	THORACIC EPIDURAL-ANESTHESIA; TOTAL INTRAVENOUS ANESTHESIA; D-ASPARTATE RECEPTORS; STRESS-RESPONSE; INTRACRANIAL-PRESSURE; SEVOFLURANE; PROPOFOL; ANALGESIA; INFUSION; ISOFLURANE	Remifentanil, a mu-opioid receptor agonist, has important characteristics for neuroanesthesia, but data about its effects on postoperative recovery and mortality are currently lacking. Using the Japanese Diagnosis Procedure Combination database in 2007, we selected patients who underwent elective brain tumor resection with open craniotomy under general anesthesia using either remifentanil or fentanyl and divided them into two categories: remifentanil patients and non-remifentanil patients. After propensity score matching for potential confounders, we compared the in-hospital mortality and postoperative length of stay (LOS) between the two groups. For comparison, the same endpoints were evaluated for patients underwent rectal cancer surgery under general anesthesia with intraoperative epidural anesthesia. In patients who underwent brain tumor resection (936 pairs), remifentanil patients had significantly lower in-hospital mortality (1.5 % vs. 3.0 %; P = 0.029). Logistic regression analysis revealed that the odds ratio for use of remifentanil for in-hospital mortality was 0.47 (95 % confidence interval, 0.25-0.91; P = 0.025). Remifentanil patients also showed earlier discharge from hospital (median LOS, 17 vs. 19 days; hazard ratio, 1.19, 95 % confidence interval, 1.08-1.30; P < 0.001). In contrast, in 2,756 pairs of patients undergoing rectal cancer surgery, no significant difference was seen in either in-hospital morality (1.2 % vs. 1.3 %; P = 0.518) or median LOS (19 vs. 19 days; P = 0.148) between the two groups. Our data suggest a possible association between use of remifentanil and better early postoperative recovery for patients undergoing neurosurgery with craniotomy. Further studies, including a randomized controlled trial, are required to confirm the present results.	[Uchida, Kanji; Sumitani, Masahiko; Yamada, Yoshitsugu] Univ Tokyo, Grad Sch Med, Dept Anesthesiol, Bunkyo Ku, Tokyo 1138655, Japan; [Yasunaga, Hideo; Horiguchi, Hiromasa] Univ Tokyo, Grad Sch Med, Dept Hlth Management & Policy, Tokyo 1138655, Japan; [Miyata, Hiroaki] Univ Tokyo, Grad Sch Med, Dept Hlth Qual Assessment, Tokyo 1138655, Japan; [Matsuda, Shinya] Univ Occupat & Environm Hlth, Dept Prevent Med & Community Hlth, Kitakyushu, Fukuoka 807, Japan	Uchida, K (reprint author), Univ Tokyo, Grad Sch Med, Dept Anesthesiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	uchidak-ane@h.u-tokyo.ac.jp		Matsuda, Shinya/0000-0002-8472-8909; Yasunaga, Hideo/0000-0002-6017-469X	Ministry of Health, Labour and Welfare, JapanMinistry of Health, Labour and Welfare, Japan [H19-Policy-001]	This study was funded by Grants-in-Aid for Research on Policy Planning and Evaluation (Grant Number: H19-Policy-001) from the Ministry of Health, Labour and Welfare, Japan.	Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; Buggy DJ, 1999, BMJ-BRIT MED J, V319, P530, DOI 10.1136/bmj.319.7209.530; Coles JP, 2000, J NEUROSURG ANESTH, V12, P15, DOI 10.1097/00008506-200001000-00004; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Fodale V, 2008, ACTA ANAESTH SCAND, V52, P319, DOI 10.1111/j.1399-6576.2007.01566.x; Gesztesi Z, 1999, ANESTH ANALG, V89, P1282, DOI 10.1213/00000539-199911000-00038; Griswold ME, 2010, ANN INTERN MED, V152, P393, DOI 10.7326/0003-4819-152-6-201003160-00010; Grossman R, 2011, ANN SURG ONCOL, V18, P521, DOI 10.1245/s10434-010-1299-2; Hahnenkamp K, 2004, ANESTHESIOLOGY, V100, P1531, DOI 10.1097/00000542-200406000-00028; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014; Holmstrom A, 2004, J NEUROSURG ANESTH, V16, P136, DOI 10.1097/00008506-200404000-00005; Ihn CH, 2009, J INT MED RES, V37, P1760, DOI 10.1177/147323000903700612; Kabon B, 2007, ANAESTHESIA, V62, P1101, DOI 10.1111/j.1365-2044.2007.05228.x; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Koppert W, 2003, ANESTHESIOLOGY, V99, P152, DOI 10.1097/00000542-200307000-00025; Kuwabara K, 2010, J TRAUMA, V68, P463, DOI 10.1097/TA.0b013e3181a60275; Loick HM, 1999, ANESTH ANALG, V88, P701, DOI 10.1097/00000539-199904000-00001; Luo Y, 2008, ANESTHESIOLOGY, V109, P782, DOI 10.1097/ALN.0b013e3181895f88; Marana E, 2010, J CLIN ANESTH, V22, P250, DOI 10.1016/j.jclinane.2009.07.011; Matsuda S., 2008, Eurohealth, V14, P25; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; Nakamura M, 2005, ACTA NEUROCHIR, V147, P603, DOI 10.1007/s00701-005-0517-3; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Ostapkovich ND, 1998, ANESTHESIOLOGY, V89, P358, DOI 10.1097/00000542-199808000-00011; Payne RS, 2005, BRAIN RES, V1034, P147, DOI 10.1016/j.brainres.2004.12.006; Peart JN, 2005, VASC PHARMACOL, V42, P211, DOI 10.1016/j.vph.2005.02.003; Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010; SAKABE T, 2001, [No title captured], P129; Sawaya R, 1998, NEUROSURGERY, V42, P1044, DOI 10.1097/00006123-199805000-00054; Schricker T, 2004, ACTA ANAESTH SCAND, V48, P169, DOI 10.1111/j.0001-5172.2004.00297.x; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Uchida K, 2011, J ANESTH, V25, P864, DOI 10.1007/s00540-011-1221-5; Viviand X, 2004, ANN FR ANESTH, V23, P383, DOI 10.1016/j.annfar.2004.03.004; Weale NK, 2004, BRIT J ANAESTH, V92, P187, DOI 10.1093/bja/aeh038; Winterhalter M, 2008, EUR J ANAESTH, V25, P326, DOI 10.1017/S0265021507003043; Yasunaga H, 2010, UROLOGY, V76, P548, DOI 10.1016/j.urology.2010.03.021; Yim APC, 2000, CHEST, V117, P1220, DOI 10.1378/chest.117.5.1220	42	7	9	0	0	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2012	26	5					711	720		10.1007/s00540-012-1397-3			10	Anesthesiology	Anesthesiology	021CI	WOS:000309862500011	22555501				2020-06-30	J	Koh, IJ; Kang, YG; Chang, CB; Song, J; Jeon, YT; Kim, TK				Koh, In Jun; Kang, Yeon Gwi; Chang, Chong Bum; Song, Junghan; Jeon, Young-Tae; Kim, Tae Kyun			Use of Reduced-Dose Periarticular Injection for Pain Management in Simultaneous Bilateral Total Knee Arthroplasty	JOURNAL OF ARTHROPLASTY			English	Article						simultaneous bilateral total knee arthroplasty; pain management; periarticular multimodal drug injection	INFILTRATION ANALGESIA; ROPIVACAINE; TRIAL; BUPIVACAINE; EFFICACY; PROTOCOL; INTERVAL; SURGERY; HIP	We investigated the safety and efficacy of the bilateral periarticular multimodal drug injection (PMDI) at a reduced dosage in patients undergoing simultaneous bilateral total knee arthroplasty (SBTKA). In total, 45 patients undergoing SBTKA received 65 mL PMDI in each knee (reduced-dose group). The incidence of drug-related adverse effects and wound complications were evaluated. Pain levels during the night of the operation and postoperative day 1 and opioid consumption during the first 24 hours after surgery were compared with the regular-dose group of 55 patients undergoing SBTKA who received 100 mL of PMDI in 1 knee. No patient experienced a serious drug-related adverse effect or wound complication. Blood levels of ropivacaine were observed to be lower than a toxic level throughout the monitored period in all patients examined. Patients in the reduced-dose group experienced less pain during the night of operation, but a similar pain level at postoperative day 1.	[Koh, In Jun] Catholic Univ Korea, Uijeongbu St Marys Hosp, Dept Orthopaed Surg, Coll Med, Uijongbu, Gyeonggi Do, South Korea; [Kang, Yeon Gwi; Chang, Chong Bum; Kim, Tae Kyun] Seoul Natl Univ, Joint Reconstruct Ctr, Bundang Hosp, Songnam, Gyeonggi Do, South Korea; [Kang, Yeon Gwi] Dankook Univ, Dept Stat, Yongin, Gyeonggi Do, South Korea; [Chang, Chong Bum; Kim, Tae Kyun] Seoul Natl Univ, Coll Med, Dept Orthopaed Surg, Seoul, South Korea; [Song, Junghan] Seoul Natl Univ, Bundang Hosp, Dept Lab Med, Songnam, Gyeonggi Do, South Korea; [Jeon, Young-Tae] Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Songnam, Gyeonggi Do, South Korea	Kim, TK (reprint author), Seoul Natl Univ, Dept Orthopaed Surg, Joint Reconstruct Ctr, Bundang Hosp, 166 Gumi Ro, Songnam 463707, Gyeonggi Do, South Korea.		Chang, Chong Bum/J-5630-2012; Kim, Tae Kyun/J-5446-2012; Jeon, Young Tae/J-5635-2012				Andersen LO, 2008, ACTA ANAESTH SCAND, V52, P1331, DOI 10.1111/j.1399-6576.2008.01777.x; Bianconi M, 2003, BRIT J ANAESTH, V91, P830, DOI 10.1093/bja/aeg277; Busch CA, 2006, J BONE JOINT SURG AM, V88A, P959, DOI 10.2106/JBJS.E.00344; Kerr DR, 2008, ACTA ORTHOP, V79, P174, DOI 10.1080/17453670710014950; Koh IJ, 2011, KNEE; Koh IJ, 2010, KNEE SURG SPORT TR A, V18, P916, DOI 10.1007/s00167-010-1051-2; Krych Aaron J, 2010, Instr Course Lect, V59, P99; Lombardi AV, 2004, CLIN ORTHOP RELAT R, P125, DOI 10.1097/01.blo.000147701.24029.cc; Maheshwari AV, 2009, CLIN ORTHOP RELAT R, V467, P1418, DOI 10.1007/s11999-009-0728-7; March LM, 2004, OSTEOARTHR CARTILAGE, V12, P400, DOI 10.1016/j.joca.2004.02.002; McClellan KJ, 2000, DRUGS, V60, P1065, DOI 10.2165/00003495-200060050-00007; Memtsoudis SG, 2009, ANESTHESIOLOGY, V111, P1206, DOI 10.1097/ALN.0b013e3181bfab7d; Mullaji A, 2010, J ARTHROPLASTY, V25, P851, DOI 10.1016/j.arth.2009.09.007; Parker DA, 2009, J ARTHROPLASTY, V24, P918, DOI 10.1016/j.arth.2008.05.001; Parvataneni HK, 2007, J ARTHROPLASTY, V22, P33, DOI 10.1016/j.arth.2007.03.034; Parvataneni Hari K, 2007, Instr Course Lect, V56, P125; Powell RS, 2006, J ARTHROPLASTY, V21, P642, DOI 10.1016/j.arth.2005.08.009; Reuben JD, 1998, J ARTHROPLASTY, V13, P172, DOI 10.1016/S0883-5403(98)90095-X; Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003; SCOTT DB, 1989, ANESTH ANALG, V69, P563, DOI 10.1213/00000539-198911000-00003; Shetty GM, 2010, KNEE, V17, P191, DOI 10.1016/j.knee.2009.08.009; Stewert J, 2003, ANESTH ANALG, V97, P412, DOI 10.1213/01.ANE.0000069506.68137.F2; Strassels SA, 2002, ANESTH ANALG, V94, P130, DOI 10.1097/00000539-200201000-00025; Straus SMJM, 2006, J AM COLL CARDIOL, V47, P362, DOI 10.1016/j.jacc.2005.08.067; TAN HL, 1995, ANN INTERN MED, V122, P701, DOI 10.7326/0003-4819-122-9-199505010-00009; Toftdahl K, 2007, ACTA ORTHOP, V78, P172, DOI 10.1080/17453670710013645; Vendittoli PA, 2006, J BONE JOINT SURG AM, V88A, P282, DOI 10.2106/JBJS.E.00173; Zeni JA, 2010, J ARTHROPLASTY, V25, P541, DOI 10.1016/j.arth.2009.02.016	28	9	9	0	1	CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS	PHILADELPHIA	CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA	0883-5403			J ARTHROPLASTY	J. Arthroplast.	OCT	2012	27	9					1731	1736		10.1016/j.arth.2012.03.054			6	Orthopedics	Orthopedics	013WA	WOS:000309335400025	22682046				2020-06-30	J	Sharma, V; Miah, M; Cameron, M				Sharma, V.; Miah, M.; Cameron, M.			LOZENGE RISKS	BRITISH DENTAL JOURNAL			English	Letter																Carver A, 2010, PHARM MANAGEMENT PAI; Kidd E., 2005, ESSENTIALS DENT CARI	2	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0610	1476-5373		BRIT DENT J	Br. Dent. J.	SEP	2012	213	5					199	199		10.1038/sj.bdj.2012.788			1	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	005YE	WOS:000308785200009	22955741				2020-06-30	J	Ripamonti, CI				Ripamonti, C. I.			Pain management	ANNALS OF ONCOLOGY			English	Article						assessment; bone pain; cancer pain; neuropathic pain; prevalence; treatment	BREAKTHROUGH CANCER PAIN; TRANSMUCOSAL FENTANYL CITRATE; RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; INTRAVENOUS MORPHINE; ANALGESIC LADDER; DOUBLE-BLIND; METHADONE; EFFICACY; TOLERABILITY	Despite published guidelines and educational programs on the assessment and treatment of cancer-related pain, in any stage of oncological disease, unrelieved pain continues to be a substantial worldwide public health concern either in patients with solid and haematological malignancies. The proper and regular self-reporting assessment of pain is the first step for an effective and individualized treatment. Opioids are the mainstay of analgesic therapy and can be associated with non-opioids drugs such as paracetamol or non-steroidal anti-inflammatory drugs and to adjuvant drugs (for neuropathic pain and symptom control). The role and the utility of weak opioids (i.e. codeine, dihydrocodeine, tramadol) are a controversy point. Morphine has been placed by World Health Organization on its Essential Drug List. In the comparative study with other strong opioids (hydromorphone, oxycodone), there is no evidence to show superiority or inferiority with morphine as the first choice opioid. Oral methadone is a useful and safe alternative to morphine. Methadone presents the potential to control pain difficult to manage with other opioids. Although the oral route of opioid administration is considered the one of choice, intravenous, subcutaneous, rectal, transdermal, sublingual, intranasal, and spinal routes must be used in particular situation. Transdermal opioids such as fentanyl and buprenorphine are best reserved for patients whose opioid requirements are stable. Switching from one opioid to another can improve analgesia and tolerability.	Fdn IRCCS, Ist Nazl Tumori, Support Care Canc Unit, I-20133 Milan, Italy	Ripamonti, CI (reprint author), Fdn IRCCS, Ist Nazl Tumori, Support Care Canc Unit, Via Venezian 1, I-20133 Milan, Italy.	carla.ripamonti@istitutotumori.mi.it	Ripamonti, Carla/C-4557-2017	Ripamonti, Carla/0000-0001-5495-5054			[Anonymous], 1986, Pain Suppl, V3, pS1; Apolone G, 2009, BRIT J CANCER, V100, P1566, DOI 10.1038/sj.bjc.6605053; Bandieri E, 2010, LEUKEMIA RES, V34, pE334, DOI 10.1016/j.leukres.2010.08.013; Benitez-Rosario MA, 2004, CANCER-AM CANCER SOC, V101, P2866, DOI 10.1002/cncr.20712; Bennett MI, 2011, PALLIATIVE MED, V25, P553, DOI 10.1177/0269216310378546; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Burton AW, 2007, PAIN MED, V8, P189, DOI 10.1111/j.1526-4637.2006.00220.x; Burza M, 1998, Clin Ter, V149, P277; Cachia Elaine, 2011, Curr Opin Support Palliat Care, V5, P15, DOI 10.1097/SPC.0b013e3283437a39; Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; CARLSON RW, 1990, PHARMACOTHERAPY, V10, P211; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Costantini M, 2009, ANN ONCOL, V20, P729, DOI 10.1093/annonc/mdn700; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; De Conno F, 2008, PALLIATIVE MED, V22, P214, DOI 10.1177/0269216308088692; DeConno F, 1996, J CLIN ONCOL, V14, P2836, DOI 10.1200/JCO.1996.14.10.2836; EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Frankish H, 2003, LANCET, V361, P1278, DOI 10.1016/S0140-6736(03)13038-3; Freynhagen R, 1994, Schmerz, V8, P210, DOI 10.1007/BF02527888; de Paredes MLG, 2011, ANN ONCOL, V22, P924, DOI 10.1093/annonc/mdq449; Genf World Health Organization, 1986, CANC PAIN REL; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Hanks GW, 1996, BRIT MED J, V312, P823; Harris JT, 2003, PALLIATIVE MED, V17, P248, DOI 10.1191/0269216303pm695oa; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Ida RC, 2012, CURR OPIN ONCOL, V24, P391, DOI 10.1097/CCO.0b013e328352eabc; King SJ, 2011, PALLIATIVE MED, V25, P454, DOI 10.1177/0269216311401948; Maltoni M, 2005, SUPPORT CARE CANCER, V13, P888, DOI 10.1007/s00520-005-0807-6; McNicol E, 2006, COCHRANE LIB; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V31, P242, DOI 10.1016/j.jpainsymman.2006.01.001; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2002, CANCER, V95, P203, DOI 10.1002/cncr.10636; Mercadante S, 2001, J CLIN ONCOL, V19, P2898, DOI 10.1200/JCO.2001.19.11.2898; Moore A, 1997, PAIN, V70, P193, DOI 10.1016/S0304-3959(96)03319-2; Morselli M, 2010, LEUKEMIA RES, V34, pE67, DOI 10.1016/j.leukres.2009.08.008; Paice JA, 2011, CA-CANCER J CLIN, V61, P157, DOI 10.3322/caac.20112; Pigni A, 2011, PALLIATIVE MED, V25, P471, DOI 10.1177/0269216310387962; Portenoy R, 2010, CANC PAIN ASSESSMENT, P53; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Puli SR, 2009, DIGEST DIS SCI, V54, P2330, DOI 10.1007/s10620-008-0651-x; Radbruch L, 1999, CLIN J PAIN, V15, P173, DOI 10.1097/00002508-199909000-00003; Ripamonti C, 2002, HEMATOL ONCOL CLIN N, V16, P543, DOI 10.1016/S0889-8588(02)00017-5; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Ripamonti C, 2011, ANN ONCOL S, V22, P69; Ripamonti C, 2010, CANC PAIN ASSESSMENT, V11, P195; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Ripamonti C, 2009, CRIT REV ONCOL HEMAT, V70, P145, DOI 10.1016/j.critrevonc.2008.12.005; Ripamonti CI, 2009, CLIN J PAIN, V25, P386, DOI 10.1097/AJP.0b013e3181929b4f; Sichetti D, 2010, ANN ONCOL, V21, P2088, DOI 10.1093/annonc/mdq155; Strobel E, 1992, Fortschr Med, V110, P411; Sun Virginia, 2008, J Cancer Surviv, V2, P65, DOI 10.1007/s11764-008-0047-0; Tassinari D, 2011, PALLIATIVE MED, V25, P410, DOI 10.1177/0269216311405090; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Ventafridda V, 1986, J Pain Symptom Manage, V1, P203, DOI 10.1016/S0885-3924(86)80042-2; Vignaroli E, 2012, J PALLIAT MED, V15, P186, DOI 10.1089/jpm.2011.0296; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; World Health Organization, 1996, CANC PAIN REL; Wyse JM, 2011, J CLIN ONCOL, V29, P3541, DOI 10.1200/JCO.2010.32.2750; Zeppetella G., 2006, COCHRANE DB SYST REV, V1, pCD004311	64	29	31	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	SEP	2012	23			10			294	301		10.1093/annonc/mds360			8	Oncology	Oncology	014YA	WOS:000309410600042	22987980	Bronze			2020-06-30	J	Kaessner, N; Nave, R; Roepcke, S; Facius, A; Lahu, G				Kaessner, Nele; Nave, Ruediger; Roepcke, Stefan; Facius, Axel; Lahu, Gezim			Population pharmacokinetic meta-analysis of an intranasal fentanyl spray as a means to enrich pharmacokinetic information in patients with cancer breakthrough pain	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS			English	Article						intranasal fentanyl; pharmacokinetics; metaanalysis; PopPK; cancer; pain	EFFICACY	Background: The development of intranasal fentanyl (INFS) aimed for a rapid treatment of breakthrough pain (BTP) in cancer patients. The pharmacokinetics (PK) of INFS was well characterized in healthy subjects, while PK investigations in cancer patients are limited. Objectives: The objective was to develop a population PK model for fentanyl in volunteers and patients following INFS administration, to evaluate the influence of potential covariates and to simulate the exposure of fentanyl after repeated dosing in cancer patients. Methods: PK data from ten clinical trials were used for model development. The final model was validated with nonparametric bootstrap and visual predictive check. In addition, the secondary PK parameters (AUC(0-tlast), C-max, t(max)) of a separate validation data set of INFS were predicted and compared to noncompartmental analysis results. Afterwards, repeated dose PK profiles in cancer patients were simulated. Results: Plasma profiles after INFS administration were best described by a three-compartment model. Significant covariate relationships were identified for naltrexone and oxymetazoline co-treatment. Influences of body weight, BMI, sex and cancer patient as subject type were considered not to be clinically relevant. PK parameters for subpopulations of cancer patients were derived. Steady state simulations revealed that an extension from the current SmPC scenario to 6 pain episodes per day would yield similar C-max values. Conclusions: A robust population PK model for INFS was developed. The model enhances the understanding of fentanyl PK after INFS dosing in cancer patients with BTP, a population for whom real-life data would be very hard to obtain.	[Kaessner, Nele; Nave, Ruediger; Roepcke, Stefan; Facius, Axel; Lahu, Gezim] Nycomed, Constance, Germany	Kaessner, N (reprint author), Takeda Pharmaceut Int GmbH, Pharmacometr, Thurgauerstr 130, CH-8152 Zurich, Switzerland.	nele.kaessner@takeda.com			Nycomed: a Takeda Company, Konstanz, Germany	Authors were or are currently employed by the sponsor of the analyzed trials (Nycomed: a Takeda Company, Konstanz, Germany).	Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Hudson RJ, 2002, CAN J ANAESTH, V49, P388, DOI 10.1007/BF03017328; Jonsson EN, 1999, COMPUT METH PROG BIO, V58, P51; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kaneda K, 2009, BURNS, V35, P790, DOI 10.1016/j.burns.2008.12.006; KARLSSON MO, 1993, J PHARMACOKINET BIOP, V21, P735, DOI 10.1007/BF01113502; MANDEMA JW, 1992, J PHARMACOKINET BIOP, V20, P511, DOI 10.1007/BF01061469; MOORE RA, 1987, BAILLIERE CLIN ANAES, V1, P829, DOI 10.1016/S0950-3501(87)80038-7; Nave R, 2009, 6 C EUR FED IASP CHA; Nycomed Danmark ApS, NYC DANM APS INST SU; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Sohota T, 2010, CHICKEN EGG INTEROCC, P19; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Wahlby U, 2002, AAPS PHARMSCI, V4	18	5	5	0	8	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0946-1965			INT J CLIN PHARM TH	Int. J. Clin. Pharmacol. Ther.	SEP	2012	50	9					665	677		10.5414/CP201737			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	018BI	WOS:000309634500008	22784611				2020-06-30	J	Al-Qadheeb, NS; Roberts, RJ; Griffin, R; Garpestad, E; Ruthazer, R; Devlin, JW				Al-Qadheeb, Nada S.; Roberts, Russel J.; Griffin, Ryan; Garpestad, Erik; Ruthazer, Robin; Devlin, John W.			Impact of Enteral Methadone on the Ability to Wean Off Continuously Infused Opioids in Critically Ill, Mechanically Ventilated Adults: A Case-Control Study	ANNALS OF PHARMACOTHERAPY			English	Article						analgesic; critical care; fentanyl; mechanical ventilation; methadone; opioid; withdrawal	SEDATION; ANALGESICS; PHARMACOKINETICS; TOLERANCE; FENTANYL; EFFICACY; PROTOCOL; SAFETY; TRIAL	BACKGROUND: Continuously infused opioids are frequently used to optimize patient comfort in the intensive care unit (ICU). However, concerns about rebound pain and opioid withdrawal may delay efforts to discontinue this therapy. OBJECTIVE: To measure the association between use of scheduled enteral methadone according to a protocol in mechanically ventilated, medical critically ill adults receiving prolonged continuously infused fentanyl and the time to discontinue continuously infused fentanyl therapy. METHODS: This case-control study included 20 consecutive mechanically ventilated adults in a medical ICU, without a history of chronic opioid use, who received 72 or more hours of continuously infused fentanyl and were prescribed scheduled enteral methadone as part of a protocol medical ICU strategy to wean off continuously infused fentanyl. Patients were matched in a 1:2 fashion, by duration of mechanical ventilation, to 40 consecutive preprotocol medical ICU patients meeting the same criteria but who were never given methadone. Duration of continuously infused fentanyl was compared between the 2 groups by constructing Kaplan-Meier plots and estimating the likelihood that methadone use was associated with a decrease in continuously infused fentanyl requirements over time, using a Cox proportional hazards model. RESULTS: The groups were well matched except the methadone patients were older (p = 0.04). Time (median [interquartile range]) to continuously infused fentanyl discontinuation was shorter in the methadone group (4.5 [3.9-5.8] vs 7.0 [4.9-11.5] days; p = 0.002). Continuously infused fentanyl was more likely to be discontinued 2 days after methadone was first initiated (hazard ratio 9.1; p = 0.0004). The proportion of patients who experienced 1 or more episodes of either QTc interval prolongation (p = 0.79) or unarousability (p = 0.47) was similar between the groups. CONCLUSIONs: Enterally administered methadone is associated with earlier cessation of continuously infused fentanyl in mechanically ventilated adults without a history of opioid dependence admitted to a medical ICU. Prospective, controlled studies are needed to further evaluate the safety and efficacy of methadone as a strategy to wean off continuously infused fentanyl in different ICU populations.	[Al-Qadheeb, Nada S.; Griffin, Ryan; Devlin, John W.] Northeastern Univ, Sch Pharm, Boston, MA 02115 USA; [Roberts, Russel J.] Tufts Med Ctr, Dept Pharm, Boston, MA USA; [Garpestad, Erik; Devlin, John W.] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA USA; [Ruthazer, Robin] Tufts Med Ctr, Biostat Res Ctr, Boston, MA USA	Devlin, JW (reprint author), Northeastern Univ, Sch Pharm, Boston, MA 02115 USA.	j.devlin@neu.edu					[Anonymous], 2009, PACK INS METH METH H; Berens RJ, 2006, ANESTH ANALG, V102, P1045, DOI 10.1213/01.ane.0000202395.94542.3e; Bowens CD, 2011, PEDIATR CRIT CARE ME, V12, P504, DOI 10.1097/PCC.0b013e3181fe38f5; Cammarano WB, 1998, CRIT CARE MED, V26, P676, DOI 10.1097/00003246-199804000-00015; Cigada M, 2005, INTENS CARE MED, V31, P482, DOI 10.1007/s00134-005-2559-7; Devlin JW, 2010, CRIT CARE MED, V38, pS231, DOI 10.1097/CCM.0b013e3181de125a; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003; DIVE A, 1994, CRIT CARE MED, V22, P441, DOI 10.1097/00003246-199403000-00014; Drew BJ, 2010, CIRCULATION, V121, P1047, DOI 10.1161/CIRCULATIONAHA.109.192704; Durand C, 2012, AM J HEALTH-SYST PH, V69, P116, DOI 10.2146/ajhp110158; Erstad BL, 2009, CHEST, V135, P1075, DOI 10.1378/chest.08-2264; Gesin G, 2011, J CRIT CARE, V26, P122, DOI 10.1016/j.jcrc.2010.09.008; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kher S, 2012, J INTENSIVE IN PRESS; Lugo RA, 2001, PHARMACOTHERAPY, V21, P1566, DOI 10.1592/phco.21.20.1566.34471; Lugo Ralph A, 2004, J Pain Palliat Care Pharmacother, V18, P17; Mao JR, 1998, NEUROSCI LETT, V250, P193, DOI 10.1016/S0304-3940(98)00472-8; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; Olafson K, 2012, ANN PHARMACOTHER, V46, P9, DOI 10.1345/aph.1Q446; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Patel SB, 2012, AM J RESP CRIT CARE, V185, P486, DOI 10.1164/rccm.201102-0273CI; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Pickham D, 2012, CRIT CARE MED, V40, P394, DOI 10.1097/CCM.0b013e318232db4a; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Robertson R C, 2000, Pediatr Crit Care Med, V1, P119, DOI 10.1097/00130478-200010000-00005; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Woien H, 2012, ACTA ANAESTH SCAND, V56, P23, DOI 10.1111/j.1399-6576.2011.02524.x; Wunsch H, 2009, CRIT CARE MED, V37, P3031, DOI 10.1097/CCM.0b013e3181b02eff	32	7	8	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	SEP	2012	46	9					1160	1166		10.1345/aph.1R132			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	005XS	WOS:000308784000003	22872749				2020-06-30	J	Mandt, MJ; Roback, MG; Bajaj, L; Galinkin, JL; Gao, DX; Wathen, JE				Mandt, Maria J.; Roback, Mark G.; Bajaj, Lalit; Galinkin, Jeffrey L.; Gao, Dexiang; Wathen, Joseph E.			Etomidate for Short Pediatric Procedures in the Emergency Department	PEDIATRIC EMERGENCY CARE			English	Article						etomidate; procedural sedation; capnography; BIS	RAPID-SEQUENCE INTUBATION; THERAPEUTIC PROCEDURES; ANESTHETIC INDUCTION; CONTROLLED-TRIAL; SEDATION; CHILDREN; CAPNOGRAPHY; PROPOFOL; SEDATION/ANALGESIA; VALIDATION	Objective: This study aimed to prospectively determine the etomidate dose associated with adequate sedation and few significant respiratory events for procedures of short duration in children. Methods: This is a prospective cohort study in an urban pediatric emergency department of patients 4 to 18 years requiring sedation and analgesia for painful procedures of short duration. Patients received fentanyl 1 mu g/kg followed by intravenously administered etomidate 0.1 to 0.2 mg/kg as a loading dose. An additional dose of etomidate 0.1 mg/kg was intravenously administered if needed. The level of sedation was determined by The Children's Hospital of Wisconsin Sedation Score. The primary outcome was to determine the etomidate dose associated with an adequate level of sedation and procedural completion. Results: Sixty patients were enrolled. The most frequent procedure was fracture reduction (50/60, 83.3%). Procedures were successfully completed for 59 (98.3%) of 60 patients. The initial dose of etomidate associated with adequate sedation was 0.2 mg/kg intravenously administered for 33 (66.7%) of 50 patients requiring fracture reduction and for 6 (60.0%) of 10 patients receiving a procedure other than fracture reduction. Respiratory depression was noted in 9 (16.4%) of 55 patients, and oxygen desaturation was noted in 23 (39.0%) of 59 patients. Of 58 patients, 21 (36.2%) experienced a respiratory adverse event requiring brief intervention including oxygen supplementation, stimulation, and/or airway repositioning. No patient experienced a significant adverse respiratory event, defined as positive pressure ventilation. Median time to discharge-ready was 21 minutes. Conclusions: For short-duration painful emergency department procedures, etomidate 0.2 mg/kg intravenously administered after fentanyl was associated with effective sedation, successful procedural completion, and readily managed respiratory adverse events in children.	[Mandt, Maria J.; Bajaj, Lalit; Wathen, Joseph E.] Univ Colorado Denver & Hlth Sci Ctr, Sect Emergency Med, Childrens Hosp, Dept Pediat, Aurora, CO 80045 USA; [Roback, Mark G.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; [Roback, Mark G.] Univ Minnesota, Sch Med, Dept Emergency Med, Minneapolis, MN 55455 USA; [Galinkin, Jeffrey L.] Univ Colorado Denver & Hlth Sci Ctr, Dept Anesthesiol, Childrens Hosp, Aurora, CO 80045 USA; [Gao, Dexiang] Univ Colorado Denver & Hlth Sci Ctr, Clin & Translat Res Ctr, Childrens Hosp, Aurora, CO 80045 USA	Mandt, MJ (reprint author), Univ Colorado Denver & Hlth Sci Ctr, Sect Emergency Med, Childrens Hosp, Dept Pediat, 13123 E 16thAve,B251, Aurora, CO 80045 USA.	Mandt.maria@tchden.org					Anderson JL, 2007, ANN EMERG MED, V49, P9, DOI 10.1016/j.annemergmed.2006.06.011; Di Liddo L, 2006, ANN EMERG MED, V48, P433, DOI 10.1016/j.annemergmed.2006.03.004; Dickinson R, 2001, ACAD EMERG MED, V8, P74, DOI 10.1111/j.1553-2712.2001.tb00558.x; Doenicke AW, 1999, ANESTHESIOLOGY, V90, P113, DOI 10.1097/00000542-199901000-00017; Falk J, 2004, ANN PHARMACOTHER, V38, P1272, DOI 10.1345/aph.1E008; GIESE JL, 1983, PHARMACOTHERAPY, V3, P251; Green SM, 2007, ANN EMERG MED, V49, P31, DOI 10.1016/j.annemergmed.2006.09.020; Guldner G, 2003, ACAD EMERG MED, V10, P134, DOI 10.1111/j.1553-2712.2003.tb00030.x; Hart LS, 1997, PEDIATR EMERG CARE, V13, P189, DOI 10.1097/00006565-199706000-00004; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kienstra AJ, 2004, PEDIATR EMERG CARE, V20, P499, DOI 10.1097/01.pec.0000136065.22328.df; Lee-Jayaram JJ, 2010, PEDIATR EMERG CARE, V26, P408, DOI 10.1097/PEC.0b013e3181e057cd; Lightdale JR, 2006, PEDIATRICS, V117, pE1170, DOI 10.1542/peds.2005-1709; MACNAB AJ, 1994, CAN J ANAESTH, V41, P913, DOI 10.1007/BF03010934; Maranets I, 1999, ANESTH ANALG, V89, P1346, DOI 10.1097/00000539-199912000-00003; MCDOWALL RH, 1995, J CLIN ANESTH, V7, P273, DOI 10.1016/0952-8180(95)00017-C; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; Miner JR, 2007, ANN EMERG MED, V49, P15, DOI 10.1016/j.annemergmed.2006.06.042; Miner JR, 2003, ACAD EMERG MED, V10, P638, DOI 10.1197/aemj.10.6.638; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Rothermel LK, 2003, CURR OPIN PEDIATR, V15, P200, DOI 10.1097/00008480-200304000-00011; Ruth WJ, 2001, ACAD EMERG MED, V8, P13, DOI 10.1111/j.1553-2712.2001.tb00539.x; Schreiber KM, 2006, AM J EMERG MED, V24, P397, DOI 10.1016/j.ajem.2005.10.025; Sokolove PE, 2000, PEDIATR EMERG CARE, V16, P18, DOI 10.1097/00006565-200002000-00005; STOCKHAM RJ, 1988, ANAESTH INTENS CARE, V16, P171, DOI 10.1177/0310057X8801600207; Tobias JD, 1999, PEDIATR EMERG CARE, V15, P173, DOI 10.1097/00006565-199906000-00002; TYLER DC, 1993, PAIN, V52, P301, DOI 10.1016/0304-3959(93)90163-J; Vinson DR, 2002, ANN EMERG MED, V39, P592, DOI 10.1067/mem.2002.123695; Yildizdas D, 2004, PEDIATR EMERG CARE, V20, P162, DOI 10.1097/01.pec.0000117922.65522.26; Zuckerbraun NS, 2006, ACAD EMERG MED, V13, P602, DOI 10.1197/j.aem.2005.12.026	31	15	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	SEP	2012	28	9					898	904		10.1097/PEC.0b013e318267c768			7	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	004HZ	WOS:000308673600015	22929142				2020-06-30	J	Davis, MP; Horvitz, HR				Davis, Mellar P.; Horvitz, Harry R.			Are There Cost Benefits to Fentanyl for Breakthrough Pain?	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									[Davis, Mellar P.] Taussig Canc Inst, Ctr Palliat Med, Cleveland, OH USA; Case Western Reserve Univ, Cleveland Clin, Lerner Sch Med, Cleveland, OH 44106 USA; Cleveland Clin, Taussig Canc Inst, Div Solid Tumor, Palliat Med & Support Oncol Serv, Cleveland, OH 44106 USA	Davis, MP (reprint author), Taussig Canc Inst, Ctr Palliat Med, Cleveland, OH USA.						Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004	2	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	SEP	2012	44	3					E1	E2		10.1016/j.jpainsymman.2012.06.002			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	996WJ	WOS:000308125200001	22939453	Bronze			2020-06-30	J	Wand, GS; Weerts, EM; Kuwabara, H; Wong, DF; Xu, XQ; McCaul, ME				Wand, Gary S.; Weerts, Elise M.; Kuwabara, Hiroto; Wong, Dean F.; Xu, Xiaoqiang; McCaul, Mary E.			The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects	ALCOHOL			English	Article						mu Opioid receptors; Naloxone; PET imaging; HPA axis; Cortisol; Alcoholism	POSITRON-EMISSION-TOMOGRAPHY; BETA-ENDORPHIN; ETHANOL-CONSUMPTION; OPIATE RECEPTORS; BINDING; HYPOTHALAMUS; CARFENTANIL; RESPONSES; PEPTIDES; EXPOSURE	The mu opioid receptor system is altered in alcohol dependent (AD) subjects. Cortisol responses to opioid receptor antagonists are assumed to impart information about opioid receptor activity. In the present study we examined naloxone-induced cortisol responses in 18 healthy control (HC) and 25 recently detoxified AD subjects and then correlated the cortisol response with mu opioid receptor availability across 15 brain regions using positron emission tomography (PET) and the mu opioid receptor selective ligand [C-11] Carfentanil (CFN). On average the AD subjects required twice the dose of naloxone to induce a peak cortisol response compared to the HC subjects. Using the rising slope of the cortisol curve (placebo to peak) as a metric we then went on to examine the relationship between cortisol responses to naloxone and [C-11]CFN BPND. There were significant negative relationships between cortisol and [C-11]CFN binding potential (BPND) in multiple brain regions of HC subjects. However, cortisol responses did not correlate with [C-11]CFN BPND across any brain region in AD subjects. In summary, naloxone imparts information about individual differences in mu opioid receptor availability throughout the mesolimbic system in healthy individuals. However pathways governing the relationship between naloxone-induced cortisol and mu opioid receptor availability are disrupted during early abstinence in AD subjects. (c) 2012 Elsevier Inc. All rights reserved.	[Wand, Gary S.; Xu, Xiaoqiang; McCaul, Mary E.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Wand, Gary S.; Weerts, Elise M.; Wong, Dean F.; McCaul, Mary E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Kuwabara, Hiroto; Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Wand, GS (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, 720 Rutland Ave,Ross Bldg,Rm 863, Baltimore, MD 21205 USA.	gwand@jhmi.edu		Weerts, Elise/0000-0002-8234-0919	National Institute of Alcohol Abuse and Alcoholism (NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Kenneth Lattman Foundation;  [R37AA12303];  [R01AA11855]	The National Institute of Alcohol Abuse and Alcoholism (NIAAA) provided financial support for research related to the subject matter of this manuscript from the grants R37AA12303 (PI: G.S. Wand) and R01AA11855 (PI:M.E. McCaul). Dr. Wand is the recipient of a gift fund from the Kenneth Lattman Foundation.	Adinoff B, 2005, ALCOHOL CLIN EXP RES, V29, P528, DOI 10.1097/01.ALC.0000158939.25531.EE; Al'Absi M, 2008, PSYCHOSOM MED, V70, P928, DOI 10.1097/PSY.0b013e31818434ab; BORSOOK D, 1995, AM J PHYSIOL-ENDOC M, V269, pE393; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149; Chen CP, 2004, J NEUROCHEM, V88, P1547, DOI 10.1046/j.1471-4159.2003.02300.x; Dawson DA, 2000, DRUG ALCOHOL DEPEN, V59, P235, DOI 10.1016/S0376-8716(99)00130-1; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; FROST JJ, 1990, J CEREBR BLOOD F MET, V10, P484, DOI 10.1038/jcbfm.1990.90; GENAZZANI AR, 1982, J CLIN ENDOCR METAB, V55, P583, DOI 10.1210/jcem-55-3-583; GIANOULAKIS C, 1990, EUR J PHARMACOL, V180, P21, DOI 10.1016/0014-2999(90)90588-W; Hall FS, 2001, PSYCHOPHARMACOLOGY, V154, P43, DOI 10.1007/s002130000622; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jankord R, 2008, ANN NY ACAD SCI, V1148, P64, DOI 10.1196/annals.1410.012; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; Kranzler HR, 2010, CURR PHARM DESIGN, V16, P2141; Leriche M, 2010, NEUROPEPTIDES, V44, P9, DOI 10.1016/j.npep.2009.11.009; Li X. W., 1996, ALCOHOL CLIN EXP RES, V20, P53; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; McCaul ME, 2000, NEUROPSYCHOPHARMACOL, V22, P480, DOI 10.1016/S0893-133X(99)00147-5; McCaul ME, 2001, NEUROPSYCHOPHARMACOL, V25, P537, DOI 10.1016/S0893-133X(01)00241-X; MELTZER CC, 1990, J COMPUT ASSIST TOMO, V14, P418, DOI 10.1097/00004728-199005000-00019; Mendez M, 2003, NEUROSCI RES, V47, P153, DOI 10.1016/S0168-0102(03)00188-3; O'Malley Stephanie S, 2003, Recent Dev Alcohol, V16, P217; Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008; Ribeiro SC, 2005, PROG NEURO-PSYCHOPH, V29, P1264, DOI 10.1016/j.pnpbp.2005.08.011; Sarkar DK, 2007, ENDOCRINOLOGY, V148, P2828, DOI 10.1210/en.2006-1606; Sinha R, 1999, ALCOHOL ALCOHOLISM, V34, P223, DOI 10.1093/alcalc/34.2.223; Sobell L, 1992, MEASURING ALCOHOL CO, P41, DOI DOI 10.1007/978-1-4612-0357-5_3; Stephens M., 2011, STRESS ALCO IN PRESS; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463; SZEKELY JI, 1990, CRIT REV NEUROBIOL, V6, P1; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Uhart M, 2004, MOL PSYCHIATR, V9, P998, DOI 10.1038/sj.mp.4001535; Wand G. S., 2012, ADDICTION B IN PRESS; Wand GS, 2011, PSYCHONEUROENDOCRINO, V36, P1453, DOI 10.1016/j.psyneuen.2011.03.019; Wand GS, 1999, J CLIN ENDOCR METAB, V84, P64, DOI 10.1210/jc.84.1.64; Wand GS, 1998, ARCH GEN PSYCHIAT, V55, P1114, DOI 10.1001/archpsyc.55.12.1114; Weerts EM, 2008, NEUROPSYCHOPHARMACOL, V33, P653, DOI 10.1038/sj.npp.1301440; Weerts EM, 2011, ALCOHOL CLIN EXP RES, V35, P2162, DOI 10.1111/j.1530-0277.2011.01565.x	42	7	7	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0741-8329	1873-6823		ALCOHOL	Alcohol	SEP	2012	46	6					511	517		10.1016/j.alcohol.2012.04.006			7	Substance Abuse; Pharmacology & Pharmacy; Toxicology	Substance Abuse; Pharmacology & Pharmacy; Toxicology	993MW	WOS:000307864800001	22717196	Green Accepted			2020-06-30	J	Lim, CBS; Schug, SA; Sunderland, VB; Paech, MJ; Liu, YD				Lim, Chin Beng Stephen; Schug, Stephan A.; Sunderland, Vivian Bruce; Paech, Michael James; Liu, Yandi			A Phase I Pharmacokinetic and Bioavailability Study of a Sublingual Fentanyl Wafer in Healthy Volunteers	ANESTHESIA AND ANALGESIA			English	Article							ORAL TRANSMUCOSAL FENTANYL; BREAKTHROUGH PAIN; CANCER-PATIENTS; BUCCAL TABLET; TRANSDERMAL FENTANYL; CROSSOVER TRIAL; DOSE-TITRATION; INCIDENT PAIN; CITRATE; ABSORPTION	BACKGROUND: The sublingual administration of opioids is a simple and noninvasive method that provides rapid analgesia. In this phase I study we investigated the pharmacokinetics and bioavailability of a fentanyl wafer in healthy volunteers. The principal study objective was to investigate the pharmacokinetic profile of a new sublingual fentanyl wafer and to establish its absolute bioavailability. METHODS: Twenty-four healthy volunteers, mean age 23 years, were randomly assigned to receive the equivalent of fentanyl 100 mu g by both the sublingual and IV routes. Blood samples were collected in sterile polypropylene tubes for 24 hours after each fentanyl administration. The pharmacokinetic parameters were determined by model-independent pharmacokinetic analyses of the plasma fentanyl concentration-time profiles. RESULTS: The mean absolute bioavailability of the sublingual fentanyl wafer was 78.9% (90% confidence interval [CI] 51.1% to 121.7%). The first detectable plasma fentanyl concentration time ranged from 2 to 10 minutes in all volunteers, and the mean (+/- SD) time to peak plasma concentration at 0.91 (+/- 0.73) hours after administration. CONCLUSION: Sublingual administration of fentanyl as a wafer product resulted in rapidly detectable plasma fentanyl concentrations. The absolute bioavailability of 78.9% indicated a high systemic availability of fentanyl and suggests that further development of this wafer is justified. (Anesth Analg 2012;115:554-9)	[Lim, Chin Beng Stephen; Sunderland, Vivian Bruce; Liu, Yandi] Curtin Univ Technol, Sch Pharm, Curtin Hlth Innovat Res Inst, Perth, WA 6854, Australia; [Lim, Chin Beng Stephen] Armadale Hlth Serv, Dept Pharm, Armadale, WA 6112, Australia; [Schug, Stephan A.; Paech, Michael James] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia; [Schug, Stephan A.] Royal Perth Hosp, Dept Anaesthesia & Pain Med, Perth, WA, Australia; [Paech, Michael James] King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Subiaco, WA 6008, Australia	Lim, CBS (reprint author), Curtin Univ Technol, Sch Pharm, Curtin Hlth Innovat Res Inst, Perth, WA 6854, Australia.	stephen.lim@health.wa.gov.au	Schug, Stephan/G-1432-2010	Schug, Stephan/0000-0002-0302-2315; PAECH, MICHAEL/0000-0001-9023-6575	iX BioPharma, Pty. Ltd., Singapore	Funding from iX BioPharma, Pty. Ltd., Singapore, for this phase 1 study.	Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; Ghosh T, 2005, DRUG DELIVERY ORAL C; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Hagen NA, 2008, J PAIN SYMPTOM MANAG, V35, P136, DOI 10.1016/j.jpainsymman.2007.03.016; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Lim CB, PILOT PHARM IN PRESS; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; RATHBONE MJ, 1991, INT J PHARMACEUT, V74, P9, DOI 10.1016/0378-5173(91)90403-B; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; STANLEY TH, 1989, ANESTH ANALG, V69, P21; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	30	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2012	115	3					554	559		10.1213/ANE.0b013e3182575cbf			6	Anesthesiology	Anesthesiology	994PI	WOS:000307942900012	22584544				2020-06-30	J	Gellerfors, M; Lundin, H; Svensen, CH				Gellerfors, M.; Lundin, H.; Svensen, C. H.			Rotational vertigo and nystagmus rapidly after an intrathecal block with bupivacaine and fentanyl	BRITISH JOURNAL OF ANAESTHESIA			English	Letter							MORPHINE; COMPLICATIONS; ANESTHESIA				mikael.gellerfors@sodersjukhuset.se					Cook TM, 2009, BRIT J ANAESTH, V102, P179, DOI 10.1093/bja/aen360; FISH DJ, 1990, ANESTHESIOLOGY, V73, P785, DOI 10.1097/00000542-199010000-00030; Gehling M, 2009, ANAESTHESIA, V64, P643, DOI 10.1111/j.1365-2044.2008.05817.x; Korff C, 2007, EUR J ANAESTH, V24, P201, DOI 10.1017/S0265021506001724; LINDER S, 1989, ANESTHESIOLOGY, V71, P782, DOI 10.1097/00000542-198911000-00025; Malhotra S K, 2007, Minerva Anestesiol, V73, P395; Neal JM, 2008, REGION ANESTH PAIN M, V33, P404, DOI 10.1016/j.rapm.2008.07.527; UEYAMA H, 1992, ANESTHESIOLOGY, V76, P153, DOI 10.1097/00000542-199201000-00033	8	1	1	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	SEP	2012	109	3					467	468		10.1093/bja/aes293			2	Anesthesiology	Anesthesiology	988PB	WOS:000307501900036	22879670	Bronze			2020-06-30	J	Kucuk, M; Ugur, B; Ogurlu, M				Kucuk, Mert; Ugur, Bakiye; Ogurlu, Mustafa			Comparing the administration of fentanyl 1 mu g kg(-1) and fentanyl 0.5 mu g kg(-1) in dilation and curettage procedures	GYNECOLOGICAL ENDOCRINOLOGY			English	Article						dilation and curettage; fentanyl; recovery	PROPOFOL ANESTHESIA; BREAKTHROUGH PAIN; MANAGEMENT; ALFENTANIL; NAUSEA; PHARMACOKINETICS; EFFICACY	Purpose: This study was carried out to compare fentanyl 0.5 mu g kg(-1)-propofol as opposed to fentanyl 1 mu g kg(-1)-propofol in terms of providing adequate analgesia, and a comparable recovery profile in dilation and curettage (D&C) procedures. Methods: Verbal Pain Scale (VPS) scores, modified Aldrete scores, and hemodynamic parameters were recorded during and after the surgical procedure. In addition, a record was also kept of adverse events, and patients and surgeons were questioned about their satisfaction with the anesthesia. Results: No difference was found between the two groups in terms of hemodynamic parameters, the VPS scores, or patient and surgeon satisfaction. The fentanyl 0.5 mu g group displayed significantly higher modified Aldrete scores at both 5- and 10-min postoperative. Adverse events in both groups were considerably few. The incidence of postoperative nausea and vomiting (PONV) in the fentanyl 0.5 mu g group was lower eventhough it did not reach the statistically significance level. In addition, faster recovery times were recorded with the administration of fentanyl 0.5 mu g kg(-1). Conclusion: Fentanyl 0.5 mu g kg(-1) appears to be as reliable as that of fentanyl 1 mu g kg(-1) with faster recovery times when used in D&C procedures.	[Ugur, Bakiye; Ogurlu, Mustafa] Adnan Menderes Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-09100 Aydin, Turkey; [Kucuk, Mert] Adnan Menderes Univ, Fac Med, Dept Obstet & Gynecol, TR-09100 Aydin, Turkey	Ogurlu, M (reprint author), Adnan Menderes Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-09100 Aydin, Turkey.	drmustafaogurlu@yahoo.com					ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Api O, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.02.029; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Beers RA, 2000, ANESTH ANALG, V91, P1420, DOI 10.1097/00000539-200012000-00022; Bilen A, 2010, AGRI, V22, P103; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Karaman S, 2006, EGE TIP DERGISI, V45, P51; LINDHOLM P, 1994, ACTA ANAESTH SCAND, V38, P545, DOI 10.1111/j.1399-6576.1994.tb03949.x; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Marshall SI, 1999, ANESTH ANALG, V88, P508, DOI 10.1097/00000539-199903000-00008; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Minkowitz Harold S, 2010, J Opioid Manag, V6, P203; Morgan GE, 2002, CLIN ANAESTHESIOL, P882; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Parlow JL, 1999, CAN J ANAESTH, V46, P719, DOI 10.1007/BF03013905; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Rattanachaiyanont M, 2005, OBSTET GYNECOL, V106, P533, DOI 10.1097/01.AOG.0000172424.09992.3e; Seitsonen ERJ, 2007, ACTA ANAESTH SCAND, V51, P751, DOI 10.1111/j.1399-6576.2007.01309.x; Song JW, 2011, ANAESTHESIA, V66, P263, DOI 10.1111/j.1365-2044.2011.06648.x; Tan PPC, 1996, J FORMOS MED ASSOC, V95, P540; Tangsiriwatthanas T, 2009, COCHRANE DB SYST REV, V1; Tassinari D, 2011, PALLIATIVE MED, V25, P478, DOI 10.1177/0269216311404274; Tramer M, 1997, BRIT J ANAESTH, V78, P247; Uerpairojkit K, 2003, J OBSTET GYNAECOL RE, V29, P79, DOI 10.1046/j.1341-8076.2003.00083.x; Ueta K, 2003, ANESTH ANALG, V96, P1079, DOI 10.1213/01.ANE.0000055364.39576.FF	26	4	4	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0951-3590	1473-0766		GYNECOL ENDOCRINOL	Gynecol. Endocrinol.	SEP	2012	28	9					736	739		10.3109/09513590.2011.652248			4	Endocrinology & Metabolism; Obstetrics & Gynecology	Endocrinology & Metabolism; Obstetrics & Gynecology	991AJ	WOS:000307672900014	22316334				2020-06-30	J	Yekkirala, AS; Banks, ML; Lunzer, MM; Negus, SS; Rice, KC; Portoghese, PS				Yekkirala, Ajay S.; Banks, Matthew L.; Lunzer, Mary M.; Negus, Stevens S.; Rice, Kenner C.; Portoghese, Philip S.			Clinically Employed Opioid Analgesics Produce Antinociception via mu-delta Opioid Receptor Heteromers in Rhesus Monkeys	ACS CHEMICAL NEUROSCIENCE			English	Article						Analgesics; Allosterism; GPCR heteromers; opioid antagonism; primates	PHARMACOLOGICAL CHARACTERIZATION; NARCOTIC ANTAGONISTS; AGONIST SNC80; MORPHINE; MICE; DEPENDENCE; CLONING; EXPRESSION; TOLERANCE; HETERODIMERIZATION	Morphine and related drugs are widely employed as analgesics despite the side effects associated with their use. Although morphine is thought to mediate analgesia through mu opioid receptors, delta opioid receptors have been implicated in mediating some side effects such as tolerance and dependence. Here we present evidence in rhesus monkeys that morphine, fentanyl, and possibly methadone selectively activate mu-delta heteromers to produce antinociception that is potently antagonized by the delta opioid receptor antagonist, naltrindole (NTI). Studies with HEK293 cells expressing mu-delta heteromeric opioid receptors exhibit a similar antagonism profile of receptor activation in the presence of NTI. In mice, morphine was potently inhibited by naltrindole when administered intrathecally, but not intracerebroventricularly, suggesting the possible involvement of mu-delta heteromers in the spinal cord of rodents. Taken together, these results strongly suggest that, in primates, mu-delta heteromers are allosterically coupled and mediate the antinociceptive effects of three clinically employed opioid analgesics that have been traditionally viewed as mu-selective. Given the known involvement of delta receptors in morphine tolerance and dependence, our results implicate mu-delta heteromers in mediating both antinociception and these side effects in primates. These results open the door for further investigation in humans.	[Yekkirala, Ajay S.; Lunzer, Mary M.; Portoghese, Philip S.] Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN 55455 USA; [Yekkirala, Ajay S.; Portoghese, Philip S.] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; [Banks, Matthew L.; Negus, Stevens S.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Rice, Kenner C.] NIDA, Chem Biol Res Branch, Bethesda, MD 20892 USA; [Rice, Kenner C.] NIAAA, NIH, DHHS, Bethesda, MD 20892 USA	Portoghese, PS (reprint author), Univ Minnesota, Coll Pharm, Dept Med Chem, 8-111 Weaver Densford Hall, Minneapolis, MN 55455 USA.	porto001@umn.edu	Banks, Matthew L/K-4429-2014	Banks, Matthew L/0000-0003-4949-5246	NIH from National Institute on Drug Abuse (NIDA) [R01-DA01533, R01-DA011460, T32-DA007027]; Intramural Research Programs of NIDA; National Institute on Alcohol Abuse and Alcoholism (NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	This work was supported by NIH Grants R01-DA01533, R01-DA011460 and T32-DA007027 from the National Institute on Drug Abuse (NIDA). A portion of this work was also supported by Intramural Research Programs of NIDA and National Institute on Alcohol Abuse and Alcoholism (NIAAA).	ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; Bowen CA, 2002, J PHARMACOL EXP THER, V302, P264, DOI 10.1124/jpet.302.1.264; Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939; Brandt MR, 1999, J PHARMACOL EXP THER, V290, P1157; Daniels DJ, 2005, P NATL ACAD SCI USA, V102, P19208, DOI 10.1073/pnas.0506627102; DEWEY WL, 1970, J PHARMACOL EXP THER, V175, P435; Dubois MY, 2009, PAIN MED, V10, P972, DOI 10.1111/j.1526-4637.2009.00696.x; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gupta A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000807; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141; Hasbi A, 2007, BIOCHEMISTRY-US, V46, P12997, DOI 10.1021/bi701436w; HYLDEN JLK, 1981, BRAIN RES, V217, P212, DOI 10.1016/0006-8993(81)90203-1; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2000, NEUROPSYCHOPHARMACOL, V23, pS5, DOI 10.1016/S0893-133X(00)00143-3; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Lenard NR, 2007, EUR J PHARMACOL, V566, P75, DOI 10.1016/j.ejphar.2007.02.040; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MENG F, 1993, P NATL ACAD SCI USA, V90, P9954, DOI 10.1073/pnas.90.21.9954; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 1998, J PHARMACOL EXP THER, V286, P362; NEGUS SS, 1994, J PHARMACOL EXP THER, V270, P1025; Nitsche JF, 2002, J NEUROSCI, V22, P10906; PORTOGHESE PS, 1988, EUR J PHARMACOL, V146, P185, DOI 10.1016/0014-2999(88)90502-X; SanchezBlazquez P, 1997, J PHARMACOL EXP THER, V280, P1423; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; van Rijn RM, 2009, BIOL PSYCHIAT, V66, P777, DOI 10.1016/j.biopsych.2009.05.019; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; Wang HB, 2010, P NATL ACAD SCI USA, V107, P13117, DOI 10.1073/pnas.1008382107; Yekkirala AS, 2011, P NATL ACAD SCI USA, V108, P5098, DOI 10.1073/pnas.1016277108; Yekkirala AS, 2010, ACS CHEM NEUROSCI, V1, P146, DOI 10.1021/cn9000236	41	23	25	0	8	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	SEP	2012	3	9					720	727		10.1021/cn300049m			8	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	009HI	WOS:000309016500010	23019498	Green Published			2020-06-30	J	Colasanti, A; Searle, GE; Long, CJ; Hill, SP; Reiley, RR; Quelch, D; Erritzoe, D; Tziortzi, AC; Reed, LJ; Lingford-Hughes, AR; Waldman, AD; Schruers, KRJ; Matthews, PM; Gunn, RN; Nutt, DJ; Rabiner, EA				Colasanti, Alessandro; Searle, Graham E.; Long, Christopher J.; Hill, Samuel P.; Reiley, Richard R.; Quelch, Darren; Erritzoe, David; Tziortzi, Andri C.; Reed, Laurence J.; Lingford-Hughes, Anne R.; Waldman, Adam D.; Schruers, Koen R. J.; Matthews, Paul M.; Gunn, Roger N.; Nutt, David J.; Rabiner, Eugenii A.			Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration	BIOLOGICAL PSYCHIATRY			English	Article						Amphetamine; carfentanil; dopamine; neuroimaging; opioids; PET; psychostimulants	MESSENGER-RNA EXPRESSION; DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; RECEPTOR-BINDING; IN-VIVO; ANTERIOR CINGULATE; OPIATE RECEPTORS; C-11 CARFENTANIL; CEREBRAL-CORTEX; BETA-ENDORPHIN	Background: We aimed to demonstrate a pharmacologically stimulated endogenous opioid release in the living human brain by evaluating the effects of amphetamine administration on [C-11] carfentanil binding with positron emission tomography (PET). Methods: Twelve healthy male volunteers underwent [C-11] carfentanil PET before and 3 hours after a single oral dose of d-amphetamine (either a "high" dose, .5 mg/kg, or a sub-pharmacological "ultra-low" dose, 1.25 mg total dose or approximately .017 mg/kg). Reductions in [C-11] carfentanil binding from baseline to post-amphetamine scans (Delta BPND) after the "high" and "ultra-low" amphetamine doses were assessed in 10 regions of interest. Results: [C-11] carfentanil binding was reduced after the "high" but not the "ultra-low" amphetamine dose in the frontal cortex, putamen, caudate, thalamus, anterior cingulate, and insula. Conclusions: Our findings indicate that oral amphetamine administration induces endogenous opioid release in different areas of human brain, including basal ganglia, frontal cortex areas, and thalamus. The combination of an amphetamine challenge and [C-11] carfentanil PET is a practical and robust method to probe the opioid system in the living human brain.	[Colasanti, Alessandro; Quelch, Darren; Erritzoe, David; Reed, Laurence J.; Lingford-Hughes, Anne R.; Gunn, Roger N.; Nutt, David J.; Rabiner, Eugenii A.] Univ London Imperial Coll Sci Technol & Med, Neuropsychopharmacol Unit, Ctr Pharmacol & Therapeut, Div Expt Med,Dept Med, London W12 0NN, England; [Colasanti, Alessandro; Searle, Graham E.; Long, Christopher J.; Hill, Samuel P.; Reiley, Richard R.; Quelch, Darren; Tziortzi, Andri C.; Matthews, Paul M.; Gunn, Roger N.; Rabiner, Eugenii A.] Hammersmith Hosp, Clin Imaging Ctr, GlaxoSmithKline, London, England; [Waldman, Adam D.] Univ London Imperial Coll Sci Technol & Med, Dept Imaging, London W12 0NN, England; [Matthews, Paul M.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Dept Med, Ctr Neurosci, London W12 0NN, England; [Tziortzi, Andri C.] Univ Oxford, Dept Clin Neurosci, FMRIB Ctr, Oxford, England; [Gunn, Roger N.] Univ Oxford, Dept Engn Sci, Oxford OX1 3PJ, England; [Schruers, Koen R. J.] Maastricht Univ, Res Inst Mental Hlth & Neurosci, Maastricht, Netherlands	Colasanti, A (reprint author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Neuropsychopharmacol Unit,Clin Imaging Ctr, Div Expt Med,Dept Med,Ctr Pharmacol & Therapeut, 2nd Floor Burlington Danes Bldg, London W12 0NN, England.	a.colasanti@imperial.ac.uk	Rabiner, Eugenii A./G-6263-2012; Gunn, Roger/H-1666-2012	Rabiner, Eugenii A./0000-0003-3612-6687; Gunn, Roger/0000-0003-1181-5769; Erritzoe, David/0000-0002-7022-6211; Matthews, Paul M/0000-0002-1619-8328; Waldman, Adam D/0000-0003-4398-6431; nutt, david/0000-0002-1286-1401; Colasanti, Alessandro/0000-0001-6017-801X	GlaxoSmithKline (GSK)GlaxoSmithKline; European College of Neuropsychopharmacology Research Grant for Young Scientists; Wellcome TrustWellcome Trust; GSKGlaxoSmithKline; European College of Neuropsychopharmacology; Medical Research CouncilMedical Research Council UK (MRC); PfizerPfizer; Merck Sharp and DohmeMerck & Company; Bristol Myers SquibbBristol-Myers Squibb; Esteve; NovartisNovartis; Asahi; Organon; Cypress; LillyEli Lilly; JanssenJohnson & Johnson USAJanssen Biotech Inc; TakedaTakeda Pharmaceutical Company Ltd; Phamacia; Therasci; Passion for Life; Hythiam; ServierServier; RocheRoche Holding; Sanofi-AventisSanofi-Aventis; Actelion; LundbeckLundbeck Corporation; WyethWyeth; Reckitt-Benkiser; Cephalon; Merck SharpMerck & Company; Dohme; Yamanouchi; AZ; P1vital; MoD; National Health Service; Medical Research CouncilMedical Research Council UK (MRC) [G1002226, G0900897]	The study has been financially supported by GlaxoSmithKline (GSK) and the European College of Neuropsychopharmacology Research Grant for Young Scientists. The authors wish to thank the study participants and the Clinical Team of the GSK Clinical Imaging Centre, Christine Parker and Robin Tyacke for their useful comments, and the colleagues of International College of Affective Neuroscience for their support.; Dr. Colasanti is supported by the Wellcome Trust and GSK, has been a part-time employee of GSK, and has received a grant from the European College of Neuropsychopharmacology. Drs. Searle, Long, Rabiner, Mr. Hill, and ProfessorGunnwere full-time employees of GSK at the time of this study. Professor Matthews and Mr. Reiley are full-time employees of GSK. Dr. Reed holds grants from the Medical Research Council and collaborations with GSK. Professor Lingford-Hughes holds grants from the National Institute for Health Research, Medical Research Council, and collaborations with GSK. Professor Nutt has received consulting fees from Pfizer, GSK, Merck Sharp and Dohme, Bristol Myers Squibb, Esteve, Novartis, Asahi, Organon, Cypress, Lilly, Janssen, Takeda, Phamacia, Therasci, Passion for Life, Hythiam, Servier, Roche, Sanofi-Aventis, Actelion, Lundbeck, and Wyeth; speaker's fees from Reckitt-Benkiser and Cephalon; grants for research or clinical trial payments from Merck Sharp and Dohme, GSK, Novartis, Servier, Janssen, Yamanouchi, Lundbeck, Pfizer, Wyeth, Organon, AZ, Cephalon, P1vital, MoD, and the National Health Service; and has worked for the UK Government Committee on Safety of Medicines, the Advisory Council on the Misuse of Drugs, and the British National Formulary.	Bernstein HG, 1996, NEUROSCI LETT, V215, P33, DOI 10.1016/S0304-3940(96)12939-6; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; Colasanti A, 2011, J PSYCHOPHARMACOL, V25, P1415, DOI 10.1177/0269881110367726; Cropley VL, 2008, SYNAPSE, V62, P399, DOI 10.1002/syn.20506; Daglish MRC, 2008, BRIT J PSYCHIAT, V193, P65, DOI 10.1192/bjp.bp.107.041228; Doron R, 2006, NEUROREPORT, V17, P1633, DOI 10.1097/01.wnr.0000234755.88560.c7; Dudas B, 2004, NEUROSCIENCE, V124, P221, DOI 10.1016/j.neuroscience.2003.11.021; Fone KCF, 2005, CURR OPIN PHARMACOL, V5, P87, DOI 10.1016/j.coph.2004.10.001; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Garcia-Cabezas MA, 2007, NEUROIMAGE, V34, P965, DOI 10.1016/j.neuroimage.2006.07.032; Ghitza UE, 2010, BIOL PSYCHIAT, V68, P697, DOI 10.1016/j.biopsych.2010.05.003; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; GRAMSCH C, 1979, BRAIN RES, V171, P261, DOI 10.1016/0006-8993(79)90332-9; Grilly DM, 2001, PSYCHOPHARMACOLOGY, V153, P155, DOI 10.1007/s002130000580; Hagelberg N, 2004, PAIN, V109, P86, DOI 10.1016/j.pain.2004.01.013; Hagelberg N, 2002, SYNAPSE, V45, P25, DOI 10.1002/syn.10078; Han Dawn D., 2006, BMC Pharmacology, V6, P6, DOI 10.1186/1471-2210-6-6; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; Hirose N, 2005, NEUROSCIENCE, V135, P213, DOI 10.1016/j.neuroscience.2005.03.065; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; JAIN S, 1980, PSYCHOPHARMACOLOGY, V70, P109, DOI 10.1007/BF00432379; Jayaram-Lindstrom N, 2004, J CLIN PSYCHOPHARM, V24, P665, DOI 10.1097/01.jcp.0000144893.29987.e5; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Laruelle M, 2000, J CEREBR BLOOD F MET, V20, P423, DOI 10.1097/00004647-200003000-00001; LARUELLE M, 1995, J NUCL MED, V36, P1182; Lewis DA, 2001, J COMP NEUROL, V432, P119, DOI 10.1002/cne.1092; Love TM, 2009, ARCH GEN PSYCHIAT, V66, P1124, DOI 10.1001/archgenpsychiatry.2009.134; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Okutsu H, 2006, NEUROPSYCHOPHARMACOL, V31, P375, DOI 10.1038/sj.npp.1300804; Olive MF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0002.2001; PASINETTI G, 1984, BRAIN RES, V293, P364, DOI 10.1016/0006-8993(84)91244-7; Paterson LM, 2010, J CEREBR BLOOD F MET, V30, P1682, DOI 10.1038/jcbfm.2010.104; Petrovic P, 2008, J NEUROSCI, V28, P10509, DOI 10.1523/JNEUROSCI.2807-08.2008; Prossin AR, 2010, AM J PSYCHIAT, V167, P925, DOI 10.1176/appi.ajp.2010.09091348; Rabiner EA, 2011, MOL PSYCHIATR, V16, P826, DOI 10.1038/mp.2011.29; Shotbolt P, 2012, J CEREBR BLOOD F MET, V32, P127, DOI 10.1038/jcbfm.2011.115; Smith HR, 2006, NEUROSCIENCE, V138, P703, DOI 10.1016/j.neuroscience.2005.11.033; Soderman AR, 2009, BRAIN RES, V1296, P63, DOI 10.1016/j.brainres.2009.08.035; SPANAGEL R, 1990, J NEUROCHEM, V55, P1734, DOI 10.1111/j.1471-4159.1990.tb04963.x; Spreckelmeyer KN, 2011, BIOL PSYCHIAT, V70, P770, DOI 10.1016/j.biopsych.2011.05.035; Steiner H, 1999, NEUROSCIENCE, V88, P795, DOI 10.1016/S0306-4522(98)00241-3; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Trigo JM, 2010, DRUG ALCOHOL DEPEN, V108, P183, DOI 10.1016/j.drugalcdep.2009.10.011; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; Varnas K, 2004, HUM BRAIN MAPP, V22, P246, DOI 10.1002/hbm.20035; WANG JQ, 1995, BRAIN RES, V673, P262, DOI 10.1016/0006-8993(94)01422-E; Way BM, 2009, P NATL ACAD SCI USA, V106, P15079, DOI 10.1073/pnas.0812612106; Yoshida Y, 1999, NEUROSCIENCE, V92, P1357, DOI 10.1016/S0306-4522(99)00046-9; Zadina JE, 2002, JPN J PHARMACOL, V89, P203, DOI 10.1254/jjp.89.203; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	54	61	61	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	SEP 1	2012	72	5					371	377		10.1016/j.biopsych.2012.01.027			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	985ZD	WOS:000307308100007	22386378				2020-06-30	J	Arendt-Nielsen, L; Andresen, T; Malver, LP; Oksche, A; Mansikka, H; Drewes, AM				Arendt-Nielsen, Lars; Andresen, Trine; Malver, Lasse P.; Oksche, Alexander; Mansikka, Heikki; Drewes, Asbjorn M.			A Double-blind, Placebo-controlled Study on the Effect of Buprenorphine and Fentanyl on Descending Pain Modulation A Human Experimental Study	CLINICAL JOURNAL OF PAIN			English	Article						experimental pain; DNIC; CPM; buprenorphine; fentanyl	NOXIOUS INHIBITORY CONTROLS; SUBNUCLEUS-RETICULARIS-DORSALIS; ROSTRAL VENTROMEDIAL MEDULLA; TRANSDERMAL FENTANYL; CONDITIONING STIMULATION; SYSTEMIC MORPHINE; RAT; ANALGESIA; FIBROMYALGIA; FACILITATION	Objectives: The descending pain inhibitory system is impaired in chronic pain and it is important to know how analgesics interact with this system. The aim of this human experimental pain, double-blind, randomized, placebo-controlled, 3 way cross-over study was to investigate the effect of 2 different opioids on descending pain inhibition using conditioning pain modulation (CPM) as a screening tool. Methods: Twenty-two healthy male volunteers were randomized to 72 hours of treatment with transdermal patches of fentanyl (25 mu g/h), buprenorphine (20 mu g/h), or placebo. The CPM was induced by immersing the hand into cold (3.0 +/- 0.3 degrees C) water and the evoked pain was continuously rated on a visual analogue scale (VAS). The test stimulus [pressure pain tolerance threshold (PPTol)] was applied to the contra-lateral arm. The CPM test was performed at baseline, 24, 48, and 72 hours after application of the patches. Results: The opioid treatments did not significantly (F = 2.249; P = 0.07) modulate the PPTol over the treatment period compared with placebo. The CPM-evoked PPTol increases (percentage increase from what was obtained at the baseline before patch application) were significantly enhanced by buprenorphine (P = 0.004) and fentanyl (P = 0.005) compared with placebo, with no differences between the 2 active drugs. Fentanyl significantly attenuated the time to cold water-evoked VAS peak compared with placebo (P = 0.005), and the same trend was observed for buprenorphine (P = 0.06). The VAS pain intensity was not affected. Discussion: The opioids buprenorphine and fentanyl significantly potentiate the effect of descending pain inhibition in healthy volunteers.	[Arendt-Nielsen, Lars] Aalborg Univ, Sch Med, Dept Hlth Sci & Technol, Ctr Sensory Motor Interact SMI, DK-9220 Aalborg E, Denmark; [Andresen, Trine; Malver, Lasse P.; Drewes, Asbjorn M.] Aarhus Univ, Aalborg Hosp, Dept Gastroenterol, Mech Sense, Aarhus, Denmark; [Oksche, Alexander] Mundipharma Res GmbH & Co KG, Limburg, Germany; [Oksche, Alexander] Univ Giessen, Rudolf Buchheim Inst Pharmakol, D-6300 Giessen, Germany; [Mansikka, Heikki] Grunenthal Ltd, Stokenchurch, Germany	Arendt-Nielsen, L (reprint author), Aalborg Univ, Sch Med, Dept Hlth Sci & Technol, Ctr Sensory Motor Interact SMI, Fredrik Bajers Vej 7,Bld D3, DK-9220 Aalborg E, Denmark.	LAN@HST.AAU.DK	Arendt-Nielsen, Lars/T-4885-2018; Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770; Arendt-Nielsen, Lars/0000-0003-0892-1579	Mundipharma	The authors T. A., L. P. M., A. M. D., and L.A.N. do not have any commercial interests in the compounds studied or any commercial relationships with the companies providing the drugs. A.O. and H. M. have been commercially involved in developing buprenorphine patches. Mundipharma is acknowledged for an unrestricted grant that made this study possible.	Andresen T, 2011, BRIT J PHARMACOL, V164, P934, DOI 10.1111/j.1476-5381.2010.01180.x; Arendt-Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003; Arendt-Nielsen L, 2009, J PAIN, V10, P556, DOI 10.1016/j.jpain.2009.02.002; ARENDTNIELSEN L, 1992, EUR J APPL PHYSIOL, V64, P56, DOI 10.1007/BF00376441; BING Z, 1989, EUR J PHARMACOL, V164, P85, DOI 10.1016/0014-2999(89)90234-3; BOUHASSIRA D, 1993, EUR J PHARMACOL, V232, P207, DOI 10.1016/0014-2999(93)90775-D; BOUHASSIRA D, 1992, BRAIN RES, V595, P353, DOI 10.1016/0006-8993(92)91071-L; de Resende MA, 2011, J PAIN, V12, P687, DOI 10.1016/j.jpain.2010.12.009; de Souza JB, 2009, CLIN J PAIN, V25, P123, DOI 10.1097/AJP.0b013e318183cfa4; DEBROUCKER T, 1990, BRAIN, V113, P1223, DOI 10.1093/brain/113.4.1223; DICKENSON AH, 1987, BRIT J PHARMACOL, V92, P271, DOI 10.1111/j.1476-5381.1987.tb11321.x; Edwards RR, 2004, PERCEPT MOTOR SKILL, V99, P679, DOI 10.2466/pms.99.2.679-687; Fields H.L., 2006, WALL MELZACKS TXB PA, P125; Granot M, 2008, PAIN, V136, P142, DOI 10.1016/j.pain.2007.06.029; Graven-Nielsen T, 2002, EXP BRAIN RES, V146, P213, DOI 10.1007/s00221-002-1169-7; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Jensen KB, 2009, PAIN, V144, P95, DOI 10.1016/j.pain.2009.03.018; Johannesson U, 2007, PAIN, V130, P31, DOI 10.1016/j.pain.2006.10.022; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; Julien N, 2005, PAIN, V114, P295, DOI 10.1016/j.pain.2004.12.032; King CD, 2009, PAIN, V143, P172, DOI 10.1016/j.pain.2008.12.027; Koltzenburg M, 2006, PAIN, V126, P165, DOI 10.1016/j.pain.2006.06.028; Koppert W, 2005, PAIN, V118, P15, DOI 10.1016/j.pain.2005.06.030; Kosek E, 2000, PAIN, V88, P69, DOI 10.1016/S0304-3959(00)00310-9; Kosek E, 1997, PAIN, V70, P41, DOI 10.1016/S0304-3959(96)03295-2; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; Kunz M, 2006, EXP BRAIN RES, V175, P363, DOI 10.1007/s00221-006-0558-8; Lariviere M, 2007, CLIN J PAIN, V23, P506, DOI 10.1097/AJP.0b013e31806a23e8; LEBARS D, 1992, PAIN, V48, P13, DOI 10.1016/0304-3959(92)90126-V; LEBARS D, 1981, BRAIN RES, V215, P257, DOI 10.1016/0006-8993(81)90506-0; Leonard G, 2009, PAIN, V147, P217, DOI 10.1016/j.pain.2009.09.009; Moont R, 2011, PAIN, V152, P1469, DOI 10.1016/j.pain.2011.01.036; Neziri AY, 2011, EUR J PAIN S5, V1, P176; Niesters M, 2011, PAIN, V152, P656, DOI 10.1016/j.pain.2010.12.015; Olesen SS, 2010, CLIN GASTROENTEROL H, V8, P724, DOI 10.1016/j.cgh.2010.03.005; Oono Y, 2011, J OROFACIAL IN PRESS; Pinto M, 2008, MOL CELL NEUROSCI, V39, P508, DOI 10.1016/j.mcn.2008.07.008; Popescu A, 2010, PAIN, V150, P309, DOI 10.1016/j.pain.2010.05.013; Porreca F, 2001, J NEUROSCI, V21, P5281, DOI 10.1523/JNEUROSCI.21-14-05281.2001; Pud D, 2009, PAIN, V144, P16, DOI 10.1016/j.pain.2009.02.015; Ram KC, 2008, PAIN, V139, P431, DOI 10.1016/j.pain.2008.05.015; Sandrini G, 2006, CEPHALALGIA, V26, P782, DOI 10.1111/j.1468-2982.2006.01130.x; Serrao M, 2004, PAIN, V112, P353, DOI 10.1016/j.pain.2004.09.018; Sittl R, 2005, CLIN THER, V27, P1022, DOI 10.1016/j.clinthera.2005.06.024; Sprenger C, 2011, PAIN, V152, P428, DOI 10.1016/j.pain.2010.11.018; Tousignant-Laflamme Y, 2008, BRAIN RES, V1230, P73, DOI 10.1016/j.brainres.2008.06.120; Tsuruoka M, 1997, BRAIN RES, V762, P264, DOI 10.1016/S0006-8993(97)00509-X; van Wijk G, 2010, J PAIN, V11, P408, DOI 10.1016/j.jpain.2009.10.009; Vanderah TW, 2001, PAIN, V92, P5, DOI 10.1016/S0304-3959(01)00311-6; Vera-Portocarrero LP, 2006, GASTROENTEROLOGY, V130, P2155, DOI 10.1053/j.gastro.2006.03.025; Wilder-Smith CH, 2004, GUT, V53, P1595, DOI 10.1136/gut.2003.028514; WILLER JC, 1990, EUR J PHARMACOL, V182, P347, DOI 10.1016/0014-2999(90)90293-F; Willoch F, 2003, PAIN, V103, P119, DOI 10.1016/S0304-3959(02)00423-2; Yarnitsky D, 2010, CURR OPIN ANESTHESIO, V23, P611, DOI 10.1097/ACO.0b013e32833c348b; Yarnitsky D, 2010, EUR J PAIN, V14, P339, DOI 10.1016/j.ejpain.2010.02.004	55	37	37	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	SEP	2012	28	7					623	627		10.1097/AJP.0b013e31823e15cb			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	990ON	WOS:000307640500010	22156892				2020-06-30	J	Takashina, Y; Naito, T; Mino, Y; Yagi, T; Ohnishi, K; Kawakami, J				Takashina, Yoshiaki; Naito, Takafumi; Mino, Yasuaki; Yagi, Tatsuya; Ohnishi, Kazunori; Kawakami, Junichi			Impact of CYP3A5 and ABCB1 Gene Polymorphisms on Fentanyl Pharmacokinetics and Clinical Responses in Cancer Patients Undergoing Conversion to a Transdermal System	DRUG METABOLISM AND PHARMACOKINETICS			English	Article						fentanyl; CYP3A5; ABCB1; pharmacokinetics; opioid switching	OPIOID RECEPTOR GENE; PALLIATIVE CARE; PAIN PATIENTS; MORPHINE; METABOLISM; ASSOCIATION; VARIABILITY; ABSORPTION; FREQUENCY; TRANSPORT	The aim of this study was to evaluate the influence of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Sixty Japanese cancer patients being treated with a fentanyl transdermal reservoir system according to the current Japanese guidelines were enrolled. Blood samples were obtained 192 h after conversion to the fentanyl transdermal system. Clinical responses after fentanyl application were evaluated by determining the incidences of adverse effects and rescue medication. The plasma concentration of fentanyl normalized with the measured absorption rate was significantly higher in the CYP3A5*3/*3 group than in the *1/*1 and *1/*3 groups (p = 0.048 and 0.021, respectively). Greater incidences of central adverse effects were observed in CYP3A5*3/*3 patients than in *1/*1+*1/*3 patients (odds ratio [OR], 3.49; 95% confidence interval [95% CI], 1.13-10.75; p = 0.029). Fewer patients with the ABCB1 1236TT allele than the 1236C allele needed rescue medication (OR, 0.17; 95% CI, 0.03-0.89; p = 0.036). CYP3A5*3 affected the pharmacokinetics of fentanyl and increased the incidence of central adverse effects. ABCB1 1236TT was associated with decreased administration of rescue medication after switching to the transdermal fentanyl system. In conclusion, these gene polymorphisms may predict clinical responses to fentanyl in cancer patients being converted to the transdermal system.	[Takashina, Yoshiaki; Naito, Takafumi; Mino, Yasuaki; Yagi, Tatsuya; Kawakami, Junichi] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Hamamatsu, Shizuoka 4313192, Japan; [Ohnishi, Kazunori] Hamamatsu Univ Sch Med, Ctr Oncol, Hamamatsu, Shizuoka 4313192, Japan	Kawakami, J (reprint author), Hamamatsu Univ Sch Med, Dept Hosp Pharm, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kawakami-ham@umin.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology in Japan	This work was supported by a Grant-in-Aid for Young Scientists (B) provided by the Japanese Ministry of Education, Culture, Sports, Science and Technology in Japan.	Agarwal S, 2007, PAIN MED, V8, P554, DOI 10.1111/j.1526-4637.2006.00246.x; Anglicheau D, 2004, CLIN PHARMACOL THER, V75, P422, DOI 10.1016/j.clpt.2004.01.009; Campa D, 2008, CLIN PHARMACOL THER, V83, P559, DOI 10.1038/sj.clpt.6100385; Chou WY, 2006, ACTA ANAESTH SCAND, V50, P787, DOI 10.1111/j.1399-6576.2006.01058.x; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Felipe CR, 2009, TRANSPL P, V41, P1441, DOI 10.1016/j.transproceed.2009.03.024; Fukuen S, 2002, PHARMACOGENETICS, V12, P331, DOI 10.1097/00008571-200206000-00009; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Japanese Society for Palliative Medicine, 2000, CANC PAIN MAN GUID; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lamba J, 2006, CLIN PHARMACOL THER, V79, P325, DOI 10.1016/j.clpt.2005.11.013; Lotsch J, 2009, PHARMACOL THERAPEUT, V124, P168, DOI 10.1016/j.pharmthera.2009.06.010; Lotsch J, 2009, PHARMACOGENET GENOM, V19, P429, DOI 10.1097/FPC.0b013e32832b89da; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Quigley C, 2005, BMJ-BRIT MED J, V331, P825, DOI 10.1136/bmj.331.7520.825; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2; Ross JR, 2008, CANCER-AM CANCER SOC, V112, P1390, DOI 10.1002/cncr.23292; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Takashina Y, 2009, J CLIN PHARM THER, V34, P523, DOI 10.1111/j.1365-2710.2009.01033.x; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872; Welsh J, 2005, PALLIATIVE MED, V19, P9, DOI 10.1191/0269216305pm971oa; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x	34	32	34	0	13	JAPANESE SOC STUDY XENOBIOTICS	TOKYO	INT MED INF CENTER SHINANOMACHI RENGAKAN, 35 SHINANO-MACHI SHINJUKU-KU, TOKYO, 160-0016, JAPAN	1347-4367			DRUG METAB PHARMACOK	Drug Metab. Pharmacokinet.	AUG 25	2012	27	4					414	421		10.2133/dmpk.DMPK-11-RG-134			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	987OR	WOS:000307427500007	22277678				2020-06-30	J	Zhang, ZX; Zhang, CC; Zhuang, JG; Xu, FD				Zhang, Zhenxiong; Zhang, Cancan; Zhuang, Jianguo; Xu, Fadi			Contribution of central mu-receptors to switching pulmonary C-fibers-mediated rapid shallow breathing into an apnea by fentanyl in anesthetized rats	BRAIN RESEARCH			English	Article						Fentanyl; Bronchopulmonary C-fiber; The medial nucleus tractus solitarius; The pre-Botzinger complex; Respiratory rhythm	VENTRAL RESPIRATORY GROUP; PRE-BOTZINGER COMPLEX; OPIOID RECEPTORS; VENTILATORY RESPONSE; VAGAL AFFERENTS; NERVOUS-SYSTEM; GROUP NEURONS; VAGUS NERVE; ACTIVATION; REFLEXES	Our previous study has shown that activating peripheral g-receptors is necessary for switching the bronchopulmonary C-fibers (PCFs) -mediated rapid shallow breathing (RSB) into an apnea by systemic administration of fentanyl. The brainstem nuclei, such as the medial nucleus tractus solitarius (mNTS) and the pre-Botzinger complex (PBC), are required for completing the PCF-mediated respiratory reflexes. Moreover, these areas contain abundant g-receptors and their activation prolongs expiratory duration (T-E). Thus, we asked if central p-receptors, especially those in the mNTS and PBC, are involved in fully expressing this RSB-apnea switch by fentanyl. In anesthetized rats, the cardiorespiratory responses to right atrial injection of phenylbiguanide (PBG, 3-6 mu g/kg) were repeated after: (1) fentanyl (iv), a mu-receptor agonist, alone (8 mu g/kg, iv); (2) fentanyl following microinjection of naloxone methiodide (NXM, an opioid receptor antagonist) into the cistema magna (10 mu g/4 mu l); (3) the bilateral mNTS (10 mM, 20 nl); or (4) PBC (10 mM, 20 nl). Our results showed that PBG shortened T-E by 37 +/- 6% (RSB, from 0.41 +/- 0.05 to 0.26 +/- 0.03 s, P < 0.01), but it markedly prolonged T-E by 5.8-fold (an apnea, from 0.50 +/- 0.04s to 2.9 +/- 0.57 s, P < 0.01) after fentanyl (iv). Pretreatment with NXM injected into the cistema magna or the PBC, but not the mNTS, prevented the fentanyl-induced switch. This study, along with our previous results mentioned above, suggests that although peripheral mu-receptors are essential for triggering the fentanyl-induced switch, central mu-receptors, especially those in the PBC, are required to fully exhibit such switch. Summary statement Our results suggest that the activation of central-mu-receptors, especially those in the pre-Botzinger complex, is required for switching the pulmonary C-fiber-mediated rapid shallow breathing into an apnea by systemic administration of fentanyl. (C) 2012 Elsevier B.V. All rights reserved.	[Zhang, Zhenxiong; Zhang, Cancan; Zhuang, Jianguo; Xu, Fadi] Lovelace Resp Res Inst, Pathophysiol Program, Albuquerque, NM 87108 USA	Xu, FD (reprint author), Lovelace Resp Res Inst, Pathophysiol Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	fxu@lrri.org			National Heart, Lung, and Blood Institute, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [RO1 HL107462]; American Lung Association Biomedical Research Grant, New York, NY [RG-191095-N]	This study is supported by RO1 HL107462 from the National Heart, Lung, and Blood Institute, Bethesda, MD and American Lung Association Biomedical Research Grant RG-191095-N, New York, NY.	AGOSTONI E, 1957, J PHYSIOL-LONDON, V135, P182, DOI 10.1113/jphysiol.1957.sp005703; Ang KK, 1999, AM J PHYSIOL-HEART C, V276, pH1552; BELLET M, 1980, BRIT J PHARMACOL, V71, P365, DOI 10.1111/j.1476-5381.1980.tb10949.x; BONHAM AC, 1991, J PHYSIOL-LONDON, V441, P95, DOI 10.1113/jphysiol.1991.sp018740; Churchill ED, 1929, J EXP MED, V49, P531, DOI 10.1084/jem.49.4.531; COLERIDGE HM, 1994, ANNU REV PHYSIOL, V56, P69, DOI 10.1146/annurev.ph.56.030194.000441; Ding YQ, 1998, BRAIN RES, V792, P149, DOI 10.1016/S0006-8993(98)00205-4; Ding YQ, 1996, J COMP NEUROL, V367, P375; Durakoglugil Murat S, 2008, Int J Biomed Sci, V4, P229; Dutta A, 2010, ACTA PHYSIOL, V200, P87, DOI 10.1111/j.1748-1716.2010.02105.x; Feldman JL, 2006, NAT REV NEUROSCI, V7, P232, DOI 10.1038/nrn1871; Gruber EM, 2003, DRUG AGING, V20, P347, DOI 10.2165/00002512-200320050-00004; Haji A, 2003, NEUROSCI LETT, V351, P37, DOI 10.1016/S0304-3940(03)00951-0; HASSEN AH, 1987, AM J PHYSIOL, V252, pH156; HATRIDGE J, 1989, J APPL PHYSIOL, V67, P2257; Hayashida K, 2004, AM J PHYSIOL-REG I, V286, pR359, DOI 10.1152/ajpregu.00214.2003; HOEHE M, 1993, PSYCHONEUROENDOCRINO, V18, P141, DOI 10.1016/0306-4530(93)90065-S; Horton Robert, 2009, J Pain Symptom Manage, V37, pe2, DOI 10.1016/j.jpainsymman.2009.02.230; JAMMES Y, 1982, J AUTONOM NERV SYST, V5, P165, DOI 10.1016/0165-1838(82)90037-6; Krajnik M, 2010, PHARMACOL REP, V62, P139, DOI 10.1016/S1734-1140(10)70251-6; Kubin L, 2006, J APPL PHYSIOL, V101, P618, DOI 10.1152/japplphysiol.00252.2006; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Lee LY, 2003, ANAT REC PART A, V270A, P17, DOI 10.1002/ar.a.10005; LINDSEY BG, 1987, J NEUROPHYSIOL, V57, P1101; Lonergan T, 2003, RESP PHYSIOL NEUROBI, V138, P165, DOI 10.1016/S1569-9048(03)00173-3; Mckay LC, 2008, AM J RESP CRIT CARE, V178, P89, DOI 10.1164/rccm.200712-1901OC; MEI N, 1980, CELL TISSUE RES, V209, P423; Miyawaki T, 2002, NEUROSCIENCE, V109, P133, DOI 10.1016/S0306-4522(01)00439-0; Montandon G, 2011, J NEUROSCI, V31, P1292, DOI 10.1523/JNEUROSCI.4611-10.2011; Moreira TS, 2007, J NEUROPHYSIOL, V98, P3627, DOI 10.1152/jn.00675.2007; Mulkey DK, 2004, NAT NEUROSCI, V7, P1360, DOI 10.1038/nn1357; Mustapic S, 2010, J NEUROPHYSIOL, V103, P409, DOI 10.1152/jn.00188.2009; Paton JFR, 1997, J PHYSIOL-LONDON, V502, P623, DOI 10.1111/j.1469-7793.1997.623bj.x; Peng WH, 2007, J APPL PHYSIOL, V102, P2201, DOI 10.1152/japplphysiol.01436.2006; Roussos C, 2003, EUR RESPIR J, V22, p3S, DOI 10.1183/09031936.03.00038503; SCHROEDER RL, 1991, NEUROSCI LETT, V121, P173, DOI 10.1016/0304-3940(91)90678-M; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Sun MK, 1995, PROG NEUROBIOL, V47, P157, DOI 10.1016/0301-0082(95)00026-8; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Wang H, 2002, J NEUROSCI, V22, P3755; WILLETTE RN, 1982, NEUROPHARMACOLOGY, V21, P1019, DOI 10.1016/0028-3908(82)90116-2; Wilson CG, 1997, J PHYSIOL-LONDON, V504, P453, DOI 10.1111/j.1469-7793.1997.453be.x; XU F, 1992, J APPL PHYSIOL, V73, P2631; Zhang Z., 2012, RESP PHYSL IN PRESS; Zhang ZX, 2007, ANESTHESIOLOGY, V107, P288, DOI 10.1097/01.anes.0000270760.46821.67; Zhang ZX, 2011, ANESTHESIOLOGY, V115, P353, DOI 10.1097/ALN.0b013e318224cc1f	46	5	6	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 21	2012	1469						73	81		10.1016/j.brainres.2012.06.028			9	Neurosciences	Neurosciences & Neurology	998UE	WOS:000308265100008	22759907	Green Accepted			2020-06-30	J	Parvizi, J				Parvizi, Javad			Pain Management Following Total Joint Arthroplasty: Making Strides	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Editorial Material							LOCAL INFILTRATION ANALGESIA; TOTAL KNEE ARTHROPLASTY; POSTOPERATIVE PAIN		Rothman Inst, Philadelphia, PA USA	Parvizi, J (reprint author), Rothman Inst, Philadelphia, PA USA.						Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Dobrydnjov I, 2011, ACTA ORTHOP, V82, P692, DOI 10.3109/17453674.2011.625535; Essving P, 2011, ANESTH ANALG, V113, P926, DOI 10.1213/ANE.0b013e3182288deb; Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Murphy TP, 2012, CLIN ORTHOP RELAT R, V470, P1151, DOI 10.1007/s11999-011-2108-3; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2	9	11	11	0	2	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	AUG 15	2012	94A	16					1441	1441		10.2106/JBJS.9416edit			1	Orthopedics; Surgery	Orthopedics; Surgery	991ZT	WOS:000307745100001	22992813				2020-06-30	J	Ghassabian, S; Moosavi, SM; Valero, YG; Shekar, K; Fraser, JF; Smith, MT				Ghassabian, Sussan; Moosavi, Seyed Mojtaba; Valero, Yarmarly Guerra; Shekar, Kiran; Fraser, John F.; Smith, Maree T.			High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Morphine; M3G, M6G; Fentanyl; Norfentanyl; Midazolam (MDZ), 1-OHMDZ; 4-OHMDZ; On-line SPE; LC-MS/MS	TANDEM MASS-SPECTROMETRY; SOLID-PHASE EXTRACTION; SENSITIVE DETERMINATION; DOG PLASMA; MORPHINE-3-GLUCURONIDE; NORFENTANYL; URINE; DRUGS; MORPHINE-6-GLUCURONIDE; BENZODIAZEPINES	A rapid LC-MS/MS assay method for simultaneous quantification of morphine, fentanyl, midazolam and their major metabolites: morphine-3-beta-D-glucuronide (M3G), morphine-6-beta-D-glucuronide (M6G), norfentanyl, 1'-hydroxymidazolam (1-OH-MDZ) and 4-hydroxymidazolam (4-OH-MDZ) in samples of human plasma has been developed and validated. Robotic on-line solid phase extraction (SPE) instrumentation was used to elute the eight analytes of interest from polymeric SPE cartridges to which had been added aliquots (150 mu L) of human plasma and aliquots (150 mu L) of a mixture of two internal standards, viz. morphine-d3 (200 ng/mL) and 1'-hydroxymidazolam-d5 (50 ng/mL) in 50 mM ammonium acetate buffer (pH 9.25). Cartridges were washed using 10% methanol in ammonium acetate buffer, pH 9.25 (1 mL, 2 mL/min) before elution with mobile phase comprising 0.1% formic acid in water (A) and acetonitrile (B) with a flow rate of 0.6 mL/min using an 11.5 min run time. The analytes were separated on a C18 X-Terre (R) analytical column. The linear concentration ranges were 0.5-100 ng/mL for fentanyl, norfentanyl and midazolam; 1-200 ng/mL for 4-hydroxymidazolam, 2.5-500 ng/mL for 1'-hydroxymidazolam and 3.5-700 ng/mL for morphine, M3G, and M6G. The method showed acceptable within-run and between-run precision (relative standard deviation (RSD) and accuracy <20%) for quality control (QC) samples spiked at concentrations of 80% and 50% of the ULOQ 3 times higher than the LLOQ and also at the LLOQ. Furthermore, analytes were stable in samples (after mixing with internal standard) for at least 48 h in the autosampler (except for 4-hydroxymidazolam which decreased by 22% after 24 h), 5 h at room temperature and after three cycles of freeze and thaw. No autosampler carry-over was observed and the absolute recovery (the area ratio of analyte in plasma relative to that in ammonium acetate buffer 50 mM, pH 9.25) was in the range 40% (midazolam) to 110% (morphine). The assay was applied successfully to the measurement of the analytes of interest in plasma samples from patients on extracorporeal membrane oxygenation (ECMO). (C) 2012 Published by Elsevier B.V.	[Ghassabian, Sussan; Moosavi, Seyed Mojtaba; Valero, Yarmarly Guerra; Smith, Maree T.] Univ Queensland, Ctr Integrated Preclin Drug Dev, Brisbane, Qld 4029, Australia; [Shekar, Kiran; Fraser, John F.] Univ Queensland, Prince Charles Hosp, Crit Care Res Grp, Brisbane, Qld 4029, Australia; [Smith, Maree T.] Univ Queensland, Sch Pharm, Brisbane, Qld 4029, Australia	Ghassabian, S (reprint author), Univ Queensland, Ctr Integrated Preclin Drug Dev, Level 7,Block 6,Herston Campus, Brisbane, Qld 4029, Australia.	s.ghassabian@uq.edu.au	Smith, Maree T/I-4005-2015; Shekar, Kiran/K-3209-2012; Valero, Yarmarly C Guerra/AAL-9683-2020; Fraser, John F/F-4570-2010	Smith, Maree T/0000-0003-2281-3734; Valero, Yarmarly C Guerra/0000-0001-6924-7237; Shekar, Kiran/0000-0002-1239-7514	Australian and New Zealand College of Anaesthetists; Prince Charles Hospital Foundation; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Queensland Government; Australian GovernmentAustralian Government	This work was supported financially by research grants from the Australian and New Zealand College of Anaesthetists, The Prince Charles Hospital Foundation and the Australian National Health and Medical Research Council. This project used research infrastructure provided by the Queensland Government's Smart State Research Facilities Fund and the Australian Government's Education Investment Fund Super Science Translating Health Discovery project.	Ardjomand-Woelkart K, 2011, ANAL BIOANAL CHEM, V400, P2371, DOI 10.1007/s00216-010-4618-3; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; de Castro A, 2007, J CHROMATOGR A, V1160, P3, DOI 10.1016/j.chroma.2007.01.137; de Jager AD, 2011, J CHROMATOGR B, V879, P2642, DOI 10.1016/j.jchromb.2011.07.029; Dostalek M, 2010, J CHROMATOGR B, V878, P1629, DOI 10.1016/j.jchromb.2010.04.001; Edwards SR, 2005, J CHROMATOGR B, V814, P241, DOI 10.1016/j.jchromb.2004.10.035; Ghassabian S, 2009, THER DRUG MONIT, V31, P239, DOI 10.1097/FTD.0b013e318197e1bf; Heinig K, 2011, J PHARMACEUT BIOMED, V54, P742, DOI 10.1016/j.jpba.2010.10.003; Jabor VAP, 2005, J CHROMATOGR B, V822, P27, DOI 10.1016/j.jchromb.2005.05.011; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Liao QF, 2009, J SEP SCI, V32, P202, DOI 10.1002/jssc.200800417; Link B, 2007, RAPID COMMUN MASS SP, V21, P1531, DOI 10.1002/rcm.2987; Mabuchi M, 2004, J PHARMACEUT BIOMED, V35, P563, DOI 10.1016/j.jpba.2004.01.026; Muchohi SN, 2005, J CHROMATOGR B, V821, P1, DOI 10.1016/j.jchromb.2005.03.015; Postigo C, 2008, ANAL CHEM, V80, P3123, DOI 10.1021/ac702060j; Quintela O, 2006, CLIN CHEM, V52, P1346, DOI 10.1373/clinchem.2005.065631; Shekar K, J CRIT CARE IN PRESS; Shimizu M, 2007, J CHROMATOGR B, V847, P275, DOI 10.1016/j.jchromb.2006.10.018; Shou WZ, 2002, J PHARMACEUT BIOMED, V27, P143, DOI 10.1016/S0731-7085(01)00497-6; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Subramanian M, 2008, THER DRUG MONIT, V30, P347, DOI 10.1097/FTD.0b013e3181678ecb; Torben B., 2011, J BIOANAL BIOMED, V3, P103; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Weng ND, 1999, J CHROMATOGR B, V735, P255, DOI 10.1016/S0378-4347(99)00429-6; Whittington D, 2003, J CHROMATOGR B, V796, P95, DOI 10.1016/j.jchromb.2003.08.007	26	45	46	1	49	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	AUG 15	2012	903						126	133		10.1016/j.jchromb.2012.07.005			8	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	995XH	WOS:000308048100018	22841553				2020-06-30	J	Kaila, R; Chen, XG; Kannikeswaran, N				Kaila, Rahul; Chen, Xinguang; Kannikeswaran, Nirupama			Postdischarge Adverse Events Related to Sedation for Diagnostic Imaging in Children	PEDIATRIC EMERGENCY CARE			English	Article						MRI; sedation; postdischarge adverse events	PROCEDURAL SEDATION; EMERGENCY-DEPARTMENT; DISCHARGE; ANALGESIA; SAFE	Objectives: The objectives of this study were to describe the type and frequency of postdischarge adverse events related to sedation for elective diagnostic imaging in children and to determine if any patient or drug characteristics were associated with such adverse events. Methods: We conducted a prospective observational study of children younger than 18 years who underwent sedation for elective magnetic resonance imaging at a tertiary care hospital. We administered a postdischarge adverse event questionnaire to families within 3 to 5 days after sedation to assess adverse events such as behavioral changes, vomiting, recovery time to baseline status, and need for medical follow-up. Results: We enrolled 322 patients, of which 253 (78.5%) completed phone follow-up. The majority of study patients were male (58.1%) and belonged to American Society of Anesthesiologists category 2 (52.2%). A combination of pentobarbital and midazolam (53.4%) was the most commonly used sedation medication; 64.4% patients experienced postdischarge adverse events. The most common postdischarge adverse event reported were incoordination of movements (53.8%), dizziness (31.2%), and agitation (19.8%); 48.6% of patients required more than 9 hours to return to baseline behavior. No patient required evaluation at a medical facility for these postdischarge adverse events. Logistic regression analysis showed that use of pentobarbital and adverse event during sedation were significantly associated with postdischarge adverse events. Conclusions: Postdischarge adverse events related to sedation for diagnostic imaging are minor, mostly behavioral, but occur in a significant number of patients. Parents should be provided with detailed discharge instructions to anticipate such adverse events at home.	[Kaila, Rahul; Kannikeswaran, Nirupama] Childrens Hosp Michigan, Dept Pediat Emergency Med, Detroit, MI 48201 USA; [Chen, Xinguang] Wayne State Univ, Detroit, MI USA; [Chen, Xinguang] Pediat Prevent Res Ctr, Detroit, MI USA	Kaila, R (reprint author), Childrens Hosp Michigan, Dept Pediat Emergency Med, 3901 Beaubein, Detroit, MI 48201 USA.	drrahulkaila@gmail.com		Chen, Xinguang/0000-0001-8263-643X	Blue Cross Blue Shield of Michigan Foundation	Funding was received from the Blue Cross Blue Shield of Michigan Foundation.	Baxter AL, 2007, PEDIATR EMERG CARE, V23, P690, DOI 10.1097/PEC.0b013e3181558d5c; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Kao SC, 1999, PEDIATR RADIOL, V29, P287, DOI 10.1007/s002470050590; Malviya S, 2004, ANESTHESIOLOGY, V100, P218, DOI 10.1097/00000542-200402000-00007; McQueen A, 2009, ANN EMERG MED, V54, P191, DOI 10.1016/j.annemergmed.2009.04.015; Newman DH, 2003, ANN EMERG MED, V42, P627, DOI 10.1016/S0196-0644(03)00446-3; Pitetti RD, 2003, ARCH PEDIAT ADOL MED, V157, P1090, DOI 10.1001/archpedi.157.11.1090	7	13	14	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	AUG	2012	28	8					796	801		10.1097/PEC.0b013e3182628829			6	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	992TV	WOS:000307803500017	22858755				2020-06-30	J	Guilfoyle, MR; Mannion, RJ; Mitchell, P; Thomson, S				Guilfoyle, Mathew R.; Mannion, Richard J.; Mitchell, Patrick; Thomson, Simon			Epidural fentanyl for postoperative analgesia after lumbar canal decompression: a randomized controlled trial	SPINE JOURNAL			English	Article						Lumbar stenosis; Lumbar canal decompression; Epidural analgesia; Fentanyl; Randomized controlled trial	INTRATHECALLY ADMINISTERED MORPHINE; DOUBLE-BLIND; SPINAL SURGERY; PAIN-CONTROL; LAMINECTOMY; BUPIVACAINE; INFILTRATION; SUFENTANIL; INFUSION; SITE	BACKGROUND CONTEXT: Postoperative back pain is common after decompression surgery for lumbar stenosis and often delays discharge from hospital. Achieving regional analgesia by intraoperative delivery of epidural opiates after lumbar canal decompression is a promising approach to reduce postoperative pain and enhance early mobilization. However, there have been concerns about opiate-related complications, such as respiratory depression and urinary retention in what is generally an elderly population of patients. PURPOSE: To assess the analgesic efficacy of bolus epidural fentanyl administered intraoperatively after lumbar decompression for degenerative canal stenosis. STUDY DESIGN/SETTING: Patient-blinded randomized controlled trial conducted at two university neurosurgical centers. PATIENT SAMPLE: Adults (older than 18 years) with neurogenic claudication and/or lower limb radiculopathy and concordant lumbar spinal canal stenosis demonstrated on magnetic resonance imaging. Patients with previous lumbar spinal surgery, a contraindication to fentanyl, or requiring instrumentation were excluded. OUTCOME MEASURES: The primary outcome measure was patient-reported Visual Analogue Score (VAS) for pain recorded preoperatively, in recovery, and on the first and second postoperative days if the patient remained in the hospital. Secondary outcomes were duration of surgery, length of stay, and any side effects or complications. METHODS: Patients underwent a one to three level lumbar canal decompression as required, via a midline incision, under general anesthesia. Before wound closure either no drug (control) or a 100-mu g bolus of fentanyl was administered via an epidural catheter inserted 10 cm rostral to the operated level. Patients were blinded to group allocation, and analysis was by intention to treat. The trial was approved by the National Health Service Research Ethics Service and the Medicines and Healthcare products Regulatory Agency. No commercial or other source of funding was received. RESULTS: Sixty patients were randomized, 29 to fentanyl and 31 to control. Demographics, duration of surgery, and preoperative VAS were not significantly different between the groups. VAS in recovery was significantly lower in patients treated with fentanyl (mean [standard deviation]: 2.6 [2.7] vs. 4.7 [2.4]; p=.003). Later VAS and postoperative length of stay were similar between groups. More patients in the fentanyl group required temporary urinary catheterization, but there was no significant difference in the incidence of side effects. CONCLUSIONS: Bolus epidural fentanyl provides effective short-term postoperative analgesia after lumbar canal decompression and may be a useful adjunct to pain management in patients undergoing lumbar spine surgery. (C) 2012 Elsevier Inc. All rights reserved.	[Thomson, Simon] Leeds Gen Infirm, Dept Neurosurg, Leeds LS1 3EX, W Yorkshire, England; [Guilfoyle, Mathew R.; Mannion, Richard J.; Thomson, Simon] Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 0QQ, England; [Mitchell, Patrick] Newcastle Gen Hosp, Dept Neurosurg, Royal Victoria Infirm, Reg Neurosci Ctr, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Thomson, S (reprint author), Leeds Gen Infirm, Dept Neurosurg, Great George St, Leeds LS1 3EX, W Yorkshire, England.	simon.thomson@leedsth.nhs.uk		Thomson, Simon/0000-0003-4827-1961	Royal College of Surgeons of England/Philip King Charitable Settlement Research Fellowship; University of Cambridge/Raymond and Beverley Sackler Scholarship	This trial was not funded by commercial or other sponsorship and the authors confirm no conflicts of interest, financial or otherwise. Commercial funds or sponsorship received by the authors outside of this study have been detailed in the disclosure section. MRG is supported by a Royal College of Surgeons of England/Philip King Charitable Settlement Research Fellowship and by a University of Cambridge/Raymond and Beverley Sackler Scholarship.	Chadduck JB, 1999, J NEUROSURG, V90, P67, DOI 10.3171/spi.1999.90.1.0067; Chan JHH, 2006, SPINE, V31, P2529, DOI 10.1097/01.brs.0000241135.79983.52; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Grass JA, 1997, ANESTH ANALG, V85, P365, DOI 10.1097/00000539-199708000-00022; Gurbet A, 2008, EUR SPINE J, V17, P1237, DOI 10.1007/s00586-008-0676-z; Jellish WS, 2003, ANESTH ANALG, V96, P874, DOI 10.1213/01.ANE.0000049682.48703.44; Jirarattanaphochai K, 2007, SPINE, V32, P609, DOI 10.1097/01.brs.0000257541.91728.a1; JOSHI GP, 1995, ANESTH ANALG, V80, P511, DOI 10.1097/00000539-199503000-00013; Kundra P, 1997, ANESTH ANALG, V85, P135, DOI 10.1097/00000539-199707000-00024; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROSS DA, 1991, NEUROSURGERY, V28, P700, DOI 10.1227/00006123-199105000-00010; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; SUDARSHAN G, 1995, BRIT J ANAESTH, V75, P19, DOI 10.1093/bja/75.1.19; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018	14	13	15	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	AUG	2012	12	8					646	651		10.1016/j.spinee.2012.07.007			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	016OE	WOS:000309527800005	22926408				2020-06-30	J	Hee, HI; Tan, YST; Hee, HT				Hee, Hwan Ing; Tan, Yi Shuen Tracy; Hee, Hwan Tak			Commentary: Postoperative analgesia after lumbar laminectomy: is there a role for single-shot epidural fentanyl?	SPINE JOURNAL			English	Editorial Material							PEDIATRIC SPINE SURGERY; INTRAVENOUS FENTANYL; DOUBLE-BLIND; PAIN-CONTROL; MORPHINE; PATIENT; THORACOTOMY; INFUSION; SUFENTANIL; MANAGEMENT		[Hee, Hwan Tak] Paragon & Mt Elizabeth Med Ctr, Ctr Spine & Scoliosis Surg, Singapore 238859, Singapore; [Hee, Hwan Ing; Tan, Yi Shuen Tracy] KK Womens & Childrens Hosp, Dept Paediat Anaesthesia, Singapore 229899, Singapore	Hee, HT (reprint author), Paragon & Mt Elizabeth Med Ctr, Ctr Spine & Scoliosis Surg, 290 Orchard Rd,09-09-10, Singapore 238859, Singapore.	hwantak@gmail.com					Aono H, 2011, J NEUROSURG-SPINE, V15, P202, DOI 10.3171/2011.3.SPINE10716; Arms DM, 1998, ORTHOPEDICS, V21, P539; BIRNBACH DJ, 1989, ANESTH ANALG, V68, P808; BOUCHARD F, 1995, REGION ANESTH, V20, P385; BROCKWAY MS, 1990, BRIT J ANAESTH, V64, P243, DOI 10.1093/bja/64.2.243; Bujedo Borja Mugabure, 2012, J Opioid Manag, V8, P177, DOI 10.5055/jom.2012.0114; Cata JP, 2008, J NEUROSURG ANESTH, V20, P256, DOI 10.1097/ANA.0b013e31817ffe90; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; COE A, 1991, ANAESTHESIA, V46, P918, DOI 10.1111/j.1365-2044.1991.tb09846.x; Fanuele JC, 2000, SPINE, V25, P1509, DOI 10.1097/00007632-200006150-00009; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; Gottschalk A, 2004, ANESTHESIOLOGY, V101, P175, DOI 10.1097/00000542-200407000-00027; Grass JA, 1997, ANESTH ANALG, V85, P365, DOI 10.1097/00000539-199708000-00022; Guilfoyle MR, 2012, SPINE J, V12, P646, DOI 10.1016/j.spinee.2012.07.007; GUINARD JP, 1995, ANESTHESIOLOGY, V82, P377, DOI 10.1097/00000542-199502000-00008; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; HARUKUNI I, 1995, ANESTH ANALG, V81, P1169, DOI 10.1097/00000539-199512000-00009; HERZ A, 1970, NEUROPHARMACOLOGY, V9, P539, DOI 10.1016/0028-3908(70)90004-3; INAGAKI Y, 1992, ANESTH ANALG, V74, P856; JOSHI GP, 1995, ANESTH ANALG, V80, P511, DOI 10.1097/00000539-199503000-00013; Kaner Tuncay, 2009, Cases J, V2, P8584, DOI 10.4076/1757-1626-2-8584; Kluba T, 2010, ORTHOP REV, V2, P27, DOI 10.4081/or.2010.e9; Kumar R J, 2003, J Orthop Surg (Hong Kong), V11, P67; Kundra P, 1997, ANESTH ANALG, V85, P135, DOI 10.1097/00000539-199707000-00024; LOMESSY A, 1984, ANESTHESIOLOGY, V61, P466, DOI 10.1097/00000542-198410000-00020; Lowry KJ, 2001, SPINE, V26, P1290; O'Hara JF, 2004, PEDIATR ANESTH, V14, P1009, DOI 10.1111/j.1460-9592.2004.01387.x; Ortiz-Cardona Jose, 2007, Anesthesiol Clin, V25, P655, DOI 10.1016/j.anclin.2007.05.003; OZUNA J, 1988, CLIN J PAIN, V4, P209, DOI 10.1097/00002508-198812000-00003; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Privado MS, 2010, SAO PAULO MED J, V128, P5, DOI 10.1590/S1516-31802010000100002; PURNELL RJ, 1982, ANAESTHESIA, V37, P1115, DOI 10.1111/j.1365-2044.1982.tb01758.x; RAY CD, 1983, NEUROSURGERY, V13, P388, DOI 10.1227/00006123-198310000-00007; RECHTINE GR, 1984, J BONE JOINT SURG AM, V66A, P113, DOI 10.2106/00004623-198466010-00015; REYNOLDS AF, 1986, ANN SURG, V203, P225, DOI 10.1097/00000658-198602000-00018; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SAWCHUK CWT, 1993, ANN THORAC SURG, V55, P1472, DOI 10.1016/0003-4975(93)91090-A; Schenk MR, 2006, ANESTH ANALG, V103, P1311, DOI 10.1213/01.ane/0000247966.49492.72; Shabat S, 2008, EUR SPINE J, V17, P193, DOI 10.1007/s00586-007-0514-8; Shaw BA, 1996, J PEDIATR ORTHOPED, V16, P374, DOI 10.1097/01241398-199605000-00016; SHIPTON EA, 1986, S AFR MED J, V70, P325; Sice PJA, 2005, BRIT J ANAESTH, V94, P378, DOI 10.1093/bja/aei061; Tobias JD, 2004, ANESTH ANALG, V98, P956, DOI 10.1213/01.ANE.0000107938.80562.75; Turner A, 2000, ANAESTHESIA, V55, P370, DOI 10.1046/j.1365-2044.2000.01117.x; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; Walcott Brian P, 2011, Surg Neurol Int, V2, P7, DOI 10.4103/2152-7806.76144; WELCHEW EA, 1991, ANAESTHESIA, V46, P438, DOI 10.1111/j.1365-2044.1991.tb11678.x; WELLS DG, 1987, ANESTHESIOLOGY, V67, P991, DOI 10.1097/00000542-198712000-00022; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652	49	0	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430	1878-1632		SPINE J	Spine Journal	AUG	2012	12	8					652	655		10.1016/j.spinee.2012.08.023			4	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	016OE	WOS:000309527800006	23021028				2020-06-30	J	Hippard, HK; Govindan, K; Friedman, EM; Sulek, M; Giannoni, C; Larrier, D; Minard, CG; Watcha, MF				Hippard, Helena K.; Govindan, Kalyani; Friedman, Ellen M.; Sulek, Marcelle; Giannoni, Carla; Larrier, Deidre; Minard, Charles G.; Watcha, Mehemoor F.			Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine, and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes	ANESTHESIA AND ANALGESIA			English	Article							SEVOFLURANE ANESTHESIA; EMERGENCE DELIRIUM; PREOPERATIVE ANXIETY; EQUALIZATION TUBES; PAIN ASSESSMENT; CHILDREN; ACETAMINOPHEN; HALOTHANE; SCALE; INSERTION	BACKGROUND: Bilateral myringotomy and placement of ventilating tubes (BMT) is one of the most common pediatric surgical procedures in the United States. Many children who undergo BMT develop behavioral changes in the postanesthesia care unit (PACU) and require rescue pain medication. The incidence of these changes is lower in children receiving intraoperative opioids by the nasal, IM, or IV route compared with placebo. However, there are no data to indicate which route of administration is better. Our study was designed to compare the immediate postoperative analgesic and behavioral effects of 3 frequently used intraoperative techniques of postoperative pain control for patients undergoing BMT under general anesthesia. METHODS: One hundred seventy-one ASA physical status I and II children scheduled for BMT were randomized into 1 of 3 groups: group 1 nasal fentanyl 2 mu g/kg with IV and IM saline placebo; group 2 IV morphine 0.1 mg/kg with nasal and IM placebo; or group 3 IM morphine 0.1 mg/kg with nasal and IV placebo. All subjects received a standardized general anesthetic with sevoflurane, N2O, and 02 and similar postoperative care. The primary end point of the study was the pain scores measured by the Faces, Legs, Activity, Cry, and Consolability (FLACC) scale in the PACU. RESULTS: There were no significant differences in peak FLACC pain among the 3 groups (mean [95% CI 2.0 [1.2-2.8] for intranasal fentanyl, 2.7 [1.7-3.6] for IV morphine, and 2.9 [2.1-3.7] for IM morphine, respectively). There were no differences in the scores on the Pediatric Anesthesia Emergence Delirium (PAED) scale, incidence of postoperative emergence delirium (PAED score >= 12), emesis, perioperative hypoxemia, or need for airway intervention, and postoperative rescue analgesia. There were also no differences in the duration of PACU stay or parental satisfaction among the groups. CONCLUSION: In this double-blind, double-dummy study, there was no difference in the efficacy of intranasal fentanyl, IM and IV morphine in controlling postoperative pain and emergence delirium in children undergoing BMT placement. The IM route is the simplest and avoids the potential for delays to establish vascular access for IV therapy and the risks of laryngospasm if intranasal drugs pass through the posterior nasopharynx and irritate the vocal cords. (Anesth Analg 2012;115:356-63)	[Hippard, Helena K.; Govindan, Kalyani; Watcha, Mehemoor F.] Texas Childrens Hosp, Dept Anesthesiol & Pediat, Baylor Coll Med, Houston, TX 77030 USA; [Friedman, Ellen M.; Sulek, Marcelle; Giannoni, Carla; Larrier, Deidre] Texas Childrens Hosp, Baylor Coll Med, Bobby R Alford Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Minard, Charles G.] Texas Childrens Hosp, Baylor Coll Med, Dan L Duncan Inst Clin & Translat Res, Houston, TX 77030 USA	Hippard, HK (reprint author), Texas Childrens Hosp, Dept Anesthesiol & Pediat, Baylor Coll Med, 6621 Fannin,Suite 3300, Houston, TX 77030 USA.	hxkarlbe@texaschildrens.org			Baylor College of Medicine	Baylor College of Medicine internal departmental support.	Allen AH, 2007, ENT-EAR NOSE THROAT, V86, P672, DOI 10.1177/014556130708601118; BeanLijewski JD, 1997, PAEDIATR ANAESTH, V7, P131, DOI 10.1046/j.1460-9592.1997.d01-47.x; Bennie RE, 1997, PAEDIATR ANAESTH, V7, P399, DOI 10.1046/j.1460-9592.1997.d01-115.x; Bennie RE, 1998, ANESTHESIOLOGY, V89, P385, DOI 10.1097/00000542-199808000-00015; Bolton P, 2002, PAEDIATR ANAESTH, V12, P29, DOI 10.1046/j.1460-9592.2002.00743.x; Bryan YF, 2009, PEDIATR ANESTH, V19, P672, DOI 10.1111/j.1460-9592.2009.03048.x; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Haupert MS, 2004, ARCH OTOLARYNGOL, V130, P1025, DOI 10.1001/archotol.130.9.1025; ISAACSON G, 1994, PEDIATRICS, V93, P924; Kain ZN, 1997, ANESTH ANALG, V85, P783, DOI 10.1097/00000539-199710000-00012; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5; Lin YC, 2009, PEDIATR ANESTH, V19, P1096, DOI 10.1111/j.1460-9592.2009.03129.x; Malviya S, 2006, PEDIATR ANESTH, V16, P258, DOI 10.1111/j.1460-9592.2005.01773.x; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Merkel S, 2002, AM J NURS, V102, P55; Merkel S I, 1997, Pediatr Nurs, V23, P293; Nilsson S, 2008, PEDIATR ANESTH, V18, P767, DOI 10.1111/j.1460-9592.2008.02655.x; Pappas AL, 2003, ANESTH ANALG, V96, P1621, DOI 10.1213/01.ANE.0000064206.51296.1D; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; TOBIAS JD, 1995, ANESTH ANALG, V81, P496, DOI 10.1097/00000539-199509000-00012; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; Westin UE, 2006, PHARM RES-DORDR, V23, P565, DOI 10.1007/s11095-006-9534-z	29	19	20	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2012	115	2					356	363		10.1213/ANE.0b013e31825afef3			8	Anesthesiology	Anesthesiology	978TU	WOS:000306769500023	22669347				2020-06-30	J	Lee, TH; Lee, CK; Park, SH; Lee, SH; Chung, IK; Choi, HJ; Cha, SW; Moon, JH; Cho, YD; Hwangbo, Y; Kim, SJ				Lee, Tae Hoon; Lee, Chang Kyun; Park, Sang-Heum; Lee, Suck-Ho; Chung, Il-Kwun; Choi, Hyun Jong; Cha, Sang Woo; Moon, Jong Ho; Cho, Young Deok; Hwangbo, Young; Kim, Sun-Joo			Balanced Propofol Sedation Versus Propofol Monosedation in Therapeutic Pancreaticobiliary Endoscopic Procedures	DIGESTIVE DISEASES AND SCIENCES			English	Article						Balanced propofol sedation; Propofol monosedation; Complication; ERCP; EUS	HIGH-RISK OCTOGENARIANS; LOW-DOSE PROPOFOL; DEEP SEDATION; GASTROINTESTINAL ENDOSCOPY; ADMINISTERED PROPOFOL; MODERATE SEDATION; RETROGRADE CHOLANGIOPANCREATOGRAPHY; MONITORED ANESTHESIA; INTRAVENOUS PROPOFOL; ROUTINE ERCP	Prolonged or complex endoscopic procedures are frequently performed under deep sedation. However, no studies of therapeutic ERCP have yet compared the use of balanced propofol sedation (BPS) to propofol alone, titrated to moderate levels of sedation. This prospective, randomized, double-blind study was planned to compare the sedation efficacy and safety of BPS (propofol in combination with midazolam and fentanyl) and propofol monosedation in therapeutic ERCP and EUS. BPS, or propofol monosedation titrated to a moderate level of sedation, was performed by trained registered nurses under endoscopist supervision. The main outcome measurements included sedation efficacy focusing on recovery time, sedation safety, endoscopic procedure outcomes, and complications. There were no significant differences in sedation efficacy, safety, procedure outcomes, and complications, with the exception of recovery time. Mean recovery time (standard deviation) was 18.37 (7.86) min in BPS and 13.4 (6.24) min in propofol monosedation (P < 0.001). In a safety analysis, cardiopulmonary complication rates related to BPS and propofol monosedation were 7.8 % (8/102) and 9.6 % (10/104), respectively (P = 0.652). No patient required assisted ventilation or permanent termination of a procedure in either group. Technical success of the endoscopic procedures was 96.3 and 97.2 %, respectively (P = 0.701). Endoscopic procedure-related complications and outcomes did not differ depending on sedation procedure. Propofol monosedation by trained, registered sedation nurses under supervision resulted in a more rapid recovery time than BPS. There were no differences in the sedation safety, endoscopic procedure outcomes, and complications between BPS and propofol monosedation.	[Lee, Tae Hoon; Park, Sang-Heum; Lee, Suck-Ho; Chung, Il-Kwun; Kim, Sun-Joo] Soonchunhyang Univ, Sch Med, Dept Internal Med, Cheonan Hosp,Div Gastroenterol, Cheonan Si 330721, Chungcheongnam, South Korea; [Lee, Chang Kyun] Kyung Hee Univ, Sch Med, Div Gastroenterol, Dept Internal Med, Seoul, South Korea; [Choi, Hyun Jong; Cha, Sang Woo; Moon, Jong Ho; Cho, Young Deok] Soonchunhyang Univ, Sch Med, Dept Internal Med, Ctr Digest Dis, Seoul, South Korea; [Hwangbo, Young] Soonchunhyang Univ, Sch Med, Dept Prevent Med, Cheonan, South Korea	Lee, TH (reprint author), Soonchunhyang Univ, Sch Med, Dept Internal Med, Cheonan Hosp,Div Gastroenterol, 23-20 Bongmyung Dong, Cheonan Si 330721, Chungcheongnam, South Korea.	thlee9@lycos.co.kr	Lee, Chang Kyun/AAI-1012-2020; MOON, JONG HO/AAJ-1316-2020	Lee, Chang Kyun/0000-0002-4279-3825; Moon, Jong Ho/0000-0002-3946-9944; Hwangbo, Young/0000-0002-8447-8372			Aldrete J A, 1998, J Perianesth Nurs, V13, P148, DOI 10.1016/S1089-9472(98)80044-0; COCKSHOTT ID, 1987, BRIT J ANAESTH, V59, P1103, DOI 10.1093/bja/59.9.1103; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2010, DIGEST DIS SCI, V55, P2425, DOI 10.1007/s10620-010-1365-4; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cohen LB, 2003, GASTROINTEST ENDOSC, V58, P725, DOI 10.1016/S0016-5107(03)02010-8; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P660, DOI 10.1016/j.cgh.2010.05.015; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; DeWitt J, 2008, GASTROINTEST ENDOSC, V68, P499, DOI 10.1016/j.gie.2008.02.092; DeWitt JM, 2008, DIGEST DIS SCI, V53, P2739, DOI 10.1007/s10620-008-0198-x; Dumonceau JM, 2010, ENDOSCOPY, V42, P960, DOI 10.1055/s-0030-1255728; Fanti L, 2007, DIGEST LIVER DIS, V39, P81, DOI 10.1016/j.dld.2006.09.004; Fanti L, 2004, GASTROINTEST ENDOSC, V60, P361, DOI 10.1016/S0016-5107(04)01713-4; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Heuss LT, 2005, ENDOSCOPY, V37, P161, DOI 10.1055/s-2004-826143; Krugliak P, 2000, ENDOSCOPY, V32, P677; Lee CK, 2011, GASTROINTEST ENDOSC, V73, P206, DOI 10.1016/j.gie.2010.09.035; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Mehta PP, 2011, DIGEST DIS SCI, V56, P2185, DOI 10.1007/s10620-011-1568-3; Nayar DS, 2010, DIGEST DIS SCI, V55, P2537, DOI 10.1007/s10620-010-1308-0; Ong WC, 2007, ENDOSCOPY, V39, P807, DOI 10.1055/s-2007-966725; Paspatis GA, 2008, ENDOSCOPY, V40, P308, DOI 10.1055/s-2007-995346; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; Qadeer MA, 2005, CLIN GASTROENTEROL H, V3, P1049, DOI 10.1016/S1542-3565(05)00742-1; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Rex Douglas K, 2008, Gastrointest Endosc Clin N Am, V18, P717, DOI 10.1016/j.giec.2008.06.002; Riphaus A, 2005, AM J GASTROENTEROL, V100, P1957, DOI 10.1111/j.1572-0241.2005.41672.x; Riphaus A, 2010, Z GASTROENTEROL, V48, P392, DOI 10.1055/s-0028-1109765; Schilling D, 2009, ENDOSCOPY, V41, P295, DOI 10.1055/s-0028-1119671; SEARLE NR, 1993, CAN J ANAESTH, V40, P730, DOI 10.1007/BF03009770; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Sipe BW, 2007, CLIN GASTROENTEROL H, V5, P563, DOI 10.1016/j.cgh.2007.01.013; Thomson A, 2010, J GASTROEN HEPATOL, V25, P469, DOI 10.1111/j.1440-1746.2009.06174.x; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Vargo JJ, 2009, GASTROINTEST ENDOSC, V70, P1053, DOI 10.1016/j.gie.2009.07.020; Wehrmann T, 1999, GASTROINTEST ENDOSC, V49, P677, DOI 10.1016/S0016-5107(99)70281-6; Wehrmann T, 2008, SCAND J GASTROENTERO, V43, P368, DOI 10.1080/00365520701679181	40	22	25	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	AUG	2012	57	8					2113	2121		10.1007/s10620-012-2234-0			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	980YM	WOS:000306930100020	22615018				2020-06-30	J	Zhuang, JG; Zhang, ZX; Zhang, CC; Xu, FD				Zhuang, Jianguo; Zhang, Zhenxiong; Zhang, Cancan; Xu, Fadi			8-OH-DPAT abolishes the pulmonary C-fiber-mediated apneic response to fentanyl largely via acting on 5HT(1A) receptors in the nucleus tractus solitarius	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						blood pressure; heart rate; opiods; ventilation	MEDULLARY RESPIRATORY NEURONS; RIGHT ATRIAL INJECTION; MU-OPIOID RECEPTOR; VAGAL REFLEX; SUBSTANCE-P; RAT; ACTIVATION; STIMULATION; MORPHINE; DEPRESSION	Zhuang J, Zhang Z, Zhang C, Xu F. 8-OH-DPAT abolishes the pulmonary C-fiber-mediated apneic response to fentanyl largely via acting on 5HT(1A) receptors in the nucleus tractus solitarius. Am J Physiol Regul Integr Comp Physiol 303: R449-R458, 2012. First published June 13, 2012; doi:10.1152/ajpregu.00016.2012.-Intravenous bolus injection of morphine causes a vagal-mediated brief apnea (similar to 3 s), while continuous injection, via action upon central mu-opioid receptor (MOR), arrests ventilation (> 20 s) that is eliminated by stimulating central 5-hydroxytryptamine 1A receptors (5HT(1A)Rs). Bronchopulmonary C-fibers (PCFs) are essential for triggering a brief apnea, and their afferents terminate at the caudomedial region of the nucleus tractus solitarius (mNTS) that densely expresses 5HT(1A)Rs. Thus we asked whether the vagal-mediated apneic response to MOR agonists was PCF dependent, and if so, whether this apnea was abolished by systemic administration of 8-hydroxy-2-(di-n-propyl-amino)tetral (8-OH-DPAT) largely through action upon mNTS 5HT(1A)Rs. Right atrial bolus injection of fentanyl (5.0 mu g/kg, a MOR agonist) was performed in the anesthetized and spontaneously breathing rats before and after: 1) selective blockade of PCFs' conduction and subsequent bivagotomy; 2) intravenous administration of 5HT(1A)R agonist 8-OH-DPAT; 3) intra-mNTS injection of 8-OH-DPAT; and 4) intra-mNTS injection of 5HT(1A)R antagonist WAY-100635 followed by 8-OH-DPAT (iv). We found the following: First, fentanyl evoked an immediate apnea (2.5 +/- 0.4 s, similar to 6-fold longer than the baseline expiratory duration, TE), which was abolished by either blocking PCFs' conduction or bivagotomy. Second, this apnea was prevented by systemic 8-OH-DPAT challenge. Third, intra-mNTS injection of 8-OH-DPAT greatly attenuated the apnea by 64%. Finally, intra-mNTS microinjection of WAY-100635 significantly attenuated (58%) the apneic blockade by 8-OH-DPAT (iv). We conclude that the vagal-mediated apneic response to MOR activation depends on PCFs, which is fully antagonized by systemic 8-OH-DPAT challenge largely via acting on mNTS 5HT(1A)Rs.	[Zhuang, Jianguo; Zhang, Zhenxiong; Zhang, Cancan; Xu, Fadi] Lovelace Resp Res Inst, Pathophysiol Program, Albuquerque, NM 87108 USA	Xu, FD (reprint author), Lovelace Resp Res Inst, Pathophysiol Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	fxu@lrri.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL-107462, ALA RG-191095-N]	This study is supported by National Institutes of Health Grants HL-107462 and ALA RG-191095-N.	Aicher SA, 2000, J COMP NEUROL, V422, P181, DOI 10.1002/(SICI)1096-9861(20000626)422:2<181::AID-CNE3>3.0.CO;2-G; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; Belvisi M. G., 2009, V187, P63, DOI 10.1007/978-3-540-79842-2_4; Berrill JW, 2003, BMJ-BRIT MED J, V327, P1288, DOI 10.1136/bmj.327.7426.1288-b; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; BONHAM AC, 1991, J PHYSIOL-LONDON, V441, P95, DOI 10.1113/jphysiol.1991.sp018740; BUDZINSKA K, 1985, EXPERIENTIA, V41, P458; Churchill ED, 1929, J EXP MED, V49, P531, DOI 10.1084/jem.49.4.531; Ding YQ, 1998, BRAIN RES, V792, P149, DOI 10.1016/S0006-8993(98)00205-4; EDWARDS E, 1990, NEUROPSYCHOPHARMACOL, V3, P129; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P812, DOI 10.1097/00000542-199005000-00007; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; GARNER SJ, 1989, AM REV RESPIR DIS, V139, P946, DOI 10.1164/ajrccm/139.4.946; GOETZ AM, 1994, CRIT CARE MED, V22, P1579; Gruber EM, 2003, DRUG AGING, V20, P347, DOI 10.2165/00002512-200320050-00004; Hall WD, 1999, MED J AUSTRALIA, V171, P34, DOI 10.5694/j.1326-5377.1999.tb123495.x; HATRIDGE J, 1989, J APPL PHYSIOL, V67, P2257; Horton Robert, 2009, J Pain Symptom Manage, V37, pe2, DOI 10.1016/j.jpainsymman.2009.02.230; Huang J, 2004, BRAIN RES, V1028, P156, DOI 10.1016/j.brainres.2004.09.009; JONES JFX, 1993, J PHYSIOL-LONDON, V459, pP354; Kaczynska K, 2005, J PHYSIOL PHARMACOL, V56, P195; Kellett DO, 2005, J PHYSIOL-LONDON, V563, P319, DOI 10.1113/jphysiol.2004.076521; Kellett DO, 2005, BRAIN RES, V1054, P61, DOI 10.1016/j.brainres.2005.06.063; LALLEY PM, 1994, BRAIN RES, V648, P87, DOI 10.1016/0006-8993(94)91909-7; LALLEY PM, 1994, J PHYSIOL-LONDON, V476, P117; Lee LY, 2001, J APPL PHYSIOL, V91, P1318; Lee LY, 1996, J APPL PHYSIOL, V81, P2349; Lee LY, 2001, RESP PHYSIOL, V125, P47, DOI 10.1016/S0034-5687(00)00204-8; Li JL, 1996, NEUROSCI LETT, V214, P91, DOI 10.1016/0304-3940(96)12894-9; Liu Q, 2010, NEUROSCIENCE, V165, P61, DOI 10.1016/j.neuroscience.2009.09.078; Machaalani R, 2009, ACTA NEUROPATHOL, V117, P257, DOI 10.1007/s00401-008-0468-x; MAY AJ, 1954, BRIT J PHARM CHEMOTH, V9, P335, DOI 10.1111/j.1476-5381.1954.tb01689.x; MERAHI N, 1995, BRAIN RES, V669, P130, DOI 10.1016/0006-8993(94)01202-S; Mutoh T, 2000, AM J PHYSIOL-REG I, V279, pR1215; Paton JFR, 1997, J PHYSIOL-LONDON, V502, P623, DOI 10.1111/j.1469-7793.1997.623bj.x; Paton JFR, 1998, J NEUROPHYSIOL, V79, P2365; Paton JFR, 1996, J PHYSIOL-LONDON, V497P, pS4; Peng WH, 2007, J APPL PHYSIOL, V102, P2201, DOI 10.1152/japplphysiol.01436.2006; Richter D W, 1992, Curr Opin Neurobiol, V2, P788, DOI 10.1016/0959-4388(92)90135-8; Richter DW, 1999, J PHYSIOL-LONDON, V514, P567, DOI 10.1111/j.1469-7793.1999.567ae.x; Roussos C, 2003, EUR RESPIR J, V22, p3S, DOI 10.1183/09031936.03.00038503; Rusyniak DE, 2007, J PHARMACOL EXP THER, V323, P477, DOI 10.1124/jpet.107.126169; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; SAPRU HN, 1981, J PHARMACOL EXP THER, V217, P228; Scott BH, 1998, INT J CARDIOL, V64, pS35, DOI 10.1016/S0167-5273(98)00034-5; SPORTON SCE, 1991, BRIT J PHARMACOL, V104, P466, DOI 10.1111/j.1476-5381.1991.tb12452.x; Szereda-Przestaszewska M, 2007, EXP PHYSIOL, V92, P953, DOI 10.1113/expphysiol.2007.037333; THOR KB, 1992, SYNAPSE, V10, P217, DOI 10.1002/syn.890100305; TRULSON ME, 1986, J PHARM PHARMACOL, V38, P380, DOI 10.1111/j.2042-7158.1986.tb04591.x; VARDHAN A, 1993, BRAIN RES, V618, P23, DOI 10.1016/0006-8993(93)90424-L; Walker JM, 2009, CURR PAIN HEADACHE R, V13, P120, DOI 10.1007/s11916-009-0021-1; Wang Y, 1997, NEUROPHARMACOLOGY, V36, P489, DOI 10.1016/S0028-3908(97)00063-4; WILLETTE RN, 1982, EUR J PHARMACOL, V78, P61, DOI 10.1016/0014-2999(82)90372-7; WILLETTE RN, 1982, NEUROPHARMACOLOGY, V21, P1019, DOI 10.1016/0028-3908(82)90116-2; Wilson CG, 1996, J PHYSIOL-LONDON, V496, P773, DOI 10.1113/jphysiol.1996.sp021726; Wilson CG, 1997, J PHYSIOL-LONDON, V504, P453, DOI 10.1111/j.1469-7793.1997.453be.x; Wojciechowski P, 2007, EUR J PHARMACOL, V563, P209, DOI 10.1016/j.ejphar.2007.02.012; Xu F, 2003, J APPL PHYSIOL, V94, P1446, DOI 10.1152/japplphysiol.00767.2002; ZARBIN MA, 1990, EXP BRAIN RES, V81, P267; Zhang ZX, 2007, ANESTHESIOLOGY, V107, P288, DOI 10.1097/01.anes.0000270760.46821.67; Zhuang J, 2012, FASEB J, V895.4, P26; Zhuang JG, 2011, RESP PHYSIOL NEUROBI, V175, P12, DOI 10.1016/j.resp.2010.08.002	63	5	5	0	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	AUG	2012	303	4					R449	R458		10.1152/ajpregu.00016.2012			10	Physiology	Physiology	992OZ	WOS:000307789600011	22696579	Green Published			2020-06-30	J	Kulkarni, S; Johnson, PCD; Kettles, S; Kasthuri, RS				Kulkarni, S.; Johnson, P. C. D.; Kettles, S.; Kasthuri, R. S.			Music during interventional radiological procedures, effect on sedation, pain and anxiety: a randomised controlled trial	BRITISH JOURNAL OF RADIOLOGY			English	Article							STATE ANXIETY; METAANALYSIS; ANALGESIA; ENDOSCOPY	Objective: To assess the effects of playing patient-selected music during interventional procedures on (1) the doses of sedation and analgesia and (2) anxiety levels. Methods: Patients undergoing interventional radiological procedures were randomised to either the intervention (music) or the control (no music) group. Patients in the intervention group had music of their choice played via headphones during the procedure. The primary outcomes were reductions in the doses of drugs for sedation (midazolam) and analgesia (fentanyl). Anxiety levels were assessed both before and after the procedure using the validated State Anxiety Inventory. Mean pulse rate and average of mean blood pressures were also recorded before and during the procedures as surrogate indicators of anxiety levels. Results: 100 patients were randomised in a 1: 1 ratio. There were 58 males and 42 females, with a mean age of 58 years. Sedation was required in 21 (42%) patients in the music group compared with 30 (60%) patients in the control group (p=0.046). The mean [standard deviation (SD)] midazolam dose was 2.1 mg (2.3 mg) in the control group and 1.3 mg (2.2 mg) in the music group (p=0.027). The mean (SD) fentanyl dose was 29 mg (40 mg) in the control group and 18 mg (34 mg) in the music group (p=0.055). There was no significant effect of music on the change from baseline in anxiety levels (p=0.74), pulse rate (p=0.56) or blood pressure (p=0.34). Conclusion: Sedation requirements are significantly reduced by playing self-selected music to the patient during interventional radiology procedures. By lowering sedation during interventional radiology, music makes the procedure safer. It also contributes favourably to the overall patient experience.	[Kulkarni, S.; Kettles, S.; Kasthuri, R. S.] Gartnavel Royal Hosp, Dept Radiol, Glasgow G12 0YN, Lanark, Scotland; [Johnson, P. C. D.] Univ Glasgow, Coll Med Vet & Life Sci, Robertson Ctr Biostat, Glasgow, Lanark, Scotland	Kasthuri, RS (reprint author), Gartnavel Royal Hosp, Dept Radiol, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland.	ram.kasthuri@ggc.scot.nhs.uk	Johnson, Paul C D/O-9695-2014	Johnson, Paul C D/0000-0001-6663-7520			Dahaba AA, 2006, ANESTH ANALG, V103, P378, DOI 10.1213/01.ane.0000223681.77120.ca; Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003; Domschke K, 2010, CLIN PSYCHOL REV, V30, P1, DOI 10.1016/j.cpr.2009.08.008; El-Hassan H, 2009, ALIMENT PHARM THER, V30, P718, DOI 10.1111/j.1365-2036.2009.04091.x; Koch ME, 1998, ANESTHESIOLOGY, V89, P300, DOI 10.1097/00000542-199808000-00005; Li XM, 2011, BREAST CANCER RES TR, V128, P411, DOI 10.1007/s10549-011-1533-z; PALAKANIS KC, 1994, DIS COLON RECTUM, V37, P478, DOI 10.1007/BF02076195; Patatas K, 2009, CLIN RADIOL, V64, P655, DOI 10.1016/j.crad.2008.11.002; R Development Core Team, 2009, R LANG ENV STAT COMP; Roy M, 2008, PAIN, V134, P140, DOI 10.1016/j.pain.2007.04.003; Rudin D, 2007, ENDOSCOPY, V39, P507, DOI 10.1055/s-2007-966362; Sabharwal T, 2007, BRIT MED BULL, V81-82, P167, DOI 10.1093/bmb/ldm006; Schupp CJ, 2005, J VASC INTERV RADIOL, V16, P1585, DOI 10.1097/01.RVI.0000185418.82287.72; SMITH RC, 1974, PSYCHOL REP, V34, P519; Tam WWS, 2008, WORLD J GASTROENTERO, V14, P5336, DOI 10.3748/wjg.14.5336	15	20	22	0	11	BRITISH INST RADIOLOGY	LONDON	36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND	0007-1285			BRIT J RADIOL	Br. J. Radiol.	AUG	2012	85	1016					1059	1063		10.1259/bjr/71897605			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	988OK	WOS:000307500200034	22422386	Green Published			2020-06-30	J	Moore, KT; Sathyan, G; Richarz, U; Natarajan, J; Vandenbossche, J				Moore, Kenneth T.; Sathyan, Gayatri; Richarz, Ute; Natarajan, Jaya; Vandenbossche, Joris			Randomized 5-Treatment Crossover Study to Assess the Effects of External Heat on Serum Fentanyl Concentrations During Treatment With Transdermal Fentanyl Systems	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Transdermal fentanyl; external heat; serum concentration	PHARMACOLOGICAL-PROPERTIES; CLINICAL PHARMACOKINETICS; THERAPEUTIC-EFFICACY; PAIN-CONTROL; ABSORPTION; DELIVERY; OVERDOSE; MISUSE	This randomized, open-label, 5-treatment, 5-sequence crossover study was designed to evaluate the effects of a heating pad on serum fentanyl concentrations with reservoir and matrix transdermal fentanyl systems. Subjects were randomized to 1 of 5 treatment sequences, receiving 5 fentanyl treatments (1 per period) for 36 hours: 25 mu g/h reservoir without heat, 25 mu g/h reservoir with heat, 25 mu g/h matrix without heat, 25 mu g/h matrix with heat, and a 50 mu g/h reservoir without heat. The 25 mu g/h systems with heat had a heating pad applied from 0 to 10 and 26 to 36 hours post application. Washout periods between treatments were 5 to 14 days. Naltrexone was given to block the opioid effects of fentanyl. Study results indicate that external heat had a similar effect on both matrix and reservoir systems, with heat applied during the first 10 hours of treatment increasing fentanyl exposure by approximately 61% to 81% at 10 hours (observed serum concentration at 10 hours) and overall exposure (area under the curve from 0 to 10 hours) by approximately 120% to 184%, but had minimal effect from 26 to 36 hours. The increased exposure observed with heat in both 25 mu g/h systems, between 0 and 10 hours, was higher than that obtained with the 50 mu g/h reservoir system applied without heat.	[Vandenbossche, Joris] Johnson & Johnson Pharmaceut Res & Dev, Clin Pharmacol, B-2340 Beerse, Belgium; [Moore, Kenneth T.] Johnson & Johnson Pharmaceut Res & Dev, Clin Pharmacol, Titusville, NJ USA; [Sathyan, Gayatri] Adamas India Pharmaceut Private Ltd, Bangalore, Karnataka, India; [Richarz, Ute] Johnson & Johnson Pharmaceut Serv, Global Med Affairs, Baar, Switzerland; [Natarajan, Jaya] Johnson & Johnson Pharmaceut Res & Dev, Biostat & Programming, Raritan, NJ USA	Vandenbossche, J (reprint author), Johnson & Johnson Pharmaceut Res & Dev, Clin Pharmacol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	JVDBOSSC@its.jnj.com	Moore, Kenneth Todd/AAI-3783-2020	Moore, Kenneth Todd/0000-0001-7505-102X	ALZA Corporation, California	This study was funded by the ALZA Corporation, 1900 Charleston Road, Mountain View, California. All authors, with the exception of Gayatri Sathyan, are employed by Johnson & Johnson Pharmaceutical Research and Development. Gayatri Sathyan is a former employee of Johnson & Johnson Pharmaceutical Research and Development.	Adams M, 2005, J CLIN PHARMACOL, V45, P337, DOI 10.1177/0091270004271969; Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; [Anonymous], 2009, DUR MED GUID; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; Chow S, 1992, DESIGN ANAL BIOAVAIL, P70; Frolich M, 2001, ANESTH ANALG, V93, P647; Gidwani S, 2004, PAIN PRACT, P288; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kroll W, 1997, EUR J ANAESTH, V14, P49; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Metropolitan Life Insurance Company, 1983, STAT B, V64, P2; Moore Kenneth Todd, 2011, J Opioid Manag, V7, P99; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Phipps B, 2004, ENCY BIOMATERIALS BI, P1677; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	26	17	18	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	AUG	2012	52	8					1174	1185		10.1177/0091270011411710			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	979UD	WOS:000306844400005	21878578				2020-06-30	J	Bobeck, EN; Haseman, RA; Hong, D; Ingram, SL; Morgan, MM				Bobeck, Erin N.; Haseman, Rachel A.; Hong, Dana; Ingram, Susan L.; Morgan, Michael M.			Differential Development of Antinociceptive Tolerance to Morphine and Fentanyl Is Not Linked to Efficacy in the Ventrolateral Periaqueductal Gray of the Rat	JOURNAL OF PAIN			English	Article						Opioid; analgesia; efficacy; pain modulation; acute tolerance	OPIOID RECEPTOR DESENSITIZATION; AGONIST-SELECTIVE MECHANISMS; CONTINUOUS INFUSION; CHRONIC PAIN; MU-AGONISTS; MICROINJECTIONS; POTENCY; INTERMITTENT; ANTAGONISM; MAGNITUDE	Systemic administration of morphine typically produces greater tolerance than higher efficacy mu-opioid receptor (MOPr) agonists such as fentanyl. The objective of the present study was to test this relationship by measuring antinociceptive efficacy and tolerance to morphine and fentanyl microinjected into the ventrolateral periaqueductal gray (vIPAG). MOPr agonist efficacy was evaluated by microinjecting the irreversible opioid receptor antagonist beta-funaltrexamine hydrochloride (beta-FNA) into the vIPAG prior to a dose-response analysis of morphine and fentanyl antinociception. In contrast to systemic administration of morphine and fentanyl, microinjection of these drugs into the vIPAG had similar efficacy as measured by similar reductions in maximal antinociception following beta-FNA administration. Analysis of tolerance revealed a rightward shift in the dose-response curve to a single pretreatment with morphine, but not fentanyl. The magnitude of tolerance to morphine was comparable following 1, 4, or 8 pretreatments. Tolerance to fentanyl also was evident following 4 or 8 microinjections. These data are surprising in that antinociceptive efficacy appears to vary depending on the site of administration. Moreover, the similar efficacy following microinjection of morphine and fentanyl into the vIPAG was associated with comparable tolerance, with the 1 exception of no tolerance to acute administration of fentanyl. Perspective: These data reveal that antinociceptive tolerance following vIPAG administration of opioids develops rapidly and is evident with both morphine and fentanyl, and the magnitude is relatively consistent regardless of the number of pretreatments. (C) 2012 by the American Pain Society	[Bobeck, Erin N.; Haseman, Rachel A.; Hong, Dana; Morgan, Michael M.] Washington State Univ, Dept Psychol, Vancouver, WA 98686 USA; [Ingram, Susan L.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA	Morgan, MM (reprint author), Washington State Univ, Dept Psychol, 14204 NE Salmon Creek Ave, Vancouver, WA 98686 USA.	mmmorgan@vancouver.wsu.edu	Bobeck, Erin/I-8839-2019	Bobeck, Erin/0000-0001-8421-883X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA015498]; State of Washington Initiative Measure [171]	Financial support was provided by NIH grant DA015498 and by funds provided for medical and biological research by the State of Washington Initiative Measure No. 171.	Bailey CP, 2003, J NEUROSCI, V23, P10515; Bobeck EN, 2009, PAIN, V147, P210, DOI 10.1016/j.pain.2009.09.008; BODNAR R, 1991, BRAIN RES, V558, P224, DOI 10.1016/0006-8993(91)90772-N; Buntin-Mushock C, 2005, ANESTH ANALG, V100, P1740, DOI 10.1213/01.ANE.0000152191.29311.9B; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Collett BJ, 1998, BRIT J ANAESTH, V81, P58; Dighe SV, 2009, PHARMACOL BIOCHEM BE, V92, P537, DOI 10.1016/j.pbb.2009.02.004; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Eisenberg E, 2005, JAMA-J AM MED ASSOC, V293, P3043, DOI 10.1001/jama.293.24.3043; Fairbanks CA, 2000, J BIOMED SCI, V7, P200, DOI 10.1007/BF02255467; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; Hull LC, 2010, J PHARMACOL EXP THER, V332, P1127, DOI 10.1124/jpet.109.161455; JACQUET YF, 1976, BRAIN RES, V103, P501, DOI 10.1016/0006-8993(76)90448-0; JACQUET YF, 1974, SCIENCE, V185, P1055, DOI 10.1126/science.185.4156.1055; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kelemen K., 1955, ACTA PHYSL HUNG, V8, P327; Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604; Lane DA, 2005, NEUROSCIENCE, V135, P227, DOI 10.1016/j.neuroscience.2005.06.014; Le Bars D, 2001, PHARMACOL REV, V53, P597; Madia PA, 2009, PSYCHOPHARMACOLOGY, V207, P413, DOI 10.1007/s00213-009-1673-6; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Meyer PJ, 2007, NEUROPHARMACOLOGY, V52, P1580, DOI 10.1016/j.neuropharm.2007.03.002; MJANGER E, 1991, J PHARMACOL EXP THER, V258, P544; Morgan MM, 2006, PHARMACOL BIOCHEM BE, V85, P214, DOI 10.1016/j.pbb.2006.08.003; Morgan MM, 2006, J PAIN, V7, P358, DOI 10.1016/j.jpain.2005.12.009; Morgan MM, 2005, BRAIN RES, V1059, P173, DOI 10.1016/j.brainres.2005.08.024; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Paxinos G, 2005, RAT BRAIN STEREOTAXI; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; Raehal KM, 2011, NEUROPHARMACOLOGY, V60, P58, DOI 10.1016/j.neuropharm.2010.08.003; Rodriguez-Munoz M, 2007, CELL SIGNAL, V19, P2558, DOI 10.1016/j.cellsig.2007.08.003; Sirohi S, 2009, J PHARMACOL EXP THER, V330, P513, DOI 10.1124/jpet.109.152678; SIUCIAK JA, 1987, BRAIN RES, V424, P311, DOI 10.1016/0006-8993(87)91476-4; STEVENS CW, 1989, J PHARMACOL EXP THER, V250, P1; STEVENS CW, 1989, J PHARMACOL EXP THER, V251, P216; TALLARIDA R, 2000, DRUG SYNERGISM DOSE; Tortorici V, 1999, BEHAV NEUROSCI, V113, P833, DOI 10.1037/0735-7044.113.4.833	39	16	16	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	AUG	2012	13	8					799	807		10.1016/j.jpain.2012.05.005			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	990JU	WOS:000307627600010	22766006	Green Accepted			2020-06-30	J	Agudelo, SC; Mencia, S; Faro, A; Escudero, V; Sanavia, E; Lopez-Herce, J				Agudelo, S. C.; Mencia, S.; Faro, A.; Escudero, V.; Sanavia, E.; Lopez-Herce, J.			Continuous propofol perfusion in critically ill children	MEDICINA INTENSIVA			Spanish	Article						Propofol; Sedation; Propofol infusion syndrome; Pediatric intensive care	PEDIATRIC INTENSIVE-CARE; INFUSION SYNDROME; SEDATION; UNIT; MULTICENTER; ANALGESIA; MIDAZOLAM; FAILURE; DISEASE	Objective: To describe sedation with continuous perfusion of propofol in critically ill children. Design: A retrospective, descriptive observational study was carried out. Setting: A pediatric intensive care unit. Patients: Pediatric patients requiring sedoanalgesia between October 1, 2009 and September 30, 2010. Interventions: None. Data collected: Demographic, clinical and laboratory test variables, diagnosis, treatment, complications and evolution in each patient. In addition, the potential adverse effects associated with propofol administration were analyzed. Results: Midazolam, fentanyl and propofol were the most commonly used sedative and analgesic drugs. Seventy-one out of 222 patients (32%) received propofol in continuous infusion. The average dose was 2.1 mg/kg/h (SD 1.3, range: 0.5 to 6), and the average duration of treatment was of 6.7 days (SD 8.5 range 0.5-40). Fifty-two percent were males, and the mean patient age was 45.8 months (median: 24; interquartile range: 7-65). No patient developed propofol infusion syndrome or other serious drug-related adverse effects. Patients treated with propofol showed more abnormal laboratory test findings, although no relationship to drug administration could be demonstrated. There were no significant differences in lactate level or in the incidence of infection in either group. Conclusions: Propofol at a dose of 1 to 4 mg/kg/h is a safe alternative for sustained sedation in critically ill children. However, further studies are needed to assess its effects and safety profile. (C) 2011 Elsevier Espana, S.L. and SEMICYUC. All rights reserved.	[Mencia, S.; Sanavia, E.; Lopez-Herce, J.] Hosp Gen Univ Gregorio Maranon, Serv Cuidados Intens Pediat, Madrid, Spain; [Agudelo, S. C.] Univ Javeriana, Fac Pontificia Med, Serv Cuidado Intens Pediat Cardiovasc, Fdn Cardioinfantil, Bogota, Colombia; [Faro, A.] Hosp Divino Espirito Santo, Serv Pediat, Ponta Delgada, Portugal; [Escudero, V.] Hosp Gen Univ Gregorio Maranon, Serv Farm Hosp, Madrid, Spain	Mencia, S (reprint author), Hosp Gen Univ Gregorio Maranon, Serv Cuidados Intens Pediat, Madrid, Spain.	santiagomencia@gmail.com	Escudero-Vilaplana, Vicente/R-6683-2018; Lopez-Herce, Jesus/A-1602-2019	Escudero-Vilaplana, Vicente/0000-0003-4417-8321; Lopez-Herce, Jesus/0000-0001-6105-9178; MENCIA, SANTIAGO/0000-0001-7786-688X			Alados-Arboledas FJ, 2011, AN PEDIATR, V75, P124, DOI 10.1016/j.anpedi.2010.11.012; Benini F, 2010, ACTA PAEDIATR, V99, P758, DOI 10.1111/j.1651-2227.2010.01705.x; Bray Robin J, 2002, Curr Opin Anaesthesiol, V15, P339, DOI 10.1097/00001503-200206000-00010; Committee on Safety of Medicines medicines Control agency, 2001, CURRENT PROBLEMS PHA, P27; Conti G, 2002, Minerva Anestesiol, V68, P240; Cornfield DN, 2002, PEDIATRICS, V110, P1177, DOI 10.1542/peds.110.6.1177; Crawford MW, 2003, CAN MED ASSOC J, V168, P669; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Felmet K, 2003, PEDIATRICS, V112, P1002, DOI 10.1542/peds.112.4.1002; Festa M, 2002, ANAESTH INTENS CARE, V30, P786, DOI 10.1177/0310057X0203000612; Goodale D, 2001, PREFECT POLICE F PEC; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; Hartman ME, 2009, PEDIATR CRIT CARE ME, V10, P246, DOI 10.1097/PCC.0b013e31819a3bb9; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; López J. M., 2007, Med. Intensiva, V31, P417; Marik PE, 2004, CURR PHARM DESIGN, V10, P3639, DOI 10.2174/1381612043382846; Mencia S, 2011, AN PEDIATR, V74, P396, DOI 10.1016/j.anpedi.2010.12.002; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Roberts RJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8145; Teng SN, 2011, CARDIOL YOUNG, V21, P46, DOI 10.1017/S1047951110001344; Tobias JD, 2005, PEDIATR ANN, V34, P636, DOI 10.3928/0090-4481-20050801-12; Ture H, 2009, ANESTH ANALG, V109, P366, DOI 10.1213/ane.0b013e3181a89641; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; Valdivielso Serna A, 1998, An Esp Pediatr, V48, P541; Valdivielso-Serna A, 2008, Med Intensiva, V32 Spec No. 1, P115; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Wooltorton E, 2002, CAN MED ASSOC J, V167, P507; Xia WF, 2011, YONSEI MED J, V52, P326, DOI 10.3349/ymj.2011.52.2.326; Zaccheo MA, 2008, CRIT CARE NURSE, V28, P18	31	4	4	0	3	ELSEVIER DOYMA SL	BARCELONA	TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN	0210-5691			MED INTENSIVA	Med. Intensiv.	AUG-SEP	2012	36	6					410	415		10.1016/j.medin.2011.11.018			6	Critical Care Medicine	General & Internal Medicine	995DJ	WOS:000307987800006	22244214				2020-06-30	J	LaPierre, CD; Johnson, KB; Randall, BR; Egan, TD				LaPierre, Cris D.; Johnson, Ken B.; Randall, Benjamin R.; Egan, Talmage D.			A Simulation Study of Common Propofol and Propofol-Opioid Dosing Regimens for Upper Endoscopy Implications on the Time Course of Recovery	ANESTHESIOLOGY			English	Article							OBSTRUCTIVE SLEEP-APNEA; VENTILATORY DEPRESSANT POTENCY; TARGET-CONTROLLED INFUSION; UPPER AIRWAY-OBSTRUCTION; GASTROINTESTINAL ENDOSCOPY; BISPECTRAL INDEX; NONSTEADY STATE; REMIFENTANIL; SEDATION; MODEL	Background: Using models of respiratory compromise, loss of response to esophageal instrumentation, and loss of responsiveness, the authors explored through simulation published dosing schemes for endoscopy using propofol alone and in combination with selected opioids. They hypothesized that models would predict adequate conditions for esophageal instrumentation and once drug administration is terminated, rapid return of responsiveness and minimal respiratory compromise. Methods: Four published dosing regimens of propofol alone or in combination with opioids were used to predict the probability of loss of response to esophageal instrumentation for a 10-min procedure and the probability of respiratory compromise and return of responsiveness once the procedure had ended. Results: Propofol alone provided a low probability (9-20%) and propofol-opioid techniques provided a moderate probability (15-58%) of loss of response to esophageal instrumentation. Once the procedure ended, all techniques provided a high likelihood of rapid return of responsiveness (less than 3 min). Propofol-opioid techniques required more time than propofol alone to achieve a high probability of no respiratory compromise (7 vs. 4 min). Conclusions: Propofol alone would likely lead to inadequate conditions for esophageal instrumentation but would provide a rapid return to responsiveness and low probability of respiratory compromise once the procedure ended. The addition of remifentanil or fentanyl improved conditions for esophageal instrumentation and had an equally rapid return to responsiveness. The time required to achieve a low probability of respiratory compromise was briefly prolonged; this is likely inconsequential given that patients are responsive and can be prompted to breathe.	[LaPierre, Cris D.; Johnson, Ken B.; Egan, Talmage D.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; [Johnson, Ken B.; Egan, Talmage D.] Univ Utah, Dept Anesthesiol, Sch Med, Salt Lake City, UT USA; [Randall, Benjamin R.] Univ Iowa, Dept Anesthesia, Iowa City, IA 52242 USA; [Egan, Talmage D.] Univ Utah, Dept Pharmaceut, Salt Lake City, UT USA	LaPierre, CD (reprint author), 30 North,1900 East,Rm 3C444 SOM, Salt Lake City, UT 84132 USA.	cristen.lapierre@hsc.utah.edu			Scott Laboratories, Lubbock, Texas; Scott Laboratories; Ethicon Endo-Surgery, Cincinnati, Ohio	Received from the Departments of Bioengineering and Anesthesiology, University of Utah, Salt Lake City, Utah. Submitted for publication September 5, 2011. Accepted for publication February 22, 2012. Supported in part by Scott Laboratories, Lubbock, Texas. Ken Johnson has received salary support and Talamage Egan has occasionally received consulting fees from Scott Laboratories and Ethicon Endo-Surgery, Cincinnati, Ohio. Presented at the 2011 International Society for Anaesthetic Pharmacology, October 14, 2011, Chicago, Illinois, and the 2011 American Society of Anesthesiologists, October 18 and 19, 2011, Chicago, Illinois.	BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Bol CJJG, 2000, J PHARMACOL EXP THER, V294, P347; Bouillon T, 2004, ANESTHESIOLOGY, V100, P240, DOI 10.1097/00000542-200402000-00010; Bouillon T, 2003, ANESTHESIOLOGY, V99, P779, DOI 10.1097/00000542-200310000-00007; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2009, NAT CLIN PRACT GASTR, V6, P76, DOI 10.1038/ncpgasthep1332; Cohen LB, 2003, GASTROINTEST ENDOSC, V58, P725, DOI 10.1016/S0016-5107(03)02010-8; CROFT CB, 1991, CLIN OTOLARYNGOL, V16, P504, DOI 10.1111/j.1365-2273.1991.tb01050.x; Drover DR, 2004, ANESTHESIOLOGY, V100, P1382, DOI 10.1097/00000542-200406000-00008; Dumonceau JM, 2010, EUR J ANAESTH, V27, P1016, DOI 10.1097/EJA.0b013e32834136bf; Fatima H, 2008, AM J GASTROENTEROL, V103, P1649, DOI 10.1111/j.1572-0241.2008.01906.x; Fidler M, 2006, ANESTHESIOLOGY, V105, P286, DOI 10.1097/00000542-200608000-00011; Gambus PL, 2011, ANESTH ANALG, V112, P331, DOI 10.1213/ANE.0b013e3182025a70; GRECO WR, 1995, PHARMACOL REV, V47, P331; Hammer GB, 2001, PAEDIATR ANAESTH, V11, P549, DOI 10.1046/j.1460-9592.2001.00731.x; Hoymork SC, 2000, ACTA ANAESTH SCAND, V44, P1138, DOI 10.1034/j.1399-6576.2000.440918.x; Johnson KB, 2008, ANESTH ANALG, V106, P471, DOI 10.1213/ane.0b013e3181606c62; Kazama T, 2000, ANESTHESIOLOGY, V93, P662, DOI 10.1097/00000542-200009000-00014; Kirkness JP, 2011, PHYSIOL MEAS, V32, P223, DOI 10.1088/0967-3334/32/2/006; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; LaPierre CD, 2011, ANESTH ANALG, V113, P490, DOI 10.1213/ANE.0b013e318210fc45; Lena P, 2006, CAN J ANAESTH, V53, P357, DOI 10.1007/BF03022499; Litman RS, 2002, ANESTHESIOLOGY, V96, P342, DOI 10.1097/00000542-200202000-00019; Luginbuhl M, 2009, CURR OPIN ANESTHESIO, V22, P524, DOI 10.1097/ACO.0b013e32832dbb7c; Mandel JE, 2008, ANESTH ANALG, V106, P434, DOI 10.1213/01.ane.0000297300.33441.32; Masui K, 2010, ANESTH ANALG, V111, P368, DOI 10.1213/ANE.0b013e3181bdcf5b; Mertens MJ, 2003, ANESTHESIOLOGY, V99, P347, DOI 10.1097/00000542-200308000-00016; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; Minto CF, 2000, ANESTHESIOLOGY, V92, P1603, DOI 10.1097/00000542-200006000-00017; Moon IJ, 2010, LARYNGOSCOPE, V120, P2546, DOI 10.1002/lary.21112; Nelson DB, 2001, GASTROINTEST ENDOSC, V53, P876; Nieuwenhuijs DJF, 2003, ANESTHESIOLOGY, V98, P312, DOI 10.1097/00000542-200302000-00008; Pambianco DJ, 2008, GASTROINTEST ENDOSC, V68, P542, DOI 10.1016/j.gie.2008.02.011; Pambianco DJ, 2011, GASTROINTEST ENDOSC, V73, P765, DOI 10.1016/j.gie.2010.10.031; Perel A, 2011, EUR J ANAESTH, V28, P580, DOI 10.1097/EJA.0b013e328348a977; Rusconi F, 1995, PEDIATR PULM, V20, P396, DOI 10.1002/ppul.1950200610; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Somma J, 1998, ANESTHESIOLOGY, V89, P1430, DOI 10.1097/00000542-199812000-00021; Stockx EM, 2010, RESPIROLOGY, V15, P326, DOI 10.1111/j.1440-1843.2009.01689.x; Togeiro SMGP, 2010, INDIAN J MED RES, V131, P230; WESTMORELAND CL, 1994, ANESTH ANALG, V78, P23	43	23	26	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	AUG	2012	117	2					252	262		10.1097/ALN.0b013e31825fb1b2			11	Anesthesiology	Anesthesiology	981RG	WOS:000306986600009	22728781	Bronze			2020-06-30	J	Iwata, Y; Mizota, Y; Mizota, T; Koyama, T; Shichino, T				Iwata, Yoshika; Mizota, Yoko; Mizota, Toshiyuki; Koyama, Tomohiro; Shichino, Tsutomu			Postoperative continuous intravenous infusion of fentanyl is associated with the development of orthostatic intolerance and delayed ambulation in patients after gynecologic laparoscopic surgery	JOURNAL OF ANESTHESIA			English	Article						Orthostatic intolerance; Gynecologic laparoscopic surgery; Opioids; Ambulation; Analgesia	CONTROLLED ANALGESIA; ENHANCED RECOVERY; OPIOID INFUSION; MOBILIZATION; MANAGEMENT; RESECTION; PCA	Early ambulation is essential for rapid functional recovery after surgery; however, orthostatic intolerance may delay recovery and cause syncope, leading to potential serious complications such as falls. Opioids may contribute to orthostatic intolerance because of reduced arterial pressure and associated reduction in cerebral blood flow and oxygenation. This study aimed to examine the effect of postoperative continuous infusion of fentanyl on orthostatic intolerance and delayed ambulation in patients after gynecologic laparoscopic surgery. In this retrospective cohort study, data from 195 consecutive patients who underwent gynecologic laparoscopic surgery were analyzed to evaluate the association between postoperative continuous infusion of fentanyl and the incidence of orthostatic intolerance or delayed ambulation. The primary outcome was defined as delayed ambulation, an inability to ambulate on postoperative day 1. The secondary outcome was defined as orthostatic intolerance and symptoms associated with ambulatory challenge, including dizziness, nausea and vomiting, feeling hot, blurred vision, and eventual syncope. Multivariate logistic regression was used to determine the independent predictors of delayed ambulation and orthostatic intolerance. There were 24 cases with documented orthostatic intolerance and 5 with delayed ambulation. After multivariate logistic regression modeling, postoperative continuous infusion of fentanyl was found to be significantly associated with both orthostatic intolerance [adjusted odds ratio (95 % confidence interval), 34.78 (11.12-131.72)] and delayed ambulation [adjusted odds ratio (95 % confidence interval), 8.37 (1.23-72.15)]. Postoperative continuous infusion of fentanyl is associated with increased orthostatic intolerance and delayed ambulation in patients after gynecologic laparoscopic surgery.	[Mizota, Toshiyuki; Koyama, Tomohiro] Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 6068507, Japan; [Iwata, Yoshika; Mizota, Yoko; Shichino, Tsutomu] Kyoto Med Ctr, Dept Anesthesia, Kyoto, Japan	Mizota, T (reprint author), Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.	mizota@kuhp.kyoto-u.ac.jp	Mizota, Toshiyuki/I-7355-2015	Mizota, Toshiyuki/0000-0003-2770-4262			Bundgaard-Nielsen M, 2009, BRIT J ANAESTH, V102, P756, DOI 10.1093/bja/aep083; Chung F, 1999, ANESTH ANALG, V89, P1352, DOI 10.1097/00000539-199912000-00004; DAWSON PJ, 1995, ANAESTH INTENS CARE, V23, P453, DOI 10.1177/0310057X9502300407; Fearon KCH, 2005, CLIN NUTR, V24, P466, DOI 10.1016/j.clnu.2005.02.002; FOLDAGER N, 1988, EUR J APPL PHYSIOL O, V57, P507, DOI 10.1007/BF00418000; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Grubb BP, 2005, CIRCULATION, V111, P2997, DOI 10.1161/CIRCULATIONAHA.104.482018; Jans O, 2012, BRIT J ANAESTH, V108, P436, DOI 10.1093/bja/aer403; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; Kehlet H, 2008, LANCET, V371, P791, DOI 10.1016/S0140-6736(08)60357-8; Khoo CK, 2007, ANN SURG, V245, P867, DOI 10.1097/01.sla.0000259219.08209.36; MOINICHE S, 1994, ACTA ANAESTH SCAND, V38, P328, DOI 10.1111/j.1399-6576.1994.tb03902.x; PARKER RK, 1992, ANESTHESIOLOGY, V76, P362, DOI 10.1097/00000542-199203000-00007; PARKER RK, 1991, JAMA-J AM MED ASSOC, V266, P1947, DOI 10.1001/jama.266.14.1947; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; Wind J, 2006, BRIT J SURG, V93, P800, DOI 10.1002/bjs.5384	16	9	9	0	6	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668			J ANESTH	J. Anesth.	AUG	2012	26	4					503	508		10.1007/s00540-012-1391-9			6	Anesthesiology	Anesthesiology	988SG	WOS:000307510400004	22526434				2020-06-30	J	Leelanukrom, R; Suraseranivongse, S; Boonrukwanich, V; Wechwinij, S				Leelanukrom, Ruenreong; Suraseranivongse, Suwannee; Boonrukwanich, Varanate; Wechwinij, Siriluk			Effect of wound infiltration with bupivacaine on postoperative analgesia in neonates and infants undergoing major abdominal surgery: a pilot randomized controlled trial	JOURNAL OF ANESTHESIA			English	Article						Pain; Neonates; Bupivacaine; Wound infiltration	INCISIONAL LOCAL-ANESTHESIA; PAIN RELIEF; CHILDREN; APPENDECTOMY; MANAGEMENT	Postoperative pain management is essential in the perioperative care of neonates and infants but it requires a high level of care. Wound infiltration with bupivacaine, a long-acting local anesthetic, is a simple method with minimal complications. However, studies on the effectiveness of wound infiltration in neonates and infants are lacking. The purpose of this study was to investigate the effectiveness of wound infiltration with bupivacaine for postoperative analgesia in neonates and infants undergoing abdominal surgery. A prospective, randomized controlled trial was conducted in 34 neonates and infants. The patients were randomized into two groups: the bupivacaine (B) group and the control (C) group. A standardized anesthetic protocol was used for each patient. Before wound closure, the surgical site of each patient in the B group was infiltrated with 2 mg/kg of bupivacaine, whereas no surgical site anesthetic infiltration was used in the C group. The neonatal infant pain scale (NIPS) score was used to evaluate postoperative pain, and fentanyl 0.5-1.5 mu g/kg was administered when the NIPS score was a parts per thousand yen4. In regard to the fentanyl requirement, the NIPS score and the numbers of patients whose NIPS score was a parts per thousand yen4 were compared between the two groups. The median fentanyl dose requirements in the B group and C group were 1 and 0.5 mu g/kg, respectively; and the difference was not statistically significant (p = 0.255). The postoperative NIPS scores in the two groups were not significantly different. In addition, there were no significant differences in the numbers of patients whose NIPS score was a parts per thousand yen4 at 6, 12, 18, and 24 h postoperatively. In neonates and infants, wound infiltration with bupivacaine had no significant effect on pain relief or fentanyl requirement during the first 24 h after major abdominal surgery.	[Leelanukrom, Ruenreong; Boonrukwanich, Varanate; Wechwinij, Siriluk] Chulalongkorn Univ, Fac Med, Dept Anesthesiol, Bangkok 10330, Thailand; [Suraseranivongse, Suwannee] Mahidol Univ, Siriraj Hosp, Dept Anesthesiol, Fac Med, Bangkok 10700, Thailand	Leelanukrom, R (reprint author), Chulalongkorn Univ, Fac Med, Dept Anesthesiol, Bangkok 10330, Thailand.	leelanukrom@hotmail.com			Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn UniversityChulalongkorn University	This study was supported by the Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University.	ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Bamigboye AA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006954.pub2; Bielsky A, 2009, PEDIATR ANESTH, V19, P541, DOI 10.1111/j.1460-9592.2009.02988.x; Delevati NM, 1999, INFANT BEHAV DEV, V22, P137, DOI 10.1016/S0163-6383(99)80011-3; FELL D, 1988, ANAESTHESIA, V43, P107; Howard RF, 2003, JAMA-J AM MED ASSOC, V290, P2464, DOI 10.1001/jama.290.18.2464; Jensen SI, 2004, EUR J PEDIATR SURG, V14, P410, DOI 10.1055/s-2004-821044; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Lawrence J, 1993, Neonatal Netw, V12, P59; Lemons JA, 2000, PEDIATRICS, V105, P454; Moiniche S, 1998, BRIT J ANAESTH, V81, P377, DOI 10.1093/bja/81.3.377; Morton NS, 2007, ARCH DIS CHILDHOOD-E, V92, pEP14, DOI 10.1136/adc.2004.070888; Morton NS, 2010, PEDIATR ANESTH, V20, P119, DOI 10.1111/j.1460-9592.2009.03187.x; Okur H, 1996, PEDIATR SURG INT, V11, P41, DOI 10.1007/BF00174583; Suraseranivongse S, 2006, BRIT J ANAESTH, V97, P540, DOI 10.1093/bja/ael184; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; TURNER GA, 1994, BRIT J ANAESTH, V72, P541, DOI 10.1093/bja/72.5.541; Willard PT, 1997, CAN J SURG, V40, P213; WRIGHT JE, 1993, BRIT J SURG, V80, P110, DOI 10.1002/bjs.1800800136	19	5	5	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	AUG	2012	26	4					541	544		10.1007/s00540-012-1355-0			4	Anesthesiology	Anesthesiology	988SG	WOS:000307510400010	22391668				2020-06-30	J	Sabatowski, R; Scharnagel, R				Sabatowski, Rainer; Scharnagel, Ruediger			Utilisation of transdermal fentanyl in Germany from 2004-2006 by Edeltraut Garbe and colleagues	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Letter							OPIOID-NAIVE PATIENTS; CANCER PAIN; MODERATE		[Sabatowski, Rainer] Tech Univ Dresden, Comprehens Paint Ctr, Univ Hosp Carl Gustav Carus, D-01307 Dresden, Germany	Sabatowski, R (reprint author), Tech Univ Dresden, Comprehens Paint Ctr, Univ Hosp Carl Gustav Carus, Fetscherstr 74, D-01307 Dresden, Germany.	rainer.sabatowski@uniklinikum-dresden.de	Sabatowski, Rainer/K-3475-2019	Sabatowski, Rainer/0000-0003-2228-3147			Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), LANGZ OP BEI NICHT T; Arzneimittelkommission der Deutschen Arzteschaft, 2012, DTSCH ARZTEBLATT, V109, pB628; Caraceni A, 2011, PALLIATIVE MED, V25, P402, DOI 10.1177/0269216310392102; Cepeda Maria Soledad, 2010, BMC Palliat Care, V9, P14, DOI 10.1186/1472-684X-9-14; Cepeda MS, J CLIN PHARMACOL, DOI [10. 1177/0091270012436561, DOI 10.1177/0091270012436561]; Garbe E, 2012, PHARMACOEPIDEM DR S, V21, P191, DOI 10.1002/pds.2164; Heads of Medicines Agencies, FENT TRANSD PATCH SP; Janssen-Cilag, 2011, DUR SMAT FACH; Klepstad P, 2011, PALLIATIVE MED, V25, P424, DOI 10.1177/0269216310386280; Mercadante S, 2009, CLIN THER, V31, P2134, DOI 10.1016/j.clinthera.2009.10.013; Pflughaupt M, 2010, SCHMERZ, V24, P267, DOI 10.1007/s00482-010-0913-3; Reinecke H, 2009, SCHMERZ, V23, P440, DOI 10.1007/s00482-009-0839-9; Schwabe U, 2012, ARZBEUVERORDNUNGS RE; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9	14	1	1	2	2	WILEY PERIODICALS, INC	SAN FRANCISCO	ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA	1053-8569			PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	AUG	2012	21	8					902	903		10.1002/pds.3315			2	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	980LQ	WOS:000306895200016	22836720				2020-06-30	J	Garbe, E; Jobski, K				Garbe, Edeltraut; Jobski, Kathrin			Utilisation of transdermal fentanyl in Germany from 2004 to 2006	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article							PAIN		[Garbe, Edeltraut; Jobski, Kathrin] BIPS Inst Epidemiol & Prevent Res, Bremen, Germany	Garbe, E (reprint author), Achterstr 30, D-28359 Bremen, Germany.	garbe@bips.uni-bremen.de					[Anonymous], 2010, FENTANL; [Anonymous], 2007, ISMP CAN SAF B; Arzneimittelkommission der deutschen Arzteschaft, 2007, TUM ARZN PRAX; FDA, 2007, FDA ISS 2 SAF WARN F; Jost L, 2010, ANN ONCOL, V21, pv257, DOI 10.1093/annonc/mdq224; Klepstad P, 2011, PALLIATIVE MED, V25, P424, DOI 10.1177/0269216310386280	6	2	2	1	1	WILEY PERIODICALS, INC	SAN FRANCISCO	ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA	1053-8569			PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	AUG	2012	21	8					904	905		10.1002/pds.3314			2	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	980LQ	WOS:000306895200017	22736572				2020-06-30	J	Falcone, M; Gold, AB; Wileyto, EP; Ray, R; Ruparel, K; Newberg, A; Dubroff, J; Logan, J; Zubieta, JK; Blendy, JA; Lerman, C				Falcone, Mary; Gold, Allison B.; Wileyto, E. Paul; Ray, Riju; Ruparel, Kosha; Newberg, Andrew; Dubroff, Jacob; Logan, Jean; Zubieta, Jon-Kar; Blendy, Julie A.; Lerman, Caryn			mu-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief	PSYCHOPHARMACOLOGY			English	Article						Smoking motivation; mu-Opioid receptor; Amygdala; Affect regulation	NICOTINE REPLACEMENT THERAPY; NALTREXONE AUGMENTATION; BETA-ENDORPHIN; BINDING; ACTIVATION; RESPONSES; MOOD; NEUROTRANSMISSION; ANTINOCICEPTION; REINFORCEMENT	The perception that smoking relieves negative affect contributes to smoking persistence. Endogenous opioid neurotransmission, and the mu-opioid receptor (MOR) in particular, plays a role in affective regulation and is modulated by nicotine. We examined the relationship of MOR binding availability in the amygdala to the motivation to smoke for negative affect relief and to the acute effects of smoking on affective responses. Twenty-two smokers were scanned on two separate occasions after overnight abstinence using [C-11]carfentanil positron emission tomography imaging: after smoking a nicotine-containing cigarette and after smoking a denicotinized cigarette. Self-reports of smoking motives were collected at baseline, and measures of positive and negative affect were collected pre- and post- cigarette smoking. Higher MOR availability in the amygdala was associated with motivation to smoke to relieve negative affect. However, MOR availability was unrelated to changes in affect after smoking either cigarette. Increased MOR availability in amygdala may underlie the motivation to smoke for negative affective relief. These results are consistent with previous data highlighting the role of MOR neurotransmission in smoking behavior.	[Falcone, Mary; Gold, Allison B.; Wileyto, E. Paul; Ray, Riju; Lerman, Caryn] Univ Penn, Dept Psychiat, Ctr Interdisciplinary Res Nicotine Addict, Philadelphia, PA 19104 USA; [Falcone, Mary; Blendy, Julie A.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Ruparel, Kosha] Hosp Univ Penn, Dept Neuropsychiat, Brain Behav Lab, Philadelphia, PA 19104 USA; [Newberg, Andrew] Thomas Jefferson Univ, Dept Emergency Med & Radiol, Myrna Brind Ctr Integrat Med, Philadelphia, PA 19107 USA; [Dubroff, Jacob] Hosp Univ Penn, Dept Nucl Med, Philadelphia, PA 19104 USA; [Logan, Jean] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; [Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA	Lerman, C (reprint author), Univ Penn, Dept Psychiat, Ctr Interdisciplinary Res Nicotine Addict, 3535 Market St,Suite 4100, Philadelphia, PA 19104 USA.	clerman@upenn.edu		Newberg, Andrew/0000-0001-8230-1752	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R21-DA027066, U01-DA020830]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50-CA143187]; Pennsylvania Department of Health; PfizerPfizer; AstraZenecaAstraZeneca; NovartisNovartis; GlaxoSmithKlineGlaxoSmithKline	We thank the following individuals for their contributions to the study: Dr. Richard Freifelder, Dr. Joel Karp, Dr. Alexander Schmitz, and Rahul Poria for [<SUP>11</SUP>C]carfentanil synthesis; Dr. Daniel Pryma and Dr. Rodolfo Perini for serving as PET center injectors; and Dr. Janet Reddin and PET center technologists for PET acquisition and preprocessing at the PET center. This research was supported by National Institute on Drug Abuse Grants R21-DA027066 (to C. L. and J.A.B.) and U01-DA020830 (to C. L.), National Cancer Institute Grant P50-CA143187 (to C. L. and J.A.B.), and a grant from the Pennsylvania Department of Health. C. L. has served as a consultant for and/or received research support from Pfizer, AstraZeneca, Novartis, and GlaxoSmithKline. R. R. has received research support from Pfizer. This research was not supported by industry funds. The authors declare that they have full control of all primary data and they agree to allow the journal to review their data if requested.	Balerio GN, 2005, PSYCHOPHARMACOLOGY, V181, P260, DOI 10.1007/s00213-005-2238-y; Benowitz NL, 2006, CLIN PHARMACOL THER, V80, P703, DOI 10.1016/j.clpt.2006.09.007; Berrendero F, 2002, J NEUROSCI, V22, P10935; Boyadjieva NI, 1997, LIFE SCI, V61, pPL59; Brody AL, 2009, INT J NEUROPSYCHOPH, V12, P305, DOI 10.1017/S146114570800922X; *CDCP, 2009, MMWR-MORBID MORTAL W, V58, P1227; Colvin PJ, 2010, NICOTINE TOB RES, V12, P1203, DOI 10.1093/ntr/ntq169; Conklin CA, 2005, J ABNORM PSYCHOL, V114, P153, DOI 10.1037/0021-843X.114.1.153; COSTA PT, 1980, INT J ADDICT, V15, P537, DOI 10.3109/10826088009040036; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; Diekhof EK, 2011, NEUROIMAGE, V58, P275, DOI 10.1016/j.neuroimage.2011.05.073; DIENER E, 1984, J PERS SOC PSYCHOL, V47, P1105, DOI 10.1037/0022-3514.47.5.1105; Epperson CN, 2010, DRUG ALCOHOL DEPEN, V112, P1, DOI 10.1016/j.drugalcdep.2010.04.021; Greenwald M, 2007, BIOL PSYCHIAT, V61, P101, DOI 10.1016/j.biopsych.2006.04.043; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; HORN D, 1966, AM J PUBLIC HEALTH N, V56, P21, DOI 10.2105/AJPH.56.12_Suppl.21; HOUDI AA, 1991, PEPTIDES, V12, P161, DOI 10.1016/0196-9781(91)90183-P; Hutchison KE, 1999, PSYCHOPHARMACOLOGY, V142, P139, DOI 10.1007/s002130050872; Ichise M, 2003, J CEREBR BLOOD F MET, V23, P1096, DOI 10.1097/01.WCB.0000085441.37552.CA; Karp JS, 2003, J NUCL MED, V44, P1340; Kassel JD, 2007, J ABNORM PSYCHOL, V116, P543, DOI 10.1037/0021-843X.116.3.543; Kim MJ, 2011, BEHAV BRAIN RES, V223, P403, DOI 10.1016/j.bbr.2011.04.025; Lee MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024203; Lerman C, 1996, ADDICT BEHAV, V21, P9, DOI 10.1016/0306-4603(95)00032-1; Lerman C, 2004, PHARMACOGENOMICS J, V4, P184, DOI 10.1038/sj.tpj.6500238; Lerman C, 1998, HEALTH PSYCHOL, V17, P56, DOI 10.1037/0278-6133.17.1.56; Lerman C, 2002, DRUG ALCOHOL DEPEN, V67, P219, DOI 10.1016/S0376-8716(02)00067-4; Lerman C, 2010, BIOL PSYCHIAT, V67, P699, DOI 10.1016/j.biopsych.2010.02.014; Mague SD, 2010, DRUG ALCOHOL DEPEN, V108, P172, DOI 10.1016/j.drugalcdep.2009.12.016; Mahler SV, 2009, J NEUROSCI, V29, P6500, DOI 10.1523/JNEUROSCI.3875-08.2009; MARTY MA, 1985, PHARMACOL BIOCHEM BE, V22, P317, DOI 10.1016/0091-3057(85)90397-1; Mills RH, 2004, J NEUROSCI, V24, P947, DOI 10.1523/JNEUROSCI.1366-03.2004; Munafo MR, 2007, PHARMACOGENOMICS J, V7, P353, DOI 10.1038/sj.tpj.6500432; O'Malley SS, 2006, ARCH INTERN MED, V166, P667, DOI 10.1001/archinte.166.6.667; Perkins KA, 2011, EXP CLIN PSYCHOPHARM; Perkins KA, 2008, BEHAV PHARMACOL, V19, P641, DOI 10.1097/FBP.0b013e32830c367c; Perkins KA, 2010, PSYCHOPHARMACOLOGY, V210, P25, DOI 10.1007/s00213-010-1811-1; Pessoa Luiz, 2010, Dialogues Clin Neurosci, V12, P433; PFEIFFER A, 1982, BRAIN RES, V248, P87, DOI 10.1016/0006-8993(82)91150-7; Ray R, 2006, PSYCHOPHARMACOLOGY, V188, P355, DOI 10.1007/s00213-006-0504-2; Ray R, 2007, NICOTINE TOB RES, V9, P1237, DOI 10.1080/14622200701648367; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Ribeiro SC, 2005, PROG NEURO-PSYCHOPH, V29, P1264, DOI 10.1016/j.pnpbp.2005.08.011; Rose JE, 2006, PSYCHOPHARMACOLOGY, V184, P274, DOI 10.1007/s00213-005-0250-x; Scott DJ, 2007, NEUROPSYCHOPHARMACOL, V32, P450, DOI 10.1038/sj.npp.1301238; SHIFFMAN S, 1993, J CONSULT CLIN PSYCH, V61, P732, DOI 10.1037/0022-006X.61.5.732; Shiffman S, 1997, J CONSULT CLIN PSYCH, V65, P292, DOI 10.1037/0022-006X.65.2.292.a; SHIFFMAN S, 1988, ADDICT BEHAV, V13, P201, DOI 10.1016/0306-4603(88)90013-5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; Strasser AA, 2005, PHARMACOL BIOCHEM BE, V82, P320, DOI 10.1016/j.pbb.2005.09.001; Strasser AA, 2005, ADDICT BEHAV, V30, P9, DOI 10.1016/j.addbeh.2004.04.005; Strasser AA, 2007, DRUG ALCOHOL DEPEN, V86, P294, DOI 10.1016/j.drugalcdep.2006.06.017; TATE JC, 1990, ADDICT BEHAV, V15, P129, DOI 10.1016/0306-4603(90)90016-Q; Walters CL, 2005, NEURON, V46, P933, DOI 10.1016/j.neuron.2005.05.005; Wewers ME, 1999, BRAIN RES, V822, P107, DOI 10.1016/S0006-8993(99)01095-1; World Health Organization, 2009, WHO REP GLOB TOB EP; Zhang Lan, 2006, Behav Brain Funct, V2, P28, DOI 10.1186/1744-9081-2-28; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	64	5	5	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	AUG	2012	222	4					701	708		10.1007/s00213-012-2673-5			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	979NQ	WOS:000306827100012	22389047	Green Accepted			2020-06-30	J	Kawa, C; Stewart, J; Hilden, K; Adler, DG; Tietze, C; Bromberg, MB; Fang, JC				Kawa, Chad; Stewart, James; Hilden, Kristen; Adler, Douglas G.; Tietze, Christopher; Bromberg, Mark B.; Fang, John C.			A Retrospective Study of Nurse-Assisted Propofol Sedation in Patients With Amyotrophic Lateral Sclerosis Undergoing Percutaneous Endoscopic Gastrostomy	NUTRITION IN CLINICAL PRACTICE			English	Article						amyotrophic lateral sclerosis; enteral nutrition; gastrostomy	QUALITY STANDARDS SUBCOMMITTEE; PRACTICE PARAMETER UPDATE; AMERICAN ACADEMY; TUBE PLACEMENT; VITAL CAPACITY; ALS PATIENTS; SURVIVAL; MANAGEMENT; NEUROLOGY; CARE	Background: Percutaneous endscopic gastrostomy (PEG) placement is standard in the care of patients with amyotrophic lateral sclerosis (ALS) unable to maintain adequate oral nutrition. This has been performed using conscious sedation with narcotics/benzodiazepines. However, recent studies suggest that propofol sedation is superior for other endoscopic procedures. In addition, endoscopic PEG placement is not recommended for patients with ALS with a forced vital capacity (FVC) <50%. The authors postulated that nurse-administered propofol sedation (NAPS) with the addition of bilevel positive airway pressure (BiPAP) would be superior to standard sedation with midazolam/fentanyl (M/F) in all patients with ALS regardless of FVC. Here the authors review their retrospective experience of PEG placements in patients with ALS using propofol +/- BiPAP vs traditional sedation +/- BiPAP. Results: Thirty-one patients received M/F, and 29 received NAPS. BiPAP was used more often in the NAPS group (24/29 NAPS vs 6/31 M/F respectively, P<.0001). Twenty-nine of 31 PEG placements in the M/F group and 27 of 29 PEG placements in the NAPS group were successful. Seven desaturation events occurred to <90% in the M/F group compared with 1 desaturation event in the NAPS group (P=.05). No other complications were noted. Conclusion: PEG placement can be performed safely in patients with ALS with FVC <50% using NAPS with BiPAP. (Nutr Clin Pract. 2012;27:540-544)	[Hilden, Kristen; Adler, Douglas G.; Tietze, Christopher; Fang, John C.] Univ Utah, Div Gastroenterol, Salt Lake City, UT 84132 USA; [Kawa, Chad] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Stewart, James] Carl T Hayden Vet Affairs Med Ctr, Phoenix, AZ USA; [Bromberg, Mark B.] Univ Utah, Div Neurol, Salt Lake City, UT 84132 USA	Hilden, K (reprint author), Univ Utah, Div Gastroenterol, 30 N 1900 E,4R118 SOM, Salt Lake City, UT 84132 USA.	kristen.hilden@hsc.utah.edu		Adler, Douglas/0000-0003-3214-6285			Andersen PM, 2007, AMYOTROPH LATERAL SC, V8, P195, DOI 10.1080/17482960701262376; Boitano LJ, 2001, NEUROLOGY, V56, P413, DOI 10.1212/WNL.56.3.413; Charcot J-M, 1865, B SOC MED HOP PAR S2, P24; Chio A, 2004, J NEUROL NEUROSUR PS, V75, P645, DOI 10.1136/jnnp.2003.020347; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P310, DOI 10.3109/17482960802566824; Czaplinski A, 2006, J NEUROL NEUROSUR PS, V77, P390, DOI 10.1136/jnnp.2005.072660; Czaplinski A, 2006, J NEUROL, V253, P1428, DOI 10.1007/s00415-006-0226-8; Gregory S, 2002, NEUROLOGY, V58, P485, DOI 10.1212/WNL.58.3.485; Kasarskis EJ, 1999, J NEUROL SCI, V169, P118, DOI 10.1016/S0022-510X(99)00230-0; Miller RG, 2009, NEUROLOGY, V73, P1227, DOI 10.1212/WNL.0b013e3181bc01a4; Miller RG, 2009, NEUROLOGY, V73, P1218, DOI 10.1212/WNL.0b013e3181bc0141; Mitsumoto H, 2003, AMYOTROPH LATERAL SC, V4, P177, DOI 10.1080/14660820310011728; PIQUET MA, 2006, REV NEUROL PARIS, V162; Rex DK, 2006, ALIMENT PHARM THER, V24, P163, DOI 10.1111/j.1365-2036.2006.02986.x; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Thornton FJ, 2002, RADIOLOGY, V224, P713, DOI 10.1148/radiol.2243010909; Vargo J, 2003, GASTROINTEST ENDOSC, V70, P1053; Vargo JJ, 2007, GASTROINTEST ENDOSC, V66, P457, DOI 10.1016/j.gie.2007.03.1035	19	6	6	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0884-5336			NUTR CLIN PRACT	Nutr. Clin. Pract.	AUG	2012	27	4					540	544		10.1177/0884533612443712			5	Nutrition & Dietetics	Nutrition & Dietetics	976TS	WOS:000306608700010	22645103				2020-06-30	J	Aissaoui, Y; Qamous, Y; Serghini, I; Zoubir, M; Salim, JL; Boughalem, M				Aissaoui, Younes; Qamous, Youssef; Serghini, Issam; Zoubir, Mohammed; Salim, Jaafar Lalaoui; Boughalem, Mohammed			Magnesium sulphate: an adjuvant to tracheal intubation without muscle relaxation - a randomised study	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						general anaesthesia; intubating conditions; magnesium sulphate; neuromuscular blocking agents; tracheal intubation	NEUROMUSCULAR BLOCKING-AGENTS; CONTROLLED-TRIAL; ANALGESIC REQUIREMENTS; MUSCULAR RELAXATION; PROPOFOL PROVIDES; COMBINATION; ANESTHESIA; ALFENTANIL; ROCURONIUM; RELAXANTS	Context Tracheal intubation without administration of a neuromuscular blocking drug is used frequently in anaesthesia. Several techniques and adjuvants have been tried to improve intubating conditions. Magnesium sulphate is an agent with analgesic, anaesthetic and muscle relaxant effects. Objective To assess the effect of magnesium sulphate on intubating conditions after induction of anaesthesia without a neuromuscular blocking drug. Design Double-blinded randomised study. Patients Sixty patients with American Society of Anesthesiologists physical status 1/2 scheduled for elective surgery under general anaesthesia were included. Setting Avicenna Military Hospital between June 2010 and March 2011. Interventions Before induction of general anaesthesia, patients were assigned to receive either a 10-min infusion of magnesium sulphate 45mgkg(-1) in 100 ml of isotonic saline (magnesium group, n = 30) or the same volume of saline (control group, n = 30). Anaesthesia was induced with fentanyl 3 mu gkg(-1) followed 3 min later by propofol 2.5mgkg(-1). Main outcome measures Intubating conditions were evaluated by a blinded anaesthesiologist using the criteria of the Copenhagen consensus conference: ease of laryngoscopy, vocal cord position and/or movement and response to intubation or cuff inflation (cough or diaphragmatic movement). Intubating conditions were considered as acceptable (excellent or good) or unacceptable (poor). Mean arterial pressure and heart rate were also recorded during the study period. Results The two groups were comparable in their demographic profiles. Clinically acceptable intubating conditions were observed more frequently in the magnesium group than in the control group: 25 (83%) vs. 18 patients (60%) (P=0.042). There was no failed intubation. There were no differences between the groups with regard to haemodynamic variables. Conclusion Addition of magnesium sulphate to propofol and fentanyl at induction of anaesthesia significantly improved intubating conditions without administration of a neuromuscular blocking drug. Eur J Anaesthesiol 2012; 29: 391-397 Published online 21 June 2012	[Aissaoui, Younes; Qamous, Youssef; Serghini, Issam; Zoubir, Mohammed; Salim, Jaafar Lalaoui; Boughalem, Mohammed] Cadi Ayyad Univ, Fac Med, Dept Anesthesiol, Avicenna Mil Hosp, Marrakech, Morocco	Aissaoui, Y (reprint author), Hop Mil Avicenne, Dept Anesthesie Reanimat, Marrakech 40000, Morocco.	younes.aissaoui@live.fr			Department of Anaesthesiology of Avicenna Military Hospital	This work was supported by the Department of Anaesthesiology of Avicenna Military Hospital. The authors have no conflicts of interest to declare.	Apan A, 2004, EUR J ANAESTH, V21, P766, DOI 10.1017/S026502150400002X; Baillard C, 2005, EUR J ANAESTH, V22, P672, DOI 10.1017/S0265021505001110; Berg H, 1997, ACTA ANAESTH SCAND, V41, P1095, DOI 10.1111/j.1399-6576.1997.tb04851.x; Bouvet L, 2008, CAN J ANAESTH, V55, P674, DOI 10.1007/BF03017743; Combes X, 2007, BRIT J ANAESTH, V99, P276, DOI 10.1093/bja/aem147; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Czarnetzki C, 2010, ACTA ANAESTH SCAND, V54, P299, DOI 10.1111/j.1399-6576.2009.02160.x; Donati F, 2008, CAN J ANAESTH, V55, P663, DOI 10.1007/BF03017741; Dube L, 2003, CAN J ANAESTH, V50, P732, DOI 10.1007/BF03018719; Erhan E, 2003, EUR J ANAESTH, V20, P37, DOI 10.1097/00003643-200301000-00007; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Fuchs-Buder T, 2007, ACTA ANAESTH SCAND, V51, P789, DOI 10.1111/j.1399-6576.2007.01352.x; GHONEIM MM, 1970, ANESTHESIOLOGY, V32, P23, DOI 10.1097/00000542-197001000-00007; Gupta K, 2006, ANAESTHESIA, V61, P1058, DOI 10.1111/j.1365-2044.2006.04801.x; Hans GA, 2012, EUR J ANAESTH, V29, P95, DOI 10.1097/EJA.0b013e32834e13a6; Herroeder S, 2011, ANESTHESIOLOGY, V114, P971, DOI 10.1097/ALN.0b013e318210483d; Jabbour-Khoury SI, 2003, CAN J ANAESTH, V50, P116, DOI 10.1007/BF03017841; Kara H, 2002, EUR J ANAESTH, V19, P52, DOI 10.1017/S026502150200008X; Klemola UM, 2000, ACTA ANAESTH SCAND, V44, P465, DOI 10.1034/j.1399-6576.2000.440419.x; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Lieutaud T, 2003, CAN J ANAESTH, V50, P121, DOI 10.1007/BF03017842; Lundstrom LH, 2009, BRIT J ANAESTH, V103, P283, DOI 10.1093/bja/aep124; Lysakowski C, 2007, ANESTH ANALG, V104, P1532, DOI 10.1213/01.ane.0000261250.59984.cd; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Mencke T, 2003, ANESTHESIOLOGY, V98, P1049, DOI 10.1097/00000542-200305000-00005; Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007; Petrun AM, 2010, EUR J ANAESTH, V27, P917, DOI 10.1097/EJA.0b013e3283392593; Pinard AM, 2003, CAN J ANAESTH, V50, P172, DOI 10.1007/BF03017852; Prakash S, 2006, ACTA ANAESTH SCAND, V50, P999, DOI 10.1111/j.1399-6576.2006.01093.x; Puri GD, 1998, ANESTH ANALG, V87, P808, DOI 10.1097/00000539-199810000-00012; Savarese JJ, 2000, ANESTHESIA, P412; Seyhan TO, 2006, BRIT J ANAESTH, V96, P247, DOI 10.1093/bja/aei291; Sneyd JR, 2010, BRIT J ANAESTH, V104, P535, DOI 10.1093/bja/aeq060; Telci L, 2002, BRIT J ANAESTH, V89, P594, DOI 10.1093/bja/aef238; Thompson SW, 1988, ANESTH ANALG, V20, P1273; Tramer MR, 2007, ANESTH ANALG, V104, P1374, DOI 10.1213/01.ane.0000263416.14948.dc; Woods AW, 2005, BRIT J ANAESTH, V94, P150, DOI 10.1093/bja/aei006	38	11	11	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	AUG	2012	29	8					391	397		10.1097/EJA.0b013e328355cf35			7	Anesthesiology	Anesthesiology	973PF	WOS:000306371500007	22717726				2020-06-30	J	Bachmann, M; Kallio, H; Kairaluoma, P; Rosenberg, PH; Pere, P				Bachmann, Martina; Kallio, Helena; Kairaluoma, Pekka; Rosenberg, Per H.; Pere, Pertti			Safety of articaine in spinal anaesthesia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter									[Bachmann, Martina; Kallio, Helena; Kairaluoma, Pekka; Pere, Pertti] Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Helsinki, Finland; [Rosenberg, Per H.] Univ Helsinki, Dept Anaesthesiol & Intens Care Med, Helsinki, Finland	Pere, P (reprint author), Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Helsinki, Finland.	pertti.pere@hus.fi					Bachmann M, 2012, EUR J ANAESTH, V29, P22, DOI 10.1097/EJA.0b013e32834a11be; Kairaluoma PM, 2011, REG ANESTH PAIN MED, V36, pE183; Malinovsky JM, 2012, EUR J ANAESTH, V29, P5, DOI 10.1097/EJA.0b013e32834de295; Sakura S, 2005, ANESTH ANALG, V101, P541, DOI 10.1213/01.ANE.0000155960.61157.12	4	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	AUG	2012	29	8					404	404		10.1097/EJA.0b013e32835417a2			1	Anesthesiology	Anesthesiology	973PF	WOS:000306371500012	22569021				2020-06-30	J	Citerio, G; Pesenti, A; Latini, R; Masson, S; Barlera, S; Gaspari, F; Franzosi, MG				Citerio, Giuseppe; Pesenti, Antonio; Latini, Roberto; Masson, Serge; Barlera, Simona; Gaspari, Flavio; Franzosi, Maria G.		NeuroMorfeo Study Grp	A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia; craniotomy; neurosurgery; randomised controlled trial	SUPRATENTORIAL INTRACRANIAL SURGERY; NEUROENDOCRINE STRESS-RESPONSE; ISOFLURANE-NITROUS-OXIDE; PATIENT SATISFACTION; GENERAL-ANESTHESIA; IOWA SATISFACTION; REMIFENTANIL; SEVOFLURANE; PROPOFOL; FENTANYL	Context A clear preference for intravenous or inhalational anaesthesia has not been established for craniotomy in patients without signs of cerebral hypertension. Objectives The NeuroMorfeo trial was designed to test equivalence of inhalational and intravenous anaesthesia maintenance techniques in the postoperative recovery of patients undergoing elective supratentorial surgery. Design This trial is a multicentre, randomised, open-label, equivalence design. A balanced stratified randomisation scheme was maintained using a centralised randomisation service. Equivalence was tested using the two one-sided tests procedure. Setting Fourteen Italian neuroanaesthesia centres participated in the study from December 2007 to March 2009. Patients Adults, 18 to 75 years old, scheduled for elective supratentorial intracranial surgery under general anaesthesia were eligible for enrolment if they had a normal preoperative level of consciousness and no clinical signs of intracranial hypertension. Interventions Patients were randomised to one of three anaesthesia maintenance protocols to determine if sevoflurane-remifentanil or sevoflurane-fentanyl were equivalent to propofol-remifentanil. Main outcome measures The primary outcome was the time to achieve an Aldrete postanaesthesia score of at least 9 after tracheal extubation. Secondary endpoints included haemodynamic parameters, quality of the surgical field, perioperative neuroendocrine stress responses and routine postoperative assessments. Results Four hundred and eleven patients [51% men, mean age 54.8 (SD 13.3) years] were enrolled. Primary outcome data were available for 380. Median (interquartiles) times to reach an Aldrete score of at least 9 were 3.48 (2.02 to 7.56), 3.25 (1.21 to 6.45) and 3.32 min (1.40 to 8.33) for sevoflurane-fentanyl, sevoflurane-remifentanil and propofol-remifentanil anaesthesia respectively, which confirmed equivalence using the two one-sided tests approach. Between-treatment differences in haemodynamic variables were small and not clinically relevant. Urinary catecholamine and cortisol responses had significantly lower activation with propofol-remifentanil. Postoperative pain and analgesic requirements were significantly higher in the remifentanil groups. Conclusion Equivalence was shown for inhalational and intravenous maintenance anaesthesia in times to reach an Aldrete score of at least 9 after tracheal extubation. Haemodynamic variables, the quality of surgical field and postoperative assessments were also similar. Perioperative endocrine stress responses were significantly blunted with propofol-remifentanil and higher analgesic requirements were recorded in the remifentanil groups. Trial registration: Eudract2007-005279-32. Eur J Anaesthesiol 2012; 29: 371-379 Published online 8 May 2012	[Citerio, Giuseppe; Pesenti, Antonio] San Gerardo Hosp, Neuroanesthesia & Neurointens Care Unit Anestesia, I-20900 Milan, Italy; [Pesenti, Antonio] Univ Milano Bicocca, Dept Expt Med, Monza, Italy; [Latini, Roberto; Masson, Serge; Barlera, Simona; Franzosi, Maria G.] Ist Ric Farmacol Mario Negri, Dept Cardiovasc Res, Milan, Italy; [Gaspari, Flavio] Ctr Ric Clin Malattie Rare Aldo & Cele Dacco, Lab Pharmacokinet & Clin Chem, Ranica, Italy	Citerio, G (reprint author), San Gerardo Hosp, Neuroanesthesia & Neurointens Care Unit Anestesia, Via Pergolesi 33, I-20900 Milan, Italy.	g.citerio@hsgerardo.org	Citerio, Giuseppe/B-1839-2015; Bassani, Tito/B-2050-2017; Antonelli, Massimo/K-9915-2016; Latini, Roberto/AAB-1410-2020; Pesenti, Antonio/H-7483-2012	Citerio, Giuseppe/0000-0002-5374-3161; Bassani, Tito/0000-0003-3312-1565; Antonelli, Massimo/0000-0003-3007-1670; Latini, Roberto/0000-0002-3729-4650; Pesenti, Antonio/0000-0003-2593-729X; Nicolis, Enrico Bjorn/0000-0001-9246-2533; Gregson, Barbara/0000-0003-4868-9137	Agenzia Italiana del Farmaco (AIFA) [FARM6FKJKK]	Agenzia Italiana del Farmaco (AIFA, the national authority responsible for drug regulation in Italy under the direction of Ministry of Health) fully financed the trial (year 2006, FARM6FKJKK).	ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Balakrishnan G, 2000, ANESTH ANALG, V91, P163, DOI 10.1097/00000539-200007000-00030; Bonhomme V, 2009, J NEUROSURG ANESTH, V21, P112, DOI 10.1097/ANA.0b013e3181963471; Boztug N, 2006, J NEUROSURG ANESTH, V18, P1, DOI 10.1097/01.ana.0000188028.80960.dd; Brodner G, 2001, ANESTH ANALG, V92, P1594, DOI 10.1097/00000539-200106000-00049; Citerio G, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-19; Del Gaudio A, 2006, MINERVA ANESTESIOL, V72, P309; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Dexter F, 1997, ANESTHESIOLOGY, V87, P865, DOI 10.1097/00000542-199710000-00021; Dexter F, 2010, ANESTH ANALG, V110, P570, DOI 10.1213/ANE.0b013e3181b5dcb7; Dinsmore J, 2007, BRIT J ANAESTH, V99, P68, DOI 10.1093/bja/aem132; Engelhard K, 2006, CURR OPIN ANESTHESIO, V19, P504, DOI 10.1097/01.aco.0000245275.76916.87; Fung D, 2005, ANESTH ANALG, V100, P1637, DOI 10.1213/01.ANE.0000154203.00434.23; Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Inada T, 2004, ANAESTHESIA, V59, P954, DOI 10.1111/j.1365-2044.2004.03837.x; KEHLET H, 1991, CAN J SURG, V34, P565; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; Lauta E, 2010, J NEUROSURG ANESTH, V22, P110, DOI 10.1097/ANA.0b013e3181c959da; Ledowski T, 2005, ANESTH ANALG, V101, P1700, DOI 10.1213/01.ane.0000184041.32175.14; Magni G, 2005, J NEUROSURG ANESTH, V17, P134, DOI 10.1097/01.ana.0000167447.33969.16; Marana E, 2003, J AM ASSOC GYN LAP, V10, P159, DOI 10.1016/S1074-3804(05)60291-5; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Nishiyama T, 2005, J CLIN ANESTH, V17, P586, DOI 10.1016/j.jclinane.2005.03.009; Ruschen H, 2005, BRIT J OPHTHALMOL, V89, P291, DOI 10.1136/bjo.2004.052167; Smith DHG, 2003, J HYPERTENS, V21, P1291, DOI 10.1097/00004872-200307000-00016; Talke P, 2002, ANESTH ANALG, V95, P430, DOI 10.1097/00000539-200208000-00036; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; TRAYNOR C, 1981, BRIT J ANAESTH, V53, P153, DOI 10.1093/bja/53.2.153; Zhou XH, 1997, BIOMETRICS, V53, P1129, DOI 10.2307/2533570	30	44	44	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	AUG	2012	29	8					371	379		10.1097/EJA.0b013e32835422db			9	Anesthesiology	Anesthesiology	973PF	WOS:000306371500004	22569025				2020-06-30	J	Koh, IJ; Kang, YG; Chang, CB; Do, SH; Seong, SC; Kim, TK				Koh, In Jun; Kang, Yeon Gwi; Chang, Chong Bum; Do, Sang-Hwan; Seong, Sang Cheol; Kim, Tae Kyun			Does periarticular injection have additional pain relieving effects during contemporary multimodal pain control protocols for TKA?: A randomised, controlled study	KNEE			English	Article						Total knee arthroplasty; Periarticular injection; Femoral nerve block; IV-PCA	TOTAL KNEE ARTHROPLASTY; TOTAL HIP; ANALGESIA	Although the analgesic effects of periarticular multimodal drug injection (PMDI) after TKA have been well documented, there is little information about additional pain relieving effects of PMDI incorporated to contemporary multimodal pain control protocols which have been proved to provide excellent analgesia. We performed a parallel-group, randomised, controlled study to determine whether PMDI provides additional clinical benefits on contemporary multimodal analgesic protocols including preemptive analgesics, continuous femoral nerve block, and IV-PCA. Eighty-seven patients were randomized to a PMDI group (n = 45) or to a No-PMDI group (n = 42). Pain level and opioid consumption were compared as primary outcomes. The incidences of narcotic and ropivacaine related side effects and complications, functional recovery, and satisfaction were also compared. The PMDI group experienced less pain during the operation night and the 1st postoperative day and showed lower opioid consumption over 24 h after surgery. However, the PMDI group had a higher VAS pain score on the 1st postoperative day than during the operation night. No group differences in side-effects and complication incidences, functional recovery, and satisfaction were found. This study demonstrates that PMDI provides additional pain relief and reduces opioid consumption only during the early postoperative period in patients managed by the contemporary pain management protocol following TKA. (C) 2011 Elsevier B.V. All rights reserved.	[Kang, Yeon Gwi; Chang, Chong Bum; Kim, Tae Kyun] Seoul Natl Univ, Joint Reconstruct Ctr, Bundang Hosp, Songnam 463707, Gyunggido, South Korea; [Koh, In Jun] Seoul St Marys Hosp, Dept Orthopaed Surg, Seoul, South Korea; [Do, Sang-Hwan] Seoul Natl Univ, Dept Anesthesiol & Pain Med, Bundang Hosp, Songnam 463707, Gyunggido, South Korea; [Kang, Yeon Gwi] Dankook Univ, Dept Stat, Yonginsi, South Korea; [Chang, Chong Bum; Seong, Sang Cheol; Kim, Tae Kyun] Seoul Natl Univ, Coll Med, Dept Orthopaed Surg, Seoul, South Korea	Kim, TK (reprint author), Seoul Natl Univ, Joint Reconstruct Ctr, Bundang Hosp, 300 Gumidong, Songnam 463707, Gyunggido, South Korea.	osktk@snubh.org	Seong, Sang Cheol/J-5514-2012; Chang, Chong Bum/J-5630-2012; Kim, Tae Kyun/J-5446-2012; Do, Sang Hwan/J-5461-2012				BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Busch CA, 2006, J BONE JOINT SURG AM, V88A, P959, DOI 10.2106/JBJS.E.00344; Fu P, 2009, KNEE; INSALL JN, 1989, CLIN ORTHOP RELAT R, P13; Kim HA, 2008, RHEUMATOLOGY, V47, P88, DOI 10.1093/rheumatology/kem308; Krenzel BA, 2009, J ARTHROPLASTY, V24, P138, DOI 10.1016/j.arth.2009.03.014; Lombardi AV, 2004, CLIN ORTHOP RELAT R, P125, DOI 10.1097/01.blo.000147701.24029.cc; Maheshwari AV, 2009, CLIN ORTHOP RELAT R, V467, P1418, DOI 10.1007/s11999-009-0728-7; Parvataneni HK, 2007, J ARTHROPLASTY, V22, P33, DOI 10.1016/j.arth.2007.03.034; Ranawat AS, 2007, J ARTHROPLASTY, V22, P12, DOI 10.1016/j.arth.2007.05.040; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Toftdahl K, 2007, ACTA ORTHOP, V78, P172, DOI 10.1080/17453670710013645; Vendittoli PA, 2006, J BONE JOINT SURG AM, V88A, P282, DOI 10.2106/JBJS.E.00173; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yoon WY, 2008, AM J EMERG MED, V26, P59, DOI 10.1016/j.ajem.2007.06.022	15	30	30	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0968-0160	1873-5800		KNEE	Knee	AUG	2012	19	4					253	259		10.1016/j.knee.2011.03.007			7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	966QK	WOS:000305852300004	21507661				2020-06-30	J	Jeurnink, SM; Steyerberg, EW; Kuipers, EJ; Siersema, PD				Jeurnink, S. M.; Steyerberg, E. W.; Kuipers, E. J.; Siersema, P. D.			The burden of endoscopic retrograde cholangiopancreatography (ERCP) performed with the patient under conscious sedation	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Conscious sedation; Endoscopic retrograde cholangiopancreatography; ERCP	UPPER GASTROINTESTINAL ENDOSCOPY; COMPLICATIONS; MIDAZOLAM; SPHINCTEROTOMY; CANCER; SATISFACTION; ACCEPTANCE; BLIND	Endoscopic retrograde cholangiopancreatography (ERCP) is an invasive procedure that proves burdensome to patients. Nevertheless, very little data are available on patient tolerance of this procedure that may improve practice guidelines and could aid in decreasing the burden of ERCP. This study therefore investigated the burden of ERCP performed with the patient under conscious sedation. Consecutive patients receiving ERCP under conscious sedation between November 2007 and December 2008 at the University Medical Center Utrecht and Erasmus MC Rotterdam (The Netherlands) were asked to participate in this study. The patients completed questionnaires on demographics, medical history, burden of ERCP (mental health, discomfort, and pain), symptoms and the EuroQol-5D (EQ-5D), including the EQ-VAS (lower EQ-5D scores and higher EQ-VAS scores represent a better quality of life). The paired t-test, the Kruskal-Wallis test, Pearson correlation, and logistic regression were used to evaluate the results. The questionnaire was returned by 149 (54%) of 276 eligible patients, 139 of whom completed the entire questionnaire (54% males; mean age, 60 +/- A 14 years). Throat ache (p < 0.001) was the only symptom higher than baseline value 1 day after the ERCP. On day 1, about one-tenth of the patients experienced moderate to severe mental health problems, which were associated with a higher EQ-5D score before ERCP (p = 0.01). Slightly fewer than half of the patients experienced pain and discomfort during and immediately after ERCP. More discomfort was experienced by patients who underwent therapeutic ERCP (p < 0.05) and those with a higher EQ-5D score (p < 0.001) or lower VAS (p < 0.01). Pain was associated with younger age (p < 0.01), higher EQ-5D score (p < 0.001), and lower VAS (p < 0.01). One-third to one-half of patients experience pain and discomfort during and immediately after ERCP when it is performed with conscious sedation for the patient. Other sedation strategies, such as the use of general anesthesia or propofol, may well reduce the burden of ERCP, particularly for patients with a higher EQ-5D score, younger age, or therapeutic ERCP treatment. However, randomized trials are warranted.	[Jeurnink, S. M.; Siersema, P. D.] Univ Med Ctr, Dept Gastroenterol & Hepatol, NL-3508 GA Utrecht, Netherlands; [Jeurnink, S. M.; Kuipers, E. J.] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; [Steyerberg, E. W.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Kuipers, E. J.] Erasmus MC Univ Med Ctr, Dept Internal Med, Rotterdam, Netherlands	Jeurnink, SM (reprint author), Univ Med Ctr, Dept Gastroenterol & Hepatol, POB 85500, NL-3508 GA Utrecht, Netherlands.	s.m.jeurnink@students.uu.nl	Kuipers, Ernst J/H-3293-2019; Siersema, Peter/V-1636-2019; Steyerberg, Ewout/C-1509-2018	Kuipers, Ernst J/0000-0002-0633-3098; Steyerberg, Ewout/0000-0002-7787-0122			Barriga J, 2008, SOUTH MED J, V101, P362, DOI 10.1097/SMJ.0b013e318168521b; Barthet M, 2002, ENDOSCOPY, V34, P991, DOI 10.1055/s-2002-35834; Campo R, 2000, EUR J GASTROEN HEPAT, V12, P187, DOI 10.1097/00042737-200012020-00009; Christensen M, 2004, GASTROINTEST ENDOSC, V60, P721, DOI 10.1016/S0016-5107(04)02169-8; Colton JB, 2009, GASTROINTEST ENDOSC, V70, P457, DOI 10.1016/j.gie.2008.11.022; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Essink-Bot ML, 2006, BREAST, V15, P673, DOI 10.1016/j.breast.2006.02.001; Essink-Bot ML, 2007, QUAL LIFE RES, V16, P1309, DOI 10.1007/s11136-007-9239-8; Essink-Bot ML, 1998, J NATL CANCER I, V90, P925, DOI 10.1093/jnci/90.12.925; Freeman ML, 2002, GASTROINTEST ENDOSC, V56, pS273, DOI 10.1067/mge.2002.129028; Johanson JF, 2002, GASTROINTEST ENDOSC, V56, P165, DOI 10.1016/S0016-5107(02)70172-7; Jung Hyuk Sang, 2009, Korean Journal of Internal Medicine, V24, P43, DOI 10.3904/kjim.2009.24.1.43; Kongkam P, 2008, J GASTROINTEST LIVER, V17, P291; Kruijshaar ME, 2006, ENDOSCOPY, V38, P873, DOI 10.1055/s-2006-944613; Masci E, 2009, J GASTROEN HEPATOL, V24, P1510, DOI 10.1111/j.1440-1746.2009.05898.x; Mehta SN, 1998, ENDOSCOPY, V30, P457, DOI 10.1055/s-2007-1001308; Menon K, 2001, AM J GASTROENTEROL, V96, P2646; Ren JL, 2000, LARYNGOSCOPE, V110, P1563, DOI 10.1097/00005537-200009000-00031; SHERMAN S, 1991, GASTROENTEROLOGY, V101, P1068, DOI 10.1016/0016-5085(91)90735-4; Yi SY, 2005, J GASTROEN HEPATOL, V20, P1873, DOI 10.1111/j.1440-1746.2004.04081.x	21	19	19	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794			SURG ENDOSC	Surg. Endosc.	AUG	2012	26	8					2213	2219		10.1007/s00464-012-2162-2			7	Surgery	Surgery	971OZ	WOS:000306215000015	22302536				2020-06-30	J	Columbano, N; Secci, F; Careddu, GM; Sotgiu, G; Rossi, G; Driessen, B				Columbano, Nicolo; Secci, Fabio; Careddu, Giovanni M.; Sotgiu, Giovanni; Rossi, Gabriele; Driessen, Bernd			Effects of lidocaine constant rate infusion on sevoflurane requirement, autonomic responses, and postoperative analgesia in dogs undergoing ovariectomy under opioid-based balanced anesthesia	VETERINARY JOURNAL			English	Article						Dog; Balanced anesthesia; Buprenorphine; Fentanyl; Lidocaine; Pain score	MINIMUM ALVEOLAR CONCENTRATION; SYSTEMIC LIDOCAINE; INTRAVENOUS-INFUSION; PAIN; ISOFLURANE; BUPRENORPHINE; FENTANYL; OVARIOHYSTERECTOMY; PHARMACOKINETICS; COMBINATION	The effects of constant rate infusion (CRI) of lidocaine on sevoflurane (SEVO) requirements, autonomic responses to noxious stimulation, and postoperative pain relief were evaluated in dogs undergoing opioid-based balanced anesthesia. Twenty-four dogs scheduled for elective ovariectomy were randomly assigned to one of four groups: BC, receiving buprenorphine without lidocaine; FC, receiving fentanyl without lidocaine; BL, receiving buprenorphine and lidocaine; FL, receiving fentanyl and lidocaine. Dogs were anesthetized with intravenous (IV) diazepam and ketamine and anesthesia maintained with SEVO in oxygen/air. Lidocaine (2 mg/kg plus 50 mu g/kg/min) or saline were infused in groups BL/FL and BC/FC, respectively. After initiation of lidocaine or saline CRI IV buprenorphine (0.02 mg/kg) or fentanyl (4 mu g/kg plus 8 mu g/kg/h CRI) were administered IV in BC/BL and FC/FL, respectively. Respiratory and hemodynamic variables, drug plasma concentrations, and end-tidal SEVO concentrations (E'SEVO) were measured. Behaviors and pain scores were subjectively assessed 1 and 2 h post-extubation. Lidocaine CRI produced median drug plasma concentrations <0.4 mu g/mL during peak surgical stimulation. Lidocaine produced a 14% decrease in E'SEVO in the BL (P < 0.01) but none in the FL group and no change in cardio-pulmonary responses to surgery or postoperative behaviors and pain scores in any group. Thus, depending on the opioid used, supplementing opioid-based balanced anesthesia with lidocaine (50 mu g/kg/min) may not have any or only a minor impact on anesthetic outcome in terms of total anesthetic dose, autonomic responses to visceral nociception, and postoperative analgesia. (C) 2011 Elsevier Ltd. All rights reserved.	[Driessen, Bernd] Univ Penn, Sch Vet Med, Dept Clin Studies, New Bolton Ctr, Kennett Sq, PA 19348 USA; [Columbano, Nicolo; Secci, Fabio; Careddu, Giovanni M.; Rossi, Gabriele] Univ Sassari, Fac Med Vet, Sez Clin Chirurg Vet, Dipartimento Patol & Clin Vet, I-07100 Sassari, Italy; [Sotgiu, Giovanni] Univ Sassari, Fac Med & Chirurg, Dipartimento Sci Biomed, I-07100 Sassari, Italy; [Driessen, Bernd] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA	Driessen, B (reprint author), Univ Penn, Sch Vet Med, Dept Clin Studies, New Bolton Ctr, Kennett Sq, PA 19348 USA.	driessen@vet.upenn.edu	Sotgiu, Giovanni/N-1032-2017; columbano, nicolo/Y-8050-2018; COLUMBANO, Nicolo'/AAK-6378-2020	Sotgiu, Giovanni/0000-0002-1600-4474; COLUMBANO, Nicolo'/0000-0003-2201-8773	Section of Veterinary Surgery, Facolta di Medicina Veterinaria, Universita degli Studi di Sassari, Italy; Section of Emergency, Critical Care and Anesthesia, Department of Clinical Studies-NBC, School of Veterinary Medicine, University of Pennsylvania	This study was supported by funding of the Section of Veterinary Surgery, Facolta di Medicina Veterinaria, Universita degli Studi di Sassari, Italy and the Section of Emergency, Critical Care and Anesthesia, Department of Clinical Studies-NBC, School of Veterinary Medicine, University of Pennsylvania. The authors are grateful to Drs. L. Soma, J. Rudy, and C. Uboh from the Pennsylvania Equine Toxicology and Research Center, West Chester, PA, USA for drug analyses.	Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; Boscan P, 2011, VET ANAESTH ANALG, V38, P260, DOI 10.1111/j.1467-2995.2011.00611.x; Bowdle TA, 1993, ANAESTH PHARM REV, V2, P135; Brodbelt DC, 1997, J VET PHARMACOL THER, V20, P284, DOI 10.1046/j.1365-2885.1997.00060.x; Carpenter RE, 2004, VET ANAESTH ANALG, V31, P46, DOI 10.1111/j.1467-2995.2004.00137.x; Concheiro M, 2010, J CHROMATOGR B, V878, P13, DOI 10.1016/j.jchromb.2009.11.005; Egger C.M., 2009, P N AM VET C ORL FL, P127; Firth AM, 1999, J AM VET MED ASSOC, V214, P651; Gupta A. K., 2009, Indian Journal of Veterinary Surgery, V30, P22; Haitjema H, 2001, AUST VET J, V79, P339, DOI 10.1111/j.1751-0813.2001.tb12008.x; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; Jaffe JH, 1990, GOODMAN GILMANS PHAR, P485; Joubert KE, 2001, J S AFR VET ASSOC, V72, P57; KAZAMA T, 1988, ANESTHESIOLOGY, V68, P435, DOI 10.1097/00000542-198803000-00020; Krejcie TC, 1997, J PHARMACOKINET BIOP, V25, P169, DOI 10.1023/A:1025780012960; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Laiju M. P., 2008, Indian Journal of Veterinary Surgery, V29, P31; Lascelles BDX, 1997, PAIN, V73, P461, DOI 10.1016/S0304-3959(97)00141-3; Lauretti Gabriela Rocha, 2008, Rev. Bras. Anestesiol., V58, P280, DOI 10.1590/S0034-70942008000300011; Lemke KA, 2002, J AM VET MED ASSOC, V221, P1268, DOI 10.2460/javma.2002.221.1268; LEMMENS HJM, 1995, CLIN PHARMACOKINET, V29, P231, DOI 10.2165/00003088-199529040-00003; MacDougall LM, 2009, VET ANAESTH ANALG, V36, P512, DOI 10.1111/j.1467-2995.2009.00480.x; Mao JR, 2000, PAIN, V87, P7, DOI 10.1016/S0304-3959(00)00229-3; Martinez EA, 1997, AM J VET RES, V58, P1280; Matsubara LM, 2009, VET ANAESTH ANALG, V36, P407, DOI 10.1111/j.1467-2995.2009.00471.x; Muir WW, 2003, AM J VET RES, V64, P1155, DOI 10.2460/ajvr.2003.64.1155; Nelis SA, 2010, J CHROMATOGR B, V878, P2018, DOI 10.1016/j.jchromb.2010.05.042; Ngo LY, 1997, J PHARM SCI-US, V86, P944, DOI 10.1021/js960399i; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Roughan JV, 2002, LAB ANIM-UK, V36, P322, DOI 10.1258/002367702320162423; SCHELLER MS, 1990, BRIT J ANAESTH, V65, P388, DOI 10.1093/bja/65.3.388; SCHUBERT A, 1992, CAN J ANAESTH, V39, P569, DOI 10.1007/BF03008320; Seliskar A, 2005, ACTA VET-BEOGRAD, V55, P435, DOI 10.2298/AVB0506435S; Slingsby LS, 2006, VET REC, V159, P705, DOI 10.1136/vr.159.21.705; Slingsby LS, 2001, VET REC, V148, P441, DOI 10.1136/vr.148.14.441; Slingsby LS, 2000, RES VET SCI, V69, P147, DOI 10.1053/rvsc.2000.0406; Smith Lesley J, 2001, Vet Anaesth Analg, V28, P87, DOI 10.1046/j.1467-2987.2000.00038.x; Smith LJ, 2004, VET ANAESTH ANALG, V31, P53, DOI 10.1111/j.1467-2995.2004.00142.x; Smith LJ, 2002, PAIN, V97, P267, DOI 10.1016/S0304-3959(02)00028-3; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Steffey EP, 2007, LUMB JONES VET ANEST, P355; TUCKER GT, 1971, ANESTHESIOLOGY, V34, P538, DOI 10.1097/00000542-197106000-00014; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; Vaisanen M, 2004, VET REC, V155, P729; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Wilson J, 2008, VET ANAESTH ANALG, V35, P289, DOI 10.1111/j.1467-2995.2007.00389.x	46	19	19	0	30	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-0233	1532-2971		VET J	Vet. J.	AUG	2012	193	2					448	455		10.1016/j.tvjl.2011.12.005			8	Veterinary Sciences	Veterinary Sciences	013LK	WOS:000309306700028	22261004				2020-06-30	J	Riviere, JE				Riviere, Jim E.			Special Issue: A Novel Long-Acting Transdermal Fentanyl Solution for Dogs	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Editorial Material																	0	0	0	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		1	1		10.1111/j.1365-2885.2012.01417.x			1	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000001	22731770				2020-06-30	J	Kukanich, B; Clark, TP				Kukanich, B.; Clark, T. P.			The history and pharmacology of fentanyl: relevance to a novel, long-acting transdermal fentanyl solution newly approved for use in dogs	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							HEALTHY LABORATORY BEAGLES; POSTOPERATIVE PAIN; ADMINISTERED FENTANYL; ORTHOPEDIC-SURGERY; OPIOID ANALGESICS; MASS-SPECTROMETRY; LIVER-MICROSOMES; PLASMA FENTANYL; TOPICAL AEROSOL; RATE INFUSION	KuKanich, B., Clark, T. P. The history and pharmacology of fentanyl: relevance to a novel, long-acting transdermal fentanyl solution newly approved for use in dogs. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 319. Fentanyl is a potent mu opioid receptor agonist that was discovered to identify an improved human health analgesic over morphine, an opioid frequently associated with histamine-release, bradycardia, hyper- or hypotension, and prolonged postoperative respiratory depression. Historically, the pharmacological features of fentanyl have been described primarily through the study of the human approved fentanyl citrate formulation. In conscious dogs, fentanyl has a wide margin of safety, possesses minimum effects on the cardiovascular and respiratory systems, and is readily reversible. Other pharmacological features include sedation, mild reductions in body temperature, and dose-dependent reduction in food intake. The short duration of effect of available fentanyl citrate solutions has limited its clinical use to perioperative injections or constant rate infusions (CRIs). To extend the analgesic effect, additional fentanyl delivery technologies have been developed for human health including the fentanyl patch that has been used in an extra-label manner in dogs. Beyond the slow onset and variability in fentanyl delivery, several additional disadvantages have precluded common use of patches in dogs. The recent approval of long-acting transdermal fentanyl solution for dogs provides a new approach for sustained delivery of fentanyl for the control of postoperative pain in dogs. It has a rapid onset of action, prolonged duration, and mitigates the disadvantages of oral, parenteral, and patch-delivered opioids. The availability of a safe and effective approved opioid in dogs may allow further optimization of postoperative analgesia in this species. The objective of this review is to summarize the history and pharmacology of fentanyl and to integrate information about the newly approved long-acting transdermal fentanyl solution.	[Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA; [Kukanich, B.] Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com	KuKanich, Butch/A-7911-2008		Nexcyon Pharmaceuticals, Inc.	The authors were employees or paid contributors to Nexcyon Pharmaceuticals, Inc.	Adams HR, 2001, VET PHARM THERAPEUTI; Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; AINSLIE SG, 1979, ANESTHESIOLOGY, V51, P293, DOI 10.1097/00000542-197910000-00003; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; BAILEY PL, 1987, ANESTH ANALG, V66, P542; BARRY B W, 1987, Journal of Controlled Release, V6, P85, DOI 10.1016/0168-3659(87)90066-6; BARRY BW, 1983, [No title captured]; BEASTALL JC, 1988, INT J PHARMACEUT, V43, P207, DOI 10.1016/0378-5173(88)90275-X; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; ECKENHOFF JE, 1960, CLIN PHARMACOL THER, V1, P483; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; FDA-CVM, 2011, GREEN BOOK DAT V 1 0; Feierman DE, 1996, ANESTH ANALG, V82, P936, DOI 10.1097/00000539-199605000-00008; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; FELDMANN RJ, 1967, J INVEST DERMATOL, V48, P181, DOI 10.1038/jid.1967.29; Fine PG, 2004, CLIN GUIDE OPIOID AN; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P65, DOI 10.1111/j.1365-2885.2012.01407.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P45, DOI 10.1111/j.1365-2885.2012.01409.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; FREYE E, 1983, BRIT J ANAESTH, V55, P71, DOI 10.1093/bja/55.1.71; Freye E, 1974, Resuscitation, V3, P105, DOI 10.1016/0300-9572(74)90034-3; GARDOCKI JF, 1964, TOXICOL APPL PHARM, V6, P48, DOI 10.1016/0041-008X(64)90021-3; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grimm KA, 2005, AM J VET RES, V66, P1222, DOI 10.2460/ajvr.2005.66.1222; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; HALL LW, 2001, VET ANAESTHESIA; HAMMEL HT, 1963, J APPL PHYSIOL, V18, P1146; Hendrix P. K., 2000, Kirk's current veterinary therapy XIII: small animal practice., P57; Hirsch L J, 1993, J Cardiothorac Vasc Anesth, V7, P50, DOI 10.1016/1053-0770(93)90118-5; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; HUG CC, 1981, ANESTHESIOLOGY, V54, P38, DOI 10.1097/00000542-198101000-00008; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; Janssen Pharmaceutica Products L.P., 2005, DUR FENT TRANSD SYST; Krotscheck U, 2004, VET THER, V5, P202; KuKanich B, 2010, J VET PHARMACOL THER, V33, P42, DOI 10.1111/j.1365-2885.2009.01105.x; KuKanich B, 2011, VET J, P190; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lafuente MP, 2005, JAVMA-J AM VET MED A, V227, P1768, DOI 10.2460/javma.2005.227.1768; LIN SN, 1981, J PHARM SCI, V70, P1276, DOI 10.1002/jps.2600701124; Linton DD, 2012, J VET PHARMACOL THER, V35, P53, DOI 10.1111/j.1365-2885.2012.01408.x; Little Amy A, 2008, Vet Ther, V9, P201; LIU WS, 1976, ANESTH ANALG, V55, P168; LOWENSTEIN E, 1971, ANESTHESIOLOGY, V35, P563, DOI 10.1097/00000542-197112000-00001; Lu P, 2005, J PHARMACOL EXP THER, V313, P518, DOI 10.1124/jpet.104.077651; Luks AM, 1998, J PHARMACOL EXP THER, V284, P136; McGuire L, 2006, ANN BEHAV MED, V31, P165, DOI 10.1207/s15324796abm3102_8; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; MONTEIRORIVIERE NA, 1990, J INVEST DERMATOL, V95, P582, DOI 10.1111/1523-1747.ep12505567; Moore ND, 2009, ACUTE PAIN, V11, P129, DOI [DOI 10.1016/J.ACPAIN.2009.09.003, 10.1016/j.acpain.2009.09.003]; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; Morgan TM, 1998, J PHARM SCI, V87, P1213, DOI 10.1021/js980025k; Morgan TM, 1998, J PHARM SCI, V87, P1226, DOI 10.1021/js9800275; Morgan TM, 1998, J PHARM SCI, V87, P1219, DOI 10.1021/js980026c; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Mutoh T, 2007, VET REC, V160, P152, DOI 10.1136/vr.160.5.152; Ohtsuka H, 2001, JAPANESE PHARM THERA, V29, P877; PADDLEFORD RR, 1973, J AM VET MED ASSOC, V163, P144; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; PALLASCH TJ, 1985, ORAL SURG ORAL MED O, V59, P15, DOI 10.1016/0030-4220(85)90108-2; Papich M. G, 2009, VET PHARM THERAPEUTI, P301; Papich MG, 2007, SAUNDERS HDB VET DRU; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; PLUMB DC, 2002, [No title captured]; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; RIVIERE JE, 1999, COMP PHARMACOKINETIC, P81; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; SALMENPERA MT, 1994, ANESTHESIOLOGY, V80, P837, DOI 10.1097/00000542-199404000-00017; SAMS RA, 1985, AM J VET RES, V46, P1677; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Savides MC, 2012, J VET PHARMACOL THER, V35, P35, DOI 10.1111/j.1365-2885.2012.01410.x; Schmiedt CW, 2007, VET ANAESTH ANALG, V34, P70, DOI 10.1111/j.1467-2995.2006.00302.x; SCHWIEGER IM, 1991, ANESTHESIOLOGY, V74, P1060, DOI 10.1097/00000542-199106000-00014; Smith HS, 2008, PAIN PHYSICIAN, V11, P201; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; VENGPEDERSEN P, 1995, J PHARM SCI, V84, P1101, DOI 10.1002/jps.2600840913; Wegner K, 2008, J NEUROSCI METH, V168, P88, DOI 10.1016/j.jneumeth.2007.09.019; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x; Wilson D, 2006, JAVMA-J AM VET MED A, V228, P1042, DOI 10.2460/javma.228.7.1042	91	20	20	1	33	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		3	19		10.1111/j.1365-2885.2012.01416.x			17	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000002	22731771				2020-06-30	J	Freise, KJ; Savides, MC; Riggs, KL; Owens, JG; Newbound, GC; Clark, TP				Freise, K. J.; Savides, M. C.; Riggs, K. L.; Owens, J. G.; Newbound, G. C.; Clark, T. P.			Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							POSTOPERATIVE PAIN; TOPICAL AEROSOL; SEX-HORMONES; DOGS; PATCHES; MANAGEMENT; ABSORPTION; DELIVERY; MORPHINE	Freise, K.J., Savides, M.C., Riggs, K.L., Owens, J.G., Newbound, G.C., Clark, T.P. Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. J. vet. Pharmacol. Therap.35 (Suppl. 2), 2126. A novel, transdermal fentanyl solution (TFS) was developed that delivers sustained concentrations of fentanyl for days following a single application. The pharmacokinetics following a single topical dose was examined. Eighteen adult Beagle dogs were divided into three groups of six dogs (3M, 3F). Each group was administered a single dose of 1.3 (25), 2.6 (50), or 5.2 mg/kg (100 mu L/kg) of TFS. The dose was applied to the clipped, ventral abdominal skin using a 1-mL tuberculin syringe. Immediately following dosing, collars were placed on each dog through 72 h to prevent direct licking of the application site. Serial jugular venous blood samples were collected at 0 (predosing), 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 240, 336, 408, and 504 h after dosing and assayed for plasma fentanyl concentration. Fentanyl was rapidly detected following application with a mean absorption lag time (tlag) of 0.333 h in the 1.3 mg/kg group and 0 in the other two groups. The mean Cmax increased with dose and were 2.28, 2.67, and 4.71 ng/mL in the 1.3, 2.6 and 5.2 mg/kg dose groups, respectively. Mean terminal half-lives were 53.7, 69.6, and 103 h in the 1.3, 2.6, and 5.2 mg/kg dose groups, respectively. The mean AUC0-LLOQ from lowest to highest dose groups were 157, 268, and 645 ng center dot h/mL and were dose proportional with a R2 value of 0.9818. Adverse reactions were limited to the highest dose group and included sedation (four of six dogs) and decreased food and water intake (one dog). A dose of 2.6 mg/kg (50 mu L/kg) is proposed for further development studies based on the lack of adverse events that were observed compared to the 5.2 mg/kg group and a more rapid onset of action and longer duration of action compared to the 1.3 mg/kg group.	[Freise, K. J.; Newbound, G. C.; Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA; [Savides, M. C.] Ric Biosci LLC, Toxicol & Pharmacol, Concord, OH USA; [Riggs, K. L.; Owens, J. G.] Elanco Anim Hlth, Greenfield, IN USA	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com			Nexcyon Pharmaceuticals, Inc.	The study was funded by Nexcyon Pharmaceuticals, Inc. All the authors were employees or paid contributors.	Adams HR, 2001, VET PHARM THERAPEUTI; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; BAILEY PL, 1987, ANESTH ANALG, V66, P542; BARRY B W, 1987, Journal of Controlled Release, V6, P85, DOI 10.1016/0168-3659(87)90066-6; BARRY BW, 1983, [No title captured]; BEASTALL JC, 1988, INT J PHARMACEUT, V43, P207, DOI 10.1016/0378-5173(88)90275-X; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; Janssen Pharmaceutica Products L.P., 2005, DUR FENT TRANSD SYST; Krotscheck U, 2004, VET THER, V5, P202; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Mathews KA, 2000, VET CLIN N AM-SMALL, V30, P729, DOI 10.1016/S0195-5616(08)70004-4; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Morgan TM, 1998, J PHARM SCI, V87, P1213, DOI 10.1021/js980025k; Morgan TM, 1998, J PHARM SCI, V87, P1226, DOI 10.1021/js9800275; Morgan TM, 1998, J PHARM SCI, V87, P1219, DOI 10.1021/js980026c; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; Neugebauer EAM, 2007, SURG ENDOSC, V21, P1047, DOI 10.1007/s00464-006-9186-4; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Schmiedt CW, 2007, VET ANAESTH ANALG, V34, P70, DOI 10.1111/j.1467-2995.2006.00302.x	28	17	17	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		21	26		10.1111/j.1365-2885.2012.01399.x			6	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000003	22731772				2020-06-30	J	Freise, KJ; Newbound, GC; Tudan, C; Clark, TP				Freise, K. J.; Newbound, G. C.; Tudan, C.; Clark, T. P.			Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							IONTOPHORESIS; SKIN; PENETRATION; DOGS	Freise, K. J., Newbound, G. C., Tudan, C., Clark, T. P. Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. J. vet. Pharmacol. Therap.35 (Suppl. 2), 2733. Application of transdermal drugs to different anatomical sites can result in different absorption characteristics. The pharmacokinetics (PKs) and bioequivalence of a single 2.6 mg/kg (50 mu L/kg) dose of a novel, long-acting transdermal fentanyl solution were determined when applied topically to the ventral abdominal or dorsal interscapular skin of 40 healthy laboratory Beagles. The PKs were differentiated by a more rapid initial absorption of fentanyl from the dorsal application site. Mean plasma fentanyl concentrations remained above 0.6 ng/mL from 4 to 96 h in the dorsal application group and from 8 to 144 h in the ventral application group. Bioequivalence analysis demonstrated that the sites were not equivalent; the 90% confidence intervals of the ratio of the geometric means for both the maximum concentration (Cmax) and the area under the curve (AUC) were not contained within the 80125% interval. The Cmax was 2.34 +/- 1.29 (mean +/- standard deviation) and 2.02 +/- 0.84 ng/mL for the ventral and dorsal application groups, respectively. The terminal elimination half-lives (t1/2) for both groups were similar with values of 137 +/- 58.9 and 117 +/- 59.6 h for the ventral and dorsal application site groups, respectively. A mean absorption rate of =2 mu g center dot kg/h was maintained from 2 to 144 h following dorsal application and from 2 to 264 h following ventral application. These results suggest that transdermal fentanyl solution could be applied as a single dose to the dorsal scapular area 24 h prior to surgery with analgesia lasting a minimum of 4 days.	[Freise, K. J.; Newbound, G. C.; Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA; [Tudan, C.] BioAccurate Enterprises Inc, Vancouver, BC, Canada	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com			Nexcyon Pharmaceuticals, Inc.	The study was funded by Nexcyon Pharmaceuticals, Inc.	Allen DG, 1999, PHARMACEUT RES, V16, P1487, DOI 10.1023/A:1018979831854; FDA-CVM, 2002, GUID IND BIOEQ GUID; FELDMANN RJ, 1967, J INVEST DERMATOL, V48, P181, DOI 10.1038/jid.1967.29; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Kyles AE, 1996, AM J VET RES, V57, P715; Magnusson BM, 2001, ADV DRUG DELIVER REV, V50, P205, DOI 10.1016/S0169-409X(01)00158-2; MONTEIRORIVIERE NA, 1990, J INVEST DERMATOL, V95, P582, DOI 10.1111/1523-1747.ep12505567; MONTEIRORIVIERE NA, 1990, FUND APPL TOXICOL, V15, P174, DOI 10.1016/0272-0590(90)90174-I; Mukhtar H., 1992, PHARM SKIN; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; PLUMB DC, 2008, PLUMBS VET DRUG HDB; RIVIERE JE, 1992, PHARMACEUT RES, V9, P211, DOI 10.1023/A:1018985323001; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Savides MC, 2012, J VET PHARMACOL THER, V35, P35, DOI 10.1111/j.1365-2885.2012.01410.x; SMITH FM, 1990, NATO ADV SCI I A-LIF, V181, P299; Veng-Pedersen P, 2001, ADV DRUG DELIVER REV, V48, P265, DOI 10.1016/S0169-409X(01)00119-3	19	18	18	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		27	33		10.1111/j.1365-2885.2012.01411.x			7	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000004	22731773				2020-06-30	J	Savides, MC; Pohland, RC; Wilkie, DA; Abbott, JA; Newbound, GC; Freise, KJ; Clark, TP				Savides, M. C.; Pohland, R. C.; Wilkie, D. A.; Abbott, J. A.; Newbound, G. C.; Freise, K. J.; Clark, T. P.			The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogs	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							POSTOPERATIVE PAIN; PATCHES; PHARMACOKINETICS; OXYMORPHONE; ABSORPTION; ANESTHESIA; ISOFLURANE; MORPHINE; BEAGLES; SURGERY	Savides, M. C., Pohland, R. C., Wilkie, D. A., Abbott, J. A., Newbound, G. C., Freise, K. J., Clark, T. P. The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogs. J. vet. Pharmacol. Therap.35 (Suppl. 2), 3543. Previous studies have demonstrated that a single, topical application of a novel, long-acting transdermal fentanyl solution provides analgesic fentanyl concentrations for at least 4 days. The objective of this study was to describe the margin of safety following application at multiples of the therapeutic dose. Twenty-four laboratory dogs were administered a single placebo or 1x, 3x, or 5x multiple of the dose of 2.6 mg/kg (50 mu L/kg) to the ventral abdominal skin and observed for 14 days. Plasma fentanyl concentrations increased in proportion to dose. Adverse reactions in the 1x group were transient and included a low prevalence (=33%) of mild sedation, reduced food intake, modest weight loss, and minimal reductions in heart rate and rectal temperature. Moderate to severe sedation emerged in the 3x and 5x groups, which was associated with a dose-limiting reduction in food and water intake, necessitating maintenance fluid replacement for the first 2 days following application. Also observed in the higher-dose groups were an increased prevalence of abnormal stools and transient lens opacities. All abnormal health observations were completely resolved prior to necropsy on day 14, and there were no histological abnormalities identified. These data support the safe use of the 1x dose and describe the outcome of an overdose of up to 5x dose in the absence of opioid reversal.	[Newbound, G. C.; Freise, K. J.; Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA; [Savides, M. C.] Ric Biosci LLC, Toxicol & Pharmacol, Concord, OH USA; [Pohland, R. C.] Elanco Anim Hlth, Greenfield, IN USA; [Wilkie, D. A.] Ohio State Univ, Dept Vet Clin Sci, Columbus, OH 43210 USA; [Abbott, J. A.] Virginia Polytech Inst & State Univ, Virginia Tech, Dept Small Anim Clin Sci, Virginia Maryland Reg Coll Vet Med, Blacksburg, VA 24061 USA	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com	Wilkie, David/AAK-5557-2020	Wilkie, David/0000-0002-4237-0371	Nexcyon Pharmaceuticals, Inc.	The authors would like to thank Dr. Deborah Linton for careful assistance for ensuring the accuracy of the results in the manuscript. The study was funded by Nexcyon Pharmaceuticals, Inc.	ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; BAILEY PL, 1987, ANESTH ANALG, V66, P542; Biswai A V, 1976, Can Anaesth Soc J, V23, P296; CALDERONE L, 1986, EXP EYE RES, V42, P331, DOI 10.1016/0014-4835(86)90026-6; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; ECKENHOFF JE, 1960, CLIN PHARMACOL THER, V1, P483; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; Freye E, 1974, Resuscitation, V3, P105, DOI 10.1016/0300-9572(74)90034-3; GARDOCKI JF, 1964, TOXICOL APPL PHARM, V6, P48, DOI 10.1016/0041-008X(64)90021-3; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; HALL LW, 2001, VET ANAESTHESIA; Hendrix P. K., 2000, Kirk's current veterinary therapy XIII: small animal practice., P57; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Holt Dorothy V, 2007, Curr Pain Headache Rep, V11, P33, DOI 10.1007/s11916-007-0019-5; Janssen Pharmaceutica Products L.P., 2005, DUR FENT TRANSD SYST; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Lafuente MP, 2005, JAVMA-J AM VET MED A, V227, P1768, DOI 10.2460/javma.2005.227.1768; LIU WS, 1976, ANESTH ANALG, V55, P168; LOWENSTEIN E, 1971, ANESTHESIOLOGY, V35, P563, DOI 10.1097/00000542-197112000-00001; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pettifer GR, 2004, VET ANAESTH ANALG, V31, P109, DOI 10.1111/j.1467-2987.2004.00158.x; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Schmiedt CW, 2007, VET ANAESTH ANALG, V34, P70, DOI 10.1111/j.1467-2995.2006.00302.x; Smith LJ, 2004, J VET PHARMACOL THER, V27, P369, DOI 10.1111/j.1365-2885.2004.00582.x; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Urquhart J, 2000, J INTERN MED, V248, P357, DOI 10.1046/j.1365-2796.2000.00758.x; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x; Wilson D, 2006, JAVMA-J AM VET MED A, V228, P1042, DOI 10.2460/javma.228.7.1042	38	12	12	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		35	43		10.1111/j.1365-2885.2012.01410.x			9	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000005	22731774				2020-06-30	J	Freise, KJ; Newbound, GC; Tudan, C; Clark, TP				Freise, K. J.; Newbound, G. C.; Tudan, C.; Clark, T. P.			Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							OPIOID ANALGESICS; DOGS	Freise, K. J., Newbound, G. C., Tudan, C., Clark, T. P. Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 4551. Opioid overdose in dogs is manifested by clinical signs such as excessive sedation, bradycardia, and hypothermia. The ability of two different intramuscular (i.m.) naloxone reversal regimens to reverse the opioid-induced effects of a fivefold overdose of long-acting transdermal fentanyl solution was evaluated in dogs. Twenty-four healthy Beagles were administered a single 13 mg/kg dose (fivefold overdose) of transdermal fentanyl solution and randomized to two naloxone reversal regimen treatment groups, hourly administration for 8 h of 40 (n = 8) or 160 mu g/kg i.m. (n = 16). All dogs were sedated and had reduced body temperatures and heart rates (HRs) prior to naloxone administration. Both dosage regimens significantly reduced sedation (P < 0.001), and the 160 mu g/kg naloxone regimen resulted in a nearly threefold lower odds of sedation than that of the 40 mu g/kg i.m. naloxone regimen (P < 0.05). Additionally, naloxone significantly increased the mean body temperatures and HR (P < 0.001), although the 160 mu g/kg regimen increased body temperature and HR more (P < 0.05). However, the narcotic side effects of fentanyl returned within 13 h following termination of the naloxone dosage regimens. The opioid-induced effects of an overdose of transdermal fentanyl solution can be safely and effectively reversed by either 40 or 160 mu g/kg i.m. naloxone administered at hourly intervals.	[Freise, K. J.; Newbound, G. C.; Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA; [Tudan, C.] BioAccurate Enterprises Inc, Vancouver, BC, Canada	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com			Nexcyon Pharmaceuticals, Inc.	The authors would like to thank Dr Deborah Linton for her careful assistance in ensuring the accuracy of the results in the manuscript. The study was funded by Nexcyon Pharmaceuticals, Inc.	Adams HR, 2001, VET PHARM THERAPEUTI; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; HOLM S, 1979, SCAND J STAT, V6, P65; Holt Dorothy V, 2007, Curr Pain Headache Rep, V11, P33, DOI 10.1007/s11916-007-0019-5; Moore ND, 2009, ACUTE PAIN, V11, P129, DOI [DOI 10.1016/J.ACPAIN.2009.09.003, 10.1016/j.acpain.2009.09.003]; PACE NL, 1979, J PHARMACOL EXP THER, V208, P254; PADDLEFORD RR, 1973, J AM VET MED ASSOC, V163, P144; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; PLUMB DC, 2002, [No title captured]; Savides MC, 2012, J VET PHARMACOL THER, V35, P35, DOI 10.1111/j.1365-2885.2012.01410.x; Smith HS, 2008, PAIN PHYSICIAN, V11, P201; Smith LJ, 2004, J VET PHARMACOL THER, V27, P369, DOI 10.1111/j.1365-2885.2004.00582.x; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Tao PL, 2010, IUBMB LIFE, V62, P103, DOI 10.1002/iub.292; Urquhart J, 2000, J INTERN MED, V248, P357, DOI 10.1046/j.1365-2796.2000.00758.x; VENGPEDERSEN P, 1995, J PHARM SCI, V84, P1101, DOI 10.1002/jps.2600840913; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x	21	16	17	1	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783			J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		45	51		10.1111/j.1365-2885.2012.01409.x			7	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000006	22731775				2020-06-30	J	Linton, DD; Wilson, MG; Newbound, GC; Freise, KJ; Clark, TP				Linton, D. D.; Wilson, M. G.; Newbound, G. C.; Freise, K. J.; Clark, T. P.			The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							MANAGEMENT	Linton, D. D., Wilson, M. G., Newbound, G. C., Freise, K. J., Clark, T. P. The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study. J. vet. Pharmacol. Therap.35 (Suppl. 2), 5364. A prospective, double-blinded, positive-controlled, multicenter, noninferiority clinical study was conducted to evaluate the safety and effectiveness of a long-acting transdermal fentanyl solution (TFS) for the control of postoperative pain. Four hundred forty-five client-owned dogs of various breeds were randomly assigned to receive a single dose of TFS (2.6 mg/kg [similar to 50 mu L/kg]) (N = 223) applied 24 h prior to surgery or buprenorphine (20 mu g/kg) (N = 222) administered intramuscularly 24 h prior to surgery and every 6 h through 90 h. There were 159 (35.7%) males and 286 (64.3%) females ranging from 0.5 to 16 years of age and 3 to 98.5 kg enrolled. Pain was scored using the modified Glasgow Composite Pain Scale with an a priori dropout criteria of =8 (20 maximum score). The one-sided upper 95% confidence interval of the mean difference between fentanyl and buprenorphine treatment failures was 5.6%, which was not greater than the a priori selected margin difference of 15%. Adverse events attributed to either treatment were minimal in impact and were approximately equal between groups. Sustained plasma fentanyl concentrations provided by a single pre-emptive dose of TFS are safe and effective and are noninferior to repeated injections of buprenorphine in controlling postoperative pain over 4 days. This long-acting fentanyl formulation provides veterinarians with a novel, registered option for the control of postoperative pain in dogs that improves dosing compliance and potentially mitigates the disadvantages of oral, parenteral, and patch delivered opioids.	[Linton, D. D.; Newbound, G. C.; Freise, K. J.; Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA; [Wilson, M. G.] Indiana Univ Sch Med, Dept Clin Pharmacol, Indianapolis, IN USA	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com			Nexcyon Pharmaceuticals, Inc.	The study was funded by Nexcyon Pharmaceuticals, Inc. The authors wish to acknowledge the clinical Investigators for recruitment and enrollment of the clinical cases included in this study.	Andaluz A, 2009, VET J, V181, P299, DOI 10.1016/j.tvjl.2008.03.001; BAILEY PL, 1987, ANESTH ANALG, V66, P542; Clark T.P, 2001, EFFECT PERIOPERATIVE; FDA-CVM, 2007, NADA 141 230 FREED I; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P65, DOI 10.1111/j.1365-2885.2012.01407.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P45, DOI 10.1111/j.1365-2885.2012.01409.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; Holton L, 2001, VET REC, V148, P525, DOI 10.1136/vr.148.17.525; Martinez S.A., 2001, EFFECT PERIOPERATIVE; Mathews KA, 2000, VET CLIN N AM-SMALL, V30, P729, DOI 10.1016/S0195-5616(08)70004-4; Moll X., 2009, VET J LONDON ENGLAND; Murrell JC, 2008, VET REC, V162, P405, DOI 10.1136/vr.162.13.403; Neugebauer EAM, 2007, SURG ENDOSC, V21, P1047, DOI 10.1007/s00464-006-9186-4; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Savides MC, 2012, J VET PHARMACOL THER, V35, P35, DOI 10.1111/j.1365-2885.2012.01410.x; Shih AC, 2008, VET ANAESTH ANALG, V35, P69, DOI 10.1111/j.1467-2995.2007.00352.x; Urquhart J, 2000, J INTERN MED, V248, P357, DOI 10.1046/j.1365-2796.2000.00758.x; VENGPEDERSEN P, 1995, J PHARM SCI, V84, P1101, DOI 10.1002/jps.2600840913	20	24	24	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		53	64		10.1111/j.1365-2885.2012.01408.x			12	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000007	22731776				2020-06-30	J	Freise, KJ; Linton, DD; Newbound, GC; Tudan, C; Clark, TP				Freise, K. J.; Linton, D. D.; Newbound, G. C.; Tudan, C.; Clark, T. P.			Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogs	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							HEALTHY LABORATORY BEAGLES; POSTOPERATIVE PAIN; PATCHES; BEHAVIOR	Freise, K. J., Linton, D. D., Newbound, G. C., Tudan, C., Clark, T. P. Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogs. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 6572. A novel, long-acting transdermal fentanyl solution (TFS) that delivers sustained plasma fentanyl concentrations following a single application for the control of postoperative pain has recently been approved for use in dogs. The pharmacokinetics (PKs) of this formulation have been evaluated in healthy laboratory dogs, but they have not been reported in a clinical population of dogs for which it is indicated. Plasma fentanyl concentrations were determined from 215 dogs following a single, small-volume (similar to 50 mu L/kg) dose of TFS administered 24 h prior to orthopedic or soft tissue surgery. A population PK model was fit, and a 1-compartment open PK model with first-order absorption and an absorption lag-time best described the data. No tested clinical covariates had a significant effect on the PKs. The final model adequately described the population PKs and gave results consistent with laboratory PK studies in healthy dogs. The PKs were primarily characterized by a rapid initial increase in plasma fentanyl concentrations and a long terminal half-life of 74.0 (95% C.I. [54.7113]) h governed by flip-flop kinetics for the typical subject. The plasma fentanyl concentrations were sustained over days in the range considered to be analgesic for postoperative pain in dogs.	[Freise, K. J.; Linton, D. D.; Newbound, G. C.; Clark, T. P.] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA; [Tudan, C.] BioAccurate Enterprises Inc, Vancouver, BC, Canada	Clark, TP (reprint author), Nexcyon Pharmaceut Inc, 644 W Washington Ave, Madison, WI 53703 USA.	clarktp@nexcyon.com			Nexcyon Pharmaceuticals, Inc.	The study was funded by Nexcyon Pharmaceuticals, Inc.	Brendel K, 2006, PHARM RES, V23, P2036, DOI 10.1007/s11095-006-9067-5; Deylon B., 1999, ANN STAT, V27, P94; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P21, DOI 10.1111/j.1365-2885.2012.01399.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P45, DOI 10.1111/j.1365-2885.2012.01409.x; Freise KJ, 2012, J VET PHARMACOL THER, V35, P27, DOI 10.1111/j.1365-2885.2012.01411.x; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Girard P., 2005, POP APPR GROUP EUR P; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Holton L, 2001, VET REC, V148, P525, DOI 10.1136/vr.148.17.525; Jonsson E. N., 2007, PHARMACOMETRICS SCI, P183; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Linton DD, 2012, J VET PHARMACOL THER, V35, P53, DOI 10.1111/j.1365-2885.2012.01408.x; Muir WW, 1995, HDB VET ANESTHESIA; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; Ohtsuka H, 2001, JAPANESE PHARM THERA, V29, P877; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Savic RM, 2009, AAPS J, V11, P558, DOI 10.1208/s12248-009-9133-0; Savides MC, 2012, J VET PHARMACOL THER, V35, P35, DOI 10.1111/j.1365-2885.2012.01410.x; Wahlby U, 2002, AAPS PHARMSCI, V4	22	14	14	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	AUG	2012	35			2	SI		65	72		10.1111/j.1365-2885.2012.01407.x			8	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	963IO	WOS:000305614000008	22731777				2020-06-30	J	Ramos-Miguel, A; Garcia-Sevilla, JA				Ramos-Miguel, A.; Garcia-Sevilla, J. A.			CROSSTALK BETWEEN CDK5 AND MEK-ERK SIGNALLING UPON OPIOID RECEPTOR STIMULATION LEADS TO UPREGULATION OF ACTIVATOR P25 AND MEK1 INHIBITION IN RAT BRAIN	NEUROSCIENCE			English	Article						opioid receptors; cdk5; p25/p35; MEK-ERK; SL327; MDL28170	CYCLIN-DEPENDENT KINASE-5; FOCAL CEREBRAL-ISCHEMIA; DOMAIN FADD PROTEIN; LOCOMOTOR SENSITIZATION; SYNAPTIC PLASTICITY; ANALGESIC TOLERANCE; APOPTOTIC PATHWAYS; ALZHEIMERS-DISEASE; TREATED RATS; M-CALPAIN	Cyclin-dependent kinase 5 (cdk5) participates in opioid receptor signalling through complex molecular mechanisms. The acute effects of selective mu-(fentanyl) and delta-(SNC-80) opioid receptor agonists, as well as the chronic effects of morphine (the prototypic opiate agonist mainly acting at mu-receptors), modulating cdk5 and activators p35/p25 and their interactions with neurotoxic/apoptotic factors, dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and extracellular signal-regulated kinase (ERK) were quantified (Western Blot analyses) in the rat corpus striatum and/or cerebral cortex. To assess the involved mechanisms, MDL28170 was used to inhibit calpain activity and SL327 to disrupt MEK (ERK kinase)-ERK activation. Acute fentanyl (0.1 mg/kg) and SNC-80 (10 mg/kg) induced rapid (7-60 min) 2- to 4-fold increases of p25 content, without induction of cdk5/p25 pro-apoptotic c-Jun NH2-terminal protein kinase or aberrant cleavage of poly(ADP-ribose)-polymerase-1, a hallmark of apoptosis. In contrast, fentanyl and SNC-80 stimulated cdk5-mediated p-Thr75 DARPP-32 (+116-166%; PKA inhibition) and p-Thr286 MEK1 (+21-82%; MEK inactivation), and this latter effect resulted in uncoupling of MEK to ERK signals. Calpain inhibition with MDL28170 (cleavage of p35 to p25) attenuated fentanyl-induced p25 accumulation (-57%), but not the stimulation of p-Thr286 MEK1 or p-Thr75 DARPP-32. MEK-ERK inhibition with SL327 fully prevented fentanyl-induced p25 upregulation. Notably, chronic morphine treatment (10-100 mg/kg for 6 days) also increased p25 content and p25/p35 ratio (and activated/inactivated MEK1) in rat brain cortex, which indicated that p25 upregulation persisted under the sustained stimulation of mu-opioid receptors. The results demonstrate that the acute stimulation of opioid receptors leads to upregulation of p25 activator through a MEK-ERK and calpain-dependent pathway, and to disruption of MEK-ERK signalling by a cdk5/p35-induced MEK1 inhibition. Moreover, the effects induced by the sustained stimulation of mu-receptors with morphine suggest the participation of cdk5/p25 complex in opiate-induced long-term neuroplasticity. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Garcia-Sevilla, J. A.] UIB, Inst Univ Invest Ciancies Salut IUNICS, Lab Neurofarmacol, E-07122 Palma De Mallorca, Spain; Redes Temat Invest Cooperat Salud Red Trastornos, E-07122 Palma De Mallorca, Spain	Garcia-Sevilla, JA (reprint author), UIB, Inst Univ Invest Ciancies Salut IUNICS, Lab Neurofarmacol, Cra Valldemossa Km 7-5, E-07122 Palma De Mallorca, Spain.	jesus.garcia-sevilla@uib.es	Ramos-Miguel, Alfredo/U-4377-2019; Garcia-Sevilla, Jesus/K-7921-2014	Ramos-Miguel, Alfredo/0000-0001-6259-1836; 	Ministerio de Ciencia e Innovacion (MICINN)Spanish Government [SAF2008-01311, SAF2011-29918]; Ministerio de Economia y Competitividad (MINECO); Fondo Europeo de Desarrollo Regional (FEDER), Spain; Redes Tematicas de Investigacion Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA) [RD06/0001/0003]; Instituto de Salud Carlos III (MICINN/MINECO/FEDER, Madrid), Spain	The study was supported in part by grants SAF2008-01311 and SAF2011-29918 from Ministerio de Ciencia e Innovacion (MICINN), Ministerio de Economia y Competitividad (MINECO), and Fondo Europeo de Desarrollo Regional (FEDER), Spain. The research was also funded by Redes Tematicas de Investigacion Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA, RD06/0001/0003), Instituto de Salud Carlos III (MICINN/MINECO/FEDER, Madrid), Spain. JAG-S is a member of the Institut d'Estudis Catalans (Barcelona, Catalonia, Spain).	Alvaro-Bartolome M, 2011, NEUROSCIENCE, V196, P1, DOI 10.1016/j.neuroscience.2011.08.074; Angelo M, 2006, J NEUROCHEM, V99, P353, DOI 10.1111/j.1471-4159.2006.04040.x; Asensio VJ, 2006, EUR J PHARMACOL, V539, P49, DOI 10.1016/j.ejphar.2006.04.001; Audet N, 2008, J BIOL CHEM, V283, P15078, DOI 10.1074/jbc.M707941200; Barnett DGS, 2011, BRAIN RES BULL, V85, P9, DOI 10.1016/j.brainresbull.2010.11.016; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Benavides DR, 2004, ANN NY ACAD SCI, V1025, P335, DOI 10.1196/annals.1316.041; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Brami-Cherrier K, 2009, J NEUROCHEM, V108, P1323, DOI 10.1111/j.1471-4159.2009.05879.x; Mlewski EC, 2008, ANN NY ACAD SCI, V1139, P89, DOI 10.1196/annals.1432.039; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chi OZ, 2010, PHARMACOLOGY, V85, P153, DOI 10.1159/000269811; Christie MJ, 2008, BRIT J PHARMACOL, V154, P384, DOI 10.1038/bjp.2008.100; Contet C, 2008, NEUROPHARMACOLOGY, V54, P475, DOI 10.1016/j.neuropharm.2007.10.015; Duric V, 2010, NAT MED, V16, P1328, DOI 10.1038/nm.2219; Eitan S, 2003, J NEUROSCI, V23, P8360; El-Rifai W, 2002, CANCER RES, V62, P4061; Engmann O, 2011, BIOL PSYCHIAT, V70, P159, DOI 10.1016/j.biopsych.2011.04.011; Ferrer-Alcon M, 2003, NEUROPSYCHOPHARMACOL, V28, P947, DOI 10.1038/sj.npp.1300095; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Garcia-Fuster MJ, 2008, NEUROSCIENCE, V157, P105, DOI 10.1016/j.neuroscience.2008.09.002; Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Hisanaga S, 2010, J NEUROCHEM, V115, P1309, DOI 10.1111/j.1471-4159.2010.07050.x; Garcia-Fuster M, 2008, NEUROPHARMACOLOGY, V55, P886, DOI 10.1016/j.neuropharm.2008.06.071; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lai KO, 2009, BBA-MOL BASIS DIS, V1792, P741, DOI 10.1016/j.bbadis.2009.05.001; Lee AM, 2008, ANN NY ACAD SCI, V1141, P22, DOI 10.1196/annals.1441.022; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lindskog M, 1999, EUR J NEUROSCI, V11, P2182, DOI 10.1046/j.1460-9568.1999.00597.x; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Meyer DA, 2008, P NATL ACAD SCI USA, V105, P18561, DOI 10.1073/pnas.0806078105; Moranta D, 2007, J NEUROSCI RES, V85, P656, DOI 10.1002/jnr.21140; Narita M, 2006, J NEUROCHEM, V97, P1494, DOI 10.1111/j.1471-4159.2006.03849.x; Narita M, 2005, J NEUROCHEM, V93, P1463, DOI 10.1111/j.1471-4159.2005.03136.x; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Ramos-Miguel A, 2011, J PSYCHOPHARMACOL, V25, P1691, DOI 10.1177/0269881110387842; Ramos-Miguel A, 2010, EUR NEUROPSYCHOPHARM, V20, P49, DOI 10.1016/j.euroneuro.2009.08.005; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Scheggi S, 2004, J NEUROCHEM, V90, P792, DOI 10.1111/j.1471-4159.2004.02510.x; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; Shen CP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-36; Sun KH, 2009, MOL BIOL CELL, V20, P4611, DOI 10.1091/mbc.E09-05-0433; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Takahashi S, 2005, P NATL ACAD SCI USA, V102, P1737, DOI 10.1073/pnas.0409456102; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474; Torres-Altoro MI, 2011, J NEUROCHEM, V119, P303, DOI 10.1111/j.1471-4159.2011.07428.x; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x; Valjent E, 2001, EUR J NEUROSCI, V14, P342, DOI 10.1046/j.0953-816x.2001.01652.x; Wang SH, 2008, BRAIN RES BULL, V76, P90, DOI 10.1016/j.brainresbull.2007.12.006; Xie WY, 2009, J NEUROSCI, V29, P3551, DOI 10.1523/JNEUROSCI.0415-09.2009; Yger M, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00056; Zadran S, 2010, J NEUROSCI, V30, P1086, DOI 10.1523/JNEUROSCI.5120-09.2010; Zhai HF, 2008, CELL MOL NEUROBIOL, V28, P157, DOI 10.1007/s10571-007-9240-3	60	20	20	2	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JUL 26	2012	215						17	30		10.1016/j.neuroscience.2012.04.035			14	Neurosciences	Neurosciences & Neurology	963XY	WOS:000305659500002	22537847				2020-06-30	J	Hagelberg, N; Aalto, S; Tuominen, L; Pesonen, U; Nagren, K; Hietala, J; Scheinin, H; Pertovaara, A; Martikainen, IK				Hagelberg, Nora; Aalto, Sargo; Tuominen, Lauri; Pesonen, Ullamari; Nagren, Kjell; Hietala, Jarmo; Scheinin, Harry; Pertovaara, Antti; Martikainen, Ilkka K.			Striatal mu-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects	NEUROSCIENCE LETTERS			English	Article						[C-11]carfentanil; mu-Opioid receptor; Pain; Positron emission tomography; Striatum	AFFECTIVE RESPONSES; TEST-RETEST; HUMAN BRAIN; IN-VIVO; BINDING; PET; MORPHINE	Previous PET studies in healthy humans have shown that brain mu-opioid receptor activation during experimental pain is associated with reductions in the sensory and affective ratings of the individual pain experience. The aim of this study was to find out whether brain mu-opioid receptor binding at the resting state, in absence of painful stimulation, can be a long-term predictor of experimental pain sensitivity. We measured mu-opioid receptor binding potential (BPND) with mu-opioid receptor selective radiotracer [C-11]carfentanil and positron emission tomography (PET) in 12 healthy male subjects. Later, we recruited these subjects to participate in a separate psychophysical testing session to measure cold pressor pain threshold, cold pressor pain tolerance and tactile sensitivity with von Frey monofilaments. We used both voxel-by-voxel and region-of-interest image analyses to examine the potential associations between mu-opioid receptor BPND and psychophysical measures. The results show that striatal mu-opioid receptor BPND predicts cold pressor pain threshold, but not cold pressor pain tolerance or tactile sensitivity. This finding suggests that striatal mu-opioid receptor density is involved in setting individual pain threshold. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Martikainen, Ilkka K.] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Hagelberg, Nora] Turku Univ Hosp, Pain Clin, FIN-20520 Turku, Finland; [Hagelberg, Nora] Turku Univ Hosp, Dept Anaesthesiol Intens Care Emergency Care & Pa, FIN-20520 Turku, Finland; [Hagelberg, Nora; Aalto, Sargo; Tuominen, Lauri; Nagren, Kjell; Hietala, Jarmo; Scheinin, Harry] Turku PET Ctr, Turku, Finland; [Aalto, Sargo] Abo Akad Univ, Dept Psychol, Turku, Finland; [Tuominen, Lauri; Hietala, Jarmo] Univ Turku, Dept Psychiat, Turku, Finland; [Pesonen, Ullamari; Scheinin, Harry] Univ Turku, Inst Biomed, Dept Pharmacol Drug Dev & Therapeut, Turku, Finland; [Nagren, Kjell] Odense Univ Hosp, Dept Nucl Med, PET & Cyclotron Unit, DK-5000 Odense, Denmark; [Pertovaara, Antti] Univ Helsinki, Inst Biomed, Dept Physiol, Helsinki, Finland; [Martikainen, Ilkka K.] Univ Turku, Inst Biomed, Dept Physiol, Turku, Finland; [Martikainen, Ilkka K.] Tampere Univ Hosp, Dept Radiol, Tampere, Finland	Martikainen, IK (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	ilkka.martikainen@utu.fi	Nagren, Kjell/AAE-7039-2019; Aalto, Sargo/K-1757-2013	Aalto, Sargo/0000-0002-8924-5447; Hietala, Jarmo/0000-0002-3179-6780; Pertovaara, Antti/0000-0002-8590-7220; Pesonen, Ullamari/0000-0002-9962-212X; Scheinin, Harry/0000-0002-1171-3511	Academy of FinlandAcademy of Finland; Finnish Association for the Study of Pain; Paulo Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; Swedish Cultural Foundation in Finland, Helsinki, Finland	This study was supported by grants from the Academy of Finland, Finnish Association for the Study of Pain, Paulo Foundation, Sigrid Juselius Foundation, and Swedish Cultural Foundation in Finland, Helsinki, Finland. We thank Elina Sormunen, BM, for technical assistance.	Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Casey KL, 2000, J NEUROPHYSIOL, V84, P525; Cleeland CS, 1996, NEUROPSYCHOPHARMACOL, V15, P252, DOI 10.1016/0893-133X(95)00205-R; Comer SD, 2010, PSYCHOPHARMACOLOGY, V208, P45, DOI 10.1007/s00213-009-1703-4; Gear RW, 2011, EXP NEUROL, V229, P502, DOI 10.1016/j.expneurol.2011.03.021; GEAR RW, 1995, J NEUROSCI, V15, P3154; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; JARVIK LF, 1981, PSYCHOPHARMACOLOGY, V75, P124, DOI 10.1007/BF00432173; JONES SF, 1988, PAIN, V34, P117, DOI 10.1016/0304-3959(88)90156-X; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lundberg J, 2006, SYNAPSE, V60, P256, DOI 10.1002/syn.20297; Martikainen IK, 2005, NEUROSCI LETT, V376, P149, DOI 10.1016/j.neulet.2004.11.045; RAINVILLE P, 1992, SOMATOSENS MOT RES, V9, P265, DOI 10.3109/08990229209144776; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Ribeiro SC, 2005, PROG NEURO-PSYCHOPH, V29, P1264, DOI 10.1016/j.pnpbp.2005.08.011; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	22	18	18	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 11	2012	521	1					11	14		10.1016/j.neulet.2012.05.042			4	Neurosciences	Neurosciences & Neurology	974PG	WOS:000306448100003	22622175				2020-06-30	J	Tuominen, L; Salo, J; Hirvonen, J; Nagren, K; Laine, P; Melartin, T; Isometsa, E; Viikari, J; Raitakari, O; Keltikangas-Jarvinen, L; Hietala, J				Tuominen, Lauri; Salo, Johanna; Hirvonen, Jussi; Nagren, Kjell; Laine, Pauliina; Melartin, Tarja; Isometsa, Erkki; Viikari, Jorma; Raitakari, Olli; Keltikangas-Jarvinen, Liisa; Hietala, Jarmo			Temperament trait Harm Avoidance associates with mu-opioid receptor availability in frontal cortex: A PET study using [C-11]carfentanil	NEUROIMAGE			English	Article							MAJOR DEPRESSION; INDIVIDUAL-DIFFERENCES; PERSONALITY-TRAITS; ANTERIOR CINGULATE; ANXIETY; BINDING; STRESS; AMYGDALA; MODEL; CIRCUITRY	Harm Avoidance is a temperament trait that associates with sensitivity to aversive and non-rewarding stimuli, higher anticipated threat and negative emotions during stress as well as a higher risk for affective disorders. The neurobiological correlates of interindividual differences in Harm Avoidance are largely unknown. We hypothesized that variability in Harm Avoidance trait would be explained by differences in the activity of p-opioid system as the opioid system is known to regulate affective states and stress sensitivity. Brain p-opioid receptor availability was measured in 22 healthy subjects using positron emission tomography and [11(C)]carfentanil, a selective mu-opioid receptor agonist. The subjects were selected from a large Finish population-based cohort (N = 2075) on the basis of their pre-existing Temperament and Character Scores. Subjects scoring consistently in the upper (10) and lower (12) quartiles for the Harm Avoidance trait were studied. High Harm Avoidance score associated with high p-opioid receptor availability (i.e. lower endogenous p-opioid drive) in anterior cingulate cortex, ventromedial and dorsolateral prefrontal cortices and anterior insular cortex. These associations were driven by two subscales of Harm Avoidance; Shyness with Strangers and Fatigability and Asthenia. In conclusion, higher Harm Avoidance score in healthy subjects is associated with higher p-opioid availability in regions involved in the regulation of anxiety as well as in the control of emotions, affective component of pain and interoceptive awareness. The results have relevance in the research of vulnerability factors for affective disorders. (c) 2012 Elsevier Inc. All rights reserved.	[Tuominen, Lauri; Hirvonen, Jussi; Laine, Pauliina; Hietala, Jarmo] Univ Turku, Dept Psychiat, Turku 20700, Finland; [Tuominen, Lauri; Hirvonen, Jussi; Hietala, Jarmo] Turku Univ, Cent Hosp, Turku PET Ctr, Turku, Finland; [Salo, Johanna; Keltikangas-Jarvinen, Liisa] Univ Helsinki, Dept Behav Sci, Helsinki, Finland; [Nagren, Kjell] Odense Univ Hosp, PET & Cyclotron Unit, Dept Nucl Med, Odense, Denmark; [Melartin, Tarja; Isometsa, Erkki] Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland; [Viikari, Jorma] Univ Turku, Dept Internal Med, Turku 20700, Finland; [Raitakari, Olli] Univ Turku, Dept Clin Physiol, Turku 20700, Finland	Hietala, J (reprint author), Univ Turku, Dept Psychiat, Kunnallissairaalantie 20,Bldg 9, Turku 20700, Finland.	jahi@utu.fi	Hirvonen, Jussi/AAC-1864-2020; Nagren, Kjell/AAE-7039-2019; Isometsa, Erkki/K-8579-2014	Isometsa, Erkki/0000-0001-5956-2399			AMIR S, 1980, NEUROSCI BIOBEHAV R, V4, P77, DOI 10.1016/0149-7634(80)90027-5; Asakawa A, 1998, NEUROREPORT, V9, P2265, DOI 10.1097/00001756-199807130-00022; Baeken C, 2009, BRAIN RES, V1296, P94, DOI 10.1016/j.brainres.2009.08.010; Bilkei-Gorzo A, 2008, PSYCHONEUROENDOCRINO, V33, P425, DOI 10.1016/j.psyneuen.2007.12.010; Borg J, 2003, AM J PSYCHIAT, V160, P1965, DOI 10.1176/appi.ajp.160.11.1965; Buckholtz JW, 2008, MOL PSYCHIATR, V13, P313, DOI 10.1038/sj.mp.4002020; Carver CS, 2006, PSYCHIAT RES, V144, P1, DOI 10.1016/j.psychres.2006.03.013; Cloninger C.R., 1994, TEMPERAMENT CHARACTE; Cloninger CR, 2006, J AFFECT DISORDERS, V92, P35, DOI 10.1016/j.jad.2005.12.034; Cloninger CR, 1997, DEV PSYCHOPATHOL, V9, P881, DOI 10.1017/S095457949700148X; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008; CLONINGER CR, 1986, PSYCHIAT DEV, V4, P167; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Elovainio M, 2004, J AFFECT DISORDERS, V83, P227, DOI 10.1016/j.jad.2004.06.005; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Etkin A, 2006, NEURON, V51, P871, DOI 10.1016/j.neuron.2006.07.029; Etkin A, 2010, CURR TOP BEHAV NEURO, V2, P251, DOI 10.1007/7854_2009_5; Fichna J, 2007, NEUROPSYCHOPHARMACOL, V32, P813, DOI 10.1038/sj.npp.1301149; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Gil S, 2006, PSYCHOSOM MED, V68, P904, DOI 10.1097/01.psy.0000242124.21796.f8; Heponiemi T, 2005, COGNITION EMOTION, V19, P879, DOI 10.1080/02699930541000011; Hirvonen J, 2008, J CEREBR BLOOD F MET, V28, P1059, DOI 10.1038/sj.jcbfm.9600607; Iidaka T, 2006, BRAIN RES, V1125, P85, DOI 10.1016/j.brainres.2006.09.015; Ingman K, 2005, NEUROPSYCHOPHARMACOL, V30, P2245, DOI 10.1038/sj.npp.1300790; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; KALIN NH, 1988, BRAIN RES, V440, P285, DOI 10.1016/0006-8993(88)90997-3; Kalisch R, 2006, J COGNITIVE NEUROSCI, V18, P1266, DOI 10.1162/jocn.2006.18.8.1266; Karlsson H, 2011, MOL PSYCHIATR, V16, P282, DOI 10.1038/mp.2009.126; Kendler KS, 2006, ARCH GEN PSYCHIAT, V63, P1113, DOI 10.1001/archpsyc.63.10.1113; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Larsen P, 1997, APPL RADIAT ISOTOPES, V48, P153, DOI 10.1016/S0969-8043(96)00177-7; Lesscher HMB, 2003, EUR J NEUROSCI, V17, P1006, DOI 10.1046/j.1460-9568.2003.02502.x; Levesque J, 2003, BIOL PSYCHIAT, V53, P502, DOI 10.1016/S0006-3223(02)01817-6; Liberzon I, 2007, BIOL PSYCHIAT, V61, P1030, DOI 10.1016/j.biopsych.2006.06.021; Love TM, 2009, ARCH GEN PSYCHIAT, V66, P1124, DOI 10.1001/archgenpsychiatry.2009.134; McConalogue K, 1999, NEUROSCIENCE, V90, P1051, DOI 10.1016/S0306-4522(98)00514-4; Mechias ML, 2010, NEUROIMAGE, V49, P1760, DOI 10.1016/j.neuroimage.2009.09.040; Miettunen J, 2011, COMPR PSYCHIAT; Moresco FM, 2002, NEUROIMAGE, V17, P1470, DOI 10.1006/nimg.2002.1239; Nagren K., 2003, J LABEL COMPD RAD S1, V46; O'Gorman RL, 2006, NEUROIMAGE, V31, P489, DOI 10.1016/j.neuroimage.2005.12.048; Phelps EA, 2004, NEURON, V43, P897, DOI 10.1016/j.neuron.2004.08.042; Preter M, 2008, PROG NEURO-PSYCHOPH, V32, P603, DOI 10.1016/j.pnpbp.2007.07.029; Prossin AR, 2010, AM J PSYCHIAT, V167, P925, DOI 10.1176/appi.ajp.2010.09091348; Rabiner EA, 2002, NEUROIMAGE, V15, P620, DOI 10.1006/nimg.2001.0984; Raitakari OT, 2008, INT J EPIDEMIOL, V37, P1220, DOI 10.1093/ije/dym225; Ravaja N, 2006, J PERS, V74, P287, DOI 10.1111/j.1467-6494.2005.00376.x; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Reimold M, 2008, MOL PSYCHIATR, V13, P606, DOI 10.1038/sj.mp.4002149; SCHEDLOWSKI M, 1995, PSYCHONEUROENDOCRINO, V20, P103, DOI 10.1016/0306-4530(94)00048-4; Schreckenberger M, 2008, J NUCL MED, V49, P1257, DOI 10.2967/jnumed.108.050849; Sehlmeyer C, 2011, PSYCHOL MED, V41, P789, DOI 10.1017/S0033291710001248; Simmons A, 2006, NEUROIMAGE, V29, P655, DOI 10.1016/j.neuroimage.2005.07.040; Urry HL, 2006, J NEUROSCI, V26, P4415, DOI 10.1523/JNEUROSCI.3215-05.2006; Youn T, 2002, BIOL PSYCHOL, V60, P109, DOI 10.1016/S0301-0511(02)00047-9; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952; ZUBIN J, 1977, J ABNORM PSYCHOL, V86, P103, DOI 10.1037/0021-843X.86.2.103	61	23	24	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUL 2	2012	61	3					670	676		10.1016/j.neuroimage.2012.03.063			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	951OL	WOS:000304729800016	22484309				2020-06-30	J	Moeller, C; Pawlowski, J; Pappas, AL; Fargo, K; Welch, K				Moeller, Carl; Pawlowski, Julius; Pappas, Ana L.; Fargo, Keith; Welch, Kevin			The safety and efficacy of intravenous ketorolac in patients undergoing primary endoscopic sinus surgery: a randomized, double-blinded clinical trial	INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY			English	Article						ketorolac; endoscopic sinus surgery; nonsteroidal antiinflammatory agents; postoperative hemorrhage; postoperative complications; postoperative pain	POSTOPERATIVE PAIN MANAGEMENT; ANTIINFLAMMATORY DRUGS; ANALGESIC EFFICACY; REDUCING PAIN; TONSILLECTOMY; HEMORRHAGE; TROMETHAMINE; PARECOXIB; RECOVERY; CHILDREN	Background: Ketorolac (KT) is an intravenous (IV) nonsteroidal anti-inflammatory drug (NSAID) for acute, moderate pain. KT is safe, but may be linked to increased risk of post-tonsillectomy hemorrhage. The safety and efficacy of KT following primary endoscopic sinus surgery (ESS) is unknown. Methods: All patients underwent primary ESS and septoplasty. Patients randomly received either IVKT 30 mg or IV fentanyl (IVF) 25 mu g postprocedure. Postoperative pain was recorded at 0, 30, and 60 minutes via visual analog scale (VAS), and patients received as needed fentanyl and hydrocodone/ acetaminophen for additional pain. Postoperative bleeding questionnaires were completed on postoperative days 1 and 7 (POD 1 and POD 7). Preoperative and POD 7 hemoglobin was assessed. Results: A total of 34 patients enrolled in the study over 1 year. Sixteen patients received IVKT and 18 patients received IVF. The average time of administration was 23 +/- 6 minutes postprocedure. There were no significant differences in preoperative and postoperative hemoglobin levels between groups and bleeding assessments. There were no incidences of postoperative hemorrhage. There was no significant difference in pain VAS between the IVKT and IVF groups (3.5, 3.2, 2.1 vs 3.0, 4.4, 3.8 at 0, 30, and 60 minutes, respectively). There was no significant difference between the number of doses of supplemental analgesics for the IVKT and IVF groups (2.0 vs 3.4 doses IV; 1.0 vs 1.4 doses orally, respectively). Conclusion: In this study, IVKT was a safe analgesic in the setting of primary ESS. There was no increased risk of hemorrhage or acute blood-loss anemia. IVKT did not appear to offer statistically significant pain control over IVF. (C) 2012 ARS-AAOA, LLC.	[Welch, Kevin] Loyola Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Sch Med, Maywood, IL 60153 USA; [Pawlowski, Julius; Pappas, Ana L.] Loyola Univ, Sch Med, Dept Anesthesiol, Maywood, IL 60153 USA	Welch, K (reprint author), Loyola Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Sch Med, Bldg 105,Rm 1870,2160 S 1st Ave, Maywood, IL 60153 USA.	kwelch1@lumc.edu					Agrawal A, 1999, OTOLARYNG HEAD NECK, V120, P335, DOI 10.1016/S0194-5998(99)70271-8; Al-Qudah M, 2010, ANN OTO RHINOL LARYN, V119, P266, DOI 10.1177/000348941011900410; Antisdel JL, 2009, OTOLARYNG HEAD NECK, V141, P353, DOI 10.1016/j.otohns.2009.06.078; Bailey R, 1997, LARYNGOSCOPE, V107, P166, DOI 10.1097/00005537-199702000-00006; Cho DY, 2011, INT FORUM ALLERGY RH, V1, P212, DOI 10.1002/alr.20040; Dawkins TN, 2009, CARDIOL YOUNG, V19, P105, DOI 10.1017/S1047951109003527; Dsida R, 2004, ANESTHESIOLOGY, V100, P749, DOI 10.1097/00000542-200403000-00051; GALLAGHER JE, 1995, LARYNGOSCOPE, V105, P606, DOI 10.1288/00005537-199506000-00008; GUNTER JB, 1995, ANESTH ANALG, V81, P1136, DOI 10.1097/00000539-199512000-00004; Ikeda Y, 1977, Keio J Med, V26, P213; Issioui T, 2002, ANESTHESIOLOGY, V97, P931, DOI 10.1097/00000542-200210000-00027; Judkins JH, 1996, ARCH OTOLARYNGOL, V122, P937; Keles GT, 2010, BRAZ J MED BIOL RES, V43, P806, DOI 10.1590/S0100-879X2010000800015; Kemppainen TP, 2007, LARYNGOSCOPE, V117, P1434, DOI 10.1097/MLG.0b013e3180600a16; Leykin Y, 2008, MINERVA ANESTESIOL, V74, P475; Lin J C, 1999, Heart Surg Forum, V2, P169; Marret E, 2003, ANESTHESIOLOGY, V98, P1497; Mehlisch DR, 2003, J ORAL MAXIL SURG, V61, P1030, DOI 10.1016/S0278-2391(03)00315-X; Niemi TT, 2000, ACTA ANAESTH SCAND, V44, P69, DOI 10.1034/j.1399-6576.2000.440113.x; Orlandi RR, 2004, LARYNGOSCOPE, V114, P1541, DOI 10.1097/00005537-200409000-00007; Reinhart DJ, 1997, CAN J ANAESTH, V44, P377, DOI 10.1007/BF03014457; Roche Laboratories, 1995, FDA B DEAR HEALTHC P; Romsing J, 1998, ACTA ANAESTH SCAND, V42, P770, DOI 10.1111/j.1399-6576.1998.tb05320.x; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Shin D, 2001, J CRANIOFAC SURG, V12, P129, DOI 10.1097/00001665-200103000-00007; Splinter WM, 1996, CAN J ANAESTH, V43, P560, DOI 10.1007/BF03011766; SUTTERS KA, 1995, PAIN, V61, P145, DOI 10.1016/0304-3959(94)00166-C; Thaler ER, 1997, AM J RHINOL, V11, P409, DOI 10.2500/105065897780914929; Weitzel EK, 2008, AM J RHINOL, V22, P302, DOI 10.2500/ajr.2008.22.3171	29	13	13	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2042-6976	2042-6984		INT FORUM ALLERGY RH	Int. Forum Allergy Rhinol.	JUL-AUG	2012	2	4					342	347		10.1002/alr.21028			6	Otorhinolaryngology	Otorhinolaryngology	007ZR	WOS:000308927400014	22411639				2020-06-30	J	Sullivan, JT; Higgins, N; Toledo, P; Scavone, BM; McCarthy, RJ; Wong, CA				Sullivan, J. T.; Higgins, N.; Toledo, P.; Scavone, B. M.; McCarthy, R. J.; Wong, C. A.			The effect of intravenous magnesium therapy on the duration of intrathecal fentanyl labor analgesia	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Labor analgesia; Intrathecal opioid; Fentanyl; Magnesium	SPINAL-ANESTHESIA; POSTOPERATIVE ANALGESIA; PAIN RELIEF; LAPAROSCOPIC CHOLECYSTECTOMY; ORTHOPEDIC-SURGERY; CONTROLLED-TRIAL; SULFATE; REQUIREMENTS; INFUSION; PREECLAMPSIA	Background: Magnesium has been reported to augment the analgesic effects of opioids when co-administered into the cerebrospinal fluid. The purpose of this study was to determine the influence of intravenous magnesium therapy administered for preeclampsia on the duration of intrathecal fentanyl analgesia for labor. Methods: Thirty-four nulliparous parturients having labor induced for preeclampsia and receiving intravenous magnesium therapy were recruited. Thirty-four nulliparous patients having labor induced for elective or medical reasons were recruited as controls. At request for analgesia, baseline serum magnesium levels were obtained and combined spinal-epidural analgesia was initiated with intrathecal fentanyl 25 mu g. Before injection of fentanyl, a sample of cerebrospinal fluid was obtained for magnesium assay. An epidural catheter was sited but no additional medications were administered until the second request for analgesia. The primary outcome was duration of intrathecal fentanyl analgesia. Results: There was no difference in the median duration of analgesia between the magnesium [79 min (95% CI 76 to 82)] and control groups [69 min (95% CI 56 to 82)] (difference between medians: 10 min (95% CI 4 to 21 min; P = 0.16). There was neither a relationship between the serum and cerebrospinal fluid magnesium concentrations nor the cerebrospinal magnesium concentration and duration of intrathecal fentanyl analgesia. Conclusions: Intravenous magnesium therapy at doses typically used for seizure prophylaxis in preeclampsia did not influence the duration of intrathecal fentanyl labor analgesia. However, this study may have been underpowered to detect a difference and future study is warranted. (C) 2012 Elsevier Ltd. All rights reserved.	[Sullivan, J. T.; Higgins, N.; Toledo, P.; McCarthy, R. J.; Wong, C. A.] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA; [Scavone, B. M.] Univ Chicago, Med Ctr, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA	Sullivan, JT (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron St,F5-704, Chicago, IL 60611 USA.	sullivan@northwestern.edu	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311; Toledo, Paloma/0000-0003-4564-4849; Wong, Cynthia/0000-0002-7144-7008; Sullivan, John/0000-0001-5445-708X	Department of Anesthesiology, Northwestern Feinberg School of Medicine	This study was supported only by departmental funds from the Department of Anesthesiology, Northwestern Feinberg School of Medicine. The authors have no conflicts of interest to declare.	Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; Bhatia A, 2004, J CLIN ANESTH, V16, P262, DOI 10.1016/j.jclinane.2003.08.012; Bilir A, 2007, BRIT J ANAESTH, V98, P519, DOI 10.1093/bja/aem029; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Dayioglu H, 2009, J ANESTH, V23, P19, DOI 10.1007/s00540-008-0677-4; FONG J, 1995, OBSTET GYNECOL, V85, P444, DOI 10.1016/0029-7844(94)00413-8; Ghrab BE, 2009, ANN FR ANESTH, V28, P454, DOI 10.1016/j.annfar.2009.03.004; Hwang JY, 2010, BRIT J ANAESTH, V104, P89, DOI 10.1093/bja/aep334; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Levaux C, 2003, ANAESTHESIA, V58, P131, DOI 10.1046/j.1365-2044.2003.02999.x; Lysakowski C, 2007, ANESTH ANALG, V104, P1532, DOI 10.1213/01.ane.0000261250.59984.cd; Malleeswaran S, 2010, INT J OBSTET ANESTH, V19, P161, DOI 10.1016/j.ijoa.2009.08.007; MELZACK R, 1984, CAN MED ASSOC J, V130, P579; Mentes O, 2008, ACTA ANAESTH SCAND, V52, P1353, DOI 10.1111/j.1399-6576.2008.01816.x; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; Ozcan PE, 2007, J CARDIOTHOR VASC AN, V21, P827, DOI 10.1053/j.jvca.2006.11.013; Ryu JH, 2008, BRIT J ANAESTH, V100, P397, DOI 10.1093/bja/aem407; Saadawy IM, 2010, ACTA ANAESTH SCAND, V54, P549, DOI 10.1111/j.1399-6576.2009.02165.x; Seyhan TO, 2006, BRIT J ANAESTH, V96, P247, DOI 10.1093/bja/aei291; Tauzin-Fin P, 2006, EUR J ANAESTH, V23, P1055, DOI 10.1017/S0265021506001062; THURNAU GR, 1987, AM J OBSTET GYNECOL, V157, P1435, DOI 10.1016/S0002-9378(87)80239-9	21	4	4	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2012	21	3					212	216		10.1016/j.ijoa.2012.01.006			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	991ET	WOS:000307685000002	22632744				2020-06-30	J	Twycross, R; Prommer, EE; Mihalyo, M; Wilcock, A				Twycross, Robert; Prommer, Eric E.; Mihalyo, Mary; Wilcock, Andrew			Fentanyl (transmucosal)	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Review							BREAKTHROUGH CANCER PAIN; OPIOID-TOLERANT PATIENTS; BUCCAL SOLUBLE FILM; PEDIATRIC EMERGENCY-DEPARTMENT; LONG-TERM SAFETY; INTRANASAL FENTANYL; DOUBLE-BLIND; OPEN-LABEL; TRANSDERMAL FENTANYL; DOSE-TITRATION		[Twycross, Robert] Univ Oxford, Oxford, England; [Prommer, Eric E.] Mayo Clin Arizona, Scottsdale, AZ USA; [Mihalyo, Mary] Duquesne Univ, Mylan Sch Pharm, Pittsburgh, PA 15219 USA; [Wilcock, Andrew] Univ Nottingham, Nottingham NG7 2RD, England	Wilcock, A (reprint author), Nottingham Univ Hosp NHS Trust, Hayward House Macmillan Specialist Palliat Care U, Nottingham NG5 1PB, England.	andrew.wilcock@nottingham.ac.uk		Wilcock, Andrew/0000-0002-3214-1188			Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Baxter K., 2010, STOCKLEYS DRUG INTER; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Duncan A, 2002, PALLIATIVE MED, V16, P550, DOI 10.1191/0269216302pm610xx; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; England Ruth, 2011, BMJ Support Palliat Care, V1, P349, DOI 10.1136/bmjspcare-2011-000037; *EUR MED AG, 2009, ASS REP INST; European Medicines Agency, 2008, EFF EPAR SCI DISC; European Medicines Agency, 2010, ASS REP PECF; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Finn AL, 2012, CLIN DRUG INVEST, V32, P63, DOI 10.2165/11594670-000000000-00000; Finn Andrew L, 2011, J Pain Res, V4, P245, DOI 10.2147/JPR.S22641; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Freye Enno, 2007, Pain Pract, V7, P324, DOI 10.1111/j.1533-2500.2007.00157.x; Gardner-Nix J, 2001, J PAIN SYMPTOM MANAG, V22, P627, DOI 10.1016/S0885-3924(01)00321-9; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Markman JD, 2008, PAIN, V136, P227, DOI 10.1016/j.pain.2008.03.011; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Morii H, 2007, J PAIN SYMPTOM MANAG, V33, P5, DOI 10.1016/j.jpainsymman.2006.08.005; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Nalamachu SR, 2012, PAIN PRACT, V12, P449, DOI 10.1111/j.1533-2500.2011.00525.x; Nunez-Olarte JM, 2011, J PAIN SYMPTOM MANAG, V42, pE6, DOI 10.1016/j.jpainsymman.2011.07.006; Palliativedrugs. com, AGUUST 2003 NEWSLETT; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Sasson M, 2006, J PAIN SYMPTOM MANAG, V31, P389, DOI 10.1016/j.jpainsymman.2005.12.015; SAWE J, 1983, EUR J CLIN PHARMACOL, V24, P537, DOI 10.1007/BF00609900; Shear ML, 2010, AM J EMERG MED, V28, P847, DOI 10.1016/j.ajem.2009.04.011; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Takane H, 2005, ANN PHARMACOTHER, V39, P2139, DOI 10.1345/aph.1G370; U.S. Food and Drug Administration, 2009, SUMM REV; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2010, PAIN PRACT, V10, P287, DOI 10.1111/j.1533-2500.2010.00359.x	65	11	11	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2012	44	1					131	149		10.1016/j.jpainsymman.2012.05.001			19	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	981TI	WOS:000306993200016	22770488	Bronze			2020-06-30	J	Maier, C; Leclerc-Springer, J				Maier, C.; Leclerc-Springer, J.			Life-threatening fentanyl and propofol addiction. Interview with a survivor	ANAESTHESIST			German	Article						Opioids; Tilidine; Naloxone; Health personnel; Addiction	OF-THE-LITERATURE; NUCLEUS-ACCUMBENS; DRUG-ADDICTION; ABUSE; DOPAMINE; TILIDINE; DEATH; ANESTHETISTS; DEPENDENCE; MISUSE	Anesthesiologists have a well-known increased risk of substance abuse including the intravenous administration of opioids and propofol. However, katamnestic reports from the point of view of propofol-addicted anesthesiologists themselves are missing which would aid a better understanding of the dynamics and progress of addiction. This article presents an interview with a formerly addicted female anesthesiologist who after long-term abuse with oral tilidine combined with naloxone switched to intravenous administration of fentanyl and later on propofol. Several life-threatening incidents occurred but after some severe setbacks occupational rehabilitation outside the field of anesthesiology was successful following inpatient treatment. This case shows exemplarily in accordance with the current literature that warning signs in addicted physicians are often ignored by colleagues and supervisors and rehabilitation is possible under professional therapy and continuous surveillance. Additionally, this case emphasizes the necessity of controlling the distribution of propofol to reduce the life-threatening professional risk to anesthesiologists.	[Maier, C.] Ruhr Univ Bochum, Berufsgenossenschaftliches Univ Klinikum Bergmann, Abt Schmerzmed, D-44789 Bochum, Germany	Maier, C (reprint author), Ruhr Univ Bochum, Berufsgenossenschaftliches Univ Klinikum Bergmann, Abt Schmerzmed, Burkle de la Camp Pl 1, D-44789 Bochum, Germany.	christoph.maier@rub.de					Beaujouan L, 2005, ANN FR ANESTH, V24, P471, DOI 10.1016/j.annfar.2005.02.023; Boening JAL, 2001, J NEURAL TRANSM, V108, P755, DOI 10.1007/s007020170050; Boger RH, 2011, ARZNEIVERORDNUNGS RE, P254; Bonnet U, 2011, FORTSCHR NEUROL PSYC, V79, P442, DOI 10.1055/s-0031-1273411; Boyd JW, 2008, TXB SUBSTANCE ABUSE, V4, P609; Brennscheidt U, 2007, ARZNEIMITTELFORSCH, V57, P106; Bryson EO, 2011, INT ANESTHESIOL CLIN, V49, P173, DOI 10.1097/AIA.0b013e3181f2bcb0; CANADAY BR, 1993, CLIN PHARMACY, V12, P449; Cicero TJ, 2008, PAIN, V139, P127, DOI 10.1016/j.pain.2008.03.021; Cicero TJ, 2007, DRUG ALCOHOL DEPEN, V91, P115, DOI 10.1016/j.drugalcdep.2007.05.008; Collins GB, 2005, ANESTH ANALG, V101, P1457, DOI 10.1213/01.ANE.0000180837.78169.04; Daunderer M, 1977, DTSCH APOTH Z, V117, P1439; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; DIECKHOFER K, 1977, MUNCHEN MED WOCHEN, V119, P1431; Gatch MB, 2011, BEHAV PHARMACOL, V22, P718, DOI 10.1097/FBP.0b013e32834aff84; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gundel H, 1992, ANASTH INTENSIVMED, V27, P181; Heinzow B, 1979, DTSCH ARZTEBL, V15, P1003; Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; Iwersen-Bergmann S, 2001, INT J LEGAL MED, V114, P248, DOI 10.1007/s004149900129; JASINSKI DR, 1986, DRUG ALCOHOL DEPEN, V18, P273, DOI 10.1016/0376-8716(86)90059-1; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Kirby RR, 2009, ANESTH ANALG, V108, P1182, DOI 10.1213/ane.0b013e318198d45e; Kranioti EF, 2007, FORENSIC SCI INT, V167, P56, DOI 10.1016/j.forsciint.2005.12.027; Maulen B, 2010, ANAESTHESIST, V59, P395, DOI 10.1007/s00101-009-1660-7; Maier C, 2010, ANASTH INTENSIVMED, V51, P20; Maier C, 2010, ANASTH INTENSIV NOTF, V45, P648, DOI 10.1055/s-0030-1267531; Marshall EJ, 2008, OCCUP MED-OXFORD, V58, P334, DOI 10.1093/occmed/kqn081; Maulen B, 1996, KASSENARZT, V36, P48; Monroe T, 2011, SUBST USE MISUSE, V46, P1199, DOI 10.3109/10826084.2011.564705; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Pain L, 2002, ANESTH ANALG, V95, P915, DOI 10.1097/00000539-200210000-00022; Riezzo I, 2009, CLIN TOXICOL, V47, P358, DOI 10.1080/15563650902887842; Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093; Robledo P, 2010, CURR DRUG TARGETS, V11, P429, DOI 10.2174/138945010790980330; Roussin A, 2006, BRIT J ANAESTH, V97, P268, DOI 10.1093/bja/ael168; Roussin A, 2007, FUND CLIN PHARMACOL, V21, P459, DOI 10.1111/j.1472-8206.2007.00497.x; Schifano F, 2008, J CLIN PSYCHOPHARM, V28, P114, DOI 10.1097/JCP.0b013e3181612cdc; Schultz W, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-24; SIEGEL R K, 1978, National Institute on Drug Abuse Research Monograph, P119; Soyka M, 1997, ADDICTION, V92, P1369, DOI 10.1111/j.1360-0443.1997.tb02856.x; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; TRINKOFF AM, 1994, DRUG ALCOHOL DEPEN, V36, P215, DOI 10.1016/0376-8716(94)90147-3; TROJAN A, 1978, DRUG ALCOHOL DEPEN, V3, P383, DOI 10.1016/0376-8716(78)90010-8; Wallace JE, 2009, LANCET, V374, P1714, DOI 10.1016/S0140-6736(09)61424-0; WARD CF, 1992, ANESTHESIOLOGY, V77, P621, DOI 10.1097/00000542-199210000-00001; Wasan Ajay D, 2006, J Opioid Manag, V2, P16; Weetman DB, 2004, AM J HEALTH-SYST PH, V61, P1185, DOI 10.1093/ajhp/61.11.1185; Wilson C, 2010, CLIN TOXICOL, V48, P165, DOI 10.3109/15563651003757954; Wilson JE, 2008, ANAESTHESIA, V63, P616, DOI 10.1111/j.1365-2044.2008.05444.x; Wischmeyer PE, 2007, ANESTH ANALG, V105, P1066, DOI 10.1213/01.ane.0000270215.86253.30; Wise RA, 2008, NEUROTOX RES, V14, P169, DOI 10.1007/BF03033808; Wysowski DK, 2006, ANESTHESIOLOGY, V105, P1047, DOI 10.1097/00000542-200611000-00027; Xiong M, 2011, ANESTH ANALG, V113, P259, DOI 10.1213/ANE.0b013e318222af17; Yang B, 2011, ACTA PHARMACOL SIN, V32, P1460, DOI 10.1038/aps.2011.123; Yucel M, 2007, AUST NZ J PSYCHIAT, V41, P957, DOI 10.1080/00048670701689444; ZACNY JP, 1993, ANESTH ANALG, V77, P544; Zernikow B, 2008, DTSCH ARZTEBL INT, V105, P511, DOI 10.3238/arztebl.2008.0511	58	5	5	1	12	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	JUL	2012	61	7					601	607		10.1007/s00101-012-2036-y			7	Anesthesiology	Anesthesiology	976NO	WOS:000306591800005	22714402				2020-06-30	J	Smith, MD; Wang, Y; Cudnik, M; Smith, DA; Pakiela, J; Emerman, CL				Smith, Michael D.; Wang, Yang; Cudnik, Michael; Smith, Dawn A.; Pakiela, John; Emerman, Charles L.			THE EFFECTIVENESS AND ADVERSE EVENTS OF MORPHINE VERSUS FENTANYL ON A PHYSICIAN-STAFFED HELICOPTER	JOURNAL OF EMERGENCY MEDICINE			English	Article						helicopter; analgesia; analgesics; efficacy; adverse; reactions; fentanyl; morphine; prehospital	EMERGENCY-DEPARTMENT; RATING-SCALE; ACUTE PAIN; ANALGESIA; DISPARITIES; VALIDATION; SEDATION; SAFETY; TRAUMA; CARE	Background: Morphine and fentanyl are both frequently used in prehospital trauma patients, but due to limited formulary size, we sought to study whether both drugs should be included. Objectives: The purpose of this study was to evaluate the effectiveness and safety of fentanyl as compared to morphine for patients requiring analgesic medications for a traumatic injury during transport via a physician-staffed air medical service. Methods: Trauma patients were grouped by even and odd days (even - morphine 4 mg, odd - fentanyl 50 mu g). Patients were excluded based on age (< 18 or > 64 years), hypotension, inability to communicate a pain score (intubated), or known allergy to the study drugs. During the flight, medical crew assessed numeric pain score, vital signs, and incidence of pruritis or nausea. Results: There were 103 patients enrolled in the morphine arm and 97 patients in the fentanyl arm. The mean pain score at the beginning of enrollment was 8.0 +/- 2.0 in the morphine arm and 8.0 +/- 1.8 in the fentanyl arm. The mean final pain score was 5.8 +/- 2.7 in the morphine arm and 5.5 +/- 2.4 in the fentanyl arm (n.s. by either t-test or non-parametric testing). There was no significant difference in analgesia between fentanyl and morphine. There were no significant differences in the incidence of pruritis or vomiting between the two groups. Average transport time was 37 +/- 8 min in the morphine group, and 43 +/- 11 min in the fentanyl group. Average number of morphine doses was 3 +/- 1.2. For fentanyl, average number of doses was 3 +/- 1.3. Conclusion: In our study, there was not a significant difference in analgesic effectiveness between morphine and fentanyl. There was no significant difference in the incidence of adverse effects between the two drugs. Our study suggests that either drug can be used safely with equivalent effectiveness. (C) 2012 Elsevier Inc.	[Smith, Michael D.; Wang, Yang; Emerman, Charles L.] Metrohlth Med Ctr, Dept Emergency Med, Cleveland, OH 44109 USA; [Cudnik, Michael] Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA; [Smith, Dawn A.] Dept Bioeth, Akron, OH USA; [Pakiela, John] Akron Gen Med Ctr, Akron, OH USA	Smith, MD (reprint author), Metrohlth Med Ctr, Dept Emergency Med, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.		Smith, Michael/E-9855-2015	Smith, Michael/0000-0002-1634-9632			Abbuhl Frederick B, 2003, Prehosp Emerg Care, V7, P445; ADNET F, 2000, ANN FR ANESTH, V9, P56; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Bounes V, 2008, AM J EMERG MED, V26, P148, DOI 10.1016/j.ajem.2007.04.020; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; Cicero TJ, 2005, J PAIN, V6, P662, DOI 10.1016/j.jpain.2005.05.004; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863; Green CR, 2003, PAIN MED, V4, P277, DOI 10.1046/j.1526-4637.2003.03034.x; Innes G, 1999, J EMERG MED, V17, P145, DOI 10.1016/S0736-4679(98)00135-8; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Kendrick DB, 2005, AM J EMERG MED, V23, P828, DOI 10.1016/j.ajem.2005.07.009; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Krauss WC, 2011, J EMERG MED, V40, P182, DOI 10.1016/j.jemermed.2009.02.009; Mader Timothy J, 2003, J Emerg Nurs, V29, P322, DOI 10.1067/men.2003.107; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; Quazi S, 2008, AM J EMERG MED, V26, P462, DOI 10.1016/j.ajem.2007.05.007; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; THOMAS SH, 1996, AIR MED J, V15, P57; Tousignant-Laflamme Y, 2005, J PAIN, V6, P341, DOI 10.1016/j.jpain.2005.01.351; Ware LJ, 2006, PAIN MANAG NURS, V7, P117, DOI 10.1016/j.pmn.2006.06.005	25	21	22	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679			J EMERG MED	J. Emerg. Med.	JUL	2012	43	1					69	74		10.1016/j.jemermed.2011.05.018			6	Emergency Medicine	Emergency Medicine	978GP	WOS:000306729100014	21689900				2020-06-30	J	Thompson, EM; Andrews, DD; Christ-Libertin, C				Thompson, Elaine M.; Andrews, David D.; Christ-Libertin, Cheryl			Efficacy and Safety of Procedural Sedation and Analgesia for Burn Wound Care	JOURNAL OF BURN CARE & RESEARCH			English	Article							PRACTICE GUIDELINES; PAIN; DISTRESS; MANAGEMENT; INJURIES	The study aim was to quantify efficacy and patient safety of registered nurse-administered procedural sedation and analgesia in a regional burn center. The investigators conducted a review of procedural sedation forms for all pediatric and adult patients admitted to this burn center from January 1, 2005, through December 31, 2005, for demographic and clinical data including patient age, gender, body weight, TBSA, dates of burn injury and wound care procedures, length of procedure, pre- and postprocedural pain assessment, procedural sedation/analgesia medications and doses, adverse drug events, and related interventions. During the 12-month study period, a total of 328 burn patients received 1293 procedural sedation procedures; child subjects (<= 18 years) received 356 procedures and adult subjects (19-87 years) received 937 procedures. The mean (SD) length of the procedure was 60.1 (22.49) minutes with a range of 10 to 170 minutes. The mean subject age was 34.2 years (range: 6 weeks to 87 years), 67% were male, and the mean TBSA was 17% (0.5-68%). Ninety-four percent received fentanyl for analgesia and 85% received midazolam for anxiolysis and amnesia. The mean preprocedural pain score was 3.2 and the mean postprocedural pain score was 2 (t = 14.795; df = 1243; P < .001). Ten adverse events, all respiratory related, were documented in eight patients, two of whom experienced a second adverse event for an overall adverse event rate of 0.77%. No patient required intubation. Procedural sedation administered by a registered nurse competent in administration and monitoring in a burn center provided safe and effective pain management during wound care. (J Burn Care Res 2012;33:504-509)	[Thompson, Elaine M.] Akron Childrens Hosp, Paul & Carol David Fdn Burn Inst, Akron, OH 44308 USA; [Andrews, David D.] Akron Childrens Hosp, Dept Surg, Akron, OH 44308 USA; [Christ-Libertin, Cheryl] Akron Childrens Hosp, Ctr Excellence Nursing Educ, Akron, OH 44308 USA	Thompson, EM (reprint author), Akron Childrens Hosp, Paul & Carol David Fdn Burn Inst, 1 Perkins Sq, Akron, OH 44308 USA.						Amer Acad Pediat, 2001, PEDIATRICS, V107, P777; American Society of Anesthesiologists, 2004, POL STAT PROC SED EM; American Society of Anesthesiologists (ASA) Quality Management and Departmental Administration Committee, 2009, POL STAT CONT DEPTH; [Anonymous], 2004, ANN EMERG MED, V44, P342, DOI 10.1016/j.annemergmed.2004.04.012; [Anonymous], 1974, MICR 1 0 HEALTHC SER; [Anonymous], 2011, JOINT COMM ACCR MAN; Emergency Nurses Association (ENA), 2005, JOINT STAT ENA AM CO; Faucher L, 2006, J BURN CARE RES, V27, P659, DOI 10.1097/01.BCR.0000238117.41490.00; Fauerbach JA, 2007, PSYCHOSOM MED, V69, P473, DOI 10.1097/psy.0b013e31806bf393; Foertsch CE, 1998, J BURN CARE REHABIL, V19, P219, DOI 10.1097/00004630-199805000-00007; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Laterjet J, 2002, WORLD WIDE WOUNDS, P5; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; Pal SK, 1997, BURNS, V23, P404, DOI 10.1016/S0305-4179(97)00029-6; Patterson DR, 2000, J BURN CARE REHABIL, V21, P490, DOI 10.1097/00004630-200021060-00004; Taal LA, 1997, BURNS, V23, P288, DOI 10.1016/S0305-4179(97)89874-9; Thorp JM, 2010, GUIDE PAIN MANAGEMEN; Ulmer JF, 1997, J PAIN SYMPTOM MANAG, V13, P148, DOI 10.1016/S0885-3924(96)00301-6; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x; Wilson D, 2001, WONGS ESSENTIALS PED	21	10	12	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1559-047X	1559-0488		J BURN CARE RES	J. Burn Care Res.	JUL-AUG	2012	33	4					504	509		10.1097/BCR.0b013e318236fe4f			6	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	972KC	WOS:000306275000018	22079919				2020-06-30	J	Jimenez, A; Blazquez, D; Cruz, J; Palacios, A; Ordonez, O; Marin, M; Ruiz-Contreras, J				Jimenez, Ana; Blazquez, Daniel; Cruz, Jaime; Palacios, Alba; Ordonez, Olga; Marin, Milagros; Ruiz-Contreras, Jesus			Use of Combined Transmucosal Fentanyl, Nitrous Oxide, and Hematoma Block for Fracture Reduction in a Pediatric Emergency Department	PEDIATRIC EMERGENCY CARE			English	Article						transmucosal fentanyl; reduction; fracture; nitrous oxide; hematoma block	INTRAVENOUS MORPHINE; PAINFUL PROCEDURES; LACERATION REPAIR; ORAL MIDAZOLAM; CLINICAL-TRIAL; CHILDREN; CITRATE; SEDATION; ANALGESIA; EFFICACY	Objective: The objective of this study was to evaluate the use of combined inhaled nitrous oxide (NO), hematoma block (HB), and transmucosal fentanyl (TMF) as sedoanalgesia in the reduction of radioulnar fractures in children in a pediatric emergency department (PED). Methods: A retrospective, analytical observational study examining the cases of radioulnar fracture reduction in PED from 2007 to 2009 in children from 4 to 15 years old. The cases were divided into 2 groups: those in which only NO + HB was used and those in which TMF was combined with NO + HB. The pain perceived by the child, the doctor, and the nurse was studied during the procedure with 0- to 10-point scales (10 being severe pain). Satisfaction of the medical professionals, duration of the procedure, and the adverse effects that appeared were also studied. Results: Eighty-one children were included. Sixty-four children (79%) received NO + TMF + HB, and 17 children (21%) received NO + HB only. The pain perceived by the child during the procedure in the group receiving NO + TMF + HB was 2.5 (95% confidence interval [CI], 1.8-3.1) compared with 3.9 (95% CI, 2.3-5.5) in the NO + HB group (P = 0.035), the pain perceived by the doctor was 2.6 (95% CI, 2-3.2) compared with 4 (95% CI, 1.6-4), and by the nurse was 2.7 (95% CI, 2-3.3) compared with 3.9 (95% CI, 2.3-5.5), respectively. Adverse events appeared in 15.3% of the NO + TMF + HB group and in 40% of the NO + HB group. Conclusions: The association of NO + TMF + HB in the reduction of radioulnar fractures in PED improves pain control compared with the NO + HB combination. New studies are required to confirm the benefit and safety of this drug combination.	[Jimenez, Ana; Blazquez, Daniel; Cruz, Jaime; Palacios, Alba; Ordonez, Olga; Marin, Milagros; Ruiz-Contreras, Jesus] Hosp Univ 12 Octubre, Dept Pediat, Madrid 28041, Spain	Blazquez, D (reprint author), Hosp Univ 12 Octubre, Dept Pediat, Avda Cordoba Sn, Madrid 28041, Spain.	danielblazquez@hotmail.com		Blazquez-Gamero, Daniel/0000-0001-6483-8329; RUIZ-CONTRERAS, JESUS/0000-0002-2788-7524			Annequin D, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e47; Bar-Meir E, 2006, PLAST RECONSTR SURG, V117, P1571, DOI 10.1097/01.prs.0000206298.71083.df; Binstock W, 2004, PEDIATR ANESTH, V14, P759, DOI 10.1111/j.1460-9592.2004.01296.x; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; EVANS JK, 1995, J PEDIATR ORTHOPED, V15, P73, DOI 10.1097/01241398-199501000-00016; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Gall O, 2001, LANCET, V358, P1514, DOI 10.1016/S0140-6736(01)06575-8; Gregory PR, 1996, J PEDIATR ORTHOPED, V16, P187, DOI 10.1097/01241398-199603000-00010; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; HENNRIKUS WL, 1994, J PEDIATR ORTHOPED, V14, P538, DOI 10.1097/01241398-199407000-00023; HENNRIKUS WL, 1995, J BONE JOINT SURG AM, V77A, P335, DOI 10.2106/00004623-199503000-00001; Kanagasundaram SA, 2001, ARCH DIS CHILD, V84, P492, DOI 10.1136/adc.84.6.492; Kennedy Robert M, 2004, Paediatr Drugs, V6, P11; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Litman RS, 1996, ARCH PEDIAT ADOL MED, V150, P671, DOI 10.1001/archpedi.1996.02170320017002; Luhmann JD, 2006, PEDIATRICS, V118, pE1078, DOI 10.1542/peds.2005-1694; Lyons RA, 2000, BRIT MED J, V320, P149, DOI 10.1136/bmj.320.7228.149; Mahar PJ, 2007, PEDIATR EMERG CARE, V23, P544, DOI 10.1097/PEC.0b013e318128f80b; Migita RT, 2006, ARCH PEDIAT ADOL MED, V160, P46, DOI 10.1001/archpedi.160.1.46; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; Schutzman SA, 1996, ANN EMERG MED, V28, P385, DOI 10.1016/S0196-0644(96)70001-X; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Wattenmaker I, 1990, J Orthop Trauma, V4, P35	25	4	4	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	JUL	2012	28	7					676	679		10.1097/PEC.0b013e31825d20f6			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	970LD	WOS:000306129300012	22743745				2020-06-30	J	Lista, F; Doherty, CD; Backstein, RM; Ahmad, J				Lista, Frank; Doherty, Chris D.; Backstein, Richard M.; Ahmad, Jamil			The Impact of Perioperative Warming in an Outpatient Aesthetic Surgery Setting	AESTHETIC SURGERY JOURNAL			English	Article						aesthetic surgery; cosmetic surgery; patient safety; warming; normothermia; hypothermia; research	VENOUS THROMBOEMBOLISM; POSTOPERATIVE PAIN; WOUND-INFECTION; BLOOD-LOSS; HYPOTHERMIA; PREVENTION; THERMOREGULATION; COMPLICATIONS; TEMPERATURE; ANESTHESIA	Background: Perioperative hypothermia can lead to surgical complications, including bleeding, infection, increased patient discomfort, and longer recovery time. Plastic surgeons have become increasingly aware of this important patient safety issue. Objectives: The authors evaluate the impact of perioperative warming in an outpatient plastic surgery setting. Methods: A retrospective review was performed of 108 patients who received several simple measures to prevent perioperative hypothermia. Patients dressed in warm clothing and were covered with an electric blanket in both the holding area and the recovery room. Intraoperative interventions included higher ambient room temperature, skin exposure only at the surgical site, forced-air warming, and the use of warmed fluids. This warmed group was compared with a historical control group of 106 patients who underwent plastic surgery in the period immediately before implementation of these measures. Patient demographics and procedural characteristics were similar for the 2 groups. Results: The requirement for intraoperative analgesia was significantly lower for the warmed group (111 vs 125 mu g fentanyl in the control group; P=.042). Patients in the warmed group required less time in the recovery room and met discharge criteria sooner (127 vs 141 minutes; P=.001). No significant difference was observed in the incidence of complications. Conclusions: Simple measures to maintain perioperative normothermia improve patient comfort and recovery following aesthetic surgery. Through a continuous-improvement culture, the authors have successfully implemented warming strategies that prevent perioperative hypothermia and improve surgical outcomes.	[Doherty, Chris D.] Univ Calgary, Div Plast Surg, Dept Surg, Calgary, AB, Canada; [Backstein, Richard M.] Univ Toronto, Div Plast & Reconstruct Surg, Dept Surg, Toronto, ON, Canada	Ahmad, J (reprint author), 1421 Hurontario St, Mississauga, ON L5G 3H5, Canada.	drahmad@theplasticsurgeryclinic.com					Adams ES, 2011, AESTHET SURG J, V31, P122, DOI 10.1177/1090820X10391211; Adams ES, 2001, AESTHETIC SURG J, V31, P122; Adams WP, 2009, CLIN PLAST SURG, V36, P119, DOI 10.1016/j.cps.2008.08.007; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Alexander JW, 2011, ANN SURG, V253, P1082, DOI 10.1097/SLA.0b013e31821175f8; Anderson DJ, 2011, INFECT DIS CLIN N AM, V25, P135, DOI 10.1016/j.idc.2010.11.004; Bock M, 1998, BRIT J ANAESTH, V80, P159, DOI 10.1093/bja/80.2.159; Buggy DJ, 2000, BRIT J ANAESTH, V84, P615, DOI 10.1093/bja/84.5.615; Casati A, 1999, Minerva Anestesiol, V65, P507; Cavallini M, 2005, PLAST RECONSTR SURG, V116, P316, DOI 10.1097/01.PRS.0000170798.45679.7A; Colwell Amy S, 2008, Aesthet Surg J, V28, P437, DOI 10.1016/j.asj.2008.04.007; Davison SP, 2008, CLIN PLAST SURG, V35, P173, DOI 10.1016/j.cps.2007.08.002; Forstot RM, 1995, J CLIN ANESTH, V7, P657, DOI 10.1016/0952-8180(95)00099-2; Haeck PC, 2009, PLAST RECONSTR SURG, V124, p57S, DOI 10.1097/PRS.0b013e3181b53fb0; Hamza MA, 2005, J LAPAROENDOSC ADV A, V15, P6, DOI 10.1089/lap.2005.15.6; Ikeda T, 1998, AM J SURG, V175, P33, DOI 10.1016/S0002-9610(97)00237-7; Kenkel JM, 2004, PLAST RECONSTR SURG, V114, P516, DOI 10.1097/01.PRS.0000128423.84607.61; Kenkel JM, 2004, PLAST RECONSTR SURG, V114, P503, DOI 10.1097/01.PRS.0000132676.19913.A3; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Kurz A, 2008, BEST PRACT RES-CLIN, V22, P627, DOI 10.1016/j.bpa.2008.06.004; Kurz A, 2008, BEST PRACT RES-CLIN, V22, P39, DOI 10.1016/j.bpa.2007.10.004; Lenhardt R, 1997, ANESTHESIOLOGY, V87, P1318, DOI 10.1097/00000542-199712000-00009; Lenhardt Rainer, 2003, Best Pract Res Clin Anaesthesiol, V17, P569, DOI 10.1016/S1521-6896(03)00048-X; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; Melling AC, 2001, LANCET, V358, P876, DOI 10.1016/S0140-6736(01)06071-8; Michaels J, 2011, PLAST RECONSTR SURG, V127, P1352, DOI 10.1097/PRS.0b013e3182063144; Nguyen NT, 2002, SURG ENDOSC, V16, P1050, DOI 10.1007/s00464-001-8237-0; Rajagopalan S, 2008, ANESTHESIOLOGY, V108, P71, DOI 10.1097/01.anes.0000296719.73450.52; Reynolds L, 2008, BEST PRACT RES-CLIN, V22, P645, DOI 10.1016/j.bpa.2008.07.005; Richards Mark E, 2003, Aesthet Surg J, V23, P345, DOI 10.1016/S1090-820X(03)00207-3; Robles-Cervantes JA, 2005, PLAST RECONSTR SURG, V116, P1077, DOI 10.1097/01.prs.0000178790.99010.59; Sajid MS, 2009, SAO PAULO MED J, V127, P231, DOI 10.1590/S1516-31802009000400009; Sessler DI, 1997, NEW ENGL J MED, V336, P1730, DOI 10.1056/NEJM199706123362407; Sessler DI, 2001, ANESTHESIOLOGY, V95, P531, DOI 10.1097/00000542-200108000-00040; Sessler DI, 2002, CLIN INFECT DIS, V35, P1397, DOI 10.1086/344275; Slim K, 1999, SURG ENDOSC-ULTRAS, V13, P1110, DOI 10.1007/s004649901184; Somogyi RB, 2012, AESTHET SURG J, V32, P322, DOI 10.1177/1090820X12438896; Torossian A, 2008, BEST PRACT RES-CLIN, V22, P659, DOI 10.1016/j.bpa.2008.07.006; Venturi ML, 2009, AESTHET SURG J, V29, P421, DOI 10.1016/j.asj.2009.04.008; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; Widman J, 2002, ANESTH ANALG, V95, P1757, DOI 10.1097/00000539-200212000-00053; Wong PF, 2007, BRIT J SURG, V94, P421, DOI 10.1002/bjs.5631; Young V Leroy, 2006, Aesthet Surg J, V26, P551, DOI 10.1016/j.asj.2006.08.009	43	17	25	2	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1090-820X	1527-330X		AESTHET SURG J	Aesthet. Surg. J.	JUL	2012	32	5					613	620		10.1177/1090820X12449342			8	Surgery	Surgery	966RV	WOS:000305856000011	22745450	Bronze			2020-06-30	J	Rinehart, JB; Baker, B; Raphael, D				Rinehart, Joseph B.; Baker, Brandee; Raphael, Darren			Postoperative Global Amnesia Reversed With Flumazenil	NEUROLOGIST			English	Article						global amnesia; flumazenil; postoperative global amnesia	RETROGRADE-AMNESIA; GENERAL-ANESTHESIA; HUMAN-MEMORY; TRANSIENT; MIDAZOLAM; BENZODIAZEPINES; ANTEROGRADE	Global postoperative amnesia (profound anterograde and retrograde amnesia) is rare and usually attributed to transient global amnesia-a poorly understood condition with no broadly accepted mechanism. We report an incident of probable transient global amnesia in a patient after endoscopic retrograde cholangiopancreatogram under general anesthesia, which was successfully treated with flumazenil. On the basis of the results of flumazenil administration in this and a previous case report, we would recommend a trial dose of 0.2 mg for cases of global postoperative amnesia, repeated if the first dose seems effective.	[Rinehart, Joseph B.; Baker, Brandee; Raphael, Darren] Univ Calif Irvine, Dept Anesthesiol & Perioperat Care, Orange, CA 92868 USA	Rinehart, JB (reprint author), Univ Calif Irvine, Dept Anesthesiol & Perioperat Care, 333 City Blvd W,Suite 2150, Orange, CA 92868 USA.	jrinehar@uci.edu		Rinehart, Joseph/0000-0003-2975-196X			AMREIN R, 1988, EUR J ANAESTH, P65; Bortolon RJ, 2005, ANESTH ANALG, V101, P916, DOI 10.1213/01.ANE.0000175208.76574.54; CHERNIK DA, 1992, CLIN THER, V14, P861; Danek A, 2002, J NEUROL, V249, P628, DOI 10.1007/s004150200075; GHONEIM MM, 1993, ANESTHESIOLOGY, V79, P1183, DOI 10.1097/00000542-199312000-00008; GHONEIM MM, 1990, ANESTHESIOLOGY, V72, P926; Hupp J R, 1988, J Conn State Dent Assoc, V62, P80; Kohase H, 1998, Masui, V47, P481; Koht A, 1997, ANESTH ANALG, V85, P211, DOI 10.1097/00000539-199707000-00037; Kritchevsky M, 1997, PHILOS T R SOC B, V352, P1747, DOI 10.1098/rstb.1997.0157; KRITCHEVSKY M, 1988, NEUROLOGY, V38, P213, DOI 10.1212/WNL.38.2.213; KRITCHEVSKY M, 1989, NEUROLOGY, V39, P213, DOI 10.1212/WNL.39.2.213; Lewis SL, 1998, LANCET, V352, P397, DOI 10.1016/S0140-6736(98)01442-1; MILLER JW, 1987, NEUROLOGY, V37, P733, DOI 10.1212/WNL.37.5.733; Pantoni L, 2000, ACTA NEUROL SCAND, V102, P275, DOI 10.1034/j.1600-0404.2000.102005275.x; Skues M A, 1989, J Clin Anesth, V1, P387; Tong DC, 2004, NEUROLOGY, V62, P2154, DOI 10.1212/01.WNL.0000132256.64800.CB; TWERSKY RS, 1993, ANESTHESIOLOGY, V78, P51, DOI 10.1097/00000542-199301000-00009; WOOD T, 1985, ANESTHESIOLOGY, V62, P807, DOI 10.1097/00000542-198506000-00022; Yamaji A, 1989, Masui, V38, P236	20	5	5	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1074-7931			NEUROLOGIST	Neurologist	JUL	2012	18	4					216	218		10.1097/NRL.0b013e31825bbef4			3	Clinical Neurology	Neurosciences & Neurology	967HZ	WOS:000305899000012	22735251				2020-06-30	J	Nalamachu, SR; Rauck, RL; Wallace, MS; Hassman, D; Howell, J				Nalamachu, Srinivas R.; Rauck, Richard L.; Wallace, Mark S.; Hassman, David; Howell, Julian			Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open-Label Titration Studies	PAIN PRACTICE			English	Article						analgesics; opioid; cancer	BUCCAL SOLUBLE FILM; BREAKTHROUGH PAIN; CANCER; PHARMACOKINETICS; OXYCODONE; CITRATE; PREVALENCE	Objective: This analysis was conducted to determine the likelihood of identifying an effective dose of fentanyl sublingual tablet during the initial titration phase of 2 clinical trials, to characterize the actual effective dose in patients achieving successful titration, and to examine the relationship between baseline characteristics and likelihood of achieving an effective dose. Methods: Data were derived from 2 clinical trials (Study 1, n = 131; Study 2, n = 139) of fentanyl sublingual tablet in patients with cancer-associated breakthrough pain (BTP). Both trials comprised a 2-week titration phase and 12-month maintenance phase. The initial dose was 100 mu g, titrated to an effective dose (producing effective relief of all BTP episodes on 2 consecutive days) of 100 to 800 mu g. Results: A total of 270 patients entered the titration phase. Mean (SD) baseline BTP opioid dose was 25.7 (88.9) mg morphine equivalent, and mean baseline around-the-clock opioid dose was 196.5 (151.6) mg morphine equivalent. Using conservative criteria for determining effective dose, 174 patients (64.4%) were successfully titrated to an effective dose (mean [SD], 498.2 [234.8] mu g). The most frequent (27.6%) effective dose was 800 mu g, and more than 85% of patients required an effective dose = 300 mu g. There were no significant relationships between any baseline characteristics and titration success. Conclusion: Despite stringent criteria, 64.4% of patients achieved an effective dose of fentanyl sublingual tablet within the dose range of 100 to 800 mu g. Baseline characteristics were not identified to be associated with the likelihood of successful titration or with the actual effective dose of fentanyl sublingual tablet.	[Nalamachu, Srinivas R.] Int Clin Res Inst, Overland Pk, KS 66211 USA; [Rauck, Richard L.] Carolinas Pain Inst, Clin Res Ctr, Winston Salem, NC USA; [Wallace, Mark S.] Univ Calif San Diego, San Diego, CA 92103 USA; [Hassman, David] Comprehens Clin Res, Berlin, NJ USA; [Howell, Julian] ProStrakan Grp Plc, Galashiels, England	Nalamachu, SR (reprint author), Int Clin Res Inst, 11120 Tomahawk Creek Pkwy, Overland Pk, KS 66211 USA.	nalamachu@yahoo.com			Biodelivery Sciences Inc.; Achimedes; Insys; ProStrakan; MEDA; ProStrakan, Inc., Bridgewater, NJ, U.S.A.	Srinivas R. Nalamachu reports that he is a consultant, serves on the advisory board, and receives honoraria from ProStrakan, Cephalon, Endo Pharmaceuticals, and Covidien. He also reports that he is on the speakers' bureau for ProStrakan, Cephalon, and Covidien. Richard L. Rauck reports that he is a consultant for and receives research support from Biodelivery Sciences Inc. In addition, he serves on the speakers' bureau and receives research support from Achimedes. Dr. Rauck also receives research support from Insys, ProStrakan, and MEDA. Mark S. Wallace reports that he is a consultant and serves on the advisory board for Cephalon. David Hassman reports that he has no conflicts to disclose. Julian Howell reports that he is an employee of ProStrakan. Presented in part at PAINWeek, September 7 to 10, 2010, Las Vegas, NV, U.S.A.; Editorial and medical writing support was provided by Amanda McGeary, MS, and Kara Quick, ELS, of Synchrony Medical LLC, West Chester, PA, U.S.A. Statistical analysis support was provided by Ann Yellowlees, BA, MSc, PhD, and Kelly Fleetwood, BSc, of Quantics Consulting Limited, Edinburgh, U.K. Manuscript development and statistical support were funded by ProStrakan, Inc., Bridgewater, NJ, U.S.A.	[Anonymous], 2009, ONS FENT BUCC SOL FI; BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Cephalon Inc, 2009, ACT FENT CITR OR TRA; Cephalon Inc, 2009, FENT FENT BUCC TABL; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 1997, NEW ENGL J MED, V336, P1465; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; LEOW KP, 1992, THER DRUG MONIT, V14, P479, DOI 10.1097/00007691-199212000-00008; LEOW KP, 1992, CLIN PHARMACOL THER, V52, P487, DOI 10.1038/clpt.1992.176; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; POYHIA R, 1992, BRIT J CLIN PHARMACO, V33, P617, DOI 10.1111/j.1365-2125.1992.tb04090.x; ProStrakan Ltd, 2010, ABSTR FENT SUBL TABL; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; Ward J, 2011, COMP COLL ANN SCI M; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	28	4	4	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	JUL	2012	12	6					449	456		10.1111/j.1533-2500.2011.00525.x			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	968SR	WOS:000306005600005	22226371				2020-06-30	J	Dorfelt, R; Ambrisko, TD; Moens, Y				Doerfelt, Rene; Ambrisko, Tamas D.; Moens, Yves			Influence of fentanyl on intra-abdominal pressure during laparoscopy in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anaesthesia; capnoperitoneum; dog; fentanyl; intra-abdominal pressure; laparoscopy	INDUCED MUSCULAR RIGIDITY; LOCUS-CERULEUS; ANESTHESIA; RAT; INVOLVEMENT; CHOLECYSTECTOMY; ISOFLURANE; CHANNELS; SURGERY; BINDING	Objective To evaluate the influence of fentanyl on intra-abdominal pressures in spontaneously breathing dogs during capnoperitoneum. Study design Prospective clinical study. Animals Eleven healthy client-owned and five healthy experimental dogs undergoing laparoscopy. Methods Dogs were premedicated with acepromazine (0.03 mg kg(-1) IV) and carprofen (4 mg kg(-1) IV). Anaesthesia was induced with propofol and maintained with isoflurane in oxygen. The abdomen was insufflated with CO2 (11-16 cm H2O). Intra-abdominal pressures were measured with a transducer. Respiratory variables were measured with a spirometry sensor and side-stream capnography. Following preparation, fentanyl (1 mu g kg(-1)) was injected over 30 seconds IV. Data were recorded 5 minutes before, during and 5 minutes after treatment. The following time points were selected for statistical analysis (ANOVA, p < 0.05): -160, -140, -120, -100, -80, -60, -40, -20, 0, 30, 50, 70, 90, 110, 130 and 150 seconds after the start of fentanyl injection. Results Intra-abdominal pressure increased during inspiration in 15 dogs but decreased in one dog. Fentanyl treatment did not alter these patterns. Peak inspiratory and end-expiratory intra-abdominal pressures continuously decreased over time during the whole experiment and fentanyl exaggerated the decrease in inspiratory pressures but did not affect the rate of decrease in expiratory pressures. Differences between intra-abdominal pressures were stable before, but decreased after fentanyl administration from 4.1 +/- 1.4 to 3.3 +/- 1.2 cm H2O (at 0 and 150 seconds time points). End-tidal CO2 partial pressures increased from 6.0 +/- 0.8 to 6.6 +/- 0.9 kPa, respiratory rate decreased from 10.8 +/- 2.6 to 7.8 +/- 2.2 breaths per minute and tidal volume decreased from 13.7 +/- 4.4 to 12.4 +/- 2.9 mL kg(-1) after fentanyl but these variables did not change before fentanyl treatment. Airway pressures did not change. Conclusions and clinical relevance Fentanyl did not increase intra-abdominal pressures in dogs.	[Doerfelt, Rene; Ambrisko, Tamas D.; Moens, Yves] Univ Vet Med, Div Anaesthesia & Perioperat Intens Care, A-1210 Vienna, Austria	Ambrisko, TD (reprint author), Univ Vet Med, Div Anaesthesia & Perioperat Intens Care, Vet Pl 1, A-1210 Vienna, Austria.	tamas.ambrisko@vetmeduni.ac.at		Dorfelt, Rene/0000-0003-1831-377X			ANDREWS CJH, 1983, BRIT J ANAESTH, V55, pS211; ASKGAARD B, 1977, ACTA ANAESTH SCAND, V21, P1, DOI 10.1111/j.1399-6576.1977.tb01185.x; Bailey J. E., 1999, VET ENDOSURGERY, P25; BONNET F, 1986, EUR J ANAESTH, V3, P413; CASPI J, 1988, CRIT CARE MED, V16, P238, DOI 10.1097/00003246-198803000-00006; Devitt CM, 2005, JAVMA-J AM VET MED A, V227, P921, DOI 10.2460/javma.2005.227.921; Drummond GB, 2003, BRIT J ANAESTH, V91, P73, DOI 10.1093/bja/aeg145; Drummond GB, 2002, BRIT J ANAESTH, V88, P384, DOI 10.1093/bja/88.3.384; Fiorbianco V, 2010, 19 EUR COLL VET SURG; Freeman LJ, 1999, VETERINARY ENDOSURGERY, P92; Fu MJ, 1997, ANESTHESIOLOGY, V87, P1450, DOI 10.1097/00000542-199712000-00024; FU MJ, 1994, NEUROSCI LETT, V165, P199, DOI 10.1016/0304-3940(94)90744-7; Haeseler G, 2001, ANESTH ANALG, V92, P1192, DOI 10.1097/00000539-200105000-00021; Hellyer PW, 2003, VET ANAESTH ANALG, V30, P172, DOI 10.1046/j.1467-2995.2003.00143.x; IDE T, 1993, ACTA ANAESTH SCAND, V37, P253, DOI 10.1111/j.1399-6576.1993.tb03710.x; Kazama T, 1996, BRIT J ANAESTH, V76, P530; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; LEE TY, 1995, NEUROSCI LETT, V199, P195, DOI 10.1016/0304-3940(95)12049-A; Meininger D, 2008, ANAESTHESIST, V57, P760, DOI 10.1007/s00101-008-1422-y; Muller P, 2000, AM J PERINAT, V17, P23, DOI 10.1055/s-2000-7289; Nickel R, 2007, KLEINTIERPRAXIS, V52, P413; Nishina K, 2003, ANESTH ANALG, V96, P1674, DOI 10.1213/01.ANE.0000060455.94684.69; PLUMB D, 2005, PLUMBS VET DRUG HDB, P327; Prasad CV, 2004, ANAESTHESIA, V59, P715, DOI 10.1111/j.1365-2044.2004.03683.x; TSOU MY, 1989, NEUROPHARMACOLOGY, V28, P1163, DOI 10.1016/0028-3908(89)90206-2; VACANTI CA, 1992, J CLIN ANESTH, V4, P399, DOI 10.1016/0952-8180(92)90165-W; Vaughn R L, 1981, Anesth Prog, V28, P50; WARNER DO, 1994, J APPL PHYSIOL, V76, P2802; WEINGER MB, 1995, BRAIN RES, V669, P10, DOI 10.1016/0006-8993(94)01216-5	29	3	3	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2012	39	4					390	397		10.1111/j.1467-2995.2012.00710.x			8	Veterinary Sciences	Veterinary Sciences	962BL	WOS:000305514100010	22414245				2020-06-30	J	Gadek, A; Wordliczek, J; Zajaczkowska, R				Gadek, Artur; Wordliczek, Jerzy; Zajaczkowska, Renata			Evaluation of Analgesic Efficacy of Intra-Articular Opioids (Morphine, Fentanyl) After Arthroscopic Knee Surgery	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Letter																Mitra S, 2011, ARTHROSCOPY, V27, P1637, DOI 10.1016/j.arthro.2011.08.295	1	3	4	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063	1526-3231		ARTHROSCOPY	Arthroscopy	JUL	2012	28	7					897	898		10.1016/j.arthro.2012.05.008			3	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	966AS	WOS:000305809600006	22738748				2020-06-30	J	Meleine, M; Rivat, C; Laboureyras, E; Cahana, A; Richebe, P				Meleine, Mathieu; Rivat, Cyril; Laboureyras, Emilie; Cahana, Alex; Richebe, Philippe			Sciatic Nerve Block Fails in Preventing the Development of Late Stress-Induced Hyperalgesia When High-Dose Fentanyl Is Administered Perioperatively in Rats	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							OPIOID-INDUCED HYPERALGESIA; LONG-LASTING HYPERALGESIA; HIND PAW INFLAMMATION; POSTOPERATIVE PAIN; KETAMINE; BUPIVACAINE; MODEL; TETRODOTOXIN; ANALGESIA; CYTOKINES	Sciatic nerve block fails in preventing the development of late stress-induced hyperalgesia (SIH) when high-dose fentanyl is administered perioperatively in rats. Background and Objectives: The aim of our study was to evaluate the effect of regional anesthesia (RA) on hyperalgesia and long-term pain vulnerability after surgery in rats exposed or not to high doses of fentanyl intraoperatively. Methods: Experiment 1 evaluated the effects of D-0 RA on hyperalgesia after incision and on the variations of nociceptive threshold (NT) after non-nociceptive environmental stress (NNES) at D-10. Four groups were compared: control K1 (saline in sciatic nerve catheter, no plantar surgery), I (incision: saline in sciatic nerve catheter and plantar surgery), ISSR (incision-single-shot ropivacaine: single-shot ropivacaine, plantar surgery), and IMSR (incision-multiple-shot ropivacaine: 1 shot of ropivacaine, plantar surgery, and then 3 more ropivacaine injections every 2 h). Experiment 2 evaluated the effects of D-0 RA (4 injections) on NT variations after surgery (D-1-D-10) and after stress (D-10) in rats treated with fentanyl at the time of surgery (FI and FIMSR groups). Results: Postoperative hyperalgesia lasted for 7, 4, and 2 days for groups I, ISSR, and IMSR, respectively. Non-nociceptive environmental stress at D-10 showed analgesia during stress in K1 (Dunnett, P < 0.05). Poststress area of hyperalgesia showed that I group developed greater hyperalgesia after NNES than ISSR and IMSR did (Mann-Whitney, P < 0.05). In experiment 2 in the FIMSR group, NT was significantly higher at postoperative D-1 and D-2 (Dunnett, P < 0.05), but no difference was shown from D-3 to D-10 (Dunnett, P > 0.05). Hyperalgesic indices calculated for FI and FIMSR groups after NNES at D-10 did no show any significant difference (Dunnett, P > 0.05). Conclusions: Perioperative use of long-lasting RA reduced both acute postoperative hyperalgesia and the development of long-term pain vulnerability. However, high doses of fentanyl for intraoperative analgesia induce central sensitization that cannot be reversed by using long-lasting RA.	[Rivat, Cyril; Cahana, Alex; Richebe, Philippe] Univ Washington, Med Ctr, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Laboureyras, Emilie] Univ Bordeaux, CNRS, INCIA UMR 5287, Bordeaux, France; [Meleine, Mathieu] Univ Auvergne, INSERM, UMR Pharmacol Fondamentale & Clin Douleur 1107, Fac Med, F-63000 Clermont Ferrand, France	Richebe, P (reprint author), Univ Washington, Med Ctr, Dept Anesthesiol & Pain Med, Campus Box 356540,1959 NE Pacific St, Seattle, WA 98195 USA.	prichebe@uw.edu	MELEINE, Mathieu/Y-4193-2019; Rivat, Cyril/F-8482-2019	MELEINE, Mathieu/0000-0002-0925-087X; Rivat, Cyril/0000-0002-7491-6113			Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Beloeil H, 2006, ANESTHESIOLOGY, V105, P128, DOI 10.1097/00000542-200607000-00022; Beloeil H, 2006, ANESTHESIOLOGY, V105, P139, DOI 10.1097/00000542-200607000-00023; Bouaziz H, 2010, ANN FR ANESTH, V29, P440, DOI 10.1016/j.annfar.2010.02.029; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Cabanero D, 2009, PAIN, V141, P88, DOI 10.1016/j.pain.2008.10.011; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; De Kock M, 2001, PAIN, V92, P373, DOI 10.1016/S0304-3959(01)00278-0; Eisenach JC, 2006, REGION ANESTH PAIN M, V31, P1, DOI 10.1016/j.rapm.2005.11.008; Estebe JP, 2002, CAN J ANAESTH, V49, P690, DOI 10.1007/BF03017447; Hung YC, 2007, REGION ANESTH PAIN M, V32, P288, DOI 10.1016/j.rapm.2007.03.008; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Kau YC, 2006, REGION ANESTH PAIN M, V31, P14, DOI 10.1016/j.rapm.2005.08.008; KAYSER V, 1990, BRAIN RES, V508, P329, DOI 10.1016/0006-8993(90)90418-B; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Richebe P, 2011, ANESTHESIOLOGY, V114, P1280, DOI 10.1097/ALN.0b013e31821c112b; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Rivat C, 2007, NEUROPSYCHOPHARMACOL, V32, P2217, DOI 10.1038/sj.npp.1301340; Rivat C, 2009, EUR J NEUROSCI, V29, P727, DOI 10.1111/j.1460-9568.2009.06616.x; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001	22	8	9	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUL-AUG	2012	37	4					448	454		10.1097/AAP.0b013e318257a87a			7	Anesthesiology	Anesthesiology	965QI	WOS:000305781900014	22660486				2020-06-30	J	Makkar, JK; Jain, K; Singh, NP				Makkar, Jeetinder Kaur; Jain, Kajal; Singh, Narinder Pal			The Starting Dose	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Letter							HYPERBARIC BUPIVACAINE; CESAREAN DELIVERY; ED50		[Makkar, Jeetinder Kaur; Jain, Kajal] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India; [Singh, Narinder Pal] Alchemist Hosp, Chandigarh, India	Makkar, JK (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India.						Danelli G, 2001, Minerva Anestesiol, V67, P573; Dixon WJ, 1983, INTRO STAT ANAL, P426; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; Paul M, 2001, ANESTHESIOLOGY, V95, P1362, DOI 10.1097/00000542-200112000-00014; Tyagi A, 2012, REGION ANESTH PAIN M, V37, P40, DOI 10.1097/AAP.0b013e318233c5f5	5	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUL-AUG	2012	37	4					461	462		10.1097/AAP.0b013e3182580694			4	Anesthesiology	Anesthesiology	965QI	WOS:000305781900020	22722572				2020-06-30	J	Mccannel, CA; Olson, EJ; Donaldson, MJ; Bakri, SJ; Pulido, JS; Mueller, D				Mccannel, Colin A.; Olson, Eric J.; Donaldson, Mark J.; Bakri, Sophie J.; Pulido, Jose S.; Mueller, Donna			SNORING IS ASSOCIATED WITH UNEXPECTED PATIENT HEAD MOVEMENT DURING MONITORED ANESTHESIA CARE VITREORETINAL SURGERY	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						conscious sedation; head movement; local anesthesia; ophthalmologic surgical procedures; snoring; continuous infusion propofol	OBSTRUCTIVE SLEEP-APNEA	Purpose: To assess whether snoring is associated with sudden patient movement during local anesthesia with intravenous sedation. Methods: In this prospective cohort study, patients undergoing ocular surgery with local anesthesia with intravenous sedation were studied. The occurrence or absence of snoring, and whether patient movement was noted were prospectively recorded. Complications that arose from patient movement were also noted. Results: A total of 230 surgical procedures were included in the study. All cases were vitreoretinal surgery cases. During 37 procedures, snoring was noted, and among these, 18 patients (48.6%) moved their head suddenly. In contrast, movement occurred during only 2 of 193 procedures (1.0%) without documented snoring (P < 0.001). Thus, sudden patient head movement was approximately 49 times more prevalent in patients who snored. Continuous infusion propofol was also associated with sudden unexpected head movement (P = 0.0028). No complications as a result of the movement were identified in this study. Conclusion: Snoring during local anesthesia with intravenous sedation predicts a high likelihood of sudden patient movement during local anesthesia with intravenous sedation. The use of continuous infusion propofol anesthetic may increase the chance of head movement. Eye surgeons should be aware of these associations to help minimize the risk of complications caused by patient movement. RETINA 32:1324-1327, 2012	[Mccannel, Colin A.; Donaldson, Mark J.; Bakri, Sophie J.; Pulido, Jose S.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA; [Olson, Eric J.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA; [Olson, Eric J.] Mayo Clin, Ctr Sleep Med, Rochester, MN USA; [Mueller, Donna] Mayo Clin, Dept Surg Serv, Rochester, MN USA	Mccannel, CA (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.	cmccannel@jsei.ucla.edu	Donaldson, Mark/B-4504-2011	Donaldson, Mark/0000-0002-7269-8028; McCannel, Colin/0000-0003-0774-6414	Research to Prevent Blindness, NY, NYResearch to Prevent Blindness (RPB); Mayo Foundation	Supported in part by an unrestricted grant from the Research to Prevent Blindness, NY, NY, and the Mayo Foundation.	Berry RB, 1997, SLEEP, V20, P654, DOI 10.1093/sleep/20.8.654; Caples SM, 2005, ANN INTERN MED, V142, P187, DOI 10.7326/0003-4819-142-3-200502010-00010; Fanard L, 1988, Anaesthesia, V43 Suppl, P87, DOI 10.1111/j.1365-2044.1988.tb09082.x; GILD WM, 1992, ANESTHESIOLOGY, V76, P204, DOI 10.1097/00000542-199202000-00008; GUILLEMINAULT C, 1993, CHEST, V104, P781, DOI 10.1378/chest.104.3.781; Meoli AL, 2003, SLEEP, V26, P1060; SALMON JF, 1992, BRIT J OPHTHALMOL, V76, P598, DOI 10.1136/bjo.76.10.598; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	8	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0275-004X			RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	JUL	2012	32	7					1324	1327		10.1097/IAE.0b013e31823bea54			4	Ophthalmology	Ophthalmology	965QK	WOS:000305782100014	22466474				2020-06-30	J	Ohtori, S; Inoue, G; Orita, S; Eguchi, Y; Ochiai, N; Kishida, S; Takaso, M; Aoki, Y; Kuniyoshi, K; Nakamura, J; Ishikawa, T; Arai, G; Miyagi, M; Kamoda, H; Suzuki, M; Toyone, T; Takahashi, K				Ohtori, Seiji; Inoue, Gen; Orita, Sumihisa; Eguchi, Yawara; Ochiai, Nobuyasu; Kishida, Shunji; Takaso, Masashi; Aoki, YaSuchika; Kuniyoshi, Kazuki; Nakamura, Junichi; Ishikawa, Tetsuhiro; Arai, Gen; Miyagi, Masayuki; Kamoda, Hiroto; Suzuki, Miyako; Toyone, Tomoaki; Takahashi, Kazuhisa			Transdermal Fentanyl for Chronic Low Back Pain	YONSEI MEDICAL JOURNAL			English	Article						Transdermal fentanyl; low back pain; efficacy; adverse events	TRAMADOL/ACETAMINOPHEN COMBINATION TABLETS; CHRONIC NONCANCER PAIN; RELEASE ORAL MORPHINE; CONTROLLED-TRIAL; DOUBLE-BLIND; EFFICACY; MULTICENTER; OPIOIDS; OUTPATIENT; MANAGEMENT	Purpose: Chronic low back pain is a common clinical problem. As medication, non-steroidal anti-inflammatory drugs are generally used; however, they are sometimes non-effective. Recently, opioids have been used for the treatment of chronic low back pain, and since 2010, transdermal fentanyl has been used to treat chronic non-cancer pain in Japan. The purpose of the current study was to examine the efficacy of transdermal fentanyl in the treatment of chronic low back pain. Materials and Methods: This study included patients (n=62) that suffered from chronic low back pain and were non-responsive to non-steroidal anti-inflammatory drugs. Their conditions consisted of non-specific low back pain, multiple back operations, and specific low back pain awaiting surgery. Patients were given transdermal fentanyl for chronic low back pain. Scores of the visual analogue scale and the Oswestry Disability Index, as well as adverse events were evaluated before and after therapy. Results: Overall, visual analogue scale scores and Oswestry Disability Index scores improved significantly after treatment. Transdermal fentanyl (12.5 to 50 mu g/h) was effective in reducing low back pain in 45 of 62 patients; however, it was not effective in 17 patients. Patients who experienced the most improvement were those with specific low back pain awaiting surgery. Adverse events were seen in 40% of patients (constipation, 29%; nausea, 24%; itching, 24%). Conclusion: Transdermal fentanyl significantly improved visual analog scale scores and Oswestry Disability Index scores. in 73% of patients, especially those with specific low back pain awaiting surgery; however, it did not decrease pain in 27% of patients, including patients with non-specific low back pain or multiple back operations.	[Ohtori, Seiji] Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan	Ohtori, S (reprint author), Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	sohtori@faculty.chiba-u.jp	Eguchi, Yawara/AAH-1244-2019; Eguchi, Yawara/AAA-2473-2020	Eguchi, Yawara/0000-0003-2247-5376; 			Adams LL, 2004, J PAIN SYMPTOM MANAG, V27, P440, DOI 10.1016/j.jpainsymman.2003.10.009; Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Franco ML, 2002, PAIN CLINIC, V14, P99, DOI 10.1163/156856902760196315; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Kalso E, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-39; Kosinski MR, 2005, CURR MED RES OPIN, V21, P849, DOI 10.1185/030079905X46377; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; MCNAIRY SL, 1984, PAIN, V18, P169, DOI 10.1016/0304-3959(84)90884-4; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; Mirza SK, 2007, SPINE, V32, P816, DOI 10.1097/01.brs.0000259225.37454.38; Ohtori S, 2011, SPINE, V36, P347, DOI 10.1097/BRS.0b013e3181d0c944; Peloso PM, 2004, J RHEUMATOL, V31, P2454; Ruoff GE, 2003, CLIN THER, V25, P1123, DOI 10.1016/S0149-2918(03)80071-1; Schnitzer TJ, 2000, J RHEUMATOL, V27, P772; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	17	7	8	0	10	YONSEI UNIV COLLEGE MEDICINE	SEOUL	IN-HONG CHOI, M.D., PH D, 50 SEONGSAN-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796			YONSEI MED J	Yonsei Med. J.	JUL 1	2012	53	4					788	793		10.3349/ymj.2012.53.4.788			6	Medicine, General & Internal	General & Internal Medicine	958RQ	WOS:000305258500018	22665347	DOAJ Gold, Green Published			2020-06-30	J	Mittal, N; Tan, M; Egbuta, O; Desai, N; Crawford, C; Xie, CW; Evans, C; Walwyn, W				Mittal, Nitish; Tan, Miao; Egbuta, Onyemachi; Desai, Nina; Crawford, Cynthia; Xie, Cui-Wei; Evans, Christopher; Walwyn, Wendy			Evidence that Behavioral Phenotypes of Morphine in beta-arr2-/- Mice Are Due to the Unmasking of JNK Signaling	NEUROPSYCHOPHARMACOLOGY			English	Article						mu opioid receptor; JNK; beta-arrestin 2; morphine; analgesia; locomotion	MU-OPIOID RECEPTORS; KNOCK-OUT MICE; PROTEIN-KINASE-C; BETA-ARRESTIN 2; ANTINOCICEPTIVE TOLERANCE; JUN ACTIVATION; BETA-ARRESTIN-2; IDENTIFICATION; TRAFFICKING; DESENSITIZATION	The altered behavioral effects of morphine, but not most other mu agonists, in mice lacking beta-arrestin 2, suggest that this scaffolding protein regulates the signaling cascade of this commonly used analgesic. One of the cascades that could be regulated by beta-arrestin 2 is cJun-N-terminal kinase (JNK), which binds with beta-arrestin 2 and modulates the analgesic effects of morphine. Using neurons lacking beta-arrestin 2 (beta-arr2-/-) to examine this interaction, we found that beta-arr-/- neurons show altered intracellular distribution of JNK and cJun, and that morphine, but not fentanyl, increased the nuclear localization of the phosphorylated, therefore activated, form of cJun, a JNK target in dorsal root ganglia neurons. This suggests that deleting beta-arrestin 2 affects the JNK cascade. We therefore examined whether some of the behavioral phenotypes of mice lacking beta-arrestin 2 could be a result of altered JNK signaling. Indeed, two different JNK inhibitors reversed the enhanced analgesic effect of morphine, a known phenotype of beta-arr2-/- mice, to +/+ levels. Both the reduced locomotor effect of morphine and the psychomotor sensitization to repeated morphine administration in beta-arr2-/- mice were also returned to +/+ levels by inhibiting JNK. In contrast, the behavioral effects of fentanyl were neither genotype-dependent nor affected by JNK inhibition. Furthermore, a PKC inhibitor had a similar effect as inhibiting JNK in reducing the enhanced analgesic effect of morphine in beta-arr2-/- mice to +/+ levels. In summary, removing beta-arrestin 2 reveals mu receptor activation of the JNK cascade in a ligand-specific manner explaining several behavioral phenotypes of beta-arr2-/- mice.	[Mittal, Nitish; Tan, Miao; Egbuta, Onyemachi; Desai, Nina; Xie, Cui-Wei; Evans, Christopher; Walwyn, Wendy] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Stefan Hatos Ctr Neuropharmacol, Semel Inst, Los Angeles, CA 90095 USA; [Mittal, Nitish; Crawford, Cynthia] Calif State Univ San Bernardino, Dept Psychol, San Bernardino, CA 92407 USA	Walwyn, W (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Stefan Hatos Ctr Neuropharmacol, Semel Inst, Los Angeles, CA 90095 USA.	wwalwyn@ucla.edu	Crawford, cynthia/G-2603-2012	Mittal, Nitish/0000-0002-4934-3157; Crawford, Cynthia/0000-0001-8884-562X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA05010, R24-DA025319]; Hatos Scholarships; Gates Millennium Scholars program	This work was supported by NIH Grants DA05010 and R24-DA025319. O Egbuta, N Desai, N Mittal, and WM Walwyn are supported in part by Hatos Scholarships. N Mittal was also supported by the Gates Millennium Scholars program. Thanks to the laboratory of Robert Lefkowitz for the beta-arrestin-1 and 2 knockout mice.	Arttamangkul S, 2008, MOL PHARMACOL, V74, P972, DOI 10.1124/mol.108.048512; Becker A, 2001, N-S ARCH PHARMACOL, V363, P562, DOI 10.1007/s002100100404; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2003, J NEUROSCI, V23, P10265; Bohn LM, 2002, J NEUROSCI, V22, P10494; Bohn LM, 2000, J NEUROSCI, V20, P9040; Borgkvist A, 2008, NEUROPHARMACOLOGY, V55, P230, DOI 10.1016/j.neuropharm.2008.05.028; Borgkvist A, 2007, NEUROPSYCHOPHARMACOL, V32, P1995, DOI 10.1038/sj.npp.1301321; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Bruchas MR, 2010, PSYCHOPHARMACOLOGY, V210, P137, DOI 10.1007/s00213-010-1806-y; Chen Y, 2008, J NEUROSCI, V28, P5836, DOI 10.1523/JNEUROSCI.4170-07.2008; Dang VC, 2011, J NEUROSCI, V31, P7122, DOI 10.1523/JNEUROSCI.5999-10.2011; Galandrin S, 2008, MOL PHARMACOL, V74, P162, DOI 10.1124/mol.107.043893; GEE KW, 1983, ADV BIOCHEM PSYCHOPH, V38, P1; Groer CE, 2011, J BIOL CHEM, V286, P31731, DOI 10.1074/jbc.M111.248310; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Lam H, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-24; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Peng YY, 2009, BIOORGAN MED CHEM, V17, P6442, DOI 10.1016/j.bmc.2009.07.007; Ping PP, 2003, CIRC RES, V93, P595, DOI 10.1161/01.RES.0000093221.98213.E0; Pontrelli P, 2004, KIDNEY INT, V65, P2249, DOI 10.1111/j.1523-1755.2004.00644.x; Pradhan AAA, 2010, J NEUROSCI, V30, P16459, DOI 10.1523/JNEUROSCI.3748-10.2010; Quillinan N, 2011, J NEUROSCI, V31, P4434, DOI 10.1523/JNEUROSCI.4874-10.2011; Raehal KM, 2011, NEUROPHARMACOLOGY, V60, P58, DOI 10.1016/j.neuropharm.2010.08.003; Reiter E, 2012, ANNU REV PHARMACOL, V52, P179, DOI 10.1146/annurev.pharmtox.010909.105800; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Shenoy SK, 2011, TRENDS PHARMACOL SCI, V32, P521, DOI 10.1016/j.tips.2011.05.002; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Shukla AK, 2011, TRENDS BIOCHEM SCI, V36, P457, DOI 10.1016/j.tibs.2011.06.003; Song XF, 2006, J BIOL CHEM, V281, P21491, DOI 10.1074/jbc.M603659200; Song XF, 2009, J BIOL CHEM, V284, P685, DOI 10.1074/jbc.M806124200; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Stebbins JL, 2008, P NATL ACAD SCI USA, V105, P16809, DOI 10.1073/pnas.0805677105; Tan M, 2003, J NEUROSCI, V23, P10292; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Urs NM, 2011, NEUROPSYCHOPHARMACOL, V36, P551, DOI 10.1038/npp.2010.186; Vanderschuren LJMJ, 2010, CURR TOP BEHAV NEURO, V3, P179, DOI 10.1007/7854_2009_21; Walwyn W, 2007, J NEUROSCI, V27, P5092, DOI 10.1523/JNEUROSCI.1157-07.2007; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Willoughby EA, 2005, J BIOL CHEM, V280, P25651, DOI 10.1074/jbc.M501926200; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Xiao KH, 2010, P NATL ACAD SCI USA, V107, P15299, DOI 10.1073/pnas.1008461107; Zheng H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.177089	47	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JUL	2012	37	8					1953	1962		10.1038/npp.2012.42			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	960EZ	WOS:000305372100018	22491351	Green Published			2020-06-30	J	Holmgaard, R; Benfeldt, E; Nielsen, JB; Gatschelhofer, C; Sorensen, JA; Hofferer, C; Bodenlenz, M; Pieber, TR; Sinner, F				Holmgaard, R.; Benfeldt, E.; Nielsen, J. B.; Gatschelhofer, C.; Sorensen, J. A.; Hoefferer, C.; Bodenlenz, M.; Pieber, T. R.; Sinner, F.			Comparison of Open-Flow Microperfusion and Microdialysis Methodologies When Sampling Topically Applied Fentanyl and Benzoic Acid in Human Dermis Ex Vivo	PHARMACEUTICAL RESEARCH			English	Article						dermal; ex vivo; human; microdialysis; open-flow microperfusion	VITRO PERCUTANEOUS PENETRATION; SUBCUTANEOUS ADIPOSE-TISSUE; IN-VITRO; HUMAN-SKIN; DERMATOPHARMACOKINETIC METHOD; TRANSDERMAL FENTANYL; LIPOPHILIC COMPOUNDS; MODEL COMPOUNDS; ABSORPTION; RECOVERY	The purpose of this study is to compare two sampling methods-dermal Open-Flow Microperfusion (dOFM) and dermal Microdialysis (dMD) in an international joint experiment in a single-laboratory setting. We used human ex-vivo skin and sampled topically administered Fentanyl and Benzoic Acid. The second purpose was to provide guidance to researchers in choosing the most efficient method for a given penetrant and give suggestions concerning critical choices for successful dermal sampling. The dOFM and dMD techniques are compared in equal set-ups using three probe-types (one dOFM probe and two dMD probe-types) in donor skin (n = 9) - 27 probes of each type sampling each penetrant in solutions applied in penetrationchambers glued to the skin surface over a time range of 20 h. Pharmacokinetic results demonstrated concordance between dOFM and dMD sampling technique under the given experimental conditions. The methods each had advantages and limitations in technical, practical and hands-on comparisons. When planning a study of cutaneous penetration the advantages and limitations of each probe-type have to be considered in relation to the scientific question posed, the physico-chemical characteristics of the substance of interest, the choice of experimental setting e.g. ex vivo/in vivo and the analytical skills available.	[Holmgaard, R.] Univ Copenhagen, Roskilde Hosp, Dept Plast Surg, DK-4000 Roskilde, Denmark; [Holmgaard, R.; Nielsen, J. B.] Univ So Denmark, Dept Environm Med, Odense, Denmark; [Benfeldt, E.] Univ Copenhagen, Roskilde Hosp, Fac Hlth Sci, Dept Dermatol, DK-4000 Roskilde, Denmark; [Sorensen, J. A.] Odense Univ Hosp, Dept Plast & Reconstruct Surg, DK-5000 Odense, Denmark; [Pieber, T. R.; Sinner, F.] Med Univ Graz, Dept Endocrinol & Metab, Graz, Austria; [Gatschelhofer, C.; Hoefferer, C.; Bodenlenz, M.; Pieber, T. R.; Sinner, F.] Joanneum Res GmbH, HEALTH Inst Biomed & Hlth Sci, Graz, Austria	Holmgaard, R (reprint author), Univ Copenhagen, Roskilde Hosp, Dept Plast Surg, Kogevej 7-9, DK-4000 Roskilde, Denmark.	rikkeholmgaard@gmail.com	sorensen, jens/D-6279-2014	Sorensen, Jens Ahm/0000-0003-4903-0094; Bodenlenz, Manfred/0000-0001-7246-5120	Danish Agency of Science Technology and Innovation; Aage Bang's Foundation; Else and Mogens Wedell-Wedellsborgs Foundation; Aase and Ejnar Danielsens Foundation	R.H. holds a research grant from The Danish Agency of Science Technology and Innovation. This study was supported in part by grants from Aage Bang's Foundation, Else and Mogens Wedell-Wedellsborgs Foundation, Aase and Ejnar Danielsens Foundation, which are gratefully acknowledged.	ANDERSON C, 1991, ACTA DERM-VENEREOL, V71, P389; [Anonymous], 2004, OECD428; Au WL, 2012, SKIN PHARMACOL PHYS, V25, P17, DOI 10.1159/000330489; Benfeldt E, 1999, BRIT J DERMATOL, V140, P739; Benfeldt E, 2007, J INVEST DERMATOL, V127, P170, DOI 10.1038/sj.jid.5700495; Bodenlenz M, 2005, AM J PHYSIOL-ENDOC M, V289, pE296, DOI 10.1152/ajpendo.00431.2004; Bodenlenz M, 2011, J INVEST DERMATOL, V131, pS44; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; BRONAUGH RL, 1986, J PHARM SCI, V75, P1094, DOI 10.1002/jps.2600751115; CARNEHEIM C, 1991, PHARMACOL TOXICOL, V69, P378, DOI 10.1111/j.1600-0773.1991.tb01315.x; Chaurasia CS, 2007, PHARM RES, V24, P1014, DOI 10.1007/s11095-006-9206-z; Clough GF, 2005, AAPS J, V7, pE686, DOI 10.1208/aapsj070369; ECETOC, 1993, PERC ABS, V20, P1; Ellmerer M, 1999, DIABETES, V48, pA286; Ellmerer M, 1998, J CLIN ENDOCR METAB, V83, P4394, DOI 10.1210/jc.83.12.4394; Ellmerer M, 2000, AM J PHYSIOL-ENDOC M, V278, pE352; Ellmerer M, 1997, OPEN FLOW MICROPERFU; Gill C, 2011, AAPS J, V13, P309, DOI 10.1208/s12248-011-9269-6; Groth L, 1997, ANAL CHIM ACTA, V355, P75, DOI 10.1016/S0003-2670(97)81614-5; GUY RH, 1987, XENOBIOTICA, V17, P325, DOI 10.3109/00498258709043943; Herrero-Beaumont G, 2004, RHEUMATOL INT, V24, P325, DOI 10.1007/s00296-004-0520-7; Holmgaard R, 2012, SKIN PHARMACOL PHYS, V25, P9, DOI 10.1159/000330491; Holmgaard R, 2010, SKIN PHARMACOL PHYS, V23, P225, DOI 10.1159/000314698; Khramov AN, 1999, ANALYST, V124, P1027, DOI 10.1039/a901236b; KRILL SL, 1992, BIOCHIM BIOPHYS ACTA, V1112, P273, DOI 10.1016/0005-2736(92)90402-8; Larsen RH, 2003, PHARMACOL TOXICOL, V93, P244, DOI 10.1046/j.1600-0773.2003.pto930508.x; McCleverty D, 2006, INT J PHARMACEUT, V308, P1, DOI 10.1016/j.ijpharm.2005.09.020; Nielsen JB, 2011, SKIN PHARMACOL PHYS, V24, P93, DOI 10.1159/000322304; Nielsen JB, 2005, ARCH DERMATOL RES, V296, P560, DOI 10.1007/s00403-005-0555-y; Nielsen JB, 2004, ANN OCCUP HYG, V48, P697, DOI 10.1093/annhyg/meh070; Nielsen JB, 2010, INT ARCH OCC ENV HEA, V83, P683, DOI 10.1007/s00420-010-0546-y; Nielsen JB, 2009, J TOXICOL ENV HEAL A, V72, P315, DOI 10.1080/15287390802529872; OBATA Y, 1993, INT J PHARM, V89, P191, DOI 10.1016/0378-5173(93)90243-9; OECD, 28 OECD; Ortiz PG, 2008, CONTACT DERMATITIS, V59, P23, DOI 10.1111/j.1600-0536.2008.01348.x; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; ROUGIER A, 1990, ARCH DERMATOL RES, V282, P498, DOI 10.1007/BF00371943; Schaupp L, 1999, AM J PHYSIOL-ENDOC M, V276, pE401; Sjogren S, 2002, BRIT J DERMATOL, V146, P375, DOI 10.1046/j.1365-2133.2002.04621.x; Tettey-Amlalo RNO, 2009, EUR J PHARM SCI, V36, P219, DOI 10.1016/j.ejps.2008.09.002; Trajanoski Z, 1997, DIABETES CARE, V20, P1114, DOI 10.2337/diacare.20.7.1114; Trickler W, 2003, J PHARM SCI, V92, P1419, DOI 10.1002/jps.10410; van de Sandt JJM, 2004, REGUL TOXICOL PHARM, V39, P271, DOI 10.1016/j.yrtph.2004.02.004; Wang XD, 2006, ANAL CHEM, V78, P6026, DOI 10.1021/ac0602930; Ward KW, 2003, BIOPHARM DRUG DISPOS, V24, P17, DOI 10.1002/bdd.332; ZHAO YP, 1995, ANAL CHIM ACTA, V316, P403, DOI 10.1016/0003-2670(95)00379-E	46	20	20	1	19	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	JUL	2012	29	7					1808	1820		10.1007/s11095-012-0705-9			13	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	958FN	WOS:000305222000010	22419258				2020-06-30	J	Levy, BF; Fawcett, WJ; Scott, MJP; Rockall, TA				Levy, B. F.; Fawcett, W. J.; Scott, M. J. P.; Rockall, T. A.			Intra-operative oxygen delivery in infusion volume-optimized patients undergoing laparoscopic colorectal surgery within an enhanced recovery programme: the effect of different analgesic modalities	COLORECTAL DISEASE			English	Article						Oxygen delivery; laparoscopic; analgesia; fluid optimization	RANDOMIZED CONTROLLED-TRIAL; MAJOR ELECTIVE SURGERY; RISK SURGICAL PATIENTS; ESOPHAGEAL DOPPLER; HOSPITAL STAY; PREOPERATIVE OPTIMIZATION; FLUID MANAGEMENT; CLINICAL-TRIAL; BOWEL SURGERY; DOPEXAMINE	Aim Patients undergoing major open surgery who have an indexed oxygen delivery (DO2I) > 600 ml/min/m2 have been shown to have a lower incidence of morbidity and mortality compared with those whose DO2I is below this level. Laparoscopy and Trendelenburg positioning cause a reduction in DO2I. We aimed to quantify the effect of the type of analgesia on DO2I and to correlate the DO2I achieved with the incidence of anastomotic leakage in patients undergoing laparoscopic surgery. Method Following ethical approval, patients were randomized to receive spinal anaesthesia (Group S), epidural analgesia (Group E) or intravenous morphine (Group P) followed by postoperative patient-controlled analgesia (PCA). In addition to standard monitoring, oesophageal Doppler monitoring of the stroke volume allowed directed intravenous fluid therapy. The mean DO2I was compared with the anastomotic leakage rate. Results Seventy-five patients were recruited (Group S, 27; Group E, 23; Group P, 25). The mean (range) DO2I for all patients was 490 (230-750) ml/min/m2. The analgesic modality had no effect on DO2I. Of the 18 patients with a DO2I of < 400 ml/min/m2, four (22%) developed anastomotic leakage compared with one (%) of the 57 patients with a DO2I of > 400 ml/min/m2 (P = 0.01). Conclusion The analgesic modality used had no effect on the DO2I achieved. Anastomotic leakage was significantly higher in patients with a DO2I of < 400 ml/min/m2. A further study assessing the outcome after raising the DO2I with inotropes is required.	[Levy, B. F.; Rockall, T. A.] Univ Surrey, Post Grad Med Sch, Dept Surg, Inst Minimal Access Therapy Training Unit, Guildford GU2 7WG, Surrey, England; [Fawcett, W. J.; Scott, M. J. P.] Univ Surrey, Post Grad Med Sch, Dept Anesthesia, Inst Minimal Access Therapy Training Unit, Guildford GU2 7WG, Surrey, England	Levy, BF (reprint author), Univ Surrey, Post Grad Med Sch, Dept Surg, Inst Minimal Access Therapy Training Unit, Manor Pk, Guildford GU2 7WG, Surrey, England.	brucelevy22@hotmail.com					BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; Conway DH, 2002, ANAESTHESIA, V57, P845, DOI 10.1046/j.1365-2044.2002.02708.x; Dexter SPL, 1999, SURG ENDOSC, V13, P376, DOI 10.1007/s004649900993; Fearon KCH, 2005, CLIN NUTR, V24, P466, DOI 10.1016/j.clnu.2005.02.002; Fenwick E, 2002, INTENS CARE MED, V28, P599, DOI 10.1007/s00134-002-1257-y; Gan TJ, 2002, ANESTHESIOLOGY, V97, P820, DOI 10.1097/00000542-200210000-00012; Haxby EJ, 1997, BRIT J ANAESTH, V78, P515; Joshi GP, 2005, J CLIN ANESTH, V17, P117, DOI 10.1016/j.jclinane.2004.06.007; Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a; Koliopanos A, 2005, SURG LAPARO ENDO PER, V15, P332, DOI 10.1097/01.sle.0000191631.66505.4a; Meininger D, 2008, WORLD J SURG, V32, P1400, DOI 10.1007/s00268-007-9424-5; Noblett SE, 2006, BRIT J SURG, V93, P1069, DOI 10.1002/bjs.5454; Pearse RM, 2008, CRIT CARE MED, V36, P1323, DOI 10.1097/CCM.0b013e31816a091b; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; Sinclair S, 1997, BMJ-BRIT MED J, V315, P909; Stone MD, 2003, BRIT J ANAESTH, V91, P619, DOI 10.1093/bja/aeg245; Venn R, 2002, BRIT J ANAESTH, V88, P65, DOI 10.1093/bja/88.1.65; Wakeling HG, 2005, BRIT J ANAESTH, V95, P634, DOI 10.1093/bja/aei223; Wilson J, 1999, BRIT MED J, V318, P1099, DOI 10.1136/bmj.318.7191.1099	19	13	16	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8910			COLORECTAL DIS	Colorectal Dis.	JUL	2012	14	7					887	892		10.1111/j.1463-1318.2011.02805.x			6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	955CG	WOS:000304994100031	21895923				2020-06-30	J	Rabbitts, JA; Groenewald, CB; Rasanen, J				Rabbitts, Jennifer A.; Groenewald, Cornelius B.; Raesaenen, Jukka			Geographic differences in perioperative opioid administration in children	PEDIATRIC ANESTHESIA			English	Article						pain; pediatric; fentanyl; ethnicity; pharmacodynamic; pharmacokinetic	PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; ETHNIC-DIFFERENCES; AFRICAN-AMERICANS	Objectives: To investigate whether geographic differences exist in perioperative opioid administration to children. Aim: To investigate whether perioperative fentanyl use for cleft lip and palate surgery varies between children of three different geographic regions. Background: Differences have been found in perioperative opioid administration to children of differing ethnicity in the USA. Whether similar differences exist in perioperative opioid administration to children residing in different geographic regions is unknown. Methods/Materials: We retrospectively reviewed the medical records of ASA I children who underwent surgery under standardized general anesthesia between January 2010 and April 2011 during SMILE Network International mission trips to Africa, India and Central and South America. Perioperative administration of fentanyl was compared between these three locations. Results: We analyzed data from 79 children who underwent surgery in Africa, 76 in India and 153 in Central and South America. Children in Central and South America were given <50% of the intraoperative amount of fentanyl (2.0 +/- 1.2 mcg.kg-1) administered to children in Africa (4.1 +/- 2.4 mcg.kg-1; P < 0.001) and children in India (4.3 +/- 2.2 mcg.kg-1; P < 0.001). Postoperatively, fentanyl was administered in equivalent doses to all groups. Conclusions: Children in Central and South America received less opioid intraoperatively than African and Indian children, under standardized anesthesia for cleft surgeries. Further research is necessary to elucidate the mechanisms underlying these group differences.	[Rabbitts, Jennifer A.; Groenewald, Cornelius B.] Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA 98105 USA; [Rabbitts, Jennifer A.; Groenewald, Cornelius B.] Univ Washington, Seattle, WA 98105 USA; [Raesaenen, Jukka] Mayo Clin, Dept Anesthesiol, Rochester, MN USA	Rabbitts, JA (reprint author), Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, 4800 Sand Point Way NE,W9824, Seattle, WA 98105 USA.	jennifer.rabbitts@seattlechildrens.org			NIH/NCRR CTSAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)NIH National Center for Research Resources (NCRR) [UL1 RR024150]	The authors would like to thank Smile Network International for participating in this study and to acknowledge the life-changing charity service SNI and their volunteers and donors provide to children around the world http://www.smilenetwork.org. This project was supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Campbell CM, 2005, PAIN, V113, P20, DOI 10.1016/j.pain.2004.08.013; Fortier MA, 2009, PEDIATRICS, V124, P378, DOI 10.1542/peds.2008-3332; Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Jimenez N, 2010, J HEALTH CARE POOR U, V21, P229, DOI 10.1353/hpu.0.0236; Kain ZN, 2006, PEDIATRICS, V118, P651, DOI 10.1542/peds.2005-2920; Mechlin MB, 2005, PSYCHOSOM MED, V67, P948, DOI 10.1097/01.psy.0000188466.14546.68; Ng B, 1996, PSYCHOSOM MED, V58, P125, DOI 10.1097/00006842-199603000-00005; Ng B, 1996, PAIN, V66, P9, DOI 10.1016/0304-3959(96)02955-7; Palermo T M, 1998, Clin Nurs Res, V7, P275, DOI 10.1177/105477389800700305; Palermo TM, 1996, J PEDIATR PSYCHOL, V21, P683, DOI 10.1093/jpepsy/21.5.683; Rabbitts JA, 2010, PEDIATR ANESTH, V20, P1078, DOI 10.1111/j.1460-9592.2010.03453.x; Rahim-Williams FB, 2007, PAIN, V129, P177, DOI 10.1016/j.pain.2006.12.016; STRELTZER J, 1981, PSYCHOSOM MED, V43, P397, DOI 10.1097/00006842-198110000-00002; Tan EC, 2008, J PAIN, V9, P849, DOI 10.1016/j.jpain.2008.04.004	16	5	5	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUL	2012	22	7					676	681		10.1111/j.1460-9592.2012.03806.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	951IP	WOS:000304714500009	22324378	Green Accepted			2020-06-30	J	Maguma, HT; Dewey, WL; Akbarali, HI				Maguma, Hercules T.; Dewey, William L.; Akbarali, Hamid I.			Differences in the characteristics of tolerance to mu-opioid receptor agonists in the colon from wild type and beta-arrestin2 knockout mice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						mu-Opioid receptor; beta-Arrestin2; Opioid; Circular smooth muscle; Tolerance	PROTEIN-KINASE-C; BETA-ARRESTIN; MORPHINE-TOLERANCE; 7-TRANSMEMBRANE RECEPTORS; CIRCULAR MUSCLE; MOUSE; DESENSITIZATION; EFFICACY; RAT; MECHANISMS	Drawbacks to opioid use include development of analgesic tolerance and persistent constipation. We previously reported that tolerance to morphine develops upon repeated exposure in the isolated ileum but not the isolated colon. The cellular mechanisms of antinociceptive tolerance vary among mu-opioid receptor agonists. In this study, we assess beta-arrestin2 deletion on the development of tolerance to different opioids in ileum and colon circular muscle. Tolerance was determined by assessing the ability of repeated in-vitro opioid exposure to induce contraction of the circular muscle from C57BL/6 wild type (WT) and beta-arrestin2 knockout (KO) mice. Repeated exposure every 30 min with in-between washes resulted in tolerance to all agonists in the ileum of both WT and KO mice. However, in the colon of WT mice, comparison of the contractions between the 4th exposure and 1st response was similar to DAMGO (100 +/- 10%; N = 5) but reduced to fentanyl (62 +/- 13%; N = 8) and etorphine (38 +/- 4%; N = 7) indicative of tolerance to fentanyl and etorphine but not DAMGO. In contrast, all agonists produced tolerance in the colon of KO: DAMGO response at the 4th exposure decreased to 52 +/- 10% (N = 5), fentanyl to 20 +/- 5% (N = 6) and etorphine 33 +/- 7% (N = 6). Differences in tolerance among opioid agonists in the colon suggest ligand bias. The deletion of beta-arrestin2 in colon appears to be necessary for tolerance to DAMGO but not fentanyl or etorphine. beta-arrestin2 potentially represents an important target for treating opioid-induced bowel dysfunction and warrants further exploration of its ligand bias. (C) 2012 Elsevier B.V. All rights reserved.	[Maguma, Hercules T.; Dewey, William L.; Akbarali, Hamid I.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, VCU Program Enter Neuromuscular Sci, Richmond, VA 23298 USA	Akbarali, HI (reprint author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, VCU Program Enter Neuromuscular Sci, 1112 E Clay St,McGuire Hall 317, Richmond, VA 23298 USA.	hiakbarali@vcu.edu	Akbarali, Hamid/Q-9344-2019	Akbarali, Hamid/0000-0003-1423-0774	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA024009]	This work was supported by NIH DA024009.	AKBARALI H, 1987, CAN J PHYSIOL PHARM, V65, P23, DOI 10.1139/y87-005; Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Bernstein MA, 1998, MOL BRAIN RES, V55, P237, DOI 10.1016/S0169-328X(98)00005-9; BLOOM AS, 1978, PSYCHOPHARMACOLOGY, V57, P243, DOI 10.1007/BF00426745; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 2002, J NEUROSCI, V22, P10494; Gray AC, 2005, BRIT J PHARMACOL, V144, P687, DOI 10.1038/sj.bjp.0706107; GRIDER JR, 1987, J PHARMACOL EXP THER, V243, P205; HINE B, 1985, PSYCHOPHARMACOLOGY, V87, P34, DOI 10.1007/BF00431774; Holzer Peter, 2009, J Opioid Manag, V5, P145; Holzer P, 2009, REGUL PEPTIDES, V155, P11, DOI 10.1016/j.regpep.2009.03.012; Hull LC, 2010, J PHARMACOL EXP THER, V332, P1127, DOI 10.1124/jpet.109.161455; Iwata H, 2007, EUR J PHARMACOL, V574, P66, DOI 10.1016/j.ejphar.2007.06.029; Johnson EA, 2006, MOL PHARMACOL, V70, P676, DOI 10.1124/mol.106.022376; Kang MH, 2012, J PHARMACOL EXP THER, V340, P567, DOI 10.1124/jpet.111.186320; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; McPherson J, 2010, MOL PHARMACOL, V78, P756, DOI 10.1124/mol.110.066613; Narita M, 1996, BRIT J PHARMACOL, V118, P1829, DOI 10.1111/j.1476-5381.1996.tb15610.x; Nobles KN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001707; Pawar M, 2007, EUR J PHARMACOL, V563, P92, DOI 10.1016/j.ejphar.2007.01.059; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Raehal KM, 2011, PHARMACOL REV, V63, P1001, DOI 10.1124/pr.111.004598; Ross GR, 2008, J PHARMACOL EXP THER, V327, P561, DOI 10.1124/jpet.108.143438; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shukla AK, 2008, P NATL ACAD SCI USA, V105, P9988, DOI 10.1073/pnas.0804246105; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Smith FL, 2006, PHARMACOL RES, V54, P474, DOI 10.1016/j.phrs.2006.09.007; Thomas J, 2008, J PAIN SYMPTOM MANAG, V35, P103, DOI 10.1016/j.jpainsymman.2007.01.017; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	31	25	25	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JUN 15	2012	685	1-3					133	140		10.1016/j.ejphar.2012.04.001			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	944MC	WOS:000304205600018	22521552	Green Accepted			2020-06-30	J	Cha, SM; Kang, H; Baek, CW; Jung, YH; Koo, GH; Kim, BG; Choi, YS; Cha, SJ; Cha, YJ				Cha, Su Man; Kang, Hyun; Baek, Chong Wha; Jung, Yong Hun; Koo, Gill Hoi; Kim, Beom Gyu; Choi, Yoo Shin; Cha, Seong Jae; Cha, Young Joo			Peritrocal and Intraperitoneal Ropivacaine for Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-Blind Controlled Trial	JOURNAL OF SURGICAL RESEARCH			English	Article						intraperitoneal instillation; laparoscopic cholecystectomy; peritrocal infiltration; postoperative pain; ropivacaine	POSTOPERATIVE PAIN; PREEMPTIVE ANALGESIA; LOCAL-ANESTHESIA; BUPIVACAINE; PNEUMOPERITONEUM; PRESSURE	Background. The goal of this study was to evaluate the effect of peritrocal, intraperitoneal, or combined peritrocal-intraperitoneal ropivacaine on the parietal, visceral, and shoulder tip pain after laparoscopic cholecystectomy. Methods. Eighty patients were randomly assigned to four groups. Group A received peritrocal and intraperitoneal saline. Group B received peritrocal saline and intraperitoneal ropivacaine. Group C received peritrocal ropivacaine and intraperitoneal saline. Group D received peritrocal and intraperitoneal ropivacaine. The parietal, visceral, and shoulder tip pain were assessed at 2, 4, 8, 12, 24, and 48 h postoperatively using a visual analog scale (VAS). The frequency of the patient pushing the button of the PCA and fentanyl use were also recorded. Results. In visceral pain, significantly lower VAS scores were observed in Group B from 2 to 4 h and in Group D from 2 to 8 h. In parietal pain, significantly lower VAS scores were observed in Group C from 4 to 24 h and in Group D from 2 to 12 h. In shoulder tip pain, significantly lower VAS scores were observed in Group B from 4 to 48 h and in Group D from 2 to 12 h. The fentanyl use and the frequency to push the button of the PCA were the highest in Group A and the lowest in Group D at every time point. Conclusions. We conclude that peritrocal infiltration of ropivacaine significantly decreases parietal pain and intraperitoneal instillation of ropivacaine significantly decreases the visceral and shoulder tip pain. Their effects are additive with respect to the total pain. (C) 2012 Elsevier Inc. All rights reserved.	[Cha, Su Man; Kang, Hyun; Baek, Chong Wha; Jung, Yong Hun; Koo, Gill Hoi] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 156755, South Korea; [Kim, Beom Gyu; Choi, Yoo Shin; Cha, Seong Jae] Chung Ang Univ, Coll Med, Dept Surg, Seoul 156755, South Korea; [Cha, Young Joo] Chung Ang Univ, Coll Med, Dept Lab Med, Seoul 156755, South Korea; [Kang, Hyun; Cha, Young Joo] Chung Ang Univ, Coll Med, Med Device Clin Trials Ctr, Seoul 156755, South Korea	Kang, H (reprint author), Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 224-1 Heukseok Dong, Seoul 156755, South Korea.	roman00@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	Ministry of Health and Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A100054]	This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea. (A100054).	Ahmed BH, 2008, AM SURGEON, V74, P201; Barczynski M, 2006, SURG ENDOSC, V20, P1088, DOI 10.1007/s00464-005-0458-1; Bisgaard T, 1999, ANESTH ANALG, V89, P1017, DOI 10.1097/00000539-199910000-00036; Celik AS, 2010, SURG LAPARO ENDO PER, V20, P220, DOI 10.1097/SLE.0b013e3181e21bd1; Di Pace MR, 2009, J LAPAROENDOSC ADV S, V19, P821, DOI 10.1089/lap.2008.0227; HELVACIOGLU A, 1992, FERTIL STERIL, V57, P548; Jensen MP, 2010, BONICAS MANAGEMENT P, P251; JORGENSEN JO, 1995, AUST NZ J SURG, V65, P466, DOI 10.1111/j.1445-2197.1995.tb01787.x; JORIS J, 1995, ANESTH ANALG, V81, P379, DOI 10.1097/00000539-199508000-00029; Joshi GP, 2004, ANESTH ANALG, V98, P336, DOI 10.1213/01.ANE.0000093390.94921.4A; Lee IO, 2001, CAN J ANAESTH, V48, P545, DOI 10.1007/BF03016830; LIU J, 1993, ANESTH ANALG, V76, P1061; Liu YY, 2009, WORLD J GASTROENTERO, V15, P2376, DOI 10.3748/wjg.15.2376; Maestroni U, 2002, SURG ENDOSC, V16, P1336, DOI 10.1007/s00464-001-9181-8; McClure JH, 1996, BRIT J ANAESTH, V76, P300; Mouton WG, 1999, SURG ENDOSC, V13, P445, DOI 10.1007/s004649901011; NARCHI P, 1991, LANCET, V338, P1569, DOI 10.1016/0140-6736(91)92384-E; Pandey CK, 2004, CAN J ANAESTH, V51, P358, DOI 10.1007/BF03018240; Pasqualucci A, 1996, ANESTHESIOLOGY, V85, P11, DOI 10.1097/00000542-199607000-00003; Sarac AM, 1996, SURG LAPAROSC ENDOSC, V6, P362, DOI 10.1097/00019509-199610000-00005; Sarli L, 2000, BRIT J SURG, V87, P1161, DOI 10.1046/j.1365-2168.2000.01507.x; SOPER NJ, 1992, ARCH SURG-CHICAGO, V127, P917; URE BM, 1994, SURG ENDOSC-ULTRAS, V8, P90, DOI 10.1007/BF00316616; Wallace DH, 1997, BRIT J SURG, V84, P455; Wills VL, 2000, BRIT J SURG, V87, P273, DOI 10.1046/j.1365-2168.2000.01374.x	25	26	28	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	JUN 15	2012	175	2					251	258		10.1016/j.jss.2011.04.033			8	Surgery	Surgery	939AB	WOS:000303774400019	21658722				2020-06-30	J	Rousseau, P				Rousseau, Paul			Rocky	PALLIATIVE & SUPPORTIVE CARE			English	Editorial Material									[Rousseau, Paul] Med Univ S Carolina, Dept Gen Internal Med, Charleston, SC 29425 USA; [Rousseau, Paul] Med Univ S Carolina, Dept Geriatr, Charleston, SC 29425 USA; [Rousseau, Paul] Med Univ S Carolina, Dept Palliat & Support Care, Charleston, SC 29425 USA	Rousseau, P (reprint author), 81 Harbor Dr, Mt Pleasant, SC 29464 USA.	palliativedoctor@aol.com						0	0	0	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1478-9515			PALLIAT SUPPORT CARE	Palliat. Support Care	JUN	2012	10	2					141	142		10.1017/S1478951511000769			2	Health Policy & Services	Health Care Sciences & Services	022WX	WOS:000309996000010	22436531				2020-06-30	J	Rittgen, J; Putz, M; Zimmermann, R				Rittgen, Jan; Puetz, Michael; Zimmermann, Ralf			Identification of fentanyl derivatives at trace levels with nonaqueous capillary electrophoresis-electrospray-tandem mass spectrometry (MSn, n=2, 3): Analytical method and forensic applications	ELECTROPHORESIS			English	Article						Capillary electrophoresis-electrospray ionization mass spectrometry; Fentanyl derivatives; Forensic toxicology; Illicit drugs; Trace analysis	TOXICOLOGICAL DETECTION; HUMAN URINE; DRUGS; CARFENTANIL; METABOLISM; 3-METHYLFENTANYL; DISCRIMINATION; QUANTITATION; EXTRACTION; PEPTIDES	The identification of fentanyl derivatives at trace levels employing capillary electrophoresis coupled to electrospray ionization tandem mass spectrometry (CE-ESI-MSn, n = 2, 3) is presented. The studied synthetic opioid fentanyl and its derivatives have an exceeding analgesic potency which can be up to 8000 times higher that of morphine. Apart from their therapeutical applications, there is an abuse of them in the drug scene as a heroin substitute. The identification of these opioids at trace levels is of further significant forensic interest with respect to recent seizures of clandestine fentanyl laboratories in Germany. In this work, a nonaqueous capillary electrophoresis (NACE)-ESI-MSn procedure was developed for the separation and identification of six fentanyl derivatives including fentanyl, cis- and trans-methylfentanyl, sufentanil, alfentanil, and carfentanil. Their fragmentation pattern in MSn experiments were investigated as well as the influence of the sheath-liquid mixture and the influence of the inside diameter of the fused silica capillary on the peak shape and the signal to noise ratio. Method validation included determination of the detection limits (about 12 nmol/L) and the repeatability of migration time (at most 0.07% relative standard deviation). The NACE-MS procedure was successfully applied for the analysis of real samples from seizures in illegal fentanyl laboratories.	[Puetz, Michael] Bundeskriminalamt Fed Criminal Police Off, Forens Sci Inst, KT Toxicol 34, D-65203 Wiesbaden, Germany; [Rittgen, Jan; Zimmermann, Ralf] Univ Rostock, Chair Analyt Chem, Inst Chem, Joint Mass Spectrometry Ctr, Rostock, Germany; [Zimmermann, Ralf] German Res Ctr Environm Hlth GmbH, Cooperat Grp CMA Comprehens Mol Analyt, Helmholtz Zentrum Munchen, Joint Mass Spectrometry Ctr, Neuherberg, Germany	Putz, M (reprint author), Bundeskriminalamt Fed Criminal Police Off, Forens Sci Inst, KT Toxicol 34, Appelallee 45, D-65203 Wiesbaden, Germany.	michael.puetz@bka.bund.de					Alnajjar A, 2007, J CHROMATOGR B, V856, P62, DOI 10.1016/j.jchromb.2007.05.038; CAI JY, 1995, J CHROMATOGR A, V703, P667, DOI 10.1016/0021-9673(94)01178-H; CHENG MT, 1982, ANAL CHEM, V54, P2204, DOI 10.1021/ac00250a016; COOPER D, 1986, J FORENSIC SCI, V31, P511; Dieckmann S., 2008, BEITR GTFCH S AKT BE, P509; Enserink M, 2002, SCIENCE, V298, P1150, DOI 10.1126/science.298.5596.1150; Geiser L, 2003, ELECTROPHORESIS, V24, P3049, DOI 10.1002/elps.200305564; Gelpi E, 2002, J MASS SPECTROM, V37, P241, DOI 10.1002/jms.297; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Geschwinde T, 2007, RAUSCHDROGEN, P724; Gross ML, 2009, NATURE, V461, P340, DOI 10.1038/461340a; Huhn C, 2005, ELECTROPHORESIS, V26, P1389, DOI 10.1002/elps.200410163; Hunter RP, 2003, J CHROMATOGR B, V793, P351, DOI 10.1016/S1570-0232(03)00351-9; Ivanovic MD, 2004, J SERB CHEM SOC, V69, P511, DOI 10.2298/JSC0407511I; JANSSEN PAJ, 1960, J MED PHARMACEUT CH, V2, P31; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kearns KS, 1999, ZOO BIOL, V18, P397, DOI 10.1002/(SICI)1098-2361(1999)18:5&lt;397::AID-ZOO4&gt;3.0.CO;2-U; Kennedy S. K., 1990, PHARM BASICS THERAPE, P508; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Meyer MR, 2011, PHARMACOGENOMICS, V12, P215, DOI [10.2217/pgs.10.171, 10.2217/PGS.10.171]; Moini M, 2002, ANAL BIOANAL CHEM, V373, P466, DOI 10.1007/s00216-002-1283-1; Neususs C, 2002, ELECTROPHORESIS, V23, P3149, DOI 10.1002/1522-2683(200209)23:18<3149::AID-ELPS3149>3.0.CO;2-8; Ohnesorge J, 2005, ELECTROPHORESIS, V26, P3973, DOI 10.1002/elps.200500398; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; OLIVARES JA, 1987, ANAL CHEM, V59, P1230, DOI 10.1021/ac00135a034; Peer CJ, 2007, J ANAL TOXICOL, V31, P515, DOI 10.1093/jat/31.8.515; Pihlainen K, 2005, J MASS SPECTROM, V40, P539, DOI 10.1002/jms.831; Putz M., 2008, BEITR GTFCH S AKT BE, P487; Rieder J, 2003, LANCET, V361, P1131, DOI 10.1016/S0140-6736(03)12869-3; Riekkola ML, 2002, ELECTROPHORESIS, V23, P3865, DOI 10.1002/elps.200290007; Rittgen J, 2008, ELECTROPHORESIS, V29, P2094, DOI 10.1002/elps.200800055; Schiermeier Q, 2002, NATURE, V420, P7, DOI 10.1038/420007a; Schmitt-Kopplin P, 2003, ELECTROPHORESIS, V24, P3837, DOI 10.1002/elps.200305659; Simo C, 2005, ELECTROPHORESIS, V26, P1306, DOI 10.1002/elps.200410108; Staat K., 2007, DARMSTADTER ECHO, V63, P13; STANLEY TH, 1978, ANESTH ANALG, V57, P411; Stutz H, 2005, ELECTROPHORESIS, V26, P1254, DOI 10.1002/elps.200410130; SUZUKI S, 1986, CHEM PHARM BULL, V34, P1340; SUZUKI S, 1989, FORENSIC SCI INT, V43, P15, DOI 10.1016/0379-0738(89)90117-5; Theobald DS, 2006, J MASS SPECTROM, V41, P872, DOI 10.1002/jms.1045; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; von Brocke A, 2001, ELECTROPHORESIS, V22, P1251, DOI 10.1002/1522-2683(200105)22:7<1251::AID-ELPS1251>3.3.CO;2-0; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; YELNOSKY J, 1964, TOXICOL APPL PHARM, V6, P63, DOI 10.1016/0041-008X(64)90022-5	44	20	20	3	58	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	JUN	2012	33	11					1595	1605		10.1002/elps.201100655			11	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	965FW	WOS:000305753600015	22736362				2020-06-30	J	Sun, Q; Zhou, W; Wu, B; Ji, MH; Peng, YG				Sun, Qiang; Zhou, Wei; Wu, Bo; Ji, Mu-huo; Peng, Yong G.			Dezocine: a novel drug to prevent fentanyl-induced cough during general anesthesia induction?	JOURNAL OF ANESTHESIA			English	Letter									[Zhou, Wei; Ji, Mu-huo] Nanjing Univ, Sch Med, Jinling Hosp, Dept Anesthesiol, Nanjing 210002, Jiangsu, Peoples R China; [Sun, Qiang; Wu, Bo] Nanjing Med Univ, Coll Stomatol, Dept Anesthesiol, Inst Stomatol, Nanjing, Jiangsu, Peoples R China; [Peng, Yong G.] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL USA	Ji, MH (reprint author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Anesthesiol, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	ufo5201981@gmail.com					Sun ZT, 2011, J ANESTH	1	6	13	0	14	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	JUN	2012	26	3					470	470		10.1007/s00540-011-1318-x			1	Anesthesiology	Anesthesiology	958LY	WOS:000305240400028	22228499	Bronze			2020-06-30	J	Veldhorst-Janssen, NML; Fiddelers, AAA; Zandstra, H; Kessels, AGH; Zandstra, H; Marcus, MAE; Neef, C; van der Kuy, PHM				Veldhorst-Janssen, Nicole M. L.; Fiddelers, Audrey A. A.; Zandstra, Heleen; Kessels, Alfons G. H.; Zandstra, Heleen; Marcus, Marco A. E.; Neef, Cees; van der Kuy, Paul-Hugo M.			Patient Satisfaction with Intranasal Fentanyl for Breakthrough Pain	JOURNAL OF PALLIATIVE MEDICINE			English	Letter							CROSSOVER TRIAL; CANCER PAIN; OPEN-LABEL; SPRAY		[Veldhorst-Janssen, Nicole M. L.; Fiddelers, Audrey A. A.; Neef, Cees] Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, NL-6202 AZ Maastricht, Netherlands; [Fiddelers, Audrey A. A.; Zandstra, Heleen; Zandstra, Heleen; Marcus, Marco A. E.] Maastricht Univ, Med Ctr, Dept Anaesthesiol, Maastricht, Netherlands; [Kessels, Alfons G. H.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands; [van der Kuy, Paul-Hugo M.] Orbis Med Ctr Sittard, Dept Clin Pharmacol, Sittard, Netherlands	Veldhorst-Janssen, NML (reprint author), Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, POB 5800, NL-6202 AZ Maastricht, Netherlands.	n.veldhorst@mumc.nl					Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Veldhorst-Janssen NML, 2009, CLIN THER, V31, P2954, DOI 10.1016/j.clinthera.2009.12.015; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	7	5	5	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218			J PALLIAT MED	J. Palliat. Med.	JUN	2012	15	6					631	632		10.1089/jpm.2012.0013			2	Health Care Sciences & Services	Health Care Sciences & Services	952GA	WOS:000304778200002	22656053				2020-06-30	J	Vasudevan, A; Kundra, P; Priya, G; Nagalakshmi, P				Vasudevan, Arumugam; Kundra, Pankaj; Priya, Ganesan; Nagalakshmi, Palanisamy			Giant occipital encephalocele: a new paradigm	PEDIATRIC ANESTHESIA			English	Letter							AIRWAY MANAGEMENT		[Vasudevan, Arumugam; Kundra, Pankaj; Priya, Ganesan; Nagalakshmi, Palanisamy] JIPMER, Dept Anaesthesiol & Crit Care, Pondicherry, India	Vasudevan, A (reprint author), JIPMER, Dept Anaesthesiol & Crit Care, Pondicherry, India.	jipmervasu@gmail.com	Vasudevan, Arumugam/E-8975-2011				Dey N, 2007, PEDIATR ANESTH, V17, P1119, DOI 10.1111/j.1460-9592.2007.02311.x; Manhas Y, 2006, ANESTH ANALG, V103, P1632, DOI 10.1213/01.ane.0000247194.66024.d0; Ozlu O, 2008, PEDIATR ANESTH, V18, P792, DOI 10.1111/j.1460-9592.2008.02543.x; Quezado Z, 2008, ANESTH ANALG, V107, P1446, DOI 10.1213/ane.0b013e318183374f; Walia B, 2005, ARMED FORCES MED J I, V61, P293	5	3	3	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUN	2012	22	6					586	588		10.1111/j.1460-9592.2012.03850.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	943PP	WOS:000304137100019	22594415				2020-06-30	J	Shiota, M; Oda, Y; Taniguchi, M; Hamabata, T; Mizumoto, H; Hata, D				Shiota, Mitsutaka; Oda, Yutaka; Taniguchi, Masashi; Hamabata, Takayuki; Mizumoto, Hiroshi; Hata, Daisuke			Dexmedetomidine infusion for sedation in the intensive care setting in an infant with airway compromise due to congenital mediastinal neuroblastoma	PEDIATRIC ANESTHESIA			English	Letter									[Shiota, Mitsutaka; Taniguchi, Masashi; Hamabata, Takayuki; Mizumoto, Hiroshi; Hata, Daisuke] Kitano Hosp, Dept Pediat, Med Res Inst, Osaka, Japan; [Oda, Yutaka] Osaka City Univ, Grad Sch Med, Dept Anesthesiol & Intens Care Med, Osaka 558, Japan	Shiota, M (reprint author), Kitano Hosp, Dept Pediat, Med Res Inst, Osaka, Japan.	mi-shiota@kitano-hp.or.jp					ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027; GLASCOE FP, 1992, PEDIATRICS, V89, P1221; Hammer GB, 2005, PEDIATR ANESTH, V15, P616, DOI 10.1111/j.1460-9592.2005.01656.x; Lam F, 2012, PEDIATR CARDIOL, V33, P1069, DOI 10.1007/s00246-012-0227-6; Oda Y, 2007, ANESTH ANALG, V105, P1272, DOI 10.1213/01.ane.0000281075.77316.98; Potts AL, 2009, PEDIATR ANESTH, V19, P1119, DOI 10.1111/j.1460-9592.2009.03133.x	6	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	JUN	2012	22	6					603	605		10.1111/j.1460-9592.2012.03865.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	943PP	WOS:000304137100030	22594426				2020-06-30	J	Tran, KM; Maxwell, LG; Cohen, DE; Adamson, PC; Moll, V; Kurth, CD; Galinkin, JL				Tran, Kha M.; Maxwell, Lynne G.; Cohen, David E.; Adamson, Peter C.; Moll, Vanessa; Kurth, C. Dean; Galinkin, Jeffrey L.			Quantification of Serum Fentanyl Concentrations from Umbilical Cord Blood During Ex Utero Intrapartum Therapy	ANESTHESIA AND ANALGESIA			English	Article							FETAL PAIN; PHARMACOKINETICS	Fetal IM injection of fentanyl is frequently performed during ex utero intrapartum therapy (EXIT procedure). We quantified the concentration of fentanyl in umbilical vein blood. Thirteen samples from 13 subjects were analyzed. Medians and ranges are reported as follows. Weight of the newborn at delivery was 3000 g (2020-3715 g). The dose of fentanyl was 60 mu s (45-65 mu g). The time between IM administration of fentanyl and collection of the sample was 37 minutes (5-86 minutes). Fentanyl was detected in all of the samples, with a median serum concentration of 14.0 ng/mL (4.3-64.0 ng/mL). (Anesth Analg 2012;114:1265-7)	[Tran, Kha M.; Maxwell, Lynne G.; Cohen, David E.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Adamson, Peter C.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Moll, Vanessa; Galinkin, Jeffrey L.] Univ Colorado Denver, Dept Anesthesiol, Aurora, CO USA; [Galinkin, Jeffrey L.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Kurth, C. Dean] Univ Cincinnati, Coll Med, Dept Anesthesia, Cincinnati, OH USA; [Kurth, C. Dean] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA	Tran, KM (reprint author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, 34th St & Civ Ctr Blvd,9th Floor,Room 9304, Philadelphia, PA 19104 USA.	trank@email.chop.edu		Moll, Vanessa/0000-0001-6092-0202; Maxwell, Lynne/0000-0002-4406-9232			Adzick NS, 2011, NEW ENGL J MED, V364, P993, DOI 10.1056/NEJMoa1014379; Bouchard S, 2002, J PEDIATR SURG, V37, P418, DOI 10.1053/jpsu.2002.30839; COLLINS C, 1985, ANESTH ANALG, V64, P1078; Derbyshire SWG, 2006, BRIT MED J, V332, P909, DOI 10.1136/bmj.332.7546.909; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Fisk NM, 2001, ANESTHESIOLOGY, V95, P828, DOI 10.1097/00000542-200110000-00008; Gaiser RR, 1997, ANESTH ANALG, V84, P1150, DOI 10.1097/00000539-199705000-00039; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; Lee SJ, 2005, JAMA-J AM MED ASSOC, V294, P947, DOI 10.1001/jama.294.8.947; Myers LB, 2006, JAMA-J AM MED ASSOC, V295, P159, DOI 10.1001/jama.295.2.159-a; Tran KM, 2010, SEMIN FETAL NEONAT M, V15, P40, DOI 10.1016/j.siny.2009.05.004; Tworetzky W, 2004, CIRCULATION, V110, P2125, DOI 10.1161/01.CIR.0000144357.29279.54; Van de Velde M, 2006, SEMIN FETAL NEONAT M, V11, P232, DOI 10.1016/j.siny.2006.02.012	14	8	9	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2012	114	6					1265	1267		10.1213/ANE.0b013e3182378d21			3	Anesthesiology	Anesthesiology	948LF	WOS:000304504000018	22025493				2020-06-30	J	Gitto, E; Pellegrino, S; Manfrida, M; Aversa, S; Trimarchi, G; Barberi, I; Reiter, RJ				Gitto, Eloisa; Pellegrino, Salvatore; Manfrida, Maria; Aversa, Salvatore; Trimarchi, Giuseppe; Barberi, Ignazio; Reiter, Russel J.			Stress response and procedural pain in the preterm newborn: the role of pharmacological and non-pharmacological treatments	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						Preterm; Stress response; Interleukins; Procedural pain	RANDOMIZED CONTROLLED-TRIAL; INTENSIVE-CARE-UNIT; PREMATURE-INFANTS; LEUKOCYTE RECRUITMENT; VENTILATORY SUPPORT; SENSORY SATURATION; PERIPHERAL TISSUE; SOLUBLE RECEPTOR; NEONATAL PAIN; ANALGESIA	Repeated invasive procedures occur routinely in neonates who require intensive care, causing pain at a time when it is developmentally unexpected. Multiple lines of evidence suggest that repeated and prolonged pain exposure alters their subsequent pain processing, long-term development, and behaviour. Primary outcome of this study was to evaluate the reduction of procedural pain induced by "heel-lances" in preterm newborns with three different treatment [administration of fentanyl (FE, 1-2 mu g/kg), facilitated tucking (FT), sensorial saturation (SS)]. Secondary outcome was the measurement of the levels of cytokines as markers of stress correlated to pain. A prospective randomized controlled trial (RCT) comparing three different pharmacological or non-pharmacological treatments was performed involving 150 preterm newborn (gestational age 27-32 weeks). No other analgesic treatment was performed during the study. CRIES score was used to evaluate the procedural pain. The results showed that the reduction in the pain score was greater in FE and SS groups than FS group. The differences were statistically significant (p < 0.01). The levels of IL-6, IL-8, and TNF-alpha were higher in the FT individuals than in the FE or SS-treated infants at 1 day (p < 0.01), at 3 days (p < 0.01), and at 7 days (p < 0.01) of life. Conclusions: The findings of this study suggest that FE and SS provide a superior analgesia in preterm neonates during procedural pain. In particular, sensorial saturation seems to be an important non-pharmacological alternative treatment to prevent and reduce the procedural pain in preterm newborn.	[Gitto, Eloisa; Manfrida, Maria; Aversa, Salvatore; Barberi, Ignazio] Univ Messina, Neonatal Intens Care Unit, Dept Pediat, Messina, Italy; [Pellegrino, Salvatore] Univ Hosp G Martino, Messina, Italy; [Trimarchi, Giuseppe] Univ Messina, Dept Stat, Messina, Italy; [Reiter, Russel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	Gitto, E (reprint author), Univ Messina, Neonatal Intens Care Unit, Dept Pediat, Via Consolare Valeria,CAP 98100, Messina, Italy.	egitto@unime.it	Aversa, Salvatore/AAA-9665-2019	Aversa, Salvatore/0000-0003-2634-1498; Pellegrino, Salvatore/0000-0003-1163-0748; Gitto, Eloisa/0000-0001-7442-8630; TRIMARCHI, Giuseppe/0000-0003-3720-0404			Adams H A, 1991, Anasthesiol Intensivmed Notfallmed Schmerzther, V26, P294, DOI 10.1055/s-2007-1000588; ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; Anand KJS, 2000, BIOL NEONATE, V77, P69, DOI 10.1159/000014197; Anand KJS, 2006, PEDIATRICS, V117, pS9, DOI 10.1542/peds.2005-0620C; Anand KJS, 1998, BIOL NEONATE, V73, P1, DOI 10.1159/000013953; Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; ANAND KJS, 1985, MODERN PROBLEMS PAED, V23, P143; Aretz S, 2004, BIOL NEONATE, V85, P243, DOI 10.1159/000076238; ARNOLD JH, 1991, J PEDIATR-US, V119, P639, DOI 10.1016/S0022-3476(05)82419-9; Bellieni C V, 2003, Ethics Med, V19, P5; Bellieni CV, 2007, CLIN J PAIN, V23, P219, DOI 10.1097/AJP.0b013e31802e3bd7; Bellieni CV, 2003, BIOL NEONATE, V84, P202, DOI 10.1159/000072303; Bellieni CV, 2002, PEDIATR RES, V51, P460, DOI 10.1203/00006450-200204000-00010; Bellieni CV, 2001, BIOL NEONATE, V80, P15, DOI 10.1159/000047113; Bellu R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004212.pub3; Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542-200603000-00005; Carbajal Ricardo, 2004, Expert Rev Neurother, V4, P491, DOI 10.1586/14737175.4.3.491; Carvalho B, 2008, J PAIN, V9, P650, DOI 10.1016/j.jpain.2008.02.004; Chichorro JG, 2004, BRIT J PHARMACOL, V141, P1175, DOI 10.1038/sj.bjp.0705724; Cignacco E, 2007, EUR J PAIN, V11, P139, DOI 10.1016/j.ejpain.2006.02.010; Corff K E, 1995, J Obstet Gynecol Neonatal Nurs, V24, P143, DOI 10.1111/j.1552-6909.1995.tb02456.x; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; CZLONKOWSKI A, 1993, EUR J PHARMACOL, V242, P229, DOI 10.1016/0014-2999(93)90246-E; De Jongh RF, 2003, ANESTH ANALG, V96, P1096, DOI 10.1213/01.ANE.0000055362.56604.78; DYKE MP, 1995, J PAEDIATR CHILD H, V31, P176, DOI 10.1111/j.1440-1754.1995.tb00780.x; FITZGERALD M, 1988, LANCET, V1, P292; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Goldman RD, 2002, CLIN PERINATOL, V29, P415, DOI 10.1016/S0095-5108(02)00014-3; Goldstein R F, 1991, J Perinatol, V11, P365; Grunau R, 2002, CLIN PERINATOL, V29, P373; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; Hall RW, 2007, SEMIN PERINATOL, V31, P289, DOI 10.1053/j.semperi.2007.07.002; Huang Chin-Mei, 2004, J Nurs Res, V12, P31; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Jones JE, 2001, CLIN OBSTET GYNECOL, V44, P750, DOI 10.1097/00003081-200112000-00012; Kehlet H, 1988, Acta Anaesthesiol Belg, V39, P143; Khadra A, 2006, BJU INT, V97, P1043, DOI 10.1111/j.1464-410X.2006.06133.x; KRECHEL SW, 1995, PAEDIATR ANAESTH, V5, P53, DOI 10.1111/j.1460-9592.1995.tb00242.x; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; Menon G, 1998, SEMIN PERINATOL, V22, P417, DOI 10.1016/S0146-0005(98)80057-8; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; POKELA ML, 1994, PEDIATRICS, V93, P379; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Steed DL, 1997, SURG CLIN N AM, V77, P575, DOI 10.1016/S0039-6109(05)70569-7; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; Stevens B, 2000, PEDIATR CLIN N AM, V47, P633, DOI 10.1016/S0031-3955(05)70230-3; STEVENS BJ, 1994, NURS RES, V43, P226; Suganuma M, 2002, INT J ONCOL, V20, P131; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; Uceyler N, 2008, NEUROSCI LETT, V437, P194, DOI 10.1016/j.neulet.2008.03.050; Wang XM, 2009, PAIN, V142, P275, DOI 10.1016/j.pain.2009.02.001; Ward-Larson Charlotte, 2004, MCN Am J Matern Child Nurs, V29, P151, DOI 10.1097/00005721-200405000-00004; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Winberg J, 1998, ACTA PAEDIATR, V87, P723, DOI 10.1080/080352598750013761; Yamada J, 2008, PAIN RES MANAG, V13, P413, DOI 10.1155/2008/232316	62	22	25	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6199	1432-1076		EUR J PEDIATR	Eur. J. Pediatr.	JUN	2012	171	6					927	933		10.1007/s00431-011-1655-7			7	Pediatrics	Pediatrics	945WC	WOS:000304306100007	22207490				2020-06-30	J	Bjelland, TW; Dale, O; Kaisen, K; Haugen, BO; Lydersen, S; Strand, K; Klepstad, P				Bjelland, Thor W.; Dale, Ola; Kaisen, Kjell; Haugen, Bjorn O.; Lydersen, Stian; Strand, Kristian; Klepstad, Pal			Propofol and remifentanil versus midazolam and fentanyl for sedation during therapeutic hypothermia after cardiac arrest: a randomised trial	INTENSIVE CARE MEDICINE			English	Article						Induced hypothermia; Heart arrest; Coma; Deep sedation; Analgesia; Clinical pharmacology	CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; EUROPEAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; MILD HYPOTHERMIA; COMATOSE SURVIVORS; STROKE-FOUNDATION; PRACTICAL SCALE; OPEN-LABEL; PHARMACOKINETICS	To compare two protocols for sedation and analgesia during therapeutic hypothermia: midazolam and fentanyl versus propofol and remifentanil. The primary outcome was the time from discontinuation of infusions to extubation or decision not to extubate (offset time). Secondary outcomes were blood pressure, heart rate, use of vasopressors and inotropic drugs, pneumonia and neurological outcome. This was an open, randomised, controlled trial on 59 patients treated with therapeutic hypothermia (33-34 A degrees C for 24 h) after cardiac arrest in two Norwegian university hospitals between April 2008 and May 2009. The intervention was random allocation to sedation and analgesia with propofol/remifentanil or midazolam/fentanyl. Twenty-nine patients received propofol and remifentanil, and 30 midazolam and fentanyl. Baseline characteristics were similar. Sedation and analgesia were stopped in 35 patients, and extubation was performed in 17 of these. Sedation had to be continued for 24 patients. Time to offset was significantly lower in patients given propofol and remifentanil [mean (95 % confidence intervals) 13.2 (2.3-24) vs. 36.8 (28.5-45.1) h, respectively, < 0.001]. Patients given propofol and remifentanil needed norepinephrine infusions twice as often (23 vs. 12 patients, = 0.003). Incidence of pneumonia and 3-month neurological outcome were similar in the two groups. Time to offset was significantly shorter in patients treated with propofol and remifentanil. However, the clinical course in 40 % of patients prevented discontinuation of sedation and potential benefits from a faster recovery. The propofol and remifentanil group required norepinephrine twice as often, but both protocols were tolerated in most patients.	[Bjelland, Thor W.; Dale, Ola; Haugen, Bjorn O.; Klepstad, Pal] Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Dale, Ola; Klepstad, Pal] St Olavs Hosp, Dept Anaesthesiol & Emergency Med, N-7006 Trondheim, Norway; [Haugen, Bjorn O.] St Olavs Hosp, Dept Cardiol, N-7006 Trondheim, Norway; [Kaisen, Kjell; Strand, Kristian] Stavanger Univ Hosp, Dept Anaesthesiol & Intens Care, N-4011 Stavanger, Norway; [Lydersen, Stian] Norwegian Univ Sci & Technol, Unit Appl Clin Res, N-7491 Trondheim, Norway	Bjelland, TW (reprint author), Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway.	thor.w.bjelland@ntnu.no			Norwegian University of Science and Technology; St. Olavs Hospital; Royal Norwegian Society of Sciences and Letters	PK and KK received support for travel to a scientific meeting. No other authors have declared potential conflicts of interest. This study was funded by the Norwegian University of Science and Technology. Grants for sub-studies were given by St. Olavs Hospital and The Royal Norwegian Society of Sciences and Letters. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	ALCARAZ C, 1989, ARCH INT PHARMACOD T, V297, P133; Arpino PA, 2008, PHARMACOTHERAPY, V28, P102, DOI 10.1592/phco.28.1.102; Bauer C, 2007, ANAESTHESIST, V56, P128, DOI 10.1007/s00101-006-1130-4; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Chamorro C, 2010, ANESTH ANALG, V110, P1328, DOI 10.1213/ANE.0b013e3181d8cacf; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Galili T, 2010, BARNARDS EXACT TEST; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; JENNETT B, 1975, LANCET, V1, P480; KELSEY SF, 1986, AM J EMERG MED, V4, P72; Komatsu R, 2007, ANAESTHESIA, V62, P1266, DOI 10.1111/j.1365-2044.2007.05221.x; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Luna CM, 2003, CRIT CARE MED, V31, P676, DOI 10.1097/01.CCM.0000055380.86458.1E; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Marchick MR, 2009, INTENS CARE MED, V35, P1261, DOI 10.1007/s00134-009-1448-x; Michelsen LG, 2001, ANESTH ANALG, V93, P1100, DOI 10.1097/00000539-200111000-00006; Mongardon N, 2011, CRIT CARE MED, V39, P1359, DOI 10.1097/CCM.0b013e3182120b56; MORTENSEN B, 1995, ACTA ANAESTH SCAND, V39, P199, DOI 10.1111/j.1399-6576.1995.tb04043.x; Muellejans B, 2006, CRIT CARE, V10, DOI 10.1186/cc4939; Muller L, 2008, ANN FR ANESTH, V27; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2011, CRIT CARE MED, V39, P57, DOI 10.1097/CCM.0b013e3181fa4301; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; R Development Core Team, 2008, R LANG ENV STAT COMP; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; SEBEL PS, 1995, ANESTH ANALG, V80, P990, DOI 10.1097/00000539-199505000-00024; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Spies C, 2011, INTENS CARE MED, V37, P469, DOI 10.1007/s00134-010-2100-5; TEASDALE G, 1974, LANCET, V2, P81; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Varghese JM, 2010, CURR OPIN ANESTHESIO, V23, P472, DOI 10.1097/ACO.0b013e328339ef0a; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Zwarenstein M, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2390	41	41	42	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2012	38	6					959	967		10.1007/s00134-012-2540-1			9	Critical Care Medicine	General & Internal Medicine	943RO	WOS:000304143100006	22527063				2020-06-30	J	Welzing, L; Oberthuer, A; Junghaenel, S; Harnischmacher, U; Stutzer, H; Roth, B				Welzing, Lars; Oberthuer, Andre; Junghaenel, Shino; Harnischmacher, Urs; Stuetzer, Hartmut; Roth, Bernhard			Remifentanil/midazolam versus fentanyl/midazolam for analgesia and sedation of mechanically ventilated neonates and young infants: a randomized controlled trial	INTENSIVE CARE MEDICINE			English	Article						Mechanically ventilated infants; Analgesia and sedation; Remifentanil; Efficacy; Safety; Extubation time	INTENSIVE-CARE-UNIT; CRITICALLY-ILL CHILDREN; PHARMACOKINETICS; FENTANYL; SURGERY; EXPERIENCE; ANESTHESIA; MIDAZOLAM	Common opioids for analgesia and sedation of mechanically ventilated infants may tend to accumulate and cause prolonged sedation with an unpredictable extubation time. Remifentanil is a promising option due to its unique pharmacokinetic properties, which seem to be valid in adults as well as in infants. In this double-blind, randomized, controlled trial mechanically ventilated neonates and young infants (< 60 days) received either a remifentanil or fentanyl-based analgesia and sedation regimen with low dose midazolam. The primary endpoint of the trial was the extubation time following discontinuation of the opioid infusion. Secondary endpoints included efficacy and safety aspects. Between November 2006 and March 2010, we screened 431 mechanically ventilated infants for eligibility. The intention to treat group included 23 infants who were assigned to receive either remifentanil ( = 11) or fentanyl ( = 12). Although this was designed as a pilot study, median extubation time was significantly shorter in the remifentanil group (80.0 min, IQR = 15.0-165.0) compared to the fentanyl group (782.5 min, IQR = 250.8-1,875.0) ( = 0.005). Remifentanil and fentanyl provided comparable efficacy with more than two-thirds of the measurements indicating optimal analgesia and sedation (66.4 and 70.2 %, respectively; = 0.743). Overall, both groups had good hemodynamic stability and a comparably low incidence of adverse events. As neonates and young infants have a decreased metabolism of common opioids like fentanyl and are more prone to respiratory depression, remifentanil could be the ideal opioid for analgesia and sedation of mechanically ventilated infants.	[Welzing, Lars; Oberthuer, Andre; Junghaenel, Shino; Roth, Bernhard] Univ Hosp Cologne, Childrens Hosp, Dept Neonatol & Paediat Intens Care, D-50937 Cologne, Germany; [Harnischmacher, Urs] Univ Cologne, Clin Trials Ctr Cologne, BMBF 01KN1106, ZKS Koeln, Cologne, Germany; [Stuetzer, Hartmut] Univ Hosp Cologne, Inst Med Stat Informat & Epidemiol, D-50937 Cologne, Germany	Welzing, L (reprint author), Univ Hosp Cologne, Childrens Hosp, Dept Neonatol & Paediat Intens Care, Kerpener Str 62, D-50937 Cologne, Germany.	lars.welzing@uk-koeln.de			GlaxoSmithKline (Munich, Germany)GlaxoSmithKline; University of Cologne	This study was supported by a grant from GlaxoSmithKline (Munich, Germany) and by departmental sources. GlaxoSmithKline had no influence on study design, data analysis, or writing of the manuscript. The sponsor of the clinical trial, in accordance with Good Clinical Practice, was the University of Cologne.	Akinci SB, 2005, PEDIATR ANESTH, V15, P870, DOI 10.1111/j.1460-9592.2005.01574.x; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; BURTIN P, 1994, CLIN PHARMACOL THER, V56, P615, DOI 10.1038/clpt.1994.186; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; Giannantonio C, 2009, ACTA PAEDIATR, V98, P1111, DOI 10.1111/j.1651-2227.2009.01318.x; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Hunseler C, 2011, EUR J PEDIATR, V170, P837, DOI 10.1007/s00431-010-1354-9; Jackson DL, 2010, CRIT CARE, V14, DOI 10.1186/cc8956; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Marsh DF, 2009, ANAESTHESIA, V64, P301, DOI 10.1111/j.1365-2044.2008.05731.x; Michel F, 2008, PEDIATR ANESTH, V18, P532, DOI 10.1111/j.1460-9592.2008.02514.x; Molina PE, 2006, J INTERN MED, V259, P138, DOI 10.1111/j.1365-2796.2005.01569.x; Muellejans B, 2004, CRIT CARE, V8, pR1, DOI 10.1186/cc2398; Notterman DA, 1997, CLIN PEDIATR, V36, P449, DOI 10.1177/000992289703600803; Penido MG, 2010, ACTA PAEDIATR, V99, P1454, DOI 10.1111/j.1651-2227.2010.01868.x; Pereira e Silva Y, 2005, PAEDIATR ANAESTH, V15, P993; Pietrini D, 2005, PEDIATR ANESTH, V15, P653, DOI 10.1111/j.1460-9592.2005.01498.x; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Ross AK, 2001, ANESTH ANALG, V93, P1393, DOI 10.1097/00000539-200112000-00008; Roulleau P, 2003, PAEDIATR ANAESTH, V13, P701, DOI 10.1046/j.1460-9592.2003.01102.x; Schmidt B, 2010, KLIN PADIATR, V222, P62, DOI 10.1055/s-0029-1225348; Spies C, 2011, INTENS CARE MED, V37, P469, DOI 10.1007/s00134-010-2100-5; Stoppa F, 2004, Minerva Anestesiol, V70, P753; Welzing L, 2006, DRUGS, V66, P1339, DOI 10.2165/00003495-200666100-00003; Welzing L, 2011, EUR J PEDIATR, V170, P477, DOI 10.1007/s00431-010-1312-6; Welzing L, 2011, ANESTHESIOLOGY, V114, P570, DOI 10.1097/ALN.0b013e318204e043	29	16	17	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2012	38	6					1017	1024		10.1007/s00134-012-2532-1			8	Critical Care Medicine	General & Internal Medicine	943RO	WOS:000304143100013	22456770				2020-06-30	J	Saunders, DL; Messina, J; Darwish, M; Xie, F; Leary, KJ; Cantilena, LR				Saunders, David L.; Messina, John; Darwish, Mona; Xie, Fang; Leary, Kevin J.; Cantilena, Louis R.			Assessment of the Relative Potency of Fentanyl Buccal Tablet to Intravenous Morphine in Healthy Volunteers Using a Thermally Induced Hyperalgesia Pain Model	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						analgesic effects; fentanyl buccal tablet; intravenous morphine; relative potency; thermally induced hyperalgesia	PUPILLARY DILATION; POSTOPERATIVE PAIN; BREAKTHROUGH PAIN; PHARMACOKINETICS; CAPSAICIN; PLACEBO; BIOAVAILABILITY; CITRATE; REFLEX; SKIN	This exploratory randomized, double-blind, placebo-controlled, 5-treatment, 5-period crossover study was conducted using a thermally induced hyperalgesia pain model in 51 healthy volunteers (33 evaluable) to characterize the relative potency of fentanyl buccal tablet (FBT) versus intravenous morphine. Relative potency was assessed using the sum of pain intensity differences over 60 minutes after the application of a 43 degrees C, 46 degrees C, and 49 degrees C painful stimulus following thermally induced hyperalgesia. Relative potency was also assessed by pupil diameter and responses to subjective questionnaires. The relative potency of FBT was 46.2 times that of intravenous morphine (95% confidence interval [CI] 17.6-575.3) based on the 49 C stimulus. The relative potency of FBT based on opiate-induced miosis was 44.6 (95% CI, 29.7-77.0) at 60 minutes. These results are an initial relative potency assessment and should not be considered guidance for dose-equivalent switching between agents in clinical practice.	[Cantilena, Louis R.] Uniformed Serv Univ Hlth Sci, Div Clin Pharmacol & Med Toxicol, Bethesda, MD 20814 USA; [Messina, John; Darwish, Mona; Xie, Fang] Cephalon Inc, Clin Res, Frazer, PA USA	Cantilena, LR (reprint author), Uniformed Serv Univ Hlth Sci, Div Clin Pharmacol & Med Toxicol, Bldg 53,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	lcantilena@usuhs.mil			Cephalon, Inc (Frazer, Pennsylvania); Cephalon, Inc.	This study was sponsored by Cephalon, Inc (Frazer, Pennsylvania). Writing support was provided by Peloton Advantage, LLC, funded by Cephalon, Inc. Dr Saunders, Dr Leary, and Dr Cantilena have no conflicts of interest to report. Dr Messina is a former employee of and Dr Darwish and Dr Xie are current employees of Cephalon, Inc.	Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; [Anonymous], 2011, FENTORA PACK INS; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Dershwitz M, 2000, ANESTHESIOLOGY, V93, P619, DOI 10.1097/00000542-200009000-00009; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eisenach JC, 1998, ANESTH ANALG, V87, P591, DOI 10.1097/00000539-199809000-00018; FINNEY DJ, 1978, STAT METHODS BIOL AS; Freye E., 2008, OPIOIDS MED COMPREHE; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; HOSKIN PJ, 1989, BRIT J CLIN PHARMACO, V27, P499, DOI 10.1111/j.1365-2125.1989.tb05399.x; KILO S, 1994, BRAIN, V117, P385, DOI 10.1093/brain/117.2.385; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Larson MD, 1997, ANESTHESIOLOGY, V87, P849, DOI 10.1097/00000542-199710000-00019; Larson MD, 1996, ANESTHESIOLOGY, V85, P748, DOI 10.1097/00000542-199610000-00009; LEVINE JD, 1981, PAIN, V10, P379, DOI 10.1016/0304-3959(81)90099-3; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Petersen KL, 1997, IASP NEWSLETTERS, V11, P3; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Sang CN, 1998, ANESTHESIOLOGY, V89, P1060, DOI 10.1097/00000542-199811000-00005; Sethna NF, 1998, ANESTH ANALG, V86, P1250, DOI 10.1097/00000539-199806000-00022; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; ZACNY JP, 1994, J PHARMACOL EXP THER, V268, P1	28	8	8	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2012	52	6					870	879		10.1177/0091270011407496			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	944UI	WOS:000304228900009	21646442				2020-06-30	J	Ceelen, L; De Zwart, L; Voets, M; Hillewaert, V; Monbaliu, J; Teuns, G; Coussement, W; Greway, T				Ceelen, Liesbeth; De Zwart, Loeckie; Voets, Marieke; Hillewaert, Vera; Monbaliu, Johan; Teuns, Greet; Coussement, Werner; Greway, Tony			Postmortem Redistribution of Fentanyl in the Rabbit Blood	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						Durogesic pain patch; fentanyl; postmortem redistribution; rabbit	PHARMACOKINETICS; DURAGESIC(R); ALFENTANIL; PATCHES	Postmortem redistribution of fentanyl in the rabbit was investigated after application of the 50-mu g/h Durogesic pain patch. Patches were applied for 48 hours. Two cycles of patch administration were used before characterization of the postmortem redistribution. Fentanyl showed marked redistribution into the femoral and pulmonary veins of the rabbit through 48 hours after the animals were humanely killed and the pain patches removed. The plasma concentration of 2.34 ng/mL in the femoral blood before killing the animals increased 5.6-fold by 48 hours after patch removal to 13.2 ng/mL. This postmortem concentration is approximately 3-fold the C-max determined during antemortem pharmacokinetic analysis, 4 ng/mL, which was achieved 24 hours after the application of the second 50-mu g/h Durogesic pain patch. After blood sampling for 48 hours after animal termination with patch removal compared with sampling for 48 hours from animals not terminated and with patch removal, the exposure ratios in the terminated animals were approximately 30-fold, indicating that between the postmortem redistribution of fentanyl and the cessation of hepatic clearance of fentanyl in the rabbit, the postmortem redistribution of fentanyl leads to an elevated measures of postmortem blood concentrations relative to antemortem blood concentrations.	[Ceelen, Liesbeth] Vrije Univ Brussel, Fac Med & Pharm, Dept Toxicol Dermatocosmetol & Pharmacognosy, B-1090 Brussels, Belgium; [De Zwart, Loeckie; Voets, Marieke; Hillewaert, Vera; Monbaliu, Johan; Teuns, Greet; Coussement, Werner] Janssen Pharmaceut, Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium; [Greway, Tony] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA	Ceelen, L (reprint author), Vrije Univ Brussel, Fac Med & Pharm, Dept Toxicol Dermatocosmetol & Pharmacognosy, Laarbeeklaan 103, B-1090 Brussels, Belgium.	lceelen@vub.ac.be					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Cook DS, 2000, J CLIN PATHOL, V53, P282, DOI 10.1136/jcp.53.4.282; De Letter EA, 2002, INT J LEGAL MED, V116, P216, DOI 10.1007/s00414-002-0292-0; Ferner RE, 2008, BRIT J CLIN PHARMACO, V66, P430, DOI 10.1111/j.1365-2125.2008.03231.x; Foley PL, 2001, COMPARATIVE MED, V51, P239; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; HESS R, 1971, J PHARMACOL EXP THER, V179, P474; ILKIW JE, 1991, AM J VET RES, V52, P581; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; Jung BF, 2005, CLIN PHARMACOL THER, V77, P324, DOI 10.1016/j.clpt.2004.10.013; Leclercq L, 2009, CHEM RES TOXICOL, V22, P280, DOI 10.1021/tx800432c; Leikin JB, 2003, J TOXICOL-CLIN TOXIC, V41, P47, DOI 10.1081/CLT-120018270; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; Pelissier-Alicot AL, 2006, INT J LEGAL MED, V120, P226, DOI 10.1007/s00414-005-0022-5; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Yarema MC, 2005, CLIN TOXICOL, V43, P235, DOI 10.1081/CLT-200058950	23	7	7	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	JUN	2012	33	2					119	123		10.1097/PAF.0b013e3181fbbb49			5	Medicine, Legal; Pathology	Legal Medicine; Pathology	943BM	WOS:000304095400005	21389904				2020-06-30	J	Danelli, G; Bonarelli, S; Tognu, A; Ghisi, D; Fanelli, A; Biondini, S; Moschini, E; Fanelli, G				Danelli, G.; Bonarelli, S.; Tognu, A.; Ghisi, D.; Fanelli, A.; Biondini, S.; Moschini, E.; Fanelli, G.			Prospective randomized comparison of ultrasound-guided and neurostimulation techniques for continuous interscalene brachial plexus block in patients undergoing coracoacromial ligament repair	BRITISH JOURNAL OF ANAESTHESIA			English	Article						acute pain; nerve stimulation; orthopaedic surgery regional anaesthesia; ropivacaine; ultrasonography	PERIPHERAL-NERVE BLOCK; REGIONAL ANESTHESIA; CATHETER PLACEMENT; SHOULDER SURGERY; GUIDANCE; STIMULATION; TRIAL; TIME	There are few data comparing the onset time of interscalene brachial plexus block performed using ultrasound (US) guidance or nerve stimulation (NS) technique for elective coracoacromial ligament repair. Fifty ASA IIII patients were randomly allocated to receive a continuous interscalene brachial plexus block with 20 ml of 1 ropivacaine with either NS or US guidance. The time of block performance, number of skin punctures and needle redirections, inadvertent vascular punctures, and procedure-related pain scores were recorded. The onsets of sensory and motor blocks in the distribution of radial, axillary, and musculocutaneous nerves were blindly assessed every 5 min until 30 min from the end of local anaesthetic (LA) injection. Intraoperative fentanyl, general anaesthesia (GA) requirements, postoperative pain scores, LA consumption, and patients requirements for subcutaneous morphine during the first 24 h were compared. Block onset times were similar. The time to complete the block and the number of skin punctures and vascular punctures were significantly lower in Group US. There were no differences in needle redirections, incidence of paraesthesiae, intraoperative fentanyl consumption, and requirements for GA or postoperative morphine. The US group required significantly less LA only at 16 h after surgery and had lower pain scores at rest at 24 h after surgery. Block onset times and success rate were similar whether NS or US was used, although US guidance allowed shorter procedural times, fewer needle punctures, and fewer vascular punctures.	[Danelli, G.; Ghisi, D.; Fanelli, A.] Ist Ospitalieri Cremona, Dept Anaesthesia & Perioperat Med, I-26100 Cremona, CR, Italy; [Bonarelli, S.; Tognu, A.] Ist Ortoped Rizzoli, Dept Anaesthesia & Postoperat Intens Care, Bologna, BO, Italy; [Biondini, S.; Moschini, E.; Fanelli, G.] Univ Parma, Dept Anaesthesia Intens Care & Pain Therapy, I-43100 Parma, PR, Italy	Ghisi, D (reprint author), Ist Ospitalieri Cremona, Dept Anaesthesia & Perioperat Med, Viale Concordia 1, I-26100 Cremona, CR, Italy.	ghisidan@hotmail.com		Fanelli, Andrea/0000-0001-9325-877X; Ghisi, Daniela/0000-0002-7972-4305; Fanelli, Guido/0000-0002-2991-3378			Abrahams MS, 2009, BRIT J ANAESTH, V102, P408, DOI 10.1093/bja/aen384; Baciarello M, 2009, REGION ANESTH PAIN M, V34, P278, DOI 10.1097/AAP.0b013e31819aab1; Casati A, 1999, BRIT J ANAESTH, V83, P872, DOI 10.1093/bja/83.6.872; Denny NA, 2005, BRIT J ANAESTH, V94, P1, DOI 10.1093/bja/aei001; Fredrickson MJ, 2010, ANAESTHESIA, V65, P608, DOI 10.1111/j.1365-2044.2009.06231.x; Fredrickson MJ, 2009, REGION ANESTH PAIN M, V34, P590, DOI 10.1097/AAP.0b013e3181ada622; Fredrickson MJ, 2009, ANESTH ANALG, V108, P1695, DOI 10.1213/ane.0b013e31819c29b8; Kapral S, 2008, REGION ANESTH PAIN M, V33, P253, DOI 10.1016/j.rapm.2007.10.011; Liu SS, 2010, REGION ANESTH PAIN M, V35, pS26, DOI 10.1097/AAP.0b013e3181d266f0; Liu SS, 2009, ANESTH ANALG, V109, P265, DOI 10.1213/ane.0b013e3181a3272c; Marhofer P, 2010, BRIT J ANAESTH, V104, P673, DOI 10.1093/bja/aeq086; Marhofer P, 2010, BRIT J ANAESTH, V104, P538, DOI 10.1093/bja/aeq069; McNaught A, 2011, BRIT J ANAESTH, V106, P124, DOI 10.1093/bja/aeq306; Orebaugh SL, 2007, REGION ANESTH PAIN M, V32, P448, DOI 10.1016/j.rapm.2007.05.004; Soeding PF, 2005, ANAESTH INTENS CARE, V33, P719, DOI 10.1177/0310057X0503300603	15	19	21	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUN	2012	108	6					1006	1010		10.1093/bja/aes031			5	Anesthesiology	Anesthesiology	944KG	WOS:000304199500017	22408273	Bronze			2020-06-30	J	Gelberg, J; Jonmarker, C; Stenqvist, O; Werner, O				Gelberg, J.; Jonmarker, C.; Stenqvist, O.; Werner, O.			Intravenous boluses of fentanyl, 1 mu g kg(-1), and remifentanil, 0.5 mu g kg(-1), give similar maximum ventilatory depression in awake volunteers	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesics opioid; fentanyl; analgesics opioid; remifentanil; analgesics techniques; i; v; i; v; agents	ALVEOLAR CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; ALFENTANIL; REDUCTION; OPIOIDS; MODEL	Background. The relative respiratory effects of fentanyl and remifentanil, administered as i.v. bolus, have not previously been studied. We determined what remifentanil bolus dose gave the same maximum depression of ventilation as 1 mu g kg(-1) of fentanyl. Methods. Twelve healthy volunteers rebreathed in a system designed to dampen variations in end-tidal carbon dioxide tension PE'(CO2) so that measurements would be obtained at similar levels of CO2 stimulation. The minute ventilation was measured before ((V) over dot(preinj)) and after injection ((V) over dot(nadir)) of fentanyl, 1 mu g kg(-1), and remifentanil, 0.25, 0.5, and 1 mu g kg(-1). The remifentanil doses were plotted against (V) over dot(nadir)/(V) over dot(preinj) in a log-probit diagram to determine what amount gave the same maximum ventilatory depression as the fentanyl dose. Results. (V) over dot(nadir) was [median (inter-quartile range)] 51 (38-64)% of (V) over dot(preinj) after fentanyl, and 70 (61-77), 50 (46-56), and 29 (24-38)%, respectively, after remifentanil. The nadir occurred 5.0 (4.4-7.0) min after fentanyl, and 3.8 (2.7-4.6), 2.9 (2.7-3.2), and 3.0 (2.7-3.2) min after remifentanil injection. PE'(CO2) at ventilation nadir was 6.26 (5.98-6.62) kPa after fentanyl, and 6.18 (6.12-6.50), 6.11 (5.91-6.45), and 6.11 (5.93-6.45) kPa after remifentanil 0.25, 0.5, and 1 mu g kg(-1), respectively. A remifentanil dose of 0.47 (0.42-0.62) mu g kg(-1) was equidepressant to 1 mu g kg(-1) of fentanyl. Fifteen minutes after fentanyl injection, the median minute ventilation was 30-40% less than after injection of remifentanil, 0.25 and 0.5 mu g kg(-1) (P<0.5). Conclusions. Fentanyl, 1 mu g kg(-1), and remifentanil, 0.5 mu g kg(-1), gave similar maximum ventilatory depression. The onset of and recovery from ventilatory depression were faster with remifentanil.	[Gelberg, J.; Werner, O.] Lund Univ, Skane Univ Hosp, Childrens Hosp, Dept Paediat Anaesthesia & Intens Care, S-22185 Lund, Sweden; [Jonmarker, C.] Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Jonmarker, C.] Univ Washington, Seattle, WA 98195 USA; [Stenqvist, O.] Sahlgrens Univ Hosp, Dept Anaesthesia & Intens Care, Gothenburg, Sweden	Gelberg, J (reprint author), Lund Univ, Skane Univ Hosp, Childrens Hosp, Dept Paediat Anaesthesia & Intens Care, S-22185 Lund, Sweden.	jan.gelberg@skane.se		Gelberg, Jan/0000-0001-6261-2916	Drager Medical; GE HealthcareGE Healthcare	O.S. has received lecture fees from Drager Medical and GE Healthcare. He has also received a lump sum from Drager Medical for a patent application. O.S. research group has received equipment support from Maquet, Drager Medical, and GE Healthcare and has received funding from Drager Medical and GE Healthcare during two previous studies. O.S. also took part on one occasion on the GE Healthcare advisory board. O.W. has received a lecture honorarium from Glaxo-Smith-Kline.	Babenco HD, 2000, ANESTHESIOLOGY, V92, P393, DOI 10.1097/00000542-200002000-00020; Beers R, 2004, CNS DRUGS, V18, P1085, DOI 10.2165/00023210-200418150-00004; Berman AH, 2005, EUR ADDICT RES, V11, P22, DOI 10.1159/000081413; BLOUIN RT, 1991, ANESTHESIOLOGY, V75, P940, DOI 10.1097/00000542-199112000-00003; Bouillon T, 2003, ANESTHESIOLOGY, V99, P779, DOI 10.1097/00000542-200310000-00007; Bowdle TA, 1996, ANESTH ANALG, V83, P1292, DOI 10.1097/00000539-199612000-00028; Drummond GB, 2010, BRIT J ANAESTH, V104, P661, DOI [10.1093/bja/aeq070, 10.1093/bja/aeq076]; Egan TD, 1996, ANESTHESIOLOGY, V84, P821, DOI 10.1097/00000542-199604000-00009; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Gross JB, 2003, ANESTHESIOLOGY, V99, P767, DOI 10.1097/00000542-200310000-00002; Gustorff B, 2002, ANESTH ANALG, V94, P1223, DOI 10.1097/00000539-200205000-00032; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; MAPLESON W W, 1954, Br J Anaesth, V26, P323, DOI 10.1093/bja/26.5.323; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; MERILAINEN P, 1993, J CLIN MONITOR, V9, P374, DOI 10.1007/BF01618680; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Ramsay JO, 1997, BEHAV RES METH INS C, V29, P99, DOI 10.3758/BF03200573; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schuttler J, 1997, ANAESTHESIA, V52, P307, DOI 10.1111/j.1365-2044.1997.24-az0051.x; Servin F. S., 2008, V182, P283, DOI 10.1007/978-3-540-74806-9_14	21	10	10	2	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JUN	2012	108	6					1028	1034		10.1093/bja/aes029			7	Anesthesiology	Anesthesiology	944KG	WOS:000304199500021	22440314	Bronze			2020-06-30	J	Suen, SSH; Khaw, KS; Law, LW; Sahota, DS; Lee, SWY; Lau, TK; Leung, TY				Suen, Stephen Sik Hung; Khaw, Kim S.; Law, Lai Wa; Sahota, Daljit Singh; Lee, Shara Wee Yee; Lau, Tze Kin; Leung, Tak Yeung			The force applied to successfully turn a foetus during reattempts of external cephalic version is substantially reduced when performed under spinal analgesia	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE			English	Article						external cephalic version; force; piezo-resistive; spinal analgesia	RANDOMIZED CONTROLLED-TRIAL; PHENYLEPHRINE INFUSION; EPIDURAL-ANESTHESIA; TERM; PRESSURE; DELIVERY; CIRCULATION	Objective: To compare the forces exerted during external cephalic version (ECV) on the maternal abdomen between (1) the primary attempts performed without spinal analgesia (SA), which failed and (2) the subsequent reattempts performed under SA. Methods: Patients with an uncomplicated singleton breech-presenting pregnancy suitable for ECV were recruited. During ECV, the operator wore a pair of gloves, which had thin piezo-resistive pressure sensors measuring the contact pressure between the operator's hands and maternal abdomen. For patients who had failed ECV, reattempts by the same operator was made with patients under SA, and the applied force was measured in the same manner. The profile of the exerted forces over time during each attempt was analyzed and denoted by pressure-time integral (PTI: mmHg sec). Pain score was also graded by patients using visual analogue scale. Both PTI and pain score before and after the use of SA were then compared. Results: Overall, eight patients who had a failed ECV without SA underwent a reattempt with SA. All of them had successful version and the median PTI of the successful attempts under SA were lower than that of the previous failed attempts performed without SA (127 386 mmHg sec vs. 298,424 mmHg sec; p = 0.017). All of them also reported a 0 pain score, which was significantly lower than that of before (median 7.5; p = 0.016). Conclusions: SA improves the success rate of ECV as well as reduces the force required for successful version.	[Suen, Stephen Sik Hung; Law, Lai Wa; Sahota, Daljit Singh; Lau, Tze Kin; Leung, Tak Yeung] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; [Khaw, Kim S.; Lee, Shara Wee Yee] Chinese Univ Hong Kong, Dept Anaesthesia & Intens, Shatin, Hong Kong, Peoples R China; [Lee, Shara Wee Yee] Chinese Univ Hong Kong, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China	Suen, SSH (reprint author), Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	shsuen@cuhk.edu.hk	Khaw, K/J-9469-2013; Lee, Shara WY/G-1874-2014	Khaw, K/0000-0002-5950-0275; Lee, Shara WY/0000-0001-5257-2076; Lau, Tze Kin/0000-0002-0242-1410			Caughey AB, 2010, J PERINATOL, V30, P569, DOI 10.1038/jp.2010.89; Delisle MF, 2001, AM J OBSTET GYNECOL, V185, pS115, DOI 10.1016/S0002-9378(01)80159-9; Dugoff L, 1999, OBSTET GYNECOL, V93, P345, DOI 10.1016/S0029-7844(98)00456-6; FELL MR, 1953, LANCET, V265, P364; Fok WY, 2005, ACTA OBSTET GYN SCAN, V84, P748, DOI 10.1111/j.0001-6349.2005.00505.x; HOFMEYR GJ, 2000, [No title captured], DOI DOI 10.1002/14651858.CD000083; HOFMEYR GJ, 2004, [No title captured], DOI DOI 10.1002/14651858.CD000184.PUB2; Hollard A, 2003, AM J OBSTET GYNECOL, V189, pS140, DOI 10.1016/j.ajog.2003.10.288; Kee WDN, 2005, ANESTHESIOLOGY, V103, P744, DOI 10.1097/00000542-200510000-00012; Kee WDN, 2004, BRIT J ANAESTH, V92, P469, DOI 10.1093/bja/aeh088; Kok M, 2009, ULTRASOUND OBST GYN, V33, P76, DOI 10.1002/uog.6277; Kok M, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.03.008; Lau TK, 2000, AM J OBSTET GYNECOL, V183, P712, DOI 10.1067/mob.2000.106582; Lau TK, 2000, AM J OBSTET GYNECOL, V182, P1239, DOI 10.1067/mob.2000.104769; Lau TK, 2000, BRIT J OBSTET GYNAEC, V107, P401, DOI 10.1111/j.1471-0528.2000.tb13237.x; Lau TK, 1997, BRIT J OBSTET GYNAEC, V104, P798, DOI 10.1111/j.1471-0528.1997.tb12023.x; Leung TY, 2000, AUST NZ J OBSTET GYN, V40, P253, DOI 10.1111/j.1479-828X.2000.tb03331.x; Leung TY, 2006, ACTA OBSTET GYN SCAN, V85, P182, DOI 10.1080/00016340500408440; Leung TY, 2004, BJOG-INT J OBSTET GY, V111, P430, DOI 10.1111/j.1471-0528.2004.00127.x; Leung TY, 2003, ACTA OBSTET GYN SCAN, V82, P1017, DOI 10.1034/j.1600-0412.2003.00269.x; Leung TY, 2005, J PERINAT MED S, V33, P194; Mancuso KM, 2000, OBSTET GYNECOL, V95, P648, DOI 10.1016/S0029-7844(99)00611-0; RANNEY B, 1973, AM J OBSTET GYNECOL, V116, P239, DOI 10.1016/0002-9378(73)91058-2; Schorr SJ, 1997, AM J OBSTET GYNECOL, V177, P1133, DOI 10.1016/S0002-9378(97)70029-2; Weiniger CF, 2010, BRIT J ANAESTH, V104, P613, DOI 10.1093/bja/aeq053; Weiniger CF, 2007, OBSTET GYNECOL, V110, P1343, DOI 10.1097/01.AOG.0000295605.38175.7b; Yoshida M, 2010, J PERINATOL, V30, P580, DOI 10.1038/jp.2010.61	27	12	12	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1476-7058	1476-4954		J MATERN-FETAL NEO M	J. Matern.-Fetal Neonatal Med.	JUN	2012	25	6					719	722		10.3109/14767058.2011.589931			4	Obstetrics & Gynecology	Obstetrics & Gynecology	943CH	WOS:000304097600032	22043832				2020-06-30	J	Mercadante, S; Gatti, A; Porzio, G; Lo Presti, C; Aielli, F; Adile, C; Casuccio, A				Mercadante, Sebastiano; Gatti, Antonio; Porzio, Giampiero; Lo Presti, Claudio; Aielli, Federica; Adile, Claudio; Casuccio, Alessandra			Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrough pain; Cancer pain; Dose titration; Fentanyl buccal tablet; Rapid onset opioids	PALLIATIVE CARE-UNIT; INTRAVENOUS MORPHINE; TRANSMUCOSAL FENTANYL; OPIOIDS; RECOMMENDATIONS; ASSOCIATION; REGIMEN	Objectives: The aim of this study was to compare the efficacy and safety of doses of fentanyl buccal tablet (FBT) proportional to doses of opioids used for background analgesia versus dose titration starting with the minimal dose for the management of breakthrough cancer pain (BTcP). Methods: A total of 82 cancer patients with BTcP who were receiving strong opioids in doses of at least 60 mg of oral morphine equivalents and having acceptable background analgesia, were selected for a multicenter unblinded study. Forty-one patients were randomized to receive FBT in doses proportional to the daily opioid doses for four consecutive episodes of BTcP (group P). Forty-one patients underwent dose titration of FBT, with an initial dose of 100 mg, for four consecutive episodes (group T). Pain intensity and symptoms associated with opioid therapy were measured before administering any dose of FBT (T0) and 15 minutes after (T15). Results: In all, 80 patients were considered for analysis (39 and 41 patients in group P and T, respectively). Patients were receiving a mean of 126 +/- 100 mg of oral morphine equivalents (range 60-480 mg) for background analgesia. A total of 293 episodes of BTcP (144 and 149 in group P and T, respectively) were treated and considered for analysis. No differences were found in the decrease of pain intensity between the two groups. However, in patients receiving doses of oral morphine equivalents of >120 mg/day, a significant number of patients obtained a decrease in pain intensity >50% in group P in comparison with group T (p = 0.040). Also, the need for rescue medication was significantly more frequently reported in group T for the first episode of BTcP (p<0.0005). No differences in the level of adverse effects were observed between the two groups. No differences in patients' satisfaction were reported. Conclusion: According to the data obtained in this study, there is no evidence for the use of dose titration in the management of BTcP in opioid-tolerant patients. Indeed, doses proportional to basal opioid regimen for background pain seem to be effective and safe in the majority of patients. Further studies should confirm this data in patients receiving higher doses of opioids, with other rapid-onset opioids, and in other settings.	[Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy; [Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Palermo, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy; [Gatti, Antonio] Univ Roma Tor Vergata, Chair Anesthesiol, Rome, Italy; [Porzio, Giampiero; Aielli, Federica] Univ LAquila, Dept Oncol, Laquila, Italy; [Porzio, Giampiero; Aielli, Federica] Home Care Program LAquila Vita, Laquila, Italy; [Lo Presti, Claudio] San Filippo Neri Hosp, Rome, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535; Porzio, Giampiero/0000-0002-9875-9220; Adile, Claudio/0000-0002-0664-3520; AIELLI, Federica/0000-0003-2785-0702			Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Darwish M, 2010, CLIN DRUG INVEST, V30, P365, DOI 10.2165/11533360-000000000-00000; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S., 2011, EUR J PAIN S, P443; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	23	29	29	0	4	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	JUN	2012	28	6					963	968		10.1185/03007995.2012.683112			6	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	960VT	WOS:000305421100008	22480130	Green Published			2020-06-30	J	Schroder, B; Nickel, U; Meyer, E; Lee, G				Schroeder, Britta; Nickel, Ulrich; Meyer, Elisabeth; Lee, Geoffrey			Transdermal delivery using a novel electrochemical device, part 2: In Vivo study in humans	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						transdermal; electrochemical patch; fentanyl; in vivo	POSTOPERATIVE PAIN; FENTANYL; PHARMACOKINETICS; ANALGESIA; SYSTEM; IONTOPHORESIS; ABSORPTION; OPIOIDS; IV	A single-center, open-label, and dose-escalation clinical trial has been performed using a novel electrochemical transdermal patch comprising a drug-loaded hydrogel sandwiched between two silver electrodes. The lower electrode is attached flatly to skin via an adhesive layer. This noniontophoretic device produces flux enhancement via voltage-induced electrolysis of the water in the hydrogel. A voltage application of 2 V over 60 s produced release of approximately 315 to 340 mu g of fentanyl from a patch. A single-voltage application at t = 16 h produced a maximum plasma level of approximately 200 pg/mL before patch removal at t = 41 h. Consecutive voltage applications at t = 16 h and t = 40 h produced a maximum plasma level of approximately 730 pg/mL. The lag time between voltage application and achievement of a plasma profile plateau is longer than that reported for an iontophoretic patch. The patch's advantage is production of an on-demand plasma profile without the use of potentially irritating iontophoresis. In contrast to a passive transdermal system, it is possible to adjust the plasma profile by using voltage application. It is not necessary to apply a continual current, in contrast to iontophoretic systems. (C) 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 101:22622268, 2012	[Lee, Geoffrey] Univ Erlangen Nurnberg, Div Pharmaceut, D-91077 Erlangen, Germany; [Schroeder, Britta; Meyer, Elisabeth] Acino AG, D-83714 Miesbach, Germany; [Nickel, Ulrich] Univ Erlangen Nurnberg, Div Phys Chem, D-91077 Erlangen, Germany	Lee, G (reprint author), Univ Erlangen Nurnberg, Div Pharmaceut, D-91077 Erlangen, Germany.	lee@pharmtech.uni-erlangen.de					BRONAUGH RL, 1982, TOXICOL APPL PHARM, V62, P481, DOI 10.1016/0041-008X(82)90149-1; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Jadoul A, 1999, ADV DRUG DELIVER REV, V35, P89, DOI 10.1016/S0169-409X(98)00065-9; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; REILLY CS, 1985, ANAESTHESIA, V40, P837, DOI 10.1111/j.1365-2044.1985.tb11043.x; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan G, 2009, CURR MED RES OPIN, V25, P363, DOI 10.1185/03007990802594941 ; Schroder B, 2012, J PHARM SCI-US, V101, P245, DOI 10.1002/jps.22765; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; THYSMAN S, 1994, INT J PHARM, V101, P105, DOI 10.1016/0378-5173(94)90081-7; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7	23	6	6	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	JUN	2012	101	6					2262	2268		10.1002/jps.23108			7	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	925ZE	WOS:000302800300031	22411742				2020-06-30	J	Patel, NP; Armstrong, SL; Fernando, R; Columb, MO; Bray, JK; Sodhi, V; Lyons, GR				Patel, N. P.; Armstrong, S. L.; Fernando, R.; Columb, M. O.; Bray, J. K.; Sodhi, V.; Lyons, G. R.			Combined spinal epidural vs epidural labour analgesia: does initial intrathecal analgesia reduce the subsequent minimum local analgesic concentration of epidural bupivacaine?	ANAESTHESIA			English	Article							NEURAXIAL ANALGESIA; BREAKTHROUGH PAIN; RANDOMIZED-TRIAL; DURAL PUNCTURE; FENTANYL	Labour analgesia initiated using a combined spinal-epidural (CSE) technique may reduce subsequent epidural bupivacaine requirements compared with an epidural-only technique. We compared the minimum local analgesic concentrations (MLAC) of epidural bupivacaine following initial intrathecal or epidural injection. In a prospective, double-blind study, 115 women requesting epidural analgesia were randomly assigned to receive either an epidural with bupivacaine 20 mg and fentanyl 40 mu g or a CSE with intrathecal bupivacaine 2.5 mg and fentanyl 5 mu g. Analgesia was assessed using a visual analogue pain score. When further analgesia was requested, bupivacaine 20 ml was given, and the concentration was determined using the technique of up-down sequential allocation. The MLAC of bupivacaine in the epidural group was 0.032% wt/vol (95% CI 0.0200.044) compared with 0.047% wt/vol (95% CI 0.0420.052) in the CSE group. Bupivacaine requirements for the second injection were increased following intrathecal analgesia by a factor of 1.45 (p = 0.026) compared with epidural analgesia.	[Patel, N. P.; Armstrong, S. L.; Fernando, R.] Univ Coll London Hosp NHS Trust, London, England; [Columb, M. O.] S Manchester Univ Hosp NHS Trust, Wythenshawe, England; [Bray, J. K.] St Marys Hosp NHS Trust, London, England; [Sodhi, V.] Queen Charlottes & Chelsea Hosp, London W6 0XG, England; [Lyons, G. R.] St James Univ Hosp, Leeds, W Yorkshire, England	Fernando, R (reprint author), Univ Coll London Hosp NHS Trust, London, England.	r.fernando@btinternet.com	Columb, Malachy/F-9588-2016	Columb, Malachy/0000-0001-7837-4262	Obstetric Anaesthetists' Association; Smiths Medical, Ashford, Kent, UK; University College London Hospitals/University College London (UCLH/UCL) Comprehensive Biomedical Research Centre; UK Department of Health's National Institute of Health research (NIHR) Biomedical Research CenterNational Institute for Health Research (NIHR)	NPP was supported by an unrestricted research fellowship grant from the Obstetric Anaesthetists' Association. JKB and VS were supported by a research fellowship grant from Smiths Medical, Ashford, Kent, UK. RF was supported by the University College London Hospitals/University College London (UCLH/UCL) Comprehensive Biomedical Research Centre which receives a proportion of funding from the UK Department of Health's National Institute of Health research (NIHR) Biomedical Research Center's funding scheme. No competing interests declared.	CAMPBELL DC, 1995, ANESTH ANALG, V81, P305, DOI 10.1097/00000539-199508000-00017; Cappiello E, 2008, ANESTH ANALG, V107, P1646, DOI 10.1213/ane.0b013e318184ec14; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Columb MO, 2000, REGIONAL ANALGESIA IN OBSTETRICS, P157; COLUMB MO, 1995, ANESTH ANALG, V81, P833, DOI 10.1097/00000539-199510000-00030; De Jong RH, 1994, LOCAL ANESTHETICS, P230; Eappen S, 1998, INT J OBSTET ANESTH, V7, P220, DOI 10.1016/S0959-289X(98)80042-3; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Goodman SR, 2009, ANESTH ANALG, V108, P246, DOI 10.1213/ane.0b013e31818f896f; Hess PE, 2001, ANESTH ANALG, V93, P414; Leighton BL, 1996, ANESTH ANALG, V83, P526, DOI 10.1097/00000539-199609000-00015; Loubert C, 2011, ANAESTHESIA, V66, P191, DOI 10.1111/j.1365-2044.2010.06616.x; Lyons G, 1997, BRIT J ANAESTH, V78, P493; Miro M, 2008, INT J OBSTET ANESTH, V17, P15, DOI 10.1016/j.ijoa.2007.07.003; Nageotte MP, 1997, NEW ENGL J MED, V337, P1715, DOI 10.1056/NEJM199712113372402; Norris MC, 2000, INT J OBSTET ANESTH, V9, P3, DOI 10.1054/ijoa.1999.0301; Norris MC, 2001, ANESTHESIOLOGY, V95, P913, DOI 10.1097/00000542-200110000-00020; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Price C, 1998, ANAESTHESIA, V53, P951, DOI 10.1046/j.1365-2044.1998.00523.x; Simmons SW, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003401.pub2; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Thomas JA, 2005, ANESTHESIOLOGY, V103, P1046, DOI 10.1097/00000542-200511000-00019; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; Wilson R, 2000, REGIONAL ANALGESIA IN OBSTETRICS, P111; Wong CA, 2004, INT J OBSTET ANESTH, V13, P19, DOI 10.1016/S0959-289X(03)00106-7	28	12	12	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUN	2012	67	6					584	593		10.1111/j.1365-2044.2011.07045.x			10	Anesthesiology	Anesthesiology	937MK	WOS:000303662400004	22420645				2020-06-30	J	Zheng, H; Zou, HB; Liu, XP; Chu, J; Zhou, YL; Loh, HH; Law, PY				Zheng, Hui; Zou, Haibo; Liu, Xiaopeng; Chu, Ji; Zhou, Yali; Loh, Horace H.; Law, Ping-Yee			Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans	JOURNAL OF LIPID RESEARCH			English	Article						anesthesia; cAMP signaling; G protein coupling; simvastatin	PROTEIN-COUPLED RECEPTORS; LIPID RAFTS; MEMBRANE MICRODOMAINS; ALZHEIMERS-DISEASE; ACTIVATION; BRAIN; SIMVASTATIN; KINASES	Cholesterol regulates the signaling of mu-opioid receptor in cell models, but it has not been demonstrated in mice or humans. Whether cholesterol regulates the signaling by mechanisms other than supporting the entirety of lipid raft microdomains is still unknown. By modulating cholesterol-enriched lipid raft microdomains and/or total cellular cholesterol contents in human embryonic kidney cells stably expressing mu-opioid receptor, we concluded that cholesterol stabilized opioid signaling both by supporting the lipid raft's entirety and by facilitating G protein coupling. Similar phenomena were observed in the primary rat hippocampal neurons. In addition, reducing the brain cholesterol level with simvastatin impaired the analgesic effect of opioids in mice, whereas the opioid analgesic effect was enhanced in mice fed a high-cholesterol diet. Furthermore, when the records of patients were analyzed, an inverse correlation between cholesterol levels and fentanyl doses used for anesthesia was identified, which suggested the mechanisms above could also be applicable to humans. Our results identified the interaction between opioids and cholesterol, which should be considered in clinics as a probable route for drug-drug interaction. Our studies also suggested that a low cholesterol level could lead to clinical issues, such as the observed impairment in opioid functions.-Zheng, H., H. Zou, X. Liu, J. Chu, Y. Zhou, H. H. Loh, and P-Y. Law. Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans. J. Lipid Res. 2012. 53: 1153-1162.	[Zheng, Hui; Liu, Xiaopeng] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Key Lab Regenerat Biol, Guangzhou 510530, Guangdong, Peoples R China; [Zheng, Hui; Chu, Ji; Zhou, Yali; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; [Zou, Haibo] China Japan Friendship Hosp, Dept Orthopaed Surg, Beijing 100029, Peoples R China	Zheng, H (reprint author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Key Lab Regenerat Biol, Guangzhou 510530, Guangdong, Peoples R China.	zheng_hui@gibh.ac.cn		Law, Ping-Yee/0000-0002-5364-1093; Zheng, Hui/0000-0001-6801-0529	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31100773]; Chinese Academy of SciencesChinese Academy of Sciences [XDA01020302]; Major New Drugs Innovation of the Major National Scientific and Technological Project [2011ZX09102-010-01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA-023905, DA-011806]	This work was supported by the National Natural Science Foundation of China (Grant 31100773), the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant XDA01020302), the Major New Drugs Innovation of the Major National Scientific and Technological Project (Grant 2011ZX09102-010-01), and the National Institutes of Health (Grants DA-023905 and DA-011806). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Chakrabarti S, 1998, J NEUROCHEM, V71, P231; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Chini B, 2009, J MOL ENDOCRINOL, V42, P371, DOI 10.1677/JME-08-0114; Chu J, 2008, CELL SIGNAL, V20, P1616, DOI 10.1016/j.cellsig.2008.05.004; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; DUANE WC, 1988, HEPATOLOGY, V8, P1147, DOI 10.1002/hep.1840080531; Eckert GP, 2001, NEUROREPORT, V12, P883, DOI 10.1097/00001756-200104170-00003; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; INOKUCHI J, 1987, CANCER LETT, V38, P23, DOI 10.1016/0304-3835(87)90196-0; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Lewington S, 2007, LANCET, V370, P1829; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Milligan G, 2007, ERNST SCHERING FOUND, V2, P145, DOI 10.1007/2789_2006_007; Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200; Nagafuku M, 2003, J BIOL CHEM, V278, P51920, DOI 10.1074/jbc.M307674200; Navratil AM, 2003, J BIOL CHEM, V278, P31593, DOI 10.1074/jbc.M304273200; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Reid PC, 2007, J CELL MOL MED, V11, P383, DOI 10.1111/j.1582-4934.2007.00054.x; Robson J, 2008, HEART, V94, P1331, DOI 10.1136/hrt.2008.150979; Stefani M, 2009, CURR ALZHEIMER RES, V6, P15, DOI 10.2174/156720509787313899; Szoke E, 2010, EUR J PHARMACOL, V628, P67, DOI 10.1016/j.ejphar.2009.11.052; Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136; Zhang L, 2006, MOL PHARMACOL, V69, P1810, DOI 10.1124/mol.105.021352; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293; Zhu D, 2006, J NEUROSCI, V26, P4841, DOI 10.1523/JNEUROSCI.2807-05.2006	33	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0022-2275	1539-7262		J LIPID RES	J. Lipid Res.	JUN	2012	53	6					1153	1162		10.1194/jlr.M024455			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	940SK	WOS:000303913200012	22377533	Green Published, Bronze			2020-06-30	J	Miranda, HF; Noriega, V; Zepeda, RJ; Sierralta, F; Prieto, JC				Miranda, Hugo F.; Noriega, Viviana; Zepeda, Ramiro J.; Sierralta, Fernando; Prieto, Juan C.			Synergism Between Fentanyl and Tramadol in Tonic Inflammatory Pain: the Orofacial Formalin Test	INFLAMMATION			English	Article						tonic inflammatory pain; opioids; isobolographic analysis, synergism, orofacial formalin test	ANALGESIC EFFICACY; MECHANISMS; MORPHINE; MOUSE	Opioids have been used for long time to management of pain, the coadministration of two opioids may induce synergism. The present study was conducted to determine the antinociceptive interaction between the dual mechanism of action of tramadol compared to the main of fentanyl antinociception in the orofacial formalin which represents a model of persistent cutaneous nociception in the region innervated by the trigeminal nerve. The i.p. administration of tramadol and fentanyl induced a dose-dependent antinociception with an ED50 of 2.97 +/- 0.32 mg/kg for phase I and 1.79 +/- 0.30 mg/kg for phase II and 0.062 +/- 0.0040 mg/kg in phase I and 0.041 +/- 0.0039 mg/kg in phase II, respectively. The coadministration of fentanyl with tramadol induced synergism in both phases of the test with an interaction index of 0.343 and 0.163 for phase I and phase II, respectively. This finding could be explained by the more complex pharmacology of tramadol compared to fentanyl.	[Miranda, Hugo F.; Zepeda, Ramiro J.; Sierralta, Fernando; Prieto, Juan C.] Univ Chile, Fac Med, ICBM, Sch Med,Pharmacol Program, Santiago 7, Chile; [Miranda, Hugo F.; Noriega, Viviana] Univ Andres Bello, Sch Pharm, Fac Med, Santiago, Chile; [Prieto, Juan C.] Univ Chile, Hosp Clin, Cardiovasc Dept, Santiago 7, Chile	Miranda, HF (reprint author), Univ Chile, Fac Med, ICBM, Sch Med,Pharmacol Program, Independencia 1027, Santiago 7, Chile.	hmiranda@med.uchile.cl		Zepeda, Ramiro/0000-0001-8300-9382	Universidad Andres Bello [DI-02-11/CB]	This work was partially supported by project DI-02-11/CB from Universidad Andres Bello. The expert technical assistance of Jose Lopez and Alejandro Correa is gratefully recognized.	Barrera NP, 2005, TRENDS PHARMACOL SCI, V26, P526, DOI 10.1016/j.tips.2005.08.003; Bolan EA, 2002, J PHARMACOL EXP THER, V303, P557, DOI 10.1124/jpet.102.035881; Curatolo M, 2002, BEST PRACTICE RES CL, V216, P507; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Gercek Arzu, 2004, Agri, V16, P53; Kenakin T, 2007, TRENDS PHARMACOL SCI, V28, P407, DOI 10.1016/j.tips.2007.06.009; Lewis KS, 1997, AM J HEALTH-SYST PH, V54, P643, DOI 10.1093/ajhp/54.6.643; Luccarini P, 2006, J PAIN, V7, P908, DOI 10.1016/j.jpain.2006.04.010; Miranda HF, 2009, FUND CLIN PHARMACOL, V23, P81, DOI 10.1111/j.1472-8206.2008.00636.x; Miranda HF, 2009, PHARMACOL BIOCHEM BE, V92, P314, DOI 10.1016/j.pbb.2008.12.018; Munro G, 2008, NEUROPHARMACOLOGY, V54, P331, DOI 10.1016/j.neuropharm.2007.10.005; Ozdogan UK, 2006, EUR J PHARMACOL, V529, P105, DOI 10.1016/j.ejphar.2005.10.029; Pan YX, 2005, MOL PHARMACOL, V68, P866, DOI 10.1124/mol.105.011858; Raffa R.B, 2008, J PHARM EXPT THERAPE, V303, P557; Romero A, 2010, PHARMACOL BIOCHEM BE, V97, P363, DOI 10.1016/j.pbb.2010.09.005; Romero A, 2010, PHARMACOL RES, V61, P511, DOI 10.1016/j.phrs.2010.02.011; Sessle B J, 2005, Minerva Anestesiol, V71, P117; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Smith HS, 2008, PAIN PHYSICIAN, V11, P201; Stein C, 2009, BRAIN RES REV, V60, P90, DOI 10.1016/j.brainresrev.2008.12.017; Tallarida RJ, 2000, DRUG SYNERGISM DOSE, P26; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940	24	7	7	0	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	JUN	2012	35	3					1132	1137		10.1007/s10753-011-9420-7			6	Cell Biology; Immunology	Cell Biology; Immunology	933SI	WOS:000303382400043	22198345				2020-06-30	J	Oliveira, G; Hadgraft, J; Lane, ME				Oliveira, Gabriela; Hadgraft, Jonathan; Lane, Majella E.			Toxicological implications of the delivery of fentanyl from gel extracted from a commercial transdermal reservoir patch	TOXICOLOGY IN VITRO			English	Article						Fentanyl; Transdermal patch; Reservoir; In vitro; Human skin	INTRAVENOUS MISUSE; PERMEATION	Fentanyl in a rate controlling membrane (RCM) transdermal patch form has been available since the early 1990s for outpatient management of chronic pain. Fatalities associated with misuse or overuse of fentanyl patches have been reported. Concerns have also been raised about the possibility that defects in such patches may result in leaking of the reservoir of the patch onto patients' skin and consequent overdose. In order to investigate the possibility of fentanyl toxicity arising from leaking of patches, the permeation of fentanyl from the reservoir gel of a commercially available fentanyl transdermal patch was examined in vitro. Finite doses of the formulation were applied to human skin and permeation was monitored, at 32 degrees C under non-occluded conditions, for 48 h. Similar levels of skin permeation of fentanyl from the 1% gel formulation were obtained for the two skin donor samples tested. After 48 h, the dose of fentanyl that had permeated was 7.4 (+/- 3.6)% and 7.7 (+/- 1.9)% of the respective total amounts applied. At the end of the experiment, most of the drug was found in the residual formulation at the skin surface (i.e. 63-66%). For both the skin samples, a relatively small amount of the fentanyl applied (2-3%) was present in the skin at 48 h after application. The maximum flux from the data generated was between 6 and 24 h over which time frame it was 0.31 mu g/cm(2)/h. Assuming spreading of leaked gel over an area of 100 cm(2), this would result in a plasma level of 0.6 ng/ml.. The anticipated plasma levels from a 100 mu g/h patch are known to be approximately 2.5 ng/ml. Thus, the maximum increase in the plasma levels from a patch which leaks gel is calculated to be, at most, about 25%. (C) 2012 Elsevier Ltd. All rights reserved.	[Oliveira, Gabriela; Hadgraft, Jonathan; Lane, Majella E.] Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England	Lane, ME (reprint author), Univ London, Sch Pharm, Dept Pharmaceut, 29-39 Brunswick Sq, London WC1N 1AX, England.	majella.lane@btinternet.com		Oliveira, Gabriela/0000-0002-9092-6565			Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; Anissimov YG, 2001, J PHARM SCI, V90, P504, DOI 10.1002/1520-6017(200104)90:4<504::AID-JPS1008>3.0.CO;2-H; [Anonymous], 2003, DURAGESIC PATIENT IN; Dias M, 2007, INT J PHARM, V340, P65, DOI 10.1016/j.ijpharm.2007.03.030; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; KLIGMAN AM, 1963, ARCH DERMATOL, V88, P702, DOI 10.1001/archderm.1963.01590240026005; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Medical Officer Review, 1990, PHARM PHARM, V2, P1; MICHAELS AS, 1975, AICHE J, V21, P985, DOI 10.1002/aic.690210522; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Santos P, 2011, INT J PHARMACEUT, V416, P155, DOI 10.1016/j.ijpharm.2011.06.024; Watkinson RM, 2009, SKIN PHARMACOL PHYS, V22, P15, DOI 10.1159/000183922	13	11	11	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-2333			TOXICOL IN VITRO	Toxicol. Vitro	JUN	2012	26	4					645	648		10.1016/j.tiv.2012.02.007			4	Toxicology	Toxicology	937ZN	WOS:000303702900013	22405881				2020-06-30	J	Barrett, MJ; Cronin, J; Murphy, A; McCoy, S; Hayden, J; Fhaili, SA; Grant, T; Wakai, A; McMahon, C; Walsh, S; O'Sullivan, R				Barrett, Michael Joseph; Cronin, John; Murphy, Adrian; McCoy, Siobhan; Hayden, John; Fhaili, SineadNic An; Grant, Tim; Wakai, Abel; McMahon, Corrina; Walsh, Sean; O'Sullivan, Ronan			Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: Study protocol for a randomised controlled trial	TRIALS			English	Article						Sickle cell disease; Paediatric; Pain; Analgesia; Intranasal; Fentanyl; Randomised Controlled Trial; Double blind	PEDIATRIC-PATIENTS; ORAL MORPHINE; RISK-FACTORS; DISEASE; MANAGEMENT; ANALGESIA; EFFICACY; ANESTHESIA; MIDAZOLAM; EPISODES	Background: Children with sickle cell disease (SCD) frequently and unpredictably present to the emergency department (ED) with pain. The painful event is the hallmark acute clinical manifestation of SCD, characterised by sudden onset and is usually bony in origin. This study aims to establish if 1.5mcg/kg of intranasal fentanyl (INF; administered via a Mucosal Atomiser Device, MAD (TM)) is non-inferior to intravenous morphine 0.1 mg/kg in severe SCD-associated pain. Methods/design: This study is a randomised, double-blind, double-dummy active control trial of children (weighing more than 10 kg) between 1 year and 21 years of age with severe painful sickle cell crisis. Severe pain is defined as rated seven or greater on a 0 to 10 age-appropriate numeric pain scale or equivalent. The trial will be conducted in a single tertiary urban paediatric ED in Dublin, Ireland. Each patient will receive a single active agent and a single placebo via the intravenous and intranasal routes. All clinical and research staff, patients and parents will be blinded to the treatment allocation. The primary endpoint is severity of pain scored at 10 min from administration of the study medications. Secondary endpoints include pain severity measured at 0, 5, 15, 20, 30, 60 and 120 min after the administration of analgesia, proportion of patients requiring rescue analgesia and incidence of adverse events. The trial ends at 120 min after the administration of the study drugs. A clinically meaningful difference in validated pain scores has been defined as 13 mm. Setting the permitted threshold to 50% of this limit (6 mm) and assuming both treatments are on average equal, a sample size of 30 patients (15 per group) will provide at least 80% power to demonstrate that INF is non-inferior to IV morphine with a level of significance of 0.05. Discussion: This clinical trial will inform of the role of INF 1.5mcg/kg via MAD in the acute treatment of severe painful sickle cell crisis in children in the ED setting.	[Barrett, Michael Joseph; Cronin, John; Murphy, Adrian; McCoy, Siobhan; Walsh, Sean; O'Sullivan, Ronan] Our Ladys Childrens Hosp OLCHC, Emergency Dept, PERU, Dublin 12, Ireland; [Barrett, Michael Joseph; Cronin, John; Murphy, Adrian; McCoy, Siobhan; Hayden, John; Fhaili, SineadNic An; Walsh, Sean; O'Sullivan, Ronan] OLCHC, Natl Childrens Res Ctr, Dublin 12, Ireland; [Barrett, Michael Joseph; O'Sullivan, Ronan] UCD, Dept Paediat, Dublin 4, Ireland; [Grant, Tim] UCD, CSTAR, Dublin 4, Ireland; [Wakai, Abel] Royal Coll Surgeons Ireland, ECRU, HRB Ctr Primary Care Res, Div Populat Hlth Sci PHS, Dublin 2, Ireland; [McMahon, Corrina] OLCHC, Dept Haematol, Dublin 12, Ireland	O'Sullivan, R (reprint author), Our Ladys Childrens Hosp OLCHC, Emergency Dept, PERU, Dublin 12, Ireland.	ronan.osullivan@olchc.ie	Barrett, Michael/AAH-2075-2020	Hayden, John/0000-0003-3344-6888; McMahon, Corrina/0000-0001-7011-0158; Wakai, Abel/0000-0003-2021-2388; Barrett, Michael/0000-0003-1775-8347	National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland; Clinical Research Centre, University College Dublin, Ireland	This study is funded by the National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland, and sponsored by the Clinical Research Centre, University College Dublin, Ireland.	Andrews C, 1983, CLIN ANAESTHESIOL, V1, P97; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Chung S, 2010, PEDIATR RADIOL, V40, P1236, DOI 10.1007/s00247-009-1521-1; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darbari DS, 2008, AM J HEMATOL, V83, P233, DOI 10.1002/ajh.21027; Darbari DS, 2011, J PAIN, V12, P531, DOI 10.1016/j.jpain.2010.10.012; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Frei-Jones MJ, 2008, J PEDIATR, V152, P281, DOI 10.1016/j.jpeds.2007.06.040; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Holsti M, 2010, ARCH PEDIAT ADOL MED, V164, P747, DOI 10.1001/archpediatrics.2010.130; Jacobson SJ, 1997, LANCET, V350, P1358, DOI 10.1016/S0140-6736(97)08462-6; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; KARL HW, 1992, ANESTHESIOLOGY, V76, P209, DOI 10.1097/00000542-199202000-00009; Kavanagh PL, 2011, PEDIATRICS, V128, pE1552, DOI 10.1542/peds.2010-3686; Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x; Kirsh KL, 2002, CLIN J PAIN, V18, pS52, DOI 10.1097/00002508-200207001-00006; Klepstad P, 2005, ACTA ANAESTH SCAND, V49, P902, DOI 10.1111/j.1399-6576.2005.00772.x; Manjushree R, 2002, CAN J ANAESTH, V49, P190; McClain BC, 2007, PEDIATRICS, V119, P612, DOI 10.1542/peds.2006-3580; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056/NEJM200001133420203; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Shapiro BS, 1997, J PAIN SYMPTOM MANAG, V14, P168, DOI 10.1016/S0885-3924(97)00019-5; Smith LA, 2006, PEDIATRICS, V117, P1763, DOI 10.1542/peds.2005-1611; Solomon LR, 2008, BLOOD, V111, P997, DOI 10.1182/blood-2007-07-089144; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; Telfer P, 2009, ARCH DIS CHILD, V94, P979, DOI 10.1136/adc.2008.138875; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Todd KH, 2006, J PAIN, V7, P453, DOI 10.1016/j.jpain.2006.05.004; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Younge P, 1999, EMERGEN MED, V11, P90; Yusuf HR, 2010, AM J PREV MED, V38, pS536, DOI 10.1016/j.amepre.2010.01.001; Zempsky WT, 2010, CLIN PEDIATR EMERG M, V11, P265, DOI 10.1016/j.cpem.2010.09.002; Zempsky WT, 2009, JAMA-J AM MED ASSOC, V302, P2479, DOI 10.1001/jama.2009.1811	42	10	10	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1745-6215			TRIALS	Trials	MAY 30	2012	13								74	10.1186/1745-6215-13-74			7	Medicine, Research & Experimental	Research & Experimental Medicine	985VC	WOS:000307297600001	22647439	DOAJ Gold, Green Published			2020-06-30	J	Ringkamp, M; Raja, SN				Ringkamp, M.; Raja, S. N.			Dissecting the relative contribution of central versus peripheral opioid analgesia: Are the analgesic and adverse effects of opioids inseparable?	EUROPEAN JOURNAL OF PAIN			English	Editorial Material							MEDIATED GENE-TRANSFER; OPIATE RECEPTORS; PAIN; DELIVERY; THERAPY		[Ringkamp, M.; Raja, S. N.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA	Raja, SN (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.	sraja@jhmi.edu		Yang, Shuman/0000-0002-9638-0890			Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0; Fink DJ, 2011, ANN NEUROL, V70, P207, DOI 10.1002/ana.22446; Glorioso JC, 2004, ANNU REV MICROBIOL, V58, P253, DOI 10.1146/annurev.micro.58.030603.123709; Guan Y, 2008, PAIN, V138, P318, DOI 10.1016/j.pain.2008.01.004; Khalefa BI, 2012, EUR J PAIN, V16, P690, DOI 10.1002/j.1532-2149.2011.00070.x; KUHAR MJ, 1973, NATURE, V245, P447, DOI 10.1038/245447a0; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Snyder SH, 2004, NEUROPHARMACOLOGY, V47, P274, DOI 10.1016/j.neuropharm.2004.06.006; SNYDER SH, 1979, ANNU REV NEUROSCI, V2, P35, DOI 10.1146/annurev.ne.02.030179.000343; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Stein Christoph, 2009, Handb Exp Pharmacol, P495, DOI 10.1007/978-3-540-79090-7_14; Vadivelu Nalini, 2011, J Opioid Manag, V7, P55; Wallace M, 2000, REGION ANESTH PAIN M, V25, P117; Wilson SP, 2002, ANN NY ACAD SCI, V971, P515, DOI 10.1111/j.1749-6632.2002.tb04516.x; YAKSH TL, 1976, SCIENCE, V192, P1357, DOI 10.1126/science.1273597; Yeomans DC, 2009, GENE THER, V16, P502, DOI 10.1038/gt.2009.25; Zhang GH, 2008, ANESTHESIOLOGY, V108, P305, DOI 10.1097/01.anes.0000299836.61785.79	17	3	3	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAY	2012	16	5					621	623		10.1002/j.1532-2149.2012.00110.x			3	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	980OC	WOS:000306901700001	22337072				2020-06-30	J	Khalefa, BI; Shaqura, M; Al-Khrasani, M; Furst, S; Mousa, SA; Schafer, M				Khalefa, B. I.; Shaqura, M.; Al-Khrasani, M.; Fuerst, S.; Mousa, S. A.; Schaefer, M.			Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids	EUROPEAN JOURNAL OF PAIN			English	Article							ROOT GANGLION NEURONS; INFLAMMATORY PAIN; P-GLYCOPROTEIN; SENSORY NEURONS; NEUROPATHIC PAIN; VISCERAL PAIN; DORSAL-HORN; RAT; MORPHINE; ANALGESIA	The contribution of supraspinal, spinal or peripheral mu-opioid receptors (MORs) to the overall antinociception of systemic centrally penetrating versus peripherally restricted opioids has not been thoroughly investigated. Therefore, we examined paw pressure thresholds in Wistar rats with complete Freund's adjuvant hindpaw inflammation following different doses of intraplantar (i.pl.) as well as intravenous (i.v.) fentanyl (6.25-50 mu g/kg), morphine (1-7.5 mg/kg) or loperamide (1-7.5 mg/kg). Antagonism of the i. v. mu-opioid agonists by intracerebroventricular (i. c. v.), intrathecal (i.t.) or i.pl. naloxone-methiodide (NLXM) revealed the relative contributions of supraspinal, spinal and peripheral MOR to the overall antinociceptive effects. In parallel, the MOR density at these three levels of pain transmission was assessed by radioligand binding. Antinociceptive effects of i. v. fentanyl and morphine, but not of the peripherally restricted loperamide were two-to threefold greater and longer lasting compared with their i.pl. administration. I. c. v. but not i. pl. NLXM significantly antagonized fentanyl's and morphine's antinociception by 70-80%, whereas i.t. NLXM reduced it by 20-30%. In contrast, antinociception of i. v. loperamide was abolished by i. pl. but not by i. c. v. or i.t. NLXM. In parallel, a respective 32- and sixfold higher MOR density in supraspinal and spinal versus peripheral sensory neurons was detected. In conclusion, in comparison with supraspinal and spinal opioid receptors, peripheral opioid receptors do not significantly contribute to the antinociception of systemic fentanyl and morphine during inflammatory pain. Antinociception of their i. v. administration was superior over both i. v and i. pl. loperamide, acting exclusively via peripheral MOR. These findings may guide the future development of novel peripherally restricted opioids.	[Khalefa, B. I.; Shaqura, M.; Mousa, S. A.; Schaefer, M.] Charite, Campus Virchow Klinikum, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany; [Al-Khrasani, M.; Fuerst, S.] Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, H-1085 Budapest, Hungary	Mousa, SA (reprint author), Charite, Campus Virchow Klinikum, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany.	shaaban.mousa@charite.de	Schafer, Michael/AAB-1395-2020		DFGGerman Research Foundation (DFG) [KFO100, MO 1006/1-4, SCHA 820/3-2]; OTKA (Hungarian Research Grant)Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K-60999]	This work was supported by the DFG grants KFO100, MO 1006/1-4, SCHA 820/3-2 to S. M. and M. S. and by OTKA K-60999 (Hungarian Research Grant) to M. A. and S.F.	Abram SE, 1997, ANESTHESIOLOGY, V87, P127, DOI 10.1097/00000542-199707000-00017; Aldrich JV, 2009, AAPS J, V11, P312, DOI 10.1208/s12248-009-9105-4; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; BARBER A, 1992, MED RES REV, V12, P525, DOI 10.1002/med.2610120505; BARTHO L, 1981, EUR J PHARMACOL, V73, P101, DOI 10.1016/0014-2999(81)90152-7; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; Butelman ER, 2008, PSYCHONEUROENDOCRINO, V33, P292, DOI 10.1016/j.psyneuen.2007.11.011; Choo EF, 2006, J PHARMACOL EXP THER, V317, P1012, DOI 10.1124/jpet.105.099648; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; Criado AB, 2000, LAB ANIM, V34, P252, DOI 10.1258/002367700780384717; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; DAHLSTROM BE, 1975, J PHARMACOKINET BIOP, V3, P293, DOI 10.1007/BF01082303; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Endres-Becker J, 2007, MOL PHARMACOL, V71, P12, DOI 10.1124/mol.106.026740; Enginar H, 2010, CANCER BIOTHER RADIO, V25, P409, DOI 10.1089/cbr.2010.0774; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Furst S, 2005, J PHARMACOL EXP THER, V312, P609, DOI 10.1124/jpet.104.075176; Gaveriaux-Ruff C, 2011, PAIN, V152, P1238, DOI 10.1016/j.pain.2010.12.031; Gold MS, 1996, NEUROSCI LETT, V212, P83, DOI 10.1016/0304-3940(96)12791-9; Gonzalez-Rodriguez S, 2010, CELL MOL NEUROBIOL, V30, P113, DOI 10.1007/s10571-009-9436-9; Groenendaal D, 2007, BRIT J PHARMACOL, V151, P713, DOI 10.1038/sj.bjp.0707258; Guan Y, 2008, PAIN, V138, P318, DOI 10.1016/j.pain.2008.01.004; Heinke B, 2011, J NEUROSCI, V31, P1313, DOI 10.1523/JNEUROSCI.4060-10.2011; Herz A., 1971, ADV DRUG RES, V6, P79; JORIS JL, 1987, ANESTH ANALG, V66, P1277; Joshi SK, 2008, J PAIN, V9, P146, DOI 10.1016/j.jpain.2007.09.004; KAYSER V, 1991, BRAIN RES, V567, P197, DOI 10.1016/0006-8993(91)90796-X; Kedlaya Divakara, 2002, Best Pract Res Clin Anaesthesiol, V16, P651, DOI 10.1053/bean.2002.0253; Kline RH, 2008, J NEUROSCI, V28, P904, DOI 10.1523/JNEUROSCI.4452-07.2008; Kohno T, 2005, PAIN, V117, P77, DOI 10.1016/j.pain.2005.05.035; MANSOUR A, 1995, J CHEM NEUROANAT, V8, P283, DOI 10.1016/0891-0618(95)00055-C; MOLINA N, 1983, BRAZ J MED BIOL RES, V16, P345; Mousa SA, 1996, EUR J PHARMACOL, V311, P221, DOI 10.1016/0014-2999(96)00440-2; Mousa SA, 2007, NEUROPSYCHOPHARMACOL, V32, P2530, DOI 10.1038/sj.npp.1301393; Mousa SA, 2007, BRAIN, V130, P502, DOI 10.1093/brain/awl330; Mousa SA, 2010, J COMP NEUROL, V518, P3836, DOI 10.1002/cne.22427; Nagaraja RY, 2004, N-S ARCH PHARMACOL, V370, P26, DOI 10.1007/s00210-004-0942-5; National Research Council. Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research National Research Council, 2003, P NOV 2003 INT WORKS; NIEMEGEERS CJE, 1979, J PHARMACOL EXP THER, V210, P327; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Park C, 2010, P NATL ACAD SCI USA, V107, P14857, DOI 10.1073/pnas.1009532107; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; REYNOLDS DV, 1969, SCIENCE, V164, P444, DOI 10.1126/science.164.3878.444; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Riviere PJM, 2004, BRIT J PHARMACOL, V141, P1331, DOI 10.1038/sj.bjp.0705763; Romero A, 2010, PHARMACOL BIOCHEM BE, V97, P363, DOI 10.1016/j.pbb.2010.09.005; ROSSIER J, 1979, SCIENCE, V203, P279, DOI 10.1126/science.83674; Saito T, 2001, ACTA OTO-LARYNGOL, V121, P735, DOI 10.1080/00016480152583683; Sasaki A, 2007, J PHARMACOL SCI, V104, P218, DOI 10.1254/jphs.FP0070294; Schmitt TK, 2003, ANESTHESIOLOGY, V98, P195, DOI 10.1097/00000542-200301000-00030; Schneider SP, 1998, J NEUROPHYSIOL, V80, P2954; Shaqura MA, 2004, J PHARMACOL EXP THER, V308, P712, DOI 10.1124/jpet.103.057257; Shinoda K, 2007, NEUROSCI LETT, V411, P143, DOI 10.1016/j.neulet.2006.10.027; STEIN C, 1988, NEUROSCI LETT, V84, P225, DOI 10.1016/0304-3940(88)90412-0; Stein C, 2009, BRAIN RES REV, V60, P90, DOI 10.1016/j.brainresrev.2008.12.017; Storkson RV, 1996, J NEUROSCI METH, V65, P167, DOI 10.1016/0165-0270(95)00164-6; Su YF, 1998, J PHARMACOL EXP THER, V287, P815; Takeda M, 2004, NEUROSCIENCE, V125, P995, DOI 10.1016/j.neuroscience.2004.02.029; Vanderah TW, 2010, CLIN J PAIN, V26, pS10, DOI 10.1097/AJP.0b013e3181c49e3a; Wang HB, 2010, P NATL ACAD SCI USA, V107, P13117, DOI 10.1073/pnas.1008382107; WOMACK MD, 1995, J NEUROPHYSIOL, V73, P1793; Wu ZZ, 2004, J PHARMACOL EXP THER, V311, P939, DOI 10.1124/jpet.104.073429; YAKSH TL, 1978, PAIN, V4, P299, DOI 10.1016/0304-3959(77)90145-2; YAKSH TL, 1976, SCIENCE, V192, P1357, DOI 10.1126/science.1273597; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; YEUNG JC, 1980, J PHARMACOL EXP THER, V215, P626	69	27	28	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAY	2012	16	5					690	705		10.1002/j.1532-2149.2011.00070.x			16	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	980OC	WOS:000306901700008	22337491				2020-06-30	J	Seemann, EA; Willis, KD; Mueller, ML; Stephenson, DD; Harden, CK; George, JM; Pinkerton, LA; White, MR				Seemann, Eric A.; Willis, K. Dean; Mueller, Marie L.; Stephenson, David D.; Harden, Christina Kay; George, James Michael; Pinkerton, Leah A.; White, Megan R.			Sufentanil versus Fentanyl: Efficacy and Patient Satisfaction with Intrathecal Pain Management	NEUROMODULATION			English	Article						Fentanyl; intrathecal drug delivery system; satisfaction with care; sufentanil	NONCANCER PAIN; DRUG-DELIVERY; INFUSION	Objectives: This study compared fentanyl vs. sufentanil in intrathecal pain pumps. H1: both reduce patient subjective pain ratings. H2: sufentanil is more effective than fentanyl. H3: overall satisfaction with pain control is greater with sufentanil. Materials/Method: This is an archival study of patients in tertiary pain management (N= 97, mean age = 58.77, standard deviation = 14.88). Pain was measured using the subjective units of discomfort scale. Satisfaction with pain control/relief was measured by asking patients each visit if they are satisfied with pain management and is recorded in a yes/ no manner. Pain ratings were analyzed with repeated measures analysis of variance and satisfaction was analyzed with chi square. Results/Discussion: Sufentanil was found to be marginally more effective, but both medications controlled a significant degree of variance in pain reduction over time. A significantly greater number of patients maintained on sufentanil were satisfied with care than patients on fentanyl.	[Seemann, Eric A.; Mueller, Marie L.; Stephenson, David D.; Harden, Christina Kay; White, Megan R.] Univ Alabama, Huntsville, AL 35806 USA; [Willis, K. Dean; George, James Michael; Pinkerton, Leah A.] Alabama Pain Ctr, Huntsville, AL USA	Seemann, EA (reprint author), Univ Alabama, Huntsville, AL 35806 USA.	dr.seemann@gmail.com					Arnstein Paul, 2004, Pain Manag Nurs, V5, P34, DOI 10.1016/j.pmn.2004.10.003; Chavda H, 2009, INTERNET J ANESTHESI, P20; Deer T, 2007, NEUROMODULATION, V10, P300, DOI 10.1111/j.1525-1403.2007.00128.x; Deer TR, 2010, PAIN PHYSICIAN, V13, pE175; Gupta A, 2010, PAIN MED, V11, P847, DOI 10.1111/j.1526-4637.2010.00860.x; HANSDOTTIR V, 1991, ANESTHESIOLOGY, V74, P264, DOI 10.1097/00000542-199102000-00012; Hicks D, 2010, MED NEWS        1029; Kumar K, 2002, J NEUROSURG, V97, P803, DOI 10.3171/jns.2002.97.4.0803; LAMER TJ, 1994, MAYO CLIN PROC, V69, P473, DOI 10.1016/S0025-6196(12)61647-4; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Patel VB, 2009, PAIN PHYSICIAN, V12, P345; Ramamurti B, 2005, DRUG DELIV TECHNOL, V5, P1; Reynolds L, 2004, PAIN, V110, P182, DOI 10.1016/j.pain.2004.03.024; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P264; Waara-Wolleat KL, 2006, PAIN MED, V7, P251, DOI 10.1111/j.1526-4637.2006.00155.x; Wallace AS, 2009, SPINE J, V9, P721, DOI 10.1016/j.spinee.2009.04.022	17	2	3	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159			NEUROMODULATION	Neuromodulation	MAY-JUN	2012	15	3					194	199		10.1111/j.1525-1403.2012.00432.x			6	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	952SB	WOS:000304811400004	22376060				2020-06-30	J	Rauck, R; Reynolds, L; Geach, J; Bull, J; Stearns, L; Scherlis, M; Parikh, N; Dillaha, L				Rauck, Richard; Reynolds, Lowell; Geach, Jonathan; Bull, Janet; Stearns, Lisa; Scherlis, Morris; Parikh, Neha; Dillaha, Larry			Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrough pain; Cancer; Fentanyl; Opioid; Spray; Sublingual	LONG-TERM; DOSE-TITRATION; BUCCAL TABLET; CITRATE; PREVALENCE; ABSORPTION; SITES	Background and objectives: A number of transmucosal fentanyl formulations have been developed for the management of breakthrough cancer pain ( BTCP). Sublingual delivery of fentanyl, formulated as fentanyl sublingual spray, offers the potential for more rapid and greater absorption of fentanyl and associated onset of analgesic effect compared with other formulations. The objective of this study was to assess the efficacy and safety of fentanyl sublingual spray for the treatment of BTCP. Research design and methods: This was a randomized, double-blind, placebo-controlled phase III trial conducted in opioid-tolerant patients with BTCP. An open-label titration period was followed by a double-blind treatment period during which patients received fentanyl sublingual spray (100-1600 mcg) or placebo. Clinical trial registration: ClinicalTrials.gov NCT00538850. Main outcome measures: The primary efficacy measure was summed pain intensity difference at 30 minutes (SPID30). Secondary efficacy measures included total pain relief at 30 minutes (TOTPAR(30)) and patient global evaluation of study medication at 30 minutes. Efficacy measures were also assessed at various time points from 5-60 minutes postdose. Adverse events were monitored throughout the study. Results: A total of 130 patients were treated during the titration period, of whom 98 (75.4%) entered the double-blind period. Relative to placebo, fentanyl sublingual spray significantly improved mean SPID scores from 5 minutes (p = 0.0219) through 60 minutes (p<0.0001), including the primary endpoint at 30 minutes (p<0.0001). Fentanyl sublingual spray produced significantly greater pain relief (expressed in terms of TOTPAR) from 5 through 60 minutes (p<0.0001), and significantly greater global evaluation of treatment effectiveness (p<0.0001), compared with placebo. During double-blind treatment, the most frequently reported adverse events were nausea (7.1%), hyperhidrosis (5.1%), and peripheral edema (5.1%). Serious adverse events occurred in seven patients (5.4%) during titration and six (6.1%) during double-blind treatment; none were considered related to treatment. Conclusions: These findings indicate that treatment with fentanyl sublingual spray results in effective relief of BTCP, with a rapid onset of action, and is well tolerated.	[Rauck, Richard] Clin Res Ctr, Carolinas Pain Inst, Winston Salem, NC 27103 USA; [Reynolds, Lowell; Geach, Jonathan] Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA USA; [Bull, Janet] Four Seasons Hosp & Palliat Care, Flat Rock, NC USA; [Stearns, Lisa] Ctr Pain & Support Care, Scottsdale, AZ USA; [Scherlis, Morris] Tenessee Valley Pain Consultants, Huntsville, AL USA; [Parikh, Neha; Dillaha, Larry] Insys Therapeut Inc, Phoenix, AZ USA	Rauck, R (reprint author), Clin Res Ctr, Carolinas Pain Inst, 145 Kimel Pk Dr, Winston Salem, NC 27103 USA.	rrauck@ccrpain.org			Insys Therapeutics, Inc., Phoenix, AZ, USA; MedtronicMedtronic; Medasys Inc.; Alfred Mann Foundation; Azur Pharmaceuticals	Funding for this study was provided by Insys Therapeutics, Inc., Phoenix, AZ, USA. Funding for the preparation and publication of this manuscript was provided by Insys Therapeutics, Inc. Two employees of the sponsor participated as authors of this study.; R.R. reports grant/research funding and consultant/advisor funding from Medtronic, Medasys Inc., the Alfred Mann Foundation, and Azur Pharmaceuticals. He has also participated in speakers' bureaus for Azur Pharmaceuticals. L.R. reports grant/research funding from Insys Therapeutics, Inc. J.B. has participated in scientific advisory boards for Archimedes and Salix. She has also participated in speakers' bureaus for Salix, Pfizer, and Meda. L.S. participates in contracted research with Medtronic and also receives consulting fees from Medtronic. J.G. and M.S. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article. N.P. and L.D. are full-time employees of Insys Therapeutics, Inc., the sponsor of this study.	Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; Atkinson Mark J, 2004, Health Qual Life Outcomes, V2, P12, DOI 10.1186/1477-7525-2-12; Atkinson MJ, 2005, VALUE HEALTH, V8, pS9, DOI 10.1111/j.1524-4733.2005.00066.x; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fishbain David A, 2008, Am J Manag Care, V14, pS123; HARRIS D, 1992, J PHARM SCI-US, V81, P1, DOI 10.1002/jps.2600810102; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; Narang N, 2011, INT J PHARM PHARM S2, V3, P18; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; PIMLOTT SJ, 1985, ORAL SURG ORAL MED O, V60, P35, DOI 10.1016/0030-4220(85)90211-7; PIMLOTT SJ, 1985, ORAL SURG ORAL MED O, V59, P145, DOI 10.1016/0030-4220(85)90006-4; Porta-Sales J, 2010, EUR J PALLIAT CAR S3, V17, P20; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stevens R A, 2000, Cancer Control, V7, P132; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003	32	28	28	1	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	MAY	2012	28	5					859	870		10.1185/03007995.2012.683111			12	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	942SI	WOS:000304066900022	22480131				2020-06-30	J	Mrvos, R; Feuchter, AC; Katz, KD; Duback-Morris, LF; Brooks, DE; Krenzelok, EP				Mrvos, Rita; Feuchter, Alexander C.; Katz, Kenneth D.; Duback-Morris, Lynn F.; Brooks, Daniel E.; Krenzelok, Edward P.			WHOLE FENTANYL PATCH INGESTION: A MULTI-CENTER CASE SERIES	JOURNAL OF EMERGENCY MEDICINE			English	Article						fentanyl; transdermal; opioid; toxicity; patch; ingestion		Background: Fentanyl is a potent synthetic opioid with large abuse potential. A common preparation of fentanyl is a sustained-release transdermal patch. To our knowledge, there are only two published case reports of whole patch ingestion. A case series of 76 patients with a history of whole patch ingestion is reported. Study Objectives: To characterize whole fentanyl patch ingestion to develop a clinical guideline for management. Methods: This was a retrospective review of all patients who ingested intact fentanyl patches as reported to three regional poison information centers (RPIC) from 2000 to 2008. The three RPIC medical record databases were queried for all exposures with a substance code matching the Micromedex (R) (Thomson Reuters, New York, NY) fentanyl product codes. Collected data included: age, gender, reason for the exposure, number of patches ingested, dose (nth), symptoms, symptom onset and duration, treatment hospital flow (level of care), and outcome. Results: A total of 76 patients met the inclusion criteria. Two patients had both time of onset and symptom duration documented. In both patients, the signs and symptoms developed within 2 h of the exposure, and the patients were asymptomatic at 6 1/2 and 9 h, respectively. Fifty-eight (78.3%) patients were admitted. Of those patients who were admitted, 56 (96.5%) were admitted to a critical care unit. Fourteen patients required intubation, and naloxone infusions were documented in eight cases. Conclusion: Ingestion of whole fentanyl patches may lead to prolonged and significant toxicity based on these poison center data. (C) 2012 Elsevier Inc.	[Mrvos, Rita; Feuchter, Alexander C.; Katz, Kenneth D.; Krenzelok, Edward P.] Univ Pittsburgh, Med Ctr, Pittsburgh Poison Ctr, Pittsburgh, PA 15213 USA; [Duback-Morris, Lynn F.] W Virginia Univ, W Virginia Poison Ctr, Charleston, WV 25304 USA; [Brooks, Daniel E.] Banner Poison Control Ctr, Phoenix, AZ USA	Feuchter, AC (reprint author), Univ Pittsburgh, Med Ctr, Pittsburgh Poison Ctr, 230 McKee Pl,Suite 500, Pittsburgh, PA 15213 USA.						Arroyo AM, 2009, CLIN TOXICOL, V47, P706; Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; System Reference Manual, 2007, AM ASS POISON CONTRO; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; US Department of Justice Drug Enforcement Administration Office of Diversion Control, DRUGS CHEM CONC FENT	8	19	19	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	MAY	2012	42	5					549	552		10.1016/j.jemermed.2011.05.017			4	Emergency Medicine	Emergency Medicine	944DW	WOS:000304179600010	21683542				2020-06-30	J	Lyttle, MD; Verma, S; Isaac, R				Lyttle, Mark D.; Verma, Sapna; Isaac, Rhian			Transdermal Fentanyl in Deliberate Overdose in Pediatrics	PEDIATRIC EMERGENCY CARE			English	Article						overdose; fentanyl; opioid	PATCH; CHILD; ABUSE	The use of the fentanyl skin patch to provide pain relief in chronic pain conditions and oncology in adult practice has been common for several years, and an increase in use is now being seen in pediatric practice. Its use in drug misuse and suicide has also increased in recent years. We present the case of an adolescent who deliberately overdosed using fentanyl skin patches and describe the implications for management. This report serves to remind clinicians to consider this method of drug administration in children who display signs of opioid toxicity, where overdose may be subsequent to its use in therapy, recreation, or deliberate self-harm.	[Lyttle, Mark D.] Bristol Royal Hosp Children, Emergency Dept, Bristol BS2 8BJ, Avon, England; [Verma, Sapna] Birmingham Childrens Hosp, Emergency Dept, Birmingham, W Midlands, England; [Isaac, Rhian] Birmingham Childrens Hosp, Dept Pharm, Birmingham, W Midlands, England	Lyttle, MD (reprint author), Bristol Royal Hosp Children, Emergency Dept, Upper Maudlin St, Bristol BS2 8BJ, Avon, England.	Mark.lyttle@uhbristol.nhs.uk		Lyttle, Mark/0000-0002-8634-7210			Barrueto F, 2004, VET HUM TOXICOL, V46, P30; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Fodale V, 2008, EXPERT OPIN DRUG SAF, V7, P213, DOI [10.1517/14740338.7.3.213, 10.1517/14740338.7.3.213 ]; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; Magdalan Jan, 2009, Przegl Lek, V66, P341; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	9	7	7	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	MAY	2012	28	5					463	464		10.1097/PEC.0b013e31825358b4			2	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	937RT	WOS:000303676700014	22561319				2020-06-30	J	Dewhirst, E; Naguib, A; Tobias, JD				Dewhirst, Elisabeth; Naguib, Aymen; Tobias, Joseph D.			Chest Wall Rigidity in Two Infants After Low-Dose Fentanyl Administration	PEDIATRIC EMERGENCY CARE			English	Article						fentanyl; chest wall rigidity; synthetic opioids	INDUCED MUSCLE RIGIDITY; INDUCED COUGH; INFUSION; ANESTHESIA; INDUCTION	Since its introduction into clinical practice, it has been known that fentanyl and other synthetic opioids may cause skeletal muscle rigidity. Involvement of the respiratory musculature, laryngeal structures, or the chest wall may impair ventilation, resulting in hypercarbia and hypoxemia. Although most common with the rapid administration of large doses, this rare adverse effect may occur with small doses especially in neonates and infants. We present 2 infants who developed chest wall rigidity, requiring the administration of neuromuscular blocking agents and controlled ventilation after analgesic doses of fentanyl. Previous reports regarding chest wall rigidity after the administration of low-dose fentanyl in infants and children are reviewed, the pathogenesis of the disorder is discussed, and treatment options offered.	[Dewhirst, Elisabeth; Naguib, Aymen; Tobias, Joseph D.] Nationwide Childrens Hosp, Dept Anesthesiol, Columbus, OH 43205 USA; [Tobias, Joseph D.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA	Tobias, JD (reprint author), Nationwide Childrens Hosp, Dept Anesthesiol & Pain Med, 700 Childrens Dr, Columbus, OH 43205 USA.	Joseph.Tobias@Nationwidechildrens.org					Anand KJS, 2001, ANESTHESIOLOGY, V95, P823, DOI 10.1097/00000542-200110000-00006; ARNOLD JH, 1991, J PEDIATR-US, V119, P639, DOI 10.1016/S0022-3476(05)82419-9; ECKENHOFF JE, 1960, CLIN PHARMACOL THER, V1, P483; Elakkumanan LB, 2008, PEDIATR ANESTH, V18, P1115, DOI 10.1111/j.1460-9592.2008.02602.x; ELLENBROEK B, 1985, BRAIN RES, V345, P132, DOI 10.1016/0006-8993(85)90843-1; Eventov-Friedman S, 2010, J PERINATOL, V30, P149, DOI 10.1038/jp.2009.66; Fahnenstich H, 2000, CRIT CARE MED, V28, P835; Glick C, 1996, SOUTHERN MED J, V89, P1119, DOI 10.1097/00007611-199611000-00023; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; HILL AB, 1981, ANESTHESIOLOGY, V55, P452, DOI 10.1097/00000542-198110000-00021; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; IRAZUZTA J, 1993, CRIT CARE MED, V21, P1001, DOI 10.1097/00003246-199307000-00013; Jaros Tomasz, 1995, Polish Journal of Pharmacology, V47, P19; Kashimoto Satoshi, 2009, Masui, V58, P984; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lui P W, 1991, Ma Zui Xue Za Zhi, V29, P542; LUI PW, 1992, EUR J ANAESTH, V9, P419; MacGregor DA, 1996, J CLIN ANESTH, V8, P251, DOI 10.1016/0952-8180(96)00020-7; MARTY J, 1981, ACTA ANAESTH SCAND, V25, P293, DOI 10.1111/j.1399-6576.1981.tb01654.x; Muller P, 2000, AM J PERINAT, V17, P23, DOI 10.1055/s-2000-7289; Nakada J, 2009, J ANESTH, V23, P323, DOI 10.1007/s00540-009-0769-9; NEIDHART P, 1989, ACTA ANAESTH SCAND, V33, P1, DOI 10.1111/j.1399-6576.1989.tb02849.x; Prakash Smita, 2010, J Anaesthesiol Clin Pharmacol, V26, P567; WEINGER MB, 1989, ANESTHESIOLOGY, V71, P242, DOI 10.1097/00000542-198908000-00013; WELLS S, 1994, HEART LUNG, V23, P196; YASTER M, 1987, ANESTHESIOLOGY, V66, P524, DOI 10.1097/00000542-198704000-00013; YASTER M, 1987, ANESTHESIOLOGY, V66, P433, DOI 10.1097/00000542-198703000-00035; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021	28	21	23	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	MAY	2012	28	5					465	468		10.1097/PEC.0b013e3182535a2a			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	937RT	WOS:000303676700015	22561320				2020-06-30	J	Chapman, E; Leipsic, J; Satkunam, N; Churg, A				Chapman, Erin; Leipsic, Jonathon; Satkunam, Niranjala; Churg, Andrew			Pulmonary Alveolar Proteinosis as a Reaction to Fentanyl Patch Smoke	CHEST			English	Article							AUTOIMMUNE	We report a patient who developed shortness of breath and systemic symptoms after starting to smoke fentanyl patches. CT scan showed ground glass centrilobular nodules, and biopsy demonstrated alveolar proteinosis. Her symptoms disappeared and her chest imaging changes largely resolved when she stopped smoking the patches. Alveolar proteinosis is an uncommon drug reaction and in this case presented in a very unusual fashion as an inhalation injury. CHEST 2012; 141(5):1321-1323	[Churg, Andrew] Univ British Columbia, Dept Pathol, Vancouver, BC V6T 2B5, Canada; [Chapman, Erin; Churg, Andrew] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada; [Leipsic, Jonathon] St Pauls Hosp, Dept Radiol, Vancouver, BC V6Z 1Y6, Canada; [Satkunam, Niranjala] Royal Alexandra Hosp, Dept Pathol, Edmonton, AB, Canada	Churg, A (reprint author), Univ British Columbia, Dept Pathol, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	achurg@interchange.ubc.ca			GE HealthcareGE Healthcare; AstraZeneca RDAstraZeneca	The authors have reported to CHEST the following conflicts of interest: Dr Leipsic has received a grant of $60,000 from GE Healthcare and is a member of the Medical Advisory Board of GE Healthcare. Dr Churg has received research grants totaling $1,500,000 from AstraZeneca R&D. Drs Chapman and Satkunam have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.	[Anonymous], PNEUMOTOX ON LINE; Frazier AA, 2008, RADIOGRAPHICS, V28, P883, DOI 10.1148/rg.283075219; Holbert JM, 2001, AM J ROENTGENOL, V176, P1287, DOI 10.2214/ajr.176.5.1761287; Inoue Y, 2008, AM J RESP CRIT CARE, V177, P752, DOI 10.1164/rccm.200708-1271OC; Ishii H, 2009, CHEST, V136, P1348, DOI 10.1378/chest.09-0097; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Seymour JF, 2002, AM J RESP CRIT CARE, V166, P215, DOI 10.1164/rccm.2109105; Verma H, 2010, RESPIROLOGY, V15, P1197, DOI 10.1111/j.1440-1843.2010.01848.x	8	9	10	0	1	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2012	141	5					1321	1323		10.1378/chest.11-1462			3	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	940PO	WOS:000303905700031	22553265				2020-06-30	J	Balaban, F; Yagar, S; Ozgok, A; Koc, M; Gullapoglu, H				Balaban, Fatih; Yagar, Seyhan; Ozgok, Aysegul; Koc, Mihrican; Gullapoglu, Hayriye			A randomized, placebo-controlled study of pregabalin for postoperative pain intensity after laparoscopic cholecystectomy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Laparoscopic cholecystectomy; Postoperative pain; Pregabalin	PROTECTIVE PREMEDICATION; GABAPENTIN; MORPHINE; CONSUMPTION; ATTENUATION; ANALGESIA; DRUGS	Study Objective: To determine the efficacy of two different doses (150 mg and 300 mg) of preoperative pregabalin on pain relief and total opioid consumption after laparoscopic cholecystectomy. Design: Prospective, randomized, placebo-controlled, double-blinded study. Setting: Training and research hospital. Patients: 90 adult, ASA physical status 1 and 2 patients. Interventions: Patients were randomly assigned to three groups to receive orally one hour before surgery, a placebo (Group 1), pregabalin 150 mg (Group 2), or pregabalin 300 mg (Group 3). Patients were observed for pregabalin side effects, somnolence via Ramsay Sedation Scale, dizziness, confusion, and ataxia. Measurements: In the operating room, heart rate and noninvasive systolic and diastolic blood pressures were measured. Visual analog scale (VAS), Ramsay Sedation Scale, and Aldrete scores were also recorded on arrival at the Postanesthesia Care Unit (time 0), 15, 30, 60, 120 minutes and 3, 4, 6, 8, 10, 12 and 24 hours after surgery. Additional doses of drugs (fentanyl and/or metoclopramide) were also recorded. Main Results: Preemptive pregabalin decreased pain scores and postoperative fentanyl consumption in patients after laparoscopic cholecystectomy in a dose-dependent manner. There were no differences between the groups in side effects. Conclusion: Preoperative pregabalin may be a useful analgesic for patients after laparoscopic cholecystectomy, as it lowers pain intensity and opiod consumption, and does not increase the frequency of side effects. (C) 2012 Elsevier Inc. All rights reserved.	[Balaban, Fatih; Yagar, Seyhan; Ozgok, Aysegul; Koc, Mihrican; Gullapoglu, Hayriye] Turkiye Yuksek Ihtisas Educ & Res Hosp, Dept Anesthesiol & Reanimat, TR-06100 Ankara, Turkey	Yagar, S (reprint author), Turkiye Yuksek Ihtisas Hosp, Anesthesiol & Reanimat Dept, TR-06100 Ankara, Turkey.	seyhanyagar@yahoo.com	ozgok, Aysegul/AAG-4356-2019				Agarwal A, 2008, BRIT J ANAESTH, V101, P700, DOI 10.1093/bja/aen244; Bromley L, 2006, BIOMED PHARMACOTHER, V60, P336, DOI 10.1016/j.biopha.2006.06.012; Chang SH, 2009, ANESTH ANALG, V109, P1284, DOI 10.1213/ane.0b013e3181b4874d; Chia YY, 1998, ANESTH ANALG, V86, P1245, DOI 10.1097/00000539-199806000-00021; Dahl JB, 2004, ACTA ANAESTH SCAND, V48, P1130, DOI 10.1111/j.1399-6576.2004.00484.x; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Gajraj Noor M, 2005, Pain Pract, V5, P95, DOI 10.1111/j.1533-2500.2005.05205.x; Gilron I, 2006, CAN J ANAESTH, V53, P562, DOI 10.1007/BF03021846; Hill CM, 2001, EUR J PAIN, V5, P119, DOI 10.1053/eujp.2001.0235; Hurley RW, 2002, ANESTHESIOLOGY, V97, P1263, DOI 10.1097/00000542-200211000-00033; Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316; Paech MF, 2007, ANESTH ANALG, V105, P1449, DOI 10.1213/01.ane.0000286227.13306.d7; Park J, 1996, CAN J ANAESTH, V43, P900, DOI 10.1007/BF03011802; Seib RK, 2006, CAN J ANAESTH, V53, P461, DOI 10.1007/BF03022618; Tiippana EM, 2007, ANESTH ANALG, V104, P1545, DOI 10.1213/01.ane.0000261517.27532.80	16	40	42	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAY	2012	24	3					175	178		10.1016/j.jclinane.2011.06.027			4	Anesthesiology	Anesthesiology	939EL	WOS:000303790200001	22459341				2020-06-30	J	Gollapudy, S; Kumar, V; Dhamee, MS				Gollapudy, Suneeta; Kumar, Vikram; Dhamee, M. Saeed			A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion	JOURNAL OF CLINICAL ANESTHESIA			English	Letter							INHIBITORS; TOXICITY		[Gollapudy, Suneeta; Kumar, Vikram; Dhamee, M. Saeed] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Anesthesiol, Milwaukee, WI 53226 USA	Gollapudy, S (reprint author), Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Anesthesiol, Milwaukee, WI 53226 USA.	gsuneeta@mcw.edu					Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Bpharm SR, 2003, CAN J ANAESTH, V50, P32, DOI 10.1007/BF03020183; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Ingelman-Sundberg M, 2004, TRENDS PHARMACOL SCI, V25, P193, DOI 10.1016/j.tips.2004.02.007; NOBLE WH, 1992, CAN J ANAESTH, V39, P1061, DOI 10.1007/BF03008376; Turkel SB, 2001, PSYCHOSOMATICS, V42, P258, DOI 10.1176/appi.psy.42.3.258	8	23	23	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2012	24	3					251	252		10.1016/j.jclinane.2011.04.017			2	Anesthesiology	Anesthesiology	939EL	WOS:000303790200015	22537574				2020-06-30	J	Jeitziner, MM; Schwendimann, R; Hamers, JPH; Rohrer, O; Hantikainen, V; Jakob, SM				Jeitziner, M. -M.; Schwendimann, R.; Hamers, J. P. H.; Rohrer, O.; Hantikainen, V.; Jakob, S. M.			Assessment of pain in sedated and mechanically ventilated patients: an observational study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							INTENSIVE-CARE UNIT; CRITICALLY-ILL; CONTENT VALIDITY; OBSERVATION TOOL; MANAGEMENT; SCALE; VALIDATION; STIMULI; INDEX; TIME	Background: Critically ill patients often undergo unpleasant procedures. We quantified the effects of an unpleasant stimulus on physiological and behavioral parameters and evaluated how they are modified by sedation and analgesia. Methods: A 6-month study in the 30-bed intensive care unit (ICU) of a university hospital examined 21 sedated patients from various diagnostic groups. Hemodynamic and respiratory parameters, pupil size, facial expression, muscle tone, body movement, and the Richmond Agitation-Sedation Scale (RASS) score were measured before and during intratracheal suctioning, first in sedated patients, after sedation was stopped, and after an opioid bolus. Results: Before intratracheal suctioning, patients had RASS scores of -1.8 +/- 1.2 (mean +/- standard deviation; sedation), -0.6 +/- 1.7 (sedation stop), and -0.9 +/- 1.4 (analgesia) (P = 0.014). Intratracheal suctioning significantly increased RASS during both sedation (to -0.6 +/- 1.7) and sedation stop (to 1.0 +/- 1.5) (both P < 0.01), but not during analgesia. Systolic blood pressure increased during sedation (by 9 +/- 10 mmHg), during sedation stop (by 15 +/- 17 mmHg) and during analgesia (by 9 +/- 4 mmHg; all P < 0.01), but diastolic pressure only during sedation and sedation stop (both P < 0.01). Facial expression, body movement, and muscle tone changed significantly during the episodes of intratracheal suctioning. Heart rate, tidal volume, and pupil size remained stable under all conditions. Conclusions: Intratracheal suctioning evoked significant changes in some physiological and behavioral parameters. Some physiological changes were suppressed by analgesia, but at our ICU's standard doses, neither analgesia nor sedation attenuated changes in behavioral parameters at the intensity tested.	[Jeitziner, M. -M.; Rohrer, O.; Jakob, S. M.] Inselspital Bern, Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland; [Jeitziner, M. -M.; Rohrer, O.; Jakob, S. M.] Univ Bern, Bern, Switzerland; [Schwendimann, R.] Univ Basel, Inst Nursing Sci, Basel, Switzerland; [Hamers, J. P. H.] Univ Maastricht, Dept Hlth Care Studies, Maastricht, Netherlands; [Hantikainen, V.] Univ St Gallen, Inst Appl Nursing Sci, St Gallen, Switzerland	Jakob, SM (reprint author), Inselspital Bern, Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland.	stephan.jakob@insel.ch	Drozd, Vadym/B-2518-2009; Mao, Hokwang/K-8013-2013	Drozd, Vadym/0000-0001-9421-5712; 	Abbott Nutrition International; B. Braun Medical AG; CSEM SA; Edwards Lifesciences Services GmbH; Kenta Biotech Ltd; Maquet Critical Care AB; Omnicare Clinical Research AG; Orion Corporation; Edwards Lifesciences SA; Nestle; Berner Forum for Intensive Care: Fresenius Kabi; GSKGlaxoSmithKline; MSD; LillyEli Lilly; Baxter; AstellasAstellas Pharmaceuticals; AstraZenecaAstraZeneca; B|Braun; CSL Behring; Maquet; NovartisNovartis; Covidien; Mycomed; RobaPharma	The authors have no conflicts of interest. The Department of Intensive Care Medicine has, or has had in the past, research contracts with Abbott Nutrition International, B. Braun Medical AG, CSEM SA, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, and Orion Corporation; and research and development/consulting contracts with Edwards Lifesciences SA, Maquet Critical Care AB, and Nestle. The money is/was paid into a departmental fund; no author receives/received any personal financial gain. The department has received unrestricted educational grants from the following organizations for organizing a quarterly postgraduate educational symposium, the Berner Forum for Intensive Care: Fresenius Kabi; GSK; MSD; Lilly; Baxter; Astellas; AstraZeneca; B|Braun; CSL Behring; Maquet; Novartis; Covidien; Mycomed; RobaPharma.	Aissaoui Y, 2005, ANESTH ANALG, V101, P1470, DOI 10.1213/01.ANE.0000182331.68722.FF; Arroyo-Novoa Carmen Mabel, 2008, Intensive Crit Care Nurs, V24, P20, DOI 10.1016/j.iccn.2007.05.002; Aslan Fatma Eti, 2003, Nurs Crit Care, V8, P62, DOI 10.1046/j.1478-5153.2003.00006.x; Carroll K C, 1999, Am J Crit Care, V8, P105; Chaboyer Wendy, 2003, Nurs Crit Care, V8, P149, DOI 10.1046/j.1478-5153.2003.00020.x; Cignacco E, 2004, EARLY HUM DEV, V78, P125, DOI 10.1016/j.earlhumdev.2004.04.001; Doi M, 2005, INTENS CARE MED, V31, P41, DOI 10.1007/s00134-004-2516-x; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; FERRELL BR, 1994, J PAIN SYMPTOM MANAG, V9, P221, DOI 10.1016/0885-3924(94)90099-X; Gelinas C, 2004, AM J CRIT CARE, V13, P126; Gelinas C, 2007, CLIN J PAIN, V23, P497, DOI 10.1097/ajp.0b013e31806a23fb; Gelinas C, 2009, J ADV NURS, V65, P203, DOI 10.1111/j.1365-2648.2008.04847.x; Gelinas Celine, 2007, Intensive Crit Care Nurs, V23, P298, DOI 10.1016/j.iccn.2007.03.002; Granja C, 2005, CRIT CARE, V9, pR96, DOI 10.1186/cc3026; Haenggi M, 2008, CRIT CARE, V12, DOI 10.1186/cc7015; Jeitziner Marie-Madlen, 2006, Pflege, V19, P335, DOI 10.1024/1012-5302.19.6.335; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Li D, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2008.07.005; Mateo O M, 1992, J Post Anesth Nurs, V7, P15; Pasero Chris, 2003, J Perianesth Nurs, V18, P422, DOI 10.1016/j.jopan.2003.09.003; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Polit DF, 2007, RES NURS HEALTH, V30, P459, DOI 10.1002/nur.20199; Polit DF, 2006, RES NURS HEALTH, V29, P489, DOI 10.1002/nur.20147; Prkachin KM, 2002, PAIN, V95, P23, DOI 10.1016/S0304-3959(01)00369-4; PRKACHIN KM, 1992, PAIN, V51, P297, DOI 10.1016/0304-3959(92)90213-U; Puntillo K A, 1994, Am J Crit Care, V3, P116; PUNTILLO KA, 1990, HEART LUNG, V19, P526; Puntillo KA, 2004, CRIT CARE MED, V32, P421, DOI 10.1097/01.CCM.0000108875.35298.D2; Puntillo KA, 2002, HEART LUNG, V31, P303, DOI 10.1067/mhl.2002.125652; Puntillo KA, 1997, CRIT CARE MED, V25, P1159, DOI 10.1097/00003246-199707000-00017; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Stanik-Hutt J A, 2001, Am J Crit Care, V10, P252; Stannard D, 1996, Am J Crit Care, V5, P433; Takala J, 2008, INTENS CARE MED, V34, P1401, DOI 10.1007/s00134-008-1084-x; TEASDALE G, 1974, LANCET, V2, P81; WHIPPLE JK, 1995, PHARMACOTHERAPY, V15, P592, DOI 10.1002/j.1875-9114.1995.tb02868.x; Zwakhalen SMG, 2004, J ADV NURS, V45, P236, DOI 10.1046/j.1365-2648.2003.02884.x	38	15	16	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2012	56	5					645	654		10.1111/j.1399-6576.2012.02660.x			10	Anesthesiology	Anesthesiology	923FD	WOS:000302603900017	22404146				2020-06-30	J	Menozzi, A; Pozzoli, C; Zullian, C; Poli, E; Serventi, P; Bertini, S				Menozzi, A.; Pozzoli, C.; Zullian, C.; Poli, E.; Serventi, P.; Bertini, S.			Inhibition of motility in isolated horse small intestine is mediated by kappa but not mu opioid receptors	EQUINE VETERINARY JOURNAL			English	Article						horse; small intestine; motility; opioid receptor; morphine	GUINEA-PIG ILEUM; GASTROINTESTINAL-TRACT; FEMALE PONIES; MORPHINE; BUTORPHANOL; INVOLVEMENT; ANTAGONISTS; AGONISTS; OPIATE; DRUGS	The effects of preferential mu (morphine), selective mu (fentanyl), selective ? (compound U69593) opioid receptor agonists, and nonselective (naloxone) and selective mu (naloxonazine) antagonists on equine small intestinal motility were evaluated in vitro. Samples of circular muscle from equine jejunum were placed in isolated organ baths and drug-induced modifications of both spontaneous and electrically evoked contractile activity were measured. None of the opioid agonists induced a significant change in spontaneous contractions. Fentanyl and U69593 reduced electrically induced contractions, whereas morphine reduced them only slightly. Naloxone competitively antagonised U69593, but both naloxone and naloxonazine were unable to counteract the inhibition of contractions induced by fentanyl. The inhibition of contractions shown by fentanyl is therefore probably not mediated by opioid receptors, but due to an anticholinergic activity of this drug. In summary, these data showed an inhibitory effect exerted by ? receptors on equine small intestinal motility, whereas the role of mu receptors seemed marginal and would need further characterisation.	[Menozzi, A.; Zullian, C.; Serventi, P.; Bertini, S.] Univ Parma, Dept Anim Hlth, I-43100 Parma, Italy; [Pozzoli, C.; Poli, E.] Univ Parma, Dept Human Anat Pharmacol & Med Forens Sci, I-43100 Parma, Italy	Bertini, S (reprint author), Univ Parma, Dept Anim Hlth, I-43100 Parma, Italy.	simone.bertini@unipr.it	Menozzi, Alessandro/B-5752-2013	Menozzi, Alessandro/0000-0003-2957-0018; Bertini, Simone/0000-0002-7048-4544	Italian Ministry of Education, University and ResearchMinistry of Education, Universities and Research (MIUR)	The present work was supported by a local grant from the Italian Ministry of Education, University and Research (FIL 2009).	Bagnol D, 1997, NEUROSCIENCE, V81, P579, DOI 10.1016/S0306-4522(97)00227-3; Boscan P, 2006, AM J VET RES, V67, P992, DOI 10.2460/ajvr.67.6.992; Brown DR, 2004, NEUROGASTROENT MOTIL, V16, P50, DOI 10.1111/j.1743-3150.2004.00475.x; COMBIE J, 1981, AM J VET RES, V42, P716; CREESE I, 1975, J PHARMACOL EXP THER, V194, P205; DAVIES JV, 1983, RES VET SCI, V34, P334, DOI 10.1016/S0034-5288(18)32233-1; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; HUSTVEIT O, 1993, ACTA ANAESTH SCAND, V37, P541, DOI 10.1111/j.1399-6576.1993.tb03761.x; HUTCHINSON M, 1975, BRIT J PHARMACOL, V55, P541, DOI 10.1111/j.1476-5381.1975.tb07430.x; Kosterlitz H W, 1973, Adv Biochem Psychopharmacol, V8, P319; KROMER W, 1988, PHARMACOL REV, V40, P121; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; Merritt A M, 1989, Equine Vet J Suppl, P21; Mircica E, 2003, VET ANAESTH ANALG, V30, P147, DOI 10.1046/j.1467-2995.2003.00092.x; PATON WDM, 1957, BRIT J PHARM CHEMOTH, V12, P119, DOI 10.1111/j.1476-5381.1957.tb01373.x; POLI E, 1994, J PHARMACOL EXP THER, V270, P788; Rakestraw PC, 1996, AM J VET RES, V57, P1206; ROGER T, 1994, CAN J VET RES, V58, P163; ROGER T, 1985, AM J VET RES, V46, P31; RUTKOWSKI JA, 1989, AM J VET RES, V50, P1096; SOJKA JE, 1988, AM J VET RES, V49, P527; Zullian C, 2011, VET J, V187, P342, DOI 10.1016/j.tvjl.2009.12.015	23	8	9	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0425-1644	2042-3306		EQUINE VET J	Equine Vet. J.	MAY	2012	44	3					368	370		10.1111/j.2042-3306.2011.00426.x			3	Veterinary Sciences	Veterinary Sciences	920IH	WOS:000302397000020	21883413				2020-06-30	J	Kvarnstrom, AL; Sarbinowski, RT; Bengtson, JP; Jacobsson, LM; Bengtsson, AL				Kvarnstrom, A. L.; Sarbinowski, R. T.; Bengtson, J. -P.; Jacobsson, L. M.; Bengtsson, A. L.			Complement Activation and Interleukin Response in Major Abdominal Surgery	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Article							ANTIINFLAMMATORY CYTOKINE RESPONSE; SYSTEMIC INFLAMMATORY RESPONSE; TOTAL INTRAVENOUS ANESTHESIA; PROPOFOL; SEVOFLURANE; MAINTENANCE; ISOFLURANE	The objective of this study was to evaluate whether major abdominal surgery leads to complement activation and interleukin response and whether the kind of anaesthesia influence complement activation and the release of inflammatory interleukins. The study design was prospective and randomised. Fifty patients undergoing open major colorectal surgery due to cancer disease or inflammatory bowel disease were studied. Twenty-five patients were given total intravenous anaesthesia (TIVA) with propofol and remifentanil, and 25 patients were given inhalational anaesthesia with sevoflurane and fentanyl. To determine complement activation (C3a and SC5b-9) and the release of pro- and anti-inflammatory interleukins (tumour necrosis factor-a (TNF-a)), interleukin-1b (IL-1b), IL-6, IL-8, IL-4 and IL-10), blood samples were drawn preoperatively, 60 minutes after start of surgery, 30 minutes after end of surgery and 24 hours postoperatively. Complement was activated and pro-inflammatory interleukins (IL-6 and IL-8) and anti-inflammatory interleukins (IL-10) were released during major colorectal surgery. There was no significant difference between TIVA and inhalational anaesthesia regarding complement activation and cytokine release. Major colorectal surgery leads to activation of the complement cascade and the release of both pro-inflammatory and anti-inflammatory cytokines. There are no significant differences between total intravenous anaesthesia (TIVA) with propofol and remifentanil and inhalational anaesthesia with sevoflurane and fentanyl regarding complement activation and the release of pro- and anti-inflammatory interleukins.	[Kvarnstrom, A. L.; Sarbinowski, R. T.; Jacobsson, L. M.; Bengtsson, A. L.] Sahlgrenska Univ Hosp E, Dept Anaesthesiol & Intens Care, S-41645 Gothenburg, Sweden	Kvarnstrom, AL (reprint author), Sahlgrenska Univ Hosp E, Dept Anaesthesiol & Intens Care, S-41645 Gothenburg, Sweden.	andreas.kvarnstrom@vgregion.se			ALF [7271]; Goteborg Medical Society [GLS-13114, GLS-42261]	Authors acknowledge Thomas Marlow B.Sc (Hons), for statistical advice and analytical support and Department of Neuropsychiatric Epidemiology, Sahlgrenska Academy, University of Gothenburg, Sweden. This study was supported by grants from ALF (grant number 7271) and The Goteborg Medical Society (grant number GLS-13114 and GLS-42261).	Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Baker EA, 2006, WOUND REPAIR REGEN, V14, P566, DOI 10.1111/j.1743-6109.2006.00163.x; Catena F, 2009, INT J COLORECTAL DIS, V24, P803, DOI 10.1007/s00384-009-0677-3; CROZIER TA, 1994, BRIT J ANAESTH, V72, P280, DOI 10.1093/bja/72.3.280; Dimopoulou I, 2007, CYTOKINE, V37, P55, DOI 10.1016/j.cyto.2007.02.023; Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139; El Azab SR, 2002, EUR J ANAESTH, V19, P276, DOI 10.1017/S0265021502000443; Evans C, 2009, AM J SURG, V197, P238, DOI 10.1016/j.amjsurg.2008.01.021; Gilliland HE, 1997, ANESTH ANALG, V85, P1394, DOI 10.1097/00000539-199712000-00039; GREWE M, 1995, J INVEST DERMATOL, V104, P3, DOI 10.1111/1523-1747.ep12613446; Ihn CH, 2009, J INT MED RES, V37, P1760, DOI 10.1177/147323000903700612; Kawamura T, 2006, J CARDIOTHOR VASC AN, V20, P503, DOI 10.1053/j.jvca.2006.01.011; Ke JJ, 2008, ANAESTH INTENS CARE, V36, P74, DOI 10.1177/0310057X0803600113; Lausevic Z, 2008, CAN J SURG, V51, P97; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moreira AD, 2010, SURG ENDOSC, V24, P1280, DOI 10.1007/s00464-009-0761-3; Nakayama H, 2000, JPN J CLIN ONCOL, V30, P301, DOI 10.1093/jjco/hyd078; Ohmizo H, 1999, ANAESTH INTENS CARE, V27, P623, DOI 10.1177/0310057X9902700611; Sarbinowski R, 2005, ACTA ANAESTH SCAND, V49, P191, DOI 10.1111/j.1399-6576.2004.00565.x; Schneemilch CE, 2005, J CLIN ANESTH, V17, P517, DOI 10.1016/j.jclinane.2004.12.017; Wei HF, 2008, ANESTHESIOLOGY, V108, P251, DOI 10.1097/01.anes.0000299435.59242.0e; Wichmann MW, 2005, ARCH SURG-CHICAGO, V140, P692, DOI 10.1001/archsurg.140.7.692	22	19	21	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2012	75	5					510	516		10.1111/j.1365-3083.2012.02672.x			7	Immunology	Immunology	922JT	WOS:000302543900006	22229650				2020-06-30	J	Wolff, RF; Aune, D; Truyers, C; Hernandez, AV; Misso, K; Riemsma, R; Kleijnen, J				Wolff, Robert F.; Aune, Dagfinn; Truyers, Carla; Hernandez, Adrian V.; Misso, Kate; Riemsma, Rob; Kleijnen, Jos			Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Review						Administration; Buprenorphine; Chronic pain; Cutaneous; Drug toxicity; Fentanyl; Pain; Transdermal patch	RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; DOUBLE-BLIND; TTS-FENTANYL; CANCER; TOLERABILITY; MULTICENTER; TRIAL	Objective: To systematically assess efficacy and safety of buprenorphine patch versus fentanyl patch in patients with chronic moderate to severe pain. Methods: Fifteen databases were searched up to December 2010. Randomised and quasi-randomised trials assessing the efficacy in patients with chronic pain were included. Quantitative methods for data synthesis were used and two network meta-analyses were conducted. Results: Fourteen unique trials (17 publications) were included. No head-to-head randomised trials of buprenorphine patch compared with fentanyl patch were identified. Therefore, less robust evidence from indirect comparisons was used. Results from a network meta-analysis of non-enriched designs (eight trials), using trials versus placebo and trials versus morphine for indirect comparisons, indicated that transdermal fentanyl, in comparison with transdermal buprenorphine, showed significantly more nausea (odds ratio [OR] 4.66, 95% confidence interval (CI) 1.07 to 20.39), a significantly higher number of treatment discontinuations due to adverse events (OR 5.94, 95% CI 1.78 to 19.87), and non-significant differences on all other outcomes, including pain measures. In comparison with morphine, transdermal buprenorphine had a significantly higher decrease of pain intensity (MD [mean difference] -16.20, 95% CI -28.92 to -3.48) while morphine caused more cases of constipation (OR 7.50, 95% CI 1.45 to 38.85) and a significantly higher number of treatment discontinuations due to adverse events (OR 5.80, 95% CI 1.68 to 20.11). All other outcomes showed non-significant differences between transdermal buprenorphine and morphine. The results were similar when also including six trials using enriched designs with the exception of more cases of vomiting for fentanyl (OR 17.32, 95% CI 4.43 to 67.71) and morphine (OR 15.85, 95% CI 3.92 to 64.13) compared to buprenorphine. Conclusions: The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine.	[Wolff, Robert F.; Hernandez, Adrian V.; Misso, Kate; Riemsma, Rob; Kleijnen, Jos] Kleijnen Systemat Reviews Ltd, York YO19 6FD, N Yorkshire, England; [Aune, Dagfinn] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, Sch Publ Hlth, London, England; [Truyers, Carla] Katholieke Univ Leuven, Dept Gen Practice, Louvain, Belgium; [Hernandez, Adrian V.] Cleveland Clin, Dept Quantitat Hlth Sci, Lerner Res Inst, Cleveland, OH 44106 USA; [Kleijnen, Jos] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands	Wolff, RF (reprint author), Kleijnen Systemat Reviews Ltd, Unit 6,Escrick Business Pk,Riccall Rd, York YO19 6FD, N Yorkshire, England.	robert@systematic-reviews.com	Riemsma, Rob/E-2319-2016; Misso, Kate/D-2060-2016; Wolff, Robert F/E-2322-2016	Riemsma, Rob/0000-0001-8892-0861; Misso, Kate/0000-0002-4924-4327; Wolff, Robert F/0000-0003-3270-7791; Hernandez, Adrian V./0000-0002-9999-4003; Aune, Dagfinn/0000-0002-4533-1722	Grunenthal GmbH; Grunenthal	This study was sponsored by Grunenthal GmbH. Grunenthal GmbH was given the opportunity to comment on the draft paper, but the authors had full editorial freedom.; R.F.W., K.M., R.R. and J.K. have disclosed that they are employees of Kleijnen Systematic Reviews Ltd (KSR) while D.A., C.T. and A.V.H. worked as consultants for KSR. KSR is a company that received funding from Grunenthal to conduct this study. The authors declared no other relevant relationships (financial, employment, other significant/relevant relationships).	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Ahmedzai S, 1995, EUR J CANCER, V31A, P874; Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Allan L, 2003, PAIN EUR 4 4 C EUR F; Bohme K, 2003, PAIN CLINIC, V15, P193, DOI 10.1163/156856903321579334; Centre for Reviews and Dissemination, 2009, SYST REV CRDS GUID U; CHANGE PAIN Advisory Panel, 2010, CHANGE PAIN OP TREAT; Davis M, 2005, OPIOIDS CANC PAIN; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Kongsgaard UE, 1998, EUR J PAIN-LONDON, V2, P53, DOI 10.1016/S1090-3801(98)90046-5; Kongsgaard UE, 1997, SUPPORT CARE CANC S1, V5, P177; Langford R, 2006, ARTHRITIS RHEUM-US, V54, P1829, DOI 10.1002/art.21884; Medsafe, 2008, DBL FENT INJ DAT; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Ozturk T, 2008, AGRI, V20, P20; Pace MC, 2007, FRONT BIOSCI-LANDMRK, V12, P1291, DOI 10.2741/2147; Pergolizzi J, 2010, PAIN PRACT, V10, P428, DOI 10.1111/j.1533-2500.2010.00378.x; Poulain P, 2008, J PAIN SYMPTOM MANAG, V36, P117, DOI 10.1016/j.jpainsymman.2007.09.011; Puhan MA, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-2; Reid KJ, 2011, CURR MED RES OPIN, V27, P449, DOI 10.1185/03007995.2010.545813; Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251; Sittl R, 2003, CLIN THER, V25, P150, DOI 10.1016/S0149-2918(03)90019-1; Song FJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1147; Sorge J, 2004, CLIN THER, V26, P1808, DOI 10.1016/j.clinthera.2004.11.008; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Wolff RF, 2012, PAIN MANAG IN PRESS; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; World Health Organization, 2011, WHOS PAIN LADD	30	27	28	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	MAY	2012	28	5					833	845		10.1185/03007995.2012.678938			13	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	942SI	WOS:000304066900020	22443154				2020-06-30	J	Tramullas, M; Dinan, TG; Cryan, JF				Tramullas, Monica; Dinan, Timothy G.; Cryan, John F.			Chronic psychosocial stress induces visceral hyperalgesia in mice	STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS			English	Article						Brain-gut axis; chronic stress; colorectal distension; social avoidance; somatic analgesia; visceral hypersensitivity	IRRITABLE-BOWEL-SYNDROME; PSEUDO-AFFECTIVE RESPONSES; FUNCTIONAL GI-DISORDERS; SOCIAL DEFEAT STRESS; DSS-INDUCED COLITIS; BRAIN-GUT AXIS; COLORECTAL DISTENSION; ANIMAL-MODELS; COLONIC INFLAMMATION; MATERNAL SEPARATION	Experimental and clinical evidence has shown that chronic stress plays an important role in the onset and/or exacerbation of symptoms of functional gastrointestinal disorders. Here, we aimed to investigate whether exposure to a chronic and temporally unpredictable psychosocial stressor alters visceral and somatic nociception as well as anxiety-related behaviour. In male C57BL/6J mice, chronic stress was induced by repeated exposure to social defeat (SD, 2 h) and overcrowding (OC, 24 h) during 19 consecutive days. Visceral and somatic nociception was evaluated by colorectal distension and a hot plate, respectively. The social interaction test was used to assess social anxiety. Mice exposed to psychosocial stress developed visceral hyperalgesia and somatic hypoalgesia 24 h following the last stress session. SD/OC mice also exhibited social anxiety-like behaviour. All these changes were also associated with physiological alterations, measured as a decreased faecal pellet output and hypothalamic-pituitary-adrenal (HPA) axis disruption. Taken together, these data confirm that this mouse model of chronic psychosocial stress may be useful for studies on the pathophysiological mechanisms underlying such stress-associated disorders and to further test potential therapies.	[Cryan, John F.] Natl Univ Ireland Univ Coll Cork, Dept Anat, Coll Rd, Cork, Ireland; [Tramullas, Monica; Dinan, Timothy G.; Cryan, John F.] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland; [Dinan, Timothy G.] Natl Univ Ireland Univ Coll Cork, Dept Psychiat, Cork, Ireland	Cryan, JF (reprint author), Natl Univ Ireland Univ Coll Cork, Dept Anat, Coll Rd, Cork, Ireland.	J.Cryan@ucc.ie	Cryan, John F./A-6950-2013; Tramullas, Monica/F-6153-2016	Cryan, John F./0000-0001-5887-2723; Tramullas, Monica/0000-0002-2447-8928; Dinan, Timothy/0000-0002-2316-7220			Arvidsson S, 2006, J PAIN, V7, P108, DOI 10.1016/j.jpain.2005.09.003; Barreau F, 2004, GASTROENTEROLOGY, V127, P524, DOI 10.1053/j.gastro.2004.05.019; Bartolomucci A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004331; Beitia G, 2005, BRAIN BEHAV IMMUN, V19, P530, DOI 10.1016/j.bbi.2004.11.002; Bennett EJ, 1998, GUT, V43, P256, DOI 10.1136/gut.43.2.256; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; Bradesi S, 2005, AM J PHYSIOL-GASTR L, V289, pG42, DOI 10.1152/ajpgi.00500.2004; Bradesi S, 2009, DIGEST DIS, V27, P55, DOI 10.1159/000268122; Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003; Choung RS, 2009, AM J GASTROENTEROL, V104, P1772, DOI 10.1038/ajg.2009.239; Coutinho SV, 2002, AM J PHYSIOL-GASTR L, V282, pG307, DOI 10.1152/ajpgi.00240.2001; Cryan JF, 2011, NEUROGASTROENT MOTIL, V23, P187, DOI 10.1111/j.1365-2982.2010.01664.x; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Dinan TG, 2010, NAT REV GASTRO HEPAT, V7, P465, DOI 10.1038/nrgastro.2010.99; Drossman DA, 2002, GASTROENTEROLOGY, V123, P2108, DOI 10.1053/gast.2002.37095; Elsenbruch S, 2010, GUT, V59, P489, DOI 10.1136/gut.2008.175000; File SE, 2003, EUR J PHARMACOL, V463, P35, DOI 10.1016/S0014-2999(03)01273-1; Finger BC, 2011, NEUROSCIENCE, V192, P351, DOI 10.1016/j.neuroscience.2011.06.072; Finger B.C., 2011, PSYCHONEUROENDOCRINO; Gosselin RD, 2010, GASTROENTEROLOGY, V138, P2418, DOI 10.1053/j.gastro.2010.03.003; Gros DF, 2009, J ANXIETY DISORD, V23, P290, DOI 10.1016/j.janxdis.2008.08.004; Holschneider DP, 2011, EXPERT REV GASTROENT, V5, P43, DOI 10.1586/EGH.10.88; Huhman KL, 2006, HORM BEHAV, V50, P640, DOI 10.1016/j.yhbeh.2006.06.022; Imbe H, 2006, FRONT BIOSCI-LANDMRK, V11, P2179, DOI 10.2741/1960; Jones MP, 2006, NEUROGASTROENT MOTIL, V18, P91, DOI 10.1111/j.1365-2982.2005.00730.x; Koolhaas JM, 1997, ACTA PHYSIOL SCAND, V161, P69; Lackner JM, 2010, NEUROGASTROENT MOTIL, V22, P893, DOI 10.1111/j.1365-2982.2010.01516.x; Larauche M, 2012, EXP NEUROL, V233, P49, DOI 10.1016/j.expneurol.2011.04.020; Larauche M, 2010, STRESS, V13, P344, DOI 10.3109/10253891003664166; Larsson M, 2003, NEUROGASTROENT MOTIL, V15, P371, DOI 10.1046/j.1365-2982.2003.00418.x; Larsson M H, 2009, Stress, V12, P434, DOI 10.1080/10253890802626603; Larsson MH, 2006, NEUROGASTROENT MOTIL, V18, P144, DOI 10.1111/j.1365-2982.2005.00736.x; Martinez M, 1998, AGGRESSIVE BEHAV, V24, P241; Martinez V, 2008, EUR J PAIN, V12, P934, DOI 10.1016/j.ejpain.2007.12.011; Mayer EA, 2008, GUT, V57, DOI 10.1136/gut.2006.101675; Mayer EA, 2000, GUT, V47, P861, DOI 10.1136/gut.47.6.861; Mayer EA, 2011, ANNU REV MED, V62, P381, DOI 10.1146/annurev-med-012309-103958; McEwen BS, 2004, ANN NY ACAD SCI, V1032, P1, DOI 10.1196/annals.1314.001; Melgar S, 2008, STRESS, V11, P348, DOI 10.1080/10253890701820166; MICZEK KA, 1982, SCIENCE, V215, P1520, DOI 10.1126/science.7199758; Moles A, 2006, PSYCHONEUROENDOCRINO, V31, P623, DOI 10.1016/j.psyneuen.2006.01.004; O'Mahony SM, 2011, PSYCHOPHARMACOLOGY, V214, P71, DOI 10.1007/s00213-010-2010-9; O'Malley D, 2011, BRAIN BEHAV IMMUN, V25, P1333, DOI 10.1016/j.bbi.2011.04.009; OBrien MD, 1997, DIGEST DIS SCI, V42, P26, DOI 10.1023/A:1018868601475; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Ouyang A, 2006, AM J GASTROENTEROL, V101, pS602, DOI 10.1111/j.1572-0241.2006.00975.x; Reber SO, 2007, ENDOCRINOLOGY, V148, P670, DOI 10.1210/en.2006-0983; Reber SO, 2006, ENDOCRINOLOGY, V147, P4968, DOI 10.1210/en.2006-0347; Savignac HM, 2011, NEUROSCIENCE, V192, P524, DOI 10.1016/j.neuroscience.2011.04.054; Savignac HM, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00013; Savignac HM, 2011, BEHAV BRAIN RES, V216, P576, DOI 10.1016/j.bbr.2010.08.049; Schwetz I, 2004, AM J PHYSIOL-GASTR L, V286, pG683, DOI 10.1152/ajpgi.00358.2003; Spinelli A, 2007, CLIN DRUG INVEST, V27, P15, DOI 10.2165/00044011-200727010-00002; Tache Y, 2007, J CLIN INVEST, V117, P33, DOI 10.1172/JCI30085; Tamashiro KLK, 2005, FRONT NEUROENDOCRIN, V26, P27, DOI 10.1016/j.yfrne.2005.03.001; Tammpere A, 2005, PAIN, V116, P220, DOI 10.1016/j.pain.2005.04.012; TERMAN GW, 1984, SCIENCE, V226, P1270, DOI 10.1126/science.6505691; Tramullas M, 2010, J NEUROSCI, V30, P1502, DOI 10.1523/JNEUROSCI.2584-09.2010; Vicario M, 2011, PSYCHONEUROENDOCRINO; VIDAL C, 1982, NEUROSCI LETT, V32, P75, DOI 10.1016/0304-3940(82)90232-4; Yu YB, 2010, NEUROCHEM RES, V35, P797, DOI 10.1007/s11064-010-0137-z	61	37	39	2	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-3890	1607-8888		STRESS	Stress	MAY	2012	15	3					281	292		10.3109/10253890.2011.622816			12	Behavioral Sciences; Endocrinology & Metabolism; Neurosciences	Behavioral Sciences; Endocrinology & Metabolism; Neurosciences & Neurology	916AP	WOS:000302069100004	21992065				2020-06-30	J	Zuo, XL; Li, Z; Liu, XP; Li, CQ; Ji, R; Wang, P; Zhou, CJ; Liu, H; Li, YQ				Zuo, Xiu-Li; Li, Zhen; Liu, Xiao-Ping; Li, Chang-Qing; Ji, Rui; Wang, Peng; Zhou, Cheng-Jun; Liu, Han; Li, Yan-Qing			Propofol vs midazolam plus fentanyl for upper gastrointestinal endomicroscopy: A randomized trial	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Confocal laser endomicroscopy; Conscious sedation; Randomized trial; Sensitivity and specificity; Image quality	CONFOCAL LASER ENDOMICROSCOPY; CANCER IN-VIVO; SQUAMOUS-CELL CARCINOMA; CONSCIOUS SEDATION; INTRAEPITHELIAL NEOPLASIA; OUTPATIENT COLONOSCOPY; ENDOSCOPIC PROCEDURES; ULCERATIVE-COLITIS; DIAGNOSIS; MEPERIDINE	AIM: To compare the endonnicroscopic image quality of integrated confocal laser endomicroscopy (iCLE) and sedation efficacy of propofol vs midazolam plus fentanyl (M/F). METHODS: Consecutive outpatients undergoing iCLE were prospectively recruited and randomized to the propofol group (P group) or M/F group. The patient, performing endoscopist and endoscopic assistant were blinded to the randomization. The quality of endomicroscopic images and anesthetic efficacy outcomes were blindly evaluated after iCLE examination. RESULTS: There were significantly more good quality endomicroscopic images in the propofol group than in the M/F group (72.75% vs 52.89%, P < 0.001). The diagnostic accuracy for upper gastrointestinal mucosal lesions using confocal laser endomicroscopy favors the P group, although this did not reach statistical significance. Adverse events and patient assessment were not significantly different for M/F vs propofol except for more frequent intraprocedural recall with M/F. Procedure duration and sedation times were significantly longer in the M/F group, while the scores of endoscopist, anesthetist and assistant assessment were all significantly better in the P group. CONCLUSION: Sedation with propofol might increase the proportion of good quality endomicroscopic images, and may result in improved procedural efficacy and diagnostic accuracy during iCLE examination. (C) 2012 Baishideng. All rights reserved.	[Zuo, Xiu-Li; Li, Zhen; Li, Chang-Qing; Ji, Rui; Wang, Peng; Liu, Han; Li, Yan-Qing] Shandong Univ, Qilu Hosp, Dept Gastroenterol, Jinan 250012, Shandong, Peoples R China; [Liu, Xiao-Ping] Shandong Univ, Qilu Hosp, Dept Anesthesiol, Jinan 250012, Shandong, Peoples R China; [Zhou, Cheng-Jun] Shandong Univ, Affiliated Hosp 2, Dept Pathol, Jinan 250033, Shandong, Peoples R China	Li, YQ (reprint author), Shandong Univ, Qilu Hosp, Dept Gastroenterol, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.	liyanqing@sdu.edu.cn			Ministry of Health of China; Shandong Province Science and Technology Committee [2007BSB02087]; Shandong University	Supported by Grants from Ministry of Health of China (2010); Shandong Province Science and Technology Committee, No. 2007BSB02087; and Graduate Independent Innovation Fund of Shandong University	ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; Chin K. W., 1994, Annals Academy of Medicine Singapore, V23, P330; Faulx AL, 2005, GASTROINTEST ENDOSC, V62, P9, DOI 10.1016/S0016-5107(05)00518-3; Foersch S, 2010, GUT, V59, P1046, DOI 10.1136/gut.2009.202986; Goetz M, 2008, ATLAS ENDOMICROSCOPY, P37; Guo YT, 2008, ENDOSCOPY, V40, P547, DOI 10.1055/s-2007-995633; Heuss LT, 2003, AM J GASTROENTEROL, V98, P1751, DOI 10.1016/S0002-9270(03)00447-7; Hurlstone DP, 2007, CLIN GASTROENTEROL H, V5, P1235, DOI 10.1016/j.cgh.2007.06.003; Kakeji Y, 2006, ENDOSCOPY, V38, P886, DOI 10.1055/s-2006-944735; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Kiesslich R, 2004, GASTROENTEROLOGY, V127, P706, DOI 10.1053/j.gastro.2004.06.050; Kiesslich R, 2007, GASTROENTEROLOGY, V133, P1769, DOI 10.1053/j.gastro.2007.09.011; Kiesslich R, 2007, GASTROENTEROLOGY, V132, P874, DOI 10.1053/j.gastro.2007.01.048; Kiesslich R, 2006, CLIN GASTROENTEROL H, V4, P979, DOI 10.1016/j.cgh.2006.05.010; Kitabatake S, 2006, ENDOSCOPY, V38, P1110, DOI 10.1055/s-2006-944855; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Krugliak P, 2000, ENDOSCOPY, V32, P677; LaLuna L, 2001, GASTROINTEST ENDOSC, V53, P289, DOI 10.1067/mge.2001.112192; Leong RWL, 2008, GASTROENTEROLOGY, V135, P1870, DOI 10.1053/j.gastro.2008.08.054; Li Z, 2010, GASTROINTEST ENDOSC, V72, P1146, DOI 10.1016/j.gie.2010.08.031; Liu H, 2009, ENDOSCOPY, V41, P99, DOI 10.1055/s-0028-1119492; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Meining A, 2007, ENDOSCOPY, V39, P345, DOI 10.1055/s-2006-945195; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Ng JM, 2001, GASTROINTEST ENDOSC, V54, P8, DOI 10.1067/mge.2001.116110; PATTERSON KW, 1991, BRIT J ANAESTH, V67, P108, DOI 10.1093/bja/67.1.108; Pech O, 2008, CLIN GASTROENTEROL H, V6, P89, DOI 10.1016/j.cgh.2007.10.013; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Zhang JN, 2008, GASTROINTEST ENDOSC, V67, P843, DOI 10.1016/j.gie.2008.01.036	32	8	10	0	4	BAISHIDENG PUBL GRP CO LTD	BEIJING	RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU, BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA	1007-9327			WORLD J GASTROENTERO	World J. Gastroenterol.	APR 21	2012	18	15					1814	1821		10.3748/wjg.v18.i15.1814			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	932GM	WOS:000303278400014	22553407	Green Published, Other Gold			2020-06-30	J	Hellinger, WC; Bacalis, LP; Kay, RS; Thompson, ND; Xia, GL; Lin, YL; Khudyakov, YE; Perz, JF				Hellinger, Walter C.; Bacalis, Laura P.; Kay, Robyn S.; Thompson, Nicola D.; Xia, Guo-Liang; Lin, Yulin; Khudyakov, Yury E.; Perz, Joseph F.			Health Care-Associated Hepatitis C Virus Infections Attributed to Narcotic Diversion	ANNALS OF INTERNAL MEDICINE			English	Article							OPERATING-ROOM; UNITED-STATES; TRANSMISSION; ANESTHESIOLOGIST; PERSONNEL; PATIENT; WORKERS; SYSTEM; ORGAN; TIME	Background: Three cases of genetically related hepatitis C virus (HCV) infection that were unattributable to infection control breaches were identified at a health care facility. Objective: To investigate HCV transmission from an HCV-infected health care worker to patients through drug diversion. Design: Cluster and look-back investigations. Setting: Acute care hospital and affiliated multispecialty clinic. Patients: Inpatients and outpatients during the period of HCV transmission. Measurements: Employee work and narcotic dispensing records, blood testing for HCV antibody and RNA, and sequencing of the NS5B gene and the hypervariable region 1 of the E2 gene. Results: 21 employees were recorded as being at work or as retrieving a narcotic from an automated dispensing cabinet in an area where a narcotic was administered to each of the 3 case patients; all employees provided blood samples for HCV testing. One employee was infected with HCV that had more than 95% NS5B sequence homology with the HCV strains of the 3 case patients. Quasi-species analysis showed close genetic relatedness with variants from each of the case patients and more than 97.9% nucleotide identity. The employee acknowledged parenteral opiate diversion. An investigation identified 6132 patients at risk for exposure to HCV because of the drug diversion. Of the 3929 living patients, 3444 (87.7%) were screened for infection. Two additional cases of genetically related HCV infection attributable to the employee were identified. Limitation: Of the living patients at risk for HCV exposure, 12.3% were not tested. Conclusion: Five cases of HCV infection occurring over 3 to 4 years were attributed to drug diversion by an HCV-infected health care worker. Studies of drug diversion and assessments of strategies to prevent narcotics tampering in all health care settings are needed.	[Hellinger, Walter C.] Mayo Clin, Div Infect Dis, Jacksonville, FL 32224 USA; Florida Dept Hlth, Tallahassee, FL USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Hellinger, WC (reprint author), Mayo Clin, Div Infect Dis, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	helling@mayo.edu					Berge KH, 2008, ANESTHESIOLOGY, V109, P762, DOI 10.1097/ALN.0b013e31818a3814; Bosch X, 2000, LANCET, V355, P818, DOI 10.1016/S0140-6736(05)72446-6; Cody SH, 2002, ARCH INTERN MED, V162, P345, DOI 10.1001/archinte.162.3.345; Colorado Department of Public Health and Environment, 2009, FAQS COL HEP C INV; Domino KB, 2005, JAMA-J AM MED ASSOC, V293, P1453, DOI 10.1001/jama.293.12.1453; Dudzinski DM, 2010, NEW ENGL J MED, V363, P978, DOI 10.1056/NEJMhle1003134; Dunn D, 2005, AORN J, V82, P599; Dunn D, 2005, AORN J, V82, P592, DOI [DOI 10.1016/S0001-2092(06)60028-8, 10.1016/S0001-2092(06) 60028-8]; Dunn Debra, 2005, AORN J, V82, P573; Dunn S., 2005, AORN J, V82; Epstein RH, 2007, ANESTH ANALG, V105, P1053, DOI 10.1213/01.ane.0000281797.00935.08; Hadfield S, 2011, HEPATITIS C WOMAN LA; Henderson DK, 2010, INFECT CONT HOSP EP, V31, P203, DOI 10.1086/650298; Lee KC, 2005, 43 ANN M INF DIS SOC; MAKI DG, 1991, JAMA-J AM MED ASSOC, V265, P981, DOI 10.1001/jama.265.8.981; Nainan OV, 2006, GASTROENTEROLOGY, V131, P478, DOI 10.1053/j.gastro.2006.06.007; Ostrowsky BE, 2002, NEW ENGL J MED, V346, P1529, DOI 10.1056/NEJMoa012370; Perz Joseph F, 2010, Clin Liver Dis, V14, P137, DOI 10.1016/j.cld.2009.11.004; Ramachandran S, 2008, J VIROL METHODS, V151, P217, DOI 10.1016/j.jviromet.2008.05.005; Ross RS, 2000, NEW ENGL J MED, V343, P1851, DOI 10.1056/NEJM200012213432505; SCHMIDT KA, 1993, ANESTHESIOLOGY, V78, P184, DOI 10.1097/00000542-199301000-00025; SEHULSTER L, 1997, [No title captured], P293; Shemer-Avni Y, 2007, CLIN INFECT DIS, V45, pE32, DOI 10.1086/520014; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Substance Abuse and Mental Health Services Administration Office of Applied Studies, 1996, DHHS PUBL; Thompson ND, 2009, TRANSPL INFECT DIS, V11, P324, DOI 10.1111/j.1399-3062.2009.00406.x; Thompson ND, 2009, ANN INTERN MED, V150, P33, DOI 10.7326/0003-4819-150-1-200901060-00007; Tugwell BD, 2005, ANN INTERN MED, V143, P648, DOI 10.7326/0003-4819-143-9-200511010-00008; Williams IT, 2006, J CLIN VIROL, V36, pS43, DOI 10.1016/S1386-6532(06)80135-6; Williams IT, 2004, CLIN INFECT DIS, V38, P1592, DOI 10.1086/420935; Willock M, 1998, INT ANESTHESIOL CLIN, V36, P65, DOI 10.1097/00004311-199803610-00009	31	16	16	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 3	2012	156	7					477	U34		10.7326/0003-4819-156-7-201204030-00002			7	Medicine, General & Internal	General & Internal Medicine	921GP	WOS:000302466400001	22473434				2020-06-30	J	DeMaria, A; Snydman, DR				DeMaria, Alfred, Jr.; Snydman, David R.			Nosocomial Hepatitis C: More of a Hidden Epidemic	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARE-ASSOCIATED INFECTIONS; VIRUS TRANSMISSION; USA		[Snydman, David R.] Tufts Med Ctr, Boston, MA 02111 USA; [DeMaria, Alfred, Jr.] Massachusetts Dept Publ Hlth, Boston, MA 02130 USA	Snydman, DR (reprint author), Tufts Med Ctr, Box 238,800 Washington St, Boston, MA 02111 USA.	dsnydman@tuftsmedicalcenter.org	Snydman, David R/O-3889-2014	Snydman, David R/0000-0003-0119-3978			Association of State and Territorial Health Officials, 2011, EL HEALTHC ASS INF S; Centers for Disease Control and Prevention, 2009, VIR HEP SURV US; Chak E, 2011, LIVER INT, V31, P1090, DOI 10.1111/j.1478-3231.2011.02494.x; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; Hellinger WC, 2012, ANN INTERN MED, V156, P477, DOI 10.7326/0003-4819-156-7-201204030-00002; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Kohn L., 2000, ERR IS HUMAN BUILDIN; Michelin Angela, 2010, Clin Liver Dis, V14, P119, DOI 10.1016/j.cld.2009.11.005; Reagan J, 2012, INFECT CONT HOSP EP, V33, P75, DOI 10.1086/663204; Savey A, 2005, INFECT CONT HOSP EP, V26, P752, DOI 10.1086/502613; Thompson ND, 2009, ANN INTERN MED, V150, P33, DOI 10.7326/0003-4819-150-1-200901060-00007; U.S. Department of Health and Human Services, 2011, COMB SIL EP VIR HEP; Weber SG, 2007, INFECT CONT HOSP EP, V28, P249, DOI 10.1086/512261; Widell A, 1999, ANN INTERN MED, V130, P130, DOI 10.7326/0003-4819-130-2-199901190-00007; Williams IT, 2006, J CLIN VIROL, V36, pS43, DOI 10.1016/S1386-6532(06)80135-6; Williams IT, 2004, CLIN INFECT DIS, V38, P1592, DOI 10.1086/420935	16	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 3	2012	156	7					534	U109		10.7326/0003-4819-156-7-201204030-00011			3	Medicine, General & Internal	General & Internal Medicine	921GP	WOS:000302466400008	22473438				2020-06-30	J	Jain, K; Makkar, JK; Yadanappudi, S; Anbarasan, I; Gander, S				Jain, K.; Makkar, J. K.; Yadanappudi, S.; Anbarasan, I.; Gander, S.			Two doses of spinal bupivacaine for caesarean delivery in severe preeclampsia: a pilot study	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							EPIDURAL-ANESTHESIA; HYPOTENSION		[Jain, K.; Makkar, J. K.; Yadanappudi, S.; Anbarasan, I.] Post Grad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh, India; [Gander, S.] Post Grad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh, India	Jain, K (reprint author), Post Grad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh, India.	kajalteji@gmail.com					Aya AGM, 2003, ANESTH ANALG, V97, P867, DOI 10.1213/01.ANE.0000073610.23885.F2; BENEDETTI TJ, 1985, AM J OBSTET GYNECOL, V152, P330, DOI 10.1016/S0002-9378(85)80222-2; Dyer RA, 2003, ANESTHESIOLOGY, V99, P561, DOI 10.1097/00000542-200309000-00010; Jain K, 2004, INT J OBSTET ANESTH, V13, P215, DOI 10.1016/j.ijoa.2004.04.006; Ramanathan J, 2001, REGION ANESTH PAIN M, V26, P46, DOI 10.1053/rapm.2001.18182; Roofthooft E, 2008, CURR OPIN ANESTHESIO, V21, P259, DOI 10.1097/ACO.0b013e3282ff5e41; Visalyaputra S, 2005, ANESTH ANALG, V101, P862, DOI 10.1213/01.ANE.0000160535.95678.34	7	5	6	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2012	21	2					195	196		10.1016/j.ijoa.2011.12.010			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	936WB	WOS:000303619600018	22341891				2020-06-30	J	Mumby, DM; Hartsilver, EL				Mumby, D. M.; Hartsilver, E. L.			Magnetic resonance imaging of sciatic nerve compression injury after epidural blockade	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter									[Mumby, D. M.; Hartsilver, E. L.] Royal Devon & Exeter Hosp, Dept Anaesthesia, Exeter EX2 5DW, Devon, England	Mumby, DM (reprint author), Royal Devon & Exeter Hosp, Dept Anaesthesia, Exeter EX2 5DW, Devon, England.	dominiquemumby@hotmail.com					Loo CC, 2000, INT J OBSTET ANESTH, V9, P99, DOI 10.1054/ijoa.1999.0347; Royal College of Anaesthetists, 2009, NAT AUD MAJ COMPL CE; Silva M, 1996, ANAESTHESIA, V51, P1144, DOI 10.1111/j.1365-2044.1996.tb15052.x	3	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X			INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2012	21	2					199	200		10.1016/j.ijoa.2011.12.004			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	936WB	WOS:000303619600021	22336490				2020-06-30	J	Ozcan, A; Ozcan, N; Gulec, H; Yalcin, F; Basar, H				Ozcan, Ayse; Ozcan, Namik; Gulec, Handan; Yalcin, Fatma; Basar, Hulya			Comparison of the effects of fentanyl, remifentanil, and dexmedetomidine on neuromuscular blockade	JOURNAL OF ANESTHESIA			English	Article						Alpha-2 agonists; Dexmedetomidine; Opioids; Remifentanil; Neuromuscular blockade; Anesthesia	INTRAVENOUS DEXMEDETOMIDINE; BLOCKING ACTION; RAT; CLONIDINE; VECURONIUM; HUMANS	The aim of our study was to compare the effects of fentanyl, remifentanil, and dexmedetomidine on neuromuscular blockade under sevoflurane anesthesia. Eighty-four patients were randomized to fentanyl, remifentanil, and dexmedetomidine groups. In the fentanyl group, fentanyl 1.5 mu g/kg was given before induction of anesthesia, and additional 50-mu g boluses were administered. In the remifentanil group, the initial dose of remifentanil 1 mu g/kg was infused in 10 min before induction and 0.1 mu g/kg/min infusion was continued during anesthesia. In the dexmedetomidine group, the initial dose of dexmedetomidine 1 mu g/kg was infused in 10 min before induction and 1 mu g/kg/h infusion was continued during anesthesia. Heart rate, blood pressure, SpO(2), EtCO2, and TOF (train-of-four) values of all patients were monitored during anesthesia. Times to reach TOF 0 and TOF 25% and intubation quality were recorded. T (0) times and quality of intubation were found to be similar among the groups. T (25) time was found to be significantly longer in the dexmedetomidine group than in the fentanyl and remifentanil groups. Dexmedetomidine infusion increased the duration of neuromuscular blockade with vecuronium during general anesthesia. In addition to analgesic and sedative effects, dexmedetomidine may enhance the duration of neuromuscular blockade and may be used as an adjuvant anesthetic during general anesthesia.	[Ozcan, Ayse; Ozcan, Namik; Basar, Hulya] Ankara Numune Training & Res Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Gulec, Handan] Ankara Kecioren Training & Res Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Yalcin, Fatma] Nallihan Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey	Ozcan, A (reprint author), 1506 Cadde Ucler Safir Evleri,24-5 Cigdem, TR-06520 Ankara, Turkey.	ayseongun@gmail.com	Ozcan, Namik/AAC-2388-2019				Abelson KSP, 2004, BASIC CLIN PHARMACOL, V94, P153; AHO M, 1991, ANESTHESIOLOGY, V74, P997, DOI 10.1097/00000542-199106000-00005; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; DONATI F, 1988, Canadian Journal of Anaesthesia, V35, pS52; Lawrence CJ, 1996, ANESTH ANALG, V83, P1160, DOI 10.1097/00000539-199612000-00005; Mantz J, 2011, EUR J ANAESTH, V28, P3, DOI 10.1097/EJA.0b013e32833e266d; Musgrave IF, 1996, CLIN EXP PHARMACOL P, V23, P990, DOI 10.1111/j.1440-1681.1996.tb01156.x; Nakahara T, 1995, Masui, V44, P1458; Narimatsu E, 2007, ANESTH ANALG, V104, P1116, DOI 10.1213/01.ane.0000260317.02748.83; Savarese JJ, 2000, ANESTHESIA, P412; TAKAHASHI H, 1995, CAN J ANAESTH, V42, P511, DOI 10.1007/BF03011690; Talke PO, 1999, ANESTH ANALG, V88, P633, DOI 10.1097/00000539-199903000-00031; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; WEINGER MB, 1989, ANESTHESIOLOGY, V71, P242, DOI 10.1097/00000542-198908000-00013; WEINGER MB, 1995, BRIT J ANAESTH, V74, P455, DOI 10.1093/bja/74.4.455	16	3	6	0	2	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	APR	2012	26	2					196	199		10.1007/s00540-011-1270-9			4	Anesthesiology	Anesthesiology	929ZF	WOS:000303103800007	22057309				2020-06-30	J	Hosokawa, Y; Morisaki, H; Nakatsuka, I; Hashiguchi, S; Miyakoshi, K; Tanaka, M; Yoshimura, Y; Takeda, J				Hosokawa, Yuki; Morisaki, Hiroshi; Nakatsuka, Itsuo; Hashiguchi, Saori; Miyakoshi, Kei; Tanaka, Mamoru; Yoshimura, Yasunori; Takeda, Junzo			Retrospective evaluation of intravenous fentanyl patient-controlled analgesia during labor	JOURNAL OF ANESTHESIA			English	Article						Labor analgesia; Fentanyl; Intravenous patient-controlled analgesia	NULLIPAROUS WOMEN; OPIOID ANALGESIA; CESAREAN DELIVERY; PAIN RELIEF; METAANALYSIS; MEPERIDINE; SECTION; BIRTH; RISK	Because the safety of intravenous fentanyl patient-controlled analgesia (iv-PCA) administered during labor remains unclear, we retrospectively examined the labor records from January 2005 to December 2007 in our institution, with a focus on both maternal and neonatal outcomes, as compared to no analgesia. Parturients over 35 weeks of gestational age who received fentanyl iv-PCA (iv-PCA group) or no analgesia (control group) during labor were enrolled. The former group received iv-PCA through a pump programmed to give a loading dose of 0.05 mg fentanyl, followed by bolus injection of 0.02 mg fentanyl, with a lock-out interval of 5 min. This analgesia was initiated at the parturient's request and was discontinued before the second stage of labor, to ensure neonatal safety. During labor, both maternal and fetal heart rates, maternal pulse oximeter oxygen saturation (SpO(2)), respiratory rate, and sedation and nausea scores were continuously monitored, and the neonatal outcomes including umbilical arterial pH, Apgar scores, and other parameters were recorded. The data of 129 of the 143 parturients who received fentanyl iv-PCA were analyzed, while 697 parturients delivered without any analgesia during the 3-year study period. While iv-PCA prolonged the duration of labor and increased oxytocin use, no obvious maternal or neonatal complications of fentanyl use were recorded. Except for the significantly lower rate of emergency cesarean section in the iv-PCA group, both the maternal and neonatal outcomes were comparable between the groups. As compared to no analgesia, fentanyl iv-PCA appears to be safe and clinically acceptable as analgesia during labor, particularly in nulliparous women.	[Hosokawa, Yuki; Morisaki, Hiroshi; Nakatsuka, Itsuo; Hashiguchi, Saori; Takeda, Junzo] Keio Univ, Dept Anesthesiol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Miyakoshi, Kei; Tanaka, Mamoru; Yoshimura, Yasunori] Keio Univ, Dept Obstet & Gynecol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan	Morisaki, H (reprint author), Keio Univ, Dept Anesthesiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	morisaki@z8.keio.jp	Morisaki, Hiroshi/J-5960-2013				Camann W, 2005, NEW ENGL J MED, V352, P718, DOI 10.1056/NEJMe048350; Evron S, 2007, CURR OPIN ANESTHESIO, V20, P181, DOI 10.1097/ACO.0b013e328136c1d1; Fun W, 2008, MINERVA ANESTESIOL, V74, P77; Goetzl Laura M, 2002, Obstet Gynecol, V100, P177; Gouyon JB, 2010, INT J EPIDEMIOL, V39, P769, DOI 10.1093/ije/dyq037; Halpern SH, 1998, JAMA-J AM MED ASSOC, V280, P2105, DOI 10.1001/jama.280.24.2105; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; Hill David, 2008, Anesthesiol Clin, V26, P169, DOI 10.1016/j.anclin.2007.11.004; Jonsson M, 2008, ACTA OBSTET GYN SCAN, V87, P745, DOI 10.1080/00016340802220352; Liu EHC, 2004, BMJ-BRIT MED J, V328, P1410, DOI 10.1136/bmj.38097.590810.7C; Lowe NK, 2002, AM J OBSTET GYNECOL, V186, pS16, DOI 10.1067/mob.2002.121427; Morley-Forster PK, 1998, INT J OBSTET ANESTH, V7, P103, DOI 10.1016/S0959-289X(98)90005-X; Nelson KE, 2005, ANESTHESIOLOGY, V102, P1008, DOI 10.1097/00000542-200505000-00021; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Reynolds F, 2002, BJOG-INT J OBSTET GY, V109, P1344, DOI 10.1016/S1470-0328(02)01961-4; Reynolds F, 1997, LANCET, V349, P4, DOI 10.1016/S0140-6736(05)62156-3; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Sharma SK, 2004, ANESTHESIOLOGY, V100, P142, DOI 10.1097/00000542-200401000-00023; Sheiner E, 2001, AM J OBSTET GYNECOL, V185, P888, DOI 10.1067/mob.2001.117308; Victory R, 2004, AM J OBSTET GYNECOL, V191, P2021, DOI 10.1016/j.ajog.2004.04.026; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573	24	6	6	0	8	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	APR	2012	26	2					219	224		10.1007/s00540-011-1292-3			6	Anesthesiology	Anesthesiology	929ZF	WOS:000303103800011	22120170				2020-06-30	J	Wei, X; Wei, W				Wei, Xin; Wei, Wei			Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats	JOURNAL OF ANESTHESIA			English	Article						Gabapentin; Opioid; Morphine; Fentanyl; Hyperalgesia; Tolerance	OPIOID-INDUCED HYPERALGESIA; PROTEIN-KINASE-C; NEUROPATHIC PAIN; DORSAL-HORN; ANTINOCICEPTIVE ACTIONS; INTRATHECAL GABAPENTIN; THERMAL HYPERALGESIA; POSTOPERATIVE PAIN; ADENYLYL-CYCLASE; SPINAL-CORD	This study was undertaken to examine the effect of gabapentin for preventing hyperalgesia induced by morphine and fentanyl withdrawal in rats. To induce hyperalgesia, Sprague Dawley (SD) rats were subcutaneously injected with fentanyl four times at 15-min intervals (60 mu g/kg per injection), resulting in total dose of 240 mu g/kg over 1 h, and morphine 10 mg/kg twice daily for 7 days. The effect of gabapentin was detected with behavioral tail-flick and paw-withdrawal tests. Drug termination produced significant decrease in antinociception thresholds (P < 0.05 vs. saline group), indicating that the rats became sensitive to thermal stimuli. In rats that received combined treatment with fentanyl/morphine and gabapentin (25/50 mg/kg), results demonstrated that there were no significant decreases in antinociception thresholds (vs. saline group) after opioid withdrawal. Gabapentin (50 mg/kg) could also prevent morphine tolerance. The 50% effective dose (ED50) value was 12.5 mg/kg in tail-flick and 13.6 mg/kg in paw-withdrawal tests. The study showed that gabapentin can significantly prevented opioid-induced hyperalgesia (OIH) induced caused by fentanyl and morphine, suggesting a role for the addition of gabapentin in the perioperative period and during chronic pain treatment as an effective drug to prevent OIH.	[Wei, Wei] Anhui Med Univ, Dept Inst Clin Pharmacol, Hefei 230032, Peoples R China; [Wei, Xin] Anhui Med Univ, Auhui Prov Hosp, Dept Anesthesiol, Hefei 230001, Peoples R China; [Wei, Xin; Wei, Wei] Anhui Med Univ, Key Lab Antiinflammatory & Immunopharmacol, Inst Clin Pharmacol, Minist Educ, Hefei 230032, Peoples R China	Wei, W (reprint author), Anhui Med Univ, Dept Inst Clin Pharmacol, 81 Meishan Rd, Hefei 230032, Peoples R China.	wwei5161208@yahoo.cn					Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Baillie JK, 2006, CURR OPIN INVEST DR, V7, P33; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; De la O-Arciniega M, 2009, PHARMACOL BIOCHEM BE, V92, P457, DOI 10.1016/j.pbb.2009.01.013; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Field MJ, 1997, J PHARMACOL EXP THER, V282, P1242; Galeotti N, 2006, PAIN, V123, P294, DOI 10.1016/j.pain.2006.03.008; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; GUNTZ, 2007, EUR J ANAESTH, V24, P205; Hansen C, 2004, ANESTH ANALG, V99, P1180, DOI 10.1213/01.ANE.0000130383.87438.A9; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; LaBuda CJ, 2005, J NEUROSCI METH, V144, P175, DOI 10.1016/j.jneumeth.2004.11.008; Li XQ, 2001, MOL BRAIN RES, V86, P56, DOI 10.1016/S0169-328X(00)00260-6; Lin JA, 2005, BRAIN RES, V1054, P167, DOI 10.1016/j.brainres.2005.06.058; Maneuf YP, 2001, BRIT J PHARMACOL, V134, P237, DOI 10.1038/sj.bjp.0704227; MAO JR, 1995, NEUROSCI LETT, V198, P75, DOI 10.1016/0304-3940(95)11975-3; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Matthews EA, 2002, ANESTHESIOLOGY, V96, P633, DOI 10.1097/00000542-200203000-00020; Mayer DJ, 1999, P NATL ACAD SCI USA, V96, P7731, DOI 10.1073/pnas.96.14.7731; Okon TR, 2008, J PAIN SYMPTOM MANAG, V35, P327, DOI 10.1016/j.jpainsymman.2007.04.023; Partridge BJ, 1998, ANESTHESIOLOGY, V88, P196, DOI 10.1097/00000542-199801000-00028; Raghavendra V, 2004, NEUROPSYCHOPHARMACOL, V29, P327, DOI 10.1038/sj.npp.1300315; Rode F, 2006, PSYCHOPHARMACOLOGY, V187, P364, DOI 10.1007/s00213-006-0430-3; Ross JR, 2005, J PALLIAT MED, V8, P1118, DOI 10.1089/jpm.2005.8.1118; Shimoyama M, 2000, PAIN, V85, P405, DOI 10.1016/S0304-3959(99)00283-3; Shy M, 2008, MOL PHARMACOL, V73, P868, DOI 10.1124/mol.107.042184; Singh L, 1996, PSYCHOPHARMACOLOGY, V127, P1, DOI 10.1007/BF02805968; Van Elstracte AC, 2006, CAN J ANAESTH, V53, P1180, DOI 10.1007/BF03021578; Van Elstraete AC, 2008, ANESTHESIOLOGY, V108, P484, DOI 10.1097/ALN.0b013e318164cf85; Waxman AR, 2009, NEUROSCI LETT, V462, P68, DOI 10.1016/j.neulet.2009.06.061; Wong CS, 2000, BRIT J ANAESTH, V85, P747, DOI 10.1093/bja/85.5.747; Yoshikawa M, 2000, BRAIN RES, V859, P217, DOI 10.1016/S0006-8993(00)01961-2	36	10	11	0	5	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	APR	2012	26	2					236	241		10.1007/s00540-011-1272-7			6	Anesthesiology	Anesthesiology	929ZF	WOS:000303103800014	22048285				2020-06-30	J	Jensen, D; Alsuhail, A; Viola, R; Dudgeon, DJ; Webb, KA; O'Donnell, DE				Jensen, Dennis; Alsuhail, Abdullah; Viola, Raymond; Dudgeon, Deborah J.; Webb, Katherine A.; O'Donnell, Denis E.			Inhaled Fentanyl Citrate Improves Exercise Endurance During High-Intensity Constant Work Rate Cycle Exercise in Chronic Obstructive Pulmonary Disease	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Dyspnea; exercise; COPD; opioids; fentanyl citrate; nebulized; symptom management	GUINEA-PIG AIRWAYS; NEBULIZED MORPHINE; CHOLINERGIC NEUROTRANSMISSION; LUNG HYPERINFLATION; OPIOID RECEPTORS; FLOW LIMITATION; HEALTH-STATUS; DYSPNEA; STANDARDIZATION; BREATHLESSNESS	Context. Activity limitation and dyspnea are the dominant symptoms of chronic obstructive pulmonary disease (COPD). Traditionally, efforts to alleviate these symptoms have focused on improving ventilatory mechanics, reducing ventilatory demand, or both of these in combination. Nevertheless, many patients with COPD remain incapacitated by dyspnea and exercise intolerance despite optimal therapy. Objectives. To determine the effect of single-dose inhalation of nebulized fentanyl citrate (a m-opioid agonist drug) on exercise tolerance and dyspnea in COPD. Methods. In a randomized, double-blind, placebo-controlled, crossover study, 12 stable patients with COPD (mean +/- standard error of the mean post-b2-agonist forced expiratory volume in one second [FEV1] and FEV1 to forced vital capacity ratio of 69% +/- 4% predicted and 49% +/- 3%, respectively) received either nebulized fentanyl citrate (50 mcg) or placebo on two separate days. After each treatment, patients performed pulmonary function tests and a symptom-limited constant work rate cycle exercise test at 75% of their maximum incremental work rate. Results. There were no significant postdose differences in spirometric parameters or plethysmographic lung volumes. Neither the intensity nor the unpleasantness of perceived dyspnea was, on average, significantly different at isotime (5.0 +/- 0.6 minutes) or at peak exercise after treatment with fentanyl citrate vs. placebo. Compared with placebo, fentanyl citrate was associated with 1) increased exercise endurance time by 1.30 +/- 0.43 minutes or 25% +/- 8% (P = 0.01); 2) small but consistent increases in dynamic inspiratory capacity by similar to 0.10 L at isotime and at peak exercise (both P <= 0.03); and 3) no concomitant change in ventilatory demand, breathing pattern, pulmonary gas exchange, and/or cardiometabolic function during exercise. The mean rate of increase in dyspnea intensity (1.2 +/- 0.3 vs. 2.9 +/- 0.8 Borg units/minute, P = 0.03) and unpleasantness ratings (0.5 +/- 0.2 vs. 2.9 +/- 1.3 Borg units/minute, P = 0.06) between isotime and peak exercise was less after treatment with fentanyl citrate vs. placebo. Conclusion. Single-dose inhalation of fentanyl citrate was associated with significant and potentially clinically important improvements in exercise tolerance in COPD. These improvements were accompanied by a delay in the onset of intolerable dyspnea during exercise near the limits of tolerance. J Pain Symptom Manage 2012; 43: 706-719. (C) 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Jensen, Dennis] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ H2W 1S4, Canada; [Jensen, Dennis; Webb, Katherine A.; O'Donnell, Denis E.] Queens Univ, Resp Invest Unit, Div Respirol & Crit Care Med, Dept Med, Kingston, ON, Canada; [Alsuhail, Abdullah; Viola, Raymond; Dudgeon, Deborah J.] Queens Univ, Palliat Care Med Program, Dept Med, Kingston, ON, Canada; Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada	Jensen, D (reprint author), McGill Univ, Dept Kinesiol & Phys Educ, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	dennis.jensen@mcgill.ca			Department of Medicine; Queen's University; Kingston General Hospital; Canadian Thoracic Society/Canadian Lung Association	Financial support was provided by the Department of Medicine Research Awards Program and the Michael J. Raftis Palliative Care Development Fund, Queen's University and Kingston General Hospital. D. Jensen was supported by a Canadian Thoracic Society/Canadian Lung Association Post-Doctoral Research Fellowship Awards and a Queen's University Post-Doctoral Fellow Excellence in Research Award. The funding sources were not involved in study design or in the conduct of the study or development of the submission. None of the authors have any real or perceived financial or personal relationships with individuals, organizations, or companies to disclose.	Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; ATS, 2003, AM J RESP CRIT CARE, V167, P211, DOI 10.1164/rccm.167.2.211; BEAUFORD W, 1993, CHEST, V104, P175, DOI 10.1378/chest.104.1.175; Belvisi M. G., 2009, V187, P63, DOI 10.1007/978-3-540-79842-2_4; BELVISI MG, 1988, BRIT J PHARMACOL, V95, P413, DOI 10.1111/j.1476-5381.1988.tb11661.x; BELVISI MG, 1990, BRIT J PHARMACOL, V100, P131, DOI 10.1111/j.1476-5381.1990.tb12064.x; BELVISI MG, 1992, J APPL PHYSIOL, V72, P1096; Bhargava HN, 1997, PEPTIDES, V18, P1603, DOI 10.1016/S0196-9781(97)00247-7; BLACKIE SP, 1989, AM REV RESPIR DIS, V139, P1424, DOI 10.1164/ajrccm/139.6.1424; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; Brown SJ, 2005, ANN PHARMACOTHER, V39, P1088, DOI 10.1345/aph.1E328; BURROWS B, 1961, AM REV RESPIR DIS, V84, P789; CABOT PJ, 1994, EUR J PHARM-MOLEC PH, V268, P247, DOI 10.1016/0922-4106(94)90195-3; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; Davenport PW, 2009, RESP PHYSIOL NEUROBI, V167, P72, DOI 10.1016/j.resp.2008.10.001; Foral PA, 2004, CHEST, V125, P691, DOI 10.1378/chest.125.2.691; FROSSARD N, 1987, EUR J PHARMACOL, V141, P519, DOI 10.1016/0014-2999(87)90578-4; HAMILTON AL, 1995, AM J RESP CRIT CARE, V152, P2021, DOI 10.1164/ajrccm.152.6.8520771; HARRISEZE AO, 1995, AM J RESP CRIT CARE, V152, P1940, DOI 10.1164/ajrccm.152.6.8520759; Jankelson D, 1997, EUR RESPIR J, V10, P2270, DOI 10.1183/09031936.97.10102270; JENNINGS AL, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002066; JOHANSSON IGM, 1989, ACTA PHYSIOL SCAND, V135, P411, DOI 10.1111/j.1748-1716.1989.tb08595.x; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones PW, 2001, THORAX, V56, P880, DOI 10.1136/thorax.56.11.880; Krajnik M, 2010, PHARMACOL REP, V62, P139, DOI 10.1016/S1734-1140(10)70251-6; Krajnik M, 2010, HUM PATHOL, V41, P632, DOI 10.1016/j.humpath.2009.08.025; Leppa M, 2006, NEUROIMAGE, V31, P661, DOI 10.1016/j.neuroimage.2005.12.019; Leung R, 1996, THORAX, V51, P596, DOI 10.1136/thx.51.6.596; LIGHT RW, 1989, AM REV RESPIR DIS, V139, P126, DOI 10.1164/ajrccm/139.1.126; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Mahler DA, 2009, EUR RESPIR J, V33, P771, DOI 10.1183/09031936.00145208; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MASOOD AR, 1995, THORAX, V50, P629, DOI 10.1136/thx.50.6.629; MCGAVIN CR, 1978, BRIT MED J, V2, P241, DOI 10.1136/bmj.2.6132.241; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MORRIS JF, 1988, CHEST, V93, P123, DOI 10.1378/chest.93.1.123; O'Donnell DE, 2004, EUR RESPIR J, V23, P832, DOI 10.1183/09031936.04.00116004; O'Donnell DE, 2004, EUR RESPIR J, V24, P86, DOI 10.1183/09031936.04.00072703; O'Donnell DE, 1998, AM J RESP CRIT CARE, V158, P1557, DOI 10.1164/ajrccm.158.5.9804004; O'Donnell DE, 2001, AM J RESP CRIT CARE, V163, P892, DOI 10.1164/ajrccm.163.4.2007026; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770, DOI 10.1164/ajrccm.164.5.2012122; O'Donnell DE, 2007, CAN RESPIR J, V14, p5B, DOI 10.1155/2007/830570; ODONNELL DE, 1987, AM REV RESPIR DIS, V135, P912, DOI 10.1164/arrd.1987.135.4.912; Oga T, 2000, AM J RESP CRIT CARE, V161, P1897, DOI 10.1164/ajrccm.161.6.9905045; Oga T, 2003, CHEST, V123, P1810, DOI 10.1378/chest.123.6.1810; Patel HJ, 1999, EUR J PHARMACOL, V374, P21, DOI 10.1016/S0014-2999(99)00308-8; Pattinson KTS, 2007, J CEREBR BLOOD F MET, V27, P414, DOI 10.1038/sj.jcbfm.9600347; Pattinson KTS, 2009, J NEUROSCI, V29, P8177, DOI 10.1523/JNEUROSCI.1375-09.2009; PELLEGRINO R, 1993, J APPL PHYSIOL, V74, P2552; Peters MM, 2006, THORAX, V61, P559, DOI 10.1136/thx.2005.053470; Pype JL, 1996, EUR RESPIR J, V9, P2280, DOI 10.1183/09031936.96.09112280; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Ries Andrew L, 2005, COPD, V2, P105; Roca J, 1997, EUR RESPIR J, V10, P2662; SAPRU HN, 1981, J PHARMACOL EXP THER, V217, P228; Somfay A, 2001, EUR RESPIR J, V18, P77, DOI 10.1183/09031936.01.00082201; STOLLER JK, 1986, AM REV RESPIR DIS, V134, P1129; Tagaya E, 1995, J PHARMACOL EXP THER, V275, P1288; Varkey B, 2010, CURR OPIN PULM MED, V16, P150, DOI 10.1097/MCP.0b013e3283364378; von Leupoldt A, 2005, CHEST, V128, P345, DOI 10.1378/chest.128.1.345; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; WILLETTE RN, 1982, EUR J PHARMACOL, V78, P61, DOI 10.1016/0014-2999(82)90372-7; WILLETTE RN, 1982, PHARMACOL BIOCHEM BE, V17, P19, DOI 10.1016/0091-3057(82)90256-8; WILLETTE RN, 1982, NEUROPHARMACOLOGY, V21, P1019, DOI 10.1016/0028-3908(82)90116-2; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; YOUNG IH, 1989, THORAX, V44, P387, DOI 10.1136/thx.44.5.387; Yu Y, 2006, PEPTIDES, V27, P1846, DOI 10.1016/j.peptides.2006.01.016; Zappi L, 1997, ANESTHESIOLOGY, V86, P1334, DOI 10.1097/00000542-199706000-00015; ZAPPI L, 1995, ANESTHESIOLOGY, V83, P543, DOI 10.1097/00000542-199509000-00013; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	73	47	47	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	APR	2012	43	4					706	719		10.1016/j.jpainsymman.2011.05.007			14	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	931DG	WOS:000303194400010	22168961	Bronze			2020-06-30	J	Michetti, CP; Maguire, JF; Kaushik, A; Pullarkat, RR; Boro, TV; Rizzo, AG; Seoudi, H; Meehan, M; Robinson, L				Michetti, Christopher P.; Maguire, John F.; Kaushik, Aditya; Pullarkat, Ranjit R.; Boro, Thomas V.; Rizzo, Anne G.; Seoudi, Hani; Meehan, Melody; Robinson, Linda			Single-drug sedation with fentanyl for prehospital postintubation sedation in trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Fentanyl; prehospital; postintubation sedation; trauma	ANALGESIA; GUIDELINES	BACKGROUND: A fentanyl-only (FO) regimen for prehospital postintubation sedation in trauma patients was compared with the standard protocol (SP) of fentanyl + benzodiazepine. METHODS: Intubated patients transported to a Level I trauma center from December 1, 2005, to April 30, 2009, were retrospectively reviewed. Before 2007, only SP was used; afterward both regimens were used. Groups were compared for hemodynamic and neurologic parameters in the prehospital setting and trauma bay, fluid volumes, time until general or neurosurgical intervention (NSI), and other outcomes. RESULTS: Groups were comparable with respect to age, sex, mechanism, alcohol level, intensive care unit length of stay, and hospital length of stay. Comorbidities were similar except hypertension (p = 0.019), and stroke (p = 0.029) were more frequent in FO patients. Prehospital heart rate and Glasgow Coma Scale (GCS) were similar. Trauma bay hemodynamic parameters and fluid resuscitation volumes were comparable, but pupil nonreactivity was more frequent in the FO group both overall (p = 0.032) and when comparing only patients with traumatic brain injury (TBI; p = 0.014). The incidence of TBI was comparable. Although the frequency of craniotomy (13% FO vs. 7% SP) and mortality (17% FO vs. 11% SP) were not statistically different overall, in patients with TBI, there was a higher incidence of NSI (28% vs. 14%, p = 0.015), craniotomy (14% vs. 3%, p = 0.02), and time to initial NSI (446 minutes vs. 193 minutes, p = 0.042) in the FO patients. CONCLUSIONS: In this study, an FO regimen was associated with similar hemodynamic but worse neurologic variables compared with the SP regimen. Prospective evaluation is warranted before adoption of this regimen, especially in TBI patients. (J Trauma. 2012;72:924-929. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Michetti, Christopher P.] Inova Fairfax Hosp, Inova Reg Trauma Ctr, Trauma Serv, Dept Serv, Falls Church, VA 22042 USA; [Boro, Thomas V.] Piedmont Surg Specialists, Danville Reg Med Ctr, Danville, PA USA; [Meehan, Melody] Petr Helicopters, Leesburg, VA USA	Michetti, CP (reprint author), Inova Fairfax Hosp, Inova Reg Trauma Ctr, Trauma Serv, Dept Serv, 3300 Gallows Rd, Falls Church, VA 22042 USA.	christopher.michetti@inova.org		Michetti, Christopher/0000-0002-3744-0603			Bonomo JB, 2008, AM J EMERG MED, V26, P469, DOI 10.1016/j.ajem.2007.05.024; Chao A, 2006, J TRAUMA, V60, P579, DOI 10.1097/01.ta.0000195644.58761.93; Davis D P, 2001, Prehosp Emerg Care, V5, P163, DOI 10.1080/10903120190940065; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; Frakes MA, 2006, AM J EMERG MED, V24, P286, DOI 10.1016/j.ajem.2005.11.021; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Krauss WC, 2011, J EMERG MED, V40, P182, DOI 10.1016/j.jemermed.2009.02.009; Shapiro MB, 2007, J TRAUMA, V63, P945, DOI 10.1097/TA.0b013e318142d21b; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; Thomas SH, 2007, AM J EMERG MED, V25, P842, DOI 10.1016/j.ajem.2007.02.010; Thomson Reuters Healthcare Inc, MICR 2 0 EV BAS CLIN	12	1	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2012	72	4					924	929		10.1097/TA.0b013e3182479884			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	925TO	WOS:000302784600029	22491606				2020-06-30	J	Boudreau, AE; Bersenas, AME; Kerr, CL; Holowaychuk, MK; Johnson, RJ				Boudreau, Ainsley E.; Bersenas, Alexa M. E.; Kerr, Carolyn L.; Holowaychuk, Marie K.; Johnson, Ron J.			A comparison of 3 anesthetic protocols for 24 hours of mechanical ventilation in cats	JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE			English	Article						analgesia; anesthetic agents; cardiovascular monitoring; critical care; small animal anesthesiology	POSITIVE-PRESSURE VENTILATION; TOTAL INTRAVENOUS ANESTHESIA; HYPOXIC PULMONARY VASOCONSTRICTION; CHRONICALLY INSTRUMENTED DOGS; PROPOFOL INFUSION SYNDROME; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; VASCULAR-RESISTANCE; RANDOMIZED-TRIAL; CARBON-DIOXIDE	Objective - To compare the recovery times, recovery quality, and cardiovascular (CV) effects of 3 anesthetic protocols during 24 hours of mechanical ventilation (MV) in healthy cats. Design - Prospective, randomized, crossover study. Setting - Research laboratory at a veterinary teaching hospital. Animals - Six healthy intact male purpose-bred cats. Interventions - Each cat was randomly assigned to receive 3 anesthetic protocols for 24 hours of MV; Protocol K consisted of ketamine, Protocol P, propofol; and Protocol PK, propofol plus fixed-rate low-dose ketamine. Each infusion drug dose was adjusted using a sedation scoring system. All protocols included fixed doses of fentanyl (10 mu g/kg/h) and midazolam (0.5 mg/kg/h). Measurements and Main Results - Drug doses and recovery times were recorded. Recovery quality was scored. Blood gas results, CV parameters, and frequency of bradycardia or hypotension requiring interventions were recorded. The mean d dose +/- standard error of K was 81.3 +/- 3.3 mu g/kg/m. The median dose (95% cardiac index) of propofol (mu g/kg/m) in PK was 16.0 (13.1, 19.6) and in P was 48.1 (39.3, 58.9). P necessitated significantly more propofol than PK (P < 0.05). Protocol K (35.6 +/- 3.2 hours) had significantly longer times to full recovery compared to P (18.2 +/- 3.2 hours). Protocol K had significantly longer times to head up, crawling, and standing compared to P and PK. Cats sedated with PK (2.33 +/- 0.47) required significantly more interventions for hypotension than K (0.50 +/- 0.47). Protocol P (3.2 +/- 0.4) and PK (1.4 +/- 0.3) required significantly more interventions for bradycardia compared to K (0.8 +/- 0.3). When comparing protocol K to P and PK, significant differences in blood pressure, lactate, oxygen delivery, and oxygen consumption were noted. Conclusions - Cats anesthetized with P had shorter times to full recovery compared to K. Cats anesthetized with K required fewer interventions for bradycardia or hypotension but had longer recovery times compared to P or PK. Protocol PK reduced the propofol dose required to maintain optimal anesthesia.	[Boudreau, Ainsley E.; Bersenas, Alexa M. E.; Kerr, Carolyn L.; Holowaychuk, Marie K.] Univ Guelph, Dept Clin Studies, Ontario Vet Coll, Guelph, ON N1G 2W1, Canada; [Johnson, Ron J.] Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, Guelph, ON N1G 2W1, Canada	Boudreau, AE (reprint author), Univ Guelph, Dept Clin Studies, Ontario Vet Coll, 50 Stone Rd, Guelph, ON N1G 2W1, Canada.	aboudrea@uoguelph.ca			Ontario Veterinary College, Pet Trust	Funding for this study was provided by the Ontario Veterinary College, Pet Trust Fund.	ANDRESS JL, 1995, VET SURG, V24, P277, DOI 10.1111/j.1532-950X.1995.tb01331.x; BARATZ RA, 1971, ANESTHESIOLOGY, V34, P510, DOI 10.1097/00000542-197106000-00005; BARK H, 1980, AM J PHYSIOL, V239, pE474; BEDNARSKI R. M., 2007, LUMB JONES VET ANEST, P705; Brainard B, 2008, P INT VET EM CRIT CA, P235; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; BREARLEY JC, 1988, J SMALL ANIM PRACT, V29, P315, DOI 10.1111/j.1748-5827.1988.tb02290.x; Brown JE, 2009, J VET EMERG CRIT CAR, V19, P416, DOI 10.1111/j.1476-4431.2009.00458.x; Bufalari A, 1995, J VET ANAESTH, V22, P1924; Campbell VL, 2004, TXB RESP DIS DOGS CA, P53; Carrasco G, 2000, CRIT CARE, V4, P217, DOI 10.1186/cc697; CARTWRIGHT PD, 1984, ANAESTHESIA, V39, P439, DOI 10.1111/j.1365-2044.1984.tb07312.x; Chanzan S, 2008, J OPIOID MANAG, V4, P173; Clemmesen O, 2004, CURR OPIN CRIT CARE, V46, P216; Costa MG, 2006, TRANSPLANT P, V38, P803, DOI 10.1016/j.transproceed.2006.01.038; CULLEN DJ, 1974, ANESTHESIOLOGY, V41, P345, DOI 10.1097/00000542-197410000-00006; De Pinto Mario, 2008, J Opioid Manag, V4, P54; Devlin JW, 2005, PHARMACOTHERAPY, V25, P1348, DOI 10.1592/phco.2005.25.10.1348; Drellich S, 2002, VET CLIN N AM-SMALL, V32, P1087, DOI 10.1016/S0195-5616(02)00034-7; Ethier MR, 2008, AM J VET RES, V69, P1351, DOI 10.2460/ajvr.69.10.1351; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; Fukuda K, 2005, MILLERS ANESTHESIA, V1, P379; Gassner S, 1974, ANESTHESIA, V19, P141; Harrison JM, 1999, BRIT J ANAESTH, V83, P839, DOI 10.1093/bja/83.6.839; Haskins S, 2005, COMPARATIVE MED, V55, P156; HASKINS SC, 1986, AM J VET RES, V47, P795; Haskins SC, 2006, J VET EMERG CRIT CAR, V16, P300, DOI 10.1111/j.1476-4431.2006.00188.x; Heikkila H, 1988, ACTA ANAESTH SCAND, V28, P683; HICKEY PR, 1985, ANESTHESIOLOGY, V62, P287, DOI 10.1097/00000542-198503000-00013; Hopper K, 2009, SMALL ANIMAL CRITICA, P900; Hopper K, 2007, JAVMA-J AM VET MED A, V230, P64, DOI 10.2460/javma.230.1.64; HUI TW, 1995, ANESTHESIOLOGY, V82, P641, DOI 10.1097/00000542-199503000-00005; Ilkiw JE, 2003, AM J VET RES, V64, P907, DOI 10.2460/ajvr.2003.64.907; Ilkiw JE, 2003, AM J VET RES, V64, P913, DOI 10.2460/ajvr.2003.64.913; Ilkiw JE, 1998, J VET PHARMACOL THER, V21, P54, DOI 10.1046/j.1365-2885.1998.00102.x; KING LG, 1994, J AM VET MED ASSOC, V204, P1045; Kotani Y, 2008, CNS NEUROSCI THER, V14, P95, DOI 10.1111/j.1527-3458.2008.00043.x; Kress JP, 2006, CRIT CARE MED, V34, P2541, DOI 10.1097/01.CCM.0000239117.39890.E3; Kress JP, 2006, PRINCIPLES PRACTICE, P1093; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; Lee JA, 2005, JAVMA-J AM VET MED A, V226, P924, DOI 10.2460/javma.2005.226.924; Lennon PF, 1996, ANESTHESIOLOGY, V84, P404, DOI 10.1097/00000542-199602000-00020; Lin H. C., 2007, LUMB JONES VET ANEST, P301; Marshall BE, 1985, EFFECTS ANESTHESIA, P121; MARTY J, 1986, ANESTH ANALG, V65, P113; Mellema MS, 2000, CLIN TECH SMALL AN P, V15, P157, DOI 10.1053/svms.2000.18293; Mendes GM, 2003, J AM VET MED ASSOC, V223, P1608, DOI 10.2460/javma.2003.223.1608; Nakayama M, 1999, ANESTHESIOLOGY, V91, P760, DOI 10.1097/00000542-199909000-00029; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P2, DOI 10.1111/j.1467-2995.2005.00216.x; Pereira GG, 2004, VET ANAESTH ANALG, V31, P235, DOI 10.1111/j.1467-2987.2004.00157.x; Plumb DC, 2002, VET DRUG HDB, P461; Reves JG, 2004, MILLERS ANESTHESIA, V1, P317; Rezende ML, 2008, AM J VET RES, V69, P1135, DOI 10.2460/ajvr.69.9.1135; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Robertson SA, 2001, AM J VET RES, V62, P1922, DOI 10.2460/ajvr.2001.62.1922; SAS OnlineDOC (R), 2004, SAS ONLINEDOC R VERS; STETZ CW, 1982, AM REV RESPIR DIS, V126, P1001; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; TOMICHEK RC, 1982, ANESTH ANALG, V61, P217; Trim CM, 1994, ANAESTHESIA CAT, P194; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; WHITE DA, 1990, ANESTH ANALG, V71, P29; Yang CY, 1997, CAN J ANAESTH, V44, P775, DOI 10.1007/BF03013394; Zaki S, 2009, AUST VET J, V87, P82, DOI 10.1111/j.1751-0813.2009.00390.x	64	6	7	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1479-3261			J VET EMERG CRIT CAR	J. Vet. Emerg. Crit. Care	APR	2012	22	2					239	252		10.1111/j.1476-4431.2012.00722.x			14	Veterinary Sciences	Veterinary Sciences	927YK	WOS:000302946300013	23016813				2020-06-30	J	Darwish, M; Xie, F				Darwish, Mona; Xie, Fang			Pharmacokinetics of Fentanyl Buccal Tablet: A Pooled Analysis and Review	PAIN PRACTICE			English	Review						pharmacokinetics; breakthrough pain; chronic pain; fentanyl; fentanyl buccal tablet; opioid analgesics; opioid-tolerant; pain; rapid-onset opioids	OPIOID-TOLERANT PATIENTS; HEALTHY ADULT VOLUNTEERS; 1300 MU-G; BREAKTHROUGH PAIN; DOUBLE-BLIND; OPEN-LABEL; RELATIVE BIOAVAILABILITY; DOSE PROPORTIONALITY; CANCER PAIN; TREATED PATIENTS	Fentanyl buccal tablet (FBT) is indicated for the treatment of breakthrough pain in patients who are already receiving and are tolerant to opioid therapy for underlying, persistent cancer pain. FBT is designed to enhance the rate and efficiency of absorption of fentanyl through the buccal mucosa. FBT was shown to be dose proportional from 100 to 1,300 mu g. This analysis provides an overview of the pharmacokinetic profile of FBT based on pooled data from nine pharmacokinetic studies. In all, 365 healthy non-opioid-tolerant adults receiving naltrexone were included in the analysis. Single-dose (100 to 1,300 mu g) pharmacokinetic parameters were dose normalized to 100 mu g. Pharmacokinetic measures included maximum observed plasma drug concentration (Cmax), plasma drug concentration versus time curve from time zero to infinity (AUC08), time to reach Cmax (Tmax), apparent plasma terminal elimination rate constant, and elimination half-life. After FBT administration, fentanyl was rapidly absorbed, with Tmax ranging from 20 minutes to 4 hours postdose. Mean AUC08 was 1.49 nghour/mL, and mean Cmax was 0.237 ng/mL. However, plasma fentanyl concentration reached 80% of Cmax within 25 minutes and was maintained through 2 hours after administration. Based on the individual studies, bioequivalence was shown for sublingual and buccal tablet placement, and no significant effect of dwell time (duration of FBT presence in the oral cavity) was observed. The pharmacokinetic profile of FBT was characterized by rapid absorption, which is consistent with the rapid-onset efficacy profile of FBT observed in clinical studies.	[Darwish, Mona; Xie, Fang] Cephalon Inc, Clin Res, Frazer, PA 19355 USA	Darwish, M (reprint author), Cephalon Inc, Clin Res, 41 Moores Rd, Frazer, PA 19355 USA.	mdarwish@cephalon.com			Cephalon, Inc. (Frazer, PA, U.S.A.); Cephalon, Inc.	This analysis was sponsored by Cephalon, Inc. (Frazer, PA, U.S.A.). Writing support was provided by Peloton Advantage, LLC, funded by Cephalon, Inc.	[Anonymous], 2011, FENTORA; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Darwish M, 2007, EXPERT OPIN PHARMACO, V8, P2011, DOI 10.1517/14656566.8.13.2011; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2006, CLIN PHARMACOKINET, V45, P843, DOI 10.2165/00003088-200645080-00006; Darwish M, 2010, CLIN DRUG INVEST, V30, P365, DOI 10.2165/11533360-000000000-00000; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; FDA, GUID IND BI IN PRESS; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Pather SI, 2001, DRUG DELIV TECH, V1, P54; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Saunders DL, 2011, J CLIN PHARM; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	37	5	6	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	APR	2012	12	4					307	314		10.1111/j.1533-2500.2011.00491.x			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	921HO	WOS:000302468900006	21831253				2020-06-30	J	Rahmanian-Schwarz, A; Held, M; Knoeller, T; Amr, A; Schaller, HE; Jaminet, P				Rahmanian-Schwarz, Afshin; Held, Manuel; Knoeller, Tabea; Amr, Amro; Schaller, Hans-Eberhard; Jaminet, Patrick			The Effect of Repetitive Intraperitoneal Anesthesia by Application of Fentanyl-Medetomidine and Midazolam in Laboratory Rats	JOURNAL OF INVESTIGATIVE SURGERY			English	Article						anesthesia; anesthetic-analgesic regimens; rat; recovery; anesthetic combination; repeated anesthetic procedures		Background: Literature reviews show numerous options for anesthesia in the small laboratory animals. Many methods are associated with complications, such as high technical effort, difficult monitoring, respiratory and cardiovascular depression, and prolonged sedation. In the present study, we report first time results after repeated use of an intraperitoneal combined anesthesia with a high tolerability. Methods: Three hundred and seventy-four anesthesias were performed on 38 adult male lewis rats (280-460g). Each animal was anesthetized repeatedly over a period of three months, using an intraperitoneal combination of Fentanyl-Medetomidine and Midazolam (FMM). The time required for the animals to lose ear pinch response and the ability to perform a righting and pedal withdrawal reflex was measured. For evaluation of the clinical state, a four-point vitality scale was developed. The anesthesia was antagonized with Naloxone, Flumazenil, and Atipamezole (s.c.). Results: The animals lost all three reflex responses within 5 (+/- 2.4) min of injection. Without antagonism of anesthesia, the ear pinch response returned on average within 125 (+/- 21.5) min. After antagonism of anesthesia, the rats needed 5 (+/- 2.9) min to regain all three reflex responses. No significant differences of vitality-index were measured after repeated use of FMM during the investigation period. Conclusions: A repeatable and secure anesthesia is indispensable for any experimental studies that require multiple anesthesia of a single animal. Intraperitoneal combination of FMM provides an adequate procedure to induce a well tolerable, repeatable state of anesthesia, which conforms to all the necessary requirements for laboratory rats.	[Rahmanian-Schwarz, Afshin; Held, Manuel; Knoeller, Tabea; Amr, Amro; Schaller, Hans-Eberhard; Jaminet, Patrick] Univ Tubingen, BG Trauma Ctr, Dept Plast Reconstruct Hand & Burn Surg, D-72074 Tubingen, Germany	Rahmanian-Schwarz, A (reprint author), Univ Tubingen, BG Trauma Ctr, Dept Plast Reconstruct Hand & Burn Surg, D-72074 Tubingen, Germany.	arahmanian@bgu-tuebingen.de					Davis J. A, 2001, CURRENT PROTOCOLS NE; Flecknell P. A., 1996, HDB RODENT RABBIT ME, P219; FLECKNELL PA, 1993, BRIT J ANAESTH, V71, P885, DOI 10.1093/bja/71.6.885; Hackbarth H, 2000, LAB ANIM, V34, P91, DOI 10.1258/002367700780578055; Henke J, 2004, J VET MED A, V51, P259, DOI 10.1111/j.1439-0442.2004.00632.x; Henke J, 1998, REVERSAL ANAESTHESIA; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Lumb WV, 1964, ANESTHESIOLOGY, V25, P583; Nagate T, 2007, J VET MED SCI, V69, P1137, DOI 10.1292/jvms.69.1137; Panni MK, 2002, ANESTH ANALG, V95, P656, DOI 10.1097/00000539-200209000-00030; Rivard AL, 2006, J INVEST SURG, V19, P267, DOI 10.1080/08941930600778297; WAUGAMAN WR, 1991, NURS CLIN N AM, V26, P451	12	10	10	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0894-1939			J INVEST SURG	J. Invest. Surg.	APR	2012	25	2					123	126		10.3109/08941939.2011.611582			4	Surgery	Surgery	915KU	WOS:000302024700009	22439839				2020-06-30	J	Hansen, MS; Mathiesen, O; Trautner, S; Dahl, JB				Hansen, M. S.; Mathiesen, O.; Trautner, S.; Dahl, J. B.			Intranasal fentanyl in the treatment of acute pain - a systematic review	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Review							RANDOMIZED CONTROLLED-TRIAL; BREAKTHROUGH CANCER PAIN; RELEASE MORPHINE-SULFATE; POSTOPERATIVE PAIN; DOUBLE-BLIND; NASAL FENTANYL; TRANSNASAL BUTORPHANOL; PATIENT ACCEPTABILITY; INTRAVENOUS MORPHINE; CROSSOVER TRIAL	Due to its non-invasive mode of administration, intranasal (IN) application of drugs may be a valuable alternative to non-invasive pain management. With characteristics that appear to be ideal for IN application, IN fentanyl may have a place in the out-of-hospital treatment and the paediatric population. The objective of this systematic review was to evaluate the current evidence of IN fentanyl in the treatment of acute pain. Reports of randomized controlled trials (RCTs) of IN fentanyl in treatment of pain were systematically sought using the PubMed database, Embase, Google scholar, Cochrane database, and Cumulative Index to Nursing and Allied Health Literature. Reports were considered for inclusion if they were double-blinded randomized controlled trials (RCTs) of IN fentanyl in the treatment of acute pain. Thirty-two RCTs were identified, and 16 were included in the final analysis. No significant analgesic differences between IN fentanyl and intravenous (IV) fentanyl were demonstrated in treatment of acute and post-operative pain. Significant analgesic effect of IN fentanyl was demonstrated in the treatment of breakthrough pain in cancer patients. In the paediatric population, results demonstrated some analgesic effect of IN fentanyl following myringotomy, no analgesic effect following voiding cystourethrography, and finally, no significant analgesic difference after long bone fractures, in burns patients, and in post-operative pain relief when compared to IV morphine, oral morphine, or IV fentanyl, respectively. Significant analgesic effect of IN fentanyl was demonstrated in the treatment of breakthrough pain in cancer patients. However, the significant deficiencies in trials investigating acute and post-operative pain, and the paediatric population makes firm recommendations impossible.	[Hansen, M. S.; Dahl, J. B.] Copenhagen Univ Hosp, Dept Anaesthesia 4231, Ctr Head & Orthopaed, Rigshosp, DK-2100 Copenhagen, Denmark; [Mathiesen, O.] Copenhagen Univ Hosp, Dept Anaesthesia, Ctr Head & Orthopaed, Rigshosp,Sect Acute Pain Management & Palliat Med, DK-2100 Copenhagen, Denmark; [Trautner, S.] Falck Danmark AS, Dept Med, Copenhagen, Denmark	Hansen, MS (reprint author), Copenhagen Univ Hosp, Dept Anaesthesia 4231, Ctr Head & Orthopaed, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	morten_sejer@yahoo.dk	Hansen, Morten/S-7809-2016	Mathiesen, Ole/0000-0003-4544-0619	Falck A/S, Denmark	The work was supported by a grant from Falck A/S, Denmark.	ABBOUD TK, 1991, ACTA ANAESTH SCAND, V35, P14, DOI 10.1111/j.1399-6576.1991.tb03234.x; Anez Simon C, 2006, Rev Esp Anestesiol Reanim, V53, P643; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Cheng Xiang, 2008, Zhonghua Yi Xue Za Zhi, V88, P2898; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Chung S, 2010, PEDIATR RADIOL, V40, P1236, DOI 10.1007/s00247-009-1521-1; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Fallon M, 2009, EJC SUPPL, V7, P15, DOI 10.1016/S1359-6349(09)72064-6; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Garner D, 2006, J EMERG PRIM HLTH CA, V4, P6; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Greenfield MLVH, 2009, ANESTH ANALG, V108, P1916, DOI 10.1213/ane.0b013e31819fe6d7; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Kress HG, 2009, EUR J PAIN, V13, P197; Manjushree R, 2002, CAN J ANAESTH, V49, P190; MARXER N, 2009, KRANKENHAUSPHARMAZIE, V30, P437; Mathieu N, 2006, CAN J ANAESTH, V53, P60, DOI 10.1007/BF03021528; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Nave R, 2009, EUR J PAIN, V13, P206; Oyee J, 2010, PALLIATIVE MED, V24, P223; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Sandner F, 2009, J PHARM THERAPIE, V18, P133; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Schwagmeier R, 1996, ANAESTHESIST, V45, P231, DOI 10.1007/s001010050257; SCHWESINGER WH, 1992, ADV THER, V9, P123; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Striebel H W, 1993, Schmerz, V7, P174, DOI 10.1007/BF02530425; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Striebel HW, 1996, J CLIN ANESTH, V8, P4, DOI 10.1016/0952-8180(95)00167-0; Striebel HW, 1996, ANASTH INTENSIVMED, V37, P128; STRIEBEL WH, 1993, ANESTH ANALG, V76, P1047; Taylor Donald, 2010, J Support Oncol, V8, P184; Telfer P, 2009, ARCH DIS CHILD, V94, P979, DOI 10.1136/adc.2008.138875; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Voronov P, 2008, PEDIATR ANESTH, V18, P1196, DOI 10.1111/j.1460-9592.2008.02789.x; Wermeling DP, 2005, CLIN THER, V27, P430, DOI 10.1016/j.clinthera.2005.04.002; Wilkes G, 2006, CAN J EMERG MED, V8, pS103; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; Younge P, 1999, EMERGEN MED, V11, P90; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	58	23	23	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2012	56	4					407	419		10.1111/j.1399-6576.2011.02613.x			13	Anesthesiology	Anesthesiology	906HC	WOS:000301334500003	22260169				2020-06-30	J	Mercadante, S				Mercadante, Sebastiano			Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						breakthrough pain; opioids; oral transmucosal fentanyl citrate	TRANSMUCOSAL FENTANYL; DOSE-TITRATION; MANAGEMENT; TRIAL; PHARMACOKINETICS; MULTICENTER; MORPHINE; OTFC(R); OPIOIDS	Introduction: Breakthrough cancer pain has been defined as a transitory increase in pain intensity that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain. The availability of supplemental doses of oral opioids, in addition to the continuous analgesic medication, is the main treatment suggested to manage pain flares. Areas covered: Oral transmucosal fentanyl citrate (OTFC) is the first product of a new generation of delivery systems, named rapid-onset opioids (ROOs), characterized by rapidity of effect and the short duration of analgesia. Controlled studies and long-term experience have shown that OTFC is an effective treatment for breakthrough pain management and its use should be considered in any patient experiencing breakthrough pain related to cancer. Expert opinion: The onset of action of OTFC - demonstrated to start within 15 min - and the short time to maximum concentration make it a useful indication for breakthrough pain; dose titration is commonly recommended. However, it is likely that patients receiving high doses of opioids for background analgesia will not be candidates for titration with minimal initial doses of OTFC, as they are opioid tolerant and the process would be time consuming.	[Mercadante, Sebastiano] Univ Palermo, La Maddalena Canc Ctr, I-90145 Palermo, Italy; [Mercadante, Sebastiano] Dept Anesthesia Intens Care & Emergencies, Anesthesia & Intens Care Unit, I-90145 Palermo, Italy; [Mercadante, Sebastiano] Dept Anesthesia Intens Care & Emergencies, Pain Relief & Palliat Care Unit, I-90145 Palermo, Italy	Mercadante, S (reprint author), Univ Palermo, La Maddalena Canc Ctr, Via san Lorenzo 312, I-90145 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it					Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; ASHBURN MA, 1994, DRUG SAFETY, V11, P295, DOI 10.2165/00002018-199411050-00001; Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Csaba N, 2006, EXPERT OPIN DRUG DEL, V91, P463; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Mandel L, 2011, J AM DENT ASSOC, V142, P406, DOI 10.14219/jada.archive.2011.0195; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2006, DRUGS, V66, P2394, DOI 10.2165/00003495-200666180-00015; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Shaiova L, 2004, SUPPORT CARE CANCER, V12, P268, DOI 10.1007/s00520-004-0595-4; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	27	6	9	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	APR	2012	13	6					873	878		10.1517/14656566.2012.663353			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	912YJ	WOS:000301837600010	22424558				2020-06-30	J	Lee, SA; Alston, TA				Lee, Sarah A.; Alston, Theodore A.			A little hypothermia goes a long way	CRITICAL CARE MEDICINE			English	Editorial Material						cytochrome P450; Leonor Michaelis; Maud Menten; resuscitation; Svante Arrhenius	TEMPERATURE		[Lee, Sarah A.; Alston, Theodore A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA	Lee, SA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.			Alston, Theodore/0000-0001-6500-502X			Anson ML, 1934, J GEN PHYSIOL, V17, P393, DOI 10.1085/jgp.17.3.393; Arrhenius S., 1896, PHILOS MAG, V41, P237, DOI [DOI 10.1080/14786449608620846, 10.1080/14786449608620846]; Arrhenius S, 1889, Z PHYS CHEM, V4, P226, DOI DOI 10.1515/ZPCH-1889-0116; Daniel RM, 2010, BIOCHEM J, V425, P353, DOI 10.1042/BJ20091254; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; KELETI T, 1983, BIOCHEM J, V209, P277, DOI 10.1042/bj2090277; MELLERGARD P, 1995, SURG NEUROL, V43, P91, DOI 10.1016/0090-3019(95)80049-M; Michaelis L, 1913, BIOCHEM Z, V49, P333; Peterson ME, 2004, J BIOL CHEM, V279, P20717, DOI 10.1074/jbc.M309143200; Ziegeler S, 2010, J CLIN ANESTH, V22, P340, DOI 10.1016/j.jclinane.2009.09.007	11	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2012	40	4					1369	1370		10.1097/CCM.0b013e31823b8b6a			2	Critical Care Medicine	General & Internal Medicine	912QC	WOS:000301813700062	22425848				2020-06-30	J	Lebwohl, B; Hassid, B; Ludwin, S; Lewis, SK; Tennyson, CA; Neugut, AI; Green, PHR				Lebwohl, Benjamin; Hassid, Benjamin; Ludwin, Steven; Lewis, Suzanne K.; Tennyson, Christina A.; Neugut, Alfred I.; Green, Peter H. R.			Increased Sedation Requirements During Endoscopy in Patients with Celiac Disease	DIGESTIVE DISEASES AND SCIENCES			English	Article						Celiac disease; Gastrointestinal endoscopy; Colonoscopy; Conscious sedation	IRRITABLE-BOWEL-SYNDROME; GLUTEN-FREE DIET; SYMPTOMS; SENSITIVITY; ASSOCIATION; DEPRESSION; ACTIVATION; ILLNESS; ANXIETY; ATAXIA	Celiac disease (CD) is associated with increased rates of neuropsychiatric disease and irritable bowel syndrome, and patients may exhibit visceral hypersensitivity. The purpose of this study was to determine whether patients with CD have increased sedation requirements during endoscopic procedures. In this retrospective cohort study, we identified CD patients undergoing either a colonoscopy or esophagogastroduodenoscopy (EGD), but not a dual procedure. CD patients were matched with control patients according to age, gender and endoscopist. For sedation requirements we defined "high" as falling outside of the 75th percentile of the entire cohort. In the colonoscopy analysis we identified 113 CD patients and 278 controls. In the CD group, 29 individuals (26%) required high amounts of both opioids and midazolam, as compared to 46 (17%) controls (P = 0.05). Differences were similar when considering only opioids (P = 0.06) and midazolam (P = 0.06). In the EGD analysis we identified 314 CD patients and 314 controls who met the inclusion criteria. Among the CD patients, 70 (22%) required high amounts of both opioids and midazolam compared to 51 (16%) controls (P = 0.05). Differences were similar when considering only opioids (P = 0.06) and midazolam (P = 0.04). Patients with CD require higher doses of sedation during upper and lower endoscopy compared to age and gender-matched controls. Putative explanations, such as visceral hypersensitivity, chronic opioid/anxiolytic use, or underlying neuropsychiatric illness, should be evaluated prospectively.	[Lebwohl, Benjamin; Hassid, Benjamin; Ludwin, Steven; Lewis, Suzanne K.; Tennyson, Christina A.; Green, Peter H. R.] Columbia Univ, Celiac Dis Ctr, New York, NY 10027 USA; [Neugut, Alfred I.] Columbia Univ, Med Ctr, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA	Lebwohl, B (reprint author), Columbia Univ, Celiac Dis Ctr, 180 Ft Washington Ave,Suite 936, New York, NY 10027 USA.	BL114@columbia.edu; BH2185@columbia.edu; SL3154@columbia.edu; SKL3@columbia.edu; CT2398@columbia.edu; AIN1@columbia.edu; PG11@columbia.edu					Addolorato G, 1996, HEPATO-GASTROENTEROL, V43, P1513; Bonaz B, 2003, J Physiol Pharmacol, V54 Suppl 4, P27; Cellier C, 1998, AM J GASTROENTEROL, V93, P1527, DOI 10.1111/j.1572-0241.1998.00439.x; Chadwick VS, 2002, GASTROENTEROLOGY, V122, P1778, DOI 10.1053/gast.2002.33579; Ciacci C, 1998, SCAND J GASTROENTERO, V33, P247; Dorn SD, 2010, DIGEST DIS SCI, V55, P3154, DOI 10.1007/s10620-010-1342-y; Ersoy O, 2009, DIGEST DIS SCI, V54, P825, DOI 10.1007/s10620-008-0402-z; Gonda TA, 2010, DIGEST DIS SCI, V55, P2899, DOI 10.1007/s10620-009-1086-8; Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600; Hadjivassiliou M, 2006, NEUROLOGY, V66, P373, DOI 10.1212/01.wnl.0000196480.55601.3a; Hadjivassiliou M, 1997, J NEUROL NEUROSUR PS, V63, P770, DOI 10.1136/jnnp.63.6.770; Hadjivassiliou M, 1998, LANCET, V352, P1582, DOI 10.1016/S0140-6736(98)05342-2; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; Hadjivassiliou M, 2001, NEUROLOGY, V56, P385, DOI 10.1212/WNL.56.3.385; Hauser W, 2010, WORLD J GASTROENTERO, V16, P2780, DOI 10.3748/wjg.v16.i22.2780; Kim ES, 2010, J GASTROEN HEPATOL, V25, P1232, DOI 10.1111/j.1440-1746.2010.06338.x; Lebwohl B, 2010, ALIMENT PHARM THER, V32, P1037, DOI 10.1111/j.1365-2036.2010.04440.x; Mulak A, 2010, J CLIN GASTROENTEROL, V44, pE249, DOI 10.1097/MCG.0b013e3181e04d0b; O'Leary C, 2002, AM J GASTROENTEROL, V97, P1463, DOI 10.1111/j.1572-0241.2002.05690.x; Sanders DS, 2001, LANCET, V358, P1504, DOI 10.1016/S0140-6736(01)06581-3; Usai P, 2007, DIGEST LIVER DIS, V39, P824, DOI 10.1016/j.dld.2007.05.017; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U	22	3	3	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116			DIGEST DIS SCI	Dig. Dis. Sci.	APR	2012	57	4					994	999		10.1007/s10620-011-1959-5			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	912XV	WOS:000301835600025	22052448				2020-06-30	J	Andresen, H; Gullans, A; Veselinovic, M; Anders, S; Schmoldt, A; Iwersen-Bergmann, S; Mueller, A				Andresen, Hilke; Gullans, Annemarie; Veselinovic, Michele; Anders, Sven; Schmoldt, Achim; Iwersen-Bergmann, Stefanie; Mueller, Alexander			Fentanyl: Toxic or Therapeutic? Postmortem and Antemortem Blood Concentrations After Transdermal Fentanyl Application	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							TISSUE REDISTRIBUTION; FORENSIC TOXICOLOGY; INTRAVENOUS MISUSE; PHARMACOKINETICS; ALFENTANIL; DEATHS; DRUG; PATCHES; ABUSE; PHARMACODYNAMICS		[Andresen, Hilke; Gullans, Annemarie; Veselinovic, Michele; Anders, Sven; Schmoldt, Achim; Iwersen-Bergmann, Stefanie; Mueller, Alexander] Univ Med Ctr Hamburg Eppendorf, Inst Legal Med, Hamburg, Germany	Andresen, H (reprint author), Univ Med Ctr Hamburg Eppendorf, Inst Legal Med, Hamburg, Germany.	h.andresen@uke.uni-hamburg.de	Anders, Sven/D-7670-2014		Johanna und Fritz Buch Gedachtnis-Stiftung	The authors thank Prof. Dr. med. Helge Beck and Dr. med. Kamayni Agarwal, Department of Anaesthesiology, University Medical Center Hamburg-Eppendorf, for their assistance in our study. Thanks to the "Johanna und Fritz Buch Gedachtnis-Stiftung" for supporting our study.	Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; BOWER S, 1982, J PHARM PHARMACOL, V34, P181, DOI 10.1111/j.2042-7158.1982.tb04217.x; Ceelen L., 2011, AM J FOREN MED PATH, DOI [10.1097/PAF.0b013e3181tbbb4, DOI 10.1097/PAF.0B013E3181FBBB4]; Cook DS, 2000, J CLIN PATHOL, V53, P282, DOI 10.1136/jcp.53.4.282; Coon T., 2005, ANN EMERG MED, V46, P437; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Ferner RE, 2008, BRIT J CLIN PHARMACO, V66, P430, DOI 10.1111/j.1365-2125.2008.03231.x; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Janssen Pharmaceutica and Products, 2009, PHARM PROD DUR FENT; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Klockgether-Radke AP, 2002, ANAESTHESIST, V51, P269, DOI 10.1007/s00101-002-0299-4; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Latasch L, 1989, Acta Anaesthesiol Belg, V40, P113; Leikin JB, 2003, J TOXICOL-CLIN TOXIC, V41, P47, DOI 10.1081/CLT-120018270; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Moriya F, 1999, J FORENSIC SCI, V44, P10; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Paul LD, 2009, TOXICHEM KRIMTECH, V76, P142; Pohland RC, 1997, J FORENSIC SCI, V42, P812; POUNDER DJ, 1994, AM J FOREN MED PATH, V15, P231, DOI 10.1097/00000433-199409000-00010; Pounder J., 1989, FORENSIC SCI INT, V45, P253; Pounder J., 1994, AM J FOREN MED PATH, V15, P231; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741; Suzuki O., 2005, DRUGS POISONS HUMANS; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Yarema MC, 2005, CLIN TOXICOL, V43, P235, DOI 10.1081/CLT-200058950	50	24	24	0	24	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	APR	2012	36	3					182	194		10.1093/jat/bks005			13	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	913NI	WOS:000301884300006	22417834	Green Published, Bronze			2020-06-30	J	Empey, PE; Miller, TM; Philbrick, AH; Melick, JA; Kochanek, PM; Poloyac, SM				Empey, Philip E.; Miller, Tricia M.; Philbrick, Ashley H.; Melick, John A.; Kochanek, Patrick M.; Poloyac, Samuel M.			Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest	CRITICAL CARE MEDICINE			English	Article						cardiac arrest; drug metabolism; fentanyl; hypothermia; midazolam; pharmacokinetics	THERAPEUTIC MODERATE HYPOTHERMIA; DRUG-METABOLISM; PHARMACOKINETICS; PHARMACODYNAMICS; CHLORZOXAZONE; TEMPERATURE; ALFENTANIL; MECHANISMS; VECURONIUM; TRANSPORT	Objectives: Therapeutic hypothermia is widely employed for neuroprotection after cardiac arrest. However, concern regarding elevated drug concentrations during hypothermia and increased adverse drug reaction risk complicates concurrent pharmacotherapy. Many commonly used medications in critically ill patients rely on the cytochrome P450 3A isoform for their elimination. Therefore, our study objectives were to determine the effect of mild hypothermia on the in vivo pharmacokinetics of fentanyl and midazolam, two clinically relevant cytochrome P450 3A substrates, after cardiac arrest and to investigate the mechanisms of these alterations. Design: Prospective, randomized, controlled study. Setting: University research laboratory. Subjects: Thirty-two adult male Sprague-Dawley rats. Interventions: An asphyxial cardiac arrest rat model was used and mild hypothermia (33 degrees C) was induced 1 hr post injury by surface cooling and continued for 10 hrs to mimic the prolonged clinical application of hypothermia accompanied by intensive care interventions. Fentanyl and midazolam were independently administered by intravenous infusion and plasma and brain concentrations were analyzed using ultraperformance liquid chromatography tandem mass spectrometry. Cytochrome P450 3a2 protein expression was measured and a Michaelis-Menten enzyme kinetic analysis was performed at 37 degrees C and 33 degrees C using control rat microsomes. Measurements and Main Results: Mild hypothermia decreased the systemic clearance of both fentanyl (61.5 +/- 11.5 to 48.9 +/- 8.95 mL/min/kg; p < .05) and midazolam (89.2 +/- 12.5 to 73.6 +/- 12.1 mL/min/kg; p < .05) after cardiac arrest. The elevated systemic concentrations did not lead to parallel increased brain exposures of either drug. Mechanistically, no differences in cytochrome P450 3a2 expression was observed, but the in vitro metabolism of both drugs was decreased at 33 degrees C vs. 37 degrees C through reductions in enzyme metabolic capacity rather than substrate affinity. Conclusions: Mild hypothermia reduces the systemic clearances of fentanyl and midazolam in rats after cardiac arrest through alterations in cytochrome P450 3a2 metabolic capacity rather than enzyme affinity as observed with other cytochrome P450s. Contrasting effects on blood and brain levels further complicates drug dosing. Consideration of the impact of hypothermia on medications whose clearance is dependent on P450 3A metabolism is warranted. (Crit Care Med 2012; 40:1221-1228)	[Miller, Tricia M.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Empey, Philip E.; Philbrick, Ashley H.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Melick, John A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Poloyac, SM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA.	poloyac@pitt.edu	Philip Empey, PharmD/L-9604-2019; Kochanek, Patrick M/D-2371-2015	Philip Empey, PharmD/0000-0001-7474-2339; Kochanek, Patrick M/0000-0002-2627-913X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01GM073031, S10RR023461, P01NS30318]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024154]	Supported, in part, by the National Institutes of Health grants R01GM073031 (SMP), S10RR023461 (SMP), and P01NS30318 (PMK). Dr. Empey was supported by KL2RR024154 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bjorkman S, 2000, J PHARM PHARMACOL, V52, P1065, DOI 10.1211/0022357001774985; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; Bjorkman S, 1996, J PHARM SCI, V85, P887, DOI 10.1021/js960113+; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Cullen DJ, 1997, CRIT CARE MED, V25, P1289, DOI 10.1097/00003246-199708000-00014; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Empey P, 2009, CRIT CARE MED, V37, pA33; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Higashikawa F, 1999, J PHARM PHARMACOL, V51, P405, DOI 10.1211/0022357991772600; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Jin JS, 2006, NEUROL MED-CHIR, V46, P321, DOI 10.2176/nmc.46.321; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Link B, 2007, RAPID COMMUN MASS SP, V21, P1531, DOI 10.1002/rcm.2987; MOL WEM, 1988, J PHARMACOL EXP THER, V244, P268; Nishida K, 2007, BIOL PHARM BULL, V30, P1763, DOI 10.1248/bpb.30.1763; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Pang K S, 1977, J Pharmacokinet Biopharm, V5, P625, DOI 10.1007/BF01059688; Pang K S, 1977, J Pharmacokinet Biopharm, V5, P655, DOI 10.1007/BF01059689; PANG SK, 1977, J PHARMACOKINET BIOP, V5, P681; Rockich K, 1999, DRUG METAB DISPOS, V27, P1074; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; SCOPES RK, 1995, CLIN CHIM ACTA, V237, P17, DOI 10.1016/0009-8981(95)06060-Q; Spriet I, 2009, INTENS CARE MED, V35, P603, DOI 10.1007/s00134-008-1383-2; Statler KD, 2003, CRIT CARE MED, V31, P1134, DOI 10.1097/01.CCM.0000054864.43122.52; Tortorici MA, 2006, CRIT CARE MED, V34, P785, DOI 10.1097/01.CCM.0000201899.52739.4F; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Tortorici MA, 2009, CRIT CARE MED, V37, P263, DOI 10.1097/CCM.0b013e3181931ed3; Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127	36	42	42	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2012	40	4					1221	1228		10.1097/CCM.0b013e31823779f9			8	Critical Care Medicine	General & Internal Medicine	912QC	WOS:000301813700024	22067624	Green Accepted			2020-06-30	J	Dong, ZL; Li, H; Chen, QX; Hu, Y; Wu, SJ; Tang, LY; Gong, WY; Xie, GH; Fang, XM				Dong, Z-L; Li, H.; Chen, Q-X.; Hu, Y.; Wu, S-J.; Tang, L-Y; Gong, W-Y; Xie, G-H.; Fang, X-M.			Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article						cytochrome P450 3A4; fentanyl; patient-controlled analgesia; single nucleotide polymorphisms	MU-OPIOID RECEPTOR; SINGLE NUCLEOTIDE POLYMORPHISM; MORPHINE CONSUMPTION; GENETIC-POLYMORPHISM; POSTOPERATIVE PAIN; DRUG-INTERACTIONS; ASSOCIATION; VARIABILITY; METABOLISM; PHARMACOKINETICS	What is known and Objective: Clinical investigations into postoperative intravenous patient-controlled analgesia (PCA) have indicated interindividual differences in fentanyl consumption. Cytochrome P450 3A4 (CYP3A4) is the main metabolism enzyme of fentanyl, and single nucleotide polymorphisms within the CYP3A4 gene may contribute to the variability of fentanyl analgesic efficacy. The aim of this study was to investigate whether the most common genetic variation in Chinese, CYP3A4*1G, has an impact on the fentanyl consumption for intravenous PCA in Chinese Han women undergone abdominal total hysterectomy. Methods: A total of 79 female patients (American Society of Anesthesiologist physical status I or II) scheduled to undergo elective abdominal total hysterectomy were enrolled. All patients received combined spinal-epidural anaesthesia with bupivacaine. Intravenous fentanyl PCA was provided postoperatively for satisfactory analgesia. The doses of fentanyl consumption were recorded 2, 4, 24 and 48 h after the initiation of PCA postoperatively. Pain at rest and adverse effects were measured with rating scales. CYP3A4*1G was screened by means of direct sequencing and further confirmed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results and Discussion: Forty-six patients were GG homozygotes, 27 patients were GA heterozygotes, and six patients were AA homozygotes, respectively. The distribution of the CYP3A4* 1G allele was consistent with Hardy-Weinberg equilibrium (P > 0 05). At 2 and 4 h, the doses of fentanyl required for patients with GA/AA genotypes were 80 0 (45.0, 112.5) mu g and 120.0 (80, 173.8) lg, respectively, and significantly lower than those for GG homozygotes [91 3 (80.0, 125.0) mu g and 169 0 (112.5, 226.3) lg, respectively, P < 0 05]. There was trend of decreasing fentanyl consumption at 24 and 48 h in patients with GA/AA genotypes, relative to GG homozygotes, but the difference was not statistical significant (P > 0 05). What is new and Conclusions: CYP3A4* 1G has an impact on the analgesic effect of fentanyl in Chinese Han subjects. Further validation of our results in a well-powered study would be helpful.	[Li, H.; Chen, Q-X.; Hu, Y.; Wu, S-J.; Xie, G-H.; Fang, X-M.] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Anesthesiol, Hangzhou 310003, Zhejiang, Peoples R China; [Dong, Z-L] Tongji Univ, Tongji Hosp, Dept Rehabil Med, Shanghai 200092, Peoples R China; [Tang, L-Y] Shanghai Changning Dist Cent Hosp, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Gong, W-Y] Shanghai First Peoples Hosp, Baoshan Branch, Dept Anesthesiol, Shanghai, Peoples R China	Fang, XM (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Anesthesiol, Qingchun Rd 79, Hangzhou 310003, Zhejiang, Peoples R China.	xiangming_fang@163.com			National Science Fund for Distinguished Young ScholarsNational Natural Science Foundation of ChinaNational Science Fund for Distinguished Young Scholars [30825037]; Changjiang Scholar Program of China; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talent; Shanghai Health Bureau [2008101]	This study was supported by National Science Fund for Distinguished Young Scholars (30825037), Changjiang Scholar Program of China, Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talent, and a grant from Shanghai Health Bureau (2008101).	Bessler H, 2006, NEUROSCI LETT, V404, P154, DOI 10.1016/j.neulet.2006.05.030; Chen QX, 2008, HUM IMMUNOL, V69, P220, DOI 10.1016/j.humimm.2008.01.013; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; Gao Y, 2008, EUR J CLIN PHARMACOL, V64, P877, DOI 10.1007/s00228-008-0502-x; Hu YF, 2006, CLIN EXP PHARMACOL P, V33, P1093, DOI 10.1111/j.1440-1681.2006.04492.x; Janicki PK, 2006, ANESTH ANALG, V103, P1011, DOI 10.1213/01.ane.0000231634.20341.88; Klees TM, 2005, ANESTHESIOLOGY, V102, P550, DOI 10.1097/00000542-200503000-00012; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Landau R, 2006, ANESTHESIOLOGY, V105, P235, DOI 10.1097/00000542-200608000-00003; Liu CH, PHARMACOGENOMICS, V6, P731; Rodriguez-Antona C, 2005, BIOCHEM BIOPH RES CO, V338, P299, DOI 10.1016/j.bbrc.2005.09.020; Romberg RR, 2005, ANESTHESIOLOGY, V102, P522, DOI 10.1097/00000542-200503000-00008; Samer CF, 2005, CAN J ANAESTH, V52, P806, DOI 10.1007/BF03021775; Sarton E, 2003, ADV EXP MED BIOL, V523, P71; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Solus JF, 2004, PHARMACOGENOMICS, V5, P895, DOI 10.1517/14622416.5.7.895; Tan EC, 2008, J PAIN, V9, P849, DOI 10.1016/j.jpain.2008.04.004; Tateishi T., 1996, Anesthesia and Analgesia, V82, P167, DOI 10.1097/00000539-199601000-00031; Wallden J, 2008, ACTA ANAESTH SCAND, V52, P708, DOI 10.1111/j.1399-6576.2008.01624.x; Xiao JH, 2006, GENET MOL BIOL, V29, P562, DOI 10.1590/S1415-47572006000300028	20	30	34	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-4727	1365-2710		J CLIN PHARM THER	J. Clin. Pharm. Ther.	APR	2012	37	2					153	156		10.1111/j.1365-2710.2011.01268.x			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	903JB	WOS:000301111400006	21535061				2020-06-30	J	Zelaya, FO; Zois, E; Muller-Pollard, C; Lythgoe, DJ; Lee, S; Andrews, C; Smart, T; Conrod, P; Vennart, W; Williams, SCR; Mehta, MA; Reed, LJ				Zelaya, Fernando O.; Zois, Evangelos; Muller-Pollard, Christopher; Lythgoe, David J.; Lee, Sarah; Andrews, Caroline; Smart, Trevor; Conrod, Patricia; Vennart, William; Williams, Steven C. R.; Mehta, Mitul A.; Reed, Laurence J.			The response to rapid infusion of fentanyl in the human brain measured using pulsed arterial spin labelling	MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE			English	Article						Arterial spin labelling; Perfusion; Blood flow; Opioid; Fentanyl; Naloxone	CEREBRAL-BLOOD-FLOW; RECEPTOR-BINDING; OPIOID RECEPTOR; DOPAMINE RELEASE; PERFUSION; BOLD; ACTIVATION; NALOXONE; MU; REMIFENTANIL	We evaluated the sensitivity of pulsed Arterial Spin Labelling (pASL) for the detection of changes in regional cerebral blood perfusion (CBP) during and after intra-venous (i.v.) infusion of an opioid agonist (fentanyl) and an opioid antagonist (naloxone). Twenty-three subjects were scanned four times, receiving i.v. infusion of fentanyl, naloxone, placebo and a second fentanyl administration, in four separate scanning sessions in randomised order. End-tidal CO2, respiration rate and heart rate were recorded continuously throughout each scan. pASL time series were collected using single shot EPI for 15 min (including 5 min of baseline prior to infusion). Significant increases in CBP were detected during and after administration of fentanyl, (when compared to placebo and naloxone), in most areas of high concentration of mu-opioid receptors (thalamus, lingual gyrus, para-hippocampal gyrus, and insula); near-significant increases were also observed in the insula. No increases in perfusion were observed during or after naloxone infusion. No correlation was found between regional rCBF changes and end-tidal CO2, respiration rate or heart rate. Good reliability was found between the first and second fentanyl sessions but the regions of high reliability did not overlap completely with those of highest perfusion change. pASL is a suitable method for examining rapid, dynamic effects of opioid administration on brain physiology.	[Zelaya, Fernando O.; Lythgoe, David J.; Lee, Sarah; Andrews, Caroline; Williams, Steven C. R.; Mehta, Mitul A.] Kings Coll London, Inst Psychiat, Ctr Neuroimaging Sci, Dept Neuroimaging, London SE5 8AF, England; [Zois, Evangelos] Dept Addict Behav & Addict Med, D-68159 Mannheim, Germany; [Muller-Pollard, Christopher; Conrod, Patricia] Kings Coll London, Inst Psychiat, Dept Addict, London SE5 8AF, England; [Smart, Trevor; Vennart, William] Pfizer Global Res & Dev, Sandwich, Kent, England; [Reed, Laurence J.] Univ London Imperial Coll Sci Technol & Med, Neuropsychopharmacol Unit, London, England	Zelaya, FO (reprint author), Kings Coll London, Inst Psychiat, Ctr Neuroimaging Sci, Dept Neuroimaging, De Crespigny Pk, London SE5 8AF, England.	fernando.zelaya@kcl.ac.uk	Conrod, Patricia J/P-4187-2018; Lythgoe, David J/E-5275-2010; Zelaya, Fernando O/I-3125-2012; Mehta, Mitul/F-3960-2010; Williams, Steve C/D-6979-2011	Zelaya, Fernando O/0000-0002-9525-1560; Williams, Steve C/0000-0003-4299-1941; Lee, Sarah/0000-0002-4130-1892; Lythgoe, David/0000-0002-5078-9025; opoku, anita/0000-0001-7243-8157	Pfizer Pharmaceuticals UKPfizer	The authors are grateful to Pfizer Pharmaceuticals UK for funding towards this project, to Mr Jeffrey Dalton for help with the implementation of software for the measurement of physiological variables and to Dr Eric Wong for providing a hyperbolic secant adiabatic RF pulse for use with arterial spin labelling.	Adler LJ, 1997, ANESTH ANALG, V84, P120, DOI 10.1097/00000539-199701000-00023; Aguirre GK, 2002, NEUROIMAGE, V15, P488, DOI 10.1006/nimg.2001.0990; Baumgartner U, 2006, NEUROIMAGE, V30, P692, DOI 10.1016/j.neuroimage.2005.10.033; Borras MC, 2004, J NEUROPHYSIOL, V91, P2723, DOI 10.1152/jn.00249.2003; Brett M, 2002, NEUROIMAGE, V16, P2, DOI DOI 10.1016/S1053-8119(02)90010-8; Bullmore ET, 2003, CEREB CORTEX, V13, P144, DOI 10.1093/cercor/13.2.144; Caceres A, 2009, NEUROIMAGE, V45, P758, DOI 10.1016/j.neuroimage.2008.12.035; Detre JA, 1999, EUR J RADIOL, V30, P115, DOI 10.1016/S0720-048X(99)00050-9; Detre JA, 2002, CLIN NEUROPHYSIOL, V113, P621, DOI 10.1016/S1388-2457(02)00038-X; DEVINE JO, 1995, BRAIN RES, V675, P257, DOI 10.1016/0006-8993(95)00081-Z; Fernandez-Seara MA, 2011, BRIT J PHARMACOL, V163, P1639, DOI 10.1111/j.1476-5381.2010.01161.x; Firestone LL, 1996, ANESTH ANALG, V82, P1247, DOI 10.1097/00000539-199606000-00025; First M.B., 2002, BIOMETRICS RES; Franceschini MA, 2010, NEUROIMAGE, V51, P1367, DOI 10.1016/j.neuroimage.2010.03.060; Frost JJ, 2001, NUCL MED BIOL, V28, P509, DOI 10.1016/S0969-8051(01)00221-9; Glascher J, 2008, SPM NOTES SPM LIB LI; Handley R, 2011, HUM BRAIN M IN PRESS; Hayasaka S, 2004, NEUROIMAGE, V22, P676, DOI 10.1016/j.neuroimage.2004.01.041; Honey GD, 2003, BRAIN, V126, P1767, DOI 10.1093/brain/awg184; Kofke WA, 2007, ANESTH ANALG, V105, P167, DOI 10.1213/01.ane.0000266490.64814.ff; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kornetsky C, 1995, NIDA Res Monogr, V147, P33; Kurata, 1999, Curr Rev Pain, V3, P359; Lappin JM, 2009, J CEREBR BLOOD F MET, V29, P554, DOI 10.1038/jcbfm.2008.146; Liu TT, 2005, NEUROIMAGE, V24, P207, DOI 10.1016/j.neuroimage.2004.09.047; MacIntosh BJ, 2008, J CEREBR BLOOD F MET, V28, P1514, DOI 10.1038/jcbfm.2008.46; Martin-Soelch C, 2001, EUR J NEUROSCI, V14, P1360, DOI 10.1046/j.0953-816x.2001.01753.x; Martinez D, 2003, J CEREBR BLOOD F MET, V23, P285, DOI 10.1097/01.WCB.0000048520.34839.1A; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30; Melichar JK, 2003, EUR J PHARMACOL, V459, P217, DOI 10.1016/S0014-2999(02)02872-8; Mulderink TA, 2002, NEUROIMAGE, V15, P37, DOI 10.1006/nimg.2001.0973; O'Gorman RL, 2008, NEUROIMAGE, V42, P36, DOI 10.1016/j.neuroimage.2008.04.169; Ozaki S, 2002, J NEUROCHEM, V82, P1192, DOI 10.1046/j.1471-4159.2002.01071.x; PEROUTKA SJ, 1980, SCIENCE, V208, P610, DOI 10.1126/science.6102801; Perthen JE, 2008, NEUROIMAGE, V40, P237, DOI 10.1016/j.neuroimage.2007.10.049; PFEIFFER A, 1982, BRAIN RES, V248, P87, DOI 10.1016/0006-8993(82)91150-7; Schad CA, 2002, J PHARMACOL EXP THER, V300, P932, DOI 10.1124/jpet.300.3.932; Schlaepfer TE, 1998, AM J PSYCHIAT, V155, P470, DOI 10.1176/ajp.155.4.470; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Stefanovic B, 2006, NEUROIMAGE, V30, P726, DOI 10.1016/j.neuroimage.2005.10.038; van Hell HH, 2011, INT J NEUROPSYCHOPH, V14, P1377, DOI 10.1017/S1461145711000526; Velasco M, 1998, STEREOT FUNCT NEUROS, V71, P90; VILLIGER JW, 1983, NEUROPHARMACOLOGY, V22, P447, DOI 10.1016/0028-3908(83)90162-4; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Wise RG, 2004, NEUROIMAGE, V21, P1652, DOI 10.1016/j.neuroimage.2003.11.025; Wong EC, 1997, NMR BIOMED, V10, P237, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<237::AID-NBM475>3.0.CO;2-X; Worsley KJ, 1999, HUM BRAIN MAPP, V8, P98, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<98::AID-HBM5>3.0.CO;2-F; Young KA, 2007, BIOL PSYCHIAT, V61, P813, DOI 10.1016/j.biopsych.2006.08.047; ZACNY JP, 1992, PSYCHOPHARMACOLOGY, V107, P319, DOI 10.1007/BF02245155; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	50	16	16	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0968-5243	1352-8661		MAGN RESON MATER PHY	Magn. Reson. Mat. Phys. Biol. Med.	APR	2012	25	2			SI		163	175		10.1007/s10334-011-0293-4			13	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	918KE	WOS:000302247600011	22113518				2020-06-30	J	Makkar, JK; Ghai, B; Bhardwaj, N; Wig, J				Makkar, Jeetinder K.; Ghai, Babita; Bhardwaj, Neerja; Wig, Jyotsna			Minimum alveolar concentration of desflurane with fentanyl for laryngeal mask airway removal in anesthetized children	PEDIATRIC ANESTHESIA			English	Article						age; pediatrics; airway; laryngeal mask; end tidal concentration; ED50; inhalation; desflurane	TRACHEAL EXTUBATION; AWAKE REMOVAL; ANESTHESIA; SEVOFLURANE; ISOFLURANE; ENFLURANE; EMERGENCE; RECOVERY	Background: Desflurane provides rapid emergence from anesthesia. So, it can be used for the removal of a laryngeal mask airway in an anesthetized child. We conducted this study to determine the optimal endtidal concentrations of desflurane with fentanyl that would allow removal of a laryngeal mask airway without airway complication in children. Methods: Thirty-six children of American Society of Anesthesiologist status I between 1 and 10 year of age undergoing ophthalmic surgery were recruited. General anesthesia was induced with sevoflurane and oxygen given via mask and laryngeal mask airway inserted. Anesthesia was maintained with desflurane in 100% oxygen. At the end of the surgery, predetermined target concentration was maintained for 10 min and laryngeal mask airway removed. Each target concentration at the time of removal was predetermined by the Dixon up-down method (with 0.5% as a step size) starting at 5% endtidal concentration. A removal accomplished without coughing, teeth clenching, gross purposeful movement, breath holding, or laryngospasm, during or within 1 min after removal, was considered to be successful. Results: Endtidal concentration of desflurane required for successful laryngeal mask airway removal in 50% (ED50) was 3.56% desflurane (95% confidence limits, 3.22-3.87%) along with fentanyl. Conclusion: Removal of laryngeal mask airway can be safely accomplished without coughing, moving, or any other airway complications at 3.57%	[Makkar, Jeetinder K.; Ghai, Babita; Bhardwaj, Neerja; Wig, Jyotsna] Post Grad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh, India	Makkar, JK (reprint author), PGIMER, Dept Anaesthesia, Sect 12, Chandigarh 160012, India.	jeet1516@gmail.com					Cohen IT, 2001, ANESTH ANALG, V93, P88; Cranfield KAW, 1997, BRIT J ANAESTH, V78, P370; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; Docquier MA, 2003, ANESTH ANALG, V97, P1033, DOI 10.1213/01.ANE.0000078587.51622.D0; Dolling S, 2003, ANAESTHESIA, V58, P1224, DOI 10.1046/j.1365-2044.2003.03413.x; GATAURE PS, 1995, CAN J ANAESTH, V42, P1113, DOI 10.1007/BF03015098; Ghai B, 2008, PEDIATR ANESTH, V18, P308, DOI 10.1111/j.1460-9592.2008.02434.x; Howard R, 2008, PEDIATR ANESTH, V18, P36, DOI 10.1111/j.1460-9592.2008.02431.x; JONES RM, 1990, BRIT J ANAESTH, V64, P11, DOI 10.1093/bja/64.1.11; Joseph PC, 2001, CLIN ANESTH, P1199; Kitching AJ, 1996, BRIT J ANAESTH, V76, P874; Kong CF, 2000, BRIT J ANAESTH, V85, P364, DOI 10.1093/bja/85.3.364; Lee JR, 2007, ANESTH ANALG, V104, P528, DOI 10.1213/01.ane.0000253035.96490.22; Lerman J, 2010, PEDIATR ANESTH, V20, P495, DOI 10.1111/j.1460-9592.2010.03305.x; Nordmann GR, 2006, BRIT J ANAESTH, V96, P779, DOI 10.1093/bja/ael092; Pappas AL, 2001, J CLIN ANESTH, V13, P498, DOI 10.1016/S0952-8180(01)00318-X; Samarkandi AH, 1998, CAN J ANAESTH, V45, P150, DOI 10.1007/BF03013254; Shim YH, 2005, ANESTH ANALG, V101, P1034, DOI 10.1213/01.ane.0000166977.17442.63; SMITH I, 1994, ANESTH ANALG, V79, P642; Splinter WM, 1997, J CLIN ANESTH, V9, P4, DOI 10.1016/S0952-8180(96)00217-6; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; TerRiet MF, 2000, BRIT J ANAESTH, V85, P305, DOI 10.1093/bja/85.2.305; Valley RD, 2003, ANESTH ANALG, V96, P1320, DOI 10.1213/01.ANE.0000058844.77403.16; Xiao WJ, 2002, CAN J ANAESTH, V49, P194, DOI 10.1007/BF03020495; Xiao WJ, 2001, ANESTH ANALG, V92, P72	25	4	6	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2012	22	4					335	340		10.1111/j.1460-9592.2011.03712.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	901SJ	WOS:000300986800004	22017661				2020-06-30	J	Lim, B; Pawar, D; Ng, O				Lim, Beatrice; Pawar, Dilip; Ng, Oriana			Pressure support ventilation vs spontaneous ventilation via ProSeal (TM) laryngeal mask airway in pediatric patients undergoing ambulatory surgery: a randomized controlled trial	PEDIATRIC ANESTHESIA			English	Article						pressure support ventilation; spontaneous ventilation; pediatric anesthesia; ambulatory surgery		Aim: To investigate the advantages of using pressure support ventilation (PSV) vs spontaneous ventilation via ProSeal (TM) laryngeal mask airway in children undergoing ambulatory surgery. Background: In our ambulatory surgical unit, the use of unassisted spontaneous breathing via laryngeal mask airway is a common anesthetic technique during general anesthesia. However, this may be associated with inadequate ventilation. PSV is a ventilatory mode that is synchronized with the patient's respiratory effort and may improve gaseous exchange under general anesthesia. Materials and methods: After the approval from the ethics committee, a randomized controlled trial involving 24 pediatric patients was conducted in our ambulatory surgical unit. They were randomized into two groups, namely Group PSV (receiving PSV) and Group SV (unassisted spontaneous ventilation). Outcome measures included intraoperative respiratory and hemodynamic parameters as well as recovery room data. Results: There were no significant differences in baseline characteristics between the two groups. Patients in Group PSV had lower ETCO2 (42.8 +/- 5.8 vs 50.4 +/- 4.0, P = 0.001) and higher expiratory tidal volume per kg bodyweight (8.3 +/- 1.8 ml kg(-1) vs 5.8 +/- 0.8 ml kg(-1), P = 0.001) compared with patients in Group SV. There were no significant differences in other respiratory and hemodynamic parameters or recovery room data between the two groups. Conclusion: Pressure support ventilation via ProSeal TM laryngeal mask airway during general anesthesia improves ventilation in pediatric patients undergoing ambulatory surgery. However, this did not translate to a difference in clinical outcome among our study patients.	[Lim, Beatrice; Pawar, Dilip; Ng, Oriana] KK Womens & Childrens Hosp, Dept Pediat Anesthesia, Singapore, Singapore	Lim, B (reprint author), Blk 420,Tampines St 41,09-118, Singapore 520420, Singapore.	limchinling@gmail.com					Cereda M, 2000, CRIT CARE MED, V28, P1269, DOI 10.1097/00003246-200005000-00002; Farias JA, 2004, INTENS CARE MED, V30, P918, DOI 10.1007/s00134-004-2225-5; Garcia-Fernandez J, 2007, ANESTH ANALG, V105, P1585, DOI 10.1213/01.ane.0000287674.64086.f1; Hoshi K, 2001, TOHOKU J EXP MED, V194, P45, DOI 10.1620/tjem.194.45; TOKIOKA H, 1993, ANESTHESIOLOGY, V78, P880, DOI 10.1097/00000542-199305000-00012; Tokioka H, 1997, ANESTH ANALG, V85, P789, DOI 10.1097/00000539-199710000-00013; TUSIEWICZ K, 1977, ANESTHESIOLOGY, V47, P327, DOI 10.1097/00000542-197710000-00002; von Goedecke A, 2005, ANESTH ANALG, V100, P357, DOI 10.1213/01.ANE.0000143563.39519.FD; YAMAKAGE M, 1994, [No title captured], V4, P53	9	8	12	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2012	22	4					360	364		10.1111/j.1460-9592.2012.03819.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	901SJ	WOS:000300986800009	22380745				2020-06-30	J	Hoemberg, M; Vierzig, A; Roth, B; Eifinger, F				Hoemberg, Marc; Vierzig, Anne; Roth, Bernhard; Eifinger, Frank			Plasma fluoride concentrations during prolonged administration of isoflurane to a pediatric patient requiring renal replacement therapy	PEDIATRIC ANESTHESIA			English	Letter							SEDATION		[Hoemberg, Marc; Vierzig, Anne; Roth, Bernhard; Eifinger, Frank] Univ Childrens Hosp, Dept Neonatol & Pediat Intens Care, Cologne, Germany	Hoemberg, M (reprint author), Univ Childrens Hosp, Dept Neonatol & Pediat Intens Care, Cologne, Germany.	marc.hoemberg@uk-koeln.de					Kharasch ED, 2006, ANESTHESIOLOGY, V105, P726, DOI 10.1097/00000542-200610000-00019; Nishiyama T, 1996, ANESTH ANALG, V83, P574, DOI 10.1097/00000539-199609000-00024; Sackey PV, 2005, PEDIATR ANESTH, V15, P879, DOI 10.1111/j.1460-9592.2005.01704.x; Soukup J, 2009, J CRIT CARE, V24, P535, DOI 10.1016/j.jcrc.2009.01.003; SPENCER EM, 1991, ANESTH ANALG, V73, P731	5	1	1	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2012	22	4					412	413		10.1111/j.1460-9592.2012.03814.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	901SJ	WOS:000300986800019	22380747				2020-06-30	J	Lin, BF; Ju, DT; Cherng, CH; Hung, NK; Yeh, CC; Chan, SM; Wu, CT				Lin, Bo-Feng; Ju, Da-Tong; Cherng, Chen-Hwan; Hung, Nan-Kai; Yeh, Chun-Chang; Chan, Shun-Ming; Wu, Ching-Tang			Comparison Between Intraoperative Fentanyl and Tramadol to Improve Quality of Emergence	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						emergence quality; cough; tramadol; fentanyl; lumbar microdiscectomy	TOTAL INTRAVENOUS ANESTHESIA; RECEPTOR-INDUCED RESPONSES; POSTOPERATIVE SORE THROAT; TRACHEAL EXTUBATION; GENERAL-ANESTHESIA; XENOPUS OOCYTES; PRIOR INJECTION; LIDOCAINE; COUGH; ISOFLURANE	Background: Cough causes poor quality of emergence from anesthesia and risks of several complications. We compared fentanyl and an antitussive action of tramadol on the quality of emergence and postoperative outcome. Methods: A total of 110 adults (18 to 83 y) of American Society of Anesthesiologists physical status I-III undergoing elective lumbar microdiscectomy with intubated total intravenous anesthesia were randomly divided into 2 groups of 55 each. The patients assigned to the fentanyl group received a dose of 1 mg/kg of fentanyl, whereas those assigned to the tramadol group received 1mg/kg of tramadol, at the beginning of skin closure. We recorded the incidence of cough, quality of extubation at fixed times, maximal heart rates, maximal blood pressure during emergence, postoperative pain scores, and consumption of fentanyl. In addition, postoperative sore throat (POST), hoarseness, postoperative nausea and vomiting, and other anesthetic and surgical-related complications were recorded. Results: Tramadol reduced cough incidence, improved extubation quality, and provided more stable hemodynamics during emergence. There was no significant difference in postoperative pain, fentanyl consumption, incidence and severity of POST, hoarseness, and postoperative nausea and vomiting between groups. Moreover, we found that the incidence of POST did not correlate with cough incidence. Conclusions: A dose of 1 mg/kg of tramadol administered intravenously 30 minutes before the expected extubation, compared with 1 mg/kg of fentanyl, decreased cough incidence, improved emergence quality, and provided stable hemodynamics. However, there was no significant difference between tramadol and fentanyl in pain scores and fentanyl consumption postoperatively.	[Lin, Bo-Feng; Cherng, Chen-Hwan; Hung, Nan-Kai; Yeh, Chun-Chang; Chan, Shun-Ming; Wu, Ching-Tang] Triserv Gen Hosp, Dept Anesthesiol, Natl Def Med Ctr, Taipei 114, Taiwan; [Ju, Da-Tong] Triserv Gen Hosp, Dept Neurosurg, Natl Def Med Ctr, Taipei 114, Taiwan	Wu, CT (reprint author), Triserv Gen Hosp, Dept Anesthesiol, Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.	aneswu@gmail.com	Hung, Nan-Kai/C-7178-2016	Hung, Nan-Kai/0000-0002-1853-0793	Tri-Service General Hospital of Taiwan, Republic of China [TSGH-C99-157]	Supported by grants from Tri-Service General Hospital (TSGH-C99-157) of Taiwan, Republic of China. The authors have no conflicts of interest to disclose.	BIDWAI AV, 1979, ANESTHESIOLOGY, V51, P171, DOI 10.1097/00000542-197908000-00020; Chiaretti A, 2000, CHILD NERV SYST, V16, P93, DOI 10.1007/s003810050019; Fagan C, 2000, ANESTH ANALG, V91, P201; GEFKE K, 1983, ACTA ANAESTH SCAND, V27, P111, DOI 10.1111/j.1399-6576.1983.tb01917.x; Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088-200443130-00004; Hans P, 2008, BRIT J ANAESTH, V101, P731, DOI 10.1093/bja/aen271; Hara K, 2005, ANESTH ANALG, V100, P1400, DOI 10.1213/01.ANE.0000150961.24747.98; Higgins PP, 2002, BRIT J ANAESTH, V88, P582, DOI 10.1093/bja/88.4.582; Hohlrieder M, 2007, BRIT J ANAESTH, V99, P587, DOI 10.1093/bja/aem203; Irwin RS, 2006, CHEST, V129, p54S, DOI 10.1378/chest.129.1_suppl.54S; KAMEI J, 1989, EUR J PHARMACOL, V168, P153; Kamei J, 1996, PULM PHARMACOL THER, V9, P349, DOI 10.1006/pulp.1996.0046; KAMEI J, 1992, EUR J PHARMACOL, V212, P61, DOI 10.1016/0014-2999(92)90072-C; Koga K, 1998, ANAESTHESIA, V53, P540, DOI 10.1046/j.1365-2044.1998.00397.x; Kuo Chang-Po, 2006, Acta Anaesthesiol Taiwan, V44, P205; LEECH P, 1974, BRIT J ANAESTH, V46, P315, DOI 10.1093/bja/46.4.315-a; Louly PG, 2009, CLIN THER, V31, P1007, DOI 10.1016/j.clinthera.2009.05.015; Maruyama K, 2004, BRIT J ANAESTH, V92, P541, DOI 10.1093/bja/aeh098; McHardy FE, 1999, ANAESTHESIA, V54, P444, DOI 10.1046/j.1365-2044.1999.00780.x; MENDEL P, 1995, J CLIN ANESTH, V7, P114, DOI 10.1016/0952-8180(94)00024-X; Minogue SC, 2004, ANESTH ANALG, V99, P1253, DOI 10.1213/01.ANE.0000132779.27085.52; NEELAKANTA G, 1994, ANESTHESIOLOGY, V80, P811, DOI 10.1097/00000542-199404000-00013; NISHINA K, 1995, ACTA ANAESTH SCAND, V39, P85, DOI 10.1111/j.1399-6576.1995.tb05597.x; Saghaei Mahmood, 2005, Acta Anaesthesiol Taiwan, V43, P205; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; Shajar MA, 1999, BRIT J ANAESTH, V83, P654; Shiga Y, 2002, ANESTH ANALG, V95, P1269, DOI 10.1097/00000539-200211000-00031; Shiraishi M, 2001, J PHARMACOL EXP THER, V299, P255; Valley RD, 1999, ANESTH ANALG, V88, P742, DOI 10.1097/00000539-199904000-00010; Yorukoglu D, 2006, J NEUROSURG ANESTH, V18, P165	30	13	14	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2012	24	2					127	132		10.1097/ANA.0b013e31823c4a24			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	902RJ	WOS:000301055900004	22089326				2020-06-30	J	Dogan, R; Karalezli, A; Sahin, D; Gumus, F				Dogan, Rafi; Karalezli, Aylin; Sahin, Durmus; Gumus, Funda			Comparison of Sedative Drugs Under Peribulbar or Topical Anesthesia During Phacoemulsification	OPHTHALMIC SURGERY LASERS & IMAGING			English	Article							CATARACT-SURGERY; INTRAOCULAR-PRESSURE; PATIENT COMFORT; LOCAL-ANESTHESIA; DEXMEDETOMIDINE; MIDAZOLAM; SATISFACTION; FENTANYL; RETROBULBAR; RECOVERY	BACKGROUND AND OBJECTIVE: To compare dexmedetomidine and midazolam+fentanyl sedation primarily based on patient satisfaction during phacoemulsification under topical and peribulbar anesthesia. PATIENTS AND METHODS: Prospective, randomized, and double-blind study of 80 American Society of Anesthesiology grade I-II patients who underwent phacoemulsification with local anesthesia under sedation. Patients were divided into four groups (20 patients for each): dexmedetomidine and topical anesthesia, dexmedetomidine and peribulbar anesthesia, midazolam+fentanyl and topical anesthesia, and midazolam+fentanyl and peribulbar anesthesia. Patient and surgeon satisfaction were determined on a 5-point scale. The pain was determined by verbal pain scale intraoperatively and postoperatively. Drugs were given to a Ramsay sedation scale of 3. Topical and peribulbar anesthesia were performed by an ophthalmologist. Hemodynamic, respiratory, and intraocular pressure monitoring was done. Operative and recovery times were recorded. RESULTS: In the midazolam+fentanyl groups, better patient and surgeon satisfaction scores were obtained (P < .005), verbal pain scale scores were significantly lower (P < .001), and patients needed less postoperative analgesia. Ramsay sedation scale scores were between 3 and 4 in all patients and there were no significant differences. Intraocular pressure alterations were similar between groups. Recovery time was longer in the dexmedetomidine groups (P < .05). CONCLUSION: The study demonstrated that the midazolam+fentanyl combination provided high-level patient satisfaction scores, low-level pain scores, and shorter recovery time. Also, both of the peribulbar and topical anesthesia procedures showed similar efficiency.	[Karalezli, Aylin] Baskent Univ, Dept Ophthalmol, TR-06490 Ankara, Turkey; [Dogan, Rafi; Sahin, Durmus; Gumus, Funda] Baskent Univ, Dept Anesthesiol, TR-06490 Ankara, Turkey	Karalezli, A (reprint author), Baskent Univ Hosp, TR-42080 Saray Caddesi, Konya, Turkey.	akaralezli@yahoo.com			Baskent University Research Committee, Ankara, TurkeyBaskent University	Supported by grants provided by Baskent University Research Committee, Ankara, Turkey.	Abdalla Mahmoud I M, 2006, J Anesth, V20, P54, DOI 10.1007/s00540-005-0351-z; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; Apan A, 2009, MINERVA ANESTESIOL, V75, P239; Aydin ON, 2004, J CLIN ANESTH, V16, P98, DOI 10.1016/j.jclinane.2003.05.008; Aydin ON, 2002, J CATARACT REFR SURG, V28, P1968, DOI 10.1016/S0886-3350(02)01429-3; Cok OY, 2008, ACTA ANAESTH BELG, V59, P27; Crandall AS, 1999, OPHTHALMOLOGY, V106, P60, DOI 10.1016/S0161-6420(99)90007-6; Erdurmus M, 2008, EUR J OPHTHALMOL, V18, P361; FITZGIBBON DR, 2001, BONICAS MANAGEMENT P, P623; Fung D, 2005, ANESTH ANALG, V100, P1644, DOI 10.1213/01.ANE.0000154206.81132.B9; Georgiou M, 2002, EUR J ANAESTH, V19, P819, DOI 10.1017/S0265021502001321; Gombos K, 2007, ACTA OPHTHALMOL SCAN, V85, P309, DOI 10.1111/j.1600-0420.2007.00924.x; Habib NE, 2004, J CATARACT REFR SURG, V30, P437, DOI 10.1016/S0886-3350(03)00557-1; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Judge AJ, 1997, OPHTHALMOLOGY, V104, P1373, DOI 10.1016/S0161-6420(97)30128-6; Kallio H, 2000, BRIT J ANAESTH, V85, P708, DOI 10.1093/bja/85.5.708; Mathew MRK, 2002, J CATARACT REFR SURG, V28, P1977, DOI 10.1016/S0886-3350(02)01369-X; Mowafi HA, 2008, BRIT J ANAESTH, V100, P485, DOI 10.1093/bja/aen020; Muttu S, 2005, J CATARACT REFR SURG, V31, P1845, DOI 10.1016/j.jcrs.2005.09.019; Rodrigues PA, 2008, EUR J OPHTHALMOL, V18, P356; Sator-Katzenschlager SM, 2004, EUR J ANAESTH, V21, P95, DOI 10.1017/S0265021504002030; SULLIVAN KL, 1983, OPHTHALMOLOGY, V90, P373; VARTIAINEN J, 1992, INVEST OPHTH VIS SCI, V33, P2019	24	5	5	0	3	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	1542-8877	1938-2375		OPHTHAL SURG LAS IM	Ophthalmic Surg. Lasers Imaging	MAR-APR	2012	43	2					121	127		10.3928/15428877-20120102-01			7	Ophthalmology; Surgery	Ophthalmology; Surgery	959VC	WOS:000305342900005	22320409				2020-06-30	J	Dang, D; Robinson, PC; Winnicki, S; Jersmann, HPA				Dang, D.; Robinson, P. C.; Winnicki, S.; Jersmann, H. P. A.			The safety of flexible fibre-optic bronchoscopy and proceduralist-administered sedation: a tertiary referral centre experience	INTERNAL MEDICINE JOURNAL			English	Article						bronchoscopy; complication; safety; sedation	UNITED-KINGDOM; COMPLICATIONS; PROPOFOL; MIDAZOLAM; GUIDELINES; PHYSICIANS; CHILDREN; YIELD	Background: Flexible fibre-optic bronchoscopy has become an essential investigation and is widely regarded as safe, but wider published prospective data regarding delayed complications are limited. There is continuing debate concerning the safety of proceduralist-administered sedation. We evaluated complication rates of bronchoscopy and proceduralist-administered sedation at our tertiary institution, and their clinical significance. Methods: Prospective evaluation of all patients undergoing bronchoscopy over a 12-month period at a tertiary referral centre. Immediate minor and major complications were documented within 4 h of bronchoscopy, delayed complications at 48 h, case notes and bronchoscopy records were reviewed 1 month later. Results: Five hundred and fifty-eight flexible fibre-optic bronchoscopies were performed, 216 with transbronchial biopsy or nodal aspiration, 19 had therapeutic airways intervention. The minor complication rate at 4 h was 4.12% (23), rising to 26% (145) at 48 h. All 2.2% (12) major complications occurred exclusively within 4 h of bronchoscopy. No complications could be attributed to proceduralist-administered sedation. Discussion: Complication rates at 4 h were comparable with previously reported data. Delayed minor complications were greater than expected, and did not require additional medical input. There were no complications from proceduralist-administered sedation. Flexible fibre-optic bronchoscopy and proceduralist-administered sedation within our institution's guidelines are safe.	[Dang, D.; Robinson, P. C.; Winnicki, S.; Jersmann, H. P. A.] Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA 5000, Australia	Dang, D (reprint author), Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA 5000, Australia.	dien.dang@health.sa.gov.au			Boehringer Ingelheim Pty Ltd.Boehringer Ingelheim	This manuscript is not industry sponsored. Dr Peter Carter Robinson has received fees as a speaker at several educational symposia sponsored by Boehringer Ingelheim Pty Ltd. These honoraria are completely unrelated to the conception or carrying out of this project.	Alamoudi OS, 2000, SAUDI MED J, V21, P1043; Alzeer AH, 2008, SAUDI MED J, V29, P55; [Anonymous], 2001, THORAX, V56, P1; [Anonymous], 2008, PROFESSIONAL STANDAR; [Anonymous], 2002, ANESTHESIOLOGY, V96, P1004; Barlow D, 2001, IMPLEMENTING ENSURIN; Clark G, 2009, EUR RESPIR J, V34, P1277, DOI 10.1183/09031936.00142108; CRAWFORD M, 1993, BRIT J ANAESTH, V70, P419, DOI 10.1093/bja/70.4.419; de Blic J, 2002, EUR RESPIR J, V20, P1271, DOI 10.1183/09031936.02.02072001; DREISIN RB, 1978, CHEST, V74, P144, DOI 10.1378/chest.74.2.144; Ernst A, 2003, CHEST, V123, P1693, DOI 10.1378/chest.123.5.1693; Jin FG, 2008, RESPIRATION, V76, P429, DOI 10.1159/000151656; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; McLean AN, 1998, RESP MED, V92, P1110, DOI 10.1016/S0954-6111(98)90403-6; Pereira JW, 1978, CHEST, V73, P813; Pickles J, 2003, EUR RESPIR J, V22, P203, DOI 10.1183/09031936.03.00118302; PUE CA, 1995, CHEST, V107, P430, DOI 10.1378/chest.107.2.430; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; SIMPSON FG, 1986, THORAX, V41, P311, DOI 10.1136/thx.41.4.311; Smyth CM, 2002, EUR RESPIR J, V19, P458, DOI 10.1183/09031936.02.00103702; SURATT PM, 1976, CHEST, V69, P747, DOI 10.1378/chest.69.6.747; Wehrmann T, 1999, GASTROINTEST ENDOSC, V49, P677, DOI 10.1016/S0016-5107(99)70281-6	22	13	13	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1444-0903			INTERN MED J	Intern. Med. J.	MAR	2012	42	3					300	305		10.1111/j.1445-5994.2010.02261.x			6	Medicine, General & Internal	General & Internal Medicine	911LE	WOS:000301717500018	20492004				2020-06-30	J	Krishnamurthy, RB; Upton, RN; Fajumi, AO; Lai, S; Charlton, CS; Ousley, RM; Martinez, AM; McConnell, H; O'Connor, SN; Ong, J; Macintyre, PE; Chapman, MJ; Ludbrook, GL				Krishnamurthy, R. B.; Upton, R. N.; Fajumi, A. O.; Lai, S.; Charlton, C. S.; Ousley, R. M.; Martinez, A. M.; McConnell, H.; O'Connor, S. N.; Ong, J.; Macintyre, P. E.; Chapman, M. J.; Ludbrook, G. L.			Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort	ANAESTHESIA AND INTENSIVE CARE			English	Article						oxycodone; pharmacokinetics; subcutaneous; critically ill	MORPHINE; ANALGESIA	This study aimed to characterise and compare the absorption pharmacokinetics of a single subcutaneous dose of oxycodone in critically ill patients and healthy subjects. Blood samples taken at intervals from two minutes to eight hours after a subcutaneous dose of oxycodone in patients (5 mg) and healthy volunteers (10 mg) were assayed using high performance liquid chromatography. Data were analysed using a non-compartmental approach and presented as mean (SD). Parameters were corrected for dose differences between the groups assuming linear kinetics. Ten patients (eight male, two female) and seven healthy male subjects were included. Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 +/- 0.06 vs 0.05 +/- 0.02 mu g/ml (P <0.0001); area under the concentration curve 19.50 +/- 9.15 vs 9.72 +/- 2.71 mu g/ml*minute (P <0.001) respectively. However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 +/- 18.0 vs 20.50 +/- 16.10 minutes (P=0.81); mean residence time 353 +/- 191 vs 291 +/- 80 minutes (P=0.26). Kinetic parameters were less variable in patients than in volunteers. The patients therefore had reduced exposure to subcutaneous oxycodone. This warrants further model-based analysis and experimentation. Dose regimens for subcutaneous oxycodone developed in healthy volunteers cannot be directly translated to critically ill patients.	[Krishnamurthy, R. B.; Upton, R. N.; Fajumi, A. O.; Lai, S.; Charlton, C. S.; Ousley, R. M.; Martinez, A. M.; McConnell, H.; O'Connor, S. N.; Ong, J.; Macintyre, P. E.; Chapman, M. J.; Ludbrook, G. L.] Royal Adelaide Hosp, Dept Intens Care, Adelaide, SA 5000, Australia		ravibk123@gmail.com	Upton, Richard N/G-4727-2011	Upton, Richard N/0000-0001-9996-4886			Australian and New Zealand College of Anaesthetists, APM SE WORM GROUP AU; Cheremina O, 2005, BIOMED CHROMATOGR, V19, P777, DOI 10.1002/bmc.516; Cooper IM, 1996, ANAESTH INTENS CARE, V24, P574, DOI 10.1177/0310057X9602400512; Falk E, 1917, MUNCHEN MED WOCHEN, V20, P381; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; Lamacraft G, 1997, J PAIN SYMPTOM MANAG, V13, P43, DOI 10.1016/S0885-3924(96)00200-X; Macintyre PE, 2007, ACUTE PAIN MANAGEMEN; POYHIA R, 1992, BRIT J CLIN PHARMACO, V33, P617, DOI 10.1111/j.1365-2125.1992.tb04090.x; POYHIA R, 1994, PHARMACOL TOXICOL, V74, P23; R Development Core Team, 2005, R LANG ENV STAT COMP; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Takala A, 1997, ACTA ANAESTH SCAND, V41, P309, DOI 10.1111/j.1399-6576.1997.tb04684.x; Turncliff RZ, 2005, J CLIN PHARMACOL, V45, P1259, DOI 10.1177/0091270005280199; Upton R.N., 2006, ACUTE PAIN, V8, P109, DOI [DOI 10.1016/J.ACPAIN.2006.06.002, 10.1016/j.acpain.2006.06.002]; UPTON RN, 1988, J PHARMACOKINET BIOP, V16, P13, DOI 10.1007/BF01061860	16	6	6	0	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	MAR	2012	40	2					269	274		10.1177/0310057X1204000209			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	915BT	WOS:000301998600009	22417021	Bronze			2020-06-30	J	Marwah, R; Hassan, S; Carvalho, JCA; Balki, M				Marwah, Radhika; Hassan, Samah; Carvalho, Jose C. A.; Balki, Mrinalini			Remifentanil versus fentanyl for intravenous patient-controlled labour analgesia: an observational study	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							PAIN RELIEF; OBSTETRIC ANALGESIA; MEPERIDINE; PHARMACOKINETICS	Purpose We undertook a retrospective study to compare the analgesic efficacy and effects on neonatal outcome of administering either remifentanil or fentanyl intravenous patient-controlled analgesia (IVPCA) during labour. Methods A five-year retrospective cohort study was undertaken of women with more than 24 weeks of gestation who had received either IVPCA remifentanil or fentanyl for labour analgesia at Mount Sinai Hospital. The sampling timeframe was from November 2005 to March 2010. The standard IVPCA regimen for the remifentanil group consisted of a PCA bolus 0.25 mu g.kg(-1) with a lockout interval of two minutes, a four-hour limit of 3 mg, and a background infusion of 0.025-0.05 mu g.kg(-1).min(-1), whereas the standard IVPCA regimen for the fentanyl group consisted of a PCA bolus 25-50 mu g with a lockout interval of three to six minutes and a four-hour limit of 1-1.5 mg. The following data were compared: maternal hourly pain scores (verbal pain score scale 0-10), sedation scores (scale 0-3), adverse effects, and neonatal outcomes. Mixed linear modelling was used to analyze longitudinal data on pain scores over time. The exact Wilcoxon test and the Fisher's exact test were used for other comparisons. Results Ninety-eight women were studied. There was no significant difference in the model-adjusted pain scores between the two groups (P = 0.86). There was a moderate decrease in pain scores in both groups compared with the baseline values. There was no difference in maternal side effects between the two groups, although transient oxygen desaturation was observed more frequently in the remifentanil group than in the fentanyl group (13% vs 2%, respectively; odds ratio, 7.32; 95% confidence interval [CI], 0.85 to 63.3). A larger number of neonates in the fentanyl group required resuscitation compared with neonates in the remifentanil group (59% vs 25%, respectively; odds ratio, 4.33; 95% CI, 1.75 to 10.76); adjusted (44% vs 8%, respectively; odds ratio, 8.56; 95% CI, 2.17 to 33.77). Conclusions Intravenous patient-controlled analgesia with either remifentanil or fentanyl provides a moderate degree of labour analgesia, whereas transient maternal oxygen desaturation is observed more commonly with remifentanil. Fentanyl is associated with a higher need for neonatal resuscitation.	[Marwah, Radhika; Hassan, Samah; Carvalho, Jose C. A.; Balki, Mrinalini] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1X5, Canada	Balki, M (reprint author), Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, 600 Univ Ave,Room 1514, Toronto, ON M5G 1X5, Canada.	mrinalini.balki@uhn.ca	Balki, Mrinalini/A-2669-2015				[Anonymous], BIRTHWEIGHT LOW BIRT; Babenco HD, 2000, ANESTHESIOLOGY, V92, P393, DOI 10.1097/00000542-200002000-00020; Balcioglu O, 2007, EXPERT OPIN PHARMACO, V8, P3089, DOI 10.1517/14656566.8.18.3089; Balki M, 2007, CAN J ANAESTH, V54, P626, DOI 10.1007/BF03022956; Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Blair JM, 2001, BRIT J ANAESTH, V87, P415, DOI 10.1093/bja/87.3.415; Castro C, 2003, CAN J ANAESTH, V50, P1039, DOI 10.1007/BF03018370; D'Onofrio P, 2009, ANESTH ANALG, V109, P1922, DOI 10.1213/ane.0b013e3181acc6fc; Dhileepan S, 2001, ANESTH ANALG, V92, P1358; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; Evron S, 2005, ANESTH ANALG, V100, P233, DOI 10.1213/01.ANE.0000143351.64538.BC; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; GLASS PSA, 1995, J CLIN ANESTH, V7, P558, DOI 10.1016/0952-8180(95)00127-1; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; Hill David, 2008, Anesthesiol Clin, V26, P169, DOI 10.1016/j.anclin.2007.11.004; Hinova A, 2009, ANESTH ANALG, V109, P1925, DOI 10.1213/ANE.0b013e3181c03e0c; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Kattwinkel J, 2006, PEDIATRICS, V117, pE1029, DOI 10.1542/peds.2006-0349; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; Morley-Forster PK, 1998, INT J OBSTET ANESTH, V7, P103, DOI 10.1016/S0959-289X(98)90005-X; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; Olufolabi AJ, 2000, ANESTH ANALG, V91, P606, DOI 10.1213/00000539-200009000-00020; Owen MD, 2002, ANESTH ANALG, V94, P918, DOI 10.1097/00000539-200204000-00027; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Roelants F, 2001, CAN J ANAESTH, V48, P175, DOI 10.1007/BF03019731; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; Thurlow JA, 2002, BRIT J ANAESTH, V88, P374, DOI 10.1093/bja/88.3.374; Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2; Volikas I, 2005, BRIT J ANAESTH, V95, P504, DOI 10.1093/bja/aei219; Volmanen P, 2008, ACTA ANAESTH SCAND, V52, P249, DOI 10.1111/j.1399-6576.2007.01509.x; Volmanen P, 2002, ANESTH ANALG, V94, P913, DOI 10.1097/00000539-200204000-00026	34	24	24	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	MAR	2012	59	3					246	254		10.1007/s12630-011-9625-0			9	Anesthesiology	Anesthesiology	916KT	WOS:000302103100002	22057875	Bronze			2020-06-30	J	Bujak-Gizycka, B; Kacka, K; Suski, M; Olszanecki, R; Madej, J; Dobrogowski, J; Korbut, R				Bujak-Gizycka, Beata; Kacka, Katarzyna; Suski, Maciej; Olszanecki, Rafal; Madej, Jozef; Dobrogowski, Jan; Korbut, Ryszard			Beneficial Effect of Amantadine on Postoperative Pain Reduction and Consumption of Morphine in Patients Subjected to Elective Spine Surgery	PAIN MEDICINE			English	Article						Postoperative Pain; Amantadine; Analgesia; Morphine; NMDA Receptor Antagonist	ASPARTATE RECEPTOR ANTAGONISTS; DOUBLE-BLIND; DEXTROMETHORPHAN; PLACEBO; DEPENDENCE	Objective. To analyze the effect of coadministration of morphine and amantadine on postoperative pain reduction and morphine consumption in patients after elective spine surgery. Methods. In double-blinded study, 60 patients (ASA physical status I-II) were randomized into two groups. Group A was given oral amantadine 50 or 100 mg 1 hour before surgery and 8, 20, 32 hours after operation. Group P received placebo at identical times. Pain was assessed using numerical rating scale before first administration of morphine and in 2, 3, 4, 6, 24, and 48 hours after operation. The amounts of morphine consumed were recorded up to 48 hours after surgery. Blood samples were taken twice in 2 hours after surgery and plasma levels of morphine and its main metabolites were measured. Results. As compared with placebo, amantadine significantly reduced intra-operative Fentanyl use and sensation of postoperative pain. Up to 48 hours after operation, the cumulative consumption of morphine was 25% lower in the amantadine group. Moreover, intensity of nausea and vomiting tended to be lower in A group. Starting from 12th hour after surgery, the level of postoperative sedation was lower in patients who received amantadine, as compared with placebo group. No significant differences in plasma levels of morphine ant its metabolites were observed between A and P groups. Conclusions. Pre- and postoperative administration of amantadine significantly reduced fentanyl use during operation, as well as reduced the postoperative pain and decreased morphine consumption in young patients undergoing orthopedic surgery.	[Olszanecki, Rafal] Jagiellonian Univ, Coll Med, Chair Pharmacol, Mol Pharmacol Lab, PL-31531 Krakow, Poland; [Kacka, Katarzyna] Jagiellonian Univ, Coll Med, Dept Orthoped & Rehabil Zakopane, Div Anesthesiol & Intens Care, PL-31531 Krakow, Poland; [Dobrogowski, Jan] Jagiellonian Univ, Coll Med, Dept Pain Res & Treatment, PL-31531 Krakow, Poland	Olszanecki, R (reprint author), Jagiellonian Univ, Coll Med, Chair Pharmacol, Mol Pharmacol Lab, 16 Grzegorzecka Str, PL-31531 Krakow, Poland.	mfolszan@cyf-kr.edu.pl		Suski, Maciej/0000-0001-7575-2184			Buvanendran A, 2007, BEST PRACT RES-CLIN, V21, P31, DOI 10.1016/j.bpa.2006.12.003; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Dickenson AH, 1997, ACTA ANAESTH SCAND, V41, P112, DOI 10.1111/j.1399-6576.1997.tb04624.x; Eisenberg E, 2007, J PAIN, V8, P223, DOI 10.1016/j.jpain.2006.08.003; Gerner Peter, 2008, Anesthesiol Clin, V26, P355, DOI 10.1016/j.anclin.2008.01.007; Hazelrigg SR, 2002, SURG CLIN N AM, V82, P849, DOI 10.1016/S0039-6109(02)00031-2; Kauppila T, 1998, NEUROREPORT, V9, P1071, DOI 10.1097/00001756-199804200-00020; KORNHUBER J, 1995, NEUROPHARMACOLOGY, V34, P713, DOI 10.1016/0028-3908(95)00056-C; Kornhuber J, 1999, ACTA NEUROPATHOL, V98, P85, DOI 10.1007/s004010051054; KORNHUBER J, 1994, J NEURAL TRANSM-SUPP, P91; Mao JR, 1996, PAIN, V67, P361, DOI 10.1016/0304-3959(96)03120-X; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; Medrik-Goldberg T, 1999, REGION ANESTH PAIN M, V24, P534, DOI 10.1016/S1098-7339(99)90045-7; Morris ME, 2003, PHARMACOL REV, V55, P229, DOI 10.1124/pr.55.2.1; Nemmani KVS, 2004, PAIN, V109, P274, DOI 10.1016/j.pain.2004.01.035; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; Price DD, 2000, J PAIN SYMPTOM MANAG, V19, pS7; Pud D, 1998, PAIN, V75, P349, DOI 10.1016/S0304-3959(98)00014-1; Singla N, 2010, PAIN MED, V11, P1284, DOI 10.1111/j.1526-4637.2010.00896.x; Snijdelaar DG, 2005, PAIN, V119, P159, DOI 10.1016/j.pain.2005.09.027; Snijdelaar DG, 2004, ANESTHESIOLOGY, V100, P134, DOI 10.1097/00000542-200401000-00022; Suski M, 2010, BASIC CLIN PHARMACOL, V107, P680, DOI 10.1111/j.1742-7843.2010.00559.x; Williams BS, 2009, ADV ANAESTH, V27, P111	23	10	12	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAR	2012	13	3					459	465		10.1111/j.1526-4637.2011.01321.x			7	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	909NV	WOS:000301572300016	22313516	Bronze			2020-06-30	J	Radbruch, L; Torres, LM; Ellershaw, JE; Gatti, A; Lerzo, GL; Revnic, J; Taylor, D				Radbruch, Lukas; Torres, Luis M.; Ellershaw, John E.; Gatti, Antonio; Luis Lerzo, Guillermo; Revnic, Julia; Taylor, Donald			Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain	SUPPORTIVE CARE IN CANCER			English	Article						Fentanyl; Intranasal; Breakthrough pain; Cancer; Patient acceptability	MULTIPLE-CROSSOVER; PALLIATIVE-CARE; DRUG-DELIVERY; DOUBLE-BLIND; MANAGEMENT; ASSOCIATION; MULTICENTER; PREVALENCE; MORPHINE; OPIOIDS	Purpose Previous studies show that fentanyl pectin nasal spray (FPNS) rapidly provides clinically meaningful pain relief in the treatment of breakthrough cancer pain (BTCP). This study assessed the long-term tolerability, acceptability and consistency of effect of FPNS in patients with BTCP. Methods Patients (new and rolled over from earlier controlled studies) with cancer experiencing one to four episodes per day of BTCP whilst taking >= 60 mg/day of morphine (or equivalent) given orally for cancer pain entered an open-label 16-week safety study. Safety and tolerability were assessed by adverse events (AEs), adverse drug reactions (ADRs), withdrawal due to AEs and by nasal assessments. Acceptability assessments included ratings of overall satisfaction with each treated episode and ease of use and convenience of FPNS. Additional rescue medication and dose stability were used to evaluate the consistency of effect. Results Four hundred three patients were included in the safety and intent-to-treat analysis (42,227 episodes), 356 entered the treatment phase and 110 completed 16 weeks. Overall, 24.6% of 403 patients reported treatment-related treatment-emergent AEs that were generally mild/moderate and typical of opioids; 20 patients discontinued treatment due to an AE (9 were ADRs). Nasal assessments revealed no clinically significant effects; 94% of FPNS-treated episodes required no additional rescue medication. More than 90% of patients did not have to increase their dose during the study. Patients reported overall satisfaction with FPNS for 90.1% of episodes. At week 12, 96.9% of patients were satisfied with the ease of use and 97.9% with the convenience of FPNS. Conclusions FPNS was generally well tolerated and well accepted for the treatment of BTCP, and doses remained stable over the 4-month study period.	[Radbruch, Lukas] Univ Klinikum Bonn, Klin Palliativ Med, D-53127 Bonn, Germany; [Torres, Luis M.] Hosp Puerta Mar, Cadiz 11009, Spain; [Ellershaw, John E.] Marie Curie Palliat Care Inst, Liverpool L25 8QA, Merseyside, England; [Gatti, Antonio] Azienda Policlin Tor Vergata, AFA Emergenza Urgenza Terapia Intens & Terapia Do, I-00133 Rome, Italy; [Luis Lerzo, Guillermo] Invest Med Buenos Aires, RA-1185 Buenos Aires, DF, Argentina; [Revnic, Julia] Ctr Soins Palliatifs & Traitement Douleur, F-75004 Paris, France; [Taylor, Donald] Taylor Res LLC, PC, Comprehens Pain Care, Marietta, GA 30060 USA	Radbruch, L (reprint author), Univ Klinikum Bonn, Klin Palliativ Med, Sigmund Freud Str 25, D-53127 Bonn, Germany.	Lradbruch@Ukaachen.de; luismtorres@arrakis.es; J.E.Ellershaw@liverpool.ac.uk; antonio.gatti@ptvonline.it; guillelerzo@indicom.com.ar; julia.revnic@htd.aphp.fr; dtaylor@cpcnopain.com	Torres, Luis M/Q-6983-2019; Torres, Luis Miguel/O-1720-2015	Torres, Luis Miguel/0000-0002-0194-7875	Archimedes Development Ltd.; ApotheCom	This study was sponsored by Archimedes Development Ltd. The authors wish to acknowledge i3Research, which conducted the study, and the technical and editorial support provided by Anita Chadha-Patel and ApotheCom.	BENNETT D, 2005, [No title captured], V30, P354; Brennan F, 2007, J PAIN SYMPTOM MANAG, V33, P494, DOI 10.1016/j.jpainsymman.2007.02.022; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davies AN, 2001, J PAIN SYMPTOM MANAG, V22, P820, DOI 10.1016/S0885-3924(01)00318-9; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon M, 2009, EJC SUPPL, V7, P15, DOI 10.1016/S1359-6349(09)72064-6; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Miaskowski C, 2001, J CLIN ONCOL, V19, P4275, DOI 10.1200/JCO.2001.19.23.4275; Petzke F, 1999, J PAIN SYMPTOM MANAG, V17, P391, DOI 10.1016/S0885-3924(99)00023-8; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]	21	20	23	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	MAR	2012	20	3					565	573		10.1007/s00520-011-1124-x			9	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	908VI	WOS:000301520700017	21424794				2020-06-30	J	Kao, CW; Wu, SC; Lin, KC; Chen, CL; Huang, CJ; Cheng, KW; Jawan, B; Wang, CH				Kao, C-W.; Wu, S-C.; Lin, K-C.; Chen, C-L.; Huang, C-J.; Cheng, K-W.; Jawan, B.; Wang, C-H.			Pain Management of Living Liver Donors With Morphine With or Without Ketorolac	TRANSPLANTATION PROCEEDINGS			English	Article							PATIENT-CONTROLLED ANALGESIA; HEPATECTOMY	Background. To compare the efficacy and dose requirements for intravenous (IV) patient-controlled analgesia (PCA) with morphine only versus morphine with ketorolac for living liver donors after partial hepatectomy. Patients and methods. Eighty living liver donors who had undergone partial hepatectomy received 3 days of IV PCA for postoperative pain control. Some were prescribed a PCA with morphine alone (group I) or morphine with ketorolac (group II), while both had a rescue dose of IV fentanyl (25 mu g). The daily consumption of morphine, pain score, and frequency of rescue fentanyl doses were compared retrospectively using the Mann-Whitney U test and the incidence of side effects with chi-square tests; a P value of .05 was regarded as significant. All the data are shown as mean values +/- standard deviations. Results. The 80 subjects were distributed as 57 group I and in 23 group II patients. The daily consumption of morphine, Visual Analogue Scale (VAS) and side effects were not different between the groups, but group II required significantly fewer rescue doses to achieve pain relief. Conclusion. Both regimens provided acceptable pain control with daily VAS less than 3. The use of ketorolac in the PCA did not reduce the daily total morphine requirements with a similar incidence of side effects but a significantly reduced requirement for rescue doses, which subsequently reduced the work load of personnel in the pain control service.	[Kao, C-W.; Wu, S-C.; Lin, K-C.; Cheng, K-W.; Jawan, B.; Wang, C-H.] Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung, Taiwan; [Chen, C-L.] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung, Taiwan; [Chen, C-L.] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Program, Kaohsiung, Taiwan; Chang Gung Univ, Coll Med, Kaohsiung, Taiwan	Wang, CH (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung, Taiwan.	cchwang@adm.cgmh.org.tw					Chen JP, 2010, TRANSPL P, V42, P701, DOI 10.1016/j.transproceed.2010.02.024; Cronin DC, 2001, NEW ENGL J MED, V344, P1633, DOI 10.1056/NEJM200105243442112; Cywinski JB, 2004, ANESTH ANALG, V99, P1747, DOI 10.1213/01.ANE.0000136423.17446.5D; Gillis JC, 1997, DRUGS, V53, P139, DOI 10.2165/00003495-199753010-00012; Kim SY, 2008, THYROID, V18, P1285, DOI 10.1089/thy.2008.0007; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Viscusi ER, 2008, REGION ANESTH PAIN M, V33, P146, DOI 10.1016/j.rapm.2007.11.005	8	13	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345			TRANSPL P	Transplant. Proc.	MAR	2012	44	2					360	362		10.1016/j.transproceed.2011.12.040			3	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	913YD	WOS:000301912400013	22410016				2020-06-30	J	Ko, JS; Shin, YH; Gwak, MS; Jang, CH; Kim, GS; Lee, SK				Ko, J. S.; Shin, Y. H.; Gwak, M. S.; Jang, C. H.; Kim, G. S.; Lee, S. -K.			The Relationship between Postoperative Intravenous Patient-Controlled Fentanyl Analgesic Requirements and Severity of Liver Disease	TRANSPLANTATION PROCEEDINGS			English	Article							TRANSPLANT RECIPIENTS; MORPHINE; STAGE	Purpose. Decreased inhalational anesthetic requirements during orthotopic liver transplantation (OLT) have been reported according to the severity of the pre-existent disease as well as decreased opioid requirements thereafter. The aim of the present study was to determine the relationship between postoperative opioid requirements and severity of liver disease among OLT patients. Methods. We retrospectively reviewed 44 recipients who used intravenous fentanyl-based patient-controlled analgesia (PCA) after OLT from November 2009 to May 2010. The severity of liver disease was assessed using the model for end-stage liver disease (MELD) score. Recipients were divided into a low-MELD group (<20; n = 30) and a high-MELD group (>= 20; n = 14). The amounts of PCA infusion and rescue opioid up to 3 postoperative days (POD) were compared between the 2 groups. The intensity of pain at rest and when coughing was assessed using visual analog scale (VAS) scores. Results. The cumulative opioid requirements via PCA on POD 1, 2, and 3 were significantly lower in the high-MELD than the low-MELD group. The amounts of rescue opioid were similar between the 2 groups. However, the intensity of pain at both rest and when coughing on POD 1, 2, and 3 were significantly less severe in the high-MELD than the low-MELD group. Conclusions. OLT patients with high MELD scores required less postoperative opioids and experienced less pain than those with low scores. Therefore, postoperative pain control after OLT should be carefully titrated according to the severity of the liver disease.	[Ko, J. S.; Shin, Y. H.; Gwak, M. S.; Jang, C. H.; Kim, G. S.] Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea; [Lee, S. -K.] Sungkyunkwan Univ, Dept Surg, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea	Kim, GS (reprint author), Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, 50 Ilwon Dong, Seoul 135710, South Korea.	gskim@skku.edu					Chen JP, 2010, TRANSPL P, V42, P701, DOI 10.1016/j.transproceed.2010.02.024; Donovan KL, 1997, TRANSPLANTATION, V63, P1423, DOI 10.1097/00007890-199705270-00010; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Kang JG, 2010, TRANSPL P, V42, P854, DOI 10.1016/j.transproceed.2010.02.057; Moretti EW, 2002, J CLIN ANESTH, V14, P416, DOI 10.1016/S0952-8180(02)00390-2; SPIVEY JR, 1994, AM J GASTROENTEROL, V89, P2028	6	4	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345			TRANSPL P	Transplant. Proc.	MAR	2012	44	2					445	447		10.1016/j.transproceed.2012.01.017			3	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	913YD	WOS:000301912400036	22410039				2020-06-30	J	Soriya, GC; McVaney, KE; Liao, MM; Haukoos, JS; Byyny, RL; Gravitz, C; Colwell, CB				Soriya, Gina C.; McVaney, Kevin E.; Liao, Michael M.; Haukoos, Jason S.; Byyny, Richard L.; Gravitz, Craig; Colwell, Christopher B.			Safety of prehospital intravenous fentanyl for adult trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine (SAEM)	JUN, 2010	Phoenix, AZ	Soc Acad Emergency Med (SAEM)		Fentanyl; pain management; trauma; prehospital; safety	SHOCK INDEX; EMERGENCY-MEDICINE; ADVANCED STATISTICS; PAIN; MANAGEMENT; ANALGESIA; REVIEWS; INJURY	BACKGROUND: Little is known about the safety of intravenous fentanyl for adult trauma patients in the prehospital setting. Our objective was to study the hemodynamic effect of prehospital intravenous fentanyl in initially normotensive adult trauma patients. METHODS: A quasi-experimental design was used to compare adult trauma patients who received intravenous fentanyl and those who did not receive fentanyl in a large regional prehospital system and its affiliated Level I trauma center. Emergent adult trauma patients were included with an initial prehospital Glasgow Coma Scale score of >= 13 and systolic blood pressure >90 mm Hg. Patients were stratified into two groups, those who received a single dose of intravenous fentanyl (100 mu g) and those who did not. The outcome was initial emergency department (ED) shock index (heart rate divided by systolic blood pressure). Multivariable linear regression was used to estimate the effect of fentanyl on ED shock index while adjusting for prehospital shock index, age, gender, Trauma Injury Severity Score, and the propensity for receiving fentanyl. RESULTS: Seven hundred sixty-three patients were included, of whom 217 (28%) received fentanyl. The groups had comparable demographics (age, gender, and race/ethnicity) but different clinical characteristics (ED vital signs, Injury Severity Score, mechanism, and ED disposition). The adjusted ED shock index of fentanyl patients improved (-0.03; 95% confidence interval: -0.05 to 0.00; p = 0.02) compared with no fentanyl. CONCLUSION: Prehospital intravenous fentanyl did not adversely affect the initial ED shock index in adult trauma patients. Additional research should be performed to confirm and extend our findings. (J Trauma. 2012; 72: 755-759. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[McVaney, Kevin E.; Liao, Michael M.; Haukoos, Jason S.; Byyny, Richard L.; Colwell, Christopher B.] Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO 80204 USA; [Soriya, Gina C.] St Anthony Hosp, Dept Emergency Med, Denver, CO USA; [McVaney, Kevin E.; Liao, Michael M.; Haukoos, Jason S.; Byyny, Richard L.; Colwell, Christopher B.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA; [Haukoos, Jason S.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Gravitz, Craig] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA	Colwell, CB (reprint author), Denver Hlth Med Ctr, Dept Emergency Med, 777 Bannock St,MC 0108, Denver, CO 80204 USA.	Christopher.Colwell@dhha.org		Byyny, Richard/0000-0002-9145-7457	AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [F32 HS018123, K02 HS017526]		Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Birkhahn RH, 2005, AM J EMERG MED, V23, P323, DOI 10.1016/j.ajem.2005.02.029; Bledsoe Bryan, 2005, JEMS, V30, P56, DOI 10.1016/S0197-2510(05)70166-2; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; Cannon CM, 2009, J TRAUMA, V67, P1426, DOI 10.1097/TA.0b013e3181bbf728; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Jennings PA, 2011, EMERG MED J, V28, P530, DOI 10.1136/emj.2010.098954; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; Lowenstein SR, 2005, ANN EMERG MED, V45, P452, DOI 10.1016/j.annemergmed.2005.01.032; Maio RF, 1999, ANN EMERG MED, V33, P423, DOI 10.1016/S0196-0644(99)70307-0; Newgard CD, 2004, ACAD EMERG MED, V11, P953, DOI 10.1197/j.aem.2004.02.530; RADY MY, 1994, ANN EMERG MED, V24, P685, DOI 10.1016/S0196-0644(94)70279-9; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; Thomas SH, 2007, AM J EMERG MED, V25, P842, DOI 10.1016/j.ajem.2007.02.010; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Worster A, 2004, ACAD EMERG MED, V11, P187, DOI 10.1197/j.aem.2003.03.002	19	11	11	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2012	72	3					755	759		10.1097/TA.0b013e31823c4444			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	906TR	WOS:000301371100047	22491566				2020-06-30	J	Colque, A; Eisemann, ML				Colque, Alex; Eisemann, Michael L.			Breast Augmentation and Augmentation-Mastopexy With Local Anesthesia and Intravenous Sedation	AESTHETIC SURGERY JOURNAL			English	Article						breast enhancement; breast enlargement; breast lift; mastopexy; minimally invasive plastic surgery; perioperative nausea and pain; risks; submuscular; subpectoral; implants	FOLLOW-UP	Background: Administration of intravenous sedation and intercostal nerve blocks has resulted in reduced postoperative nausea and faster recovery as compared to general anesthesia. Objectives: The authors present their experience with intercostal nerve blocks and intravenous sedation in breast augmentation, with and without simultaneous mastopexy. Their protocol does not include propofol and thus can be administered by the surgeon and circulating nurse. Methods: The initial dose of intravenous sedation was administered by the surgeon, starting with midazolam, fentanyl, and ketamine; additional doses (as needed) were given by the circulating nurse. Local anesthesia blocks were injected into Intercostal Spaces 3-7 at the midaxillary line. The anesthetic solution was injected at the lateral sternal boarder in varying amounts.. A retrospective review was performed of 171 patients who underwent bilateral breast augmentation or augmentation-mastopexy with this protocol. The two groups were analyzed for age, body mass index, operating time, total amount of sedation/anesthesia, recovery room time, postoperative nausea, and complications. Results: Of the 171 patients, 132 underwent augmentation and 39 had augmentation-mastopexy. All recovered well from anesthesia. The mean recovery room time was 49.9 minutes for the augmentation group and 52.9 minutes for the augmentation-mastopexy group. Postoperative nausea occurred in 14 (10.6%) patients who received augmentation alone and in five (12.8%) who underwent augmentation-mastopexy. There were no serious complications or hospital admissions. Conclusions: Breast augmentation with or without mastopexy can be performed safely, with minimal discomfort and complications, by employing local anesthesia with intravenous sedation. Although augmentation-mastopexy requires more operating time than augmentation alone, the recovery times are comparable.	[Colque, Alex; Eisemann, Michael L.] Methodist Hosp, Houston, TX 77030 USA	Colque, A (reprint author), 22370 Bluemound Rd, Waukesha, WI 53186 USA.	apcolque@hotmail.com					Cooter RD, 2007, AESTHET PLAST SURG, V31, P666, DOI 10.1007/s00266-006-0230-5; Eldor L, 2008, ANN PLAS SURG, V61, P243, DOI 10.1097/SAP.0b013e31815bfe98; Huang TT, 1978, BREAST SURG, V63, P299; Jabs Dean, 2008, Aesthet Surg J, V28, P528, DOI 10.1016/j.asj.2008.07.005; Kitowski NJ, 2010, ARCH SURG-CHICAGO, V154, P592; Kolawole IK, 2006, J NATL MED ASSOC, V98, P450; Lai CS, 1996, ANN PLAS SURG, V36, P113, DOI 10.1097/00000637-199602000-00001; Mahabir RC, 2008, PLAST RECONSTR SURG, V121, P638, DOI 10.1097/01.prs.0000298112.52389.e1; Marcus JR, 1999, PLAST RECONSTR SURG, V104, P1338, DOI 10.1097/00006534-199910000-00015; Michaels BM, 2009, PLAST RECONSTR SURG, V124, P635, DOI 10.1097/PRS.0b013e3181addbd7; Mustoe Thomas A, 2007, Aesthet Surg J, V27, P442, DOI 10.1016/j.asj.2007.05.003; Parker Wendy L, 2004, Aesthet Surg J, V24, P436, DOI 10.1016/j.asj.2004.06.003; Reece EM, 2009, AESTHET SURG J, V29, P116, DOI 10.1016/j.asj.2008.12.006; Rezai Allen, 2004, Aesthet Surg J, V24, P277, DOI 10.1016/j.asj.2004.02.006; Saint Louis C, 2010, NY TIMES        0407; Spear SL, 2001, PLAST RECONSTR SURG, V108, P771, DOI 10.1097/00006534-200109010-00029; The American Society for Aesthetic Plastic Surgery Cosmetic Surgery National Data Bank, COSM SURG NAT DAT BA; Zukowski ML, 1996, PLAST RECONSTR SURG, V97, P952, DOI 10.1097/00006534-199604001-00010	18	13	13	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1090-820X			AESTHET SURG J	Aesthet. Surg. J.	MAR	2012	32	3					303	307		10.1177/1090820X12436601			5	Surgery	Surgery	907CD	WOS:000301394500005	22290411	Bronze			2020-06-30	J	Oberg, TJ; Sikder, S; Jorgensen, AJ; Mifflin, MD				Oberg, Thomas J.; Sikder, Shameema; Jorgensen, Adam J.; Mifflin, Mark D.			Topical-intracameral anesthesia without preoperative mydriatic agents for Descemet-stripping automated endothelial keratoplasty and phacoemulsification cataract surgery with intraocular lens implantation	JOURNAL OF CATARACT AND REFRACTIVE SURGERY			English	Article							LIDOCAINE	We describe a technique for a new triple procedure comprising phacoemulsification and intraocular lens (IOL) implantation followed immediately by Descemet-stripping automated endothelial keratoplasty (DSAEK). It is performed under topical anesthesia, with dilation accomplished using methylparaben-free lidocaine 1% with no added epinephrine. In a case series of 32 patients, adequate dilation was achieved and no patient reported significant intraoperative discomfort. No operative or postoperative complications were encountered, and visual rehabilitation was quick and satisfactory. Topical anesthesia eliminated the risks associated with retrobulbar and peribulbar blocks, as well as the risks associated with general anesthesia. Intracameral dilation with preservative-free lidocaine 1% provided adequate and short-lived dilation, alleviating the need for intraoperative pharmacologic constriction when transitioning from IOL implantation to DSAEK.	[Oberg, Thomas J.; Jorgensen, Adam J.; Mifflin, Mark D.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA; [Sikder, Shameema] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA	Mifflin, MD (reprint author), Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.	mark.mifflin@hsc.utah.edu			Research to Prevent Blindness Foundation, New York, New York, USAResearch to Prevent Blindness (RPB)	Supported in part by the Research to Prevent Blindness Foundation, New York, New York, USA.	Anderson NJ, 1999, ARCH OPHTHALMOL-CHIC, V117, P225, DOI 10.1001/archopht.117.2.225; Covert DJ, 2007, OPHTHALMOLOGY, V114, P1272, DOI 10.1016/j.ophtha.2006.12.030; Fang JP, 2007, J CATARACT REFR SURG, V33, P187, DOI 10.1016/j.jcrs.2006.09.026; Fichman RA, 1996, J CATARACT REFR SURG, V22, P612, DOI 10.1016/S0886-3350(96)80019-8; Melles GRJ, 2004, CORNEA, V23, P286, DOI 10.1097/00003226-200404000-00011; Nikeghbali A, 2007, J CATARACT REFR SURG, V33, P101, DOI 10.1016/j.jcrs.2006.08.044; Price FW, 2006, J CATARACT REFR SURG, V32, P411, DOI 10.1016/j.jcrs.2005.12.078; Terry MA, 2003, CORNEA, V22, P619, DOI 10.1097/00003226-200310000-00006; Terry MA, 2009, OPHTHALMOLOGY, V116, P631, DOI 10.1016/j.ophtha.2008.11.004; Tsoumani AT, 2010, CLIN OPHTHALMOL, V4, P967, DOI 10.2147/OPTH.S11755	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0886-3350	1873-4502		J CATARACT REFR SURG	J. Cataract. Refract. Surg.	MAR	2012	38	3					384	386		10.1016/j.jcrs.2011.12.025			3	Ophthalmology; Surgery	Ophthalmology; Surgery	904OS	WOS:000301208400002	22261326				2020-06-30	J	Wang, Y; Barker, K; Shi, SP; Diaz, M; Mo, B; Gutstein, HB				Wang, Yan; Barker, Katherine; Shi, Shanping; Diaz, Miguel; Mo, Bing; Gutstein, Howard B.			Blockade of PDGFR-beta activation eliminates morphine analgesic tolerance	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; INHIBITION; DEPENDENCE; CHANNEL; BRAIN; CELLS	For centuries, opioid drugs have been the mainstay of chronic pain treatment. However, over time analgesic tolerance develops, leaving few treatment options. Here we show that platelet-derived growth factor receptor-beta (PDGFR-beta)-mediated signaling plays a key role in morphine tolerance. PDGFR-beta inhibition selectively eliminates morphine tolerance in rats. PDGFR-beta inhibitors are widely used and well tolerated, suggesting that clinical translation of our findings could reduce the suffering endured by individuals with intractable pain.	[Wang, Yan; Barker, Katherine; Shi, Shanping; Diaz, Miguel; Mo, Bing; Gutstein, Howard B.] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol, Houston, TX 77030 USA; [Wang, Yan; Barker, Katherine; Shi, Shanping; Diaz, Miguel; Mo, Bing; Gutstein, Howard B.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Gutstein, Howard B.] Univ Texas MD Anderson Canc Ctr, Genes & Dev Grad Program, Houston, TX 77030 USA	Gutstein, HB (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol, Houston, TX 77030 USA.	hgutstein@mdanderson.org			US National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA15146]; US National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA16157]	We thank J. Dulin, T. Sylvester and C. Schultz for technical support. This work was funded by grants from the US National Institute on Drug Abuse R01DA15146 and the US National Institute on Alcohol Abuse and Alcoholism R01AA16157 to H. B. G. We dedicate this work to the memory of our colleague and dear friend Bing Mo, who tragically passed away before these studies were completed.	AGHAJANIAN GK, 1987, NEUROPHARMACOLOGY, V26, P793, DOI 10.1016/0028-3908(87)90054-2; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Black MJ, 2003, J NEUROSCI RES, V74, P23, DOI 10.1002/jnr.10748; Chen C, 2006, CURR NEUROVASC RES, V3, P171, DOI 10.2174/156720206778018767; CODERRE TJ, 1994, PAIN, V59, P345, DOI 10.1016/0304-3959(94)90020-5; Dai HQ, 2003, J PHARMACOL EXP THER, V304, P1085, DOI 10.1124/jpet.102.045260; FRACE AM, 1989, P NATL ACAD SCI USA, V86, P2511, DOI 10.1073/pnas.86.7.2511; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOLD LH, 1994, EUR J PHARMACOL, V253, P45, DOI 10.1016/0014-2999(94)90755-2; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kolesnikov Y, 1998, J PHARMACOL EXP THER, V284, P455; MALMBERG AB, 1993, PAIN, V54, P291, DOI 10.1016/0304-3959(93)90028-N; Rice ASC, 2006, ANNU REV MED, V57, P535, DOI 10.1146/annurev.med.57.121304.131324; TIMPE LC, 1994, J NEUROSCI, V14, P1195; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Valenzuela CF, 1996, J BIOL CHEM, V271, P16151, DOI 10.1074/jbc.271.27.16151; Williams JT, 2001, PHYSIOL REV, V81, P299	20	30	32	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2012	18	3					385	387		10.1038/nm.2633			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905IF	WOS:000301264800039	22344297	Green Accepted			2020-06-30	J	Kranke, P; Lavand'homme, P				Kranke, Peter; Lavand'homme, Patricia			The relief of pain in labour and the role of remifentanil	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; EPIDURAL ANALGESIA; INTRAVENOUS REMIFENTANIL; 1ST STAGE; PETHIDINE; DELIVERY; CHILDBIRTH; MEPERIDINE; MEPTAZINOL; EXPERIENCE		[Kranke, Peter] Univ Hosp Wurzburg, Dept Anaesthesia & Crit Care, D-97080 Wurzburg, Germany; [Lavand'homme, Patricia] Catholic Univ Louvain, St Luc Hosp UCL Med Sch, Dept Anesthesiol, Brussels, Belgium	Kranke, P (reprint author), Univ Hosp Wurzburg, Dept Anaesthesia & Crit Care, Oberdurrbacher St 6, D-97080 Wurzburg, Germany.	kranke_p@klinik.uni-Wurzburg.de					Anim-Somuah M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub2; [Anonymous], 1953, LANCET, V61, P453; [Anonymous], 2009, BEH AK PER POSTTR SC, P63; [Anonymous], EXPERIENCES REMIFENT; Capogna G, 2007, INT J OBSTET ANESTH, V16, P110, DOI 10.1016/j.ijoa.2006.08.009; Choong K, 2010, ARCH DIS CHILD-FETAL, V95, pF80, DOI 10.1136/adc.2009.167338; CHRISTENSENSZALANSKI JJJ, 1984, MED DECIS MAKING, V4, P47, DOI 10.1177/0272989X8400400108; Cohain Judy Slome, 2010, Midwifery Today Int Midwife, P21; Douma MR, 2011, INT J OBSTET ANESTH, V20, P118, DOI 10.1016/j.ijoa.2010.11.009; Eker HE, 2010, EUR J ANAESTH, V27, P996, DOI 10.1097/EJA.0b013e32833cadc3; Eltzschig HK, 2003, NEW ENGL J MED, V348, P319, DOI 10.1056/NEJMra021276; Frambach T, 2010, Z GEBURTSH NEONATOL, V214, P145, DOI 10.1055/s-0030-1255025; Giannantonio C, 2009, ACTA PAEDIATR, V98, P1111, DOI 10.1111/j.1651-2227.2009.01318.x; Goetzl Laura M, 2002, Obstet Gynecol, V100, P177; Halpern SH, 2010, CURR OPIN ANESTHESIO, V23, P317, DOI 10.1097/ACO.0b013e3283385492; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Hill D, 2008, INT J OBSTET ANESTH, V17, P336, DOI [10.1016/j.ijoa.2008.03.005, 10.1016/j.ijoa.2008.03.006]; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Jones R, 1999, ANAESTHESIA, V54, P461, DOI 10.1046/j.1365-2044.1999.00857.x; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Khooshideh M, 2009, AUST NZ J OBSTET GYN, V49, P59, DOI 10.1111/j.1479-828X.2009.00949.x; Kranke P, 2009, ANASTH INTENSIV NOTF, V44, P660, DOI 10.1055/s-0029-1242434; KUHNERT BR, 1985, ANESTH ANALG, V64, P335; KUHNERT BR, 1985, AM J OBSTET GYNECOL, V151, P410, DOI 10.1016/0002-9378(85)90314-X; Lago P, 2008, PEDIATR ANESTH, V18, P736, DOI 10.1111/j.1460-9592.2008.02636.x; Landau R, 2011, IASP PAIN CLIN UPDAT, P19; Lavand'homme P, 2009, ACTA ANAESTH BELG, V60, P75; Leong WL, 2011, ANESTH ANALG, V113, P818, DOI 10.1213/ANE.0b013e3182289fe9; Leppa M, 2006, NEUROIMAGE, V31, P661, DOI 10.1016/j.neuroimage.2005.12.019; MELZACK R, 1981, CAN MED ASSOC J, V125, P357; NEL CP, 1981, S AFR MED J, V59, P908; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; OSLER M, 1987, EUR J OBSTET GYN R B, V26, P15, DOI 10.1016/0028-2243(87)90004-9; Reynolds F, 2011, INT J OBSTET ANESTH, V20, P38, DOI 10.1016/j.ijoa.2010.08.004; Schnabel A, 2011, ANAESTHESIST, V60, P995, DOI 10.1007/s00101-011-1933-9; Schnabel A, 2010, ANASTH INTENSIVMED, V51, pS485; Simpson JY, 1847, LANCET, V50, P623; Simpson JY, 1847, LANCET, V21, P549; Sosa CG, 2006, EUR J OBSTET GYN R B, V129, P135, DOI 10.1016/j.ejogrb.2005.11.033; Tveit TO, 2009, ACTA ANAESTH SCAND, V53, P794, DOI 10.1111/j.1399-6576.2009.01988.x; Tveit TO, 2012, EUR J ANAESTH, V29, P129, DOI 10.1097/EJA.0b013e32834dfa98; Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2; Volmanen P, 2008, ACTA ANAESTH SCAND, V52, P249, DOI 10.1111/j.1399-6576.2007.01509.x; Waring J, 2007, ANESTH ANALG, V104, P1616, DOI 10.1213/01.ane.0000260645.48266.f1; Wassen MMLH, 2011, BJOG-INT J OBSTET GY, V118, P655, DOI 10.1111/j.1471-0528.2011.02906.x; Wetsch WA, 2010, EUR J ANAESTH, V27, P1069, DOI 10.1097/EJA.0b013e32833cf083; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573	47	6	6	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAR	2012	29	3					116	120		10.1097/EJA.0b013e32834f986d			5	Anesthesiology	Anesthesiology	894FH	WOS:000300412000002	22317773				2020-06-30	J	Tveit, TO; Seiler, S; Halvorsen, A; Rosland, JH				Tveit, Tor O.; Seiler, Stephen; Halvorsen, Arthur; Rosland, Jan H.			Labour analgesia: a randomised, controlled trial comparing intravenous remifentanil and epidural analgesia with ropivacaine and fentanyl	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						epidural; intravenous patient-controlled analgesia; maternal opioids; obstetric analgesia; remifentanil	PATIENT-CONTROLLED ANALGESIA; PAIN RELIEF; OBSTETRIC ANALGESIA; MEPERIDINE; PETHIDINE	Background and objective To compare the analgesic efficacy and side-effects of remifentanil intravenous patient-controlled analgesia (IVPCA) with walking epidural analgesia (EDA) during labour. Methods Thirty-nine parturient patients of mixed parity, with normal singleton pregnancies, were randomised to receive either remifentanil IVPCA (RA group) or EDA (EA group). The epidural solution contained ropivacaine 1mgml(-1) and fentanyl 2 mu gml(-1), and the initial dose was 10 ml h(-1). Starting bolus of remifentanil was 0.15 mu gkg(-1), with subsequent steps of 0.15 mu gkg(-1). Lock-out time was 2 min, bolus infusion speed 2 ml min(-1) (100 mu g min(-1)) and there was no background infusion. Visual analogue scale was used for pain assessment. Maternal heart rate, blood pressure, oxygen saturation, respiratory rate, sedation, nausea/vomiting, itching, satisfaction and fetal/neonatal outcome were recorded. Results Thirty-seven parturient patients were analysed. Both treatments provided good analgesia, but with higher pain scores in the RA group. Pain reduction at the end of first and during second stage and maximum pain reduction were similar (RA/EA group): 27/26 (P = 0.920), 31/29 (P = 0.909) and 61/59 (P = 0.855), respectively. Maternal satisfaction was similar. Two parturients receiving remifentanil (6%) converted to epidural, one because of inadequate analgesia. Remifentanil produced more maternal sedation, desaturation (SaO(2) < 92%) and need for supplemental oxygen. Neonatal outcome was reassuring. Highest mean total dose of remifentanil was 0.70 mu g kg(-1) (range 0.30-1.05). Conclusion Remifentanil IVPCA and epidural provided effective analgesia, with high maternal satisfaction scores and reassuring neonatal outcome. Remifentanil produced more maternal sedation and oxygen desaturation. Close monitoring is, therefore, mandatory.	[Tveit, Tor O.; Halvorsen, Arthur] Sorlandet Hosp Kristiansand, Dept Anaesthesia & Intens Care, N-4004 Kristiansand, Norway; [Tveit, Tor O.; Rosland, Jan H.] Univ Bergen, Dept Surg Sci, Bergen, Norway; [Seiler, Stephen] Univ Agder, Fac Hlth & Sport, Kristiansand, Norway; [Rosland, Jan H.] Haraldsplass Deaconess Hosp, Dept Palliat Care, Bergen, Norway	Tveit, TO (reprint author), Sorlandet Hosp Kristiansand, Dept Anaesthesia & Intens Care, N-4004 Kristiansand, Norway.	tor.tveit@sshf.no			Sorlandet Hospital HF; Sorlandets kompetansefond; Helse Sor-Ost, Norway	The work was funded by Sorlandet Hospital HF, Sorlandets kompetansefond and Helse Sor-Ost, Norway.	Althaus J, 2005, OBSTET GYN CLIN N AM, V32, P231, DOI 10.1016/j.ogc.2005.01.002; Assad S, 2003, TECH REG ANES PAIN M, V7, P127; Balki M, 2007, CAN J ANAESTH, V54, P626, DOI 10.1007/BF03022956; Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Blair JM, 2001, BRIT J ANAESTH, V87, P415, DOI 10.1093/bja/87.3.415; D'Onofrio P, 2009, ANESTH ANALG, V109, P1922, DOI 10.1213/ane.0b013e3181acc6fc; Douma MR, 2011, INT J OBSTET ANESTH, V20, P118, DOI 10.1016/j.ijoa.2010.11.009; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Egan TD, 1998, ANESTHESIOLOGY, V89, P562, DOI 10.1097/00000542-199809000-00004; Evron S, 2005, ANESTH ANALG, V100, P233, DOI 10.1213/01.ANE.0000143351.64538.BC; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; Hill D, 2008, CURR OPIN ANESTHESIO, V21, P270, DOI 10.1097/ACO.0b013e3282f8e26c; Hinova A, 2009, ANESTH ANALG, V109, P1925, DOI 10.1213/ANE.0b013e3181c03e0c; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Landau R, 2004, ANESTHESIOLOGY, V100, P1030, DOI 10.1097/00000542-200404000-00042; Lavand'homme P, 2009, ACTA ANAESTH BELG, V60, P75; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; Saravanakumar K, 2007, INT J OBSTET ANESTH, V16, P221, DOI 10.1016/j.ijoa.2007.01.010; Thurlow JA, 2002, BRIT J ANAESTH, V88, P374, DOI 10.1093/bja/88.3.374; Van de Velde M, 2008, Int J Obstet Anesth, V17, P339, DOI 10.1016/j.ijoa.2008.03.006; Volikas I, 2005, BRIT J ANAESTH, V95, P504, DOI 10.1093/bja/aei219; Volikas I, 2001, INT J OBSTET ANESTH, V10, P86, DOI 10.1054/ijoa.2000.0831; Volmanen P, 2008, ACTA ANAESTH SCAND, V52, P249, DOI 10.1111/j.1399-6576.2007.01509.x; Volmanen P, 2005, ACTA ANAESTH SCAND, V49, P453, DOI 10.1111/j.1399-6576.2005.00639.x; Volmanen P, 2002, ANESTH ANALG, V94, P913, DOI 10.1097/00000539-200204000-00026	26	38	42	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAR	2012	29	3					129	136		10.1097/EJA.0b013e32834dfa98			8	Anesthesiology	Anesthesiology	894FH	WOS:000300412000004	22249153				2020-06-30	J	He, L; Xu, JM; Dai, RP				He, Liang; Xu, Jun-Mei; Dai, Ru-Ping			Dexmedetomidine reduces the incidence of fentanyl-induced cough: A double-blind, randomized, and placebo-controlled study	UPSALA JOURNAL OF MEDICAL SCIENCES			English	Article						Cough; dexmedetomidine; fentanyl; opioid-induced muscular rigidity	PROLONGED INJECTION TIME; INTRAVENOUS LIDOCAINE; SUPPRESSES; ANESTHESIA; INDUCTION; PROPOFOL; PRETREATMENT; SUFENTANIL; DECREASE; REFLEXES	Objectives. The incidence of fentanyl-induced cough (FIC) during induction of general anesthesia varies around 40% and is undesirable. It increases intracranial, intraocular, and intra-abdominal pressures. This prospective, randomized, double-blind, placebo-controlled study evaluated the effect of dexmedetomidine (DEX) pretreatment on the incidence and severity of FIC. Methods. Altogether 300 patients undergoing elective surgical procedures were randomly allocated into three groups (I, II, III; n = 100) and administered intravenously, over 10 min, 10 mL isotonic saline, DEX 0.5 mu g/kg in 10 mL isotonic saline, or DEX 1 mu g/kg in 10 mL isotonic saline, respectively. All groups subsequently received a fentanyl (4.0 mu g/kg) intravenous push. The incidence and severity of cough were recorded for 1 min after fentanyl administration. Results. The incidence of FIC was 61%, 40%, and 18% in groups I, II, and III, respectively (P < 0.05 for treatment groups II and III versus control group I). There was no significant difference in the severity or onset time of cough, or hemodynamic variables, among the three groups. Conclusions. Intravenous DEX (0.5 mu g/kg or 1 mu g/kg) immediately before the administration of intravenous fentanyl (4.0 mu g/kg) significantly reduced the incidence of FIC.	[He, Liang; Xu, Jun-Mei; Dai, Ru-Ping] Cent S Univ, Dept Anesthesia, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China	Xu, JM (reprint author), Cent S Univ, Dept Anesthesia, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.	doctorjmxu@163.com					Agarwal A, 2007, ANAESTHESIA, V62, P1230, DOI 10.1111/j.1365-2044.2007.05249.x; Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ai Q, 2010, PHARMACOL REP, V62, P747, DOI 10.1016/S1734-1140(10)70333-9; Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Guler G, 2005, ACTA ANAESTH SCAND, V49, P1088, DOI 10.1111/j.1399-6576.2005.00780.x; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Hung KC, 2009, ACTA ANAESTH SCAND, V53, P1227, DOI 10.1111/j.1399-6576.2009.02058.x; Kabukcu HK, 2011, ANAESTHESIST, V60, P427, DOI 10.1007/s00101-010-1842-3; Kadoi Y, 2008, BRIT J ANAESTH, V100, P224, DOI 10.1093/bja/aem343; Koroglu A, 2005, BRIT J ANAESTH, V94, P821, DOI 10.1093/bja/aei119; Kunisawa T, 2009, J CLIN ANESTH, V21, P194, DOI 10.1016/j.jclinane.2008.08.015; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Schapermeier U, 2008, ACTA ANAESTH SCAND, V52, P1071, DOI 10.1111/j.1399-6576.2008.01721.x; Schlimp CJ, 2005, CAN J ANAESTH, V52, P207, DOI 10.1007/BF03027731; Shehabi Y, 2004, INTENS CARE MED, V30, P2188, DOI 10.1007/s00134-004-2417-z; Tanaka M, 2005, J PHARMACOL SCI, V99, P77, DOI 10.1254/jphs.FPJ05014X; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Tanskanen PE, 2006, BRIT J ANAESTH, V97, P658, DOI 10.1093/bja/ael220; Venn RM, 2003, INTENS CARE MED, V29, P201, DOI 10.1007/s00134-002-1579-9; Vilo S, 2008, BRIT J ANAESTH, V100, P697, DOI 10.1093/bja/aen070; WEINGER MB, 1995, BRAIN RES, V669, P10, DOI 10.1016/0006-8993(94)01216-5; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	27	15	25	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-9734	2000-1967		UPSALA J MED SCI	Ups. J. Med. Sci.	MAR	2012	117	1					18	21		10.3109/03009734.2011.629749			4	Medicine, General & Internal	General & Internal Medicine	892RT	WOS:000300304000003	22335390	DOAJ Gold, Green Published			2020-06-30	J	Orbach-Zinger, S; Bessler, H; Arnovetzky, R; Levin, Y; Sulkes, J; Bardin, R; Peleg, D; Eidelman, L				Orbach-Zinger, Sharon; Bessler, Hanna; Arnovetzky, Rosana; Levin, Yivgenia; Sulkes, Jaqueline; Bardin, Ron; Peleg, Dan; Eidelman, Leonid			Effect of early versus conventional epidural analgesia during labor on cytokine production	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE			English	Article						Epidural analgesia; cytokines; labor	FETAL INFLAMMATORY RESPONSE; INTERLEUKIN-6 CONCENTRATIONS; SERUM INTERLEUKIN-6; PREMATURE LABOR; PREGNANT-WOMEN; DELIVERY; TERM; PERIPARTUM; SMOKING	Objective. To compare the effect of early epidural analgesia (EEA) vs. conventional epidural analgesia (CEA) on cytokine production in mother and neonate. Methods. Healthy parturients with uncomplicated term pregnancies were randomized into two groups: EEA - parturients who would receive epidural analgesia before onset of pain and the control group, CEA - parturients who would receive epidural analgesia after onset of pain. Cytokines were measured in maternal blood at randomization Visual Analog Scale (VAS) < 30], 24 h postpartum, and in cord blood. Results. Forty-one women were studied. Epidural was performed in EEA when VAS was 23 +/- 10 and in CEA when VAS was77 +/- 10 (p < 0.0001). Background data were similar except for ruptured membranes at admission (EEA 15%, CEA 46.6%; p = 0.03), transient hypotension (EEA 20%, CEA 0%; p = 0.03), and meconium (EEA 25%, CEA 0%; p = 0.01). No significant differences were found in cytokine levels between groups at any time. Interleukin (IL)-6 levels changed significantly only in the control group (p = 0.046). There was significant correlation between baseline maternal IL-6 level and cord blood level in CEA (r = 0.59, p = 0.005), while no significant correlation existed in EEA (r = 0.33, p = 0.16). Conclusion. Although there was no significant difference in cytokine levels between the groups, EEA prevented the significant increase in IL-6 during labor and interrupted IL-6 fetal-maternal dependency.	[Orbach-Zinger, Sharon; Arnovetzky, Rosana; Levin, Yivgenia; Eidelman, Leonid] Beilinson Med Ctr, Rabin Med Ctr, Dept Anesthesiol, IL-49101 Petah Tiqwa, Israel; [Bessler, Hanna] Rabin Med Ctr, Lab Immunol Res, Petah Tiqwa, Israel; [Sulkes, Jaqueline] Rabin Med Ctr, Epidemiol Unit, Petah Tiqwa, Israel; [Bardin, Ron] Rabin Med Ctr, Dept Obstet & Gynecol, Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Orbach-Zinger, S (reprint author), Beilinson Med Ctr, Rabin Med Ctr, Dept Anesthesiol, IL-49101 Petah Tiqwa, Israel.	sharonorbach@yahoo.com					Arntzen KJ, 1998, J PERINAT MED, V26, P17, DOI 10.1515/jpme.1998.26.1.17; Arntzen KJ, 1997, ACTA OBSTET GYN SCAN, V76, P55, DOI 10.3109/00016349709047785; Beilin Y, 2009, OBSTET GYNECOL, V114, P764, DOI 10.1097/AOG.0b013e3181b6beee; Bessler H, 1998, AM J REPROD IMMUNOL, V39, P27; BRIZGYS RV, 1987, ANESTHESIOLOGY, V67, P782; Coussons-Read ME, 2005, PSYCHOSOM MED, V67, P625, DOI 10.1097/01.psy.0000170331.74960.ad; De Jongh RF, 1999, AM J PERINAT, V16, P121, DOI 10.1055/s-2007-993845; DeJongh RF, 1997, ACTA ANAESTH SCAND, V41, P853, DOI 10.1111/j.1399-6576.1997.tb04800.x; Gotsch F, 2007, CLIN OBSTET GYNECOL, V50, P652, DOI 10.1097/GRF.0b013e31811ebef6; Greig PC, 1997, OBSTET GYNECOL, V90, P465, DOI 10.1016/S0029-7844(97)00294-9; Hasegawa K, 2003, J PERIODONTOL, V74, P1764, DOI 10.1902/jop.2003.74.12.1764; Hebisch G, 2004, J PERINAT MED, V32, P475, DOI 10.1515/JPM.2004.131; Hebisch G, 2001, ACTA OBSTET GYN SCAN, V80, P840, DOI 10.1034/j.1600-0412.2001.080009840.x; Huang HC, 2004, EARLY HUM DEV, V77, P29, DOI 10.1016/j.earlhumdev.2004.01.001; Menon R, 2006, AM J REPROD IMMUNOL, V56, P112, DOI 10.1111/j.1600-0897.2006.00394.x; Murtha AP, 2007, OBSTET GYNECOL, V109, P121, DOI 10.1097/01.AOG.0000250474.35369.12; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Radaelli T, 2006, J SOC GYNECOL INVEST, V13, P53, DOI 10.1016/j.jsgi.2005.10.003; Samuelsson AM, 2004, ENDOCRINOLOGY, V145, P4897, DOI 10.1210/en.2004-0742; Smulian JC, 2003, AM J OBSTET GYNECOL, V188, P269, DOI 10.1067/mob.2003.11; Tsunoda M, 2003, INT ARCH ALLERGY IMM, V130, P158, DOI 10.1159/000069008; Winkler M, 2003, BJOG-INT J OBSTET GY, V110, P118, DOI 10.1016/S1470-0328(03)00062-4; Yoon BH, 1999, AM J OBSTET GYNECOL, V181, P773, DOI 10.1016/S0002-9378(99)70299-1; Yoon BH, 1996, AM J OBSTET GYNECOL, V174, P1433, DOI 10.1016/S0002-9378(96)70585-9	24	3	4	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1476-7058			J MATERN-FETAL NEO M	J. Matern.-Fetal Neonatal Med.	MAR	2012	25	3					290	294		10.3109/14767058.2011.574298			5	Obstetrics & Gynecology	Obstetrics & Gynecology	888RO	WOS:000300021600016	21635200				2020-06-30	J	Motamed, F; Aminpour, Y; Hashemian, H; Soltani, AE; Najafi, M; Farahmand, F				Motamed, Farzaneh; Aminpour, Yasaman; Hashemian, Hesam; Soltani, Alireza E.; Najafi, Mehri; Farahmand, Fatemeh			Midazolam-Ketamine Combination for Moderate Sedation in Upper GI Endoscopy	JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION			English	Article						fentanyl; ketamine; midazolam; upper GI endoscopy	UPPER GASTROINTESTINAL ENDOSCOPY; SMALL-DOSE KETAMINE; PEDIATRIC SEDATION; CONSCIOUS SEDATION; DEEP SEDATION; SAFETY; PROPOFOL; FENTANYL; CHILDREN; PREMEDICATION	Objectives: The aim of the study was to compare the quality of sedation with 3 different sedation regimens in upper gastrointestinal endoscopy (UGIE) in pediatric patients. Methods: One hundred fifty consecutive children who underwent UGIE were randomly assigned to 1 of the 3 medication regimens. Patients in group A (n = 49) received placebo. Forty-five minutes after the placebo was given, repeated intravenous (IV) doses of 0.1 mg/kg midazolam were administered titrated to achieve a level of deep sedation. Patients in group B (n = 51) received oral ketamine instead of placebo, and patients in group C (n = 50) received oral fentanyl instead of placebo with the same methodology and sedation endpoint. Results: The mean dose of midazolam administered in group B patients was remarkably lower compared with that of groups A and C. Patients in group B showed less distress in IV line placement and separation from parents, higher comfort level, more endoscopist satisfaction, and higher sedation depth compared with groups A and C. The recovery time was significantly shorter in group B. All of the 3 regimens were safe. All of the complications were managed successfully. Conclusions: Our data suggest that synergistic sedation with oral ketamine and IV midazolam for UGIE in children is a suitable and safe sedation. The higher rate of vomiting in group B in contrast to previous studies must be caused mainly by the oral route of ketamine administration.	[Hashemian, Hesam] Univ Tehran Med Sci, Dept Ophthalmol, Farabi Hosp, Tehran, Iran; [Motamed, Farzaneh; Aminpour, Yasaman; Najafi, Mehri; Farahmand, Fatemeh] Univ Tehran Med Sci, Dept Gastroenterol, Tehran, Iran; [Soltani, Alireza E.] Univ Tehran Med Sci, Dept Anesthesiol, Tehran, Iran	Hashemian, H (reprint author), Univ Tehran Med Sci, Dept Ophthalmol, Farabi Hosp, Tehran, Iran.	shhlucky@yahoo.com	Hashemian, H./M-3740-2013; Soltani, alireza Ebrahim/R-8654-2019	Hashemian, H./0000-0003-0836-8937; 			Amornyotin S, 2010, INT J PEDIAT, DOI 10.1155/2010/748564; Annequin D, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e47; [Anonymous], 2008, PEDIATR ANESTH, V18, P11, DOI 10.1111/j.1460-9592.2007.02405.x; Balsells F, 1997, GASTROINTEST ENDOSC, V45, P375, DOI 10.1016/S0016-5107(97)70147-0; Chuang E, 2001, Gastrointest Endosc Clin N Am, V11, P569; CHUANG E, 1995, GASTROINTEST ENDOSC, V42, P156, DOI 10.1016/S0016-5107(95)70073-0; Dilos BM, 2009, INT ANESTHESIOL CLIN, V47, P55, DOI 10.1097/AIA.0b013e3181aeabf5; Gilger MA, 2004, GASTROINTEST ENDOSC, V59, P659, DOI 10.1016/S0016-5107(04)00180-4; Gilger MA, 2001, CURR OPIN PEDIATR, V13, P429, DOI 10.1097/00008480-200110000-00008; Gilger MA, 2007, GASTROINTEST ENDOSC, V65, P211, DOI 10.1016/j.gie.2006.10.047; GRANT IS, 1981, BRIT J ANAESTH, V53, P805, DOI 10.1093/bja/53.8.805; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; Green SM, 2000, ACAD EMERG MED, V7, P278, DOI 10.1111/j.1553-2712.2000.tb01076.x; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; HARGROVE CB, 1984, PEDIATRICS, V74, P828; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Koh TL, 2001, J PEDIATR GASTR NUTR, V33, P314, DOI 10.1097/00005176-200109000-00016; Lightdale JR, 2008, GASTROINTEST ENDOSC, V67, P1067, DOI 10.1016/j.gie.2007.11.038; Lowrie L, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e30; Mamula P, 2007, GASTROINTEST ENDOSC, V65, P203, DOI 10.1016/j.gie.2006.05.002; Martinez JL, 2002, J PEDIATR GASTR NUTR, V35, P51, DOI 10.1097/00005176-200207000-00012; Menigaux C, 2000, ANESTH ANALG, V90, P129, DOI 10.1097/00000539-200001000-00029; Michaud L, 2005, ENDOSCOPY, V37, P167, DOI 10.1055/s-2004-826144; Mistry RB, 2005, PHARMACOTHERAPY, V25, P1104, DOI 10.1592/phco.2005.25.8.1104; Montes RG, 2000, J PEDIATR GASTR NUTR, V31, P41, DOI 10.1097/00005176-200007000-00010; Paspatis GA, 2006, J PEDIATR GASTR NUTR, V43, P195, DOI 10.1097/01.mpg.0000228099.04702.39; Petrack EM, 2000, CLIN PED EMERG MED, V1, P281; Schwarz SM, 2007, J PEDIATR GASTR NUTR, V44, P295, DOI 10.1097/MPG.0b013e31802f6435; Sury MRJ, 2008, PEDIATR ANESTH, V18, P18, DOI 10.1111/j.1460-9592.2007.02379.x; Tolia V, 2000, J PEDIATR GASTR NUTR, V30, P477, DOI 10.1097/00005176-200005000-00003; Tosun Z, 2007, PEDIATR ANESTH, V17, P983, DOI 10.1111/j.1460-9592.2007.02206.x; Varadarajulu S, 2007, ALIMENT PHARM THER, V25, P987, DOI 10.1111/j.1365-2036.2007.03285.x; Verhage Jan, 2003, Rom J Gastroenterol, V12, P273	33	16	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-2116	1536-4801		J PEDIATR GASTR NUTR	J. Pediatr. Gastroenterol. Nutr.	MAR	2012	54	3					422	426		10.1097/MPG.0b013e3182323c75			5	Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics	Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics	898RT	WOS:000300760200022	21857244				2020-06-30	J	Marton, J; Glaenzel, B; Roessler, J; Golaszewski, D; Henriksen, G				Marton, Janos; Glaenzel, Brita; Roessler, Julia; Golaszewski, Daniela; Henriksen, Gjermund			A Convenient Route to 4-Carboxy-4-Anilidopiperidine Esters and Acids	MOLECULES			English	Article						4-anilidopiperidines; tert-butyl ester; opioid receptors; positron emission tomography	MU-OPIOID-RECEPTOR; PHARMACOLOGICAL EVALUATION; CARFENTANIL; RADIOSYNTHESIS; ANALGESICS; CHEMISTRY	The route selection and development of a convenient synthesis of 4-carboxy-4-anilidopiperidines is described. Previous routes were hampered by the low yield of the target esters as well as the inability to convert the esters to the required free acids. Considerations for large-scale production led to a modified synthesis that utilised a tert-butyl ester of 4-carboxy-4-anilidopiperidines which resulted in a dramatic increase in the overall yield of the target N-propionylated-4-anilidopiperidine-4-carboxylic acids and their corresponding methyl esters. These compounds are now available for use as precursors and reference standards, of particular value for the production of C-11 and F-18-labelled 4-carboxy-4-anilidopiperidine radiotracers.	[Marton, Janos; Glaenzel, Brita; Roessler, Julia; Golaszewski, Daniela] Biomed Forsch Reagenzien GmbH, ABX Adv Biochem Cpds, D-01454 Radeberg, Germany; [Henriksen, Gjermund] Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, D-81675 Munich, Germany	Henriksen, G (reprint author), Scint N AS, Utveien 15, N-1430 As, Norway.	marton@abx.de; glaenzel@abx.de; julia.roessler@chemie.tu-dresden.de; golaszewski@abx.de; henriksen@scintomics.no					ABDULLA RF, 1979, TETRAHEDRON, V35, P1675, DOI 10.1016/0040-4020(79)88001-1; ARMSTRONG A, 1988, TETRAHEDRON LETT, V29, P2483, DOI 10.1016/S0040-4039(00)87913-7; COLAPRET JA, 1989, J MED CHEM, V32, P968, DOI 10.1021/jm00125a008; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; FELDMAN PL, 1991, J MED CHEM, V34, P2202, DOI 10.1021/jm00111a041; FELDMAN PL, 1990, J ORG CHEM, V55, P4207, DOI 10.1021/jo00300a047; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; GALZI JL, 1990, J MED CHEM, V33, P2456, DOI 10.1021/jm00171a020; Greenwald Mark K., 2009, P45, DOI 10.1007/978-1-59745-197-0_3; Henriksen G, 2005, J MED CHEM, V48, P7720, DOI 10.1021/jm0507274; Henriksen G, 2005, J LABELLED COMPD RAD, V48, P771, DOI 10.1002/jlcr.995; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; JANSSEN PA, 1976, Patent No. 3998834; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kiessling AJ, 1997, SYNTHETIC COMMUN, V27, P923, DOI 10.1080/00397919708004212; Lee YS, 2007, BIOORG MED CHEM LETT, V17, P2161, DOI 10.1016/j.bmcl.2007.01.114; Meusel M, 2004, ORG PREP PROCED INT, V36, P391, DOI 10.1080/00304940409356627; Saji H, 1992, Ann Nucl Med, V6, P63; Studenov AR, 2003, J LABELLED COMPD RAD, V46, P837, DOI 10.1002/jlcr.722; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; Wadsak W, 2007, RADIOCHIM ACTA, V95, P33, DOI 10.1524/ract.2007.95.1.33	22	1	1	0	4	MDPI AG	BASEL	POSTFACH, CH-4005 BASEL, SWITZERLAND	1420-3049			MOLECULES	Molecules	MAR	2012	17	3					2823	2832		10.3390/molecules17032823			10	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	916RJ	WOS:000302120600040	22399137	DOAJ Gold, Green Published			2020-06-30	J	Cha, MH; Eom, JH; Lee, YS; Kim, WY; Park, YC; Min, SH; Kim, JH				Cha, Moon Ho; Eom, Ji Hye; Lee, Yoon Sook; Kim, Woon Young; Park, Young Cheol; Min, Sam Hong; Kim, Jae Hwan			Beneficial Effects of Adding Ketamine to Intravenous Patient-Controlled Analgesia with Fentanyl after the Nuss Procedure in Pediatric Patients	YONSEI MEDICAL JOURNAL			English	Article						Fentanyl; funnel chest; ketamine; patient-controlled analgesia; pediatrics	POSTOPERATIVE PAIN MANAGEMENT; MAJOR ABDOMINAL-SURGERY; PECTUS EXCAVATUM REPAIR; MORPHINE CONSUMPTION; CHILDREN; COMBINATION	Purpose: The aim of this prospective, double-blind, randomized study was to investigate the analgesic effects of low-dose ketamine on intravenous patient-controlled analgesia (IV-PCA) with fentanyl for pain control in pediatric patients following the Nuss procedure for pectus excavatum. Materials and Methods: Sixty pediatric patients undergoing the Nuss procedure were randomly assigned to receive fentanyl (Group F, n=30) or fentanyl plus ketamine (Group FK, n=30). Ten minutes before the end of surgery, following the loading dose of each solution, 0.5 pg/kg/hr of fentanyl or 0.5 mu g/kg/hr of fentanyl plus 0.15 mg/kg/hr of ketamine was infused via an IV-PCA pump (basal rate, I mL/hr; bolus, 0.5 mL; lock out interval, 30 min). Fentanyl consumption, pain score, ketorolac use, nausea/vomiting, ondansetron use, pruritus, respiratory depression, hallucination, dreaming, and parent satisfaction with pain control were measured throughout the 48 hours following surgery. Results: The pain scores, ketorolac use, and fentanyl consumption of Group FK were significantly lower than in Group F (p<0.05). The incidence of nausea/vomiting and ondansetron use in Group FK was significantly lower than in Group F (p<0.05). There were no reports of respiratory depression, hallucination or dreaming. Parent satisfaction with pain control was similar between the two groups. Conclusion: We concluded that low-dose ketamine added to IV-PCA with fentanyl after the Nuss procedure in pediatric patients can reduce pain scores, consumption of fentanyl, and incidence of nausea/vomiting without increasing side effects.	[Cha, Moon Ho; Eom, Ji Hye; Lee, Yoon Sook; Kim, Woon Young; Park, Young Cheol; Min, Sam Hong; Kim, Jae Hwan] Korea Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 136705, South Korea	Kim, JH (reprint author), Korea Univ, Coll Med, Dept Anesthesiol & Pain Med, 123 Jeokgeum Ro, Ansan 425707, South Korea.	anejhkim@korea.ac.kr		Lee, Yoon Sook/0000-0002-6455-0680			Adriaenssens G, 1999, BRIT J ANAESTH, V83, P393; Ahn Ki-Rhang, 2005, Korean Journal of Anesthesiology, V49, P624; Badrinath S, 2000, ANESTH ANALG, V90, P858, DOI 10.1213/00000539-200004000-00016; Butkovic D, 2007, BRIT J ANAESTH, V98, P677, DOI 10.1093/bja/aem055; EDWARDS ND, 1993, ANAESTHESIA, V48, P124; Fleron MH, 2003, ANESTH ANALG, V97, P2, DOI 10.1213/01.ANE.0000066355.07482.0C; GRANT IS, 1983, BRIT J ANAESTH, V55, P1107, DOI 10.1093/bja/55.11.1107; Javery KB, 1996, CAN J ANAESTH, V43, P212, DOI 10.1007/BF03011736; Jensen LL, 2008, ACTA ANAESTH SCAND, V52, P479, DOI 10.1111/j.1399-6576.2008.01602.x; Kollender Y, 2008, EUR J CANCER, V44, P954, DOI 10.1016/j.ejca.2008.02.021; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Michelet P, 2007, BRIT J ANAESTH, V99, P396, DOI 10.1093/bja/aem168; Murdoch CJ, 2002, ANAESTHESIA, V57, P484, DOI 10.1046/j.0003-2409.2001.02409.x; Nesher N, 2009, CHEST, V136, P245, DOI 10.1378/chest.08-0246; Nesher N, 2008, PHARMACOL RES, V58, P38, DOI 10.1016/j.phrs.2008.06.003; Nuss D, 1998, J PEDIATR SURG, V33, P545, DOI 10.1016/S0022-3468(98)90314-1; Phillips WJ, 2004, J AM ACAD ORTHOP SUR, V12, P221, DOI 10.5435/00124635-200407000-00003; Reeves M, 2001, ANESTH ANALG, V93, P116; Rugyte DC, 2010, PEDIATR SURG INT, V26, P665, DOI 10.1007/s00383-010-2619-0; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Sveticic G, 2008, ANESTH ANALG, V106, P287, DOI 10.1213/01.ane.0000289637.11065.8f; Unlugenc H, 2002, ACTA ANAESTH SCAND, V46, P1025, DOI 10.1034/j.1399-6576.2002.460817.x; Visser E, 2006, BIOMED PHARMACOTHER, V60, P341, DOI 10.1016/j.biopha.2006.06.021; Werawatganon T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004088.pub2	25	10	11	0	1	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	MAR 1	2012	53	2					427	432		10.3349/ymj.2012.53.2.427			6	Medicine, General & Internal	General & Internal Medicine	891JS	WOS:000300213600026	22318834	DOAJ Gold, Green Published			2020-06-30	J	Fanning, JJ; Stucke, AG; Christensen, MA; Cassidy, LD; Berens, RJ				Fanning, Jeffrey J.; Stucke, Astrid G.; Christensen, Melissa A.; Cassidy, Laura D.; Berens, Richard J.			Perioperative opiate requirements in children with previous opiate infusion	PEDIATRIC ANESTHESIA			English	Article						opiate; tolerance; pediatrics	TOLERANCE; DEPENDENCE; FENTANYL	Background: Critically ill children often require continuous opiate infusions. Tolerance may develop requiring a weaning strategy to prevent withdrawal symptoms. These children may also require subsequent surgical procedures. This is the first study to investigate whether previously opiate-tolerant patients require higher doses of opiates for adequate pain management perioperatively. Methods: A retrospective study was conducted at a tertiary children's hospital to investigate whether children previously exposed to continuous opiates for 10 or more days with subsequent weaning from those opiates will have similar or increased perioperative opiate requirements when compared to opioid-naive controls. Study patients included 31 children with previous continuous opiate exposure for 10 or more days followed by weaning and without signs of withdrawal for at least 72 h prior to the surgical procedure. Excluded were patients over 18 years of age, those whose surgical procedures would be unlikely to require perioperative opiates, oncological patients, burn patients, neurologically devastated patients, and patients who received regional anesthesia in addition to perioperative narcotics. The control group consisted of 31 age-and case-matched opiate-naive patients who underwent a surgical procedure during a similar time frame as the study patient. The medication administration record was reviewed for the length of continuous opiate exposure, date of last opiate use prior to a subsequent surgical procedure, and opiate use during the perioperative period. Opiate use was calculated as morphine equivalents per kilogram body weight (MSEQ.kg(-1)). The Wilcoxon rank sum test was used for univariate comparisons between matched pairs, and P-values < 0.05 were considered statistically significant. Results: The perioperative opiate requirements in opiate-exposed patients (median, interquartile range: 0.14, 0.08-0.25 MSEQ.kg(-1)) were not significantly different from opiate-naive patients (median, interquartile range 0.10, 0.05-0.2 MSEQ.kg(-1), P = 0.19). Pain scores indicated that patients were generally comfortable in the perioperative period. Conclusions: The perioperative opiate requirements of pediatric patients who were successfully weaned after prolonged opiate use were similar to opiate-naive patients. A history of prolonged opiate use alone does not necessitate special pain management for future procedures.	[Stucke, Astrid G.; Christensen, Melissa A.; Cassidy, Laura D.; Berens, Richard J.] Childrens Hosp Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Stucke, Astrid G.; Christensen, Melissa A.; Cassidy, Laura D.; Berens, Richard J.] Childrens Hosp Wisconsin, Med Coll Wisconsin, Div Crit Care Med, Dept Anesthesiol, Milwaukee, WI 53226 USA; [Stucke, Astrid G.; Christensen, Melissa A.; Cassidy, Laura D.; Berens, Richard J.] Childrens Hosp Wisconsin, Med Coll Wisconsin, Div Crit Care Med, Dept Pediat, Milwaukee, WI 53226 USA; [Fanning, Jeffrey J.] Med City Childrens Hosp, PA Pediat Crit Care Med, Dallas, TX USA	Berens, RJ (reprint author), Childrens Hosp Wisconsin, Dept Surg, Pediat Crit Care MS 681,POB 1997,9000 W Wisconsin, Milwaukee, WI 53226 USA.	rberens@chw.org					Anand K J, 1996, Crit Care Nurse, V16, P87; ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Berens RJ, 2006, ANESTH ANALG, V102, P1045, DOI 10.1213/01.ane.0000202395.94542.3e; Franck L S, 1998, Am J Crit Care, V7, P364; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Heard CMB, 2006, PEDIAT CRITICAL CARE, P1748; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Lim G, 2005, PAIN, V114, P81, DOI 10.1016/j.pain.2004.11.019; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; Mitra Sukanya, 2008, J Opioid Manag, V4, P123; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Robertson R C, 2000, Pediatr Crit Care Med, V1, P119, DOI 10.1097/00130478-200010000-00005	14	5	6	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAR	2012	22	3					203	208		10.1111/j.1460-9592.2011.03732.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	882FK	WOS:000299548000002	22070472				2020-06-30	J	Thompson, ME; Aasheim, H				Thompson, Mark E.; Aasheim, Heidi			Migrating thoracic epidural catheter in an infant	PEDIATRIC ANESTHESIA			English	Article						infant; epidural; postoperative complication; acute pain	POSTOPERATIVE ANALGESIA; COLONIZATION	Infants have a shorter neuraxial length and shorter skin to epidural space than adults. Even small amounts of migration may produce significant and unintended effects. Optimal fixation to prevent migration, bacterial colonization, and leakage is not clear from the literature. We report the case of a thoracic epidural that migrated inward for six centimeters, associated with loss of analgesic effect.	[Thompson, Mark E.] Childrens Hosp Colorado, Dept Anesthesia, Aurora, CO 80045 USA; Univ Colorado, Aurora, CO USA	Thompson, ME (reprint author), Childrens Hosp Colorado, Dept Anesthesia, 13123 E 16th Ave,Box B090, Aurora, CO 80045 USA.	mark.thompson@childrenscolorado.org		Thompson, Mark/0000-0002-1789-312X			Maria BD, 2011, PEDIATR ANESTH, V21, P974, DOI 10.1111/j.1460-9592.2011.03598.x; Ho KM, 2006, J ANTIMICROB CHEMOTH, V58, P281, DOI 10.1093/jac/dkl234; Marino M, 2009, J CLIN ANESTH, V21, P538, DOI 10.1016/j.jclinane.2009.03.003; MOURISSE J, 1989, ANAESTHESIA, V44, P574, DOI 10.1111/j.1365-2044.1989.tb11445.x; PHILLIPS DC, 1987, ANAESTHESIA, V42, P661, DOI 10.1111/j.1365-2044.1987.tb03096.x; Steffen P, 2004, J CLIN ANESTH, V16, P92, DOI 10.1016/j.jclinane.2003.05.007; Yuan HB, 2008, ANESTHESIOLOGY, V108, P130, DOI 10.1097/01.anes.0000296066.79547.f3	7	6	6	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	MAR	2012	22	3					285	287		10.1111/j.1460-9592.2011.03781.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	882FK	WOS:000299548000015	22212050				2020-06-30	J	Verplaetse, R; Tytgat, J				Verplaetse, Ruth; Tytgat, Jan			Development and validation of a sensitive UPLC-MS/MS method for the analysis of narcotic analgesics in urine and whole blood in forensic context	FORENSIC SCIENCE INTERNATIONAL			English	Article; Proceedings Paper	Joint Meeting of the Society-of-Toxicological-and-Forensic-Chemistry (GTFCh)/48th Annual Meeting of the International-Association-of-Forensic-Toxicologists (TIAFT)	AUG 29-SEP 02, 2010	Bonn, GERMANY	Int Assoc Forens Toxicologists, Soc Toxicol & Forens Chem		LC-MS/MS; High pH mobile phase; UFLC or UPLC; Opioids; Post-mortem samples	TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ELECTROSPRAY-IONIZATION; TISSUE DISTRIBUTION; HPLC-MS/MS; BUPRENORPHINE; METABOLITES; TRAMADOL; FENTANYL; NORBUPRENORPHINE	Narcotic analgesics are widely (ab) used and sometimes only occur in low concentrations in biological samples. Therefore, a highly sensitive liquid chromatography tandem mass spectrometry method was developed for simultaneous analysis of 9 narcotic analgesics and metabolites (buprenorphine, O-desmethyltramadol, fentanyl, norbuprenorphine, norfentanyl, pethidine, piritramide, tilidine and tramadol) in urine and whole blood. Sample preparation was performed on a mixed-mode cation exchange solid phase extraction cartridge with an additional alkaline wash step to decrease matrix effects and thus increase sensitivity. Ionization with electrospray ionization was found to be more efficient than atmospheric pressure chemical ionization. The use of a mobile phase of high pH resulted in higher electrospray ionization signals than the conventional low pH mobile phases. In the final method, gradient elution with 10 mM ammonium bicarbonate (pH 9) and methanol was performed on a small particle column (Acquity C18, 1.7 mu m, 2.1 mm x 50 mm). Selectivity, matrix effects, recovery, linearity, sensitivity, precision, accuracy and stability were validated in urine and whole blood. All parameters were successfully evaluated and the method showed very high sensitivity, which was the major aim of this study. The applicability of the method was demonstrated by analysis of several forensic cases involving narcotic analgesics. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Verplaetse, Ruth; Tytgat, Jan] Katholieke Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium	Verplaetse, R (reprint author), Katholieke Univ Leuven, Toxicol Lab, Campus Gasthuisberg O&N 2,POB 922,Herestr 49, B-3000 Louvain, Belgium.	ruth.verplaetse@pharm.kuleuven.be; jan.tytgat@pharm.kuleuven.be		Tytgat, Jan/0000-0003-1778-6022			Allen KR, 2006, CLIN TOXICOL, V44, P147, DOI 10.1080/15563650500514434; Bruins AP, 1998, J CHROMATOGR A, V794, P345, DOI 10.1016/S0021-9673(97)01110-2; Churchwell MI, 2005, J CHROMATOGR B, V825, P134, DOI 10.1016/j.jchromb.2005.05.037; Drummer O.H., 2001, FORENSIC PATHOLOGY D; Drummer OH, 2004, FORENSIC SCI INT, V142, P101, DOI 10.1016/j.forsciint.2004.02.013; Favretto D, 2006, RAPID COMMUN MASS SP, V20, P1257, DOI 10.1002/rcm.2444; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Hakala KS, 2006, RAPID COMMUN MASS SP, V20, P2081, DOI 10.1002/rcm.2562; Hopfgartner G, 2004, J MASS SPECTROM, V39, P845, DOI 10.1002/jms.659; Huang W, 2006, THER DRUG MONIT, V28, P245, DOI 10.1097/01.ftd.0000197094.92559.b4; Kacinko SL, 2008, ANAL BIOANAL CHEM, V392, P903, DOI 10.1007/s00216-008-2326-z; Kahlich R, 2006, RAPID COMMUN MASS SP, V20, P275, DOI 10.1002/rcm.2257; Kahlich R., 2005, STUDIES STEREOSPECIF; Kronstrand R, 2003, J ANAL TOXICOL, V27, P464, DOI 10.1093/jat/27.7.464; Liu AC, 2008, TALANTA, V75, P198, DOI 10.1016/j.talanta.2007.10.050; Moore KA, 1999, AM J FOREN MED PATH, V20, P98, DOI 10.1097/00000433-199903000-00023; Musshoff F, 2006, J MASS SPECTROM, V41, P633, DOI 10.1002/jms.1021; Musshoff F, 2005, FORENSIC SCI INT, V154, P247, DOI 10.1016/j.forsciint.2004.10.012; Musshoff F, 2001, FORENSIC SCI INT, V116, P197, DOI 10.1016/S0379-0738(00)00374-1; Novakova L, 2006, J SEP SCI, V29, P2433, DOI 10.1002/jssc.200600147; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; POLETTINI A, 2006, APPL LC MS TOXICOLOG; Saccomanni G, 2010, J PHARMACEUT BIOMED, V53, P194, DOI 10.1016/j.jpba.2010.03.016; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Van De Steene JC, 2008, J AM SOC MASS SPECTR, V19, P713, DOI [10.1016/j.jasms.2008.01.01.3, 10.1016/j.jasms.2008.01.013]; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Zhou SL, 1996, J CHROMATOGR A, V755, P189, DOI 10.1016/S0021-9673(96)00617-6	28	19	20	1	34	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	FEB 10	2012	215	1-3					136	145		10.1016/j.forsciint.2011.01.047			10	Medicine, Legal	Legal Medicine	891ND	WOS:000300223000027	21356580				2020-06-30	J	Kesimci, E; Engin, AB; Kanbak, O; Karahalil, B				Kesimci, E.; Engin, A. B.; Kanbak, O.; Karahalil, B.			Association between ABCB1 gene polymorphisms and fentanyl's adverse effects in Turkish patients undergoing spinal anesthesia	GENE			English	Article						ABCB1 polymorphism; Spinal anesthesia; Fentanyl	BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN; INTESTINAL-ABSORPTION; MDR1 GENE; TRANSPORT; PHARMACODYNAMICS; POPULATION; INHIBITION; QUINIDINE; MORPHINE	The ATP-binding cassette transporter (ABCB1) gene product, P-glycoprotein plays an important role in the prevention of intracellular accumulation of potentially toxic substances and metabolites in various tissues. Single nucleotide polymorphisms in this gene are claimed to be correlated with changes in the function of P-glycoprotein. There is evidence that fentanyl, may be a substrate for P-glycoprotein. The aim of the study was to assess whether an association exists between ABCB1 gene polymorphism and early respiratory and sedative adverse effects of intravenous fentanyl in Turkish patients who underwent spinal anesthesia In all 83 unrelated Turkish patients were enrolled in this study. In this study, spinal anesthesia was provided and a single dose of intravenous fentanyl (2.5 mu g.kg(-1)) at the beginning of surgery was used as a sedative agent. Bispectral index, respiration rate and peripheral oxygen saturation were measured continuously and recorded throughout the study. The allele and genotype frequencies were similar to previous data from Turkish population. Respiratory rate (RR) and SpO(2) parameters of the patients did not show any significant difference according to the genotype distribution for C1236T and C3435T SNPs. Fentanyl-induced decrease in respiration rate was most remarkable at 15 min (23%) in CC genotype of C1236T, whereas in TT genotype of C3435T (18%) polymorphism. SpO(2) parameters in allele distribution were also not significant among the groups (p = 0.374, p = 0.985, respectively). For the C1236T polymorphism, patients carrying T allele showed a significant decrease in pH, and a significant increase in pCO(2) (p<0.001). ABCB1 polymorphisms did not seem to have a significant effect on sedation and respiratory depression caused by intravenous fentanyl in spinal anesthesia in Turkish patients. (C) 2011 Elsevier B.V. All rights reserved.	[Kesimci, E.; Kanbak, O.] Ataturk Training & Res Hosp, Anesthesiol & Intens Care Dept, Ankara, Turkey; [Engin, A. B.; Karahalil, B.] Gazi Univ, Fac Pharm, Dept Toxicol, Ankara, Turkey	Kesimci, E (reprint author), Ankaraluar Cad Ankara Evleri 17, TR-06810 Ankara, Turkey.	elvinku@yahoo.com	kanbak, orhan/L-3767-2019	kanbak, orhan/0000-0001-9171-4604	Gazi UniversityGazi University [02/2009-07]	This study was supported by grants from the Scientific Research Projects of Gazi University (Project No: 02/2009-07). The authors wish to thank all patients and Salih Ergocen MSc for statistical analysis.	Akin M, 2011, GENE, V487, P80, DOI 10.1016/j.gene.2011.06.019; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; CIRELLA VN, 1987, ANESTH ANALG, V66, P703; Consales G, 2006, MINERVA ANESTESIOL, V72, P329; Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027; Elkiweri IA, 2009, ANESTH ANALG, V108, P149, DOI 10.1213/ane.0b013e31818e0bd1; Gumus-Akay G, 2008, GENET MOL RES, V7, P1193, DOI 10.4238/vol7-4gmr496; Hamabe W, 2007, J PHARMACOL SCI, V105, P353, DOI 10.1254/jphs.FP0071287; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Kato M, 2008, PROG NEURO-PSYCHOPH, V32, P398, DOI 10.1016/j.pnpbp.2007.09.003; Kharasch ED, 2004, J CLIN PHARMACOL, V44, P224, DOI 10.1177/0091270003262075; Kharasch ED, 2004, BRIT J CLIN PHARMACO, V57, P600, DOI 10.1111/j.1365-2125.2003.02053.x; Kharasch ED, 2003, CLIN PHARMACOL THER, V74, P543, DOI 10.1016/j.clpt.2003.08.011; Kocabas NA, 2006, INT J TOXICOL, V25, P419, DOI 10.1080/10915810600870567; Kosarac B, 2009, CURR OPIN ANESTHESIO, V22, P476, DOI 10.1097/ACO.0b013e32832e34c9; Marzolini C, 2004, CLIN PHARMACOL THER, V75, P13, DOI 10.1016/j.clpt.2003.09.012; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Pauli-Magnus C, 2003, CLIN PHARMACOL THER, V74, P487, DOI 10.1016/S0009-9236(03)00234-0; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Saricaoglu H, 2011, GENET MOL RES, V10, P1, DOI 10.4238/vol10-1gmr824; Sia AT, 2010, INT J OBSTET ANESTH, V19, P254, DOI 10.1016/j.ijoa.2010.03.001; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; Taniguchi K, 1996, CANCER RES, V56, P4124; Westerlund M, 2009, PARKINSONISM RELAT D, V15, P422, DOI 10.1016/j.parkreldis.2008.11.010; Xhemo E, 2007, P ANN INT IEEE EMBS, P4592; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723	28	18	19	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-1119			GENE	Gene	FEB 10	2012	493	2					273	277		10.1016/j.gene.2011.11.040			5	Genetics & Heredity	Genetics & Heredity	895DM	WOS:000300476400014	22197686				2020-06-30	J	Paech, MJ; Bloor, M; Schug, SA				Paech, M. J.; Bloor, M.; Schug, S. A.			NEW FORMULATIONS OF FENTANYL FOR ACUTE PAIN MANAGEMENT	DRUGS OF TODAY			English	Review						Fentanyl; Opioid; Breakthrough pain; Cancer pain	IONTOPHORETIC TRANSDERMAL SYSTEM; RANDOMIZED CONTROLLED-TRIAL; BREAKTHROUGH CANCER PAIN; CONTROLLED INTRANASAL ANALGESIA; PATIENT-CONTROLLED ANALGESIA; OPIOID-TOLERANT PATIENTS; PLACEBO-CONTROLLED TRIAL; BUCCAL SOLUBLE FILM; POSTOPERATIVE PAIN; DOUBLE-BLIND	Intravenous fentanyl citrate has stood the test of time as a valuable formulation for pain management. The desirable physicochemical properties of fentanyl have allowed the development of several alternative formulations for delivery using less invasive routes, for example, transmucosal (intranasal, oral buccal and oral sublingual) and transdermal. These new formulations have been applied to clinical settings in which rapid onset of analgesia is desired, using convenient but noninvasive methods. Recent commercialization of various formulations has been driven largely by the needs of cancer patients, for whom severe but self-limiting "breakthrough" pain is less suitably treated by parenteral or oral routes of opioid administration. However, these formulations are also used for acute analgesia in prehospital and in-hospital emergency department care, and for pediatric acute pain management. Finally, they are increasingly used by patients with chronic pain of nonmalignant origin, although there is considerable debate about their merit in this group. We searched the databases MEDLINE, PubMed, EMBASE, CINAHL and Cochrane up to October 2011, using search terms "fentanyl AND nasal; intranasal; transmucosal; buccal; sublingual; oral; inhaled; inhalation; transdermal" The characteristics of several formulations of fentanyl are reviewed, detailing their pharmacokinetics, pharmacodynamics and clinical experience with their use for acute pain management.	[Paech, M. J.; Schug, S. A.] Univ Western Australia, Sch Med & Pharmacol, Pharmacol & Anaesthesiol Unit, Perth, WA 6009, Australia; [Paech, M. J.; Bloor, M.] King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Subiaco, WA 6008, Australia	Paech, MJ (reprint author), Univ Western Australia, Sch Med & Pharmacol, Pharmacol & Anaesthesiol Unit, Perth, WA 6009, Australia.	michael.paech@health.wa.gov.au	Schug, Stephan/G-1432-2010	Schug, Stephan/0000-0002-0302-2315; PAECH, MICHAEL/0000-0001-9023-6575	Janssen PharmaceuticalsJohnson & Johnson USAJanssen Biotech Inc; iX Biopharma, Ltd. Pte.; Pfizer, Inc.Pfizer	The department of Prof. S. Schug receives research and consultancy funding from Janssen Pharmaceuticals and iX Biopharma, Ltd. Pte., which manufacture some of the products mentioned in the review. The department of Prof. M. Paech, similarly, receives research funding from Pfizer, Inc. M. floor states no conflicts of interest.	Adverse Events Inc., ACT; Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; British Pain Society, 2010, OP PERS PAIN GOOD PR; Burton AW, 2004, CLIN J PAIN, V20, P195, DOI 10.1097/00002508-200405000-00011; Bushnaq M, 2009, J PALLIAT MED, V12, P511, DOI 10.1089/jpm.2009.9618; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Clinical Effectiveness Committee of the College of Emergency Medicine, GUID MAN PAIN CHILDR; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2011, PAIN PRACT; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; European Medicines Agency, ION FENT NONR MARK A; Fallon M., 2010, PALLIATIVE MED, V24; Fine PG, 2000, REGION ANESTH PAIN M, V25, P1, DOI 10.1016/S1098-7339(00)80002-4; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; GIZURARSON S, 1993, ADV DRUG DELIVER REV, V11, P329, DOI 10.1016/0169-409X(93)90015-V; Graff GR, 2004, RESPIRATION, V71, P646, DOI 10.1159/000081769; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Illum L, 2007, J PHARM SCI-US, V96, P473, DOI 10.1002/jps.20718; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Landy SH, 2004, HEADACHE, V44, P762, DOI 10.1111/j.1526-4610.2004.04142.x; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Leppert Wojciech, 2010, Cancer Manag Res, V2, P225, DOI 10.2147/CMR.S7926; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lim C.B., 2012, ANESTH ANAL IN PRESS; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Mandel L, 2011, J AM DENT ASSOC, V142, P406, DOI 10.14219/jada.archive.2011.0195; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Manning H L, 2000, Respir Care, V45, P1342; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; O'Connor AB, 2008, PAIN MED, V9, P258, DOI 10.1111/j.1526-4637.2008.00413.x; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PENNINGTON AK, 1988, INT J PHARM, V43, P221, DOI 10.1016/0378-5173(88)90277-3; Pennington P, 2009, PAIN MANAG NURS, V10, P124, DOI 10.1016/j.pmn.2007.09.001; Poon KH, 2009, ACUTE PAIN, V11, P65; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Sathyan S, 2005, CLIN PHARMACOKINET, V44, P17, DOI 10.2165/00003088-200544001-00004; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Shaiova L, 2004, J NATL MED ASSOC, V96, P984; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stam W., 2009, EUR J PAIN S1, V13, P5241; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stiebel H.W., 1993, SCHMERZ, V7, P174; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; Taylor D., 2010, J SUPPORT ONCOL, V8, P201; Taylor Donald, 2010, J Support Oncol, V8, P184; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; US Food and Drug Administration, IMP SAF INF FENT; US Food and Drug Administration, QUEST ANSW ONS FENT; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Watkins Nicholas, 2006, Emerg Med Australas, V18, P51, DOI 10.1111/j.1742-6723.2006.00808.x; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Zappetella G., 2006, COCHRANE DB SYST REV	107	18	18	0	30	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	1699-3993	1699-4019		DRUG TODAY	Drugs Today	FEB	2012	48	2					119	132		10.1358/dot.2012.48.2.1745275			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	033QP	WOS:000310814400003	22384452				2020-06-30	J	Kamata, M; Nagahama, S; Kakishima, K; Sasaki, N; Nishimura, R				Kamata, Masatoshi; Nagahama, Shotaro; Kakishima, Kei; Sasaki, Nobuo; Nishimura, Ryohei			Comparison of Behavioral Effects of Morphine and Fentanyl in Dogs and Cats	JOURNAL OF VETERINARY MEDICAL SCIENCE			English	Article						behavior; canine; feline; fentanyl; morphine	PAIN MANAGEMENT; ATTITUDES; ANALGESIA; HORSE	Behavioral effects induced by intravenous administration of morphine at 0.3, 0.6, 1.2, and 2.4 mu g/kg and fentanyl at 5, 10, 20, and 40 mu g/kg were evaluated in dogs and cats. In dogs, fentanyl and morphine depressed activity and level of consciousness in a dose-dependant manner. In cats, higher doses of fentanyl stimulated activity temporarily, but excitement, so-called "opioid mania," was not observed. Morphine induced distinctive behavioral changes characterized by sitting with fixed staring, and "opioid mania" was not observed in cats.	[Kamata, Masatoshi; Kakishima, Kei; Nishimura, Ryohei] Univ Tokyo, Lab Vet Emergency Med, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; [Nagahama, Shotaro] Univ Tokyo, Ctr Vet Med, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; [Sasaki, Nobuo] Univ Tokyo, Lab Vet Surg, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan	Nishimura, R (reprint author), Univ Tokyo, Lab Vet Emergency Med, Grad Sch Agr & Life Sci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	arn@mail.ecc.u-tokyo.ac.jp					Barbara E. P., 1978, VET CLIN N AM-SMALL, V8, P317; DHASMANA KM, 1972, PSYCHOPHARMACOLOGIA, V24, P380, DOI 10.1007/BF00402532; Dohoo SE, 1998, CAN VET J, V39, P491; Donald C. P, 2008, PLUMBS VET DRUG HDB, P632; GRANDY JL, 1987, J AM VET MED ASSOC, V191, P59; Hellyer PW, 2003, VET ANAESTH ANALG, V30, P172, DOI 10.1046/j.1467-2995.2003.00143.x; Hugonnard M, 2004, VET ANAESTH ANALG, V31, P154, DOI 10.1111/j.1467-2987.2004.00175.x; Lascelles BDX, 1999, VET REC, V145, P601, DOI 10.1136/vr.145.21.601; MAMA KR, 1993, CAN J VET RES, V57, P106; Narita M, 2001, PHARMACOL THERAPEUT, V89, P1, DOI 10.1016/S0163-7258(00)00099-1; NOLAN AM, 1994, J VET PHARMACOL THER, V17, P323, DOI 10.1111/j.1365-2885.1994.tb00253.x; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P917, DOI 10.1016/S0195-5616(08)70015-9	12	7	7	0	18	JAPAN SOC VET SCI	TOKYO	UNIV TOKYO, 1-1-1 YAYOI, BUNKYO-KU, TOKYO, 103, JAPAN	0916-7250			J VET MED SCI	J. Vet. Med. Sci.	FEB	2012	74	2					231	234		10.1292/jvms.10-0565			4	Veterinary Sciences	Veterinary Sciences	913NU	WOS:000301885500016	21952398	Bronze			2020-06-30	J	Fernandez-Duenas, V; Poveda, R; Sanchez, S; Ciruela, F				Fernandez-Duenas, Victor; Poveda, Raquel; Sanchez, Silvia; Ciruela, Francisco			Synergistic Interaction Between Fentanyl and a Tramadol:Paracetamol Combination on the Inhibition of Nociception in Mice	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						opioid multimodal analgesia; drug drug interaction; synergy	PAIN; TRAMADOL; OPIOIDS	Multimodal analgesic approaches to manage acute and chronic pain are commonly used in humans. Here, we attempted to characterize a synergistic interaction between fentanyl, tramadol, and paracetamol on the inhibition of nociception in a model of visceral pain in mice. The three-drug combined treatment displayed a potent synergistic antinociceptive effect, together with a significant reduction of gastrointestinal transit inhibition. Furthermore, selective and K-opioid receptor antagonists reversed these synergistic antinociceptive effects, thus suggesting a pivotal role of the opioid system. Overall, this study presents accurate pre-clinical data that might be useful to improve the clinical management of opioid-mediated analgesia.	[Fernandez-Duenas, Victor; Poveda, Raquel; Sanchez, Silvia; Ciruela, Francisco] Univ Barcelona, Fac Med, Dept Pathol & Expt Therapeut, Pharmacol Unit, Barcelona 08907, Spain	Fernandez-Duenas, V (reprint author), Univ Barcelona, Fac Med, Dept Pathol & Expt Therapeut, Pharmacol Unit, Barcelona 08907, Spain.	vfernandez@ub.edu	Ciruela, F./A-5096-2013; Fernandez Duenas, Victor/E-5337-2014	Ciruela, F./0000-0003-0832-3739; Fernandez Duenas, Victor/0000-0001-7834-2965	Ministry of Science and InnovationSpanish Government [SAF2008-01462, CSD2008-00005]; Bellvitge Research Commission (University of Barcelona)	The authors belong to the "Neuropharmacology and Pain" accredited research group (Generalitat de Catalunya, 2009 SGR 232). This work was supported by grants SAF2008-01462 and Consolider-Ingenio CSD2008-00005 from Ministry of Science and Innovation to FC and ACESB from Bellvitge Research Commission (University of Barcelona) to VF and RP. The authors acknowledge Ms. Salud Sanchez for technical assistance.	Christo PJ, 2008, ANN NY ACAD SCI, V1138, P278, DOI 10.1196/annals.1414.033; Devulder J, 2009, BRIT J ANAESTH, V103, P576, DOI 10.1093/bja/aep253; Dhillon S, 2010, CLIN DRUG INVEST, V30, P711, DOI 10.2165/11205830-000000000-00000; Fernandez-Duenas V, 2011, PHARMACOL BIOCHEM BE, V98, P331, DOI 10.1016/j.pbb.2011.01.023; Gong Ya-Hong, 2011, Acta Anaesthesiol Taiwan, V49, P16, DOI 10.1016/j.aat.2011.01.003; Hama AT, 2010, NEUROPHARMACOLOGY, V58, P758, DOI 10.1016/j.neuropharm.2009.12.010; Langley PC, 2010, CURR MED RES OPIN, V26, P239, DOI 10.1185/03007990903426787; Lee EY, 2006, CLIN THER, V28, P2052, DOI 10.1016/j.clinthera.2006.12.019; MAGNAN J, 1982, N-S ARCH PHARMACOL, V319, P197, DOI 10.1007/BF00495865; Puig MM, 1998, J PHARMACOL EXP THER, V287, P1068; Raffa RB, 2004, EUR J PHARMACOL, V503, P209, DOI 10.1016/j.ejphar.2004.08.055; RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275; Romero A, 2010, PHARMACOL RES, V61, P511, DOI 10.1016/j.phrs.2010.02.011; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; TALLARIDA RJ, 1996, [No title captured], V58, P23, DOI DOI 10.1016/0024-3205(95)02271-6	15	4	4	0	9	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613			J PHARMACOL SCI	J. Pharmacol. Sci.	FEB	2012	118	2					299	302		10.1254/jphs.11161SC			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	900UC	WOS:000300915400023	22302020				2020-06-30	J	Taylor, DR; Gabrail, N				Taylor, Donald R.; Gabrail, Nash			Fentanyl pectin nasal spray for breakthrough cancer pain	FUTURE ONCOLOGY			English	Article						breakthrough cancer pain; fentanyl; intranasal; pectin	PHARMACOKINETICS; BIOAVAILABILITY; ASSOCIATION; MANAGEMENT; OPIOIDS	Optimal management of breakthrough cancer pain (BTCP) requires analgesics with a rapid onset of action, consistent efficacy, improved patient acceptability and tolerability and ease of use. Fentanyl pectin nasal spray (FPNS) incorporates a proprietary pectin-based gelling agent to enhance absorption and produce a faster onset of action and consistent plasma concentration. FPNS is indicated for the treatment of breakthrough pain in cancer patients who are tolerant to opioid therapy for their underlying persistent cancer pain. FPNS has been evaluated in clinical studies in patients with BTCP and shown to be effective, safe and well tolerated. In addition, FPNS has demonstrated high levels of patient satisfaction, convenience and ease of use. FPNS therefore represents an important addition to the treatment options for BTCP.	[Taylor, Donald R.] Comprehens Pain Care PC, Marietta, GA 30060 USA; [Gabrail, Nash] Gabrail Canc Ctr, Canton, OH USA	Taylor, DR (reprint author), Comprehens Pain Care PC, 840 Church St NE D, Marietta, GA 30060 USA.	dtaylor@cpcnopain.com			Archimedes Pharma, Bedminster, New Jersey; Archimedes Pharma	DR Taylor and N Gabrail were investigators on clinical studies of fentanyl pectin nasal spray that were funded by Archimedes Pharma, Bedminster, New Jersey. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed; The authors would like to acknowledge the editorial assistance of RS Perry, PharmD in the preparation of this manuscript, which was supported by Archimedes Pharma.	Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; [Anonymous], CONSENSUS PANEL RE 1; [Anonymous], LAZ PACK INS; [Anonymous], CONSENSUS PANEL RE 2; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davis G, 2007, 10 C EUR ASS PALL CA; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Fisher T, 2011, 14 C EUR ASS PALL CA; Gabrail NY, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e19604; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2010, J PAIN SYMPTOM MANAG, V40, P183, DOI 10.1016/j.jpainsymman.2010.01.010; Mercadante S, 2011, CURR PAIN HEADACHE R, V15, P244, DOI 10.1007/s11916-011-0191-5; Nguyen A, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e19659; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Radbruch L, 2012, SUPPORT CARE CANCER, V20, P565, DOI 10.1007/s00520-011-1124-x; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Taylor Donald, 2010, J Support Oncol, V8, P184; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Zeppetella G, 2011, PALLIATIVE MED, V25, P516, DOI 10.1177/0269216310385601	28	3	3	0	2	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1479-6694	1744-8301		FUTURE ONCOL	Future Oncol.	FEB	2012	8	2					121	130		10.2217/FON.11.146			10	Oncology	Oncology	895DB	WOS:000300475300006	22335576				2020-06-30	J	Takayama, A; Yamaguchi, S; Ishikawa, K; Shinozaki, M; Kimura, Y; Nagao, M; Kitajima, T				Takayama, Aki; Yamaguchi, Shigeki; Ishikawa, Kazuyoshi; Shinozaki, Mio; Kimura, Yoshiyuki; Nagao, Masaru; Kitajima, Toshimitsu			Recovery of psychomotor function after total intravenous anesthesia with remifentanil-propofol or fentanyl-propofol	JOURNAL OF ANESTHESIA			English	Article						Psychomotor function; Trieger dot test; Remifentanil; Fentanyl; Propofol	SUFENTANIL-PROPOFOL; AMBULATORY SURGERY; CRANIOTOMY; SEVOFLURANE; ALFENTANIL; DESFLURANE; SEDATION; INFUSION; TRIAL	Total intravenous anesthesia (TIVA) with propofol combined with remifentanil or fentanyl has commonly been used to achieve general anesthesia. The purpose of this study was to examine recovery of psychomotor function, by use of the Trieger dot test, after TIVA with remifentanil-propofol or with fentanyl-propofol. Forty patients were randomly divided into two groups of 20, to receive TIVA with either remifentanil-propofol (group R) or fentanyl-propofol (group F). Anesthesia was induced by intravenous injection of propofol. In group R, remifentanil at 0.3 mu g/kg/min was infused continuously during surgery. In group F, 3 mu g/kg fentanyl was injected as an initial dose and 1 mu g/kg fentanyl was administered intravenously every 30 min during surgery. Psychomotor function, as measured by the Trieger dot test, was evaluated before anesthesia and 30, 60, 90, 120, and 150 min after the end of TIVA. From assessment of the Trieger dot test, the number of dots missed in group R from 30 to 120 min after the end of TIVA was significantly lower than in group F. The maximum distance of dots missed in group R from 30 to 120 min after the end of TIVA was significantly shorter than in group F. The average distance of dots missed in group R from 30 to 120 min after the end of TIVA was significantly shorter than in group F. Recovery of psychomotor function in TIVA with remifentanil-propofol is faster than that in TIVA with fentanyl-propofol.	[Yamaguchi, Shigeki; Ishikawa, Kazuyoshi; Shinozaki, Mio; Kimura, Yoshiyuki; Nagao, Masaru; Kitajima, Toshimitsu] Dokkyo Med Univ, Sch Med, Dept Anesthesiol, Mibu, Tochigi 3210293, Japan; [Takayama, Aki] Dokkyo Med Univ, Sch Med, Dept Oral & Maxillofacial Surg, Mibu, Tochigi 3210293, Japan	Yamaguchi, S (reprint author), Dokkyo Med Univ, Sch Med, Dept Anesthesiol, Mibu, Tochigi 3210293, Japan.	shigeki@dokkyomed.ac.jp					Alhashemi JA, 2006, CAN J ANAESTH, V53, P449, DOI 10.1007/BF03022616; Black ML, 1999, ANESTHESIOLOGY, V90, P718, DOI 10.1097/00000542-199903000-00013; Coskun D, 2010, J ANESTH, V24, P373, DOI 10.1007/s00540-010-0898-1; De Witte JL, 2002, ANESTH ANALG, V95, P1601, DOI 10.1097/00000539-200212000-00024; Del Gaudio A, 2006, MINERVA ANESTESIOL, V72, P309; Djian MC, 2006, CLIN THER, V28, P560, DOI 10.1016/j.clinthera.2006.04.001; Dressler I, 2007, EUR J ANAESTH, V24, P347, DOI 10.1017/S0265021506001530; Eikaas H, 2009, CURR OPIN ANESTHESIO, V22, P725, DOI 10.1097/ACO.0b013e3283310f6b; Gerlach K, 2003, EUR J ANAESTH, V20, P813, DOI 10.1097/00003643-200310000-00007; GUPTA A, 1995, ANAESTHESIA, V50, P937, DOI 10.1111/j.1365-2044.1995.tb05923.x; Gutstein HA, 2001, GOODMAN GILMANS PHAR, P596; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; KORTTILA K, 1992, ANESTHESIOLOGY, V76, P676, DOI 10.1097/00000542-199205000-00003; Lacombe GF, 2006, J ORAL MAXIL SURG, V64, P215, DOI 10.1016/j.joms.2005.10.026; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; Lobo F, 2007, J NEUROSURG ANESTH, V19, P183, DOI 10.1097/ANA.0b013e31805f66ad; Martorano PP, 2008, MINERVA ANESTESIOL, V74, P233; Mi WD, 2003, J CLIN ANESTH, V15, P103, DOI 10.1016/S0952-8180(02)00510-X; NEWMAN MG, 1969, ANESTH ANAL CURR RES, V48, P136, DOI 10.1213/00000539-196948010-00028; Shinozaki N, 2002, CAN J ANAESTH, V49, P927, DOI 10.1007/BF03016876; Suttner S, 1999, ANESTH ANALG, V88, P77, DOI 10.1097/00000539-199901000-00015; VESELIS RA, 1994, ANESTH ANALG, V79, P952; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; Wilhelm W, 2001, BRIT J ANAESTH, V86, P44, DOI 10.1093/bja/86.1.44; Yli-Hankala A, 1999, ACTA ANAESTH SCAND, V43, P545, DOI 10.1034/j.1399-6576.1999.430510.x	25	7	7	0	4	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2012	26	1					34	38		10.1007/s00540-011-1266-5			5	Anesthesiology	Anesthesiology	893HC	WOS:000300345900005	22048284				2020-06-30	J	Medeiros, LF; de Souza, AC; de Souza, A; Cioato, SG; Scarabelot, VL; Caumo, W; Fernandes, LC; Torres, ILS				Medeiros, Liciane Fernandes; de Souza, Ana Claudia; de Souza, Andressa; Cioato, Stefania Giotti; Scarabelot, Vanessa Leal; Caumo, Wolnei; Fernandes, Luciana Carvalho; Torres, Iraci L. S.			Fentanyl administration in infant rats produces long-term behavioral responses	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Fentanyl; S(+)-ketamine; Infant rat; Behavior	DORSAL PERIAQUEDUCTAL GRAY; OPIOID RECEPTORS; POSTNATAL-DEVELOPMENT; HEMODYNAMIC-RESPONSE; NUCLEUS-ACCUMBENS; BETA-ENDORPHIN; DOSE FENTANYL; ANIMAL-MODELS; FORMALIN TEST; MORPHINE	Considering the importance of studies in animal models that are focused on systems involved in pain mechanisms, this investigation aimed to evaluate the effects of pharmacological treatments on the behavioral responses of younger animals. To this end, we evaluated the effect of an acute dose of fentanyl (FEN) or S(+)-ketamine (KET) at postnatal day 14 (P14) upon behavioral responses in the short- (P14), medium(P30) and long-term (P60) using the open field (OF), elevated plus-maze (EPM) and formalin tests (FT) and tail-flick latency. Fourteen-day-old male Wistar rats were divided into three groups: control (CT), fentanyl (FEN) and S(+)ketamine (KET) groups for statistical analysis, it was performed two-way ANOVA followed by Bonferroni. We found that, regardless of the test performed (OF or EPM), between-group differences occurred over time in all behaviors analyzed, including in the second phase of FT. In addition, EPM showed significant differences in behavioral responses related to acute administration (at P14) of fentanyl or S(+)-ketamine, in behaviors such as number of entries in open and closed arms, time spent in open and closed arms, and number of head-dipping. In relation to nociceptive response, the FEN group exhibited a decrease in the first phase of FT. These results indicate that unique administration of fentanyl or S(+)ketamine in an early period of life (P14) can promote changes in behavioral responses. In addition, our findings highlight the importance of extending the investigation of the effect of drug administration in young rats into adulthood. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Medeiros, Liciane Fernandes; de Souza, Ana Claudia; de Souza, Andressa; Cioato, Stefania Giotti; Scarabelot, Vanessa Leal; Caumo, Wolnei; Torres, Iraci L. S.] Univ Fed Rio Grande do Sul, Dept Pharmacol, Lab Pharmacol Pain, Inst Basic Hlth Sci, BR-90050170 Porto Alegre, RS, Brazil; [Medeiros, Liciane Fernandes; Torres, Iraci L. S.] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Post Grad Program Biol Sci Physiol, BR-90050170 Porto Alegre, RS, Brazil; [Medeiros, Liciane Fernandes; de Souza, Ana Claudia; de Souza, Andressa; Cioato, Stefania Giotti; Scarabelot, Vanessa Leal; Caumo, Wolnei; Torres, Iraci L. S.] Hosp Clin Porto Alegre, Anim Expt Unit, Res & Post Grad Grp, BR-90035003 Porto Alegre, RS, Brazil; [Fernandes, Luciana Carvalho] Ctr Univ UNIVATES, Fac Pharm, BR-95900000 Lajeado, RS, Brazil	Torres, ILS (reprint author), Univ Fed Rio Grande do Sul, Dept Pharmacol, Lab Pharmacol Pain, Inst Basic Hlth Sci, Rua Sarmento Leite,500 Sala 202, BR-90050170 Porto Alegre, RS, Brazil.	iracitorres@gmail.com	Medeiros, Liciane/A-3626-2014; Fernandes, Luis C/G-2226-2012; Torres, Iraci L. S./G-6693-2012; caumo, wolnei/Q-8728-2016; de Souza, Andressa/Q-2446-2016	Medeiros, Liciane/0000-0002-6842-7241; Torres, Iraci L. S./0000-0002-3081-115X; de Souza, Andressa/0000-0002-6608-4695; Caumo, Wolnei/0000-0002-5083-4658	National Council for Scientific and Technological Development - CNPqNational Council for Scientific and Technological Development (CNPq); Graduate Research Group (GPPG) of Hospital de Clinicas de Porto Alegre [100186]; Committee for the Development of Higher Education Personnel - CAPES	This study was supported by the following Brazilian funding agencies: National Council for Scientific and Technological Development - CNPq (Dr. I.L.S. Torres); Graduate Research Group (GPPG) of Hospital de Clinicas de Porto Alegre (Dr I.L.S. Torres - Grant # 100186); Committee for the Development of Higher Education Personnel - CAPES (L.F. Medeiros).	Adachi YU, 2002, ANESTH ANALG, V95, P233, DOI 10.1097/00000539-200207000-00043; Anseloni VCZ, 1999, EXP BRAIN RES, V129, P260, DOI 10.1007/s002210050896; BAYER SA, 1993, NEUROTOXICOLOGY, V14, P83; Beland B, 2001, PAIN, V90, P143, DOI 10.1016/S0304-3959(00)00397-3; Bhutta AT, 2007, SEMIN PERINATOL, V31, P303, DOI 10.1053/j.semperi.2007.07.005; BIANCHIN M, 1993, BEHAV NEURAL BIOL, V59, P83, DOI 10.1016/0163-1047(93)90782-D; BONNYCASTLE DD, 1953, ACTA PHARMACOL TOX, V9, P332; BRITTON DR, 1981, PHARMACOL BIOCHEM BE, V15, P577, DOI 10.1016/0091-3057(81)90212-4; Byrnes ML, 2001, NEUROTOXICOL TERATOL, V23, P355, DOI 10.1016/S0892-0362(01)00150-7; Carlini VP, 2002, BIOCHEM BIOPH RES CO, V299, P739, DOI 10.1016/S0006-291X(02)02740-7; Castilho VM, 2002, PSYCHOPHARMACOLOGY, V165, P77, DOI 10.1007/s00213-002-1246-4; Cepeda MS, 2004, REGUL PEPTIDES, V118, P39, DOI 10.1016/j.regpep.2003.10.027; CHUNG F, 1985, CAN ANAESTH SOC J, V32, P622, DOI 10.1007/BF03011409; Danneman PJ, 1997, LAB ANIM SCI, V47, P386; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; FITZGERALD M, 1995, BRIT J ANAESTH, V75, P177, DOI 10.1093/bja/75.2.177; Hallak JEC, 2011, PROG NEURO-PSYCHOPH, V35, P198, DOI 10.1016/j.pnpbp.2010.11.002; Han JI, 2010, J CLIN ANESTH, V22, P3, DOI 10.1016/j.jclinane.2009.01.019; Hayase T., 2006, BMC NEUROSCI, V16, P7; IRIFUNE M, 1991, PHARMACOL BIOCHEM BE, V40, P399, DOI 10.1016/0091-3057(91)90571-I; IRWIN S, 1951, J PHARMACOL EXP THER, V101, P132; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Kouvaras E, 2008, NEUROPHARMACOLOGY, V55, P1172, DOI 10.1016/j.neuropharm.2008.07.025; Kronenberg Robert H, 2002, J Pain Palliat Care Pharmacother, V16, P27; Le Bars D, 2001, PHARMACOL REV, V53, P597; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; Lynn DA, 2009, DEV PSYCHOBIOL, V51, P513, DOI 10.1002/dev.20386; Martindale J, 2001, NEUROSCI LETT, V316, P33, DOI 10.1016/S0304-3940(01)02362-X; McQueen AL, 2002, ANN PHARMACOTHER, V36, P1614; Medeiros LF, 2011, BEHAV BRAIN RES, V218, P51, DOI 10.1016/j.bbr.2010.10.028; Mellon RD, 2007, ANESTH ANALG, V104, P509, DOI 10.1213/01.ane.0000255729.96438.b0; MITCHELL D, 1977, PROC R SOC SER B-BIO, V197, P169, DOI 10.1098/rspb.1977.0064; Moore C, 2008, FORENSIC SCI INT, V176, P47, DOI 10.1016/j.forsciint.2007.06.027; Moreira FA, 2007, NEUROPHARMACOLOGY, V52, P958, DOI 10.1016/j.neuropharm.2006.10.013; Morgan G.E., 1996, CLIN ANAESTHESIOL, p[109, 726]; MOTTA V, 1995, PSYCHOPHARMACOLOGY, V120, P470, DOI 10.1007/BF02245820; NETTO CA, 1987, BEHAV NEURAL BIOL, V48, P304, DOI 10.1016/S0163-1047(87)90850-8; Pattinson D, 2004, REGION ANESTH PAIN M, V29, P36, DOI 10.1016/j.rapm.2003.10.018; Rahman W, 1998, DEV BRAIN RES, V108, P239, DOI 10.1016/S0165-3806(98)00054-6; Rahman W, 1999, REGION ANESTH PAIN M, V24, P383, DOI 10.1016/S1098-7339(99)90001-9; Roesler R, 1999, MOL BRAIN RES, V71, P349, DOI 10.1016/S0169-328X(99)00193-X; Rozisky JR, 2008, INT J DEV NEUROSCI, V26, P561, DOI 10.1016/j.ijdevneu.2008.05.005; Rozisky JR, 2011, BRAIN RES, V1367, P122, DOI 10.1016/j.brainres.2010.10.041; Sevostianova N, 2003, EUR J PHARMACOL, V462, P109, DOI 10.1016/S0014-2999(03)01345-1; SHIBATA M, 1989, PAIN, V38, P347, DOI 10.1016/0304-3959(89)90222-4; Silveira PP, 2005, INT J DEV NEUROSCI, V23, P93, DOI 10.1016/j.ijdevneu.2004.07.018; SINCLAIR JG, 1988, PAIN, V33, P357, DOI 10.1016/0304-3959(88)90296-5; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-24; SPRUIJT BM, 1992, PHYSIOL REV, V72, P825; Stein C, 2001, Curr Opin Pharmacol, V1, P62, DOI 10.1016/S1471-4892(01)00005-4; Tai YH, 2006, PAIN, V124, P77, DOI 10.1016/j.pain.2006.03.018; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; TSENG LF, 1990, J PHARMACOL EXP THER, V252, P546; Wells CE, 2009, BEHAV BRAIN RES, V197, P234, DOI 10.1016/j.bbr.2008.08.013	55	5	6	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	FEB	2012	30	1					25	30		10.1016/j.ijdevneu.2011.10.004			6	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	888CX	WOS:000299982500004	22027620				2020-06-30	J	Jayasundera, S; Mackinnon, R				Jayasundera, S.; Mackinnon, R.			Dexamathasone and ondansetron in paediatric tonsillectomy	ANAESTHESIA			English	Letter									[Jayasundera, S.; Mackinnon, R.] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England	Jayasundera, S (reprint author), Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England.	suraj.jayasundera@gmail.com					Carr AS, 2009, GUIDELINES PREVENTIO; Rawlinson E, 2011, ANAESTHESIA, V66, P919, DOI 10.1111/j.1365-2044.2011.06851.x; Williams DG, 2002, BRIT J ANAESTH, V89, P839, DOI 10.1093/bja/aef284; Wolf AR, 1999, BRIT J ANAESTH, V82, P319, DOI 10.1093/bja/82.3.319	4	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0003-2409			ANAESTHESIA	Anaesthesia	FEB	2012	67	2					192	192		10.1111/j.1365-2044.2011.07037.x			1	Anesthesiology	Anesthesiology	877DW	WOS:000299158200024	22251121				2020-06-30	J	Morad, A; Winters, B; Stevens, R; White, E; Weingart, J; Yaster, M; Gottschalk, A				Morad, Athir; Winters, Bradford; Stevens, Robert; White, Elizabeth; Weingart, Jon; Yaster, Myron; Gottschalk, Allan			The Efficacy of Intravenous Patient-Controlled Analgesia After Intracranial Surgery of the Posterior Fossa: A Prospective, Randomized Controlled Trial	ANESTHESIA AND ANALGESIA			English	Article							PAIN FOLLOWING CRANIOTOMY; POSTOPERATIVE PAIN; HEADACHE; MORPHINE; PCA	BACKGROUND: Surgery of the posterior fossa often produces intense postoperative pain. However, this pain is infrequently treated because of concern that opioid administration may mask the postoperative neurologic examination and/or produce hypercarbia. In this prospective, randomized controlled trial, we sought to determine whether IV patient-controlled analgesia (PCA) would lead to reductions in postoperative pain after neurosurgical procedures of the posterior fossa compared with conventional IV nurse-administered as-needed (PRN) therapy. METHODS: Eighty patients (age range, 18-82 years) undergoing elective posterior fossa surgery were randomized to receive postoperative IV fentanyl PRN 25 to 50 mu g every 30 minutes or via PCA 0.5 mu g/kg/dose, with a maximal dose limit of 50 mu g, and 15-minute lockout (4 doses/hour). We measured pain (Numerical Rating Scale, 0-10), analgesic use, sedation (Ramsay Sedation Scale and Glasgow Coma Scale), respiration, hemodynamics, and adverse events hourly. RESULTS: Sixty-five patients completed the study. Thirty-one patients received IV PCA and 34 received PRN analgesia. Patient demographics did not differ between groups. Patients in the PCA group reported less pain at rest (mean [95% confidence interval]: 3.7 [3.0, 4.4] vs 5.2 [4.5, 5.8], P = 0.003) and received more fentanyl (mean [95% confidence interval]: 54.8 [42.1, 67.6] vs 29.9 [24.2, 35.7] mu g/h, P = 0.002) than those in the PRN group. There were no differences in side effects and no adverse events related to analgesic therapy. CONCLUSIONS: IV PCA use resulted in reduction in postoperative pain compared with PRN analgesic therapy after surgery of the posterior fossa. Larger studies will be required to determine the safety of IV PCA in this patient population. (Anesth Analg 2012;114:416-23)	[Morad, Athir; Winters, Bradford; Stevens, Robert; White, Elizabeth; Weingart, Jon; Yaster, Myron; Gottschalk, Allan] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA	Morad, A (reprint author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Meyer 8-140, Baltimore, MD 21287 USA.	morada@jhmi.edu			Jacob and Hilda Blaustein Foundation; Richard J. Traystman Endowed Chair; Departments of Neurosurgery and Anesthesiology and Critical Care Medicine of the johns Hopkins School of Medicine; Neurosciences Critical Care Unit of the Johns Hopkins Hospital	Supported by The Jacob and Hilda Blaustein Foundation and the Richard J. Traystman Endowed Chair.; The authors acknowledge the support of Dr. James Campbell, Dr. Henry Brem, Dr. Donlin Long, Dr. Marek Mirski, and Dr. John Ulatowski of the Departments of Neurosurgery and Anesthesiology and Critical Care Medicine of the johns Hopkins School of Medicine. Additionally, the authors acknowledge the support of the nursing staff of the Neurosciences Critical Care Unit of the Johns Hopkins Hospital and Ms. Claire Levine for her editorial assistance. Finally, this study would not have been possible without the generous financial support of the Jacob and Hilda Blaustein Foundation and the Richard J. Traystman Endowed Chair.	Fernandez AA, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-S1-S1; Batoz H, 2009, ANESTH ANALG, V109, P240, DOI 10.1213/ane.0b013e3181a4928d; COLD GE, 1993, NEUROSURGERY, V32, P327, DOI 10.1097/00006123-199302000-00032; de Gray LC, 2005, ANAESTHESIA, V60, P693, DOI 10.1111/j.1365-2044.2005.03997.x; DeBenedittis G, 1996, NEUROSURGERY, V38, P466, DOI 10.1227/00006123-199603000-00008; Gottschalk A, 2007, J NEUROSURG, V106, P210, DOI 10.3171/jns.2007.106.2.210; Gottschalk A, 2009, NEUROCRIT CARE, V10, P387, DOI 10.1007/s12028-008-9150-3; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; HARNER SG, 1995, NEUROSURGERY, V36, P1097; Irefin Samuel A, 2003, J Anesth, V17, P227, DOI 10.1007/s00540-003-0182-8; Jellish WS, 2006, OTOLARYNG HEAD NECK, V135, P175, DOI 10.1016/j.otohns.2006.02.027; Koperer H, 1999, MINIM INVAS NEUROSUR, V42, P175, DOI 10.1055/s-2008-1053393; Morad AH, 2009, J NEUROSURG, V111, P343, DOI 10.3171/2008.11.JNS08797; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Schankin C J, 2009, Cephalalgia, V29, P760, DOI 10.1111/j.1468-2982.2008.01790.x; SCHESSEL DA, 1992, OTOLARYNG HEAD NECK, V107, P424, DOI 10.1177/019459989210700314; Silverman DA, 2004, SKULL BASE-INTERD AP, V14, P77, DOI 10.1055/s-2004-828698; Stoneham MD, 1996, ANAESTHESIA, V51, P1176, DOI 10.1111/j.1365-2044.1996.tb15065.x; STONEHAM MD, 1995, EUR J ANAESTH, V12, P571; Talke PO, 2005, EUR J ANAESTH, V22, P325, DOI 10.1017/S0265021505000542; Thibault M, 2007, CAN J ANAESTH, V54, P544, DOI 10.1007/BF03022318; VIJAYAN N, 1995, HEADACHE, V35, P98, DOI 10.1111/j.1526-4610.1995.hed3502098.x	22	14	15	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2012	114	2					416	423		10.1213/ANE.0b013e31823f0c5a			8	Anesthesiology	Anesthesiology	881MQ	WOS:000299491200022	22156333				2020-06-30	J	Sima, L; Fang, WX; Wu, XM; Li, F				Sima, L.; Fang, W. X.; Wu, X. M.; Li, F.			Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article						oxycodone; pain; paracetamol	CONTROLLED-RELEASE OXYCODONE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACETAMINOPHEN; MANAGEMENT	What is known and Objective: Bone-cancer pain is a common and refractory cancer pain. Opioids, on their own, do not control this type of pain well enough, and co-analgesics are necessary. Methods: Patients with bone metastasis-related pain at Numeric Rating Scale 4 were enrolled to this randomized placebo-controlled trial. They had also received morphine or transdermal fentanyl patches for at least 1 week. During the 3-day efficacy phase, patients received placebo or 1-3 tablets of oxycodone/paracetamol (5/325 mg), four times daily for 3 days. All patients kept a daily pain diary. The primary endpoint was the Pain Intensity Difference (PID). Secondary endpoints were cases of breakthrough pain and rescue morphine consumption. Additional analyses included the Short Form-6 Dimensions (SF-6D) quality-of-life scale and a general impression (GI) of patient satisfaction with treatment at the end of the phase. Results and Discussion: Of the 246 patients in the intent-to-treat set, 89.4% completed the 3-day efficacy phase. PIDs were 0.9 and 0.3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0.001), and 1.5 and 0.3 respectively on day 3 (P < 0.001). Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0.001). The SF-6D score decreased to 21.2 +/- 2.5 in the oxycodone/paracetamol group at the end of the phase (P = 0.001). In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent. What is new and Conclusion: Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.	[Sima, L.] China Japan Friendship Hosp, Natl Pain Management & Res Ctr, Beijing 100029, Peoples R China; [Fang, W. X.] Peking Univ, Dept Anesthesia, Hosp 1, Beijing 100871, Peoples R China; [Wu, X. M.] Chinese Acad Med Sci, Dept Polyclin, Canc Inst & Hosp, Beijing 100730, Peoples R China; [Wu, X. M.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Li, F.] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China	Sima, L (reprint author), China Japan Friendship Hosp, Natl Pain Management & Res Ctr, 2 Yinghua E St, Beijing 100029, Peoples R China.	simalei@yahoo.cn					Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Collins SL, 2001, PAIN, V91, P189, DOI 10.1016/S0304-3959(00)00435-8; Danninger R, 1993, EUROPEAN J PAIN, V14, P14; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fallon M, 2008, SUPPORT CARE CANCER, V16, P771, DOI 10.1007/s00520-008-0402-8; Rodriguez RF, 2007, CLIN THER, V29, P581, DOI 10.1016/j.clinthera.2007.04.004; GALASKO CSB, 1976, NATURE, V263, P508, DOI 10.1038/263508a0; Gammaitoni AR, 2003, J CLIN PHARMACOL, V43, P296, DOI 10.1177/0091270003251147; Gaskell H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002763.pub2; Gatti A, 2009, CLIN DRUG INVEST, V29, P31, DOI 10.2165/0044011-200929001-00005; Grossman SA, 2000, ONCOLOGY-NY, V14, P135; Hermos JA, 2004, ARCH INTERN MED, V164, P2361, DOI 10.1001/archinte.164.21.2361; McNicol E, 2004, J CLIN ONCOL, V22, P1975, DOI 10.1200/JCO.2004.10.524; Muth-Selbach US, 1999, ANESTHESIOLOGY, V91, P231, DOI 10.1097/00000542-199907000-00032; Nielsen CK, 2007, PAIN, V132, P289, DOI 10.1016/j.pain.2007.03.022; Ong EC, 2008, ONCOLOGY-BASEL, V74, P72, DOI 10.1159/000143223; Raffa RB, 2001, J CLIN PHARM THER, V26, P257, DOI 10.1046/j.1365-2710.2001.00355.x; Shaiova L, 2006, CANCER J, V12, P330, DOI 10.1097/00130404-200609000-00002; Stockler M, 2004, J CLIN ONCOL, V22, P3389, DOI 10.1200/JCO.2004.09.122; Urch C, 2004, PALLIATIVE MED, V18, P267, DOI 10.1191/0269216304pm887ra; Wee HL, 2004, CLIN THER, V26, P1137, DOI 10.1016/S0149-2918(04)90186-5	22	13	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-4727	1365-2710		J CLIN PHARM THER	J. Clin. Pharm. Ther.	FEB	2012	37	1					27	31		10.1111/j.1365-2710.2010.01239.x			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	882FU	WOS:000299549500005	21208247				2020-06-30	J	Tan, PCS; Hassan, SK; Mohamad, NAN; Gan, SH				Tan, P. C. S.; Hassan, S. K.; Mohamad, N. A. N.; Gan, S. H.			Cytochrome P450 3A4 genetic polymorphisms and post-operative fentanyl requirements	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Article						CYP3A4 polymorphism; fentanyl; patient-controlled analgesia; pharmacogenomics	SINGLE NUCLEOTIDE POLYMORPHISMS; CYP3A4-ASTERISK-18 ALLELE; CYP3A4; PHARMACOGENOMICS; IDENTIFICATION; METABOLISM; GENOMICS	What is known and Objective: Interindividual variability in drug responses may be attributable to genetically determined alteration in enzyme activity. In this study, we investigated the association between cytochrome P450 3A4 (CYP3A4) genetic polymorphisms and post-operative fentanyl requirements. Methods: Patients (n = 94) scheduled for gynaecological laparotomy received i.v. fentanyl infusion (3 mu g/kg/h) after induction of general anaesthesia. Post-operative fentanyl requirements were quantified by using a patient-controlled analgesia and the number of i.v. fentanyl rescue analgesia required were recorded. Pain control was assessed using visual analogue scores (VAS) and fentanyl's adverse effects were documented. CYP3A4*4, CYP3A4*5 and CYP3A4*18 alleles of cytochrome P450 3A4 were identified by polymerase chain reaction-restriction fragment length polymorphism. Differences in fentanyl requirements, VAS scores and adverse effects among the various genotypes were compared. Results and Discussion: No CYP3A4*4 and CYP3A4*5 alleles were detected. Eighty-nine patients (94.7%) were wild-type, five (5.3%) were heterozygous and none was homozygous. No significant difference was demonstrated between the genotype groups in terms of fentanyl consumption, pain control and adverse effects. What is new and Conclusion: CYP3A4*4 and CYP3A4*5 are rare in the Malaysian Malay population. Genetic polymorphism of CYP3A4*18 may not play an important role in influencing postoperative fentanyl requirements.	[Gan, S. H.] Univ Sci Malaysia, Ctr Human Genome, Sch Med Sci, Kubang Kerian, Kelantan, Malaysia; [Tan, P. C. S.; Hassan, S. K.; Mohamad, N. A. N.] Univ Sci Malaysia, Dept Anaesthesiol & Intens Care, Kubang Kerian, Kelantan, Malaysia	Gan, SH (reprint author), Univ Sci Malaysia, Ctr Human Genome, Sch Med Sci, Hlth Campus, Kubang Kerian, Kelantan, Malaysia.	shgan@kck.usm.my	gan, siew hua/A-6266-2011	gan, siew hua/0000-0001-6470-3651	Research University Grant [1001/PPSP/815022]	This study was financially supported by a Research University Grant (grant no. 1001/PPSP/815022). We thank Mr Chua Yung An for his skilful assistance in processing the samples for PCR and RFLP.	Dai D, 2001, J PHARMACOL EXP THER, V299, P825; Edwards AWF, 2008, GENETICS, V179, P1143, DOI 10.1534/genetics.104.92940; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Garcia-Barcelo M, 2000, CLIN CHEM, V46, P18; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Hsieh KP, 2001, DRUG METAB DISPOS, V29, P268; Hu YF, 2007, XENOBIOTICA, V37, P315, DOI 10.1080/00498250601149206; Hu YF, 2005, CLIN CHIM ACTA, V353, P187, DOI 10.1016/j.cccn.2004.11.005; Jamison RN, 1993, POSTOPERATIVE PAIN M, P119; Jin M, 2005, J ANAL TOXICOL, V29, P590, DOI 10.1093/jat/29.7.590; Jung H, 2003, CLIN PHARMACOL THER, V73, pP41, DOI 10.1016/S0009-9236(03)90506-6; Kang YS, 2009, CLIN PHARMACOL THER, V85, P312, DOI 10.1038/clpt.2008.215; Kissin I, 2009, ANESTH ANALG, V108, P1945, DOI 10.1213/ane.0b013e3181a1a481; Lee SJ, 2007, DRUG METAB DISPOS, V35, P2095, DOI 10.1124/dmd.107.016733; Liu CH, 2005, PHARMACOGENOMICS, V6, P731, DOI 10.2217/14622416.6.7.731; Pandit JJ, 2008, ANAESTHESIA, V63, P1284, DOI 10.1111/j.1365-2044.2008.05736.x; Rendic S, 1997, DRUG METAB REV, V29, P413, DOI 10.3109/03602539709037591; Ruzilawati AB, 2007, CLIN CHIM ACTA, V383, P158, DOI 10.1016/j.cca.2007.05.004; Ruzilawati AB, 2008, DRUG METABOLISM R S1, V40, P139; Tateishi T, 1996, ANESTH ANALG, V82, P167; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Yamamoto Takehito, 2003, Drug Metab Pharmacokinet, V18, P267, DOI 10.2133/dmpk.18.267	23	10	15	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-4727	1365-2710		J CLIN PHARM THER	J. Clin. Pharm. Ther.	FEB	2012	37	1					100	104		10.1111/j.1365-2710.2010.01232.x			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	882FU	WOS:000299549500019	21128989				2020-06-30	J	Garbe, E; Jobski, K; Schmid, U				Garbe, Edeltraut; Jobski, Kathrin; Schmid, Ulrike			Utilisation of transdermal fentanyl in Germany from 2004 to 2006	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						transdermal fentanyl; drug utilisation; opioid-naive; acute pain; German Pharmacoepidemiological Research Database	CHRONIC CANCER PAIN; PRESCRIPTION; MANAGEMENT; OPIOIDS; SYSTEM; TRIAL	Purpose Oral morphine is the first-choice opioid for moderate to severe cancer pain. Transdermal fentanyl is an alternative in patients with stable requirements of high-potency opioids (HPO) or if drugs cannot be taken orally. Drug regulatory authorities have issued several alerts to use transdermal fentanyl only for chronic pain and in HPO-tolerant patients to minimise the risk of severe opioid side effects. The aim of this study was to characterise utilisation of transdermal fentanyl in Germany. Methods The analysis was based on data from four German statutory health insurances from the years 2004-2006. Descriptive analyses were performed in new users of transdermal fentanyl to assess HPO-naivety, potential difficulties with the oral route in HPO-na ve patients and the number of transdermal fentanyl dispensations. The initial dose in new users was assessed in 2005-2006 after marketing of transdermal fentanyl 12.5 mu g/hour. Results Of 35 262 patients with new use of transdermal fentanyl, 29 793 (84.5%) were assessed as HPO-na ve. Of those, 21 596 (72.5%) did not have diagnoses indicating difficulties with the oral route. For 71.2% of the HPO-na ve new users of transdermal fentanyl, the first dose exceeded the recommended dose of 12.5 mu g/hour, and 49.3% of them received only one prescription of the drug. Conclusions Transdermal fentanyl was used as a first-choice opioid, which may increase the risk of serious opioid side effects, in a substantial number of HPO-na ve patients. Inappropriate prescribing included also high initial doses in HPO-na ve patients and possible prescription for acute pain in a considerable proportion of patients. Copyright (C) 2011 John Wiley & Sons, Ltd.	[Garbe, Edeltraut; Jobski, Kathrin; Schmid, Ulrike] Bremen Inst Prevent Res & Social Med BIPS, Bremen, Germany	Garbe, E (reprint author), Achterstr 30, D-28359 Bremen, Germany.	garbe@bips.uni-bremen.de					Arzneimittelkommission der deutschen Arzteschaft, 2007, TUM ARZN PRAX; Bandieri E, 2009, ANN ONCOL, V20, P961, DOI 10.1093/annonc/mdp041; Bell JS, 2009, AM J GERIATR PHARMAC, V7, P355, DOI 10.1016/j.amjopharm.2009.11.006; Boger RH, 2009, ARZNEIVERORDNUNGS RE, P237; Breekveldt-Postma NS, 2005, PHARMACOEPIDEM DR S, V14, P129, DOI 10.1002/pds.1008; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Duragesic&REG;, 2009, DUR FENT TRANSD SYST; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Jansen-Ortho, 2005, HLTH CAN END IMP SAF; Janssen-Cilag, 2008, DUR SMAT FACH; Jost L, 2010, ANN ONCOL, V21, pv257, DOI 10.1093/annonc/mdq224; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; McLoughlin R, 1997, PALLIATIVE MED, V11, P419; Medicines and Healthcare Products Regulatory Agency, 2008, DRUG SAFETY UPDATE, V2, P2; Mercadante S, 2002, LANCET, V360, P1254, DOI 10.1016/S0140-6736(02)11261-X; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Pigeot I, 2008, PHARMACOEPIDEM DR S, V17, P215, DOI 10.1002/pds.1545; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Schink T, 2009, 54 JAHR DTSCH GES ME; Stammschulte T, 2010, DEUT MED WOCHENSCHR, V135, P870, DOI 10.1055/s-0030-1253672; US Food and Drug Administration, 2008, FDA ISS UPD SAF WARN; US Food and Drug Administration, 2009, FENT TRANSD PATCH; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; World Health Organization, 1996, CANC PAIN REL	30	15	16	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	FEB	2012	21	2					191	198		10.1002/pds.2164			8	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	882FV	WOS:000299549600010	21681850				2020-06-30	J	Vaghadia, H; Neilson, G; Lennox, PH				Vaghadia, H.; Neilson, G.; Lennox, P. H.			Selective spinal anesthesia for outpatient transurethral prostatectomy (TURP): randomized controlled comparison of chloroprocaine with lidocaine	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							GYNECOLOGICAL LAPAROSCOPY; 2-CHLOROPROCAINE; FENTANYL; BUPIVACAINE; DESFLURANE		[Vaghadia, H.; Neilson, G.; Lennox, P. H.] Univ British Columbia, Vancouver Gen Hosp, Dept Anesthesia, Vancouver, BC V5Z 1M9, Canada	Lennox, PH (reprint author), Vancouver Gen Hosp, Dept Anesthesia JPP 2449, 855 W 12th Ave, Vancouver, BC V5Z 1M9, Canada.	pamela.lennox@vch.ca					Ahn KS, 2011, REGION ANESTH PAIN M, V36, P403, DOI 10.1097/AAP.0b013e31821e6503; BEERS RA, 1994, CAN J ANAESTH, V41, P807, DOI 10.1007/BF03011588; BREEN TW, 1993, ANESTH ANALG, V77, P919; Casati A, 2007, ANESTH ANALG, V104, P959, DOI 10.1213/01.ane.0000258766.73612.d8; Chen TY, 2001, ANESTH ANALG, V92, P1020; Forster JG, 2011, ACTA ANAESTH SCAND, V55, P273, DOI 10.1111/j.1399-6576.2010.02325.x; GISSEN AJ, 1984, [No title captured], V9, P124; Hejtmanek MR, 2011, ACTA ANAESTH SCAND, V55, P267, DOI 10.1111/j.1399-6576.2010.02371.x; Korhonen AM, 2004, ANESTH ANALG, V99, P1668, DOI 10.1213/01.ANE.0000139351.40608.05; Kouri ME, 2004, ANESTH ANALG, V98, P75, DOI 10.1213/01.ANE.0000093228.61443.EE; Lennox PH, 2002, ANESTH ANALG, V94, P565, DOI 10.1097/00000539-200203000-00016; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; REISNER LS, 1980, ANESTH ANALG, V59, P452; Schnider TW, 1996, ANESTHESIOLOGY, V85, P502, DOI 10.1097/00000542-199609000-00009; Sell A, 2008, ACTA ANAESTH SCAND, V52, P695, DOI 10.1111/j.1399-6576.2008.01639.x; Stewart AVG, 2001, BRIT J ANAESTH, V86, P570, DOI 10.1093/bja/86.4.570; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011; Vaghadia H, 2001, CAN J ANAESTH, V48, P273, DOI 10.1007/BF03019758; WANG BC, 1984, ANESTH ANALG, V63, P445; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019; Yoos JR, 2005, ANESTH ANALG, V100, P553, DOI 10.1213/01.ANE.0000130397.38849.4A; Zaric D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003006.pub3	23	20	20	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2012	56	2					217	223		10.1111/j.1399-6576.2011.02599.x			7	Anesthesiology	Anesthesiology	874TX	WOS:000298982100011	22236346				2020-06-30	J	Bedirli, N; Egritas, O; Cosarcan, K; Bozkirli, F				Bedirli, Nurdan; Egritas, Odul; Cosarcan, Kaan; Bozkirli, Fusun			A comparison of fentanyl with tramadol during propofol-based deep sedation for pediatric upper endoscopy	PEDIATRIC ANESTHESIA			English	Article						tramadol; sedation; endoscopy	CHILDREN; ANALGESIA; MIDAZOLAM; MORPHINE; KETAMINE	Aim: This study was conducted to compare the efficacy and safety of tramadol with those of fentanyl and to evaluate the impact of age in pediatric patients undergoing upper gastrointestinal endoscopy (UGIE). Methods: Eighty patients with ASA I-II, aged 1-16 years, undergoing UGIE were included in this study. Baseline anesthesia was maintained with 1 mg.kg(-1) propofol, and then, the patients were randomly assigned to receive 2 mu g.kg(-1) fentanyl (group F, n = 40) or 2 mg.kg(-1) tramadol (group T, n = 40). Additional propofol, 0.5-1 mg.kg(-1), was administered when needed. Heart rate, mean arterial pressure, oxygen saturation (SpO(2)), and sedation scores were recorded at baseline, induction, and every 5 min. Endoscopy duration, recovery time, and adverse effects were recorded. The data were separated for subgroup analyses based on the age of 0-2, 2-12, and over 12 years. Results: Fentanyl significantly decreased the saturation at induction, 5th min and 10th min in patients of 0-2 years; at 5th and 10th min in 212 years; and at 5th min in > 12 years. In all age subgroups, sedation scores at 10th, 15th, and 20th min, the overall frequency of adverse effects, and the recovery time were significantly lower in group T compared with group F. Conclusion: Tramadol in pediatric patients undergoing UGIE provided sedation as efficient as fentanyl with a better hemodynamic and respiratory stability and provided a superior safety and tolerance in younger children.	[Bedirli, Nurdan; Cosarcan, Kaan; Bozkirli, Fusun] Gazi Univ, Anesthesiol & Reanimat Dept, Fac Med, TR-06510 Ankara, Turkey; [Egritas, Odul] Dept Pediat Gastroenterol, Ankara, Turkey	Bedirli, N (reprint author), Gazi Univ, Anesthesiol & Reanimat Dept, Fac Med, TR-06510 Ankara, Turkey.	nurbedirli@yahoo.com	Gurkan, Odul Egritas/O-1363-2016	Gurkan, Odul Egritas/0000-0003-0230-7551; Bedirli, Nurdan/0000-0003-2624-0259			Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; Amornyotin S, 2009, PEDIATR ANESTH, V19, P784, DOI 10.1111/j.1460-9592.2009.03063.x; [Anonymous], 2008, PEDIATR ANESTH, V18, P11, DOI 10.1111/j.1460-9592.2007.02405.x; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bloch MB, 2002, ANESTH ANALG, V94, P523, DOI 10.1097/00000539-200203000-00009; Chu Y, 2006, ANESTH ANALG, V102, P1668, DOI 10.1213/01.ANE.0000219587.02263.A0; Coetzee JF, 1998, BRIT J ANAESTH, V81, P737, DOI 10.1093/bja/81.5.737; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; Gilger MA, 2004, GASTROINTEST ENDOSC, V59, P659, DOI 10.1016/S0016-5107(04)00180-4; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; GUIT JBM, 1991, ANAESTHESIA, V46, P24, DOI 10.1111/j.1365-2044.1991.tb09308.x; Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1016/S1053-0770(03)00200-3; Lee-Jayaram JJ, 2010, PEDIATR EMERG CARE, V26, P408, DOI 10.1097/PEC.0b013e3181e057cd; MCDOWALL RH, 1995, J CLIN ANESTH, V7, P273, DOI 10.1016/0952-8180(95)00017-C; Murthy BVS, 2000, BRIT J ANAESTH, V84, P346; Nimmaanrat S, 2007, MINERVA ANESTESIOL, V73, P623; Ramsay MA, 1974, BJM, V22, P569; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Sury MRJ, 2008, PEDIATR ANESTH, V18, P18, DOI 10.1111/j.1460-9592.2007.02379.x; Tosun Z, 2007, PEDIATR ANESTH, V17, P983, DOI 10.1111/j.1460-9592.2007.02206.x; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x	24	8	9	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	FEB	2012	22	2					150	155		10.1111/j.1460-9592.2011.03707.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	870MC	WOS:000298672500006	21958025				2020-06-30	J	Lim, BG; Lee, JY; Kim, H; Lee, DK; Lee, MK				Lim, Byung Gun; Lee, Jea Yeun; Kim, Heezoo; Lee, Dong Kyu; Lee, Mi Kyoung			Nystagmus caused by epidural fentanyl	JOURNAL OF ANESTHESIA			English	Article						Opioid; Nystagmus; Fentanyl; Epidural analgesia	VERTICAL NYSTAGMUS; INFUSION; OPIOIDS	Anesthesiologists commonly use opioids for pain control in the operating room and postanesthesia care unit, and are constantly vigilant in looking for possible adverse outcomes. Therefore, common complications such as nausea, vomiting, and pruritus are well known. However, neurologic complications after opioid administration are relatively rare except for reduced consciousness, for example drowsiness or sedation. We recently experienced a case in which a 73-year-old woman presented predominantly vertical nystagmus as a neurological complication after epidural administration of fentanyl. A few previous reports on opioids as causative agents for nystagmus have all after use of epidural morphine, and there are yet no publications reporting epidural fentanyl as the cause of nystagmus. Physicians should keep in mind that epidural fentanyl could cause the nystagmus as a neurological complication even though it is used within conventional dosage ranges, although this is very rare. Also, when a patient develops nystagmus after epidural fentanyl, it could be a benign side effect caused by epidural fentanyl as we have experienced, but it could also be a sign of serious central nervous system lesions especially in patients with underlying risk factors such as old age, diabetes mellitus, hypertension, and cerebrovascular disease, and thus special attention should be paid to this.	[Lim, Byung Gun; Lee, Jea Yeun; Kim, Heezoo; Lee, Dong Kyu; Lee, Mi Kyoung] Korea Univ, Guro Hosp, Dept Anesthesiol & Pain Med, Seoul 152703, South Korea	Lee, MK (reprint author), Korea Univ, Guro Hosp, Dept Anesthesiol & Pain Med, 97 Gurodong Gil, Seoul 152703, South Korea.	mknim@hotmail.com					ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P981, DOI 10.1097/00000542-199006000-00006; FISH DJ, 1990, ANESTHESIOLOGY, V73, P785, DOI 10.1097/00000542-199010000-00030; Fukuda K, 2010, MILLERS ANESTHESIA, P810; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Hamber Elizabeth A., 1999, Regional Anesthesia and Pain Medicine, V24, P255, DOI 10.1016/S1098-7339(99)90139-6; Hurley RW, 2010, MILLERS ANESTHESIA, P2765; KANAYA T, 1994, ORL J OTO-RHINO-LARY, V56, P236, DOI 10.1159/000276662; Liu SS, 2002, REGION ANESTH PAIN M, V27, P122, DOI 10.1053/rapm.2002.30660; LOPER KA, 1990, ANESTH ANALG, V70, P72; Pierrot-Deseilligny C, 2005, BRAIN, V128, P1237, DOI 10.1093/brain/awh532; STEVENS RA, 1991, ANESTHESIOLOGY, V74, P390, DOI 10.1097/00000542-199102000-00046	12	2	2	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2012	26	1					94	96		10.1007/s00540-011-1263-8			3	Anesthesiology	Anesthesiology	893HC	WOS:000300345900013	22038616				2020-06-30	J	Silva-Moreno, A; Gonzalez-Espinosa, C; Leon-Olea, M; Cruz, SL				Silva-Moreno, Arturo; Gonzalez-Espinosa, Claudia; Leon-Olea, Martha; Cruz, Silvia L.			Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: Correlation with mu-opioid receptor internalization	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Fentanyl; Morphine; mu-Opioid receptor internalization; Synergism; Tolerance; Isobologram	SPLICE VARIANTS; TAIL-FLICK; EFFICACY; COMBINATION; ENDOCYTOSIS; MECHANISMS; PAIN; ENHANCEMENT; TRAFFICKING; ADAPTATIONS	It has been described that coadministration of opioids with low doses of other analgesics can reduce adverse effects and increase antinociception, but combinations of two mu-opioid receptor agonists have been poorly explored. The objective of this work was threefold: 1) to evaluate the antinociceptive combination of i.c.v. morphine and fentanyl at different doses; 2) to compare the antinociception produced by acute or repeated administration of an effective morphine dose (1 mu g) alone, or combined with a low fentanyl dose (1 g); and 3) to correlate these effects with mu-opioid receptor internalization in periaqueductal gray matter and locus coeruleus. Antinociception was evaluated by the tail-flick test and receptor internalization was analyzed by confocal microscopy in Wistar rats. Drug interactions were examined by administering combinations of opioids in 1:3,1:1 and 3:1 ratios of their respective ED50 fractions. For tolerance and internalization studies, animals were i.c.v. injected only once (acute treatment) or twice a day until five administrations were completed. Our results show that morphine and fentanyl have synergistic effects. The combination of 1 ng fentanyl with 1 mu g morphine increases the magnitude and duration of antinociception not only after a single injection, but also after five administrations when tolerance develops to morphine alone. Increased and long-lasting antinociception correlates positively with increased beta-arrestin 2 activity and mu-opioid receptor internalization in periaqueductal gray matter and locus coeruleus. These results suggest that combined administration of morphine and fentanyl increases long-lasting antinociception and beta-arrestin 2 signaling contributes to the combination effects. (C) 2011 Elsevier B.V. All rights reserved.	[Silva-Moreno, Arturo; Gonzalez-Espinosa, Claudia; Cruz, Silvia L.] CINVESTAV, Dept Farmacobiol, Mexico City 14330, DF, Mexico; [Leon-Olea, Martha; Cruz, Silvia L.] Inst Nacl Psiquiatria Ramon Fuente Muniz, Dept Neuromorfol Func, Direcc Invest Neurociencias, Mexico City 14370, DF, Mexico	Cruz, SL (reprint author), Calzada Tenorios 235, Mexico City 14330, DF, Mexico.	slcruz@cinvestav.mx	Leon-Olea, Martha/C-4026-2018; Gonzalez-Espinosa, Claudia/C-4417-2019	Leon-Olea, Martha/0000-0003-1164-885X; Gonzalez-Espinosa, Claudia/0000-0001-7332-3829; Cruz, Silvia/0000-0002-8617-3556	ConacytConsejo Nacional de Ciencia y Tecnologia (CONACyT) [200325]; INPRFM [NC093290.0]	This paper includes data from Arturo Silva-Moreno's doctoral dissertation and was supported by scholarship 200325 from Conacyt. This work was partially funded by a grant to MLO from the INPRFM (project No. NC093290.0). Authors wish to thank Dr. Vinicio Granados-Soto for valuable comments to the manuscript and Mr. Abraham Contreras and Isai Mendez for technical assistance.	Abbadie C, 2000, J COMP NEUROL, V419, P244, DOI 10.1002/(SICI)1096-9861(20000403)419:2<244::AID-CNE8>3.0.CO;2-R; Aceto MD, 1990, TESTING EVALUATION D, P67; Barrera NP, 2005, TRENDS PHARMACOL SCI, V26, P526, DOI 10.1016/j.tips.2005.08.003; Beaulieu JM, 2005, J NEUROSCI, V25, P10061, DOI 10.1523/JNEUROSCI.3914-05.2005; Bohn LM, 2004, MOL PHARMACOL, V66, P106, DOI 10.1124/mol.66.1.106; Bolan EA, 2002, J PHARMACOL EXP THER, V303, P557, DOI 10.1124/jpet.102.035881; Deciga-Campos M, 2003, EUR J PHARMACOL, V460, P99, DOI 10.1016/S0014-2999(02)02920-5; DOTTRENS M, 1992, BRIT J ANAESTH, V69, P9, DOI 10.1093/bja/69.1.9; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Friedman Zeev, 2008, Pain Pract, V8, P248, DOI 10.1111/j.1533-2500.2008.00212.x; Goldstein Frederick J., 2002, Journal of the American Osteopathic Association, V102, pS15; Granados-Soto V, 2005, PHARMACOLOGY, V74, P200, DOI 10.1159/000085700; Hashimoto T, 2006, ANESTHESIOLOGY, V105, P574, DOI 10.1097/00000542-200609000-00023; He L, 2005, CURR BIOL, V15, P1028, DOI 10.1016/j.cub.2005.04.052; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hernandez-Delgadillo GP, 2003, EUR J PHARMACOL, V469, P71, DOI 10.1016/S0014-2999(03)01727-8; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Johnson EE, 2005, NEUROSIGNALS, V14, P290, DOI 10.1159/000093044; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; LANGERMAN L, 1995, J PHARMACOL TOX MET, V34, P23, DOI 10.1016/1056-8719(94)00077-H; Le Bars D, 2001, ANN FR ANESTH, V20, P452; Luttrell LM, 2010, PHARMACOL REV, V62, P305, DOI 10.1124/pr.109.002436; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Mercadante S, 2004, SUPPORT CARE CANCER, V12, P762, DOI 10.1007/s00520-004-0650-1; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; NANCE PW, 1987, J PHARMACOL EXP THER, V240, P972; Pan YX, 2009, P NATL ACAD SCI USA, V106, P4917, DOI 10.1073/pnas.0811586106; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Romero A, 2010, PHARMACOL RES, V61, P511, DOI 10.1016/j.phrs.2010.02.011; Scavone JL, 2009, ANAT REC, V292, P401, DOI 10.1002/ar.20860; Silva-Moreno A, 2009, EUR J PHARMACOL, V607, P84, DOI 10.1016/j.ejphar.2009.02.010; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Smith HS, 2008, PAIN PHYSICIAN, V11, P201; Smith MA, 1998, PSYCHOPHARMACOLOGY, V140, P57, DOI 10.1007/s002130050739; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Virk MS, 2008, MOL PHARMACOL, V73, P1301, DOI 10.1124/mol.107.042952; von Zastrow M, 2010, DRUG ALCOHOL DEPEN, V108, P166, DOI 10.1016/j.drugalcdep.2010.02.014; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; Walwyn WM, 2010, DRUG ALCOHOL DEPEN, V108, P156, DOI 10.1016/j.drugalcdep.2010.01.001; Williams JT, 2001, PHYSIOL REV, V81, P299; Xu J, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-9; Yoshikawa M, 2007, EUR J PHARMACOL, V565, P89, DOI 10.1016/j.ejphar.2007.02.042; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	50	6	7	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JAN 15	2012	674	2-3					239	247		10.1016/j.ejphar.2011.10.034			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	891EM	WOS:000300200000021	22079772				2020-06-30	J	Fyneface-Ogan, S; Abam, DS; Numbere, C				Fyneface-Ogan, S.; Abam, D. S.; Numbere, C.			Anaesthetic management of a super morbidly obese patient for total abdominal hysterectomy: a few more lessons to learn	AFRICAN HEALTH SCIENCES			English	Article							POSTOPERATIVE ANALGESIA; RESPIRATORY DEPRESSION; GENERAL-ANESTHESIA; AMBULATORY SURGERY; EPIDURAL MORPHINE; BREAST SURGERY; BLOCK	Background: The prevalence of obesity is on the upward trend world-wide. This epidemic has challenging implications for anaesthetists, following the anthropometric changes associated with the disease. Objective: To highlight some of the challenges, the management and the lessons learnt during the management of this patient. Methods: This is a case report of a 52-year old super morbidly obese, diabetic, and hypertensive patient that presented for total abdominal hysterectomy. Surgery was carried out under a single-shot spinal anaesthesia with bupivacaine/fentanyl. Results: Under bupivacaine/fentanyl anaesthesia, she became very drowsy and had moderate to severe respiratory depression. She was arousable but had an obstructive sleep apnoea. Surgery was carried out successfully Conclusion: A better understanding of the pathophysiology and complications that accompany obesity is needed to manage an obese patient under anaesthesia. African Health Sciences 2012; 12(2): 181 - 185 http://dx.doi.org/10.4314/ahs.v12i2.16	[Fyneface-Ogan, S.; Numbere, C.] Univ Port Harcourt, Dept Anaesthesiol, Fac Clin Sci, Coll Hlth Sci, Port Harcourt, Nigeria; [Abam, D. S.] Nimley Hosp Women, Port Harcourt, Nigeria	Fyneface-Ogan, S (reprint author), Univ Port Harcourt, Dept Anaesthesiol, Fac Clin Sci, Coll Hlth Sci, Port Harcourt, Nigeria.	soglonye@yahoo.com					Adams JP, 2000, BRIT J ANAESTH, V85, P91, DOI 10.1093/bja/85.1.91; BENNETT R, 1982, PHARMACOTHERAPY, V2, P50; BILOTTA J J, 1990, Gastrointestinal Endoscopy, V36, pS5; Bray GA, 1992, AM J CLIN NUTR, V55, p488 S; BRODSKY JB, 1984, WESTERN J MED, V140, P750; COOPER JR, 1987, SEMIN ANESTH, V6, P260; Coveney E, 1998, ANN SURG, V227, P496, DOI 10.1097/00000658-199804000-00008; DALESSIO JG, 1995, REGION ANESTH, V20, P62; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Gentili M, 1998, BRIT J ANAESTH, V81, P970; Grant SA, 2001, REGION ANESTH PAIN M, V26, P209, DOI 10.1053/rapm.2001.22256; Horlocker TS, 2007, ASA NEWSLETTER, V71, P24; Klein SM, 2002, ANESTH ANALG, V94, P65, DOI 10.1097/00000539-200201000-00012; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; LYNCH EP, 1995, ANN SURG, V222, P663, DOI 10.1097/00000658-199511000-00009; Perilli V, 2003, OBES SURG, V13, P605, DOI 10.1381/096089203322190826; Pusch F, 1999, ACTA ANAESTH SCAND, V43, P770, DOI 10.1034/j.1399-6576.1999.430714.x; RAWAL N, 1984, ANESTH ANALG, V63, P583; READY LB, 1991, ANESTHESIOLOGY, V75, P452, DOI 10.1097/00000542-199109000-00012; Schulz-Stubner S, 2004, ACTA ANAESTH SCAND, V48, P126, DOI 10.1111/j.1399-6576.2004.00276.x; Shapiro A, 2005, J CLIN ANESTH, V17, P537, DOI 10.1016/j.jclinane.2005.01.006; SHENKMAN Z, 1993, BRIT J ANAESTH, V70, P349, DOI 10.1093/bja/70.3.349; VANDERCAR DH, 1991, ANESTHESIOLOGY, V74, P623, DOI 10.1097/00000542-199103000-00036; VAUGHAN RW, 1982, ANESTHESIA OBESE PAT, P71; Weinger M., 2006, APSF NEWSL, V21, P61	25	1	3	0	2	MAKERERE UNIV, FAC MED	KAMPALA	PO BOX 7072, KAMPALA, 00000, UGANDA	1680-6905			AFR HEALTH SCI	Afr. Health Sci.		2012	12	2					181	185		10.4314/ahs.v12i2.16			5	Medicine, General & Internal	General & Internal Medicine	093IK	WOS:000315184900016	23056025	Other Gold, Green Published			2020-06-30	J	Wanzuita, R; Poli-de-Figueiredo, LF; Pfuetzenreiter, F; Cavalcanti, AB; Westphal, GA				Wanzuita, Raquel; Poli-de-Figueiredo, Luiz F.; Pfuetzenreiter, Felipe; Cavalcanti, Alexandre Biasi; Westphal, Glauco Adrieno			Replacement of fentanyl infusion by enteral methadone decreases the weaning time from mechanical ventilation: a randomized controlled trial	CRITICAL CARE			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; OPIOID ABSTINENCE SYNDROME; SEDATION; ANALGESIA; DURATION; PROTOCOL; REMIFENTANIL; DEPENDENCY; WITHDRAWAL	Introduction: Patients undergoing mechanical ventilation (MV) are frequently administered prolonged and/or high doses of opioids which when removed can cause a withdrawal syndrome and difficulty in weaning from MV. We tested the hypothesis that the introduction of enteral methadone during weaning from sedation and analgesia in critically ill adult patients on MV would decrease the weaning time from MV. Methods: A double-blind randomized controlled trial was conducted in the adult intensive care units (ICUs) of four general hospitals in Brazil. The 75 patients, who met the criteria for weaning from MV and had been using fentanyl for more than five consecutive days, were randomized to the methadone (MG) or control group (CG). Within the first 24 hours after study enrollment, both groups received 80% of the original dose of fentanyl, the MG received enteral methadone and the CG received an enteral placebo. After the first 24 hours, the MG received an intravenous (IV) saline solution (placebo), while the CG received IV fentanyl. For both groups, the IV solution was reduced by 20% every 24 hours. The groups were compared by evaluating the MV weaning time and the duration of MV, as well as the ICU stay and the hospital stay. Results: Of the 75 patients randomized, seven were excluded and 68 were analyzed: 37 from the MG and 31 from the CG. There was a higher probability of early extubation in the MG, but the difference was not significant (hazard ratio: 1.52 (95% confidence interval (CI) 0.87 to 2.64; P = 0.11). The probability of successful weaning by the fifth day was significantly higher in the MG (hazard ratio: 2.64 (95% CI: 1.22 to 5.69; P < 0.02). Among the 54 patients who were successfully weaned (29 from the MG and 25 from the CG), the MV weaning time was significantly lower in the MG (hazard ratio: 2.06; 95% CI 1.17 to 3.63; P < 0.004). Conclusions: The introduction of enteral methadone during weaning from sedation and analgesia in mechanically ventilated patients resulted in a decrease in the weaning time from MV.	[Wanzuita, Raquel; Pfuetzenreiter, Felipe; Westphal, Glauco Adrieno] Ctr Hosp Unimed, Adult ICU, BR-89204060 Joinville, Brazil; [Wanzuita, Raquel] Hosp Reg Hans Dieter Schmidt, Adult ICU, BR-89227680 Joinville, Brazil; [Poli-de-Figueiredo, Luiz F.] Univ Sao Paulo, Hosp Clin, LIM 08, BR-01246903 Sao Paulo, Brazil; [Pfuetzenreiter, Felipe; Westphal, Glauco Adrieno] Hosp Municipal Sao Jose, Adult ICU, BR-89202000 Joinville, Brazil; [Cavalcanti, Alexandre Biasi] Hosp Coracao, Res Inst, BR-04005000 Sao Paulo, Brazil	Wanzuita, R (reprint author), Ctr Hosp Unimed, Adult ICU, Rua Orestes Guimaraes 905, BR-89204060 Joinville, Brazil.	raquelwan@uol.com.br	Cavalcanti, Alexandre/K-5529-2013	Cavalcanti, Alexandre/0000-0003-2798-6263			Amato L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003409.pub3; ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Cammarano WB, 1998, CRIT CARE MED, V26, P676, DOI 10.1097/00003246-199804000-00015; DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002; Epstein J, 1999, CRIT CARE CLIN, V15, P17, DOI 10.1016/S0749-0704(05)70037-3; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gowing L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002025.pub4; Gowing L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002024.pub3; Honey BL, 2009, ANN PHARMACOTHER, V43, P1506, DOI 10.1345/aph.1M161; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Lugo RA, 2001, PHARMACOTHERAPY, V21, P1566, DOI 10.1592/phco.21.20.1566.34471; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; Novaes MAFP, 1999, INTENS CARE MED, V25, P1421, DOI 10.1007/s001340051091; Nseir S, 2010, CRIT CARE, V14, DOI 10.1186/cc8907; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; PUNTILLO KA, 1990, HEART LUNG, V19, P526; Robertson R C, 2000, Pediatr Crit Care Med, V1, P119, DOI 10.1097/00130478-200010000-00005; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; Salluh JIF, 2009, J CRIT CARE, V24, P556, DOI 10.1016/j.jcrc.2009.04.004; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; TOBIAS JD, 1994, INTENS CARE MED, V20, P504, DOI 10.1007/BF01711905; TOBIAS JD, 1990, CRIT CARE MED, V18, P1292, DOI 10.1097/00003246-199011000-00024; 1998, J AM MED ASS, V280, P1936, DOI DOI 10.1001/JAMA.280.22.1936	33	12	13	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2012	16	2							R49	10.1186/cc11250			9	Critical Care Medicine	General & Internal Medicine	066CF	WOS:000313196800015	22420584	DOAJ Gold, Green Published			2020-06-30	J	Qin, Y; Li, L; Chen, J; Tang, XM; Liao, CJ; Xie, YB; Xiao, Q				Qin, Yi; Li, Li; Chen, Jing; Tang, Xiaoman; Liao, Chunjie; Xie, Yubo; Xiao, Qiang			Fentanyl Inhibits Progression of Human Gastric Cancer MGC-803 Cells by NF-kappa B Downregulation and PTEN Upregulation In Vitro	ONCOLOGY RESEARCH			English	Article						Fentanyl; Gastric cancer; Tumor progression; NF-kappa B; PTEN	BONE DESTRUCTION; MURINE MODEL; NITRIC-OXIDE; MORPHINE; PAIN; EXPRESSION; IMPACT; ACTIVATION; APOPTOSIS; OPIOIDS	Fentanyl is used as an analgesic to treat pain in a variety of patients with cancer. Moreover, fentanyl may affect tumor growth in many cell lines. To gain better insight into the interaction between fentanyl and tumor, we investigated the effects of fentanyl on the growth of gastric carcinoma cells and the expression of some apoptosis-related genes including NF-kappa B and PTEN. A human gastric cancer cell line MGC-803 was used. The viability and proliferation of gastric cancer MGC-803 cells were detected by MTT assay and colony formation assay. The cell cycle progression and apoptosis were assessed by flow cytometry and the ultrastructure of cells was examined with transmission electron microscope. The migration of cells was investigated by wound healing assay. The expression of NF-kappa B and PTEN was evaluated by semiquantitative RT-PCR and Western blot. Our data showed that fentanyl could inhibit cell growth and proliferation and made cell cycle arrest at G(2)/M phase. Compared with control cells, MGC-803 cells that were incubated with fentanyl also had a higher apoptotic rate. Fentanyl could lead to morphological changes of gastric cancer cells and reduce the motility of MGC-803 cells. Moreover, fentanyl could downregulate NF-kappa B and upregulate PTEN, which might be the mechanism of fentanyl inhibiting gastric cancer progression in vitro.	[Qin, Yi; Li, Li; Chen, Jing; Liao, Chunjie; Xie, Yubo] Guangxi Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanning 530021, Guangxi, Peoples R China; [Tang, Xiaoman] First Peoples Hosp Nanning, Dept Anesthesiol, Nanning, Guangxi, Peoples R China; [Xiao, Qiang] Guangxi Med Univ, Affiliated Hosp 1, Dept Surg, Nanning 530021, Guangxi, Peoples R China	Xie, YB (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Anesthesiol, 6 Shuang Yong Rd, Nanning 530021, Guangxi, Peoples R China.	xieyubo715001@yahoo.com.cn; xiaoqiang20050@yahoo.com.cn			Natural Science Foundation of ChinaNational Natural Science Foundation of China [81160289, 81060277]; Science Study and Technology Development Program of Guangxi, P.R. China [1140003A-12]	This work was supported by grants from the Natural Science Foundation of China (No. 81160289 and No. 81060277), and the Science Study and Technology Development Program of Guangxi (No. 1140003A-12), P.R. China.	Andjelkovic T, 2011, TRANSL RES, V157, P19, DOI 10.1016/j.trsl.2010.09.004; Coban TA, 2007, BIOL PHARM BULL, V30, P2257, DOI 10.1248/bpb.30.2257; Delogu G, 2004, J TRAUMA, V57, P75, DOI 10.1097/01.TA.0000075349.66640.3E; El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016; El Mouedden M, 2007, PHARMACOL BIOCHEM BE, V87, P30, DOI 10.1016/j.pbb.2007.03.017; Hara S, 2008, ONCOLOGY-BASEL, V74, P52, DOI 10.1159/000143219; Hatzoglou A, 1996, EUR J PHARMACOL, V296, P199, DOI 10.1016/0014-2999(95)00703-2; HOUSE RV, 1995, IMMUNOL LETT, V46, P117, DOI 10.1016/0165-2478(95)00035-4; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jia GH, 2009, J CELL MOL MED, V13, P547, DOI 10.1111/j.1582-4934.2008.00384.x; Lan HB, 2010, INT J MOL MED, V26, P893, DOI 10.3892/ijmm_00000539; Li FH, 2010, WORLD J GASTROENTERO, V16, P5881, DOI 10.3748/wjg.v16.i46.5881; Moon SK, 2004, ARCH BIOCHEM BIOPHYS, V421, P267, DOI 10.1016/j.abb.2003.11.007; Page GG, 1998, BRIT J ANAESTH, V81, P216; Pape M, 2006, ANESTH ANALG, V103, P173, DOI 10.1213/01.ane.0000222634.51192.a4; Payabvash S, 2006, LIFE SCI, V79, P972, DOI 10.1016/j.lfs.2006.05.008; Stefano GB, 2005, MED SCI MONITOR, V11, pMS47; Sueoka E, 1998, BIOCHEM BIOPH RES CO, V252, P566, DOI 10.1006/bbrc.1998.9695; Welters ID, 2000, ANESTHESIOLOGY, V92, P1677, DOI 10.1097/00000542-200006000-00027; Welters ID, 2000, MED HYPOTHESES, V54, P263, DOI 10.1054/mehy.1999.0032; YEAGER MP, 1991, ARCH SURG-CHICAGO, V126, P454	21	15	22	0	8	COGNIZANT COMMUNICATION CORP	PUTNAM VALLEY	18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA	0965-0407			ONCOL RES	Oncol. Res.		2012	20	2-3					61	69		10.3727/096504012X13473664562501			9	Oncology	Oncology	036UX	WOS:000311058800002	23193912				2020-06-30	J	Saracoglu, KT; Saracoglu, A; Cakar, K; Fidan, V; Ay, B				Saracoglu, Kemal Tolga; Saracoglu, Ayten; Cakar, Kubra; Fidan, Vural; Ay, Binnaz			Comparative study of intravenous opioid consumption in the postoperative period	BIOMEDICAL PAPERS-OLOMOUC			English	Article						patient-controlled analgesia; fentanyl; tramadol; spinal anesthesia	PATIENT-CONTROLLED ANALGESIA; GENERAL-ANESTHESIA; PAIN RELIEF; TRAMADOL; FENTANYL; METAANALYSIS	Background. Intravenous patient-controlled analgesia (IV PCA) using opiods is an accepted method for delivering postoperative analgesia. The aim of this study was to compare fentanyl and tramadol with IV PCA after spinal anesthesia (SA) and general anesthesia (GA) following cesarean section (C/S). Methods. Ninety women were randomly assigned to three groups (n=30). Group 1 was treated with IV fentanyl PCA after SA. Groups 2 and 3 were treated with IV fentanyl PCA and IV tramadol PCA after GA. Outcome measures were recorded for the first 24 h post-anesthesia. Results. PCA use was significantly lower after SA (P<0.05). Eighteen patients in the SA Group and 27 patients and 24 patients from the GA groups required additional opioid. Opioid consumption and patient satisfaction were similar for groups after GA (P>0.05). 638.4 +/- 179.1 mu g fentanyl was consumed by patients of Group 2, 356.3 +/- 87.0 mu g fentanyl and 559.5 +/- 207.0 mg tramadol was consumed by Group 1 and Group 3 respectively. There was no significant difference in the overall severity and incidence of nausea, drowsiness or pruritus. Conclusion. Our study shows that analgesic consumption and post-operative pain scores after SA in C/S decreased, without increase in adverse reactions.	[Saracoglu, Kemal Tolga; Saracoglu, Ayten] Marmara Univ, Sch Med, Dept Anesthesiol & Reanimat, Istanbul, Turkey; [Cakar, Kubra] Maltepe Univ, Fac Med, Istanbul, Turkey; [Fidan, Vural] Cent Educ & Res Hosp, Dept Ear Nose & Throat Surg, Erzurum, Turkey; [Ay, Binnaz] Acibadem Univ, Fac Med, Dept Anesthesiol & Reanimat, Istanbul, Turkey	Saracoglu, KT (reprint author), Marmara Univ, Sch Med, Dept Anesthesiol & Reanimat, Istanbul, Turkey.	saracoglukt@gmail.com					Beilin B, 2008, J CLIN EXP NEUROPSYC, V30, P674, DOI 10.1080/13803390701667310; Bessa SS, 2010, J LAPAROENDOSC ADV S, V20, P515, DOI 10.1089/lap.2010.0041; Chazan S, 2010, PAIN MANAG NURS, V11, P169, DOI 10.1016/j.pmn.2009.06.003; Chiaretti A, 2008, CHILD NERV SYST, V24, P119, DOI 10.1007/s00381-007-0429-z; Fassoulaki A, 2008, J OBSTET GYNAECOL, V29, P25, DOI 10.1080/01443610802628569; Gogus Y, 2003, AGRI, V15, P12; Gulur P, 2006, BEST PRACT RES-CLIN, V20, P249, DOI 10.1016/j.bpa.2005.10.002; Hadi M A, 2006, Med J Malaysia, V61, P570; Imbelloni LE, 2010, REV BRAS ANESTESIOL, V60, P217, DOI [10.1590/S0034-70942010000300001, 10.1016/S0034-7094(10)70030-1]; Kocabas S, 2005, Clin Exp Obstet Gynecol, V32, P45; Lcsi FE, 2006, COCHRANE DB SYST REV, V18, DOI C0004350; Liu SS, 2005, ANESTH ANALG, V101, P1634, DOI 10.1213/01.ANE.0000180829.70036.4F; Long JJ, 2003, CHINESE MED J-PEKING, V116, P1752; Mauermann WJ, 2006, ANESTH ANALG, V103, P1018, DOI 10.1213/01.ane.0000237267.75543.59; Ng KFJ, 2006, J CLIN ANESTH, V18, P205, DOI 10.1016/j.jclinane.2005.08.004; Prakash S, 2004, ANESTH ANALG, V99, P552, DOI 10.1213/01.ANE.0000125110.56886.90; Roussier M, 2006, BRIT J ANAESTH, V96, P492, DOI 10.1093/bja/ael025; Sudheer PS, 2007, ANAESTHESIA, V62, P555, DOI 10.1111/j.1365-2044.2007.05038.x; Sumida Shawn, 2009, J Opioid Manag, V5, P301; Teng Yun-Hui, 2004, Chang Gung Med J, V27, P877	20	3	3	0	3	PALACKY UNIV, MEDICAL FAC	OLOMOUC	CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC	1213-8118	1804-7521		BIOMED PAP	Biomed. Pap-Olomouc		2012	156	1					48	51		10.5507/bp.2011.037			4	Engineering, Biomedical; Medicine, Research & Experimental	Engineering; Research & Experimental Medicine	925HV	WOS:000302753000007	22580860	DOAJ Gold			2020-06-30	J	Meyer, RA; Macarthur, AJ; Downey, K				Meyer, R. A.; Macarthur, A. J.; Downey, K.			Study of equivalence: spinal bupivacaine 15 mg versus bupivacaine 12 mg with fentanyl 15 mu g for cesarean delivery	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Cesarean delivery; Spinal anesthesia; Bupivacaine; Fentanyl; Equivalence	HYPERBARIC BUPIVACAINE; INTRATHECAL FENTANYL; ANESTHESIA; SECTION; OPIOIDS; PHENYLEPHRINE; PREVENTION; TRIALS; ED50; ED95	Background: A safe and effective intrathecal dose of bupivacaine alone for cesarean delivery has not yet been established. This study tested the hypothesis that an intrathecal dose of hyperbaric bupivacaine 15 mg would produce equivalent spinal anesthesia for cesarean delivery as the combination of hyperbaric bupivacaine 12 mg and fentanyl 15 mu g. Methods: This was a single center, double-blind, randomized clinical trial of equivalence. One hundred and thirty-eight healthy parturients scheduled for elective cesarean delivery were randomized to receive either intrathecal hyperbaric bupivacaine 15 mg (Group B) or hyperbaric bupivacaine 12 mg with fentanyl 15 mu g (Group BF). Parturients where asked to describe their degree of sensation during surgery using a four-point scale 20 min after spinal injection. Secondary outcomes included the incidence of maternal side effects, maternal hemodynamics and the need for supplemental analgesia. Results: There was no difference in the quality of anesthesia between the two groups. Sixty-eight of 69 and 69/69 patients in Group B and Group BF, respectively had anesthesia classified as successful (RR = 1.01; 95% CI 0.85, 1.22). The only two secondary outcomes that were different between the groups were the largest change in mean arterial pressure (decrease of 40 mmHg and 34 mmHg for Group B and Group BF, respectively; P = 0.004) and the incidence of nausea (59% and 35% for Group B and Group BF, respectively; P = 0.006). Conclusion: There was no difference in the degree of sensation at 20 min between Group B and Group BF. The only significant differences between the two techniques were a higher incidence of nausea and decrease in maternal blood pressure in Group B. (C) 2011 Elsevier Ltd. All rights reserved.	[Meyer, R. A.; Macarthur, A. J.; Downey, K.] Mt Sinai Hosp, Dept Anesthesia, Toronto, ON M5G 1X5, Canada	Macarthur, AJ (reprint author), Mt Sinai Hosp, Dept Anesthesia, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	alison.macarthur@uhn.on.ca			Department of Anesthesia at Mount Sinai Hospital	This research was funded internally by the Department of Anesthesia at Mount Sinai Hospital. We have no commercial or non-commercial affiliations, nor other associations that would be perceived as a conflict of interest with our research.	BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Carvalho B, 2005, ANESTHESIOLOGY, V103, P606, DOI 10.1097/00000542-200509000-00025; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; DESIMONE CA, 1995, REGION ANESTH, V20, P90; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; Kee WDN, 2004, BRIT J ANAESTH, V92, P469, DOI 10.1093/bja/aeh088; Manullang TR, 2000, ANESTH ANALG, V90, P1162, DOI 10.1097/00000539-200005000-00030; Morgan PJ, 1999, INT J OBSTET ANESTH, V8, P165, DOI 10.1016/S0959-289X(99)80132-0; PEDERSEN H, 1989, ANESTH ANALG, V69, P46; SANTOS A, 1984, ANESTH ANALG, V63, P1009; Saravanan S, 2006, BRIT J ANAESTH, V96, P95, DOI 10.1093/bja/aei265; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; Siddiqui M, 2007, OBSTET GYNECOL, V110, P570, DOI 10.1097/01.AOG.0000277712.67230.22; TARONE RE, 1990, BIOMETRICS, V46, P515, DOI 10.2307/2531456; Turhanoglu S, 2009, J ANESTH, V23, P353, DOI 10.1007/s00540-009-0750-7	20	3	4	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2012	21	1					17	23		10.1016/j.ijoa.2011.09.010			7	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	906DT	WOS:000301325800004	22119634				2020-06-30	J	Carvalho, B; Drover, DR; Ginosar, Y; Cohen, SE; Riley, ET				Carvalho, B.; Drover, D. R.; Ginosar, Y.; Cohen, S. E.; Riley, E. T.			Intrathecal fentanyl added to bupivacaine and morphine for cesarean delivery may induce a subtle acute opioid tolerance	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Analgesic-opioids; Anesthesia-obstetric; Anesthesia-spinal; Tolerance; Spinal; Anesthesia; Intrathecal; Fentanyl; Acute; Tolerance	LIDOCAINE SPINAL-ANESTHESIA; DOSE-RESPONSE RELATIONSHIP; RELEASE EPIDURAL MORPHINE; POSTCESAREAN ANALGESIA; POSTOPERATIVE PAIN; SECTION; HYPERALGESIA; HUMANS	Background: Previous studies have demonstrated that the addition of intrathecal fentanyl to a spinal anesthetic for cesarean delivery improves intraoperative analgesia. However, intrathecal fentanyl may induce acute tolerance to opioids. The objective of this study was to investigate whether the addition of intrathecal fentanyl to spinal anesthesia with intrathecal morphine increases postoperative analgesic requirements and pain scores. Methods: In this randomized, double-blinded study, 40 women having elective cesarean delivery were enrolled. Patients received spinal anesthesia with hyperbaric bupivacaine 12 mg, morphine 200 mu g, and fentanyl 0, 5, 10 or 25 mu g. Each patient received intravenous patient-controlled analgesia morphine for 24 h postoperatively. Outcome measures included postoperative morphine usage and pain scores, as well as intraoperative pain, nausea, hypotension and vasopressor use. Results: Total morphine use over the 24-h post-spinal study period was similar among the study groups (P = 0.129). Postoperative pain scores were higher in patients receiving fentanyl 5, 10 and 25 mu g compared to fentanyl 0 mu g control group (P = 0.003). Conclusions: The study results suggest that intrathecal fentanyl may induce acute tolerance to intrathecal morphine. However, because there was no difference in postoperative analgesia requirement and the difference in pain scores was small, the clinical significance of this finding is uncertain. (C) 2011 Elsevier Ltd. All rights reserved.	[Carvalho, B.; Drover, D. R.; Cohen, S. E.; Riley, E. T.] Stanford Univ, Dept Anesthesiol, Stanford, CA 94305 USA; [Ginosar, Y.] Hadassah Hebrew Univ Med Sch, Dept Anesthesiol & Crit Care Med, Jerusalem, Israel	Carvalho, B (reprint author), Stanford Univ, Med Ctr, Dept Anesthesia, 300 Pasteur Ave, Stanford, CA 94305 USA.	bcarvalho@stanford.edu			Department of Anesthesia, Stanford University School of Medicine, Stanford, California	The authors involved in this study and the preparation of the manuscript received no external funding. This study was financially supported by the Department of Anesthesia, Stanford University School of Medicine, Stanford, California. We thank Karen Giarrusso, MD for her valuable help with patient enrollment and data collection. We would also like to thank Alex McMillan, Human Health and Policy Biostatistics, Stanford University. For his expertise and advice on this analysis.	Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Carvalho B, 2005, ANESTH ANALG, V101, P1182, DOI 10.1213/01.ane.0000167774.36833.99; Carvalho B, 2005, ANESTH ANALG, V100, P1150, DOI 10.1213/01.ANE.0000149544.58230.FF; Carvalho B, 2007, ANESTH ANALG, V105, P176, DOI 10.1213/01.ane.0000265533.13477.26; COHEN SE, 1991, REGION ANESTH, V16, P141; CONNELLY NR, 1994, ANESTH ANALG, V78, P918; Cooper DW, 1997, BRIT J ANAESTH, V78, P311; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Fishbain DA, 2009, PAIN MED, V10, P829, DOI 10.1111/j.1526-4637.2009.00653.x; Fournier R, 2000, ACTA ANAESTH SCAND, V44, P940, DOI 10.1034/j.1399-6576.2000.440808.x; Girgin NK, 2008, J CLIN ANESTH, V20, P180, DOI 10.1016/j.jclinane.2007.07.010; Gustorff G, 2004, ANESTH ANALG, V98, P401, DOI 10.1213/01/ANE.0000095150.76735.5D; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Manullang TR, 2000, ANESTH ANALG, V90, P1162, DOI 10.1097/00000539-200005000-00030; PALMER CM, 1995, REGION ANESTH, V20, P389; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	21	15	15	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2012	21	1					29	34		10.1016/j.ijoa.2011.09.002			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	906DT	WOS:000301325800006	22100823				2020-06-30	J	Bang, EC; Lee, HS; Kang, YI; Cho, KS; Kim, SY; Park, H				Bang, E. C.; Lee, H. S.; Kang, Y. I.; Cho, K. S.; Kim, S. Y.; Park, H.			Onset of labor epidural analgesia with ropivacaine and a varying dose of fentanyl: a randomized controlled trial	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Analgesia; Epidural; Labor; Fentanyl; Ropivacaine	EXTRADURAL FENTANYL; BUPIVACAINE; PAIN; SUFENTANIL; OPIOIDS	Background: This study was conducted to investigate the onset of labor epidural analgesia using 0.17% ropivacaine with a varying dose of fentanyl. We hypothesized that the onset of analgesia would be shortened in proportion to an increase in fentanyl dose. Methods: Women requesting labor epidural analgesia were enrolled in this randomized controlled clinical trial. Each woman was randomly assigned to receive fentanyl 0, 50, 75, or 100 mu g with 0.17% ropivacaine 12 mL. The onset and duration of analgesia, the incidence of side effects and patient satisfaction were measured. Results: Data from 102 women were analyzed. The onset of analgesia (mean +/- SD) was shortened with an increasing dose of fentanyl (14.3 +/- 5.4, 14.2 +/- 6.5, 12.1 +/- 5.1, and 8.7 +/- 3.8 min with fentanyl 0, 50, 75, or 100 mu g, respectively, P = 0.001). The duration of analgesia was prolonged with an increasing dose of fentanyl (87.4 +/- 20.8, 112.3 +/- 19.5, 140.8 +/- 18.8, and 143.6 +/- 18.6 min with fentanyl 0, 50, 75, or 100 mu g, respectively, P < 0.001). The incidence of pruritus increased with an increasing dose of fentanyl (P = 0.027) but there were no differences for other maternal side effects. There was a significant difference in satisfaction score among groups (P = 0.009). Conclusion: The addition of increasing doses of fentanyl to 0.17% ropivacaine contributed to shortened onset as well as prolonged duration of labor epidural analgesia and improved patient satisfaction. (C) 2011 Elsevier Ltd. All rights reserved.	[Bang, E. C.; Lee, H. S.; Kang, Y. I.; Cho, K. S.; Kim, S. Y.] CHA Univ Hosp, Dept Anesthesia & Pain Med, Seoul, South Korea; [Park, H.] CHA Univ Hosp, Dept Obstet & Gynecol, Seoul, South Korea	Bang, EC (reprint author), Gangnam CHA Gen Hosp, 650-9 Yeoksam 1 Dong, Seoul 135081, South Korea.	ecbang63@hanmail.net					Birnbach DJ, 1997, NEW ENGL J MED, V337, P1764, DOI 10.1056/NEJM199712113372411; CELLENO D, 1988, CAN J ANAESTH, V35, P375, DOI 10.1007/BF03010859; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; Debon R, 2001, ANESTH ANALG, V92, P180; Edward TR, 1999, OBSTETR ANESTHESIA, P333; Eichenberger U, 2003, BRIT J ANAESTH, V90, P467, DOI 10.1093/bja/aeg100; Fun W, 2008, MINERVA ANESTESIOL, V74, P77; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; George MJ, 2006, ANAESTHESIA, V61, P659, DOI 10.1111/j.1365-2044.2006.04713.x; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; Herman NL, 1997, ANESTH ANALG, V84, P1256, DOI 10.1097/00000539-199706000-00016; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; Kreek MJ, 2005, PHARMACOL REV, V57, P1, DOI 10.1124/pr.57.1.1; Kuthiala G, 2011, INDIAN J ANAESTH, V55, P104, DOI 10.4103/0019-5049.79875; Lyons G, 1997, BRIT J ANAESTH, V78, P493; LYSAK SZ, 1990, ANESTHESIOLOGY, V72, P44, DOI 10.1097/00000542-199001000-00009; MANTHA S, 1993, ANESTH ANALG, V77, P1041; Ngarnprasertwong Pornswan, 2007, Journal of the Medical Association of Thailand, V90, P1368; Nickells JS, 2000, ANAESTHESIA, V55, P17, DOI 10.1046/j.1365-2044.2000.01071.x; Segal BS, 2000, ANESTH ANALG, V90, P775, DOI 10.1213/00000539-200004000-00001; Siddik-Sayyid SM, 2008, ACTA ANAESTH SCAND, V52, P1285, DOI 10.1111/j.1399-6576.2008.01765.x; STIENSTRA R, 1995, ANESTH ANALG, V80, P285, DOI 10.1097/00000539-199502000-00014; VELLA LM, 1985, ANAESTHESIA, V40, P741, DOI 10.1111/j.1365-2044.1985.tb10997.x	24	8	9	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2012	21	1					45	50		10.1016/j.ijoa.2011.10.002			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	906DT	WOS:000301325800009	22153132				2020-06-30	J	DeMaria, S; Govindaraj, S; Chinosorvatana, N; Kang, S; Levine, AI				DeMaria, Samuel, Jr.; Govindaraj, Satish; Chinosorvatana, Nina; Kang, Stanley; Levine, Adam I.			Bilateral sphenopalatine ganglion blockade improves postoperative analgesia after endoscopic sinus surgery	AMERICAN JOURNAL OF RHINOLOGY & ALLERGY			English	Article							INFRAORBITAL NERVE BLOCK; OUTPATIENT NASAL SURGERY; CLEFT-LIP REPAIR; AMBULATORY SURGERY; REGIONAL ANESTHESIA; PAIN; MANAGEMENT; DISCHARGE; HEADACHE; STAY	Background: Endoscopic sinus surgery (ESS) is a common procedure preferably done with an anesthetic technique ensuring effective postoperative analgesia while speeding discharge home. Although anesthesia administered locally in conjunction with vasoconstricting agents is known to minimize intraoperative bleeding, its usefulness in providing postoperative analgesia has not been well characterized. The results supporting the use of regional anesthesia for sinus surgery have also been limited. Using a randomized, double-blinded and placebo-controlled design, we evaluated recovery times, opioid consumption, and nausea and vomiting after ESS when patients were randomized to either general anesthesia (GA) alone or with regional blockade. Methods: Subjects were 70 adults scheduled for sinus surgery. All participants underwent propofol/remifentanil/nitrous oxide anesthesia and similar intraoperative care. Patients received either GA alone or with sphenopalatine ganglion (SPG) blocks in a double-masked study design. Independent observers recorded readiness for discharge, incidence of nausea/vomiting, and pain scores every 15 minutes until discharge. Overall opioid use in the recovery area was also a secondary end point. Twenty-four hours later, patients were called and asked to rate their pain and overall satisfaction with their pain control. Results: Block group participants were considered ready for discharge after 45 minutes and discharged from the hospital similar to 40 minutes sooner than GA group participants. The block group required less total fentanyl in the recovery room than did the GA group. The incidences of nausea and vomiting did not differ significantly. Data at 24 hours postoperatively did not differ significantly between groups but trended toward increased satisfaction in the block group. No lasting adverse events were observed. Conclusion: Regional anesthesia using targeted nerve blocks is effective in ESS. The combination of GA and SPG blockade appears to shorten hospital stay and reduce narcotic requirements in the recovery area. No demonstrable benefits were observed after 24 hours regarding pain management. (Am J Rhinol Allergy 26, e23-e27, 2012; doi: 10.2500/ajra.2012.26.3709)	[DeMaria, Samuel, Jr.; Levine, Adam I.] Mt Sinai Med Ctr, Dept Anesthesiol, New York, NY 10029 USA; [Govindaraj, Satish; Chinosorvatana, Nina] Mt Sinai Med Ctr, Dept Otolaryngol, New York, NY 10029 USA; [Kang, Stanley] Massachusetts Gen Hosp, Dept Pain Management, Boston, MA 02114 USA	DeMaria, S (reprint author), Mt Sinai Med Ctr, Dept Anesthesiol, 1 Gustave L Levy Pl,Box 1010, New York, NY 10029 USA.	samuel.demaria@mountsinai.org	DeMaria, Samuel/I-8138-2013	DeMaria, Samuel/0000-0003-2808-5539	Department of Anesthesiology, Mount Sinai Medical Center	Funded by the Department of Anesthesiology, Mount Sinai Medical Center	Ahmed MHM, 2007, J MED SCI, V7, P1297; Baker AR, 2010, ACTA ANAESTH SCAND, V54, P795, DOI 10.1111/j.1399-6576.2010.02259.x; BOSENBERG AT, 1995, BRIT J ANAESTH, V74, P506, DOI 10.1093/bja/74.5.506; Chidambaram A, 2001, CLIN OTOLARYNGOL, V26, P104, DOI 10.1046/j.1365-2273.2001.00433.x; Chung F, 1999, ANESTH ANALG, V89, P1352, DOI 10.1097/00000539-199912000-00004; DANIELSEN A, 1992, CLIN OTOLARYNGOL, V17, P473, DOI 10.1111/j.1365-2273.1992.tb01699.x; Elvir-Lazo Ofelia Loani, 2010, Anesthesiol Clin, V28, P217, DOI 10.1016/j.anclin.2010.02.011; Friedman M, 1996, LARYNGOSCOPE, V106, P1382, DOI 10.1097/00005537-199611000-00014; Higashizawa T, 2001, J Anesth, V15, P136, DOI 10.1007/s005400170014; Hwang JH, 2003, LARYNGOSCOPE, V113, P1423, DOI 10.1097/00005537-200308000-00030; Lee WC, 1997, ANN OTO RHINOL LARYN, V106, P767, DOI 10.1177/000348949710600910; Levin M, 2010, NEUROTHERAPEUTICS, V7, P197, DOI 10.1016/j.nurt.2010.03.001; Mariano ER, 2009, CAN J ANAESTH, V56, P584, DOI 10.1007/s12630-009-9119-5; McAdam D, 2005, REGION ANESTH PAIN M, V30, P572, DOI 10.1016/j.rapm.2005.07.192; Molliex S, 1996, BRIT J ANAESTH, V76, P151; Narouze S, 2009, HEADACHE, V49, P571, DOI 10.1111/j.1526-4610.2008.01226.x; Osguthorpe JD, 1999, OTOLARYNG HEAD NECK, V120, P451, DOI 10.1053/hn.1999.v120.a95228; Pavlin DJ, 2002, ANESTH ANALG, V95, P627, DOI 10.1097/00000539-200209000-00025; Rajamani A, 2007, PEDIATR ANESTH, V17, P133, DOI 10.1111/j.1460-9592.2006.02032.x; Singh G, 2004, BMC EAR NOSE THROAT, V4, P2, DOI DOI 10.1186/1472-6815-4-2; Waddle JP, 1998, ANESTH ANALG, V87, P628, DOI 10.1097/00000539-199809000-00026; Waldman SD, 2009, RAIN REV, P324	22	17	18	0	4	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1945-8924			AM J RHINOL ALLERGY	Am. J. Rhinol. Allergy	JAN-FEB	2012	26	1					E23	E27		10.2500/ajra.2012.26.3709			5	Otorhinolaryngology	Otorhinolaryngology	898VB	WOS:000300769300006	22391074				2020-06-30	J	Seith, RW; Theophilos, T; Babl, FE				Seith, Robert W.; Theophilos, Theane; Babl, Franz E.			Intranasal Fentanyl and High-concentration Inhaled Nitrous Oxide for Procedural Sedation: A Prospective Observational Pilot Study of Adverse Events and Depth of Sedation	ACADEMIC EMERGENCY MEDICINE			English	Article							PEDIATRIC EMERGENCY-DEPARTMENT; RANDOMIZED CONTROLLED-TRIAL; ANALGESIC EFFICACY; PAINFUL PROCEDURES; KETAMINE SEDATION; DOUBLE-BLIND; CHILDREN; REDUCTION; MIDAZOLAM; MORPHINE	Objectives: Nitrous oxide (N2O) is an attractive agent for pediatric procedural sedation and analgesia (PSA) with rapid onset and offset of sedation. However, it has limited analgesic efficacy. Intranasal fentanyl (INF) provides nonparenteral analgesia. There are currently no data on the combined use of N2O and INF for PSA in children. The authors set out to prospectively assess the depth of sedation and incidence of adverse events when N2O and INF are used in combination in pediatric patients. Methods: This was a prospective observational pilot study of combined N2O and INF for PSA at a tertiary childrens hospital emergency department (ED). INF was administered at a precalculated dose of 1.5 mu g/kg for preascertained weight ranges. N2O concentration, dose, timing of INF, adverse events, and sedation depth were recorded. Sedation depth was recorded using the University of Michigan Sedation Scale (UMSS). Results: A total of 41 patients, aged 1 to 14 years, received INF within 2 hours prior to N2O. N2O was administered at a maximal concentration of 70% in 40 patients, and at 50% in one patient. Most patients (80%) were minimally to moderately sedated (sedation score 1 or 2). Deep sedation (sedation score 3) was recorded in 14.6% of patients (95% confidence interval [CI] = 3.4% to 24.6%). No patients had serious adverse events; vomiting was recorded in 19.5% (95% CI = 7.4% to 31.6%). There were two patients (4.9%) who were deeply sedated and vomited during the procedure. Conclusions: There were no serious adverse events identified in this pilot study of combined N2O and INF. However, there was an increased incidence of vomiting and deeper levels of sedation when compared to published data of single-agent use of N2O, which could lead to more serious adverse events. Further investigation is needed to establish the analgesic efficacy of combining N2O and INF and to clarify the safety profile before this combination can be recommended for PSA in children.	[Seith, Robert W.; Theophilos, Theane; Babl, Franz E.] Royal Childrens Hosp, Emergency Dept, Parkville, Vic 3052, Australia; [Seith, Robert W.] Univ Melbourne, Monash Med Ctr, Emergency Dept, Melbourne, Vic, Australia; [Theophilos, Theane; Babl, Franz E.] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Babl, FE (reprint author), Royal Childrens Hosp, Emergency Dept, Flemington Rd, Parkville, Vic 3052, Australia.	franz.babl@rch.org.au			Murdoch Children's Research Institute, Melbourne, Australia	The authors acknowledge grant support from the Murdoch Children's Research Institute, Melbourne, Australia.	Annequin D, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e47; Babl FE, 2008, EMERG MED J, V25, P717, DOI 10.1136/emj.2007.053751; Babl FE, 2005, PEDIATR EMERG CARE, V21, P736, DOI 10.1097/01.pec.0000186427.07636.fc; BABL FE, SEDATION MANUAL; Babl Franz, 2006, Emerg Med Australas, V18, P489, DOI 10.1111/j.1742-6723.2006.00904.x; Babl FE, 2008, PEDIATRICS, V121, pE528, DOI 10.1542/peds.2007-1044; Babl FE, 2010, EMERG MED J, V27, P607, DOI 10.1136/emj.2009.084384; Babl FE, 2010, EMERG MED J, V27, P577, DOI 10.1136/emj.2009.077024; Bhatt M, 2009, ANN EMERG MED, V53, P426, DOI 10.1016/j.annemergmed.2008.09.030; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; BURTON JH, 1998, ACAD EMERG MED, V5, P1191; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Green SM, 2003, ANN EMERG MED, V42, P647, DOI 10.1016/S0196-0644(03)00636-X; Green SM, 2002, ACAD EMERG MED, V9, P35, DOI 10.1197/aemj.9.1.35; Green SM, 2007, ANN EMERG MED, V49, P454, DOI 10.1016/j.annemergmed.2006.08.017; HENNRIKUS WL, 1994, J PEDIATR ORTHOPED, V14, P538, DOI 10.1097/01241398-199407000-00023; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Krauss B, 2000, NEW ENGL J MED, V342, P938, DOI 10.1056/NEJM200003303421306; Krauss B, 2001, ANN EMERG MED, V37, P61, DOI 10.1067/mem.2001.112004; Langston WT, 2008, ANN EMERG MED, V52, P30, DOI 10.1016/j.annemergmed.2008.01.326; Luhmann JD, 2006, PEDIATRICS, V118, pE1078, DOI 10.1542/peds.2005-1694; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Zier JL, 2010, ANESTH ANALG, V110, P1399, DOI 10.1213/ANE.0b013e3181d539cf	30	22	23	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JAN	2012	19	1					31	36		10.1111/j.1553-2712.2011.01241.x			6	Emergency Medicine	Emergency Medicine	877CT	WOS:000299155200005	22251190				2020-06-30	J	Schroder, B; Nickel, U; Meyer, E; Lee, G				Schroeder, Britta; Nickel, Ulrich; Meyer, Elisabeth; Lee, Geoffrey			Transdermal delivery using a novel electrochemical device, Part 1: Device design and in vitro release/permeation of fentanyl	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						controlled release; diffusion; fentanyl; iontophoresis; skin; transdermal system; electrochemistry; flux enhancement	NARCOTIC ANALGESICS; STRATUM-CORNEUM; DRUG-DELIVERY; IONTOPHORESIS; BEHAVIOR	A new type of electrochemical transdermal patch has been investigated using release/permeation experiments with excised nude mouse skin. The patch comprises a drug-containing hydrogel sandwiched between two electrodes that are arranged parallel to the skin surface. The objective was to determine the mechanism of working of enhanced flux for the drug fentanyl when low voltages are applied. The results indicate that a voltage-induced hydrolysis of the water present in the patch's hydrogel occurs. This causes a pH shift that results in deprotonization of the fentanyl and hence enhanced release/permeation. The enhanced flux is up to approximately 30 mu g/(cm2 h) over 20h and requires only a low-voltage application over a duration of just 60s. Because the enhancement mechanism occurs in the patch and not in the skin, the potential for substantially reduced skin irritation compared with iontophoresis is given. (c) 2011 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 101:245255, 2012	[Lee, Geoffrey] Univ Erlangen Nurnberg, Div Pharmaceut, D-91077 Erlangen, Germany; [Nickel, Ulrich] Univ Erlangen Nurnberg, Div Phys Chem, D-91077 Erlangen, Germany; [Schroeder, Britta; Meyer, Elisabeth] Acino AG, D-83714 Miesbach, Germany	Lee, G (reprint author), Univ Erlangen Nurnberg, Div Pharmaceut, D-91077 Erlangen, Germany.	lee@pharmtech.uni-erlangen.de					Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Comerford D, 2008, ANAEST INTENS CARE M, V9, P21, DOI 10.1016/j.mpaic.2007.10.005; Conjeevaram R, 2002, PHARMACEUT RES, V19, P440, DOI 10.1023/A:1015135426838; Corish J, 1992, Patent, Patent No. [U55533995, 5533995]; Cussler E, 1997, DIFFUSION MASS TRANS, P143; Dixit Nitin, 2007, Current Drug Delivery, V4, P1, DOI 10.2174/156720107779314802; Fischer W, 2000, Patent, Patent No. [U56757560, 6757560]; GOPFERICH A, 1991, INT J PHARM, V71, P245, DOI 10.1016/0378-5173(91)90396-6; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Guy RH, 2001, SKIN PHARMACOL APPL, V14, P35, DOI 10.1159/000056388; Inoue K, 2000, DRUG DEV IND PHARM, V26, P45, DOI 10.1081/DDC-100100326; Jadoul A, 1999, ADV DRUG DELIVER REV, V35, P89, DOI 10.1016/S0169-409X(98)00065-9; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Murdan S, 2003, J CONTROL RELEASE, V92, P1, DOI 10.1016/S0168-3659(03)00303-1; Prasad MA, 2004, ELECTROCHIM ACTA, V49, P445, DOI 10.1016/j.electacta.2003.05.003; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; THYSMAN S, 1994, INT J PHARM, V101, P105, DOI 10.1016/0378-5173(94)90081-7; Weast R, 1985, HDB CHEM PHYSICS, pD	20	7	7	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	JAN	2012	101	1					245	255		10.1002/jps.22765			11	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	861KO	WOS:000298018000024	21953528				2020-06-30	J	Meyer, MR; Dinger, J; Schwaninger, AE; Wissenbach, DK; Zapp, J; Fritschi, G; Maurer, HH				Meyer, Markus R.; Dinger, Julia; Schwaninger, Andrea E.; Wissenbach, Dirk K.; Zapp, Josef; Fritschi, Giselher; Maurer, Hans H.			Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography-linear ion trap-mass spectrometry (LC-MSn)	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						3-Methylfentanyl; Isofentanyl; Metabolism; LC-MS; Rat urine; CYP isoenzymes	1-(2-PHENETHYL)-4-(N-PROPIONYLANILINO)PIPERIDINE FENTANYL; URINE; EPIDEMIC	The opioid 3-methylfentanyl, a designer drug of the fentanyl type, was scheduled by the Controlled Substance Act due to its high potency and abuse potential. To overcome this regulation, isofentanyl, another designer fentanyl, was synthesized in a clandestine laboratory and seized by the German police. The aims of the presented study were to identify the phase I and phase II metabolites of 3-methylfentanyl and isofentanyl in rat urine, to identify the cytochrome P450 (CYP) isoenzymes involved in their initial metabolic steps, and, finally, to test their detectability in urine. Using liquid chromatography (LC)-linear ion trap-mass spectrometry (MSn), nine phase I and five phase II metabolites of 3-methylfentanyl and 11 phase I and four phase II metabolites of isofentanyl could be identified. The following metabolic steps could be postulated for both drugs: N-dealkylation followed by hydroxylation of the alkyl and aryl moiety, hydroxylation of the propanamide side chain followed by oxidation to the corresponding carboxylic acid, and, finally, hydroxylation of the benzyl moiety followed by methylation. In addition, N-oxidation of isofentanyl could also be observed. All hydroxy metabolites were partly excreted as glucuronides. Using recombinant human isoenzymes, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 were found to be involved in the initial metabolic steps. Our LC-MSn screening approach allowed the detection of 0.01 mg/L of 3-methylfentanyl and isofentanyl in spiked urine. However, in urine of rats after the administration of suspected recreational doses, the parent drugs could not be detected, but their common nor metabolite, which should therefore be the target for urine screening.	[Meyer, Markus R.; Dinger, Julia; Schwaninger, Andrea E.; Wissenbach, Dirk K.; Maurer, Hans H.] Univ Saarland, Dept Expt & Clin Toxicol, Inst Expt & Clin Pharmacol & Toxicol, D-66421 Homburg, Saar, Germany; [Zapp, Josef] Univ Saarland, Dept Pharmaceut Biol, D-66123 Saarbrucken, Germany; [Fritschi, Giselher] Hess Landeskriminalamt, D-65187 Wiesbaden, Germany	Meyer, MR (reprint author), Univ Saarland, Dept Expt & Clin Toxicol, Inst Expt & Clin Pharmacol & Toxicol, D-66421 Homburg, Saar, Germany.	markus.meyer@uks.eu	Wissenbach, Dirk/B-1230-2012	Steuer, Andrea Eva/0000-0001-8983-2353; Maurer, Hans/0000-0003-4579-4660			Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Higashikawa Y, 2008, J HEALTH SCI, V54, P629, DOI 10.1248/jhs.54.629; JH Weng, 1990, ACTA PHARMACOL SINIC, V25, P178; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Maurer H. H., 2011, MASS SPECTRAL LIB DR; Maurer H. H., 2011, MASS SPECTRAL GC DAT; Meyer MR, 2010, J MASS SPECTROM, V45, P1426, DOI 10.1002/jms.1859; Meyer MR, 2009, CHEM RES TOXICOL, V22, P1205, DOI 10.1021/tx900134e; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003; VANWIJNGAARDEN I, 1968, LIFE SCI PT 1 PHYSI, V7, P1239, DOI 10.1016/0024-3205(68)90236-1; Wissenbach DK, 2011, ANAL BIOANAL CHEM, V400, P3481, DOI 10.1007/s00216-011-5032-1; Wissenbach DK, 2011, ANAL BIOANAL CHEM, V400, P79, DOI 10.1007/s00216-010-4398-9	17	29	30	0	14	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642	1618-2650		ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	JAN	2012	402	3					1249	1255		10.1007/s00216-011-5528-8			7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	870CE	WOS:000298645900024	22065349				2020-06-30	J	Finn, AL; Vasisht, N; Stark, JG; Gever, LN; Tagarro, I				Finn, Andrew L.; Vasisht, Niraj; Stark, Jeffrey G.; Gever, Larry N.; Tagarro, Ignacio			Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects A Phase I, Open-Label, Three-Period, Crossover Study	CLINICAL DRUG INVESTIGATION			English	Article							BREAKTHROUGH PAIN; CANCER-PATIENTS; CITRATE; TITRATION; TRIAL; OTFC	Background and Objectives: Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA (TM)) that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. It is approved for the treatment of cancer breakthrough pain in adult opioid-tolerant patients. The objective of this study was to evaluate the dose proportionality of the pharmacokinetics of FBSF in healthy subjects across a range of doses. Methods: This was a phase I, open-label, single-dose, three-period, Latin-square crossover study in which 12 healthy subjects received single FBSF doses of 200, 600 and 1200 mu g with 72 hours between doses. Oral naltrexone was administered to each subject prior to and after each study dose. Serial venous blood samples were collected for 48 hours after study drug administration. Adverse events were recorded throughout the study. Dose linearity was examined using a power model (P=axDose(b)), where P represents the dependent variable (maximum plasma drug concentration [C(max)], area under the plasma concentration-time curve [AUC] from time zero to time of the last measurable concentration [AUC(last)], or AUC from time zero to infinity [AUC(infinity)]), and a and b are constants. A value of b approximate to 1 indicated linearity. Results: Following administration of FBSF doses of 200-1200 mu g, mean C(max) values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19 ng/mL, respectively. Mean AUC(last) values increased from 3.001 ng.h/mL to 19.17 ng.h/mL and mean AUC(infinity) increased in a linear manner from 3.456 ng.h/mL to 20.43 ng.h/mL. All reported adverse events were considered to be mild to moderate in severity. Conclusions: This study demonstrates that peak fentanyl plasma concentrations and overall exposure increase in a dose-proportional manner following administration of FBSF.	[Finn, Andrew L.; Vasisht, Niraj] BioDelivery Sci Int Inc, Raleigh, NC 27607 USA; [Stark, Jeffrey G.] Worldwide Clin Trials Drug Dev Solut, Austin, TX USA; [Gever, Larry N.; Tagarro, Ignacio] Meda Pharmaceut Inc, Somerset, NJ USA; [Tagarro, Ignacio] Meda Pharma SAU, Madrid, Spain	Finn, AL (reprint author), BioDelivery Sci Int Inc, 801 Corp Ctr Dr,Suite 210, Raleigh, NC 27607 USA.	afinn@bdsinternational.com			Meda Pharmaceuticals, Inc.	The authors thank MK. Grandison, PhD, Nila Bhana, MSc, and Alan J. Klopp, PhD, of inScience Communications, a Wolters Kluwer business, for providing medical writing support funded by Meda Pharmaceuticals, Inc.	[Anonymous], 2009, ONS FENT BUCC SOL FI; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Gever L, 2010, PAINWEEK NAT C PAIN; Gordon D, 2008, J PALLIAT MED, V11, P633, DOI 10.1089/jpm.2008.9922; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Slatkin N, 2010, 26 ANN M AM AC PAIN; Slatkin Neal E, 2007, J Support Oncol, V5, P327; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000	18	10	10	0	3	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1173-2563			CLIN DRUG INVEST	Clin. Drug Invest.		2012	32	1					63	71		10.2165/11594670-000000000-00000			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	872RK	WOS:000298826800006	22128878				2020-06-30	J	Florio, P; Puzzutiello, R; Filippeschi, M; D'Onofrio, P; Mereu, L; Morelli, R; Marianello, D; Litta, P; Mencaglia, L; Petraglia, F				Florio, Pasquale; Puzzutiello, Rosa; Filippeschi, Marco; D'Onofrio, Pasquale; Mereu, Liliana; Morelli, Rosita; Marianello, Daniele; Litta, Pietro; Mencaglia, Luca; Petraglia, Felice			Low-Dose Spinal Anesthesia with Hyperbaric Bupivacaine with Intrathecal Fentanyl for Operative Hysteroscopy: A Case Series Study	JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY			English	Article						Hysteroscopy; Resectoscopy; Myomectomy; Uterine septum; Polyps; Abnormal uterine bleeding; Endometrial resection; ASA classification	OUTPATIENT KNEE ARTHROSCOPY; REGIONAL ANESTHESIA; PROLONGING RECOVERY; RISK-FACTORS; LIDOCAINE; SURGERY; BLOCKS; MG	Study Objective: To estimate the efficacy and tolerability of low dose spinal anesthesia during operative hysteroscopy in a group of patients with high surgical risks. Design: Case series study (Canadian Task Force Classification II-2). Setting: Tertiary centers for women health care. Patients: A total of 47 women affected by endometrial polyps (n = 32), myomas (n = 8), and abnormal uterine bleeding (n = 7) scheduled for inpatient operative hysteroscopy. Interventions: Transvaginal ultrasonography; office diagnostic hysteroscopy; preoperative evaluation of American Society of Anesthesiologist (ASA) classification; inpatient operative hysteroscopy; low-dose spinal anesthesia with hyperbaric bupivacaine; compilation of a questionnaire. Main Outcome Measures: Practicability and patients' subjective experiences with spinal anesthesia; duration of cervical dilation and for operative hysteroscopy; infusion volume needed; incidence of surgical complications. Results: Resectoscopy was performed in all patients, with the exception of 1 woman (2.1%) in which spinal anesthesia was unsuccessful. No statistically significant differences were noted among groups in terms of intra- and peri-operative findings. Sensory block induced by spinal anesthesia was suitable for surgery in all patients, and side effects occurred far less frequently than mentioned in the literature. Data reported in the questionnaire revealed that 93.5% of women would choose a spinal anesthesia again for a potential operative hysteroscopy in the future, since for 89.1% of them long lasting anesthesia is of relevance. Conclusions: Low-dose spinal anesthesia is a feasible technique in the inpatient setting for operative hysteroscopy in women with high surgical risks. journal of Minimally Invasive Gynecology (2012) 19, 107-112 (C) 2012 AAGL. All rights reserved.	[Florio, Pasquale] Univ Siena, Dept Pediat Obstet & Reprod Med, Sect Obstet & Gynecol, Policlin Le Scotte, I-53100 Siena, Italy; [Florio, Pasquale; Petraglia, Felice] AOUS, Dept Pediat Obstet & Reprod Med, Sect Obstet & Gynecol, I-53100 Empoli, Italy; [Puzzutiello, Rosa; D'Onofrio, Pasquale; Morelli, Rosita; Marianello, Daniele] AOUS, Dept Anaesthesia & Intens Care, I-53100 Empoli, Italy; [Filippeschi, Marco] San Giuseppe Hosp, UOC Obstet & Gynecol, Siena, Empoli, Italy; [Mereu, Liliana; Mencaglia, Luca] Ctr Oncol Fiorentino, Sect Gynecol, Sesto Fiorentino, Italy; [Litta, Pietro] Univ Padua, Dept Gynecol Sci & Human Reprod, Padua, Italy	Florio, P (reprint author), Univ Siena, Dept Pediat Obstet & Reprod Med, Sect Obstet & Gynecol, Policlin Le Scotte, I-53100 Siena, Italy.	florio@unisi.it	Petraglia, Felice/D-4373-2019	Petraglia, Felice/0000-0002-8851-625X			Atallah MM, 2006, ACTA ANAESTH SCAND, V50, P798, DOI 10.1111/j.1399-6576.2006.01063.x; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Borgeat A, 2003, ANESTHESIOLOGY, V98, P530, DOI 10.1097/00000542-200302000-00036; Borgeat A, 2010, CURR OPIN ANESTHESIO, V23, P466, DOI 10.1097/ACO.0b013e328339eef2; Buckenmaier CC, 2002, ANESTH ANALG, V95, P1253, DOI 10.1097/00000539-200211000-00028; Davenport DL, 2006, ANN SURG, V243, P636, DOI 10.1097/01.sla.0000216508.95556.cc; Edris F, 2007, J MINIM INVAS GYN, V14, P68, DOI 10.1016/j.jmig.2006.08.007; Franco CD, 2006, ANESTH ANALG, V102, P1252, DOI 10.1213/01.ane.0000198341.53062.a2; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Lehavi A, 2010, J PERIANESTH NURS, V25, P371, DOI 10.1016/j.jopan.2010.07.011; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Mulroy Michael F, 2002, Curr Opin Anaesthesiol, V15, P641, DOI 10.1097/00001503-200212000-00007; Nathani F, 2006, J MINIM INVAS GYN, V13, P260, DOI 10.1016/j.jmig.2006.03.015; Nielsen KC, 2005, ANESTHESIOLOGY, V102, P181, DOI 10.1097/00000542-200501000-00027; Prandoni P, 2006, PATHOPHYSIOL HAEMO T, V35, P128, DOI 10.1159/000093554; Sardo ADS, 2008, HUM REPROD UPDATE, V14, P101, DOI 10.1093/humupd/dmm041; Sardo AD, 2010, J MINIM INVAS GYN, V17, P436, DOI 10.1016/j.jmig.2010.03.014; Solakovic Nedim, 2010, Med Arh, V64, P158; Valanne JV, 2001, ANESTH ANALG, V93, P1377, DOI 10.1097/00000539-200112000-00005; Valle RF, 2007, J MINIM INVAS GYN, V14, P407, DOI 10.1016/j.jmig.2007.03.002; Wu CL, 2001, REGION ANESTH PAIN M, V26, P196, DOI 10.1053/rapm.2001.22257	21	21	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1553-4650	1553-4669		J MINIM INVAS GYN	J. Mimim. Invasive Gynecol.	JAN-FEB	2012	19	1					107	112		10.1016/j.jmig.2011.08.728			6	Obstetrics & Gynecology	Obstetrics & Gynecology	879BQ	WOS:000299305100019	22070928				2020-06-30	J	Minkowski, CP; Epstein, D; Frost, JJ; Gorelick, DA				Minkowski, Carolynne P.; Epstein, David; Frost, J. James; Gorelick, David A.			Differential response to IV carfentanil in chronic cocaine users and healthy controls	ADDICTION BIOLOGY			English	Article						Agonist; carfentanil; cocaine; mu-opioid receptor; PET scan; receptor	OPIOID RECEPTOR-BINDING; PREPROENKEPHALIN MESSENGER-RNA; ADENYLYL-CYCLASE ACTIVITY; NUCLEUS-ACCUMBENS; RAT-BRAIN; OPIATE; EXPRESSION; PET; SUFENTANIL; ALFENTANIL	Chronic cocaine exposure in both rodents and humans increases regional brain mu-opioid receptor (mOR) binding potential, suggesting that cocaine users might have an altered response to mOR agonists. We evaluated the response to IV carfentanil (a selective mOR agonist) in 23 cocaine users [mean (standard deviation) age 33.8 (4.0) years, 83% men] who underwent positron emission tomography (PET) scanning with [C-11]-carfentanil [44.7 (19.5) ng/kg] while housed on a closed research ward and 15 healthy non-drug-using controls [43.9 (14.2) years, 80% men] scanned [49.5 (12.6) ng/kg] as outpatients. Cocaine users had used for 8.7 (4.3) years and on 73 (22)% of days in the two weeks prior to PET scanning. Common adverse effects associated with mOR agonists (nausea, dizziness, headache, vomiting, itchiness) were assessed by self-report (five-point Likert scales) during and for 90 minutes after the scans. Cocaine users were significantly less likely than controls to report any symptom (30.4% versus 60%) and had fewer total symptoms [0.43 (0.73) versus 1.1 (1.0)] during scans, even after statistically controlling for age and carfentanil dose. These differences were also present after the scans and at repeat scans performed after about one week or 12 weeks of monitored cocaine abstinence. In a larger group of cocaine users and separate controls, there was no significant group difference in carfentanil half-life, suggesting that the observed difference was pharmacodynamically, rather than pharmacokinetically, based. These findings suggest that cocaine users are less responsive than healthy controls to mOR agonist adverse effects despite having increased regional brain mOR binding potential.	[Minkowski, Carolynne P.; Epstein, David; Gorelick, David A.] Natl Inst Drug Abuse, Intramural Res Program, NIH, Bethesda, MD 20892 USA	Gorelick, DA (reprint author), 251 Bayview Blvd,200, Baltimore, MD 21224 USA.	dgorelic@intra.nida.nih.gov			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA-09479, DA-11774, DA-12274]; IRP, National Institutes of Health, NIDA	Supported by the IRP, National Institutes of Health, NIDA and NIH grants DA-09479, DA-11774 & DA-12274 (to Dr Frost). We thank Dr John Hilton for assay of plasma carfentanil concentrations.	COMPTON MA, 1994, J PAIN SYMPTOM MANAG, V9, P462, DOI 10.1016/0885-3924(94)90203-8; Dackis CA, 2001, J SUBST ABUSE TREAT, V21, P111, DOI 10.1016/S0740-5472(01)00192-1; Daunais JB, 1997, PHARMACOL BIOCHEM BE, V57, P471, DOI 10.1016/S0091-3057(96)00432-7; Gorelick DA, 2005, BIOL PSYCHIAT, V57, P1573, DOI 10.1016/j.biopsych.2005.02.026; Gorelick DA, 2008, PSYCHOPHARMACOLOGY, V200, P475, DOI 10.1007/s00213-008-1225-5; GUTSTEIN H, 2006, [No title captured]; HAMMER RP, 1989, SYNAPSE, V3, P55, DOI 10.1002/syn.890030108; Hilton J, 2000, NUCL MED BIOL, V27, P627, DOI 10.1016/S0969-8051(00)00125-6; Izenwasser S, 1996, EUR J PHARMACOL, V297, P187, DOI 10.1016/0014-2999(95)00828-4; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; Ladona MG, 2000, LIFE SCI, V68, P431, DOI 10.1016/S0024-3205(00)00952-8; LaForge KS, 2003, BRAIN RES BULL, V59, P353, DOI 10.1016/S0361-9230(02)00927-9; Lutfy K, 2002, BRAIN RES BULL, V58, P7, DOI 10.1016/S0361-9230(01)00787-0; MATUSSEK N, 1989, NEUROPSYCHOBIOLOGY, V21, P1, DOI 10.1159/000118542; Pellinen P, 1996, HEPATOLOGY, V23, P515; Porreca F, 2009, PAIN MED, V10, P654, DOI 10.1111/j.1526-4637.2009.00583.x; Przewlocka B, 1995, EUR NEUROPSYCHOPHARM, V5, P465; Reich A, 2010, CLIN EXP DERMATOL, V35, P2, DOI 10.1111/j.1365-2230.2009.03463.x; Ross VH, 2003, ANESTH ANALG, V97, P1504, DOI 10.1213/01.ANE.0000083372.87670.09; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Schroeder JA, 2003, SYNAPSE, V47, P26, DOI 10.1002/syn.10148; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; *U WASH, 1997, CLIN NUTR SOURC BOOK; Unterwald EM, 2001, ANN NY ACAD SCI, V937, P74; UNTERWALD EM, 1993, SYNAPSE, V15, P33, DOI 10.1002/syn.890150104; UNTERWALD EM, 1994, NEUROREPORT, V5, P1613, DOI 10.1097/00001756-199408150-00018; VEZINA P, 1990, BRAIN RES, V516, P99, DOI 10.1016/0006-8993(90)90902-N; YOKOO H, 1994, EUR J PHARMACOL, V256, P335, DOI 10.1016/0014-2999(94)90560-6; YUN CH, 1992, ANESTHESIOLOGY, V77, P467, DOI 10.1097/00000542-199209000-00011; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	31	17	18	1	9	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1355-6215			ADDICT BIOL	Addict. Biol.	JAN	2012	17	1					149	155		10.1111/j.1369-1600.2010.00256.x			7	Biochemistry & Molecular Biology; Substance Abuse	Biochemistry & Molecular Biology; Substance Abuse	865HW	WOS:000298303000013	21054687	Green Accepted			2020-06-30	J	Zhou, RL; Perez-Aguilar, JM; Meng, QC; Saven, JG; Liu, RY				Zhou, Renlong; Perez-Aguilar, Jose Manuel; Meng, Qingcheng; Saven, Jeffery G.; Liu, Renyu			Opioid Binding Sites in Human Serum Albumin	ANESTHESIA AND ANALGESIA			English	Article							PLASMA-PROTEIN BINDING; GENERAL-ANESTHETICS; DRUG-BINDING; CANCER PAIN; ALFENTANIL; HALOTHANE; AGE	BACKGROUND: Human serum albumin (HSA) is an important carrier for opioids. However, the locations of the binding sites remain unclear. In the present study, we have characterized opioid-HSA interactions using multiple biochemical and biophysical techniques to reveal: (a) the location of the binding site(s); (b) whether naloxone shares the binding site with morphine; and (c) whether opioid agonists share their binding site(s) with general anesthetics. METHODS: Elution chromatography to determine the global interactions and tryptophan intrinsic fluorescence to determine the localized interactions of opioids with HSA were used. Competition studies using isothermal titration calorimetry were used to determine the overlap of binding site(s) among opioid agonists, antagonists, and general anesthetics. An automatic docking calculation was used to predict the possible binding sites and to assess findings of the solution studies. RESULTS: For elution chromatography with immobilized HSA, the retention times of naloxone, morphine, and fentanyl were prolonged but shorter than that of propofol. The inhibition of tryptophan fluorescence by naloxone was not affected by morphine or fentanyl. The calorimetric heat profiles of propofol and halothane interaction with HSA were changed significantly, but not equally by morphine, naloxone, or fentanyl. Consistent with direct binding studies, docking results demonstrated that opioids share sites with general anesthetics; a distinct binding site for naloxone was revealed near the sole tryptophan in HSA that is not shared with morphine. CONCLUSIONS: The interaction of opioids with HSA is weak in comparison with propofol. Naloxone has a distinct binding site in HSA not shared with opioid agonists. Opioids share binding sites with general anesthetics in HSA. (Anesth Analg 2012; 114: 122-8)	[Zhou, Renlong; Meng, Qingcheng; Liu, Renyu] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Perez-Aguilar, Jose Manuel; Saven, Jeffery G.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	Liu, RY (reprint author), Univ Penn, Dept Anesthesiol & Crit Care, 336 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	liur@uphs.upenn.edu			Department of Anesthesiology and Critical Care at the University of Pennsylvania; Foundation for Anesthesia Education and Research; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01GM055876]; NSFNational Science Foundation (NSF) [NSEC DMR08-32802]	Department of Anesthesiology and Critical Care at the University of Pennsylvania and the Foundation for Anesthesia Education and Research. Jeffery G. Saven acknowledges support from NIH (P01GM055876) and NSF (NSEC DMR08-32802).	ASALI LA, 1984, EUR J CLIN PHARMACOL, V27, P459, DOI 10.1007/BF00549595; Ascenzi P, 2006, MINI-REV MED CHEM, V6, P483, DOI 10.2174/138955706776361448; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; Chan K, 2002, ANAL BIOCHEM, V301, P308, DOI 10.1006/abio.2001.5506; CHAUVIN M, 1987, ANESTH ANALG, V66, P53; Christo PJ, 2008, ANN NY ACAD SCI, V1138, P278, DOI 10.1196/annals.1414.033; Dockal M, 1999, J BIOL CHEM, V274, P29303, DOI 10.1074/jbc.274.41.29303; Ghuman J, 2005, J MOL BIOL, V353, P38, DOI 10.1016/j.jmb.2005.07.075; Hazai Eszter, 2009, Acta Pharm Hung, V79, P17; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; Liu R, 2002, J BIOL CHEM, V277, P36373, DOI 10.1074/jbc.M205479200; Liu RY, 2005, ANESTHESIOLOGY, V102, P799, DOI 10.1097/00000542-200504000-00016; Liu RY, 2004, BIOCHEM J, V380, P147, DOI 10.1042/BJ20031652; Mashayekhi Simin O, 2007, J Pain Palliat Care Pharmacother, V21, P5; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MEISTELMAN C, 1990, ANESTHESIOLOGY, V72, P470, DOI 10.1097/00000542-199003000-00013; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Przewlocki R, 2001, EUR J PHARMACOL, V429, P79, DOI 10.1016/S0014-2999(01)01308-5; Ripamonti C, 2001, DRUGS, V61, P955, DOI 10.2165/00003495-200161070-00005; RUSSO H, 1993, J PHARM SCI, V82, P493, DOI 10.1002/jps.2600820512; Simard JR, 2006, J MOL BIOL, V361, P336, DOI 10.1016/j.jmb.2006.06.028; SOLIS FJ, 1981, MATH OPER RES, V6, P19, DOI 10.1287/moor.6.1.19; Wilson AS, 1997, ANESTH ANALG, V84, P315, DOI 10.1097/00000539-199702000-00013; Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958; WOOD M, 1986, ANESTH ANALG, V65, P786; Zhang T, 2003, BIOPHYS J, V85, P3279, DOI 10.1016/S0006-3495(03)74746-8; Zunszain PA, 2008, J MOL BIOL, V381, P394, DOI 10.1016/j.jmb.2008.06.016; Zunszain Patricia A, 2003, BMC Struct Biol, V3, P6, DOI 10.1186/1472-6807-3-6	30	6	8	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2012	114	1					122	128		10.1213/ANE.0b013e318232e922			7	Anesthesiology	Anesthesiology	866UM	WOS:000298410400014	22025496				2020-06-30	J	Hallett, BR; Chalkiadis, GA				Hallett, B. R.; Chalkiadis, G. A.			Suspected opioid-induced hyperalgesia in an infant	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesia; opioid; paediatrics; pain	PAIN; DEXMEDETOMIDINE; APOPTOSIS; KETAMINE	One explanation for diminished opioid analgesic efficacy is opioid-induced hyperalgesia (OIH). We report a case of OIH in an infant with gastroschisis, requiring multiple surgical interventions and prolonged sedation for ventilation. This is the first report of OIH in an infant. On day 41 of life after nine separate surgical interventions, the patient's pain scores increased and remained elevated, despite increasing opioid administration. The patient also developed hyperalgesia, allodynia, and photophobia and became extremely irritable upon handling. Other possible causes were excluded, including interruption to opioid delivery, sepsis, acid-base and electrolyte disturbance, and ongoing surgical pathology. An opioid rotation to hydromorphone was initiated and ketamine was commenced. Sedation for ventilation was achieved with dexmedetomidine and midazolam infusions. Over a period of 24 h after opioid de-escalation, pain scores reduced rapidly and the patient became significantly less irritable with handling. All infusions were gradually weaned and eventually ceased.	[Hallett, B. R.; Chalkiadis, G. A.] Royal Childrens Hosp, Dept Paediat Anaesthesia & Pain Management, Parkville, Vic 3052, Australia	Hallett, BR (reprint author), Cabrini Hosp, Malvern, Vic 3144, Australia.	benhallett@benhallett.com.au					*ANZCA, 2010, ACUT PAIN MAN SCI EV; Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43; Colvin LA, 2010, BRIT J ANAESTH, V104, P125, DOI 10.1093/bja/aep392; Guinter JR, 2010, AM J HEALTH-SYST PH, V67, P1246, DOI 10.2146/ajhp090300; Hammer GB, 2005, PEDIATR ANESTH, V15, P616, DOI 10.1111/j.1460-9592.2005.01656.x; Hodgkinson K, 1994, Aust J Adv Nurs, V12, P17; Istaphanous GK, 2010, BEST PRACT RES-CLIN, V24, P433, DOI 10.1016/j.bpa.2010.02.013; Mercadante S, 2003, J PAIN SYMPTOM MANAG, V26, P769, DOI 10.1016/S0885-3924(03)00258-6; Mitra Sukanya, 2008, J Opioid Manag, V4, P123; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Silverman SM, 2009, PAIN PHYSICIAN, V12, P679; Soriano SG, 2010, ANESTHESIOLOGY, V112, P1155, DOI 10.1097/ALN.0b013e3181d3e0c2; Walker SM, 2005, PEDIATR ANESTH, V15, P909, DOI 10.1111/j.1460-9592.2005.01758.x; Walker SM, 2010, ANESTHESIOLOGY, V113, P147, DOI 10.1097/ALN.0b013e3181dcd71c; Wolf AR, 1999, PAEDIATR ANAESTH, V9, P7	15	8	8	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JAN	2012	108	1					116	118		10.1093/bja/aer332			3	Anesthesiology	Anesthesiology	863UJ	WOS:000298193400015	22021900	Bronze			2020-06-30	J	Naito, T; Takashina, Y; Yagi, T; Kawakami, J				Naito, Takafumi; Takashina, Yoshiaki; Yagi, Tatsuya; Kawakami, Junichi			Simple and Rapid HPLC-UV Method Using an Ultrafine Particle Octadecylsilane for Determination of Residual Fentanyl in Applied Durotep (R) MT Transdermal Matrix Patches and Its Clinical Application	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						fentanyl; transdermal therapeutic system; matrix; HPLC-UV; ultrafine particle octadecylsilane	RESERVOIR; CANCER; PAIN; PHARMACOKINETICS; EFFICACY; DELIVERY; ABSORPTION; CITRATE; PLASMA	A few complicated and time-consuming methods are available for the determination of residual fentanyl in Durotep (R) MT transdermal patches, however, their application to clinical settings is limited. The aim of this study was to develop a simple and rapid HPLC-UV method using an ultrafine particle octadecylsilane (ODS) for the determination of residual fentanyl in applied Durotep (R) MT transdermal matrix patches. Patch extraction involved sonicating a shredded Durotep (R) MT patch in acetonitrile for 15 min. Fentanyl separation was completed within 2 min using a 2.3-mu m particle ODS column (50x4.6mm i.d.) at a flow rate of 1.5 mL/min. No peaks interfering with fentanyl (1.27 min) and papaverine (0.89 min) as an internal standard were observed. The calibration curve for fentanyl was linear over the range of 0.015-9.0 mg as a Durotep (R) MT patch. The intra- and inter-assay precisions and accuracies of each patch were within 5.3% and 103.9-110.5% and within 8.2% and 97.1-104.3%, respectively. The validated method was applied to determine residual fentanyl in Durotep (R) MT patches used in 35 cancer patients. Although the plasma fentanyl concentration was significantly correlated with its measured absorption rate, the measured absorption rate normalized fentanyl concentration showed a large inter-individual variation. The validated simple and rapid HPLC-UV method established in the present study is helpful for evaluating the absorption rate of fentanyl in patients receiving Durotep (R) MT patches.	[Naito, Takafumi; Takashina, Yoshiaki; Yagi, Tatsuya; Kawakami, Junichi] Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Kawakami, J (reprint author), Hamamatsu Univ Sch Med, Dept Hosp Pharm, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kawakami-ham@umin.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	This work was supported by a Grant-in-Aid for Young Scientists (B) provided by The Japanese Ministry of Education, Culture, Sports, Science and Technology.	Chesnut SM, 2007, J SEP SCI, V30, P1183, DOI 10.1002/jssc.200600505; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Hoy SM, 2008, DRUGS, V68, P1711, DOI 10.2165/00003495-200868120-00008; Kanbayashi Y, 2011, CLIN J PAIN, V27, P664, DOI 10.1097/AJP.0b013e3182168fed; Karst M, 2001, PAIN MED, V2, P225, DOI 10.1046/j.1526-4637.2001.01028.x; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; MacNair JE, 1997, ANAL CHEM, V69, P983, DOI 10.1021/ac961094r; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Takashina Y, 2009, J CLIN PHARM THER, V34, P523, DOI 10.1111/j.1365-2710.2009.01033.x; U. S. Food and Drug Administration, 2007, FDA ISS 2 SAF WARN F; US Food and Drug Administration, 2001, GUID IND BIOAN METH; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872	22	2	3	0	9	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	JAN	2012	60	1					56	61		10.1248/cpb.60.56			6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	869TM	WOS:000298621100007	22223375	Bronze			2020-06-30	J	Levitzky, BE; Lopez, R; Dumot, JA; Vargo, JJ				Levitzky, B. E.; Lopez, R.; Dumot, J. A.; Vargo, J. J.			Moderate sedation for elective upper endoscopy with balanced propofol versus fentanyl and midazolam alone: a randomized clinical trial	ENDOSCOPY			English	Article							OUTPATIENT COLONOSCOPY; CONSCIOUS SEDATION; REGISTERED NURSES; ADMINISTERED PROPOFOL; GI ENDOSCOPY; GASTROENTEROLOGIST; SAFE; MEPERIDINE	Background and study aims: Balanced propofol sedation (BPS) combines propofol with opiates and benzodiazepines and targets at moderate sedation. Data comparing outcomes of BPS and standard sedation with opiates and benzodiazepines during elective esophagogastroduodenoscopy (EGD) are sparse. The primary end point of this study was to compare, in the recovery area, patient satisfaction with EGD following BPS versus standard sedation. Patients and methods: Prospective, single-blinded randomized trial in 110 outpatients undergoing elective EGD and randomized 1: 1 to BPS or standard sedation. Upon full recovery, the primary outcome of patient satisfaction was assessed using a 100-mm visual analogue scale (VAS) (1 = not at all satisfied, 100 = completely satisfied). Sedation recovery times and recall of pain and gagging (1 = none, 100 = severe) were also evaluated using a VAS. Results: The BPS and standard sedation groups were similar regarding American Society of Anesthesiologists (ASA), Mallampati class, age, sex, and body mass index (BMI). Compared with the standard sedation arm, the BPS group exhibited higher median procedural satisfaction (99 vs. 85, P<0.001), and lower median scores for recall of pain (P<0.001) and gagging (P<0.001). BPS resulted in a shorter median recovery time (min) (11 vs. 23, P<0.001). On multivariable regression analysis, predictors of patient satisfaction included use of propofol, increased age, and higher fentanyl dosage. Conclusions: BPS targeted to moderate sedation by adequately trained endoscopists results in superior patient satisfaction and shorter recovery times than standard sedation alone during EGD.	[Levitzky, B. E.; Dumot, J. A.; Vargo, J. J.] Case Western Univ, Dept Gastroenterol & Hepatol, Inst Digest Dis, Cleveland Clin Lerner Coll Med, Cleveland, OH 44195 USA; [Lopez, R.] Case Western Univ, Dept Biostat, Cleveland Clin Lerner Coll Med, Cleveland, OH 44195 USA	Vargo, JJ (reprint author), Case Western Univ, Dept Gastroenterol & Hepatol, Inst Digest Dis, Cleveland Clin Lerner Coll Med, Desk A30,9500 Euclid Ave, Cleveland, OH 44195 USA.	vargoj@ccf.org		Vargo, John/0000-0001-7638-5283	Ethicon Endo-Surgery; CSA Medical Inc.	J.J. Vargo has received consulting fees from Ethicon Endo-Surgery and honoraria for teaching and speaking from Olympus America, Inc. J. A. Dumot has received research funding from CSA Medical Inc. All other authors have no financial relationships relevant to this publication.	ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Clarke AC, 2001, ENDOSCOPY, V33, P95; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Cohen LB, 2003, GASTROINTEST ENDOSC, V58, P725, DOI 10.1016/S0016-5107(03)02010-8; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Heuss LT, 2003, ALIMENT PHARM THER, V17, P1493, DOI 10.1046/j.1365-2036.2003.01608.x; Heuss LT, 2003, GASTROINTEST ENDOSC, V57, P664, DOI 10.1067/mge.2003.191; Heuss LT, 2003, AM J GASTROENTEROL, V98, P1751, DOI 10.1016/S0002-9270(03)00447-7; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Kulling D, 2003, ENDOSCOPY, V35, P679; Qadeer MA, 2005, CLIN GASTROENTEROL H, V3, P1049, DOI 10.1016/S1542-3565(05)00742-1; Qadeer MA, 2009, GASTROENTEROLOGY, V136, P1568, DOI 10.1053/j.gastro.2009.02.004; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Rex DK, 2002, AM J GASTROENTEROL, V97, P1159; Rex Douglas K, 2003, Rev Gastroenterol Disord, V3, P70; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; Tohda G, 2006, ENDOSCOPY, V38, P360, DOI 10.1055/s-2005-921192; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; Vargo JJ, 2002, GASTROENTEROLOGY, V123, P8, DOI 10.1053/gast.2002.34232; Vargo JJ, 2009, GASTROENTEROLOGY, V137, P2161, DOI 10.1053/j.gastro.2009.09.050; White P F, 1991, J Clin Anesth, V3, P32, DOI 10.1016/0952-8180(91)90203-Y; Yusoff IF, 2004, GASTROINTEST ENDOSC, V60, P356, DOI 10.1016/S0016-5107(04)01711-0	26	27	30	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X			ENDOSCOPY	Endoscopy	JAN	2012	44	1					13	20		10.1055/s-0031-1291421			8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	866TF	WOS:000298405400003	22068700				2020-06-30	J	Malinovsky, JM				Malinovsky, Jean-Marc			Is 4% articaine suitable for spinal anaesthesia?	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Editorial Material							RAT SCIATIC-NERVE; LOCAL-ANESTHETICS; NEUROTOXICITY; LIDOCAINE; BUPIVACAINE; PARESTHESIA; ROPIVACAINE; INJURY; BLOCK		CHU Reims, Hop Maison Blanche, Serv Anesthesie & Reanimat, Pole URAD, F-51092 Reims, France	Malinovsky, JM (reprint author), CHU Reims, Hop Maison Blanche, Serv Anesthesie & Reanimat, Pole URAD, 45 Rue Cognacq Jay, F-51092 Reims, France.	jmmalinovsky@chu-reims.fr					Bachmann M, 2012, EUR J ANAESTH, V29, P22, DOI 10.1097/EJA.0b013e32834a11be; Garisto GA, 2010, J AM DENT ASSOC, V141, P836, DOI 10.14219/jada.archive.2010.0281; Haas D A, 1995, J Can Dent Assoc, V61, P319; Hendriks MP, 2009, BRIT J ANAESTH, V102, P259, DOI 10.1093/bja/aen357; Hillerup S, 2006, INT J ORAL MAX SURG, V35, P437, DOI 10.1016/j.ijom.2005.10.004; Hillerup S, 2011, ANESTH ANALG, V112, P1330, DOI 10.1213/ANE.0b013e3182172a2e; Johnson ME, 2000, MAYO CLIN PROC, V75, P921, DOI 10.4065/75.9.921; KALICHMAN MW, 1989, J PHARMACOL EXP THER, V250, P406; Kallio H, 2006, BRIT J ANAESTH, V97, P704, DOI 10.1093/bja/ael222; KAUKINEN S, 1978, ANN CLIN RES, V10, P191; LAMBERT LA, 1994, ANESTHESIOLOGY, V80, P1082, DOI 10.1097/00000542-199405000-00017; Leuschner J, 1999, ARZNEIMITTEL-FORSCH, V49, P126; Malinovsky JM, 2002, ANESTHESIOLOGY, V97, P429, DOI 10.1097/00000542-200208000-00021; Oertel R, 1997, CLIN PHARMACOKINET, V33, P417, DOI 10.2165/00003088-199733060-00002; Pedlar J, 2003, BRIT DENT J, V195, P119, DOI 10.1038/sj.bdj.4810421; Radwan IAM, 2002, ANESTH ANALG, V94, P319, DOI 10.1097/00000539-200202000-00016; RIGLER ML, 1991, ANESTH ANALG, V72, P275; Sakura S, 2005, ANESTH ANALG, V101, P541, DOI 10.1213/01.ANE.0000155960.61157.12; SCHELL RM, 1991, CAN J ANAESTH, V38, P908, DOI 10.1007/BF03036972; Schneider MC, 2001, ANESTH ANALG, V92, P287, DOI 10.1213/00000539-200102000-00001; Zaric D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003006.pub3	21	4	4	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	JAN	2012	29	1					5	6		10.1097/EJA.0b013e32834de295			2	Anesthesiology	Anesthesiology	863AM	WOS:000298135200003	22127267				2020-06-30	J	Bachmann, M; Pere, P; Kairaluoma, P; Rosenberg, PH; Kallio, H				Bachmann, Martina; Pere, Pertti; Kairaluoma, Pekka; Rosenberg, Per H.; Kallio, Helena			Randomised comparison of hyperbaric articaine and hyperbaric low-dose bupivacaine along with fentanyl in spinal anaesthesia for day-case inguinal herniorrhaphy	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						articaine; bupivacaine; day-case surgery; fentanyl; inguinal herniorrhaphy; local anaesthetics; postoperative pain; regional anaesthesia; spinal anaesthesia	PLAIN ARTICAINE; CARTICAINE; 5-PERCENT	Background and objective Low-dose mixture of hyperbaric bupivacaine and fentanyl is commonly used in day-case spinal anaesthesia. Using hyperbaric articaine, the onset may be faster and duration more predictable than with bupivacaine-fentanyl. We compared these two spinal anaesthetics for inguinal herniorrhaphy. Methods Adult patients were randomised to spinal anaesthesia with hyperbaric articaine 84 mg (group A, n 40) or hyperbaric bupivacaine 7 mg along with fentanyl 10 mu g (group B+F, n 40). A blinded observer tested the block characteristics. Aiming at sensory block spread to T10 dermatome, the operating table was tilted head-end up or down 10 degrees (once or twice), as required. Postoperative telephone interviews were performed. Results All patients in group A had a sensory block to T10 in a median time of 4 (range 2-20) min. In group B+F, the median onset time of T10 analgesia was 10 (2-30) min (P<0.001), but T10 analgesia was not reached in seven of 40 B+F patients. A head-up tilt was needed in 37 of 40 group A patients to prevent from too extensive cephalad spread of block, and 34 of 40 group B+F patients needed a head-down tilt to enhance cephalad spread of analgesia. To treat hypotension, 6.4 mg of ephedrine was required, on average, in group A and 1.8 mg in group B+F (P=0.01). Median time to recovery from sensory block was significantly shorter in group A (2.5 h) than in group B+F (3h; P=0.002). General anaesthesia was needed in three patients (group A, two patients: sensory block too short; group B+F, one patient: sensory block too limited). Conclusion Hyperbaric articaine leads to faster onset of block and faster recovery than bupivacaine along with fentanyl. Hypotension is more common with articaine. The onset and extension of the spinal block are unpredictable when using these techniques. Eur J Anaesthesiol 2012;29:22-27 Published online 22 August 2011	[Bachmann, Martina; Pere, Pertti; Kairaluoma, Pekka; Rosenberg, Per H.; Kallio, Helena] Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Helsinki, Finland; [Rosenberg, Per H.] Univ Helsinki, Helsinki, Finland	Pere, P (reprint author), Helsinki Univ Hosp, Dept Anaesthesiol & Intens Care Med, Helsinki, Finland.	pertti.pere@hus.fi			Helsinki University Central Hospital	The authors wish to thank the National Standards Laboratory, Centre for Metrology and Accreditation, Espoo, Finland, for the density measurements of the study drugs. The study was supported by Helsinki University Central Hospital research funds (EVO). There are no relevant conflicts of interest.	Bachmann M, 2008, BRIT J ANAESTH, V101, P848, DOI 10.1093/bja/aen294; Dijkstra T, 2008, BRIT J ANAESTH, V100, P104, DOI 10.1093/bja/aem332; Drasner K, 2005, ANESTH ANALG, V100, P549, DOI 10.1213/01.ANE.0000143382.89888.C3; Forster JG, 2011, ACTA ANAESTH SCAND, V55, P273, DOI 10.1111/j.1399-6576.2010.02325.x; GREENE NM, 1985, ANESTH ANALG, V64, P715; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; HAUENSCHILD E, 1977, ANAESTHESIST, V26, P398; Hendriks MP, 2009, BRIT J ANAESTH, V102, P259, DOI 10.1093/bja/aen357; Kallio H, 2006, BRIT J ANAESTH, V97, P704, DOI 10.1093/bja/ael222; KAUKINEN S, 1978, ANN CLIN RES, V10, P191; Pitkanen MT, 1984, REGIONAL ANESTHESIA, V9, P175; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; TIMMERMAN L, 2007, REGION ANESTH PAIN M, V32, P9; Vree TB, 2005, BEST PRACT RES-CLIN, V19, P293, DOI 10.1016/j.bpa.2004.12.006; Zaric D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003006.pub3	15	16	17	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JAN	2012	29	1					22	27		10.1097/EJA.0b013e32834a11be			6	Anesthesiology	Anesthesiology	863AM	WOS:000298135200006	21857520				2020-06-30	J	Tyagi, A; Kakkar, A; Kumar, S; Sethi, AK; Salhotra, R				Tyagi, Asha; Kakkar, Aanchal; Kumar, Surendra; Sethi, Ashok K.; Salhotra, Rashmi			ED50 of Hyperbaric Bupivacaine With Fentanyl for Cesarean Delivery Under Combined Spinal Epidural in Normotensive and Preeclamptic Patients	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							INTRATHECAL BUPIVACAINE; ANESTHESIA; SECTION; SPREAD; LEVOBUPIVACAINE; PARTURIENTS; HYPOTENSION; WOMEN	Background and Objectives: The use of reduced intrathecal doses is advised for spinal anesthesia during cesarean delivery. However, there are inadequate data regarding the minimum effective dose of intrathecal bupivacaine for cesarean delivery. Preeclampsia is caused by an endothelial dysfunction leading to generalized vasoconstriction. Whether this can offset the pregnancy-induced decrease in intrathecal dose requirement caused by epidural venous dilation and consequent thecal compression is not known. There are no data to evaluate the minimum effective dose of intrathecal drug for cesarean delivery in pre-eclamptic patients. This study aimed to determine the minimum effective dose represented by the ED50 of intrathecal hyperbaric bupivacaine for normotensive and severely preeclamptic patients undergoing elective cesarean delivery. Methods: Combined spinal epidural anesthesia was administered using a standardized technique on 18 consecutively preeclamptic and normotensive patients, each carrying an otherwise uncomplicated singleton pregnancy. The dose of intrathecal hyperbaric bupivacaine was decided by using the up-and-down method with an initial dose of 9 mg and dosing change of 1 mg. All patients received 20 Kg of fentanyl intrathecally with bupivacaine. A successful block was defined as one that resulted in a sensory block to T4 level with modified Bromage score of 1 or 2 within 15 minutes of intrathecal injection. Results: ED50 of intrathecal hyperbaric bupivacaine was identical in severely preeclamptic and normotensive parturients undergoing elective cesarean delivery (4.7 mg; 95% confidence interval, 4.5-4.9 mg). Conclusions: When a combined-spinal epidural is planned in normotensive or severely preeclamptic patients for an elective cesarean delivery, the ED50 of intrathecal hyperbaric bupivacaine along with 20 Kg of fentanyl is 4.7 mg.	Univ Coll Med Sci, Dept Anesthesiol & Crit Care, Delhi 110095, India; GTB Hosp, Delhi, India	Tyagi, A (reprint author), 103 Siddhartha Enclave, New Delhi 110014, India.	drashatyagi@gmail.com					[Anonymous], 2002, OBSTET GYNECOL, V99, P159; Aya AGM, 2005, ANESTH ANALG, V101, P869, DOI 10.1213/01.ANE.0000175229.98493.2B; Aya AGM, 2003, ANESTH ANALG, V97, P867, DOI 10.1213/01.ANE.0000073610.23885.F2; BREEN TW, 1993, ANESTH ANALG, V77, P919; Clark VA, 2005, INT J OBSTET ANESTH, V14, P9, DOI 10.1016/j.ijoa.2004.08.002; Cooper DW, 2004, ANESTHESIOLOGY, V101, P28, DOI 10.1097/00000542-200407000-00007; Cunningham F, 2009, WILLIAMS OBSTET; Danelli G, 2001, Minerva Anestesiol, V67, P573; Dixon WJ, 1983, INTRO STAT ANAL; Gaiser R, 2009, CHESTNUTS OBSTET ANE; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; HARTWELL BL, 1991, REGION ANESTH, V16, P17; Hocking G, 2004, BRIT J ANAESTH, V93, P568, DOI 10.1093/bja/aeh204; Hood DD, 1999, ANESTHESIOLOGY, V90, P1276, DOI 10.1097/00000542-199905000-00009; Ngan Kee WD, 2008, ANESTH ANALG, V107, P1295, DOI 10.1213/ane.0b013e31818065bc; Ngan Kee WD, 2010, CURR OPIN ANESTHESIO, V23, P304, DOI 10.1097/ACO.0b013e328337ffc6; Pace NL, 2007, ANESTHESIOLOGY, V107, P144, DOI 10.1097/01.anes.0000267514.42592.2a; Parpaglioni R, 2009, ACTA ANAESTH SCAND, V53, P1214, DOI 10.1111/j.1399-6576.2009.02033.x; PITKANEN MT, 1987, ANESTH ANALG, V66, P127, DOI 10.1213/00000539-198702000-00005; POLLEY LS, 2009, CHESTNUTS OBSTET ANE; Ramanathan J, 2001, REGION ANESTH PAIN M, V26, P46, DOI 10.1053/rapm.2001.18182; Sell A, 2005, BRIT J ANAESTH, V94, P239, DOI 10.1093/bja/aei015; Teoh WHL, 2006, INT J OBSTET ANESTH, V15, P273, DOI 10.1016/j.ijoa.2006.03.004; Teoh WHL, 2006, ANAESTHESIA, V61, P511, DOI 10.1111/j.1365-2044.2006.04630.x; Van Bogaert LJ, 1998, E AFR MED J, V75, P227; Van Elstraete AC, 2008, ANESTHESIOLOGY, V108, P484, DOI 10.1097/ALN.0b013e318164cf85; Visalyaputra S, 2005, ANESTH ANALG, V101, P862, DOI 10.1213/01.ANE.0000160535.95678.34	27	10	11	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JAN-FEB	2012	37	1					40	44		10.1097/AAP.0b013e318233c5f5			5	Anesthesiology	Anesthesiology	866FS	WOS:000298366500008	22030721				2020-06-30	J	de Alencar, AJC; Sanudo, A; Sampaio, VMR; de Gois, RP; Benevides, FAB; Guinsburg, R				Couto de Alencar, Ana Julia; Sanudo, Adriana; Ramos Sampaio, Virginia Maria; de Gois, Rosicler Pereira; Barbosa Benevides, Fernando Antonio; Guinsburg, Ruth			Efficacy of tramadol versus fentanyl for postoperative analgesia in neonates	ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION			English	Article							MECHANICAL VENTILATION; RANDOMIZED-TRIAL; PAIN; SURGERY; ANESTHESIA; CHILDREN; MORPHINE; INFANTS; SEDATION; NEWBORN	Objective To assess, in newborn infants submitted to surgical procedures, the efficacy of two opioids-fentanyl and tramadol-regarding time to extubate, time to achieve 100 ml/kg of enteral feeding and pain in the first 72 h after surgery. Design Controlled, blind, randomised clinical trial. Setting Neonatal intensive care unit. Patients 160 newborn infants up to 28 days of life requiring major or minor surgeries. Interventions Patients were randomised to receive analgesia with fentanyl (1-2 mu g/kg/h intravenously) or tramadol (0.1-0.2 mg/kg/h intravenously) in the first 72 h of the postoperative period, stratified by surgical size and by patient's gender. Main outcome measures Pain assessed by validated neonatal scales (Crying, Requires oxygen, Increased vital signs, Expression and Sleepless Scale and the Neonatal Facial Coding System), time until extubation and time to reach 100 ml/kg enteral feeding. Statistical analysis included repeated measures analysis of variance adjusted for confounding variables and Kaplan-Meier curve adjusted by a Cox model of proportional risks. Results Neonatal characteristics were (mean +/- SD) birth weight of 2924 +/- 702 g, gestational age of 37.6 +/- 2.2 weeks and age at surgery of 199 +/- 63 h. The main indication of surgery was gastrointestinal malformation (85 newborns; 53%). Neonates who received fentanyl or tramadol were similar regarding time until extubation, time to reach 100 ml/kg of enteral feeding and pain scores in the first 72 h after surgery. Conclusion Tramadol was as effective as fentanyl for postoperative pain relief in neonates but does not appear to offer advantages over fentanyl regarding the duration of mechanical ventilation and time to reach full enteral feeding.	[Sanudo, Adriana; Guinsburg, Ruth] Univ Fed Sao Paulo, Dept Pediat, Div Neonatal Med, BR-01410020 Sao Paulo, Brazil; [Couto de Alencar, Ana Julia] Univ Fed Ceara, Dept Pediat, Fortaleza, Ceara, Brazil; [Ramos Sampaio, Virginia Maria; de Gois, Rosicler Pereira; Barbosa Benevides, Fernando Antonio] Albert Sabin Hosp, Fortaleza, Ceara, Brazil	Guinsburg, R (reprint author), Univ Fed Sao Paulo, Dept Pediat, Div Neonatal Med, Rua Vicente Felix 77,Apt 09, BR-01410020 Sao Paulo, Brazil.	ruthgbr@netpoint.com.br	Sanudo, Adriana/AAD-1133-2019; Guinsburg, Ruth/F-1984-2013	Sanudo, Adriana/0000-0003-1187-0143; Guinsburg, Ruth/0000-0003-1967-9861			Allegaert K, 2008, BRIT J ANAESTH, V100, P525, DOI 10.1093/bja/aen019; Allegaert K, 2011, PEDIATR ANESTH, V21, P266, DOI 10.1111/j.1460-9592.2010.03389.x; Allegaert Karel, 2007, J Opioid Manag, V3, P59; Anand KJS, 2006, PEDIATRICS, V117, pS9, DOI 10.1542/peds.2005-0620C; ANAND KJS, 1987, LANCET, V1, P62; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Bellu R, 2010, ARCH DIS CHILD-FETAL, V95, pF241, DOI 10.1136/adc.2008.150318; Berde CB, 2005, CLIN THER, V27, P900, DOI 10.1016/j.clinthera.2005.06.020; Bozkurt P, 2005, PEDIATR ANESTH, V15, P1041, DOI 10.1111/j.1460-9592.2005.01738.x; Chu Y, 2006, ANESTH ANALG, V102, P1668, DOI 10.1213/01.ANE.0000219587.02263.A0; Couto RC, 2007, AM J INFECT CONTROL, V35, P183, DOI 10.1016/j.ajic.2006.06.013; Deo SH, 2008, AM J PHYSIOL-HEART C, V294, pH829, DOI 10.1152/ajpheart.01141.2007; Eagle KA, 2002, CIRCULATION, V105, P1257, DOI 10.1161/hc1002.104956; Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001; FINNEGAN LP, 1985, FED PROC, V44, P2314; Fitzgerald M, 2005, NAT REV NEUROSCI, V6, P507, DOI 10.1038/nrn1701; GRUNAU RVE, 1987, PAIN, V28, P395, DOI 10.1016/0304-3959(87)90073-X; HOUMES RJM, 1992, ANESTH ANALG, V74, P510; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; Kohlrausch FB, 2009, PHARMACOGENOMICS, V10, P1457, DOI 10.2217/PGS.09.76; KRECHEL SW, 1995, PAEDIATR ANAESTH, V5, P53, DOI 10.1111/j.1460-9592.1995.tb00242.x; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; LEHMANN KA, 1990, CLIN J PAIN, V6, P212, DOI 10.1097/00002508-199009000-00008; Miaskowski C, 2009, J PERIANESTH NURS, V24, P222, DOI 10.1016/j.jopan.2009.05.095; Mikhel'son VA, 2003, ANESTEZIOL REANIMAT, V1, P24; Okada Y, 1998, PEDIATR SURG INT, V13, P508, DOI 10.1007/s003830050385; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; Ozkose Z, 2000, INT J PEDIATR OTORHI, V53, P207, DOI 10.1016/S0165-5876(00)82008-X; PARK MK, 1989, AM J DIS CHILD, V143, P860, DOI 10.1001/archpedi.1989.02150190110034; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; Valle M, 2000, J PHARMACOL EXP THER, V293, P646	33	9	10	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1359-2998			ARCH DIS CHILD-FETAL	Arch. Dis. Child.-Fetal Neonatal Ed.	JAN	2012	97	1					F24	F29		10.1136/adc.2010.203851			6	Pediatrics	Pediatrics	875TG	WOS:000299057300007	21471025				2020-06-30	J	Elhabazi, K; Trigo, JM; Mollereau, C; Mouledous, L; Zajac, JM; Bihel, F; Schmitt, M; Bourguignon, JJ; Meziane, H; Petit-demouliere, B; Bockel, F; Maldonado, R; Simonin, F				Elhabazi, K.; Trigo, J. M.; Mollereau, C.; Mouledous, L.; Zajac, J-M; Bihel, F.; Schmitt, M.; Bourguignon, J. J.; Meziane, H.; Petit-demouliere, B.; Bockel, F.; Maldonado, R.; Simonin, F.			Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						RF9; NPFF receptors; anti-opioid system; RFamide; opioid-induced hyperalgesia; morphine tolerance; reward; withdrawal dependence	CONDITIONED PLACE PREFERENCE; MORPHINE ANALGESIC TOLERANCE; LONG-TERM POTENTIATION; RAT DORSAL RAPHE; MICE LACKING; OPIOID ACTIVITIES; PAIN; ANTAGONIST; DEPENDENCE; HYPERALGESIA	BACKGROUND AND PURPOSE Opiates remain the most effective compounds for alleviating severe pain across a wide range of conditions. However, their use is associated with significant side effects. Neuropeptide FF (NPFF) receptors have been implicated in several opiate-induced neuroadaptive changes including the development of tolerance. In this study, we investigated the consequences of NPFF receptor blockade on acute and chronic stimulation of opioid receptors in mice by using RF9, a potent and selective antagonist of NPFF receptors that can be administered systemically. EXPERIMENTAL APPROACH The effects of RF9 were investigated on opioid pharmacological responses including locomotor activity, antinociception, opioid-induced hyperalgesia, rewarding properties and physical dependence. KEY RESULTS RF9 had no effect on morphine-induced horizontal hyperlocomotion and slightly attenuated the decrease induced in vertical activity. Furthermore, RF9 dose-dependently blocked the long-lasting hyperalgesia produced by either acute fentanyl or chronic morphine administration. RF9 also potentiated opiate early analgesic effects and prevented the development of morphine tolerance. Finally, RF9 increased morphine-induced conditioned place preference without producing any rewarding effect by itself and decreased naltrexone-precipitated withdrawal syndrome following chronic morphine treatment. CONCLUSION AND IMPLICATIONS The NPFF system is involved in the development of two major undesirable effects: tolerance and dependence, which are clinically associated with prolonged exposure to opiates. Our findings suggest that NPFF receptors are interesting therapeutic targets to improve the analgesic efficacy of opiates by limiting the development of tolerance, and for the treatment of opioid dependence.	[Simonin, F.] Univ Strashourg, IREBS UMR7242, Ecole Super Biotechnol Strasbourg, Inst Rech,CNRS, F-67412 Illkirch Graffenstaden, France; [Trigo, J. M.; Maldonado, R.] Univ Pompeu Fabra, Lab Neurofarmacol, Barcelona, Spain; [Mollereau, C.; Mouledous, L.; Zajac, J-M] Univ Toulouse, CNRS, Inst Pharmacol & Biol Struct, Toulouse, France; [Bihel, F.; Schmitt, M.; Bourguignon, J. J.] Univ Strashourg, CNRS, Lab Innovat Therapeut, F-67412 Illkirch Graffenstaden, France; [Meziane, H.; Petit-demouliere, B.] Univ Strashourg, CNRS, INSERM, Inst Clin Souris,IGBMC, F-67412 Illkirch Graffenstaden, France; [Bockel, F.] Phenopro, Illkirch Graffenstaden, France	Simonin, F (reprint author), Univ Strashourg, IREBS UMR7242, Ecole Super Biotechnol Strasbourg, Inst Rech,CNRS, Blvd Sebastien Brant, F-67412 Illkirch Graffenstaden, France.	simonin@unistra.fr	Zajac, jean-marie/E-5129-2010; BIHEL, Frederic/K-7004-2019; BIHEL, Frederic/B-2895-2008; Schmitt, Martine/B-5878-2016; Maldonado, Rafael/F-5657-2014	BIHEL, Frederic/0000-0002-4122-0929; BIHEL, Frederic/0000-0002-4122-0929; Schmitt, Martine/0000-0002-8723-9502; Maldonado, Rafael/0000-0002-4359-8773; Mouledous, Lionel/0000-0002-7675-3493; Mollereau, Catherine/0000-0003-1543-5624	Agence National de la RechercheFrench National Research Agency (ANR) [ANR-06-Neuro-041-01]; Generale des Entreprises; Association de la Recherche pour le CancerFondation ARC pour la Recherche sur le Cancer [4955]; Spanish 'Ministerio de Ciencia e Innovacion'Instituto de Salud Carlos IIISpanish Government [SAF2007-64062]; Instituto de Salud Carlos IIIInstituto de Salud Carlos III [RD06/001/001]; Catalan Government [SGR2009-00131]; ICREA FoundationICREA; 'becas para estancias cortas de especializacion e investigacion en psiquiatria y psicologia de la infancia y adolescencia o en neurociencias', Fundacion Alicia Koplowitz	We gratefully acknowledge jean Paul Humbert and Claire Gaveriaux for technical assistance. This work was supported by grants from Agence National de la Recherche (ANR-06-Neuro-041-01), Direction Generale des Entreprises, Association de la Recherche pour le Cancer (4955). This work was also supported by the Spanish 'Ministerio de Ciencia e Innovacion' (#SAF2007-64062), 'Instituto de Salud Carlos III' (#RD06/001/001), the Catalan Government (SGR2009-00131), the ICREA Foundation (ICREA Academia-2008). JMT was supported by 'becas para estancias cortas de especializacion e investigacion en psiquiatria y psicologia de la infancia y adolescencia o en neurociencias', Fundacion Alicia Koplowitz.	Calo' G, 2000, BRIT J PHARMACOL, V129, P1183, DOI 10.1038/sj.bjp.0703169; Celerier E, 2004, NEUROPHARMACOLOGY, V46, P264, DOI 10.1016/j.neuropharm.2003.08.008; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; DOURISH CT, 1990, EUR J PHARMACOL, V176, P35, DOI 10.1016/0014-2999(90)90129-T; Drdla R, 2009, SCIENCE, V325, P207, DOI 10.1126/science.1171759; Gelot A, 1998, EUR J PHARMACOL, V358, P203, DOI 10.1016/S0014-2999(98)00625-6; Gouarderes C, 2004, SYNAPSE, V51, P249, DOI 10.1002/syn.10305; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; IdanpaanHeikkila JJ, 1997, J PHARMACOL EXP THER, V282, P1366; Jhamandas JH, 2007, AM J PHYSIOL-REG I, V292, pR1872, DOI 10.1152/ajpregu.00407.2006; Kersante F, 2006, PEPTIDES, V27, P980, DOI 10.1016/j.peptides.2005.07.025; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Kotlinska J, 2008, PEPTIDES, V29, P933, DOI 10.1016/j.peptides.2008.01.008; Kotlinska J, 2007, PEPTIDES, V28, P2235, DOI 10.1016/j.peptides.2007.08.006; LAKE JR, 1992, NEUROSCI LETT, V146, P203, DOI 10.1016/0304-3940(92)90078-L; LAKE JR, 1991, NEUROSCI LETT, V132, P29, DOI 10.1016/0304-3940(91)90425-S; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MALIN DH, 1990, PEPTIDES, V11, P969, DOI 10.1016/0196-9781(90)90018-Z; MALIN DH, 1995, DRUG ALCOHOL DEPEN, V40, P37, DOI 10.1016/0376-8716(95)01178-1; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Marchand S, 2006, PEPTIDES, V27, P964, DOI 10.1016/j.peptides.2005.07.023; MARCO N, 1995, NEUROSCIENCE, V64, P1035, DOI 10.1016/0306-4522(94)00383-G; Max MB, 2008, NAT REV DRUG DISCOV, V7, P647, DOI 10.1038/nrd2595; McNally GP, 1999, NEUROSCI BIOBEHAV R, V23, P1059, DOI 10.1016/S0149-7634(99)00040-8; Mollereau C, 2005, CURR TOP MED CHEM, V5, P341, DOI 10.2174/1568026053544515; Mollereau C, 2005, MOL PHARMACOL, V67, P965, DOI 10.1124/mol.104.004614; Mouledous L, 2010, BIOFACTORS, V36, P423, DOI 10.1002/biof.116; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Rebeyrolles S, 1996, NEUROREPORT, V7, P2979; ROTHMAN RB, 1992, SYNAPSE, V12, P129, DOI 10.1002/syn.890120206; Roumy M, 1999, BRAIN RES, V845, P208, DOI 10.1016/S0006-8993(99)01965-4; Roumy M, 2003, NEUROSCI LETT, V348, P159, DOI 10.1016/S0304-3940(03)00791-2; Rutten K, 2011, DRUG ALCOHOL DEPEN, V114, P253, DOI 10.1016/j.drugalcdep.2010.10.004; Scoto GM, 2010, PEPTIDES, V31, P696, DOI 10.1016/j.peptides.2009.12.028; Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Simonin F, 2006, DRUG FUTURE, V31, P603, DOI 10.1358/dof.2006.031.07.1007143; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Tan PPC, 1999, PEPTIDES, V20, P1211, DOI 10.1016/S0196-9781(99)00125-4; Trigo JM, 2009, NEUROPHARMACOLOGY, V56, P1147, DOI 10.1016/j.neuropharm.2009.03.013; Ueda H, 2004, ANN NY ACAD SCI, V1025, P376, DOI 10.1196/annals.1307.046; Ueda H, 2009, FRONT BIOSCI, V14, P5260, DOI 10.2741/3596; Wang YQ, 2008, PEPTIDES, V29, P1183, DOI 10.1016/j.peptides.2008.02.016; Wilson George R, 2003, Am J Hosp Palliat Care, V20, P459, DOI 10.1177/104990910302000608; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; Zeng ZZ, 2003, J CHEM NEUROANAT, V25, P269, DOI 10.1016/S0891-0618(03)00038-3; Zhou HY, 2010, J NEUROSCI, V30, P4460, DOI 10.1523/JNEUROSCI.5857-09.2010	48	45	45	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.	JAN	2012	165	2					424	435		10.1111/j.1476-5381.2011.01563.x			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	867UV	WOS:000298481200011	21718302	Green Published			2020-06-30	J	Turek, Z; Lehmann, C; Parizkova, R; Samek, J; Kaska, M; Cerny, V				Turek, Zdenek; Lehmann, Christian; Parizkova, Renata; Samek, Jindrich; Kaska, Milan; Cerny, Vladimir			Differential effects of intravenous anesthetics on hepatosplanchnic microcirculation in rats: Sidestream dark-field imaging study	CLINICAL HEMORHEOLOGY AND MICROCIRCULATION			English	Article						Intravenous anesthetics; hepatosplanchnic microcirculation; SDF imaging	SKELETAL-MUSCLE MICROCIRCULATION; HEPATIC BLOOD-FLOW; IN-VIVO; THIOPENTAL ANESTHESIA; PROPOFOL; MIDAZOLAM; KETAMINE; ENDOTHELIN-1; ULTRASOUND; ETOMIDATE	This study aimed to investigate the effects of intravenous anesthetics on hepatosplanchnic microcirculation in laparotomized mechanically ventilated rats using Sidestream Dark-field (SDF) imaging. Thirty male Wistar rats were divided into 5 groups (n = 6 each). All rats were initially anesthetized with 60 mg/kg pentobarbital (i.p.) for instrumentation. This was followed by either ketamine, propofol, thiopental, midazolam or saline+fentanyl (iv bolus over 5 min and then maintenance over 90 min). SDF imaging of the liver and distal ileum microcirculation was performed at the baseline and at t = 5, 35, 65 and 95 min. In propofol group there was increase of functional sinusoidal density (FSD) following induction (+25%, P < 0.05) and maintenance at t = 95 min (+10.3%, P < 0.05), in ketamine and midazolam group decrease of FSD was observed after induction (-20.4%, P < 0.05; -10.1%, P < 0.05) and during maintenance at t = 65 min (-11.6%, P < 0.05; -11.4%, P < 0.05) when compared to baseline. Following induction with propofol functional capillary density (FCD) of ileal longitudinal muscle layer increased (+10.6%, P < 0.05) and returned to baseline values during maintenance. Ketamine and midazolam decreased FCD of longitudinal layer after induction (-24.6%, P < 0.05; -21.1%, P < 0.05) and remained decreased during maintenance at t = 95 min (-10.8%, P < 0.05; -15.5%, P < 0.05). In thiopental and control group, changes in microcirculatory parameters were not significant throughout the study. In conclusion, intravenous anesthetics affect the hepatosplanchnic microcirculation differentially, propofol has shown protective effect on the liver and intestinal microcirculation.	[Turek, Zdenek; Parizkova, Renata; Samek, Jindrich; Cerny, Vladimir] Charles Univ Prague, Univ Hosp Hradec Kralove, Dept Anesthesiol & Intens Care Med, Fac Med Hradec Kralove, Hradec Kralove 50005, Czech Republic; [Lehmann, Christian; Cerny, Vladimir] Dalhousie Univ, Dept Anesthesia, Halifax, NS, Canada; [Kaska, Milan] Charles Univ Prague, Univ Hosp Hradec Kralove, Dept Surg, Fac Med Hradec Kralove, Hradec Kralove 50005, Czech Republic	Turek, Z (reprint author), Charles Univ Prague, Univ Hosp Hradec Kralove, Dept Anesthesiol & Intens Care Med, Fac Med Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic.	turek@fnhk.cz	Lehmann, Christian/G-4837-2013; Turek, Zdenek/O-1641-2017; Kaska, Milan/K-4311-2017	Turek, Zdenek/0000-0002-2270-6317; Kaska, Milan/0000-0001-8778-6074	Charles University [135809]; Czech RepublicCzech Republic Government [MZO 00179906]	Grant Agency of Charles University (research project 135809) and Research project MZO 00179906, Czech Republic.	[Anonymous], 2010, CLIN HEMORHEOL MICRO, V44, P1, DOI 10.3233/CH-2010-1256A; Bauer M, 2000, HEPATOLOGY, V31, P937, DOI 10.1053/he.2000.5922; BECKER KE, 1978, ANESTHESIOLOGY, V49, P197, DOI 10.1097/00000542-197809000-00009; Boerma EC, 2005, CRIT CARE, V9, pR601, DOI 10.1186/cc3809; BOHLEN HG, 1976, MICROVASC RES, V11, P103, DOI 10.1016/0026-2862(76)90081-9; Brookes ZL, 2004, BRIT J ANAESTH, V93, P249, DOI 10.1093/bja/aeh190; Brookes ZLS, 2002, BRIT J ANAESTH, V88, P255, DOI 10.1093/bja/88.2.255; Brookes ZLS, 2003, ANESTH ANALG, V96, P456, DOI 10.1097/00000539-200302000-00030; Brookes ZLS, 2002, SHOCK, V18, P542, DOI 10.1097/00024382-200212000-00010; Buljubasic N, 1996, ANESTHESIOLOGY, V85, P1092, DOI 10.1097/00000542-199611000-00018; Cerny V, 2009, PHYSIOL RES, V58, P49; Christiansen CL, 1998, J CARDIOTHOR VASC AN, V12, P418, DOI 10.1016/S1053-0770(98)90195-1; De Backer D, 2007, CRIT CARE, V11, DOI 10.1186/cc6118; EBERT TJ, 1990, ANESTH ANALG, V71, P319; Franke RP, 2008, MICROVASC RES, V76, P110, DOI 10.1016/j.mvr.2008.05.002; GELMAN S, 1983, ANESTH ANALG, V62, P135; Girlich C, 2010, CLIN HEMORHEOL MICRO, V45, P207, DOI 10.3233/CH-2010-1299; Girlich C, 2009, CLIN HEMORHEOL MICRO, V43, P141, DOI 10.3233/CH-2009-1228; Gonzalez-Correa JA, 2008, N-S ARCH PHARMACOL, V376, P331, DOI 10.1007/s00210-007-0220-4; Gori T, 2006, CLIN HEMORHEOL MICRO, V35, P509; Harris AG, 1998, AM J PHYSIOL-HEART C, V274, pH1009; HOLZMANN A, 1995, BRIT J ANAESTH, V75, P452, DOI 10.1093/bja/75.4.452; Laffey JG, 2002, ANESTHESIOLOGY, V97, P215; Langer S, 2001, TRANSPLANTATION, V71, P1249, DOI 10.1097/00007890-200105150-00012; Leaphart CL, 2007, SURGERY, V141, P563, DOI 10.1016/j.surg.2007.01.021; Lehmann C, 2007, LAB ANIM-UK, V41, P55, DOI 10.1258/002367707779399491; Lindert J, 2002, J VASC RES, V39, P368, DOI 10.1159/000065549; Lubbers D W, 1979, Bibl Anat, P3; Lump W.V., 1973, VET ANESTHESIA; Miller LS, 1996, INT J MICROCIRC, V16, P147, DOI 10.1159/000179165; Nacul FE, 2010, ANESTH ANALG, V110, P547, DOI 10.1213/ANE.0b013e3181c88af1; Neukirchen M, 2008, ANESTHESIOLOGY, V109, P1113, DOI 10.1097/ALN.0b013e31818e435c; Neviere R.R., 1999, AM J PHYSL 1, V276, P6933; Nieuwenhuijzen G A, 1999, Curr Opin Clin Nutr Metab Care, V2, P399, DOI 10.1097/00075197-199909000-00008; Paes-da-Silva F, 2003, SHOCK, V19, P55, DOI 10.1097/00024382-200301000-00011; Pannen BHJ, 2002, ANESTH ANALG, V94, P1448; Piriou V, 1999, EUR J ANAESTH, V16, P615, DOI 10.1046/j.1365-2346.1999.00550.x; STOWE DF, 1992, ANESTH ANALG, V74, P547; Suliburk JW, 2005, J TRAUMA, V58, P711, DOI 10.1097/01.TA.0000159245.60495.00; Turek Z, 2008, PHYSIOL RES, V57, P365; Turek Z., 2009, VASC ANESTH, V13, P249; Vasileiou I, 2009, EUR J PHARMACOL, V605, P1, DOI 10.1016/j.ejphar.2009.01.007; Vollmar B, 2009, PHYSIOL REV, V89, P1269, DOI 10.1152/physrev.00027.2008; Weigelt H, 1979, Bibl Anat, P81; ZHANG JX, 1995, AM J PHYSIOL-GASTR L, V269, pG269; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624; Zhu T, 2008, CAN J ANAESTH, V55, P364, DOI 10.1007/BF03021492	47	5	7	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1386-0291	1875-8622		CLIN HEMORHEOL MICRO	Clin. Hemorheol. Microcirc.		2012	51	3					213	223		10.3233/CH-2011-1527			11	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	972QH	WOS:000306291700006	22240346				2020-06-30	J	Novikova, N; Cluver, C				Novikova, Natalia; Cluver, Catherine			Local anaesthetic nerve block for pain management in labour	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							OBSTETRICAL CAUDAL ANESTHESIA; 1 PERCENT MEPIVACAINE; PARACERVICAL-BLOCK; PUDENDAL BLOCK; BUPIVACAINE; LIDOCAINE; ANALGESIA; 2-CHLOROPROCAINE; 0.25-PERCENT; DELIVERY	Background Local anaesthetic nerve block is an important modality for pain management in labour. Pudendal and paracervical block (PCB) are most commonly performed local anaesthetic nerve blocks which have been used for decades. Objectives To establish the efficacy and safety of local anaesthetic nerve blocks for pain relief in labour. Search methods We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (28 February 2012). Selection criteria We included randomised controlled trials (RCTs) assessing pain management in labour with the use of local anaesthetic nerve blocks. We did not include results from quasi-RCTs. Data collection and analysis We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third person. We entered and analysed data using Review Manager software and checked for accuracy. Main results We found 41 trials for consideration of inclusion into this review. We included only 12 RCTs (1549 participants) of unclear quality. We excluded 29 studies (30 reports). The majority of excluded studies were not relevant to this review, and a few were not randomised. Local anaesthetic nerve block versus placebo or no treatment We found that more women were satisfied with pain relief after local anaesthetic nerve block (in particular 2% lidocaine PCB) than after placebo (one study, 198 participants, risk ratio (RR) 32.31, 95% confidence interval (CI) 10.60 to 98.54). Local anaesthetic nerve block was associated with more side effects (one study, 200 participants, RR 29.0, 95% CI 1.75 to 479.61). Local anaesthetic nerve block (in particular, PCB) versus opioid Local anaesthetic nerve block (in particular, PCB) in comparison with opioid (in particular, intramuscular pethidine or fentanyl patient-controlled analgesia) was found to be more effective for pain relief (one study, 109 participants, RR 2.52, 95% CI 1.65 to 3.83) and was not associated with an increased rate of assisted vaginal birth (two studies, 129 participants, RR 1.02, 95% CI 0.56 to 1.87) or with an increased caesarean section rate (two studies, 129 participants, RR 0.23, 95% CI 0.03 to 1.87). Local anaesthetic nerve block versus non-opioid agents Satisfaction with pain relief and rate of caesarean sections were found to be the same in women receiving local anaesthetic nerve block and non-opioid agents (one study, 100 participants, RR 1.11, 95% CI 0.67 to 1.84; RR 2.0, 95% CI 0.19 to 21.36, respectively). More women who received non-opioid agent in comparison with women who received local anaesthetic nerve block required additional interventions for pain relief (one study, 100 participants, RR 0.06, 95% CI 0.02 to 0.25). Local anaesthetic nerve block using different anaesthetic agents There was no difference in pain relief satisfaction, assisted vaginal birth, caesarean section, side effects for mother, Apgar score or admission to the neonatal intensive care unit between different anaesthetic agents, e. g. bupivacaine, carbocaine, lidocaine, chloroprocaine. Authors' conclusions Local anaesthetic nerve blocks are more effective than placebo, opioid and non-opioid analgesia for pain management in labour based on RCTs of unclear quality and limited numbers. Side effects are more common after local anaesthetic nerve blocks in comparison with placebo. Different local anaesthetic agents used for pain relief provide similar satisfaction with pain relief. Further high-quality studies are needed to confirm the findings, to assess other outcomes and to compare local anaesthetic nerve blocks with various modalities for pain relief in labour.	[Novikova, Natalia] Walter Sisulu Univ, Dept Obstet & Gynaecol, ZA-5200 E London, South Africa; [Cluver, Catherine] Univ Stellenbosch, Fac Hlth Sci, Dept Obstet & Gynaecol, ZA-7505 Tygerberg, South Africa; [Cluver, Catherine] Tygerberg Hosp, Tygerberg, South Africa	Novikova, N (reprint author), Walter Sisulu Univ, Dept Obstet & Gynaecol, E London Hosp Complex,Private Bag X9047, ZA-5200 E London, South Africa.	novikovanatalia@gmail.com	Cluver, Catherine/O-7978-2018	Cluver, Catherine/0000-0002-0406-8964	University of Liverpool, UK; National Institute for Health Research, UKNational Institute for Health Research (NIHR); UK Cochrane-NHS [10/4000/02]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [10/4000/02]	Internal sources; The University of Liverpool, UK.; External sources; National Institute for Health Research, UK.; UK Cochrane-NHS Engagement Project No: 10/4000/02	Anim-Somuah M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub3; Loayza IMB, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006168.pub2; BELFRAGE P, 1983, ACTA OBSTET GYN SCAN, V62, P245, DOI 10.3109/00016348309155800; BRIDENBAUGH LD, 1977, ANESTHESIOLOGY, V46, P357, DOI 10.1097/00000542-197705000-00013; BRIDENBAUGH PO, 1969, ANESTH ANAL CURR RES, V48, P824; Cluett ER, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000111.pub3; Decks JJ, 2001, SYSTEMATIC REV HLTH; Derry S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009107.pub2; Dowswell T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007214.pub2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FISCHER WM, 1970, ARCH GYNAKOL, V211, P278; Gaskin IM, 2003, I MAYS GUIDE CHILDBI, P150; GIBBS CP, 1986, ANESTHESIOLOGY, V65, P298; GUNTHER RE, 1969, ANESTHESIOLOGY, V31, P5, DOI 10.1097/00000542-196907000-00003; GUNTHER RE, 1972, ANESTHESIOLOGY, V37, P288, DOI 10.1097/00000542-197209000-00004; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; HOEKEGARD KH, 1969, AM J OBSTET GYNECOL, V105, P278, DOI 10.1016/0002-9378(69)90072-6; HUTCHINS CJ, 1980, ANAESTHESIA, V35, P376, DOI 10.1111/j.1365-2044.1980.tb05122.x; JACOB J, 1962, ANESTH ANALG, V41, P546; JENSEN F, 1984, OBSTET GYNECOL, V64, P724; JENSSEN H, 1975, ACTA OBSTET GYN SCAN, P5; JENSSEN H, 1973, ACTA OBSTET GYN SCAN, V52, P13, DOI 10.3109/00016347309158483; JOHNSON GT, 1957, BRIT MED J, V2, P386, DOI 10.1136/bmj.2.5041.386; Jones L, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009167, DOI 10.1002/14651858.CD009167]; Jones L, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd009234, 10.1002/14651858.CD009234.pub2, DOI 10.1002/14651858.CD009234]; Junttila EK, 2009, INT J OBSTET ANESTH, V18, P15, DOI 10.1016/j.ijoa.2008.01.020; Klomp T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009351.pub2; Kuah KB, 1968, J OBSTET GYN BR COMM, V75, P749; Kujansuu E., 1987, SUOM LAAKARILEHTI, V42, P2038; LANGHOFFROOS J, 1985, ACTA OBSTET GYN SCAN, V64, P269, DOI 10.3109/00016348509155127; Leighton BL, 1999, ANESTHESIOLOGY, V90, P1039, DOI 10.1097/00000542-199904000-00017; Lowe NK, 2002, AM J OBSTET GYNECOL, V186, pS16, DOI 10.1067/mob.2002.121427; Madden K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009356.pub3; Manninen T, 2000, ACTA ANAESTH SCAND, V44, P441, DOI 10.1034/j.1399-6576.2000.440414.x; Mehrangiz Z, 2004, INTERNET J PAIN SYMP, V3; MELZACK R, 1984, PAIN, V19, P321, DOI 10.1016/0304-3959(84)90079-4; MERKOW AJ, 1980, ANESTHESIOLOGY, V52, P309, DOI 10.1097/00000542-198004000-00004; Nabhan AF, 2009, J MATERN-FETAL NEO M, V22, P867, DOI 10.1080/14767050902994614; NESHEIM BI, 1983, ACTA OBSTET GYN SCAN, V62, P261, DOI 10.3109/00016348309155804; NESHEIM BI, 1979, ACTA OBSTET GYN SCAN, V58, P41, DOI 10.3109/00016347909154911; Nieminen K, 1997, ACTA OBSTET GYN SCAN, V76, P50, DOI 10.3109/00016349709047784; Nieminen K, 1994, P 14 EUR C PER MED 1; Nikkola E M, 2000, J Clin Monit Comput, V16, P597, DOI 10.1023/A:1012268617009; NYIRJESY I, 1963, AM J OBSTET GYNECOL, V87, P231; Othman M, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009223, DOI 10.1002/14651858.CD009223]; Pace MC, 2004, ANN NY ACAD SCI, V1034, P356, DOI 10.1196/annals.1335.037; Pages H, 2008, J GYNECOL OBST BIO R, V37, P415, DOI 10.1016/j.jgyn.2008.01.010; Palomaki O, 2005, ACTA OBSTET GYN SCAN, V84, P956, DOI 10.1111/j.0001-6349.2005.00709.x; Palomaki O, 2005, ACTA OBSTET GYN SCAN, V84, P962, DOI 10.1111/j.0001-6349.2005.00710.x; Pearce M, 1982, J OBSTET GYNAECOLOGY, V3, P68; PETERSON WF, 1961, AM J OBSTET GYNECOL, V81, P1249, DOI 10.1016/S0002-9378(15)33361-5; PITKIN RM, 1963, OBSTET GYNECOL, V21, P737; QVIST I, 1983, ACTA OBSTET GYN SCAN, P77; SALTS L, 1976, ANESTH ANALG, V55, P829; SCHIERUP L, 1988, ACTA OBSTET GYN SCAN, V67, P195, DOI 10.3109/00016348809004200; SEEDS AE, 1962, OBSTET GYNECOL, V20, P462; Shravage JC, 2001, J OBST GYN INDIA, V51, P71; Simkin P, 2004, J MIDWIFERY WOM HEAL, V49, P489, DOI 10.1016/j.jmwh.2004.07.007; Simmons SW, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003401.pub2; Smith CA, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009290.pub2; Smith CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009514; Smith CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009232; Smith CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009215; Teramo K, 1969, J Obstet Gynaecol Br Commonw, V76, P881; The Nordic Cochrane Centre The Cochrane Collaboration, 2008, REV MAN REVMAN 5 1, V5.1; Thorp JA, 1998, DRUG TODAY, V34, P525, DOI 10.1358/dot.1998.34.6.485249; Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2; ULMSTEN U, 1980, ACTA OBSTET GYN SCAN, V59, P209, DOI 10.3109/00016348009155397; VANDORSTEN JP, 1981, OBSTET GYNECOL, V58, P696; Vidaeff AC, 2010, PUDENDAL PARACERVICA, V19.1; WEISS RR, 1983, ANESTH ANALG, V62, P168; WESTHOLM H, 1970, ACTA OBSTET GYN SCAN, V49, P335, DOI 10.3109/00016347009157263; WESTHOLM H, 1970, ACTA ANAESTH SC    S, V37, P276	74	11	13	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2012		4							CD009200	10.1002/14651858.CD009200.pub2			53	Medicine, General & Internal	General & Internal Medicine	928UR	WOS:000303012300037	22513972				2020-06-30	J	Youngblood, FE; Knaak, E; Rose, J; Malesker, MA				Youngblood, Frederick E.; Knaak, Elizabeth; Rose, Jessica; Malesker, Mark A.			Use of Dexmedetomidine to Discontinue High-Dose Fentanyl	ANNALS OF PHARMACOTHERAPY			English	Letter							INFUSION; SEDATION		[Youngblood, Frederick E.; Rose, Jessica] Creighton Univ, Med Ctr, Dept Anesthesiol, Omaha, NE 68178 USA; [Malesker, Mark A.] Creighton Univ, Med Ctr, Dept Pharm Practice, Sch Pharm & Hlth Profess, Omaha, NE USA	Youngblood, FE (reprint author), Creighton Univ, Med Ctr, Dept Anesthesiol, Omaha, NE 68178 USA.	FrederickYoungblood@creighton.edu					Belgrade M, 2010, PAIN MED, V11, P1819, DOI 10.1111/j.1526-4637.2010.00973.x; Finkel JC, 2005, CRIT CARE MED, V33, P2110, DOI 10.1097/01.CCM.0000178183.21883.23; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Honey BL, 2009, ANN PHARMACOTHER, V43, P1506, DOI 10.1345/aph.1M161; Multz AS, 2003, ANESTH ANALG, V96, P1054, DOI 10.1213/01.ANE.0000050773.70232.08; Tobias Joseph D, 2006, J Opioid Manag, V2, P201; Wallace S, 2009, MIL MED, V174, P1228, DOI 10.7205/MILMED-D-00-6009	7	1	1	0	3	HARVEY WHITNEY BOOKS CO	CINCINNATI	PO BOX 42696, CINCINNATI, OH 45242 USA	1060-0280			ANN PHARMACOTHER	Ann. Pharmacother.	DEC	2011	45	12					1589	1590		10.1345/aph.1Q389			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	868JI	WOS:000298519200016	22068243				2020-06-30	J	Kariman, H; Majidi, A; Amini, A; Dolatabadi, AA; Derakhshanfar, H; Hatamabadi, H; Shahrami, A; Yaseri, M; Sheibani, K				Kariman, Hamid; Majidi, Alireza; Amini, Afshin; Dolatabadi, Ali Arhami; Derakhshanfar, Hojjat; Hatamabadi, Hamidreza; Shahrami, Ali; Yaseri, Mahdi; Sheibani, Kourosh			Nitrous oxide/oxygen compared with fentanyl in reducing pain among adults with isolated extremity trauma: A randomized trial	EMERGENCY MEDICINE AUSTRALASIA			English	Article						emergency medical services; fentanyl; nitrous oxide/oxygen; pain	OXIDE; ENTONOX; EMERGENCY; COLONOSCOPY; SEDATION	Objective: To compare the effectiveness of nitrous oxide/oxygen (N2O/O-2) and fentanyl in relieving pain among patients with an isolated long bone fracture or main joint dislocation of the limbs. Methods: Patients with isolated long bone fracture or main joint dislocation with moderate to severe pain were randomized into two groups. For the first group, nitrous oxide/oxygen (50: 50) was self-administered until pain relief was achieved up to a maximum of 15 min. Fentanyl (2 mg/kg) as a single dose was administered for the second group. Pain intensity was measured with a visual analogue scale before and at minutes three, six and nine after the start of the drug administration. We also recorded observed adverse effects in these two groups. Results: One hundred patients were enrolled in the study. No statistically significant difference in pain score was detected between the two groups with one exception. The mean visual analogue scale scores at 9 min were 2.2 and 3.1 for nitrous oxide/oxygen and fentanyl, respectively (difference -0.9 [95% CI -1.7 -0.1]) (P = 0.006). There was no statistically significant difference between two groups regarding adverse effects. Conclusions: Neither nitrous oxide/oxygen or fentanyl appeared to be superior to the other in relieving moderate to severe pain among emergency patients presenting with isolated limb fracture or dislocation. In an ED, increased use of nitrous oxide might reduce the overall need for opiate analgesia, and in our setting, the need for constant monitoring.	[Kariman, Hamid; Majidi, Alireza; Amini, Afshin; Dolatabadi, Ali Arhami; Derakhshanfar, Hojjat; Hatamabadi, Hamidreza; Shahrami, Ali] Shahid Beheshti Univ Med Sci, Dept Emergency Med, Imam Hossein Med Ctr, Tehran, Iran; [Yaseri, Mahdi] Shahid Beheshti Univ Med Sci, Imam Hossein Med Ctr, Clin Res & Dev Ctr, Tehran, Iran; [Sheibani, Kourosh] Tehran Univ Med Sci Tehran, Sch Publ Hlth, Tehran, Iran; [Sheibani, Kourosh] Tehran Univ Med Sci Tehran, Publ Hlth Res Inst, Tehran, Iran	Majidi, A (reprint author), 12,Block 16,Afsariye Highway, Tehran 1617763141, Iran.	alimajidi1349@yahoo.com	Shahrami, Ali/AAM-1213-2020; Yaseri, Mehdi/I-1645-2018; Amini, Afshin/AAN-5713-2020; Hatamabadi, Hamid Reza/B-9715-2016; Arhami dolatabadi, Ali/D-3508-2016	Yaseri, Mehdi/0000-0002-4066-873X; Kariman, Hamid/0000-0001-8082-0356; Hatamabadi, Hamid Reza/0000-0002-9085-8806; Shahrami, Ali/0000-0002-3001-6762; amini, afshin/0000-0001-8928-8212; Arhami dolatabadi, Ali/0000-0001-9492-9520; Hatamabadi, Hamid Reza/0000-0002-8338-8156			AMESS JAL, 1978, LANCET, V2, P339; BASKETT PJF, 1970, BRIT MED J, V2, P41, DOI 10.1136/bmj.2.5700.41; BASKETT PJF, 1971, BRIT MED J, V2, P509, DOI 10.1136/bmj.2.5760.509; Dell PF, 2009, DISSOCIATION DISSOCI, pxix; Descamps M J L, 2007, Accid Emerg Nurs, V15, P223, DOI 10.1016/j.aaen.2007.07.008; Evans Andrea, 2003, Br J Community Nurs, V8, P488; GILLMAN MA, 1986, LIFE SCI, V39, P1209, DOI 10.1016/0024-3205(86)90181-5; HAUGEN FP, 1957, ANESTHESIOLOGY, V18, P183; LATTO IP, 1973, BRIT J ANAESTH, V45, P1029, DOI 10.1093/bja/45.10.1029; MARSDEN AK, 1979, INJURY, V10, P311, DOI 10.1016/0020-1383(79)90050-0; Maslekar S, 2011, COLORECTAL DIS, V13, P48, DOI 10.1111/j.1463-1318.2009.01988.x; Maslekar S, 2009, BRIT J SURG, V96, P361, DOI 10.1002/bjs.6467; O'Sullivan I, 2003, EMERG MED J, V20, P214, DOI 10.1136/emj.20.3.214; PAYNE CGL, 1991, ARCH EMERG MED, V8, P24; Peate I, 2000, Br J Nurs, V9, P231; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Sweetman SC, 2005, MARTINDALE COMPLETE, P71; Wattenmaker I, 1990, J Orthop Trauma, V4, P35; 1970, BMJ, V1, P709	19	23	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731	1742-6723		EMERG MED AUSTRALAS	Emerg. Med. Australas.	DEC	2011	23	6					761	768		10.1111/j.1742-6723.2011.01447.x			8	Emergency Medicine	Emergency Medicine	860DW	WOS:000297930000014	22151676				2020-06-30	J	Nunez-Olarte, JM; Alvarez-Jimenez, P				Nunez-Olarte, Juan M.; Alvarez-Jimenez, Pablo			Emerging Opioid Abuse in Terminal Cancer Patients Taking Oral Transmucosal Fentanyl Citrate for Breakthrough Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									[Nunez-Olarte, Juan M.] Hosp Gen Univ Gregorio Maranon, Palliat Care Unit, Madrid, Spain; [Alvarez-Jimenez, Pablo] Area Gest Sanitaria Granada, Palliat Support Team, Unidad Gest Clin Bloque Quirurg, Motril, Spain	Nunez-Olarte, JM (reprint author), Hosp Gen Univ Gregorio Maranon, Palliat Care Unit, Madrid, Spain.						Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; McAuliffe PF, 2006, MED HYPOTHESES, V66, P874, DOI 10.1016/j.mehy.2005.10.030; Morgan AD, 2002, PHARMACOL BIOCHEM BE, V72, P873, DOI 10.1016/S0091-3057(02)00774-8; Passik SD, 2007, PAIN MED, V8, P130, DOI 10.1111/j.1526-4637.2006.00295.x; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9	6	11	11	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	DEC	2011	42	6					E6	E8		10.1016/j.jpainsymman.2011.07.006			4	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	865WU	WOS:000298342400004	22048003	Bronze			2020-06-30	J	Cushing, A; McClean, M; Stanford, M; Lohe, T; Alcantar, BE; Chirife, AD				Cushing, Andrew; McClean, Modesto; Stanford, Michael; Lohe, Tessa; Alcantar, Benjamin E.; Chirife, Andrea Denise			ANESTHESIA OF TIBETAN YAK (BOS GRUNNIENS) USING THIAFENTANIL - XYLAZINE AND CARFENTANIL - XYLAZINE	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Anesthesia; Bos grunniens; carfentanil; renarcotization; thiafentanil; yak	MEDETOMIDINE; KETAMINE; COMBINATION; PHARMACOKINETICS; NALTREXONE; GAURUS; A3080; ORYX	The use of 0.025 +/- 0.012 mg/kg (median +/- interquartile range) thiafentanil with 0.15 +/- 0.03 mg/kg xylazine (TX) and 0.011 +/- 0.0015 mg/kg carfentanil with 0.25 +/- 0.093 mg/kg xylazine (CX), with dosages based on estimated bodyweight, was used in the anesthesia of 37 Tibetan yak (Bos grunniens) housed within a drive-through animal park setting. The median time to lateral recumbency was 5 and 7 mm for each group, respectively. With the addition of propofol in 8 CX animals and 17 TX animals, the anesthetic plane was suitable for a wide range of procedures. The median time to standing recovery following administration of naltrexone was 4 +/- 3.5 min with TX and 7 +/- 1.5 min with CX. There was one fatality and one case of renarcotization in the TX group. Overall, the dosages used in the study provided a reliable and useful anesthetic induction protocol, with TX animals demonstrating a more rapid induction and recovery with less cardiac depression than CX animals.	[Cushing, Andrew; Stanford, Michael] Birch Heath Vet Clin, Tarporley CW6 9UU, England; [Cushing, Andrew; McClean, Modesto; Lohe, Tessa; Alcantar, Benjamin E.; Chirife, Andrea Denise] Wildlife Safari, Winston, OR 97496 USA	Cushing, A (reprint author), Birch Heath Vet Clin, Birch Heath Rd, Tarporley CW6 9UU, England.	a.c.cushing@hotmail.co.uk		Cushing, Andrew/0000-0002-5258-1543			Alcantar B. E., 2007, P AM ASS ZOO VET, P47; Caulkett NA, 2000, CAN VET J, V41, P49; Citino SB, 2002, J WILDLIFE DIS, V38, P457, DOI 10.7589/0090-3558-38.2.457; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; Cole A, 2006, J ZOO WILDLIFE MED, V37, P318, DOI 10.1638/05-070.1; Cooper DV, 2005, J S AFR VET ASSOC, V76, P18; Curro Thomas G., 2007, P635, DOI 10.1002/9780470376478.ch57; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; Jalanka H. H., 1992, P AM ASS ZOO VET, P236; Janssen DL, 1991, P AM ASS ZOO VET, P333; Kilgallon CP, 2010, J ZOO WILDLIFE MED, V41, P567, DOI 10.1638/2010-0021.1; Kumar A., 2004, P INT C YAK 2004; Mutlow A, 2004, J ZOO WILDLIFE MED, V35, P489, DOI 10.1638/03-074; Napier JE, 2011, J ZOO WILDLIFE MED, V42, P430, DOI 10.1638/2010-0242.1; Portas TJ, 2003, J ZOO WILDLIFE MED, V34, P269, DOI 10.1638/02-062; WILSON SC, 1993, J ZOO WILDLIFE MED, V24, P93; Zhang R C, 2000, RECENT ADV YAK REPRO	17	5	6	0	7	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2011	42	4					713	717		10.1638/2010-0140.1			5	Veterinary Sciences	Veterinary Sciences	867FJ	WOS:000298440000023	22204068				2020-06-30	J	Schaufele, MK; Marin, DR; Tate, JL; Simmons, AC				Schaufele, Michael K.; Marin, Daniel R.; Tate, Jordan L.; Simmons, Adam C.			Adverse events of conscious sedation in ambulatory spine procedures	SPINE JOURNAL			English	Article						Conscious sedation; Adverse event; Interventional spine procedure; Epidural	GASTROINTESTINAL ENDOSCOPY; COMPLICATIONS; ANESTHESIA; ANALGESIA; MIDAZOLAM; SAFETY	BACKGROUND CONTEXT: Interventional spine procedures are commonly performed in the ambulatory surgical setting, often using conscious sedation. The rate of adverse events with conscious sedation has not been previously assessed in the interventional spine procedure setting. PURPOSE: The goal of this study was to determine the rate of adverse events when using conscious sedation in the ambulatory interventional spine setting. STUDY DESIGN: A retrospective cohort chart review analysis was performed on all interventional spine procedures performed during one calendar year at a university-affiliated ambulatory surgery center by six nonanesthesia-trained spine interventionalists. PATIENT SAMPLE: Of the 3,342 procedures performed that year, 2,494 charts (74.6%) were available for review. OUTCOME MEASURES: Adverse events were documented immediately after the procedure and at a maximum 3-day follow-up phone call. METHODS: The rate and type of adverse events were analyzed and compared between those who received conscious sedation with local anesthesia and those who received local anesthesia alone. RESULTS: Of the 2,494 cases reviewed, 1,228 spine procedures were performed with local anesthesia and conscious sedation, and 1,266 procedures were performed with local anesthesia alone. Of these cases, 66 immediate adverse events (5.12%) were documented in the conscious sedation group, and 61 immediate adverse events (4.82%) were documented in the local anesthesia alone group. At maximum 3-day follow-up, 670 patients of the conscious sedation group were available for contact, and 699 patients were available from the local anesthesia group. Thirty-two adverse events (4.77%) were noted in the conscious sedation group, and 28 adverse events (4.00%) were noted in the local anesthesia group. Comparison of these rates found no significant statistical difference. However, patients in the local anesthesia group had a significantly higher rate of postoperative hypertension. Adverse events reported both immediately and at follow-up were determined to be mild, with no serious adverse events reported. CONCLUSION: The findings of this study suggest that mild to moderate conscious sedation in interventional spine procedures is associated with low rates of adverse events when established protocols are followed. (C) 2011 Elsevier Inc. All rights reserved.	[Schaufele, Michael K.] Emory Healthcare, Emory Orthopaed & Spine Ctr, Atlanta, GA 30329 USA; [Marin, Daniel R.] Univ S Florida, Dept Neurosurg & Brain Repair, Comprehens Spine Care Program, Tampa, FL 33606 USA; [Tate, Jordan L.] Dept Rehabil Med, Atlanta, GA 30322 USA; [Simmons, Adam C.] Childrens Hosp, Boston, MA 02115 USA	Schaufele, MK (reprint author), Emory Univ, Sch Med, Emory Spine Ctr, 59 Execut Pk S, Atlanta, GA 30329 USA.	mschauf@emory.edu			MedtronicMedtronic	Fellowship Support: Medtronic	[Anonymous], 2007, LID LEX DRUGS ONL; Arepally A, 2001, CARDIOVASC INTER RAD, V24, P185, DOI 10.1007/s002700002549; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bitar G, 2003, PLAST RECONSTR SURG, V111, P150, DOI 10.1097/01.PRS.0000037756.88297.BC; Botwin KP, 2003, ARCH PHYS MED REHAB, V84, P627, DOI 10.1016/S0003-9993(03)04862-1; Botwin KP, 2006, AM J PHYS MED REHAB, V85, P14, DOI 10.1097/01.phm.0000184475.44853.82; Botwin KP, 2000, ARCH PHYS MED REHAB, V81, P1045, DOI 10.1053/apmr.2000.7166; Centre for Reviews and Dissemination, 2008, COMPL ASS EP STER IN, V4; D'Eramo EM, 2003, J ORAL MAXIL SURG, V61, P793, DOI 10.1016/S0278-2391(03)00238-6; Dreyfuss P, 2009, PM&R, V1, P60, DOI 10.1016/j.pmrj.2008.10.006; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Higgins TL, 1996, CLEV CLIN J MED, V63, P355, DOI 10.3949/ccjm.63.6.355; Huang Robert, 2004, Gastrointest Endosc Clin N Am, V14, P269, DOI 10.1016/j.giec.2004.01.011; Hung C. T., 2002, Hong Kong Medical Journal, V8, P114; Innes G, 1999, J EMERG MED, V17, P145, DOI 10.1016/S0736-4679(98)00135-8; LAUVEN PM, 1990, SCAND J GASTROENTERO, V25, P1, DOI 10.3109/00365529009093164; Martin ML, 2003, J VASC INTERV RADIOL, V14, P1119, DOI 10.1097/01.RVI.0000086536.86489.82; MCCLOY R, 1992, SCAND J GASTROENTERO, V27, P97, DOI 10.3109/00365529209095987; Michalodimitrakis M, 1999, AM J FOREN MED PATH, V20, P93, DOI 10.1097/00000433-199903000-00022; Mueller PR, 2000, RADIOLOGY, V215, P684, DOI 10.1148/radiology.215.3.r00jn33684; Trummel J, 2007, CURR OPIN ANESTHESIO, V20, P359, DOI 10.1097/ACO.0b013e32827ab467; WALDMAN SD, 1989, REGION ANESTH, V14, P149; Warner MA, 1999, ANESTHESIOLOGY, V90, P896	24	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1529-9430	1878-1632		SPINE J	Spine Journal	DEC	2011	11	12					1093	1100		10.1016/j.spinee.2011.07.028			8	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	870LE	WOS:000298670000001	21920824				2020-06-30	J	O'Neill, CW				O'Neill, Conor W.			Commentary: I want to be sedated	SPINE JOURNAL			English	Editorial Material									Calif Spine Diagnost, San Francisco, CA 94115 USA	O'Neill, CW (reprint author), Calif Spine Diagnost, 2100 Webster St,Suite 518, San Francisco, CA 94115 USA.	coneill@sbcglobal.net					Schaufele MK, 2011, SPINE J, V11, P1093, DOI 10.1016/j.spinee.2011.07.028; Schaufele MK, 2011, SPINE J, V11, P1093	2	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1529-9430			SPINE J	Spine Journal	DEC	2011	11	12					1101	1101		10.1016/j.spinee.2011.11.015			1	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	870LE	WOS:000298670000002	22208853				2020-06-30	J	Kunisawa, T; Ueno, M; Kurosawa, A; Nagashima, M; Hayashi, D; Sasakawa, T; Suzuki, A; Takahata, O; Iwasaki, H				Kunisawa, Takayuki; Ueno, Megumi; Kurosawa, Atsushi; Nagashima, Michio; Hayashi, Dai; Sasakawa, Tomoki; Suzuki, Akihiro; Takahata, Osamu; Iwasaki, Hiroshi			Dexmedetomidine can stabilize hemodynamics and spare anesthetics before cardiopulmonary bypass	JOURNAL OF ANESTHESIA			English	Article; Proceedings Paper	1st World Congress of Total Intravenous Anesthesia (TCI)	SEP-NOV -, 2007	Venice, ITALY			Dexmedetomidine; Anesthetic-sparing effect; Adjuvant; Before cardiopulmonary bypass	INFUSION; SURGERY	We previously confirmed the effectiveness of dexmedetomidine (DEX) for stabilizing hemodynamics as well as sparing anesthetics during anesthetic induction in patients undergoing cardiac surgery (Kunisawa et al. in J Clin Anesth 21:194-199, 1). In this study, we investigated whether these effects of DEX continue until the start of cardiopulmonary bypass (CPB). Twenty-two patients with mild to moderate cardiovascular disease were randomized into two groups [DF2 group: DEX dose of 0.7 mu g/kg/h after initial dose and effect-site concentration (ESC) of fentanyl of 2 ng/ml; PF4 group: saline and ESC of fentanyl of 4 ng/ml]. Propofol was administered for anesthetic induction and maintenance. Hemodynamics, cardiovascular drugs, ESC of propofol, and cardiovascular responses to skin incision (SI) and sternotomy (St) were measured or calculated. Blood pressure (BP) at the pre-/post-SI periods was higher in the DEX group (137 +/- A 17/140 +/- A 16 mmHg) than in the placebo group (85 +/- A 9/109 +/- A 24 mmHg). Percent increases in cardiovascular response to SI or St were lower in the DEX group than in the placebo group (for example, 1.9 +/- A 2.2 vs. 27.4 +/- A 19.9% in systolic BP due to SI). ESCs of propofol at SI and St in the DEX group were lower than those in the placebo group. DEX combined with 2 ng/ml fentanyl before CPB can suppress the decrease in blood pressure at the pre- and post-SI periods, can blunt the cardiovascular responses to SI and St, and can spare the required ESC of propofol despite fentanyl concentration, which was half of that in the placebo group.	[Kunisawa, Takayuki; Ueno, Megumi; Kurosawa, Atsushi; Nagashima, Michio; Hayashi, Dai; Sasakawa, Tomoki; Suzuki, Akihiro; Takahata, Osamu; Iwasaki, Hiroshi] Asahikawa Med Coll, Dept Anesthesiol & Crit Care Med, Asahikawa, Hokkaido 0788510, Japan	Kunisawa, T (reprint author), Asahikawa Med Coll, Dept Anesthesiol & Crit Care Med, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	taka.kunisawa@nifty.ne.jp		Nagashima, Michio/0000-0001-7416-5367			Biccard BM, 2008, ANAESTHESIA, V63, P4, DOI 10.1111/j.1365-2044.2007.05306.x; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Jalonen J, 1997, ANESTHESIOLOGY, V86, P331; Kanda Hirotsugu, 2009, Masui, V58, P1496; Kunisawa T, 2009, J CLIN ANESTH, V21, P194, DOI 10.1016/j.jclinane.2008.08.015; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; TALKE P, 1995, ANESTHESIOLOGY, V82, P620, DOI 10.1097/00000542-199503000-00003	8	20	32	0	1	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	DEC	2011	25	6					818	822		10.1007/s00540-011-1215-3			5	Anesthesiology	Anesthesiology	861VM	WOS:000298047600004	21901330				2020-06-30	J	Sun, ZT; Yang, CY; Cui, Z; Zhang, J; Han, XP				Sun, Zhen-Tao; Yang, Chun-Yao; Cui, Zhi; Zhang, Jie; Han, Xue-Ping			Effect of intravenous dezocine on fentanyl-induced cough during general anesthesia induction: a double-blinded, prospective, randomized, controlled trial	JOURNAL OF ANESTHESIA			English	Article						Fentanyl; Cough; Dezocine; General anesthesia; Suppress	OPIOID RECEPTORS; INJECTION	To evaluate the suppressive effect of intravenous dezocine on fentanyl-induced cough during the induction of general anesthesia. A total of 120 patients, American Society of Anesthesiologists (ASA) physical status I-II, were randomized into two equally sized groups (n = 60). These two groups were given either intravenous dezocine 0.1 mg/kg or a matching placebo (equal volume of 0.9% saline) 10 min before the induction of general anesthesia. Patients were induced with midazolam 0.1 mg/kg, fentanyl 5 mu g/kg, propofol 1-1.5 mg/kg, and suxamethonium 1.5 mg/kg. The injection time of fentanyl was less than 2 s in all patients. The occurrence of cough was recorded 2 min after fentanyl bolus. No patient in the dezocine group had cough, and 42 patients in the control group had cough. This difference was statistically different between these two groups (P = 0.000). These results demonstrate that intravenous dezocine 0.1 mg/kg 10 min prior to induction was effective in suppressing fentanyl-induced cough in our patients.	[Sun, Zhen-Tao; Yang, Chun-Yao; Cui, Zhi; Zhang, Jie; Han, Xue-Ping] Zhengzhou Univ, Dept Anesthesia, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China	Han, XP (reprint author), Zhengzhou Univ, Dept Anesthesia, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.	xuepinghan@live.cn			Department of Anesthesia, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	This work was supported the Department of Anesthesia, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.	Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Chen Ye-ming, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P339; Cho HB, 2010, ACTA ANAESTH SCAND, V54, P717, DOI 10.1111/j.1399-6576.2009.02203.x; Gharagozlou P, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-19; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; KARLSSON JA, 1990, J PHARMACOL EXP THER, V252, P863; Lin CS, 2005, CAN J ANAESTH, V52, P207; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lin JA, 2007, J FORMOS MED ASSOC, V106, P649, DOI 10.1016/S0929-6646(08)60022-4; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu MS, 2011, KOREAN J ANESTHESIOL, V60, P403, DOI 10.4097/kjae.2011.60.6.403	16	24	36	0	17	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2011	25	6					860	863		10.1007/s00540-011-1237-x			4	Anesthesiology	Anesthesiology	861VM	WOS:000298047600011	21935685				2020-06-30	J	DeSousa, K; Ali, MS				DeSousa, Kalindi; Ali, Mohamed Shaaban			Sevoflurane to alleviate pain on propofol injection	JOURNAL OF ANESTHESIA			English	Article						Propofol; Pain; Sevoflurane; Lidocaine	SURGICAL-PATIENTS; REDUCING PAIN; DOUBLE-BLIND; PRETREATMENT; LIDOCAINE; REMIFENTANIL; PREVENTION; ANALGESIA; COMBINATION; ISOFLURANE	Since the introduction of propofol, several drugs and methods have been used to alleviate the pain on its injection. This study was designed to evaluate the effect of adding sevoflurane 3% during preoxygenation in alleviation of pain on propofol injection. In this randomized single-blinded study, 100 patients were randomly allocated equally into five groups: sevoflurane-lidocaine-tourniquet (SLT), sevoflurane-lidocaine (SL), lidocaine-tourniquet (LT), lidocaine (L), and sevoflurane (S). Approximately 10 min before the induction of anesthesia, midazolam 1-2 mg was administered intravenously to all patients. All patients received fentanyl 1 A mu g/kg as pretreatment and a full induction dose of propofol. A blinded anesthesia nurse assessed pain and hand movements throughout the injection of propofol. In the SLT group, all patients (100%) were pain free and had no hand movements. There was no significant difference in pain grade or in hand movements between the L and the S groups, or between the SLT and the SL groups. However, significant differences were observed in pain grade between the SLT and the L groups as well as between the SLT and the S groups. In addition, a significant difference in hand movement was observed only between the SLT and the S groups. The addition of 3% sevoflurane at the time of preoxygenation for 1 min along with routine use of lidocaine-tourniquet completely prevented pain upon propofol injection, whereas sevoflurane by itself provided similar analgesia to premixed lidocaine with propofol.	[DeSousa, Kalindi; Ali, Mohamed Shaaban] Al Salam Int Hosp, Dept Anaesthesia, Kuwait 35151, Kuwait; [DeSousa, Kalindi; Ali, Mohamed Shaaban] Al Salam Int Hosp, ICU, Kuwait 35151, Kuwait; [Ali, Mohamed Shaaban] Assiut Univ Hosp, Assiut, Egypt	DeSousa, K (reprint author), Changi Gen Hosp, Dept Anaesthesia, Singapore 529889, Singapore.	kalindidesousa@gmail.com; msali58@hotmail.com					Al-Refal AR, 2007, MINERVA ANESTESIOL, V73, P219; BAHAR M, 1982, ANAESTHESIA, V37, P847, DOI 10.1111/j.1365-2044.1982.tb01821.x; Canbay O, 2008, BRIT J ANAESTH, V100, P95, DOI 10.1093/bja/aem301; Cheong MA, 2002, ANESTH ANALG, V95, P1293, DOI 10.1097/00000539-200211000-00035; Doenicke AW, 1996, ANESTH ANALG, V82, P472, DOI 10.1097/00000539-199603000-00007; Duarte R, 2008, BRIT J ANAESTH, V100, P203, DOI 10.1093/bja/aem369; Fujii Y, 2008, CLIN THER, V30, P280, DOI 10.1016/j.clinthera.2008.02.018; HELMERS JHJH, 1990, CAN J ANAESTH, V37, P267, DOI 10.1007/BF03005485; Holdcroft A, 1999, BRIT J ANAESTH, V83, P618; Huang YW, 2002, ACTA ANAESTH SCAND, V46, P1021, DOI 10.1034/j.1399-6576.2002.460816.x; Hwang J, 2009, ANAESTH INTENS CARE, V37, P584, DOI 10.1177/0310057X0903700404; Iwata M, 2010, J ANESTH, V24, P31, DOI 10.1007/s00540-009-0833-5; Jalota L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1110; JOHNSON RA, 1990, ANAESTHESIA, V45, P439, DOI 10.1111/j.1365-2044.1990.tb14328.x; Kang HJ, 2010, KOREAN J ANESTHESIOL, V58, P239, DOI 10.4097/kjae.2010.58.3.239; Kwak K, 2007, EUR J ANAESTH, V24, P746, DOI 10.1017/S026502150600233X; Kwak KH, 2008, CLIN THER, V30, P1113, DOI 10.1016/j.clinthera.2008.05.019; Lockwood GG, 1997, BRIT J ANAESTH, V79, P586; Ma Yu-shan, 2009, Sichuan Da Xue Xue Bao Yi Xue Ban, V40, P536; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; Mohta M, 2004, ANAESTH INTENS CARE, V32, P765, DOI 10.1177/0310057X0403200606; Patel SS, 1996, DRUGS, V51, P658, DOI 10.2165/00003495-199651040-00009; Philip BK, 1999, ANESTH ANALG, V89, P623, DOI 10.1097/00000539-199909000-00014; Picard P, 2000, ANESTH ANALG, V90, P963; Suzuki Satomi, 2002, Masui, V51, P140; Tan CH, 1998, ANAESTHESIA, V53, P468, DOI 10.1046/j.1365-2044.1998.00405.x; Toscano A, 2003, INT J OBSTET ANESTH, V12, P79, DOI 10.1016/S0959-289X(02)00195-4; Wong W. H., 2001, SMJ Singapore Medical Journal, V42, P193; Yeo ST, 2007, BRIT J ANAESTH, V98, P110, DOI 10.1093/bja/ael327; Yeo ST, 2007, BRIT J ANAESTH, V98, P105, DOI 10.1093/bja/ael326	30	4	4	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2011	25	6					879	883		10.1007/s00540-011-1212-6			5	Anesthesiology	Anesthesiology	861VM	WOS:000298047600014	21881932				2020-06-30	J	Onuki, K; Onuki, N; Imamura, T; Yamanishi, Y; Yoshikawa, S; Hagihira, S; Shimada, J; Nagasaka, H				Onuki, Kazuyuki; Onuki, Noriko; Imamura, Toshikatsu; Yamanishi, Yuichiro; Yoshikawa, Shumei; Hagihira, Satoshi; Shimada, Jun; Nagasaka, Hiroshi			Pentazocine increases bispectral index without surgical stimulation during nitrous oxide-sevoflurane anesthesia	JOURNAL OF ANESTHESIA			English	Article						Pentazocine; Fentanyl; Bispectral index	ELECTROENCEPHALOGRAPHIC BICOHERENCE; FENTANYL; KETAMINE	Although there have been a large number of reports on the effects of opioids on the bispectral index (BIS) during anesthesia, the effects of pentazocine on the BIS have not been reported. In this study, 60 patients scheduled for elective oral surgery [30 females, 30 males; all American Society of Anesthesiologists Physical Status (ASA PS) category 1] were enrolled in the trials. Maintaining gender parity, we randomly assigned the patients to one of three groups: pentazocine group (0.3 mg/kg; n = 20), fentanyl group (1 mu g/kg; n = 20), or saline group (n = 20); these opioids were administered intravenously 15 min after the intubation. Anesthesia was induced with thiopental and vecuronium bromide and maintained with nitrous oxide (4 l/min)-oxygen (2 l/min)-sevoflurane (1%). At 15 min after the intubation, mean arterial blood pressure (MAP), heart rate (HR), and BIS index were recorded as baseline values. MAP, HR, and BIS values were measured at 2.5-min after the intubation up to 30 min. All data were expressed as the mean +/- A standard deviation. Differences in BIS values, MAP, and HR among the three groups throughout the experiment were analyzed using two-way repeated-measures analysis of variance (ANOVA), and demographic data among the three groups were analyzed using one-way ANOVA. Post hoc comparisons were performed using Fisher's protected least significant difference test. A P value of < 0.05 was considered to indicate statistically significance. MAP and HR showed no significant differences among the three groups during the study. BIS values significantly increased between 5 and 15 min after the intubation relative to the baseline value in the pentazocine group (P < 0.001), and BIS values in this group were significantly during this time period than those in the fentanyl and saline group (P < 0.001). BIS values were not significantly different between the fentanyl group and saline group. These results indicated that pentazocine, but not fentanyl, under nitrous oxide-sevoflurane anesthesia caused a statistically significant increase in BIS in our patients.	[Onuki, Kazuyuki; Onuki, Noriko; Imamura, Toshikatsu; Yamanishi, Yuichiro; Nagasaka, Hiroshi] Meikai Univ, Div Anesthesiol, Dept Comprehens Med Sci, Sch Dent, Sakado, Saitama 3500283, Japan; [Yoshikawa, Shumei; Shimada, Jun] Meikai Univ, Div Oral & Maxillofacial Surg, Dept Diagnost & Therapeut Sci, Sch Dent, Sakado, Saitama 3500283, Japan; [Hagihira, Satoshi] Osaka Univ, Dept Anesthesiol, Grad Sch Med, Suita, Osaka, Japan	Nagasaka, H (reprint author), Meikai Univ, Div Anesthesiol, Dept Comprehens Med Sci, Sch Dent, 1-1 Keyakidai, Sakado, Saitama 3500283, Japan.	hnagasak@dent.meikai.ac.jp					Bailey OL, 2000, ANESTHESIA, P282; GUSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Hagihira S, 2004, ANESTHESIOLOGY, V100, P818, DOI 10.1097/00000542-200404000-00011; Hirota K., 1999, European Journal of Anaesthesiology, V16, P779, DOI 10.1046/j.1365-2346.1999.00585.x; Koitabashi T, 2002, ANESTH ANALG, V94, P1530, DOI 10.1097/00000539-200206000-00028; Morimoto Y, 2006, ANESTH ANALG, V103, P641, DOI 10.1213/01.ane.0000229699.99371.3c; Tsuda N, 2007, ACTA ANAESTH SCAND, V51, P472, DOI 10.1111/j.1399-6576.2006.01246.x; YANAGIDA H, 1971, CAN ANAESTH SOC J, V18, P621, DOI 10.1007/BF03026182	8	1	3	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2011	25	6					946	949		10.1007/s00540-011-1224-2			4	Anesthesiology	Anesthesiology	861VM	WOS:000298047600026	21904779				2020-06-30	J	Maathuis, MHJ; Dijkstra, DDP				Maathuis, M. Hugo J.; Dijkstra, Daniel D. P.			Disaster after the plaster. Fentanyl withdrawal symptoms in a curable hospice patient	EUROPEAN JOURNAL OF GENERAL PRACTICE			English	Review						Transdermal fentanyl; tapering strategies; withdrawal symptoms; palliative care	TRANSDERMAL FENTANYL; PAIN; OPIOIDS	Opioids have been used for thousands of years for pain relief. Transdermal fentanyl (TDF) is a synthetic opioid that is prescribed for the treatment of chronic pain. This clinical lesson demonstrates that TDF may be easy to start but sometimes difficult to stop. Like any other opioid there is a substantial risk of physical dependence and subsequent withdrawal symptoms after discontinuation of the drug. Here, we present a case of a hospice patient who developed withdrawal symptoms after a first TDF tapering attempt according to the manufacturer's instructions. A second, more gradual tapering regimen did not result in withdrawal symptoms. The mechanisms and treatment modalities for physical dependence along with a tailor-made tapering strategy that is suitable for general practice are presented in this clinical lesson.	[Maathuis, M. Hugo J.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6500 HB Nijmegen, Netherlands; [Maathuis, M. Hugo J.] Hospice Rozenheuvel, Rozendaal, Netherlands; [Dijkstra, Daniel D. P.] Meander Med Ctr, Dept Anaesthesiol, Amersfoort, Netherlands	Maathuis, MHJ (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, POB 9101, NL-6500 HB Nijmegen, Netherlands.	h.maathuis@elg.umcn.nl					Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Ashburn MA, 1999, LANCET, V353, P1865, DOI 10.1016/S0140-6736(99)04088-X; Bailey JA, 2010, PAIN MED, V11, P1803, DOI 10.1111/j.1526-4637.2010.00982.x; Baron Michael J, 2006, J Opioid Manag, V2, P277; Benich JJ, 2011, PRIMARY CARE, V38, P59, DOI 10.1016/j.pop.2010.11.005; BUCKNALL ABV, 1985, FAM PRACT, V2, P244, DOI 10.1093/fampra/2.4.244; Geppetti P, 2009, CLIN DRUG INVEST, V29, P3, DOI 10.2165/0044011-200929001-00002; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Ishihara C, 2005, PHARM WORLD SCI, V27, P13, DOI 10.1007/s11096-004-2271-7; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Le Loet X, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-31; Lugo RA, 2001, PHARMACOTHERAPY, V21, P1566, DOI 10.1592/phco.21.20.1566.34471; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Strain EC, 2006, TREATMENT OPIOID DEP, P275; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133	19	2	2	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1381-4788	1751-1402		EUR J GEN PRACT	Eur. J. Gen. Pract.	DEC	2011	17	4					229	232		10.3109/13814788.2011.602966			4	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	865NV	WOS:000298318500006	21877907				2020-06-30	J	Ewan, EE; Martin, TJ				Ewan, Eric E.; Martin, Thomas J.			Rewarding Electrical Brain Stimulation in Rats after Peripheral Nerve Injury Decreased Facilitation by Commonly Abused Prescription Opioids	ANESTHESIOLOGY			English	Article							VENTRAL TEGMENTAL AREA; NEUROPATHIC PAIN; SELF-STIMULATION; MORPHINE; DOPAMINE; SUPPRESSION; HEROIN; ACTIVATION; METHADONE; LIGATION	Background: Prescription opioid abuse is a significant concern in treating chronic pain, yet few studies examine how neuropathic pain alters the abuse liability of commonly abused prescription opioids. Methods: Normal and spinal nerve ligated (SNL) rats were implanted with electrodes into the left ventral tegmental area (VTA). Rats were trained to lever press for intracranial electrical stimulation (VTA ICSS), and the effects of methadone, fentanyl, hydromorphone, and oxycodone on facilitation of VTA ICSS were assessed. A second group of neuropathic rats were implanted with intrathecal catheters, and the effects of intrathecal clonidine, adenosine, and gabapentin on facilitation of VTA ICSS were assessed. The effects of electrical stimulation of the VTA on mechanical allodynia were assessed in SNL rats. Results: Responding for VTA ICSS was similar in control and SNL rats. Methadone, fentanyl, and hydromorphone were less potent in facilitating VTA ICSS in SNL rats. Oxycodone produced a significant facilitation of VTA ICSS in control (maximum shift 24.10 +/- 6.19 Hz) but not SNL rats (maximum shift 16.32 +/- 7.49 Hz), but also reduced maximal response rates in SNL rats. Intrathecal administration of clonidine, adenosine, and gabapentin failed to facilitate VTA ICSS in SNL rats, and electrical stimulation of the VTA did not alter mechanical allodynia following nerve injury. Conclusions: The present data suggests that the positive reinforcing effects of commonly abused prescription opioids are diminished following nerve injury. In addition, alleviation of mechanical allodynia with nonopioid analgesics does not appear to stimulate limbic dopamine pathways originating from the VTA in SNL rats.	[Ewan, Eric E.; Martin, Thomas J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; [Martin, Thomas J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA	Ewan, EE (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	eewan@wfubmc.edu			National Institute on Drug Abuse of the National Institutes of Health (Bethesda, Maryland)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-022599, T32-DA-007246]	Received from the Departments of Physiology and Pharmacology and Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina. Submitted for publication April 14, 2011. Accepted for publication August 1, 2011. Supported by grants Nos. DA-022599 (awarded to Dr. Martin) and T32-DA-007246 (awarded to Mr. Ewan) from the National Institute on Drug Abuse of the National Institutes of Health (Bethesda, Maryland).	Altier N, 1999, LIFE SCI, V65, P2269, DOI 10.1016/S0024-3205(99)00298-2; Benedetti F, 1998, PAIN, V74, P205, DOI 10.1016/S0304-3959(97)00172-3; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Ewan EE, 2011, ANESTHESIOLOGY, V114, P624, DOI 10.1097/ALN.0b013e31820a4edb; Garzon M, 2001, SYNAPSE, V41, P311, DOI 10.1002/syn.1088; GYSLING K, 1983, BRAIN RES, V277, P119, DOI 10.1016/0006-8993(83)90913-7; Hernandez G, 2009, BEHAV BRAIN RES, V198, P91, DOI 10.1016/j.bbr.2008.10.017; King T, 2009, NAT NEUROSCI, V12, P1364, DOI 10.1038/nn.2407; Martin TJ, 2006, PAIN, V125, P257, DOI 10.1016/j.pain.2006.05.027; Martin TJ, 2007, ANESTHESIOLOGY, V106, P312, DOI 10.1097/00000542-200702000-00020; MILIARESSIS E, 1986, PHYSIOL BEHAV, V37, P85, DOI 10.1016/0031-9384(86)90388-4; Nichols ML, 1995, J PHARMACOL EXP THER, V275, P1339; Niikura K, 2008, NEUROSCI LETT, V435, P257, DOI 10.1016/j.neulet.2008.02.059; Niikura K, 2010, TRENDS PHARMACOL SCI, V31, P299, DOI 10.1016/j.tips.2010.04.003; OLDENDORF WH, 1972, SCIENCE, V178, P984, DOI 10.1126/science.178.4064.984; Ozaki S, 2004, J NEUROCHEM, V88, P1389, DOI 10.1046/j.1471-4159.2003.02272.x; Ozaki S, 2002, J NEUROCHEM, V82, P1192, DOI 10.1046/j.1471-4159.2002.01071.x; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9; Paxinos G., 1998, RAT BRAIN STEREOTAXI; Pierce RC, 2006, NEUROSCI BIOBEHAV R, V30, P215, DOI 10.1016/j.neubiorev.2005.04.016; Rosenblum A, 2007, DRUG ALCOHOL DEPEN, V90, P64, DOI 10.1016/j.drugalcdep.2007.02.012; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; Selley DE, 2001, BIOCHEM PHARMACOL, V62, P447, DOI 10.1016/S0006-2952(01)00689-X; Strassels SA, 2009, J MANAGE CARE PHARM, V15, P556, DOI 10.18553/jmcp.2009.15.7.556; *US DEP HHS, 2009, OFF APPL STUD HHS PU; WAY EL, 1960, J PHARMACOL EXP THER, V129, P144; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535	28	26	27	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	2011	115	6					1271	1280		10.1097/ALN.0b013e3182330448			10	Anesthesiology	Anesthesiology	855RL	WOS:000297581800017	21946150	Green Accepted, Bronze			2020-06-30	J	Rastogi, R; Swarm, RA; Patel, TA				Rastogi, Rahul; Swarm, Robert A.; Patel, Trusharth A.			Case Scenario: Opioid Association with Serotonin Syndrome Implications to the Practitioners	ANESTHESIOLOGY			English	Article							CHRONIC-PAIN; TOXICITY; COMBINATION; VENLAFAXINE; ANALGESICS; CITALOPRAM; DIAGNOSIS; CRITERIA; THERAPY; UPDATE		[Rastogi, Rahul; Swarm, Robert A.; Patel, Trusharth A.] Washington Univ, Sch Med, Dept Anesthesia, Div Pain Management, St Louis, MO 63110 USA	Rastogi, R (reprint author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA.	rastogir@anest.wustl.edu		Rastogi, Rahul/0000-0002-3082-1032			Ables AZ, 2010, AM FAM PHYSICIAN, V81, P1139; Ailawadhi S, 2007, J CLIN PHARM THER, V32, P199, DOI 10.1111/j.1365-2710.2007.00813.x; Altman EM, 2007, PSYCHOSOMATICS, V48, P361, DOI 10.1176/appi.psy.48.4.361-a; Bijl D, 2004, NETH J MED, V62, P309; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Brown TM, 2004, AM J EMERG MED, V22, P510, DOI 10.1016/j.ajem.2004.07.028; CODD EE, 1995, J PHARMACOL EXP THER, V274, P1263; Dagtekin O, 2011, MINERVA ANESTESIOL, V77, P93; Dannawi M, 2002, J PSYCHOPHARMACOL, V16, P401, DOI 10.1177/026988110201600420; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Ener RA, 2003, PAIN MED, V4, P63, DOI 10.1046/j.1526-4637.2003.03005.x; Gillman PK, 2006, BIOL PSYCHIAT, V59, P1046, DOI 10.1016/j.biopsych.2005.11.016; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Gillman PK, 1998, FUND CLIN PHARMACOL, V12, P482, DOI 10.1111/j.1472-8206.1998.tb00976.x; Gillman PK, 1997, MED J AUSTRALIA, V167, P109; Gnanadesigan Nallini, 2005, J Am Med Dir Assoc, V6, P265, DOI 10.1016/j.jamda.2005.04.012; Isbister GK, 2005, CLIN NEUROPHARMACOL, V28, P205, DOI 10.1097/01.wnf.0000177642.89888.85; Isenberg D, 2008, AM J EMERG MED, V26; Karunatilake H, 2006, ANN PHARMACOTHER, V40, P155, DOI 10.1345/aph.1E671; Kroenke K, 2009, GEN HOSP PSYCHIAT, V31, P206, DOI 10.1016/j.genhosppsych.2008.12.006; Lai MW, 2006, CLIN TOXICOL, V44, P803, DOI 10.1080/15563650600907165; Lee J, 2009, PSYCHOSOMATICS, V50, P638, DOI 10.1176/appi.psy.50.6.638; Mackay FJ, 1999, BRIT J GEN PRACT, V49, P871; Mao JR, 2011, J PAIN, V12, P157, DOI 10.1016/j.jpain.2010.07.006; MCALLEN KJ, CRIT CARE MED, V38, pS244; Mills KC, 1997, CRIT CARE CLIN, V13, P763, DOI 10.1016/S0749-0704(05)70368-7; Ng BKW, 2010, PSYCHOSOMATICS, V51, P194, DOI 10.1176/appi.psy.51.3.194; Parrott AC, 2002, PHARMACOL BIOCHEM BE, V71, P837, DOI 10.1016/S0091-3057(01)00711-0; PATEL TA, 2010, AM SOC REG AN PAIN M; Pilgrim JL, 2011, FORENSIC SCI MED PAT, V7, P162, DOI 10.1007/s12024-010-9188-3; Radomski JW, 2000, MED HYPOTHESES, V55, P218, DOI 10.1054/mehy.2000.1047; Schenck CH, 1996, JAMA-J AM MED ASSOC, V276, P1220, DOI 10.1001/jama.276.15.1220; Schwartz AR, 2008, CLIN TOXICOL, V46, P771, DOI 10.1080/15563650701668625; Sheline YI, 2002, AM J PSYCHIAT, V159, P430, DOI 10.1176/appi.ajp.159.3.430; Sun-Edelstein C, 2008, EXPERT OPIN DRUG SAF, V7, P587, DOI [10.1517/14740338.7.5.587, 10.1517/14740338.7.5.587 ]; Tashakori A, 2010, CLIN TOXICOL, V48, P337, DOI 10.3109/15563651003709427; Tirkkonen T, 2004, CLIN PHARMACOL THER, V76, P639, DOI 10.1016/j.clpt.2004.08.017	37	59	62	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	2011	115	6					1291	1298		10.1097/ALN.0b013e31823940c0			8	Anesthesiology	Anesthesiology	855RL	WOS:000297581800019	22037635	Bronze			2020-06-30	J	Mitra, S; Kaushal, H; Gupta, RK				Mitra, Sukanya; Kaushal, Harpreet; Gupta, Ravi K.			Evaluation of Analgesic Efficacy of Intra-Articular Bupivacaine, Bupivacaine Plus Fentanyl, and Bupivacaine Plus Tramadol After Arthroscopic Knee Surgery	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article							POSTOPERATIVE PAIN; TOURNIQUET USE; DOUBLE-BLIND; MORPHINE; RELIEF	Purpose: To compare the efficacy of intra-articular (IA) bupivacaine, bupivacaine-fentanyl, and bupivacaine-tramadol for relief of postoperative pain after arthroscopic knee surgery. Methods: In a randomized double-blind design, 60 adult American Society of Anesthesiologists class I or class II patients undergoing elective arthroscopic knee surgery under general anesthesia were randomized to 3 groups: all received 30 mL of 0.25% bupivacaine, plus either 1 mL of normal saline solution (group I), 1 mL (50 mu g) of fentanyl (group II), or 1 mL (50 mg) of tramadol (group III). Pain was assessed by use of a 100-mm visual analog scale (VAS) at 0, 1, 2, 4, 6, and 8 hours postoperatively. Intramuscular diclofenac sodium was used as rescue analgesic. Postoperative adverse effects were noted. Results: The mean VAS pain scores were the lowest for group II, intermediate for group III, and highest for group I. There was a significant main effect for group differences on pain scores (F = 41.138, P<.001). The main effect for the time factor was also significant (F = 6.097, P<.001). However, both group II and group III were comparable and both were superior to group I with regard to supplementary analgesia in terms of (1) number of patients receiving it, (2) total consumption during the study period, and (3) time to first supplementary analgesic requirement. The incidence of adverse event was comparable among the 3 groups. Conclusions: On the primary outcome measure (VAS pain score), both bupivacaine with fentanyl and bupivacaine with tramadol were better than IA bupivacaine, and bupivacaine with fentanyl was better than that with tramadol. However, both the combinations were comparable to each other with regard to the secondary outcome measure (supplementary analgesic requirement). Thus IA bupivacaine-fentanyl appears to be the best combination for relief of postoperative pain in patients undergoing arthroscopic knee surgery, followed by IA bupivacaine-tramadol. Level of Evidence: Level I, randomized controlled	[Mitra, Sukanya; Kaushal, Harpreet] Govt Med Coll & Hosp, Dept Anaesthesiol & Intens Care, Chandigarh, India; [Gupta, Ravi K.] Govt Med Coll & Hosp, Dept Orthopaed, Chandigarh, India	Mitra, S (reprint author), 203-B,Sect 24-A, Chandigarh 160023, India.	drsmitra12@yahoo.com					Akinci SB, 2003, CAN J ANAESTH, V50, P423, DOI 10.1007/BF03021046; Alagol A, 2004, KNEE SURG SPORT TR A, V12, P184, DOI 10.1007/s00167-003-0454-8; Atanassoff PG, 1997, ANESTH ANALG, V84, P1340, DOI 10.1097/00000539-199706000-00030; Ayoglu H, 2010, ARCH ORTHOP TRAUM SU, V130, P307, DOI 10.1007/s00402-008-0770-z; BEYZADEOQLU T, 2006, KNEE SURG SPORT TR A, V10, P102; Ekman EF, 2004, J BONE JOINT SURG AM, V86A, P1316; John HP, 1996, OPERATIVE ARTHROSCOP, P145; Johnson DS, 2000, ARTHROSCOPY, V16, P648, DOI 10.1053/jars.2000.4826; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kirkley A, 2000, ARTHROSCOPY, V16, P121, DOI 10.1016/S0749-8063(00)90024-0; Mandal P, 2002, INDIAN J ANESTHESIA, V46, P107; Ng HP, 2006, REGION ANESTH PAIN M, V31, P26, DOI 10.1016/j.rapm.2005.09.009; Saryazdi H, 2006, J RES MED SCI, V11, P156; Scheffel PT, 2010, J SHOULDER ELB SURG, V19, P944, DOI 10.1016/j.jse.2010.01.023; Smith TO, 2009, KNEE, V16, P317, DOI 10.1016/j.knee.2009.01.004; Stoelting RK, 2006, PHARM PHYSL ANESTHET, P87; Tabboush Z, 2008, ANESTH ANALG, V107, P2092, DOI 10.1213/ane.0b013e3181898ffb; Tuncer B, 2007, AGRI, V19, P42; Tverskoy M, 1998, ANESTH ANALG, V87, P1121, DOI 10.1097/00000539-199811000-00026; Uysalel A, 1995, ARTHROSCOPY, V11, P660, DOI 10.1016/0749-8063(95)90105-1; Varkel V, 1999, CAN J ANAESTH, V46, P867, DOI 10.1007/BF03012977; Webb ST, 2009, BRIT J ANAESTH, V102, P439, DOI 10.1093/bja/aep036; Wiater BP, 2011, J BONE JOINT SURG AM, V93A, P615, DOI 10.2106/JBJS.I.01386; Zeidan A, 2008, ANESTH ANALG, V107, P292, DOI 10.1213/ane.0b013e31816ba364	24	13	13	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063			ARTHROSCOPY	Arthroscopy	DEC	2011	27	12					1637	1643		10.1016/j.arthro.2011.08.295			7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	859AK	WOS:000297845900011	22047926				2020-06-30	J	O'Sullivan, MJ; Mislovic, B; Alexander, E				O'Sullivan, Michael J.; Mislovic, Branislav; Alexander, Elise			Dorsal penile nerve block for male pediatric circumcision - randomized comparison of ultrasound-guided vs anatomical landmark technique	PEDIATRIC ANESTHESIA			English	Article						regional analgesia; postoperative pain; ultrasound; circumcision	REGIONAL ANESTHESIA; CHILDREN	Background: Dorsal penile nerve block (DPNB) is a commonly performed regional anesthetic technique for male circumcision. Traditionally, DPNB is based on an anatomical landmark technique. Recently, an ultrasound-guided technique for DPNB has been described. Objectives: The aim of our study was to compare the anatomical landmark technique with this ultrasound-guided technique. The hypothesis to be tested was that ultrasound guidance of DPNB would lead to less administration of opioid when compared to the anatomical landmark technique. Methods: Boys of ASA status I/II scheduled for day case circumcision were prospectively recruited and randomized. DPNB was performed under general anesthesia using the anatomical landmark technique or ultrasound guidance. Fentanyl was administered intraoperatively and immediately postoperatively if patients demonstrated signs of pain. Similarly, oral codeine was given prior to discharge if required. The primary outcome measure was the number of patients requiring fentanyl. Secondary outcome measures included initial pain score on emergence from general anesthesia, requirement for codeine predischarge, and time to perform block. Results: A total of 32 patients were recruited to the landmark group and 34 to the ultrasound group. There was no significant difference between the two groups in terms of fentanyl administration. The ultrasound technique took longer to perform but was associated with a reduction in codeine requirement prior to discharge. Conclusions: This study does not support the routine use of ultrasound for the performance of DPNB in male pediatric circumcision. Nonetheless, an associated reduction in codeine administration postoperatively suggests some benefit in terms of postoperative pain.	[O'Sullivan, Michael J.; Mislovic, Branislav; Alexander, Elise] Our Ladys Childrens Hosp, Dublin, Ireland	O'Sullivan, MJ (reprint author), Hosp Sick Children, Dept Anesthesia, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	miosul06@yahoo.com					BATEMAN DV, 1975, ANAESTHESIA, V30, P1; BROWN TCK, 1989, ANAESTH INTENS CARE, V17, P34, DOI 10.1177/0310057X8901700108; Choi WY, 2003, ANESTH ANALG, V96, P396, DOI 10.1097/00000539-200302000-00018; Cyna AM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003005.pub2; DALENS B, 1989, ANESTH ANALG, V69, P41; Faraoni D, 2010, PEDIATR ANESTH, V20, P931, DOI 10.1111/j.1460-9592.2010.03405.x; Marhofer P, 2010, CURR OPIN ANESTHESIO, V23, P632, DOI 10.1097/ACO.0b013e32833e2891; Sandeman DJ, 2007, ANAESTH INTENS CARE, V35, P266, DOI 10.1177/0310057X0703500217; Sandeman DJ, 2010, ANAESTH INTENS CARE, V38, P519, DOI 10.1177/0310057X1003800317; SEROUR F, 1994, ANESTH ANALG, V79, P129; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Yang CC, 1999, J UROLOGY, V161, P97, DOI 10.1016/S0022-5347(01)62075-5	12	21	21	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	DEC	2011	21	12					1214	1218		10.1111/j.1460-9592.2011.03722.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	854RF	WOS:000297511200007	22023417				2020-06-30	J	Kannikeswaran, N; Chen, XG; Sethuraman, U				Kannikeswaran, Nirupama; Chen, Xinguang; Sethuraman, Usha			Utility of endtidal carbon dioxide monitoring in detection of hypoxia during sedation for brain magnetic resonance imaging in children with developmental disabilities	PEDIATRIC ANESTHESIA			English	Article						sedation; endtidal carbon dioxide; adverse events; developmental disabilities; children	PROCEDURAL SEDATION; ADVERSE EVENTS; CAPNOGRAPHY; PROPOFOL	Background: We have shown previously that children with developmental disabilities have three times higher incidence of sedation-related hypoxia when compared with normal children. Objectives: Our objectives were to describe the changes in endtidal carbon dioxide (ETCO2) values and the utility of ETCO2 monitoring in earlier identification of hypoxia during sedation for brain magnetic resonance imaging (MRI) in children with developmental disabilities. Methods: We conducted a prospective observational study of a convenience sample of 150 children with developmental disabilities aged 1-10 years who received intravenous sedation for brain MRI. Children were sedated and monitored according to the institution's sedation protocol. We recorded ETCO2 levels, hypoxia, and adverse events during sedation. Hypoxia was defined as SpO(2) < 93%. A change in ETCO2 level >= 10 mm Hg from presedation baseline, an intra-sedation >= 50 mm Hg, and loss of capnographic waveform were considered as significant ETCO2 abnormalities. Results: Of the children, 80.7% (121/150) were sedated with a combination of pentobarbital and fentanyl. ETCO2 abnormalities were noted in 42.6% (64/150) of sedation encounters. Hypoxia occurred in 18% (27/150) of subjects. ETCO2 abnormalities were documented in 19(70%) patients with hypoxia before changes in pulse oximetry were noted. ETCO2 changes were noted a mean of 4.38 +/- 1.89 min prior to occurrence of hypoxia. Conclusions: ETCO2 abnormalities and hypoxia occur commonly during sedation in children with developmental disabilities. ETCO2 monitoring is useful in early recognition of impending hypoxia during sedation in children with developmental disabilities.	[Kannikeswaran, Nirupama; Sethuraman, Usha] Wayne State Univ, Childrens Hosp Michigan, Carman & Ann Adams Dept Pediat, Div Emergency Med, Detroit, MI 48201 USA; [Chen, Xinguang] Wayne State Univ, Prevent Res Ctr, Detroit, MI 48201 USA	Kannikeswaran, N (reprint author), Wayne State Univ, Childrens Hosp Michigan, Carman & Ann Adams Dept Pediat, Div Emergency Med, 3901 Beaubien Blvd, Detroit, MI 48201 USA.	nkannike@dmc.org		Chen, Xinguang/0000-0001-8263-643X	Cardinal Health	This project was supported by a patient safety grant from Cardinal Health. The nasal cannulas used in the study for the ETCO<INF>2</INF> monitoring were provided by Oridion Inc.	Anderson JL, 2007, ANN EMERG MED, V49, P9, DOI 10.1016/j.annemergmed.2006.06.011; Burton JH, 2006, ACAD EMERG MED, V13, P500, DOI 10.1197/j.aem.2005.12.017; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cravero JP, 2006, PEDIATRICS, V118, P1087, DOI 10.1542/peds.2006-0313; Cutter KO, 2007, AM J EMERG MED, V25, P654, DOI 10.1016/j.ajem.2006.11.043; Deitch K, 2008, ANN EMERG MED, V52, P1, DOI 10.1016/j.annemergmed.2007.11.040; Deitch K, 2010, ANN EMERG MED, V55, P258, DOI 10.1016/j.annemergmed.2009.07.030; Green SM, 2010, ANN EMERG MED, V55, P265, DOI 10.1016/j.annemergmed.2009.08.019; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hart LS, 1997, PEDIATR EMERG CARE, V13, P189, DOI 10.1097/00006565-199706000-00004; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; *JOINT COMM ACCR H, 2001, REV AN CAR STAND COM; Kannikeswaran N, 2009, PEDIATR ANESTH, V19, P250, DOI 10.1111/j.1460-9592.2008.02900.x; Krauss B, 2007, ANN EMERG MED, V50, P172, DOI 10.1016/j.annemergmed.2006.10.016; Lightdale JR, 2006, PEDIATRICS, V117, pE1170, DOI 10.1542/peds.2005-1709; Malviya S, 1997, ANESTH ANALG, V85, P1207, DOI 10.1097/00000539-199712000-00005; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Poirier MP, 1998, AM J EMERG MED, V16, P350, DOI 10.1016/S0735-6757(98)90125-5	18	11	11	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	DEC	2011	21	12					1241	1246		10.1111/j.1460-9592.2011.03660.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	854RF	WOS:000297511200011	21824212				2020-06-30	J	Mandal, B; Kaur, G; Batra, YK; Mahajan, S				Mandal, Banashree; Kaur, Gurpreet; Batra, Yatindra K.; Mahajan, Sachin			Manifestation of Long QT syndrome with normal QTc interval under anesthesia: a case report	PEDIATRIC ANESTHESIA			English	Article						anesthetic; Long QT syndrome; syndactyly		Patients with congenital Long QT are known to have normal QT interval in symptom-free period and in the early years of life. Precipitating factors like surgical stress, interactions with anesthetic agents prolonging QT interval, and electrolyte imbalances can manifest with life threatening arrhythmias in congenital or acquired Long QT syndrome. We report a case of concealed LQTS manifesting under anesthesia and its subsequent perioperative course.	[Mandal, Banashree; Kaur, Gurpreet; Batra, Yatindra K.] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India; [Mahajan, Sachin] Postgrad Inst Med Educ & Res, Dept Cardiothorac & Vasc Surg, Chandigarh 160012, India	Batra, YK (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India.	ykbatrapgi@gmail.com					Crotti L, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-18; Kies SJ, 2005, ANESTHESIOLOGY, V102, P204, DOI 10.1097/00000542-200501000-00029; Lu JT, 2010, CURR OPIN CARDIOL, V25, P216, DOI 10.1097/HCO.0b013e32833846b3; Nathan AT, 2011, ANESTH ANALG, V112, P1163, DOI 10.1213/ANE.0b013e3182121d57; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; Vincent G Michael, 2002, Card Electrophysiol Rev, V6, P57, DOI 10.1023/A:1017935121656; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204	7	7	7	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	DEC	2011	21	12					1265	1267		10.1111/j.1460-9592.2011.03679.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	854RF	WOS:000297511200015	21824216				2020-06-30	J	Krinsky, CS; Lathrop, SL; Crossey, M; Baker, G; Zumwalt, R				Krinsky, Clarissa S.; Lathrop, Sarah L.; Crossey, Michael; Baker, Ginger; Zumwalt, Ross			A Toxicology-Based Review of Fentanyl-Related Deaths in New Mexico (1986-2007)	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						fentanyl; prescription drugs; overdose; patches; toxicology	ABUSE; CIRCUMSTANCES; DURAGESIC(R); MISUSE	Since its approval in the United States, fentanyl has become increasingly popular for the medical management of pain and as a substance of abuse. Fentanyl is unique among the opioids in its widespread use with a transdermal delivery system, which contributes to its unique pharmacokinetics and abuse potential. We examined the demographics of deaths with fentanyl identified on toxicologic analysis and reviewed specific challenges in the laboratory detection of postmortem fentanyl levels. The New Mexico Office of the Medical Investigator database was searched for all cases from January 1986 through December 2007 with fentanyl reported as present or quantified. Those deaths with a cause of death identified as drug overdose were then analyzed separately. From 1986 to 2007, 154 cases were identified with fentanyl present in postmortem samples, with 96 of the cases identified as fentanyl-related drug overdoses. The number of fentanyl-related deaths has increased over the past 20 years, corresponding to both statewide increases in the medical use of fentanyl and the abuse of prescription opioids. The demographics of these fentanyl-related overdoses showed that subjects were more likely to be female, white non-Hispanic, and older than those in previously described overdose deaths. Several cases were identified with central and peripheral blood samples and antemortem and postmortem samples available for fentanyl quantification. Given the uncharacteristic demographics of fentanyl-related deaths and the complexity of the laboratory analysis of fentanyl, forensic scientists must use caution in both the detection and interpretation of fentanyl concentrations.	[Krinsky, Clarissa S.; Lathrop, Sarah L.; Zumwalt, Ross] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Baker, Ginger] New Mexico Dept Hlth, Div Sci Lab, Toxicol Bur, Albuquerque, NM USA; [Crossey, Michael] TriCore Reference Labs, Albuquerque, NM USA	Krinsky, CS (reprint author), Univ New Mexico, Hlth Sci Ctr, MSC11 6030,1 Univ New Mexico, Albuquerque, NM 87131 USA.	ckrinsky@salud.unm.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Drummer OH, 2002, THER DRUG MONIT, V24, P199, DOI 10.1097/00007691-200204000-00002; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Jones TS, 2008, JAMA-J AM MED ASSOC, V300, P1512; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; Kuehn BM, 2007, JAMA-J AM MED ASSOC, V297, P249, DOI 10.1001/jama.297.3.249; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; US Department of Justice Drug Enforcement Administration, 2009, AUT REP CONS ORD SYS; US Department of Justice National Drug Intelligence Center, 2006, SR000001 US DEP JUST; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	19	20	20	2	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2011	32	4					347	351		10.1097/PAF.0b013e31822ad269			5	Medicine, Legal; Pathology	Legal Medicine; Pathology	851GE	WOS:000297255600017	21986276				2020-06-30	J	Drummond, GB; Dhonneur, G; Kirov, K; Duvaldestin, P				Drummond, G. B.; Dhonneur, G.; Kirov, K.; Duvaldestin, P.			Effects of airway occlusion on breathing muscle electromyogram signals, during isoflurane anaesthesia, with and without the effects of fentanyl and hypercapnia	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics; inhalation; analgesics; opioid; electromyography; respiratory muscles; respiratory physiological processes	NITROUS-OXIDE; HALOTHANE ANESTHESIA; RESPIRATORY MUSCLES; ABDOMINAL-MUSCLES; REFLEX CONTROL; CATS; PRESSURE; HUMANS; METHOXYFLURANE; AFFERENTS	Background. Expiratory muscle action is prominent during anaesthesia and can impair lung function. This activity is exaggerated by the use of opioids. Airway pressure during occlusion of expiration would be a valuable measure in the study of expiratory muscle activation. However, this would only be valid if the imposed occlusion did not itself alter muscle activation. This possibility can be checked by directly assessing muscle activity by electromyography; varying arterial carbon dioxide tensions and opioid action should be considered. Methods. We studied seven spontaneously breathing patients, anaesthetized with nitrous oxide and isoflurane, in four conditions: during an infusion of fentanyl and after naloxone, breathing normally and with breathing stimulated with CO2. We compared diaphragm and external oblique abdominal electromyogram (EMG) signals during normal and occluded breaths. We also measured chest wall volume and compared airway occlusion pressure, during inspiration and expiration, with the EMG results. Results. Inspiratory occlusion increased the duration of inspiration during hypercapnia by 20%, but not the rate of electrical activation of the diaphragm, indicating that occlusion does not cause a reflex increase in diaphragm contraction. In contrast, expiratory occlusion did not affect either the duration of expiration or the electrical activity of the external oblique muscles. Conclusions. In these conditions, except for a change in inspiratory duration, respiratory muscle activity is unaffected by airway occlusion. Airway occlusion will permit valid measures of muscle activity in inspiration and expiration and provide simple measurements of respiratory muscle function during anaesthesia.	[Drummond, G. B.; Dhonneur, G.; Kirov, K.; Duvaldestin, P.] Hop Henri Mondor, Dept Anesthesie & Reanimat, F-94010 Creteil, France; [Dhonneur, G.] CHU Jean Verdier, AP HP, Dept Anesthesie & Reanimat, F-93143 Bondy, France; [Kirov, K.] Inst Curie, Dept Anesthesie Reanimat & Douleur, F-75005 Paris, France; [Duvaldestin, P.] CHU Henri Mondor, AP HP, Dept Anesthesie & Reanimat Chirurg, F-94010 Creteil, France	Drummond, GB (reprint author), Royal Infirm, Dept Anaesthesia & Pain Med, 51 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.	g.b.drummond@ed.ac.uk			Clinical and Biomedical Research Committee of the Scottish Home and Health Department [R/NMD/2/2/C375]	The development and purchase of the apparatus for the optical measurement system was supported by a grant from the Clinical and Biomedical Research Committee of the Scottish Home and Health Department, grant R/NMD/2/2/C375.	Balkowiec A, 2008, J PHYSIOL-LONDON, V483, P759; Barrett J, 2008, J APPL PHYSIOL, V76, P2473; BISHOP B, 1964, J APPL PHYSIOL, V19, P224; BRADLEY GW, 1972, RESP PHYSIOL, V16, P142, DOI 10.1016/0034-5687(72)90047-3; Butler JE, 1997, J NEUROPHYSIOL, V78, P170; CHANG NJ, 1995, PHARMACOL BIOCHEM BE, V50, P351, DOI 10.1016/0091-3057(94)00272-K; Chawla G, 2008, BRIT J ANAESTH, V100, P411, DOI 10.1093/bja/aem376; CLARK FJ, 1972, J PHYSIOL-LONDON, V222, P267, DOI 10.1113/jphysiol.1972.sp009797; Corda M, 1965, J PHYSIOL-LONDON, V178, P171; DAVIS J N, 1975, Journal of Physiology (Cambridge), V245, P481; DAVIS JN, 1970, J PHYSIOL-LONDON, V209, P711, DOI 10.1113/jphysiol.1970.sp009188; DERENNE JP, 1976, J APPL PHYSIOL, V40, P805; DETROYER A, 1988, J APPL PHYSIOL, V64, P1546; Drummond GB, 2010, BRIT J ANAESTH, V104, P661, DOI [10.1093/bja/aeq070, 10.1093/bja/aeq076]; DRUMMOND GB, 1984, BRIT J ANAESTH, V56, P215, DOI 10.1093/bja/56.3.215; DRUMMOND GB, 1986, BRIT J ANAESTH, V58, P586, DOI 10.1093/bja/58.6.586; Drummond GB, 2002, BRIT J ANAESTH, V88, P384, DOI 10.1093/bja/88.3.384; Drummond GB, 2001, PHYSIOL MEAS, V22, P489, DOI 10.1088/0967-3334/22/3/307; DURON B, 1978, ANAT EMBRYOL, V152, P171, DOI 10.1007/BF00315923; FINCK AD, 1995, ANESTH ANALG, V80, P664, DOI 10.1097/00000539-199504000-00003; FRAZIER DT, 1991, J APPL PHYSIOL, V70, P491; GAUTIER H, 1981, J APPL PHYSIOL, V51, P1162; HALL LW, 1988, BRIT J ANAESTH, V60, P207, DOI 10.1093/bja/60.2.207; HOWARD RS, 1991, J PHYSIOL-LONDON, V437, P181, DOI 10.1113/jphysiol.1991.sp018590; KELSEN SG, 1976, AM J PHYSIOL, V230, P675; LOPATA M, 1977, AM REV RESPIR DIS, V116, P449, DOI 10.1164/arrd.1977.116.3.449; MISEROCCHI G, 1976, J APPL PHYSIOL, V41, P277; Murray A, 2009, EUR J ANAESTH, V26, P9, DOI 10.1097/EJA.0b013e328318c6bd; Parthasarathy S, 2000, AM J RESP CRIT CARE, V162, P546, DOI 10.1164/ajrccm.162.2.9901024; PASKIN S, 1968, ANESTHESIOLOGY, V29, P550, DOI 10.1097/00000542-196805000-00033; POLACHECK J, 1980, J APPL PHYSIOL, V49, P609; SEARS TA, 1964, J PHYSIOL-LONDON, V175, P386, DOI 10.1113/jphysiol.1964.sp007523; SOKOLL MD, 1972, ANESTH ANAL CURR RES, V51, P16; SUGAI N, 1982, BRIT J ANAESTH, V54, P567, DOI 10.1093/bja/54.5.567; Warner DO, 1998, ANESTH ANALG, V86, P1058, DOI 10.1097/00000539-199805000-00030; Warner DO, 1996, ANESTHESIOLOGY, V84, P309, DOI 10.1097/00000542-199602000-00008; WHITELAW WA, 1975, RESP PHYSIOL, V23, P181, DOI 10.1016/0034-5687(75)90059-6	37	4	4	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2011	107	6					989	997		10.1093/bja/aer301			9	Anesthesiology	Anesthesiology	849VG	WOS:000297152800021	21965051	Bronze			2020-06-30	J	Kusre, SR; Costello, J				Kusre, Sandeep Rahul; Costello, Jonathan			IS INTRANASAL FENTANYL BETTER THAN PARENTERAL MORPHINE FOR MANAGING ACUTE SEVERE PAIN IN CHILDREN?	EMERGENCY MEDICINE JOURNAL			English	Editorial Material							EMERGENCY-DEPARTMENT	A short cut review was carried out to establish whether intranasal fentanyl is better than parenteral morphine for managing acute severe pain in children. 51 papers were found using the reported searches, of which 4 presented the best evidence to answer the clinical question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these best papers are tabulated. It is concluded that intranasal fentanyl is an effective and safe alternative to IV or IM morphine for managing acute pain in children presenting to the Emergency Department.	Royal Free Hosp, London NW3 2QG, England	Kusre, SR (reprint author), Royal Free Hosp, Pond St, London NW3 2QG, England.						Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Younge P, 1999, EMERGEN MED, V11, P90	4	5	5	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	DEC	2011	28	12					1077	1078		10.1136/emermed-2011-200892			4	Emergency Medicine	Emergency Medicine	851OX	WOS:000297281800026	22101600				2020-06-30	J	Clavijo, CF; Thomas, JJ; Cromie, M; Schniedewind, B; Hoffman, KL; Christians, U; Galinkin, JL				Clavijo, Claudia F.; Thomas, James Joseph; Cromie, Meghan; Schniedewind, Bjoern; Hoffman, Keith L.; Christians, Uwe; Galinkin, Jeffrey L.			A low blood volume LC-MS/MS assay for the quantification of fentanyl and its major metabolites norfentanyl and despropionyl fentanyl in children	JOURNAL OF SEPARATION SCIENCE			English	Article						Despropionyl fentanyl; Dried blood spots; Fentanyl; Human plasma; Norfentanyl	CHROMATOGRAPHY-MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOLID-PHASE MICROEXTRACTION; GAS-CHROMATOGRAPHY; HUMAN PLASMA; ULTRAVIOLET DETECTION; SCREENING METHOD; SUFENTANIL; ALFENTANIL; INFANTS	Preterm and term neonates often require surgical procedures and analgesia. However, our knowledge about neonatal pharmacokinetics of fentanyl, the most commonly used drug for these procedures, and its metabolites is still incomplete. To facilitate pharmacokinetic studies of fentanyl and its metabolites in neonates and other children, we developed and validated an LC-MS/MS method based on minimally invasive, low blood volume sampling. LC-MS/MS was used for the simultaneous analysis of fentanyl, despropionyl fentanyl (DPF), and norfentanyl from dried blood samples (DBS) collected on filter paper. Positive ions were monitored using multiple reaction monitoring. Since the standard matrix for measuring fentanyl blood concentrations is plasma, the assay was developed and validated in plasma, whole blood, and then DBS. Our method was able to measure clinically relevant levels of fentanyl and its metabolites. In DBS, the lower limits of quantification were 100?pg/mL for fentanyl with a range of reliable response from 0.1 to 100?ng/mL (r2>0.99) and 250?pg/mL for both DPF and norfentanyl with a range of reliable response from 0.25 to 100?ng/mL (r2>0.99). In plasma and in DBS inter-day accuracy and precisions of fentanyl met predefined acceptance criteria and also indicated comparable assay performance in both matrices.	[Clavijo, Claudia F.; Thomas, James Joseph; Cromie, Meghan; Schniedewind, Bjoern; Hoffman, Keith L.; Christians, Uwe; Galinkin, Jeffrey L.] Univ Colorado Denver, Dept Anesthesiol, Aurora, CO 80045 USA; [Galinkin, Jeffrey L.] Childrens Hosp Colorado, Aurora, CO USA	Galinkin, JL (reprint author), Univ Colorado Denver, Dept Anesthesiol, Mailstop B-117,1999 N Fitzsimons Pkwy,Suite 100, Aurora, CO 80045 USA.	Claudia.clavijo@ucdenver.edu; jeffrey.galinkin@ucdenver.edu			United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 DK048520, UL1RR025780, 3UL1RR025744-02S3]	This study was supported in part by the United States National Institutes of Health, grants P30 DK048520 Mass Spectrometry Core, UL1RR025780 and 3UL1RR025744-02S3.	Abdel-Rehim M, 2003, ANAL CHIM ACTA, V492, P253, DOI 10.1016/S0003-2670(03)00574-9; Bagheri H, 2007, J PHARMACEUT BIOMED, V43, P1763, DOI 10.1016/j.jpba.2006.12.016; Bjorksten AR, 2002, J CHROMATOGR B, V775, P97, DOI 10.1016/S1570-0232(02)00178-2; *CDER, 2001, GUID IND BIOAN METH; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; Clavijo CF, 2011, ANAL BIOANAL CHEM, V400, P715, DOI 10.1007/s00216-011-4775-z; Clinical and Laboratory Standards Institute, 2004, EP5A2 CLSI; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Dotsikas Y, 2004, ANAL CHIM ACTA, V509, P103, DOI 10.1016/j.aca.2003.12.007; Dotsikas Y, 2002, ANAL CHIM ACTA, V459, P177, DOI 10.1016/S0003-2670(02)00133-2; Ebrahimzadeh H, 2008, ANAL CHIM ACTA, V626, P193, DOI 10.1016/j.aca.2008.07.047; Esplin MS, 2006, OBSTET GYNECOL SURV, V61, P800, DOI 10.1097/01.ogx.0000248747.52343.5f; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; Hakkola J, 2001, BIOL NEONATE, V80, P193, DOI 10.1159/000047142; Hines RN, 2008, PHARMACOL THERAPEUT, V118, P250, DOI 10.1016/j.pharmthera.2008.02.005; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MCDONALD J, 1987, RES COMMUN CHEM PATH, V57, P389; Mei JV, 2001, J NUTR, V131, p1631S; Miller RS, 1995, BRIT J CLIN PHARMACO, V40, P553; Muller C, 2002, J CHROMATOGR B, V773, P47, DOI 10.1016/S1570-0232(02)00142-3; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Statistics, 2004, STAT NCFH PERIOD LIN; Taddio A, 2002, CLIN PERINATOL, V29, P493, DOI 10.1016/S0095-5108(02)00017-9; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Van Nimmen NFJ, 2004, J CHROMATOGR A, V1035, P249, DOI 10.1016/j.chroma.2004.02.074; Wang CS, 2009, MICROCHEM J, V91, P149, DOI 10.1016/j.microc.2008.09.002; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; Yuansheng L., 1996, MICROCHEM J, V53, P130	35	27	28	0	24	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1615-9306	1615-9314		J SEP SCI	J. Sep. Sci.	DEC	2011	34	24					3568	3577		10.1002/jssc.201100422			10	Chemistry, Analytical	Chemistry	860NI	WOS:000297954600015	21916010				2020-06-30	J	Bendall, JC; Simpson, PM; Middleton, PM				Bendall, Jason C.; Simpson, Paul M.; Middleton, Paul M.			Prehospital Analgesia in New South Wales, Australia	PREHOSPITAL AND DISASTER MEDICINE			English	Article						analgesia; fentanyl; methoxy-flurane; morphine; opiate; paramedic; prehospital		Introduction: With at least 20% of ambulance patients reporting pain of moderate to severe intensity, pain management has become a primary function of modern ambulance services. The objective of this study was to describe the use of intravenous morphine, inhaled methoxyflurane, and intranasal fentanyl when administered in the out-of-hospital setting by paramedics within a large Australian ambulance service. Methods: A retrospective analysis was conducted using data from ambulance patient health care records (PHCR) for all cases from 01 July 2007 through 30 June 2008 in which an analgesic agent was administered (alone or in combination). Results: During the study period, there were 97,705 patients <= 100 years of age who received intravenous (IV) morphine, intranasal (IN) fentanyl, or inhaled methoxyflurane, either alone or in combination. Single-agent analgesia was administered in 87% of cases. Methoxyflurane was the most common agent, being administered in almost 60% of cases. Females were less likely to receive an opiate compared to males (RR = 0.83, 95% CI, 0.82-0.84, p <0.0001). Pediatric patients were less likely to receive opiate analgesia compared to adults (RR = 0.65, 95% CI, 0.63-0.67, p <0.0001). The odds of opiate analgesia (compared to pediatric patients 0-15 years) were 1.47; 2.10; 2.56 for 16-39 years, 40-59 years, and = 60 years, respectively. Pediatric patients were more likely to receive fentanyl than morphine (RR = 1.69, 95% CI, 1.64-1.74, p < 0.0001). Conclusion: In this ambulance service, analgesia most often is provided through the use of a single agent. The majority of patients receive non-opioid analgesia with methoxyflurane, most likely because all levels of paramedics are authorized to administer that analgesic. Females and children are less likely to receive opiate-based analgesia than their male and adult counterparts, respectively. Paramedics appear to favor intranasal opiate delivery over intravenous delivery in children with acute pain.	[Bendall, Jason C.; Simpson, Paul M.; Middleton, Paul M.] Ambulance Serv New South Wales, Ambulance Res Inst, Locked Bag 105, Rozelle, NSW 2039, Australia	Bendall, JC (reprint author), Ambulance Serv New South Wales, Ambulance Res Inst, Locked Bag 105, Rozelle, NSW 2039, Australia.	jbendall@ambulance.nsw.gov.au	Simpson, Paul/N-7447-2019; Middleton, Paul M/A-9084-2012	Simpson, Paul/0000-0003-3875-0061; Middleton, Paul M/0000-0003-0760-1098; Bendall, A/Prof Jason/0000-0002-8688-2192			Barker R, 2006, ACAD EMERG MED, V13, P19, DOI 10.1197/j.aem.2005.07.014; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Jennings PA, 2011, EMERG MED J, V28, P530, DOI 10.1136/emj.2010.098954; Johnston S, 2011, EMERG MED J, V28, P57, DOI 10.1136/emj.2009.078717; Kober A, 2003, ANESTH ANALG, V96, P1447, DOI 10.1213/01.ANE.0000056825.55397.1F; Kober A, 2002, ANESTH ANALG, V95, P723, DOI 10.1097/00000539-200209000-00035; Lang T, 2007, AM J EMERG MED, V25, P887, DOI 10.1016/j.ajem.2007.01.016; Lord B, 2011, EMERG MED J, V28, P147, DOI 10.1136/emj.2009.079384; Lord B, 2009, AM J EMERG MED, V27, P525, DOI 10.1016/j.ajem.2008.04.003; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; Michael GE, 2007, AM J EMERG MED, V25, P901, DOI 10.1016/j.ajem.2007.02.001; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Nuhr M, 2004, SPINE, V29, P1499, DOI 10.1097/01.BRS.0000131439.87553.99; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; RAFTERY KA, 1995, ANN EMERG MED, V26, P414, DOI 10.1016/S0196-0644(95)70107-9; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Vassiliadis John, 2002, Emerg Med (Fremantle), V14, P261, DOI 10.1046/j.1442-2026.2002.00341.x; Watkins Nicholas, 2006, Emerg Med Australas, V18, P51, DOI 10.1111/j.1742-6723.2006.00808.x; White L J, 2000, Prehosp Emerg Care, V4, P205, DOI 10.1080/10903120090941209	23	23	23	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1049-023X	1945-1938		PREHOSP DISASTER MED	Prehospital Disaster Med.	DEC	2011	26	6					422	426		10.1017/S1049023X12000180			5	Emergency Medicine	Emergency Medicine	VG0ZY	WOS:000445120500005	22559307				2020-06-30	J	Walaszczyk, M; Knapik, P; Misiolek, H; Korlacki, W				Walaszczyk, Malgorzata; Knapik, Piotr; Misiolek, Hanna; Korlacki, Wojciech			Epidural and opioid analgesia following the Nuss procedure	MEDICAL SCIENCE MONITOR			English	Article						pectus excavatum; Nuss procedure; epidural analgesia; ropivacaine; opioids	POSTOPERATIVE PAIN; PECTUS EXCAVATUM; ANESTHESIA; BUPIVACAINE; ROPIVACAINE; EFFICACY; FENTANYL; SURGERY; CONSENT; PARENTS	Background: Parents have the right to decide on behalf of their children and deny consent to regional anaesthesia. The investigators decided to investigate quality of postoperative analgesia in adolescents undergoing epidural and opioid analgesia following the Nuss procedure. Material/Methods: The study subjects were 61 adolescents aged 11-18 years who underwent pectus excavatum repair with the Nuss procedure. Patients were divided into epidural (n=41) and opioid (n=20) groups, depending on their parents' consent to epidural catheter insertion. Intraoperatively, 0.5% epidural ropivacaine with fentanyl or intermittent intravenous injections of fentanyl were used. Postoperative analgesia was achieved with either epidural infusion of 0.1% ropivacaine with fentanyl, or subcutaneous morphine via an intraoperatively inserted "butterfly" cannula. Additionally, both groups received metamizol and paracetamol. Primary outcome variables were postoperative pain scores (Numeric Rating Scale and Prince Henry Hospital Pain Score). Secondary outcome variables included hemodynamic parameters, additional analgesia and side effects. Results: Heart rate and blood pressure values in the postoperative period were significantly higher in the opioid group. Pain scores requiring intervention were noted almost exclusively in the opioid group. Conclusions: Denial of parental consent to epidural analgesia following the Nuss procedure results in significantly worse control of postoperative pain. Our data may be useful when discussing with parents the available anaesthetic techniques for exceptionally painful procedures.	[Knapik, Piotr] Med Univ Silesia, Silesian Ctr Heart Dis, Dept Cardiac Anaesthesia & Intens Therapy, PL-41800 Zabrze, Poland; [Walaszczyk, Malgorzata; Misiolek, Hanna] Med Univ Silesia, Univ Dept Anesthesiol & Intens Therapy, PL-41800 Zabrze, Poland; [Korlacki, Wojciech] Med Univ Silesia, Dept Paediat Surg, PL-41800 Zabrze, Poland	Knapik, P (reprint author), Med Univ Silesia, Silesian Ctr Heart Dis, Dept Cardiac Anaesthesia & Intens Therapy, Szpitalna 2 Str, PL-41800 Zabrze, Poland.	pknapik@sum.edu.pl		Knapik, Piotr/0000-0002-1058-1502			Bromage PR, 1978, EPIDURAL ANALGESIA; Brull R, 2007, REGION ANESTH PAIN M, V32, P7, DOI 10.1016/j.rapm.2006.07.005; Chadha Meenu, 2008, Middle East Journal of Anesthesiology, V19, P1255; Coupe N, 2005, PEDIATR ANESTH, V15, P220, DOI 10.1111/j.1460-9592.2005.01426.x; Dabbagh A, 2007, MED SCI MONITOR, V13, pCR464; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Domino KB, 2007, REGION ANESTH PAIN M, V32, P1, DOI 10.1016/j.rapm.2006.10.001; Franck LS, 2005, PATIENT EDUC COUNS, V59, P117, DOI 10.1016/j.pec.2004.11.002; Haller J A Jr, 2000, Chest Surg Clin N Am, V10, P227; Hansen TG, 2000, BRIT J ANAESTH, V85, P347, DOI 10.1093/bja/85.3.347; Inanoglu K, 2009, MED SCI MONITOR, V15, pCR539; Ivani G, 2002, PAEDIATR ANAESTH, V12, P383, DOI 10.1046/j.1460-9592.2002.00859.x; KOHRMAN A, 1995, PEDIATRICS, V95, P314; Lam MWC, 2008, J PEDIATR SURG, V43, P819, DOI 10.1016/j.jpedsurg.2007.12.020; Llewellyn N, 2007, PEDIATR ANESTH, V17, P520, DOI 10.1111/j.1460-9592.2007.02230.x; LONNQVIST PA, 1994, ACTA ANAESTH SCAND, V38, P346; Lonnqvist PA, 2009, PEDIATR ANESTH, V19, P958, DOI 10.1111/j.1460-9592.2009.03098.x; McBride WJ, 1996, J PEDIATR SURG, V31, P105, DOI 10.1016/S0022-3468(96)90329-2; McNeely JK, 1997, REGION ANESTH, V22, P16, DOI 10.1016/S1098-7339(06)80051-9; Miller KM, 1999, ANESTH ANALG, V88, P251, DOI 10.1097/00000539-199902000-00005; Molik KA, 2001, J PEDIATR SURG, V36, P324, DOI 10.1053/jpsu.2001.20707; Nagaso T, 2010, J THORAC CARDIOV SUR, V140, P39, DOI 10.1016/j.jtcvs.2009.12.027; Nuss D, 1998, J PEDIATR SURG, V33, P545, DOI 10.1016/S0022-3468(98)90314-1; Pilegaard HK, 2010, EUR J CARDIO-THORAC, V38, P208, DOI 10.1016/j.ejcts.2010.02.018; Protopapas AD, 2008, J CARDIOTHORAC SURG, V3, DOI 10.1186/1749-8090-3-40; SALOMAKI TE, 1993, ANESTHESIOLOGY, V79, P672; Taenzer AH, 2010, PEDIATR ANESTH, V20, P135, DOI 10.1111/j.1460-9592.2009.03226.x; TISO RL, 1993, REGION ANESTH, V18, P308; TORDA TA, 1995, BRIT J ANAESTH, V74, P35, DOI 10.1093/bja/74.1.35	29	11	13	0	5	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	NOV	2011	17	11					PH81	PH86		10.12659/MSM.882032			6	Medicine, Research & Experimental	Research & Experimental Medicine	861RH	WOS:000298036400004	22037752	Green Published			2020-06-30	J	Osinaike, B; Ogah, J				Osinaike, Babatunde; Ogah, Johnson			Anaesthesia for emergency Caesarean section in a patient with peripartum cardiomypathy	CARDIOVASCULAR JOURNAL OF AFRICA			English	Article						peripartum cardiomyopathy; combined spinal epidural anesthesia; Caesarean section	DILATED CARDIOMYOPATHY; EPIDURAL-ANESTHESIA; CARDIAC-FAILURE; HEART-FAILURE; MANAGEMENT; ECHOCARDIOGRAPHY; DEFINITION; PROGNOSIS; ZARIA	Peripartum cardiomyopathy (PPCM) is defined as the onset of acute heart failure without demonstrable cause in the last trimester of pregnancy or within the first six months after delivery. We report a case of PPCM (LVEF < 39%) in a 30-year-old housekeeper requiring emergency Caesarean section, who was successfully managed with combined spinal-epidural anesthesia, using low-dose fentanyl for the spinal anesthesia.	[Osinaike, Babatunde] Univ Ibadan, Dept Anesthesia, Coll Med, Ibadan, Nigeria; [Ogah, Johnson] Univ Coll Hosp, Dept Anesthesia, Ibadan, Nigeria	Osinaike, B (reprint author), Univ Ibadan, Dept Anesthesia, Coll Med, Ibadan, Nigeria.	drosinaike@yahoo.co.uk		Osinaike, Babatunde/0000-0002-5848-5018			Brar SS, 2007, AM J CARDIOL, V100, P302, DOI 10.1016/j.amjcard.2007.02.092; BREEN TW, 1991, CAN J ANAESTH, V38, P895, DOI 10.1007/BF03036969; Chan F, 1999, CAN J ANAESTH, V46, P1146, DOI 10.1007/BF03015524; Chapa JB, 2005, OBSTET GYNECOL, V105, P1303, DOI 10.1097/01.AOG.0000161382.30233.ba; Chee KH, 2009, INT J CLIN PRACT, V63, P722, DOI 10.1111/j.1742-1241.2007.01449.x; Danbauchi SS, 2002, TROP DOCT, V32, P24, DOI 10.1177/004947550203200112; DESAI D, 1995, TROP DOCT, V25, P118, DOI 10.1177/004947559502500310; Dob DP, 2006, INT J OBSTET ANESTH, V15, P137, DOI 10.1016/j.ijoa.2005.07.005; Domenech Asensi P, 2002, REV ESP ANESTESIOL R, V49, P156; Fett JD, 2005, MAYO CLIN PROC, V80, P1602, DOI 10.4065/80.12.1602; FILLMORE SJ, 1977, CIRCULATION, V56, P1058, DOI 10.1161/01.CIR.56.6.1058; GAMBLING DR, 1987, CAN J ANAESTH, V34, P505, DOI 10.1007/BF03014358; Heider A L, 1999, Obstet Gynecol Surv, V54, P526, DOI 10.1097/00006254-199908000-00023; Hibbard JU, 1999, OBSTET GYNECOL, V94, P311, DOI 10.1016/S0029-7844(99)00293-8; Indira K, 2007, INDIAN J ANAESTH, V51, P137; Isezuo SA, 2007, ETHNIC DIS, V17, P228; Kaufman I, 2003, CAN J ANAESTH, V50, P161, DOI 10.1007/BF03017850; LAMPERT MB, 1995, AM HEART J, V130, P860, DOI 10.1016/0002-8703(95)90089-6; McCarroll CP, 2001, BRIT J ANAESTH, V86, P135, DOI 10.1093/bja/86.1.135; Morrison WL, 1991, HOSP UPDATE, V17, P693; Peng T C, 2001, Acta Anaesthesiol Sin, V39, P47; SANDERSON JE, 1979, AM HEART J, V97, P613, DOI 10.1016/0002-8703(79)90189-3; SHARROCK NE, 1994, ANESTH ANALG, V79, P899; Shnaider R, 2001, CAN J ANAESTH, V48, P681, DOI 10.1007/BF03016203; Shrestha B R, 2006, Kathmandu Univ Med J (KUMJ), V4, P503; THORNHILL ML, 1994, OBSTET ANESTHESIA, P765; van Spaendonck-Zwarts KY, 2010, CIRCULATION, V121, P2169, DOI 10.1161/CIRCULATIONAHA.109.929646; VEILLE JC, 1984, AM J OBSTET GYNECOL, V148, P805, DOI 10.1016/0002-9378(84)90572-6; WEIS FR, 1975, OBSTET GYNECOL, V46, P211; 1980, [No title captured], V44, P672	30	3	4	0	0	CLINICS CARDIVE PUBL PTY LTD	DURBANVILLE	PO BOX 1013, DURBANVILLE, 7551, SOUTH AFRICA	1995-1892			CARDIOVASC J AFR	Cardiovasc. J. Afr.	NOV-DEC	2011	22	6					337	U126		10.5830/CVJA-2010-067			4	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	866GO	WOS:000298368700014	22159324				2020-06-30	J	Wang, X; Gorini, C; Sharp, D; Bateman, R; Mendelowitz, D				Wang, Xin; Gorini, Christopher; Sharp, Douglas; Bateman, Ryan; Mendelowitz, David			Anaesthetics differentially modulate the trigeminocardiac reflex excitatory synaptic pathway in the brainstem	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							PEDIATRIC STRABISMUS SURGERY; CARDIAC VAGAL NEURONS; OCULOCARDIAC REFLEX; DORSAL-HORN; ACTIVATION; RECEPTORS; KETAMINE; CHILDREN; NEUROTRANSMISSION; SEVOFLURANE	The trigeminocardiac reflex (TCR) occurs upon excitation of the trigeminal nerve with a resulting bradycardia and hypotension. While several anaesthetics and analgesics have been reported to alter the incidence and strength of the TCR the mechanisms for this modulation are unclear. This study examines the mechanisms of action of ketamine, isoflurane and fentanyl on the synaptic TCR responses in both neurones in the spinal trigeminal interpolaris (Sp5I) nucleus and cardiac vagal neurones (CVNs) in the Nucleus Ambiguus (NA). Stimulation of trigeminal afferent fibres evoked an excitatory postsynaptic current (EPSC) in trigeminal neurones with a latency of 1.8 +/- 0.1 ms, jitter of 625 mu s, and peak amplitude of 239 +/- 45 pA. Synaptic responses further downstream in the reflex pathway in the CVNs occurred with a latency of 12.1 +/- 1.1 ms, jitter of 0.8-2 ms and amplitude of 57.8 +/- 7.5 pA. The average conduction velocity to the Sp5I neurones was 0.94 +/- 0.18 mm ms(-1) indicating a mixture of A-delta and C fibres. Stimulation-evoked EPSCs in both Sp5I and CVNs were completely blocked by AMPA/kainate and NMDA glutamatergic receptor antagonists. Ketamine (10 mu M) inhibited the peak amplitude and duration in Sp5I as well as more distal synapses in the CVNs. Isoflurane (300 mu M) significantly inhibited, while fentanyl (1 mu M) significantly enhanced, EPSC amplitude and area in CVNs but had no effect on the responses in Sp5l neurones. These findings indicate glutamatergic excitatory synaptic pathways are critical in the TCR, and ketamine, isoflurane and fentanyl differentially alter the synaptic pathways via modulation of both AMPA/kainate and NMDA receptors at different synapses in the TCR.	[Mendelowitz, David] George Washington Univ, Dept Physiol & Pharmacol, Washington, DC 20037 USA; George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA	Mendelowitz, D (reprint author), George Washington Univ, Dept Physiol & Pharmacol, 2300 Eye St NW, Washington, DC 20037 USA.	dmendel@gwu.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1S10RR025565-01, S10 RR025565]; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL059895, R01 HL049965, R01 HL072006, HL 49965, HL72006, HL59895]		Allison CE, 2000, ANESTH ANALG, V90, P306, DOI 10.1097/00000539-200002000-00012; Arnold Robert W, 2004, Binocul Vis Strabismus Q, V19, P215; Avendano C, 2005, J COMP NEUROL, V493, P538, DOI 10.1002/cne.20778; BARNARD NA, 1990, J CRANIO MAXILL SURG, V18, P359, DOI 10.1016/S1010-5182(05)80056-3; Choi SH, 2007, ACTA ANAESTH SCAND, V51, P759, DOI 10.1111/j.1399-6576.2007.01329.x; CHRISTIAN EP, 1993, J NEUROSCI METH, V47, P147, DOI 10.1016/0165-0270(93)90031-L; Chung CJ, 2008, ACTA ANAESTH SCAND, V52, P1273, DOI 10.1111/j.1399-6576.2008.01745.x; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Ghai B, 2009, ANESTH ANALG, V108, P1132, DOI 10.1213/ane.0b013e318198a3fd; Gorini C, 2010, J NEUROPHYSIOL, V104, P1841, DOI 10.1152/jn.00442.2010; Gorini C, 2009, J NEUROPHYSIOL, V102, P1443, DOI 10.1152/jn.00287.2009; Hahnenkamp K, 2000, PAEDIATR ANAESTH, V10, P601, DOI 10.1046/j.1460-9592.2000.00588.x; Hollmann MW, 2001, ANESTH ANALG, V92, P1182; HUANG LYM, 1989, J PHYSIOL-LONDON, V411, P161, DOI 10.1113/jphysiol.1989.sp017566; KUMADA M, 1978, AM J PHYSIOL, V234, pH67; KUMADA M, 1977, BRAIN RES, V119, P305, DOI 10.1016/0006-8993(77)90313-4; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; MCCULLOCH PF, 1995, AM J PHYSIOL-REG I, V269, pR669; McCulloch PF, 2005, BRAIN RES, V1051, P194, DOI 10.1016/j.brainres.2005.05.059; McCulloch PF, 1997, NEUROSCIENCE, V78, P913, DOI 10.1016/S0306-4522(96)00633-1; MENDELOWITZ D, 1991, NEUROSCI LETT, V132, P217, DOI 10.1016/0304-3940(91)90305-D; Oh AY, 2007, BRIT J ANAESTH, V99, P262, DOI 10.1093/bja/aem145; Orser BA, 1997, ANESTHESIOLOGY, V86, P903, DOI 10.1097/00000542-199704000-00021; Schaller B, 1999, J NEUROSURG, V90, P215, DOI 10.3171/jns.1999.90.2.0215; Schaller B, 2005, J NEUROSURG ANESTH, V17, P45; Schaller B, 2004, J NEUROL, V251, P658, DOI 10.1007/s00415-004-0458-4; Schaller BJ, 2006, OPHTHALMOLOGICA, V220, P348, DOI 10.1159/000094629; VIANA F, 1990, NEUROSCIENCE, V38, P829, DOI 10.1016/0306-4522(90)90075-F; Wang JJ, 2002, NEUROSCI LETT, V332, P195, DOI 10.1016/S0304-3940(02)00957-6; Wang X, 2009, ANESTH ANALG, V108, P134, DOI 10.1213/ane.0b013e31818f871c	30	13	13	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	NOV	2011	589	22					5431	5442		10.1113/jphysiol.2011.215392			12	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	853IX	WOS:000297420500014	21930602	Green Published			2020-06-30	J	Bawden, J; Villa-Roel, C; Singh, M; Fabris, G; Bond, K; Boyko, D; Anstett, D; Fassbender, K; Rowe, BH				Bawden, Jaime; Villa-Roel, Cristina; Singh, Mira; Fabris, Gregg; Bond, Ken; Boyko, Debbie; Anstett, Danielle; Fassbender, Konrad; Rowe, Brian H.			Procedural sedation and analgesia in a Canadian ED: a time-in-motion study	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Scientific Meeting of Canadian-Association-of-Emergency-Physicians	MAY 29-JUN 02, 2010	Montreal, CANADA	Canadian Assoc Emergency Phys			RANDOMIZED CLINICAL-TRIAL; EMERGENCY-DEPARTMENT; PROPOFOL; MIDAZOLAM; PHYSICIAN; ETOMIDATE; SAFETY	Introduction: Some patients presenting to emergency departments (EDs) suffer from conditions requiring potentially painful treatment; procedural sedation and analgesia (PSA) are important components of their management. The purpose of this study was to determine the resources used during the administration of PSA. Methods: This prospective observational study was conducted in a Canadian urban teaching center. Detailed data concerning the dosage of PSA medications, adverse events, and ED times for patients requiring PSA for treatment of fractures, reductions of joint dislocations, and cardioversion for atrial fibrillation were collected. Descriptive analyses included proportions, means with standard deviations, and medians with interquartile ranges. Results: Of the 177 PSA cases considered for analysis, 69.5% were orthopedic manipulations and 30.5% were cardioversions. Propofol alone or combined with fentanyl was the commonest medication, and 27 minor adverse events were documented. The median number of staff used in each PSA was 4 (4, 4). The median time from triage to the start of the procedure was 175 minutes (98, 259). The median time from the end of monitoring to discharge was 186 minutes (104, 316). The median time from the start of PSA administration to the end of patient monitoring was 12 minutes for fractures/dislocations and 7 minutes for cardioversion. The total ED length of stay was 6.6 hours. Conclusion: Procedural sedation and analgesia are potentially time-consuming interventions requiring the coordination of ED staff; delays in procedures represent opportunities to reduce ED overcrowding. Procedural sedation and analgesia guidelines may assist with standardization. (C) 2011 Elsevier Inc. All rights reserved.	[Bawden, Jaime; Villa-Roel, Cristina; Singh, Mira; Boyko, Debbie; Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Edmonton, AB T6G 2B7, Canada; [Bawden, Jaime; Anstett, Danielle] Natl Univ Ireland Galway, Fac Med, Galway, Ireland; [Fabris, Gregg] Dalhousie Univ, Dept Econ, Halifax, NS, Canada; [Bond, Ken] Univ Alberta, Dept Pediat, Edmonton, AB T6G 2B7, Canada; [Fassbender, Konrad] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2B7, Canada; [Rowe, Brian H.] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2B7, Canada	Rowe, BH (reprint author), Univ Alberta, Dept Emergency Med, Edmonton, AB T6G 2B7, Canada.	brian.rowe@ualberta.ca					[Anonymous], 2008, ADV DIS SURVEILLANCE, V6, P1, DOI DOI 10.2903/j.efsa.2008.754; BOND K, 2008, 109 CAN AG DRUGS TEC; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; Campbell Sam G, 2006, CJEM, V8, P85; Canadian Agency for Drugs and Technologies in Health, 2006, GUID EC EV HLTH TECH; Canadian Institute for Health Information, 2007, UND EM DEP WAIT TIM; Hendey GW, 2000, ANN EMERG MED, V36, P108, DOI 10.1067/mem.2000.108314; Hogan K, 2006, EMERG MED J, V23, P922, DOI 10.1136/emj.2006.040956; Hohl CM, 2008, ACAD EMERG MED, V15, P32, DOI 10.1111/j.1553-2712.2007.00023.x; Holger JS, 2005, AM J EMERG MED, V23, P248, DOI 10.1016/j.ajem.2005.01.001; Holroyd BR, 2007, ACAD EMERG MED, V14, P702, DOI 10.1197/j.aem.2007.04.018; Innes G, 1999, J EMERG MED, V17, P145, DOI 10.1016/S0736-4679(98)00135-8; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; Messenger DW, 2008, ACAD EMERG MED, V15, P877, DOI 10.1111/j.1553-2712.2008.00219.x; Miner JR, 2007, ANN EMERG MED, V49, P15, DOI 10.1016/j.annemergmed.2006.06.042; Sacchetti A, 2007, ACAD EMERG MED, V14, P41, DOI 10.1197/j.aem.2006.05.023; Sakland M, 1941, ANESTHESIOLOGY, V2, P281, DOI DOI 10.1097/00000542-194105000-00004; Swann A, 2007, EMERG MED J, V24, P322, DOI 10.1136/emj.2006.040923; Willman EV, 2007, ANN EMERG MED, V49, P23, DOI 10.1016/j.annemergmed.2006.08.002; Zed PJ, 2007, CAN J EMERG MED, V9, P421; 2010, AM SOC ANESTHESIOL	21	10	10	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	NOV	2011	29	9					1083	1088		10.1016/j.ajem.2010.06.036			6	Emergency Medicine	Emergency Medicine	851OP	WOS:000297280800019	20947278				2020-06-30	J	Goldmann, K; Kuhlmann, S; Gerlach, M; Borntrager, C				Goldmann, K.; Kuhlmann, S.; Gerlach, M.; Borntraeger, C.			Removal of the laryngeal mask airway in the post-anesthesia care unit. A means of process optimization?	ANAESTHESIST			German	Article						Anesthesia; general; Postoperative Care; Safety; Economics; Prospective studies	TRACHEAL EXTUBATION; SCORING SYSTEM; ADULT PATIENTS; ANESTHESIA; EFFICACY; SAFETY; RECOVERY	Removal of the laryngeal mask airway in the post-anesthesia care unit could potentially contribute to a faster turnover from one operation to the next. The aim of this study was, therefore, to obtain an insight into the potential time saving and the safety of planned removal of the ProSeal (TM)-LMA (PLMA) in the post-anesthesia care unit. In this study 120 adult patients with American Society of Anesthesiologists (ASA) classification I-II, age range 18-85 years, undergoing a surgical procedure under general anesthesia in which the PLMA was used were randomly assigned to one of two groups. In group I, the PLMA was removed in the awake patient in the operating room close to the end of the procedure. In group II, the anesthetised but spontaneously breathing patients were moved to the recovery room and the PLMA removed when the patient was awake. The anesthesia technique was standardized [balanced, sevoflurane, fentanyl, bispectral index-guided (BIS) target value=35 +/- 5] and identical in both groups until randomization. Patients were breathing room air during transport to the recovery room. Different time intervals as well as the incidence of critical incidents were compared between groups. An oxygen saturation (S(p)O(2)) value < 95% was considered a clinically relevant and S(p)O(2) values < 90% as clinically critical O(2)-desaturation. Removal of the PLMA took place after an average of 4.9 +/- 5.1 min in group I and after 19.5 +/- 9.6 min in group II. There was no difference in the availability of the anesthetist in the operating room for the following procedure between groups (group I: 12 +/- 5.6 min vs. group II: 10.7 +/- 4.2 min, p > 0.05) despite the fact that patients of group II left the operating room faster (4.9 +/- 3.9 min) than patients of group I (7.1 +/- 5.1 min, p < 0.01). In group II patients were ready for discharge (White score=12) from the recovery room later (13.2 +/- 8.2 min) than in group I (3.6 +/- 4.8 min, p < 0.01). There were no significant differences in other process related time intervals between group I and group II: duration of the operation (113.2 +/- 45.9 min vs. 105.3 +/- 42.6 min), duration of dressing (5.1 +/- 3.7 min vs. 4.6 +/- 2.8 min), duration of transport to the recovery room (3.9 +/- 1.3 min vs. 3.6 +/- 1.3 min) and information at end of surgery by the surgeon (22.5 +/- 9.3 min vs. 22.4 +/- 10.5 min). The incidence of clinically relevant as well as clinically critical O(2) desaturation at the time of recovery room arrival (S(p)O(2) a parts per thousand currency signaEuro parts per thousand 90%) was increased in group II with 33.3% vs. 56.6% and 13.3% vs. 6.7%, p < 0.01, respectively. Planned PLMA removal in the recovery room after BIS-guided balanced anesthesia did not enable the anesthetist to be available earlier for induction of anesthesia in the following patient. Hence the anesthetist could not contribute to a faster turnover of cases. Obviously, with the type of close communication between surgeon and anesthetist dictated by the study protocol (announcement of expected end of surgery by the surgeon 20 min before end of surgery) it is possible for the patient to regain consciousness within a very small time window following the end of surgery. Following this kind of protocol, postponement of removal of the LMA in the recovery room does not seem to be attractive neither from a clinical nor an economic point of view. In contrast, removal of LMA in the recovery room should be restricted to occasional cases with an abrupt end of the operation or prolonged emergence from anesthesia. The obvious risk of hypoxemia necessitates continuous O(2) application and S(p)O(2) monitoring during transport to the recovery room.	[Goldmann, K.] Dubai Hlth Author, Dept Anaesthesia, Dubai Hosp, Dubai 7272, U Arab Emirates; [Goldmann, K.; Kuhlmann, S.; Gerlach, M.; Borntraeger, C.] Univ Klinikum Giessen Marburg, Klin Anasthesie & Intens Therapie, Marburg, Germany	Goldmann, K (reprint author), Dubai Hlth Author, Dept Anaesthesia, Dubai Hosp, Dubai 7272, U Arab Emirates.	kgoldmann@dha.gov.ae					Brain AIJ, 2000, BRIT J ANAESTH, V84, P650, DOI 10.1093/bja/84.5.650; BRIMACOMBE J, 1993, ANESTH ANALG, V76, P457; BRIMACOMBE JR, 2005, LARYNGEAL MASK ANEST, pS265; Dob DP, 1999, CAN J ANAESTH, V46, P179, DOI 10.1007/BF03012554; GATAURE PS, 1995, CAN J ANAESTH, V42, P1113, DOI 10.1007/BF03015098; Goldmann K, 2005, ANASTH INTENSIV NOTF, V40, P469, DOI 10.1055/s-2005-870105; Goldmann K, 2011, ANAESTHESIST, V60, P729, DOI 10.1007/s00101-011-1875-2; Goldmann K, 2008, ANESTH ANALG, V107, P1856, DOI 10.1213/ane.0b013e318189ac84; Keller C, 1999, BRIT J ANAESTH, V82, P286, DOI 10.1093/bja/82.2.286; Koga K, 1998, ANAESTHESIA, V53, P540, DOI 10.1046/j.1365-2044.1998.00397.x; Leslie K, 2005, ANAESTH INTENS CARE, V33, P443, DOI 10.1177/0310057X0503300404; LopezGil M, 1996, ANAESTHESIA, V51, P969, DOI 10.1111/j.1365-2044.1996.tb14968.x; Pavlin JD, 2005, ANESTHESIOLOGY, V102, P566, DOI 10.1097/00000542-200503000-00015; Punjasawadwong Y, 2007, COCHRANE DB SYST REV, V17, P4; Verghese C, 1996, ANESTH ANALG, V82, P129, DOI 10.1097/00000539-199601000-00023; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018	16	1	1	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	NOV	2011	60	11					1002	1008		10.1007/s00101-011-1936-6			7	Anesthesiology	Anesthesiology	852NM	WOS:000297364700004	21881929				2020-06-30	J	Ogilvie, MP; Pereira, BMT; Ryan, ML; Gomez-Rodriguez, JC; Pierre, EJ; Livingstone, AS; Proctor, KG				Ogilvie, Michael P.; Pereira, Bruno M. T.; Ryan, Mark L.; Gomez-Rodriguez, Juan Carlos; Pierre, Edgar J.; Livingstone, Alan S.; Proctor, Kenneth G.			Bispectral Index to Monitor Propofol Sedation in Trauma Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Electroencephalography; Electromyography; Heart rate variability; Fentanyl; Midazolam	INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; DEXMEDETOMIDINE/REMIFENTANIL; MIDAZOLAM/REMIFENTANIL; ELECTROENCEPHALOGRAM; ISOFLURANE; POTENTIALS; MIDAZOLAM; DEPTH; EEG	Background: This study tested the hypothesis that the bispectral index (BIS) is reliable relative to clinical judgment for estimating sedation level during daily propofol spontaneous awakening trials (SATs) in trauma patients. Methods: This was a prospective observational trial with waiver of consent conducted in the intensive care unit of Level I trauma center in 94 mechanically ventilated trauma patients sedated with propofol alone or in combination with midazolam. BIS, Richmond Agitation Sedation Scale (RASS), electromyography, and heart rate variability, as a test of autonomic function, were measured for 45 minutes during daily SATs. Data were evaluated with analysis of variance, linear regression, and nonparametric tests. Results: The BIS wave form coincided almost exactly with propofol on/off. Steady-state BIS correlated with RASS (p < 0.0001) and with propofol dose (p < 0.0001), but the strengths of association were relatively low (all r(2) < 0.5). BIS wave form was not altered by age, heart rate, or heart rate variability and was similar with propofol alone or propofol plus midazolam, but the presence of brain injury or the use of paralytics shifted the curve downward (both p < 0.001). The overall test characteristics for BIS versus RASS without neuromuscular blockade were sensitivity: 90% versus 77% (p = 0.034); specificity: 90% versus 75% (p = 0.021); positive predictive value: 90% versus 76% (p = 0.021), and negative predictive value: 90% versus 76% (p = 0.021). Conclusions: In the first trial in trauma patients and largest trial in any surgical population, the (1) BIS was reliable and has advantages over RASS of being continuous and objective, at least during a propofol SAT; (2) BIS interpretation remains somewhat subjective in patients receiving paralytic agents or with traumatic brain injury.	Univ Miami, Miller Sch Med, Daughtry Family Dept Surg, Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Daughtry Family Dept Surg, Div Surg Crit Care, Miami, FL 33136 USA	Proctor, KG (reprint author), Univ Miami, Miller Sch Med, Dept Surg & Anesthesiol, Ryder Trauma Ctr, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Pereira, Bruno M/D-4542-2015; Livingstone, Alan/AAA-4026-2019	Pereira, Bruno M/0000-0003-3763-1749; 	Office of Naval ResearchOffice of Naval Research [N140610670]	Supported, in part, by Grant no. N140610670 from the Office of Naval Research.	Arbour R, 2009, HEART LUNG, V38, P336, DOI 10.1016/j.hrtlng.2008.10.010; Consales G, 2006, MINERVA ANESTESIOL, V72, P329; Consales G, 2007, MINERVA ANESTESIOL, V73, P609; Cooke SE, 2002, AM J HEALTH-SYST PH, V59, P150; Ely EW, 2004, INTENS CARE MED, V30, P1537, DOI 10.1007/s00134-004-2298-1; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Haenggi M, 2006, ANESTH ANALG, V103, P1163, DOI 10.1213/01.ane.0000237394.21087.85; Haenggi M, 2009, ANESTH ANALG, V109, P807, DOI 10.1213/ane.0b013e3181acc85d; Haenggi M, 2009, CRIT CARE, V13, DOI 10.1186/cc7723; Hernandez-Gancedo Carmen, 2007, J Clin Monit Comput, V21, P295, DOI 10.1007/s10877-007-9087-7; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; King DR, 2009, J TRAUMA, V67, P436, DOI 10.1097/TA.0b013e3181ad67de; LeBlanc JM, 2006, ANN PHARMACOTHER, V40, P490, DOI 10.1345/aph.1E491; Lu CH, 2008, ANESTH ANALG, V107, P1290, DOI 10.1213/ane.0b013e31818061ae; MARINO PL, 2006, ICU BOOK; McKeage K, 2003, CNS DRUGS, V17, P235, DOI 10.2165/00023210-200317040-00003; Mondello Epifanio, 2002, J Clin Monit Comput, V17, P271, DOI 10.1023/A:1021250320103; Nasraway  SA, 2002, AM J HEALTH-SYST PH, V59, P147, DOI 10.1093/ajhp/59.2.147; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Riker RR, 2003, PHARMACOTHERAPY, V23, P1087, DOI 10.1592/phco.23.10.1087.32766; Roustan JP, 2005, ANESTH ANALG, V101, P1141, DOI 10.1213/01.ane.0000167782.47957.e1; Sackey PV, 2007, ANAESTH INTENS CARE, V35, P348, DOI 10.1177/0310057X0703500305; Sackey PV, 2008, CRIT CARE, V12, DOI 10.1186/cc7029; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Tonner PH, 2005, CRIT CARE MED, V33, P580, DOI 10.1097/01.ccm.0000156291.04287.7F; Trope RM, 2005, CHEST, V128, P303, DOI 10.1378/chest.128.1.303; Tukenmez Baris, 2008, J Opioid Manag, V4, P34; Weatherburn C, 2007, ANAESTH INTENS CARE, V35, P204, DOI 10.1177/0310057X0703500208	28	16	17	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1415	1421		10.1097/TA.0b013e3182178b8b			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600062	21768900				2020-06-30	J	Amann, M; Blain, GM; Proctor, LT; Sebranek, JJ; Pegelow, DF; Dempsey, JA				Amann, Markus; Blain, Gregory M.; Proctor, Lester T.; Sebranek, Joshua J.; Pegelow, David F.; Dempsey, Jerome A.			Implications of group III and IV muscle afferents for high-intensity endurance exercise performance in humans	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							CENTRAL MOTOR DRIVE; HEALTHY HUMANS; VOLUNTARY CONTRACTIONS; ARTERIAL OXYGENATION; SUPRASPINAL FACTORS; PERIPHERAL FATIGUE; LOCOMOTOR MUSCLES; RHYTHMIC EXERCISE; ACUTE HYPERCAPNIA; DYNAMIC EXERCISE	We investigated the influence of group III/IV muscle afferents on peripheral fatigue, central motor drive (CMD) and endurance capacity during high-intensity leg-cycling. In a double-blind, placebo-controlled design, seven males performed constant-load cycling exercise (318 +/- 9W; 80% of peak power output (W-peak)) to exhaustion under placebo conditions and with lumbar intrathecal fentanyl impairing spinal mu-opioid receptor-sensitive group III/IV muscle afferents. Peripheral fatigue was assessed via changes in pre- vs. post-exercise quadriceps force in response to supramaximal magnetic femoral nerve stimulation (Delta Q(tw,pot)). CMD was estimated via quadriceps electromyogram. To rule out a direct central effect of fentanyl, we documented unchanged resting cardioventilatory responses. Compared to placebo, significant hypoventilation during the fentanyl trial was indicated by the 9% lower (V) over dot(E)/(V) over dot(CO2), causing a 5 mmHg increase in end-tidal P-CO2 and a 3% lower haemoglobin saturation. Arterial pressure and heart rate averaged 8 and 10% lower, respectively, during the fentanyl trial and these differences progressively diminished towards end-exercise. Although initially similar, the percent change in CMD was 9 +/- 3% higher at end-exercise with fentanyl vs. placebo (P < 0.05). Time to exhaustion was shorter (6.8 +/- 0.3 min vs. 8.7 +/- 0.3 min) and end-exercise Delta Q(tw,pot) was about one-third greater (-44 +/- 2% vs. -34 +/- 2%) following fentanyl vs. placebo. The rate of peripheral fatigue development was 67 +/- 10% greater during the fentanyl trial (P < 0.01). Our findings suggest that feedback from group III/IV muscle afferents limits CMD but also minimizes locomotor muscle fatigue development by stimulating adequate ventilatory and circulatory responses to exercise. In the face of blocked group III/IV muscle afferents, CMD is less inhibited but O-2 transport compromised and locomotor muscle fatigability is exacerbated with a combined net effect of a reduced endurance performance.	[Amann, Markus] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Amann, Markus; Blain, Gregory M.; Pegelow, David F.; Dempsey, Jerome A.] Univ Wisconsin, John Rankin Lab Pulm Med, Madison, WI USA; [Proctor, Lester T.; Sebranek, Joshua J.] Univ Wisconsin, Dept Anaesthesiol, Madison, WI USA	Amann, M (reprint author), VA Med Ctr, 500 Foothill Dr,GRECC 182, Salt Lake City, UT 84148 USA.	markus.amann@hsc.utah.edu		Amann, Markus/0000-0002-4012-8880	US National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-15469, HL-103786-02]	We acknowledge Mr Anthony J. Jacques valuable assistance during the study. This work was supported by the US National Heart, Lung, and Blood Institute (HL-15469 and HL-103786-02).	Adreani CM, 1997, J APPL PHYSIOL, V82, P1811; Amann M, 2004, MED SCI SPORT EXER, V36, P613, DOI 10.1249/01.MSS.0000122076.21804.10; Amann M, 2008, J APPL PHYSIOL, V104, P861, DOI 10.1152/japplphysiol.01008.2007; Amann M, 2008, J PHYSIOL-LONDON, V586, P161, DOI 10.1113/jphysiol.2007.141838; Amann M, 2007, AM J PHYSIOL-REG I, V293, pR2036, DOI 10.1152/ajpregu.00442.2007; Amann M, 2006, J PHYSIOL-LONDON, V575, P937, DOI 10.1113/jphysiol.2006.113936; Amann M, 2006, J APPL PHYSIOL, V101, P119, DOI 10.1152/japplphysiol.01596.2005; Amann M, 2011, MED SCI SPORT EXER, V43, P2039, DOI 10.1249/MSS.0b013e31821f59ab; Amann M, 2011, J PHYSIOL-LONDON, V589, P3855, DOI 10.1113/jphysiol.2011.209353; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2010, J APPL PHYSIOL, V108, P452, DOI 10.1152/japplphysiol.00976.2009; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Amann M, 2008, J APPL PHYSIOL, V105, P1714, DOI 10.1152/japplphysiol.90456.2008; Babcock MA, 2002, J APPL PHYSIOL, V93, P201, DOI 10.1152/japplphysiol.00612.2001; Borg G, 1998, BORGS PERCEIVED EXER; Brooks JCW, 2005, NEUROIMAGE, V27, P201, DOI 10.1016/j.neuroimage.2005.03.041; Craig AD, 2003, ANNU REV NEUROSCI, V26, P1, DOI 10.1146/annurev.neuro.26.041002.131022; CRAIG AD, 1995, J COMP NEUROL, V361, P225, DOI 10.1002/cne.903610204; Dousset E, 2004, J NEUROSCI RES, V76, P734, DOI 10.1002/jnr.20110; EDWARDS RHT, 1977, J PHYSIOL-LONDON, V272, P769, DOI 10.1113/jphysiol.1977.sp012072; ENOKA RM, 1992, J APPL PHYSIOL, V72, P1631; Farina D, 2004, J APPL PHYSIOL, V96, P1486, DOI 10.1152/japplphysiol.01070.2003; Gagnon P, 2009, J APPL PHYSIOL, V107, P832, DOI 10.1152/japplphysiol.91546.2008; Gandevia SC, 2001, PHYSIOL REV, V81, P1725; Gandevia SC, 1996, J PHYSIOL-LONDON, V490, P529, DOI 10.1113/jphysiol.1996.sp021164; Hepple RT, 2002, CAN J APPL PHYSIOL, V27, P56, DOI 10.1139/h02-004; Hilty L, 2011, EXP PHYSIOL, V96, P505, DOI 10.1113/expphysiol.2010.056226; Hogan MC, 1999, J APPL PHYSIOL, V86, P1367; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; JOHNSON BD, 1993, J PHYSIOL-LONDON, V460, P385, DOI 10.1113/jphysiol.1993.sp019477; Katayama K, 2007, AM J PHYSIOL-REG I, V292, pR1279, DOI 10.1152/ajpregu.00554.2006; Kaufman MP, 2002, ADV EXP MED BIOL, V508, P25; KAUFMAN MP, 1996, HDB PHYSL EXERCISE R, V12, P381; Keenan KG, 2005, J APPL PHYSIOL, V98, P120, DOI 10.1152/japplphysiol.00894.2004; KNIFFKI KD, 1981, CIRC RES, V48, P25; Kufel TJ, 2002, MUSCLE NERVE, V25, P438, DOI 10.1002/mus.10047; Light AR, 2008, J NEUROPHYSIOL, V100, P1184, DOI 10.1152/jn.01344.2007; LIGHT AR, 2009, TRANSLATIONAL PAIN R, P251; Mador MJ, 1997, AM J RESP CRIT CARE, V155, P1590, DOI 10.1164/ajrccm.155.5.9154862; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; Petersen NT, 2003, J NEUROSCI, V23, P7974; PICKAR JG, 1994, J NEUROPHYSIOL, V71, P753; Polkey MI, 1996, MUSCLE NERVE, V19, P549, DOI 10.1002/(SICI)1097-4598(199605)19:5<549::AID-MUS1>3.0.CO;2-B; Romer LM, 2007, AM J PHYSIOL-REG I, V292, pR598, DOI 10.1152/ajpregu.00269.2006; Romer LM, 2006, J PHYSIOL-LONDON, V571, P425, DOI 10.1113/jphysiol.2005.099697; Strojnik V, 1998, J APPL PHYSIOL, V84, P344; Taylor JL, 2008, J APPL PHYSIOL, V104, P542, DOI 10.1152/japplphysiol.01053.2007; VIANNA LG, 1990, J APPL PHYSIOL, V69, P1486; Wilson LB, 2002, J NEUROPHYSIOL, V87, P1641, DOI 10.1152/jn.00609.2001; Wilson LB, 1997, BRAIN RES REV, V23, P196, DOI 10.1016/S0165-0173(96)00019-7	51	133	133	2	25	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	NOV	2011	589	21					5299	5309		10.1113/jphysiol.2011.213769			11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	839MA	WOS:000296369000024	21878520	Green Published			2020-06-30	J	Fan, YX; Ji, MH; Zang, L; Wang, WH; Yin, Q; Xu, J; Yang, JJ				Fan, Yunxia; Ji, Muhuo; Zang, Lina; Wang, Wenhui; Yin, Qi; Xu, Jian; Yang, Jianjun			Comparison of epidural tramadol-ropivacaine and fentanyl-ropivacaine for labor analgesia: A prospective randomized study	UPSALA JOURNAL OF MEDICAL SCIENCES			English	Article						Analgesia; epidural; fentanyl; labor; tramadol	POSTOPERATIVE PAIN; LEVOBUPIVACAINE; BUPIVACAINE	Background. To test the hypothesis that 5 mg/mL tramadol is superior to 3 mg/mL fentanyl when combined with 0.125% ropivacaine in parturients undergoing labor during epidural analgesia. Methods. Sixty-one parturients undergoing labor selected for delivery with epidural analgesia were randomized into two groups: Group tramadol (0.125% ropivacaine plus tramadol 5 mg/mL) and Group fentanyl (0.125% ropivacaine plus fentanyl 3 mu g/mL). Hemodynamics, rate of cesarean delivery, sensory block level, Bromage motor scale scores, instrument-assisted delivery, oxytocin use, visual analog scale (VAS) scores, Apgar scores, umbilical cord artery gas analysis, and maternal side-effects including nausea, vomiting, pruritus, urinary retention, shivering, hypotension, and respiratory depression were recorded. Results. The two groups had no significant differences with respect to maternal hemodynamics, neonatal heart rate, VAS scores, rate of cesarean delivery, sensory block level, Bromage motor scale scores, instrument-assisted delivery, oxytocin use, hypotension, nausea, vomiting, and respiratory depression (p > 0.05). The incidence of pruritus, shivering, and urinary retention were more commonly observed in Group fentanyl despite there was no significant difference between the two groups. Umbilical artery pH was significantly lower while PCO2 was higher in Group fentanyl than Group tramadol (p = 0.003 and p = 0.026, respectively). Birth-weight, umbilical artery PO2 and base deficit, and Apgar scores at 1 and 5 min were comparable between the two groups (p > 0.05). Conclusions. Our observations suggest that tramadol seems to be a safe alternative to fentanyl for labor analgesia due to its similar analgesic efficacy.	[Ji, Muhuo; Yang, Jianjun] Nanjing Univ, Dept Anaesthesiol, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China; [Fan, Yunxia; Zang, Lina; Wang, Wenhui; Yin, Qi; Xu, Jian] Jiangsu Univ, Jintan Hosp, Dept Anaesthesiol, Changzhou, Peoples R China	Yang, JJ (reprint author), Nanjing Univ, Dept Anaesthesiol, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	yjyangjj@126.com					Bromage PR, 1978, EPIDURAL ANALGESIA, P513; Casey BM, 2001, NEW ENGL J MED, V344, P467, DOI 10.1056/NEJM200102153440701; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Chan AMH, 1999, CAN J ANAESTH, V46, P253, DOI 10.1007/BF03012605; Gurses E, 2003, CAN J ANAESTH, V50, P147; Halpern SH, 2003, ANESTHESIOLOGY, V98, P1431, DOI 10.1097/00000542-200306000-00020; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Kee WDN, 2004, BRIT J ANAESTH, V92, P469, DOI 10.1093/bja/aeh088; Keskin HL, 2003, INT J GYNECOL OBSTET, V82, P11, DOI 10.1016/S0020-7292(03)00047-X; Lehmann KA, 1997, DRUGS, V53, P25, DOI 10.2165/00003495-199700532-00007; McNamara HM, 1999, OBSTET GYN CLIN N AM, V26, P671, DOI 10.1016/S0889-8545(05)70106-6; Porter J, 1998, ANESTHESIOLOGY, V89, P79, DOI 10.1097/00000542-199807000-00014; Ruban P, 2000, ANAESTH INTENS CARE, V28, P517, DOI 10.1177/0310057X0002800505; Siddik-Sayyid S, 1999, CAN J ANAESTH, V46, P731, DOI 10.1007/BF03013907; van de Velde M, 2007, ANESTHESIOLOGY, V106, P149, DOI 10.1097/00000542-200701000-00024; Wang JTC, 2010, CAN J ANAESTH, V57, P659, DOI 10.1007/s12630-010-9301-9; White CRH, 2010, AUST NZ J OBSTET GYN, V50, P318, DOI 10.1111/j.1479-828X.2010.01192.x; Yildiz TS, 2010, PEDIATR ANESTH, V20, P524, DOI 10.1111/j.1460-9592.2010.03296.x	18	6	7	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-9734	2000-1967		UPSALA J MED SCI	Ups. J. Med. Sci.	NOV	2011	116	4					252	257		10.3109/03009734.2011.601532			6	Medicine, General & Internal	General & Internal Medicine	845AB	WOS:000296794100005	22066973	DOAJ Gold, Green Published			2020-06-30	J	Mahmoud, S; Thorsell, A; Sommer, WH; Heilig, M; Holgate, JK; Bartlett, SE; Ruiz-Velasco, V				Mahmoud, Saifeldin; Thorsell, Annika; Sommer, Wolfgang H.; Heilig, Markus; Holgate, Joan K.; Bartlett, Selena E.; Ruiz-Velasco, Victor			Pharmacological Consequence of the A118G mu Opioid Receptor Polymorphism on Morphine- and Fentanyl-mediated Modulation of Ca2+ Channels in Humanized Mouse Sensory Neurons	ANESTHESIOLOGY			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISM; GENE POLYMORPHISM; PAIN; OPRM1; ANALGESIA; ASSOCIATION; ADDICTION; CONSUMPTION; VARIANT; DESENSITIZATION	Background: The most common functional single nucleotide polymorphism of the human OPRM1 gene, A118G, has been shown to be associated with interindividual differences in opioid analgesic requirements, particularly with morphine, in patients with acute postoperative pain. The purpose of this study was to examine whether this polymorphism would modulate the morphine and fentanyl pharmacological profile of sensory neurons isolated from a humanized mouse model homozygous for either the 118A or 118G allele. Methods: The coupling of wild-type and mutant mu opioid receptors to voltage-gated Ca2+ channels after exposure to either ligand was examined by employing the whole cell variant of the patch-clamp technique in acutely dissociated trigeminal ganglion neurons. Morphine-mediated antinociception was measured in mice carrying either the 118AA or 118GG allele. Results: The biophysical parameters (cell size, current density, and peak current amplitude potential) measured from both groups of sensory neurons were not significantly different. In 118GG neurons, morphine was approximately fivefold less potent and 26% less efficacious than that observed in 118AA neurons. On the other hand, the potency and efficacy of fentanyl were similar for both groups of neurons. Morphine-mediated analgesia in 118GG mice was significantly reduced compared with the 118AA mice. Conclusions: This study provides evidence to suggest that the diminished clinical effect observed with morphine in 118G carriers results from an alteration of the receptor's pharmacology in sensory neurons. In addition, the impaired analgesic response with morphine may explain why carriers of this receptor variant have an increased susceptibility to become addicted to opioids.	[Mahmoud, Saifeldin; Thorsell, Annika; Sommer, Wolfgang H.; Heilig, Markus; Holgate, Joan K.; Bartlett, Selena E.; Ruiz-Velasco, Victor] Penn State Coll Med, Dept Anesthesiol, Hershey, PA 17033 USA	Ruiz-Velasco, V (reprint author), Penn State Coll Med, Dept Anesthesiol, 500 Univ Dr, Hershey, PA 17033 USA.	vruizvelasco@psu.edu	Sommer, Wolfgang H./I-4809-2019; Thorsell, Annika/J-4188-2015	Sommer, Wolfgang H./0000-0002-5903-6521; Thorsell, Annika/0000-0003-3535-3845	National Institute of Arthritis and Musculoskeletal and Skin Diseases (Bethesda, Maryland)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [AR-059397]; National Institute on Alcohol Abuse and Alcoholism (Bethesda, Maryland)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases (Bethesda, Maryland) research grant AR-059397 and intramural National Institute on Alcohol Abuse and Alcoholism (Bethesda, Maryland) funds.	Arias A, 2006, DRUG ALCOHOL DEPEN, V83, P262, DOI 10.1016/j.drugalcdep.2005.11.024; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; BRADY LS, 1982, J PHARMACOL EXP THER, V222, P190; Chong RY, 2006, NEUROPSYCHOPHARMACOL, V31, P204, DOI 10.1038/sj.npp.1300856; Chou WY, 2006, ANESTHESIOLOGY, V105, P334, DOI 10.1097/00000542-200608000-00016; Compton P, 2003, AM J MED GENET B, V121B, P76, DOI 10.1002/ajmg.b.20057; Connor M, 2004, BRIT J PHARMACOL, V143, P685, DOI 10.1038/sj.bjp.0705938; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; He JQ, 2002, BIOCHEM BIOPH RES CO, V297, P565, DOI 10.1016/S0006-291X(02)02259-3; Hishimoto A, 2008, J NEURAL TRANSM, V115, P531, DOI 10.1007/s00702-007-0853-y; Huang J, 2008, ADDICT BIOL, V13, P88, DOI 10.1111/j.1369-1600.2007.00089.x; Janicki PK, 2006, ANESTH ANALG, V103, P1011, DOI 10.1213/01.ane.0000231634.20341.88; Klepstad P, 2005, ACTA ANAESTH SCAND, V49, P902, DOI 10.1111/j.1399-6576.2005.00772.x; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d; Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Lotsch J, 2005, TRENDS MOL MED, V11, P82, DOI 10.1016/j.molmed.2004.12.006; Mague SD, 2010, DRUG ALCOHOL DEPEN, V108, P172, DOI 10.1016/j.drugalcdep.2009.12.016; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; Margas W, 2007, J NEUROPHYSIOL, V97, P1058, DOI 10.1152/jn.01007.2006; Mayer P, 2006, PHARMACOGENET GENOM, V16, P1, DOI 10.1097/01.fpc.0000182781.87932.0d; Oertel BG, 2006, PHARMACOGENET GENOM, V16, P625, DOI 10.1097/01.fpc.0000220566.90466.a2; Oertel BG, 2009, J BIOL CHEM, V284, P6530, DOI 10.1074/jbc.M807030200; Ramchandani VA, 2011, MOL PSYCHIATR, V16, P809, DOI 10.1038/mp.2010.56; Ray LA, 2004, ALCOHOL CLIN EXP RES, V28, P1789, DOI 10.1097/01.ALC.0000148114.34000.B9; Shi JX, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9026; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Walter C, 2009, PAIN, V146, P270, DOI 10.1016/j.pain.2009.07.013; Wand GS, 2002, NEUROPSYCHOPHARMACOL, V26, P106, DOI 10.1016/S0893-133X(01)00294-9; Zamponi GW, 2009, BRAIN RES REV, V60, P84, DOI 10.1016/j.brainresrev.2008.12.021; Zhang W, 2010, ANAESTHESIA, V65, P130, DOI 10.1111/j.1365-2044.2009.06193.x; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200	36	41	44	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	NOV	2011	115	5					1054	1062		10.1097/ALN.0b013e318231fc11			9	Anesthesiology	Anesthesiology	842AR	WOS:000296558400021	21926562	Bronze, Green Accepted			2020-06-30	J	Hillyard, SG; Bate, TE; Corcoran, TB; Paech, MJ; O'Sullivan, G				Hillyard, S. G.; Bate, T. E.; Corcoran, T. B.; Paech, M. J.; O'Sullivan, G.			Extending epidural analgesia for emergency Caesarean section: a meta-analysis	BRITISH JOURNAL OF ANAESTHESIA			English	Article						Caesarean section; epidural anaesthesia; epidural analgesia	BUPIVACAINE 0.5-PERCENT; EXTRADURAL ANESTHESIA; LABOR ANALGESIA; TOP-UP; LEVOBUPIVACAINE; ROPIVACAINE; ADRENALINE; EXTENSION; BLOCKADE; FENTANYL	There is no high-level evidence supporting an optimal top-up solution to convert labour epidural analgesia to surgical anaesthesia for Caesarean section. The aim of this meta-analysis was to identify the best epidural solutions for emergency Caesarean section anaesthesia, with respect to rapid onset and low supplementation of intraoperative block. Eleven randomized controlled trials, involving 779 parturients, were identified for inclusion after a systematic literature search and risk of bias assessment. 'Top-up' boluses were classified into three groups: 0.5% bupivacaine or levobupivacaine (Bup/Levo); lidocaine and epinephrine, with or without fentanyl (LE +/- F); and 0.75% ropivacaine (Ropi). Pooled analysis using the fixed-effects method was used to calculate the mean difference (MD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes. Lidocaine and epinephrine, with or without fentanyl, resulted in a significantly faster onset of sensory block [MD -4.51 min, 95% confidence interval (CI) -5.89 to -3.13 min, P<0.00001]. Bup/Levo was associated with a significantly increased risk of intraoperative supplementation compared with the other groups (RR 2.03; 95% CI 1.22-3.39; P=0.007), especially compared with Ropi (RR 3.24, 95% CI 1.26-8.33, P=0.01). Adding fentanyl to a local anaesthetic resulted in a significantly faster onset but did not affect the need for intraoperative supplementation. Bupivacaine or levobupivacaine 0.5% was the least effective solution. If the speed of onset is important, then a lidocaine and epinephrine solution, with or without fentanyl, appears optimal. If the quality of epidural block is paramount, then 0.75% ropivacaine is suggested.	[Hillyard, S. G.; Corcoran, T. B.] Royal Perth Hosp, Dept Anaesthesia & Pain Med, Perth, WA 6847, Australia; [Hillyard, S. G.; Bate, T. E.; O'Sullivan, G.] Guys & St Thomas NHS Fdn Trust, Dept Anaesthesia, London SE1 7EH, England; [Corcoran, T. B.; Paech, M. J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Paech, M. J.] King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Perth, WA, Australia	Hillyard, SG (reprint author), Royal Perth Hosp, Dept Anaesthesia & Pain Med, Wellington St Campus,Box X2213 GPO, Perth, WA 6847, Australia.	sghillyard@yahoo.co.uk		PAECH, MICHAEL/0000-0001-9023-6575			Allam J, 2008, ANAESTHESIA, V63, P243, DOI 10.1111/j.1365-2044.2007.05342.x; Alves C, 2005, P ANN M EUR SOC REG, P29; Bader AM, 1999, ANESTHESIOLOGY, V90, P1596, DOI 10.1097/00000542-199906000-00015; Balaji P, 2009, INT J OBSTET ANESTH, V18, P335, DOI 10.1016/j.ijoa.2009.03.011; Bardsley H, 1997, Expert Opin Investig Drugs, V6, P1883, DOI 10.1517/13543784.6.12.1883; Benhamou D, 2003, ANESTHESIOLOGY, V99, P1383, DOI 10.1097/00000542-200312000-00022; Bolad N, 2005, P OBST AN ASS ANN M, pS33; Brau ME, 2000, ANESTH ANALG, V91, P1499; BROMAGE PR, 1964, BRIT J ANAESTH, V36, P342, DOI 10.1093/bja/36.6.342; Campbell DC, 2009, CAN J ANAESTH, V56, P19, DOI 10.1007/s12630-008-9004-7; CLARK V, 1994, BRIT J ANAESTH, V72, P221, DOI 10.1093/bja/72.2.221; Cole P, 2001, P OBST AN ASS ANN M, P215; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; Crosby E, 1998, CAN J ANAESTH, V45, P1066, DOI 10.1007/BF03012393; Curatolo M, 1998, ACTA ANAESTH SCAND, V42, P910, DOI 10.1111/j.1399-6576.1998.tb05349.x; DICKSON MAS, 1994, ANAESTHESIA, V49, P636; Eidelman LA, 2004, P AM SOC AN ANN M SA, pA; Gaiser R R, 1994, Int J Obstet Anesth, V3, P208, DOI 10.1016/0959-289X(94)90070-1; Gaiser RR, 1998, INT J OBSTET ANESTH, V7, P27, DOI 10.1016/S0959-289X(98)80025-3; Gilmour FJ, 2006, P ANN M OBST AN ASS, pS18; Goring-Morris J, 2006, INT J OBSTET ANESTH, V15, P109, DOI 10.1016/j.ijoa.2005.11.005; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hillyard SG, 2009, P OBST AN ASS ANN M; Hong JY, 2010, J KOREAN MED SCI, V25, P287, DOI 10.3346/jkms.2010.25.2.287; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Kampe S, 2004, CURR MED RES OPIN, V20, P7, DOI 10.1185/030079903125002649; Kinsella SM, 2008, ANAESTHESIA, V63, P822, DOI 10.1111/j.1365-2044.2008.05499.x; LAISHLEY RS, 1988, BRIT J ANAESTH, V60, P180, DOI 10.1093/bja/60.2.180; Lam DTC, 2001, ANAESTHESIA, V56, P790; Liu SS, 2009, CLIN ANESTH, P531; Lucas DN, 2000, BRIT J ANAESTH, V84, P494; Lucas DN, 1999, ANAESTHESIA, V54, P1173, DOI 10.1046/j.1365-2044.1999.01108.x; LUND PC, 1975, BRIT J ANAESTH, V47, P313; Lyons G, 1998, BRIT J ANAESTH, V81, P899; Malhotra S, 2007, ANAESTHESIA, V62, P667, DOI 10.1111/j.1365-2044.2007.05096.x; MANTEL N, 1959, J NATL CANCER I, V22, P719; McClure JH, 2011, BRIT J ANAESTH, V107, P127, DOI 10.1093/bja/aer192; MOGENSEN T, 1988, BRIT J ANAESTH, V60, P515, DOI 10.1093/bja/60.5.515; National Institute for Health and Clinical Excellence, CG 13 CAES SECT NICE; *NORD COCHR CTR, 2008, [No title captured]; NORTON AC, 1988, ANAESTHESIA, V43, P844; Polley LS, 2003, ANESTHESIOLOGY, V99, P1354, DOI 10.1097/00000542-200312000-00017; Price M L, 1991, Int J Obstet Anesth, V1, P13, DOI 10.1016/0959-289X(91)90024-K; Regan KJ, 2008, ANAESTHESIA, V63, P136, DOI 10.1111/j.1365-2044.2007.05319.x; Sanders RD, 2004, ANAESTHESIA, V59, P988, DOI 10.1111/j.1365-2044.2004.03753.x; Sng BL, 2008, ANAESTH INTENS CARE, V36, P659, DOI 10.1177/0310057X0803600505; Takahashi Y, 2010, P INT AN RES SOC ANN, pS; The NHS information centre for health and social care, TABL 14 NUMB CAES LE; Thomas J, 2004, BRIT MED J, V328, P665, DOI 10.1136/bmj.38031.775845.7C; Tortosa JC, 2003, BRIT J ANAESTH, V91, P532, DOI 10.1093/bja/aeg214; Yentis SM, 2006, INT J OBSTET ANESTH, V15, P2, DOI 10.1016/j.ijoa.2005.06.010; Yentis SM, 2003, INT J OBSTET ANESTH, V12, P246, DOI 10.1016/S0959-289X(03)00009-8	55	37	37	1	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	NOV	2011	107	5					668	678		10.1093/bja/aer300			11	Anesthesiology	Anesthesiology	834RN	WOS:000295981100004	21997149	Bronze			2020-06-30	J	Fant, F; Axelsson, K; Sandblom, D; Magnuson, A; Andersson, SO; Gupta, A				Fant, F.; Axelsson, K.; Sandblom, D.; Magnuson, A.; Andersson, S. -O.; Gupta, A.			Thoracic epidural analgesia or patient-controlled local analgesia for radical retropubic prostatectomy: a randomized, double-blind study	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics, local; analgesia, epidural; analgesia, patient-controlled; prostatectomy, retropubic	POSTOPERATIVE PAIN RELIEF; CONTROLLED INTRAVENOUS ANALGESIA; TOTAL KNEE ARTHROPLASTY; ABDOMINAL HYSTERECTOMY; INFILTRATION ANALGESIA; SURGERY; ANESTHESIA; PLACEBO; INTRAPERITONEAL; COMPLICATIONS	Background. Postoperative pain after radical retropubic prostatectomy is moderate to severe. The primary aim of this study was to assess whether intra-abdominal local anaesthetics provide similar analgesia compared with thoracic epidural analgesia (TEA). Methods. Fifty patients, ASA I-II, participated in this prospective, double-blinded study. All patients had TEA. After operation, they were randomized into two groups of 25 patients: Group PCLA (patient-controlled local analgesia): self-administration of 10 ml of ropivacaine 2 mg ml(-1) via the intra-abdominal catheter for 48 h. Group TEA: infusion of 10 ml h(-1) of ropivacaine 1 mg ml(-1), fentanyl 2 mu g ml(-1), and epinephrine 2 mu g ml (-1) epidurally for 48 h. The primary endpoint was pain on coughing at 4 h after operation. Rescue medication was morphine i.v. as required. Results. Pain on coughing at 4, 24, and 48 h was significantly lower in Group TEA [0 (0-10)] compared with Group PCLA [4 (0-10)] (P<0.05). Significantly lower pain intensity was also found in Group TEA compared with Group PCLA at the incision site, deep pain, and pain on coughing at 4 and 24 h (P<0.05). Morphine consumption was significantly greater in Group PCLA [12 (0-46)] compared with Group TEA [0 (0-20)] at 0-48 h after operation [median (range)] (P=0.015). Maximum expiratory pressure was higher in Group TEA compared with Group PCLA at 24 h (P<0.01). Conclusions. TEA provides superior postoperative pain relief with better preservation of expiratory muscle strength compared with PCLA.	[Fant, F.; Axelsson, K.; Gupta, A.] Orebro Univ, Dept Med, Div Anesthesiol & Intens Care, SE-70185 Orebro, Sweden; [Sandblom, D.; Andersson, S. -O.] Orebro Univ, Div Urol, SE-70185 Orebro, Sweden; [Magnuson, A.] Orebro Univ, Orebro Univ Hosp, Clin Epidemiol & Biostat Unit, SE-70185 Orebro, Sweden; [Gupta, A.] Linkoping Univ, Div Anesthesiol & Intens Care, Linkoping, Sweden	Fant, F (reprint author), Orebro Univ, Dept Med, Div Anesthesiol & Intens Care, SE-70185 Orebro, Sweden.	federica.fant@orebroll.se			Hospital Research Committee, Orebro County Council, Orebro, Sweden	This study was funded in part by the Hospital Research Committee, Orebro County Council, Orebro, Sweden.	Andersen LO, 2008, ACTA ANAESTH SCAND, V52, P1331, DOI 10.1111/j.1399-6576.2008.01777.x; Axelsson K, 2003, ACTA ANAESTH SCAND, V47, P993, DOI 10.1034/j.1399-6576.2003.00146.x; Bartha E, 2006, BRIT J ANAESTH, V96, P111, DOI 10.1093/bja/aei270; Beaussier M, 2007, ANESTHESIOLOGY, V107, P461, DOI 10.1097/01.anes.0000278903.91986.19; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Boddy AP, 2006, ANESTH ANALG, V103, P682, DOI 10.1213/01.ane.0000226268.06279.5a; Brennan Timothy J, 2005, Anesthesiol Clin North Am, V23, P1, DOI 10.1016/j.atc.2004.11.009; Cameron CM, 2007, ANESTHESIOLOGY, V106, P997, DOI 10.1097/01.anes.0000265160.32309.10; CHOW SC, 2007, SAMPLE SIZE CALCULAT, P57; Dahl JB, 2009, PAIN, V143, P7, DOI 10.1016/j.pain.2009.02.020; El-Sherbiny W, 2009, INT J GYNECOL OBSTET, V106, P213, DOI 10.1016/j.ijgo.2009.04.016; Essving P, 2010, ACTA ORTHOP, V81, P354, DOI 10.3109/17453674.2010.487241; Gupta A, 1993, Int J Obstet Anesth, V2, P129, DOI 10.1016/0959-289X(93)90004-2; Gupta A, 2004, ANESTH ANALG, V99, P1173, DOI 10.1213/01.ANE.0000130260.24433.A2; Gupta A, 2006, ANESTHESIOLOGY, V105, P784, DOI 10.1097/00000542-200610000-00025; Hanna MN, 2009, CURR OPIN ANESTHESIO, V22, P672, DOI 10.1097/ACO.0b013e32832f330a; Liu SS, 2006, J AM COLL SURGEONS, V203, P914, DOI 10.1016/j.jamcollsurg.2006.08.007; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Moiniche S, 1998, BRIT J ANAESTH, V81, P377, DOI 10.1093/bja/81.3.377; Ng A, 2002, ANESTH ANALG, V95, P158, DOI 10.1097/00000539-200207000-00028; Perniola A, 2009, EUR J ANAESTH, V26, P421, DOI 10.1097/EJA.0b013e3283261b53; Popping DM, 2008, ARCH SURG-CHICAGO, V143, P990, DOI 10.1001/archsurg.143.10.990; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Turunen P, 2009, SURG ENDOSC, V23, P31, DOI 10.1007/s00464-008-0100-0; WALSH PC, 1980, UROL CLIN N AM, V7, P583; WICKSTROM KE, 2006, BMC NURS, V5, P1; Wu CL, 2005, UROLOGY, V66, P366, DOI 10.1016/j.urology.2005.02.030; Zingg U, 2009, SURG ENDOSC, V23, P276, DOI 10.1007/s00464-008-9888-x	29	19	19	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	NOV	2011	107	5					782	789		10.1093/bja/aer296			8	Anesthesiology	Anesthesiology	834RN	WOS:000295981100019	21948951	Bronze			2020-06-30	J	Jung, HJ; Kim, JB; Im, KS; Cho, HJ; Kim, JW; Lee, JM				Jung, H. J.; Kim, J. B.; Im, K. S.; Cho, H. J.; Kim, J. W.; Lee, J. M.			Effects of a Priming Dose of Fentanyl during Anaesthesia on the Incidence and Severity of Fentanyl-induced Cough in Current, Former and Non-smokers	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						FENTANYL; PRIMING DOSE; FENTANYL-INDUCED COUGH; SMOKING	PROLONGED INJECTION TIME; INTRAVENOUS LIDOCAINE; REFLEX SENSITIVITY; SMOKING-CESSATION; BOLUS; PRETREATMENT; INDUCTION; SYMPTOMS; PROPOFOL; SMOKERS	Fentanyl is commonly used during anaesthesia and can cause fentanyl-induced cough (FTC). This study investigated whether a priming dose of fentanyl reduced FIC, and determined the factors associated with increased risk of FIC. Subjects undergoing elective surgery under general anaesthesia (n = 800) were randomized into four groups: group 1 received 2 mu g/kg fentanyl bolus; groups 2, 3 and 4 received a priming dose of fentanyl 0.5 mu g/kg followed by 1.5 mu g/kg after 1, 2 or 3 min, respectively. The incidence of FIC was 17.0%, 10.0%, 12.5% and 11.5% for groups 1, 2, 3 and 4, respectively, with no significant between-group differences in FTC incidence or severity. The mean FIC onset time was 22 s. Former smokers were 2.91 times more likely than current smokers to experience cough. A fentanyl priming dose did not reduce the incidence and severity of FTC. Former smokers were hyper-reactive to fentanyl compared with current smokers.	[Jung, H. J.; Kim, J. B.; Im, K. S.; Kim, J. W.; Lee, J. M.] Catholic Univ Korea, Dept Anaesthesiol & Pain Med, Uijeongbu St Marys Hosp, Coll Med, Seoul 480130, South Korea; [Cho, H. J.] Catholic Univ Korea, Dept Trauma Surg, Uijeongbu St Marys Hosp, Coll Med, Seoul 480130, South Korea	Lee, JM (reprint author), Catholic Univ Korea, Dept Anaesthesiol & Pain Med, Uijeongbu St Marys Hosp, Coll Med, 65-1 Geumo Dong, Seoul 480130, South Korea.	jaemng@catholic.ac.kr					Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; CUMMINGS KM, 1985, ADDICT BEHAV, V10, P373, DOI 10.1016/0306-4603(85)90034-6; Dicpinigaitis PV, 2006, EUR RESPIR J, V28, P786, DOI 10.1183/09031936.06.00007806; Dicpinigaitis PV, 2003, CHEST, V123, P685, DOI 10.1378/chest.123.3.685; Elcock DH, 2010, ANAESTHESIA, V65, P536, DOI 10.1111/j.1365-2044.2010.06321.x; Horng HC, 2007, ACTA ANAESTH SCAND, V51, P862, DOI 10.1111/j.1399-6576.2007.01335.x; Hung KC, 2010, ANAESTHESIA, V65, P4, DOI 10.1111/j.1365-2044.2009.06109.x; Hung KC, 2009, ACTA ANAESTH SCAND, V53, P1227, DOI 10.1111/j.1399-6576.2009.02058.x; Lee LY, 2010, LUNG, V188, pS23, DOI 10.1007/s00408-009-9191-1; Lin CS, 2004, CAN J ANAESTH, V51, P654, DOI 10.1007/BF03018421; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Lin JA, 2007, J FORMOS MED ASSOC, V106, P649, DOI 10.1016/S0929-6646(08)60022-4; Lui PW, 1996, CAN J ANAESTH, V43, P1216; Millqvist E, 2001, RESP MED, V95, P19, DOI 10.1053/rmed.2000.0965; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; Oshima T, 2006, CAN J ANAESTH, V53, P753, DOI 10.1007/BF03022790; Pandey CK, 2005, CAN J ANAESTH, V52, P172, DOI 10.1007/BF03027724; Pandey CK, 2004, ANESTH ANALG, V99, P1696, DOI 10.1213/01.ANE.0000136967.82197.82; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Schlimp CJ, 2005, CAN J ANAESTH, V52, P207, DOI 10.1007/BF03027731; Sitkauskiene B, 2007, PULM PHARMACOL THER, V20, P240, DOI 10.1016/j.pupt.2006.08.005; Sitkauskiene B, 2010, LUNG, V188, pS29, DOI 10.1007/s00408-009-9188-9; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Tweed WA, 2001, ANESTH ANALG, V92, P1442; Uvelin A, 2009, ACTA ANAESTH SCAND, V53, P1228, DOI 10.1111/j.1399-6576.2009.02041.x; Willemse BWM, 2004, EUR RESPIR J, V23, P464, DOI 10.1183/09031936.04.00012704; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	32	5	6	0	2	FIELD HOUSE PUBLISHING LLP	WORTHING	6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND	0300-0605			J INT MED RES	J. Int. Med. Res.	NOV-DEC	2011	39	6					2379	2384		10.1177/147323001103900638			6	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	887HC	WOS:000299916500038	22289557				2020-06-30	J	Park, YH; Kang, H; Woo, YC; Park, SG; Baek, CW; Jung, YH; Kim, JY; Koo, GH; Kim, SD; Park, JS				Park, Yong Hee; Kang, Hyun; Woo, Young Cheol; Park, Sun Gyoo; Baek, Chong Wha; Jung, Yong Hun; Kim, Jin Yun; Koo, Gill Hoi; Kim, Seong Deok; Park, Jun Seok			The Effect of Intraperitoneal Ropivacaine on Pain after Laparoscopic Colectomy: A Prospective Randomized Controlled Trial	JOURNAL OF SURGICAL RESEARCH			English	Article						intraperitoneal local anesthesia; laparoscopic colectomy; postoperative pain; ropivacaine	POSTOPERATIVE PAIN; DOUBLE-BLIND; LOCAL-ANESTHESIA; CHOLECYSTECTOMY; BUPIVACAINE; PNEUMOPERITONEUM; PHARMACOKINETICS; INSTILLATION; ANALGESIA; RELIEF	Background. Although laparoscopic procedures are becoming more common, postoperative pain remains a major factor causing delayed patient recovery. There have been several trials to reduce pain by instilling local anesthetics into the peritoneal cavity, but there has been no study on prolonged (similar to 300 min) or intensive surgery. We investigated the analgesic effect of intraperitoneal ropivacaine instillation after laparoscopic colectomy. Materials and Methods. Sixty patients were randomized to three groups. Twenty patients in each group received 50 mL of appropriate solutions after the formation of a pneumoperitoneum. The solution was normal saline (control) in group C and 1 mg/kg of ropivacaine in each of groups I and D. In group D, ropivacaine was sprayed again before the elimination of the pneumoperitoneum. Patients reported their postoperative pain using a subjective visual analogue scale. Fentanyl use for pain relief and frequency of pushing a button (FPB) for a bolus of patient controlled analgesia were evaluated, and scales of recovery rates were obtained. Results. The immediate postoperative pain score was lower in groups I and D than in group C. In groups I and D, FPB measures and fentanyl use were both less than in group C. The time taken to resume a regular diet was shorter in group D than in group C. Conclusions. The intraperitoneal instillation of ropivacaine was effective in reducing postoperative pain and in shortening the recovery course after laparoscopic colectomy. The additional instillation of ropivacaine at the end of the surgery proved even more effective. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.	[Kang, Hyun; Woo, Young Cheol; Park, Sun Gyoo; Baek, Chong Wha; Jung, Yong Hun; Kim, Jin Yun; Koo, Gill Hoi; Kim, Seong Deok] Chung Ang Univ, Dept Anaesthesiol & Pain Med, Coll Med, Seoul 156755, South Korea; [Park, Yong Hee] Seoul Natl Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul, South Korea; [Park, Jun Seok] Kyungpook Natl Univ, Dept Surg, Kyungpook Natl Univ Hosp, Sch Med, Dae Gu, South Korea	Kang, H (reprint author), Chung Ang Univ, Dept Anaesthesiol & Pain Med, Coll Med, 224-1 Heukseok Dong, Seoul 156755, South Korea.	roman00@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	Chung-Ang University	This research was supported by the Chung-Ang University Research Grants in 2009.	Barczynski M, 2006, SURG ENDOSC, V20, P1088, DOI 10.1007/s00464-005-0458-1; Bellows Charles F, 2006, JSLS, V10, P345; Berde C. B., 2009, MILLERS ANESTHESIA, P928; Boddy AP, 2006, ANESTH ANALG, V103, P682, DOI 10.1213/01.ane.0000226268.06279.5a; FREDMAN B, 1994, ANESTH ANALG, V79, P152; JORGENSEN H, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001893; JORIS J, 1995, ANESTH ANALG, V81, P379, DOI 10.1097/00000539-199508000-00029; KATZ JA, 1990, ANESTH ANALG, V70, P16; KENNY GNC, 1994, ANAESTHESIA, V49, P6, DOI 10.1111/j.1365-2044.1994.tb03576.x; Labaille T, 2002, ANESTH ANALG, V94, P100, DOI 10.1097/00000539-200201000-00019; Louizos AA, 2005, SURG ENDOSC, V19, P1503, DOI 10.1007/s00464-005-3002-4; Palmes D, 2007, BRIT J SURG, V94, P824, DOI 10.1002/bjs.5810; Pappas-Gogos G, 2008, SURG ENDOSC, V22, P2036, DOI 10.1007/s00464-008-9762-x; SCOTT DB, 1989, ANESTH ANALG, V69, P563, DOI 10.1213/00000539-198911000-00003; Slim K, 2000, BRIT J SURG, V87, P1249, DOI 10.1046/j.1365-2168.2000.01522-3.x; Thompson Jon S, 2002, Adv Surg, V36, P297; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; WATTWIL M, 1989, ANESTH ANALG, V68, P353; Wills VL, 2000, BRIT J SURG, V87, P273, DOI 10.1046/j.1365-2168.2000.01374.x	19	25	26	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	NOV	2011	171	1					94	100		10.1016/j.jss.2010.03.024			7	Surgery	Surgery	839LS	WOS:000296368000035	20605604				2020-06-30	J	Yoo, YC; Na, S; Jeong, JJ; Choi, EM; Moon, BE; Lee, JR				Yoo, Y. -C.; Na, S.; Jeong, J. -J.; Choi, E. -M.; Moon, B. -E.; Lee, J. -R.			Dose-dependent attenuation by fentanyl on cough during emergence from general anesthesia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							EFFECT-SITE CONCENTRATION; TRACHEAL EXTUBATION; REMIFENTANIL ANESTHESIA; PREVENTING COUGH; RESPONSES; PRESSURE; PROPOFOL; SEVOFLURANE; INJECTION; LIDOCAINE	Background: Although fentanyl suppresses tracheal tube-induced cough during anesthetic recovery, it has not been proven if its antitussive effect is dose dependent and complication free. The purpose of this study is to evaluate the relationship between fentanyl doses and cough suppression during emergence from sevoflurane anesthesia. Methods: Sixty patients undergoing thyroidectomy were randomly allocated to one of four groups (F0, F1, F1.5, and F2) according to the fentanyl dose (0 mcg/kg, 1 mcg/kg, 1.5 mcg/kg, or 2 mcg/kg). Fentanyl was administered immediately after sevoflurane discontinuation. Coughing was assessed throughout the periextubation period. The relationship between fentanyl dose and incidence of cough was analyzed using Cochran-Armitage trend test. Incidence of more than 30% elevation of mean arterial pressure (MAP) and heart rate (HR), awakening time, extubation time, and respiratory rate after extubation were recorded and compared using Mantel-Haenszel chi-square test and one-way analysis of variance. Results: Fentanyl suppressed emergence cough in a dose-related manner (P = 0.002), and the ED50 and ED90 were 1.1 mcg/kg and 2.1 mcg/kg, respectively. The higher dose of fentanyl further reduced the number of patient with MAP and HR elevation (P = 0.003 and 0.005, respectively). Awakening time (8.4 +/- 1.9 min) in F2 was comparable with that in F1 and F1.5. Respiratory rate (9 +/- 2 bpm) and extubation time (11.9 +/- 1.8 min) in F2 were only different from those in F0 (13 +/- 3 bpm and 10.4 +/- 1.1 min, respectively). Conclusions: Fentanyl suppressed cough in a dose-related manner during recovery from general sevoflurane anesthesia, and 2 mcg/kg may be considered as a proper dose.	[Yoo, Y. -C.; Na, S.; Moon, B. -E.; Lee, J. -R.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Anaesthesia & Pain Res Inst, Seoul 120752, South Korea; [Jeong, J. -J.] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; [Choi, E. -M.] Hallyn Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Anaesthesiol & Pain Med, Seoul, South Korea	Lee, JR (reprint author), Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Anaesthesia & Pain Res Inst, 250 Seongsan No, Seoul 120752, South Korea.	leejeongrim@gmail.com		Na, Sungwon/0000-0002-1170-8042; Jeong, Jong Ju/0000-0002-4155-6035; Lee, Jeong-Rim/0000-0002-7425-0462; Yoo, Young Chul/0000-0002-6334-7541			ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Aouad MT, 2009, ANESTH ANALG, V108, P1157, DOI 10.1213/ane.0b013e31819b03d8; BIDWAI AV, 1979, ANESTHESIOLOGY, V51, P171, DOI 10.1097/00000542-197908000-00020; Bolser D. C., 2009, V187, P203, DOI 10.1007/978-3-540-79842-2_10; Chen J, 2010, ACTA ANAESTH SCAND, V54, P1197, DOI 10.1111/j.1399-6576.2010.02303.x; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; HOLDEN R, 1991, ANAESTHESIA, V46, P922, DOI 10.1111/j.1365-2044.1991.tb09847.x; Inagaki Y, 1997, ANESTH ANALG, V85, P328; Irwin RS, 2006, CHEST, V129, p54S, DOI 10.1378/chest.129.1_suppl.54S; Iwakiri H, 2003, ANESTH ANALG, V96, P1651, DOI 10.1213/01.ANE.0000062772.28479.2B; Jun NH, 2010, ANAESTHESIA, V65, P930, DOI 10.1111/j.1365-2044.2010.06450.x; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; KATOH T, 1994, BRIT J ANAESTH, V73, P322, DOI 10.1093/bja/73.3.322; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Lee B, 2009, BRIT J ANAESTH, V102, P775, DOI 10.1093/bja/aep090; LEECH P, 1974, BRIT J ANAESTH, V46, P315, DOI 10.1093/bja/46.4.315-a; Miller RD, 2010, MILLERS ANESTHESIA; NISHINA K, 1995, ACTA ANAESTH SCAND, V39, P85, DOI 10.1111/j.1399-6576.1995.tb05597.x; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Shajar MA, 1999, BRIT J ANAESTH, V83, P654; STEINHAUS JE, 1963, ANESTHESIOLOGY, V24, P285, DOI 10.1097/00000542-196305000-00006; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007	22	11	13	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2011	55	10					1215	1220		10.1111/j.1399-6576.2011.02529.x			6	Anesthesiology	Anesthesiology	831GQ	WOS:000295717800006	22092126				2020-06-30	J	Pestieau, SR; Quezado, ZMN; Johnson, YJ; Anderson, JL; Cheng, YI; McCarter, RJ; Pena, MT; Finkel, JC				Pestieau, Sophie R.; Quezado, Zenaide M. N.; Johnson, Yewande J.; Anderson, Jennifer L.; Cheng, Yao I.; McCarter, Robert J.; Pena, Maria T.; Finkel, Julia C.			The effect of dexmedetomidine during myringotomy and pressure-equalizing tube placement in children	PEDIATRIC ANESTHESIA			English	Article						dexmedetomidine; pain; postanesthesia care unit; children; myringotomy; agitation	SEVOFLURANE ANESTHESIA; BILATERAL MYRINGOTOMY; INTRANASAL DEXMEDETOMIDINE; POSTOPERATIVE ANALGESIA; EMERGENCE AGITATION; AMBULATORY SURGERY; PEDIATRIC-PATIENTS; ACETAMINOPHEN; INSERTION; PREMEDICATION	Background: Bilateral myringotomy (BMT) is a commonly performed otolaryngologic procedure in children. Objectives: To examine the effects of intranasal dexmedetomidine, an alpha(2)-adrenoceptor agonist, on time-averaged pain scores, pain control, need for rescue analgesia, and agitation scores in children undergoing BMT. Methods: We designed a trial to enroll 160 children randomized to one of four groups: two study groups, dexmedetomidine (1 or 2 mu g.kg(-1)), or two control groups representing our institutional standards of practice (intranasal fentanyl-2 mu g.kg(-1) or acetaminophen as needed postoperatively). Results: After 101 children were enrolled, patient caregivers observed that some enrollees were excessively sedated and required prolonged postanesthesia care unit (PACU) stay. This observation led to an unplanned interim analysis and early trial termination. After data were collected, severe non-normality of pain and agitation scores necessitated a switch of the outcome to assess repeated measurements of the proportion of patients with pain, severe pain, and agitation. Demographics, time to emergence, and agitation were similar among all groups. The risk of requiring acetaminophen rescue (P < 0.0001) and proportion of patients having pain (P = 0.016) was significantly higher in one control group (rescue analgesia only) compared with fentanyl or dexmedetomidine groups. Importantly, length of stay in the PACU was significantly longer in dexmedetomidine-2 mu g.kg(-1)-treated compared with dexmedetomidine-1 mu g.kg(-1)-treated, fentanyl-treated, or the control group, P = 0.0037. Conclusions: In this trial, we were unable to answer the original question as to the role of dexmedetomidine on time-averaged pain and agitation scores after BMT. However, our findings clearly demonstrate that in children undergoing BMT, at higher doses, dexmedetomidine significantly prolongs length of stay in the PACU.	[Pestieau, Sophie R.; Quezado, Zenaide M. N.; Finkel, Julia C.] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Div Anesthesiol & Pain Med,Sheikh Zayed Inst Pedi, Washington, DC 20010 USA; [McCarter, Robert J.] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Childrens Res Inst,Ctr Clin & Community Res, Washington, DC 20010 USA; [Pena, Maria T.] George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Div Otolaryngol, Washington, DC 20010 USA	Pestieau, SR (reprint author), George Washington Univ, Sch Med & Hlth Sci, Childrens Natl Med Ctr, Div Anesthesiol & Pain Med,Sheikh Zayed Inst Pedi, 111 Michigan Ave NW, Washington, DC 20010 USA.	spestiea@cnmc.org	Quezado, Zenaide/O-4860-2016	Quezado, Zenaide/0000-0001-9793-4368	Division of Anesthesiology and Pain Medicine; Sheikh Zayed Institute for Pediatric Surgical Innovation, and Hospira Inc., Lake Forest, IL	This study was supported in part by the Division of Anesthesiology and Pain Medicine and the Sheikh Zayed Institute for Pediatric Surgical Innovation, and Hospira Inc., Lake Forest, IL (research support to Julia C. Finkel, MD).	Anttila M, 2003, BRIT J CLIN PHARMACO, V56, P691, DOI 10.1046/j.1365-2125.2003.01944.x; Bhattacharyya N, 2010, LARYNGOSCOPE, V120, P821, DOI 10.1002/lary.20852; Compliment JM, 2003, INT J PEDIATR OTORHI, V67, P1159, DOI 10.1016/S0165-5876(03)00190-3; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Lin YC, 2009, PEDIATR ANESTH, V19, P1096, DOI 10.1111/j.1460-9592.2009.03129.x; Olutoye OA, 2010, ANESTH ANALG, V111, P490, DOI 10.1213/ANE.0b013e3181e33429; OROBELLO PW, 1991, INT J PEDIATR OTORHI, V21, P51, DOI 10.1016/0165-5876(91)90059-K; Pappas AL, 2003, ANESTH ANALG, V96, P1621, DOI 10.1213/01.ANE.0000064206.51296.1D; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; Siddappa R, 2011, PEDIATR ANESTH, V21, P153, DOI 10.1111/j.1460-9592.2010.03502.x; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Su F, 2011, EXPERT OPIN DRUG SAF, V10, P55, DOI 10.1517/14740338.2010.512609; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; Yuen VM, 2010, ANAESTHESIA, V65, P922, DOI 10.1111/j.1365-2044.2010.06453.x; Yuen VM, 2008, ANESTH ANALG, V106, P1715, DOI 10.1213/ane.0b013e31816c8929; Yuen VM, 2007, ANESTH ANALG, V105, P374, DOI 10.1213/01.ane.0000269488.06546.7c	24	19	20	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2011	21	11					1128	1135		10.1111/j.1460-9592.2011.03615.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	828RK	WOS:000295519900009	21575102				2020-06-30	J	Rampersad, S; Jimenez, N; Lynn, A				Rampersad, Sally; Jimenez, Nathalia; Lynn, Anne			Reply to Aidan Cullen Re: Two-agent analgesia versus acetaminophen in children having bilateral myringotomies and tubes surgery, letter	PEDIATRIC ANESTHESIA			English	Letter							SEVOFLURANE ANESTHESIA; INTRANASAL FENTANYL; PLACEMENT		[Rampersad, Sally] Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USA; Univ Washington, Seattle, WA 98195 USA	Rampersad, S (reprint author), Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, Seattle, WA USA.	sally.rampersad@seattlechildrens.org		Jimenez, Nathalia/0000-0002-6785-8330			Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006	3	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	NOV	2011	21	11					1164	1165		10.1111/j.1460-9592.2011.03641.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	828RK	WOS:000295519900018	21966963				2020-06-30	J	Ravera, E; Di Santo, S; Bosco, R; Arboscello, C; Chiarlone, R				Ravera, Enrico; Di Santo, Salvatore; Bosco, Rosa; Arboscello, Claudio; Chiarlone, Renato			Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain	AGING CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						Chronic pain; oxycodone CR; quality of life; transdermal opioids	AROUND-THE-CLOCK; DOUBLE-BLIND; PHARMACOLOGICAL-TREATMENT; MORPHINE; EFFICACY; MANAGEMENT; SAFETY; HYDROMORPHONE; MODEL	Background and aims: Several publications and guidelines stress the efficacy and safety of opioid-based therapy for cancer and non-cancer pain management. The first point of the World Health Organization (WHO) guidelines recommends that, if possible, analgesics should be given by mouth. This advice fully matches the European Society for Medical Oncology (ESMO) guidelines, which advise that opioids should be titrated to take effect as rapidly as possible. The European Association for Palliative Care (EAPC) guidelines specify that transdermal fentanyl should be administered only in patients with stable analgesic requirements. The aim of this study was to assess the efficacy and influence on the quality of life of controlled-release (CR) oxycodone in patients who had obtained no or only partial pain relief after transdermal (TTD)-based opioid therapy. Methods: Forty-one consecutive patients experiencing persistent cancer and non-cancer related pain and in treatment with transdermal-based opioid therapy for at least 5 days were enrolled in this open-label, multicenter observational study. All patients were switched from transdermal to oral opioid therapy with oxycodone CR for 21 days. Pain intensity was rated on a numeric rating scale (NRS) from 0 to 10 (0=no pain, 10=maximum severity). Patients were asked to rate their perceptions on efficacy and pain interference on the quality of life on an NRS from 0 to 10 (0=no interference, 10=maximum interference). Results: After 3 days with oxycodone CR, pain intensity decreased by 38.83% (p<0.001) and maintained a significant decrease throughout the period (T0-T7: -59.71%, p<0.001; T0-T21: -65.75%, p<0.001). The average daily dose of oxycodone CR increased from 68.75 mg at baseline to 72.39 mg after 7 days and was maintained stable until the study ended. At T0, 56.10% of patients suffered from severe pain (NRS 7-10); this percentage had decreased to 2.56% at the end of the study. About 7% of patients considered transdermal therapy effective at baseline; after 21 days, 72.22% and 19.44% of patients considered it effective and very effective, respectively. Quality of life improved significantly during the 21 days with the oral treatment (p<0.001). Conclusions: Switching from transdermal opioid to oxycodone CR treatment is effective and leads to patients' improved satisfaction and quality of life. (Aging Clin Exp Res 2011; 23: 328-332) (C)2011, Editrice Kurtis	[Ravera, Enrico; Di Santo, Salvatore; Bosco, Rosa] Osped Bra, Azienda Sanitaria Locale Alba Bra Cn CN2, Savona, Italy; [Arboscello, Claudio; Chiarlone, Renato] Osped San Paolo, ASL Savonese 2, Savona, Italy	Ravera, E (reprint author), Osped Santo Spirito, Via Vittorio Emanuele, I-12042 Bra, Cn, Italy.	eravera@aslcn2.it					American Pain Society, 1999, PRINC AN US TREATM A, P22; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Chang HM, 1999, MED CLIN N AM, V83, P711, DOI 10.1016/S0025-7125(05)70131-0; Chou R, 2004, DRUG CLASS REV LONG; Curtis GB, 1999, EUR J CLIN PHARMACOL, V55, P425, DOI 10.1007/s002280050651; Dios PD, 2010, ORAL ONCOL, V46, P448, DOI 10.1016/j.oraloncology.2010.02.017; Fukshansky M, 2005, PAIN PRACT, V53-54; Fukshansky Mikhail, 2005, Pain Pract, V5, P43, DOI 10.1111/j.1533-2500.2005.05106.x; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Gatti A, 2009, EUR NEUROL, V61, P129, DOI 10.1159/000186502; Grossman S A, 1994, Oncology (Williston Park), V8, P93; HADDOX JD, [No title captured]; Hagen NA, 1997, CANCER-AM CANCER SOC, V79, P1428; Hale M, 2007, CLIN THER, V29, P874, DOI 10.1016/j.clinthera.2007.05.016; Hale ME, 1999, CLIN J PAIN, V15, P179, DOI 10.1097/00002508-199909000-00004; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; HILL CS, 1993, CANCER PAIN, P129; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; JOST LM, 2005, ANN ONCOL         S1, V16, P83; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Mandema JW, 1996, BRIT J CLIN PHARMACO, V42, P747, DOI 10.1046/j.1365-2125.1996.00481.x; Mercadante S, 2001, VALUTAZIONE DIAGNOSI, P249; Mercadante S, 2007, EUR J PAIN, V11, P823, DOI 10.1016/j.ejpain.2007.01.003; Miaskowski C, 2002, J PAIN, V3, P12, DOI 10.1054/jpai.2002.27002; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; Pappagallo M, 1999, RHEUM DIS CLIN N AM, V25, P193, DOI 10.1016/S0889-857X(05)70060-0; Portenoy RK, 2007, CLIN J PAIN, V23, P287, DOI 10.1097/AJP.0b013e31802b582f; Riley J, 2008, CURR MED RES OPIN, V24, P175, DOI 10.1185/030079908X253708; Roth SH, 2000, ARCH INTERN MED, V160, P853, DOI 10.1001/archinte.160.6.853; Salzman RT, 1999, J PAIN SYMPTOM MANAG, V18, P271, DOI 10.1016/S0885-3924(99)00079-2; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; World Health Organization, 1996, CANC PAIN REL	35	2	2	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1594-0667	1720-8319		AGING CLIN EXP RES	Aging Clin. Exp. Res.	OCT-DEC	2011	23	5-6					328	332		10.1007/BF03325231			5	Geriatrics & Gerontology	Geriatrics & Gerontology	932ID	WOS:000303283200002	22526067				2020-06-30	J	Zielinski, J; Jaworski, R; Smietanska, I; Irga, N; Wujtewicz, M; Jaskiewicz, J				Zielinski, Jacek; Jaworski, Radoslaw; Smietanska, Irmina; Irga, Ninela; Wujtewicz, Maria; Jaskiewicz, Janusz			A randomized, double-blind, placebo-controlled trial of preemptive analgesia with bupivacaine in patients undergoing mastectomy for carcinoma of the breast	MEDICAL SCIENCE MONITOR			English	Article						preemptive analgesia; breast cancer; bupivacaine; mastectomy	POSTMASTECTOMY PAIN SYNDROME; POSTOPERATIVE PAIN; ORTHOPEDIC-SURGERY; WOUND INFILTRATION; CANCER SURGERY; EFFICACY; ROPIVACAINE; PREVENTION; KETAMINE; RELIEF	Background: In this prospective, randomized, placebo-controlled, double-blinded clinical trial we tested the hypothesis that preemptive analgesia with bupivacaine applied in the area of the surgical incision in patients undergoing mastectomy for breast cancer would reduce post-operative acute pain and would reduce the amount of analgesics used during surgery and in the post-operative period. Material/Methods: Participants were assigned into 1 of 2 groups - with bupivacaine applied in the area of surgical incision or with placebo. We assessed the intraoperative consumption of fentanyl, the postoperative consumption of morphine delivered using a PCA method, and the subjective pain intensity according to VAS score reported by patients in the early post-operative period. Results: Out of 121 consecutive cases qualified for mastectomy, 112 women were allocated randomly to 1 of 2 groups - group A (bupivacaine) and group B (placebo). The final study group comprised 106 breast cancer cases. Between the groups, a statistically significant difference was observed with respect to: lower fentanyl consumption during surgery (p=0.011), lower morphine (delivered by means of a PCA) consumption between the 4-12(th) postoperative hours (p=0.02) and significantly lower pain intensity assessed according to VAS score at the 4(th) and 12(th) hours after surgery (p=0.004 and p=0.02 respectively) for the group A patients. Conclusions: Preemptive analgesia application in the form of infiltration of the area of planned surgical incisions with bupivacaine in breast cancer patients undergoing mastectomy decreases post-operative pain sensation, limits the amount of fentanyl used during surgery, and reduces the demand for opiates in the hours soon after surgery.	[Zielinski, Jacek; Jaworski, Radoslaw; Jaskiewicz, Janusz] Med Univ Gdansk, Dept Surg Oncol, PL-80952 Gdansk, Poland; [Smietanska, Irmina; Wujtewicz, Maria] Med Univ Gdansk, Dept Anesthesiol & Intens Care, PL-80952 Gdansk, Poland; [Irga, Ninela] Med Univ Gdansk, Dept Pediat Hematol Oncol & Endocrinol, PL-80952 Gdansk, Poland	Zielinski, J (reprint author), Med Univ Gdansk, Dept Surg Oncol, Debinki 7 Str, PL-80952 Gdansk, Poland.	jaziel@gumed.edu.pl	Zielinski, Jacek/O-9716-2019; Irga-Jaworska, Ninela/N-8660-2018	Zielinski, Jacek/0000-0001-5584-1921; Irga-Jaworska, Ninela/0000-0002-7637-4397; Jaworski, Radoslaw/0000-0002-0590-9470			Adam F, 1999, ANESTH ANALG, V89, P444, DOI 10.1097/00000539-199908000-00036; Aida Sumihisa, 1999, Anesthesia and Analgesia, V89, P711, DOI 10.1097/00000539-199909000-00034; Baudry G, 2008, ANN FR ANESTH, V27, P979, DOI 10.1016/j.annfar.2008.10.006; de Kok M, 2010, BRIT J SURG, V97, P189, DOI 10.1002/bjs.6812; DOHDA NM, 2010, EGYPT J ANESTH, V26, P287; Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979; Grape S, 2007, BEST PRACT RES-CLIN, V21, P51, DOI 10.1016/j.bpa.2006.11.004; Inanoglu K, 2009, MED SCI MONITOR, V15, pCR539; Kaufman Eliezer, 2005, Anesth Prog, V52, P29, DOI 10.2344/0003-3006(2005)52[29:PAALAA]2.0.CO;2; Kelly DJ, 2001, CAN J ANAESTH, V48, P1091, DOI 10.1007/BF03020375; Kelly DJ, 2001, CAN J ANAESTH, V48, P1000, DOI 10.1007/BF03016591; Lakdja F, 1997, B CANCER, V84, P259; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; Myles PS, 1999, ANESTH ANALG, V89, P1517, DOI 10.1097/00000539-199912000-00038; Ong CKS, 2005, ANESTH ANALG, V100, P757, DOI 10.1213/01.ANE.0000144428.98767.0E; Pettersson N, 2001, EUR J SURG, V167, P825; Pogatzki-Zahn EM, 2006, CURR OPIN ANESTHESIO, V19, P551, DOI 10.1097/01.aco.0000245283.45529.f9; Reuben SS, 2007, J BONE JOINT SURG AM, V89A, P1343, DOI 10.2106/JBJS.F.00906; Reuben SS, 2004, J PAIN SYMPTOM MANAG, V27, P133, DOI 10.1016/j.jpainsymman.2003.06.004; Rica MAI, 2007, ASIAN J SURG, V30, P34, DOI 10.1016/S1015-9584(09)60125-1; Riest G, 2006, EUR J ANAESTH, V23, P219, DOI 10.1017/S026502150500222X; Romsing J, 2000, ACTA ANAESTH SCAND, V44, P672, DOI 10.1034/j.1399-6576.2000.440607.x; Shen XF, 2008, PHARMACOL REP, V60, P415; Sidiropoulou T, 2008, ANESTH ANALG, V106, P997, DOI 10.1213/ane.0b013e31816152da; SOBIN LH, 2002, TNM CLASSIFICATION M; Vallejo MC, 2006, REGION ANESTH PAIN M, V31, P227, DOI 10.1016/j.rapm.2006.02.007; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2; WANG FZ, 2008, ACUTE PAIN, V10, P65	28	21	22	0	8	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	OCT	2011	17	10					CR589	CR597		10.12659/MSM.881986			9	Medicine, Research & Experimental	Research & Experimental Medicine	861QL	WOS:000298034200025	21959614	Green Published			2020-06-30	J	Chon, J; Lee, J				Chon, JinYoung; Lee, JiYoung			IS TRAMADOL BETTER THAN FENTANYL FOR CONSCIOUS SEDATION?	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Letter									[Chon, JinYoung; Lee, JiYoung] Catholic Univ, Seoul, South Korea	Chon, J (reprint author), Catholic Univ, Seoul, South Korea.						Goktay O, 2011, J ORAL MAXIL SURG, V69, P1594, DOI 10.1016/j.joms.2010.09.005; Matsuzaki Satoshi, 2004, Anesth Prog, V51, P52; Ong CKS, 2005, J ORAL MAXIL SURG, V63, P1162, DOI 10.1016/j.joms.2005.04.028; Padmanabhan MY, 2009, J CLIN PEDIATR DENT, V34, P183, DOI 10.17796/jcpd.34.2.cgn410227k80751l; Yaksh T, GOODMAN GILMANS PHAR	5	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	OCT	2011	69	10					2485	2485		10.1016/j.joms.2011.06.229			1	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	835XV	WOS:000296071200005	21939811				2020-06-30	J	Rodgers, SF; Rodgers, MS				Rodgers, Steven F.; Rodgers, Matthew S.			Safety of Intravenous Sedation Administered by the Operating Oral Surgeon: The Second 7 Years of Office Practice	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							OUTPATIENT ANESTHESIA; MASSACHUSETTS EXPERIENCE; MAXILLOFACIAL SURGEONS; MORTALITY; MORBIDITY; PROPOFOL	Purpose: This follow-up study provides an additional 7 years of data (December 2001 through November 2008) pertaining to complications that occurred in patients who received intravenous sedation in the practice of a single board-certified oral and maxillofacial surgeon. Together with the previously published 7 years of data (December 1994 through November 2001), this study summarizes the frequency of various complications encountered in patients sedated intravenously by the surgeon over a 14-year period. Materials and Methods: The files of intravenous sedation cases from the second 7-year period were reviewed for complications. These data were then compared, contrasted, and combined with the previously published sedation cases from the first 7 years. Results: A total of 3,320 sedations were performed by the surgeon during this second 7-year period, with only 1.57% of patients having complications (52 patients having 60 adverse events). These results showed a slight decline in the frequency of complications. Over the entire 14-year period of study, a total of 6,209 sedations were performed by the surgeon, with 1.96% of patients having complications (122 patients having 137 adverse events). There were no deaths, and no patients required emergency transport to a hospital. Conclusions: The results of this follow-up study confirm the previous findings. The administration of intravenous sedation by the operating surgeon for outpatient oral surgery is safe, with a low frequency of complications. Numerous patients were also made aware of previously undiagnosed medical problems, improving overall patient health. (C) 2011 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 69:2525-2529, 2011	[Rodgers, Matthew S.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN USA; [Rodgers, Matthew S.] Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA	Rodgers, SF (reprint author), Newburgh Oral Surg PC, 4855 Hwy 261, Newburgh, IN 47630 USA.	paulscharge@integrity.com					Casagrande AM, 2006, J ORAL MAXIL SURG, V64, P693, DOI 10.1016/j.joms.2005.11.039; Cillo JE, 2006, J ORAL MAXIL SURG, V64, P1338, DOI 10.1016/j.joms.2006.05.018; D'Eramo EM, 2008, J ORAL MAXIL SURG, V66, P2421, DOI 10.1016/j.joms.2008.06.095; D'Eramo EM, 2003, J ORAL MAXIL SURG, V61, P793, DOI 10.1016/S0278-2391(03)00238-6; D'Eramo EM, 1999, J ORAL MAXIL SURG, V57, P531, DOI 10.1016/S0278-2391(99)90069-1; DERAMO EM, 1992, J ORAL MAXIL SURG, V50, P700, DOI 10.1016/0278-2391(92)90101-5; Hunter MJ, 1997, J ORAL MAXIL SURG, V55, P684, DOI 10.1016/S0278-2391(97)90575-9; Perrott DH, 2003, J ORAL MAXIL SURG, V61, P983, DOI 10.1016/S0278-2391(03)00668-2; Rodgers SF, 2005, J ORAL MAXIL SURG, V63, P1478, DOI 10.1016/j.joms.2005.05.320	9	13	13	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	OCT	2011	69	10					2525	2529		10.1016/j.joms.2011.02.030			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	835XV	WOS:000296071200013	21724314				2020-06-30	J	Svendsen, K; Borchgrevink, PC; Fredheim, O; Hamunen, K; Mellbye, A; Dale, O				Svendsen, Kristian; Borchgrevink, P. C.; Fredheim, O.; Hamunen, K.; Mellbye, A.; Dale, O.			Choosing the unit of measurement counts: The use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses	PALLIATIVE MEDICINE			English	Article						Analgesics; drug utilization; opioid; pharmacoepidemiology	EUROPEAN COUNTRIES; CANCER-PATIENTS; TRENDS; ANALGESICS; FENTANYL; COHORT; PAIN	Aim: Defined daily dose (DDD) is the most common measurement unit used in drug consumption studies. The DDD for opioids may not reflect their relative clinical potencies. The aim of this study was to explore whether opioid consumption data may be interpreted differently when adding oral morphine equivalent (OMEQ) dose as a measurement unit compared with using DDD. Methods: The equianalgesic ratio of each opioid relative to morphine was tabulated. Data on opioid consumption expressed in DDD were converted to OMEQs using the equianalgesic ratios. The opioid consumption was compared in three different study settings: clinical data from an opioid switching study, trends within one country and a comparison between countries. Results: Using DDD, the opioid consumption in Norway between 2004-2008 increased of 6.7%, while the increase was 23.6% using OMEQ. While DDD/1000 inhabitants/day showed that Sweden had the highest consumption of opioids among the Nordic countries, OMEQ/1000 inhabitants/day showed that Denmark had the highest consumption. In the switching study DDD indicated a reduction in analgesic dosing and OMEQ an increase when switching from WHO step II to III. Conclusion: OMEQ reflects clinical dosing better than DDD, and can give additional insight into opioid consumption when combined with DDD. Using OMEQ can also lead to different conclusions in opioid consumption studies compared with using DDD alone.	[Svendsen, Kristian; Borchgrevink, P. C.; Fredheim, O.; Mellbye, A.; Dale, O.] NTNU, Fac Med, Pain & Palliat Res Grp, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Svendsen, Kristian; Borchgrevink, P. C.; Fredheim, O.] St Olavs Univ Hosp, Dept Pain & Complex Disorders, Trondheim, Norway; [Fredheim, O.] Telemark Hosp, Dept Emergency Med, Skien, Norway; [Hamunen, K.] Univ Helsinki, Cent Hosp, Dept Anaesthesia & Intens Care, Pain Clin, Helsinki, Finland; [Dale, O.] St Olavs Univ Hosp, Dept Anaesthesia & Emergency Med, Trondheim, Norway	Svendsen, K (reprint author), NTNU, Fac Med, Pain & Palliat Res Grp, Dept Circulat & Med Imaging, Postbox 8905, N-7491 Trondheim, Norway.	kristian.svendsen@ntnu.no		Svendsen, Kristian/0000-0003-3481-3539; Fredheim, Olav/0000-0002-0931-0027			Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; Back IN, PALLIATIVE MED HDB; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; CLAUSEN TG, 1995, EUR J CLIN PHARMACOL, V48, P321; Curry EA, 2007, AM J HEALTH-SYST PH, V64, P1619, DOI 10.2146/ajhp060608; Dale A, 2005, PALLIATIVE MED, V19, P177, DOI 10.1191/0269216305pm1012ed; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; DIVVELA S, 2006, HOSP PHARM, V41, P1130; Fredheim OMS, 2008, ACTA ANAESTH SCAND, V52, P879, DOI 10.1111/j.1399-6576.2008.01597.x; Fredheim OMS, 2010, EUR J PAIN, V14, P289, DOI 10.1016/j.ejpain.2009.05.006; Genf World Health Organization, 1986, CANC PAIN REL; Hamunen K, 2008, EUR J PAIN, V12, P705, DOI 10.1016/j.ejpain.2007.10.012; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Hudec R, 2004, EUR J CLIN PHARMACOL, V60, P445, DOI 10.1007/s00228-004-0793-5; International Narcotics Control Board, 2009, ANN REP NARC DRUGS; Jarlbaek L, 2005, J PAIN SYMPTOM MANAG, V29, P336, DOI 10.1016/j.jpainsymman.2004.07.010; Klepstad P, 2000, J PAIN SYMPTOM MANAG, V20, P19, DOI 10.1016/S0885-3924(00)00167-6; MacAuley D, NARCOTIC ANALGESIC C; Norwegian Medicines Agency, SUMM PROD CHAR KET; Norwegian Medicines Agency, SUMM PROD CHAR ACT; OHQVIST G, 1991, ACTA ANAESTH SCAND, V35, P44; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Sittl R, 2005, CLIN THER, V27, P225, DOI 10.1016/j.clinthera.2005.02.012; SOUTER KJ, 2004, SEMIN ANESTH PERIO M, V23, P271, DOI DOI 10.1053/j.sane.2004.06.001; Wall PD, 2006, WALL MELZACKS TXB PA; *WHO COLL CTR DRUG, 2010, GUID ATC CLASS DDD A	27	82	84	0	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.	OCT	2011	25	7					725	732		10.1177/0269216311398300			8	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	831LX	WOS:000295733400008	21378066				2020-06-30	J	El Tahan, MR				El Tahan, Mohamed R.			Effects of aminophylline on cognitive recovery after sevoflurane anesthesia	JOURNAL OF ANESTHESIA			English	Article						Aminophylline; Sevoflurane; Anesthesia; Cognitive function; Recovery; Entropy	BISPECTRAL INDEX; REMIFENTANIL-PROPOFOL; AMBULATORY ANESTHESIA; SPECTRAL ENTROPY; ISOFLURANE; CRANIOTOMY; IMPAIRMENT; DESFLURANE; EMERGENCE; DEPTH	Purpose Aminophylline accelerates the recovery from sevoflurane anesthesia. We studied the effects of escalating doses of aminophylline on cognitive and clinical recovery after sevoflurane anesthesia. Methods After ethical approval and informed consent, 150 patients scheduled for elective surgery under sevoflurane-fentanyl anesthesia were randomly allocated to receive saline or 2, 3, 4 or 5 mg/kg of aminophylline (n = 30 for each) at the end of anesthesia (T (0)). Short Orientation Memory Concentration Test (SOMCT) scores, entropy values, end-tidal sevoflurane concentrations (EtSevo), times to eyes opening and extubation, respiratory rate (RR) and tidal volume (TV) were recorded. Results Compared to placebo, patients receiving 2, 3, 4 and 5 mg/kg of aminophylline had higher SOMCT scores [median (25th percentile/75th percentile) 20.6 (19/23), 21.5 (21/22), 24.5 (24-25), 25.5 (25/26), respectively, vs. 13.5 (13/14) at 30 min after extubation, and 24 (22/26), 25 (24/26), 27.5 (27-28), 27.5 (27/28), respectively, vs. 18.5 (18/19) at 45 min after extubation], higher entropy values for the first 10 min after T (0), lower EtSevo for the first 4 min after T (0), shorter times to eyes opening [5 (4.0/6.0), 5 (4.0/6.0), 4 (2.0/5.5), and 4 (2.0/6.0), respectively, vs. 9.8 (8.0/11.0) min], shorter times to extubation, shorter times to home discharge (P < 0.001), and higher RR and larger TV values. Patients who received 4 and 5 mg/kg of aminophylline showed higher SOMCT scores, 6 min shorter times to eyes opening and to extubation, and 58 min shorter times to home discharge. Conclusion The administration of escalating doses of aminophylline accelerates postoperative cognitive recovery from sevoflurane anesthesia, as measured by the SOMCT, due to increased ventilatory elimination of sevoflurane.	[El Tahan, Mohamed R.] Univ Dammam, Coll Med, Dept Anesthesiol, Dammam 31952, Al Khobar, Saudi Arabia; [El Tahan, Mohamed R.] Mansoura Univ, Coll Med, Dept Anesthesiol, Mansoura, Egypt	El Tahan, MR (reprint author), Univ Dammam, Coll Med, Dept Anesthesiol, PO 40289, Dammam 31952, Al Khobar, Saudi Arabia.	mohamedrefaateltahan@yahoo.com		El Tahan, Mohamed/0000-0002-9730-6406			Aho AJ, 2011, BRIT J ANAESTH, V106, P69, DOI 10.1093/bja/aeq300; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Biedler A, 2000, ANAESTHESIST, V49, P286, DOI 10.1007/s001010050830; Bilotta F, 2007, EUR J ANAESTH, V24, P122, DOI 10.1017/S0265021506001244; Bilotta F, 2009, J NEUROSURG ANESTH, V21, P207, DOI 10.1097/ANA.0b013e3181a19c52; Bronco A, 2010, EUR J ANAESTH, V27, P912, DOI 10.1097/EJA.0b013e32833b652d; Cohen IT, 2003, PAEDIATR ANAESTH, V13, P63, DOI 10.1046/j.1460-9592.2003.00948.x; Hupfl M, 2008, ANAESTHESIA, V63, P583, DOI 10.1111/j.1365-2044.2008.05445.x; Jagers JV, 2009, RESP PHYSIOL NEUROBI, V167, P273, DOI 10.1016/j.resp.2009.05.008; Johr M, 2002, PAEDIATR ANAESTH, V12, P293, DOI 10.1046/j.1460-9592.2002.00799.x; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KESECIOGLU J, 1991, ACTA ANAESTH SCAND, V35, P616, DOI 10.1111/j.1399-6576.1991.tb03359.x; KRINTEL JJ, 1987, ACTA ANAESTH SCAND, V31, P352, DOI 10.1111/j.1399-6576.1987.tb02582.x; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; Mahajan VA, 2007, EUR J ANAESTH, V24, P505, DOI 10.1017/S0265021506001980; Mato M, 2002, Rev Esp Anestesiol Reanim, V49, P197; Morgaz J, 2011, VET J, V188, P352, DOI 10.1016/j.tvjl.2010.06.001; Philip BK, 1996, ANESTH ANALG, V83, P314, DOI 10.1097/00000539-199608000-00019; Riad W, 2007, EUR J ANAESTH, V24, P684, DOI 10.1017/S026502150700018X; Tas PWL, 2005, EUR J ANAESTH, V22, P694, DOI 10.1017/S0265021505001158; Turan A, 2004, ACTA ANAESTH SCAND, V48, P408, DOI 10.1111/j.0001-5172.2004.00350.x; Turan A, 2002, EUR J ANAESTH, V19, P452, DOI 10.1017/S0265021502000728; Vakkuri A, 2005, ANESTHESIOLOGY, V103, P274, DOI 10.1097/00000542-200508000-00010; Wu CC, 2006, EUR J ANAESTH, V23, P937, DOI 10.1017/S0265021506001220	24	8	8	0	6	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	OCT	2011	25	5					648	656		10.1007/s00540-011-1190-8			9	Anesthesiology	Anesthesiology	832YL	WOS:000295846700002	21755342				2020-06-30	J	Liu, ZF; Chai, XQ; Chen, KZ				Liu, Zhao-Fang; Chai, Xiao-Qing; Chen, Kun-Zhou			Flurbiprofen axetil enhances analgesic effect of fentanyl associated with increase in beta-endorphin levels	JOURNAL OF ANESTHESIA			English	Article						Flurbiprofen; Fentanyl; beta-Endorphin; Analgesic	CORTICOTROPIN-RELEASING FACTOR; RAT ADENOHYPOPHYSIS INVITRO; CENTRAL-NERVOUS-SYSTEM; POSTOPERATIVE PAIN; PROSTAGLANDIN E-2; INTRAVENOUS FLURBIPROFEN; ENDOGENOUS OPIOIDS; UP-REGULATION; SURGERY; HUMANS	Purpose To examine the analgesic effect of preoperative administration of flurbiprofen axetil and that of postoperative administration of a combination of flurbiprofen axetil and fentanyl, as well as perioperative plasma beta-endorphin (beta-EP) levels in patients undergoing esophagectomy. Methods Forty-five patients were randomly divided into three groups: group A: 100 mg flurbiprofen axetil preoperative, 10 mu g/kg fentanyl + 10 ml placebo postoperative; group B: 100 mg flurbiprofen axetil preoperative, 10 mu g/kg fentanyl + 100 mg flurbiprofen axetil postoperative; group C: 10 ml placebo preoperative, 10 mu g/kg fentanyl + 10 ml placebo postoperative. Postoperative analgesia was achieved by intravenous infusion containing flurbiprofen axetil and/or fentanyl at 2.0 ml/h (total volume, 100 ml) using infusion pumps. The beta-EP was measured at preanesthesia (T(1)), the end of surgery (T(2)), 24 h (T(3)), and 48 h (T(4)) after surgery. Visual analog scale scores (VAS) at T3, T4 (at rest), and rescue analgesic tramadol requirement was recorded. Results The VAS of group B was significantly lower than group A and C (P < 0.01) at T(3) and T(4). The beta-EP levels at T(2)-T(4) in group A did not differ significantly from those at T(1) (P > 0.05); however, the beta-EP levels in group B at T(3)-T(4) increased significantly (P < 0.05), while those in group C increased at T(2) and decreased at T(4) (P < 0.05). The beta-EP levels in group B at T(3) and T(4) were the highest as compared to its levels in groups A and C (P < 0.01). Tramadol consumption in group B was significantly lower than in groups A and C (P < 0.01). Conclusion These results show that flurbiprofen axetil enhances the analgesic effect of fentanyl associated with increase in beta-EP levels.	[Chai, Xiao-Qing; Chen, Kun-Zhou] Anhui Prov Hosp, Dept Anesthesiol, Hefei 230001, Peoples R China; [Liu, Zhao-Fang] Wannan Med Coll, Yijishan Hosp, Dept Anesthesiol, Wuhu 241001, Peoples R China	Chai, XQ (reprint author), Anhui Prov Hosp, Dept Anesthesiol, Hefei 230001, Peoples R China.	xiaoqingchai62@yahoo.cn					Arrigoni-Martelli E, 1979, Methods Find Exp Clin Pharmacol, V1, P157; Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542-200603000-00005; Cashman JN, 1996, DRUGS, V52, P13, DOI 10.2165/00003495-199600525-00004; [柴小青 CHAI Xiaoqing], 2007, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V27, P603; De Cosmo G, 2009, MINERVA ANESTESIOL, V75, P393; [辜晓岚 Gu Xiaolan], 2010, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V26, P391; HARGREAVES KM, 1987, CLIN PHARMACOL THER, V42, P601, DOI 10.1038/clpt.1987.206; HARGREAVES KM, 1987, BRAIN RES, V422, P154, DOI 10.1016/0006-8993(87)90550-6; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; Hartwig A C, 1991, Anesth Prog, V38, P75; Hashida M, 2005, CHEM PHARM BULL, V53, P871, DOI 10.1248/cpb.53.871; Hernandez-Delgadillo GP, 2006, EUR J PHARMACOL, V546, P54, DOI 10.1016/j.ejphar.2006.07.027; HERZ A, 1990, PHYSIOL BOHEMOSLOV, V39, P395; KNEPEL W, 1986, N-S ARCH PHARMACOL, V333, P149, DOI 10.1007/BF00506518; Korak-Leiter M, 2005, INTENS CARE MED, V31, P380, DOI 10.1007/s00134-005-2579-3; Kroin JS, 2006, ANESTH ANALG, V103, P334, DOI 10.1213/01.ane.0000223674.52364.5c; KULLICH W, 1992, AKTUEL RHEUMATOL, V17, P128, DOI 10.1055/s-2008-1047362; Max M B, 1987, Anesth Prog, V34, P113; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; Nakayama M, 2001, CAN J ANAESTH, V48, P234, DOI 10.1007/BF03019751; Ohmukai O, 1996, ADV DRUG DELIVER REV, V20, P203, DOI 10.1016/0169-409X(95)00123-O; Orti E, 1999, PHARMACOLOGY, V58, P190, DOI 10.1159/000028281; Parikh D, 2011, EUR J PHARMACOL, V650, P563, DOI 10.1016/j.ejphar.2010.10.050; Reuben SS, 2006, ANESTHESIOLOGY, V104, P411, DOI 10.1097/00000542-200603000-00006; Rittner HL, 2008, BRIT J ANAESTH, V101, P40, DOI 10.1093/bja/aen078; Spaziante R, 1990, J Neurosurg Sci, V34, P99; Suganuma T, 1998, BIOL PHARM BULL, V21, P756; Takada M, 2009, J ANESTH, V23, P500, DOI 10.1007/s00540-009-0799-3; Troullos E, 1997, CLIN PHARMACOL THER, V62, P74, DOI 10.1016/S0009-9236(97)90153-3; TSIKLAURI N, 2006, [No title captured], V137, P121; VLASKOVSKA M, 1984, ENDOCRINOLOGY, V115, P895, DOI 10.1210/endo-115-3-895; Yamashita Kazunori, 2006, J Anesth, V20, P92, DOI 10.1007/s00540-006-0389-6	32	12	23	2	5	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	OCT	2011	25	5					679	684		10.1007/s00540-011-1192-6			6	Anesthesiology	Anesthesiology	832YL	WOS:000295846700006	21725634				2020-06-30	J	Almousa, AA; Ikeda, R; Wada, M; Kuroda, N; Hanajiri, RK; Nakashima, K				Almousa, Ahmed A.; Ikeda, Rie; Wada, Mitsuhiro; Kuroda, Naotoka; Hanajiri, Ruri-Kikura; Nakashima, Kenichiro			HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Fentanyl; High performance liquid chromatography; Deproteinization; UV detection; Rat plasma; Pharmacokinetics	PERFORMANCE LIQUID-CHROMATOGRAPHY; NORFENTANYL; VALIDATION; EXTRACTION; ABUSE	A simple, rapid and validated high performance liquid chromatography method with UV detection for the quantification of an opioid agonist, fentanyl (FEN), in rat plasma was developed. The assay procedure involved chromatographic separation using a ZIC-HILIC SeQUANT column (250 mm x 4.6 mm, id., 5 mu m) and a mobile phase of acetonitrile and acetate buffer (pH 3.4, 20 mM) of ratio (=65:35, v/v) at a flow rate of 1.2 mL/min and detection wavelength of 201 nm. Plasma sample (100 mu L) pretreatment was based on simple deprotienization by acetonitrile spiked with clonidine as an internal standard (I.S.) of 20 ng/mL followed by extraction with tert-butyl methyl ether and centrifugation. The organic layer was evaporated under N-2 gas and reconstituted with 100 mu L of acetate buffer (pH 3.4, 20 mM), and 50-mu L portions of reconstituted sample were injected onto the column. Sample analysis including sample pretreatment was achieved within 35 min. Calibration curve was linear (r >= 0.998) from 5 to 100 ng/mL Both intra- and inter-clay assay precisions that are presented through RSD were lower than 12.6% for intra-day and lower than 12.0% for inter-day assessment. Limit of detection was 0.8 ng/mL at S/N of 3. This method was omitting the use of expensive solid phase extraction and time consuming liquid extraction procedures. Moreover, the present method was successfully applied to study pharmacokinetic parameters of FEN after intraperitoneal administration to male Wistar rat. Pharmacokinetic parameters estimated by using moment analysis were T-1/2 198.3 +/- 44.7 min, T-max 28.3 +/- 2.9 min and AUC(0-180) 15.6 +/- 2.9 (x 10(2)) ngmin/mL. (C) 2011 Elsevier B.V. All rights reserved.	[Almousa, Ahmed A.; Ikeda, Rie; Wada, Mitsuhiro; Kuroda, Naotoka; Nakashima, Kenichiro] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan; [Hanajiri, Ruri-Kikura] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan	Nakashima, K (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	naka-ken@nagasaki-u.ac.jp					[Anonymous], 1996, INT C HARM ICH TECHN; Bansal R, 1996, J LIQ CHROMATOGR R T, V19, P353, DOI 10.1080/10826079608001220; Alves HN, 2010, J AM ASSOC LAB ANIM, V49, P454; Chang YW, 2007, J CHROMATOGR B, V857, P195, DOI 10.1016/j.jchromb.2007.07.014; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Ebrahimzadeh H, 2008, ANAL CHIM ACTA, V626, P193, DOI 10.1016/j.aca.2008.07.047; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; KuKanich B, 2011, VET J, V188, P1, DOI 10.1016/j.tvjl.2011.02.015; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Stewart L. S. A., 2003, COMPARATIVE MED, V29, P53; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	16	10	11	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	OCT 1	2011	879	27					2941	2944		10.1016/j.jchromb.2011.08.029			4	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	831CI	WOS:000295705900015	21917532	Green Published			2020-06-30	J	Bellei, E; Roncada, P; Pisoni, L; Joechler, M; Zaghini, A				Bellei, E.; Roncada, P.; Pisoni, L.; Joechler, M.; Zaghini, A.			The use of fentanyl-patch in dogs undergoing spinal surgery: plasma concentration and analgesic efficacy	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article							TRANSDERMAL FENTANYL; POSTOPERATIVE PAIN; PHARMACOKINETICS; ANESTHESIA	Objectives of this study were to evaluate plasma concentrations and analgesic efficacy of fentanyl administered transdermically in dogs undergoing spinal surgery. At the end of the surgery and before awakening, a fentanyl-patch was applied and was maintained in situ for 72 h. Blood samples were taken before the application of the patch, at 2, 4, 6, 8, 10, 12, 18, 24, 32, 40, 48, 60, and 72 h after application and then 2, 4, 6, 8, 10, and 12 h after its removal. Before each blood sampling, pain evaluation was carried out using the Glasgow pain score, appropriately modified. Plasma concentrations of fentanyl were determined using a specific immuno-enzymatic kit. In this study, the minimum analgesic plasma concentration (0.23 ng/mL) required to achieve analgesia in human and considered to apply also for dogs was reached in all animals. No animal showed pain in the range of 'intense pain'; in two cases, the level of the pain was slight or moderate. No undesired effects were found. Results suggest that the use of transdermic patches could represent a valid aid in pain therapy in small animals; in particular, it contributes to the postoperative well-being of patients undergoing major surgery.	[Roncada, P.; Zaghini, A.] Univ Bologna, Fac Vet Med, Dept Vet Publ Hlth & Anim Pathol, I-40064 Bologna, Italy; [Bellei, E.; Pisoni, L.; Joechler, M.] Univ Bologna, Fac Vet Med, Vet Clin Dept, I-40064 Bologna, Italy	Roncada, P (reprint author), Univ Bologna, Fac Vet Med, Dept Vet Publ Hlth & Anim Pathol, Via Tolara Sopra 50, I-40064 Bologna, Italy.	paola.roncada@unibo.it					BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; CARROLL GL, 1998, SMALL ANIMAL PAIN MA, P1; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Firth AM, 1999, J AM VET MED ASSOC, V214, P651; Gilberto DB, 2003, CONTEMP TOP LAB ANIM, V42, P21; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; HELLYER PW, 2002, [No title captured], P82; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Holton LL, 1998, J AM VET MED ASSOC, V212, P61; Johnson C, 1999, IN PRACTICE, V21, P111; Johnston KD, 2010, ACTA ANAESTH SCAND, V54, P132, DOI 10.1111/j.1399-6576.2009.02115.x; Kyles AE, 1996, AM J VET RES, V57, P715; Martini L, 2000, J SURG RES, V88, P114, DOI 10.1006/jsre.1999.5789; MCKELVEY D, 2003, SMALL ANIMAL ANESTHE; Muir WW, 1998, COMP CONT EDUC PRACT, V20, P473; Nolan A. M., 1991, Journal of Veterinary Anaesthesia, V18, P30; Nolan A.M., 2000, PAIN MANAGEMENT ANIM, P21; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; ROBERTSON SA, 2008, PERSPECTIVES AGR VET, V3; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Sawyer DC, 1998, APPL ANIM BEHAV SCI, V59, P135, DOI 10.1016/S0168-1591(98)00128-2; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; Schultheiss P J, 1995, Contemp Top Lab Anim Sci, V34, P75; WONG PL, 1992, VET CLIN N AM-SMALL, V22, P471, DOI 10.1016/S0195-5616(92)50675-1; Xellyerw P, 2007, J AM ANIM HOSP ASSOC, V43, P235, DOI 10.5326/0430235	26	7	7	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	OCT	2011	34	5					437	441		10.1111/j.1365-2885.2010.01263.x			5	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	823AQ	WOS:000295093700004	21323929				2020-06-30	J	Rawlinson, E; Walker, A; Skone, R; Thillaivasan, A; Bagshaw, O				Rawlinson, E.; Walker, A.; Skone, R.; Thillaivasan, A.; Bagshaw, O.			A randomised controlled trial of two analgesic techniques for paediatric tonsillectomy	ANAESTHESIA			English	Article							POSTOPERATIVE NAUSEA; CODEINE PHOSPHATE; CHILDREN; PAIN; DEXAMETHASONE; ONDANSETRON; PROPHYLAXIS; PREVENTION; IBUPROFEN; SAFETY	Investigators from Bristol described a fentanyl- and diclofenac-based analgesic technique for tonsillectomy with low postoperative nausea and vomiting rates and low pain scores. This study compared the effectiveness of a modified Bristol technique with a codeine-based regimen with respect to PONV and analgesia. Sixty-five children, ASA 1-2, were randomly assigned to either the Bristol group (fentanyl 1-2 mu g.kg(-1) and diclofenac 1-2 mg.kg(-1)) or codeine group (codeine 1.5 mg.kg(-1)). All children received paracetamol 15 mg.kg(-1) and dexamethasone 0.1 mg.kg(-1). Postoperative nausea and vomiting and pain scores were recorded hourly, and fitness for discharge was assessed at 4 h. The overall incidence of postoperative nausea and vomiting was 21% with no difference between groups (Bristol group 8/30, codeine group 5/32, p = 0.29). Children in the Bristol group required analgesia earlier than those in the codeine group (p < 0.005), but maximum pain scores were not different (Bristol group median (IQR [range) 4.5 (3-5 [0-5]), codeine group 4.0 (2-5 [1-5]), p = 0.15). Twenty-three per cent of children were assessed as not fit for discharge at 4 h. The codeine-based regimen may have a small advantage over the Bristol regimen, but neither technique seems ideally suited for a day-case service without a longer period of observation.	[Walker, A.; Skone, R.; Thillaivasan, A.; Bagshaw, O.] Birmingham Childrens Hosp Children NHS Fdn Trust, Birmingham, W Midlands, England; [Rawlinson, E.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England	Bagshaw, O (reprint author), Birmingham Childrens Hosp Children NHS Fdn Trust, Birmingham, W Midlands, England.	oliver.bagshaw@bch.nhs.uk					Allford M, 2009, PEDIATR ANESTH, V19, P145, DOI 10.1111/j.1460-9592.2008.02860.x; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Bennett AMD, 2005, CLIN OTOLARYNGOL, V30, P418, DOI 10.1111/j.1365-2273.2005.01060.x; Bolton CM, 2006, BRIT J ANAESTH, V97, P593, DOI 10.1093/bja/ael256; Cardwell ME, 2005, COCHRANE DB SYST REV, V2; Carr AS, 2009, GUIDELINES PREVENTIO; Courtman SP, 1999, PAEDIATR ANAESTH, V9, P467, DOI 10.1046/j.1460-9592.1999.00416.x; Ewah BN, 2006, ANAESTHESIA, V61, P116, DOI 10.1111/j.1365-2044.2005.04463.x; Hamid SK, 1998, ANESTH ANALG, V86, P496, DOI 10.1097/00000539-199803000-00008; Hellier WPL, 1999, CLIN OTOLARYNGOL, V24, P208, DOI 10.1046/j.1365-2273.1999.00252.x; Husband AD, 1996, CLIN OTOLARYNGOL, V21, P99, DOI 10.1111/j.1365-2273.1996.tb01310.x; Kanerva M, 2003, INT J PEDIATR OTORHI, V67, P777, DOI 10.1016/S0165-5876(03)00097-1; Mills N, 2004, INT J PEDIATR OTORHI, V68, P1367, DOI 10.1016/j.ijporl.2004.04.009; Mukherjee K, 2001, ANAESTHESIA, V56, P1193; Pickering AE, 2002, BRIT J ANAESTH, V88, P72, DOI 10.1093/bja/88.1.72; Rose JB, 1999, BRIT J ANAESTH, V83, P104; Semple D, 1999, PAEDIATR ANAESTH, V9, P135, DOI 10.1046/j.1460-9592.1999.9220317.x; Splinter W, 1997, ANESTH ANALG, V85, P534, DOI 10.1097/00000539-199709000-00010; Splinter WM, 1996, ANESTH ANALG, V83, P913, DOI 10.1097/00000539-199611000-00004; StCharles CS, 1997, OTOLARYNG HEAD NECK, V117, P76, DOI 10.1016/S0194-5998(97)70211-0; Stewart DL, 2003, COCHRANE DB SYST REV, V1; Tramer MR, 1997, ANESTHESIOLOGY, V87, P1277, DOI 10.1097/00000542-199712000-00004; Tremlett M, 2010, PEDIATR ANESTH, V20, P183, DOI 10.1111/j.1460-9592.2009.03234.x; Whaley L, 1987, NURSING CARE INFANT; White MC, 2005, PEDIATR ANESTH, V15, P683, DOI 10.1111/j.1460-9592.2004.01516.x; Williams DG, 2002, BRIT J ANAESTH, V89, P839, DOI 10.1093/bja/aef284; Williams DG, 2001, BRIT J ANAESTH, V86, P413, DOI 10.1093/bja/86.3.413	27	9	10	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	OCT	2011	66	10					919	924		10.1111/j.1365-2044.2011.06851.x			6	Anesthesiology	Anesthesiology	820IP	WOS:000294899300012	21883125				2020-06-30	J	Strano-Rossi, S; Alvarez, I; Tabernero, MJ; Cabarcos, P; Fernandez, P; Bermejo, AM				Strano-Rossi, Sabina; Alvarez, Ivan; Tabernero, Maria Jesus; Cabarcos, Pamela; Fernandez, Purificacion; Bermejo, Ana Maria			Determination of fentanyl, metabolite and analogs in urine by GC/MS	JOURNAL OF APPLIED TOXICOLOGY			English	Article						fentanyl and analogs; urine analysis; GC/MS; forensic toxicology; doping analysis	SOLID-PHASE MICROEXTRACTION; CLINICAL PHARMACOKINETICS; SCREENING METHOD; HUMAN PLASMA; GAS; SUFENTANIL; ALFENTANIL; DEATHS; MISUSE; ABUSE	A rapid and sensitive method for the simultaneous determination of alfentanyl, sufentanyl and fentanyl (and its major metabolite norfentanyl) in urine was developed and validated. The method involved a liquid-liquid extraction in alkaline conditions, derivatization with pentafluoropropionic anhydride to improve the sensitivity for norfentanyl and subsequent analysis in GC/MS. The LODs are 0.08 ng ml(-1) for all substances (0.04 ng ml(-1) for alfentanyl). Intra-and inter-day precision coefficient of variation was always below 15%; mean relative error (accuracy) was always below 15%. The method was linear for all analytes, with quadratic regression of calibration curves always higher than 0.99. The method was applied to real samples of subjects who had received therapeutic doses of fentanyl, showing its suitability for the determination of low levels of these substances. The method was also applied to a subject whose death was attributed to fentanyl overdose. Copyright (C) 2010 John Wiley & Sons, Ltd.	[Strano-Rossi, Sabina] FMSI, Antidoping Lab, I-00168 Rome, Italy; [Alvarez, Ivan; Tabernero, Maria Jesus; Cabarcos, Pamela; Fernandez, Purificacion; Bermejo, Ana Maria] Univ Santiago de Compostela, Forens Toxicol Serv, Inst Legal Med, Santiago De Compostela, Spain	Strano-Rossi, S (reprint author), FMSI, Antidoping Lab, Lgo G Onesti 1, I-00168 Rome, Italy.	sabina.stranorossi@gmail.com	Tabernero-Duque, MariaJesus/H-6781-2015; Strano Rossi, Sabina/G-6866-2012; Bermejo, Ana/H-3221-2015; Rossi, Sabina Strano/P-4848-2019	Tabernero-Duque, MariaJesus/0000-0003-1069-6200; Rossi, Sabina Strano/0000-0001-7530-2968; Alvarez Freire, Ivan/0000-0003-3967-5366			Bagheri H, 2007, J PHARMACEUT BIOMED, V43, P1763, DOI 10.1016/j.jpba.2006.12.016; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Goldberger BA, 2010, METHODS MOL BIOL, V603, P245, DOI 10.1007/978-1-60761-459-3_22; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Gunnar T, 2005, J MASS SPECTROM, V40, P739, DOI 10.1002/jms.846; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; LEMMENS HJM, 1995, CLIN PHARMACOKINET, V29, P231, DOI 10.2165/00003088-199529040-00003; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Paradis C, 2002, THER DRUG MONIT, V24, P768, DOI 10.1097/00007691-200212000-00014; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Porreca F, 2009, PAIN MED, V10, P654, DOI 10.1111/j.1526-4637.2009.00583.x; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x; *WORLD ANT AG, 2010, WORLD ANT COD 2010 P; *WORLD ANT AG, 2010, 2009MRPL WADA	22	19	20	2	48	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0260-437X	1099-1263		J APPL TOXICOL	J. Appl. Toxicol.	OCT	2011	31	7					649	654		10.1002/jat.1613			6	Toxicology	Toxicology	847NK	WOS:000296979400007	21132842				2020-06-30	J	Le Roy, C; Laboureyras, E; Gavello-Baudy, S; Chateauraynaud, J; Laulin, JP; Simonnet, G				Le Roy, Chloe; Laboureyras, Emilie; Gavello-Baudy, Stephanie; Chateauraynaud, Jeremy; Laulin, Jean-Paul; Simonnet, Guy			Endogenous Opioids Released During Non-Nociceptive Environmental Stress Induce Latent Pain Sensitization Via a NMDA-Dependent Process	JOURNAL OF PAIN			English	Article						Stress; pain sensitization; hyperalgesia; endogenous opioids; NMDA receptors	PROTEIN-KINASE-C; LONG-LASTING HYPERALGESIA; SMALL-DOSE KETAMINE; POSTOPERATIVE PAIN; ANTINOCICEPTIVE TOLERANCE; THERMAL HYPERALGESIA; DELAYED HYPERALGESIA; RECEPTOR ANTAGONIST; MORPHINE-TOLERANCE; POSTSURGICAL PAIN	Although stress induces analgesia, there is evidence that stressful events may exacerbate pain syndromes. Here, we studied the effects of 1 to 3 prestressful events (days 0, 2, and 7), such as non-nociceptive environmental stress, on inflammatory hyperalgesia induced by a carrageenan injection (day 14) in 1 rat hind paw. Changes in nociceptive threshold were evaluated by the paw pressure vocalization test. The higher the number of stress sessions presented to the rats, the greater was the inflammatory hyperalgesia. Blockade of opioid receptors by naltrexone before each stress inhibited stress-induced analgesia and suppressed the exaggerated inflammatory hyperalgesia. Stressed versus nonstressed animals could be discriminated by their response to a fentanyl ultra-low dose (fULD), that produced hyperalgesia or analgesia, respectively. This pharmacological test permitted the prediction of the pain vulnerability level of prestressed rats because fULD analgesic or hyperalgesic indices were positively correlated with inflammatory hyperalgesic indices (r(2) = .84). In prestressed rats, fULD-induced hyperalgesia and the exaggerated inflammatory hyperalgesia were prevented NMDA receptor antagonists. This study provides some preclinical evidence that pain intensity is not only the result of nociceptive input level but is also dependent on the individual history, especially prior life stress events associated with endogenous opioid release. Perspective: Based on these preclinical data, it would be of clinical interest to evaluate whether prior stressful events may also affect further pain sensation in humans. Moreover, this preclinical model could be a good tool for evaluating new therapeutic strategies for relieving pain hypersensitivity. (C) 2011 by the American Pain Society	[Le Roy, Chloe; Laboureyras, Emilie; Gavello-Baudy, Stephanie; Chateauraynaud, Jeremy; Laulin, Jean-Paul; Simonnet, Guy] Univ Bordeaux, INCIA, CNRS UMR 5287, F-33076 Bordeaux, France	Simonnet, G (reprint author), Univ Bordeaux 2, Lab CNRS UMR 5287, Team Homeostasie Allostasie Pathol Rehabil, Zone Nord Bat 4A 3Eme Etage,146 Rue Leo Saignat, F-33076 Bordeaux, France.	gsimonnet@yahoo.com			Universite Victor Segalen Bordeaux 2; Universite Bordeaux 1; Ministere de l'Education Nationale; de l'enseignement superieur et de la Recherche; Centre National de la Recherche Scientifique (CNRS)Centre National de la Recherche Scientifique (CNRS); Ministere de la Recherche et de l'Enseignement Superieur	Supported by Universite Victor Segalen Bordeaux 2, Universite Bordeaux 1, the Ministere de l'Education Nationale, de l'enseignement superieur et de la Recherche and the Centre National de la Recherche Scientifique (CNRS). C. Le Roy has a fellowship from the Ministere de la Recherche et de l'Enseignement Superieur.	AKIL H, 1976, [No title captured], P63; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; BASBAUM AI, 1995, PAIN, V61, P349, DOI 10.1016/0304-3959(95)00009-H; Cabanero D, 2009, ANESTHESIOLOGY, V111, P1334, DOI 10.1097/ALN.0b013e3181bfab61; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Chizh BA, 2001, TRENDS PHARMACOL SCI, V22, P636, DOI 10.1016/S0165-6147(00)01863-0; Chung F, 1996, CAN J ANAESTH, V43, P1121, DOI 10.1007/BF03011838; Coderre TJ, 1997, BEHAV BRAIN SCI, V20, P404, DOI 10.1017/S0140525X97251484; CODERRE TJ, 1997, BEHAV BRAIN SCI, V20, P435; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Fletcher D, 1997, PAIN, V69, P303, DOI 10.1016/S0304-3959(96)03227-7; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Guignard B, 2002, ANESTH ANALG, V95, P103, DOI 10.1097/00000539-200207000-00018; Hirbec H, 2000, BRAIN RES, V859, P177, DOI 10.1016/S0006-8993(99)02420-8; Hoizey G, 2001, INT J PHARM, V229, P147, DOI 10.1016/S0378-5173(01)00842-0; Imbe H, 2006, FRONT BIOSCI-LANDMRK, V11, P2179, DOI 10.2741/1960; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Juni A, 2007, NEUROSCIENCE, V147, P439, DOI 10.1016/j.neuroscience.2007.04.030; Juni A, 2006, BRAIN RES, V1070, P35, DOI 10.1016/j.brainres.2005.11.054; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Khasar SG, 2008, J NEUROSCI, V28, P5721, DOI 10.1523/JNEUROSCI.0256-08.2008; Laboureyras E, 2009, ANESTH ANALG, V109, P623, DOI 10.1213/ane.0b013e3181aa956b; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; MAO J, 1994, J NEUROSCI, V14, P2301; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; McLean SA, 2004, MED HYPOTHESES, V63, P653, DOI 10.1016/j.mehy.2004.03.022; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Quintero L, 2000, PHARMACOL BIOCHEM BE, V67, P449, DOI 10.1016/S0091-3057(00)00374-9; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; RIVAT C, 2007, PAIN, V25, P25; Rivat C, 2007, NEUROPSYCHOPHARMACOL, V32, P2217, DOI 10.1038/sj.npp.1301340; Rivat C, 2010, PAIN, V150, P358, DOI 10.1016/j.pain.2010.05.031; Shenker N, 2003, RHEUMATOLOGY, V42, P1279, DOI 10.1093/rheumatology/keg397; Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103; Suarez-Roca H, 2006, BEHAV BRAIN RES, V167, P205, DOI 10.1016/j.bbr.2005.09.006; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20-18-07074.2000; Waxman AR, 2009, NEUROSCI LETT, V462, P68, DOI 10.1016/j.neulet.2009.06.061; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xie JY, 2005, J NEUROSCI, V25, P409, DOI 10.1523/JNEUROSCI.4054-04.2005; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	50	31	31	1	4	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	OCT	2011	12	10					1069	1079		10.1016/j.jpain.2011.04.011			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	834GH	WOS:000295947300006	21723199				2020-06-30	J	Cho, CH; Song, KS; Min, BW; Lee, KJ; Ha, E; Lee, YC; Lee, YK				Cho, Chul-Hyun; Song, Kwang-Soon; Min, Byung-Woo; Lee, Kyung-Jae; Ha, Eunyoung; Lee, Yong-Chul; Lee, Young-Kuk			Multimodal approach to postoperative pain control in patients undergoing rotator cuff repair	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Rotator cuff repair; Postoperative pain control; Multimodal approach	TOTAL KNEE ARTHROPLASTY; INTRAARTICULAR MORPHINE; ANALGESIA; BUPIVACAINE; INFUSION; SURGERY; BLOCK	This prospective study was undertaken to compare the effectiveness and safety of a multimodal pain control protocol with those of intravenous patient-controlled analgesia in rotator cuff repair. Seventy patients scheduled for rotator cuff repair were randomized to either a multimodal pain control group (group 1, 40 patients) or an intravenous patient-controlled analgesia group (group 2, 30 patients). We compared these two groups with respect to level of pain before surgery to the fifth postoperative day, duration of postoperative rehabilitation, consumption of additional analgesics, and adverse effects. Mean visual analogue scale scores immediately after surgery (day 0) and on postoperative days 1-5 were 6.9, 5.5, 4.3, 3.3, 3.0, and 2.6 in group 1 and 7.8, 5.9, 4.4, 4.7, 4.3, and 3.7 in group 2. Pain relief was significantly better in group 1 on days 0, 3, 4, and 5 (P = 0.026, 0.006, 0.010, and 0.009, respectively). Furthermore, functional recovery occurred earlier in group 1. No significant differences were observed between the two groups with respect to nausea, vomiting, urinary retention, and headache (n.s.), but group 1 was found to be significantly less likely to experience dizziness or urticaria (P = 0.007, 0.017, respectively). One other significant difference was observed: 1 patient (2.5%) in group 1 and 6 patients (20%) in group 2 discontinued regimen because of medication-related adverse effects (P = 0.016). The multimodal pain control protocol was found to offer more effective postoperative pain control with fewer adverse effects than intravenous patient-controlled analgesia. However, achieving adequate pain control within the first 48 h of surgery remains challenging, and thus, the developments of more effective and safer multimodal pain control protocols are required.	[Cho, Chul-Hyun; Song, Kwang-Soon; Min, Byung-Woo; Lee, Kyung-Jae; Ha, Eunyoung] Keimyung Univ, Dept Orthoped Surg, Pain Res Ctr, Dongsan Med Ctr,Sch Med, Taegu 700712, South Korea; [Lee, Yong-Chul] Keimyung Univ, Dongsan Med Ctr, Sch Med, Dept Anesthesiol, Taegu 700712, South Korea; [Lee, Young-Kuk] Beauty Korea Hosp, Dept Orthoped Surg, Taegu, South Korea	Cho, CH (reprint author), Keimyung Univ, Dept Orthoped Surg, Pain Res Ctr, Dongsan Med Ctr,Sch Med, 194 Dongsan Dong, Taegu 700712, South Korea.	oscho5362@dsmc.or.kr	teng, yj/C-4440-2011	Song, Kwang Soon/0000-0001-6029-1901; Cho, Chul-Hyun/0000-0003-0252-8741			ALBERT TJ, 2001, J ARTHROPLASTY, V6, P23; Bishop JY, 2005, J BONE JOINT SURG AM, V87A, P974, DOI 10.2106/JBJS.D.02003; Boss AP, 2004, J SHOULDER ELB SURG, V13, P630, DOI 10.1016/j.jse.2004.04.005; BURNS JW, 1989, ANAESTHESIA, V44, P2, DOI 10.1111/j.1365-2044.1989.tb11086.x; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Cho NS, 2007, AM J SPORT MED, V35, P75, DOI 10.1177/0363546506291632; Cohen DB, 2006, AM J SPORT MED, V34, P362, DOI 10.1177/0363546505280428; Dorr LD, 2008, J ARTHROPLASTY, V23, P502, DOI 10.1016/j.arth.2007.10.004; Elvir-Lazo Ofelia Loani, 2010, Anesthesiol Clin, V28, P217, DOI 10.1016/j.anclin.2010.02.011; Filos KS, 1999, EUR SURG RES, V31, P97, DOI 10.1159/000008627; Hartrick CT, 2004, AM J HEALTH-SYST PH, V61, pS4, DOI 10.1093/ajhp/61.suppl_1.S4; HEARD SO, 1992, ANESTH ANALG, V74, P822; Horlocker TT, 2002, REGION ANESTH PAIN M, V27, P105, DOI 10.1053/rapm.2002.27177; JAUREGUITO JW, 1995, AM J SPORT MED, V23, P350, DOI 10.1177/036354659502300318; Jin FL, 2001, J CLIN ANESTH, V13, P524, DOI 10.1016/S0952-8180(01)00320-8; Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P185, DOI 10.1016/j.atc.2004.11.010; Oh JH, 2007, J SHOULDER ELB SURG, V16, P295, DOI 10.1016/j.jse.2006.04.015; Parvataneni Hari K, 2007, Instr Course Lect, V56, P125; Parvizi Javad, 2009, Instr Course Lect, V58, P769; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Ruiz-Suarez M, 2008, ORTHOPEDICS, V31, P1130, DOI 10.3928/01477447-20081101-25; Scoggin JF, 2002, ARTHROSCOPY, V18, P464, DOI 10.1053/jars.2002.29895; SINATRA RS, 2002, J AM ACAD ORTHOP SUR, V10, P117; Skinner Harry B, 2004, Am J Orthop (Belle Mead NJ), V33, P5; Tang R, 2009, ORTHOP CLIN N AM, V40, P377, DOI 10.1016/j.ocl.2009.04.001; Tempfer H, 2009, ACTA ORTHOP, V80, P357, DOI 10.3109/17453670902988360; Vendittoli PA, 2006, J BONE JOINT SURG AM, V88A, P282, DOI 10.2106/JBJS.E.00173; Viscusi Eugene R, 2004, Am J Orthop (Belle Mead NJ), V33, P13; White PF, 2008, CURR OPIN INVEST DR, V9, P76; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	30	31	32	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	OCT	2011	19	10					1744	1748		10.1007/s00167-010-1294-y			5	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	822IN	WOS:000295037900022	20957469				2020-06-30	J	Andresen, T; Staahl, C; Oksche, A; Mansikka, H; Arendt-Nielsen, L; Drewes, AM				Andresen, T.; Staahl, C.; Oksche, A.; Mansikka, H.; Arendt-Nielsen, L.; Drewes, A. M.			Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						experimental pain; tissue differentiated effects; buprenorphine; fentanyl	NERVE GROWTH-FACTOR; INDUCED SECONDARY HYPERALGESIA; DOSE-DEPENDENT PAIN; HEALTHY-VOLUNTEERS; INTRADERMAL CAPSAICIN; ELECTRICAL-STIMULATION; POSTOPERATIVE PAIN; INFLAMMATORY PAIN; CANCER PAIN; BUPRENORPHINE	BACKGROUND AND PURPOSE Chronic pain and hyperalgesia can be difficult to treat with classical opioids acting predominately at the m-opioid receptor. Buprenorphine and its active metabolite are believed to act through mu-, kappa- and delta-receptors and may therefore possess different analgesic and anti-hyperalgesic effects compared with pure mu-receptor agonists, for example, fentanyl. Here, we have compared the analgesic and anti-hyperalgesic effects of buprenorphine and fentanyl. EXPERIMENTAL APPROACH Twenty-two healthy volunteers were randomized to treatment with transdermal buprenorphine (20 mu g.h(-1), 144 h), fentanyl (25 mu g.h(-1), 72 h) or placebo patches in a double-blind, cross-over experimental pain study. The experimental pain tests (phasic pain, sensitization) involved pressure at the tibial bone, cutaneous electrical and thermal stimulation, intramuscular nerve growth factor, UVB light burn injury model and intradermal capsaicin-induced hyperalgesia. Pain testing was carried out at baseline, 24, 48, 72 and 144 h after application of the drugs. KEY RESULTS Compared with placebo, buprenorphine, but not fentanyl, significantly attenuated pressure at the tibial bone as well as pressure pain in the primary hyperalgesic area induced by UVB light The two drugs were equipotent and better than placebo against cutaneous thermal pain stimulation), but failed to show significant analgesic effect to cutaneous electrical stimulation, nerve growth factor-induced muscle soreness and to capsaicin-induced hyperalgesia. CONCLUSIONS AND IMPLICATIONS Buprenorphine, but not fentanyl, showed analgesic effects against experimentally induced, bone-associated pain and primary hyperalgesia compared with placebo. These tissue-and modality-differentiated properties may reflect the variable effects of opioid drugs observed in individual patients.	[Andresen, T.; Staahl, C.; Drewes, A. M.] Aarhus Univ, Aalborg Hosp, Dept Gastroenterol, DK-8000 Aarhus C, Denmark; [Andresen, T.; Arendt-Nielsen, L.; Drewes, A. M.] Aalborg Univ, Dept Hlth Sci & Technol, Ctr Sensory Motor Interact SMI, Aalborg, Denmark; [Oksche, A.; Mansikka, H.] Mundipharma Res GmbH & Co KG, Limburg, Germany; [Oksche, A.] Univ Giessen, Rudolf Buchheim Inst Pharmakol, D-35390 Giessen, Germany	Drewes, AM (reprint author), Aalborg Univ Hosp, Dept Gastroenterol, Mollepk Vej 4, DK-9000 Aalborg, Denmark.	drewes@hst.aau.dk	Arendt-Nielsen, Lars/T-4885-2018; Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770; Arendt-Nielsen, Lars/0000-0003-0892-1579; Drewes, Asbjorn/0000-0001-7465-964X	Mundipharma; Mundipharma Research GmbH Co.	The study was supported by an unrestricted grant from Mundipharma.; The study was supported by an unrestricted grant from Mundipharma Research GmbH & Co.	Alexander SPH, 2009, BRIT J PHARMACOL, V158, pS1, DOI 10.1111/j.1476-5381.2009.00499.x; Andersen H, 2008, EXP BRAIN RES, V191, P371, DOI 10.1007/s00221-008-1531-5; Arendt-Nielsen L, 2007, CURR OPIN INVEST DR, V8, P41; ArendtNielsen L, 1997, PAIN, V69, P255, DOI 10.1016/S0304-3959(96)03244-7; Aurilio C, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-61; Ballantyne JC, 2007, PAIN, V129, P235, DOI 10.1016/j.pain.2007.03.028; Bickel A, 1998, PAIN, V76, P317, DOI 10.1016/S0304-3959(98)00062-1; Bishop T, 2009, EUR J PAIN, V13, P524, DOI 10.1016/j.ejpain.2008.06.006; Brainin-Mattos J, 2006, PAIN, V122, P174, DOI 10.1016/j.pain.2006.01.032; BRENNUM J, 1993, PAIN, V52, P75, DOI 10.1016/0304-3959(93)90117-8; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Curatolo Michele, 2006, Phys Med Rehabil Clin N Am, V17, P287, DOI 10.1016/j.pmr.2005.12.010; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; Delaney A, 2008, BRIT J ANAESTH, V101, P87, DOI 10.1093/bja/aen100; DOBKIN AB, 1977, CAN ANAESTH SOC J, V24, P195, DOI 10.1007/BF03006232; Draxler J, 2008, SCHMERZ, V22, P571, DOI 10.1007/s00482-008-0660-x; Eisenach JC, 1997, ANESTHESIOLOGY, V86, P1279, DOI 10.1097/00000542-199706000-00008; Elsner F, 1999, SCHMERZ, V13, P273, DOI 10.1007/s004820050210; Fraser GL, 2000, BRIT J PHARMACOL, V129, P1668, DOI 10.1038/sj.bjp.0703248; Gaveriaux-Ruff C, 2008, EUR J NEUROSCI, V27, P2558, DOI 10.1111/j.1460-9568.2008.06223.x; Gordon A, 2010, PAIN RES MANAG, V15, P169, DOI 10.1155/2010/216725; Gottrup H, 2004, CLIN PHYSIOL FUNCT I, V24, P103, DOI 10.1111/j.1475-097X.2004.00537.x; GRONBLAD M, 1984, ANAT REC, V209, P297, DOI 10.1002/ar.1092090306; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Gustorff B, 2004, ANESTH ANALG, V98, P173, DOI 10.1213/01.ANE.0000093224.77281.A5; Gustorff G, 2004, ANESTH ANALG, V98, P401, DOI 10.1213/01/ANE.0000095150.76735.5D; HAMILTON RC, 1967, BRIT J ANAESTH, V39, P490, DOI 10.1093/bja/39.6.490; Heldestad V, 2010, CLIN NEUROPHYSIOL, V121, P1878, DOI 10.1016/j.clinph.2010.03.055; Hoffmann RT, 1999, EUR J PAIN-LONDON, V3, P131, DOI 10.1053/eujp.1998.0106; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; Hughes A, 2002, PAIN, V99, P323, DOI 10.1016/S0304-3959(02)00161-6; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; KAYB, 1978, BRIT J ANAESTH, V50, P605; Kellgren JH, 1939, CLIN SCI, V4, P35; Koltzenburg M, 2006, PAIN, V126, P165, DOI 10.1016/j.pain.2006.06.028; Koppert W, 2005, PAIN, V118, P15, DOI 10.1016/j.pain.2005.06.030; Koppert W, 1999, ANESTH ANALG, V89, P1521, DOI 10.1097/00000539-199912000-00039; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; Lecyby R, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-5; Likar R, 2008, INT J CLIN PRACT, V62, P152, DOI 10.1111/j.1742-1241.2007.01531.x; McDowell TS, 2004, NEUROSCIENCE, V125, P1029, DOI 10.1016/j.neuroscience.2004.03.009; Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8; Mizoguchi H, 2003, J PHARMACOL EXP THER, V306, P394, DOI 10.1124/jpet.103.048835; Mousa SA, 2007, BRAIN, V130, P502, DOI 10.1093/brain/awl330; Naef M, 2003, PAIN, V105, P79, DOI 10.1016/S0304-3959(03)00163-5; Negus SS, 2006, J PHARMACOL EXP THER, V319, P507, DOI 10.1124/jpet.106.106377; NEGUS SS, 1989, PSYCHOPHARMACOLOGY, V98, P141, DOI 10.1007/BF00442021; Olesen AE, 2010, BRIT J CLIN PHARMACO, V70, P189, DOI 10.1111/j.1365-2125.2010.03700.x; Park JH, 2011, ACTA NEUROCHIR, V153, P181, DOI 10.1007/s00701-010-0785-4; Pergolizzi J, 2010, PAIN PRACT, V10, P428, DOI 10.1111/j.1533-2500.2010.00378.x; Rosier R, 1992, Am J Hosp Palliat Care, V9, P37, DOI 10.1177/104990919200900610; Scanlon GC, 2006, J INVEST MED, V54, P238, DOI 10.2310/6650.2006.05046; Schulte H, 2003, ACTA ANAESTH SCAND, V47, P1020, DOI 10.1034/j.1399-6576.2003.00204.x; Schutter Ulf, 2008, MMW Fortschr Med, V150 Suppl 2, P96; Sethna NF, 1998, ANESTH ANALG, V86, P1250, DOI 10.1097/00000539-199806000-00022; SIMONE DA, 1989, PAIN, V38, P99, DOI 10.1016/0304-3959(89)90079-1; Sittl R, 2005, CLIN THER, V27, P1022, DOI 10.1016/j.clinthera.2005.06.024; Staahl C, 2004, BASIC CLIN PHARMACOL, V95, P97; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006; Staahl C, 2009, BRIT J CLIN PHARMACO, V68, P149, DOI 10.1111/j.1365-2125.2009.03456.x; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Svensson P, 2003, PAIN, V104, P241, DOI 10.1016/S0304-3959(03)00012-5; Sycha T, 2003, BRIT J CLIN PHARMACO, V56, P165, DOI 10.1046/j.0306-5251.2003.01869.x; Taylor BK, 2009, CURR PAIN HEADACHE R, V13, P208, DOI 10.1007/s11916-009-0035-8; TOREBJORK HE, 1992, J PHYSIOL-LONDON, V448, P765, DOI 10.1113/jphysiol.1992.sp019069; Vanderah TW, 2000, J NEUROSCI, V20, P7074, DOI 10.1523/JNEUROSCI.20-18-07074.2000; VATINE JJ, 1993, ARCH PHYS MED REHAB, V74, P526, DOI 10.1016/0003-9993(93)90118-T; Wallace MS, 2002, ANESTH ANALG, V95, P973, DOI 10.1097/00000539-200210000-00034; Yassen A, 2006, ANESTHESIOLOGY, V104, P1232, DOI 10.1097/00000542-200606000-00019	71	27	28	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	OCT	2011	164	3			SI		934	945		10.1111/j.1476-5381.2010.01180.x			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	820SP	WOS:000294926000009	21182491	Green Published, Bronze			2020-06-30	J	Elshammaa, N; Chidambaran, V; Housny, W; Thomas, J; Zhang, X; Michael, R				Elshammaa, Nabil; Chidambaran, Vidya; Housny, Walaa; Thomas, Joan; Zhang, Xue; Michael, Rafik			Ketamine as an adjunct to fentanyl improves postoperative analgesia and hastens discharge in children following tonsillectomy - a prospective, double-blinded, randomized study	PEDIATRIC ANESTHESIA			English	Article						analgesia; ketamine; N-methyl-D-aspartate; tonsillectomy	SMALL-DOSE KETAMINE; INTRAOPERATIVE KETAMINE; MORPHINE CONSUMPTION; SLEEP-APNEA; PAIN; PREVENTION; RECEPTORS; TRIALS; SINGLE	Objective: To evaluate the effect of ketamine, as an adjunct to fentanyl, on postoperative analgesia and duration of Postoperative Care Unit (PACU) stay, in children undergoing tonsillectomy. Background: Ketamine, as an N-methyl-D-aspartate antagonist, has been recognized to have an opioid sparing effect. In addition, it does not depress respiration or affect airway tone. Hence, addition of ketamine could be potentially beneficial in children undergoing tonsillectomy, due to the high incidence of sleep apnea in these patients. Methods: In a double blinded, randomized trial, 60 ASA status I and 11 children between 2 and 7 years of age, scheduled to undergo elective tonsillectomy were recruited. They were randomly assigned to one of four groups to receive fentanyl 1 mcg.kg(-1) (F1 group), fentanyl 2 mcg.kg(-1) (F2 group), ketamine 0.5 mg.kg(-1) (K group), or fentanyl 1 mcg.kg(-1) plus ketamine 0.5 mg.kg(-1) (FK group) pre-incision. Postoperative pain was scored on arrival to the PACU and at 30, 60, and 90 min thereafter. Any incidence of nausea/vomiting and time to discharge from the PACU were also recorded. Results: Important predictors found for postoperative pain on arrival to the recovery room are the group (P = 0.02) and duration of surgery (P = 0.02). Least square means and standard errors of pain scores on PACU arrival were 4.87 +/- 0.69, 3.04 +/- 0.68, 2.10 +/- 0.68 and 2.03 +/- 0.69 for F1, F2, K and FK groups, respectively. On group-wise comparison adjusted for surgical time, significant difference was detected between F1 and K (P = 0.02), and F1 and FK (P = 0.0048) groups. Marginal significance was detected in duration of PACU stay among groups (P = 0.08); F2 and FK group had a shorter PACU stay than F1 (P = 0.05 and 0.04 respectively). No significant difference was detected in the need for supplemental analgesia. Conclusion: We conclude that the administration of ketamine 0.5 mg.kg(-1) with 1 mcg.kg(-1) fentanyl in children undergoing tonsillectomy may improve postoperative pain control without delaying home discharge.	[Chidambaran, Vidya] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA; [Elshammaa, Nabil; Housny, Walaa; Thomas, Joan; Michael, Rafik] Brookdale Univ Hosp & Med Ctr, Dept Anesthesia, Brooklyn, NY USA; [Zhang, Xue] Univ Cincinnati, Coll Med, Dept Stat, Cincinnati, OH USA	Chidambaran, V (reprint author), Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, 3333 Burnet Ave,MLC 2001, Cincinnati, OH 45229 USA.	vidya.chidambaran@cchmc.org			Department of Anesthesia, Brookdale University Hospital and Medical Center	This work is supported by the Department of Anesthesia, Brookdale University Hospital and Medical Center. No financial support except departmental salary support for the authors at their respective institutions.	Abu-Shahwan I, 2008, CLIN J PAIN, V24, P395, DOI 10.1097/AJP.0b013e3181668aad; Angst MS, 2010, ANESTHESIOLOGY, V113, P514, DOI 10.1097/ALN.0b013e3181e9092d; ARENDTNIELSEN L, 1995, ANESTH ANALG, V81, P63, DOI 10.1097/00000539-199507000-00013; Aydin ON, 2007, J CLIN ANESTH, V19, P115, DOI 10.1016/j.jclinane.2006.06.003; Batra YK, 2007, INT J CLIN PHARM TH, V45, P155; Bazin V, 2010, EUR J ANAESTH, V27, P47, DOI 10.1097/EJA.0b013e32832dbd2f; Bell RF, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD004603.PUB2; Bilgin H, 2005, J CLIN ANESTH, V17, P592, DOI 10.1016/j.jclinane.2005.04.005; Cardwell M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003591.pub2; Carstensen M, 2010, BRIT J ANAESTH, V104, P401, DOI 10.1093/bja/aeq041; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Dahl V, 2000, ANESTH ANALG, V90, P1419, DOI 10.1097/00000539-200006000-00031; Elhakim M, 2003, ACTA ANAESTH SCAND, V47, P604, DOI 10.1034/j.1399-6576.2003.00111.x; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Erhan OL, 2007, INT J PEDIATR OTORHI, V71, P735, DOI 10.1016/j.ijporl.2007.01.008; GUNTER JB, 1995, ANESTH ANALG, V81, P1136, DOI 10.1097/00000539-199512000-00004; Kochs E, 1996, ANESTHESIOLOGY, V85, P304, DOI 10.1097/00000542-199608000-00012; Liang Shi-wei, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1663; Loftus RW, 2010, ANESTHESIOLOGY, V113, P639, DOI 10.1097/ALN.0b013e3181e90914; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Marcus RJ, 2000, BRIT J ANAESTH, V84, P739; Menigaux C, 2001, ANESTH ANALG, V93, P606, DOI 10.1097/00000539-200109000-00016; MURRAY WB, 1987, S AFR MED J, V72, P839; Noordzij JP, 2006, LARYNGOSCOPE, V116, P1303, DOI 10.1097/01.mlg.0000225944.00189.e9; Orser BA, 1997, ANESTHESIOLOGY, V86, P903, DOI 10.1097/00000542-199704000-00021; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; Schwengel DA, 2009, ANESTH ANALG, V109, P60, DOI 10.1213/ane.0b013e3181a19e21; Thangathurai D, 2009, J CLIN SLEEP MED, V5, P480	28	28	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	OCT	2011	21	10					1009	1014		10.1111/j.1460-9592.2011.03604.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	821LE	WOS:000294975700004	21575100				2020-06-30	J	da Silva, PSL; Passos, RMA; Waisberg, DR				da Silva, Paulo S. L.; Passos, Roselene M. A.; Waisberg, Daniel R.			Withdrawal treatment with clonidine after prolonged use of chloral hydrate in a pediatric intensive care patient	PEDIATRIC ANESTHESIA			English	Letter							SEDATION; ANALGESIA; CHILDREN		[da Silva, Paulo S. L.; Passos, Roselene M. A.; Waisberg, Daniel R.] Hosp Servidor Publ Municipal, Pediat Intens Care Unit, Dept Pediat, Sao Paulo, Brazil	da Silva, PSL (reprint author), Hosp Servidor Publ Municipal, Pediat Intens Care Unit, Dept Pediat, Sao Paulo, Brazil.	psls.nat@terra.com.br	Waisberg, Daniel/AAD-9783-2019; Silva, Paulo Sergio L/P-5182-2018	Waisberg, Daniel/0000-0003-4284-0633; 			BJORKQVIST SE, 1975, ACTA PSYCHIAT SCAND, V52, P256, DOI 10.1111/j.1600-0447.1975.tb00041.x; Ista E, 2009, INTENS CARE MED, V35, P1075, DOI 10.1007/s00134-009-1487-3; Martinbiancho JK, 2009, EUR J CLIN PHARMACOL, V65, P1253, DOI 10.1007/s00228-009-0694-8; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079	5	2	2	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	OCT	2011	21	10					1082	1083		10.1111/j.1460-9592.2011.03630.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	821LE	WOS:000294975700022	21981100				2020-06-30	J	Kanbayashi, Y; Hosokawa, T; Okamoto, K; Fujimoto, S; Konishi, H; Otsuji, E; Yoshikawa, T; Takagi, T; Miki, T; Taniwaki, M				Kanbayashi, Yuko; Hosokawa, Toyoshi; Okamoto, Kousuke; Fujimoto, Sawako; Konishi, Hideyuki; Otsuji, Eigo; Yoshikawa, Toshikazu; Takagi, Tatsuya; Miki, Tsuneharu; Taniwaki, Masafumi			Factors Predicting Requirement of High-dose Transdermal Fentanyl in Opioid Switching From Oral Morphine or Oxycodone in Patients With Cancer Pain	CLINICAL JOURNAL OF PAIN			English	Article						transdermal fentanyl; opioid switching; morphine; oxycodone; cancer pain	PALLIATIVE CARE; PHARMACOKINETICS; ABSORPTION; METHADONE; SYSTEM; TRIAL	Objectives: To identify predictive factors requiring high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone to transdermal fentanyl in patients with cancer pain. Methods: The participants were 76 hospitalized terminal cancer patients who underwent opioid switching from oxycodone or morphine sustained-release tablet to transdermal fentanyl at our hospital between January 2009 and June 2010. The conversion dose was calculated as transdermal fentanyl (25 mu g/h)/oral morphine (60 mg) or oxycodone (40 mg) = 1. The response evaluated was the dose conversion ratio [transdermal fentanyl/oral morphine or oxycodone (conversion dose to fentanyl)] = Y and was taken to be 0 for Y <= 1, 1 for 1 < Y <= 2, 2 for 2 < Y <= 3, and 3 for 3 < Y. Predictors evaluated were factors potentially impacting pain. Ordered logistic regression analysis was carried out to identify the predictive factors requiring high-dose transdermal fentanyl in opioid switching. Results: Breast cancer [odds ratio (OR) = 8.218; 95% confidence interval (CI), 1.219-55.407; P = 0.0305], total protein level (OR = 0.630; 95% CI, 0.408-0.974; P = 0.0377), alanine aminotransferase level (OR = 1.017; 95% CI, 1.001-1.033; P = 0.0390), advanced age (OR = 3.700; 95% CI, 1.360-10.063; P = 0.0104), and male sex (OR = 3.702; 95% CI, 1.355-10.115; P = 0.0107) were found to be significant predictive factors requiring high-dose transdermal fentanyl in opioid switching. Discussion: Our study indicates that breast cancer, total protein, alanine aminotransferase, advanced age, and male sex are significant predictors of a need for higher dose transdermal fentanyl in opioid switching. Our results are considered likely to contribute to the establishment of evidence-based medicine in pain relief and palliative care.	[Kanbayashi, Yuko; Hosokawa, Toyoshi; Fujimoto, Sawako] Kyoto Prefectural Univ Med, Univ Hosp, Dept Pain Treatment, Kyoto 6028566, Japan; [Kanbayashi, Yuko; Hosokawa, Toyoshi; Fujimoto, Sawako] Kyoto Prefectural Univ Med, Univ Hosp, Palliat Care Unit, Kyoto 6028566, Japan; [Kanbayashi, Yuko] Kyoto Prefectural Univ Med, Univ Hosp, Dept Hosp Pharm, Kyoto 6028566, Japan; [Hosokawa, Toyoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Anaesthesiol, Kyoto 6028566, Japan; [Konishi, Hideyuki; Yoshikawa, Toshikazu] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kyoto 6028566, Japan; [Otsuji, Eigo] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Digest Surg, Kyoto 6028566, Japan; [Miki, Tsuneharu] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Urol, Kyoto 6028566, Japan; [Taniwaki, Masafumi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Hematol & Oncol, Kyoto 6028566, Japan; [Kanbayashi, Yuko; Okamoto, Kousuke; Takagi, Tatsuya] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka, Japan; [Takagi, Tatsuya] Osaka Univ, Microbial Dis Res Inst, Genome Informat Res Ctr, Suita, Osaka 565, Japan	Kanbayashi, Y (reprint author), Kyoto Prefectural Univ Med, Dept Hosp Pharm, Kamigyo Ku, Kyoto 6028566, Japan.	ykokanba@koto.kpu-m.ac.jp		Kanbayashi, Yuko/0000-0002-0095-2293; TAKAGI, Tatsuya/0000-0002-0044-0722			Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Armstrong SC, 2009, PSYCHOSOMATICS, V50, P169, DOI 10.1176/appi.psy.50.2.169; Benitez-Rosario MA, 2004, CANCER-AM CANCER SOC, V101, P2866, DOI 10.1002/cncr.20712; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; Cicek M, 2006, CANCER METAST REV, V25, P635, DOI 10.1007/s10555-006-9035-x; Clemens KE, 2007, JPN J CLIN ONCOL, V37, P302, DOI 10.1093/jjco/hym017; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Kanbayashi Y, 2009, CLIN J PAIN, V25, P65, DOI 10.1097/AJP.0b013e31817e1379; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Mercadante S, 2005, J CLIN ONCOL, V23, P5229, DOI 10.1200/JCO.2005.13.128; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Otis J, 2006, CURR MED RES OPIN, V22, P1493, DOI 10.1185/030079906X115540; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Ripamonti C, 2006, SUPPORT CARE CANCER, V14, P400, DOI 10.1007/s00520-005-0918-0; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Solassol I, 2005, ONCOL REP, V14, P1029; Tegeder I, 1999, CLIN PHARMACOKINET, V37, P17, DOI 10.2165/00003088-199937010-00002; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4	23	10	11	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	OCT	2011	27	8					664	667		10.1097/AJP.0b013e3182168fed			4	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	817XF	WOS:000294709700002	21471811				2020-06-30	J	Rahman, NHNA; Hashim, A				Rahman, Nik H. N. A.; Hashim, Ahmad			The use of propofol for procedural sedation and analgesia in the emergency department: a comparison with midazolam	EMERGENCY MEDICINE JOURNAL			English	Article							CAPNOGRAPHY; TRIAL	Introduction This study aimed to determine the effectiveness of propofol as an alternative agent for procedural sedation and analgesia (PSA) in the emergency department (ED) and to make a comparison between two different sedative (propofol vs midazolam) drugs used in combination with fentanyl. Objectives To compare outcomes between a combination of fentanyl and propofol with fentanyl and midazolam in patients during and after PSA. Methodology A randomised single blinded control trial carried out in the ED of a university hospital. 40 patients were randomly allocated equally into two groups: group A, 20 subjects received intravenous fentanyl 3 mg/kg as a bolus dose and a titration maximum bolus dose of propofol 1 mg/kg followed by a maximum titration top-up of 0.5 mg/kg if needed; group B, 20 subjects received intravenous fentanyl 3 mg/kg as a bolus dose and a titration maximum bolus dose of midazolam 0.1 mg/kg and a maximum titration top-up of 0.1 mg/kg if needed. The target sedation level was a Ramsay score of 3 or 4. Outcomes included the presence of any adverse events related to PSA and time to discharge. The Mann-Whitney U test was used to compare the two groups. Results None of the patients developed any significant adverse events during and after procedures. The mean length of stay in the propofol and midazolam groups was 29.25 (11.03) and 71.75 (60.64) min, respectively (p<0.001). Conclusion Both propofol and midazolam given at the recommended doses were equally safe and effective for PSA in the ED. The propofol group was discharged much earlier than to the midazolam group.	[Rahman, Nik H. N. A.] Univ Sains Malaysia, Sch Med Sci, Dept Emergency Med, Kota Baharu, Malaysia; [Hashim, Ahmad] Queen Elizabeth Hosp, Dept Emergency & Trauma, Sabah, Malaysia	Rahman, NHNA (reprint author), USM, Sch Med Sci, Dept Emergency Med, Kubang Kerian 16150, Malaysia.	nhliza@hotmail.com			medical school of Universiti Sains Malaysia [JKP/PPSP/USM/06]	This study was conducted by the use of a short-term grant provided by the medical school of Universiti Sains Malaysia, registered under JKP/PPSP/USM/06.	Atkins JH, 2008, CURR OPIN ANESTHESIO, V21, P759, DOI 10.1097/ACO.0b013e3283184001; Bell A, 2007, EMERG MED AUSTRALAS, V19, P411, DOI 10.1111/J.1742-6723.2007.01009.x; CHEOL HP, 2009, GASTROINTEST ENDOSC, V69, pAB228; Dumot JA, 2007, GASTROINTEST ENDOSC, V65, pAB110, DOI 10.1016/j.gie.2007.03.029; Dunn T, 2007, EMERG MED J, V24, P459, DOI 10.1136/emj.2007.046714; Frank LR, 2006, AM J EMERG MED, V24, P599, DOI 10.1016/j.ajem.2006.02.008; Frazee BW, 2005, AM J EMERG MED, V23, P190, DOI 10.1016/j.ajem.2004.05.008; GABOPOULOU Z, 2005, REG ANESTH PAIN MED, V3, P21; Gozal D, 2006, GASTROINTEST ENDOSC, V63, pAB189, DOI 10.1016/j.gie.2006.03.432; Hayee B, 2006, GASTROINTEST ENDOSC, V63, pAB191, DOI 10.1016/j.gie.2006.03.439; Hohl CM, 2008, ACAD EMERG MED, V15, P32, DOI 10.1111/j.1553-2712.2007.00023.x; JENIFER L, 2005, GASTROINTEST ENDOSC, V61, P1170; Krauss B, 2007, ANN EMERG MED, V50, P172, DOI 10.1016/j.annemergmed.2006.10.016; Lightdale JR, 2006, PEDIATRICS, V117, pE1170, DOI 10.1542/peds.2005-1709; Lightdale JR, 2002, GASTROINTEST ENDOSC, V55, pAB145; Maher EN, 2007, PEDIATR EMERG CARE, V23, P869, DOI 10.1097/pec.0b013e31815c9dbe; Miner JR, 2008, ACAD EMERG MED, V15, P955, DOI 10.1111/j.1553-2712.2008.00249.x; Miner JR, 2007, ANN EMERG MED, V50, P182, DOI 10.1016/j.annemergmed.2006.12.017; Nagler J, 2008, EMERG MED CLIN N AM, V26, P881, DOI 10.1016/j.emc.2008.08.005; RIPHAUS A, 2006, GASTROINTEST ENDOSC, V28, P677; Tohda G, 2006, ENDOSCOPY, V38, P684, DOI 10.1055/s-2006-925374; Vargo JJ, 2007, GASTROINTEST ENDOSC, V17, pv	22	11	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	OCT	2011	28	10					861	865		10.1136/emj.2009.085019			5	Emergency Medicine	Emergency Medicine	819QX	WOS:000294845500011	21098799				2020-06-30	J	Klein, KU; Boehme, S; Hartmann, EK; Szczyrba, M; David, M; Markstaller, K; Engelhard, K				Klein, Klaus Ulrich; Boehme, Stefan; Hartmann, Erik Kristopher; Szczyrba, Marc; David, Matthias; Markstaller, Klaus; Engelhard, Kristin			A Novel Technique for Monitoring of Fast Variations in Brain Oxygen Tension Using an Uncoated Fluorescence Quenching Probe (Foxy AL-300)	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						partial pressure of oxygen; brain tissue; fluorescence quenching; Foxy-AL 300; clark-type electrode; Licox	IN-VITRO ACCURACY; TISSUE OXYGEN; NEWBORN PIGLETS; CEREBRAL PERFUSION; SWINE MODEL; INJURY; RESUSCITATION; PRESSURE; CORTEX; VENTILATION	Background: A novel uncoated fluorescence quenching probe allows fast measurement of oxygen tension in vessels and tissue. The present study reports the first use of the technology for dual measurements of arterial (paO(2)) and brain tissue oxygen tension (ptiO(2)) during hypoxic challenge in a pig model. Methods: Eight pigs were anesthetized using fentanyl and propofol. Fluorescence quenching pO(2) probes (Foxy AL-300, Ocean Optics, Dunedin, FL) were placed in the ascending aorta (Foxy-paO(2)) and subcortically at 14 mm in brain tissue (Foxy-ptiO(2)). As reference, a clark-type electrode probe (Licox-ptiO(2)) was placed into brain tissue close to the Foxy probe (Licox, Integra Neurosciences, Plainsboro, NJ). Measurements were taken at baseline (FiO(2) 1.0), during episodes of apnea, and during recovery (FiO(2) 1.0). Statistics: descriptive results. Results: Individual Foxy-paO(2), Foxy-ptiO(2), and Licox-ptiO(2) courses were related to episodes of apnea. The response time of the Foxy measurements was 10Hz. Baseline values at FiO(2) 1.0 were Foxy-paO(2) 520 +/- 120 mm Hg, Foxy-ptiO(2) 62 +/- 24 mm Hg, and Licox-ptiO(2) 55 +/- 29 mm Hg; apnea values were Foxy-paO(2) 64 +/- 10 mm Hg, Foxy-ptiO(2) 37 +/- 12 mm Hg, and Licox-ptiO(2) 31 +/- 16 mm Hg; recovery values at FiO(2) 1.0 were Foxy-paO(2) 478 +/- 98 mm Hg, Foxy-ptiO(2) 78 +/- 26 mm Hg, and Licox-ptiO(2) 62 +/- 32 mm Hg. Conclusions: The present study demonstrates the feasibility of pO(2) measurements in macrocirculation and cerebral microcirculation using a novel uncoated fluorescence quenching probe. The technology allows for real-time investigation of pO(2) changes at a temporal resolution of 0.05 to 10 Hz.	[Klein, Klaus Ulrich; Boehme, Stefan; Markstaller, Klaus] Med Univ Vienna, Dept Anesthesiol Intens Care Med & Pain Therapy, A-1090 Vienna, Austria; [Klein, Klaus Ulrich; Boehme, Stefan; Hartmann, Erik Kristopher; Szczyrba, Marc; David, Matthias; Markstaller, Klaus; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, Mainz, Germany	Klein, KU (reprint author), Med Univ Vienna, Dept Anesthesiol Intens Care Med & Pain Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	ulrich.klein@meduniwien.ac.at		Klein, Klaus Ulrich/0000-0001-7446-0542	German Research Council (DFG)German Research Foundation (DFG) [Pak 415/EN 904]	Supported by a research grant of the German Research Council (DFG Pak 415/EN 904). All experiments have been performed at the Department of Anesthesiology, Medical Center of the Johannes Gutenberg-University in Mainz, Germany.	Baumgardner JE, 2002, AM J RESP CRIT CARE, V166, P1556, DOI 10.1164/rccm.200207-717OC; Bickenbach J, 2009, ANESTH ANALG, V109, P847, DOI 10.1213/ane.0b013e3181ad5769; CLARK LC, 1958, J APPL PHYSIOL, V13, P85; CROCKARD HA, 1976, J NEUROL SCI, V27, P17, DOI 10.1016/0022-510X(76)90231-8; Fellman V, 1997, PEDIATR RES, V41, P599, DOI 10.1203/00006450-199705000-00001; Herweling A, 2005, RESUSCITATION, V65, P71, DOI 10.1016/j.resuscitation.2004.04.017; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Linner R, 2009, PEDIATR RES, V66, P391, DOI 10.1203/PDR.0b013e3181b3b110; Lubbers DW, 1997, KIDNEY INT, V51, P372, DOI 10.1038/ki.1997.49; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Ndubuizu O, 2007, ANTIOXID REDOX SIGN, V9, P1207, DOI 10.1089/ars.2007.1634; O'Hara JA, 2005, PHYSIOL MEAS, V26, P203, DOI 10.1088/0967-3334/26/3/006; Orakcioglu B, 2010, NEUROSURGERY, V67, P1716, DOI 10.1227/NEU.0b013e3181f9bb5b; Purins K, 2010, ACTA NEUROCHIR, V152, P681, DOI 10.1007/s00701-009-0532-x; Ristagno G, 2009, CRIT CARE MED, V37, P1408, DOI 10.1097/CCM.0b013e31819cedc9; Schears G, 2005, ADV EXP MED BIOL, V566, P1; Shaw AD, 2002, CRIT CARE, V6, P76, DOI 10.1186/cc1457; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Stewart C, 2008, NEUROSURGERY, V63, P1159, DOI 10.1227/01.NEU.0000333265.19131.7C; Stocchetti N, 1998, ACT NEUR S, V71, P162; Tammela OKT, 1996, BRAIN RES, V741, P160, DOI 10.1016/S0006-8993(96)00909-2; VOGT A, 2008, J EUR ANESTH, V26, P29; Wan JJ, 2009, J TRAUMA, V66, P353, DOI 10.1097/TA.0b013e318195e222; WILSON DF, 1991, J APPL PHYSIOL, V70, P2691; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	25	7	7	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2011	23	4					341	346		10.1097/ANA.0b013e31822cf893			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	818ML	WOS:000294755700009	21897296				2020-06-30	J	Daijo, H; Kai, S; Tanaka, T; Wakamatsu, T; Kishimoto, S; Suzuki, K; Harada, H; Takabuchi, S; Adachi, T; Fukuda, K; Hirota, K				Daijo, Hiroki; Kai, Shinichi; Tanaka, Tomoharu; Wakamatsu, Takuhiko; Kishimoto, Shun; Suzuki, Kengo; Harada, Hiroshi; Takabuchi, Satoshi; Adachi, Takehiko; Fukuda, Kazuhiko; Hirota, Kiichi			Fentanyl activates hypoxia-inducible factor 1 in neuronal SH-SY5Y cells and mice under non-hypoxic conditions in a mu-opioid receptor-dependent manner	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Fentanyl; Opioid; Hypoxia-inducible factor 1 (HIF-1); SH-SY5Y cells	FACTOR 1-ALPHA HIF-1-ALPHA; GROWTH-FACTOR EXPRESSION; COLON-CANCER CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; PROTEIN-KINASE; NITRIC-OXIDE; INJURY; DELTA; MECHANISMS	Hypoxia-inducible factor 1 (HIF-1) is the main transcription factor responsible for hypoxia-induced gene expression. Perioperative drugs including anesthetics have been reported to affect HIF-1 activity. However, the effect of fentanyl on HIF-1 activity is not well documented. In this study, we investigated the effect of fentanyl and other opioids on HIF-1 activity in human SH-SY5Y neuroblastoma cells, hepatoma Hep3B cells, lung adenocarcinoma A549 cells and mice. Cells were exposed to fentanyl, and HIF-1 protein expression was examined by Western blot analysis using anti-HIF-l alpha and beta antibodies. HIF-1-dependent gene expression was investigated by semi-quantitative real-time reverse transcriptase (RT)-PCR (qRT-PCR) and luciferase assay. Furthermore, fentanyl was administered intraperitoneally and HIF-1-dependent gene expression was investigated by qRT-PCR in the brains and kidneys of mice. A 10-mu M concentration of fentanyl and other opioids, including 1 mu M morphine and 4 AM remifentanil, induced HIF-1 alpha protein expression and HIF-1 target gene expression in an opioid receptor-dependent manner in SH-SY5Y cells with activity peaking at 24 h. Fentanyl did not augment HIF-1a expression during hypoxia-induced induction. HIF-l alpha stabilization assays and experiments with cycloheximide revealed that fentanyl increased translation from HIF-la mRNA but did not stabilize the HIF-1a protein. Furthermore, fentanyl induced HIF-1 target gene expression in the brains of mice but not in their kidneys in a naloxone-sensitive manner. In this report, we describe for the first time that fentanyl, both in vitro and in vivo, induces HIF-1 activation under non-hypoxic conditions, leading to increases in expression of genes associated with adaptation to hypoxia. (C) 2011 Elsevier B.V. All rights reserved.	[Hirota, Kiichi] Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 6068507, Japan; [Suzuki, Kengo] Tohoku Univ, Grad Sch Med, Dept Anesthesiol, Sendai, Miyagi 980, Japan; [Harada, Hiroshi] Kyoto Univ, Grp Radiat & Tumor Biol, Career Path Promot Unit Young Life Scientists, Kyoto, Japan; [Harada, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto, Japan; [Adachi, Takehiko] Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Anesthesia, Osaka, Japan	Hirota, K (reprint author), Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.	hif1@mac.com	Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827	Ministry of Education, Culture, Sports and Science and Technology of Japan, Japan	We thank Dr. Gregg L Semenza for providing plasmids.; This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports and Science and Technology of Japan, Japan.	Alt A, 2002, BRIT J PHARMACOL, V135, P217, DOI 10.1038/sj.bjp.0704430; Cai Z, 2008, CARDIOVASC RES, V77, P463, DOI 10.1093/cvr/cvm035; Cai ZQ, 2004, CIRCULATION, V109, P2050, DOI 10.1161/01.CIR.0000127954.98131.23; Christie MJ, 2008, BRIT J PHARMACOL, V154, P384, DOI 10.1038/bjp.2008.100; Early MA, 2009, EXP MOL PATHOL, V87, P152, DOI 10.1016/j.yexmp.2009.07.008; Fukuda K, 1996, J NEUROCHEM, V67, P1309; FUKUDA K, 2009, ANESTHESIA, P769; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuda R, 2003, CANCER RES, V63, P2330; Han RQ, 2009, ANESTH ANALG, V108, P280, DOI 10.1213/ane.0b013e318187ba6b; Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200; Hirota K, 2005, BIOCHEM BIOPH RES CO, V338, P610, DOI 10.1016/j.bbrc.2005.08.193; Hirota K, 2004, J BIOL CHEM, V279, P41521, DOI 10.1074/jbc.M405164200; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hirota Kiichi, 2002, J Anesth, V16, P150, DOI 10.1007/s005400200011; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kasuno K, 2004, J BIOL CHEM, V279, P2550, DOI 10.1074/jbc.M308197200; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Koch T, 2009, J NEUROCHEM, V110, P1288, DOI 10.1111/j.1471-4159.2009.06217.x; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lin X, 2009, FEBS J, V276, P2022, DOI 10.1111/j.1742-4658.2009.06938.x; Martin-Kleiner I, 2006, NEUROIMMUNOMODULAT, V13, P1, DOI 10.1159/000092107; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nishi K, 2008, ANTIOXID REDOX SIGN, V10, P983, DOI 10.1089/ars.2007.1825; Oda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002215; Peart JN, 2005, VASC PHARMACOL, V42, P211, DOI 10.1016/j.vph.2005.02.003; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Sanchez-Blazquez P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011278; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Shiuchi T, 2002, HYPERTENSION, V40, P329, DOI 10.1161/01.HYP.0000028979.98877.0C; Shoda T, 2001, ANESTHESIOLOGY, V95, P983, DOI 10.1097/00000542-200110000-00030; Taie S, 2009, J CLIN NEUROSCI, V16, P1056, DOI 10.1016/j.jocn.2008.09.024; Takabuchi Satoshi, 2005, J Anesth, V19, P263, DOI 10.1007/s00540-005-0327-z; Tanaka T, 2010, AM J PHYSIOL-REG I, V298, pR661, DOI 10.1152/ajpregu.00732.2009; Tanaka T, 2010, J ANESTH, V24, P54, DOI 10.1007/s00540-009-0829-1; Tegeder I, 2004, PHARMACOL REV, V56, P351, DOI 10.1124/pr.56.3.2; Wakamatsu T, 2009, EUR J PHARMACOL, V617, P17, DOI 10.1016/j.ejphar.2009.06.060; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wolf G, 2005, ANTIOXID REDOX SIGN, V7, P1337, DOI 10.1089/ars.2005.7.1337	47	11	11	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 30	2011	667	1-3					144	152		10.1016/j.ejphar.2011.06.014			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	822OA	WOS:000295056800021	21703258				2020-06-30	J	Santos, P; Watkinson, AC; Hadgraft, J; Lane, ME				Santos, P.; Watkinson, A. C.; Hadgraft, J.; Lane, M. E.			Formulation issues associated with transdermal fentanyl delivery	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Fentanyl; Supersaturation; Propylene glycol; Skin; Crystallisation; Permeation	SUPERSATURATED SOLUTIONS; HUMAN SKIN; IN-VITRO; MEMBRANE-TRANSPORT; PROPYLENE-GLYCOL; PERCUTANEOUS-ABSORPTION; PENETRATION ENHANCEMENT; HYDROCORTISONE ACETATE; SILICONE MEMBRANES; PERMEATION	Supersaturation has previously been studied as a mechanism to enhance membrane transport of fentanyl from propylene glycol:water formulations (PG:H2O) across silicone. In this study these supersaturated fentanyl formulations were evaluated in human skin. A number of polymers were also screened for their ability to stabilise the supersaturated formulations and permeation was evaluated for both infinite and finite doses. For infinite dose studies, permeation in skin increased linearly with increasing degree of drug saturation (DS) for formulations containing 0.5,1, 2 DS of fentanyl and a 3 DS formulation stabilised with 1% (w/v) hydroxypropylcellulose (HPC). An excellent correlation was obtained for flux values in silicone compared with flux values in skin, for infinite dose studies for formulations containing 0.5, 1,2 DS of fentanyl and the 3 DS formulation stabilised HPC. The concentration of the fentanyl in the stratum corneum also increased in proportion to the DS. However the same trend was not observed for finite dose studies. This is because the depletion of the solvent carrier promotes drug crystallisation with consequent implications for membrane transport. Tape-stripping experiments indicated that supersaturation of the drug is maintained in the outer layers of the stratum corneum. The ideal vehicle must, therefore, maintain the drug in solution on and in the skin in a sustained manner for effective transdermal delivery. (C) 2011 Elsevier B.V. All rights reserved.	[Santos, P.; Hadgraft, J.; Lane, M. E.] Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England; [Watkinson, A. C.] Acrux Ltd, W Melbourne, Vic 3003, Australia	Lane, ME (reprint author), Univ London, Sch Pharm, Dept Pharmaceut, 29-39 Brunswick Sq, London WC1N 1AX, England.	majella.lane@btinternet.com	Hadgraft, Jonathan/D-6184-2013				ALBERY WJ, 1979, J PHARM PHARMACOL, V31, P140, DOI 10.1111/j.2042-7158.1979.tb13456.x; BERNER B, 1989, J PHARM SCI, V78, P402, DOI 10.1002/jps.2600780512; Boix A, 2005, PHARM RES, V22, P94, DOI 10.1007/s11095-004-9014-2; Davis A. F., 1993, PHARM SKIN PENETRATI, P243; DAVIS AF, 1991, INT J PHARM, V76, P1, DOI 10.1016/0378-5173(91)90337-N; Hadgraft J, 2004, EUR J PHARM BIOPHARM, V58, P291, DOI 10.1016/j.ejpb.2004.03.002; Hou H, 2006, J PHARM SCI-US, V95, P896, DOI 10.1002/jps.20600; Iervolino M, 2000, INT J PHARM, V198, P229, DOI 10.1016/S0378-5173(00)00346-X; Iervolino M, 2001, INT J PHARM, V212, P131, DOI 10.1016/S0378-5173(00)00603-7; KURIHARABERGSTROM T, 1990, PHARMACEUT RES, V7, P762, DOI 10.1023/A:1015879925147; Leveque N, 2006, INT J PHARM, V318, P49, DOI 10.1016/j.ijpharm.2006.03.015; MEGRAB NA, 1995, J CONTROL RELEASE, V36, P277, DOI 10.1016/0168-3659(95)00062-D; Moser K, 2001, INT J PHARMACEUT, V224, P169, DOI 10.1016/S0378-5173(01)00762-1; Nacht S, 1985, PERCUTANEOUS ABSORPT, P373; Nicoli S, 2009, PHARM RES-DORDR, V26, P865, DOI 10.1007/s11095-008-9785-y; Pellett MA, 1997, INT J PHARM, V151, P91, DOI 10.1016/S0378-5173(97)04897-7; PELLETT MA, 1994, INT J PHARM, V111, P1, DOI 10.1016/0378-5173(94)90395-6; Raghavan SL, 2000, INT J PHARM, V193, P231, DOI 10.1016/S0378-5173(99)00345-2; Santos P, 2011, INT J PHARMACEUT, V407, P72, DOI 10.1016/j.ijpharm.2011.01.025; Santos P, 2010, INT J PHARMACEUT, V384, P67, DOI 10.1016/j.ijpharm.2009.09.043; Santos P, 2009, INT J PHARMACEUT, V377, P70, DOI 10.1016/j.ijpharm.2009.05.002; Smith E.W., 1995, PERCUTANEOUS PENETRA, P481; Trottet L, 2004, INT J PHARMACEUT, V274, P213, DOI 10.1016/j.ijpharm.2004.01.013; Watkinson RM, 2009, SKIN PHARMACOL PHYS, V22, P225, DOI 10.1159/000231528	24	16	16	1	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173			INT J PHARMACEUT	Int. J. Pharm.	SEP 15	2011	416	1					155	159		10.1016/j.ijpharm.2011.06.024			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	818XU	WOS:000294790800020	21723931				2020-06-30	J	Baidya, DK; Trikha, A; Menon, S; Garg, R				Baidya, D. K.; Trikha, A.; Menon, S.; Garg, R.			Anaesthetic management of emergency caesarean section in a patient with seizures and likely raised intracranial pressure due to tuberculous meningitis	ANAESTHESIA AND INTENSIVE CARE			English	Article						tuberculous meningitis; seizures; raised intracranial pressure; foetal bradycardia; caesarean section	BRAIN	We report the anaesthetic management of a term pregnant woman with active tuberculous meningitis, who had experienced seizures, had signs of raised intracranial pressure and required emergency caesarean section. Peripartum anaesthetic management of a patient with tuberculous meningitis is a rare event.	[Baidya, D. K.; Trikha, A.; Menon, S.; Garg, R.] All India Inst Med Sci, Dept Anaesthesia & Intens Care, New Delhi 110029, India; [Garg, R.] Ram Manohar Lohia Hosp, Dept Anaesthesia, New Delhi, India	Trikha, A (reprint author), All India Inst Med Sci, Dept Anaesthesia & Intens Care, 5th Floor,Teaching Block, New Delhi 110029, India.	anjantrikha@gmail.com					ATANASSOFF PG, 1994, CAN J ANAESTH, V41, P163, DOI 10.1007/BF03009818; Bensky AS, 1996, PEDIATRICS, V97, P818; Chang LL, 1999, CAN J ANAESTH, V46, P61, DOI 10.1007/BF03012517; Enye S, 2009, AM J EMERG MED, V27, DOI 10.1016/j.ajem.2008.08.020; Gasparetto EL, 2003, ARQ NEURO-PSIQUIAT, V61, P855, DOI 10.1590/S0004-282X2003000500028; GOROSZENIUK T, 1986, ANAESTHESIA, V41, P1128, DOI 10.1111/j.1365-2044.1986.tb12962.x; Inada E, 1989, J Clin Anesth, V1, P207, DOI 10.1016/0952-8180(89)90043-3; Khatri GR, 2002, NEW ENGL J MED, V347, P1420, DOI 10.1056/NEJMsa020098; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Korula G, 1998, J NEUROSURG ANESTH, V10, P30, DOI 10.1097/00008506-199801000-00007; Landrum Lisa M, 2009, Infect Dis Obstet Gynecol, V2009, P63624; Moore J, 1991, CLIN ANESTHETIC PHAR, P519; Murthy JMK, 2010, NEUROL INDIA, V58, P716, DOI 10.4103/0028-3886.72178; Murthy JMK, 2005, NEUROCRIT CARE, V2, P306, DOI 10.1385/NCC:2:3:306; ROELVINK NCA, 1987, ARCH NEUROL-CHICAGO, V44, P209, DOI 10.1001/archneur.1987.00520140069020; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P960, DOI 10.1016/0002-9378(90)91297-P; Thwaites G, 2009, J INFECTION, V59, P167, DOI 10.1016/j.jinf.2009.06.011; VALLEJO JG, 1992, CLIN CHEST MED, V13, P693; Vavilala MS, 2000, ANESTH ANALG, V90, P107, DOI 10.1097/00000539-200001000-00023; Wang LP, 2008, ANESTH ANALG, V107, P193, DOI 10.1213/ane.0b013e31816c8888	20	0	0	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	SEP	2011	39	5					951	953		10.1177/0310057X1103900523			3	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	825TV	WOS:000295305900025	21970145	Bronze			2020-06-30	J	Napier, JE; Loskutoff, NM; Simmons, LG; Armstrong, DL				Napier, Julia E.; Loskutoff, Naida M.; Simmons, Lee G.; Armstrong, Douglas L.			COMPARISON OF CARFENTANIL-XYLAZINE AND THIAFENTANIL-MEDETOMIDINE IN ELECTROEJACULATION OF CAPTIVE GAUR (BOS GAURUS)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Carfentanil; thiafentanil; gaur; electroejaculation; captive; Bos gaurus	WOOD BISON; MULE DEER; IMMOBILIZATION; ANESTHESIA; KETAMINE; COMBINATION; HYPOXEMIA; A-3080	Carfentanil citrate and thiafentanil oxalate have been used successfully to immobilize captive and free-ranging ungulates. The objective of this study was to compare the efficacy and certain physiologic parameters of protocols by using the 2 opioids in gaur (Bos gaurus). Eight adult gaur bulls were immobilized for electroejaculation at Omaha's Henry Doorly Zoo (Omaha, Nebraska, USA). All the animals were immobilized twice, by using each of the following protocols one time: 10 mg carfentanil combined with 100 mg xylazine (CX), reversed with 1,000 mg naltrexone and 24 mg yohimbine; and 12 mg thiafentanil combined with 20 mg medetomidine (TM), reversed with 120 mg naltrexone and 100 mg atipamezole. Immobilization drugs were delivered intramuscularly into the shoulder area via pole syringe. Electroejaculation was carried out by a standardized protocol to duplicate procedural stimulation on each animal. Induction and recovery times, initial rectal temperature, heart rate, respiratory rate, anesthetic depth, oxygen saturation, indirect blood pressure, and arterial blood gases were recorded at the time of initial handling, before ejaculation, and after ejaculation. Antagonists were administered 1/4 i.v. and 3/4 s.q. Both protocols require a small volume of drug for a large ungulate, provide smooth induction, and adequate anesthesia. Both protocols produced a significant hypoxemia, although the animals on CX showed slightly better blood gas values (based on lower partial pressure of carbon dioxide) and numerically lower blood pressure values. Animals on TM had better muscle relaxation and smoother recoveries, with no renarcotization noted. The results of the present study indicate the TM and CX protocols used for immobilizing gaur result in similar quality ejaculates that can be used for fertility examination as well as for assisted reproduction such as artificial insemination. Additional immobilizations need to take place to further compare these 2 combinations in this species.	[Napier, Julia E.; Loskutoff, Naida M.; Simmons, Lee G.; Armstrong, Douglas L.] Omahas Henry Doorly Zoo, Omaha, NE 68107 USA	Napier, JE (reprint author), Omahas Henry Doorly Zoo, 3701 S 10th St, Omaha, NE 68107 USA.	julie.napier@omahazoo.com					ALLEN JL, 1989, J ZOO WILDLIFE MED, V20, P423; ARMSTRONG D, 1989, P AM ASS ZOO VET 198, P8; Caulkett N, 2006, P AM ASS ZOO VET, P216; Caulkett NA, 2000, CAN J VET RES, V64, P64; Caulkett NA, 2000, CAN VET J, V41, P49; Citino S., 2006, P AM ASS ZOO VET, P211; Citino SB, 2002, J WILDLIFE DIS, V38, P457, DOI 10.7589/0090-3558-38.2.457; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; GRZIMEK B, 1972, ANIMAL LIFE ENCY, P360; HAEFELE HJ, 2005, P AM ASS ZOO VET, P261; HAIGH JC, 1995, J WILDLIFE DIS, V31, P37, DOI 10.7589/0090-3558-31.1.37; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Mutlow A, 2004, J ZOO WILDLIFE MED, V35, P489, DOI 10.1638/03-074; NEILSON L, 1996, LUMB JONES VET ANEST, P736; NOWAK RM, 1964, WALKERS MAMMALS WORL, P1424; Puffer A., 2001, Theriogenology, V55, P398; Read MR, 2003, J ZOO WILDLIFE MED, V34, P134, DOI 10.1638/1042-7260(2003)034[0134:AROAAA]2.0.CO;2; Schumacher J, 1997, J ZOO WILDLIFE MED, V28, P166; Schumacher J, 1997, AM J VET RES, V58, P157; Smith KM, 2006, J ZOO WILDLIFE MED, V37, P513, DOI 10.1638/06-027.1; WILSON SC, 1993, J ZOO WILDLIFE MED, V24, P93; Wolfe LL, 2004, J WILDLIFE DIS, V40, P282, DOI 10.7589/0090-3558-40.2.282	24	6	6	0	8	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2011	42	3					430	436		10.1638/2010-0242.1			7	Veterinary Sciences	Veterinary Sciences	827IF	WOS:000295421500008	22950315				2020-06-30	J	Mudd, S				Mudd, Shawna			Intranasal Fentanyl for Pain Management in Children: A Systematic Review of the Literature	JOURNAL OF PEDIATRIC HEALTH CARE			English	Article						Intranasal; fentanyl; administration; pediatric; pain; analgesia	PEDIATRIC EMERGENCY; ORAL MORPHINE; ANALGESIA; TRIAL	Intranasally administered fentanyl (INF) has been studied as an alternate route of delivery for pain relief in children. The purpose of this systematic review is to evaluate the available research evidence on the use of INF in the pediatric population. A search was conducted of PubMed, ISI, Scopus, Popline, CINAHL, and Embase for research studies evaluating INF in this population (0-18 years of age). The studies were graded on the strength of the evidence and the results reviewed. All of the reviewed studies showed similar or improved pain scores when compared with other opioids and administration methods. No severe adverse outcomes were reported. Current evidence suggests that INF is a safe and effective method of pain management for children in a variety of clinical settings. J Pediatr Health Care. (2011) 25, 316-322.	[Mudd, Shawna] Johns Hopkins Univ, Baltimore, MD USA	Mudd, S (reprint author), 600 N Wolfe St,CMSC 144, Baltimore, MD 21287 USA.	smudd1@jhmi.edu		Mudd, Shawna/0000-0002-2247-5985			[Anonymous], 2004, ANN EMERG MED, V44, P342, DOI 10.1016/j.annemergmed.2004.04.012; *AUSTR NZ COLL AN, 2005, AC PAIN MAN SCI EV; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Cummings EA, 1996, PAIN, V68, P25, DOI 10.1016/S0304-3959(96)03163-6; Dooks P, 2001, CANCER NURS, V24, P99, DOI 10.1097/00002820-200104000-00004; Finkel J. C., 2001, PEDIAT ANESTHESIA, V92, P116; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Food and Drug Administration, 2002, AN LIF SUPP DRUGS AD; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Friedrichsdorf SJ, 2007, PEDIATR CLIN N AM, V54, P645, DOI 10.1016/j.pcl.2007.07.007; Galinkin J. L., 2001, ANESTHESIOLOGY, V93, P1378; Goldman RD, 2006, CURR DRUG THER, V1, P127, DOI 10.2174/157488506775268470; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Holdgate A., 2010, SOC ACAD EMERGENCY M, V17, P1; Kavanagh T, 2007, CHILD HEALTH CARE, V36, P303, DOI 10.1080/02739610701377970; Kennedy Robert M, 2008, Pediatrics, V122 Suppl 3, pS130, DOI 10.1542/peds.2008-1055e; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Leykin Yigal, 2007, Expert Rev Neurother, V7, P533, DOI 10.1586/14737175.7.5.533; MacLaren J, 2008, PEDIATRICS, V122, P443, DOI 10.1542/peds.2008-1444; MacLean S, 2007, PEDIATR EMERG CARE, V23, P87, DOI 10.1097/PEC.0b013e31803; Magaret ND, 2002, ACAD EMERG MED, V9, P1379, DOI 10.1111/j.1553-2712.2002.tb01606.x; Manjushree R, 2002, CAN J ANAESTH, V49, P190; Robertson J., 2005, H LANE HDB; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Starship Children's Health, 2007, STARS CHILDR HLTH CL; Sunshine Hospital, 2008, INTR FENT; Voronov P, 2008, PEDIATR ANESTH, V18, P1196, DOI 10.1111/j.1460-9592.2008.02789.x; Younge P, 1999, EMERGEN MED, V11, P90	34	48	49	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5245	1532-656X		J PEDIATR HEALTH CAR	J. Pediatr. Health Care	SEP-OCT	2011	25	5					316	322		10.1016/j.pedhc.2010.04.011			7	Health Policy & Services; Nursing; Pediatrics	Health Care Sciences & Services; Nursing; Pediatrics	821VH	WOS:000295002000008	21867860				2020-06-30	J	Beyaz, SG; Tokgoz, O; Tufek, A				Beyaz, Serbulent Gokhan; Tokgoz, Orhan; Tufek, Adnan			Caudal epidural block in children and infants: retrospective analysis of 2088 cases	ANNALS OF SAUDI MEDICINE			English	Article							REGIONAL ANESTHESIA; PEDIATRIC-SURGERY; ANALGESIA; INJECTION	BACKGROUND AND OBJECTIVES: Regional anesthesia is usually preferred as caudal block via the epidural space. However, the number of large-scale studies including pediatric caudal blocks is small. The objective of this study was to evaluate complications and side effects of local anesthetics and adjuvant drugs. DESIGN AND SETTING: Retrospective, descriptive study of cases occurring during the period December 2007 to October 2009. METHODS: Of 4815 medical records were screened, 2088 pediatric cases were identified and included in this study. RESULTS: As a local anesthetic, we preferred mostly levobupivacaine in 1669 (79.9%) patients and bupivacaine in 419 (20.1%) patients. As adjuvant drug, we preferred mostly morphine (41 patients), fentanyl (7 patients) and adrenaline (6 patients) in 54 (2.5%) patients. For general anesthesia induction, we preferred mostly propofol (1996 patients, 94.2%); for maintenance, sevoflurane (1773 patients, 84.9%). For airway control, we preferred mostly the ProSeal laryngeal mask (PLMA), in 1008 (48.2%) patients. One thousand six hundred five (76.9%) patients were from outpatient clinics and 483 (23.1%) patients were from inpatient clinics. No permanent complication was encountered after caudal blocks. CONCLUSION: We conclude that caudal epidural blocks are a safe and effective method for subumbilical day-case pediatric surgeries when performed by anesthetists.	[Beyaz, Serbulent Gokhan] Diyarbakir Childrens Hosp, Dept Anesthesia & Reanimat, Ordu, Turkey; [Tokgoz, Orhan] Diyarbakir State Hosp, Ordu, Turkey; [Tufek, Adnan] Dicle Univ, Fac Med, Ordu, Turkey	Beyaz, SG (reprint author), Boztepe State Hosp Ordu, Dept Anesthesia & Reanimat, Ordu, Turkey.	sgbeyaz@gmail.com	Tokgoz, Orhan/H-2924-2013; Tufek, Adnan/A-4419-2013; Beyaz, Serbulent Gokhan/D-7095-2011	Beyaz, Serbulent Gokhan/0000-0001-9263-7823			Ansermino M, 2003, PAEDIATR ANAESTH, V13, P561, DOI 10.1046/j.1460-9592.2003.01048.x; Baris S, 2004, PEDIATR ANESTH, V14, P755, DOI 10.1111/j.1460-9592.2004.01287.x; BEGEC Z, 2005, JTAICS, V33, P388; BEYAZ SG, 2010, GENEL TIP DERG, V20, P27; BEYAZ SG, 2009, TIP ARA TIRMALARI DE; Brimacombe J, 2002, BRIT J ANAESTH, V88, P296, DOI 10.1093/bja/88.2.296; Congedo E, 2009, CURR DRUG TARGETS, V10, P696, DOI 10.2174/138945009788982441; DALENS B, 1989, ANESTH ANALG, V68, P83, DOI 10.1213/00000539-198902000-00002; De Negri P, 2002, Minerva Anestesiol, V68, P420; Forster JG, 2003, CURR OPIN ANESTHESIO, V16, P477, DOI 10.1097/01.aco.0000094506.08873.b7; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; Guldogus F, 2008, EUR J ANAESTH, V25, P498, DOI 10.1017/S0265021508003906; Ingelmo P M, 2005, Minerva Anestesiol, V71, P339; KRANE EJ, 1989, ANESTHESIOLOGY, V71, P48, DOI 10.1097/00000542-198907000-00009; Markakis D A, 2000, Anesthesiol Clin North Am, V18, P355, DOI 10.1016/S0889-8537(05)70168-1; OOZYURT G, 2000, REG ANESTH PAIN MED, V25, P665; Ozturk CE, 2010, TURKIYE KLIN J ANEST, V8, P79; Ross AK, 2000, ANESTH ANALG, V91, P16, DOI 10.1097/00000539-200007000-00004; Schuepfer G, 2000, REGION ANESTH PAIN M, V25, P385, DOI 10.1053/rapm.2000.7590; Sener M, 2006, ANESTEZI DERGISI, V14, P259; Silvani P, 2006, MINERVA ANESTESIOL, V72, P453; Smith RH, 2003, BRIT J ANAESTH, V90, P400, DOI 10.1093/bja/aeg539; Song DJ, 2004, ANESTH ANALG, V98, P687, DOI 10.1213/01.ANE.0000103184.36451.D7; Tobias JD, 2001, ANESTH ANALG, V93, P1156, DOI 10.1097/00000539-200111000-00018; Tobias JD, 1996, J CLIN ANESTH, V8, P634, DOI 10.1016/S0952-8180(96)00171-7; Uguralp S, 2002, J PEDIATR SURG, V37, P610, DOI 10.1053/jpsu.2002.31619; VEYCKEMANS F, 1992, REGION ANESTH, V17, P119; WARNER MA, 1987, ANESTH ANALG, V66, P995	28	18	19	1	6	K FAISAL SPEC HOSP RES CENTRE	RIYADH	PUBLICATIONS OFFICE PO BOX 3354, RIYADH 11211, SAUDI ARABIA	0256-4947			ANN SAUDI MED	Ann. Saudi Med.	SEP-OCT	2011	31	5					494	497		10.4103/0256-4947.84627			4	Medicine, General & Internal	General & Internal Medicine	820HQ	WOS:000294896700008	21911987	DOAJ Gold, Green Published			2020-06-30	J	Bowens, CD; Thompson, JA; Thompson, MT; Breitzka, RL; Thompson, DG; Sheeran, PW				Bowens, Cindy D.; Thompson, Jennifer A.; Thompson, Marita T.; Breitzka, Robin L.; Thompson, Debbie G.; Sheeran, Paul W.			A trial of methadone tapering schedules in pediatric intensive care unit patients exposed to prolonged sedative infusions	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						critically ill children; opiate dependence; sedation; withdrawal	CRITICALLY-ILL CHILDREN; ACTIVITY ASSESSMENT SCALE; OPIOID TOLERANCE; ABSTINENCE SYNDROME; WITHDRAWAL SYMPTOMS; CANCER PAIN; DOSE RATIO; DEPENDENCE; FENTANYL; MORPHINE	Objectives: To compare the efficacy of a low-dose methadone tapering schedule to a high-dose methadone tapering schedule in pediatric intensive care unit patients exposed to infusions of fentanyl, with or without infusions of midazolam, for >= 5 days. Design: Prospective, double-blind, randomized trial. Setting: Pediatric intensive care unit in a tertiary care children's hospital. Patients: Seventy-eight patients, 74 of whom had been receiving infusions of both fentanyl and midazolam, were randomized. Forty-one patients were randomized to the low-dose methadone group and 37 were randomized to the high-dose methadone group. Sixty patients successfully completed the trial, 34 were in the low-dose methadone group, and 26 were in the high-dose methadone group. Interventions: Patients were randomized to receive methadone either at a starting dose of 0.1 mg/kg/dose (low-dose methadone group) or at a starting dose based on both the patient's weight and the most recent fentanyl infusion rate (high-dose methadone group). In each group, methadone was administered every 6 hrs for the first 24 hrs and then every 12 hrs for the second 24 hrs. The methadone was then decreased to once daily and tapered off over the next 10 days. Patients were monitored for withdrawal symptoms using the Modified Narcotic Withdrawal Score. Measurements and Main Results: The percentage of patients who successfully completed the 10-day methadone taper was the same in the low-dose methadone group as in the high-dose methadone group (56% vs. 62%; p = .79). Patients that failed to complete the assigned methadone taper had a greater total fentanyl dose and longer pediatric intensive care unit length of stay compared to patients who completed the assigned methadone taper. Conclusions: Patients who received infusions of fentanyl for at least 5 days were just as likely to complete a low-dose methadone taper as a high-dose methadone taper. Because of the risks of both withdrawal and oversedation with any fixed methadone schedule, the methadone dose must be adjusted according to each patient's response. (Pediatr Crit Care Med 2011; 12:504-511)	[Bowens, Cindy D.; Thompson, Jennifer A.; Thompson, Marita T.; Sheeran, Paul W.] Univ Texas SW, Dept Pediat, Div Crit Care, Dallas, TX 75390 USA; [Sheeran, Paul W.] Univ Texas SW, Dept Anesthesia & Pain Management, Dallas, TX USA; [Breitzka, Robin L.; Thompson, Debbie G.] Childrens Med Ctr, Dallas, TX 75235 USA	Bowens, CD (reprint author), Univ Texas SW, Dept Pediat, Div Crit Care, Dallas, TX 75390 USA.	paul.sheeran@childrens.com					ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Birchley G, 2009, NURS CRIT CARE, V14, P26, DOI 10.1111/j.1478-5153.2008.00311.x; Clemmer TP, 2000, CRIT CARE MED, V28, P3124, DOI 10.1097/00003246-200008000-00096; Cunliffe M, 2004, PEDIATR ANESTH, V14, P293, DOI 10.1046/j.1460-9592.2003.01219.x; Curley MAQ, 2005, JAMA-J AM MED ASSOC, V294, P229, DOI 10.1001/jama.294.2.229; Curley MAQ, 2006, PEDIATR CRIT CARE ME, V7, P107, DOI 10.1097/01.PCC.0000200955.40962.38; Darnell CM, 2008, PEDIATRICS, V121, pE1363, DOI 10.1542/peds.2007-1468; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Dominguez KD, 2003, ANN PHARMACOTHER, V37, P473, DOI 10.1345/aph.1C324; Dumas EO, 2008, AAPS J, V10, P537, DOI 10.1208/s12248-008-9056-1; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Fonsmark L, 1999, CRIT CARE MED, V27, P196, DOI 10.1097/00003246-199901000-00052; Franck LS, 2008, PEDIATR CRIT CARE ME, V9, P573, DOI 10.1097/PCC.0b013e31818c8328; Franck Linda S, 2004, Intensive Crit Care Nurs, V20, P344, DOI 10.1016/j.iccn.2004.07.008; Gammaitoni AR, 2003, CLIN J PAIN, V19, P286, DOI 10.1097/00002508-200309000-00002; HODER EL, 1981, NEW ENGL J MED, V305, P1284; Inturrisi C E, 2005, Minerva Anestesiol, V71, P435; Ista E, 2008, CRIT CARE MED, V36, P2427, DOI 10.1097/CCM.0b013e318181600d; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; Kasai S, 2008, N-S ARCH PHARMACOL, V377, P269, DOI 10.1007/s00210-007-0205-3; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Lugo RA, 2001, PHARMACOTHERAPY, V21, P1566, DOI 10.1592/phco.21.20.1566.34471; Mayer P, 2006, PHARMACOGENET GENOM, V16, P1, DOI 10.1097/01.fpc.0000182781.87932.0d; Mendez IA, 2008, PSYCHOPHARMACOLOGY, V196, P497, DOI 10.1007/s00213-007-0984-8; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; Nishizawa D, 2010, METHODS MOL BIOL, V617, P395, DOI 10.1007/978-1-60327-323-7_29; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Raith K, 2004, INT J CLIN PHARM TH, V42, P191; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Robertson R C, 2000, Pediatr Crit Care Med, V1, P119, DOI 10.1097/00130478-200010000-00005; Shaheen PE, 2009, J PAIN SYMPTOM MANAG, V38, P409, DOI 10.1016/j.jpainsymman.2009.06.004; Suresh S, 2001, PAEDIATR ANAESTH, V11, P511, DOI 10.1046/j.1460-9592.2001.00764.x; SURY MRJ, 1989, CRIT CARE MED, V17, P301, DOI 10.1097/00003246-198903000-00027; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; TOBIAS JD, 1994, INTENS CARE MED, V20, P504, DOI 10.1007/BF01711905; TOBIAS JD, 1990, CRIT CARE MED, V18, P1292, DOI 10.1097/00003246-199011000-00024; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Twite Mark D, 2004, Pediatr Crit Care Med, V5, P521, DOI 10.1097/01.PCC.0000144710.13710.2E; Varga EV, 2003, LIFE SCI, V74, P299, DOI 10.1016/j.lfs.2003.09.017; Williams PI, 1998, BRIT J ANAESTH, V80, P92; Yaster M, 1996, PEDIATRICS, V98, P135; Zuppa AF, 2005, J CLIN PHARMACOL, V45, P1305, DOI 10.1177/0091270005280966	48	23	23	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2011	12	5					504	511		10.1097/PCC.0b013e3181fe38f5			8	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	816KP	WOS:000294598400010	21076361				2020-06-30	J	Ista, E; Wildschut, E; Tibboel, D				Ista, Erwin; Wildschut, Enno; Tibboel, Dick			Creating or preventing opioid addiction, finding the right dose	PEDIATRIC CRITICAL CARE MEDICINE			English	Editorial Material							INTENSIVE-CARE-UNIT; PEDIATRIC DELIRIUM; WITHDRAWAL; CHILDREN; TOLERANCE; SEDATION		[Ista, Erwin; Wildschut, Enno; Tibboel, Dick] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Rotterdam, Netherlands	Ista, E (reprint author), Sophia Childrens Univ Hosp, Erasmus Med Ctr, Rotterdam, Netherlands.						Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Berens RJ, 2006, ANESTH ANALG, V102, P1045, DOI 10.1213/01.ane.0000202395.94542.3e; Bowens CD, 2011, PEDIATR CRIT CARE ME, V12, P504, DOI 10.1097/PCC.0b013e3181fe38f5; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Franck LS, 2008, PEDIATR CRIT CARE ME, V9, P573, DOI 10.1097/PCC.0b013e31818c8328; Ista Erwin, 2010, J Opioid Manag, V6, P55; Ista E, 2009, INTENS CARE MED, V35, P1075, DOI 10.1007/s00134-009-1487-3; Kress JP, 2010, CRIT CARE, V14, DOI 10.1186/cc9038; Larsen GY, 2007, PEDIATR CRIT CARE ME, V8, P331, DOI 10.1097/01.PCC.0000263042.73539.99; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; Robertson R C, 2000, Pediatr Crit Care Med, V1, P119, DOI 10.1097/00130478-200010000-00005; Schieveld JN, 2010, INTENS CARE MED, V36, P1982, DOI 10.1007/s00134-010-1989-z; Schieveld JNM, 2007, INTENS CARE MED, V33, P1033, DOI 10.1007/s00134-007-0637-8; Siddappa R, 2003, PAEDIATR ANAESTH, V13, P805, DOI 10.1046/j.1460-9592.2003.01153.x; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Yang F, 2006, J PHARMACOKINET PHAR, V33, P485, DOI 10.1007/s10928-006-9018-0; Zanin A, 2010, J CHILD NEUROL, V25, P748, DOI 10.1177/0883073809343318	17	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2011	12	5					590	592		10.1097/PCC.0b013e318202f58d			3	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	816KP	WOS:000294598400024	21897158				2020-06-30	J	Haydon, ML; Larson, D; Reed, E; Shrivastava, VK; Preslicka, CW; Nageotte, MP				Haydon, Michael L.; Larson, David; Reed, Enrique; Shrivastava, Vineet K.; Preslicka, Christine W.; Nageotte, Michael P.			Obstetric outcomes and maternal satisfaction in nulliparous women using patient-controlled epidural analgesia	AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the Society-for-Maternal-Fetal-Medicine	FEB 07-12, 2011	San Francisco, CA	Soc Maternal Fetal Med		continuous epidural infusion (CEI); patient-controlled epidural analgesia (PCEA)	LABOR ANALGESIA; CONTINUOUS-INFUSION; BACKGROUND INFUSION; ROPIVACAINE; FENTANYL; INTERMITTENT; REGIMENS; PAIN	OBJECTIVE: The purpose of this study was to compare obstetric outcomes and maternal satisfaction in nulliparous women in spontaneous labor who used patient-controlled epidural analgesia (PCEA) vs continuous epidural infusion (CEI). STUDY DESIGN: We conducted a double-masked trial of 270 nulliparous women who were assigned randomly to 3 groups (with a concentration 0.1% bupivacaine and 2 mu g/mL fentanyl): group I, CEI-only (10 mL/h); group II, CEI + PCEA (CEI 10 mL/h plus PCEA 10 mL, at 20 minutes); group III, PCEA-only (10 mL, at 20 minutes). A PCEA bolus button was given to each subject. The primary outcome was the dosage of local anesthetic that was used. RESULTS: The total milligrams of bupivacaine that were used was less in the PCEA-only group compared with CEI: group I. 74.8 +/- 36 mg; group II, 97.3 +/- 53 mg; group III, 52.4 +/- 42 mg (P < .001). Pain with pushing, however, was worse in the PCEA-only group. Median satisfaction scores were similar (scale, 0 [ best] to 100 [ worst]: group I, 0; group II, 0; group III, 0 (P = .23). CONCLUSION: PCEA results in less anesthetic used, and maternal satisfaction remains high without a continuous infusion. Pain with pushing, however, was worse with the PCEA alone.	[Haydon, Michael L.; Shrivastava, Vineet K.; Preslicka, Christine W.; Nageotte, Michael P.] Miller Childrens Hosp, Long Beach Mem Med Ctr, Dept Obstet & Gynecol, Long Beach, CA USA; [Larson, David; Reed, Enrique] Miller Childrens Hosp, Long Beach Mem Med Ctr, Dept Anesthesiol, Long Beach, CA USA	Haydon, ML (reprint author), Miller Childrens Hosp, Long Beach Mem Med Ctr, Dept Obstet & Gynecol, Long Beach, CA USA.						Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Carvalho B, 2005, INT J OBSTET ANESTH, V14, P223, DOI 10.1016/j.ijoa.2005.02.003; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; CURRY PD, 1994, PAIN, V57, P125, DOI 10.1016/0304-3959(94)90116-3; Eltzschig HK, 2003, NEW ENGL J MED, V348, P319, DOI 10.1056/NEJMra021276; Eriksson SL, 2003, ACTA ANAESTH SCAND, V47, P1085, DOI 10.1034/j.1399-6576.2003.00207.x; FERRANTE FM, 1991, ANESTH ANALG, V73, P547; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; GAMBLING DR, 1993, CAN J ANAESTH, V40, P211, DOI 10.1007/BF03037032; Halpern S, 2005, CURR OPIN ANESTHESIO, V18, P247, DOI 10.1097/01.aco.0000169229.75938.c8; Halpern SH, 2009, ANESTH ANALG, V108, P921, DOI 10.1213/ane.0b013e3181951a7f; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Lim Y, 2008, ANESTH ANALG, V107, P1968, DOI 10.1213/ane.0b013e3181887ffb; Paech Michael, 2003, Anesthesiol Clin North Am, V21, P1, DOI 10.1016/S0889-8537(02)00030-5; Sia AT, 1999, ANAESTH INTENS CARE, V27, P154, DOI 10.1177/0310057X9902700204; Smedvig JP, 2001, ACTA ANAESTH SCAND, V45, P595, DOI 10.1034/j.1399-6576.2001.045005595.x; Vallejo MC, 2007, J PAIN, V8, P970, DOI 10.1016/j.jpain.2007.07.002; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x	19	18	19	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9378			AM J OBSTET GYNECOL	Am. J. Obstet. Gynecol.	SEP	2011	205	3							271.e1	10.1016/j.ajog.2011.06.041			6	Obstetrics & Gynecology	Obstetrics & Gynecology	812YF	WOS:000294330000054	22071061				2020-06-30	J	Circeo, L; Grow, D; Kashikar, A; Gibson, C				Circeo, Lori; Grow, Daniel; Kashikar, Ananth; Gibson, Charles			Prospective, observational study of the depth of anesthesia during oocyte retrieval using a total intravenous anesthetic technique and the Bispectral index monitor	FERTILITY AND STERILITY			English	Article						Total intravenous anesthesia; transvaginal oocyte retrieval; Bispectral index (BIS) monitor; deep sedation; moderate sedation; IVF; propofol	GENERAL-ANESTHESIA; PROPOFOL; SEDATION; MIDAZOLAM	Fifty patients scheduled to undergo IVF received a standard anesthetic of fentanyl and propofol for induction, followed by propofol infusion, with Bispectral index values and modified Ramsey sedation scores recorded at 5-minute intervals for the duration of anesthesia care. Moderate sedation was found only transiently during the first 5-10 minutes of the oocyte retrieval, but thereafter the level of sedation increased, with deep sedation and general anesthesia measured in all patients as determined by both the Bispectral index scores and lack of response to painful stimulation. (Fertil Steril (R) 2011;96:635-7. (C)2011 by American Society for Reproductive Medicine.)	[Circeo, Lori; Kashikar, Ananth; Gibson, Charles] Tufts Univ, Sch Med, Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA; [Grow, Daniel] Tufts Univ, Sch Med, Baystate Med Ctr, Dept Obstet & Gynecol, Springfield, MA 01199 USA	Circeo, L (reprint author), Tufts Univ, Sch Med, Baystate Med Ctr, Dept Anesthesiol, 759 Chestnut St, Springfield, MA 01199 USA.	Lori.circeo@bhs.org					*CDC, INTR 2008 ANN REP; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Christiaens F, 1999, HUM REPROD, V14, P345, DOI 10.1093/humrep/14.2.345; Christiaens F, 1998, HUM REPROD, V13, P2456, DOI 10.1093/humrep/13.9.2456; Ditkoff EC, 1997, J ASSIST REPROD GEN, V14, P145, DOI 10.1007/BF02766130; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; NYGREN KG, 2009, PRESERVATION HUMAN O, P205; Punjasawadwong Y, 2007, COCHRANE DB SYST REV, V4; Recart A, 2003, ANESTH ANALG, V97, P1667, DOI 10.1213/01.ANE.0000087041.63034.8C; Vlahos NF, 2009, INT J GYNECOL OBSTET, V105, P201, DOI 10.1016/j.ijgo.2009.01.017	12	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0015-0282			FERTIL STERIL	Fertil. Steril.	SEP	2011	96	3					635	637		10.1016/j.fertnstert.2011.06.010			3	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	814BC	WOS:000294417000034	21733507				2020-06-30	J	Van Elstraete, AC; Sitbon, P; Benhamou, D; Mazoit, JX				Van Elstraete, Alain C.; Sitbon, Philippe; Benhamou, Dan; Mazoit, Jean-Xavier			The Median Effective Dose of Ketamine and Gabapentin in Opioid-Induced Hyperalgesia in Rats: An Isobolographic Analysis of Their Interaction	ANESTHESIA AND ANALGESIA			English	Article							POSTOPERATIVE PAIN; MORPHINE; FENTANYL; TOLERANCE; NEFOPAM; DRUG	BACKGROUND: Ketamine and gabapentin have been shown to prevent the delayed hyperalgesia induced by short-term use of systemic opioids. The mechanism of this action is believed to be likely at the spinal level, through an antagonism of the N-methyl-D-aspartate receptors for ketamine, and through a specific binding site for gabapentin. In this study, we sought to determine the nature of the interaction of these 2 mechanistically distinct antihyperalgesic drugs in a model of opioid-induced hyperalgesia in rats. The median effective antihyperalgesic doses of each drug and of their combination were first defined, to assess the nature of the interaction using an isobolographic analysis. METHODS: Long-lasting hyperalgesia was induced in male Sprague Dawley rats with subcutaneous fentanyl (4 injections, 60 mu g/kg per injection at 15-minute intervals) resulting in a total dose of 240 mu g/kg. Subcutaneous ketamine, or intraperitoneal gabapentin, or their combination was administered 30 minutes before the first subcutaneous fentanyl injection. Sensitivity to nociceptive stimuli (von Frey filaments) was assessed on the day of the experiment and on the day after injections. The dose of ketamine and gabapentin received by a particular animal was determined by the response of the previous animal of the same group, using an up-and-down technique. Initial doses were 10 mg/kg and 300 mg/kg, with dose adjustment intervals of 1 mg/kg and 30 mg/kg, in the ketamine and gabapentin groups, respectively. The initial doses of ketamine and gabapentin were 5 mg/kg and 150 mg/kg, respectively, in the ketamine-gabapentin group, with the same dose adjustment intervals. Antihyperalgesic efficacy was defined as complete prevention of hyperalgesia on the day after drug injections. RESULTS: The median effective antihyperalgesic doses (median value and 95% confidence interval) of ketamine and gabapentin were 12.4 mg/kg (11.7-13.1 mg/kg) and 296.3 mg/kg (283.5-309.1 mg/kg), respectively. The median effective antihyperalgesic dose of the combination was 4.3 mg/kg (3.7-4.6 mg/kg) for ketamine and 123.9 mg/kg (111.1-136.7 mg/kg) for gabapentin. CONCLUSION: The isobolographic analysis demonstrated that the combination of the 2 drugs produces effective antihyperalgesia with a supraadditive (synergistic) action. (Anesth Analg 2011;113:634-40)	[Van Elstraete, Alain C.] Univ Paris 11, Lab Anesthesiol, INSERM U788, F-94276 Le Kremlin Bicetre, France; [Sitbon, Philippe] Inst Gustave Roussy, Dept Anesthesiol, Villejuif, France; [Benhamou, Dan; Mazoit, Jean-Xavier] Univ Paris 11, Dept Anesthesie Reanimat, Hop Bicetre, F-94276 Le Kremlin Bicetre, France	Van Elstraete, AC (reprint author), Univ Paris 11, Lab Anesthesiol, INSERM U788, F-94276 Le Kremlin Bicetre, France.	alainvanelstraete@yahoo.fr		Sitbon, Philippe/0000-0003-0520-9180			Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Beloeil H, 2004, ANESTH ANALG, V98, P395, DOI 10.1213/01.ANE.0000093780.67532.95; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Delage N, 2005, ANESTHESIOLOGY, V102, P1211, DOI 10.1097/00000542-200506000-00022; DIXON WJ, 1948, J AM STAT ASSOC, V43, P109, DOI 10.2307/2280071; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Haugan F, 2008, ACTA ANAESTH SCAND, V52, P681, DOI 10.1111/j.1399-6576.2008.01637.x; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kissin I, 1997, ANESTH ANALG, V85, P204, DOI 10.1097/00000539-199707000-00036; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Marcou TA, 2005, ANESTH ANALG, V100, P469, DOI 10.1213/01.ANE.0000142121.24052.25; Matthews EA, 2002, ANESTHESIOLOGY, V96, P633, DOI 10.1097/00000542-200203000-00020; Ossipov MH, 2004, J NEUROBIOL, V61, P126, DOI 10.1002/neu.20091; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; TALLARIDA RJ, 1989, LIFE SCI, V45, P947, DOI 10.1016/0024-3205(89)90148-3; UNKELBACH HD, 1988, ARZNEIMITTEL-FORSCH, V38-1, P1; Van Elstraete AC, 2008, ANESTHESIOLOGY, V108, P484, DOI 10.1097/ALN.0b013e318164cf85; YAKSH TL, 1994, PROG PAIN RES MANAG, V1, P151; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	24	7	7	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2011	113	3					634	640		10.1213/ANE.0b013e3182222b59			7	Anesthesiology	Anesthesiology	810WO	WOS:000294159600030	21642613				2020-06-30	J	Hoekman, JD; Ho, RJY				Hoekman, John D.; Ho, Rodney J. Y.			Enhanced Analgesic Responses After Preferential Delivery of Morphine and Fentanyl to the Olfactory Epithelium in Rats	ANESTHESIA AND ANALGESIA			English	Article							CENTRAL-NERVOUS-SYSTEM; INTRANASAL DELIVERY; BREAKTHROUGH PAIN; DRUG-DELIVERY; ORAL MORPHINE; NASAL CAVITY; BRAIN; ABSORPTION; TRIAL	BACKGROUND: Centrally acting opioid analgesics such as morphine and fentanyl are effective, but their efficacy is often limited by a delayed response or side effects resulting from systemic first pass before reaching the brain and the central nervous system (CNS). It is generally accepted that drugs applied to the nasal cavity can directly access the brain and the CNS, which could provide therapeutic advantages such as rapid onset and lower systemic exposure. The olfactory region of the nasal cavity has been implicated in facilitating this direct nose-to-CNS transfer. If the fraction of opioid administered to the olfactory region could be improved, there could be a larger fraction of drug directly delivered to the CNS, mediating greater therapeutic benefit. METHODS: We have developed a pressurized olfactory delivery (POD) device to consistently and noninvasively deposit a majority of drug on the olfactory region of the nasal cavity in Sprague-Dawley rats. Using the tail-flick latency test and analysis of plasma and CNS tissue drug exposure, we compared distribution and efficacy of the opioids morphine and fentanyl administered to the nasal olfactory region with the POD device or the nasal respiratory region with nose drops or systemically via intraperitoneal injection. RESULTS: Compared with nose drop administration, POD administration of morphine resulted in a significantly higher overall therapeutic effect (area under the curve [over the time course] [AUC](effect)) without a significant increase in plasma drug exposure (AUC(plasma)). POD of morphine resulted in a nose-to-CNS direct transport percentage of 38% to 55%. POD of fentanyl led to a faster (5 vs 10 minutes) and more intense analgesic effect compared with nasal respiratory administration. Unlike intraperitoneal injection or nose drop administration, both morphine and fentanyl given by the POD device to olfactory nasal epithelium exhibited clockwise (plasma) versus effect hysteresis after nasal POD administration, consistent with a direct nose-to-CNS drug transport mechanism. CONCLUSIONS: Deposition of opioids to the olfactory region within the nasal cavity could have a significant impact on drug distribution and pharmacodynamic effect, and thus should be considered in future nasally administered opioid studies. (Anesth Analg 2011;113:641-51)	[Hoekman, John D.; Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA	Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, 1959 NE Pacific St HSB H272, Seattle, WA 98195 USA.	rodneyho@u.washington.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI 077390, MH086351]; University of Washington Technology Innovation [TGIF-1001]; Milo Gibaldi Endowment	Supported in part by National Institutes of Health grants AI 077390 and MH086351 and University of Washington Technology Innovation grant TGIF-1001. RJYH is also supported by a Milo Gibaldi Endowment.	ANTON F, 1991, NEUROSCIENCE, V41, P617, DOI 10.1016/0306-4522(91)90354-Q; Bagger M, 2004, INT J PHARMACEUT, V269, P311, DOI 10.1016/j.ijpharm.2003.09.017; CHANDLER SG, 1994, PHARMACEUT RES, V11, P1623, DOI 10.1023/A:1018970006935; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Davis MP, 2010, EXPERT REV NEUROTHER, V10, P757, DOI [10.1586/ern.10.41, 10.1586/ERN.10.41]; DE LORENZO A J, 1960, Trans Am Laryngol Assoc, V81, P39; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Foo MY, 2007, J AEROSOL MED, V20, P495, DOI 10.1089/jam.2007.0638; Groenendaal D, 2007, BRIT J PHARMACOL, V151, P701, DOI 10.1038/sj.bjp.0707257; Groenendaal D, 2007, BRIT J PHARMACOL, V151, P713, DOI 10.1038/sj.bjp.0707258; GROSS EA, 1982, J ANAT, V135, P83; Illum L, 2002, J PHARMACOL EXP THER, V301, P391, DOI 10.1124/jpet.301.1.391; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; Letrent SP, 1999, DRUG METAB DISPOS, V27, P827; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; McMillan Susan C, 2004, Cancer Control, V11, P3; MORRISON EE, 1990, J COMP NEUROL, V297, P1, DOI 10.1002/cne.902970102; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Newman SP, 2004, CRIT REV THER DRUG, V21, P21, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.20; Perez-Urizar J, 2000, ARCH MED RES, V31, P539, DOI 10.1016/S0188-4409(00)00242-3; Shang GW, 2006, PHARMACOL BIOCHEM BE, V85, P464, DOI 10.1016/j.pbb.2006.09.016; van den Berg MP, 2004, EUR J PHARM BIOPHARM, V58, P131, DOI 10.1016/j.ejpb.2004.02.010; Westin U, 2005, EUR J PHARM SCI, V24, P565, DOI 10.1016/j.ejps.2005.01.009; Westin UE, 2006, PHARM RES-DORDR, V23, P565, DOI 10.1007/s11095-006-9534-z; Young J T, 1981, Fundam Appl Toxicol, V1, P309, DOI 10.1016/S0272-0590(81)80037-1; YUASA T, 1991, Acta Anatomica Nipponica, V66, P191; Zhang QZ, 2004, INT J PHARMACEUT, V275, P85, DOI 10.1016/j.ijpharm.2004.01.039	29	31	32	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2011	113	3					641	651		10.1213/ANE.0b013e3182239b8c			11	Anesthesiology	Anesthesiology	810WO	WOS:000294159600031	21709146	Green Accepted			2020-06-30	J	Jin, SJ; Jung, JY; Noh, MH; Lee, SH; Lee, EK; Choi, BM; Song, MH; Noh, GJ				Jin, S-J; Jung, J-Y; Noh, M-H; Lee, S-H; Lee, E-K; Choi, B-M; Song, M-H; Noh, G-J			The Population Pharmacokinetics of Fentanyl in Patients Undergoing Living-Donor Liver Transplantation	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							PLASMA; PATHOPHYSIOLOGY; PROPOFOL; DISEASE; SIZE	Fentanyl, an opioid analgesic with a high hepatic extraction ratio, is frequently used to supplement general anesthesia during liver transplantation and is also continuously infused to provide postoperative analgesia. However, because fentanyl is metabolized mainly in the liver, the pharmacokinetics of fentanyl may vary widely during the different phases of the surgery, potentially leading to adverse events. Using nonlinear mixed-effects modeling, we characterized the pharmacokinetics of fentanyl in 15 patients (American Society of Anesthesiologists Physical Status Classification 2 or 3) undergoing living-donor liver transplantation (LDLT). Fentanyl was continuously infused at the rate of 200-400 mu g/h throughout the operation. The time course of the fentanyl plasma concentration levels was best described in terms of a two-compartment model. Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) x 42.5, 113.0, and 189.0, respectively, x (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 x (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase. The preanhepatic central volume of distribution was found to be markedly influenced by the massive infusion of fluids and blood products. The more hyperdynamic the circulation was during the preanhepatic phase, the higher the distributional clearance.	[Jin, S-J; Lee, S-H; Noh, G-J] Univ Ulsan, Dept Clin Pharmacol & Therapeut, Asan Med Ctr, Coll Med, Seoul, South Korea; [Noh, M-H] Kookmin Univ, Sch Automot Engn, Seoul, South Korea; [Lee, E-K] Ewha Womans Univ, Dept Stat, Seoul, South Korea; [Choi, B-M; Song, M-H; Noh, G-J] Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, Seoul, South Korea	Noh, GJ (reprint author), Univ Ulsan, Dept Clin Pharmacol & Therapeut, Asan Med Ctr, Coll Med, Seoul, South Korea.	nohgj@amc.seoul.kr	Lee, Soohan/AAP-6976-2020		Asan Institute for Life Sciences, Seoul, Korea [2010-301]; University of Ulsan College of Medicine, Seoul, Korea [10-11]; Ministry of Health, Welfare & Family Affairs, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A070001]	This study was supported by a grant (2010-301) from the Asan Institute for Life Sciences, Seoul, Korea; a Student Research Grant (10-11) from the University of Ulsan College of Medicine, Seoul, Korea; and a grant from the Korea Healthcare Technology R&D Project, Ministry of Health, Welfare & Family Affairs, Republic of Korea (A070001). The authors are grateful to Ae-Kyung Hwang, Hyun-Jeong Park, Soo-Hyeon Kim, and Arum Kim of the Clinical Research Center of Asan Medical Center (Seoul, Korea) for carrying out the measurements of the fentanyl concentrations. The authors also thank Jeong-Sim Yang for her efforts as a clinical research coordinator. Pacific Edit reviewed the manuscript prior to submission.	Al-Jahdari Wael S, 2006, J Anesth, V20, P323, DOI 10.1007/s00540-006-0420-y; Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; Beal S.L., 1992, NONMEM USERS GUIDE 5; Black Robert E, 2003, Proc (Bayl Univ Med Cent), V16, P275; Chui AKK, 2004, TRANSPL P, V36, P2277, DOI 10.1016/j.transproceed.2004.08.036; de Vos NJ, 2005, HYDROL EARTH SYST SC, V2, P365, DOI DOI 10.5194/HESSD-2-365-2005; Fisher DM, 1997, ANESTHESIOLOGY, V86, P1306, DOI 10.1097/00000542-199706000-00012; GLASS PSA, 1990, ANESTHESIOLOGY, V73, P1082, DOI 10.1097/00000542-199012000-00004; Green B, 2004, BRIT J CLIN PHARMACO, V58, P119, DOI 10.1111/j.1365-2125.2004.02157.x; GROSZMANN RJ, 1994, HEPATOLOGY, V20, P1359, DOI 10.1002/hep.1840200538; HABERER JP, 1982, BRIT J ANAESTH, V54, P1267, DOI 10.1093/bja/54.12.1267; HENDERSON JM, 1992, HEPATOLOGY, V16, P715, DOI 10.1002/hep.1840160316; Hudson RJ, 2002, CAN J ANAESTH, V49, P388, DOI 10.1007/BF03017328; KANG YG, 1989, TRANSPLANT P, V21, P3489; Karlsson MO, 2007, CLIN PHARMACOL THER, V82, P17, DOI 10.1038/sj.clpt.6100241; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Laleman W, 2009, ACTA GASTRO-ENT BELG, V72, P9; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MORGAN MY, 1982, GUT, V23, P362, DOI 10.1136/gut.23.5.362; Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x; OZIER YM, 1995, ANESTH ANALG, V81, P1142, DOI 10.1097/00000539-199512000-00005; ROBARTS WM, 1979, BRIT J SURG, V66, P691, DOI 10.1002/bjs.1800661006; Shangraw RE, 1996, ANESTHESIOLOGY, V84, P851, DOI 10.1097/00000542-199604000-00012; SHAPIRO SS, 1968, J AM STAT ASSOC, V63, P1343, DOI 10.2307/2285889; Takizawa D, 2005, BRIT J ANAESTH, V95, P643, DOI 10.1093/bja/aei243; Turner RJ, 1999, BRIT J ANAESTH, V83, P346, DOI 10.1093/bja/83.2.346; Ulukaya S, 2005, PEDIATR TRANSPLANT, V9, P332, DOI 10.1111/j.1399-3046.2005.00284.x; Weng Xiao-Chuan, 2005, J Zhejiang Univ Sci B, V6, P869, DOI 10.1631/jzus.2005.B0869	28	15	15	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0009-9236			CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	SEP	2011	90	3					423	431		10.1038/clpt.2011.133			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	811WM	WOS:000294247900017	21814196				2020-06-30	J	Mercadante, S; Ferrera, P; Adile, C; Casuccio, A				Mercadante, Sebastiano; Ferrera, Patrizia; Adile, Claudio; Casuccio, Alessandra			Fentanyl Buccal Tablets for Breakthrough Pain in Highly Tolerant Cancer Patients: Preliminary Data on the Proportionality Between Breakthrough Pain Dose and Background Dose	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Cancer pain; breakthrough pain; opioids; fentanyl buccal tablets	PALLIATIVE CARE-UNIT; INTRAVENOUS MORPHINE; OPEN-LABEL; REGIMEN; OPIOIDS; SAFETY	Context. Cancer patients receiving high doses of opioids as background medication are challenging, and it would be useful clinically to know whether a rapid-onset opioid (ROO) for breakthrough cancer pain (BTcP) may be started at a dose proportional to the background opioid dose. Objectives. The aim of this study was to assess the efficacy and safety of the fentanyl buccal tablet (FBT) in doses proportional to the opioid dose administered for background analgesia in a sample of patients with BTcP who were receiving high doses of opioids. Methods. Twelve patients who were receiving opioids for background analgesia at doses equivalent to more than 500 mg of oral morphine and had adequately controlled pain were prospectively recruited. BTcP was treated with proportional doses of FBT: patients receiving 600 mg of oral morphine equivalents were administered 1000 mu g of FBT, patients receiving 900 mg of oral morphine equivalents were administered 1500 mu g of FBT, and so on. For each episode of BTcP, trained nurses collected pain intensity (on a 0-10 numerical rating scale) and emerging problems when called for increases in pain considered to be severe in intensity by patients (T0) and 15 minutes after FBT administration (T15). Results. Patients were receiving mean doses of oral morphine equivalents of 1340 mg (+/- 585; range 720-2400). Seventy-nine events were treated with FBT (6.6 +/- 4.9 for each patient). The median pain intensity of BTcP events was 8 (range 7-10), and the mean dose of FBT administered was 2233 mu g (+/- 975; range 1200-4000). In most events, a decrease in pain intensity >33% and >50% was observed (n = 14 and n = 48, respectively) 15 minutes after the administration of FBT. Data on 11 episodes were missed. Only six events were unsuccessfully treated. In all the patients, the level of adverse effects after FBT administration was mild and indistinguishable from that associated with the background opioid analgesia. Conclusion. FBT in doses proportional to the high doses of opioids used for background analgesia was efficacious and well tolerated when administered for BTcP. Controlled studies with a specific design and a large number of patients should confirm such preliminary results. J Pain Symptom Manage 2011;42:464-469. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Mercadante, Sebastiano; Ferrera, Patrizia; Adile, Claudio] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013	casuccio, alessandra/0000-0002-5676-9535; Adile, Claudio/0000-0002-0664-3520			DARWISH M, 2006, J PAIN S1, V7, P35; Darwish M, 2010, CLIN DRUG INVEST, V30, P365, DOI 10.2165/11533360-000000000-00000; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2010, PAIN PRACT, V10, P287, DOI 10.1111/j.1533-2500.2010.00359.x	16	21	22	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	SEP	2011	42	3					464	469		10.1016/j.jpainsymman.2010.12.010			6	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	819ZE	WOS:000294873700017	21477977	Bronze, Green Published			2020-06-30	J	Foy, L; Seeyave, DM; Bradin, SA				Foy, Lindsey; Seeyave, Desiree M.; Bradin, Stuart A.			Toxic Leukoencephalopathy Due to Transdermal Fentanyl Overdose	PEDIATRIC EMERGENCY CARE			English	Article						fentanyl overdose; toxic leukoencephalopathy; opioid intoxication	SPONGIFORM LEUKOENCEPHALOPATHY; RESPIRATORY DEPRESSION; HEROIN VAPOR; INHALATION	Children with altered mental status who present to the emergency department have a broad differential diagnosis. We report a case of a 19-month-old girl who presented in coma and who was later found to have a fentanyl patch adhered to her back. She was found to have changes on brain magnetic resonance imaging consistent with a toxic spongiform leukoencephalopathy but had a good neurologic outcome. This case report illustrates the importance of a thorough physical examination in children in coma and a rarely reported magnetic resonance imaging finding that has been seen in opioid intoxication and is usually associated with severe morbidity and mortality.	[Seeyave, Desiree M.; Bradin, Stuart A.] Univ Michigan, Dept Emergency Med, Childrens Emergency Serv, Ann Arbor, MI 48109 USA; [Foy, Lindsey] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA	Seeyave, DM (reprint author), Univ Michigan, Dept Emergency Med, Childrens Emergency Serv, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	desirees@med.umich.edu					Filley CM, 2001, NEW ENGL J MED, V345, P425, DOI 10.1056/NEJM200108093450606; Gacouin A, 2003, INTENS CARE MED, V29, P1012, DOI 10.1007/s00134-003-1691-5; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; Hill MD, 2000, CAN MED ASSOC J, V162, P236; Mills F, 2008, PEDIATR RADIOL, V38, P227, DOI 10.1007/s00247-007-0635-6; Moeller KE, 2008, MAYO CLIN PROC, V83, P66, DOI 10.4065/83.1.66; Nanan R, 2000, NEURORADIOLOGY, V42, P845, DOI 10.1007/s002340000442; Raymond Barbara, 2004, CMAJ, V171, P991; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Weber W, 1998, EUR RADIOL, V8, P749, DOI 10.1007/s003300050467; WOLTERS EC, 1982, LANCET, V2, P1233	11	18	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	SEP	2011	27	9					854	856		10.1097/PEC.0b013e31822c281f			3	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	821SU	WOS:000294995500012	21926884				2020-06-30	J	Ning, MC; Karmakar, MK				Ning, M. Cheung; Karmakar, M. K.			Right thoracic paravertebral anaesthesia for percutaneous radiofrequency ablation of liver tumours	BRITISH JOURNAL OF RADIOLOGY			English	Article							BLOCK; PAIN; COMPLICATIONS; MANAGEMENT; INJECTION	Objectives: Percutaneous radiofrequency ablation (PRFA) of liver tumours performed under local anaesthesia and intravenous sedation can cause severe pain to patients. This prospective study evaluated the efficacy of a right thoracic paravertebral block (TPVB) for anaesthesia and analgesia during PRFA of liver tumours. Methods: 20 patients, aged 44-74 years, with liver malignancies received a multiple injection TPVB at the T6-10 levels 30 min before the PRFA. An intravenous infusion of propofol (3-5 mg kg(-1) h(-1)) was administered to patients who requested to be sedated and intravenous fentanyl (25 mu g bolus) was administered as rescue analgesia. Pain during the TPVB and PRFA was assessed using a numerical rating scale (NRS; 0, no pain; 10, worst imaginable pain). Patients were also assessed for residual pain and analgesic consumption during the 24 h after the intervention. Results: The TPVB was well tolerated and produced ipsilateral sensory anaesthesia with satisfactory spread (median (range); 8 (6-11) dermatomes). The PRFA procedure caused mild pain (mean (standard deviation, SD); NRS 1.4 (1.9)) during the insertion of the ablation needle and the peak pain intensity during the therapeutic burn was moderate (mean (SD); NRS 5.0 (3.3)) in severity. During the 24 h after the PRFA, patients reported minimal pain and consumed very few analgesics. The mean (SD) satisfaction score (0, totally dissatisfied; 10, very satisfied) of the patients was 8.9 (1.1) and that of the radiologists was 8.8 (1.4). Conclusion: A right TPVB is safe and effective for anaesthesia and analgesia during PRFA of malignant liver tumours.	[Ning, M. Cheung; Karmakar, M. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China	Ning, MC (reprint author), Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	cheungning2@gmail.com	Karmakar, Manoj Kumar/J-9370-2013	Karmakar, Manoj/0000-0002-3674-2095	Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Shatin, Hong KongChinese University of Hong Kong	This work was locally funded by the Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Shatin, Hong Kong.	Baumgarten RK, 2006, REGION ANESTH PAIN M, V31, P584, DOI 10.1016/j.rapm.2006.06.204; Bonny C, 2002, GASTROEN CLIN BIOL, V26, P735; Buscarini E, 2004, EUR RADIOL, V14, P31, DOI 10.1007/s00330-003-1990-9; Crocetti L, 2008, CANCER IMAGING, V8, P19, DOI 10.1102/1470-7330.2008.0004; Culp W C, 2008, Br J Radiol, V81, pe23; Giorgio A, 2005, AM J ROENTGENOL, V184, P207, DOI 10.2214/ajr.184.1.01840207; Hall H, 1999, BRIT J ANAESTH, V83, P819; Head HW, 2007, RADIOLOGY, V243, P877, DOI 10.1148/radiol.2433060157; Hinshaw JL, 2006, AM J ROENTGENOL, V186, pS306, DOI 10.2214/AJR.05.0140; Ho AMH, 2004, BRIT J ANAESTH, V93, P458, DOI 10.1093/bja/aeh212; Hura G, 2006, EUR J ANAESTH, V23, P658, DOI 10.1017/S0265021506000561; Karmakar MK, 2001, REGION ANESTH PAIN M, V26, P169, DOI 10.1053/rapm.2001.21086; Karmakar MK, 2003, CHEST, V123, P424, DOI 10.1378/chest.123.2.424; Karmakar MK, 2000, BRIT J ANAESTH, V84, P263; Karmakar MK, 2001, ANESTHESIOLOGY, V95, P771, DOI 10.1097/00000542-200109000-00033; Klein SM, 1998, REGION ANESTH PAIN M, V23, P306, DOI 10.1016/S1098-7339(98)90059-1; Lencioni R, 2007, TECH VASC INTERV RAD, V10, P38, DOI 10.1053/j.tvir.2007.08.006; Livraghi T, 2003, RADIOLOGY, V226, P441, DOI 10.1148/radiol.2262012198; LONNQVIST PA, 1995, ANAESTHESIA, V50, P813, DOI 10.1111/j.1365-2044.1995.tb06148.x; Naja ZM, 2006, REGION ANESTH PAIN M, V31, P196, DOI 10.1016/j.rapm.2005.12.004; Ng KK, 2005, SURG ONCOL, V14, P41, DOI 10.1016/j.suronc.2005.01.001; PURCELLJONES G, 1989, ANESTH ANALG, V68, P32; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Richardson J, 1998, BRIT J ANAESTH, V81, P230; Sabo B, 1999, AANA J, V67, P467; Watkins EJ, 2000, BRIT J ANAESTH, V84, P118; Watkinson AF, 2002, BRIT J RADIOL, V75, P105, DOI 10.1259/bjr.75.890.750105	27	10	10	1	4	BRITISH INST RADIOLOGY	LONDON	36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND	0007-1285	1748-880X		BRIT J RADIOL	Br. J. Radiol.	SEP	2011	84	1005					785	789		10.1259/bjr/28983063			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	807ZY	WOS:000293943400009	21081575	Green Published			2020-06-30	J	Ozturk, E; Yilmazlar, A; Coskun, F; Isik, O; Yilmazlar, T				Ozturk, E.; Yilmazlar, A.; Coskun, F.; Isik, O.; Yilmazlar, T.			The beneficial effects of preperitoneal catheter analgesia following colon and rectal resections: a prospective, randomized, double-blind, placebo-controlled study	TECHNIQUES IN COLOPROCTOLOGY			English	Article; Proceedings Paper	28th Annual European-Society-of-Regional-Anaesthesia Congress	SEP 09-13, 2009	Salzburg, AUSTRIA	European Soc Reg Anaesthesia		Preperitoneal; Catheter; Analgesia; Local anesthetic	CONTINUOUS WOUND INFUSION; POSTOPERATIVE PAIN; COLORECTAL SURGERY; BUPIVACAINE; PERFUSION; RELIEF; HYSTERECTOMY; RECOVERY; EFFICACY; SYSTEM	Preperitoneal catheter analgesia following abdominal surgery has attracted interest in the last decade. We conducted this study to evaluate the benefits of preperitoneal catheter analgesia in managing pain after abdominal colon and rectal resections. A total of 50 patients undergoing colon and rectal resections for benign and malignant diseases received analgesic medicines via an epidural catheter placed just prior to surgery and a preperitoneal catheter placed at the end of the surgical procedure. Patients were instructed to use the epidural patient-controlled analgesia (PCA) device freely and were randomized into two groups after obtaining the approval of the Institutional Review Board: Group A received 10 ml of levobupivacaine twice a day postoperatively via preperitoneal catheter and group B received only 10 ml of saline. Demographics, surgical characteristics, pain scores recorded four days following surgery, analgesic volume used from the epidural PCA, clinical outcomes (length of stay, time to first bowel movement, time to first passage of gas or stool, time to first oral intake) and respiratory function test results (preoperative vs. postoperative) were compared. There were no significant differences in demographics or surgical characteristics between both groups. Pain scores were similar. Clinical outcomes and respiratory functions were comparable. The use of analgesic volume via epidural catheter was significantly lower in group A than in group B (P = 0.032). Preperitoneal catheter analgesia significantly decreased the need for epidural drug consumption and proved to be a beneficial adjunct for postoperative pain management of patients who underwent colon and rectal resections.	[Ozturk, E.; Isik, O.; Yilmazlar, T.] Uludag Univ Sch Med, Dept Gen Surg, TR-16069 Gorukle, Bursa, Turkey; [Yilmazlar, A.] Uludag Univ Sch Med, Dept Anesthesiol & Reanimat, TR-16069 Gorukle, Bursa, Turkey; [Coskun, F.] Uludag Univ Sch Med, Dept Pulm Dis, TR-16069 Gorukle, Bursa, Turkey	Ozturk, E (reprint author), Uludag Univ Sch Med, Dept Gen Surg, TR-16069 Gorukle, Bursa, Turkey.	drozturk@uludag.edu.tr	Coskun, Funda/AAD-1271-2019; ISIK, OZGEN/P-5779-2019; Isik, Ozgen/T-7494-2017	Coskun, Funda/0000-0003-3604-8826; Isik, Ozgen/0000-0002-9541-5035			[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Badia JM, 1996, BRIT J SURG, V83, P347, DOI 10.1002/bjs.1800830316; Baig MK, 2006, J AM COLL SURGEONS, V202, P297, DOI 10.1016/j.jamcollsurg.2005.10.022; Beaussier M, 2007, ANESTHESIOLOGY, V107, P461, DOI 10.1097/01.anes.0000278903.91986.19; Cheong WK, 2001, BRIT J SURG, V88, P357, DOI 10.1046/j.1365-2168.2001.01717.x; CHESTER JF, 1989, ANN ROY COLL SURG, V71, P394; Cornish P, 2007, ANZ J SURG, V77, P84, DOI 10.1111/j.1445-2197.2006.03982.x; DAHL JB, 1994, ACTA ANAESTH SCAND, V38, P7, DOI 10.1111/j.1399-6576.1994.tb03830.x; Fredman B, 2001, ANESTH ANALG, V92, P189; Gupta A, 2004, ANESTH ANALG, V99, P1173, DOI 10.1213/01.ANE.0000130260.24433.A2; Karthikesalingam A, 2008, WORLD J GASTROENTERO, V14, P5301, DOI 10.3748/wjg.14.5301; Kirdak T, 2008, AM SURGEON, V74, P160; Kristensen BB, 1999, REGION ANESTH PAIN M, V24, P576, DOI 10.1016/S1098-7339(99)90052-4; LEVACK ID, 1986, BRIT J ANAESTH, V58, P615, DOI 10.1093/bja/58.6.615; Liu SS, 2006, J AM COLL SURGEONS, V203, P914, DOI 10.1016/j.jamcollsurg.2006.08.007; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Polglase AL, 2007, DIS COLON RECTUM, V50, P2158, DOI 10.1007/s10350-007-9081-7; *PROSP WORK GROUP, 2008, PROC SPEC POST PAIN; Sammour T, 2010, WORLD J SURG, V34, P704, DOI 10.1007/s00268-009-0382-y	19	9	9	0	5	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1123-6337	1128-045X		TECH COLOPROCTOL	Tech. Coloproctology	SEP	2011	15	3					331	336		10.1007/s10151-011-0720-6			6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	807TT	WOS:000293923500014	21769617				2020-06-30	J	Johnston, KD; Quinlan, J				Johnston, K. D.; Quinlan, J.			The effect of combining dexamethasone with ondansetron for nausea and vomiting associated with fentanyl-based intravenous patient-controlled analgesia	ANAESTHESIA			English	Letter							PCA; PAIN		[Johnston, K. D.; Quinlan, J.] John Radcliffe Hosp, Oxford OX3 9DU, England	Johnston, KD (reprint author), John Radcliffe Hosp, Oxford OX3 9DU, England.	kevindjohnston@googlemail.com					Butkovic D, 2007, BRIT J ANAESTH, V98, P677, DOI 10.1093/bja/aem055; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; GRANT RP, 1992, CAN J ANAESTH, V39, P214, DOI 10.1007/BF03008779; Kim SY, 2008, THYROID, V18, P1285, DOI 10.1089/thy.2008.0007; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; Song JW, 2011, ANAESTHESIA, V66, P263, DOI 10.1111/j.1365-2044.2011.06648.x	7	0	0	1	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0003-2409			ANAESTHESIA	Anaesthesia	SEP	2011	66	9					840	841		10.1111/j.1365-2044.2011.06830.x			2	Anesthesiology	Anesthesiology	806GR	WOS:000293794800015	21831078				2020-06-30	J	Votava, M; Hess, L; Schreiberova, J; Malek, J; Stein, K				Votava, Martin; Hess, Ladislav; Schreiberova, Jitka; Malek, Jiri; Stein, Karel			Short term pharmacological immobilization in macaque monkeys	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alpha(2)-adrenergic agonist; anaesthesia; fentanyl; medetomidine; midazolam; primate	MACACA-MULATTA; KETAMINE; NAPHTHYLMEDETOMIDINE; MEDETOMIDINE; COMBINATION; PROTOCOLS	Objective To develop a safe and effective immobilization protocol in rhesus monkeys, which is not based on dissociative anaesthetic agent. Study design Prospective, randomised, experimental trial. Animals Twenty rhesus monkeys, weighing 2.6-8.0 kg, 1-3 years of age, of both sexes. Methods The monkeys received 50 mu g kg(-1) medetomidine, 0.25 mg kg(-1) midazolam and 5 mu g kg(-1) fentanyl with 150 IU hyaluronidase intramuscularly (IM). The animals were closely observed for behavioural changes and reaction to sound stimulus. Pulse rate and oxygen saturation of haemoglobin (SpO(2)) were monitored every 5 minutes, for 20 minutes. After this period, 250 mu g kg(-1) atipamezole or a placebo was administered IM and behavioural changes were closely observed. Results Full immobilization was observed after mean 269 +/- SD 116 seconds. Ten minutes after injection mean arterial oxygen saturation of haemoglobin was 94 +/- 4%, but did not fall significantly further. The median pulse rate was 116 beats minute(-1) 5 minutes after the administration of the drug. This level further decreased to a median level of 108 beats minute(-1) 20 minutes after the drug's administration. The median time to recover from immobilization was significantly shorter after atipamezole administration when compared to placebo (2.7 versus 55 minutes). All animals awoke smoothly and no side effects such as vomiting or agitation were observed. Conclusions Short term and reversible pharmacological immobilization was achieved using combination of midazolam, medetomidine, and fentanyl. Clinical relevance The present study demonstrates that 20-minute pharmacological immobilization with a combination of midazolam, medetomidine, and fentanyl is feasible in rhesus monkeys with minimal effect on heart rate.	[Votava, Martin] Charles Univ Prague, Dept Pharmacol, Fac Med 2, Prague 15006 5, Czech Republic; [Hess, Ladislav] Inst Clin & Expt Med, Lab Expt Anaesthesiol, Prague, Czech Republic; [Schreiberova, Jitka] Charles Univ Prague, Dept Anaesthesiol & Intens Care Med, Fac Med, Hradec Kralove, Czech Republic; [Schreiberova, Jitka] Charles Univ Prague, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Malek, Jiri] Charles Univ Prague, Dept Anaesthesiol & Crit Care Med, Fac Med 3, Prague 15006 5, Czech Republic; [Stein, Karel] Mil Hlth Insurance Co, Prague, Czech Republic	Votava, M (reprint author), Charles Univ Prague, Dept Pharmacol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.	martin.votava@lfmotol.cuni.cz	Malek, Jiri/D-6490-2017; Schreiberova, Jitka/I-8855-2017	Malek, Jiri/0000-0002-4048-341X; Schreiberova, Jitka/0000-0003-2570-5894	Czech Ministry of HealthMinistry of Health, Czech Republic [NT 11284-4/2010]	This work was supported by the grant IGA NT 11284-4/2010 from the Czech Ministry of Health.	Bentson KL, 2003, J MED PRIMATOL, V32, P148, DOI 10.1034/j.1600-0684.2003.00018.x; Henke J, 2004, J VET MED A, V51, P259, DOI 10.1111/j.1439-0442.2004.00632.x; Hess L, 2010, J MED PRIMATOL, V39, P151, DOI 10.1111/j.1600-0684.2010.00404.x; Miyabe Takako, 2001, Vet Anaesth Analg, V28, P168, DOI 10.1046/j.1467-2987.2001.00052.x; Olberg Rolf-Arne, 2007, P375; POPILSKIS SJ, 1997, ANESTHESIA ANALGESIA, P234; Pulley ACS, 2004, J ZOO WILDLIFE MED, V35, P497, DOI 10.1638/03-092; Sinclair MD, 2003, CAN VET J, V44, P885; Sun FJ, 2003, CONTEMP TOP LAB ANIM, V42, P32; Votava M, 2009, J MED PRIMATOL, V38, P241, DOI 10.1111/j.1600-0684.2009.00347.x	10	8	8	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	SEP	2011	38	5					490	493		10.1111/j.1467-2995.2011.00637.x			4	Veterinary Sciences	Veterinary Sciences	806HU	WOS:000293797700010	21831055				2020-06-30	J	Cullen, A				Cullen, Aidan			Reply to 'two-agent analgesia versus acetaminophen in children having bilateral myringotomies and tubes surgery'	PEDIATRIC ANESTHESIA			English	Letter									Craigavon Area Hosp, ST5 Anaesthet, Portadown, North Ireland	Cullen, A (reprint author), Craigavon Area Hosp, ST5 Anaesthet, Portadown, North Ireland.	aidsocullen@hotmail.com					Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x	1	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	SEP	2011	21	9					987	987		10.1111/j.1460-9592.2011.03611.x			1	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	799JP	WOS:000293283300016	21793983				2020-06-30	J	Imai, S; Sudo, Y; Nakamura, A; Ozeki, A; Asato, M; Hojo, M; Devi, LA; Kuzumaki, N; Suzuki, T; Uezono, Y; Narita, M				Imai, Satoshi; Sudo, Yuka; Nakamura, Atsushi; Ozeki, Ayumi; Asato, Megumi; Hojo, Minoru; Devi, Lakshmi A.; Kuzumaki, Naoko; Suzuki, Tsutomu; Uezono, Yasuhito; Narita, Minoru			Possible Involvement of beta-Endorphin in a Loss of the Coordinated Balance of mu-Opioid Receptors Trafficking Processes by Fentanyl	SYNAPSE			English	Article						internalization/recycling pathway; opioids; receptor trafficking; fentanyl	PROTEIN-COUPLED RECEPTORS; PAIN-LIKE STATE; ENDOCYTOSIS; MORPHINE; DESENSITIZATION; TOLERANCE		[Imai, Satoshi; Nakamura, Atsushi; Ozeki, Ayumi; Asato, Megumi; Kuzumaki, Naoko; Suzuki, Tsutomu; Narita, Minoru] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Shinagawa Ku, Tokyo 1428501, Japan; [Sudo, Yuka; Uezono, Yasuhito] Natl Canc Ctr, Res Inst, Canc Pathophysiol Div, Chuo Ku, Tokyo 1040045, Japan; [Hojo, Minoru] Nagasaki Univ, Grad Sch Biomed Sci, Dept Anesthesiol, Nagasaki 8528523, Japan; [Devi, Lakshmi A.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA; [Uezono, Yasuhito] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cellular & Mol Biol, Nagasaki 8528523, Japan	Narita, M (reprint author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Toxicol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	narita@hoshi.ac.jp	Sudo, Yuka/G-3182-2013; Kuzumaki, Naoko/L-1287-2013		NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA008863]	Contract grant sponsor: NIDA; Contract grant number: DA008863	Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Corbani M, 2004, ENDOCRINOLOGY, V145, P2876, DOI 10.1210/en.2004-0062; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Imai Satoshi, 2006, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V26, P183; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Niikura K, 2008, NEUROSCI LETT, V435, P257, DOI 10.1016/j.neulet.2008.02.059; Niikura K, 2010, TRENDS PHARMACOL SCI, V31, P299, DOI 10.1016/j.tips.2010.04.003; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Smalheiser NR, 2009, NEUROMOL MED, V11, P133, DOI 10.1007/s12017-009-8065-2; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	13	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	SEP	2011	65	9					962	966		10.1002/syn.20930			5	Neurosciences	Neurosciences & Neurology	799GU	WOS:000293275200013	21437993	Green Accepted			2020-06-30	J	Davies, A; Zeppetella, G; Andersen, S; Damkier, A; Vejlgaard, T; Nauck, F; Radbruch, L; Sjolund, KF; Stenberg, M; Buchanan, A				Davies, Andrew; Zeppetella, Giovambattista; Andersen, Steen; Damkier, Anette; Vejlgaard, Tove; Nauck, Friedemann; Radbruch, Lukas; Sjolund, Karl-Frederik; Stenberg, Mariann; Buchanan, Alison			Multi-centre European study of breakthrough cancer pain: Pain characteristics and patient perceptions of current and potential management strategies	EUROPEAN JOURNAL OF PAIN			English	Article						Pain; Breakthrough pain; Cancer; Palliative care	TRANSMUCOSAL FENTANYL CITRATE; CROSSOVER TRIAL; OPEN-LABEL; PREVALENCE; ASSOCIATION; HOSPICE; SPRAY	This study involved 320 cancer patients from four Northern European countries. Patients with breakthrough pain were questioned about the characteristics of their pain, the current management of their pain, and the acceptability/utility of alternative routes of administration. The median number of episodes was 3/day. Forty-four percent patients reported incident-type pain, 39% spontaneous-type pain, and 17% a combination of these pains. The median duration was 60 min, and the median time to peak intensity was 15 min. Three percent patients reported "mild" pain, 37% "moderate" pain, and 60% "severe'' pain. Ninety percent patients stated that the pain interfered with their daily activities. All patients were using opioids as rescue medication (mainly oral morphine/oxycodone), whilst 28% patients were using non-opioids, and 50% patients were using non-pharmacological interventions. Only 55% patients took rescue medication every time they experienced breakthrough pain. Sixty-five percent patients would definitely consider using an oral transmucosal product; patients from Denmark were less likely to answer positively, and a positive response was associated with previous use of the route for breakthrough pain. Seventy-three percent patients reported regular oral problems. Forty-two percent patients would definitely consider using an intranasal product, with 26% patients stating they would definitely not use such a preparation; patients from Denmark and Sweden were less likely to answer positively, and a positive response was associated with male gender, and previous use of the route. Forty-four percent patients reported regular nasal problems. Sixty percent patients would definitely consider using a subcutaneous product, and 44% patients would definitely consider using an intrapulmonary product. (C) 2010 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.	[Davies, Andrew] Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford GU2 7XX, Surrey, England; [Zeppetella, Giovambattista] St Clare Hosp, Hastingwood CM17 9JX, Essex, England; [Andersen, Steen] Roskilde Hosp, DK-4000 Roskilde, Denmark; [Damkier, Anette] Odense Univ Hosp, DK-5000 Odense C, Denmark; [Vejlgaard, Tove] Sankt Maria Hosp Ctr, DK-7100 Vejle, Denmark; [Nauck, Friedemann] Univ Hosp Gottingen, D-37075 Gottingen, Germany; [Radbruch, Lukas] Univ Hosp Bonn, D-53127 Bonn, Germany; [Sjolund, Karl-Frederik] Karolinska Univ Hosp, SE-17176 Stockholm, Sweden; [Stenberg, Mariann] Univ Lund Hosp, SE-22100 Lund, Sweden; [Buchanan, Alison] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England	Davies, A (reprint author), Royal Surrey Cty Hosp, St Lukes Canc Ctr, Egerton Rd, Guildford GU2 7XX, Surrey, England.	andavies@doctors.org.uk; John.Zeppetella@stclarehospice.org.uk; sad@regionsjaelland.dk; anette.damkier@ouh.regionsyddanmark.dk; tove.vejlgaard@slb.regionsyddanmark.dk; Friedemann.Nauck@med.uni-goettingen.de; Lukas.Radbruch@malteser.org; karl-fredrik.sjolund@karolinska.se; mariann.stenberg@skane.se; alison.buchanan@rmh.nhs.uk			Nycomed	The study was supported by an educational grant from Nycomed, who market Instanyl (R) (intranasal fentanyl) for the management of breakthrough cancer pain.	[Anonymous], 2009, EUR J PAIN, V13, pS207; BAILEY F, 2006, CANC RELATED BREAKTH, P43; CHRISTELIS N, 2006, CANC RELATED BREAKTH, P99; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; ZEPPETELLA G, 2009, CANC RELATED BREAKTH, P57; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	19	89	101	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3801			EUR J PAIN	Eur. J. Pain	AUG	2011	15	7					756	763		10.1016/j.ejpain.2010.12.004			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	811KX	WOS:000294210000013	21251860				2020-06-30	J	Nejati, A; Moharari, RS; Ashraf, H; Labaf, A; Golshani, K				Nejati, Amir; Moharari, Reza Shariat; Ashraf, Haleh; Labaf, Ali; Golshani, Keihan			Ketamine/Propofol Versus Midazolam/Fentanyl for Procedural Sedation and Analgesia in the Emergency Department: A Randomized, Prospective, Double-Blind Trial	ACADEMIC EMERGENCY MEDICINE			English	Article							PROPOFOL-KETAMINE COMBINATION; PATIENT DATA METAANALYSIS; RECOVERY AGITATION; PEDIATRIC PROCEDURES; ADVERSE EVENTS; 8,282 CHILDREN; ANESTHESIA; PREDICTORS; AIRWAY; PAIN	Objectives: The authors performed a prospective, double-blinded, randomized trial with emergency department (ED) patients requiring procedural sedation and analgesia (PSA) for repair of deep traumatic lacerations and reduction of bone fractures, to compare the ketamine/propofol (ketofol) combination with the midazolam/fentanyl (MF) combination. Methods: Sixty-two patients scheduled for PSA who presented between January 2009 and June 2009 were enrolled prospectively. Thirty-one were randomly assigned to the ketofol group, and 31 were assigned to the MF group. Results: The median starting doses were 0.75 mg/kg of both ketamine and propofol (interquartile range [IQR] = 0.75 to 1.5 mg/kg), 0.04 mg/kg midazolam (IQR = 0.04 to 0.06 mg/kg), and 2 mu g/kg fentanyl (IQR = 2 to 3 mu g/kg). There were no significant differences in sedation time between the groups. There were no differences in physician satisfaction (p = 0.065). Perceived pain in the ketofol group, as measured by the Visual Analog Scale (VAS), was significantly lower than in the MF group (median ketofol = 0, IQR = 0-1 vs. median MF = 3, IQR = 1-6; p < 0.001). Only one patient in each group required bag-mask ventilation, and neither of them were intubated. Conclusions: The ketamine/propofol combination provides adequate sedation and analgesia for painful procedures and appears to be a safe and useful technique in the ED. ACADEMIC EMERGENCY MEDICINE 2011; 18:800-806 (C) 2011 by the Society for Academic Emergency Medicine	[Golshani, Keihan] Isfahan Univ Med Sci, Alzahra Gen Hosp, Dept Emergency Med, Esfahan, Iran; [Nejati, Amir; Labaf, Ali] Univ Tehran Med Sci, Imam Hosp, Dept Emergency Med, Tehran, Iran; [Moharari, Reza Shariat] Univ Tehran Med Sci, Sina Hosp, Dept Anesthesiol, Tehran, Iran; [Ashraf, Haleh] Univ Tehran Med Sci, Ctr Heart, Tehran, Iran	Golshani, K (reprint author), Isfahan Univ Med Sci, Alzahra Gen Hosp, Dept Emergency Med, Esfahan, Iran.	k_golshani@med.mui.ac.ir	Golshani, Keihan/N-1748-2018; Labaf, Ali/J-9060-2017	Labaf, Ali/0000-0002-4449-2479; Nejati, Amir/0000-0001-9248-8768; Golshani, Keihan/0000-0001-8567-5119; ashraf, haleh/0000-0001-6687-995X			Akin A, 2005, INT J PEDIATR OTORHI, V69, P1541, DOI 10.1016/j.ijporl.2005.04.011; Akin A, 2005, PEDIATR CARDIOL, V26, P553, DOI 10.1007/s00246-004-0707-4; Badrinath S, 2000, ANESTH ANALG, V90, P858, DOI 10.1213/00000539-200004000-00016; Bahn EL, 2005, EMERG MED CLIN N AM, V23, P503, DOI 10.1016/j.emc.2004.12.013; Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; Bowdle TA, 1998, ANESTHESIOLOGY, V88, P82, DOI 10.1097/00000542-199801000-00015; Burns Shari M, 2003, Crit Care Nurse, V23, P66; Camu Frederic, 2002, Best Pract Res Clin Anaesthesiol, V16, P475, DOI 10.1053/bean.2002.0262; Chudnofsky CR, 2000, ACAD EMERG MED, V7, P228, DOI 10.1111/j.1553-2712.2000.tb01064.x; Frizelle HP, 1997, ANESTH ANALG, V84, P1318, DOI 10.1097/00000539-199706000-00026; Goh PK, 2005, ANAESTH INTENS CARE, V33, P223, DOI 10.1177/0310057X0503300211; Grace RF, 2003, ANAESTHESIA, V58, P904, DOI 10.1046/j.1365-2044.2003.03341.x; Green SM, 2005, AM J EMERG MED, V23, P142, DOI 10.1016/j.ajem.2004.04.030; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; GREEN SM, 1990, ANN EMERG MED, V19, P1033, DOI 10.1016/S0196-0644(05)82569-7; Green SM, 2001, J PEDIATR GASTR NUTR, V32, P26, DOI 10.1097/00005176-200101000-00010; Green SM, 2000, ANN EMERG MED, V36, P480, DOI 10.1067/mem.2000.111426; Green SM, 2009, ANN EMERG MED, V54, P158, DOI 10.1016/j.annemergmed.2008.12.011; Green SM, 2009, ANN EMERG MED, V54, P171, DOI 10.1016/j.annemergmed.2009.04.004; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; HUG CC, 1993, ANESTH ANALG, V77, pS21; Miner JR, 2010, ACAD EMERG MED, V17, P604, DOI 10.1111/j.1553-2712.2010.00776.x; Mortero RF, 2001, ANESTH ANALG, V92, P1465; Nagata A, 1998, ANESTH ANALG, V87, P1416, DOI 10.1097/00000539-199812000-00040; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Roback MG, 2005, ACAD EMERG MED, V12, P508, DOI 10.1197/j.aem.2004.12.009; Saghaei Mahmood, 2004, BMC Med Res Methodol, V4, P26, DOI 10.1186/1471-2288-4-26; Sener S, 2011, ANN EMERG MED, V57, P109, DOI 10.1016/j.annemergmed.2010.09.010; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; SHORT SM, 1991, ANAESTHESIA, V46, P783, DOI 10.1111/j.1365-2044.1991.tb09781.x; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Suzuki Satomi, 2002, Masui, V51, P140; Tan CH, 1998, ANAESTHESIA, V53, P302, DOI 10.1046/j.1365-2044.1998.00287.x; TOMODA K, 1993, BRIT J ANAESTH, V71, P383, DOI 10.1093/bja/71.3.383; Walls R, 2004, MANUAL EMERGENCY AIR; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; Willman EV, 2007, ANN EMERG MED, V49, P23, DOI 10.1016/j.annemergmed.2006.08.002	38	36	36	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	AUG	2011	18	8			SI		800	806		10.1111/j.1553-2712.2011.01133.x			7	Emergency Medicine	Emergency Medicine	807AJ	WOS:000293860400003	21843215				2020-06-30	J	Agostoni, M; Fanti, L; Gemma, M; Pasculli, N; Beretta, L; Testoni, PA				Agostoni, Massimo; Fanti, Lorella; Gemma, Marco; Pasculli, Nicola; Beretta, Luigi; Testoni, Pier Alberto			Adverse events during monitored anesthesia care for GI endoscopy: an 8-year experience	GASTROINTESTINAL ENDOSCOPY			English	Article							GASTROINTESTINAL ENDOSCOPY; TRAINED NONANESTHESIOLOGISTS; CONTROLLED INFUSION; PROPOFOL; SEDATION; RISK; MIDAZOLAM; SAFE; GUIDELINES; ERCP	Background: The importance of sedation during endoscopy is well established. There is no consensus about the best techniques for sedation, which specialist should perform it, and in which location. Objective: To provide data on the epidemiology of adverse events during sedation for endoscopy. Design: Retrospective analysis of a prospective database. Setting: Endoscopy unit of a university hospital. Procedures: A total of 17,999 procedures performed over 8 years. Interventions: Sedation for GI endoscopy. Main Outcome Measurements: We recorded the following information: sex, age, body mass index, smoking habits, American Society of Anesthesiologists and Mallampati scores, duration of the procedure, type of sedative drug administered, whether the procedure was performed emergently, and endoscopic interventions during the maneuver. Adverse events were defined as occurrences that warranted intervention and were classified as hypotension, desaturation, bradycardia, hypertension, arrhythmia, aspiration, respiratory depression, vomiting, cardiac arrest, respiratory arrest, angina, hypoglycemia, and/or allergic reaction. Results: Deep sedation with intravenous propofol target controlled infusion pump was the most frequently used means of administering sedation. Adverse events were rare in both the adult (4.5%) and pediatric (2.6%) populations. Six complications occurred in more than 0.1% of adult cases: arterial hypotension, desaturation, bradycardia, arterial hypertension, arrhythmia, and aspiration. Only bradycardia (2.1%) and hypotension (0.44%) occurred in children. Three adult patients (0.017%) died, and no pediatric patients died. Some predictive models for the occurrence of complications are proposed. Limitations: Retrospective analysis, single-center data collection. Conclusions: Deep sedation during endoscopic procedures is safe in both adults and children. Our data may be useful for the future planning of new clinical strategies in this setting. (Gastrointest Endosc 2011;74:266-75.)	[Agostoni, Massimo; Gemma, Marco; Pasculli, Nicola; Beretta, Luigi] Vita Salute Univ Milano, IRCCS H San Raffaele, Dept Anesthesiol, I-20132 Milan, Italy; [Fanti, Lorella; Testoni, Pier Alberto] Vita Salute Univ Milano, IRCCS H San Raffaele, Dept Gastroenterol, I-20132 Milan, Italy	Agostoni, M (reprint author), Vita Salute Univ Milano, IRCCS San Raffaele Hosp, Dept Anesthesiol, Via Olgettina 60, I-20132 Milan, Italy.	agostoni.massimo@hsr.it		Gemma, Marco/0000-0002-9543-3831; turi, stefano/0000-0001-7365-3510			Agostoni M, 2010, EUR J ANAESTH, V27, P216, DOI 10.1097/EJA.0b013e328330ecd2; Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; [Anonymous], 2009, CONTINUUM DEPTH SEDA; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Conigliaro R, 2006, ENDOSCOPY, V38, P1137, DOI 10.1055/s-2006-944842; Cote GA, 2010, CLIN GASTROENTEROL H, V8, P137, DOI 10.1016/j.cgh.2009.07.008; Cravero JP, 2006, PEDIATRICS, V118, P1087, DOI 10.1542/peds.2006-0313; Fanti L, 2007, DIGEST LIVER DIS, V39, P81, DOI 10.1016/j.dld.2006.09.004; Fanti L, 2004, GASTROINTEST ENDOSC, V60, P361, DOI 10.1016/S0016-5107(04)01713-4; Fanti L, 2010, WORLD J GASTROENTERO, V16, P2451, DOI 10.3748/wjg.v16.i20.2451; Fu ES, 2004, CHEST, V126, P1552, DOI 10.1378/chest.126.5.1552; Heuss LT, 2003, GASTROINTEST ENDOSC, V57, P664, DOI 10.1067/mge.2003.191; KEATS AS, 1978, ANESTHESIOLOGY, V49, P233, DOI 10.1097/00000542-197810000-00001; Koch ME, 2004, AM J GASTROENTEROL, V99, P1208, DOI 10.1111/j.1572-0241.2004.t01-1-40572.x; Leslie K, 2008, Anesth Analg, V107, P2089, DOI 10.1213/ANE.0b013e3181891464; MALLAMPATI S, 1986, CAN ANAESTH SOC J, V32, P429; Mayer J, 2008, EUR J ANAESTH, V25, P741, DOI 10.1017/S0265021508004328; Melloni C, 2005, Minerva Anestesiol, V71, P325; Minocha A, 1998, DIGEST DIS SCI, V43, P1835, DOI 10.1023/A:1018860425719; Patel S, 2005, AM J GASTROENTEROL, V100, P2689, DOI 10.1111/j.1572-0241.2005.00320.x; Qadeer MA, 2009, DIGEST DIS SCI, V54, P1035, DOI 10.1007/s10620-008-0452-2; Rex DK, 2005, GASTROENTEROLOGY, V129, P1384, DOI 10.1053/j.gastro.2005.08.014; Rex DK, 2009, GASTROENTEROLOGY, V137, P1229, DOI 10.1053/j.gastro.2009.06.042; Riphaus A, 2005, AM J GASTROENTEROL, V100, P1957, DOI 10.1111/j.1572-0241.2005.41672.x; Riphaus A, 2008, Z GASTROENTEROL, V46, P1298, DOI 10.1055/s-2008-1027850; Tohda G, 2006, ENDOSCOPY, V38, P360, DOI 10.1055/s-2005-921192; Vargo JJ, 2004, AM J GASTROENTEROL, V99, P1207, DOI 10.1111/j.1572-0241.2004.40572_4.x; Vargo JJ, 2010, CLIN GASTROENTEROL H, V8, P103, DOI 10.1016/j.cgh.2009.11.001; Vargo JJ, 2009, AM J GASTROENTEROL, V104, P2886, DOI 10.1038/ajg.2009.607; Wehrmann T, 2008, SCAND J GASTROENTERO, V43, P368, DOI 10.1080/00365520701679181; Yusoff IF, 2004, GASTROINTEST ENDOSC, V60, P356, DOI 10.1016/S0016-5107(04)01711-0; 1999, DIPRIFUSOR TARGET CO; 1999, ANESTHESIOLOGY, V90, P896	35	86	93	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	AUG	2011	74	2					266	275		10.1016/j.gie.2011.04.028			10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	808DB	WOS:000293954600005	21704990				2020-06-30	J	Shiraishi, K; Takeda, Y; Masui, K; Taninishi, H; Sasaki, T; Danura, T; Morita, K				Shiraishi, Kensuke; Takeda, Yoshimasa; Masui, Kenichi; Taninishi, Hideki; Sasaki, Toshihiro; Danura, Tetsuya; Morita, Kiyoshi			Effect of fentanyl on ischemic depolarization and ischemic neuronal damage of hippocampal CA1 in the gerbil	JOURNAL OF ANESTHESIA			English	Article						Fentanyl; Brain ischemia; Neuronal damage; Ischemic depolarization; mu-Opioid receptor	TARGET-CONTROLLED INFUSION; MU-OPIOID RECEPTOR; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; RAT; INJURY; NEUROTOXICITY; HYPOTHERMIA; OCCLUSION; RECOVERY	Temporary brain ischemia occurring during surgery under general anesthesia may induce the death of neuronal cells and cause severe neurological deficits. On the other hand, it is not clear whether mu-opioid receptor agonists promote ischemic brain injury. It is known that duration of ischemic depolarization affects the degree of neuronal damage. However, the effects of fentanyl during brain ischemia on ischemic depolarization have not been investigated. Therefore, in the current study, the effects of fentanyl on ischemic neuronal damage and ischemic depolarization were quantitatively evaluated. Forty-two male gerbils were randomly assigned to a saline-administered group (control group, n = 21) and a fentanyl-administered group (fentanyl group, n = 21). Fentanyl at 50 mu g/kg was first administered over a 10-min period and then 50 mu g/kg/h was administered continuously for the fentanyl group. Forebrain ischemia was initiated by occlusion of bilateral common carotid arteries and sustained for 3, 5, or 7 min (n = 7 in each group). Direct-current potentials were measured in bilateral CA1 regions, in which histological evaluation was performed 5 days later. There were no significant differences in onset time, duration of ischemic depolarization, and percentage of neuronal damage between the two groups with any ischemic duration. In the relationships between ischemic time and neuronal damage and those between duration of ischemic depolarization and neuronal damage, there was no significant difference in the percentage of neuronal damage between the two groups. Fentanyl at a clinically relevant dose does not affect ischemic depolarization and ischemic neuronal damage.	[Shiraishi, Kensuke; Takeda, Yoshimasa; Taninishi, Hideki; Sasaki, Toshihiro; Danura, Tetsuya; Morita, Kiyoshi] Okayama Univ, Dept Anesthesiol & Resuscitol, Sch Med, Okayama 7008558, Japan; [Masui, Kenichi] Natl Def Med Coll, Dept Anesthesiol, Tokorozawa, Saitama 359, Japan	Shiraishi, K (reprint author), Okayama Univ, Dept Anesthesiol & Resuscitol, Sch Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	shiraken@cc.okayama-u.ac.jp	Masui, Kenichi/AAQ-1660-2020				ANDERSEN P, 1975, HIPPOCAMPUS, V1, P155; Bailey PL, 2000, ANESTHESIA, P330; Cortinez LI, 2005, EUR J ANAESTH, V22, P56, DOI 10.1017/S0265021505000128; Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; HOWIE MB, 1985, ANESTH ANALG, V64, P877; Kalvass JC, 2007, J PHARMACOL EXP THER, V323, P346, DOI 10.1124/jpet.107.119560; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KISSIN I, 1983, CAN ANAESTH SOC J, V30, P623, DOI 10.1007/BF03015233; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Kofke WA, 1999, BRAIN RES, V818, P326, DOI 10.1016/S0006-8993(98)01228-1; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; LAURITZEN M, 1990, J CEREBR BLOOD F MET, V10, P115, DOI 10.1038/jcbfm.1990.14; Li J, 2000, J NEUROSURG ANESTH, V12, P247, DOI 10.1097/00008506-200007000-00009; LOSKOTA WJ, 1974, STEREOTAXIC ATLAS MO, P74; LOTSCH J, 2005, [No title captured], V29, P90, DOI DOI 10.1016/J.JPAINSYMMAN; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; Morimoto Y, 1997, J NEUROSURG ANESTH, V9, P316, DOI 10.1097/00008506-199710000-00005; NAKASHIMA K, 1995, ANESTHESIOLOGY, V82, P1199, DOI 10.1097/00000542-199505000-00015; Schifilliti D, 2010, CNS DRUGS, V24, P893, DOI 10.2165/11584760-000000000-00000; Schmidt P, 2001, FORENSIC SCI INT, V115, P219, DOI 10.1016/S0379-0738(00)00333-9; SICK TJ, 1990, CEREBRAL ISCHEMIA RE, P271; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; SOLTESZ I, 1995, HIPPOCAMPUS, V5, P101, DOI 10.1002/hipo.450050202; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; Stumm RK, 2004, J COMP NEUROL, V469, P107, DOI 10.1002/cne.10997; Suzuki H, 2006, ACTA ANAESTH SCAND, V50, P568, DOI 10.1111/j.1399-6576.2006.00986.x; Takagaki Y, 1997, J NEUROCHEM, V68, P2507; WIDMANN R, 1993, J NEUROCHEM, V61, P200, DOI 10.1111/j.1471-4159.1993.tb03556.x; WITTER MP, 1988, NEUROSCI LETT, V85, P193, DOI 10.1016/0304-3940(88)90350-3	32	2	2	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668			J ANESTH	J. Anesth.	AUG	2011	25	4					540	548		10.1007/s00540-011-1143-2			9	Anesthesiology	Anesthesiology	805QE	WOS:000293743300009	21509464				2020-06-30	J	Kraus, M; Segal, N; Shkolnik, M; Kochva, A; German, L; Kaplan, D; Greemberg, L; Puterman, M				Kraus, Mordechai; Segal, Nili; Shkolnik, Mark; Kochva, Anat; German, Larissa; Kaplan, Daniel; Greemberg, Lev; Puterman, Max			The influence of epidural anesthesia on the hearing system after normal labor	INTERNATIONAL JOURNAL OF AUDIOLOGY			English	Article						Epidural anesthesia; Hearing loss; ABR; DPOAE		Objective: The purpose of our study was to evaluate the influence of epidural anesthesia on the hearing system in women undergoing normal labor. Design: We examined two groups of patients: women with epidural anesthesia underwent four tests of distortion product otoacoustic emissions(DPOAEs): on admission, and fifteen minutes, one hour, and three hours after the last epidural bolus of local anesthetic. Auditory brainstem response (ABR) tests were performed on admission, and one hour, and three hours after the last epidural bolus. Women who gave birth without epidural anesthesia underwent DPOAEs tests on admission, during a uterine contraction, during active delivery, and three hours after labor. ABR tests were performed on admission, during a uterine contraction, and three hours after labor Study sample: twenty patients participated in the study. Twelve gave birth with epidural anesthesia and eight without anesthesia. Results: No significant changes in DPOAEs and ABR recordings were found between the two groups. Conclusions: Epidural anesthesia does not impair the sensory or the neural elements of the hearing system and therefore does not influence hearing.	[Kraus, Mordechai; Segal, Nili; Kaplan, Daniel; Puterman, Max] Soroka Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, IL-84101 Beer Sheva, Israel; [Greemberg, Lev] Soroka Univ, Med Ctr, Dept Anesthesiol, IL-84101 Beer Sheva, Israel; [Shkolnik, Mark; Kochva, Anat] Hedim Inst Audiol Ltd, Beer Sheva, Israel; [German, Larissa] Ben Gurion Univ Negev, Fac Hlth Sci, Epidemiol & Hlth Serv Evaluat Dept, IL-84105 Beer Sheva, Israel	Segal, N (reprint author), Soroka Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, POB 151, IL-84101 Beer Sheva, Israel.	segalnil@gmail.com		German, Larissa/0000-0003-3456-3509			COLLINS VJ, 1976, PRINCIPLES ANESTHESI, P690; Day CJE, 1996, REGION ANESTH, V21, P197; DREYER M, 1990, Regional-Anaesthesie, V13, P138; Finegold H, 2002, ANESTH ANALG, V95, P198, DOI 10.1097/00000539-200207000-00035	4	1	1	1	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1499-2027			INT J AUDIOL	Int. J. Audiol.	AUG	2011	50	8					519	521		10.3109/14992027.2011.568012			3	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	792LI	WOS:000292745800003	21486123				2020-06-30	J	Warschkow, R; Steffen, T; Luthi, A; Filipovic, M; Beutner, U; Schmied, BM; Muller, SA; Tarantino, I				Warschkow, Rene; Steffen, Thomas; Luethi, Andreas; Filipovic, Miodrag; Beutner, Ulrich; Schmied, Bruno M.; Mueller, Sascha A.; Tarantino, Ignazio			Epidural Analgesia in Open Resection of Colorectal Cancer: Is there a Clinical Benefit? A Retrospective Study on 1,470 Patients	JOURNAL OF GASTROINTESTINAL SURGERY			English	Article; Proceedings Paper	98th Annual Congress of the Swiss-Society-of-Surgery	MAY 25-27, 2011	Geneva, SWITZERLAND	Swiss Soc Surg		Epidural analgesia; Colorectal cancer; Postoperative; Pneumonia; Mortality	POSTOPERATIVE ANALGESIA; PULMONARY COMPLICATIONS; SURGERY; ANESTHESIA; MORTALITY; RISK	Epidural analgesia (EA) is effective for postoperative pain relief and results in an earlier recovery from postoperative paralytic ileus. This study evaluated the influence of epidural analgesia on the postoperative 30-day mortality and morbidity after open colorectal cancer resection. A retrospective observational study was performed at a single, tertiary hospital. All patients with an open colorectal cancer surgery between 1991 and 2008 were identified from the hospital database. Of the 1,470 patients included in the study, 838 (57.0%) received an EA. Mortality was lower after EA (1.5% vs. 5.7%, p < 0.001). Risk of pneumonia was reduced after EA (odds ratio (OR), 0.45; 95% confidence interval (CI), 0.28-0.74; p = 0.001), but not the risk of anastomotic leakage (OR, 1.18; 95% CI, 0.76-1.81; p = 0.465) or surgical site infections (OR, 1.09; 95% CI, 0.74-1.60; p = 0.663). A subgroup analysis of 427 patients operated on after 2002 (reflecting improved perioperative management) yielded similar results. However, no significant reduction in mortality was observed in the subgroup analysis. For patients with open colorectal cancer surgery, the application of EA leads to a reduction in pneumonia. Although this is only a retrospective study, it strongly supports the use of EA.	[Warschkow, Rene; Steffen, Thomas; Beutner, Ulrich; Schmied, Bruno M.; Mueller, Sascha A.; Tarantino, Ignazio] Kantonsspital, Dept Surg, CH-9007 St Gallen, Switzerland; [Warschkow, Rene] Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany; [Luethi, Andreas; Filipovic, Miodrag] Kantonsspital, Dept Anaesthesia, CH-9007 St Gallen, Switzerland	Tarantino, I (reprint author), Kantonsspital, Dept Surg, CH-9007 St Gallen, Switzerland.	Ignazio.Tarantino@kssg.ch	Tarantino, Ignazio/AAF-9710-2020	Steffen, Thomas/0000-0001-9374-5703; Beutner, Ulrich/0000-0001-5209-2793			Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Arozullah AM, 2003, MED CARE, V41, P979, DOI 10.1097/00005650-200308000-00011; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Fotiadis RJ, 2004, BRIT J SURG, V91, P828, DOI 10.1002/bjs.4607; Gendall KA, 2007, COLORECTAL DIS, V9, P584, DOI 10.1111/j.1463-1318.2007.01274.x; Hansdottir V, 2006, ANESTHESIOLOGY, V104, P142, DOI 10.1097/00000542-200601000-00020; Holte K, 2001, REGION ANESTH PAIN M, V26, P111, DOI 10.1053/rapm.2001.21241; Karanicolas PJ, 2009, ANN SURG, V249, P954, DOI 10.1097/SLA.0b013e3181a77bcd; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Kingham TP, 2009, J AM COLL SURGEONS, V208, P269, DOI 10.1016/j.jamcollsurg.2008.10.015; Liu SS, 2007, ANESTH ANALG, V104, P689, DOI 10.1213/01.ane.0000255040.71600.41; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; Marra F, 2009, EJSO-EUR J SURG ONC, V35, P1060, DOI 10.1016/j.ejso.2009.02.011; Marret E, 2007, BRIT J SURG, V94, P665, DOI 10.1002/bjs.5825; Nishimori M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005059.pub2; Peyton PJ, 2003, ANESTH ANALG, V96, P548, DOI 10.1097/00000539-200302000-00046; Popping DM, 2008, ARCH SURG-CHICAGO, V143, P990, DOI 10.1001/archsurg.143.10.990; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Ruppen Wilhelm, 2006, BMC Anesthesiol, V6, P10, DOI 10.1186/1471-2253-6-10; Sox HC, 2009, ANN INTERN MED, V151, P203, DOI 10.7326/0003-4819-151-3-200908040-00125; Warner DO, 2000, ANESTHESIOLOGY, V92, P1467, DOI 10.1097/00000542-200005000-00037; Werawatganon T, 2005, COCHRANE DB SYST REV, V1; Wilensky GR, 2006, HEALTH AFFAIR, V25, pW572, DOI 10.1377/hlthaff.25.w572	29	14	14	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1091-255X	1873-4626		J GASTROINTEST SURG	J. Gastrointest. Surg.	AUG	2011	15	8					1386	1393		10.1007/s11605-011-1582-y			8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	798WP	WOS:000293243200019	21647766				2020-06-30	J	Lister, N; Warrington, S; Boyce, M; Eriksson, C; Tamaoka, M; Kilborn, J				Lister, Nicola; Warrington, Steve; Boyce, Malcolm; Eriksson, Catarina; Tamaoka, Masami; Kilborn, John			Pharmacokinetics, Safety, and Tolerability of Ascending Doses of Sublingual Fentanyl, With and Without Naltrexone, in Japanese Subjects	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						Sublingual; fentanyl; Japanese; naltrexone; pharmacokinetics	EFFERVESCENT BUCCAL TABLETS; HEALTHY-VOLUNTEERS; CANCER-PATIENTS; ELECTROTRANSPORT SYSTEM; CITRATE; PROPORTIONALITY; PAIN	This open-label, nonrandomized study assessed single and repeat ascending doses of a new sublingual fentanyl (SLF) formulation in 48 healthy Japanese opiate-naive subjects (47 completed). Subjects received single-dose SLF 100, 200, 400, or 800 mu g followed by 13 doses 6 hourly, at their dose level. Subjects taking repeat-dose 400 and 800 mu g were pre-treated with naltrexone in order to block opiate-receptor-mediated effects on respiration, monitored by pulse oximetry and transcutaneous pCO(2). Sublingual fentanyl was rapidly and consistently absorbed. After single doses, median t(first) was 0.08 to 0.25 hours and t(max) 0.50 to 1.00 hours. After repeat dosing, median t(max) (t(max,ss)) was 0.50 to 2.00 hours. Plasma concentrations were dose proportional both after single and repeat dosing, and naltrexone appeared to have no effect on SLF pharmacokinetics. Plasma fentanyl reached steady state within the 72-hour dosing period and accumulation was approximately 2-fold. After single doses, effects on respiratory variables were evident after the 400-mu g and 800-mu g doses. Transcutaneous pCO(2) was not helpful in detecting respiratory depression. Thus, SLF yielded rapid absorption of fentanyl and dose-proportional plasma concentrations that, for 400 mu g and 800 mu g, were within the typical analgesic range. Respiratory depression in these opioid-naive volunteers was manageable with simple clinical measures.	[Lister, Nicola; Warrington, Steve; Boyce, Malcolm] Hammersmith Med Res, London NW10 7EW, England; [Eriksson, Catarina] Quintiles AB, Uppsala, Sweden; [Tamaoka, Masami] Kyowa Hakko Kirin Co Ltd, Tokyo, Japan	Warrington, S (reprint author), Hammersmith Med Res, Cumberland Ave,Pk Royal, London NW10 7EW, England.	swarrington@hmrlondon.com		Boyce, Malcolm/0000-0001-8807-612X	Kyowa Hakko Kirin UK Ltd.	This study was supported by Kyowa Hakko Kirin UK Ltd. Malcolm Boyce, Catarina Eriksson, Nicola Lister, Steve Warrington: None declared. John Kilborn has been employed by Kyowa Hakko Kirin UK Ltd during the last 5 years and has received consultancy fees from this company. Masami Tamaoka is an employee of Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin Co Ltd has licensed KW-2246 from Orexo for development and marketing in Japan.	Casuccio A, 2009, EXPERT OPIN PHARMACO, V10, P947, DOI [10.1517/14656560902851510, 10.1517/14656560902851510 ]; *CEPH UK LTD, 2006, ACT MON CEPH UK LTD, P6; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; Gupta SK, 1999, J PHARM SCI, V88, P835, DOI 10.1021/js980258b; GUTSTEIN H, 2006, [No title captured]; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lorch U, 2008, 13 INT PAIN CLIN C W; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Myrand SP, 2008, CLIN PHARMACOL THER, V84, P347, DOI 10.1038/sj.clpt.6100482; *PROSTRAKAN LTD, 2008, SUBL FENT ABSTR; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009; STANLEY TH, 1989, ANESTH ANALG, V69, P21; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006	22	14	14	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2700			J CLIN PHARMACOL	J. Clin. Pharmacol.	AUG	2011	51	8					1195	1204		10.1177/0091270010379410			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	794BF	WOS:000292868600006	21209242				2020-06-30	J	Davis, MP				Davis, Mellar P.			Fentanyl for breakthrough pain: a systematic review	EXPERT REVIEW OF NEUROTHERAPEUTICS			English	Review						fentanyl; global efficacy; intranasal; pain relief; summation of pain-intensity differences; transmucosal	BUCCAL SOLUBLE FILM; MULTIPLE-DOSE PHARMACOKINETICS; OPIOID-TOLERANT PATIENTS; TRANSMUCOSAL FENTANYL; INTRANASAL FENTANYL; CANCER PAIN; DOUBLE-BLIND; INTRAVENOUS MORPHINE; HEALTHY-VOLUNTEERS; OPEN-LABEL	The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal tablets, which in turn had a quicker onset to analgesia than OTFC. Patient acceptance and global rating of efficacy were greater for INFS than for buccal fentanyl. OTFC and INFS have been used effectively to reduce acute pain in children who are opioid-naive. Abuse and addiction to OTFC, fentanyl buccal tablets and INFS was low, owing to patient selection.	Case Western Reserve Univ, Cleveland Clin, Dept Solid Tumor Oncol,Taussig Canc Inst, Harry R Horvitz Ctr Palliat Med,Lerner Coll Med, Cleveland, OH 44195 USA	Davis, MP (reprint author), Case Western Reserve Univ, Cleveland Clin, Dept Solid Tumor Oncol,Taussig Canc Inst, Harry R Horvitz Ctr Palliat Med,Lerner Coll Med, 9500 Euclid Ave R35, Cleveland, OH 44195 USA.	davism6@ccf.org					*AM PHARM ASS, 2003, J AM PHARM ASSOC, V49, P729; [Anonymous], 2009, EUR J PAIN, V13, pS207; Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; ASHBURN M, 2010, J PAIN, V11, pS49; BANNING A, 1991, PAIN, V45, P45, DOI 10.1016/0304-3959(91)90163-R; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; BRUERA E, 1989, PAIN, V37, P203, DOI 10.1016/0304-3959(89)90131-0; *CEPH INC, NDA21947 CEPH INC; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Chung S, 2010, PEDIATR RADIOL, V40, P1236, DOI 10.1007/s00247-009-1521-1; Colberg T, 2008, ANN ONCOL, V19, P257; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Dale O., 2010, EUR J PAIN S, V4, P187; Darwish M, 2007, EXPERT OPIN PHARMACO, V8, P2011, DOI 10.1517/14656566.8.13.2011; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Darwish M, 2008, CLIN DRUG INVEST, V28, P1, DOI 10.2165/00044011-200828010-00001; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2007, J CLIN PHARMACOL, V47, P56, DOI 10.1177/0091270006294129; Darwish M, 2010, PERSPECT MED CHEM, V4, P11; DAVIES A, 2011, EUR J PAIN; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; FARRAR JT, 2008, J PAIN, V9, P39; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; FINE PG, 2007, J PAIN, V8, pS43; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Fodale V, 2008, EXPERT OPIN DRUG SAF, V7, P213, DOI [10.1517/14740338.7.3.213, 10.1517/14740338.7.3.213 ]; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Herd D, 2009, EMERG MED AUSTRALAS, V21, P335, DOI 10.1111/j.1742-6723.2009.01207.x; Jekunen AP, 2006, J CLIN ONCOL, V24, p499S; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kaasa S, 2008, ANN ONCOL, V19, P257; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; LU J, 2003, ASS ANN M LOC AN PAI, V99; Mahar PJ, 2007, PEDIATR EMERG CARE, V23, P544, DOI 10.1097/PEC.0b013e318128f80b; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCQUAY HJ, 1994, CANCER SURV, V21, P17; Mercadante S, 1998, EUR J CANCER, V34, P627, DOI 10.1016/S0959-8049(97)10053-3; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; Mercadante S, 2011, SUPPORT CARE CANCER, V19, P435, DOI 10.1007/s00520-010-1015-6; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; NALAMACHU S, 2007, J PAIN, V8, pS43; Nalamachu SR, 2011, CURR MED RES OPIN, V27, P751, DOI 10.1185/03007995.2011.554808; NAVE R, 2009, EUR J PAIN, V13, pS206; NAVE R, 2009, EUR J PAIN, V55, pS285; Nolte T, 2008, ANN ONCOL, V19, P254; Passik SD, 2011, J PAIN SYMPTOM MANAG, V41, P116, DOI 10.1016/j.jpainsymman.2010.03.012; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; SEGAL T, 2006, J PAIN, V7, P35; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P631, DOI 10.1097/00000542-199103000-00040; Shaiova L, 2004, SUPPORT CARE CANCER, V12, P268, DOI 10.1007/s00520-004-0595-4; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; SIMPSON D, 2007, J PAIN, V8, pS41; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Slatkin N, 2006, J CLIN ONCOL, V24, p484S; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; TAYLOR D, 2006, J PAIN, V7, P2; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Upton RN, 2004, BRIT J ANAESTH, V93, P687, DOI 10.1093/bja/aeh261; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Waters CM, 1999, J PHARMACOL EXP THER, V288, P157; Waters CM, 2000, ANESTHESIOLOGY, V93, P825, DOI 10.1097/00000542-200009000-00033; Webster LR, 2006, J PAIN, V7, P937, DOI 10.1016/j.jpain.2006.05.005; Weick JK, 2006, J CLIN ONCOL, V24, p484S; WERTHEIM M, 2006, J CLIN ONCOL, V24, pS689; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; Wong SC, 2010, J MED TOXICOL, V6, P9, DOI 10.1007/s13181-010-0031-8; Younge P, 1999, EMERGEN MED, V11, P90; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zeppetella G, 2010, PAIN PRACT, V10, P287, DOI 10.1111/j.1533-2500.2010.00359.x; ZERNIG G, 1995, LIFE SCI, V57, P2113, DOI 10.1016/0024-3205(95)02204-V; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003; 2010, PRESCRIRE INT, V19, P251	127	44	45	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1473-7175	1744-8360		EXPERT REV NEUROTHER	Expert Rev. Neurother.	AUG	2011	11	8					1197	1216		10.1586/ERN.11.63			20	Clinical Neurology; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	817DD	WOS:000294650400017	21797660				2020-06-30	J	Braidy, HF; Singh, P; Ziccardi, VB				Braidy, Hani F.; Singh, Prabhjot; Ziccardi, Vincent B.			Safety of Deep Sedation in an Urban Oral and Maxillofacial Surgery Training Program	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							PARADOXICAL REACTIONS; OUTPATIENT ANESTHESIA; MIDAZOLAM; EXPERIENCE; FLUMAZENIL; MORBIDITY; MORTALITY; CHILDREN; BENZODIAZEPINES; PREMEDICATION	Purpose: To study the safety of deep sedation in an urban-based oral maxillofacial surgery training program. Materials and Methods: Charts of patients undergoing an intravenous sedation from January 2005 through December 2009 were reviewed. Data recorded included age, gender, type of procedures performed, and intravenous medications. Patients were divided in 2 groups depending on whether they received a general anesthetic agent (propofol or ketamine) or not. Anesthesia complications and failures were recorded and categorized. Results: In total, 1,167 intravenous sedations were recorded. Eight patients developed adverse reactions, 3 of which required further evaluation in the emergency department. In addition, 7 intravenous sedations needed to be aborted because of patient agitation and combativeness. No deaths or long-term morbidities were reported. Conclusions: The safety of deep sedation in an urban-based oral maxillofacial training program is similar to office-based anesthesia. Sedations failures may be attributed to paradoxical benzodiazepine reactions. (C) 2011 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 69: 2112-2119, 2011	[Braidy, Hani F.; Singh, Prabhjot; Ziccardi, Vincent B.] Univ Med & Dent New Jersey, New Jersey Dent Sch, Dept Oral & Maxillofacial Surg, Newark, NJ 07101 USA	Braidy, HF (reprint author), Univ Med & Dent New Jersey, New Jersey Dent Sch, Dept Oral & Maxillofacial Surg, 110 Bergen St,Room C-757, Newark, NJ 07101 USA.	braidyhf@umdnj.edu					BENNETT CR, 1987, DENT CLIN N AM, V31, P81; CALDWELL CB, 1982, ANESTHESIOLOGY, V57, P125, DOI 10.1097/00000542-198208000-00011; Crum RM, 1996, DRUG ALCOHOL DEPEN, V43, P155, DOI 10.1016/S0376-8716(96)01298-7; D'Eramo EM, 2008, J ORAL MAXIL SURG, V66, P2421, DOI 10.1016/j.joms.2008.06.095; DEMBO JB, 1995, J ORAL MAXIL SURG, V53, P816, DOI 10.1016/0278-2391(95)90340-2; Finder Richard L, 2003, Int Anesthesiol Clin, V41, P1; FISET L, 1992, J ORAL MAXIL SURG, V50, P645, DOI 10.1016/0278-2391(92)90452-6; George MS, 2008, PEDIATR ANESTH, V18, P546, DOI 10.1111/j.1460-9592.2008.02500.x; Golparvar M, 2004, PEDIATR ANESTH, V14, P924, DOI 10.1111/j.1460-9592.2004.01349.x; Heller M, 2009, DERMATOL SURG, V35, P1144, DOI 10.1111/j.1524-4725.2009.01204.x; Hunter MJ, 1997, J ORAL MAXIL SURG, V55, P684, DOI 10.1016/S0278-2391(97)90575-9; Karian VE, 1999, PEDIATR RADIOL, V29, P869, DOI 10.1007/s002470050715; Khan LC, 1997, ANESTH ANALG, V85, P213, DOI 10.1097/00000539-199707000-00038; Lightdale JR, 2010, CLIN PEDIATR, V49, P35, DOI 10.1177/0009922809344425; Litchfield N B, 1980, Anesth Prog, V28, P175; LYTLE JJ, 1989, J ORAL MAXIL SURG, V47, P834, DOI 10.1016/S0278-2391(89)80043-6; Lytle JJ, 1997, J ORAL MAXIL SURG, V55, P687, DOI 10.1016/S0278-2391(97)90576-0; MACKENZIE N, 1985, BRIT J ANAESTH, V57, P725, DOI 10.1093/bja/57.8.725; Mancuso CE, 2004, PHARMACOTHERAPY, V24, P1177, DOI 10.1592/phco.24.13.1177.38089; ORAL J, 1989, J MAXILLOFAC SURG S2, V47, P1; Perrott DH, 2003, J ORAL MAXIL SURG, V61, P983, DOI 10.1016/S0278-2391(03)00668-2; RICOU B, 1986, BRIT J ANAESTH, V58, P1005, DOI 10.1093/bja/58.9.1005; Robin Christian, 2002, Anesth Prog, V49, P128; Rodgers SF, 2005, J ORAL MAXIL SURG, V63, P1478, DOI 10.1016/j.joms.2005.05.320; RODRIGO C R, 1991, Anesthesia Progress, V38, P65; ROELOFSE JA, 1990, INT J ORAL MAX SURG, V19, P2, DOI 10.1016/S0901-5027(05)80558-2; Saltik IN, 2000, AM J GASTROENTEROL, V95, P3011, DOI 10.1016/S0002-9270(00)02028-1; Senel FC, 2007, J ORAL MAXIL SURG, V65, P645, DOI 10.1016/j.joms.2006.06.252; SHORT TG, 1987, ANAESTH INTENS CARE, V15, P330, DOI 10.1177/0310057X8701500314; SMART RG, 1994, J CHILD ADOLES SUBST, V3, P37, DOI DOI 10.1300/J029V03N01_; SMITH GB, 1991, ANESTH ANALG, V72, P382; TALLMAN JF, 1985, ANNU REV NEUROSCI, V8, P21, DOI 10.1146/annurev.ne.08.030185.000321; Weinbroum AA, 2001, EUR J ANAESTH, V18, P789, DOI 10.1046/j.1365-2346.2001.00922.x	33	4	4	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	AUG	2011	69	8					2112	2119		10.1016/j.joms.2011.04.017			8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	810WT	WOS:000294160400014	21783001				2020-06-30	J	Amann, M; Runnels, S; Morgan, DE; Trinity, JD; Fjeldstad, AS; Wray, DW; Reese, VR; Richardson, RS				Amann, Markus; Runnels, Sean; Morgan, David E.; Trinity, Joel D.; Fjeldstad, Anette S.; Wray, D. Walter; Reese, Van R.; Richardson, Russell S.			On the contribution of group III and IV muscle afferents to the circulatory response to rhythmic exercise in humans	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							STATIC MUSCULAR-CONTRACTION; BLOOD-FLOW; SKELETAL-MUSCLE; CARDIOVASCULAR-RESPONSES; PRESSOR-RESPONSE; CARDIAC-OUTPUT; DYNAMIC EXERCISE; ENERGY TURNOVER; NEURAL-CONTROL; OXYGEN-UPTAKE	We investigated the role of skeletal muscle afferent feedback in circulatory control during rhythmic exercise in humans. Nine healthy males performed single leg knee-extensor exercise (15/30/45 watts, 3 min each) under both control conditions (Ctrl) and with lumbar intrathecal fentanyl impairing mu-opioid receptor-sensitive muscle afferents. Cardiac output and femoral blood flow were determined, and femoral arterial/venous blood samples were collected during the final minute of each workload. To rule out cephalad migration of fentanyl to the brain-stem, we documented unchanged resting ventilatory responses to different levels of hypercapnia. There were no haemodynamic differences between conditions at rest. However, during exercise cardiac output was similar to 20% lower with fentanyl blockade compared to control (P < 0.05), secondary to a 6% and 13% reduction in heart rate and stroke volume, respectively. Throughout exercise mean arterial pressure (MAP) was reduced by 7% (P < 0.01) which is likely to have contributed to the 15% fall in femoral blood flow. However, MAP was not completely responsible for this peripheral haemodynamic change as vascular conductance was also attenuated (similar to 9%). Evidence of increasing noradrenaline spillover (P = 0.09) implicated an elevation in sympathetic outflow in this response. The attenuated femoral blood flow during exercise with fentanyl was associated witha 17% reduction in leg O-2 delivery (P < 0.01) and a concomitant rise in the arteriovenous O-2 difference (4-9%), but leg O-2 consumption remained 7-13% lower than control (P < 0.05). Our findings reveal an essential contribution of continuous muscle afferent feedback to ensure the appropriate haemodynamic and ultimately metabolic response to rhythmic exercise in humans.	[Amann, Markus; Wray, D. Walter; Richardson, Russell S.] VA Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT 84148 USA; [Amann, Markus; Trinity, Joel D.; Fjeldstad, Anette S.; Wray, D. Walter; Reese, Van R.; Richardson, Russell S.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; [Amann, Markus; Wray, D. Walter; Richardson, Russell S.] Univ Utah, Dept Exercise & Sport Sci, Salt Lake City, UT 84112 USA; [Amann, Markus; Runnels, Sean; Morgan, David E.] Univ Utah, Dept Anesthesiol, Salt Lake City, UT 84112 USA	Amann, M (reprint author), VA Med Ctr, Geriatr Res Educ & Clin Ctr, GRECC 182,500 Foothill Dr, Salt Lake City, UT 84148 USA.	markus.amann@hsc.utah.edu		Amann, Markus/0000-0002-4012-8880	US National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-103786-02, HL-09183]	This work was supported by the US National Heart, Lung, and Blood Institute (HL-103786-02 and HL-09183).	Alam M, 1937, J PHYSIOL-LONDON, V89, P372, DOI 10.1113/jphysiol.1937.sp003485; Amann M, 2008, J APPL PHYSIOL, V104, P861, DOI 10.1152/japplphysiol.01008.2007; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Amann M, 2008, J APPL PHYSIOL, V105, P1714, DOI 10.1152/japplphysiol.90456.2008; ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794; Augustyniak RA, 2001, AM J PHYSIOL-HEART C, V280, pH1645; BERKENBOSCH A, 1989, J PHYSIOL-LONDON, V411, P367, DOI 10.1113/jphysiol.1989.sp017578; Boushel R, 2010, ACTA PHYSIOL, V199, P367, DOI 10.1111/j.1748-1716.2010.02133.x; Calbet JAL, 2003, AM J PHYSIOL-REG I, V284, pR291, DOI 10.1152/ajpregu.00155.2002; Caringi D, 1998, AM J PHYSIOL-HEART C, V274, pH139; CRAIG AD, 1995, J COMP NEUROL, V361, P225, DOI 10.1002/cne.903610204; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; FRIEDMAN DB, 1992, J APPL PHYSIOL, V73, P1982; GALBO H, 1987, J PHYSIOL-LONDON, V389, P557, DOI 10.1113/jphysiol.1987.sp016672; Grant GJ, 1996, J CLIN ANESTH, V8, P99, DOI 10.1016/0952-8180(95)00174-3; Harms CA, 1997, J APPL PHYSIOL, V82, P1573; HILL JM, 1990, J APPL PHYSIOL, V68, P2466; JOYNER MJ, 1991, J APPL PHYSIOL, V71, P1496; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; KAUFMAN MP, 1983, J APPL PHYSIOL, V55, P105; KAUFMAN MP, 1996, HDB PHYSL EXERCISE R, V12, P381; Kjaer M, 1999, AM J PHYSIOL-REG I, V277, pR76, DOI 10.1152/ajpregu.1999.277.1.R76; Krustrup P, 2008, J PHYSIOL-LONDON, V586, P6037, DOI 10.1113/jphysiol.2008.158162; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Larsen FJ, 2011, CELL METAB, V13, P149, DOI 10.1016/j.cmet.2011.01.004; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; MITCHELL JH, 1977, AM J PHYSIOL, V233, pH374; MITCHELL JH, 1983, ANNU REV PHYSIOL, V45, P229, DOI 10.1146/annurev.ph.45.030183.001305; Mortensen SP, 2007, J PHYSIOL-LONDON, V581, P853, DOI 10.1113/jphysiol.2006.127423; Mortensen SP, 2009, HYPERTENSION, V53, P993, DOI 10.1161/HYPERTENSIONAHA.109.130880; O'Leary DS, 1998, AM J PHYSIOL-HEART C, V275, pH220; Ogoh S, 2003, J PHYSIOL-LONDON, V550, P317, DOI 10.1113/jphysiol.2003.041517; OLEARY DS, 1995, AM J PHYSIOL-HEART C, V268, pH980; Olson TP, 2010, J PHYSIOL-LONDON, V588, P2487, DOI 10.1113/jphysiol.2009.186056; POMEROY G, 1986, BRAIN RES, V381, P385, DOI 10.1016/0006-8993(86)90095-8; RAY CA, 1994, AM J PHYSIOL, V266, pH79; ROWELL LB, 1991, AM J PHYSIOL, V261, pH1545; Saltin B, 1998, ACTA PHYSIOL SCAND, V162, P421, DOI 10.1046/j.1365-201X.1998.0293e.x; SAVARD GK, 1989, AM J PHYSIOL, V257, pH1812; Sheriff DD, 1998, AM J PHYSIOL-HEART C, V275, pH767; Shibasaki M, 2011, AM J PHYSIOL-REG I, V300, pR486, DOI 10.1152/ajpregu.00505.2010; Shoemaker JK, 2007, J APPL PHYSIOL, V103, P228, DOI 10.1152/japplphysiol.01334.2006; Smith SA, 2003, J PHYSIOL-LONDON, V551, P1013, DOI 10.1113/jphysiol.2003.044925; Standl TG, 2001, ANESTHESIOLOGY, V94, P230, DOI 10.1097/00000542-200102000-00011; STRANGE S, 1993, J PHYSIOL-LONDON, V470, P693, DOI 10.1113/jphysiol.1993.sp019883; Sun SY, 1996, GEN PHARMACOL, V27, P1187, DOI 10.1016/S0306-3623(96)00055-9; Swenson JD, 2001, REGION ANESTH PAIN M, V26, P306, DOI 10.1053/ramp.2001.25069; WALDROP TG, 1996, HDB PHYSIOL 12, P333; WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566; Williamson JW, 2006, EXP PHYSIOL, V91, P51, DOI 10.1113/expphysiol.2005.032037; Williamson JW, 1996, ACTA PHYSIOL SCAND, V156, P429, DOI 10.1046/j.1365-201X.1996.472186000.x; Wilson LB, 1997, BRAIN RES REV, V23, P196, DOI 10.1016/S0165-0173(96)00019-7; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pharmtox.25.1.433	54	97	97	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	AUG 1	2011	589	15					3855	3866		10.1113/jphysiol.2011.209353			12	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	798XT	WOS:000293246200016	21646407	Bronze, Green Published			2020-06-30	J	Rabiner, EA; Beaver, J; Makwana, A; Searle, G; Long, C; Nathan, PJ; Newbould, RD; Howard, J; Miller, SR; Bush, MA; Hill, S; Reiley, R; Passchier, J; Gunn, RN; Matthews, PM; Bullmore, ET				Rabiner, E. A.; Beaver, J.; Makwana, A.; Searle, G.; Long, C.; Nathan, P. J.; Newbould, R. D.; Howard, J.; Miller, S. R.; Bush, M. A.; Hill, S.; Reiley, R.; Passchier, J.; Gunn, R. N.; Matthews, P. M.; Bullmore, E. T.			Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans	MOLECULAR PSYCHIATRY			English	Article						positron emission tomography; functional MRI; experimental medicine; pharmacokinetics; pharmacodynamics; neuropharmacology	HIGH-FAT FOODS; NUCLEUS-ACCUMBENS; VENTRAL STRIATUM; TASTE HEDONICS; MU; NALTREXONE; BINDING; RESPONSES; AGONISTS; AMYGDALA	Opioid neurotransmission has a key role in mediating reward-related behaviours. Opioid receptor (OR) antagonists, such as naltrexone (NTX), can attenuate the behaviour-reinforcing effects of primary (food) and secondary rewards. GSK1521498 is a novel OR ligand, which behaves as an inverse agonist at the mu-OR sub-type. In a sample of healthy volunteers, we used [C-11]-carfentanil positron emission tomography to measure the OR occupancy and functional magnetic resonance imaging (fMRI) to measure activation of brain reward centres by palatable food stimuli before and after single oral doses of GSK1521498 (range, 0.4-100 mg) or NTX (range, 2-50 mg). GSK1521498 had high affinity for human brain ORs (GSK1521498 effective concentration 50 = 7.10 ng ml(-1)) and there was a direct relationship between receptor occupancy (RO) and plasma concentrations of GSK1521498. However, for both NTX and its principal active metabolite in humans, 6-beta-NTX, this relationship was indirect. GSK1521498, but not NTX, significantly attenuated the fMRI activation of the amygdala by a palatable food stimulus. We thus have shown how the pharmacological properties of OR antagonists can be characterised directly in humans by a novel integration of molecular and functional neuroimaging techniques. GSK1521498 was differentiated from NTX in terms of its pharmacokinetics, target affinity, plasma concentration-RO relationships and pharmacodynamic effects on food reward processing in the brain. Pharmacological differentiation of these molecules suggests that they may have different therapeutic profiles for treatment of overeating and other disorders of compulsive consumption. Molecular Psychiatry (2011) 16, 826-835; doi:10.1038/mp.2011.29; published online 19 April 2011	[Nathan, P. J.; Bullmore, E. T.] Addenbrookes Ctr Clin Invest, GSK Acad Discovery Performance Unit, Cambridge CB2 0GG, England; [Nathan, P. J.; Bullmore, E. T.] Addenbrookes Ctr Clin Invest, Clin Unit Cambridge, Cambridge CB2 0GG, England; [Rabiner, E. A.; Beaver, J.; Makwana, A.; Searle, G.; Long, C.; Newbould, R. D.; Howard, J.; Hill, S.; Reiley, R.; Passchier, J.; Gunn, R. N.; Matthews, P. M.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, GSK Clin Imaging Ctr, London, England; [Rabiner, E. A.; Gunn, R. N.; Matthews, P. M.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med & Toxicol, Ctr Neurosci, London, England; [Nathan, P. J.; Bullmore, E. T.] Univ Cambridge, Dept Psychiat, Behav & Clin Neurosci Inst, Cambridge, England; [Miller, S. R.] GSK Quantitat Sci, Stevenage, Herts, England; [Bush, M. A.] GSK Clin Pharmacol Modeling & Simulat, Res Triangle Pk, NC USA; [Gunn, R. N.] Univ Oxford, Dept Engn Sci, Oxford OX1 3PJ, England	Bullmore, ET (reprint author), Addenbrookes Ctr Clin Invest, GSK Acad Discovery Performance Unit, Cambridge Biomed Campus, Cambridge CB2 0GG, England.	edward.t.bullmore@gsk.com	Rabiner, Eugenii A./G-6263-2012; Gunn, Roger/H-1666-2012; Bullmore, Ed/C-1706-2012	Rabiner, Eugenii A./0000-0003-3612-6687; Gunn, Roger/0000-0003-1181-5769; Bullmore, Ed/0000-0002-8955-8283; Matthews, Paul M/0000-0002-1619-8328	GlaxoSmithKlineGlaxoSmithKline; Medical Research CouncilMedical Research Council UK (MRC) [G0900897]	The study was sponsored by GlaxoSmithKline (http://www.gsk.com) and the protocol was posted on http://clinicaltrials.gov (NCT00976066) before study initiation. Appropriate ethical committee and regulatory approvals were obtained from the NHS Brent Medical Ethics Committee, Northwick Park Hospital, Middlesex, UK (ref. 09/H0717/30), the Medicines and Healthcare products Regulatory Agency (MHRA Clinical Trial Authorization; EudraCT number 2009010358), and the Administration of Radioactive Substances Advisory Committee, UK Health Protection Agency (ARSAC number RPC 612/3764/24660). All PET and MRI scans were conducted at the GSK Clinical Imaging Centre, Hammersmith Hospital, London, UK. Overnight stays and non-scanning procedures were carried out by Hammersmith Medicines Research, Park Royal, London, UK. Venous plasma samples were analysed at the GlaxoSmithKline Drug Metabolism and Pharmacokinetics laboratories in Ware, UK (for GSK1521498) and in Durham, NC, USA (for naltrexone and 6-beta-naltrexol).	Abanades S, 2011, J CEREBR BLOOD F MET, V31, P944, DOI 10.1038/jcbfm.2010.175; AZUMA S, 1984, EXP BRAIN RES, V56, P12; BAKSHI VP, 1993, J PHARMACOL EXP THER, V265, P1253; Bencherif B, 2005, J NUCL MED, V46, P1349; Bruijnzeel AW, 2009, BRAIN RES REV, V62, P127, DOI 10.1016/j.brainresrev.2009.09.008; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; COOPER SJ, 1993, [No title captured], V104, P239; Derendorf H, 1999, PHARMACEUT RES, V16, P176, DOI 10.1023/A:1011907920641; DREWNOWSKI A, 1992, PHYSIOL BEHAV, V51, P371, DOI 10.1016/0031-9384(92)90155-U; DREWNOWSKI A, 1995, AM J CLIN NUTR, V61, P1206; FANTINO M, 1986, AM J PHYSIOL, V251, pR91; Figlewicz DP, 2010, PHARMACOL BIOCHEM BE, V97, P15, DOI 10.1016/j.pbb.2010.03.002; Filbey FM, 2008, NEUROPSYCHOPHARMACOL, V33, P1391, DOI 10.1038/sj.npp.1301513; Fletcher PC, 2010, J NEUROSCI, V30, P14346, DOI 10.1523/JNEUROSCI.3323-10.2010; Glass MJ, 1999, NEUROPEPTIDES, V33, P360, DOI 10.1054/npep.1999.0050; Gosnell B.A., 1996, DRUG RECEPTOR SUBTYP, P147; GOSNELL BA, 1986, LIFE SCI, V38, P1081, DOI 10.1016/0024-3205(86)90243-2; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Karlsson J, 2000, INT J OBESITY, V24, P1715, DOI 10.1038/sj.ijo.0801442; Kelley AE, 2005, PHYSIOL BEHAV, V86, P11, DOI 10.1016/j.physbeh.2005.06.018; Kelley AE, 2002, PHYSIOL BEHAV, V76, P365, DOI 10.1016/S0031-9384(02)00751-5; Ko MCH, 2006, J PHARMACOL EXP THER, V316, P772, DOI 10.1124/jpet.105.094409; LEIBOWITZ SF, 1985, PSYCHOPHARMACOL BULL, V21, P412; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MANSOUR A, 1995, BRAIN RES, V700, P89, DOI 10.1016/0006-8993(95)00928-J; MEYER MC, 1984, J CLIN PSYCHIAT, V45, P15; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; Myrick H, 2008, ARCH GEN PSYCHIAT, V65, P466, DOI 10.1001/archpsyc.65.4.466; NATHAN PJ, 2011, J CLIN PHAR IN PRESS; Nathan PJ, 2009, INT J NEUROPSYCHOPH, V12, P995, DOI 10.1017/S146114570900039X; O'Doherty JP, 2002, NEURON, V33, P815, DOI 10.1016/S0896-6273(02)00603-7; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Pecina S, 2005, J NEUROSCI, V25, P11777, DOI 10.1523/JNEUROSCI.2329-05.2005; Pelotte AL, 2009, BIOORG MED CHEM LETT, V19, P2811, DOI 10.1016/j.bmcl.2009.03.095; Petrovic P, 2008, J NEUROSCI, V28, P10509, DOI 10.1523/JNEUROSCI.2807-08.2008; Raehal KM, 2005, J PHARMACOL EXP THER, V313, P1150, DOI 10.1124/jpet.104.082966; *ROYAL PHARM SOC, 2010, BRIT NAT FORM, P59; Shippenberg TS, 2007, PHARMACOL THERAPEUT, V116, P306, DOI 10.1016/j.pharmthera.2007.06.011; Shippenberg TS, 1998, CRIT REV NEUROBIOL, V12, P267, DOI 10.1615/CritRevNeurobiol.v12.i4.10; Small DM, 2010, BRAIN STRUCT FUNCT, V214, P551, DOI 10.1007/s00429-010-0266-9; Small DM, 2005, EXP BRAIN RES, V166, P345, DOI 10.1007/s00221-005-2376-9; Snyder SH, 2003, TRENDS PHARMACOL SCI, V24, P198, DOI 10.1016/S0165-6147(03)00066-X; Stice E, 2008, J ABNORM PSYCHOL, V117, P924, DOI 10.1037/a0013600; Tziortzi AC, 2010, NEUROIMAGE, V52, pS23, DOI 10.1016/j.neuroimage.2010.04.207; Wang DX, 2007, J PHARMACOL EXP THER, V321, P544, DOI 10.1124/jpet.106.118810; Will MJ, 2004, NEUROREPORT, V15, P1857, DOI 10.1097/00001756-200408260-00004; WOLINSKY TD, 1994, BRAIN RES, V656, P274, DOI 10.1016/0006-8993(94)91470-2; Wolinsky TD, 1996, BRAIN RES, V706, P333, DOI 10.1016/0006-8993(95)01337-7; Wright CI, 1996, J NEUROSCI, V16, P1877; YAMAMOTO T, 1994, BEHAV BRAIN RES, V65, P123, DOI 10.1016/0166-4328(94)90097-3; YEOMANS MR, 1991, APPETITE, V16, P249, DOI 10.1016/0195-6663(91)90062-W; Yeomans MR, 2002, NEUROSCI BIOBEHAV R, V26, P713, DOI 10.1016/S0149-7634(02)00041-6; Yeomans MR, 1996, APPETITE, V27, P119, DOI 10.1006/appe.1996.0040; Zhang M, 1997, PSYCHOPHARMACOLOGY, V132, P350, DOI 10.1007/s002130050355	57	60	60	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	AUG	2011	16	8					826	835		10.1038/mp.2011.29			10	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	795UQ	WOS:000293001800008	21502953	Green Published, Other Gold			2020-06-30	J	Usta, B; Turkay, C; Muslu, B; Gozdemir, M; Kasapoglu, B; Sert, H; Demircioglu, RI; Karabayirli, S				Usta, Burhanettin; Turkay, Cansel; Muslu, Bunyamin; Gozdemir, Muhammet; Kasapoglu, Benan; Sert, Huseyin; Demircioglu, Ruveyda Irem; Karabayirli, Safinaz			Patient-controlled Analgesia and Sedation With Alfentanyl Versus Fentanyl for Colonoscopy A Randomized Double Blind Study	JOURNAL OF CLINICAL GASTROENTEROLOGY			English	Article						colonoscopy; sedation; alfentanyl; fentanyl; patient-controlled analgesia	CONSCIOUS SEDATION; ELDERLY-PATIENTS; ENDOSCOPIC PROCEDURES; ACUTE-PANCREATITIS; CONTROLLED-TRIAL; PROPOFOL; MIDAZOLAM; PREMEDICATION; SURVEILLANCE; FLUMAZENIL	Study Objective: The aim of this study was to evaluate whether sedo-analgesia with alfentanyl/fentanyl, using a patient-controlled analgesia (PCA) pump, may have positive outcomes in terms of safety, postprocedural workload, and expectations of the colonoscopist, nurse, and patients in elective colonoscopy. Patients: One hundred American Society of Anesthesiology physical status I and II adult patients. Interventions: Patients were randomized in a double-blind trial to receive either alfentanyl (n = 50) or fentanyl (n = 50) by PCA, and incremental doses of midazolam. Measurements: Patient expectations were assessed using hemodynamic variables, willingness to have a repeat colonoscopy in the same way, adverse events, discomfort scores, and patient/operator/nurse satisfaction associated with sedo-analgesia. Result: All patients in both groups had adequate sedo-analgesia with high satisfaction and willingness scores. There were no serious adverse effects and except for a few events, no required medication. The total sedation times were shorter in the alfentanyl group compared with the fentanyl group. Conclusions: PCA and sedation with alfentanyl and fentanyl for colonoscopy are safe, feasible, and acceptable to most patients. However, shorter sedation times make alfentanyl more attractive for postprocedural workload.	[Usta, Burhanettin; Muslu, Bunyamin; Gozdemir, Muhammet; Sert, Huseyin; Demircioglu, Ruveyda Irem] Fatih Univ, Sch Med, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Turkay, Cansel; Kasapoglu, Benan; Karabayirli, Safinaz] Fatih Univ, Sch Med, Dept Gastroenterol, Ankara, Turkey	Usta, B (reprint author), Fatih Univ, Sch Med, Dept Anesthesiol, Alparslan Turkes Cad 57, Ankara, Turkey.	drfbusta@yahoo.com					Atkins JH, 2008, CURR OPIN ANESTHESIO, V21, P759, DOI 10.1097/ACO.0b013e3283184001; Baudet JS, 2009, EUR J GASTROEN HEPAT, V21, P656, DOI 10.1097/MEG.0b013e328314b7e3; Bright E, 2003, ENDOSCOPY, V35, P683; Cirillo M, 2009, ANN ITAL CHIR, V80, P131; Fulton SA, 2000, AM J GASTROENTEROL, V95, P809; Gottschling S, 2005, PEDIATR ANESTH, V15, P1006, DOI 10.1111/j.1460-9592.2004.01562.x; Heuss LT, 2003, ALIMENT PHARM THER, V17, P1493, DOI 10.1046/j.1365-2036.2003.01608.x; Heuss LT, 2003, AM J GASTROENTEROL, V98, P1751, DOI 10.1016/S0002-9270(03)00447-7; Jawaid Q, 2002, DIGEST DIS SCI, V47, P614, DOI 10.1023/A:1017932522875; Kilpatrick GJ, 2007, ANESTHESIOLOGY, V107, P60, DOI 10.1097/01.anes.0000267503.85085.c0; Knape JTA, 2007, EUR J ANAESTH, V24, P563, DOI 10.1017/S0265021506002092; Kulling D, 2003, ENDOSCOPY, V35, P679; Kulling Daniel, 2004, Gastrointest Endosc Clin N Am, V14, P353, DOI 10.1016/j.giec.2004.01.002; Lazzaroni M, 1998, ENDOSCOPY, V30, P53, DOI 10.1055/s-2007-1001231; Lazzaroni M, 2005, ENDOSCOPY, V37, P101, DOI 10.1055/s-2004-826149; Lee DWH, 2002, GASTROINTEST ENDOSC, V56, P629, DOI 10.1067/mge.2002.128919; Leung FW, 2008, DIGEST DIS SCI, V53, P1462, DOI 10.1007/s10620-007-0025-9; MCCLOY R, 1998, PRINCIPLES PRACTICE, P119; Minocha A, 1998, DIGEST DIS SCI, V43, P1835, DOI 10.1023/A:1018860425719; Radaelli F, 2003, GASTROINTEST ENDOSC, V57, P329, DOI 10.1067/mge.2003.104; Raeder J, 2009, ANESTH ANALG, V108, P704, DOI 10.1213/ane.0b013e3181954146; Rex Douglas K, 2003, Rev Gastroenterol Disord, V3, P70; Ristikankare M, 2000, SCAND J GASTROENTERO, V35, P990; Rivera R, 2009, ANESTHESIOLOGY, V110, P1176, DOI 10.1097/ALN.0b013e3181a10207; Roseveare C, 1998, ENDOSCOPY, V30, P768, DOI 10.1055/s-2007-1001419; Sporea Ioan, 2005, Rom J Gastroenterol, V14, P195; TOMBASCO M, 2006, NURS MANAGE S, P2; Vargo JJ, 2007, J CLIN GASTROENTEROL, V41, P591, DOI 10.1097/01.mcg.0000225634.52780.0e; Weinbroum AA, 2001, EUR J ANAESTH, V18, P789, DOI 10.1046/j.1365-2346.2001.00922.x	29	11	11	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0192-0790			J CLIN GASTROENTEROL	J. Clin. Gastroenterol.	AUG	2011	45	7					E72	E75		10.1097/MCG.0b013e318201fbce			4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	791RW	WOS:000292683300002	21135703				2020-06-30	J	Staffieri, F; Sleeper, M; Larenza, MP				Staffieri, Francesco; Sleeper, Margaret; Larenza, Maria Paula			Increases in heart rate and systolic blood pressure in anesthetized dogs affected with X-linked muscular dystrophy after cisatracurium administration: a retrospective study	PEDIATRIC ANESTHESIA			English	Article						X-linked muscular dystrophy; dogs; cisatracurium; heart rate	ANESTHESIA; ATRACURIUM	Background: Most patients affected with Duchenne muscular dystrophy (DMD) present with arrhythmias and cardiomyopathies. Drugs which potentially may induce tachycardia or hypertension could precipitate acute cardiac failure in these patients and should be avoided. Methods: Thirty anesthesia records of five experimental male golden retriever cross-bred dogs affected with X-linked muscular dystrophy (GRDM), a model of DMD, were retrospectively reviewed (DMD group). Anesthesia records were compared with those of 10 golden retriever dogs not affected with muscular dystrophy (control group). Records were excluded if dogs received anticholinergics or vasoactive amines. Anesthesia was induced with fentanyl followed by propofol, both intravenously. After orotracheal intubation, all dogs' lungs were mechanically ventilated. Anesthesia was maintained with infusion of fentanyl and propofol (DMD group) or isoflurane in oxygen (control group). Pure O-2 was provided to the DMD group. Cisatracurium (0.1 mg.kg(-1)) was administered intravenously to all dogs. Five-min interval recordings of HR and systolic blood pressures (SAP) were obtained. Results: Immediately after the administration of cisatracurium, absolute values for HR and SAP significantly increased by 78.3 +/- 37.0 b.min(-1) (115.4 +/- 64.9%) and 33.0 +/- 28.3 mmHg (33.5 +/- 31.2%), respectively, in all DMD dogs and remained significantly increased for 10 and 30 min, respectively. Dogs in the control group did not show significant increases in HR or SAP after cisatracurium administration. All dogs recovered from anesthesia without complications. Conclusion: In this report, increases in HR and SAP could be associated with the administration of cisatracurium in individuals affected with X-linked muscular dystrophy. These cardiovascular changes deserve further investigation.	[Staffieri, Francesco] Univ Bari, Dipartimento Emergenza & Trapianti Organo, Sez Chirurg Vet, I-70010 Bari, Italy; [Staffieri, Francesco; Sleeper, Margaret; Larenza, Maria Paula] Univ Penn, Matthew J Ryan Vet Hosp, Sch Vet Med, Philadelphia, PA 19104 USA	Staffieri, F (reprint author), Univ Bari, Dipartimento Emergenza & Trapianti Organo, Sez Chirurg Vet, SP Casamassima Km 3, I-70010 Bari, Italy.	f.staffieri@veterinaria.uniba.it	Staffieri, Francesco/K-4230-2016	Staffieri, Francesco/0000-0002-2085-376X			Adams WA, 2006, VET ANAESTH ANALG, V33, P17, DOI 10.1111/j.1467-2995.2005.00231.x; Birnkrant DJ, 2007, CHEST, V132, P1977, DOI 10.1378/chest.07-0458; Bish LT, 2008, MOL THER, V16, P1953, DOI 10.1038/mt.2008.202; Driessen J, 2008, PEDIATR ANESTH, V18, P1007, DOI 10.1111/j.1460-9592.2008.02575.x; Fayssoil A, 2010, HEART FAIL REV, V15, P103, DOI 10.1007/s10741-009-9156-8; Finsterer J, 2003, CARDIOLOGY, V99, P1, DOI 10.1159/000068446; Grundman U, 1998, ACTA ANAESTH SCAND, V42, P845, DOI 10.1111/j.1399-6576.1998.tb05332.x; Gurnaney H, 2009, ANESTH ANALG, V109, P1043, DOI 10.1213/ane.0b013e3181aa5cf6; Inoue M, 2009, PEDIATR INT, V51, P33, DOI 10.1111/j.1442-200X.2008.02656.x; Modesti C, 2006, MINERVA ANESTESIOL, V72, P627; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; Patterson E, 2008, J CARDIOVASC ELECTR, V19, P861, DOI 10.1111/j.1540-8167.2008.01123.x; Reich DL, 1998, CAN J ANAESTH, V45, P794, DOI 10.1007/BF03012152; ROSEWARNE FA, 1986, CAN ANAESTH SOC J, V33, P250, DOI 10.1007/BF03010841; Soukup J, 1996, ANAESTHESIST, V45, P1024; Strober Jonathan B, 2006, NeuroRx, V3, P225; VALENTINE BA, 1988, J NEUROL SCI, V88, P69, DOI 10.1016/0022-510X(88)90206-7; Willmann R, 2009, NEUROMUSCULAR DISORD, V19, P241, DOI 10.1016/j.nmd.2008.11.015	18	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2011	21	8					900	906		10.1111/j.1460-9592.2011.03579.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	786UE	WOS:000292332600011	21477148				2020-06-30	J	Leandri, M; Leandri, S; Ghignotti, M; Cilli, M; Lunardi, G				Leandri, Massimo; Leandri, Silia; Ghignotti, Mariaisabella; Cilli, Michele; Lunardi, Gianluigi			The ITFR, impulsive tail flick reflex by short duration nociceptive stimuli	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Tail flick; Neurophysiology; Nociception; Analgesics; Laser; EMG; Strain gauge	TRANSCUTANEOUS ELECTRICAL-STIMULATION; WITHDRAWAL REFLEX; RAT; RESPONSES; HUMANS; SKIN; RECEPTORS; FENTANYL; SINGLE	A new method for evoking the tail flick reflex is introduced, using short duration or "impulsive" nociceptive stimuli, which allow synchronization and recording of electrophysiological responses. Ten adult rats were studied, by means of thermal (CO2 laser infrared pulse with 30 ms duration, 7.5 or 10 W), electric (a 25 ms train of five 0.2 ms pulses, with 5 or 10 mA intensity) or mechanical (pin pressed with 5 g force) stimuli. Both electromyographic and strain gauge mechanical responses were recorded from the tail. All three types of stimulation gave rise to three components, named early, late and ultralate, respectively occurring in the range of 19-97 ms, 190-519 ms, 1523-2765 ms. Conduction velocities of the underlying afferent fibres were calculated by moving the stimulation site. The early component could be linked to A delta afferents, while late and ultralate components were due to unmylinated C afferents. Experiments with Fentanyl (20 mu g/kg) showed that only the C linked components were depressed, with the ultralate component the most affected, possibly because supraspinally originated. Tail flick reflex evoked by impulsive stimuli is believed to be an important electrophysiological complement to behavioural procedures, useful in identifying the site of action of analgesics and other drugs upon the spinal and supraspinal centres involved in nociception. (C) 2011 Elsevier B.V. All rights reserved.	[Leandri, Massimo; Leandri, Silia; Ghignotti, Mariaisabella] Univ Genoa, Interuniv Ctr Pain Neurophysiol, I-16146 Genoa, Italy; [Leandri, Massimo; Cilli, Michele; Lunardi, Gianluigi] Natl Canc Inst Genova, Anim Facil, I-16132 Genoa, Italy	Leandri, M (reprint author), Univ Genoa, Interuniv Ctr Pain Neurophysiol, Via Dodecaneso 35, I-16146 Genoa, Italy.	massimo.leandri@unige.it; silialea@yahoo.it; mari.bixio@fastwebnet.it; michele.cilli@istge.it; gianluigi.lunardi@sacrocuore.it	Cilli, Michele/AAB-8529-2019	Leandri, Massimo/0000-0002-5197-7431	Interuniversity Centre for Pain Neurophysiology, University of Genova; Italian Ministry of Health and National Cancer Institute Regina Elena, Rome; Eli Lilly Italia S.p.A.Eli Lilly	This work has been funded by the following bodies and agencies:; (i) Interuniversity Centre for Pain Neurophysiology, University of Genova, statutory funding.; (ii) Italian Ministry of Health and National Cancer Institute Regina Elena, Rome, project "Oncological Rehabilitation".; (iii) Eli Lilly Italia S.p.A., liberal contribution.; The authors are grateful to Prof. G. Cruccu, University of Rome, for lending the laser equipment.	Andersen OK, 1999, MUSCLE NERVE, V22, P1520, DOI 10.1002/(SICI)1097-4598(199911)22:11<1520::AID-MUS6>3.3.CO;2-M; Arendt-Nielsen L, 2000, EUR J APPL PHYSIOL, V81, P165, DOI 10.1007/s004210050026; ARENDTNIELSEN L, 1995, ANESTH ANALG, V81, P63, DOI 10.1097/00000539-199507000-00013; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DANNEMAN PJ, 1994, PAIN, V58, P39, DOI 10.1016/0304-3959(94)90183-X; DEVISSER BWO, 1976, J NEUROL NEUROSUR PS, V39, P674; Douglass DK, 1997, J NEUROPHYSIOL, V77, P611; EDWARDS M, 1990, ANESTHESIOLOGY, V73, P273, DOI 10.1097/00000542-199008000-00015; El-Shenawy SM, 2002, PHARMACOL RES, V46, P235, DOI 10.1016/S1043-6618(02)00094-4; Haeseler G, 2006, PAIN, V126, P234, DOI 10.1016/j.pain.2006.07.003; HALLIN RG, 1982, J NEUROL NEUROSUR PS, V45, P313, DOI 10.1136/jnnp.45.4.313; JOURDAN D, 1995, PAIN, V63, P237, DOI 10.1016/0304-3959(95)00049-X; Kimura S, 2004, J PHARMACOL SCI, V95, P94, DOI 10.1254/jphs.95.94; Le Bars D, 2001, PHARMACOL REV, V53, P597; Leandri M, 2006, NEUROPHYSIOL CLIN, V36, P207, DOI 10.1016/j.neucli.2006.08.004; Leandri M, 2007, EXP NEUROL, V203, P148, DOI 10.1016/j.expneurol.2006.08.001; LEBARS D, 1992, PAIN, V48, P13, DOI 10.1016/0304-3959(92)90126-V; Mukherjee K, 2002, PHARMACOL BIOCHEM BE, V73, P601, DOI 10.1016/S0091-3057(02)00837-7; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; Romaniello A, 2003, NEUROPHYSIOL CLIN, V33, P315, DOI 10.1016/j.neucli.2003.10.010; ROSSI A, 1994, J PHYSIOL-LONDON, V481, P521, DOI 10.1113/jphysiol.1994.sp020460; Spadavecchia C, 2002, AM J VET RES, V63, P1551, DOI 10.2460/ajvr.2002.63.1551; TREEDE RD, 1995, J PHYSIOL-LONDON, V483, P747, DOI 10.1113/jphysiol.1995.sp020619	23	7	7	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUL 15	2011	199	1					69	77		10.1016/j.jneumeth.2011.05.003			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	790HB	WOS:000292578000009	21596062				2020-06-30	J	Bilotta, F; Doronzio, A; Stazi, E; Titi, L; Zeppa, IO; Cianchi, A; Rosa, G; Paoloni, FP; Bergese, S; Asouhidou, I; Ioannou, P; Abramowicz, AE; Spinelli, A; Delphin, E; Ayrian, E; Zelman, V; Lumb, P				Bilotta, Federico; Doronzio, Andrea; Stazi, Elisabetta; Titi, Luca; Zeppa, Ivan Orlando; Cianchi, Antonella; Rosa, Giovanni; Paoloni, Francesca Paola; Bergese, Sergio; Asouhidou, Irene; Ioannou, Polimnia; Abramowicz, Apolonia Elisabeth; Spinelli, Allison; Delphin, Ellise; Ayrian, Eugenia; Zelman, Vladimir; Lumb, Philip			Early postoperative cognitive dysfunction and postoperative delirium after anaesthesia with various hypnotics: study protocol for a randomised controlled trial - The PINOCCHIO trial	TRIALS			English	Article							MEMORY-CONCENTRATION TEST; SEVOFLURANE ANESTHESIA; GENERAL-ANESTHESIA; RISK-FACTORS; PROPOFOL; RECOVERY; DESFLURANE; CRANIOTOMY; ADULTS	Background: Postoperative delirium can result in increased postoperative morbidity and mortality, major demand for postoperative care and higher hospital costs. Hypnotics serve to induce and maintain anaesthesia and to abolish patients' consciousness. Their persisting clinical action can delay postoperative cognitive recovery and favour postoperative delirium. Some evidence suggests that these unwanted effects vary according to each hypnotic's specific pharmacodynamic and pharmacokinetic characteristics and its interaction with the individual patient. We designed this study to evaluate postoperative delirium rate after general anaesthesia with various hypnotics in patients undergoing surgical procedures other than cardiac or brain surgery. We also aimed to test whether delayed postoperative cognitive recovery increases the risk of postoperative delirium. Methods/Design: After local ethics committee approval, enrolled patients will be randomly assigned to one of three treatment groups. In all patients anaesthesia will be induced with propofol and fentanyl, and maintained with the anaesthetics desflurane, or sevoflurane, or propofol and the analgesic opioid fentanyl. The onset of postoperative delirium will be monitored with the Nursing Delirium Scale every three hours up to 72 hours post anaesthesia. Cognitive function will be evaluated with two cognitive test batteries (the Short Memory Orientation Memory Concentration Test and the Rancho Los Amigos Scale) preoperatively, at baseline, and postoperatively at 20, 40 and 60 min after extubation. Statistical analysis will investigate differences in the hypnotics used to maintain anaesthesia and the odds ratios for postoperative delirium, the relation of early postoperative cognitive recovery and postoperative delirium rate. A subgroup analysis will be used to categorize patients according to demographic variables relevant to the risk of postoperative delirium (age, sex, body weight) and to the preoperative score index for delirium. Discussion: The results of this comparative anaesthesiological trial should whether each the three hypnotics tested is related to a significantly different postoperative delirium rate. This information could ultimately allow us to select the most appropriate hypnotic to maintain anaesthesia for specific subgroups of patients and especially for those at high risk of postoperative delirium.	[Bilotta, Federico; Doronzio, Andrea; Stazi, Elisabetta; Titi, Luca; Zeppa, Ivan Orlando; Cianchi, Antonella; Rosa, Giovanni] Univ Roma La Sapienza, Policlin Umberto I, Dept Anaesthesiol Crit Care & Pain Med, Rome, Italy; [Paoloni, Francesca Paola] GIMEMA, Ctr Data, Rome, Italy; [Bergese, Sergio] Ohio State Univ, Dept Anesthesiol, Columbus, OH 43210 USA; [Bergese, Sergio] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Asouhidou, Irene; Ioannou, Polimnia] G Papanikolaou Gen Hosp, Dept Anesthesiol 2, Exohi Thessaloniki, Greece; [Abramowicz, Apolonia Elisabeth; Spinelli, Allison; Delphin, Ellise] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Anesthesiol, Bronx, NY 10467 USA; [Ayrian, Eugenia; Zelman, Vladimir; Lumb, Philip] Univ So Calif, Dept Anesthesiol, Los Angeles, CA USA	Bilotta, F (reprint author), Univ Roma La Sapienza, Policlin Umberto I, Dept Anaesthesiol Crit Care & Pain Med, Rome, Italy.	bilotta@tiscali.it	Asouhidou, Irene/AAK-3417-2020	Bergese, Sergio/0000-0001-5641-5908			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Bilotta F, 2007, EUR J ANAESTH, V24, P122, DOI 10.1017/S0265021506001244; Bilotta F, 2005, EUR J ANAESTH, V22, P233, DOI 10.1017/S0265021505210402; Bilotta F, 2001, ANAESTHESIA, V56, P266, DOI 10.1046/j.1365-2044.2001.01717-5.x; Bilotta F, 2006, PEDIATR ANESTH, V16, P1232, DOI 10.1111/j.1460-9592.2006.01970.x; Bilotta F, 2009, J NEUROSURG ANESTH, V21, P207, DOI 10.1097/ANA.0b013e3181a19c52; DAVOUS P, 1987, J NEUROL NEUROSUR PS, V50, P1312, DOI 10.1136/jnnp.50.10.1312; Duffy CM, 2000, J NEUROSURG ANESTH, V12, P128, DOI 10.1097/00008506-200004000-00012; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096; EBERT TJ, 1993, ANESTHESIOLOGY, V79, P444, DOI 10.1097/00000542-199309000-00006; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Gaudreau JD, 2005, J PAIN SYMPTOM MANAG, V29, P368, DOI 10.1016/j.jpainsymman.2004.07.009; George J, 2004, J GERONTOL A-BIOL, V59, P811; Hammon K, 1985, Anesth Prog, V32, P107; KARHUNEN U, 1982, ACTA ANAESTH SCAND, V26, P291, DOI 10.1111/j.1399-6576.1982.tb01769.x; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Kreuer S, 2009, J CLIN MONIT COMPUT, V23, P299, DOI 10.1007/s10877-009-9196-6; Lauta E, 2010, J NEUROSURG ANESTH, V22, P110, DOI 10.1097/ANA.0b013e3181c959da; Lepouse C, 2006, BRIT J ANAESTH, V96, P747, DOI 10.1093/bja/ael094; Leslie DL, 2005, ARCH INTERN MED, V165, P1657, DOI 10.1001/archinte.165.14.1657; Leslie DL, 2008, ARCH INTERN MED, V168, P27, DOI 10.1001/archinternmed.2007.4; Lowe D, 1996, ANESTHESIOLOGY, V85, P112, DOI 10.1097/00000542-199607000-00016; Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Papaioannou A, 2005, EUR J ANAESTH, V22, P492, DOI 10.1017/S0265021505000840; Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010; Radtke FM, 2008, BRIT J ANAESTH, V101, P338, DOI 10.1093/bja/aen193; Radtke FM, 2010, EUR J ANAESTH, V27, P411, DOI 10.1097/EJA.0b013e3283335cee; Rasmussen LS, 2003, ACTA ANAESTH SCAND, V47, P260, DOI 10.1034/j.1399-6576.2003.00057.x; Rasmussen M, 2010, ANESTHESIOLOGY, V112, P50, DOI 10.1097/ALN.0b013e3181c38bd3; Rortgen D, 2010, BRIT J ANAESTH, V104, P167, DOI 10.1093/bja/aep369; Santos FS, 2004, INT PSYCHOGERIATR, V16, P175, DOI 10.1017/S1041610204000365; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; TEASDALE G, 1974, LANCET, V2, P81; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Ushida T, 2009, SPINE, V34, P2500, DOI 10.1097/BRS.0b013e3181b321e6; Vaurio LE, 2006, ANESTH ANALG, V102, P1267, DOI 10.1213/01.ane.0000199156.59226.af; PASS 2005	40	27	28	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	JUL 6	2011	12								170	10.1186/1745-6215-12-170			7	Medicine, Research & Experimental	Research & Experimental Medicine	808FG	WOS:000293962000001	21733178	DOAJ Gold, Green Published			2020-06-30	J	Kessler, J; Bardenheuer, HJ				Kessler, J.; Bardenheuer, H. J.			Cancer breakthrough pain. Indications for rapidly effective opioids	ANAESTHESIST			German	Article						Neoplasms; Pain; Analgesia; Fentanyl; Transmucosal administration	TRANSMUCOSAL FENTANYL CITRATE; OPEN-LABEL; MU-G; RELATIVE BIOAVAILABILITY; INTRAVENOUS MORPHINE; POSTOPERATIVE PAIN; HEALTHY-VOLUNTEERS; CROSSOVER TRIAL; DOUBLE-BLIND; INTRANASAL	The pharmacotherapy of tumor pain has two main aims: to deliver an adequate basic analgesia using long-term retarded opioid medication and an effective treatment of tumor breakthrough pain using rapidly effective non-retarded opioids. Breakthrough pain is characterized by a sudden onset and rapid increase in the pain level and should be treated with correspondingly rapidly effective opioids. The pharmacological characteristics of previously available and routinely prescribed non-retarded opioids do not always correspond in oral galenics to the demands resulting from the definition of tumor breakthrough pain. As alternatives to these substances five different rapidly effective fentanyl preparations are now available for transmucosal administration.	[Kessler, J.; Bardenheuer, H. J.] Univ Klinikum Heidelberg, Klin Anaesthesiol, Zentrum Schmerztherapie & Palliat Med, D-69120 Heidelberg, Germany	Kessler, J (reprint author), Univ Klinikum Heidelberg, Klin Anaesthesiol, Zentrum Schmerztherapie & Palliat Med, Neuenheimer Feld 131, D-69120 Heidelberg, Germany.	jens.kessler@med.uni-heidelberg.de					ASHBURN MA, 1993, ANESTH ANALG, V76, P377; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Cawley Margaret M, 2005, Clin J Oncol Nurs, V9, P584, DOI 10.1188/05.CJON.584-592; Coda BA, 2003, ANESTH ANALG, V97, P117, DOI 10.1213/01.ANE.0000066311.40978.4F; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; JOBBINS J, 1992, BRIT MED J, V304, P1612, DOI 10.1136/bmj.304.6842.1612; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Mahar PJ, 2007, PEDIATR EMERG CARE, V23, P544, DOI 10.1097/PEC.0b013e318128f80b; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Slatkin Neal E, 2007, J Support Oncol, V5, P327; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	33	3	3	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417			ANAESTHESIST	Anaesthesist	JUL	2011	60	7					674	682		10.1007/s00101-011-1868-1			9	Anesthesiology	Anesthesiology	797NU	WOS:000293135400010	21491140				2020-06-30	J	Aguado, D; Benito, J; de Segura, IAG				Aguado, Delia; Benito, Javier; Gomez de Segura, Ignacio A.			Reduction of the minimum alveolar concentration of isoflurane in dogs using a constant rate of infusion of lidocaine-ketamine in combination with either morphine or fentanyl	VETERINARY JOURNAL			English	Article						Dog; Morphine; Lidocaine; Ketamine; Fentanyl	ANESTHETIC CONCENTRATION; HALOTHANE; SEVOFLURANE; MANAGEMENT; DESFLURANE; MIDAZOLAM; EFFICACY; SURGERY; POTENCY; PAIN	The objective of this study was to determine the effects of a constant rate of infusion of lidocaine and ketamine in combination with either morphine or fentanyl on the minimum alveolar concentration of isoflurane (MAC(ISO)) during ovariohysterectomy in dogs. Female dogs (n = 44) were pre-medicated with acepromazine and midazolam. Anaesthesia was induced with propofol and maintained with isoflurane. Dogs received ketamine (0.6 mg/kg/h) and lidocaine (3 mg/kg/h) together with morphine (0.24 mg/kg/h; MLK) or fentanyl (0.0036 mg/kg/h; FLK). The control group received Ringer's lactate solution. A skin incision was used as the noxious stimulus. The MAC(ISO) value was obtained with Dixon's up-and-down method. MAC(ISO) was 0.7 +/- 0.0 vol.% in the control group, 0.3 +/- 0.0 vol.% in the MLK group (45% MAC reduction) and 0.0 +/- 0.0 vol.% in the FLK group (97% MAC reduction). A combination of fentanyl with lidocaine and ketamine decreased the MAC(ISO) in dogs; this decrease was more pronounced than that produced by morphine, lidocaine and ketamine. (C) 2010 Elsevier Ltd. All rights reserved.	[Aguado, Delia; Gomez de Segura, Ignacio A.] Univ Complutense Madrid, Fac Vet, Dept Anim Med & Surg, Madrid, Spain; [Benito, Javier] N Carolina State Univ, Coll Vet Med, Comparat Pain Res Lab, Dept Clin Sci, Raleigh, NC USA	de Segura, IAG (reprint author), Univ Complutense Madrid, Fac Vet, Dept Anim Med & Surg, Madrid, Spain.	iagsegura@vet.ucm.es	de Segura, Ignacio Alvarez Gomez/E-4687-2010	de Segura, Ignacio Alvarez Gomez/0000-0001-5436-5396			COURT MH, 1992, J VET PHARMACOL THER, V15, P343, DOI 10.1111/j.1365-2885.1992.tb01026.x; DAVIES SN, 1988, NEUROSCI LETT, V92, P213, DOI 10.1016/0304-3940(88)90063-8; DIXON WJ, 1965, J AM STAT ASSOC, V60, P967, DOI 10.2307/2283398; Docquier MA, 2003, ANESTH ANALG, V97, P1033, DOI 10.1213/01.ANE.0000078587.51622.D0; Dyson DH, 2008, VET CLIN N AM-SMALL, V38, P1309, DOI 10.1016/j.cvsm.2008.06.006; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; EGER EI, 1988, ANESTH ANALG, V67, P1174; HALL RI, 1988, ANESTHESIOLOGY, V68, P862, DOI 10.1097/00000542-198806000-00005; Hansen B, 2008, VET CLIN N AM-SMALL, V38, P1353, DOI 10.1016/j.cvsm.2008.08.002; HEARD DJ, 1986, AM J VET RES, V47, P2113; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Lin CM, 2007, CAN J ANAESTH, V54, P523, DOI 10.1007/BF03022315; Liu MZ, 2001, ANESTHESIOLOGY, V94, P429, DOI 10.1097/00000542-200103000-00011; Matsubara LM, 2009, VET ANAESTH ANALG, V36, P407, DOI 10.1111/j.1467-2995.2009.00471.x; Mercado JA, 2008, AM J VET RES, V69, P189, DOI 10.2460/ajvr.69.2.189; MERKEL G, 1963, ANESTHESIOLOGY, V24, P346, DOI 10.1097/00000542-196305000-00016; Muir WW, 2003, AM J VET RES, V64, P1155, DOI 10.2460/ajvr.2003.64.1155; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Paul M, 2001, ANESTHESIOLOGY, V95, P1362, DOI 10.1097/00000542-200112000-00014; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; RAMPIL IJ, 1991, ANESTHESIOLOGY, V74, P429, DOI 10.1097/00000542-199103000-00007; SAIDMAN LJ, 1967, ANESTHESIOLOGY, V28, P994, DOI 10.1097/00000542-196711000-00009; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Smith LJ, 2004, VET ANAESTH ANALG, V31, P53, DOI 10.1111/j.1467-2995.2004.00142.x; Solano AM, 2006, AM J VET RES, V67, P21, DOI 10.2460/ajvr.67.1.21; Sonner JM, 2002, ANESTH ANALG, V95, P609, DOI 10.1097/00000539-200209000-00021; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; STEFFEY EP, 1977, AM J VET RES, V38, P1833; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; Wadhwa A, 2003, ANESTHESIOLOGY, V99, P1062, DOI 10.1097/00000542-200311000-00010; WATKINS SB, 1987, VET REC, V120, P326, DOI 10.1136/vr.120.14.326; Wilson J, 2008, VET ANAESTH ANALG, V35, P289, DOI 10.1111/j.1467-2995.2007.00389.x; Yang XL, 2006, ANESTHESIOLOGY, V104, P482, DOI 10.1097/00000542-200603000-00015	34	31	32	0	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-0233	1532-2971		VET J	Vet. J.	JUL	2011	189	1					63	66		10.1016/j.tvjl.2010.05.029			4	Veterinary Sciences	Veterinary Sciences	795BQ	WOS:000292946900011	20594878				2020-06-30	J	Pavez, JC; Hawkins, MG; Pascoe, PJ; Knych, HKD; Kass, PH				Pavez, Juan C.; Hawkins, Michelle G.; Pascoe, Peter J.; Knych, Heather K. DiMaio; Kass, Philip H.			Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						avian; fentanyl; isoflurane; MAC; red-tailed hawk; target-controlled infusion	CARDIOPULMONARY DOSE-RESPONSE; ARTERIAL BLOOD-GAS; ALVEOLAR CONCENTRATION; ACID-BASE; DOGS; REDUCTION; KETAMINE; MAC; HALOTHANE; LIDOCAINE	Objective To determine the impact of three different target plasma concentrations of fentanyl on the minimum anaesthetic concentration (MAC) for isoflurane in the red-tailed hawk and the effects on the haemodynamic profile. Study design Experimental study. Animal population Six healthy adult red-tailed hawks (Buteo jamaicensis) of unknown sex with body weights (mean +/- SD) of 1.21 +/- 0.15 kg. Methods This study was undertaken in two phases. In the first phase anaesthesia was induced with isoflurane in oxygen via facemask and maintained with isoflurane delivered in oxygen via a Bain circuit. Following instrumentation baseline determination of the MAC for isoflurane was made for each animal using the bracketing method and a supra-maximal electrical stimulus. End-tidal isoflurane concentration (E'Iso) was then set at 0.75 x MAC and after an appropriate equilibration period a bolus of fentanyl (20 mu g kg(-1)) was administered intravenously (IV) in order to determine the pharmacokinetics of fentanyl in the isoflurane-anaesthetized red-tailed hawk. During the second phase anaesthesia was induced in a similar manner and E'Iso was set at 0.75 x MAC for each individual. Fentanyl was infused IV to achieve target plasma concentrations between 8 and 32 ng mL(-1). At each fentanyl plasma concentration. the MAC for isoflurane and cardiovascular variables were determined. Data were analyzed by use of repeated-measures ANOVA. Results Mean +/- SD fentanyl plasma concentrations and isoflurane MACs were 0 +/- 0. 8.51 +/- 4. 14.85 +/- 4.82 and 29.25 +/- 11.52 ng mL(-1), and 2.05 +/- 0.45%, 1.42 +/- 0.53%. 1.14 +/- 0.31% and 0.93 +/- 0.32% for the target concentrations of 0, 8. 16 and 32 ng mL(-1), respectively. At these concentrations fentanyl significantly (p = 0.0016) decreased isoflurane MAC by 31%, 44% and 55%, respectively. Dose had no significant effect on heart rate, systolic, diastolic or mean arterial blood pressure. Conclusions and clinical relevance Fentanyl produced a dose-related decrease of isoflurane MAC with minimal effects on measured cardiovascular parameters in red-tailed hawks.	[Pascoe, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Pavez, Juan C.] Univ Calif Davis, Sch Vet Med, Vet Med Teaching Hosp, Davis, CA 95616 USA; [Hawkins, Michelle G.] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA; [Knych, Heather K. DiMaio] Univ Calif Davis, KL Maddy Equine Analyt Chem Lab, Calif Anim Hlth & Food Safety Lab, Davis, CA 95616 USA; [Kass, Philip H.] Univ Calif Davis, Dept Populat Hlth & Reprod, Sch Vet Med, Davis, CA 95616 USA	Pascoe, PJ (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, 2112 Tupper Hall, Davis, CA 95616 USA.	pjpascoe@ucdavis.edu		Pascoe, Peter/0000-0002-7401-2253			Brosnan RJ, 2007, ANESTH ANALG, V105, P103, DOI 10.1213/01.ane.0000265556.69089.78; Criado AB, 2003, VET ANAESTH ANALG, V30, P250, DOI 10.1046/j.1467-2995.2003.00123.x; CURRO TG, 1994, VET SURG, V23, P429, DOI 10.1111/j.1532-950X.1994.tb00502.x; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; HALL RI, 1987, ANESTHESIOLOGY, V67, P518, DOI 10.1097/00000542-198710000-00013; ILKIW JE, 1994, CAN J VET RES, V58, P248; Knych HKD, 2009, AM J VET RES, V70, P1193, DOI 10.2460/ajvr.70.10.1193; KOLLIAS GV, 1978, COMP BIOCHEM PHYS C, V60, P57, DOI 10.1016/0306-4492(78)90027-8; LASTER MJ, 1993, ANESTH ANALG, V76, P1310, DOI 10.1213/00000539-199376060-00021; LUDDERS JW, 1988, AM J VET RES, V49, P929; LUDDERS JW, 1990, VET SURG, V19, P304, DOI 10.1111/j.1532-950X.1990.tb01193.x; LUDDERS JW, 1989, ANESTH ANALG, V68, P511; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; Mercado JA, 2008, AM J VET RES, V69, P189, DOI 10.2460/ajvr.69.2.189; MERKEL G, 1963, ANESTHESIOLOGY, V24, P346, DOI 10.1097/00000542-196305000-00016; MOON PF, 1995, ANESTHESIOLOGY, V83, P535, DOI 10.1097/00000542-199509000-00012; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; NEAL LA, 1981, J ZOO ANIM MED, V12, P48, DOI 10.2307/20094515; Pagel P, 2009, MILLERS ANESTHESIA, P595; Pypendop BH, 2005, ANESTH ANALG, V100, P97, DOI 10.1213/01.ANE.0000139350.88158.38; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; Solano AM, 2006, AM J VET RES, V67, P21, DOI 10.2460/ajvr.67.1.21; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; van den Nieuwenhuyzen MCO, 2000, CLIN PHARMACOKINET, V38, P181, DOI 10.2165/00003088-200038020-00003	26	24	24	0	14	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2011	38	4					344	351		10.1111/j.1467-2995.2011.00627.x			8	Veterinary Sciences	Veterinary Sciences	789PV	WOS:000292528700009	21672126				2020-06-30	J	Uberall, MA; Muller-Schwefe, GHH				Ueberall, Michael A.; Mueller-Schwefe, Gerhard H. H.			Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrough pain; Cancer; Efficacy; Fentanyl; Safety; Sublingual administration; Transmucosal	HOSPITAL ANXIETY; OUTCOME MEASURES	Background and objectives: Breakthrough cancer pain (BTcP) affects more than half of patients with cancer pain and has severe detrimental impacts on quality of life (QoL). This study evaluated the efficacy, QoL impact and safety of sublingual fentanyl orally disintegrating tablet (sublingual fentanyl ODT), for the treatment of BTcP in a clinical setting. Research design and methods: This was a prospective, multi-center phase IV study. Opioid-tolerant adult patients with BTcP received sublingual fentanyl ODT in the course of routine clinical practice, and completed questionnaires over a 28-day observation period. Efficacy was assessed using measures of maximum BTcP intensity and the times to first effect and maximum effect of sublingual fentanyl ODT. Changes in QoL were evaluated using the modified pain disability index (mPDI) and the hospital anxiety and depression scale (HADS). Adverse events were recorded throughout. Results: Of 217 enrolled patients, 181 (83.4%) completed the observation period. During the study, 3163 episodes were treated with a mean dose of 401.4 mu g per episode. The study recorded a significant improvement in maximum BTcP intensity with sublingual fentanyl ODT, compared with baseline (p<0.0001). Patients reported experiencing the first effects of the study drug within 5 minutes of administration in 67.7% of episodes, and maximum effect within 30 minutes in 63.2% of episodes. mPDI and HADS scores significantly improved during the observation period (p<0.0001). Sublingual fentanyl ODT was well-tolerated, with 12 patients (5.5%) experiencing >= 1 study drug-related adverse event. Study limitations include a modest size and duration, and the single-arm design. Conclusions: Under the conditions of a phase IV study, sublingual fentanyl ODT was effective and well-tolerated for the treatment of BTcP in opioid-tolerant cancer patients. Study treatment was associated with significant improvements in BTcP intensity and QoL scores, and patients reported rapid onset of action in the majority of episodes.	[Ueberall, Michael A.] Inst Qualitatssicherung Schmerztherapie & Palliat, IQUISP, Inst Qual Assurance Pain Therapy & Palliat Care M, D-90489 Nurnberg, Germany; [Mueller-Schwefe, Gerhard H. H.] Interdisciplinary Pain & Palliat Care Ctr, Goppingen, Germany	Uberall, MA (reprint author), Inst Qualitatssicherung Schmerztherapie & Palliat, IQUISP, Inst Qual Assurance Pain Therapy & Palliat Care M, Theodorstr 1, D-90489 Nurnberg, Germany.	Michael.Ueberall@ifnap.de			ProStrakan Group Ltd.	The study concept was developed by the German Institute for Quality Assurance in Pain Therapy and Palliative Care (IQUISP). The study was commissioned by the German Pain Society (Deutsche Gesellschaft fur Schmerztherapie, DGS) and supported by an unrestricted grant from ProStrakan Group Ltd. Preparation and publication of this article was supported by ProStrakan Group Ltd.	BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; *CEPH LTD, EFF SPC; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dillmann U, 1994, Schmerz, V8, P100, DOI 10.1007/BF02530415; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; *FLYNN PHARM LTD R, ACT SPC; HERRMANN C, 1991, PSYCHOTHER PSYCH MED, V41, P83; IPROSTRAKAN GROUP, ABSTR SUBL TABL SPC; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; *NYC UK LTD, INST SPC; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; TAIT RC, 1987, ARCH PHYS MED REHAB, V68, P438; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	27	28	0	6	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	JUL	2011	27	7					1385	1394		10.1185/03007995.2011.583231			10	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	777YY	WOS:000291662300011	21561313				2020-06-30	J	Ceelie, I; van Dijk, M; Bax, NMA; de Wildt, SN; Tibboel, D				Ceelie, I.; van Dijk, M.; Bax, N. M. A.; de Wildt, S. N.; Tibboel, D.			Does minimal access major surgery in the newborn hurt less? An evaluation of cumulative opioid doses	EUROPEAN JOURNAL OF PAIN			English	Article						Surgical procedures; Minimally invasive [E04.800]; Pain; Postoperative [C23.550.767.700]; Esophageal atresia [C16.131.314.330]; Congenital diaphragmatic hernia; Minimal access surgery (MAS)	TRACHEOESOPHAGEAL FISTULA; LAPAROSCOPIC SURGERY; OPEN APPENDECTOMY; CHILDREN; PAIN; INFANTS; SCALE; ACETAMINOPHEN; THORACOSCOPY; MULTICENTER	Background: Minimal access surgery (MAS) in adults is associated with less postoperative pain in comparison to conventional 'open' surgery. It is not known whether this holds true for neonates as well. Less pain would imply that opioid consumption can be reduced, which has a beneficial effect on morbidity. Aim: To evaluate potential differences in' opioid consumption between neonates undergoing thoracoscopic minimal access surgery or conventional surgery of esophageal atresia (EA) and congenital diaphragmatic hernia (CDH). Methods: In this retrospective cohort study we included two controls for each MAS patient, matched on diagnosis, sex and age at surgery. Opioid dose titration was based on validated pain scores (VAS and COMFORT behaviour), applied by protocol. Cumulative opioid doses at 12, 24, 48 h and 7 days postoperatively were compared between groups with the Mann-Whitney test. Results: The study group consisted of 24 MAS patients (14 EA; 10 CDH). These were matched to 48 control patients (28 EA; 20 CDH). At none of the time points cumulative opioid (median in mg/kg (IQR)) doses significantly differed between MAS patients and controls, both with CDH and EA. For example at 24 h postoperative for CDH patients cumulative opioid doses were [0.84(0.61-1.83) MAS vs. 1.06(0.60-1.36) p = 1.0] controls, For EA patients at 24 h the cumulative opioid doses were [0.48(0.30-0.75) MAS vs. 0.49(0.35-0.79) p = 0.83] controls. This held true for the postoperative pain scores as well. Conclusions: Minimal access surgery for the repair of esophageal atresia or congenital diaphragmatic hernia is not associated with less cumulative opioid doses. (C) 2010 Published by Elsevier Ltd. on behalf of European Federation of International Association for the Study of Pain Chapters.	[Ceelie, I.; van Dijk, M.; Bax, N. M. A.; de Wildt, S. N.; Tibboel, D.] Sophia Childrens Univ Hosp, Dept Pediat Surg, Erasmus MC, NL-3015 GJ Rotterdam, Netherlands	Tibboel, D (reprint author), Sophia Childrens Univ Hosp, Dept Pediat Surg, Erasmus MC, Room SK 3286,Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.	d.tibboel@erasmusmc.nl	de Wildt, Saskia/A-9589-2008; van Dijk, Monique/B-6327-2009	de Wildt, Saskia/0000-0002-0502-0647; van Dijk, Monique/0000-0002-9856-0318			Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Bouwmeester NJ, 2004, BRIT J ANAESTH, V92, P208, DOI 10.1093/bja/aeh042; Durkin ET, 2008, SURG CLIN N AM, V88, P1101, DOI 10.1016/j.suc.2008.05.014; Ferreira CG, 2009, SURG ENDOSC, V23, P1650, DOI 10.1007/s00464-009-0334-5; Fujimoto T, 1999, SURG ENDOSC-ULTRAS, V13, P773, DOI 10.1007/s004649901096; Holcomb GW, 2005, ANN SURG, V242, P422, DOI 10.1097/01.sla.0000179649.15576.db; Ista Erwin, 2005, Pediatr Crit Care Med, V6, P58, DOI 10.1097/01.PCC.0000149318.40279.1A; JAUREGUIZAR E, 1985, J PEDIATR SURG, V20, P511, DOI 10.1016/S0022-3468(85)80477-2; Koivusalo AI, 2009, PEDIATRICS, V123, P332, DOI 10.1542/peds.2007-3752; Lejus C, 1996, ANESTHESIOLOGY, V84, P801, DOI 10.1097/00000542-199604000-00006; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Lintula H, 2001, BRIT J SURG, V88, P510, DOI 10.1046/j.1365-2168.2001.01723.x; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCCORMACK K, 2003, [No title captured], DOI DOI 10.1002/14651858.CD001785; McGrath P, 1985, Nurs Pap, V16, P34; McGrath PJ, 2008, J PAIN, V9, P771, DOI 10.1016/j.jpain.2008.04.007; Orzech N, 2008, J LAPAROENDOSC ADV S, V18, P140, DOI 10.1089/lap.2007.0162; Rogers ML, 2000, EUR J CARDIO-THORAC, V18, P711, DOI 10.1016/S1010-7940(00)00569-8; Sauerland S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001546.pub3; Taddio A, 2009, PAIN, V147, P141, DOI 10.1016/j.pain.2009.08.027; Tsao K, 2008, J LAPAROENDOSC ADV S, V18, P131, DOI 10.1089/lap.2007.0154; van der Marel CD, 2007, BRIT J ANAESTH, V98, P372, DOI 10.1093/bja/ael371; van der Marel CD, 2001, CLIN PHARMACOL THER, V70, P82, DOI 10.1067/mcp.2001.116794; van der Zee David C, 2007, Semin Pediatr Surg, V16, P224; van Dijk M, 2005, AM J NURS, V105, P33, DOI 10.1097/00000446-200501000-00019; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; van Dijk M, 2002, CLIN J PAIN, V18, P310, DOI 10.1097/00002508-200209000-00006; von Baeyer CL, 2007, PAIN, V127, P140, DOI 10.1016/j.pain.2006.08.014	28	11	11	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	JUL	2011	15	6					615	620		10.1016/j.ejpain.2010.11.010			6	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	780IW	WOS:000291850200010	21194998				2020-06-30	J	Weisbrodt, L; McKinley, S; Marshall, AP; Cole, L; Seppelt, IM; Delaney, A				Weisbrodt, Leonie; McKinley, Sharon; Marshall, Andrea P.; Cole, Louise; Seppelt, Ian M.; Delaney, Anthony			DAILY INTERRUPTION OF SEDATION IN PATIENTS RECEIVING MECHANICAL VENTILATION	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; RANDOMIZED-TRIAL; ADULT; SCALE; ALGORITHM; AGITATION; PAIN; RELIABILITY; GUIDELINES	Background Daily interruption of continuous infusion of sedatives has improved outcomes in patients receiving mechanical ventilation in open-label studies. Objectives To assess the feasibility of a protocol for a double-blind, randomized, controlled trial study on the impact of routine daily interruption of sedation in patients receiving mechanical ventilation. Methods A total of 50 patients receiving mechanical ventilation were randomized to daily interruption of fentanyl and/or midazolam infusions for up to 6 hours or to usual management of sedation. Blinding was achieved by using replacement infusions (saline or active drug in saline). Results The recruitment target of 80 patients was not met in an extended time frame. Propofol was used outside the protocol in 27% of patients in the intervention group and 17% of patients in the control group (P = .10). A total of 15% of the intervention group and 12% of the control group never had replacement infusions started (P = .77), and replacement infusions were started on only approximately one-third of eligible days in patients who received replacement infusions. The mean doses of fentanyl and midazolam were similar. The blinding strategy was safe and effective: no patients had unplanned extubations, and the most frequent reason for ending replacement infusions was completion of the maximum 6-hour period. Conclusions The double-blinded design for assessment of sedation interruption in patients receiving mechanical ventilation was safe and effective. Slow recruitment of patients and frequent noncompliance with the protocol suggest that modifications to the protocol are needed. (American Journal of Critical Care. 2011;20:e90-e98).	[Weisbrodt, Leonie] Nepean Hosp, Dept Intens Care Med, Intens Care Unit, Penrith, NSW 2750, Australia; [Weisbrodt, Leonie; Marshall, Andrea P.] Univ Sydney, Sydney Nursing Sch, Sydney, NSW 2006, Australia; [McKinley, Sharon] Univ Technol Sydney, Fac Nursing Midwifery & Hlth, Sydney, NSW 2007, Australia; [Cole, Louise] Univ Sydney, Nepean Clin Sch, Sydney, NSW 2006, Australia; [Seppelt, Ian M.] George Inst, Crit Care & Trauma Div, Sydney, NSW, Australia; [Delaney, Anthony] Royal N Shore Hosp, Intens Care Unit, St Leonards, NSW 2065, Australia; [Delaney, Anthony] Univ Sydney, Sydney Med School No, St Leonards, NSW, Australia	Weisbrodt, L (reprint author), Nepean Hosp, Dept Intens Care Med, Intens Care Unit, Derby St, Penrith, NSW 2750, Australia.	Leonie.Weisbrodt@sydney.edu.au	Delaney, Anthony/AAE-3365-2019	Marshall, Andrea/0000-0001-7692-403X	Hospira Inc; Intensive Care Foundation [ACTRN1260-5000043639]; Australian College of Critical Care Nurses	Leonie Weisbrodt and Ian Seppelt were members of the Sedation Advisory Board in Intensive Care for Hospira Inc, Lake Forest, Illinois, and have received honoraria, which were donated to the hospital research fund, for attending board meetings. These 2 authors are also members of the management committee for the SPICE (Sedation Practices in Intensive Care) investigators, who have been awarded an unrestricted grant from Hospira Inc to support conduct of the study. This study (clinical trial registration number ACTRN1260-5000043639) was supported by grants from the Intensive Care Foundation and Australian College of Critical Care Nurses.	Anifantaki S, 2009, J ADV NURS, V65, P1054, DOI 10.1111/j.1365-2648.2009.04967.x; Bellomo R, 2007, CURR OPIN ANESTHESIO, V20, P100, DOI 10.1097/ACO.0b013e32802c7cd5; Berwick DM, 2006, JAMA-J AM MED ASSOC, V295, P324, DOI 10.1001/jama.295.3.324; BROOK AD, 1999, [No title captured], V27, P2824; BUCKNALL TK, 2008, CRIT CARE MED, V36, P1649; Chanques G, 2006, CRIT CARE MED, V34, P1691, DOI 10.1097/01.CCM.0000218416.62457.56; College of Intensive Care Medicine, MIN STAND INT CAR UN; De Jong MMJ, 2005, AM J CRIT CARE, V14, P531; De Jonghe B, 2005, CRIT CARE MED, V33, P120, DOI 10.1097/01.CCM.0000150268.04228.68; de Wit M, 2008, CRIT CARE, V12, DOI 10.1186/cc6908; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Elliott R, 2006, INTENS CARE MED, V32, P1506, DOI 10.1007/s00134-006-0309-0; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; FRASER GL, 2007, CRIT CARE MED, V35, P393; Hogarth D Kyle, 2004, Curr Opin Crit Care, V10, P40, DOI 10.1097/00075198-200402000-00007; Jones Daryl A, 2007, Crit Care Resusc, V9, P198; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; McKinley S, 2004, AM J CRIT CARE, V13, P146, DOI 10.4037/ajcc2004.13.2.146; Mehta S, 2008, CRIT CARE MED, V36, P2092, DOI 10.1097/CCM.0b013e31817bff85; Nasraway SA, 2002, CRIT CARE MED, V30, P117, DOI 10.1097/00003246-200201000-00019; O'Connor M, 2010, AM J CRIT CARE, V19, P285, DOI 10.4037/ajcc2009541; O'Connor M, 2009, J CLIN NURS, V18, P1239, DOI 10.1111/j.1365-2702.2008.02513.x; Puntillo KA, 2004, CRIT CARE MED, V32, P421, DOI 10.1097/01.CCM.0000108875.35298.D2; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2008, ANAESTH INTENS CARE, V36, P570, DOI 10.1177/0310057X0803600423; Vender Jeffery S, 2004, Crit Care Med, V32, pS554, DOI 10.1097/01.CCM.0000145907.86298.12; VINCENT JL, 2005, CRIT CARE MED, V33, P1424; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Williams TA, 2008, AM J CRIT CARE, V17, P349	32	16	20	0	6	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264			AM J CRIT CARE	Am. J. Crit. Care	JUL 1	2011	20	4					E90	E98		10.4037/ajcc2011415			9	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	786CS	WOS:000292281500002	21724628				2020-06-30	J	Unterrainer, AF; Steiner, H; Kundt, MJ				Unterrainer, A. F.; Steiner, H.; Kundt, M. J.			Caesarean section and brain tumour resection	BRITISH JOURNAL OF ANAESTHESIA			English	Letter											a.f.unterrainer@salk.at					ABOULEISH E, 1994, BRIT J ANAESTH, V73, P336, DOI 10.1093/bja/73.3.336; McVearry KM, 2009, EPILEPSY BEHAV, V16, P609, DOI 10.1016/j.yebeh.2009.09.024; Ong BY, 2003, CAN J ANAESTH, V50, P922, DOI 10.1007/BF03018740	3	1	1	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUL	2011	107	1					111	112		10.1093/bja/aer185			3	Anesthesiology	Anesthesiology	778YT	WOS:000291746000024	21685125	Bronze			2020-06-30	J	Svenningsen, H; Tonnesen, E				Svenningsen, Helle; Tonnesen, Else			Delirium incidents in three Danish intensive care units	NURSING IN CRITICAL CARE			English	Article						Age; CAM-ICU; Critical care; Delirium; ICU-delirium; Intensive care; Nursing; Sedation	MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; RISK-FACTORS; HOSPITAL LENGTH; CAM-ICU; RELIABILITY; PREDICTOR; VALIDITY; DISORDER; IMPACT	Background: Delirium as a result of hospitalization in an intensive care unit (ICU) is defined by a mental state different from the patients' normal state and an acute fluctuating course. Both morbidity and mortality are increased in relation to delirium. The incidence of delirium has been reported from 16% to 87% in international studies primarily in elderly patients. Aims: The purpose of this study was to evaluate the incidence of delirium in adult intensive care patients in Denmark and to identify correlations between delirium, sedatives, opiod analgesics and age. Methods: In a prospective follow-up study, 139 adult patients were screened for delirium using the confusion assessment method for the ICU (CAM-ICU) from 48 h after admission to ICU, twice a day until discharged. Results: A total of 41 patients had at least one positive score for delirium, 61 had only negative scores and 37 were too heavily sedated to be scored during the study period. Thus, the incidence of delirium was 40% among patients who were able to be CAM-ICU scored. Patients who were lightly sedated had a 10-fold increased risk of delirium. There was no difference in incidence by age. Patients who received Fentanyl were more at risk of developing delirium compared with patients who received other or no analgesics. Sedative drugs did not influence the incidence. Conclusion: In this study delirium occurred in 40% of adult ICU patients of all ages.	[Svenningsen, Helle; Tonnesen, Else] Aarhus Sygehus, Aarhus Univ Hosp, Anaesthesiol Intens Dept, DK-8000 Aarhus C, Denmark	Svenningsen, H (reprint author), Aarhus Sygehus, Aarhus Univ Hosp, Anaesthesiol Intens Dept, Norrebrogade 44,Bygn 21-1, DK-8000 Aarhus C, Denmark.	hellsven@rm.dk		Svenningsen, Helle/0000-0002-2180-2163	Novo Nordisk FoundationNovo Nordisk Foundation	The study was financially supported by the Novo Nordisk Foundation. Linguistic correctness by RN Rachel Elizabeth Sutton is gratefully acknowledged.	American Psychiatric Association, 2009, PRACT GUID TREATM PA; AXELL AG, 2001, INTENSIVE CARE UNIT; Balas MC, 2007, J NURS SCHOLARSHIP, V39, P147, DOI 10.1111/j.1547-5069.2007.00160.x; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Casarett DJ, 2001, ANN INTERN MED, V135, P32, DOI 10.7326/0003-4819-135-1-200107030-00011; Devlin JW, 2008, AM J CRIT CARE, V17, P555; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Hare M, 2008, AUST J ADV NURS, V26, P21; Hewitt J, 2002, J CLIN NURS, V11, P575, DOI 10.1046/j.1365-2702.2002.00638.x; Inouye SK, 2007, ARCH INTERN MED, V167, P1406, DOI 10.1001/archinte.167.13.1406; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Jones C, 2007, INTENS CARE MED, V33, P978, DOI 10.1007/s00134-007-0600-8; Koebrugge B, 2009, DIGEST SURG, V26, P63, DOI 10.1159/000194947; Lin SM, 2008, J CRIT CARE, V23, P372, DOI 10.1016/j.jcrc.2006.09.001; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; McNicoll L, 2005, J AM GERIATR SOC, V53, P495, DOI 10.1111/j.1532-5415.2005.53171.x; Micek ST, 2005, CRIT CARE MED, V33, P1260, DOI 10.1097/01.CCM.0000164540.58515.BF; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Roberts Brigit, 2004, Intensive Crit Care Nurs, V20, P206, DOI 10.1016/j.iccn.2004.04.003; Robinson BRH, 2008, J TRAUMA, V65, P517, DOI 10.1097/TA.0b013e318181b8f6; Samuelson Karin A M, 2007, Nurs Crit Care, V12, P93; Storli SL, 2007, INT J QUALITATIVE ST, V2, P144, DOI DOI 10.1080/17482620701436921; Swigart SE, 2008, PSYCHOSOMATICS, V49, P104, DOI 10.1176/appi.psy.49.2.104; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; Van Rompaey B, 2008, CRIT CARE, V12, DOI 10.1186/cc6790; *WHO, 2009, INT KLASS PSYCH STOR, pCH5	30	17	18	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1362-1017	1478-5153		NURS CRIT CARE	Nurs. Crit. Care	JUL-AUG	2011	16	4					186	192		10.1111/j.1478-5153.2011.00421.x			7	Nursing	Nursing	796TE	WOS:000293074400007	21651659				2020-06-30	J	Zeppetella, G				Zeppetella, Giovambattista			Opioids for the management of breakthrough cancer pain in adults: A systematic review undertaken as part of an EPCRC opioid guidelines project	PALLIATIVE MEDICINE			English	Review						Neplasm; pain; opioids; breakthrough pain; transmucosal	TRANSMUCOSAL FENTANYL CITRATE; DOSE-TITRATION; BUCCAL TABLET; DOUBLE-BLIND; MORPHINE; TRIAL; RECOMMENDATIONS; TOLERABILITY; INTRANASAL; CROSSOVER	The usual management of cancer related breakthrough pain is with supplemental doses of analgesics (commonly opioids) at a dose proportional to the total around-the-clock opioid dose. The aim of this review, undertaken as part of a European Palliative Care Research Collaborative (EPCRC) project, to update the EAPC guidelines on opioid analgesics in cancer pain was to determine the evidence for the utility of opioids in the management of breakthrough pain in patients with cancer. Randomized controlled trials of opioids used as rescue medication were identified using electronic search strategies. Outcome measures sought were reduction in pain intensity measured by an appropriate scale, adverse effects, attrition, and patient satisfaction. The date of the final search was 31 July 2009. Eight studies (790 patients) met the inclusion criteria. Most studies investigated rescue medication delivery via the buccal or nasal transmucosal routes. Intravenous morphine has been compared with the transmucosal route and the two found to be effective. The oral route has not been formally tested although found to be an inferior comparator in one study. Most studies showed no meaningful relationship between the effective dose of transmucosal opioid and the around-the-clock scheduled medication or the previous rescue medication, although one study found a fixed proportion of either intravenous morphine or transmucosal fentanyl to be efficacious.	St Clare Hosp, Hastingwood CM17 9JX, Essex, England	Zeppetella, G (reprint author), St Clare Hosp, Hastingwood CM17 9JX, Essex, England.	john.zeppetella@stclarehospice.org.uk					Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Hanks G., 2001, EUR J PALLIAT CARE, V8, P6; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658	17	30	31	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.	JUL	2011	25	5			SI		516	524		10.1177/0269216310385601			9	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	783AL	WOS:000292053800017	21708858				2020-06-30	J	Reed, F; Burrow, R; Poels, KLC; Godderis, L; Veulemans, HAF; Mosing, M				Reed, Frances; Burrow, Rachel; Poels, Katrien L. C.; Godderis, Lode; Veulemans, Hendrik A. F.; Mosing, Martina			Evaluation of transdermal fentanyl patch attachment in dogs and analysis of residual fentanyl content following removal	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						attachment; canine; fentanyl; patch; transdermal delivery	PHARMACOKINETICS; ABSORPTION; TRANSMUCOSAL; SYSTEM	Objective To investigate whether the method used to attach matrix-type fentanyl patches influences the degree of skin attachment and the amount of active drug remaining in patches after use. Study design Prospective. randomised clinical study. Study population Fifteen adult dogs of mixed breeds. Methods Two equally sized matrix-type fentanyl patches were attached to the dorsal third of the lateral thorax of fifteen dogs for 72 hours. The two patches were attached using different techniques: Method AD used an adhesive dressing in combination with a transparent film. Method TO used tissue adhesive applied to the edges of the patch. After 72 hours the patches were removed and the proportion of the patch attached at this time calculated. The residual content of the patches was analysed using a validated gas chromatography mass spectrometery (GC MS) analysis technique. Results After 72 hours of continuous attachment, the mean proportion of drug uptake for method AD was 17.2 (SD +/- 11.1)% and for method TG this was 16.9 (SD +/- 7.3)%. The median proportion of attachment for method AD was 100% and for method TO was 95.6%. Conclusions The method of attachment did not significantly influence the uptake of fentanyl from matrix-type patches. The method of attachment resulted in a significant difference in the proportion of the patch attached 72 hours after placement. with method AD resulting in a greater median proportion of attachment than TO. Clinical relevance The method used to attach matrix-type fentanyl patches to dogs should not interfere with drug uptake. The residual fentanyl content remaining in these patches after 72 hours of continuous application is significant and could lead to intoxication if ingested by humans.	[Reed, Frances; Burrow, Rachel] Univ Liverpool, Small Anim Teaching Hosp, Neston, Cheshire, England; [Poels, Katrien L. C.; Godderis, Lode; Veulemans, Hendrik A. F.] Katholieke Univ Leuven, Lab Occupat Hyg & Toxicol, Dept Occupat Environm & Insurance Med, Louvain, Belgium; [Godderis, Lode] IDEWE, External Serv Protect & Prevent Work, Heverlee, Belgium; [Mosing, Martina] Univ Zurich, Vetsuisse Fac, Equine Dept, Div Anaesthesiol, Zurich, Switzerland	Reed, F (reprint author), Univ Edinburgh, Royal Dick Sch Vet Studies, Roslin EH25 9RG, Midlothian, Scotland.	freed@staffmail.ed.ac.uk	Downing, Fran/AAH-9057-2020; Godderis, Lode/AAE-5880-2019	Downing, Fran/0000-0002-9186-9662; Godderis, Lode/0000-0003-4764-8835; Mosing, Martina/0000-0002-6190-5642			Chen LK, 2000, J FORMOS MED ASSOC, V99, P549; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Fukuda K, 2009, MILLERS ANESTHESIA, P769; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Schmiedt CW, 2007, VET ANAESTH ANALG, V34, P70, DOI 10.1111/j.1467-2995.2006.00302.x; SCHWEIZERKOLLIK.M, 2009, THESIS U ZURICH ZURI, P32; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002	21	5	5	0	16	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2011	38	4					407	412		10.1111/j.1467-2995.2011.00628.x			6	Veterinary Sciences	Veterinary Sciences	789PV	WOS:000292528700015	21672129				2020-06-30	J	Mystakidou, K; Panagiotou, I; Gouliamos, A				Mystakidou, Kyriaki; Panagiotou, Irene; Gouliamos, Athanasios			Fentanyl nasal spray for the treatment of cancer pain	EXPERT OPINION ON PHARMACOTHERAPY			English	Review						breakthrough pain; cancer; chitosan fentanyl; intranasal	RELEASE MORPHINE-SULFATE; BREAKTHROUGH PAIN; DOUBLE-BLIND; INTRANASAL FENTANYL; OPEN-LABEL; MU-G; RELATIVE BIOAVAILABILITY; PATIENT ACCEPTABILITY; TRANSDERMAL FENTANYL; MULTIPLE-CROSSOVER	Introduction: Breakthrough pain, a transitory flare of pain in patients with otherwise controlled chronic pain, has been well characterized in cancer patients but despite medical awareness, sometimes remains underdiagnosed and therefore undertreated. Areas covered: Oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablets are the first medications developed specifically for the treatment of breakthrough pain in opioid-tolerant patients. Since oral administration of fentanyl is not an option for many cancer patients, the development of intranasal fentanyl spray (INFS) emerged as a more effective method of administration. Intranasal administration of fentanyl has several advantages over the oral/gastrointestinal route and clinical trials have shown that it is superior to OTFC while being well tolerated and more acceptable by the majority of patients. Expert opinion: The aim of this review is to summarize the pharmacological characteristics and data obtained from clinical studies of INFS in the past few years, and present Fentanyl Pectin Nasal Spray (PecFent (R)), which uses an innovative delivery system and is now approved in the EU. Finally, we discuss the impact that it may have in the future management of breakthrough pain in cancer patients, because an accurate diagnosis followed by the best treatment is crucial for effective pain alleviation.	[Mystakidou, Kyriaki; Panagiotou, Irene; Gouliamos, Athanasios] Univ Athens, Areteion Hosp, Dept Radiol, Pain Relief & Palliat Care Unit,Sch Med, Athens 11526, Greece	Mystakidou, K (reprint author), Univ Athens, Areteion Hosp, Dept Radiol, Pain Relief & Palliat Care Unit,Sch Med, 27 Korinthias St, Athens 11526, Greece.	mistakidou@yahoo.com	GOULIAMOS, ATHANASIOS/AAB-2367-2020				Broomhead A, 1997, J PAIN SYMPTOM MANAG, V14, P63, DOI 10.1016/S0885-3924(97)00012-2; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Coyle N, 1990, J Pain Symptom Manage, V5, P83; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Fallon M, 2009, EJC SUPPL, V7, P15, DOI 10.1016/S1359-6349(09)72064-6; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; LOWHAGEN P, 1994, NEUROPATH APPL NEURO, V20, P543, DOI 10.1111/j.1365-2990.1994.tb01008.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Mystakidou K, 2007, INT J NANOMED, V2, P49, DOI 10.2147/nano.2007.2.1.49; Mystakidou Kyriaki, 2002, Curr Opin Investig Drugs, V3, P463; Mystakidou Kyriaki, 2005, J Opioid Manag, V1, P36; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; SAWE J, 1983, EUR J CLIN PHARMACOL, V24, P537, DOI 10.1007/BF00609900; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Taylor Donald, 2010, J Support Oncol, V8, P184; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	37	11	11	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1465-6566	1744-7666		EXPERT OPIN PHARMACO	Expert Opin. Pharmacother.	JUL	2011	12	10					1653	1659		10.1517/14656566.2011.585637			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	775FS	WOS:000291444700019	21609189				2020-06-30	J	Jones, DR; Salgo, P; Meltzer, J				Jones, Dean R.; Salgo, Peter; Meltzer, Joseph			Conscious Sedation for Minor Procedures in Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRACTICE GUIDELINES; ANALGESIA; CARE		[Jones, Dean R.] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA; New York Presbyterian Hosp, New York, NY USA	Jones, DR (reprint author), Columbia Univ, Dept Anesthesiol, 622 W 168th St PH5, New York, NY 10032 USA.	dean.jones@fraserhealth.ca					Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; Brown TB, 2005, AM FAM PHYSICIAN, V71, P85; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; 1999, ANESTHESIOLOGY, V90, P896	5	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2011	364	25					E54	U113		10.1056/NEJMvcm0800732			5	Medicine, General & Internal	General & Internal Medicine	781MG	WOS:000291936100010	21696303				2020-06-30	J	Goktay, O; Satilmis, T; Garip, H; Gonul, O; Goker, K				Goktay, Ozgen; Satilmis, Tulin; Garip, Hasan; Gonul, Onur; Goker, Kamil			A Comparison of the Effects of Midazolam/Fentanyl and Midazolam/Tramadol for Conscious Intravenous Sedation During Third Molar Extraction	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							PATIENT-CONTROLLED SEDATION; PREVENTING POSTOPERATIVE PAIN; ANALGESIC EFFICACY; TRAMADOL; REMIFENTANIL; COMBINATION; 3RD-MOLAR; RECOVERY; FENTANYL; PLACEBO	Purpose: This study evaluated the effects of fentanyl and tramadol, used in combination, as sedation for third molar surgical extraction. Patients and Methods: This prospective, randomized, double-blind, placebo-controlled study included 60 patients undergoing extraction of a horizontal third molar with an Amsterdam Preoperative Anxiety and Information Scale score above 10 points. All of the patients were first given a 0.03-mg/kg bolus of midazolam, and then they were randomized into 3 groups: group A, midazolam only; group B, midazolam and 1-mu g/kg fentanyl; and group C, midazolam and 1-mg/kg tramadol. The vital signs were recorded. Patients were assessed for postoperative pain and adverse effects, and patient and surgeon satisfaction was assessed. Results: No differences were found in the heart rate among groups (P > .05). The mean blood pressure was also similar until the 40th minute, after which the mean blood pressure in the patients in group A was lower than that in the other 2 groups (P < .01). In the postoperative pain assessment, the visual analog scale scores of the patients in group C were lower than those in the other 2 groups in the first postoperative hour (P < .05). The time at which the first rescue analgesic was taken in groups A, B, and C was 3, 3.5, and 5 hours postoperatively, respectively, and was significantly later in group C (P < .01). No difference was found in patient/surgeon satisfaction among the groups. Conclusions: Tramadol has a better analgesic effect in third molar surgery than fentanyl and placebo. (C) 2011 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 69:1594-1599, 2011	[Goktay, Ozgen; Satilmis, Tulin; Garip, Hasan; Gonul, Onur; Goker, Kamil] Marmara Univ, Dept Oral & Maxillofacial Surg, Fac Dent, TR-34365 Istanbul, Marmara, Turkey	Garip, H (reprint author), Marmara Univ, Dept Oral & Maxillofacial Surg, Fac Dent, Guzelbahce Buyuk Ciftlik Sk 6, TR-34365 Istanbul, Marmara, Turkey.	hasangarip@yahoo.com					Ahmed Aliya, 2007, J Pak Med Assoc, V57, P548; Broome IJ, 1999, ANAESTHESIA, V54, P289; Collins M, 1997, BRIT J ORAL MAX SURG, V35, P54, DOI 10.1016/S0266-4356(97)90012-7; De Witte JL, 2001, ANESTH ANALG, V92, P1319; Demiraran Y, 2006, TURK J OBSTET GYNECO, V3, P191; EARL P, 1994, BRIT J ORAL MAX SURG, V32, P293, DOI 10.1016/0266-4356(94)90049-3; Esen E, 2005, J ORAL MAXIL SURG, V63, P457, DOI 10.1016/j.joms.2004.06.060; Garip H, 2007, BRIT J ORAL MAX SURG, V45, P212, DOI 10.1016/j.bjoms.2006.06.002; Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088-200443130-00004; Hirsh I, 2006, DIGEST DIS SCI, V51, P1946, DOI 10.1007/s10620-006-9413-9; Kanto D, 2005, ACTA ODONTOL SCAND, V63, P43, DOI 10.1080/00016350510019685; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; LAU W, 1993, AM J CARDIOL, V72, P177, DOI 10.1016/0002-9149(93)90156-7; LUYK NH, 1992, INT J ORAL MAX SURG, V21, P172, DOI 10.1016/S0901-5027(05)80788-X; Maimed SF, 2003, SEDATION GUIDE PATIE; Mehlisch DR, 2002, J AM DENT ASSOC, V133, P861, DOI 10.14219/jada.archive.2002.0300; Milgrom P, 1993, Anesth Prog, V40, P57; Moore PA, 1998, J CLIN PHARMACOL, V38, P554, DOI 10.1002/j.1552-4604.1998.tb05794.x; NORHOLT SE, 1998, J ORAL MAXILLOFAC SU, V27, P1; Ong CKS, 2005, J ORAL MAXIL SURG, V63, P1162, DOI 10.1016/j.joms.2005.04.028; Ong KS, 2004, INT J ORAL MAX SURG, V33, P274, DOI 10.1016/j.ijom.2003.09.015; Parworth LP, 1998, J ORAL MAXIL SURG, V56, P447, DOI 10.1016/S0278-2391(98)90710-8; Rodrigo C, 1996, AUST DENT J, V41, P159, DOI 10.1111/j.1834-7819.1996.tb04847.x; Rodrigo C R, 1990, Anesth Prog, V37, P20; ROELOFSE JA, 1994, J ORAL MAXIL SURG, V52, P247, DOI 10.1016/0278-2391(94)90293-3; SIEVERS TD, 1991, PEDIATRICS, V88, P1172; Wilson KE, 2003, BRIT J ANAESTH, V91, P850, DOI 10.1093/bja/aeg278; ZACHARIAS M, 1994, BRIT J ORAL MAX SURG, V32, P168, DOI 10.1016/0266-4356(94)90103-1; Zeyneloglu P, 2008, EUR J ANAESTH, V25, P961, DOI 10.1017/S0265021508004699	29	14	15	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUN	2011	69	6					1594	1599		10.1016/j.joms.2010.09.005			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	774RO	WOS:000291404000057	21277062				2020-06-30	J	Wong, L; Cyna, AM; Matthews, G				Wong, Lufee; Cyna, Allan M.; Matthews, Geoffrey			Rapid hypnosis as an anaesthesia adjunct for evacuation of postpartum vulval haematoma	AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY			English	Article						anaesthesia; communication; hypnosis; obstetrics; surgery	PREGNANCY; THERAPY	Hypnosis can be a useful therapeutic adjunct to pharmacological analgesia or anaesthesia in obstetrics. However, it is rarely considered a primary anaesthetic technique and is seldom employed in the acute surgical setting. Few obstetricians and anaesthetists currently utilise this technique in their clinical practice. We present a case report of a 34-year-old woman who successfully underwent evacuation of a large vulval haematoma using the simple hypnosis technique of 'believed-in imagination' as the principal anaesthetic technique with only minimal adjunctive pharmacological analgesia.	[Wong, Lufee] Womens & Childrens Hosp, Womens & Babies Div, Adelaide, SA 5006, Australia; [Cyna, Allan M.] Womens & Childrens Hosp, Dept Womens Anaesthesia, Adelaide, SA 5006, Australia; [Matthews, Geoffrey] Womens & Childrens Hosp, Dept Perinatal Med, Adelaide, SA 5006, Australia	Wong, L (reprint author), Womens & Childrens Hosp, Womens & Babies Div, 72 King William Rd, Adelaide, SA 5006, Australia.	lufeew@gmail.com					Alexander B, 2009, AM J CLIN HYPN, V52, P13, DOI 10.1080/00029157.2009.10401688; ANDREW MI, 2011, HDB COMMUNICATION AN, P97; *BMA WORK PART, 1955, BMA SUBC COUNC SUPP, P190; Enqvist B, 1997, INT J CLIN EXP HYP, V45, P102, DOI 10.1080/00207149708416112; FAYMONVILLE ME, 1995, REGION ANESTH, V20, P145; Faymonville ME, 2000, ANESTHESIOLOGY, V92, P1257, DOI 10.1097/00000542-200005000-00013; FREDERICKS LE, 2000, USE HYPNOSIS SURG AN, P99; Gaffney L, 2004, AUST NZ J OBSTET GYN, V44, P24, DOI 10.1111/j.1479-828X.2004.00161.x; Hermes D, 2004, ANAESTHESIST, V53, P326, DOI 10.1007/s00101-004-0658-4; KROGER WS, 1957, JAMA-J AM MED ASSOC, V163, P442, DOI 10.1001/jama.1957.82970410001009; Lang EV, 2000, LANCET, V355, P1486, DOI 10.1016/S0140-6736(00)02162-0; Maquet P, 1999, BIOL PSYCHIAT, V45, P327, DOI 10.1016/S0006-3223(97)00546-5; Marc I, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.01.058; Montgomery GH, 2002, ANESTH ANALG, V94, P1639, DOI 10.1097/00000539-200206000-00052; NASH M, 2001, SCI AM, V7, P47; OLNESS K, 1978, PEDIATRICS, V62, P228; Smith CA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003521.pub2	17	4	4	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0004-8666	1479-828X		AUST NZ J OBSTET GYN	Aust. N. Z. J. Obstet. Gynaecol.	JUN	2011	51	3					265	267		10.1111/j.1479-828X.2011.01310.x			3	Obstetrics & Gynecology	Obstetrics & Gynecology	772GE	WOS:000291221500016	21631449				2020-06-30	J	Osugi, T; Tatara, T; Yada, S; Tashiro, C				Osugi, Toshihiro; Tatara, Tsuneo; Yada, Sachiko; Tashiro, Chikara			Hydration Status After Overnight Fasting as Measured by Urine Osmolality Does Not Alter the Magnitude of Hypotension During General Anesthesia in Low Risk Patients	ANESTHESIA AND ANALGESIA			English	Article							BIOELECTRICAL-IMPEDANCE ANALYSIS; ABDOMINAL-SURGERY; RINGERS SOLUTION; VOLUME KINETICS; FLUID VOLUME; BLOOD-VOLUME; INDUCTION; BIOIMPEDANCE; DEHYDRATION; PROPOFOL	BACKGROUND: The increased distribution of crystalloid solution into the interstitial space may decrease the effectiveness of intravascular volume loading in patients. We investigated whether preoperative hydration status after overnight fasting affects interstitial fluid redistribution and thus the magnitude of hypotension during general anesthesia. METHODS: Sixty ASA physical status I/II patients undergoing tympanoplasty fasted from midnight. Anesthesia was induced by fentanyl and propofol and maintained with sevoflurane and remifentanil. Coinciding with the induction of anesthesia, 15 mL/kg acetated Ringer solution was infused IV over 60 minutes followed by 1 mL/kg acetated Ringer solution over the next 30 minutes. Urine osmolalities after induction of anesthesia and during the study period (pre-U(osm), post-U(osm)) and percent decreases of whole-body bioelectrical resistance for extracellular fluid relative to baseline at the end of the study period (Delta R(e)) were measured. Patients with a pre-U(osm) < the 25th percentile or with a pre-U(osm) > the 75th percentile of pre-U(osm) were categorized in the hydrated or the dehydrated group, respectively. A range of variables, including mean arterial blood pressure during the 30-to 90-minute period relative to baseline, and Delta R(e), were compared between the groups. RESULTS: The dehydrated group (pre-U(osm) > 759.5 mOsm/kg, n = 15) had a lower age (44 vs 52 years, P = 0.049) and had a higher post-U(osm) (181 vs 55 mOsm/kg, P = 0.001) compared with the hydrated group (pre-U(osm) < 378.5 mOsm/kg, n = 15). Mean arterial blood pressure during the 30-to 90-minute period relative to baseline (0.67 vs 0.67, P = 0.85) with 95% confidence interval for the difference of means (-0.070 to 0.084) and Delta R(e) (5.6% vs 6.0%, P = 0.58) with 95% confidence interval for the difference of means (-1.85% to 1.06%) were similar for the hydrated and dehydrated groups. CONCLUSIONS: Preoperative dehydration after overnight fasting as measured by urine osmolality did not alter the magnitude of hypotension during general anesthesia. This finding suggests that intravascular volume loading with crystalloid solution to prevent hypotension during general anesthesia is an unfounded practice for low risk patients after overnight fasting. (Anesth Analg 2011; 112: 1307-13)	[Osugi, Toshihiro; Tatara, Tsuneo; Yada, Sachiko; Tashiro, Chikara] Hyogo Coll Med, Dept Anesthesiol, Nishinomiya, Hyogo 6638501, Japan	Tatara, T (reprint author), Hyogo Coll Med, Dept Anesthesiol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	ttatara@hyo-med.ac.jp			Ministry of Education, Science & Culture of Japan [20591846]	Supported by a Grant-in-Aid for Scientific Research (C) (No. 20591846) from the Ministry of Education, Science & Culture of Japan.	Ackland GL, 2008, ANESTH ANALG, V106, P924, DOI 10.1213/ane.0b013e3181615247; Ackland GL, 2004, BRIT J ANAESTH, V92, P134, DOI 10.1093/bja/aeh015; Armstrong LE, 2010, INT J SPORT NUTR EXE, V20, P145, DOI 10.1123/ijsnem.20.2.145; AUKLAND K, 1981, PHYSIOL REV, V61, P556; Bracco D, 2000, CRIT CARE MED, V28, P2390, DOI 10.1097/00003246-200007000-00034; Breuer JP, 2010, ACTA ANAESTH SCAND, V54, P313, DOI 10.1111/j.1399-6576.2009.02123.x; CLARYS JP, 1986, HUM BIOL, V58, P771; DeLorenzo A, 1997, J APPL PHYSIOL, V82, P1542; Drobin D, 1999, ANESTHESIOLOGY, V90, P81, DOI 10.1097/00000542-199901000-00013; Ewaldsson CA, 2001, BRIT J ANAESTH, V87, P406, DOI 10.1093/bja/87.3.406; Holte K, 2002, ACTA ANAESTH SCAND, V46, P1089, DOI 10.1034/j.1399-6576.2002.460906.x; Itobi E, 2006, BRIT J SURG, V93, P354, DOI 10.1002/bjs.5259; Jacob M, 2008, ACTA ANAESTH SCAND, V52, P522, DOI 10.1111/j.1399-6576.2008.01587.x; Kavouras SA, 2002, CURR OPIN CLIN NUTR, V5, P519, DOI 10.1097/00075197-200209000-00010; Kazama T, 2000, ANESTHESIOLOGY, V92, P1017, DOI 10.1097/00000542-200004000-00019; Li Y, 2007, ACTA ANAESTH SCAND, V51, P880, DOI 10.1111/j.1399-6576.2007.01351.x; Lobo DN, 2010, CRIT CARE MED, V38, P464, DOI 10.1097/CCM.0b013e3181bc80f1; Morley AP, 2010, ANESTH ANALG, V111, P1373, DOI 10.1213/ANE.0b013e3181f62a2b; ORGAN LW, 1994, J APPL PHYSIOL, V77, P98; Popowski LA, 2001, MED SCI SPORT EXER, V33, P747; Shime Nobuaki, 2005, J Anesth, V19, P187, DOI 10.1007/s00540-005-0319-z; Tatara T, 1998, CRIT CARE MED, V26, P470, DOI 10.1097/00003246-199803000-00017; Tatara T, 2007, ANESTH ANALG, V104, P347, DOI 10.1213/01.ane.0000253031.70916.27; TEDNER BT, 1984, ACUTE CARE, V10, P200	24	11	12	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2011	112	6					1307	1313		10.1213/ANE.0b013e3182114df4			7	Anesthesiology	Anesthesiology	768TL	WOS:000290961200015	21415435				2020-06-30	J	Pestieau, SR; Quezado, ZMN; Johnson, YJ; Anderson, JL; Cheng, YI; McCarter, RJ; Choi, S; Finkel, JC				Pestieau, Sophie R.; Quezado, Zenaide M. N.; Johnson, Yewande J.; Anderson, Jennifer L.; Cheng, Yao I.; McCarter, Robert J.; Choi, Sukgi; Finkel, Julia C.			High-dose dexmedetomidine increases the opioid-free interval and decreases opioid requirement after tonsillectomy in children	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							PEDIATRIC TONSILLECTOMY; ANALGESIC REQUIREMENTS; ADENOTONSILLECTOMY; SLEEP; PAIN; MORPHINE; ACETAMINOPHEN; MANAGEMENT	Dexmedetomidine, a selective alpha(2) adrenoreceptor agonist, has analgesic and sedative properties, minimal impact on respiratory parameters, and reportedly decreases analgesic requirements after surgery. Given its pharmacodynamic profile, dexmedetomidine might have a role for postoperative pain control in children undergoing tonsillectomy. In this study, we hypothesized that dexmedetomidine would delay and decrease opioid requirements after tonsillectomy. In a double-blind controlled trial, participants undergoing tonsillectomy were randomized to receive one intravenous dose of fentanyl (1 mu g center dot kg(-1) or 2 mu g center dot kg(-1)) or dexmedetomidine (2 mu g center dot kg(-1) or 4 mu g center dot kg(-1)) immediately after endotracheal intubation. Primary outcomes included requirement for rescue morphine in the initial postoperative period. One hundred and one children were enrolled. During the postoperative period, dexmedetomidine (2 and 4 mu g center dot kg(-1) groups combined) significantly prolonged the opioid-free interval of children who underwent tonsillectomy compared with fentanyl (1 and 2 mu g center dot kg(-1) groups combined) (P < 0.001). Children treated with dexmedetomidine 2 mu g center dot kg(-1) vs dexmedetomidine 4 mu g center dot kg(-1) had similar cumulative incidence curves for time to morphine rescue, whereas there was a small difference in time to first morphine rescue administration when comparing fentanyl 1 mu g center dot kg(-1) vs fentanyl 2 mu g center dot kg(-1). Furthermore, length of stay in the postanesthesia care unit was significantly longer for children treated with dexmedetomidine vs children treated with fentanyl (P = 0.0016). High-dose dexmedetomidine decreases opioid requirements, prolongs the opioid-free interval after tonsillectomy, and prolongs length of stay in the postanesthesia care unit. It is conceivable that these early opioid-sparing effects could benefit patients at risk for respiratory complications early in the postoperative course after tonsillectomy (e.g., patients with obstructive sleep apnea). (ClinicalTrials.gov number, NCT00654511).	[Pestieau, Sophie R.; Quezado, Zenaide M. N.; Johnson, Yewande J.; Anderson, Jennifer L.; Finkel, Julia C.] Childrens Natl Med Ctr, Div Anesthesiol & Pain Med, Washington, DC 20010 USA; [Quezado, Zenaide M. N.; Finkel, Julia C.] Childrens Natl Med Ctr, Sheikh Zayed Inst Pediat Surg Innovat, Washington, DC 20010 USA; [Cheng, Yao I.; McCarter, Robert J.] Childrens Natl Med Ctr, Childrens Res Inst, Ctr Clin & Community Res, Washington, DC 20010 USA; [Choi, Sukgi] Childrens Natl Med Ctr, Div Otolaryngol, Washington, DC 20010 USA	Pestieau, SR (reprint author), Childrens Natl Med Ctr, Div Anesthesiol & Pain Med, 111 Michigan Ave NW, Washington, DC 20010 USA.	spestiea@cnmc.org	Quezado, Zenaide/O-4860-2016; Choi, Sukgi/AAF-6482-2019	Quezado, Zenaide/0000-0001-9793-4368; Choi, Sukgi/0000-0002-5448-1546	Division of Anesthesiology and Pain Medicine; Sheikh Zayed Institute for Pediatric Surgical Innovation; Hospira Inc., Lake Forest, IL	This study was supported, in part, by the Division of Anesthesiology and Pain Medicine, Sheikh Zayed Institute for Pediatric Surgical Innovation and by Hospira Inc., Lake Forest, IL (research support to Julia C. Finkel MD). Hospira Inc, manufacturer of dexmedetomidine, had no access to the data or its analysis and was not involved in manuscript preparation.	Al-Zaben KR, 2010, EUR J ANAESTH, V27, P247, DOI 10.1097/EJA.0b013e32833522bf; Atef A, 2008, EUR ARCH OTO-RHINO-L, V265, P571, DOI 10.1007/s00405-007-0479-6; Bean-Lijewski JD, 2007, OTOLARYNG HEAD NECK, V137, P545, DOI 10.1016/j.otohns.2007.06.731; Bhattacharyya N, 2010, LARYNGOSCOPE, V120, P821, DOI 10.1002/lary.20852; Brown KA, 2003, ANESTHESIOLOGY, V99, P586, DOI 10.1097/00000542-200309000-00013; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; Erickson BK, 2009, OTOLARYNG HEAD NECK, V140, P894, DOI 10.1016/j.otohns.2009.01.044; Fillingim RB, 2004, EUR J PAIN, V8, P413, DOI 10.1016/j.ejpain.2004.01.007; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Joels CS, 2003, J AM COLL SURGEONS, V197, P780, DOI 10.1016/S1072-7515(03)00671-9; Koroglu A, 2005, BRIT J ANAESTH, V94, P821, DOI 10.1093/bja/aei119; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; LAKATOS E, 1988, BIOMETRICS, V44, P229, DOI 10.2307/2531910; MATHER SJ, 1995, PAEDIATR ANAESTH, V5, P185, DOI 10.1111/j.1460-9592.1995.tb00275.x; Menda F, 2010, ANN CARD ANAESTH, V13, P16, DOI 10.4103/0971-9784.58829; Mukherjee K, 2001, ANAESTHESIA, V56, P1193; Mukhtar AM, 2006, ANESTH ANALG, V103, P250, DOI 10.1213/01.ANE.0000228303.92422.73; Nixon GM, 2005, PEDIATR PULM, V39, P332, DOI 10.1002/ppul.20195; Olutoye O, 2007, PEDIATR ANESTH, V17, P1007, DOI 10.1111/j.1460-9592.2007.02234.x; Olutoye OA, 2010, ANESTH ANALG, V111, P490, DOI 10.1213/ANE.0b013e3181e33429; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Raghavendran S, 2010, ANESTH ANALG, V110, P1093, DOI 10.1213/ANE.0b013e3181cfc435; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Unal Y, 2007, INT J PEDIATR OTORHI, V71, P83, DOI 10.1016/j.ijporl.2006.09.005; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; Vestergaard H, 2007, PEDIATR INFECT DIS J, V26, P1117, DOI 10.1097/INF.0b013e31814536ba; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; WATTERS CH, 1988, ANAESTHESIA, V43, P641, DOI 10.1111/j.1365-2044.1988.tb04147.x; Weingarten TN, 2011, OBES SURG, V21, P1407, DOI 10.1007/s11695-010-0217-9; Wilson K, 2002, ANESTHESIOLOGY, V96, P313, DOI 10.1097/00000542-200202000-00015	30	40	46	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	JUN	2011	58	6					540	550		10.1007/s12630-011-9493-7			11	Anesthesiology	Anesthesiology	765SY	WOS:000290730100008	21461792	Bronze			2020-06-30	J	Wang, F; Shen, SR; Xiao, DH; Xu, CX; Tang, WL				Wang, Fen; Shen, Shou-Rong; Xiao, Ding-Hua; Xu, Can-Xia; Tang, Wu-Liang			Sedation, analgesia, and cardiorespiratory function in colonoscopy using midazolam combined with fentanyl or propofol	INTERNATIONAL JOURNAL OF COLORECTAL DISEASE			English	Article						Midazolam; Fentanyl; Propofol; Colonoscopy; Anesthesia-sedation	PATIENT TOLERANCE	Background and aims The use of sedatives during colonoscopy remains controversial because of its safety concerns. We compared cardiorespiratory function and sedative and analgesic effects in sedative colonoscopy, using combinations of midazolam with either fentanyl or propofol. Methods Eligible patients (n = 480) received 1.0-2.0 mg midazolam alone (n = 160), midazolam combined with either 50-100 mg fentanyl intramuscularly (n = 160), or 0.5-2.5 mg/kg propofol intravenously, as premedication for sedative colonoscopy. Pulse rate, blood pressure, and saturation of peripheral oxygen (SpO(2)) were monitored. Levels of sedation and analgesia were semi-quantitatively scored using visual analog scales, and amnesia profiles were qualitatively evaluated. Results Combining midazolam with either fentanyl or propofol resulted in acceptable sedative and analgesic effects compared to treatment with midazolam alone (P < 0.001), with the combination with propofol giving more favorable results. More patients receiving the propofol combination became amnestic to the procedure than patients receiving the fentanyl combination. However, midazolam combined with propofol disturbed the pulse rate (P < 0.05) and blood pressure (P < 0.001) more significantly than a combination with fentanyl, or midazolam alone. Conclusion The combination of midazolam with either fentanyl or propofol allowed patients to undergo colonoscopy under comparable sedative and analgesic conditions. The combination with fentanyl had a significantly lower effect on pulse rate and blood pressure. The combination with propofol produced superior amnestic effects.	[Wang, Fen; Shen, Shou-Rong; Xiao, Ding-Hua; Xu, Can-Xia; Tang, Wu-Liang] Cent S Univ, Xiangya Hosp 3, Dept Gastroenterol, Changsha 410013, Hunan, Peoples R China	Shen, SR (reprint author), Cent S Univ, Xiangya Hosp 3, Dept Gastroenterol, 183 Tongzipo St, Changsha 410013, Hunan, Peoples R China.	shenshourong2003@hotmail.com			Hunan Science and Technology Department plans [2009FJ3106]; National Science Foundation of Hunan Province [10JJ5035]	This work was supported by Hunan Science and Technology Department plans (NO. 2009FJ3106) and National Science Foundation of Hunan Province (NO. 10JJ5035)	Agostoni M, 2007, DIGEST LIVER DIS, V39, P1024, DOI 10.1016/j.dld.2007.08.004; Barawi M, 2000, GASTROINTEST ENDOSC, V51, P365, DOI 10.1016/S0016-5107(00)70376-2; CHOKHAVATIA S, 1993, AM J GASTROENTEROL, V88, P393; DOLWANI S, 2010, CURR COLORECTAL CANC, V6, P1556; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P1, DOI 10.1016/S0016-5107(97)70295-5; Hirsh I, 2006, DIGEST DIS SCI, V51, P1946, DOI 10.1007/s10620-006-9413-9; JIANG XW, 2002, SEDATION ANALGESIA D, V1, P119; Lee D. W. H., 2004, Hong Kong Medical Journal, V10, P84; Levin TR, 2006, ANN INTERN MED, V145, P880, DOI 10.7326/0003-4819-145-12-200612190-00004; Olkkola K. T., 2008, V182, P335, DOI 10.1007/978-3-540-74806-9_16; Rathgaber SW, 2006, GASTROINTEST ENDOSC, V64, P556, DOI 10.1016/j.gie.2006.03.014; Thiis-Evensen E, 2000, GASTROINTEST ENDOSC, V52, P606, DOI 10.1067/mge.2000.109804; Trummel John Michael, 2009, J Patient Saf, V5, P153, DOI 10.1097/PTS.0b013e3181b53f80; Vargo John J, 2004, Gastrointest Endosc Clin N Am, V14, P313, DOI 10.1016/j.giec.2004.01.005	14	12	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-1958	1432-1262		INT J COLORECTAL DIS	Int. J. Colorectal Dis.	JUN	2011	26	6					703	708		10.1007/s00384-011-1162-3			6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	766TH	WOS:000290808900004	21409424				2020-06-30	J	Saraji, M; Boroujeni, MK; Bidgoli, AAH				Saraji, Mohammad; Boroujeni, Malihe Khalili; Bidgoli, Ali Akbar Hajialiakbari			Comparison of dispersive liquid-liquid microextraction and hollow fiber liquid-liquid-liquid microextraction for the determination of fentanyl, alfentanil, and sufentanil in water and biological fluids by high-performance liquid chromatography	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						Dispersive liquid-liquid microextraction; Hollow fiber liquid-liquid-liquid microextraction; Liquid chromatography; Human plasma and urine; Narcotic drugs	SOLID-PHASE MICROEXTRACTION; GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; HUMAN URINE; SAMPLE PREPARATION; HUMAN PLASMA; EXTRACTION	Dispersive liquid-liquid microextraction (DLLME) and hollow fiber liquid-liquid-liquid microextraction (HF-LLLME) combined with HPLC-DAD have been applied for the determination of three narcotic drugs (alfentanil, fentanyl, and sufentanil) in biological samples (human plasma and urine). Different DLLME parameters influencing the extraction efficiency such as type and volume of the extraction solvent and the disperser solvent, concentration of NaOH, and salt addition were investigated. In the HF-LLLME, the effects of important parameters including organic solvent type, concentration of NaOH as donor solution, concentration of H2SO4 as acceptor phase, salt addition, stirring rate, temperature, and extraction time were investigated and optimized. The results showed that both extraction methods exhibited good linearity, precision, enrichment factor, and detection limit. Under optimal condition, the limits of detection ranged from 0.4 to 1.9 mu g/L and from 1.1 to 2.3 mu g/L for DLLME and HF-LLLME, respectively. For DLLME, the intra- and inter-day precisions were 1.7-6.4% and 14.2-15.9%, respectively; and for HF-LLLME were 0.7-5.2% and 3.3-10.1%, respectively. The enrichment factors were from 275 to 325 and 190 to 237 for DLLME and HF-LLLME, respectively. The applicability of the proposed methods was investigated by analyzing biological samples. For analysis of human plasma and urine samples, HF-LLLME showed higher precision, more effective sample clean-up, higher extraction efficiency, lower organic solvent consumption than DLLME.	[Saraji, Mohammad; Boroujeni, Malihe Khalili; Bidgoli, Ali Akbar Hajialiakbari] Isfahan Univ Technol, Dept Chem, Esfahan 8415683111, Iran	Saraji, M (reprint author), Isfahan Univ Technol, Dept Chem, Esfahan 8415683111, Iran.	saraji@cc.iut.ac.ir		Saraji, Mohammad/0000-0002-1570-0718	Research Council of Isfahan University of Technology (IUT); Center of Excellence in Sensor and Green Chemistry	The authors wish to thank the Research Council of Isfahan University of Technology (IUT) and the Center of Excellence in Sensor and Green Chemistry for the financial support of this work.	Al Azzam KM, 2010, J CHROMATOGR A, V1217, P3654, DOI 10.1016/j.chroma.2010.03.055; Bagheri H, 2007, J PHARMACEUT BIOMED, V43, P1763, DOI 10.1016/j.jpba.2006.12.016; Barri T, 2008, J CHROMATOGR A, V1186, P16, DOI 10.1016/j.chroma.2008.02.002; Ojeda CB, 2009, CHROMATOGRAPHIA, V69, P1149, DOI 10.1365/s10337-009-1104-1; Chen Y, 2008, J CHROMATOGR A, V1184, P191, DOI 10.1016/j.chroma.2007.10.026; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; Cunha SC, 2010, TALANTA, V83, P117, DOI 10.1016/j.talanta.2010.08.048; Dufresne C, 2002, ANAL LETT, V35, P1575, DOI 10.1081/AL-120006732; Ebrahimzadeh H, 2008, ANAL CHIM ACTA, V626, P193, DOI 10.1016/j.aca.2008.07.047; GUO H, 1994, TALANTA, V41, P1929, DOI 10.1016/0039-9140(94)00150-2; Gupta PK, 2007, ANAL BIOANAL CHEM, V388, P579, DOI 10.1007/s00216-007-1279-y; Herrera-Herrera AV, 2010, TRAC-TREND ANAL CHEM, V29, P728, DOI 10.1016/j.trac.2010.03.016; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Janssen PAJ, 1965, US patent, Patent No. 3164600; Kataoka H, 2010, ANAL BIOANAL CHEM, V396, P339, DOI 10.1007/s00216-009-3076-2; Kozani RR, 2007, TALANTA, V72, P387, DOI 10.1016/j.talanta.2006.10.039; Lee JY, 2008, ANAL CHIM ACTA, V624, P253, DOI 10.1016/j.aca.2008.06.050; Li GH, 2008, J CHROMATOGR A, V1204, P119, DOI 10.1016/j.chroma.2008.07.081; Lv LL, 2010, J CHROMATOGR A, V1217, P2365, DOI 10.1016/j.chroma.2010.01.081; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Melwanki MB, 2009, TALANTA, V78, P618, DOI 10.1016/j.talanta.2008.12.021; Pawliszyn J., 1999, APPL SOLID PHASE MIC; Pedersen-Bjergaard S, 2005, J CHROMATOGR B, V817, P3, DOI 10.1016/j.jchromb.2004.08.034; Pedersen-Bjergaard S, 1999, ANAL CHEM, V71, P2650, DOI 10.1021/ac990055n; Pedersen-Bjergaard S, 2008, J CHROMATOGR A, V1184, P132, DOI 10.1016/j.chroma.2007.08.088; Pinto MI, 2010, MICROCHEM J, V96, P225, DOI 10.1016/j.microc.2010.06.010; Prosen H, 1999, TRAC-TREND ANAL CHEM, V18, P272, DOI 10.1016/S0165-9936(98)00109-5; Raikos N, 2009, J SEP SCI, V32, P1018, DOI 10.1002/jssc.200800447; Rezaee M, 2006, J CHROMATOGR A, V1116, P1, DOI 10.1016/j.chroma.2006.03.007; Rezaee M, 2010, J CHROMATOGR A, V1217, P2342, DOI 10.1016/j.chroma.2009.11.088; Saaid M, 2009, J CHROMATOGR A, V1216, P5165, DOI 10.1016/j.chroma.2009.04.091; Sarafraz-Yazdi A, 2010, TRAC-TREND ANAL CHEM, V29, P1, DOI 10.1016/j.trac.2009.10.003; Saraji M, 2009, J SEP SCI, V32, P4186, DOI 10.1002/jssc.200900438; Van Nimmen NFJ, 2004, J CHROMATOGR B, V804, P375, DOI 10.1016/j.jchromb.2004.01.044; Wang CS, 2009, MICROCHEM J, V91, P149, DOI 10.1016/j.microc.2008.09.002; Xiong CM, 2009, J PHARMACEUT BIOMED, V49, P572, DOI 10.1016/j.jpba.2008.11.036; Yazdi AS, 2008, TALANTA, V75, P1293, DOI 10.1016/j.talanta.2008.01.039; Zang XH, 2009, CHINESE J ANAL CHEM, V37, P161, DOI 10.1016/S1872-2040(08)60082-1; Zhao LM, 2002, J CHROMATOGR A, V963, P239, DOI 10.1016/S0021-9673(02)00544-7	39	46	46	1	38	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642	1618-2650		ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	JUN	2011	400	7					2149	2158		10.1007/s00216-011-4874-x			10	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	766QI	WOS:000290801000034	21442368				2020-06-30	J	Lin, L; Liu, C; Tan, H; Ouyang, H; Zhang, Y; Zeng, W				Lin, L.; Liu, C.; Tan, H.; Ouyang, H.; Zhang, Y.; Zeng, W.			Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic technique; ovarian serous adenocarcinoma; prognosis	KILLER-CELL-ACTIVITY; BREAST-CANCER SURGERY; TUMOR-METASTASIS; GENERAL-ANESTHESIA; COMPROMISES RESISTANCE; EPIDURAL-ANESTHESIA; SPINAL-ANESTHESIA; SURGICAL STRESS; IMMUNE-RESPONSE; SOLID TUMORS	Background. Animal studies have shown that regional anaesthesia and analgesia may prevent or attenuate the surgical stress response by preserving immune function and result in better long-term outcome. We have tested the hypothesis that patients with ovarian serous adenocarcinoma who had surgery with epidural anaesthesia and analgesia would have better long-term outcome than those who were given general anaesthesia (GA) and i.v. opioid analgesia. Methods. A retrospective review of medical records identified 143 patients with ovarian serous adenocarcinoma who underwent surgery between January 1994 and October 2006 at the Sun Yat-sen University Cancer Center. Data in the analysis included age, anaesthesia-analgesia technique, ASA status, blood loss, transfusion, duration of surgery, status of preoperative cancer antigen 125, tumour size, International Federation of Gynecology and Obstetrics stage, histological grade, lymph node status, residual macroscopic tumour, and chemotherapy. Survival analysis was made with the main outcome measure of death. Results. The 3- and 5-yr overall survival rates were 78% and 61% in the patient group who received epidural anaesthesia and analgesia (Group E, n=106), and 58% and 49% in the patient group who received GA and i.v. opioid analgesia (Group G, n=37), respectively. After adjusting for the other variables, Group G had a hazard ratio of 1.214 (P=0.043) in a multivariable Cox regression model compared with Group E. Conclusions. This retrospective analysis suggests that epidural anaesthesia and analgesia for ovarian serous adenocarcinoma surgery may reduce mortality during the initial years of follow-up.	[Lin, L.; Liu, C.; Tan, H.; Ouyang, H.; Zeng, W.] Sun Yat Sen Univ, Dept Anaesthesia, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Lin, L.] Sun Yat Sen Univ, Dept Anaesthesia, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, Y.] Sun Yat Sen Univ, Dept Gynaecol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Liu, C.] Guangdong Prov TCM Hosp, Dept Anaesthesia, Guangzhou, Guangdong, Peoples R China	Zeng, W (reprint author), Sun Yat Sen Univ, Dept Anaesthesia, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.	zengwa@sysu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30571794/C03030301]	This work was supported by National Natural Science Foundation of China 30571794/C03030301. This article was presented in part at the American Society of Anesthesiologists annual meeting, October 17-21, 2009, New Orleans, LA, USA.	Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; BARLOZZARI T, 1983, J IMMUNOL, V131, P1024; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B; BEILIN B, 1989, Brain Behavior and Immunity, V3, P129, DOI 10.1016/0889-1591(89)90013-5; Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; BenEliyahu S, 1996, NAT MED, V2, P457, DOI 10.1038/nm0496-457; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Bonnet F, 2005, BRIT J ANAESTH, V95, P52, DOI 10.1093/bja/aei038; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; Buggy DJ, 1999, BMJ-BRIT MED J, V319, P530, DOI 10.1136/bmj.319.7209.530; Coca S, 1997, CANCER-AM CANCER SOC, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P; ERSKINE R, 1992, CAN J ANAESTH, V39, P905, DOI 10.1007/BF03008337; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Galley HF, 2000, INTENS CARE MED, V26, P267, DOI 10.1007/s001340051149; Kutza J, 1997, ANESTH ANALG, V85, P918, DOI 10.1097/00000539-199710000-00037; LENNARD TWJ, 1985, BRIT J SURG, V72, P771, DOI 10.1002/bjs.1800721002; LEWIS J W, 1983, Natural Immunity and Cell Growth Regulation, V3, P43; Loop T, 2004, ANESTHESIOLOGY, V101, P710, DOI 10.1097/00000542-200409000-00020; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Milasiene V, 2007, MEDICINA-LITHUANIA, V43, P548, DOI 10.3390/medicina43070069; O'Riain SC, 2005, ANESTH ANALG, V100, P244, DOI 10.1213/01.ANE.0000143336.37946.7D; PAGE GG, 1994, BRAIN BEHAV IMMUN, V8, P241, DOI 10.1006/brbi.1994.1022; POLLOCK RE, 1992, CANCER, V70, P2192, DOI 10.1002/1097-0142(19921015)70:8<2192::AID-CNCR2820700830>3.0.CO;2-6; Recchia F, 2003, J EXP CLIN CANC RES, V22, P135; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; RYHANEN P, 1985, GYNECOL OBSTET INVES, V19, P139, DOI 10.1159/000299024; SALO M, 1992, ACTA ANAESTH SCAND, V36, P201, DOI 10.1111/j.1399-6576.1992.tb03452.x; Schlagenhauff B, 2000, MELANOMA RES, V10, P165, DOI 10.1097/00008390-200010020-00009; Shakhar G, 1998, J IMMUNOL, V160, P3251; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; ZOLLER M, 1989, INVAS METAST, V9, P46	35	100	105	1	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JUN	2011	106	6					814	822		10.1093/bja/aer055			9	Anesthesiology	Anesthesiology	766WM	WOS:000290817300008	21436156	Bronze			2020-06-30	J	Berent-Spillson, A; Love, T; Pop-Busui, R; Sowers, M; Persad, CC; Pennington, KP; Eyvazaddeh, AD; Padmanabhan, V; Zubieta, JK; Smith, YR				Berent-Spillson, Alison; Love, Tiffany; Pop-Busui, Rodica; Sowers, MaryFran; Persad, Carol C.; Pennington, Kathryn P.; Eyvazaddeh, Aimee D.; Padmanabhan, Vasantha; Zubieta, Jon-Kar; Smith, Yolanda R.			Insulin resistance influences central opioid activity in polycystic ovary syndrome	FERTILITY AND STERILITY			English	Editorial Material						Positron emission tomography; glucose regulation; mu-opioid receptors; neuroimaging; beta-endorphins; PCOS; insulin resistance	IMPAIRED GLUCOSE-TOLERANCE; LUTEINIZING-HORMONE SECRETION; TERM NALTREXONE TREATMENT; DIABETES-MELLITUS; RECEPTOR BLOCKADE; NUCLEUS-ACCUMBENS; WOMEN; PREVALENCE; PREDICTORS; DEPRESSION	This pilot study describes a relationship between insulin resistance and m-opioid neurotransmission in limbic appetite and mood-regulating regions in women with polycystic ovary syndrome (PCOS), suggesting that insulin opioid interactions may contribute to behavioral and reproductive pathologies of PCOS. We found that [1] patients with PCOS who are insulin-resistant (n = 7) had greater limbic m-opioid receptor availability (nondisplaceable binding potential) than controls (n = 5); [2] receptor availability was correlated with severity of insulin resistance; and [3] receptor availability normalized after insulin-regulating treatment. (Fertil Steril (R) 2011; 95: 2494-8. (c) 2011 by American Society for Reproductive Medicine.)	[Berent-Spillson, Alison; Love, Tiffany; Zubieta, Jon-Kar] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; [Berent-Spillson, Alison; Padmanabhan, Vasantha; Smith, Yolanda R.] Univ Michigan, Reprod Sci Program, Ann Arbor, MI 48109 USA; [Berent-Spillson, Alison] Univ Michigan, Michigan Inst Clin & Hlth Res, Postdoctoral Translat Scholars Program, Ann Arbor, MI 48109 USA; [Persad, Carol C.; Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Pennington, Kathryn P.; Eyvazaddeh, Aimee D.; Padmanabhan, Vasantha; Smith, Yolanda R.] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; [Smith, Yolanda R.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Sowers, MaryFran] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Padmanabhan, Vasantha] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Sowers, MaryFran; Eyvazaddeh, Aimee D.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	Smith, YR (reprint author), Univ Michigan Hlth Syst, Dept Obstet & Gynecol, Womens Hosp, 1500 E Med Ctr Dr,Room L4224, Ann Arbor, MI 48109 USA.	ysmith@umich.edu	Love, Tiffany/W-8427-2019; Padmanabhan, Vasantha/C-8558-2017	Love, Tiffany/0000-0001-9299-3190; Padmanabhan, Vasantha/0000-0002-8443-7212; Pop-Busui, Rodica/0000-0002-2042-1350	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Phil F. Jenkins Research Fund; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024896]; University of Michigan Office of the Vice President for ResearchUniversity of Michigan System; fMRI Laboratory; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD007048]; University of MichiganUniversity of Michigan System; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK020572]	A.B.-S. received grants from the NIH and Phil F. Jenkins Research Fund. T. L. has nothing to disclose. R.P.-B. has nothing to disclose. M. S. has nothing to disclose. C. C. P. has nothing to disclose. K. P. P. has nothing to disclose. A. D. E. has nothing to disclose. V. P. has nothing to disclose. J.-K.Z. has been a consultant Johnson & Johnson and Merck; and been on the speaker's bureau for Lilly Lecture Bureau. Y.R.S. has nothing to disclose.; Supported by the National Center for Research Resources (UL1RR024896), the University of Michigan Office of the Vice President for Research and the fMRI Laboratory Pilot Program, and for investigator support, by the National Institute for Child Health and Human Development (5T32HD007048), the University of Michigan Postdoctoral Translational Scholars Program, and the Phil F. Jenkins Research Fund. This work used Chemistry Laboratory Core of the Michigan Diabetes Research and Training Center funded by DK020572 from the National Institute of Diabetes and Digestive and Kidney Diseases.	Adam TC, 2007, PHYSIOL BEHAV, V91, P449, DOI 10.1016/j.physbeh.2007.04.011; Adriaanse MC, 2010, DIABETIC MED, V27, P718, DOI 10.1111/j.1464-5491.2010.03002.x; Ahmed MI, 2008, HUM REPROD, V23, P2564, DOI 10.1093/humrep/den273; BALEN AH, 1993, HUM REPROD, V8, P123, DOI 10.1093/humrep/8.suppl_2.123; BARNES RB, 1985, J CLIN ENDOCR METAB, V61, P779, DOI 10.1210/jcem-61-4-779; BERGA SL, 1989, CLIN ENDOCRINOL, V30, P177, DOI 10.1111/j.1365-2265.1989.tb03739.x; Blank SK, 2006, HUM REPROD UPDATE, V12, P351, DOI 10.1093/humupd/dml017; CUMMING DC, 1984, CLIN ENDOCRINOL, V20, P643, DOI 10.1111/j.1365-2265.1984.tb00114.x; Denbleyker M, 2009, NEUROSCIENCE, V162, P224, DOI 10.1016/j.neuroscience.2009.04.071; Douglas CC, 2006, FERTIL STERIL, V86, P411, DOI 10.1016/j.fertnstert.2005.12.054; Egede LE, 2010, DIABETES RES CLIN PR, V87, P302, DOI 10.1016/j.diabres.2010.01.024; Ehrmann DA, 2006, J CLIN ENDOCR METAB, V91, P48, DOI 10.1210/jc.2005-1329; Ehrmann DA, 1999, DIABETES CARE, V22, P141, DOI 10.2337/diacare.22.1.141; Esch T, 2004, NEUROENDOCRINOL LETT, V25, P235; Eyvazzadeh AD, 2009, FERTIL STERIL, V92, P1, DOI 10.1016/j.fertnstert.2009.05.012; Farrell K, 2010, FERTIL STERIL, V94, P1565, DOI 10.1016/j.fertnstert.2010.03.081; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; Franks S, 2008, HUM REPROD UPDATE, V14, P367, DOI 10.1093/humupd/dmn015; Fruzzetti F, 2002, FERTIL STERIL, V77, P936, DOI 10.1016/S0015-0282(02)02955-2; FULGHESU AM, 1993, OBSTET GYNECOL, V82, P191; Golden SH, 2007, CURR DIABETES REV, V3, P252, DOI 10.2174/157339907782330021; Guido M, 2006, CURR PHARM DESIGN, V12, P1001, DOI 10.2174/138161206776055895; Hadziomerovic D, 2006, FERTIL STERIL, V86, P651, DOI 10.1016/j.fertnstert.2006.01.039; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; KHOURY SA, 1987, J CLIN ENDOCR METAB, V64, P755, DOI 10.1210/jcem-64-4-755; KLEINROK Z, 1987, Acta Physiologica Polonica, V38, P477; LANZONE A, 1995, J CLIN ENDOCR METAB, V80, P3501, DOI 10.1210/jc.80.12.3501; LANZONE A, 1993, FERTIL STERIL, V59, P734; LANZONE A, 1991, HUM REPROD, V6, P1043, DOI 10.1093/oxfordjournals.humrep.a137482; Legro RS, 2005, J CLIN ENDOCR METAB, V90, P3236, DOI 10.1210/jc.2004-1843; Legro RS, 1999, J CLIN ENDOCR METAB, V84, P165, DOI 10.1210/jc.84.1.165; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; March WA, 2010, HUM REPROD, V25, P544, DOI 10.1093/humrep/dep399; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mohlig M, 2006, EUR J ENDOCRINOL, V154, P295, DOI 10.1530/eje.1.02095; Napier TC, 1999, ANN NY ACAD SCI, V877, P176, DOI 10.1111/j.1749-6632.1999.tb09268.x; Norman RJ, 2001, HUM REPROD, V16, P1995, DOI 10.1093/humrep/16.9.1995; PARVIZI N, 1980, BRAIN RES, V195, P363, DOI 10.1016/0006-8993(80)90072-4; Pecina S, 2005, J NEUROSCI, V25, P11777, DOI 10.1523/JNEUROSCI.2329-05.2005; Rassi A, 2010, COMPR PSYCHIAT, V51, P599, DOI 10.1016/j.comppsych.2010.02.009; Smith KS, 2007, J NEUROSCI, V27, P1594, DOI 10.1523/JNEUROSCI.4205-06.2007; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; Smith YR, 1998, J CLIN ENDOCR METAB, V83, P4498, DOI 10.1210/jc.83.12.4498; Teede H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-41; Unger JW, 1997, CELL TISSUE RES, V288, P471, DOI 10.1007/s004410050833; ZAWADZKI JK, 1992, POLYCYSTIC OVARY SYN, P377; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	51	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0015-0282	1556-5653		FERTIL STERIL	Fertil. Steril.	JUN	2011	95	8					2494	2498		10.1016/j.fertnstert.2011.03.031			5	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	782TI	WOS:000292034100042	21486668	Green Accepted			2020-06-30	J	Kim, MH; Park, H; Park, EC; Park, K				Kim, Myung-hyun; Park, HyeongGeun; Park, Eun Chul; Park, Keeho			Attitude and Knowledge of Physicians About Cancer Pain Management: Young Doctors of South Korea in Their Early Career	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						cancer; pain; attitude; knowledge; barrier	PATIENT-RELATED BARRIERS; HEALTH; STATE; PREVALENCE; NURSES	Objective: This study is aimed at evaluating the attitude and knowledge about the optimal use of opioids and finding out the barriers to cancer pain management especially for young doctors in South Korea. Methods: A survey through questionnaire form was conducted on 1204 physicians. Physicians were grouped by their medical specialties and personal characteristics. Specialties were grouped into internal medicine and family medicine doctors, surgeons, anesthesiologists, pediatricians, other board holders and general physicians. Personal characteristics were grouped by their past experiences and current surroundings. Results: Though many doctors thought that they were fairly well educated for pain management strategy, a large population of physicians showed a negative attitude and inadequate knowledge status about cancer pain management. The degree of attitude and knowledge status was different as their specialties and personal experiences. The factors that affected doctors' attitude and knowledge were: (i) medical specialty, (ii) past history of using practical pain assessment tool, (iii) self-perception of knowledge status about pain management, (iv) experience of prescribing opioids, (v) experience of education for cancer pain management. Although many physicians had a passive attitude in prescribing opioid analgesics, they are willingly open to use opioids for cancer pain management in the future. The most important perceived barriers to optimal cancer pain management were the fear for risk of tolerance, drug addiction, side effects of opioid analgesics and knowledge deficit about opioid analgesics. Conclusions: From this study, we found that further education and practical training will be needed for adequate cancer pain management for young physicians in their early career.	[Park, Keeho] Natl Canc Ctr, Natl Canc Control Res Inst, Canc Informat & Educ Branch, Goyang Si 410769, Gyeonggi Do, South Korea	Park, K (reprint author), Natl Canc Ctr, Natl Canc Control Res Inst, Canc Informat & Educ Branch, 323 Ilsan Ro, Goyang Si 410769, Gyeonggi Do, South Korea.	park.keeho@gmail.com	Park, Eun-Cheol/O-5644-2019	Park, Eun-Cheol/0000-0002-2306-5398	National Cancer Center [1010131-2]	This study was financially supported by National Cancer Center Grant 1010131-2.	Apolone G, 2006, J AMBUL CARE MANAG, V29, P332, DOI 10.1097/00004479-200610000-00009; Bagcivan G, 2009, J PAIN SYMPTOM MANAG, V38, P727, DOI 10.1016/j.jpainsymman.2009.03.004; Beck SL, 2001, PAIN, V94, P75, DOI 10.1016/S0304-3959(01)00343-8; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; Canto ME, 2000, SUPPORT CARE CANCER, V8, P464, DOI 10.1007/s005200000157; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Everdingen MHJVDBV, 2007, PAIN, V132, P312, DOI 10.1016/j.pain.2007.08.022; Fazeny B, 2000, WIEN KLIN WOCHENSCHR, V112, P978; Furstenberg CT, 1998, J PAIN SYMPTOM MANAG, V15, P335, DOI 10.1016/S0885-3924(98)00023-2; Genf World Health Organization, 1986, CANC PAIN REL; Ger LP, 2000, J PAIN SYMPTOM MANAG, V20, P335, DOI 10.1016/S0885-3924(00)00207-4; Gilson AM, 2007, CA-CANCER J CLIN, V57, P341, DOI 10.3322/CA.57.6.341; Gilson AM, 2007, J PAIN, V8, P682, DOI 10.1016/j.jpain.2007.05.012; Gunnarsdottir S, 2003, NURS CLIN N AM, V38, P419, DOI 10.1016/S0029-6465(02)00093-2; Jacobsen Ramune, 2007, J Opioid Manag, V3, P207; Jeon YS, 2007, SUPPORT CARE CANCER, V15, P463, DOI 10.1007/s00520-006-0183-x; Juarez G, 1998, CANCER PRACT, V6, P262, DOI 10.1046/j.1523-5394.1998.00020.x; Kaasalainen Sharon, 2003, Can J Nurs Res, V35, P58; Koshy Rachel C, 2004, J Pain Palliat Care Pharmacother, V18, P5; LARUE F, 1995, CANCER, V76, P2375, DOI 10.1002/1097-0142(19951201)76:11<2375::AID-CNCR2820761129>3.0.CO;2-C; LARUE F, 1995, BRIT MED J, V310, P1034, DOI 10.1136/bmj.310.6986.1034; Lim R, 2008, ONCOLOGY-BASEL, V74, P24, DOI 10.1159/000143215; Lin CC, 2000, PAIN, V88, P7, DOI 10.1016/S0304-3959(00)00303-1; LIN CC, 1995, CANCER NURS, V18, P16; Maltoni M, 2005, SUPPORT CARE CANCER, V13, P888, DOI 10.1007/s00520-005-0807-6; PARK JH, 2008, NATL CANC CTR HDB, P15; Randall-David E, 2003, SUPPORT CARE CANCER, V11, P660, DOI 10.1007/s00520-003-0497-x; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WARD SE, 1994, PAIN, V58, P233, DOI 10.1016/0304-3959(94)90203-8; Wells N, 1998, J PAIN SYMPTOM MANAG, V15, P294, DOI 10.1016/S0885-3924(98)00019-0; Xue Ying, 2007, Clin J Oncol Nurs, V11, P687; Yates PM, 2002, J PAIN SYMPTOM MANAG, V23, P393, DOI 10.1016/S0885-3924(02)00387-1; Yu SY, 2001, EUR J PAIN-LONDON, V5, P15, DOI 10.1053/eujp.2001.0274; Yun YH, 2005, KOREAN J FAM MED, V26, P397	34	33	36	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	JUN	2011	41	6					783	791		10.1093/jjco/hyr043			9	Oncology	Oncology	770BU	WOS:000291062800009	21502282	Bronze			2020-06-30	J	Connelly, NR; Freiman, JP; Lucas, T; Parker, RK; Raghunathan, K; Gibson, C; Katz, B; Iwashita, C				Connelly, Neil Roy; Freiman, Jorge P.; Lucas, Tanya; Parker, Robert K.; Raghunathan, Karthik; Gibson, Charles; Katz, Brennan; Iwashita, Chad			Addition of epinephrine to epidural bupivacaine infusions following initiation of labor analgesia with epidural fentanyl	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Ambulatory epidural; Analgesia; Epidural; Anesthesia; Obstetrical; Epinephrine	SUFENTANIL; ADRENALINE; OBSTETRICS; CLONIDINE; SURGERY; PAIN	Study Objective: To evaluate the analgesic effects of the addition of epinephrine to a bupivacaine epidural infusion in early labor after a fentanyl bolus, following a lidocaine-epinephrine test dose. Design: Randomized, double-blinded study. Setting: Labor suite of a tertiary care hospital. Patients: 60 ASA physical status 1 and 2, laboring, nulliparous women. Interventions: All laboring women received a 3 mL epidural test dose of 1.5% lidocaine with 1:200,000 epinephrine, followed by a fentanyl 100 mu g bolus in 10 mL of diluent volume. Patients were randomized to receive one of two continuous epidural infusions: bupivacaine 0.625 mg/mL at 10 mL/hr (control group) or bupivacaine 0.625 mg/mL with epinephrine 5 mu g/mL at 10 mL/hr (epinephrine group). Measurements: Time to re-dose, pain scores, and side effects were recorded. Main Results: The mean duration of satisfactory analgesia prior to re-dose was 159 +/- 62 min for the control group and 221 +/- 111 min for the epinephrine group (P < 0.02). Pain scores were significantly higher in the control group than the epinephrine group at two time periods: 2.5 hours and 4.5 hours (P < 0.04). Conclusions: The administration of 0.625 mg/mL bupivacaine with epinephrine 5 mu g/mL at 10 mL/hr, compared with plain 0.625 mg/mL bupivacaine at 10 mL/hr, provided a longer time to re-dose, decreased pain scores at two time intervals, and had no significant difference in duration of labor or side effects. (C) 2011 Elsevier Inc. All rights reserved.	[Connelly, Neil Roy; Freiman, Jorge P.; Lucas, Tanya; Parker, Robert K.; Raghunathan, Karthik; Gibson, Charles; Katz, Brennan; Iwashita, Chad] Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA	Connelly, NR (reprint author), Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA.	neil.roy.connelly@bhs.org					ABBOUD TK, 1985, ANESTH ANALG, V64, P585; Bromage PR, 1978, EPIDURAL ANALGESIA, P144; Connelly NR, 2000, ANESTH ANALG, V91, P374, DOI 10.1097/00000539-200008000-00026; Connelly NR, 2000, INT J OBSTET ANESTH, V9, P94, DOI 10.1054/ijoa.1999.0372; Connelly NR, 2003, ANESTH ANALG, V96, P1799, DOI 10.1213/01.ANE.0000061583.77068.0B; Connelly NR, 2001, ANESTH ANALG, V93, P1001, DOI 10.1097/00000539-200110000-00041; Dahl V, 1999, INT J OBSTET ANESTH, V8, P155, DOI 10.1016/S0959-289X(99)80130-7; Dunn SM, 1998, ANESTH ANALG, V87, P331, DOI 10.1097/00000539-199808000-00018; EISENACH JC, 1987, ANESTH ANALG, V66, P447, DOI 10.1213/00000539-198705000-00014; GRICE SC, 1990, ANESTHESIOLOGY, V72, P623, DOI 10.1097/00000542-199004000-00008; Niemi G, 2003, ACTA ANAESTH SCAND, V47, P439, DOI 10.1034/j.1399-6576.2003.00077.x; Okutomi T, 2000, REGION ANESTH PAIN M, V25, P228, DOI 10.1016/S1098-7339(00)90003-8; Okutomi T, 2000, REGION ANESTH PAIN M, V25, P529, DOI 10.1053/rapm.2000.7600; Parker RK, 2002, CAN J ANAESTH, V49, P600, DOI 10.1007/BF03017388; Parker RK, 2007, J ANESTH, V21, P142, DOI 10.1007/s00540-006-0476-8; Polley LS, 2002, ANESTHESIOLOGY, V96, P1123, DOI 10.1097/00000542-200205000-00015; Sakaguchi Y, 2000, ANAESTH INTENS CARE, V28, P522, DOI 10.1177/0310057X0002800506; Soetens FM, 2006, ANESTH ANALG, V103, P182, DOI 10.1213/01.ane.0000221038.46094.c0; STEINBERG RB, 1992, REGION ANESTH, V17, P131; STEINBERG RB, 1989, REGION ANESTH, V14, P225; DAILY MED CURRENT ME	21	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	JUN	2011	23	4					265	269		10.1016/j.jclinane.2010.09.005			5	Anesthesiology	Anesthesiology	782NH	WOS:000292015900003	21489769				2020-06-30	J	Manzke, T; Niebert, M; Koch, UR; Caley, A; Vogelgesang, S; Bischoff, AM; Hulsmann, S; Ponimaskin, E; Muller, U; Smart, TG; Harvey, RJ; Richter, DW				Manzke, T.; Niebert, M.; Koch, U. R.; Caley, A.; Vogelgesang, S.; Bischoff, A. -M.; Huelsmann, S.; Ponimaskin, E.; Mueller, U.; Smart, T. G.; Harvey, R. J.; Richter, D. W.			Serotonin receptor 1A-modulated dephosphorylation of glycine receptor alpha 3. A new molecular mechanism of breathing control for compensation of opioid-induced respiratory depression without loss of analgesia	SCHMERZ			German	Article						Respiratory depression; Phosphorylation; Serotinin 1A receptor; Adenylate cyclase; Opioids	PRE-BOTZINGER COMPLEX; IN-VIVO; SYNAPTIC INHIBITION; EXPIRATORY NEURONS; OSCILLATOR MICE; RHYTHM; MODULATION; NETWORK; CAT; MOUSE	To control the breathing rhythm the medullary respiratory network generates periodic salvo activities for inspiration, post-inspiration and expiration. These are under permanent modulatory control by serotonergic neurons of the raphe which governs the degree of phosphorylation of the inhibitory glycine receptor alpha 3. The specific activation of serotonin receptor type 1A (5-HTR1A), which is strongly expressed in the respiratory neurons, functions via inhibition of adenylate cyclase and the resulting reduction of the intracellular cAMP level and a gradual dephosphorylation of the glycine receptor type alpha 3 (GlyR alpha 3). This 5-HTR1A-GlyR alpha 3 signal pathway is independent of the A mu-opioidergic transduction pathway and via a synaptic inhibition caused by an increase in GlyR alpha 3 stimulates a disinhibition of some target neurons not only from excitatory but also from inhibitory neurons. Our physiological investigations show that this 5-HTR1A-GlyR alpha 3 modulation allows treatment of respiratory depression due to opioids without affecting the desired analgesic effects of opioids. The molecular mechanism presented here opens new pharmacological possibilities to treat opioid-induced respiratory depression and respiratory disorders due to disturbed inhibitory synaptic transmission, such as hyperekplexia.	[Manzke, T.; Niebert, M.; Koch, U. R.; Bischoff, A. -M.; Huelsmann, S.; Ponimaskin, E.; Richter, D. W.] Univ Gottingen, Abt Neuro & Sinnesphysiol, D-37073 Gottingen, Germany; [Manzke, T.; Niebert, M.; Vogelgesang, S.; Huelsmann, S.; Ponimaskin, E.; Richter, D. W.] DFG Forschungszentrum Mol Physiol Gehirns CMPB, Gottingen, Germany; [Caley, A.; Harvey, R. J.] Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England; [Caley, A.; Smart, T. G.] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England; [Mueller, U.] Heidelberg Univ, Inst Pharmakol & Mol Biotechnol IPMB, D-6900 Heidelberg, Germany	Manzke, T (reprint author), Univ Gottingen, Abt Neuro & Sinnesphysiol, Humboldtallee 23, D-37073 Gottingen, Germany.	tmanzke@gwdg.de	Hulsmann, Swen/F-7169-2010; Harvey, Robert J/D-3994-2016	Hulsmann, Swen/0000-0001-5042-8724; Harvey, Robert J/0000-0001-5956-6664; Ponimaskin, evgeni/0000-0002-4570-5130	Medical Research CouncilMedical Research Council UK (MRC) [G0500833]		Busselberg D, 2003, NEUROSCIENCE, V122, P831, DOI 10.1016/j.neuroscience.2003.07.014; Busselberg D, 2001, NEUROSCI LETT, V316, P99, DOI 10.1016/S0304-3940(01)02382-5; Busselberg D, 2001, PFLUG ARCH EUR J PHY, V441, P444, DOI 10.1007/s004240000453; CELENTANO JJ, 1988, BRAIN RES, V455, P377, DOI 10.1016/0006-8993(88)90098-4; CONNELLY CA, 1989, NEUROSCI LETT, V105, P34, DOI 10.1016/0304-3940(89)90007-4; Gomeza J, 2003, NEURON, V40, P797, DOI 10.1016/S0896-6273(03)00673-1; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; Harvey RJ, 2004, SCIENCE, V304, P884, DOI 10.1126/science.1094925; Heindl C, 2007, NEUROSCI LETT, V429, P59, DOI 10.1016/j.neulet.2007.10.001; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; LALLEY PM, 1994, NEUROSCI LETT, V172, P59, DOI 10.1016/0304-3940(94)90662-9; Lalley PM, 1997, J NEUROPHYSIOL, V77, P1119; LALLEY PM, 1994, J PHYSIOL-LONDON, V476, P117; Manzke T, 2010, J CLIN INVEST, V120, P4118, DOI 10.1172/JCI43029; Manzke T, 2009, PHILOS T R SOC B, V364, P2589, DOI 10.1098/rstb.2009.0068; Markstahler U, 2002, RESP PHYSIOL NEUROBI, V130, P33, DOI 10.1016/S0034-5687(01)00334-6; OGILVIE MD, 1992, AM J PHYSIOL, V263, pR962; Paton JFR, 1996, J NEUROSCI METH, V65, P63, DOI 10.1016/0165-0270(95)00147-6; Pierrefiche O, 1998, J PHYSIOL-LONDON, V509, P245, DOI 10.1111/j.1469-7793.1998.245bo.x; Renner U, 2007, MOL PHARMACOL, V72, P502, DOI 10.1124/mol.107.037085; Richter DW, 2001, TRENDS NEUROSCI, V24, P464, DOI 10.1016/S0166-2236(00)01867-1; RICHTER DW, 1982, J EXP BIOL, V100, P93; Richter DW, 1999, J PHYSIOL-LONDON, V514, P567, DOI 10.1111/j.1469-7793.1999.567ae.x; Richter DW, 2003, TRENDS MOL MED, V9, P542, DOI 10.1016/j.molmed.2003.10.010; RICHTER DW, 1991, J PHYSIOL-LONDON, V443, P231, DOI 10.1113/jphysiol.1991.sp018832; RICHTER DW, 1996, NEURAL REGULATION RE; Rybak IA, 2004, RESP PHYSIOL NEUROBI, V143, P307, DOI 10.1016/j.resp.2004.03.020; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; SCHMID K, 1991, RESP PHYSIOL, V84, P351, DOI 10.1016/0034-5687(91)90129-7; Schwarzacher SW, 2011, BRAIN, V134, P24, DOI 10.1093/brain/awq327; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Stettner GM, 2007, J PHYSIOL-LONDON, V579, P863, DOI 10.1113/jphysiol.2006.119966; Stewart J, 1996, POSTGRAD MED J, V72, P559, DOI 10.1136/pgmj.72.851.559; Wilken B, 1997, J PEDIATR-US, V130, P89, DOI 10.1016/S0022-3476(97)70315-9; Zeilhofer HU, 2005, J COMP NEUROL, V482, P123, DOI 10.1002/cne.20349; Zhang L, 2009, J BIOL CHEM, V284, P1990, DOI 10.1074/jbc.M807971200	37	0	0	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-433X	1432-2129		SCHMERZ	Schmerz	JUN	2011	25	3					272	+		10.1007/s00482-011-1044-1			9	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	780VA	WOS:000291886200005	21499860				2020-06-30	J	Moore, RA; Mhuircheartaigh, RJN; Derry, S; McQuay, HJ				Moore, Robert A.; Mhuircheartaigh, Roisin J. Ni; Derry, Sheena; McQuay, Henry J.			Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						analgesic consumption; dichotomous outcomes; post-operative; skewed distribution	PATIENT-CONTROLLED-ANALGESIA; RELEASE EPIDURAL MORPHINE; CLINICAL-TRIALS; RELIEF; METAANALYSIS; DISTRIBUTIONS; ARTHROPLASTY; FORMULATION; MANAGEMENT; SURGERY	Background and objective Post-operative analgesic consumption is often used as a surrogate measure for pain; analyses of mean data assume a Gaussian distribution and use parametric statistics to assess statistical differences, often in small samples. We used a large individual patient dataset to examine the distribution of analgesic consumption, the validity of such analyses and alternative dichotomous outcomes. Methods Analysis of individual patient data from 913 patients over 48 post-operative hours in five randomised trials. Patients had either epidural injection of placebo or morphine (as sulphate and extended release epidural morphine) and use of patient-controlled analgesia. Post-operative fentanyl consumption was calculated over 0-24, 24-48 and 0-48 h. Results The distribution of analgesic consumption for all patients over the periods 0-24, 24-48 and 0-48 h was exponential. Most patients used less than 750 mu g fentanyl over 48 h; 34% used over 1000 mu g fentanyl (100 mg morphine), 13% over 2000 mu g and 5% over 3000 mu g. Mean, median and mode were very different; 20% of patients consumed almost 60% of post-operative analgesic, and standard deviations were generally larger than means. A useful dichotomous outcome was less than 750 mu g fentanyl consumed over 48 h, a level associated with very good or excellent patient pain rating. Use of very good or excellent patient pain rating differentiated between different doses of epidural morphine. Conclusion Because of a highly skewed distribution, postoperative analgesic consumption is an uncertain method of measuring analgesic efficacy of an intervention designed to limit pain during and after surgery. Eur J Anaesthesiol 2011; 28:427-432	[Moore, Robert A.; Mhuircheartaigh, Roisin J. Ni; Derry, Sheena; McQuay, Henry J.] Univ Oxford, John Radcliffe Hosp, Pain Res & Nuffield Dept Anaesthet, Oxford OX3 9DU, England	Moore, RA (reprint author), Univ Oxford, John Radcliffe Hosp, Pain Res & Nuffield Dept Anaesthet, Level 6 West Wing, Oxford OX3 9DU, England.	andrew.moore@pru.ox.ac.uk			NIHR Biomedical Research CentreNational Institute for Health Research (NIHR)	We are grateful to Flynn Pharma for making the individual patient data available. No specific funding was received for this work. R.A.M. is funded by NIHR Biomedical Research Centre Programme. R.A.M. has acted as a consultant for Flynn Pharma, and R.Ni.M. has spoken on a voluntary basis at sponsored symposia.	Adebayo GI, 2007, EUR J INTERN MED, V18, P299, DOI 10.1016/j.ejim.2006.12.004; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Carvalho B, 2005, ANESTH ANALG, V100, P1150, DOI 10.1213/01.ANE.0000149544.58230.FF; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Delucchi KL, 2004, AM J PSYCHIAT, V161, P1159, DOI 10.1176/appi.ajp.161.7.1159; Flather MD, 1997, CONTROL CLIN TRIALS, V18, P568, DOI 10.1016/S0197-2456(97)00024-X; Gambling D, 2005, ANESTH ANALG, V100, P1065, DOI 10.1213/01.ANE.0000145009.03574.78; Gordon D B, 1999, J Palliat Med, V2, P209, DOI 10.1089/jpm.1999.2.209; Graham DY, 2009, CLIN GASTROENTEROL H, V7, P1147, DOI 10.1016/j.cgh.2009.06.006; Hartrick CT, 2006, J BONE JOINT SURG AM, V88A, P273, DOI 10.2106/JBJS.D.02738; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; Kissin I, 2009, ANESTH ANALG, V108, P1945, DOI 10.1213/ane.0b013e3181a1a481; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; Martin Gavin, 2006, J Opioid Manag, V2, P209; McQuay HJ, 2008, BRIT J ANAESTH, V101, P69, DOI 10.1093/bja/aen108; MCQUAY HJ, 1980, LANCET, V1, P768; MCQUAY HJ, 1988, PAIN, V33, P291, DOI 10.1016/0304-3959(88)90287-4; MCQUAY HJ, 1982, J ROY SOC MED, V75, P705; MCQUAY HJ, 1992, ANAESTHESIA, V47, P757, DOI 10.1111/j.1365-2044.1992.tb03253.x; Mhuircheartaigh RJN, 2009, BRIT J ANAESTH, V103, P874, DOI 10.1093/bja/aep300; MILLER WG, 1984, CLIN CHEM, V30, P18; Mitchell AM, 2001, CAN J ANAESTH, V48, P850, DOI 10.1007/BF03017348; Moore A, 2009, CLIN GASTROENTEROL H, V7, P1156, DOI 10.1016/j.cgh.2009.03.032; Moore RA, 2010, ANN RHEUM DIS, V69, P374, DOI 10.1136/ard.2009.107805; Moore RA, 2010, PAIN, V150, P386, DOI 10.1016/j.pain.2010.05.011; Moore RA, 2005, PAIN, V116, P322, DOI 10.1016/j.pain.2005.05.001; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; Ong CKS, 2005, ANESTH ANALG, V100, P757, DOI 10.1213/01.ANE.0000144428.98767.0E; PAPPER EM, 1952, SURGERY, V32, P107; PARKHOUSE J, 1961, BRIT J ANAESTH, V33, P345, DOI 10.1093/bja/33.7.345; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; SECHZER P H, 1968, Anesthesiology (Hagerstown), V29, P209, DOI 10.1097/00000542-196801000-00104; Spencer AJ, 1997, COMMUNITY DENT ORAL, V25, P52, DOI 10.1111/j.1600-0528.1997.tb00899.x; STUBHAUG A, 1995, BAILLIERE CLIN ANAES, V9, P555, DOI 10.1016/S0950-3501(95)80022-0; Temple R, 1999, JAMA-J AM MED ASSOC, V282, P790, DOI 10.1001/jama.282.8.790; Tverskoy M, 1996, ANESTH ANALG, V83, P387, DOI 10.1097/00000539-199608000-00032; Viscusi ER, 2005, ANESTHESIOLOGY, V102, P1014, DOI 10.1097/00000542-200505000-00022; Viscusi Eugene R, 2006, Am J Ther, V13, P423, DOI 10.1097/01.mjt.0000178903.72619.ee; Woodhouse A, 1999, PAIN, V80, P545, DOI 10.1016/S0304-3959(98)00247-4	40	80	80	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JUN	2011	28	6					427	432		10.1097/EJA.0b013e328343c569			6	Anesthesiology	Anesthesiology	758YK	WOS:000290204200008	21445017				2020-06-30	J	Snyder, ML; Jarolim, P; Melanson, SEF				Snyder, Marion L.; Jarolim, Petr; Melanson, Stacy E. F.			A new automated urine fentanyl immunoassay: Technical performance and clinical utility for monitoring fentanyl compliance	CLINICA CHIMICA ACTA			English	Article						Fentanyl; Immunoassay; Drugs of abuse screening; Opioid compliance monitoring; Chronic pain; Immunalysis	PAIN; MANAGEMENT; OPIOIDS; NORFENTANYL	Background: Opiate and other drugs of abuse screening assays have been available for many years, and successfully utilized for monitoring patient medication compliance and for detecting misuse. However, immunoassays designed to rapidly detect the highly potent synthetic opioid, fentanyl, have not been available. Methods: We evaluated a new fentanyl homogeneous enzyme immunoassay (HEIA) (Immunalysis Corporation) for its ability to accurately detect fentanyl in 307 urine samples from patients prescribed chronic opioid therapy. Samples were screened by HEIA and confirmed by LC-MS/MS and ELISA for diagnostic comparison. HEIA precision and interference studies were performed. Results: HEIA diagnostic sensitivity, specificity and accuracy were 97%, 99%, and 99%, respectively, in comparison with LC-MS/MS and ELISA. HEIA detected 37 of the 38 LC-MS/MS positive samples identified in our initial evaluation. including some that contained very low levels of fentanyl, < 1 ng/ml (< 3 fmol/l). HEIA showed minimal cross-reactivity with other opioid analgesics and commonly encountered drugs. Interferences by common urine contaminants were negligible, but we observed considerable signal suppression in acidic samples (pH < 4.0). Conclusions: The HEIA urine fentanyl assay allows for rapid and accurate fentanyl detection, illustrating its utility in monitoring fentanyl compliance and abuse. (C) 2011 Elsevier B.V. All rights reserved.	[Snyder, Marion L.; Jarolim, Petr; Melanson, Stacy E. F.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Melanson, SEF (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	semelanson@partners.org					Baselt RC, 2008, DISPOSITION TOXIC DR; Cone EJ, 2008, J ANAL TOXICOL, V32, P530, DOI 10.1093/jat/32.8.530; Hammett-Stabler CA, 2002, CLIN CHIM ACTA, V315, P125, DOI 10.1016/S0009-8981(01)00714-8; Heit HA, 2004, J PAIN SYMPTOM MANAG, V27, P260, DOI 10.1016/j.jpainsymman.2003.07.008; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Katz N, 2002, CLIN J PAIN, V18, pS76, DOI 10.1097/00002508-200207001-00009; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P123; Mao CL, 2006, J PHARMACEUT BIOMED, V41, P1332, DOI 10.1016/j.jpba.2006.03.009; Melanson SEF, 2009, CLIN CHEM LAB MED, V47, P971, DOI 10.1515/CCLM.2009.220; Musshoff F, 2006, J MASS SPECTROM, V41, P633, DOI 10.1002/jms.1021; Nafziger AN, 2009, CLIN J PAIN, V25, P73, DOI 10.1097/AJP.0b013e31817e13cc; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Trescot A, 2008, PAIN PHYSICIAN, V11, pS181; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Trescot Andrea M, 2006, Pain Physician, V9, P1; Wang GH, 2011, FORENSIC SCI INT, V206, P127, DOI 10.1016/j.forsciint.2010.07.022	17	16	18	4	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	MAY 12	2011	412	11-12					946	951		10.1016/j.cca.2011.01.029			6	Medical Laboratory Technology	Medical Laboratory Technology	770YU	WOS:000291125200024	21281622				2020-06-30	J	Anderson, D				Anderson, Deborah			A Review of Systemic Opioids Commonly Used for Labor Pain Relief	JOURNAL OF MIDWIFERY & WOMENS HEALTH			English	Review						butorphanol; fentanyl; labor pain; meperidine; morphine; nalbuphine; opioids; pharmacology; remifentanil	PATIENT-CONTROLLED ANALGESIA; RANDOMIZED CONTROLLED-TRIAL; DELIVERY TIME-INTERVAL; HEART-RATE PATTERN; OBSTETRIC ANALGESIA; INTRAVENOUS REMIFENTANIL; INTRAMUSCULAR PETHIDINE; NEONATAL NEUROBEHAVIOR; PARENTERAL OPIOIDS; BREAST-MILK	Parenteral opioids for pain relief during labor have been the subject of research for many decades. Commonly used systemic opioids provide limited pain relief during labor yet are used extensively for managing labor pain. These opioids share similar pharmacologic profiles but differ in potency, pharmacokinetics, and side effects. This article reviews the pharmacokinetics, pharmacodynamics, and clinical research related to the commonly used systemic labor pain analgesics morphine, meperidine, fentanyl, remifentanil, butorphanol, and nalbuphine.	[Anderson, Deborah] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Anderson, Deborah] UCSF SFGH Interdept Nurse Midwifery Educ Program, San Francisco, CA USA	Anderson, D (reprint author), San Francisco Gen Hosp, 1001 Potrero Ave,Room 6D 27, San Francisco, CA 94110 USA.	andersond@obgyn.ucsf.edu					Aly EE, 2000, ANAESTHESIA, V55, P419, DOI 10.1046/j.1365-2044.2000.01477.x; Argoff CE, 2010, CLIN J PAIN, V26, pS16, DOI 10.1097/AJP.0b013e3181c49e11; ATKINSON BD, 1994, AM J OBSTET GYNECOL, V171, P993, DOI 10.1016/0002-9378(94)90021-3; Balki M, 2007, CAN J ANAESTH, V54, P626, DOI 10.1007/BF03022956; BAUMANN TJ, 2005, PHARMACOTHERAPY PATH, P1089; BELFRAGE P, 1981, ACTA OBSTET GYN SCAN, V60, P43, DOI 10.3109/00016348109154108; Blair JM, 2005, ANAESTHESIA, V60, P22, DOI 10.1111/j.1365-2044.2004.03975.x; Bricker L, 2002, AM J OBSTET GYNECOL, V186, pS94, DOI 10.1067/mob.2002.121549; Bucklin BA, 2005, ANESTHESIOLOGY, V103, P645, DOI 10.1097/00000542-200509000-00030; CATON D, 1995, ANESTHESIOLOGY, V82, P779, DOI 10.1097/00000542-199503000-00021; CRAFT JB, 1983, ANESTH ANALG, V62, P894; DAN U, 1991, GYNECOL OBSTET INVES, V32, P39, DOI 10.1159/000292990; Douma MR, 2010, BRIT J ANAESTH, V104, P209, DOI 10.1093/bja/aep359; Evron S, 2005, ANESTH ANALG, V100, P233, DOI 10.1213/01.ANE.0000143351.64538.BC; Evron S, 2007, CURR OPIN ANESTHESIO, V20, P181, DOI 10.1097/ACO.0b013e328136c1d1; FEINSTEIN SJ, 1986, AM J OBSTET GYNECOL, V154, P159, DOI 10.1016/0002-9378(86)90420-5; FRANK M, 1987, ANAESTHESIA, V42, P697, DOI 10.1111/j.1365-2044.1987.tb05313.x; Friedman EA, 1978, LABOR CLIN EVALUATIO; GERDIN E, 1990, J PERINAT MED, V18, P479, DOI 10.1515/jpme.1990.18.6.479; GIANNINA G, 1995, OBSTET GYNECOL, V86, P441, DOI 10.1016/0029-7844(95)00164-M; Greulich B, 2007, J MIDWIFERY WOM HEAL, V52, P190, DOI 10.1016/j.jmwh.2006.12.007; GUTSTEIN HB, 2006, GOODMAN GILMANS PHAR, P547; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; HATJIS CG, 1986, OBSTET GYNECOL, V67, P377; Hinova A, 2009, ANESTH ANALG, V109, P1925, DOI 10.1213/ANE.0b013e3181c03e0c; HODGKINSON R, 1979, J INT MED RES, V7, P224, DOI 10.1177/030006057900700310; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; JACOBSON B, 1990, BRIT MED J, V301, P1067, DOI 10.1136/bmj.301.6760.1067; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Kart T, 1997, PAEDIATR ANAESTH, V7, P5, DOI 10.1046/j.1460-9592.1997.d01-30.x; KUHNERT BR, 1985, AM J OBSTET GYNECOL, V151, P406, DOI 10.1016/0002-9378(85)90313-8; KUHNERT BR, 1985, AM J OBSTET GYNECOL, V151, P410, DOI 10.1016/0002-9378(85)90314-X; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Lavand'homme P, 2009, ACTA ANAESTH BELG, V60, P75; LEUSCHEN MP, 1990, CLIN PHARMACY, V9, P336; LITTLE D M Jr, 1949, J Indiana State Med Assoc, V42, P201; Lugo Ralph A, 2002, J Pain Palliat Care Pharmacother, V16, P5; MADUSKA AL, 1978, CAN ANAESTH SOC J, V25, P398, DOI 10.1007/BF03006569; McCool WF, 2004, J MIDWIFERY WOM HEAL, V49, P505, DOI 10.1016/j.jmwh.2004.08.028; Nelson KE, 2005, ANESTHESIOLOGY, V102, P1008, DOI 10.1097/00000542-200505000-00021; Nicolle E, 1996, EUR J CLIN PHARMACOL, V49, P485, DOI 10.1007/BF00195935; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; Nissen E, 1997, ACTA PAEDIATR, V86, P201, DOI 10.1111/j.1651-2227.1997.tb08869.x; Nyberg K, 2000, EPIDEMIOLOGY, V11, P715, DOI 10.1097/00001648-200011000-00018; NYBERG K, 1992, BRIT J ADDICT, V87, P1669; Olofsson C, 1996, BRIT J OBSTET GYNAEC, V103, P968, DOI 10.1111/j.1471-0528.1996.tb09545.x; PRASERTSAWAT PO, 1986, CURR THER RES CLIN E, V40, P1022; Quilligan E J, 1980, Int J Gynaecol Obstet, V18, P363; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; Rayburn W F, 1991, Anesthesiol Rev, V18, P31; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; Saravanakumar K, 2007, INT J OBSTET ANESTH, V16, P221, DOI 10.1016/j.ijoa.2007.01.010; Smith C V, 1996, J Matern Fetal Med, V5, P89; Soontrapa Sukree, 2002, Journal of the Medical Association of Thailand, V85, P1169; Sosa CG, 2004, AM J OBSTET GYNECOL, V191, P1212, DOI 10.1016/j.ajog.2004.03.017; STEER PL, 1992, CAN J ANAESTH, V39, P231, DOI 10.1007/BF03008782; Thurlow JA, 2002, BRIT J ANAESTH, V88, P374, DOI 10.1093/bja/88.3.374; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Tsui MHY, 2004, BJOG-INT J OBSTET GY, V111, P648, DOI 10.1111/j.1471-0528.2004.00160.x; Tveit TO, 2009, ACTA ANAESTH SCAND, V53, P794, DOI 10.1111/j.1399-6576.2009.01988.x; Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2; *US FDA, 2007, PUBL HLTH ADV US COD; Volikas I, 2005, BRIT J ANAESTH, V95, P504, DOI 10.1093/bja/aei219; Volmanen P, 2008, ACTA ANAESTH SCAND, V52, P249, DOI 10.1111/j.1399-6576.2007.01509.x; Volmanen P, 2005, ACTA ANAESTH SCAND, V49, P453, DOI 10.1111/j.1399-6576.2005.00639.x; Volmanen P, 2002, ANESTH ANALG, V94, P913, DOI 10.1097/00000539-200204000-00026; Wang H, 2009, J INT MED RES, V37, P1158, DOI 10.1177/147323000903700421; WAY WL, 1965, CLIN PHARMACOL THER, V6, P454; WILSON CM, 1986, ANAESTHESIA, V41, P1207, DOI 10.1111/j.1365-2044.1986.tb13005.x; Wittels B, 1997, ANESTH ANALG, V85, P600, DOI 10.1097/00000539-199709000-00021; WITTELS B, 1990, ANESTHESIOLOGY, V73, P864, DOI 10.1097/00000542-199011000-00012; Zhou SF, 2009, CLIN PHARMACOKINET, V48, P689, DOI 10.2165/11318030-000000000-00000; 2002, [No title captured], V100, P177	74	25	29	0	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1526-9523	1542-2011		J MIDWIFERY WOM HEAL	J. Midwifery Women Health	MAY-JUN	2011	56	3					222	239		10.1111/j.1542-2011.2011.00061.x			18	Nursing	Nursing	756DR	WOS:000289992400006	21535371				2020-06-30	J	Fernandez-Duenas, V; Poveda, R; Fernandez, A; Sanchez, S; Planas, E; Ciruela, F				Fernandez-Duenas, Victor; Poveda, Raquel; Fernandez, Alejandro; Sanchez, Silvia; Planas, Eulalia; Ciruela, Francisco			Fentanyl-trazodone-paracetamol triple drug combination: Multimodal analgesia in a mouse model of visceral pain	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Fentanyl; Trazodone; Paracetamol; Antinociception; Writhing test; Synergy	ANTINOCICEPTIVE ACTION; ANTIDEPRESSANTS; MICE; PERSISTENT; ACETAMINOPHEN; HYPERALGESIA; FACILITATION; INVOLVEMENT; INHIBITION; MODULATION	Multimodal or balanced analgesia is commonly used in the management of acute and chronic pain in humans, in order to achieve the best analgesic/safety profile. Here, by using a model of visceral acute tonic pain, the acetic acid-induced writhing test of mice, we show a synergistic interaction between fentanyl, trazodone and paracetamol on the inhibition of nociception. First of all, once assessed that all drugs induced dose-related antinociceptive effects, they were mixed in fixed ratio (1:1) combinations and a synergistic drug-drug interaction was obtained in all circumstances. Thereafter, we assayed the effects of the triple combination of fentanyl-trazodone-paracetamol and it was demonstrated that they displayed a potent synergistic interaction on the inhibition of acetic acid-mediated nociception. Interestingly, drug dosage reduction permitted to reduce the incidence of possible adverse effects, namely exploratory activity and motor coordination, thus it was demonstrated that it improved the benefit/risk profile of such treatment. Afterwards, we attempted to elucidate the mechanism of action of such interaction, by means of the nonselective opioid receptor antagonist naloxone. Interestingly, naloxone completely antagonized the antinociceptive effects of fentanyl, and it also partially reversed paracetamol and trazodone mediated analgesia. Furthermore, when naloxone was co-administered with the triple-drug treatment it blocked the previously observed enhanced antinociceptive effects of the combination. Thus, these results indicated that the endogenous opioid system played a main role in the present drug-drug interaction. Overall, the triple combination of fentanyl-trazodone-paracetamol induced a potent synergistic antinociceptive effect, which could be of interest for optimal multimodal clinical analgesia. (C) 2011 Elsevier Inc. All rights reserved.	[Fernandez-Duenas, Victor; Poveda, Raquel; Fernandez, Alejandro; Sanchez, Silvia; Planas, Eulalia; Ciruela, Francisco] Univ Barcelona, Fac Med, Dept Patol & Terapeut Expt, Unitat Farmacol, Barcelona 08907, Spain	Fernandez-Duenas, V (reprint author), Univ Barcelona, Fac Med, Dept Patol & Terapeut Expt, Unitat Farmacol, Campus Bellvitge,Av Feixa Llarga S-N, Barcelona 08907, Spain.	vfernandez@ub.edu	Ciruela, F./A-5096-2013; Fernandez-Duenas, Victor/E-5337-2014	Ciruela, F./0000-0003-0832-3739; Fernandez-Duenas, Victor/0000-0001-7834-2965	Ministerio de Ciencia e InnovacionInstituto de Salud Carlos IIISpanish Government [SAF2008-01462, CSD2008-00005]; Comissio Recerca de Bellvitge (University of Barcelona)	The authors belong to the "Neuropharmacology and Pain" accredited research group (Generalitat de Catalunya, 2009 SGR 232). This work was supported by grants SAF2008-01462 and Consolider-Ingenio CSD2008-00005 from Ministerio de Ciencia e Innovacion to FC, and ACESB from Comissio Recerca de Bellvitge (University of Barcelona) to VF and RP. The authors acknowledge Ms. S. Sanchez for technical assistance.	Abdel-Salam OME, 2003, PHARMACOL RES, V48, P157, DOI 10.1016/S1043-6618(03)00106-3; Aoki M, 2006, EUR J PHARMACOL, V550, P78, DOI 10.1016/j.ejphar.2006.08.049; ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; ARDID D, 1992, PAIN, V49, P279, DOI 10.1016/0304-3959(92)90152-2; Ayoub SS, 2006, EUR J PHARMACOL, V538, P57, DOI 10.1016/j.ejphar.2006.03.061; Bomholt SF, 2005, NEUROPHARMACOLOGY, V48, P252, DOI 10.1016/j.neuropharm.2004.09.012; Botting R, 2005, PROSTAG LEUKOTR ESS, V72, P85, DOI 10.1016/j.plefa.2004.10.005; Brocco M, 2002, PHARMACOL BIOCHEM BE, V71, P667, DOI 10.1016/S0091-3057(01)00701-8; Burgess SE, 2002, J NEUROSCI, V22, P5129, DOI 10.1523/JNEUROSCI.22-12-05129.2002; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476-5381.1968.tb00973.x; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Elia N, 2005, ANESTHESIOLOGY, V103, P1296, DOI 10.1097/00000542-200512000-00025; Fernandez-Duenas V, 2008, EUR J PAIN, V12, P157, DOI 10.1016/j.ejpain.2007.03.485; Fishbain DA, 2000, PAIN MED, V1, P310, DOI 10.1046/j.1526-4637.2000.00042.x; Giron R, 2002, LIFE SCI, V71, P1023, DOI 10.1016/S0024-3205(02)01798-8; Goodwin Jeremy L R, 2009, Curr Rheumatol Rep, V11, P5; Gray AM, 1998, BRIT J PHARMACOL, V124, P669, DOI 10.1038/sj.bjp.0701882; Marcoli M, 1998, J PHARMACOL EXP THER, V285, P983; Mayers AG, 2005, HUM PSYCHOPHARM CLIN, V20, P533, DOI 10.1002/hup.726; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Miranda HF, 2008, PHARMACOL BIOCHEM BE, V88, P481, DOI 10.1016/j.pbb.2007.10.005; Okuda K, 2003, EUR J ANAESTH, V20, P409, DOI 10.1097/00003643-200305000-00011; Pini LA, 1996, EUR J PHARMACOL, V308, P31, DOI 10.1016/0014-2999(96)00261-0; Pini LA, 1997, J PHARMACOL EXP THER, V280, P934; Poveda R, 2003, EUR J PAIN, V7, P439, DOI 10.1016/S1090-3801(03)00003-X; Raffa R, 2006, CLIN RHEUMATOL, V25, pS9, DOI 10.1007/s10067-006-0201-x; Ren K, 2002, PAIN, V100, P1, DOI 10.1016/S0304-3959(02)00368-8; Robinson DA, 2004, CURR NEUROVASC RES, V1, P11, DOI 10.2174/1567202043480189; Rojas-Corrales MO, 2003, EUR NEUROPSYCHOPHARM, V13, P355, DOI 10.1016/S0924-977X(03)00017-8; Romero A, 2010, PHARMACOL RES, V61, P511, DOI 10.1016/j.phrs.2010.02.011; Schreiber S, 2000, BEHAV BRAIN RES, V114, P51, DOI 10.1016/S0166-4328(00)00185-6; Schreiber S, 1999, NEUROSCI LETT, V273, P85, DOI 10.1016/S0304-3940(99)00627-8; Skinner Harry B, 2004, Am J Orthop (Belle Mead NJ), V33, P85; SKINNER HB, 2004, AM J ORTHOP, V33, P92; Sprott H, 2005, ANN RHEUM DIS, V64, P1522, DOI 10.1136/ard.2004.033712; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; TALLARIDA RJ, 1992, PAIN, V49, P93, DOI 10.1016/0304-3959(92)90193-F; Troster A, 2006, ANESTHESIOLOGY, V105, P1016; White PF, 2008, CURR OPIN INVEST DR, V9, P76	41	9	9	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	MAY	2011	98	3					331	336		10.1016/j.pbb.2011.01.023			6	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	756KV	WOS:000290011000001	21296105				2020-06-30	J	Hilty, L; Lutz, K; Maurer, K; Rodenkirch, T; Spengler, CM; Boutellier, U; Jancke, L; Amann, M				Hilty, Lea; Lutz, Kai; Maurer, Konrad; Rodenkirch, Tobias; Spengler, Christina M.; Boutellier, Urs; Jaencke, Lutz; Amann, Markus			Spinal opioid receptor-sensitive muscle afferents contribute to the fatigue-induced increase in intracortical inhibition in healthy humans	EXPERIMENTAL PHYSIOLOGY			English	Article							MOTOR-EVOKED-POTENTIALS; TRANSCRANIAL MAGNETIC STIMULATION; STATIC MUSCULAR-CONTRACTION; GROUP-III; SILENT PERIOD; DORSAL-HORN; POSTEXERCISE FACILITATION; CORTICAL EXCITABILITY; EXERCISE PERFORMANCE; INTRATHECAL FENTANYL	We investigated the influence of spinal opioid receptor-sensitive muscle afferents on cortical changes following fatiguing unilateral knee-extensor exercise. On separate days, seven subjects performed an identical five sets of intermittent isometric right-quadriceps contractions, each consisting of eight submaximal contractions [63 +/- 7% maximal voluntary contraction (MVC)] and one MVC. The exercise was performed following either lumbar interspinous saline injection or lumbar intrathecal fentanyl injection blocking the central projection of spinal opioid receptor-sensitive lower limb muscle afferents. To quantify exercise-induced peripheral fatigue, quadriceps twitch force (Q(tw,pot)) was assessed via supramaximal magnetic femoral nerve stimulation before and after exercise. Motor evoked potentials and cortical silent periods (CSPs) were evaluated via transcranial magnetic stimulation of the motor cortex during a 3% MVC pre-activation period immediately following exercise. End-exercise quadriceps fatigue was significant and similar in both conditions (delta Q(tw,pot) -35 and -39% for placebo and fentanyl, respectively; P = 0.38). Immediately following exercise on both days, motor evoked potentials were similar to those obtained prior to exercise. Compared with pre-exercise baseline, CSP in the placebo trial was 21 +/- 5% longer postexercise (P < 0.01). In contrast, CSP following the fentanyl trial was not significantly prolonged compared with the pre-exercise baseline (6 +/- 4%). Our findings suggest that the central effects of spinal opioid receptor-sensitive muscle afferents might facilitate the fatigue-induced increase in CSP. Furthermore, since the CSP is thought to reflect inhibitory intracortical interneuron activity, which may contribute to central fatigue, our findings imply that spinal opioid receptor-sensitive muscle afferents might influence central fatigue by facilitating intracortical inhibition.	[Amann, Markus] Univ Utah, VA Med Ctr, Dept Internal Med, Salt Lake City, UT 84148 USA; [Hilty, Lea; Rodenkirch, Tobias; Spengler, Christina M.; Boutellier, Urs] Univ Zurich, ETH Zurich, CH-8006 Zurich, Switzerland; [Hilty, Lea; Rodenkirch, Tobias; Spengler, Christina M.; Boutellier, Urs] Univ Zurich, Inst Physiol, CH-8006 Zurich, Switzerland; [Lutz, Kai; Jaencke, Lutz] Univ Zurich, Dept Neuropsychol, Inst Psychol, CH-8006 Zurich, Switzerland; [Maurer, Konrad] Univ Zurich Hosp, Inst Anesthesiol, Zurich, Switzerland	Amann, M (reprint author), Univ Utah, VA Med Ctr, Dept Internal Med, GRECC 182,500 Foothill Dr, Salt Lake City, UT 84148 USA.	markus.amann@hsc.utah.edu	Jancke, Lutz/C-3792-2009; Spengler, Christina M./E-9776-2012; Jancke, Lutz/D-2910-2013; Lutz, Kai/C-1433-2011	Jancke, Lutz/0000-0002-8115-4890; Spengler, Christina M./0000-0002-4598-3595; Jancke, Lutz/0000-0003-2110-9067; Lutz, Kai/0000-0002-5628-9611; Amann, Markus/0000-0002-4012-8880	GlaxoSmithKline consumer health careGlaxoSmithKline	We are grateful to our subjects for their time and effort during the study. We thank Beatrice Beck Schimmer, Iris Haner and Maria Schlumpf for their assistance during the investigation, and we thank Ulf Ziemann for his valuable feedback on the manuscript. We acknowledge Gabriela Senti and the Clinical Trials Center (CTC) Zurich for supporting our research by providing adequate laboratory space. This study was supported in part by GlaxoSmithKline consumer health care.	Amann M, 2008, J PHYSIOL-LONDON, V586, P161, DOI 10.1113/jphysiol.2007.141838; Amann M, 2007, J PHYSIOL-LONDON, V581, P389, DOI 10.1113/jphysiol.2007.129700; Amann M, 2006, J PHYSIOL-LONDON, V575, P937, DOI 10.1113/jphysiol.2006.113936; Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Amann M, 2008, J APPL PHYSIOL, V105, P1714, DOI 10.1152/japplphysiol.90456.2008; BESSE D, 1990, BRAIN RES, V521, P15, DOI 10.1016/0006-8993(90)91519-M; BESSE D, 1991, BRAIN RES, V548, P287, DOI 10.1016/0006-8993(91)91134-M; BIGLANDRITCHIE BR, 1986, J PHYSIOL-LONDON, V379, P451, DOI 10.1113/jphysiol.1986.sp016263; BRASILNETO J, 1993, EXP BRAIN RES, V93, P181; BRASILNETO JP, 1994, MUSCLE NERVE, V17, P713, DOI 10.1002/mus.880170702; Butler JE, 2007, J PHYSIOL-LONDON, V584, P651, DOI 10.1113/jphysiol.2007.134205; Cahen P, 2001, DYNAMIC TECHNICAL AN; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; CLASSEN J, 1995, ELECTROMYOGR MOTOR C, V97, P264, DOI 10.1016/0013-4694(95)00099-K; Cohen J., 1969, STAT POWER ANAL BEHA; Darques JL, 1998, NEUROSCI LETT, V257, P109; Darques JL, 1997, BRAIN RES, V750, P147, DOI 10.1016/S0006-8993(96)01341-8; DAVIES CTM, 1982, J APPL PHYSIOL, V53, P236; FUHR P, 1991, ELECTROEN CLIN NEURO, V81, P81, DOI 10.1016/0168-5597(91)90001-E; Gandevia SC, 1996, CLIN EXP PHARMACOL P, V23, P957, DOI 10.1111/j.1440-1681.1996.tb01148.x; Gandevia SC, 2001, PHYSIOL REV, V81, P1725; Gandevia SC, 1996, J PHYSIOL-LONDON, V490, P529, DOI 10.1113/jphysiol.1996.sp021164; Garland SJ, 1995, ADV EXP MED BIOL, V384, P271; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Grant GJ, 1996, J CLIN ANESTH, V8, P99, DOI 10.1016/0952-8180(95)00174-3; HILL JM, 1990, J APPL PHYSIOL, V68, P2466; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; KALIA M, 1981, CIRC RES, V48, P48; Kalliomaki J, 1998, PAIN, V77, P323, DOI 10.1016/S0304-3959(98)00115-8; Kalmar JM, 2006, J APPL PHYSIOL, V100, P1757, DOI 10.1152/japplphysiol.01347.2005; KAUFMAN MP, 1983, J APPL PHYSIOL, V55, P105; KNIFFKI KD, 1979, BRAIN RES, V160, P549, DOI 10.1016/0006-8993(79)91085-0; Kufel TJ, 2002, MUSCLE NERVE, V25, P438, DOI 10.1002/mus.10047; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Lentz M, 2002, CLIN NEUROPHYSIOL, V113, P1092, DOI 10.1016/S1388-2457(02)00031-7; Liepert J, 1996, MUSCLE NERVE, V19, P1429, DOI 10.1002/(SICI)1097-4598(199611)19:11<1429::AID-MUS7>3.0.CO;2-E; Light AR, 2008, J NEUROPHYSIOL, V100, P1184, DOI 10.1152/jn.01344.2007; Martin PG, 2008, J PHYSIOL-LONDON, V586, P1277, DOI 10.1113/jphysiol.2007.140426; Martin PG, 2006, J NEUROSCI, V26, P4796, DOI 10.1523/JNEUROSCI.5487-05.2006; Maruyama A, 2006, CLIN NEUROPHYSIOL, V117, P864, DOI 10.1016/j.clinph.2005.12.019; MCCLOSKE.DI, 1972, J PHYSIOL-LONDON, V224, P173, DOI 10.1113/jphysiol.1972.sp009887; McKay WB, 1996, MUSCLE NERVE, V19, P1017, DOI 10.1002/mus.880190803; MCKAY WB, 1995, EXP BRAIN RES, V105, P276, DOI 10.1007/BF00240963; McNeil CJ, 2009, J PHYSIOL-LONDON, V587, P5601, DOI 10.1113/jphysiol.2009.180968; MEINTJES AF, 1995, CIRC RES, V77, P326, DOI 10.1161/01.RES.77.2.326; MENSE S, 1988, NEUROSCIENCE, V26, P1023, DOI 10.1016/0306-4522(88)90117-0; Nybo L, 2004, PROG NEUROBIOL, V72, P223, DOI 10.1016/j.pneurobio.2004.03.005; POMEROY G, 1986, BRAIN RES, V381, P385, DOI 10.1016/0006-8993(86)90095-8; Sacco P, 2000, MUSCLE NERVE, V23, P1840, DOI 10.1002/1097-4598(200012)23:12<1840::AID-MUS7>3.0.CO;2-H; Sacco P, 1997, MUSCLE NERVE, V20, P1158, DOI 10.1002/(SICI)1097-4598(199709)20:9<1158::AID-MUS11>3.0.CO;2-P; Samii A, 1996, NEUROLOGY, V46, P1376, DOI 10.1212/WNL.46.5.1376; Schomburg ED, 1999, NEUROSCI RES, V33, P195, DOI 10.1016/S0168-0102(99)00006-1; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Shannon MT, 1998, J CLIN ANESTH, V10, P452, DOI 10.1016/S0952-8180(98)00058-0; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.0.CO;2-M; Standl TG, 2001, ANESTHESIOLOGY, V94, P230, DOI 10.1097/00000542-200102000-00011; Swenson JD, 2001, REGION ANESTH PAIN M, V26, P306, DOI 10.1053/ramp.2001.25069; Taylor JL, 2008, J APPL PHYSIOL, V104, P542, DOI 10.1152/japplphysiol.01053.2007; Taylor JL, 2006, CLIN EXP PHARMACOL P, V33, P400, DOI 10.1111/j.1440-1681.2006.04363.x; Taylor JL, 2000, J PHYSIOL-LONDON, V525, P793, DOI 10.1111/j.1469-7793.2000.00793.x; Taylor JL, 2000, J APPL PHYSIOL, V89, P305; Taylor JL, 1996, J PHYSIOL-LONDON, V490, P519, DOI 10.1113/jphysiol.1996.sp021163; Taylor JL, 2001, MUSCLE NERVE, V24, P18, DOI 10.1002/1097-4598(200101)24:1<18::AID-MUS2>3.0.CO;2-D; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; VOGT BA, 1995, EXP NEUROL, V135, P83, DOI 10.1006/exnr.1995.1069; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pharmtox.25.1.433; YAKSH TL, 1981, PAIN, V11, P293, DOI 10.1016/0304-3959(81)90633-3; ZANETTE G, 1995, EXP BRAIN RES, V107, P80	71	50	50	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0958-0670	1469-445X		EXP PHYSIOL	Exp. Physiol.	MAY 1	2011	96	5					505	517		10.1113/expphysiol.2010.056226			13	Physiology	Physiology	750CO	WOS:000289522100005	21317218				2020-06-30	J	Sarotti, D; Rabozzi, R; Corletto, F				Sarotti, Diego; Rabozzi, Roberto; Corletto, Federico			Efficacy and side effects of intraoperative analgesia with intrathecal bupivacaine and levobupivacaine: a retrospective study in 82 dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						bupivacaine; cardiovascular response; dog; intrathecal; locoregional anaesthesia; side effects incidence; spinal	FAILED SPINAL ANESTHETICS; RISK-FACTORS; MORPHINE; SURGERY; REQUIREMENTS; FENTANYL; STRESS	Objective To evaluate spinal (intrathecal) anaesthesia (SA) in addition to general anaesthesia in dogs, and report the incidence of side effects and cardiovascular response (CR) to surgery. Study design Retrospective clinical study. Animals One hundred and fifteen dogs undergoing general anaesthesia for surgery caudal to the diaphragm between 2005 and 2008. Methods Records of anaesthetized dogs that had received SA with bupivacaine or levobupivacaine 0.5%, together with morphine or fentanyl were reviewed. Success rate of SA, complication rate and incidence of CR were recorded and examined in relation to the dose of local anaesthetic administered and the type of surgery. Univariate and Cusum analysis were performed to identify independent predictors of response to surgical stimulation and characterize the learning curve for the technique, respectively. Results Eighty-two dogs received successful SA. The Cusum plot suggested that a failure rate of 10% is achieved when the procedure is performed more than 66 times. Median local anaesthetic dose related to weight was 0.40 mg kg-1 (0.3-0.5), and to spinal cord length 0.1 mg cm-1 (0.07-0.12). Morphine was added to the local anaesthetic in 56 and fentanyl in 22 dogs. CR post-stimulus occurred in 29 cases: 11 of 22 ovariohysterectomies, 14 of 33 hindlimb-surgeries, 2 of 10 caudal-abdominal-surgeries and 2 of 17 Caesarean sections. Anaesthetic dose related to weight was not a predictor of CR. Bradycardia occurred in seven, hypotension in 24, urinary retention in four and hypersalivation in 6 of 82 dogs. Conclusions SA was practicable to apply, but in this study did not totally block CR, Side effects were minimal, with an incidence similar to that in humans. Clinical relevance SA can be used in clinical cases with few side effects although monitoring of and ensuing treatment of hypotension is required. Comparative prospective studies are required to establish efficacy and a reliable dose.	[Sarotti, Diego] CVF, Fossano, CN, Italy; [Rabozzi, Roberto] Clin Vet Adriat, Vasto, Italy	Sarotti, D (reprint author), CVF, Via Cuneo 29-E,12045, Fossano, CN, Italy.	diego.sarotti@libero.it					Alley EA, 2002, ANESTH ANALG, V94, P188, DOI 10.1097/00000539-200201000-00036; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Bier A., 1899, DTSCH Z CHIR, V51, P361; Brull R, 2007, ANESTH ANALG, V104, P965, DOI 10.1213/01.ane.0000258740.17193.ec; BRUN-BUISSON V, 1988, Annales Francaises d'Anesthesie et de Reanimation, V7, P383, DOI 10.1016/S0750-7658(88)80054-6; Campoy L, 2004, IN PRACTICE, V26, P262; CARPENTER RL, 1992, ANESTHESIOLOGY, V76, P906, DOI 10.1097/00000542-199206000-00006; Cuille J, 1901, REV VET, V26, P98; Curatolo M, 1997, BRIT J ANAESTH, V78, P88; DRIPPS RD, 1954, JAMA-J AM MED ASSOC, V156, P1486, DOI 10.1001/jama.1954.02950160016005; Feliciano Terry, 2008, J Perianesth Nurs, V23, P394, DOI 10.1016/j.jopan.2008.09.006; Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012; GREENE BA, 1950, ANESTHESIOLOGY, V11, P464, DOI 10.1097/00000542-195007000-00009; GREENE NM, 1985, ANESTH ANALG, V64, P715; HOGSON PS, 1999, ANESTH ANALG, V88, P797; KEHLET H, 1991, CAN J SURG, V34, P565; Kona-Boun JJ, 2003, VET ANAESTH ANALG, V30, P257, DOI 10.1046/j.1467-2995.2003.00076.x; Konrad Christoph, 1998, Anesthesia and Analgesia, V86, P635, DOI 10.1097/00000539-199803000-00037; LEVY JH, 1985, ANESTH ANALG, V64, P705; Lingaraj K., 2007, SMJ Singapore Medical Journal, V48, P213; Malinovsky JM, 1999, ANESTHESIOLOGY, V91, P1260, DOI 10.1097/00000542-199911000-00016; McCartney WT, 1997, VET REC, V141, P417, DOI 10.1136/vr.141.16.417; MODIG J, 1988, ACTA ANAESTH SCAND, V32, P44, DOI 10.1111/j.1399-6576.1988.tb02842.x; Novello L, 2006, VET SURG, V35, P191, DOI 10.1111/j.1532-950X.2006.00131.x; Novello L, 2008, VET SURG, V37, P153, DOI 10.1111/j.1532-950X.2007.00358.x; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; SAMII K, 1981, BRIT J ANAESTH, V53, P817, DOI 10.1093/bja/53.8.817; SAROTTI D, 2005, VET REG ANAESTH PAIN, V3, P53; Schlotterbeck H, 2008, BRIT J ANAESTH, V100, P230, DOI 10.1093/bja/aem371; Sevarino Ferne, 2003, Curr Opin Anaesthesiol, V16, P249, DOI 10.1097/00001503-200306000-00001; SPROTTE G, 1987, Regional-Anaesthesie, V10, P104; TARKKILA PJ, 1991, REGION ANESTH, V16, P48; Troncy E, 2002, J AM VET MED ASSOC, V221, P666, DOI 10.2460/javma.2002.221.666; WEISSMAN C, 1990, ANESTHESIOLOGY, V73, P308, DOI 10.1097/00000542-199008000-00020; Williams RK, 2006, ANESTH ANALG, V102, P67, DOI 10.1213/01.ANE.0000159162.86033.21; WYNANDS JE, 1984, ANESTH ANALG, V63, P101	36	16	16	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2011	38	3					240	251		10.1111/j.1467-2995.2011.00608.x			12	Veterinary Sciences	Veterinary Sciences	750CI	WOS:000289521500010	21492390				2020-06-30	J	Jan, WC; Chen, CH; Hsu, K; Tsai, PS; Huang, CJ				Jan, Woan-Ching; Chen, Cay-Huyen; Hsu, Kuei; Tsai, Pei-Shan; Huang, Chun-Jen			L-Type Calcium Channels and mu-Opioid Receptors are Involved in Mediating the Anti-Inflammatory Effects of Naloxone	JOURNAL OF SURGICAL RESEARCH			English	Article						NF-kappa B; chemokine; cytokine; endotoxin; macrophages	NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; ENDOTOXIN-SHOCK; EXPRESSION; MACROPHAGES; CYTOKINE; INHIBITION; MORPHINE; RAT; STIMULATION	Background. We sought to elucidate the effects of naloxone on regulating the up-regulation of inflammatory molecules and activation of the transcription factor nuclear factor-kappaB (NF-kappa B) induced by endotoxin. Possible roles of the m-opioid receptors and L-type calcium channels in mediating the effects of naloxone in this regard were also investigated. Materials and Methods. RAW264.7 cells were treated with phosphate buffered saline, naloxone, lipopolysaccharide (LPS), LPS plus naloxone, LPS plus naloxone plus morphine (i.e., the nonselective opioid receptors agonist), LPS plus naloxone plus fentanyl (i.e., the m-opioid receptors agonist), or LPS plus naloxone plus BAY-K8644 (i.e., the L-type calcium channel activator). After harvesting, production of inflammatory molecules and expression NF-kappa B were evaluated. Results. The effects of LPS on inducing the upregulation of macrophage inflammatory protein-2, tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)1b, IL-6, nitric oxide/inducible nitric oxide synthase, and prostaglandin E-2/cyclooxygenase 2 were inhibited by naloxone. Naloxone also inhibited the effects of LPS on inducing NF-kappa B activation, including inhibitor-kappa B (I-kappa B) degradation, NF-kappa B nuclear translocation, and NF-kappa B-DNA binding. The effects of naloxone on inhibiting IL-1b up-regulation and NF-kappa B activation were enhanced by morphine. In contrast, the effects of naloxone on inhibiting IL-1b up-regulation and I-kappa B degradation were counteracted by fentanyl. Moreover, except for TNF-a, the effects of naloxone on inhibiting inflammatory molecules up-regulation and NF-kappa B activation were significantly counteracted by BAY-K8644. Conclusions. Naloxone significantly inhibited endotoxin-induced up-regulation of inflammatory molecules and NF-kappa B activation. The mechanisms may involve antagonizing the L-type calcium channels and, to a lesser extent, the m-opioid receptors. (C) 2011 Elsevier Inc. All rights reserved.	[Jan, Woan-Ching] Mackay Med Nursing & Management Coll, Dept Pharmacol, Taipei, Taiwan; [Hsu, Kuei] Tao Yuan Gen Hosp, Dept Anesthesiol, Tao Yuan, Taiwan; [Tsai, Pei-Shan] Taipei Med Univ, Grad Inst Nursing, Taipei, Taiwan; [Huang, Chun-Jen] Taipei Med Univ, Dept Pharmacol, Taipei, Taiwan; [Huang, Chun-Jen] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Chen, Cay-Huyen; Huang, Chun-Jen] Buddhist Tzu Chi Gen Hosp, Dept Anesthesiol, Taipei Branch, Taipei, Taiwan	Huang, CJ (reprint author), Buddhist Tzu Chi Gen Hosp, Dept Anesthesiol, Taipei Branch, 289 Jianguo Rd, Sindian City 231, Taipei County, Taiwan.	huangcj1112@gmail.com			Mackay Medicine, Nursing and Management College [MKC98R10]; National Science Council, TaiwanNational Science Council of Taiwan [NSC 96-2314-B-195-004-MY3]	This work was supported by grants from Mackay Medicine, Nursing and Management College (MKC98R10), and National Science Council, Taiwan (NSC 96-2314-B-195-004-MY3) awarded to W.-C.J and C.-J.H, respectively.	ALMQVIST P, 1983, ACTA CHIR SCAND, V149, P23; Azenabor AA, 2003, MED MICROBIOL IMMUN, V192, P99, DOI 10.1007/s00430-002-0164-8; Benamar K, 2007, J PHARMACOL EXP THER, V323, P990, DOI 10.1124/jpet.107.129973; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Cadet P, 2004, MED SCI MONITOR, V10, pMS28; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; CHUANG GJH, 1987, ARCH SURG-CHICAGO, V122, P940; Cunneen Jane, 2004, AACN Clin Issues, V15, P18, DOI 10.1097/00044067-200401000-00003; FADEN AI, 1980, J PHARMACOL EXP THER, V212, P441; Finley MJ, 2008, CELL IMMUNOL, V252, P146, DOI 10.1016/j.cellimm.2007.09.008; Huang YH, 2008, ACTA ANAESTH SCAND, V52, P530, DOI 10.1111/j.1399-6576.2008.01590.x; Huang YH, 2006, ANESTH ANALG, V102, P1739, DOI 10.1213/01.ANE.0000219593.15109.DB; IUVONE T, 1995, BIOCHEM BIOPH RES CO, V212, P975, DOI 10.1006/bbrc.1995.2065; Jones Edward, 2007, J Inflamm (Lond), V4, P23, DOI 10.1186/1476-9255-4-23; Kim OM, 2005, ARCH PHARM RES, V28, P699, DOI 10.1007/BF02969361; LAW WR, 1988, AM J PHYSIOL, V255, pH1106; MARTIN WR, 1976, ANN INTERN MED, V85, P765, DOI 10.7326/0003-4819-85-6-765; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; Nareika A, 2005, AM J PHYSIOL-ENDOC M, V289, pE534, DOI 10.1152/ajpendo.00462.2004; Park WK, 2009, ACTA ANAESTH SCAND, V53, P1043, DOI 10.1111/j.1399-6576.2009.02023.x; RAYMOND RM, 1981, SURG GYNECOL OBSTET, V152, P159; Roy S, 1998, MOL BRAIN RES, V61, P190, DOI 10.1016/S0169-328X(98)00212-5; Sirohi S, 2009, J PHARMACOL EXP THER, V330, P513, DOI 10.1124/jpet.109.152678; Szabo C, 1995, New Horiz, V3, P2; Tsai PS, 2006, ANESTHESIOLOGY, V105, P1201, DOI 10.1097/00000542-200612000-00020; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; Yan ZP, 2004, CELL IMMUNOL, V232, P116, DOI 10.1016/j.cellimm.2005.03.001; Zhou XY, 2006, J BIOL CHEM, V281, P31337, DOI 10.1074/jbc.M602739200	30	11	12	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY	2011	167	2					E263	E272		10.1016/j.jss.2010.03.039			10	Surgery	Surgery	748RG	WOS:000289407800026	20605582				2020-06-30	J	Alcock, R; Lowe, HC				Alcock, Richard; Lowe, Harry C.			Acute Leg Pain Due to Iliac Artery Spasm During Coronary Angiography: An Unusual Consequence of an Uncommon Problem	ANGIOLOGY			English	Letter							CATHETER-INDUCED VASOSPASM; CARDIAC-CATHETERIZATION		[Lowe, Harry C.] Concord Repatiat Gen Hosp, Dept Cardiol, Concord, NSW 2139, Australia; [Alcock, Richard; Lowe, Harry C.] Univ Sydney, Sydney, NSW 2006, Australia	Lowe, HC (reprint author), Concord Repatiat Gen Hosp, Dept Cardiol, Concord, NSW 2139, Australia.	h.lowe@bigpond.net.au					Ergene O, 1999, INT J CARDIAC IMAG, V15, P189, DOI 10.1023/A:1006179113054; Fukumoto Y, 2003, J AM COLL CARDIOL, V42, P211, DOI 10.1016/S0735-1097(03)00579-5; Gallagher C, 2006, ANGIOLOGY, V57, P115, DOI 10.1177/000331970605700117; Prasad A, 2008, J INTERV CARDIOL, V21, P61, DOI 10.1111/j.1540-8183.2007.00309.x	4	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-3197	1940-1574		ANGIOLOGY	Angiology	MAY	2011	62	4					350	351		10.1177/0003319710394165			2	Peripheral Vascular Disease	Cardiovascular System & Cardiology	746RJ	WOS:000289264100013	21421634				2020-06-30	J	Nomura, M; Kamata, M; Kojima, H; Hayashi, K; Kozai, M; Sawada, S				Nomura, Motoo; Kamata, Minoru; Kojima, Hiroyuki; Hayashi, Kenji; Kozai, Masasuke; Sawada, Satoshi			Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study	SUPPORTIVE CARE IN CANCER			English	Article						Cancer pain; Opioids; Fentanyl; Transdermal; Safety	OPIOID ROTATION; DELIVERY-SYSTEM; ANALGESIA; RESERVOIR; MORPHINE; TRIAL	The objective of the present prospective study was to compare the safety and efficacy of a 12-h method to a 6-h method in chronic cancer pain management. Randomized, prospective clinical trial was conducted between December 2007 and June 2009, enrolling 90 patients with chronic cancer pain. Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method). The parameters assessed in the present study included pain intensity (on a scale of 0 to 10) and bolus use frequency, and the adverse effects were assessed with National Cancer Institute Common Terminology Criteria for Adverse Events version 3. Pain intensity and the number of boluses during conversion remained stable in both arms. The incidence of adverse events was 25.6% in the 12-h method group and 2.3% in the 6-h method group (95% confidence interval, 0.01-0.55; p = 0.002). Adverse events occurred in four patients at 6-12 h, five patients at 12-18 h, two patients at 18-24 h, and one patient at 24-48 h after application. Excellent safety profile and sustained efficacy are shown for the 6-h conversion method.	[Nomura, Motoo; Kamata, Minoru; Kojima, Hiroyuki; Hayashi, Kenji; Kozai, Masasuke; Sawada, Satoshi] Kansai Med Univ, Dept Radiol, Osaka 5731191, Japan	Nomura, M (reprint author), Kansai Med Univ, Dept Radiol, 2-3-1 Shinmachi, Osaka 5731191, Japan.	excel@hkg.odn.ne.jp					BROOME IJ, 1995, ANAESTHESIA, V50, P300, DOI 10.1111/j.1365-2044.1995.tb04603.x; DECONNO F, 1994, PAIN, V57, P161, DOI 10.1016/0304-3959(94)90219-4; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Frolich M, 2001, ANESTH ANALG, V93, P647; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; HANKS GW, 1992, LANCET, V339, P1031; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; MISER AW, 1989, PAIN, V37, P15, DOI 10.1016/0304-3959(89)90148-6; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	17	4	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	MAY	2011	19	5					691	695		10.1007/s00520-010-0890-1			5	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	744PD	WOS:000289105600014	20549247				2020-06-30	J	Dzikiti, TB; Stegmann, GF; Dzikiti, LN; Hellebrekers, LJ				Dzikiti, T. B.; Stegmann, G. F.; Dzikiti, L. N.; Hellebrekers, L. J.			Effects of fentanyl on isoflurane minimum alveolar concentration and cardiovascular function in mechanically ventilated goats	VETERINARY RECORD			English	Article							ANESTHETIC POTENCY; BISPECTRAL INDEX; HALOTHANE; MAC; REMIFENTANIL; HYPNOSIS; HORSES	The effects of fentanyl on the minimum alveolar concentration (MAC) of isoflurane and cardiovascular function in mechanically ventilated goats were evaluated using six healthy goats (three does and three wethers). Following induction of general anaesthesia with isoflurane delivered via a mask, endotracheal intubation was performed and anaesthesia was maintained with isoflurane. The baseline MAC of isoflurane (that is, the lowest alveolar concentration required to prevent gross purposeful movement) in response to clamping a claw with a vulsellum forceps was determined. Immediately after baseline isoflurane MAC determination, the goats received, on separate occasions, one of three fentanyl treatments, administered intravenously: a bolus of 0.005 mg/kg followed by constant rate infusion (CRI) of 0.005 mg/kg/hour (treatment LFENT), a bolus of 0.015 mg/kg followed by CRI of 0.015 mg/kg/hour (treatment MFENT) or a bolus of 0.03 mg/kg followed by CRI of 0.03 mg/kg/hour (treatment HFENT). Isoflurane MAC was redetermined during the fentanyl CRI treatments. Cardiopulmonary parameters were monitored. A four-week washout period was allowed between treatments. The observed baseline isoflurane MAC was 1.32 (1.29 to 1.36) per cent. Isoflurane MAC decreased to 0.98 (0.92 to 1.01) per cent, 0.75 (0.69 to 0.79) per cent and 0.58 (0.51 to 0.65) per cent following LFENT, MFENT and HFENT respectively. Cardiovascular function was not adversely affected. The quality of recovery from general anaesthesia was good, although exaggerated tail-wagging was observed in some goats following MFENT and HFENT.	[Dzikiti, T. B.; Stegmann, G. F.] Univ Pretoria, Dept Compan Anim Clin Studies, ZA-0110 Onderstepoort, South Africa; [Dzikiti, L. N.] Univ Pretoria, Sch Hlth Syst & Publ Hlth, ZA-0002 Pretoria, South Africa; [Hellebrekers, L. J.] Univ Utrecht, Fac Vet Med, Div Neurophysiol & Anaesthesiol, NL-3508 TD Utrecht, Netherlands	Dzikiti, TB (reprint author), Univ Pretoria, Dept Compan Anim Clin Studies, Post Bag X04, ZA-0110 Onderstepoort, South Africa.	brighton.dzikiti@up.ac.za	Dzikiti, T/N-8696-2014	Stegmann, George/0000-0002-6732-5980; Stegmann, Frik/0000-0002-6122-4847; Dzikiti, Tarisai Brighton/0000-0002-8050-8597	University of Pretoria; South African Veterinary Foundation (SAVF) (laboratory costs); Fresenius Kabi South Africa (propofol and lactated Ringer's); University of Pretoria - Utrecht University Memorandum of Understanding (UP-UU)	This study was jointly funded by the University of Pretoria, the South African Veterinary Foundation (SAVF) (laboratory costs), Fresenius Kabi South Africa (propofol and lactated Ringer's) and the University of Pretoria - Utrecht University Memorandum of Understanding (UP-UU) MSc/PhD Research Fund (purchase and husbandry of the goats). The authors thank Lebo Sentle and Monicca Ngobeni of the University of Pretoria Biomedical Centre, for providing technical support for the research.	Andel H, 2000, CAN J ANAESTH, V47, P81, DOI 10.1007/BF03020739; ANTOGNINI JF, 1993, LAB ANIM SCI, V43, P607; Antognini JF, 2000, VET RES COMMUN, V24, P361, DOI 10.1023/A:1006400315247; Antognini JF, 2002, BRIT J ANAESTH, V89, P156, DOI 10.1093/bja/aef156; Ayo JO, 1999, RES VET SCI, V66, P7, DOI 10.1053/rvsc.1998.0231; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Carroll GL, 1999, AM J VET RES, V60, P986; Criado AB, 2003, VET ANAESTH ANALG, V30, P250, DOI 10.1046/j.1467-2995.2003.00123.x; Doherty TJ, 2004, VET ANAESTH ANALG, V31, P97, DOI 10.1111/j.1467-2987.2004.00156.x; Doherty TJ, 2002, J VET PHARMACOL THER, V25, P65, DOI 10.1046/j.1365-2885.2002.00371.x; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; Hikasa Y, 1998, CAN J VET RES, V62, P299; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; Larsen M, 1998, BRIT J ANAESTH, V80, P634; Meredith James R, 2008, J Emerg Trauma Shock, V1, P88, DOI 10.4103/0974-2700.43189; MERKEL G, 1963, ANESTHESIOLOGY, V24, P346, DOI 10.1097/00000542-196305000-00016; MOON PF, 1995, ANESTHESIOLOGY, V83, P535, DOI 10.1097/00000542-199509000-00012; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; Satas S, 1996, ACTA ANAESTH SCAND, V40, P452, DOI 10.1111/j.1399-6576.1996.tb04468.x; Shibutani K, 1999, J Anesth, V13, P209, DOI 10.1007/s005400050059; Thomasy SM, 2006, BRIT J ANAESTH, V97, P232, DOI 10.1093/bja/ael116; Valverde A, 2005, J VET EMERG CRIT CAR, V15, P295, DOI 10.1111/j.1476-4431.2005.00168.x; Wilson D, 2006, JAVMA-J AM VET MED A, V228, P1042, DOI 10.2460/javma.228.7.1042	23	9	10	0	8	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND	0042-4900			VET REC	Vet. Rec.	APR 23	2011	168	16								10.1136/vr.d999			5	Veterinary Sciences	Veterinary Sciences	762FB	WOS:000290458000016	21493442				2020-06-30	J	Yuan, RM; Zhang, XW; Deng, QA; Wu, YA; Xiang, GF				Yuan, Ruimei; Zhang, Xianwei; Deng, Qian; Wu, Yuan; Xiang, Guifang			Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery	CLINICA CHIMICA ACTA			English	Article						Gene polymorphism; CYP3A4; Fentanyl; HPLC	CYTOCHROME-P-450 3A4; ALLELIC VARIANTS; CYP3A4; DISPOSITION	Purpose: This study aimed to investigate the impact of CYP3A4*1G genetic polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Methods: 176 patients receiving elective lower abdominal surgery under general anesthesia were recruited into this study. Genotyping of CYP3A4*1G was carried out by direct sequencing. The plasma fentanyl concentration was detected 30 min after anesthesia induction by high performance liquid chromatography-ultraviolet ray (HPLC-UV). The visual analog scale (VAS) was used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment Oh, 12 h and 24 h after operation. PCA fentanyl consumption and adverse effects were recorded during the first 24 h after surgery. Results: The frequency of CYP3A4*1G variant allele was 0.227 (80/352, 95% Cl 0.165, 0.289) in these patients. After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8 +/- 6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8 +/- 9.0 ng/ml, P < 0.01) and the *1G/*1G group (28.1 +/- 9.5 ng/ml, P < 0.01). Patients in the *1G/*1G group (247.1 +/- 73.2 mu g) consumed significantly less fentanyl than that in either the wild-type group (395.0 +/- 138.5 mu g) or the *1/*1G group (359.8 +/- 120.2 mu g) (P < 0.01). There was a significant correlation between plasma fentanyl concentration and PCA fentanyl consumption (r = -0.552, P < 0.001). Conclusions: CYP3A4*1G polymorphism is related to the pharmacokinetics of fentanyl, and patients with CYP3A4*1G variant A allele have a lower metabolic rate of fentanyl. The specific CYP3A4*1G polymorphism may predict the individual requirement of fentanyl. (C) 2011 Elsevier B.V. All rights reserved.	[Yuan, Ruimei; Zhang, Xianwei; Deng, Qian; Wu, Yuan; Xiang, Guifang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Anesthesiol, Wuhan 430030, Peoples R China	Zhang, XW (reprint author), 1095 JieFang Rd, Wuhan 430030, Peoples R China.	znpain@sina.com			Janssen Research Council of China	This work was partly supported by the Janssen Research Council of China, 2008.	AGRAWAL V, 2010, PHARMACOGENET G 0806; Cole Joanna M, 2010, J Opioid Manag, V6, P29; Du J, 2010, J PSYCHOPHARMACOL, V24, P1115, DOI 10.1177/0269881109104932; Du J, 2007, CLIN CHIM ACTA, V383, P172, DOI 10.1016/j.cca.2007.04.027; Du J, 2006, PHARMACOGENOMICS, V7, P831, DOI 10.2217/14622416.7.6.831; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Fukushima-Uesaka Hiromi, 2004, Hum Mutat, V23, P100, DOI 10.1002/humu.9210; Gao Y, 2008, EUR J CLIN PHARMACOL, V64, P877, DOI 10.1007/s00228-008-0502-x; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Hu YF, 2007, XENOBIOTICA, V37, P315, DOI 10.1080/00498250601149206; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Lamba JK, 2002, PHARMACOGENETICS, V12, P121, DOI 10.1097/00008571-200203000-00006; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Qiu H, 2010, PHARMACOGENET GENOM, V20, P167, DOI 10.1097/FPC.0b013e328336bbeb; Sata F, 2000, CLIN PHARMACOL THER, V67, P48, DOI 10.1067/mcp.2000.104391; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Tateishi T, 1996, ANESTH ANALG, V82, P167; Tsai MH, 2010, PHARMACOGENOMICS, V11, P537, DOI [10.2217/pgs.09.168, 10.2217/PGS.09.168]; Wandel C, 2000, CLIN PHARMACOL THER, V68, P82, DOI 10.1067/mcp.2000.108506; Wolf CE, 2005, J ANAL TOXICOL, V29, P711, DOI 10.1093/jat/29.7.711; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4; Zhao L, 1997, Sheng Li Ke Xue Jin Zhan, V28, P35	28	31	41	1	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	APR 11	2011	412	9-10					755	760		10.1016/j.cca.2010.12.038			6	Medical Laboratory Technology	Medical Laboratory Technology	738IW	WOS:000288634500013	21223952				2020-06-30	J	Zheng, H; Chu, J; Zhang, YH; Loh, HH; Law, PY				Zheng, Hui; Chu, Ji; Zhang, Yuhan; Loh, Horace H.; Law, Ping-Yee			Modulating mu-Opioid Receptor Phosphorylation Switches Agonist-dependent Signaling as Reflected in PKC epsilon Activation and Dendritic Spine Stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTINS; LIPID RAFTS; KINASE-C; MORPHINE; INTERNALIZATION; DESENSITIZATION; TOLERANCE; MEMBRANE; BINDING	A new role of G protein-coupled receptor (GPCR) phosphorylation was demonstrated in the current studies by using the mu-opioid receptor (OPRM1) as a model. Morphine induces a low level of receptor phosphorylation and uses the PKC epsilon pathway to induce ERK phosphorylation and receptor desensitization, whereas etorphine, fentanyl, and [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin (DAMGO) induce extensive receptor phosphorylation and use the beta-arrestin2 pathway. Blocking OPRM1 phosphorylation (by mutating Ser(363), Thr(370) and Ser(375) to Ala) enabled etorphine, fentanyl, and DAMGO to use the PKC epsilon pathway. This was not due to the decreased recruitment of beta-arrestin2 to the receptor signaling complex, because these agonists were unable to use the PKC epsilon pathway when beta-arrestin2 was absent. In addition, overexpressing G protein-coupled receptor kinase 2 (GRK2) decreased the ability of morphine to activate PKC epsilon, whereas overexpressing dominant-negative GRK2 enabled etorphine, fentanyl, and DAMGO to activate PKC epsilon. Furthermore, by overexpressing wild-type OPRM1 and a phosphorylation-deficient mutant in primary cultures of hippocampal neurons, we demonstrated that receptor phosphorylation contributes to the differential effects of agonists on dendritic spine stability. Phosphorylation blockage made etorphine, fentanyl, and DAMGO function as morphine in the primary cultures. Therefore, agonist-dependent phosphorylation of GPCR regulates the activation of the PKC pathway and the subsequent responses.	[Zheng, Hui; Chu, Ji; Zhang, Yuhan; Loh, Horace H.; Law, Ping-Yee] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; [Zheng, Hui] Chinese Acad Sci, Stem Cell & Canc Biol Grp, S China Inst Stem Cell Biol & Regenerat Med, Key Lab Regenerat Biol,Guangzhou Inst Biomed & Hl, Guangzhou 510530, Guangdong, Peoples R China	Zheng, H (reprint author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zhenhui2055@hotmail.com		Zheng, Hui/0000-0001-6801-0529; Law, Ping-Yee/0000-0002-5364-1093	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA007339, DA016674, DA000564, DA011806]	This work was supported, in whole or in part, by National Institutes of Health Grants DA007339, DA016674, DA000564, and DA011806.	Cen B, 2001, MOL PHARMACOL, V59, P758; Chae JH, 2004, MOL CELLS, V18, P271; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; Chu J, 2008, CELL SIGNAL, V20, P1616, DOI 10.1016/j.cellsig.2008.05.004; Chu J, 2010, CELL SIGNAL, V22, P684, DOI 10.1016/j.cellsig.2009.12.003; Debic HH, 2005, J NEUROSCI, V25, P7847, DOI 10.1523/JNEUROSCI.5045-04.2005; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kobayashi H, 2005, CELL SIGNAL, V17, P1248, DOI 10.1016/j.cellsig.2004.12.014; Koch T, 2005, MOL PHARMACOL, V67, P280, DOI 10.1124/mol.104.004994; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; Lan HX, 2009, MOL PHARMACOL, V75, P113, DOI 10.1124/mol.108.050534; Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li JL, 2003, J BIOL CHEM, V278, P30219, DOI 10.1074/jbc.M302385200; Liao D, 2005, P NATL ACAD SCI USA, V102, P1725, DOI 10.1073/pnas.0406797102; Liao D, 2007, MOL CELL NEUROSCI, V35, P456, DOI 10.1016/j.mcn.2007.04.007; Lin H, 2009, NEUROPSYCHOPHARMACOL, V34, P2097, DOI 10.1038/npp.2009.34; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Macey TA, 2005, J NEUROCHEM, V93, P128, DOI 10.1111/j.1471-4159.2004.02998.x; Metaye T, 2005, CELL SIGNAL, V17, P917, DOI 10.1016/j.cellsig.2005.01.002; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; Smith FL, 2007, PAIN, V127, P129, DOI 10.1016/j.pain.2006.08.009; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wess J, 1997, FASEB J, V11, P346; Xu C, 2010, J CELL SCI, V123, P4259, DOI 10.1242/jcs.073742; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2008, MOL PHARMACOL, V73, P178, DOI 10.1124/mol.107.039842; Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607; Zheng H, 2010, J NEUROSCI, V30, P8102, DOI 10.1523/JNEUROSCI.6069-09.2010; Zheng H, 2010, IUBMB LIFE, V62, P112, DOI 10.1002/iub.293; Zheng H, 2010, MOL PHARMACOL, V77, P102, DOI 10.1124/mol.109.060848	42	34	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2011	286	14								10.1074/jbc.M110.177089			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	744EN	WOS:000289077500083	21292762	Bronze, Green Published			2020-06-30	J	Santos, P; Watkinson, AC; Hadgraft, J; Lane, ME				Santos, P.; Watkinson, A. C.; Hadgraft, J.; Lane, M. E.			Enhanced permeation of fentanyl from supersaturated solutions in a model membrane	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Supersaturation; Fentanyl; Permeation; Silicone; Propylene glycol; Ethanol	HYDROCORTISONE ACETATE; TRANSDERMAL DELIVERY; NARCOTIC ANALGESICS; DRUG-DELIVERY; TRANSPORT; SKIN; SUFENTANIL; POLYMERS	The aim of the present study was to investigate the permeation of fentanyl from supersaturated formulations when applied to silicone membrane. Silicone was chosen in order to separate the effects of supersaturation from other possible influences of volatile formulation components on biological membranes. Supersaturated formulations containing either propylene glycol/water (PG/H2O) or propylene glycol/ethanol (PG/Et) were prepared containing varying degrees of saturation (DS) of fentanyl. Permeation of finite and infinite doses of the PG/H2O formulations, and finite doses of the PG/Et formulations was investigated using Franz-type diffusion cells. For the PG/H2O formulations a good correlation between the flux and the DS of the formulation up to 5 DS for infinite dose studies (r(2) = 0.99), and up to 7 DS for finite dose studies (r(2) = 0.98), was evident. Similarly, for the PG/Et formulations there is a good correlation between the mean flux and the theoretical DS of the formulation (r(2) = 0.95). Except for the 2 DS formulations, no significant differences were seen in the mean flux between PG/H2O and PG/Et finite dose studies. The larger fluxes observed for infinite doses of the PG/H2O formulations versus finite doses reflect changes in the effective area of diffusion over the time of the experiment for the latter set of experiments. The permeation enhancement observed for PG/Et formulations confirms that enhanced drug thermodynamic activity was induced by ethanol evaporation. (C) 2011 Elsevier B.V. All rights reserved.	[Santos, P.; Hadgraft, J.; Lane, M. E.] Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England; [Watkinson, A. C.] Acrux Ltd, W Melbourne, Vic 3003, Australia	Lane, ME (reprint author), Univ London, Sch Pharm, Dept Pharmaceut, 29-39 Brunswick Sq, London WC1N 1AX, England.	majella.lane@btinternet.com	Hadgraft, Jonathan/D-6184-2013				BARRY B W, 1987, Journal of Controlled Release, V6, P85, DOI 10.1016/0168-3659(87)90066-6; Davis A. F., 1993, PHARM SKIN PENETRATI, P243; DAVIS AF, 1991, INT J PHARM, V76, P1, DOI 10.1016/0378-5173(91)90337-N; Guy RH, 1996, PHARMACEUT RES, V13, P1765, DOI 10.1023/A:1016060403438; Hadgraft J, 2004, EUR J PHARM BIOPHARM, V58, P291, DOI 10.1016/j.ejpb.2004.03.002; Hadgraft J, 2001, INT J PHARM, V224, P1, DOI 10.1016/S0378-5173(01)00731-1; Hou H, 2006, J PHARM SCI-US, V95, P896, DOI 10.1002/jps.20600; Iervolino M, 2000, INT J PHARM, V198, P229, DOI 10.1016/S0378-5173(00)00346-X; PELLETT MA, 1994, INT J PHARM, V111, P1, DOI 10.1016/0378-5173(94)90395-6; Raghavan SL, 2000, INT J PHARM, V193, P231, DOI 10.1016/S0378-5173(99)00345-2; Raghavan SL, 2001, INT J PHARM, V212, P213, DOI 10.1016/S0378-5173(00)00610-4; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Santos P, 2009, INT J PHARMACEUT, V377, P70, DOI 10.1016/j.ijpharm.2009.05.002; Schwarb FP, 1999, PHARMACEUT RES, V16, P909, DOI 10.1023/A:1018890422825; Smith E.W., 1995, PERCUTANEOUS PENETRA, P481; Vanbever R, 1999, ADV DRUG DELIVER REV, V35, P77, DOI 10.1016/S0169-409X(98)00064-7; Watkinson RM, 2009, SKIN PHARMACOL PHYS, V22, P225, DOI 10.1159/000231528; Yum S., 1994, V62, P143	20	25	25	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	APR 4	2011	407	1-2					72	77		10.1016/j.ijpharm.2011.01.025			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	740FQ	WOS:000288777400009	21256946				2020-06-30	J	Bisbal, M; Arnal, JM; Passelac, A; Sallee, M; Demory, D; Donati, SY; Granier, I; Corno, G; Durand-Gasselin, J				Bisbal, M.; Arnal, J. -M.; Passelac, A.; Sallee, M.; Demory, D.; Donati, S. -Y.; Granier, I.; Corno, G.; Durand-Gasselin, J.			Efficacy, safety and cost of sedation with sevoflurane in intensive care unit	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article						Sedation; Intensive care unit; Sevoflurane	ANESTHETIC-CONSERVING-DEVICE; CRITICALLY-ILL PATIENTS; CEREBRAL BLOOD-FLOW; INTRACRANIAL-PRESSURE; SURGERY PATIENTS; ISOFLURANE; MIDAZOLAM; PROPOFOL; ELECTROENCEPHALOGRAM; DESFLURANE	Objectives. - To study efficacy, systemic and cerebral haemodynamic, and cost of sedation with sevoflurane after midazolam failure. Study design. - Prospective observational study in a mixed intensive care unit. Patients and methods. - Mechanically ventiled patients in whom deep sedation failed (Ramsay score < 5 despite midazolam 10 mg/h and fentanyl 400 mu g/h) were enrolled. Sedation with sevoflurane and fentanyl (200 mu g/h) was performed during 48 hours. Sevoflurane was administered with a dedicated filter (AnaConDa (TM)) and sevoflurane infusion rate was adjusted in order to achieve a Ramsay score >= 5. Ramsay score, mean arterial blood pressure, norepinephrine dose/24 h, intracranial pressure and cerebral perfusion pressure in patients with brain injury were measured. Directs costs for sedation were calculated. An analysis of variance for repeated measures compared values between DO (intravenous sedation), D1 and D2 (inhaled sedation). Results. - Twenty-five patients (age = 51 [38-63], SAPS II = 43 [33-49]) were enrolled. Ramsay score was 4[4.5] at D0 and 6 [6] at D1 and D2 (P < 0.05 vs D0). Mean arterial pressure was significantly lower at D1 (80[73-86] mmHg) as compared to D0 (84 [77-92] mmHg) and D2 (84 [78-91] mmHg) (P < 0.05). Norepinephrine consumption was lower at D2 as compared to D1 (P < 0.05). Intracranial pressure was lower at D1 (9 [5-13] mmHg) and D2 (11 [7-15] mmHg) as compared to D0(12 [7-17] mmHg)(P < 0.05). PPC was stable at D1 and increased at D2. Directs costs were significantly increased with sevoflurane. Conclusion. - Sevoflurane is an effective and safe alternative to midazolam in ICU patients associated with a moderate increase in costs. (C) 2011 Elsevier Masson SAS. All rights reserved.	[Bisbal, M.; Arnal, J. -M.; Demory, D.; Donati, S. -Y.; Granier, I.; Corno, G.; Durand-Gasselin, J.] Hop Font Pre, Serv Reanimat Polyvalente, F-83000 Toulon, France; [Passelac, A.] Hop Font Pre, Serv Pharm Cent, F-83000 Toulon, France; [Sallee, M.] Hop La Concept, Serv Pharm Nephrol, F-13005 Marseille, France; [Bisbal, M.] Hop La Timone, F-13385 Marseille 05, France	Bisbal, M (reprint author), Hop Font Pre, Serv Reanimat Polyvalente, 1208 Ave Colonel Picot, F-83000 Toulon, France.	magalibisbal@gmail.com		BISBAL, MAGALI/0000-0001-6571-0861			ARNAL JM, 2008, INTENS CARE MED, V34, P539; Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; Belda JF, 2008, ANESTH ANALG, V106, P1207, DOI 10.1213/ane.0b013e31816782ff; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Cammarano WB, 1998, CRIT CARE MED, V26, P676, DOI 10.1097/00003246-199804000-00015; De Hert SG, 2002, ANESTHESIOLOGY, V97, P42, DOI 10.1097/00000542-200207000-00007; de Wit Marjolein, 2007, BMC Anesthesiol, V7, P3, DOI 10.1186/1471-2253-7-3; Drummond M, 2005, METHODS EC EVALUATIO; Fraga M, 2003, ANESTHESIOLOGY, V98, P1085, DOI 10.1097/00000542-200305000-00010; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Kaisti KK, 2002, ANESTHESIOLOGY, V96, P1358, DOI 10.1097/00000542-200206000-00015; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; L'Her E, 2008, RESP CARE, V53, P1295; Lenz C, 1998, ANESTHESIOLOGY, V89, pU216; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; MATTA BF, 1995, ANESTHESIOLOGY, V83, P980, DOI 10.1097/00000542-199511000-00011; Meiser A, 2005, BEST PRACT RES-CLIN, V19, P523, DOI 10.1016/j.bpa.2005.02.006; Migliari M, 2009, INTENS CARE MED, V35, P1240, DOI 10.1007/s00134-009-1414-7; Park WK, 1996, ANESTHESIOLOGY, V84, P1166, DOI 10.1097/00000542-199605000-00019; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rohm KD, 2008, INTENS CARE MED, V34, P1683, DOI 10.1007/s00134-008-1157-x; Saeki Y, 1996, ANESTH ANALG, V82, P342, DOI 10.1097/00000539-199602000-00023; Sauder P, 2008, ANN FR ANESTH, V27, P541, DOI 10.1016/j.annfar.2008.04.021; SCHELLER MS, 1988, ANESTHESIOLOGY, V68, P548, DOI 10.1097/00000542-198804000-00012; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Soukup J, 2009, J CRIT CARE, V24, P535, DOI 10.1016/j.jcrc.2009.01.003; SPENCER EM, 1992, INTENS CARE MED, V18, P415, DOI 10.1007/BF01694344; Sturesson LW, 2009, BRIT J ANAESTH, V102, P470, DOI 10.1093/bja/aep019; Suchyta MR, 2008, INTENS CARE MED, V34, P2264, DOI 10.1007/s00134-008-1263-9	31	5	6	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0750-7658			ANN FR ANESTH	Ann. Fr. Anest. Reanim.	APR	2011	30	4					335	341		10.1016/j.annfar.2011.01.019			7	Anesthesiology	Anesthesiology	756ZA	WOS:000290052100003	21411266				2020-06-30	J	Wang, LZ; Hu, XX; Liu, X; Qian, P; Ge, JM; Tang, BL				Wang, Li-Zhong; Hu, Xiao-Xia; Liu, Xia; Qian, Ping; Ge, Jia-Mei; Tang, Bei-Lei			Influence of epidural dexamethasone on maternal temperature and serum cytokine concentration after labor epidural analgesia	INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS			English	Article						Analgesia; Dexamethasone; Epidural; Fever; Labor pain	INTRAPARTUM FEVER; PLACENTAL INFLAMMATION; MEPERIDINE ANALGESIA; CONTROLLED-TRIAL; TERM; DELIVERY	Objective: To evaluate the effects of epidural dexamethasone on maternal temperature and serum cytokine levels after labor epidural analgesia. Methods: Sixty healthy term nulliparas in spontaneous labor were randomized to receive epidural analgesia alone using bupivacaine 0.125% and fentanyl 1 mu g/mL (group I) or epidural analgesia combined with dexamethasone 0.2 mg/mL (group II) (n=30 per group). Maternal tympanic temperature was measured before epidural analgesia and hourly thereafter until delivery. Maternal and cord venous blood were sampled for analysis of interleukin-6 (IL-6), tumor necrosis factor-alpha, and interleukin-10 levels. Results: There was no difference in the incidence of intrapartum fever (38 degrees C or more) between the 2 groups (3/30 versus 1/30, P = 0.612). The mean maternal temperature increased with time in group I, with the elevation reaching statistical significance at 4 hours post analgesia and at delivery compared with baseline (P = 0.012 and P = 0.043, respectively). A similar trend was observed with maternal serum IL-6 levels in group I. In group II, maternal temperature and IL-6 levels did not differ from baseline at any time point during labor. Conclusion: Epidural dexamethasone alleviates maternal temperature elevation after epidural analgesia. This effect can be attributed to the decrease in IL-6 levels. (C) 2011 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.	[Wang, Li-Zhong; Hu, Xiao-Xia; Tang, Bei-Lei] Jiaxing Matern & Child Hlth Care Hosp, Dept Anesthesiol, Jiaxing 314000, Zhejiang, Peoples R China; [Liu, Xia; Ge, Jia-Mei] Jiaxing Matern & Child Hlth Care Hosp, Dept Obstet, Jiaxing 314000, Zhejiang, Peoples R China; [Qian, Ping] Jiaxing Matern & Child Hlth Care Hosp, Dept Pathol, Jiaxing 314000, Zhejiang, Peoples R China	Wang, LZ (reprint author), Jiaxing Matern & Child Hlth Care Hosp, Dept Anesthesiol, Jiaxing 314000, Zhejiang, Peoples R China.	jxlzw@sina.com					Dashe JS, 1999, OBSTET GYNECOL, V93, P341, DOI 10.1016/S0029-7844(98)00415-3; DeJongh RF, 1997, ACTA ANAESTH SCAND, V41, P853, DOI 10.1111/j.1399-6576.1997.tb04800.x; Evron S, 2007, J CLIN ANESTH, V19, P168, DOI 10.1016/j.jclinane.2006.10.013; FUSI L, 1989, LANCET, V1, P1250, DOI 10.1016/S0140-6736(89)92341-6; Goetzl L, 2002, AM J OBSTET GYNECOL, V187, P834, DOI 10.1067/mob.2002.127135; Goetzl L, 2007, OBSTET GYNECOL, V109, P687, DOI 10.1097/01.AOG.0000255976.14297.f6; Goetzl L, 2006, AM J OBSTET GYNECOL, V195, P1031, DOI 10.1016/j.ajog.2006.06.012; Impey L, 2001, BRIT J OBSTET GYNAEC, V108, P594, DOI 10.1016/S0306-5456(00)00145-5; Khafagy HF, 2010, J ANESTH, V24, P531, DOI 10.1007/s00540-010-0949-7; Lieberman E, 2000, PEDIATRICS, V105, P8, DOI 10.1542/peds.105.1.8; Lieberman E, 1997, PEDIATRICS, V99, P415, DOI 10.1542/peds.99.3.415; Mantha VRR, 2008, INT J OBSTET ANESTH, V17, P123, DOI 10.1016/j.ijoa.2007.07.006; SALAFIA CM, 1989, OBSTET GYNECOL, V73, P383; Sharma SK, 2002, ANESTHESIOLOGY, V96, P546, DOI 10.1097/00000542-200203000-00007; Smulian JC, 2003, AM J OBSTET GYNECOL, V188, P269, DOI 10.1067/mob.2003.11; Thomas S, 2006, CAN J ANAESTH, V53, P899, DOI 10.1007/BF03022833; Vallejo MC, 2001, CAN J ANAESTH, V48, P1122, DOI 10.1007/BF03020380; Wang YL, 1997, ANESTH ANALG, V84, P376, DOI 10.1097/00000539-199702000-00025	18	22	27	2	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0020-7292			INT J GYNECOL OBSTET	Int. J. Gynecol. Obstet.	APR	2011	113	1					40	43		10.1016/j.ijgo.2010.10.026			4	Obstetrics & Gynecology	Obstetrics & Gynecology	756KL	WOS:000290010000008	21306709				2020-06-30	J	Gunusen, I; Karaman, S; Sargin, A; Firat, V				Gunusen, Ilkben; Karaman, Semra; Sargin, Asuman; Firat, Vicdan			A randomized comparison of different doses of intrathecal levobupivacaine combined with fentanyl for elective cesarean section: prospective, double-blinded study	JOURNAL OF ANESTHESIA			English	Article						Levobupivacaine; Fentanyl; Combined spinal-epidural anesthesia; Cesarean section	SPINAL-EPIDURAL ANESTHESIA; RACEMIC BUPIVACAINE; PLAIN SOLUTIONS; ROPIVACAINE; DELIVERY; SURGERY; HYPOTENSION; SUFENTANIL; POSITION; TRIAL	Levobupivacaine may produce a sensory and motor block different from that produced by bupivacaine, which is the most popular local anesthetic in parturients undergoing cesarean section. The aim of this study was to investigate the block characteristics, the clinical efficacy, surgeon and patient satisfaction, and hemodynamic effects of using different doses of intrathecal plain levobupivacaine combined with fentanyl. One hundred twenty women undergoing elective cesarean section with a combined spinal-epidural technique were enrolled. The parturients were randomly assigned to receive one of the following: levobupivacaine 5 mg (group 5), 7.5 mg (group 7.5) or 10 mg (group 10), all combined with fentanyl 25, 15 or 10 mu g, respectively. Anesthesia was effective in 60, 82.5 and 100% of the patients in the levobupivacaine 5, 7.5 and 10 mg groups, respectively. Levobupivacaine 10 mg provided longer durations of analgesia and motor block and greater patient and surgeon satisfaction, although the incidence of hypotension was lower in groups 5 and 7.5 than in group 10 (12.5, 17.5 and 42.5%, respectively). Intraoperative epidural supplementation was higher in group 5 than in group 7.5 (40 and 17.5%, respectively), whereas no patients in group 10 were given an epidural bolus dose. The incidence of hypotension was higher in the levobupivacaine 10 mg group, even though this group presented more effective anesthesia and greater patient and surgeon satisfaction compared with the levobupivacaine 5 and 7.5 mg groups. As a result, we believe that levobupivacaine 7.5 mg combined with fentanyl 15 mu g is suitable for combined spinal-epidural anesthesia in elective cesarean section.	[Gunusen, Ilkben; Karaman, Semra; Sargin, Asuman; Firat, Vicdan] Ege Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-35100 Izmir, Turkey	Gunusen, I (reprint author), Ege Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-35100 Izmir, Turkey.	ilkben.gunusen@ege.edu.tr; semra.karaman@ege.edu.tr; asuozdemir@hotmail.com; vicdan.firat@ege.edu.tr	Sargin, Asuman/T-7242-2018	Sargin, Asuman/0000-0003-1606-1548			Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Bremerich DH, 2007, ANAESTHESIST, V56, P772, DOI 10.1007/s00101-007-1201-1; Brizzi A, 2005, Minerva Anestesiol, V71, P701; Camorcia M, 2007, ANESTH ANALG, V104, P904, DOI 10.1213/01.ane.0000256912.54023.79; Casati A, 2005, BEST PRACT RES-CLIN, V19, P247, DOI 10.1016/j.bpa.2004.12.003; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; Coppejans H C, 2006, Acta Anaesthesiol Belg, V57, P39; Coppejans HC, 2006, ANESTH ANALG, V102, P243, DOI 10.1213/01.ane.0000189049.11005.26; Cuvas O, 2009, ANAESTHESIA, V64, P14, DOI 10.1111/j.1365-2044.2008.05680.x; Cuvas Ozgun, 2010, Middle East Journal of Anesthesiology, V20, P547; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Dyer Robert A, 2004, Curr Opin Anaesthesiol, V17, P301, DOI 10.1097/01.aco.0000137088.29861.64; Erdil F, 2009, ANAESTHESIA, V64, P942, DOI 10.1111/j.1365-2044.2009.05995.x; Gautier P, 2003, BRIT J ANAESTH, V91, P684, DOI 10.1093/bja/aeg251; Glaser C, 2002, ANESTH ANALG, V94, P194, DOI 10.1097/00000539-200201000-00037; Goel S, 2003, EUR J ANAESTH, V20, P294, DOI 10.1097/00003643-200304000-00004; Guasch E, 2010, REV ESP ANEST REANIM, V57, P267, DOI 10.1016/S0034-9356(10)70226-7; Hocking G, 2004, BRIT J ANAESTH, V93, P568, DOI 10.1093/bja/aeh204; Kansal A, 2005, ANAESTHESIA, V60, P28, DOI 10.1111/j.1365-2044.2004.03994.x; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Lee YY, 2005, EUR J ANAESTH, V22, P899, DOI 10.1017/S0265021505001523; Leo S, 2009, ANESTH ANALG, V109, P1600, DOI 10.1213/ANE.0b013e3181b72d35; Luck JF, 2008, BRIT J ANAESTH, V101, P705, DOI 10.1093/bja/aen250; Malinovsky JM, 1999, ANESTHESIOLOGY, V91, P1260, DOI 10.1097/00000542-199911000-00016; McClellan KJ, 1998, DRUGS, V56, P355, DOI 10.2165/00003495-199856030-00005; Milligan KR, 2004, EUR J ANAESTH, V21, P837, DOI 10.1017/S0265021504000158; Parpaglioni R, 2006, ANAESTHESIA, V61, P110, DOI 10.1111/j.1365-2044.2005.04380.x; Parpaglioni R, 2009, ACTA ANAESTH SCAND, V53, P1214, DOI 10.1111/j.1399-6576.2009.02033.x; Sen H, 2010, MINERVA ANESTESIOL, V76, P24; VANGESSEL EF, 1991, ANESTH ANALG, V72, P779	31	8	11	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2011	25	2					205	212		10.1007/s00540-011-1097-4			8	Anesthesiology	Anesthesiology	749CU	WOS:000289440500008	21298294				2020-06-30	J	Silbermann, M				Silbermann, Michael			Current Trends in Opioid Consumption Globally and in Middle Eastern Countries	JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY			English	Article						opioid consumption; global consumption; opioid availability	PAIN	The overall consumption of opioids globally and in Middle Eastern countries has been in the rise during the past 3 decades. However, whereas the consumption of opiates (Morphine) increased by 19.8% that of the synthetic opioids (Fentanyl) increased by 31.1% for the same time period. This trend increased even further during the period 2004-2008: Morphine 16.6% vs. Fentanyl 45.2%. One possible explanation to this phenomenon, especially in developing countries is the notion that many patients and their families still believe that Morphine hasten death. The impressive rise in the consumption of Fentanyl might be associated with the fact that this drug in contrast to Morphine, might not be as directly related to "opioids" as Morphine.	Middle E Canc Consortium MECC, Haifa, Israel	Silbermann, M (reprint author), Middle E Canc Consortium MECC, Haifa, Israel.	cancer@mecc-research.com					Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; Human Rights Watch, PLEAS DO NOT MAK US; *INT ASS STUD PAIN, ED TRAIN PAIN MAN DE; *MAYD FUND, NAT PAN SOUNDS AL LA; *MED NEWS, MORPH CANC PAIN REL; OVERLAND MA, 2010, YAHOO NEWS TIME 0607; Silbermann M, 2010, ASCO ED BOOK, P217; Silbermann M, 2010, ASIAN PAC J CANCER P, V11, P1; SZALAVITZ M, 2010, TIME            0224	10	9	9	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1077-4114	1536-3678		J PEDIAT HEMATOL ONC	J. Pediatr. Hematol. Oncol.	APR	2011	33			1			S1	S5		10.1097/MPH.0b013e3182121872			5	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	748ZC	WOS:000289430900001	21448027				2020-06-30	J	Mandel, L; Carunchio, MJ				Mandel, Louis; Carunchio, Michele J.			Rampant caries from oral transmucosal fentanyl citrate lozenge abuse	JOURNAL OF THE AMERICAN DENTAL ASSOCIATION			English	Article						Fentanyl citrate; caries; sucrose; opioid	SUCROSE; PAIN; SUGARS	Background. Oral transmucosal fentanyl citrate lozenges (lollipops) are indicated for the oral management of breakthrough cancer pain. When abused, these sucrose-containing lozenges can cause rampant dental caries. Case Description The authors examined a 19-year-old man whose dentist referred him because of total dental coronal destruction. After the authors questioned the patient, they concluded that his frequent oral use of sucrose-containing opioid fentanyl citrate lozenges across a three-year period caused the dental condition. Clinical Implications. Dentists should be aware that oral transmucosal fentanyl citrate lozenges are being prescribed off-label for the control of pain from nonmalignant sources. Fentanyl citrate's effective analgesic potency can lead to misuse and potential abuse. Early recognition of its misuse could prevent severe dental caries and the need for extensive dental restoration.	[Mandel, Louis; Carunchio, Michele J.] Columbia Univ, Coll Dent Med, Salivary Gland Ctr, New York, NY 10027 USA; [Mandel, Louis] Columbia Univ, Coll Dent Med, Div Oral & Maxillofacial Surg, New York, NY USA	Mandel, L (reprint author), Columbia Univ, Coll Dent Med, Salivary Gland Ctr, 630 W 168th St, New York, NY 10027 USA.						Aires CP, 2006, CARIES RES, V40, P28, DOI 10.1159/000088902; *CEPH, 2009, ACT PACK INS; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Dawes C, 2008, J AM DENT ASSOC, V139, p18S, DOI 10.14219/jada.archive.2008.0351; Fine P G, 1998, J Palliat Med, V1, P55, DOI 10.1089/jpm.1998.1.55; GEE S, 2007, 68 ANN ASS TECHN EXH; Gotrick B, 2004, J DENT RES, V83, P393, DOI 10.1177/154405910408300508; GUSTAFSSON BENGT E., 1954, ACTA ODONT SCAND, V11, P232; Hara AT, 2006, J DENT RES, V85, P612, DOI 10.1177/154405910608500706; Kreth J, 2008, ORAL MICROBIOL IMMUN, V23, P213, DOI 10.1111/j.1399-302X.2007.00413.x; Landy SH, 2004, HEADACHE, V44, P762, DOI 10.1111/j.1526-4610.2004.04142.x; Leme AFP, 2006, J DENT RES, V85, P878, DOI 10.1177/154405910608501002; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Marshall TA, 2007, J AM DENT ASSOC, V138, P39, DOI 10.14219/jada.archive.2007.0019; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Moore P A, 2000, Anesth Prog, V47, P29; Mystakidou K, 2007, INT J NANOMED, V2, P49, DOI 10.2147/nano.2007.2.1.49; Passik SD, 2007, PAIN MED, V8, P130, DOI 10.1111/j.1526-4637.2006.00295.x; ROLLA G, 1989, SCAND J DENT RES, V97, P115; STEPHAN R. M., 1940, JOUR AMER DENTAL ASSOC, V27, P718; STEPHAN RM, 1944, J DENT RES, V23, P251; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Wolff Mark Steven, 2009, Braz. oral res., V23, P31, DOI 10.1590/S1806-83242009000500006; Zero DT, 2004, CARIES RES, V38, P277, DOI 10.1159/000077767	24	5	5	0	5	AMER DENTAL ASSOC	CHICAGO	211 E CHICAGO AVE, CHICAGO, IL 60611 USA	0002-8177	1943-4723		J AM DENT ASSOC	J. Am. Dent. Assoc.	APR	2011	142	4					406	409		10.14219/jada.archive.2011.0195			4	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	749EU	WOS:000289447200015	21454846				2020-06-30	J	Silva, A; Ferreira, DA; Venancio, C; Souza, AP; Antunes, LM				Silva, A.; Ferreira, D. A.; Venancio, C.; Souza, A. P.; Antunes, L. M.			Performance of electroencephalogram-derived parameters in prediction of depth of anaesthesia in a rabbit model	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia, depth; anaesthetics volatile, isoflurane; monitoring, depth of anaesthesia; monitoring, electroencephalography	BISPECTRAL INDEX; PERMUTATION ENTROPY; PROPOFOL ANESTHESIA; APPROXIMATE ENTROPY; SEVOFLURANE; ISOFLURANE; CONSCIOUSNESS; REMIFENTANIL; VALIDATION; DESFLURANE	Background. The index of consciousness (IoC), the permutation entropy (PE), and the approximate entropy are recent EEG-derived indices of anaesthetic depth. In this study, a rabbit model under fentanyl and isoflurane anaesthesia was used to compare the performance of these indices and also the classic median and spectral edge frequency 95%. Methods. EEG recordings were obtained from six rabbits. Animals received fentanyl for premedication, followed by induction with propofol and maintenance with isoflurane. Anaesthetic depth was evaluated according to a clinical scale from 1 (awake) to 4 (surgical anaesthesia). Animals were submitted to surgical implantation of a small device in the lumbar muscles. A correction factor for the EEG suppression ratio was applied to the spectral parameters and to the PE. The correlation of the indices with the clinical scale of anaesthesia was analysed using prediction probability. Repeated-measures analysis of variance or its non-parametric equivalent was used to analyse the indices values at the study times and to compare their variability. Results. The IoC showed the best mean prediction probability value [0.94 (0.01)] followed by burst suppression-corrected PE [0.91(0.03)]. Both parameters also showed less variability than the others. Conclusions. The IoC and PE are promising indices for anaesthetic depth monitoring. The PE might benefit from the application of a burst suppression correction at deeper stages of anaesthesia. The rabbit is useful as a translational research animal model for the validation of clinical indices.	[Silva, A.; Ferreira, D. A.; Venancio, C.; Antunes, L. M.] Univ Tras Os Montes & Alto Douro, Dept Vet Sci, Vila Real, Portugal; [Souza, A. P.] Univ Fed Campina Grande, Ctr Saude Tecnol Rural, Patos de Minas, PB, Brazil	Silva, A (reprint author), Univ Tras Os Montes & Alto Douro, Dept Vet Sci, Vila Real, Portugal.	aurasilva@utad.pt	Silva, Aura/D-4784-2013; Venancio, Carlos/K-4748-2015; Ferreira, David/M-8832-2013	Silva, Aura/0000-0002-2044-6320; Venancio, Carlos/0000-0003-3880-3442; Ferreira, David/0000-0002-9720-3140; Antunes, Luis/0000-0002-9757-6879	Fundacao para a Ciencia e Tecnologia (Portugal)Portuguese Foundation for Science and Technology [PTDC/EEA-ACR/69288/2006]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil)CAPES	Aura Silva was funded by Fundacao para a Ciencia e Tecnologia (Portugal) (project PTDC/EEA-ACR/69288/2006). Almir Souza was supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil).	Antunes LM, 2003, EUR J ANAESTH, V20, P800, DOI 10.1097/00003643-200310000-00005; Antunes LM, 2003, VET ANAESTH ANALG, V30, P15, DOI 10.1046/j.1467-2995.2003.00085.x; Bruhn J, 2000, ANESTHESIOLOGY, V92, P715, DOI 10.1097/00000542-200003000-00016; BULLOCK TH, 2004, BRAINWAVES MIND RECE, P3; Coetzee JF, 1996, BRIT J ANAESTH, V76, P415; HARTIKAINEN K, 1995, ACTA ANAESTH SCAND, V39, P814, DOI 10.1111/j.1399-6576.1995.tb04176.x; Ihmsen H, 2008, ANESTHESIOLOGY, V108, P276, DOI 10.1097/01.anes.0000300074.04200.b1; Jeleazcov C, 2007, BRIT J ANAESTH, V99, P845, DOI 10.1093/bja/aem275; Jensen EW, 2008, IEEE ENG MED BIO, P5552, DOI 10.1109/IEMBS.2008.4650472; Jordan D, 2008, ANESTHESIOLOGY, V109, P1014, DOI 10.1097/ALN.0b013e31818d6c55; KORTELAINEN J, 2009, C P IEEE ENG MED BIO, V1, P4994; Kortelainen J, 2009, ANESTHESIOLOGY, V111, P574, DOI 10.1097/ALN.0b013e3181af633c; Li XL, 2008, ANESTHESIOLOGY, V109, P448, DOI 10.1097/ALN.0b013e318182a91b; Martin-Cancho MF, 2006, LAB ANIM-UK, V40, P28, DOI 10.1258/002367706775404462; Olofsen E, 2008, BRIT J ANAESTH, V101, P810, DOI 10.1093/bja/aen290; Palanca BA, 2009, CURR OPIN ANESTHESIO, V22, P553, DOI 10.1097/ACO.0b013e3283304032; RAMPIL IJ, 1988, ANESTHESIOLOGY, V69, P298, DOI 10.1097/00000542-198809000-00002; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Rehberg B, 2008, ANESTH ANALG, V107, P117, DOI 10.1213/ane.0b013e31816f1965; Revuelta M, 2008, BRIT J ANAESTH, V101, P653, DOI 10.1093/bja/aen245; Schwender D, 1996, BRIT J ANAESTH, V77, P179, DOI 10.1093/bja/77.2.179; Silva A, 2010, ANESTHESIOLOGY, V112, P355, DOI 10.1097/ALN.0b013e3181ca3196; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; Takamatsu I, 2006, BRIT J ANAESTH, V96, P620, DOI 10.1093/bja/ael050; Vahle-Hinz C, 2002, BRIT J ANAESTH, V89, P123, DOI 10.1093/bja/aef166; Vanluchene ALG, 2004, BRIT J ANAESTH, V93, P645, DOI 10.1093/bja/aeh251; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; Vaughan DJA, 2000, BRIT J ANAESTH, V85, P705, DOI 10.1093/bja/85.5.705	28	14	15	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	APR	2011	106	4					540	547		10.1093/bja/aeq407			8	Anesthesiology	Anesthesiology	737KD	WOS:000288566800015	21296767	Bronze			2020-06-30	J	Song, JW; Park, EY; Lee, JG; Park, YS; Kang, BC; Shim, YH				Song, J. W.; Park, E. Y.; Lee, J. G.; Park, Y. S.; Kang, B. C.; Shim, Y. H.			The effect of combining dexamethasone with ondansetron for nausea and vomiting associated with fentanyl-based intravenous patient-controlled analgesia	ANAESTHESIA			English	Article							POSTOPERATIVE NAUSEA; LAPAROSCOPIC CHOLECYSTECTOMY; PREVENTION; COMBINATION; ANESTHESIA; SURGERY; HYSTERECTOMY; PROPHYLAXIS; MORPHINE; PAIN	P>We investigated whether combined dexamethasone and ondansetron is more effective than ondansetron alone in preventing postoperative nausea and vomiting in patients with fentanyl-based intravenous patient-controlled analgesia. One hundred and thirty patients undergoing video-assisted thoracoscopic surgery were assigned to either an ondansetron group or a dexamethasone and ondansetron group. In all patients, ondansetron 4 mg was administered at the end of surgery and 12 mg was added to the patient-controlled analgesia solution. The dexamethasone and ondansetron group received dexamethasone 8 mg at the induction of anaesthesia. The overall incidence of nausea and vomiting during the first 48 h postoperatively did not differ between groups (34/61 (56%) vs 28/62 (45%) in the ondansetron group and dexamethasone and ondansetron groups, respectively). The incidence of severe nausea and vomiting (>= 7 nausea on an 11-point verbal numerical rating scale, retching or vomiting) was higher in the ondansetron group than in the dexamethasone and ondansetron group (15/61 (25%) vs 6/62 (10%, respectively, p = 0.028). Combined dexamethasone and ondansetron is more effective in reducing severe nausea and vomiting than ondansetron alone in patients receiving fentanyl-based intravenous patient-controlled analgesia.	[Song, J. W.; Park, Y. S.; Shim, Y. H.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med & Anaesthesia, Seoul, South Korea; [Song, J. W.; Park, Y. S.; Shim, Y. H.] Yonsei Univ, Coll Med, Pain Res Inst, Seoul, South Korea; [Park, E. Y.] Hallym Univ, Coll Med, Sacred Heart Hosp Pyeongchon, Dept Anaesthesiol & Pain Med, Kyonggi Do, South Korea; [Lee, J. G.] Yonsei Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Seoul, South Korea; [Kang, B. C.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul, South Korea	Shim, YH (reprint author), Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med & Anaesthesia, Seoul, South Korea.	tren125@yuhs.ac		Song, Jong Wook/0000-0001-7518-2070; Shim, Yon Hee/0000-0003-1921-3391			AAPRO MS, 1981, NEW ENGL J MED, V305, P520; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Bano F, 2008, JCPSP-J COLL PHYSICI, V18, P265, DOI 05.2008/JCPSP.265269; Boonmak P, 2007, EUR J ANAESTH, V24, P664, DOI 10.1017/S0265021507000208; BUNCE KT, 1992, BRIT J ANAESTH, V69, pS60, DOI 10.1093/bja/69.supplement_1.60S; Choi YS, 2008, SPINE, V33, pE602, DOI 10.1097/BRS.0b013e31817c6bde; Elhakim M, 2002, CAN J ANAESTH, V49, P922, DOI 10.1007/BF03016875; Erhan Y, 2008, SURG ENDOSC, V22, P1487, DOI 10.1007/s00464-007-9656-3; Fischer GW, 2010, CURR OPIN ANESTHESIO, V23, P7, DOI 10.1097/ACO.0b013e3283346c6d; Fujii Y, 2010, SURG ENDOSC, V24, P692, DOI 10.1007/s00464-009-0657-2; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; HELMERS JHJH, 1993, CAN J ANAESTH, V40, P1155; Jokela RM, 2009, ANESTH ANALG, V109, P607, DOI 10.1213/ane.0b013e3181ac0f5c; Kardash KJ, 2008, ANESTH ANALG, V106, P1253, DOI 10.1213/ANE.0b013e318164f319; KEHLET H, 2002, J AM COLL SURGEONS, V195, P694; Kim JM, 2009, MOVEMENT DISORD, V24, pS13; Kim SW, 2008, EUR NEUROPSYCHOPHARM, V18, pS423, DOI 10.1016/S0924-977X(08)70619-9; Kjetil H, 2007, ANESTH ANALG, V105, P481, DOI 10.1213/01.ane.0000267261.61444.69; Kontrimaviciute E, 2005, EUR J ANAESTH, V22, P504, DOI 10.1017/S0265021505000864; Leksowski K, 2006, SURG ENDOSC, V20, P878, DOI 10.1007/s00464-005-0622-7; LopezOlaondo L, 1996, BRIT J ANAESTH, V76, P835; MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005; MITCHELSON F, 1992, DRUGS, V43, P295, DOI 10.2165/00003495-199243030-00002; Nesek-Adam V, 2007, SURG ENDOSC, V21, P607, DOI 10.1007/s00464-006-9122-7; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; SINATRA R, 1989, ANESTHESIOLOGY, V71, P502, DOI 10.1097/00000542-198910000-00005; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023	27	28	29	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	APR	2011	66	4					263	267		10.1111/j.1365-2044.2011.06648.x			5	Anesthesiology	Anesthesiology	735AN	WOS:000288385800005	21401538				2020-06-30	J	Andresen, T; Upton, RN; Foster, DJR; Christrup, LL; Arendt-Nielsen, L; Drewes, AM				Andresen, Trine; Upton, Richard N.; Foster, David J. R.; Christrup, Lona L.; Arendt-Nielsen, Lars; Drewes, Asbjorn M.			Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS; HEALTHY-VOLUNTEERS; HYPERALGESIA; ALLODYNIA; NORBUPRENORPHINE; PHARMACOLOGY; ANALGESICS; OPIOIDS; SAFETY	Pharmacokinetic/pharmacodynamic (PK/PD) modelling can be used to characterize the relationship between dose regimen of opioids, plasma concentration and effect of opioids, which in turn can lead to more rational treatment regimens of pain. The aim of this study was to investigate the concentration-effect relationship for transdermal buprenorphine and fentanyl in experimentally induced pain. Twenty-two healthy volunteers were randomized to receive transdermal patches with fentanyl (25 mu g/hr, 72 hr), buprenorphine (20 mu g/hr, 144 hr) or placebo. The experimental pain tests were pressure at the tibial bone, cutaneous thermal stimulation, cold pressor test (conditioning stimulus (3 +/- 0.3 degrees C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia. Experiments were carried out at baseline, 24, 48, 72 and 144 hr after application of patches. Time-course of placebo was described first and was afterwards added to the description of the time-courses of buprenorphine and fentanyl. This was either described by zero (no drug effect), linear or E-max model concentration-effect relationships. Time-dependent changes in pain measures in the placebo arm were described by linear or quadratic functions. The time-course of fentanyl and buprenorphine plasma concentrations was complex but could be represented by cubic spline interpolation in the models. Buprenorphine significantly attenuated bone-associated pain, heat pain, nerve growth factor-induced soreness and cold pressor pain. Fentanyl significantly attenuated cold pressor pain for the administered dose regimens. Although the PK/PD relationship for both drugs could be described with similar models, tissue-differentiated analgesic effects between buprenorphine and fentanyl was shown.	[Andresen, Trine; Drewes, Asbjorn M.] Aarhus Univ Hosp, Dept Gastroenterol, Aalborg Hosp, DK-9000 Aalborg, Denmark; [Andresen, Trine; Arendt-Nielsen, Lars; Drewes, Asbjorn M.] Aarhus Univ Hosp, Ctr Sensory Motor Interact SMI, Dept Hlth Sci & Technol, Aarhus, Denmark; [Upton, Richard N.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia; [Christrup, Lona L.] Univ Copenhagen, Dept Pharmacol & Pharmacotherapy, Fac Pharmaceut Sci, DK-1168 Copenhagen, Denmark	Drewes, AM (reprint author), Aarhus Univ Hosp, Dept Gastroenterol, Aalborg Hosp, Mollepk Vej 4, DK-9000 Aalborg, Denmark.	drewes@hst.aau.dk	Foster, David J R/D-1172-2011; Arendt-Nielsen, Lars/T-4885-2018; Upton, Richard N/G-4727-2011	Upton, Richard N/0000-0001-9996-4886; Christrup, Lona/0000-0002-4128-7373; Arendt-Nielsen, Lars/0000-0003-0892-1579; Drewes, Asbjorn/0000-0001-7465-964X; Foster, David/0000-0002-7345-4084	Mundipharma Research GmbH Co	Mundipharma Research GmbH & Co is acknowledged for supporting this study with an unrestricted grant. There are no conflicts of interests for all authors.	Arendt-Nielsen L, 2007, CURR OPIN INVEST DR, V8, P41; BOUHASSIRA D, 1993, EUR J PHARMACOL, V3, P207; Brown MB, 2006, DRUG DELIV, V13, P175, DOI 10.1080/10717540500455975; Cavero I, 2007, EXPERT OPIN DRUG SAF, V6, P465, DOI 10.1517/14740338.6.4.465; Curatolo M, 2000, ANESTHESIOLOGY, V93, P1517, DOI 10.1097/00000542-200012000-00025; Dahan A, 2006, BRIT J ANAESTH, V96, P627, DOI 10.1093/bja/ael051; Drewes AM, 2003, EUR J PAIN, V7, P539, DOI 10.1016/S1090-3801(03)00053-3; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; HAMILTON RC, 1967, BRIT J ANAESTH, V39, P490, DOI 10.1093/bja/39.6.490; Huang P, 2001, J PHARMACOL EXP THER, V297, P688; HULL CJ, 1978, BRIT J ANAESTH, V50, P1113, DOI 10.1093/bja/50.11.1113; Jensen ML, 2007, XENOBIOTICA, V37, P441, DOI 10.1080/00498250701251126; Jensen ML, 2008, BASIC CLIN PHARMACOL, V103, P94, DOI 10.1111/j.1742-7843.2008.00250.x; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Koltzenburg M, 2006, PAIN, V126, P165, DOI 10.1016/j.pain.2006.06.028; Kress HG, 2009, EUR J PAIN, V13, P219, DOI 10.1016/j.ejpain.2008.04.011; LE BD, 1981, BRAIN RES, V2, P257; Liu MW, 1998, J PAIN SYMPTOM MANAG, V16, P10, DOI 10.1016/S0885-3924(98)00026-8; Lotsch JR, 2005, J PAIN SYMPTOM MANAG, V29, pS90, DOI 10.1016/j.jpainsymman.2005.01.012; Meibohm B, 1997, INT J CLIN PHARM TH, V35, P401; Negus SS, 2006, J PHARMACOL EXP THER, V319, P507, DOI 10.1124/jpet.106.106377; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; OHTANI M, 1995, J PHARMACOL EXP THER, V272, P505; Olesen AE, 2010, CLIN PHARMACOKINET, V49, P817, DOI 10.2165/11536610-000000000-00000; PONTANI RB, 1985, XENOBIOTICA, V15, P287, DOI 10.3109/00498258509045363; Scanlon GC, 2006, J INVEST MED, V54, P238, DOI 10.2310/6650.2006.05046; SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358; Sittl R, 2005, CLIN THER, V27, P1022, DOI 10.1016/j.clinthera.2005.06.024; Staahl C, 2004, BASIC CLIN PHARMACOL, V95, P97; Staahl C, 2009, BRIT J CLIN PHARMACO, V68, P149, DOI 10.1111/j.1365-2125.2009.03456.x; Suri A, 1997, INT J CLIN PHARM TH, V35, P307; Svensson P, 2003, PAIN, V104, P241, DOI 10.1016/S0304-3959(03)00012-5; TOREBJORK HE, 1992, J PHYSIOL-LONDON, V448, P765, DOI 10.1113/jphysiol.1992.sp019069; Walsh SL, 2003, DRUG ALCOHOL DEPEN, V70, pS13, DOI 10.1016/S0376-8716(03)00056-5; WILLER JC, 1990, EUR J PHARMACOL, V182, P347, DOI 10.1016/0014-2999(90)90293-F; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; Yassen A, 2006, ANESTHESIOLOGY, V104, P1232, DOI 10.1097/00000542-200606000-00019; Yue Hongfei, 2005, Journal of Pharmacological and Toxicological Methods, V52, P314, DOI 10.1016/j.vascn.2005.04.012; 2006, NONMEM USER S GUIDES	40	21	21	1	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	APR	2011	108	4					274	284		10.1111/j.1742-7843.2010.00649.x			11	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	737DH	WOS:000288548400008	21138531				2020-06-30	J	Nalamachu, SR; Narayana, A; Janka, L				Nalamachu, S. R.; Narayana, A.; Janka, L.			Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrought pain; Fentanyl buccal tablet; Long-term pain treatment; Long-term safety; Opioids	CLINICAL-PRACTICE GUIDELINE; DOUBLE-BLIND; CANCER PAIN; AMERICAN ACADEMY; TREATED PATIENTS; BACK-PAIN; PREVALENCE; RELEASE; US; PRESCRIPTIONS	To evaluate the long-term dosing, safety, and tolerability of fentanyl buccal tablet (FBT) in a large cohort of opioid-tolerant patients with chronic noncancer pain and breakthrough pain (BTP). Combined analysis of three double-blind, placebo-controlled, and two open-label studies. Of 1160 patients who received epsilon a parts per thousand yen1 dose of FBT, 83%% achieved a successful dose, ranging from 100 to 800 mu mu g, mostly at 600 or 800 mu mu g. Not all of the patients included in this analysis were enrolled in long-term studies and 156 (13%%) patients were still receiving ongoing treatment when their study site closed. Median treatment duration was 106.0 days. The mean FBT dose in the post-titration population (n == 946) increased from 2108 to 3132 mu mu g/day, with epsilon a parts per thousand yen1 FBT dose increase in 27%% of patients; most dose increases occurred during the first 6 months. The FBT daily dose as a proportion of the daily opioid dose remained fairly stable (59--65%%) throughout the treatment period. Overall, 925 (80%%) enrolled patients had epsilon a parts per thousand yen1 adverse event (AE). The most frequent AEs were nausea (21%% of patients), vomiting (11%%), dizziness (10%%), and headache (10%%). Common AEs generally occurred within 7 days of starting treatment and lasted for a parts per thousand currency sign2 days. Serious AEs occurred in 136 (12%%) patients and included six deaths (none related to FBT) and 11 instances of opioid overdose (all with satisfactory resolution). AE-related discontinuations occurred in 163 (14%%) patients and were similar to the common AEs. Despite the limitations, including the controlled clinical setting, this pooled analysis of several clinical studies provides valuable information for the long-term management of BTP with FBT. Patients require regular evaluation and, when necessary, adjustment of opioid medications to maintain adequate pain control. FBT was generally safe and well tolerated in this setting.	[Nalamachu, S. R.] Midamer Physiatrists, Overland Pk, KS 66211 USA; [Narayana, A.; Janka, L.] Cephalon Inc, Frazer, PA USA	Nalamachu, SR (reprint author), Midamer Physiatrists, 11120 Tomahawk Creek Pkwy, Overland Pk, KS 66211 USA.	nalamachu@yahoo.com			Cephalon, Inc. (Frazer, PA, USA); Cephalon, Inc.	This analysis was sponsored by Cephalon, Inc. (Frazer, PA, USA).; Writing support for the preparation of this manuscript was provided by David Peters, MSc; funding for this support was provided by Cephalon, Inc.	Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Farrar JT, 2010, PAIN MED, V11, P1313, DOI 10.1111/j.1526-4637.2010.00939.x; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Kalso E, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-39; Katz N, 2007, CURR MED RES OPIN, V23, P117, DOI 10.1185/030079906X162692; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; MURPHY K, 2009, J PAIN S1, V10, pS58; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Olsen Y, 2006, J PAIN, V7, P225, DOI 10.1016/j.jpain.2005.11.006; PASSIK SD, 2010, J PAIN SYMPTOM  0624; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2007, CLIN J PAIN, V23, P287, DOI 10.1097/AJP.0b013e31802b582f; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Rauck Richard L, 2006, J Opioid Manag, V2, P155; Russell IJ, 2008, PAIN, V136, P432, DOI 10.1016/j.pain.2008.02.024; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; WEBSTER LR, 2011, EFFECTS FENTAN UNPUB; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2	37	12	12	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	APR	2011	27	4					751	760		10.1185/03007995.2011.554808			10	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	734YW	WOS:000288380900006	21288055				2020-06-30	J	Borland, M; Milsom, S; Esson, A				Borland, Meredith; Milsom, Samantha; Esson, Amanda			Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: A randomized controlled trial	EMERGENCY MEDICINE AUSTRALASIA			English	Article						concentration; fentanyl; intranasal	FACES PAIN SCALE; INTRAVENOUS MORPHINE; ORAL MORPHINE; DOUBLE-BLIND; PHARMACOKINETICS; RELIEF; ADULT; CARE	Objective: Intranasal fentanyl's (INF) effectiveness is established using highly concentrated INF (HINF). Standard concentration INF (SINF) is more widely available. We aimed to illustrate the equivalence of SINF to HINF. Methods: Double-blinded randomized controlled trial was used within a children's hospital ED. Children aged 3-15 years with fractures were randomized to SINF or HINF. Outcome measures included pain scores at time zero and every 10 min until 30 min. Additional analgesic agents were noted. Results: Data in 189 children (91 HINF, 98 SINF) were obtained. Pre-analgesia median VAS was 80.0 mm (interquartile range [IQR] 60.0-95.5) in SINF, 77.5 mm (IQR 60.0-100) in HINF. At 10 min median VAS was 49.5 mm (IQR 26.5-68.5) and 43.0 mm (IQR 15.2-66.0), respectively, at 20 min 27.5 mm (IQR 18.5-56.5) and 35.0 mm (IQR 9.0-57.0) and at 30 min 20.0 mm (IQR 10.0-46.0) and 21.5 mm (IQR 4.75-51.0). Each agent demonstrated significant decrease in pain scores (median decrease 40 mm, P = 0.000). Additional analgesia was given in 67 (42 SINF, 25 HINF) (P = 0.028). The decrease in pain scores between children < and >= 50 kg in SINF was significant both overall (P = 0.005) and between 10 and 20 min (P = 0.003). There was no difference in HINF at any time by weight. Conclusions: The two concentrations of INF were equivalent in reducing pain, with a trend to increased oral additional agents in the more dilute solution. The widespread use of this readily available analgesic in the standard concentration can be supported, particularly in patients < 50 kg.	[Borland, Meredith; Milsom, Samantha; Esson, Amanda] Univ Western Australia, Princess Margaret Hosp Children, Emergency Dept, Perth, WA 6009, Australia; [Borland, Meredith] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia	Borland, M (reprint author), GPO D184, Perth, WA 6840, Australia.	meredith.borland@health.wa.gov.au					Arendts G, 2006, J PAIN, V7, P682, DOI 10.1016/j.jpain.2006.03.003; Belville RG, 2005, PEDIATR EMERG CARE, V21, P90, DOI 10.1097/01.pec.0000159051.26812.8b; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Brenchley J, 2006, EMERG MED J, V23, P488, DOI 10.1136/emj.2005.029165; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Clark E, 2007, PEDIATRICS, V119, P460, DOI 10.1542/peds.2006-1347; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Drendel AL, 2009, ANN EMERG MED, V54, P553, DOI 10.1016/j.annemergmed.2009.06.005; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Herd D, 2009, EMERG MED AUSTRALAS, V21, P335, DOI 10.1111/j.1742-6723.2009.01207.x; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Jadav MAR, 2009, EMERG MED J, V26, P695, DOI 10.1136/emj.2008.065193; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; MCLEAN AR, 2010, WILDERNESS ENV MED, V21, P68, DOI DOI 10.1016/J.WEM.2009.12.037; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Powell CV, 2001, ANN EMERG MED, V37, P28; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Singer AJ, 2002, ACAD EMERG MED, V9, P609, DOI 10.1111/j.1553-2712.2002.tb02298.x; St-Laurent-Gagnon T, 1999, ACTA PAEDIATR, V88, P422, DOI 10.1080/08035259950169819; Zempsky WT, 2004, PEDIATRICS, V114, P1348, DOI 10.1542/peds.2004-1752	28	29	29	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731	1742-6723		EMERG MED AUSTRALAS	Emerg. Med. Australas.	APR	2011	23	2					202	208		10.1111/j.1742-6723.2011.01391.x			7	Emergency Medicine	Emergency Medicine	750CZ	WOS:000289523300012	21489168				2020-06-30	J	Fulkerson, DH; Satyan, KB; Wilder, LM; Riviello, JJ; Stayer, SA; Whitehead, WE; Curry, DJ; Dauser, RC; Luerssen, TG; Jea, A				Fulkerson, Daniel H.; Satyan, Krishna B.; Wilder, Lillian M.; Riviello, James J.; Stayer, Stephen A.; Whitehead, William E.; Curry, Daniel J.; Dauser, Robert C.; Luerssen, Thomas G.; Jea, Andrew			Intraoperative monitoring of motor evoked potentials in very young children Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						intraoperative monitoring; pediatrics; spine surgery; motor evoked potentials	TRANSCRANIAL ELECTRICAL-STIMULATION; PROPOFOL INFUSION SYNDROME; LOW-DOSE PROPOFOL; NITROUS-OXIDE; SPINAL SURGERY; SPATIAL FACILITATION; AORTIC-SURGERY; ANESTHESIA; RESPONSES; CORD	Object. Neurophysiological monitoring of motor evoked potentials (MEPs) during complex spine procedures may reduce the risk of injury by providing feedback to the operating surgeon. While this tool is a well-established surgical adjunct in adults, clinical data in children are sparse. The purpose of this study was to determine the reliability and safety of MEP monitoring in a group of children younger than 3 years of age undergoing neurosurgical spine procedures. Methods. A total of 10 consecutive spinal procedures in 10 children younger than 3 years of age (range 5-31 months, mean 16.8 months) were analyzed between January I, 2008, and May 1, 2010. Motor evoked potentials were elicited by transcranial electric stimulation. A standardized anesthesia protocol for monitoring consisted of a titrated propofol drip combined with bolus dosing of fentanyl or sufentanil. Results. Motor evoked potentials were documented at the beginning and end of the procedure in all 10 patients. A mean baseline stimulation threshold of 533 +/- 124 V (range 321-746 V) was used. Six patients maintained MEP signals >= 50% of baseline amplitude throughout the surgery. There was a greater than 50% decrease in intraoperative MEP amplitude in at least 1 extremity in 4 patients. Two of these patients returned to baseline status by the end of the case. Two patients had a persistent decrement or variability in MEP signals at the end of the procedure; this correlated with postoperative weakness. There were no complications related to the technique of monitoring MEPs. Conclusions. A transcranial electric stimulation protocol monitoring corticospinal motor pathways during neurosurgical procedures in children younger than 3 years of age was reliably and safely implemented. A persistent intraoperative decrease of greater than 50% in this small series of 10 pediatric patients younger than 3 years of age predicted a postoperative neurological deficit. The authors advocate routine monitoring of MEPs in this pediatric age group undergoing neurosurgical spine procedures. (DOI: 10.3171/2011.1.PEDS10255)	[Fulkerson, Daniel H.; Satyan, Krishna B.; Whitehead, William E.; Curry, Daniel J.; Dauser, Robert C.; Luerssen, Thomas G.; Jea, Andrew] Texas Childrens Hosp, Baylor Coll Med, Dept Neurosurg, Neurospine Program,Div Pediat Neurosurg, Houston, TX 77030 USA; [Wilder, Lillian M.; Riviello, James J.] Texas Childrens Hosp, Div Neurophysiol, Houston, TX 77030 USA; [Riviello, James J.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Stayer, Stephen A.] Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol, Div Pediat Anesthesiol, Houston, TX 77030 USA	Jea, A (reprint author), Texas Childrens Hosp, Baylor Coll Med, Dept Neurosurg, Neurospine Program,Div Pediat Neurosurg, 6621 Fannin St,CCC 1230-01,12th Floor, Houston, TX 77030 USA.	ajea@bcm.tmc.edu			Texas Children's Hospital	The authors would like to thank Katherine Relya for her medical illustrations in Figure 1. Dr. Fulkerson completed fellowship at Texas Children's Hospital in July 2010, and is now in practice at Indiana University School of Medicine, Goodman Campbell Brain and Spine, Department of Neurosurgery, Indianapolis, Indiana.	ALI HH, 1981, ANESTHESIOLOGY, V54, P294, DOI 10.1097/00000542-198104000-00007; Andersson G, 1999, CLIN NEUROPHYSIOL, V110, P720, DOI 10.1016/S1388-2457(98)00049-2; BOOKE JS, 1993, SPINE, V18, P518; BOYD SG, 1986, J NEUROL NEUROSUR PS, V49, P251, DOI 10.1136/jnnp.49.3.251; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Chen X, 2007, J CLIN NEUROPHYSIOL, V24, P281, DOI 10.1097/WNP.0b013e31802ed2d4; Chen ZM, 2004, FASEB J, V18, pA1272; DiCindio S, 2003, SPINE, V28, P1851, DOI 10.1097/01.BRS.0000083202.62956.A8; Erb TO, 2005, ANESTH ANALG, V100, P1634, DOI 10.1213/01.ANE.0000149896.52608.08; Frei FJ, 2007, SPINE, V32, P911, DOI 10.1097/01.brs.0000259836.84151.75; Fudickar A, 2009, MINERVA ANESTESIOL, V75, P339; GINSBURG HH, 1985, J NEUROSURG, V63, P296, DOI 10.3171/jns.1985.63.2.0296; Hagelthorn KM, 2000, DEV NEUROPSYCHOL, V18, P11, DOI 10.1207/S15326942DN1801_2; Hays SR, 1999, ANESTHESIOLOGY, V90, P314, DOI 10.1097/00000542-199901000-00042; Inoue S, 2002, J NEUROSURG ANESTH, V14, P213, DOI 10.1097/00008506-200207000-00007; KALKMAN CJ, 1991, ANESTH ANALG, V73, P410; KALKMAN CJ, 1997, CURR OPIN ANESTHESIO, V10, P327; Kam PCA, 2007, ANAESTHESIA, V62, P690, DOI 10.1111/j.1365-2044.2007.05055.x; Kawaguchi M, 2000, SPINE, V25, P974, DOI 10.1097/00007632-200004150-00013; LESSER RP, 1986, ANN NEUROL, V19, P22, DOI 10.1002/ana.410190105; Lieberman JA, 2006, ANESTH ANALG, V103, P316, DOI 10.1213/01.ane.0000226142.15746.b2; Lyon R, 2005, J NEUROSURG ANESTH, V17, P13; MacDonald DB, 2002, J CLIN NEUROPHYSIOL, V19, P416, DOI 10.1097/00004691-200210000-00005; Mahmoud M, 2008, PEDIATR ANESTH, V18, P902, DOI 10.1111/j.1460-9592.2008.02704.x; Minahan RE, 2008, PRACTICAL APPROACH N, P21; Nathan N, 2003, BRIT J ANAESTH, V91, P493, DOI 10.1093/bja/aeg211; Nezu A, 1997, BRAIN DEV-JPN, V19, P176, DOI 10.1016/S0387-7604(96)00552-9; PARIKH SN, 2003, SPINE, V21, pE21; Pelosi L, 2001, CLIN NEUROPHYSIOL, V112, P1076, DOI 10.1016/S1388-2457(01)00529-6; Sala F, 2002, CHILD NERV SYST, V18, P264, DOI 10.1007/s00381-002-0582-3; Scheufler KM, 2002, J NEUROSURG, V96, P571, DOI 10.3171/jns.2002.96.3.0571; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; Sloan T, 2010, CHILD NERV SYST, V26, P227, DOI 10.1007/s00381-009-1023-3; Ubags LH, 1997, BRIT J ANAESTH, V79, P590; Ubags LH, 1998, NEUROSURGERY, V43, P90, DOI 10.1097/00006123-199807000-00058; van Dongen EP, 2000, ACTA ANAESTH SCAND, V44, P799, DOI 10.1034/j.1399-6576.2000.440705.x; van Dongen EP, 1999, BRIT J ANAESTH, V82, P323, DOI 10.1093/bja/82.3.323; van Dongen EP, 1999, J CARDIOTHOR VASC AN, V13, P30, DOI 10.1016/S1053-0770(99)90169-6; Weidenheim KM, 1996, J NEUROPATH EXP NEUR, V55, P734, DOI 10.1097/00005072-199606000-00008; Wilson-Holden TJ, 1999, SPINE, V24, P1685, DOI 10.1097/00007632-199908150-00010	40	27	30	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	APR	2011	7	4					331	337		10.3171/2011.1.PEDS10255			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	739NX	WOS:000288726000003	21456902				2020-06-30	J	Ponde, VC; Desai, AP; Shah, DM; Johari, AN				Ponde, Vrushali C.; Desai, Ankit P.; Shah, Dipal M.; Johari, Ashok N.			Feasibility and efficacy of placement of continuous sciatic perineural catheters solely under ultrasound guidance in children: a descriptive study	PEDIATRIC ANESTHESIA			English	Article						continuous sciatic block; ultrasound guidance; tuohy needle; catheter		P>Background: Placement of sciatic catheters with ultrasound and stimulating catheters is known. Literature regarding catheter placements with only ultrasound is limited. We aimed to investigate the feasibility of performing continuous sciatic nerve block exclusively with ultrasound guidance and minimal equipment. Method: Forty ASA 1 and 2 patients aged 8 months-10 years posted for congenital talipoequinovarus surgery were included in the study. Continuous sciatic catheters were placed under ultrasound guidance with 18- gauge Tuohy needle at the infragluteal fold. Then, 0.25% of bupivacaine 0.5 ml center dot kg-1 bolus was injected followed by continuous infusion later. Half the volume of the drug was injected prior to catheter insertion to improve visibility. The sciatic nerve, needle tip and shaft, catheter tip and the drug spread were visualized. The efficacy of the block intraoperatively and postoperatively was evaluated. Results: The sciatic nerve, needle shaft, and tip were well visualized in all 40 patients. The catheter tip was seen in 72.5% of patients. The effect of block was complete intraoperatively and postoperatively. Clinically significant complications were absent. Conclusion: We conclude that in children, continuous sciatic catheters can be accurately and efficaciously placed with minimal equipment with ultrasound alone.	[Ponde, Vrushali C.; Johari, Ashok N.] All India Inst Phys Med & Rehabil, Dept Anesthesia, Ctr Children Orthopaed, Mahalaxmi 400034, Maharashtra, India; [Desai, Ankit P.; Shah, Dipal M.] BJ Wadia Hosp Children, Childrens Orthopaed Ctr, Bombay, Maharashtra, India	Ponde, VC (reprint author), All India Inst Phys Med & Rehabil, Dept Anesthesia, Ctr Children Orthopaed, Mahalaxmi 400034, Maharashtra, India.	vrushaliponde@yahoo.co.in					Dadure C, 2009, CAN J ANAESTH, V56, P843, DOI 10.1007/s12630-009-9169-8; EDWARD RM, 2008, PEDIAT ANESTH, V18, P598; GEERT JVG, 2006, ANESTH ANALG, V103, P328; Oberndorfer U, 2007, BRIT J ANAESTH, V98, P797, DOI 10.1093/bja/aem092; STEPHEN MK, 2007, ANESTH ANALG, V105, P1858	5	9	10	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2011	21	4					406	410		10.1111/j.1460-9592.2011.03526.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	730EQ	WOS:000288016500009	21324045				2020-06-30	J	Bendall, JC; Simpson, PM; Middleton, PM				Bendall, Jason C.; Simpson, Paul M.; Middleton, Paul M.			EFFECTIVENESS OF PREHOSPITAL MORPHINE, FENTANYL, AND METHOXYFLURANE IN PEDIATRIC PATIENTS	PREHOSPITAL EMERGENCY CARE			English	Article						prehospital; analgesia; morphine; fentanyl; methoxyflurane	RANDOMIZED CONTROLLED-TRIAL; VISUAL ANALOG SCALE; EMERGENCY-DEPARTMENT; INTRANASAL FENTANYL; ACUTE PAIN; INHALED METHOXYFLURANE; INTRAVENOUS MORPHINE; BURNS DRESSINGS; ANALGESIA; CHILDREN	Objectives. To compare the effectiveness of intravenous morphine, intranasal (IN) fentanyl, and inhaled methoxyflurane for managing moderate to severe pain in pediatric patients in the out-of-hospital setting. Methods. We conducted a retrospective comparative study of 3,312 pediatric patients aged between 5 and 15 years who had moderate to severe pain (pain score >= 5) and who received intravenous morphine, IN fentanyl, or inhaled methoxyflurane, either alone or in combination, between January 1, 2004, and November 30, 2006. Multivariate logistic regression was used to analyze data extracted from a clinical database containing routinely entered information from patient health care records. The primary outcome measure was effective analgesia, defined as a reduction in pain severity of >= 30% of initial pain score using an 11-point verbal numeric rating scale. Results. Effective analgesia was achieved in 82.5% of cases overall. All analgesic agents were effective in the majority of patients (87.5%, 89.5%, and 78.3% for morphine, fentanyl, and methoxyflurane, respectively). There was evidence that methoxyflurane was less effective than both morphine (odds ratio [OR] 0.52; 95% confidence interval [CI] 0.36-0.74) and fentanyl (OR 0.43; 95% CI 0.29-0.62; p < 0.0001). There was no clinical or statistical evidence of difference in the effectiveness of fentanyl and morphine in this population (OR 1.22; 95% CI 0.74-2.01). There was no evidence that combination analgesia was better than either fentanyl or morphine alone. Conclusion. Intranasal fentanyl and intravenous morphine are equally effective analgesic agents in pediatric patients with moderate to severe acute pain in the out-of-hospital setting. Methoxyflurane is less effective in comparison with both morphine and fentanyl, but is an effective analgesic in the majority of children.	[Bendall, Jason C.; Simpson, Paul M.; Middleton, Paul M.] Ambulance Serv New S Wales, Ambulance Res Inst, Rozelle, NSW 2039, Australia	Bendall, JC (reprint author), Ambulance Serv New S Wales, Ambulance Res Inst, Locked Bag 105, Rozelle, NSW 2039, Australia.	jben-dall@ambulance.nsw.gov.au	Simpson, Paul/N-7447-2019; Middleton, Paul M/A-9084-2012	Simpson, Paul/0000-0003-3875-0061; Middleton, Paul M/0000-0003-0760-1098; Bendall, A/Prof Jason/0000-0002-8688-2192			Affleck G, 1999, PAIN, V83, P601, DOI 10.1016/S0304-3959(99)00167-0; Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; *AMB SERV NEW S WA, 2007, ANN REP 2006 07; BABL EE, 2006, EMERG MED AUSTRALAS, V18, P404; Babl F, 2007, PEDIATR ANESTH, V17, P148, DOI 10.1111/j.1460-9592.2006.02037.x; Bailey B, 2007, ANN EMERG MED, V50, P379, DOI 10.1016/j.annemergmed.2007.04.021; BENDALL J, 2009, J EMERG PRIM HLTH CA, V7, P19; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Buntine P, 2007, EMERG MED AUSTRALAS, V19, P509, DOI 10.1111/j.1742-6723.2007.01017.x; Edwards RR, 1999, CLIN J PAIN, V15, P233, DOI 10.1097/00002508-199909000-00011; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; FIRN S, 1972, BRIT J ANAESTH, V44, P517, DOI 10.1093/bja/44.5.517; FIRN S, 1972, BRIT J ANAESTH, V44, P590; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Galinski M, 2010, PREHOSP EMERG CARE, V14, P334, DOI 10.3109/10903121003760218; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Holdgate Anna, 2003, Emerg Med (Fremantle), V15, P441, DOI 10.1046/j.1442-2026.2003.00499.x; HOSMER D. W., 2000, APPL LOGISTIC REGRES; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; LAIRD SM, 1971, BRIT J ANAESTH, V43, P149, DOI 10.1093/bja/43.2.149; Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5; Lord B, 2009, EMERG MED J, V26, P123, DOI 10.1136/emj.2008.058719; Macintyre PE, 2009, ACUTE PAIN MANAGEMENT, P204, DOI 10.1017/CBO9780511576706.016; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; Swor Robert, 2005, Prehosp Emerg Care, V9, P40, DOI 10.1080/10903120590891930; Unruh AM, 1999, CLIN J PAIN, V15, P31, DOI 10.1097/00002508-199903000-00006; Vassiliadis John, 2002, Emerg Med (Fremantle), V14, P261, DOI 10.1046/j.1442-2026.2002.00341.x; Watkins Nicholas, 2006, Emerg Med Australas, V18, P51, DOI 10.1111/j.1742-6723.2006.00808.x; White L J, 2000, Prehosp Emerg Care, V4, P205, DOI 10.1080/10903120090941209	39	35	35	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1090-3127			PREHOSP EMERG CARE	Prehosp. Emerg. Care	APR-JUN	2011	15	2					158	165		10.3109/10903127.2010.541980			8	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	729FG	WOS:000287933400003	21294628				2020-06-30	J	Wang, GH; Huynh, K; Barhate, R; Rodrigues, W; Moore, C; Coulter, C; Vincent, M; Soares, J				Wang, Guohong; Huynh, Kim; Barhate, Rekha; Rodrigues, Warren; Moore, Christine; Coulter, Cynthia; Vincent, Michael; Soares, James			Development of a homogeneous immunoassay for the detection of fentanyl in urine	FORENSIC SCIENCE INTERNATIONAL			English	Article						Homogeneous immunoassay; Fentanyl; Fentanyl metabolite; Urine screening; Antibody; Enzyme conjugate	DRUGS; NORFENTANYL; METABOLITES; HAIR	Objective: Fentanyl is an extremely potent synthetic opioid that is widely used for chronic pain treatment; it is highly addictive and prone to abuse. The objective is to develop a high throughput homogeneous enzyme immunoassay (HEIA) for the rapid detection of fentanyl in human urine. Methods: The HEIA is based on an immunoassay format in which both the antibody and enzyme-drug conjugate are in ready-to-use solution. In the absence of the target analyte in the specimen, enzyme-labeled drug conjugate binds to the antibody and results in a decrease of the enzyme (G6PDH) activity; hence there is lower absorbance at 340 nm. If the target analyte is present in the specimen, it competes with the enzyme-labeled drug to bind to limited amount of specific antibody that result in more enzyme activity and yields an increased absorbance at 340 nm. A polyclonal "in-house" antibody was selected that is capable of measuring fentanyl at low concentrations thus the assay detection limit was determined to be 1 ng/mL. The assay was validated with clinical urine specimens that previously confirmed positively or negatively for fentanyl/norfentanyl by LC-MS/MS. Results: The intra-day (n = 20) and inter-day (n = 100) precision of the assay was less than 1% CV. No interferences from structurally unrelated and commonly ingested drugs were observed at a concentration of 10,000 ng/mL. A total of 209 LC-MS/MS confirmed urine specimens (149 positive and 57 negative samples) were analyzed by HEIA. The sensitivity, specificity, and accuracy values were 99%, 95%, and 98% respectively. Conclusion: This paper describes the development of a highly sensitive homogenous enzyme immunoassay for detecting fentanyl in urine at a cut-off concentration of 2 ng/mL. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Wang, Guohong; Huynh, Kim; Barhate, Rekha; Rodrigues, Warren; Moore, Christine; Coulter, Cynthia; Vincent, Michael; Soares, James] Immunalysis Corp, Pomona, CA 91767 USA	Wang, GH (reprint author), Immunalysis Corp, 829 Towne Ctr Dr, Pomona, CA 91767 USA.	gwang@immunalysis.com					Cone EJ, 2008, J ANAL TOXICOL, V32, P530, DOI 10.1093/jat/32.8.530; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Higashikawa Y, 2008, J HEALTH SCI, V54, P629, DOI 10.1248/jhs.54.629; *IMM CORP, FENT ELISA PROD INS; Lafreniere NM, 2010, FORENSIC SCI INT, V194, P60, DOI 10.1016/j.forsciint.2009.10.008; LIN SN, 1981, J PHARM SCI, V70, P1276, DOI 10.1002/jps.2600701124; MCDONALD J, 1987, RES COMMUN CHEM PATH, V57, P389; Moore C, 2008, FORENSIC SCI INT, V176, P47, DOI 10.1016/j.forsciint.2007.06.027; *NAT DRUG INT CTR, 2006, SR000001 US DEP JUST; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Stout PR, 1998, DRUG METAB DISPOS, V26, P689	13	18	19	1	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	MAR 20	2011	206	1-3					127	131		10.1016/j.forsciint.2010.07.022			5	Medicine, Legal	Legal Medicine	732PO	WOS:000288200400045	20801588				2020-06-30	J	Medeiros, LF; Rozisky, JR; de Souza, A; Hidalgo, MP; Netto, CA; Caumo, W; Battastini, AMO; Torres, ILD				Medeiros, Liciane Fernandes; Rozisky, Joanna Ripoll; de Souza, Andressa; Hidalgo, Maria Paz; Netto, Carlos Alexandre; Caumo, Wolnei; Oliveira Battastini, Ana Maria; da Silva Torres, Iraci Lucena			Lifetime behavioural changes after exposure to anaesthetics in infant rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Anaesthesia; Surgery; Infant rat; Behaviour; Plus-maze; Open-field	OPIOID RECEPTORS; POSTNATAL-DEVELOPMENT; DOPAMINE; BRAIN; ISOFLURANE; KETAMINE; MEMORY; HIPPOCAMPUS; ONTOGENY; MORPHINE	The aim of this study was to assess the effect of acute use of general anaesthetic with or without a surgical procedure, at post-natal day 14 (P14), on behavioural responses in the short-, medium- and long-term, evaluated in open field (CIF) and elevated plus-maze (EPM) tests. Fourteen-day-old male Wistar rats were divided into two experimental designs (ED): inhalation and intravenous anaesthetic, and these groups were subdivided into: 1st ED - control (C), isoflurane (ISO), isoflurane/surgery (ISO-SUR); 2nd ED - control (C), fentanyl/S(+)-ketamine (FK) and fentanyl + ketamine-s/surgery (FK-SUR). In the OF the following were found: (a) in theist ED: an increase in the locomotor activity in the ISO group at P14, and ISO and ISO-SUR groups at P30; the ISO-SUR group showed a reduced latency to leave the first quadrant at P30 and P60; (b) in the 2nd ED: FK and FK-SUR groups presented increased locomotor activity at P30, and the FK group showed a reduction in the number of faecal boluses. In the EPM the following were found: FK and FK-SUR groups presented an increase in the number of non-protected head-dipping (NPHD) movements and in the number of entries and time spent in open arms at P30; the FK group showed an increased number of protected head-dipping movements, NPHD and entries and time spent in the open arms at P60. The behavioural changes observed may be related to locomotor activity (1st ED) and anxiety level (2nd ED) and they may result from changes in neurotransmitters/hormones (DA, 5HT, CRH) and glutamate/NMDA receptors, respectively. (C) 2010 Elsevier B.V. All rights reserved.	[Medeiros, Liciane Fernandes; da Silva Torres, Iraci Lucena] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci ICBS, Post Grad Program Biol Sci Physiol, BR-90050170 Porto Alegre, RS, Brazil; [Medeiros, Liciane Fernandes; Rozisky, Joanna Ripoll; de Souza, Andressa; Caumo, Wolnei; da Silva Torres, Iraci Lucena] Univ Fed Rio Grande do Sul, ICBS, Dept Pharmacol, Lab Pharmacol Pain & Inflammat, BR-90050170 Porto Alegre, RS, Brazil; [Netto, Carlos Alexandre; Oliveira Battastini, Ana Maria] Univ Fed Rio Grande do Sul, ICBS, Dept Biochem, BR-90050170 Porto Alegre, RS, Brazil; [Hidalgo, Maria Paz] Univ Fed Rio Grande do Sul, Fac Med, Dept Psychiat, BR-90035003 Porto Alegre, RS, Brazil; [Medeiros, Liciane Fernandes; Rozisky, Joanna Ripoll; de Souza, Andressa; Caumo, Wolnei; da Silva Torres, Iraci Lucena] Hosp Clin Porto Alegre, Anim Expt & Res Grp, BR-90035003 Porto Alegre, RS, Brazil; [Medeiros, Liciane Fernandes; Rozisky, Joanna Ripoll; de Souza, Andressa; Caumo, Wolnei; da Silva Torres, Iraci Lucena] Hosp Clin Porto Alegre, Post Grad Unit, BR-90035003 Porto Alegre, RS, Brazil	Torres, ILD (reprint author), Univ Fed Rio Grande do Sul, Dept Farmacol, Inst Ciencias Basicas Saude, Rua Sarmento Leite 500,Sala 202, BR-90050170 Porto Alegre, RS, Brazil.	iracitorres@gmail.com	de Souza, Andressa/Q-2446-2016; Torres, Iraci L. S./G-6693-2012; Medeiros, Liciane/A-3626-2014; caumo, wolnei/Q-8728-2016; Rozisky, Joanna/F-6584-2015; Hidalgo, Maria Paz Loayza/V-5612-2019	de Souza, Andressa/0000-0002-6608-4695; Torres, Iraci L. S./0000-0002-3081-115X; Medeiros, Liciane/0000-0002-6842-7241; Hidalgo, Maria Paz Loayza/0000-0002-7886-770X; Netto, Carlos Alexandre/0000-0002-0596-5667; Caumo, Wolnei/0000-0002-5083-4658	National Council for Scientific and Technological Development - CNPqNational Council for Scientific and Technological Development (CNPq); Graduate Research Group (GPPG) of Hospital de Clinicas de Porto Alegre [08149]; Committee for the Development of Higher Education Personnel - CAPES; Dean for Research Universidade Federal do Rio Grande do Sul (PROPESQ-UFRGS).	This research was supported by the following Brazilian funding agencies: National Council for Scientific and Technological Development - CNPq (Dr. I.L.S. Torres); Graduate Research Group (GPPG) of Hospital de Clinicas de Porto Alegre (Dr. I.L.S. Torres - Grant # 08149); Committee for the Development of Higher Education Personnel - CAPES (L.F. Medeiros, J.R. Rozisky); Dean for Research Universidade Federal do Rio Grande do Sul (PROPESQ-UFRGS).	ARNT J, 1987, [No title captured], P199; Bannerman DM, 2002, BEHAV NEUROSCI, V116, P884, DOI 10.1037//0735-7044.116.5.884; BARG J, 1989, INT J DEV NEUROSCI, V7, P173, DOI 10.1016/0736-5748(89)90067-1; Barkus C, 2010, EUR J PHARMACOL, V626, P49, DOI 10.1016/j.ejphar.2009.10.014; Beland B, 2001, PAIN, V90, P143, DOI 10.1016/S0304-3959(00)00397-3; Bhutta AT, 2001, PHYSIOL BEHAV, V73, P51, DOI 10.1016/S0031-9384(01)00432-2; BIANCHIN M, 1993, BEHAV NEURAL BIOL, V59, P83, DOI 10.1016/0163-1047(93)90782-D; BRITTON DR, 1981, PHARMACOL BIOCHEM BE, V15, P577, DOI 10.1016/0091-3057(81)90212-4; CAILLE I, 1995, EUR J NEUROSCI, V7, P714, DOI 10.1111/j.1460-9568.1995.tb00675.x; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Carlini VP, 2002, BIOCHEM BIOPH RES CO, V299, P739, DOI 10.1016/S0006-291X(02)02740-7; Culley DJ, 2003, ANESTH ANALG, V96, P1004, DOI 10.1213/01.ANE.0000052712.67573.12; Danneman PJ, 1997, LAB ANIM SCI, V47, P386; de Lima AD, 2004, EUR J NEUROSCI, V19, P2931, DOI 10.1111/j.0953-816X.2004.03403.x; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; ELMAGHRABI EA, 1993, ANESTHESIOLOGY, V78, P750, DOI 10.1097/00000542-199304000-00019; FISHMAN RHB, 1983, PROG NEUROBIOL, V20, P55, DOI 10.1016/0301-0082(83)90010-2; Fredriksson A, 2004, BEHAV BRAIN RES, V153, P367, DOI 10.1016/j.bbr.2003.12.026; Fredriksson A, 2007, ANESTHESIOLOGY, V107, P427, DOI 10.1097/01.anes.0000278892.62305.9c; Freo U, 2004, ANESTHESIOLOGY, V100, P1172, DOI 10.1097/00000542-200405000-00020; GUIMARAES FS, 1991, PSYCHOPHARMACOLOGY, V103, P91, DOI 10.1007/BF02244080; Hayase T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-25; Hayashi H, 2002, PAEDIATR ANAESTH, V12, P770, DOI 10.1046/j.1460-9592.2002.00883.x; IRIFUNE M, 1991, PHARMACOL BIOCHEM BE, V40, P399, DOI 10.1016/0091-3057(91)90571-I; Jansson A, 2004, EXP NEUROL, V190, P535, DOI 10.1016/j.expneurol.2004.08.027; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Kandasamy SB, 2000, RADIAT RES, V154, P39, DOI 10.1667/0033-7587(2000)154[0039:PIOLTV]2.0.CO;2; Kennett GA, 1997, NEUROPHARMACOLOGY, V36, P609, DOI 10.1016/S0028-3908(97)00038-5; Kouvaras E, 2008, NEUROPHARMACOLOGY, V55, P1172, DOI 10.1016/j.neuropharm.2008.07.025; LEDEZ KM, 1987, ANESTHESIOLOGY, V67, P301, DOI 10.1097/00000542-198709000-00004; LEVITT P, 1982, DEV BRAIN RES, V4, P35, DOI 10.1016/0165-3806(82)90095-5; Linthorst ACE, 1997, J NEUROSCI, V17, P4448; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; Loizzo Alberto, 2009, Open Biochem J, V3, P18, DOI 10.2174/1874091X00903010018; Lynn DA, 2009, DEV PSYCHOBIOL, V51, P513, DOI 10.1002/dev.20386; MANTZ J, 1994, ANESTHESIOLOGY, V80, P352, DOI 10.1097/00000542-199402000-00015; MARTIN DC, 1988, BRAIN RES, V455, P360, DOI 10.1016/0006-8993(88)90095-9; MARTIN DC, 1990, NEUROCHEM RES, V15, P969, DOI 10.1007/BF00965741; McCann ME, 2009, NEUROTOXICOLOGY, V30, P766, DOI 10.1016/j.neuro.2009.02.013; Moreira FA, 2007, NEUROPHARMACOLOGY, V52, P958, DOI 10.1016/j.neuropharm.2006.10.013; MOTOYAMA EK, 1996, SMITHS ANESTHESIA IN; Niewoehner B, 2007, EUR J NEUROSCI, V25, P837, DOI 10.1111/j.1460-9568.2007.05312.x; OPACKAJUFFRY J, 1991, SYNAPSE, V7, P169, DOI 10.1002/syn.890070210; Pattinson D, 2004, REGION ANESTH PAIN M, V29, P36, DOI 10.1016/j.rapm.2003.10.018; Puelles L, 1998, J COMP NEUROL, V394, P283, DOI 10.1002/(SICI)1096-9861(19980511)394:3<283::AID-CNE2>3.0.CO;2-Y; Rahman W, 1998, DEV BRAIN RES, V108, P239, DOI 10.1016/S0165-3806(98)00054-6; RAO PA, 1991, DEV BRAIN RES, V60, P161, DOI 10.1016/0165-3806(91)90045-K; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Roesler R, 1999, MOL BRAIN RES, V71, P349, DOI 10.1016/S0169-328X(99)00193-X; Rozisky JR, 2008, INT J DEV NEUROSCI, V26, P561, DOI 10.1016/j.ijdevneu.2008.05.005; SALES N, 1989, NEUROSCIENCE, V28, P673, DOI 10.1016/0306-4522(89)90014-6; SCHAMBRA B, 1994, NEUROSCIENCE, V62, P65, DOI 10.1016/0306-4522(94)90315-8; Silveira PP, 2005, INT J DEV NEUROSCI, V23, P93, DOI 10.1016/j.ijdevneu.2004.07.018; Skaer TL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-24; Smith JC, 2004, LAB ANIM-UK, V38, P38, DOI 10.1258/00236770460734371; Soriano SG, 2005, CURR OPIN ANESTHESIO, V18, P293, DOI 10.1097/01.aco.0000169238.36927.c2; SPRUIJT BM, 1992, PHYSIOL REV, V72, P825; Takahashi H, 2002, HIPPOCAMPUS, V12, P304, DOI 10.1002/hipo.10012; Varju P, 2001, CELL TISSUE RES, V305, P239, DOI 10.1007/s004410100356; Wells CE, 2009, BEHAV BRAIN RES, V197, P234, DOI 10.1016/j.bbr.2008.08.013; WOHLTMANN M, 1982, DEV BRAIN RES, V3, P679, DOI 10.1016/0165-3806(82)90066-9; Xiang Q, 2008, MED HYPOTHESES, V71, P868, DOI 10.1016/j.mehy.2008.07.035	62	9	9	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 17	2011	218	1					51	56		10.1016/j.bbr.2010.10.028			6	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	745AV	WOS:000289137200007	21056062				2020-06-30	J	Vissers, DCJ; Lenre, M; Tolley, K; Jakobsson, J; Sendersky, V; Jansen, JP				Vissers, Debby C. J.; Lenre, Malin; Tolley, Keith; Jakobsson, Jan; Sendersky, Veronica; Jansen, Jeroen P.			An Economic Evaluation of Short-Acting Opioids for Treatment of Breakthrough Pain in Patients with Cancer	VALUE IN HEALTH			English	Article							TRANSMUCOSAL FENTANYL CITRATE; MIXED TREATMENT COMPARISONS; HEALTH-STATE UTILITIES; CONTROLLED-TRIAL; CROSSOVER TRIAL; OPEN-LABEL; PREVALENCE; EFFICACY; SPRAY; METAANALYSIS	Objective: Breakthrough cancer pain (BTCP) represents a considerable economic burden. A decision-analysis model was developed to evaluate the cost-effectiveness of intranasal fentanyl spray (INFS) compared with oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT) for the treatment of BTCP. Methods: The model was parameterized for Sweden to estimate the costs and benefits associated with treatments. Expected reductions in pain intensity (PI; measured on a numeric rating scale ranging from 0 to 10) per BTCP episodes were translated into resource use and quality-adjusted life years (QALYs). Relative analgesic efficacy of interventions was derived from a mixed treatment comparison of six randomized controlled trials. The relationship between PI and utility was obtained from a time-trade off study in the general population. Resource use and unit cost data were obtained from the literature and validated by Swedish clinical experts. The base case scenario assumed three BTCP episodes/day, a background PI of 2, and a time horizon of 180 days. Prices of INFS and OTFC were assumed to be equal with FBT similar to 14% less. Uncertainty in the source data was incorporated by probabilistic sensitivity analyses and different scenario analyses. Results: With INFS, 55% of BTCP (95% uncertainty interval [UI]: 46-68%) was avoided, which is greater than expected with OTFC (29%; UI 22-38%) or FBT (31%; UI 25-39%). INFS was dominating OTFC (resulting in 0.046 QALY gain and saving 174 Euros with a time horizon of 180 days) and cost-effective versus FBT (incremental cost-effectiveness ratio 12203 Euros/QALY). Despite uncertainty in the source data, there is a >99% probability that INFS is the most cost-effective intervention. Conclusion: Given inherent limitations of modelling studies, the greater efficacy of INFS translates to cost and QALY advantages over competing interventions in the treatment for BTCP in Sweden. Copyright (C) 2011, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.	[Jansen, Jeroen P.] Mapi Values, Boston, MA 02114 USA; [Vissers, Debby C. J.] Mapi Values, Houten, Netherlands; [Lenre, Malin; Sendersky, Veronica] Nycomed, Taastrup, Denmark; [Tolley, Keith] Tolley Hlth Econ Ltd, Buxton, England; [Jakobsson, Jan] Karolinska Inst, Dept Anaesthesia & Intens Care, Stockholm, Sweden; [Jakobsson, Jan] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden	Jansen, JP (reprint author), Mapi Values, 133 Portland St,3rd Floor, Boston, MA 02114 USA.	jeroen.jansen@mapivalues.com		Jansen, Jeroen Paul/0000-0003-2686-9217	Nycomed	This analysis was conducted by Mapi Values and funded by Nycomed.	Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897; Caraceni A, 2004, PALLIATIVE MED, V18, P77; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Green CR, 2009, J PAIN SYMPTOM MANAG, V37, P831, DOI 10.1016/j.jpainsymman.2008.05.011; Hauber AB, 2008, VALUE HEALTH, V11, pA353, DOI 10.1016/S1098-3015(10)66218-3; Jansen JP, 2008, VALUE HEALTH, V11, P956, DOI 10.1111/j.1524-4733.2008.00347.x; Jensen MP, 1986, PAIN, V27, P1147; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lu G, 2007, STAT MED, V26, P3681, DOI 10.1002/sim.2831; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2004, OXFORD TXB PALLIATIV; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Tandvards-och lakemedelsformansverket, WELC DENT PHARM BEN; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Wolfe F, 2003, ARTHRITIS RHEUM, V48, pS399; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012; Zethraeus N, 2005, INT J TECHNOL ASSESS, V21, P433, DOI 10.1017/S0266462305050609	32	16	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1098-3015			VALUE HEALTH	Value Health	MAR-APR	2011	14	2					274	281		10.1016/j.jval.2010.09.007			8	Economics; Health Care Sciences & Services; Health Policy & Services	Business & Economics; Health Care Sciences & Services	875OJ	WOS:000299040300008	21402296	Bronze			2020-06-30	J	Traynor, K				Traynor, Kate			First standardized REMS approved	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	News Item																	0	1	1	0	2	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082			AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	MAR 1	2011	68	5					366	368		10.2146/news110010			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	858CD	WOS:000297772600002	21330671				2020-06-30	J	Kleeberg, UR; Filbet, M; Zeppetella, G				Kleeberg, Ulrich R.; Filbet, Marilene; Zeppetella, Giovambattista			Fentanyl Buccal Tablet for Breakthrough Cancer Pain: Why Titrate?	PAIN PRACTICE			English	Review						breakthrough cancer pain; rapid onset opioid; titration	OPIOID-TOLERANT PATIENTS; OPEN-LABEL; PREVALENCE; MORPHINE; CITRATE; ASSOCIATION; MEDICINE	Breakthrough cancer pain is a significant problem for many patients with cancer because of the fast onset and often unpredictable nature of the pain episodes. The rapid onset opioids therefore have a central role to play in the management of breakthrough cancer pain. The rapid onset opioid fentanyl buccal tablet provides a fast analgesic effect and is easy to administer. However, titration of the medication is essential in order to optimize the management of pain. This is because individual patient characteristics, comorbidities, and other treatments may influence the absorption, pharmacokinetics, and pharmacodynamics of drugs. It is therefore important to individualize treatment by determining the effective dose for each patient, which is the dose that provides adequate analgesia and minimizes undesirable adverse effects. Data from clinical studies of fentanyl buccal tablet show that patients' effective doses ranged from 100 to 800 mu g per episode, highlighting the need for the titration process. Following successful dose titration, treatment with fentanyl buccal tablet can achieve significant pain relief as early as 10 minutes after administration, resulting in a high level of patient satisfaction.	[Filbet, Marilene] Ctr Hosp Lyon Sud, Ctr Soins Palliatifs, CHU Lyon, F-69310 Pierre Benite, France; [Zeppetella, Giovambattista] St Clare Hosp, Hastingwood, Essex, England	Kleeberg, UR (reprint author), Tagesklin Struensee Haus,Morkenstr 47, D-22767 Hamburg, Germany.	urkleeberg@hopa-hamburg.de			LillyEli Lilly; Cephalon; Nycomed; Mundipharma	Marilene Filbet has, during the past year: participated in conference symposia or advisory boards organized by Archimedes, Cephalon, Nycomed, and BEMA; received research funding from Lilly, Cephalon, Nycomed, and Mundipharma.	*AM PAIN SOC, 2007, PRINC AN US TREATM A; BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dahan A, 2008, ANESTH ANALG, V107, P83, DOI 10.1213/ane.0b013e31816a66a4; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Friedrich C, 2003, ONKOLOGIE, V26, P355, DOI 10.1159/000072096; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Lossignol DA, 2010, CURR OPIN ONCOL, V22, P302, DOI 10.1097/CCO.0b013e32833a873a; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mystakidou Kyriaki, 2005, J Opioid Manag, V1, P36; Pather SI, 2001, DRUG DELIV TECH, V1, P54; Patt RB, 1998, ONCOLOGY-NY, V12, P1035; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493; ZEPPETELLA G, 2009, EUR J PALLIAT CARE, V16, P13; 2010, EFFENTORA SUMMARY PR	32	13	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	MAR-APR	2011	11	2					185	190		10.1111/j.1533-2500.2010.00414.x			6	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	840UD	WOS:000296465900011	20807349				2020-06-30	J	Kang, H; Kim, BG				Kang, H.; Kim, B-G			Intravenous Lidocaine for Effective Pain Relief after Inguinal Herniorrhaphy: a Prospective, Randomized, Double-blind, Placebo-controlled Study	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						LIDOCAINE; INTRAVENOUS INJECTION; INGUINAL HERNIORRHAPHY; POST-OPERATIVE PAIN	ASPARTATE NMDA RECEPTORS; POSTOPERATIVE PAIN; LOCAL-ANESTHETICS; AMBULATORY SURGERY; BOWEL FUNCTION; HERNIA REPAIR; CAUDAL BLOCK; INFUSION; ANALGESIA; RECOVERY	This prospective, randomized, double-blind, placebo-controlled study evaluated the effectiveness of intravenous lidocaine to reduce post-operative pain in 64 inguinal herniorrhaphy patients. Intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg per h was randomly assigned to 32 patients (lidocaine group) and intravenous normal saline bolus injection followed by infusion of normal saline was assigned to 32 other patients (control group). Visual analogue scale pain scores, fentanyl consumption and the frequency at which analgesia was administered from a patient-controlled analgesia device (measured by number of button pushes) were significantly lower in the lidocaine group than in the control group until 12 h after surgery. Total fentanyl consumption (patient-controlled plus investigator-controlled rescue administration) and the total number of button pushes were significantly lower in the lidocaine group than in the control group. It is concluded that intravenous lidocaine injection reduced post-operative pain after inguinal herniorrhaphy, is easy to administer and may have potential to become routine practice for this type of surgery.	[Kim, B-G] Chung Ang Univ, Coll Med, Dept Surg, Seoul 156755, South Korea; [Kang, H.] Chung Ang Univ, Coll Med, Dept Anaesthesiol & Pain Med, Seoul 156755, South Korea	Kim, BG (reprint author), Chung Ang Univ, Coll Med, Dept Surg, 224-1 Heukseok Dong, Seoul 156755, South Korea.	roman00@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	Chung-Ang University	This research was supported by Chung-Ang University Research Grants in 2010.	AGUILAR JS, 1980, EUR J PHARMACOL, V68, P317, DOI 10.1016/0014-2999(80)90529-4; BOAS RA, 1982, BRIT J ANAESTH, V54, P501, DOI 10.1093/bja/54.5.501; Callesen T, 1997, ANESTHESIOLOGY, V87, P1219, DOI 10.1097/00000542-199711000-00027; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; Edwards A D, 1999, J Intraven Nurs, V22, P273; Groudine SB, 1998, ANESTH ANALG, V86, P235, DOI 10.1097/00000539-199802000-00003; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Hollmann MW, 2001, ANESTHESIOLOGY, V95, P113, DOI 10.1097/00000542-200107000-00021; INSLER SR, 1995, J CARDIOTHOR VASC AN, V9, P541, DOI 10.1016/S1053-0770(05)80138-7; Ivani G, 2003, ANESTH ANALG, V97, P368, DOI 10.1213/01.ANE.0000068881.01031.09; Jin FL, 1998, CAN J ANAESTH, V45, P293, DOI 10.1007/BF03012017; Junger A, 2001, EUR J ANAESTH, V18, P314, DOI 10.1046/j.0265-0215.2000.00837.x; Kaba A, 2007, ANESTHESIOLOGY, V106, P11, DOI 10.1097/00000542-200701000-00007; KASTRUP J, 1987, PAIN, V28, P69, DOI 10.1016/0304-3959(87)91061-X; Kawamata M, 2002, PAIN, V100, P77, DOI 10.1016/S0304-3959(02)00233-6; Kehlet H, 2001, ANESTH ANALG, V93, P1367; Koppert W, 2000, PAIN, V85, P217, DOI 10.1016/S0304-3959(99)00268-7; Kuo CP, 2006, BRIT J ANAESTH, V97, P640, DOI 10.1093/bja/ael217; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; MARKHAM SJ, 1986, ANAESTHESIA, V41, P1098, DOI 10.1111/j.1365-2044.1986.tb12956.x; Marret E, 2008, BRIT J SURG, V95, P1331, DOI 10.1002/bjs.6375; Martin F, 2008, ANESTHESIOLOGY, V109, P118, DOI 10.1097/ALN.0b013e31817b5a9b; MCCARTHY GC, [No title captured], V70, P1149; Mui WLM, 2006, ANN SURG, V244, P27, DOI 10.1097/01.sla.0000217691.81562.7e; Orstavik K, 2003, BRAIN, V126, P567, DOI 10.1093/brain/awg060; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RIMBACK G, 1990, ANESTH ANALG, V70, P414; ROWLAND M, 1971, ANN NY ACAD SCI, V179, P383, DOI 10.1111/j.1749-6632.1971.tb46915.x; Sugimoto M, 2003, BRIT J PHARMACOL, V138, P876, DOI 10.1038/sj.bjp.0705107; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; Vatansev C, 2002, SURG LAPARO ENDO PER, V12, P243, DOI 10.1097/00129689-200208000-00008; Wallace MS, 2000, ANESTHESIOLOGY, V92, P75, DOI 10.1097/00000542-200001000-00017	35	18	20	0	1	FIELD HOUSE PUBLISHING LLP	WORTHING	6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND	0300-0605			J INT MED RES	J. Int. Med. Res.	MAR-APR	2011	39	2					435	445		10.1177/147323001103900211			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	771FI	WOS:000291142200011	21672347	Green Published			2020-06-30	J	Kanamori, C; Kanamori, T; Tanaka, Y; Kanzaki, H				Kanamori, Chiharu; Kanamori, Takanobu; Tanaka, Yoshiaki; Kanzaki, Hideharu			Three-cycle fentanyl patch system contributes to stable control of plasma fentanyl concentration in gynecologic cancer pain patients	TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY			English	Article						Cancer pain; Opioid rotation; Opioid therapy; Pain control; Transdermal fentanyl	TRANSDERMAL FENTANYL; MORPHINE; MANAGEMENT	Objective: Pain affects many cancer patients in advancing stages, lowering the level of their quality of life. Morphine has long been the "gold standard" for the treatment of cancer pain; however, its side effects, particularly sedation and cognitive impairment at high doses, have encouraged the use of "opioid rotation". The transdermal fentanyl patch has advantages over oral morphine, with reduced side effects and increased convenience in practical usage. The side effects were reduced in patients who changed to the fentanyl patch, but rescue analgesia was often needed because of the decrease of fentanyl release from the patch, especially on patch replacement day. To maintain a stable fentanyl plasma level before patch replacement, we have established a three-cycle fentanyl patch system and reported that it provided appropriate pain control. The objective of this study was to investigate the individual variability of plasma fentanyl concentration in a three-cycle fentanyl patch system. Case Report: The gynecologic cancer patients were treated using the three-cycle fentanyl patch system. Blood samples were taken from the patients and plasma fentanyl concentration was analyzed. A stable plasma fentanyl level was observed, and good pain control was achieved in each patient using the three-cycle fentanyl patch system. A stable plasma fentanyl level was maintained the day before the conventional patch replacement day. Discussion: The three-cycle fentanyl patch system provided a stable plasma fentanyl concentration and excellent pain relief and should be considered for pain control in cancer patients. Copyright (C) 2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.	[Kanamori, Chiharu; Kanzaki, Hideharu] Kansai Med Univ, Dept Obstet & Gynecol, Osaka 5708506, Japan; [Kanamori, Takanobu; Tanaka, Yoshiaki] Kayashima Ikuno Hosp, Dept Obstet & Gynecol, Osaka, Japan; [Kanamori, Takanobu] Kanamori Ladies Clin, Kyoto, Japan	Kanamori, C (reprint author), Kansai Med Univ, Dept Obstet & Gynecol, Osaka 5708506, Japan.	goldwoodchiharu@yahoo.co.jp					CALIS KA, 1992, CLIN PHARMACY, V11, P22; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; HAYS H, 1995, AM PAIN SOC 14 ANN M, P17; *JANSS PHARM, 1995, 1097592 JANSS PHARM; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kanamori C, 2006, J OBSTET GYNAECOL RE, V32, P605, DOI 10.1111/j.1447-0756.2006.00457.x; Konishi H, 2005, PHARM WORLD SCI, V27, P353, DOI 10.1007/s11096-005-5972-7; Mystakidou K, 2003, INT J CANCER, V107, P486, DOI 10.1002/ijc.11416; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	12	3	3	0	0	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	1028-4559			TAIWAN J OBSTET GYNE	Taiwan. J. Obstet. Gynecol.	MAR	2011	50	1					79	84		10.1016/j.tjog.2011.01.006			6	Obstetrics & Gynecology	Obstetrics & Gynecology	758SY	WOS:000290188000016	21482380	DOAJ Gold			2020-06-30	J	Coura, LEF; Manoel, CHU; Poffo, R; Bedin, A; Westphal, GA				Faria Coura, Luiz Eduardo; Uratsuka Manoel, Claudia Hideco; Poffo, Robinson; Bedin, Antonio; Westphal, Glauco Adrieno			Randomised, controlled study of preoperative eletroacupuncture for postoperative pain control after cardiac surgery	ACUPUNCTURE IN MEDICINE			English	Article							CHOLECYSTOKININ-OCTAPEPTIDE CCK-8; MET-ENKEPHALIN; ACUPUNCTURE; ELECTROACUPUNCTURE; STIMULATION; ANALGESIA; NAUSEA; NEURONS; TRIAL	Background This study aims to evaluate the effects of preoperative electroacupuncture (EA) on the need for opioids in the postoperative stage of conventional cardiac surgery. Methods A prospective, randomised and controlled study was conducted at Unimed Hospital Centre in Joinville, SC, Brazil. The day before the surgery, 32 patients undergoing cardiac surgery were randomised into two groups: patients from the treatment group received preoperative EA at bilateral points (LI4-LI11, LR3-ST36, PC6-TE5) for 30 min with alternating frequencies of 3 and 15 Hz. Patients from the control group received sham transcutaneous electrical nerve stimulation (TENS). Use of fentanyl during the postoperative period was measured. Results 10 patients were excluded because of hemodynamic and ventilatory instability leaving 13 (10 male) in the treatment group and 9 (4 male) in the control group. The average total doses of fentanyl given were 13.1+/-2.2 and 16.3+/-1.6 mu g/kg in the treatment and control groups respectively (p<0.002). The doses of patient controlled analgesia were 4.1+/-2.0 and 6.9+/-1.7 mu g/kg in the treatment and control groups respectively (p<0.003). The number of boluses issued also differed (treatment 13.9+/-7.0 vs control 24.8+/-7.0, p<0.002). Pain intensity scores differed between the groups (treatment 2.5+/-1.1 vs control 4.0+/-2.0, p<0.04). One patient from the control group experienced drowsiness that justified a change in fentanyl infusion, as decided by the anaesthetist. Conclusion Preoperative electro-acupuncture in conventional cardiac surgery may reduce the postoperative consumption of fentanyl.	[Uratsuka Manoel, Claudia Hideco] Ctr Estudos Acupuntura Parana, Curitiba, Parana, Brazil		ludoterapia@bol.com.br	cmu, library/L-1810-2013				AMESTOY RD, 2005, ELETROTERAPIA ELETRO; BALDRY PE, 2008, NEUROFISIOLOGIA DOR, P60; BOWSHER D, 1968, J NEUROPHYSIOL, V31, P288; BOWSHER D, 1976, PAIN, V2, P361, DOI 10.1016/0304-3959(76)90079-8; Bowsher D, 1990, ACUPUNCT MED, V7, P17; Cassileth BR, 2007, CHEST, V132, p340S, DOI 10.1378/chest.07-1389; DUNDEE JW, 1988, BRIT J ANAESTH, V61, pP116; DUNDEE JW, 1991, CLIN PHARMACOL THER, V50, P78, DOI 10.1038/clpt.1991.106; DUNDEE JW, 1989, BRIT J ANAESTH, V63, P612, DOI 10.1093/bja/63.5.612; El-Rakshy M, 2009, ACUPUNCT MED, V27, P9, DOI 10.1136/aim.2008.000075; Han JS, 1995, PROG BRAIN RES, V105, P263; HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M; HAN JS, 1986, PAIN, V27, P101, DOI 10.1016/0304-3959(86)90227-7; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; HAN JS, 1984, PAIN S, V2, P543; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P47, DOI 10.1113/jphysiol.1985.sp015574; HURLEY RW, 2009, ACUTE POSTOPERATIVE; KARAVIS M, 1997, ACUPUNCT MED, V15, P33; Korinenko Y, 2009, ANN THORAC SURG, V88, P537, DOI 10.1016/j.athoracsur.2009.04.106; LIOETING O, 1992, ACUPUNCT MED, V10, P47; Ma SX, 2004, EVID-BASED COMPL ALT, V1, P41, DOI 10.1093/ecam/neh017; RUDA MA, 1984, J NEUROSCI, V4, P2117; SHANKS MF, 1981, BRAIN RES, V212, P403, DOI 10.1016/0006-8993(81)90472-8; SHERWOOD ER, 2007, ANESTHESIOLOGY PRINC; Sim Chin-Keng, 2002, Acupunct Med, V20, P56; SLINGER PD, 2009, ANESTHESIA THORACIC; Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b; WEIGHTMAN WM, 1987, BRIT MED J, V295, P1379, DOI 10.1136/bmj.295.6610.1379; WHITE A, 2002, ANALGESIA ELETROACUP, P185; Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064	30	33	34	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0964-5284	1759-9873		ACUPUNCT MED	Acupunct. Med.	MAR	2011	29	1					16	20		10.1136/aim.2010.003251			5	Integrative & Complementary Medicine	Integrative & Complementary Medicine	744FN	WOS:000289080400006	21383391				2020-06-30	J	Botterman, J; Criel, N				Botterman, J.; Criel, N.			Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit	PALLIATIVE MEDICINE			English	Article						Opioids; opioid analgesics; pain; palliative care; transdermal fentanyl	OPIOID-INDUCED HYPERALGESIA; CANCER PAIN; RESPIRATORY DEPRESSION; EAPC RECOMMENDATIONS; ORAL MORPHINE; PRESCRIPTIONS; TOXICITY; LAW	A retrospective study was conducted to determine the patterns of strong opioid use in patients admitted to a hospice inpatient unit, with special attention to the use of the transdermal fentanyl patch. This study was conducted to validate or negate the subjective feeling that many patients, treated at admittance with the fentanyl patch, received inappropriately high doses compared to patients treated with oral or parenteral opioids. The case notes of 1154 patients were reviewed and data collected on age, sex, diagnosis, care settings, opioid form and dose on referral, maximal dose during admission and opioid use during the last 24 hours of their life. At admission opioids had been prescribed for 47% of patients. Thirty-two percent of these patients received oral morphine. The median dose at admission of those patients was 60 mg (oral morphine equivalent (OME)). Thirty-six percent of the patients on opioids were using the fentanyl patch. The median dose at admission was triple that of the orally treated patients (median 180 mg OME). In the 199 patients using transdermal fentanyl at admission, in most patients the dose of the patch was gradually diminished and finally stopped in 58% of patients. Only 83 kept it until the last 24 hours. We would like to draw attention to the fact that (sometimes inappropriately) high doses of fentanyl were used at admission, probably due to lack of knowledge of the relative strength of the opioid involved and to the failure to recognize the phenomenon of opioid-induced hyperalgesia. In addition, in our experience the long action of the patch can be a disadvantage during the last days and weeks of life, due to the difficulty of dose adjustment and the risk for toxicity.		Botterman, J (reprint author), AZ St Lucas, Palliat Care Unit, Groene Briel 1, B-9000 Ghent, Belgium.	jacky.botterman@azstlucas.be			Mundipharma Belgium	This research received a research grant from Mundipharma Belgium for data collection and statistical analysis.	Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Angst MS, 2006, ANESTHESIOLOGY, V104, P570, DOI 10.1097/00000542-200603000-00025; Bandieri E, 2009, ANN ONCOL, V20, P961, DOI 10.1093/annonc/mdp041; Botterman J, 2004, PALLIATIVE MED, V18, P663, DOI 10.1191/0269216304pm915xx; BRESCIA FJ, 1992, J CLIN ONCOL, V10, P149, DOI 10.1200/JCO.1992.10.1.149; BROOKS DJ, 1995, PALLIATIVE MED, V9, P229, DOI 10.1177/026921639500900308; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; Chinellato A, 2006, BRIT J CLIN PHARMACO, V62, P130, DOI 10.1111/j.1365-2125.2006.02600.x; Daeninck PJ, 1999, ACTA ANAESTH SCAND, V43, P924, DOI 10.1034/j.1399-6576.1999.430910.x; Davies A, 1997, PALLIATIVE MED, V11, P168; Davis MP, 2007, J CLIN ONCOL, V25, P4497, DOI 10.1200/JCO.2006.09.1462; De Conno F, 2005, PALLIATIVE MED, V19, P179, DOI 10.1191/0269216305pm1002oa; del Pozo JG, 2008, EUR J CLIN PHARMACOL, V64, P411, DOI 10.1007/s00228-007-0419-9; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Fallon M, 2008, PALLIATIVE MED, V22, P5, DOI 10.1177/0269216307086857; FEELY J, 1990, BRIT MED J, V300, P22, DOI 10.1136/bmj.300.6716.22; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; LANG C C, 1992, Palliative Medicine, V6, P246, DOI 10.1177/026921639200600309; LOMBARD DJ, 1989, PALLIATIVE MED, V3, P27; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; McLoughlin R, 1997, PALLIATIVE MED, V11, P419; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Mercadante S, 2002, LANCET, V360, P1254, DOI 10.1016/S0140-6736(02)11261-X; Nauck F, 2000, EUR J PALLIAT CARE, V7, P81; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Ripamonti C, 2006, SUPPORT CARE CANCER, V14, P400, DOI 10.1007/s00520-005-0918-0; Valerz JP, 2000, EUR J PALLIAT CARE, V7, P178; Welsh J, 2005, PALLIATIVE MED, V19, P9, DOI 10.1191/0269216305pm971oa; FEDERAL SOCIAL SECUR	31	5	5	1	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.	MAR	2011	25	2					111	116		10.1177/0269216310384901			6	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	734VG	WOS:000288367500002	20937611				2020-06-30	J	Carvalho, B; Collins, J; Drover, DR; Ralls, LA; Riley, ET				Carvalho, Brendan; Collins, Jeremy; Drover, David R.; Ralls, Lindsey Atkinson; Riley, Edward T.			ED50 and ED95 of Intrathecal Bupivacaine in Morbidly Obese Patients Undergoing Cesarean Delivery	ANESTHESIOLOGY			English	Article							SPINAL-ANESTHESIA; HYPERBARIC BUPIVACAINE; 0.5-PERCENT BUPIVACAINE; TERM PARTURIENT; REGIONAL ANESTHESIA; DOUBLE-BLIND; SECTION; SPREAD; ANALGESIA; BLOCK	Background: It has been suggested that morbidly obese parturients may require less local anesthetic for spinal anesthesia. The aim of this study was to determine the effective dose (ED50/ED95) of intrathecal bupivacaine for cesarean delivery in morbidly obese patients. Methods: Morbidly obese parturients (body mass index equal to or more than 40) undergoing elective cesarean delivery were enrolled in this double-blinded study. Forty-two patients were randomly assigned to receive intrathecal hyperbaric bupivacaine in doses of 5, 6, 7, 8, 9, 10, or 11 mg (n = 6 per group) coadministered with 200 mu g morphine and 10 mu g fentanyl. Success (induction) was defined as block height to pinprick equal to or more than T6 and success (operation) as success (induction) plus no requirement for epidural supplementation throughout surgery. The ED50/ED95 values were determined using a logistic regression model. Results: ED50 and ED95 (with 95% confidence intervals) for success (operation) were 9.8 (8.6-11.0) and 15.0 (10.0-20.0), respectively, and were similar to corresponding values of a nonobese population determined previously using similar methodology. We were unable to measure ED50/ED95 values for success (induction) because so few blocks failed initially, even at the low-dose range. There were no differences with regard to secondary outcomes (i.e., hypotension, vasopressor use, nausea, and vomiting). Conclusions: Obese and nonobese patients undergoing cesarean delivery do not appear to respond differently to modest doses of intrathecal bupivacaine. This dose-response study suggests that doses of intrathecal bupivacaine less than 10 mg may not adequately ensure successful intraoperative anesthesia. Even when the initial block obtained with a low dose is satisfactory, it will not guarantee adequate anesthesia throughout surgery.	[Carvalho, Brendan; Collins, Jeremy; Drover, David R.; Ralls, Lindsey Atkinson; Riley, Edward T.] Stanford Univ, Sch Med, Dept Anesthesiol, Stanford, CA 94305 USA	Carvalho, B (reprint author), Stanford Univ, Sch Med, Dept Anesthesiol, H3580, Stanford, CA 94305 USA.	bcarvalho@stanford.edu					Aiono-Le Tagaloa L, 2009, ANESTHESIOL RES PRAC; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Brodsky JB, 2007, OBES SURG, V17, P1146, DOI 10.1007/s11695-007-9207-y; Butwick A, 2010, J CLIN ANESTH, V22, P519, DOI 10.1016/j.jclinane.2010.01.005; Carvalho B, 2005, ANESTHESIOLOGY, V103, P606, DOI 10.1097/00000542-200509000-00025; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Danelli G, 2001, Minerva Anestesiol, V67, P573; das Neves Jose Francisco Nunes Pereira, 2003, Rev Bras Anestesiol, V53, P573; Dershwitz M, 1998, J CLIN ANESTH, V10, P314, DOI 10.1016/S0952-8180(98)00035-X; FAN SZ, 1994, ANESTH ANALG, V78, P474; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; GREENE NM, 1985, ANESTH ANALG, V64, P715; HARTWELL BL, 1991, REGION ANESTH, V16, P17; HODGKINSON R, 1980, ANESTH ANALG, V59, P89; Hogan QH, 1996, ANESTHESIOLOGY, V84, P1341, DOI 10.1097/00000542-199606000-00010; Ithnin F, 2006, ANESTH ANALG, V102, P577, DOI 10.1213/01.ane.0000195440.51717.37; Kang F C, 1998, Acta Anaesthesiol Sin, V36, P207; Lee Yung, 2009, Rev. Bras. Anestesiol., V59, P674, DOI 10.1590/S0034-70942009000600003; MCCULLOCH WJD, 1986, BRIT J ANAESTH, V58, P610, DOI 10.1093/bja/58.6.610; NORRIS MC, 1990, ANESTHESIOLOGY, V72, P478, DOI 10.1097/00000542-199003000-00015; NORRIS MC, 1988, ANESTH ANALG, V67, P555; PEDERSEN H, 1989, ANESTH ANALG, V69, P46; PITKANEN MT, 1987, ANESTH ANALG, V66, P127, DOI 10.1213/00000539-198702000-00005; Reyes M, 2004, INT J OBSTET ANESTH, V13, P99, DOI 10.1016/j.ijoa.2003.09.004; Richardson MG, 1998, ANESTH ANALG, V87, P336, DOI 10.1097/00000539-199808000-00019; Roofthooft E, 2009, CURR OPIN ANESTHESIO, V22, P341, DOI 10.1097/ACO.0b013e328329a5b8; Russell IF, 2006, INT J OBSTET ANESTH, V15, P294, DOI 10.1016/j.ijoa.2006.06.006; Russell IF, 2004, INT J OBSTET ANESTH, V13, P146, DOI 10.1016/j.ijoa.2003.12.007; RUSSELL IF, 1987, BRIT J ANAESTH, V59, P347, DOI 10.1093/bja/59.3.347; SANTOS A, 1984, ANESTH ANALG, V63, P1009; Schnider TW, 1996, ANESTHESIOLOGY, V85, P502, DOI 10.1097/00000542-199609000-00009; Soens MA, 2008, ACTA ANAESTH SCAND, V52, P6, DOI 10.1111/j.1399-6576.2007.01483.x; TAIVAINEN T, 1990, BRIT J ANAESTH, V64, P542, DOI 10.1093/bja/64.5.542; VANHEMELRIJCK J, 1994, ANESTHESIOLOGY, V80, P36; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014	35	39	41	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2011	114	3					529	535		10.1097/ALN.0b013e318209a92d			7	Anesthesiology	Anesthesiology	725QH	WOS:000287660300012	21307769	Bronze			2020-06-30	J	Johnstone, RE; Katz, RL; Stanley, TH				Johnstone, Robert E.; Katz, Ronald L.; Stanley, Theodore H.			Homicides Using Muscle Relaxants, Opioids, and Anesthetic Drugs Anesthesiologist Assistance in Their Investigation and Prosecution	ANESTHESIOLOGY			English	Article							MURDER; ROCURONIUM; SUICIDE; PLASMA		[Johnstone, Robert E.; Katz, Ronald L.; Stanley, Theodore H.] W Virginia Univ, Dept Anesthesiol, Morgantown, WV 26506 USA	Johnstone, RE (reprint author), W Virginia Univ, Dept Anesthesiol, POB 9134, Morgantown, WV 26506 USA.	johnstoner@rcbhsc.wvu.edu					Ballard KD, 2006, J AM SOC MASS SPECTR, V17, P1456, DOI 10.1016/j.jasms.2006.06.026; Benedict B, 2004, AM J FOREN MED PATH, V25, P159, DOI 10.1097/01.paf.0000127383.69760.72; Curfman GD, 2008, NEW ENGL J MED, V358, P403, DOI 10.1056/NEJMe0800032; Epstein RH, 2007, ANESTH ANALG, V105, P1053, DOI 10.1213/01.ane.0000281797.00935.08; Furbee RB, 2006, CLIN LAB MED, V26, P255, DOI 10.1016/j.cll.2006.02.001; Gao L, 2002, BRIT J ANAESTH, V88, P764, DOI 10.1093/bja/88.6.764; GLATT J, 2010, PLAYING FIRE TRUE ST, P1; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; HALL LH, 1979, ANAL CHEM, V51, pA812, DOI 10.1021/ac50044a001; KAZZI ZN, 2011, OPIOIDS CRIMINAL POI, P103; Kirby RR, 2009, ANESTH ANALG, V108, P1182, DOI 10.1213/ane.0b013e318198d45e; KLIFF S, 2010, NEWSWEEK        0315; Madea B, 1999, INT J LEGAL MED, V113, P47, DOI 10.1007/s004140050278; Martinez MA, 2006, J ANAL TOXICOL, V30, P120, DOI 10.1093/jat/30.2.120; NEER TM, 2011, EVALUATING POTENTIAL, P19; Pitts NI, 2000, BRIT J ANAESTH, V85, P592, DOI 10.1093/bja/85.4.592; RAMSLAND K, 2007, INSIDE MINDS HEALTHC, P85; Reynolds LM, 1997, ANESTHESIOLOGY, V87, P1096, DOI 10.1097/00000542-199711000-00014; Risse M, 2001, FORENSIC SCI INT, V124, P209, DOI 10.1016/S0379-0738(01)00589-8; SEVERO R, 1999, NY TIMES        0321; Shepherd G, 2009, CLIN TOXICOL, V47, P342, DOI 10.1080/15563650902893089; Tuffs Annette, 2003, BMJ, V327, P830, DOI 10.1136/bmj.327.7419.830-e; Verhagen E, 2005, NEW ENGL J MED, V352, P959, DOI 10.1056/NEJMp058026	23	8	9	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2011	114	3					713	716		10.1097/ALN.0b013e31820b8d19			4	Anesthesiology	Anesthesiology	725QH	WOS:000287660300033	21343726	Bronze			2020-06-30	J	Nalamachu, S; Hassman, D; Wallace, MS; Dumble, S; Derrick, R; Howell, J				Nalamachu, Srinivas; Hassman, David; Wallace, Mark S.; Dumble, Sam; Derrick, Rob; Howell, Julian			Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Breakthrough pain; Cancer; Effectiveness; Fentanyl; Safety; Sublingual administration; Transmucosal	PREVALENCE; CITRATE	Background and objectives: Breakthrough cancer pain (BTcP) is a transient exacerbation of cancer pain in patients with otherwise stable, persistent background pain. This study evaluated the long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet (sublingual fentanyl ODT), for the treatment of BTcP in opioid-tolerant patients with cancer. Research design and methods: This was a non-randomized, open-label, multi-center, Phase III study conducted in opioid-tolerant patients (aged >= 17 years) with BTcP. The study comprised a 2-week titration phase, followed by a maintenance phase of up to 12 months. Patients self-administered sublingual fentanyl ODT for episodes of BTcP. Effectiveness was assessed using patients' global evaluation of medication (PGEM), the brief pain inventory (BPI) and the depression, anxiety and positive outlook scale (DAPOS). Adverse events were recorded throughout. Clinical trial registration: NCT00263575 (http://www.clinicaltrials.gov/). Results: Of 139 recruited patients, 69% identified an effective dose of sublingual fentanyl ODT (a dosage that successfully treated all episodes of BTcP over two consecutive days) and entered the maintenance phase, during which they were treated for a median of 149.0 days (mean dose 507.5 mu g). The study recorded a significant increase in reported satisfaction with pain medication at the 6-month and end-of-study visits, compared to screening (p <= 0.01). Evaluation of quality of life using BPI and DAPOS identified no deterioration in scores and significant improvements in certain parameters (p < 0.05). Sublingual fentanyl ODT was well tolerated, with no study drug-related deaths, and 49 patients (35.3%) experiencing >= 1 study drug-related adverse event. The most common of these included nausea (8.6%), constipation (5.8%) and somnolence (5.8%). There was no evidence of sublingual mucosal irritation due to the study medication. The pattern of adverse events was similar to that previously observed with transmucosal fentanyl. Conclusions: Sublingual fentanyl ODT was effective and well tolerated for the long-term treatment of BTcP in opioid-tolerant cancer patients. There was an increase in satisfaction with pain medication during the study, and sublingual fentanyl ODT showed an acceptable safety profile over 12 months of treatment.	[Nalamachu, Srinivas] Int Clin Res Inst, Overland Pk, KS USA; [Hassman, David] Comprehens Clin Res, Berlin, NJ USA; [Wallace, Mark S.] Univ Calif San Diego, San Diego, CA 92103 USA; [Dumble, Sam] Quant Consulting Ltd, Roslin BioCtr, Roslin, Midlothian, Scotland; [Derrick, Rob; Howell, Julian] ProStrakan Inc, Clin Dev, Bedminster, NJ USA	Derrick, R (reprint author), ProStrakan Grp Plc, Galabank Business Pk, Galashiels TD1 1QH, Scotland.	rob.derrick@prostrakan.com			ProStrakan Group Ltd.; ProStrakan; Endo Pharmaceuticals; Archimedes	This study was sponsored by ProStrakan Group Ltd. Preparation and publication of this article was supported by ProStrakan.; S.N. has disclosed that he has acted as a principal investigator and speaker/consultant for Endo Pharmaceuticals. M. W. has disclosed that he has received research support from Endo Pharmaceuticals and Archimedes. S. D. has disclosed that he has acted as a consultant for ProStrakan. R. D. and J.H. have disclosed that they are employees of ProStrakan. D. H. has disclosed that he has no relevant financial relationships.	[Anonymous], 2010, EFF SPC; [Anonymous], 2010, ACT SPC; BENNETT D, 2005, [No title captured], V30, P354; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Coyle N, 1990, J Pain Symptom Manage, V5, P83; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Freye E., 2009, J PAIN RES, V2, P13; Geppetti P, 2009, CLIN DRUG INVEST, V29, P3, DOI 10.2165/0044011-200929001-00002; HARRIS D, 1992, J PHARM SCI-US, V81, P1, DOI 10.1002/jps.2600810102; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; *NCCN, 2009, [No title captured]; Pincus T, 2004, PAIN, V109, P181, DOI 10.1016/j.pain.2004.02.004; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Simmonds MA, 1999, ONCOLOGY-NY, V13, P1103; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	23	24	24	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	MAR	2011	27	3					519	530		10.1185/03007995.2010.545380			12	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	720ZZ	WOS:000287322500005	21208151				2020-06-30	J	Parkes, MJ				Parkes, M. J.			Has intrathecal fentanyl no effects during arm exercise?	JOURNAL OF APPLIED PHYSIOLOGY			English	Letter									Univ Birmingham, Sch Sport & Exercise Sci, Birmingham B15 2TT, W Midlands, England	Parkes, MJ (reprint author), Univ Birmingham, Sch Sport & Exercise Sci, Birmingham B15 2TT, W Midlands, England.	M.J.Parkes@bham.ac.uk					Amann M, 2010, J APPL PHYSIOL, V109, P966, DOI 10.1152/japplphysiol.00462.2010	1	1	1	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	MAR	2011	110	3					860	860		10.1152/japplphysiol.01413.2010			1	Physiology; Sport Sciences	Physiology; Sport Sciences	731RN	WOS:000288127100042	21386012				2020-06-30	J	Garten, L; Degenhardt, P; Buhrer, C				Garten, Lars; Degenhardt, Petra; Buehrer, Christoph			Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone	JOURNAL OF PEDIATRIC SURGERY			English	Article						Bowel dysfunction; Newborn; Opiate mu-receptor antagonist; Abdominal surgery	INDUCED CONSTIPATION; ADVANCED ILLNESS; BOWEL RESECTION; ALVIMOPAN; MORPHINE; RATS	Transient impairment of bowel function is a frequent and distressing problem in neonates on opioid-induced analgesia. Methylnaltrexone, a peripheral-acting mu-opioid receptor antagonist, has been studied in adults for the treatment of opioid-induced constipation in advanced illness and has been suggested as a promising therapeutic concept for reducing postoperative ileus. Here, we report on a newborn infant on fentanyl analgesia after major abdominal surgery with aggravated ileus. After 8 days of quiescent bowel, the patient's intestinal dysmotility resolved within 15 minutes after intravenous administration of methylnaltrexone (0.15 mg/kg body weight). Methylnatrexone was repeated daily until cessation of fentanyl administration. There were no signs of pain or opioid withdrawal. (C) 2011 Elsevier Inc. All rights reserved.	[Garten, Lars] Charite, Klin Neonatol, Dept Neonatol, Med Ctr, D-13353 Berlin, Germany; [Degenhardt, Petra] Charite, Med Ctr, Dept Pediat Surg, D-13353 Berlin, Germany	Garten, L (reprint author), Charite, Klin Neonatol, Dept Neonatol, Med Ctr, Augustenburger Pl 1, D-13353 Berlin, Germany.	lars.garten@charite.de					Delaney CP, 2007, ANN SURG, V245, P355, DOI 10.1097/01.sla.0000232538.72458.93; Hummel P, 2008, J PERINATOL, V28, P55, DOI 10.1038/sj.jp.7211861; Kraft MD, 2008, EXPERT OPIN INV DRUG, V17, P1365, DOI [10.1517/13543784.17.9.1365, 10.1517/13543784.17.9.1365 ]; Kraft MD, 2007, AM J HEALTH-SYST PH, V64, pS13, DOI 10.2146/ajhp070430; Leslie JB, 2005, ANN PHARMACOTHER, V39, P1502, DOI 10.1345/aph.1E615; Liu MW, 2002, J PAIN SYMPTOM MANAG, V23, P48, DOI 10.1016/S0885-3924(01)00369-4; MANARA L, 1986, J PHARMACOL EXP THER, V237, P945; Portenoy RK, 2008, J PAIN SYMPTOM MANAG, V35, P458, DOI 10.1016/j.jpainsymman.2007.12.005; Slatkin Neal, 2009, J Support Oncol, V7, P39; TAVANI A, 1980, LIFE SCI, V27, P2211, DOI 10.1016/0024-3205(80)90386-0; Thomas J, 2008, NEW ENGL J MED, V358, P2332, DOI 10.1056/NEJMoa0707377; Wolff BG, 2007, J AM COLL SURGEONS, V204, P609, DOI 10.1016/j.jamcollsurg.2007.01.041; Yuan CS, 2000, JAMA-J AM MED ASSOC, V283, P367, DOI 10.1001/jama.283.3.367	13	12	12	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	MAR	2011	46	3					E13	E15		10.1016/j.jpedsurg.2010.10.015			3	Pediatrics; Surgery	Pediatrics; Surgery	729QG	WOS:000287965000004	21376180				2020-06-30	J	Mercadante, S; Ferrera, P; Arcuri, E				Mercadante, Sebastiano; Ferrera, Patrizia; Arcuri, Edoardo			The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study	SUPPORTIVE CARE IN CANCER			English	Article						Breakthrough pain; Methadone therapy; Fentanyl buccal tables; Cancer pain	PALLIATIVE CARE-UNIT; CANCER PAIN; INTRAVENOUS MORPHINE; OPIOID ROTATION; ORAL METHADONE; MANAGEMENT; RECOMMENDATIONS; REGIMEN; RATIO	Data on the treatment of beakthrough cancer pain (BTcP) in patients receiving methadone therapy are lacking. Whether methadone produces tolerance to other opioids, other opioids should be less effective when administered as a BTcP medication. The aim of this preliminary study was to assess the efficacy of fentanyl buccal tablets (FBT) for the treatment of BTcP in patients who receive methadone as a background analgesic. A prospective study was carried out for a period of 1 year in a consecutive sample of 13 advanced cancer patients admitted to an acute pain relief and palliative care unit-patients who were receiving stable doses of oral methadone for their background analgesia. The dose of FBT was 100 mu g for patients who were receiving 12 mg of oral methadone. For higher doses of methadone, proportional doses of FBT were given. For each episode, trained nurses collected changes in pain intensity (on numerical scale 0-10) and emerging problems when called for pain increases considered to be severe in intensity by patients) (T0) and 15 min after FBT administration (T15). The mean age was 58.1 (SD 9.9), and nine patients were males. Sixty-four events were treated with FBT (4.9 +/- 3.1 for each patient, on average). Patients were receiving mean doses of oral methadone of 68 mg (range 15-240). In the majority of events, a decrease in pain intensity > 33% and > 50% was observed (n = 20 and n = 26, respectively), 15 min after the administration of FBT. Data on ten episodes were unavailable. Nine events were unsuccessfully treated. In all the patients, the level of adverse effects after FBT administration was mild and undistinguishable from that associated with basal opioid analgesia. FBT was effective as breakthrough pain medication in patients receiving methadone for their background analgesia, confirming that this group of patients are not inevitably resistant to other opioids.	[Mercadante, Sebastiano; Ferrera, Patrizia] La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy; [Arcuri, Edoardo] Sacro Cuore Hosp, Rome, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care Unit, Pain Relief & Palliat Care Unit, Via S Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it					Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; DARWISH M, 2006, J PAIN S1, V7, P35; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Eugenio Kenneth R, 2004, J Pain Palliat Care Pharmacother, V18, P47; Fisher K, 2004, J PAIN SYMPTOM MANAG, V28, P619, DOI 10.1016/j.jpainsymman.2004.03.003; Hagen NA, 2007, J PALLIAT MED, V10, P331, DOI 10.1089/jpm.2006.0163; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P255, DOI 10.1016/S0885-3924(00)00236-0; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Slatkin Neal E, 2007, J Support Oncol, V5, P327; WALTER P, 2008, J PALLIAT MED, V11, P1103	22	7	7	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	MAR	2011	19	3					435	438		10.1007/s00520-010-1015-6			4	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	728CL	WOS:000287851500015	20882391				2020-06-30	J	Kawano, C; Hirayama, T; Kuroyama, M				Kawano, Chihiro; Hirayama, Takeshi; Kuroyama, Masakazu			Dose Conversion in Opioid Rotation from Continuous Intravenous Infusion of Morphine Hydrochloride Injection to Fentanyl Patch in the Management of Cancer Pain	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			English	Article						dose conversion; opioid rotation; morphine hydrochloride; fentanyl patch; cancer pain	CONTROLLED-RELEASE OXYCODONE; TRANSDERMAL FENTANYL; PHARMACOKINETICS	Opioid rotation has been proposed for management of cancer pain. No studies directly investigating dose equivalence between morphine injection (continuous IV administration) and the transdermal fentanyl patch have been reported. Therefore, we examined dose conversion ratios in patients undergoing opioid rotation from morphine injection to fentanyl patches. The subjects consisted of 45 patients admitted to Kitasato University East Hospital. Medical records were consulted to determine the "basic dose of morphine injection immediately prior to rotation" and the "basic dose of fentanyl patch after rotation". Equivalent doses and conversion ratios obtained with the expression of (daily dose of morphine injection (mg)/daily delivered dose of fentanyl patch (mg)) were determined from the relationship between the data by regression analysis. The regression equation obtained was Y=50.882X-13.96, r(2)=0.8922, where X and Y are daily doses of morphine injection and fentanyl patch, respectively. Equivalent doses and conversion ratios for daily dose of morphine injection (mg) : daily delivered dose of fentanyl patch (mg) (patch dose mg/3 days) were 16.6 mg: 0.6 mg (2.5 mg) =28 : 1, 47.1 mg: 1.2 mg (5 mg) = 39 : 1 and 169.2 mg : 3.6 mg (15 mg) =47 :1. In other reports, the ratio of morphine vs. fentanyl at 50 : 1 had no relation to the dose. While the present study suggested that in opioid rotation from low dose, 50 : 1 is not enough for the fentanyl patch. The dose conversion ratio of morphine injection to fentanyl patch was different at the low doses and high doses of morphine.	[Kawano, Chihiro; Hirayama, Takeshi; Kuroyama, Masakazu] Kitasato Univ, Sch Pharm, East Hosp, Minato Ku, Tokyo 1088641, Japan; [Kawano, Chihiro; Hirayama, Takeshi; Kuroyama, Masakazu] Kitasato Univ, Dept Pharm, East Hosp, Minami Ku, Kanagawa 2520380, Japan	Kawano, C (reprint author), Kitasato Univ, Sch Pharm, East Hosp, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	c-kawano@kitasato-u.ac.jp					Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; DOI T, 2003, TERMINAL CAR, V13, P5; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GLARE PA, 1991, THER DRUG MONIT, V13, P1, DOI 10.1097/00007691-199101000-00001; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Heiskanen T, 1997, PAIN, V73, P37, DOI 10.1016/S0304-3959(97)00072-9; HOSKIN PJ, 1989, BRIT J CLIN PHARMACO, V27, P499, DOI 10.1111/j.1365-2125.1989.tb05399.x; *JIH INC, 2008, DRUGS JAP ETH DRUGS, P1977; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; Kato K, 2004, YAKUGAKU ZASSHI, V124, P287, DOI 10.1248/yakushi.124.287; MARUYAMA K, 2003, PAIN CLINIC, V24, P12571; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; MIZUGUCHI T, 2001, IYAKU J, V37, P2389; MOORE A, 1984, CLIN PHARMACOL THER, V35, P641, DOI 10.1038/clpt.1984.88; MOSSER KH, 1992, AM FAM PHYSICIAN, V45, P2289; *THOMS HEALTHC INC, 2008, PHYS DESK REF, P2352	18	5	5	0	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAR	2011	131	3					463	467		10.1248/yakushi.131.463			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	727IR	WOS:000287792400022	21372544	Bronze			2020-06-30	J	Ashburn, MA; Slevin, KA; Messina, J; Xie, F				Ashburn, Michael A.; Slevin, Kieran A.; Messina, John; Xie, Fang			The Efficacy and Safety of Fentanyl Buccal Tablet Compared with Immediate-Release Oxycodone for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain	ANESTHESIA AND ANALGESIA			English	Article							CHRONIC NONCANCER PAIN; LONG-TERM SAFETY; CANCER PAIN; TREATED PATIENTS; CITRATE OTFC(R); DOSE-TITRATION; PREVALENCE; MULTICENTER; GUIDELINES; THERAPY	BACKGROUND: Current clinical guidelines have identified the need for studies comparing the effect of different short-acting or rapid-onset opioids for the treatment of breakthrough pain (BTP). In this study we evaluated the efficacy and safety of treatment with fentanyl buccal tablet (FBT) in comparison with immediate-release oxycodone in alleviating BTP in opioid-tolerant patients with chronic pain. METHODS: In this cross-over design study, opioid-tolerant patients were randomized to open-label titration with FBT (200, 400, 600, 800 mu g) followed by oxycodone (15, 30, 45, 60 mg) or vice versa for the management of BTP. After titration to a successful dose of both study drugs, patients were rerandomized to double-blind treatment for 10 BTP episodes with 1 of the already identified successful doses of study drug followed by cross-over to double-blind treatment for 10 BTP episodes with the other study drug. The primary efficacy measure was the difference in pain intensity (based on an 11-point numerical scale) 15 minutes after administration of study drug (PID15). Other efficacy measures included PID at other time points postdose (5 through 60 minutes), the sum of pain intensity differences (SPID) at 30 and 60 minutes postdose, pain relief (5 through 60 minutes), proportion of BTP episodes for which patients experienced meaningful reduction in pain intensity, and patient preference for BTP medication. Adverse events were also recorded. RESULTS: Of the 323 patients enrolled, 203 achieved a successful dose of both study drugs, 191 completed the titration phase, and 180 completed the double-blind phase. PID15 was significantly greater after FBT versus oxycodone (mean [SD], 0.82 [1.12] vs. 0.60 [0.88]; 95% confidence interval [CI] = 0.18, 0.29; P < 0.0001). Secondary efficacy measures favored FBT and showed differences versus oxycodone from 5 minutes postdose for PID and 10 minutes postdose for pain relief. SPID30 and SPID60 were greater with FBT than with oxycodone (P < 0.0001 for both measures). A >= 33% improvement in pain intensity occurred in a larger proportion of FBT-treated episodes versus oxycodone beginning 15 through 45 minutes postdose (P < 0.05). FBT was preferred by 52% of patients, oxycodone by 33%. Adverse events with both study drugs were generally typical of opioids, and the majority occurred during titration. Two serious adverse events (pneumonia) were reported in 1 patient; both occurrences were considered unrelated to study drug. CONCLUSION: FBT resulted in more rapid onset of analgesia and was generally well tolerated in comparison with oxycodone for the treatment of BTP in opioid-tolerant patients. (Anesth Analg 2011;112:693-702)	[Ashburn, Michael A.; Slevin, Kieran A.] Hosp Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Messina, John; Xie, Fang] Cephalon Inc, Frazer, PA USA	Ashburn, MA (reprint author), Penn Pain Med Ctr, Tuttleman Ctr, Penn Med Rittenhouse,1840 South St,2nd Floor, Philadelphia, PA 19146 USA.	Michael.Ashburn@uphs.upenn.edu			Cephalon, Inc. (Frazer, PA); Cephalon, Inc.	This study was sponsored by Cephalon, Inc. (Frazer, PA). Writing support was provided by Peloton Advantage, LLC, funded by Cephalon, Inc.	Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; Bennett D, 2005, MANAGEMENT PHARM THE, V30, P354; *CEPH INC, 2009, FENT PACK INS; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Derby S, 1998, CNS DRUGS, V9, P99, DOI 10.2165/00023210-199809020-00003; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Fine PG, 2010, J PAIN SYMPTOM MANAG, V40, P747, DOI 10.1016/j.jpainsymman.2010.02.009; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; International Conference on Harmonisation Working Group, 1996, INT C HARM TECHN REQ; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Saunders DL, 2009, CLIN PHARMACOL THER, V85, pS82; Shojaei A H, 1998, J Pharm Pharm Sci, V1, P15; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Taylor DR, 2007, PAIN MED, V8, P281, DOI 10.1111/j.1526-4637.2007.00298.x; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	35	37	39	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2011	112	3					693	702		10.1213/ANE.0b013e318209d320			10	Anesthesiology	Anesthesiology	726DG	WOS:000287698400036	21304148				2020-06-30	J	Wetzel, B; Pavlovic, D; Kuse, R; Gibb, A; Merk, H; Lehmann, C; Wendt, M; Usichenko, TI				Wetzel, Bert; Pavlovic, Dragan; Kuse, Renate; Gibb, Andreas; Merk, Harry; Lehmann, Christian; Wendt, Michael; Usichenko, Taras I.			The Effect of Auricular Acupuncture on Fentanyl Requirement During Hip Arthroplasty A Randomized Controlled Trial	CLINICAL JOURNAL OF PAIN			English	Article						auricular acupuncture; general anesthesia; fentanyl requirement	PAIN RELIEF; ELECTROACUPUNCTURE; STIMULATION	Objectives: Although auricular acupuncture (AA) is suggested to be effective in treatment of pain, it has not yet been used for intraoperative analgesia. Therefore, we studied whether the AA reduces intraoperative analgesic requirement during total hip arthroplasty (THA). Methods: One hundred and twenty patients scheduled for THA were enrolled in this patient-anesthesiologist-blinded study. The patients were randomly assigned to receive needling of specific AA points or a sham procedure (needling of 3 nonacupoints on the ear helix) ipsilateral to the surgery site. Fixed indwelling AA needles were placed in the evening before THA and withdrawn on the day after surgery. The patients received general anesthesia with desflurane, which end-tidal concentration was kept within 3.5 volume % to 5.5 volume% to maintain the Bispectral Index within 40% to 55%. The anesthesiologists were asked to titrate fentanyl to keep the heart rate and blood pressure within 20% of baseline values. The primary outcome was fentanyl amount given during surgery. The secondary outcome measures were incidence of nausea and vomiting and time to first request of analgesics in the recovery room. The success of patients' and anesthesiologist blinding was also documented. Results: The data of fentanyl requirement of 116 patients were available for the final analysis. Patients from AA group required 15% less fentanyl during surgery than the controls (4.6 +/- 1.1 mu g/kg vs. 5.2 +/- 1.3 mu g/kg; mean +/- SD; P = 0.008). Demographic data and secondary outcome measures were comparable in both groups. Discussion: Regarding the modest clinical effect, AA should be further investigated for its clinical usefulness for complementary analgesia during the surgery.	[Wetzel, Bert; Pavlovic, Dragan; Kuse, Renate; Gibb, Andreas; Lehmann, Christian; Wendt, Michael; Usichenko, Taras I.] Ernst Moritz Arndt Univ Greifswald, Dept Anesthesiol & Intens Care Med, D-17487 Greifswald, Germany; [Merk, Harry] Ernst Moritz Arndt Univ Greifswald, Dept Orthoped Surg, D-17487 Greifswald, Germany	Usichenko, TI (reprint author), Ernst Moritz Arndt Univ Greifswald, Dept Anesthesiol & Intens Care Med, Friedrich Loeffler St 23B, D-17487 Greifswald, Germany.	taras@uni-greifswald.de	Lehmann, Christian/G-4837-2013				Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011; Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024; CLEMENTJONES V, 1980, LANCET, V2, P946; Greif R, 2002, ANESTHESIOLOGY, V96, P306, DOI 10.1097/00000542-200202000-00014; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Karst M, 2007, ANESTH ANALG, V104, P295, DOI 10.1213/01.ane.0000242531.12722.fd; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; MacPherson H, 2001, COMPLEMENT THER MED, V9, P246, DOI 10.1054/ctim.2001.0488; MacPherson H, 2008, J ALTERN COMPLEM MED, V14, P883, DOI 10.1089/acm.2008.SAR-5; Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356; Remy C, 2005, BRIT J ANAESTH, V94, P505, DOI 10.1093/bja/aei085; Sator-Katzenschlager SM, 2007, EXPERT REV MED DEVIC, V4, P23, DOI 10.1586/17434440.4.1.23; Sator-Katzenschlager SM, 2006, HUM REPROD, V21, P2114, DOI 10.1093/humrep/del110; Simmons M S, 1993, Anesth Prog, V40, P14; Southworth S, 2009, CLIN THER, V31, P1922, DOI 10.1016/j.clinthera.2009.08.026; Taguchi A, 2002, ANAESTHESIA, V57, P1159, DOI 10.1046/j.1365-2044.2002.02832.x; ULETT GA, 1998, BIOL PSYCHIAT, V44, P29; Usichenko TI, 2006, ACUPUNCTURE ELECTRO, V31, P213, DOI 10.3727/036012906815844265; Usichenko TI, 2005, PAIN, V114, P320, DOI 10.1016/j.pain.2004.08.021	19	20	23	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	MAR-APR	2011	27	3					262	267		10.1097/AJP.0b013e3181fd516c			6	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	718MP	WOS:000287127400011	21346689				2020-06-30	J	Kahn, SA; Beers, RJ; Lentz, CW				Kahn, Steven Alexander; Beers, Ryan J.; Lentz, Christopher W.			Do Fentanyl and Morphine Influence Body Temperature After Severe Burn Injury?	JOURNAL OF BURN CARE & RESEARCH			English	Article							BROWN ADIPOSE-TISSUE; CARDIOPULMONARY BYPASS; RATS; MICE; THERMOREGULATION; HYPERTHERMIA; INVOLVEMENT; DEPENDENCE; LEUKOCYTES; RECEPTOR	Fentanyl lacks the antiinflammatory properties of morphine. Morphine attenuates the inflammatory response through differential stimulation of mu-receptor subtypes. Patients who receive morphine during coronary artery bypass graft have been shown to experience less postoperative fever than those who receive fentanyl. Patients who receive continuous fentanyl infusions in increased room temperatures after thermal injury may be at increased risk to experience higher body temperature than those who receive morphine. The records of 28 patients with >20% TBSA burn in 30 intensive care unit rooms (13 received fentanyl and 15 received morphine or hydromorphone) and 12 trauma patients who received fentanyl in 22 degrees C intensive care unit rooms were reviewed. Mean maximum core temperature and percentage of temperature recordings > 39 degrees C in the first 48 hours of admission were compared between burn patients who received fentanyl, those who did not, and with trauma patients. Burn patients exposed to fentanyl experienced significantly higher temperatures (40.1 +/- 0.9 degrees C) compared with those given morphine (38.7 +/- 0.8 degrees C) and compared with trauma patients (37.5 +/- 2.4 degrees C), P < .01 and P < .001, respectively. Burn patients on fentanyl had temperatures > 39 degrees C for a higher percentage of time (33 +/- 27%) than those without fentanyl (7.2 +/- 13%) and trauma patients (1 +/- 2.8%), P < .01 and P < .001, respectively. No differences in other medications administered, acute physiology and chronic health evaluation II scores, or the number of infections that could account for temperature disparities between groups existed. Burn patients who receive fentanyl in 30 degrees C rooms experience higher body temperatures and are febrile for a higher percentage of time than those receiving morphine only. Morphine has well-established antiinflammatory properties and likely attenuates the postburn inflammatory response more than fentanyl, resulting in lower body temperatures. This phenomenon needs to be further investigated in additional studies. (J Burn Care Res 2011; 32: 309-316)	[Lentz, Christopher W.] Univ New Mexico, Dept Surg, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Kahn, Steven Alexander; Beers, Ryan J.] Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA	Lentz, CW (reprint author), Univ New Mexico, Dept Surg, Hlth Sci Ctr, Albuquerque, NM 87131 USA.						ADLER MW, 1988, ANNU REV PHARMACOL, V28, P429, DOI 10.1146/annurev.pa.28.040188.002241; Adler MW, 1993, HDB EXPT PHARM, P205; Bencsics A, 1997, J NEUROIMMUNOL, V73, P1, DOI 10.1016/S0165-5728(96)00163-4; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Cao WH, 2005, AM J PHYSIOL-REG I, V288, pR723, DOI 10.1152/ajpregu.00669.2004; COX B, 1976, EUR J PHARMACOL, V36, P33, DOI 10.1016/0014-2999(76)90253-3; GELLER EB, 1983, J PHARMACOL EXP THER, V225, P391; GHOSH S, 1995, PHARMACOL BIOCHEM BE, V52, P73, DOI 10.1016/0091-3057(95)00001-D; Gore DC, 2003, ARCH SURG-CHICAGO, V138, P169, DOI 10.1001/archsurg.138.2.169; Gore DC, 2003, ARCH SURG-CHICAGO, V138, P174; Herrmann Julian B., 1942, JOUR PHARMACOL AND EXP THERAP, V76, P309; HOLTZMAN SG, 1969, J PHARMACOL EXP THER, V166, P125; KRUMHOLZ W, 1993, ACTA ANAESTH SCAND, V37, P386, DOI 10.1111/j.1399-6576.1993.tb03734.x; Murphy GS, 2007, ANESTH ANALG, V104, P1334, DOI 10.1213/01.ane.0000264108.47280.f5; Nachreiner R, 2006, J BURN CARE RES, V27, P237, DOI 10.1097/01.BCR.0000202644.17987.3F; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; ROSOW CE, 1982, J PHARMACOL EXP THER, V220, P464; ROSOW CE, 1980, J PHARMACOL EXP THER, V213, P273; Roy S, 1998, MOL BRAIN RES, V61, P190, DOI 10.1016/S0169-328X(98)00212-5; SPENCER RL, 1988, J PHARMACOL EXP THER, V246, P92; STEFANO GB, 1995, J CARDIOVASC SURG, V36, P25; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; Thornton SR, 1997, J PHARMACOL EXP THER, V281, P514; Vuckovic S, 1998, JPN J PHARMACOL, V78, P523, DOI 10.1254/jjp.78.523; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; WILMORE DW, 1978, SURG CLIN N AM, V58, P1173	26	3	3	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1559-047X	1559-0488		J BURN CARE RES	J. Burn Care Res.	MAR-APR	2011	32	2					309	316		10.1097/BCR.0b013e31820aaf7f			8	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	722ZO	WOS:000287475100024	21240000				2020-06-30	J	Spies, C; MacGuill, M; Heymann, A; Ganea, C; Krahne, D; Assman, A; Kosiek, HR; Scholtz, K; Wernecke, KD; Martin, J				Spies, Claudia; MacGuill, Martin; Heymann, Anja; Ganea, Christina; Krahne, Daniel; Assman, Angelika; Kosiek, Heinrich-Rudolf; Scholtz, Kathrin; Wernecke, Klaus-Dieter; Martin, Joerg			A prospective, randomized, double-blind, multicenter study comparing remifentanil with fentanyl in mechanically ventilated patients	INTENSIVE CARE MEDICINE			English	Article						Remifentanil; Analgesia; Critical care; Hypnotics and sedatives	INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; ANALGESIA-BASED SEDATION; CONTROLLED-TRIAL; MORPHINE REQUIREMENT; DECREASED DURATION; DAILY INTERRUPTION; CLINICAL-TRIALS; PROPOFOL; DELIRIUM	To compare the quality of analgesia provided by a remifentanil-based analgesia regime with that provided by a fentanyl-based regime in critically ill patients. This was a registered, prospective, two-center, randomized, triple-blind study involving adult medical and surgical patients requiring mechanical ventilation (MV) for more than 24 h. Patients were randomized to either remifentanil infusion or a fentanyl infusion for a maximum of 30 days. Sedation was provided using propofol (and/or midazolam if required). Primary outcome was the proportion of patients in each group maintaining a target analgesia score at all time points. Secondary outcomes included duration of MV, discharge times, and morbidity. At planned interim analysis (n = 60), 50% of remifentanil patients (n = 28) and 63% of fentanyl patients (n = 32) had maintained target analgesia scores at all time points (p = 0.44). There were no significant differences between the groups with respect to mean duration of ventilation (135 vs. 165 h, p = 0.80), duration of hospital stay, morbidity, or weaning. Interim analysis strongly suggested futility and the trial was stopped. The use of remifentanil-based analgesia in critically ill patients was not superior regarding the achievement and maintenance of sufficient analgesia compared with fentanyl-based analgesia.	[Spies, Claudia; MacGuill, Martin; Heymann, Anja; Ganea, Christina; Krahne, Daniel; Scholtz, Kathrin] Charite, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany; [Assman, Angelika; Kosiek, Heinrich-Rudolf; Martin, Joerg] Hosp Eichert, Dept Anesthesiol Intens Care Med & Pain Therapy, D-73035 Goppingen, Germany; [Wernecke, Klaus-Dieter] SOSTANA GmbH CRO, D-10318 Berlin, Germany	Spies, C (reprint author), Charite, Dept Anesthesiol & Intens Care Med, Campus Charite Mitte & Campus Virchow Klinikum,A, D-13353 Berlin, Germany.	claudia.spies@charite.de	Spies, Claudia/AAJ-5412-2020	Spies, Claudia/0000-0002-1062-0495	GlaxoSmithKline GmbH Co.	We would like to thank Dr. Oliver Betz, Hendrik Marius Mende, Dr. Klaus Kohlhammer, and Doris Endele from the Department of Anesthesiology, Intensive Care Medicine and Pain Therapy and Anton Plangger, Pharmacy Department, Hospital am Eichert, Eicherstrasse 3, 73035 Goppingen, Germany. We would also like to express our gratitude to Sabine Reichelt, Beatrix Laetsch, Esther Maahs, Dr. Heike Wendt (nee Marquardt) from the Department of Anesthesiology and Intensive Care Medicine, and Dr. Rybka-Golm from the Pharmacy Department of the Charite-Universitatsmedizin Berlin, Campus Virchow Klinikum and Campus Charite Mitte, Berlin, Germany. We are indebted to Professor Ralf Kuhlen (formerly of University Hospital Aachen), and Professor Michael Quintel (University Hospital Gottingen) for their discussion of the preliminary study design and to the members of the IDMC for their time and skills (Professor Gernot Marx of University Hospital Aachen, Professor Andreas Hoeft of University Hospital Bonn, Professor Christian Waydhas of University Hospital Essen, and Professor Ludwig A. Hothorn of the Institute for Biostatistics, Hannover). This study was fully supported by GlaxoSmithKline GmbH & Co.	ALAZIA M, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P465, DOI 10.1016/S0750-7658(87)80376-3; Amor MB, 2007, ANN FR ANESTH, V26, P1041, DOI 10.1016/j.annfar.2007.10.005; Baillard CB, 2005, ANN FR ANESTH, V24, P480, DOI 10.1016/j.annfar.2005.02.027; Bird SM, 2001, BRIT MED J, V323, P1424, DOI 10.1136/bmj.323.7326.1424; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; Calderon E, 2002, Rev Esp Anestesiol Reanim, V49, P421; Carrer S, 2007, Minerva Anestesiol, V73, P327; Chinachoti Thitima, 2002, Journal of the Medical Association of Thailand, V85, pS848; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003; Egan TD, 1996, ANESTHESIOLOGY, V84, P821, DOI 10.1097/00000542-199604000-00009; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Karabinis A, 2004, CRIT CARE, V8, pR268, DOI 10.1186/cc2896; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Luetz A, 2010, CRIT CARE MED, V38, P409, DOI 10.1097/CCM.0b013e3181cabb42; Martin J, 2005, CRIT CARE, V9, pR117, DOI 10.1186/cc3035; Martin J, 2010, GER MED SCI, V8; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Muellejans B, 2004, CRIT CARE, V8, pR1, DOI 10.1186/cc2398; Muellejans B, 2006, CRIT CARE, V10, DOI 10.1186/cc4939; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Payen JF, 2009, ANESTHESIOLOGY, V111, P1308, DOI 10.1097/ALN.0b013e3181c0d4f0; Pisani MA, 2009, CRIT CARE MED, V37, P177, DOI 10.1097/CCM.0b013e318192fcf9; Rauf K, 2005, BRIT J ANAESTH, V95, P611, DOI 10.1093/bja/aei237; Rello J, 1999, AM J RESP CRIT CARE, V159, P1742, DOI 10.1164/ajrccm.159.6.9808030; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; Schoenfeld DA, 2005, CRIT CARE, V9, P34, DOI 10.1186/cc3013; Skrobik Y, 2010, ANESTH ANALG, V111, P451, DOI 10.1213/ANE.0b013e3181d7e1b8; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Tan JA, 2009, ANAESTHESIA, V64, P1342, DOI 10.1111/j.1365-2044.2009.06129.x; WHIPPLE JK, 1995, PHARMACOTHERAPY, V15, P592, DOI 10.1002/j.1875-9114.1995.tb02868.x	34	24	26	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAR	2011	37	3					469	476		10.1007/s00134-010-2100-5			8	Critical Care Medicine	General & Internal Medicine	723NG	WOS:000287512900014	21165734	Bronze			2020-06-30	J	Kim, HS; Kim, CS; Kim, SD; Lee, JR				Kim, Hee-Soo; Kim, Chong Sung; Kim, Seong Deok; Lee, Jeong-Rim			Fascia iliaca compartment block reduces emergence agitation by providing effective analgesic properties in children	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Anesthesia, local; Emergence agitation; Fascia iliaca compartment block; Pediatric anesthesia	PATIENT-CONTROLLED ANALGESIA; SEVOFLURANE ANESTHESIA; DESFLURANE ANESTHESIA; REGIONAL ANESTHESIA; CAUDAL BLOCK; FENTANYL; SURGERY; ADOLESCENTS; DELIRIUM	Study Objective: To determine whether fascia iliaca compartment block (FICB) reduces emergence agitation. Design: Prospective, randomized, blinded clinical trial. Setting: Operating room and Postanesthesia Care Unit (PACU) of a university hospital. Patients: 64 ASA physical status 1 and 2 pediatric patients aged three to 7 years, scheduled for orthopedic surgery involving the anterior or lateral thigh. Interventions: Patients enrolled in the FICB group received FICB immediately after the operation, while control group patients received intravenous (IV) patient/parent-controlled analgesia (PCA) with fentanyl. Measurements: Severity of agitation and pain were evaluated using the Pediatric Agitation and Emergence Delirium (PAED) scale and the Children's Hospital of Eastern Ontario Pain Scale (CHEOPS). Data were collected at 10-minute intervals in the PACU. The results were analyzed using the t-test. Main Results: PAED scores in the FICB group were significantly lower than those of the control group on arrival at the PACU (7.3 +/- 2.9 vs 10.4 +/- 3.2, P < 0.001). The FICB group also had significantly lower CHEOPS pain scores than the control group, both on arrival at the PACU and 10 minutes after arrival (6.4 +/- 1.5 vs 10.4 +/- 1.8, P < 0.001 and 6.7 +/- 1.6 vs 8.0 +/- 1.4, P = 0.009, respectively). Conclusion: In children having surgery on the thigh, FICB effectively reduced the severity of emergence agitation and postoperative pain during the immediate postoperative period. (C) 2011 Elsevier Inc. All rights reserved.	[Lee, Jeong-Rim] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Seoul 120752, South Korea; [Kim, Hee-Soo; Kim, Chong Sung; Kim, Seong Deok] Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 110744, South Korea	Lee, JR (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, Seoul 120752, South Korea.	leejeongrim@gmail.com	Kim, Chong Sung/J-5436-2012; Kim, Hee Soo/J-5453-2012	Lee, Jeong-Rim/0000-0002-7425-0462			Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Berde C, 1996, ANESTH ANALG, V83, P897, DOI 10.1097/00000539-199611000-00001; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; Capdevila X, 1998, ANESTH ANALG, V86, P1039, DOI 10.1097/00000539-199805000-00025; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2001, ANESTH ANALG, V93, P88; DALENS B, 1989, ANESTH ANALG, V69, P705; DALENS B, 2005, MILLERS ANESTHESIA, P1740; Finkel JC, 2001, ANESTH ANALG, V92, P1164; GRECO CD, 2002, PEDIAT ANESTHESIA, P755; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; INAGAKI Y, 1994, ANESTH ANALG, V79, P368; Khalil SN, 2009, PEDIATR ANESTH, V19, P1220, DOI 10.1111/j.1460-9592.2009.03164.x; LIN YC, 2006, POSTOPERATIVE PAIN M, P211; MALVIYA S, 2009, PRACTICE ANESTHESIA, P953; Mayer J, 2006, ANESTH ANALG, V102, P400, DOI 10.1213/01.ane.0000189561.44016.99; Monitto CL, 2000, ANESTH ANALG, V91, P573, DOI 10.1213/00000539-200009000-00014; Peters JWB, 1999, PAEDIATR ANAESTH, V9, P235, DOI 10.1046/j.1460-9592.1999.00358.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Tverskoy M, 1996, REGION ANESTH, V21, P209; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; WEISMAN SJ, 2006, SMITHS ANESTHESIA IN, P439; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08; Zwass Maurice S, 2005, Anesthesiol Clin North Am, V23, P815, DOI 10.1016/j.atc.2005.09.003	26	16	20	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAR	2011	23	2					119	123		10.1016/j.jclinane.2010.08.007			5	Anesthesiology	Anesthesiology	739MX	WOS:000288723100007	21377075				2020-06-30	J	Fetherston, CM; Ward, S				Fetherston, Catherine M.; Ward, Sarah			Relationships between post operative pain management and short term functional mobility in total knee arthroplasty patients with a femoral nerve catheter: A preliminary study	JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH			English	Article							CONTROLLED ANALGESIA; QUADRICEPS STRENGTH; POSTOPERATIVE PAIN; JOINT REPLACEMENT; 3-IN-ONE BLOCK; HOSPITAL STAY; REHABILITATION; RECOVERY; DURATION; MORPHINE	Background: Effective pain management following total knee arthroplasty (TKA) is fundamental in achieving positive rehabilitation outcomes. The purpose of our study was to investigate post operative pain management in relation to short term functional mobility in an intervention group receiving concomitant use of an IV narcotic PCA and a continuous infusion of local anaesthetic via a femoral nerve catheter (CFNC), compared to a group receiving narcotic PCA alone. This was a preliminary study conducted to establish an appropriate design for a larger investigative study. Methods: A prospective design was used to measure the effect of a CFNC on post operative pain management and functional mobility prior to hospital discharge. The amount of fentanyl used, pain and nausea scores, timed up and go (TUG) tests and active range of knee movement (AROM) were used to compare a CFNC and supplemental narcotic patient controlled analgesia (PCA) group (n = 27) with a PCA only group (n = 25). Results: The CFNC group used significantly less fentanyl than the PCA only group (p < .001) but there was no significant difference in TUG times between the two groups. There was however a significantly lower AROM reported for both extension (p < .04) and flexion (p < .006,) in the FNC group. Women had significantly slower TUG times (p < .005,) and there were moderate to strong positive correlations between post operative TUG times and the preoperative TUG time (r(s) = .505 p < .001), the time since oral analgesia (r(s) = .529 p < .014), and pain scores (rs = .328, p = .034) Conclusions: In this small preliminary study improved TUG performance at Day 4 post op was not influenced by the use of a CFNC but was positively correlated with male gender, preoperative performance, time elapsed since last oral analgesia and pain score. However AROM was decreased in the CFNC group suggesting further research on the relationship between CFNCs, local anaesthetic concentration and quadriceps strength should be incorporated in the follow up study's design.	[Fetherston, Catherine M.] Murdoch Univ, Sch Nursing & Midwifery, Mandurah, WA 6210, Australia	Fetherston, CM (reprint author), Murdoch Univ, Sch Nursing & Midwifery, Educ Dr, Mandurah, WA 6210, Australia.	C.Fetherston@murdoch.edu.au					[Anonymous], 2008, STAT PROGR SOC SCI; Bohannon Richard W, 2006, J Geriatr Phys Ther, V29, P64; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Carli F, 2010, BRIT J ANAESTH, V105, P185, DOI 10.1093/bja/aeq112; Clark-Carter D., 2004, QUANTITATIVE PSYCHOL; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; De Ruyter ML, 2006, J ARTHROPLASTY, V21, P1111, DOI 10.1016/j.arth.2005.12.005; Fischer HBJ, 2008, ANAESTHESIA, V63, P1105, DOI 10.1111/j.1365-2044.2008.05565.x; Forst J, 1999, ARCH ORTHOP TRAUM SU, V119, P267, DOI 10.1007/s004020050407; Fortin PR, 2002, ARTHRITIS RHEUM, V46, P3327, DOI 10.1002/art.10631; Freter SH, 2000, CLIN REHABIL, V14, P96, DOI 10.1191/026921500675545616; Ganapathy S, 1999, ANESTH ANALG, V89, P1197, DOI 10.1213/00000539-199911000-00021; Holm B, 2010, DISABIL REHABIL, V32, P300, DOI 10.3109/09638280903095965; Ilfeld BM, 2006, ANESTH ANALG, V102, P87, DOI 10.1213/01.ane.0000189562.86969.9f; Ilfeld Brian M, 2008, Anesthesiology, V108, P703, DOI 10.1097/ALN.0b013e318167af46; Ilfeld BM, 2009, ANESTH ANALG, V108, P1320, DOI 10.1213/ane.0b013e3181964937; Jones CA, 2003, PHYS THER, V83, P696, DOI 10.1093/ptj/83.8.696; Kadic L, 2009, ACTA ANAESTH SCAND, V53, P914, DOI 10.1111/j.1399-6576.2009.01965.x; Kandasami M, 2009, KNEE, V16, P98, DOI 10.1016/j.knee.2008.10.007; KATZ JN, 1994, ARTHRITIS RHEUM, V37, P687, DOI 10.1002/art.1780370512; Kennedy DM, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-100; Kennedy LG, 2003, KNEE, V10, P161, DOI 10.1016/S0968-0160(02)00138-2; Lingard EA, 2004, J BONE JOINT SURG AM, V86A, P2179, DOI 10.2106/00004623-200410000-00008; McLeod GA, 2009, BRIT J ANAESTH, V102, P528, DOI 10.1093/bja/aep010; Mizner RL, 2005, J RHEUMATOL, V32, P1533; Mizner RL, 2005, J ORTHOP SPORT PHYS, V35, P424, DOI 10.2519/jospt.2005.35.7.424; Oldmeadow LB, 2002, AUST J PHYSIOTHER, V48, P117, DOI 10.1016/S0004-9514(14)60205-1; Petterson SC, 2007, J BONE JOINT SURG AM, V89A, P2327, DOI 10.2106/JBJS.F.01144; Petterson SC, 2009, ARTHRIT RHEUM-ARTHR, V61, P174, DOI 10.1002/art.24167; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Salinas FV, 2006, ANESTH ANALG, V102, P1234, DOI 10.1213/01.ane.0000198675.20279.81; Seet E, 2006, ANAESTH INTENS CARE, V34, P25, DOI 10.1177/0310057X0603400110; Serpell MG, 2004, CAN J ANAESTH, V51, P45; Serpell MG, 2005, CAN J ANAESTH, V52, P119; Singelyn FJ, 1998, ANESTH ANALG, V87, P88, DOI 10.1097/00000539-199807000-00019; Soever L, 2005, BEST PRACTICES CONTI; Wang H, 2002, REGION ANESTH PAIN M, V27, P139, DOI 10.1053/rapm.2002.29253; WATKINS MA, 1991, PHYS THER, V71, P90, DOI 10.1093/ptj/71.2.90	38	9	9	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-799X			J ORTHOP SURG RES	J. Orthop. Surg. Res.	FEB 7	2011	6								7	10.1186/1749-799X-6-7			8	Orthopedics	Orthopedics	971SX	WOS:000306225300001	21294923	DOAJ Gold, Green Published			2020-06-30	J	Kishimoto, S; Hirota, K; Segawa, H; Fukuda, K				Kishimoto, Shun; Hirota, Kiichi; Segawa, Hajime; Fukuda, Kazuhiko			Ectopic ACTH syndrome revealed as severe hypokalemia and persistent hypertension during the perioperative period: a case report	JOURNAL OF ANESTHESIA			English	Article						Hypokalemia; Ectopic ACTH syndrome; Cushing's syndrome; Licorice; Perioperative period	ENDOCRINE NEOPLASIA TYPE-1; MINERALOCORTICOID HYPERTENSION; THYMIC CARCINOIDS	Both severe hypokalemia and persistent hypertension are clinical symptoms of hyperaldosteronism. Hyperaldosteronism may occur as a primary or secondary syndrome. Excess ACTH produced ectopically by tumors may induce hyperaldosteronism through the mineralocorticoid activity of glucocorticoids that are upregulated by ACTH. Licorice, with the active ingredient glycyrrhiza, is also a well-known inducer of hyperaldosteronism under specific conditions. In this report, we describe a case of severe hypokalemia caused by ectopic ACTH syndrome (EAS) elicited by an intrathoracic carcinoid tumor, which had transformed to produce ACTH during the 6-year clinical course, and was modulated by licorice ingestion. Hypokalemia was not clearly recognized preoperatively but became obvious within 3 h of general anesthesia with epidural blockade. At the end of anesthesia, arterial blood gas analysis indicated severe hypokalemia ([K(+)] = 1.7 mEq/l) and metabolic alkalosis (pH 7.56, PaCO(2) = 54.9 mmHg, HCO(3)(-) = 44.5 mmol/l, BE = 21.8 mmol/l), without any typical symptoms such as muscle weakness or ECG abnormalities. The hypokalemia was resistant to potassium supplementation and persisted for 4 days. Perioperative imbalance between the administration and elimination of potassium and surgical stress might contribute to the rapid exacerbation and induce the clinical manifestation of EAS.	[Kishimoto, Shun; Hirota, Kiichi; Segawa, Hajime; Fukuda, Kazuhiko] Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 6068507, Japan; [Segawa, Hajime; Fukuda, Kazuhiko] Kyoto Univ Hosp, Intens Care Unit, Kyoto 6068507, Japan	Hirota, K (reprint author), Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.	hif1@mac.com	Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827			FARESE RV, 1991, NEW ENGL J MED, V325, P1223, DOI 10.1056/NEJM199110243251706; Funder JW, 1996, EUR J ENDOCRINOL, V134, P267, DOI 10.1530/eje.0.1340267; Gibril F, 2003, J CLIN ENDOCR METAB, V88, P1066, DOI 10.1210/jc.2002-021314; GORDON RD, 1994, LANCET, V344, P240, DOI 10.1016/S0140-6736(94)93003-1; Isidori AM, 2006, J CLIN ENDOCR METAB, V91, P371, DOI 10.1210/jc.2005-1542; LIDDLE GW, 1965, CANCER RES, V25, P1057; ROSAI J, 1972, CANCER, V29, P1061, DOI 10.1002/1097-0142(197204)29:4<1061::AID-CNCR2820290456>3.0.CO;2-3; Salgado LR, 2006, EUR J ENDOCRINOL, V155, P725, DOI 10.1530/eje.1.02278; Sigurjonsdottir HA, 2001, J HUM HYPERTENS, V15, P549, DOI 10.1038/sj.jhh.1001215; Stewart PM, 1999, LANCET, V353, P1341, DOI 10.1016/S0140-6736(98)06102-9; Teh BT, 1997, MEDICINE, V76, P21, DOI 10.1097/00005792-199701000-00002; Torpy DJ, 2002, ANN NY ACAD SCI, V970, P134, DOI 10.1111/j.1749-6632.2002.tb04419.x	12	1	1	0	3	SPRINGER TOKYO	TOKYO	1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN	0913-8668			J ANESTH	J. Anesth.	FEB	2011	25	1					104	107		10.1007/s00540-010-1041-z			4	Anesthesiology	Anesthesiology	749YH	WOS:000289507400015	21052735				2020-06-30	J	Okawa, H; Ono, T; Hashiba, E; Tsubo, T; Ishihara, H; Hirota, K				Okawa, Hirobumi; Ono, Tomoko; Hashiba, Eiji; Tsubo, Toshihito; Ishihara, Hironori; Hirota, Kazuyoshi			Use of bispectral index monitoring for a patient with hepatic encephalopathy requiring living donor liver transplantation: a case report	JOURNAL OF ANESTHESIA			English	Article						Bispectral index; Hepatic encephalopathy; Living donor liver transplantation	MIDAZOLAM; SEDATION; FAILURE	We report the use of perioperative bispectral index (BIS) monitoring in a patient who underwent living donor liver transplantation (LDLT). Hepatic encephalopathy featuring extreme excitement developed in a 42-year-old male and was diagnosed as acute hepatitis. Sedation with continuous infusion of midazolam was necessary. BIS value gradually decreased and reached 0 17 h after commencement of continuous infusion of midazolam. Midazolam infusion was stopped but BIS value remained 0. Brain CT scan revealed an almost normal image. Multi-lead electroencephalogram was recorded revealing almost no electrical activity. Administration of flumazenil did not improve his consciousness and BIS value. Adequate spontaneous respiration was maintained and the possibility of brain death was excluded. LDLT was performed on the 5th ICU day. BIS value remained 0 throughout surgery. BIS value suddenly increased 2 h after surgery and reached 60 11 h after surgery. It became possible to communicate with the patient and his trachea was extubated on the 4th postoperative day. We believe that, with BIS, we were able to follow preoperative exacerbation of the "pathological'' process of hepatic encephalopathy, and predict postoperative emergence from general anesthesia, suggesting normal graft function.	[Okawa, Hirobumi; Ishihara, Hironori; Hirota, Kazuyoshi] Hirosaki Univ, Grad Sch Med, Dept Anesthesia, Hirosaki, Aomori 0368216, Japan; [Ono, Tomoko; Hashiba, Eiji; Tsubo, Toshihito] Hirosaki Univ Hosp, Intens Care Unit, Hirosaki, Aomori, Japan	Okawa, H (reprint author), Hirosaki Univ, Grad Sch Med, Dept Anesthesia, 5 Zaifu Cho, Hirosaki, Aomori 0368216, Japan.	Okawa66@cc.hirosaki-u.ac.jp	Hirota, Kazuyoshi/S-3292-2019				Avidan MS, 2008, NEW ENGL J MED, V358, P1097, DOI 10.1056/NEJMoa0707361; Dahaba AA, 2008, GUT, V57, P77, DOI 10.1136/gut.2007.129130; Dahaba AA, 2009, GUT, V58, P605, DOI 10.1136/gut.2008.165118; Dumans-Nizard V, 2010, ANAESTHESIA, V65, P196, DOI 10.1111/j.1365-2044.2009.06163.x; Hassanein TI, 2008, DIGEST DIS SCI, V53, P529, DOI 10.1007/s10620-007-9895-0; Kasuya Y, 2009, ANESTH ANALG, V109, P1811, DOI 10.1213/ANE.0b013e3181c04e58; Khurana P, 2009, INDIAN J ANAESTH, V53, P662; Kobayashi S, 2003, HEPATO-GASTROENTEROL, V50, P515; Kobayashi T, 2010, TRANSPL P, V42, P990, DOI 10.1016/j.transproceed.2010.03.024; Miyake W, 2010, J ANESTH, V24, P386, DOI 10.1007/s00540-010-0907-4; Reeves RR, 2006, CLIN EEG NEUROSCI, V37, P34, DOI 10.1177/155005940603700108; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; SUNZEL M, 1988, BRIT J CLIN PHARMACO, V25, P561, DOI 10.1111/j.1365-2125.1988.tb03346.x; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006	14	2	3	0	1	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2011	25	1					117	119		10.1007/s00540-010-1055-6			3	Anesthesiology	Anesthesiology	749YH	WOS:000289507400018	21127916				2020-06-30	J	Fleet, J; Jones, M; Belan, I				Fleet, Julie; Jones, Meril; Belan, Ingrid			Non-axial administration of fentanyl in childbirth: a review of the efficacy and safety of fentanyl for mother and neonate	MIDWIFERY			English	Review						fentanyl; Sublimaze (R); Pain relief; Labour/labour; Childbirth; Efficacy; Narcotic; Systemic pain relief; Subcutaneous	PATIENT-CONTROLLED ANALGESIA; LABOR; PAIN; MEPERIDINE; PARTURIENT; ANESTHESIA; PETHIDINE; OPIOIDS; CITRATE; CHOICES	Objective: to investigate the use of fentanyl for pain relief during child birth administered by routes other than epidural or spinal (non-axial). In particular, aspects relating to the efficacy and safety of fentanyl for mother and neonate are explored. Background: currently, pethidine is the most widely used intramuscular opioid for the relief of labour pain but has been shown to have numerous side-effects on the mother and neonate. An alternative opioid, fentanyl, has been shown to have fewer side-effects on both mother and neonate than pethidine. Therefore, its use during child birth was examined in this literature review. Review methods: a search of articles relating to the administration of fentanyl via non-axial routes was conducted using electronic databases, key journals and reference lists of selected research papers and reviews. Results: only studies of IV administration were identified from the literature findings from showed that IV administered fentanyl appeared to be a safe, efficacious opioid when administered for pain relief in childbirth. Fentanyl is a short-acting analgesic causing less sedation and nausea in adults than pethidine. In addition, no long-term fetal or neonatal effects of fentanyl were identified, with normal neonatal neurological and adaptive capacities at two hours and 24 hours after birth supporting its safe use in childbirth. Key conclusion: in the studies identified, fentanyl was found to be efficacious, providing prompt analgesia with minimal side-effects to both mother and infant when administered intravenously (IV) during childbirth. In addition, no long-term fetal effects were found. Recommendations for further research: there is a paucity of research relating to the maternal, fetal and neonatal effects of non-axial administered fentanyl other than that of IV. Further research should explore alternate routes of administration such as subcutaneous, sublingual and nasal which are less invasive and can be administered by midwives. Implication for practice: in confirming the safe use of non-axial administration of fentanyl during childbirth, benefits include midwives being able to offer women analternative option for pain relief. Alternative routes, such as subcutaneous, can be managed by midwives through a standing order, potentially reducing the need for additional resources. In particular, this will benefit midwifery practice in rural and remote settings where resources and access to specialised services are limited. (C) 2009 Elsevier Ltd. All rights reserved.	[Fleet, Julie; Jones, Meril; Belan, Ingrid] Flinders Univ S Australia, Sch Nursing & Midwifery, Adelaide, SA 5001, Australia	Fleet, J (reprint author), Flinders Univ S Australia, Sch Nursing & Midwifery, GPO Box 2100, Adelaide, SA 5001, Australia.	degr0013@flinders.edu.au	Fleet, Julie-Anne/I-3015-2015	Fleet, Julie-Anne/0000-0001-6228-5636; Belan, Ingrid/0000-0002-7007-2961	Flinders University; School of Nursing; Midwifery Summer Student Research Scholarship	We wish to acknowledge the support of Flinders University, School of Nursing and Midwifery Summer Student Research Scholarship.	Althaus J, 2005, OBSTET GYN CLIN N AM, V32, P231, DOI 10.1016/j.ogc.2005.01.002; ATKINSON BD, 1994, AM J OBSTET GYNECOL, V171, P993, DOI 10.1016/0002-9378(94)90021-3; *AUSTR GOV, NH MRC GUID; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; BORLAND ML, 2002, PAEDIATRIC EMERGENCY, V14, P275; Castro C, 2003, CAN J ANAESTH, V50, P1039, DOI 10.1007/BF03018370; Craft J. B., 1983, J ANESTHESIA ANALGES, V63, P894; CROWELL MK, 1994, J NURSE-MIDWIFERY, V39, P150, DOI 10.1016/0091-2182(94)90097-3; Dietrich C. C., 2003, AM J PAIN MANAGEMENT, V13, P146; ELBOURNE D, 2002, COCHRANE REV, V97, P1567; ENKIN M, 2004, GUIDE EFFECTIVE CARE; Fairlie FM, 1999, BRIT J OBSTET GYNAEC, V106, P1181, DOI 10.1111/j.1471-0528.1999.tb08145.x; Florence DJ, 2003, J PERINAT NEONAT NUR, V17, P238, DOI 10.1097/00005237-200310000-00002; GARNER EG, 1994, J REPROD MED, V39, P818; *HCPRDU, EV TOOL QUANT STUD; Heelbeck L., 1999, BRIT J MIDWIFERY, V7, P372; HODGKINSON R, 1978, PEDIATRICS, V62, P294; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Jaslow D, 2007, J EMERG MED SERV, V36, P105; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; KLEIMAN SJ, 1991, CAN J ANAESTH, V38, P489, DOI 10.1007/BF03007585; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; McCool WF, 2004, J MIDWIFERY WOM HEAL, V49, P505, DOI 10.1016/j.jmwh.2004.08.028; Morley-Forster PK, 1998, INT J OBSTET ANESTH, V7, P103, DOI 10.1016/S0959-289X(98)90005-X; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Nikkola E M, 2000, J Clin Monit Comput, V16, P597, DOI 10.1023/A:1012268617009; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; Rayburn W F, 1991, Anesthesiol Rev, V18, P31; RAYBURN WF, 1989, OBSTET GYNECOL, V74, P604; RIGHARD L, 1990, LANCET, V336, P1105, DOI 10.1016/0140-6736(90)92579-7; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; Rowlands S, 1998, BAILLIERE CLIN OB GY, V12, P347, DOI 10.1016/S0950-3552(98)80071-0; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Smith C V, 1996, J Matern Fetal Med, V5, P89; Sosa CG, 2006, EUR J OBSTET GYN R B, V129, P135, DOI 10.1016/j.ejogrb.2005.11.033; STEER PL, 1992, CAN J ANAESTH, V39, P231, DOI 10.1007/BF03008782; TORRANCE E, 2003, BRIT J MIDWIFERY, V11, P243	40	5	5	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0266-6138			MIDWIFERY	Midwifery	FEB	2011	27	1					E106	E113		10.1016/j.midw.2009.11.002			8	Nursing	Nursing	711WI	WOS:000286621700001	20060203				2020-06-30	J	Strano-Rossi, S; Bermejo, AM; de la Torre, X; Botre, F				Strano-Rossi, Sabina; Maria Bermejo, Ana; de la Torre, Xavier; Botre, Francesco			Fast GC-MS method for the simultaneous screening of THC-COOH, cocaine, opiates and analogues including buprenorphine and fentanyl, and their metabolites in urine	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						Drugs of abuse; Fast GC; Forensic toxicology; Drugs screening; GC-MS	GAS CHROMATOGRAPHY/MASS SPECTROMETRY; IONIZATION MASS-SPECTROMETRY; DOPING ANALYSIS; DRUGS; ABUSE; VALIDATION; GUIDELINES	A fast gas chromatography (GC)-MS method has been developed and validated for the simultaneous screening of different classes of drugs of abuse in urine. Tetrahydrocannabinol metabolite, cocaine, opiates such as morphine, O-6-monoacetylmorphine (O-6-MAM), codeine, opioids such as buprenorphine, methadone, pentazocine, fentanyl and analogues and their main metabolites can be detected and quantified after a simple liquid-liquid extraction in alkaline conditions and derivatisation to obtain the corresponding trimethylsilyl derivatives. The chromatographic separation is performed in a total time of 6 min, using a short GC column (5% phenyl methyl silicone, 10-m length x 0.18-mm internal diameter). The Limits of Detection are satisfactory for forensic purposes for all the substances; the repeatability of concentrations (percent coefficients of variation) are always lower than 15% at high and low concentration levels, and accuracy, intended as % error on the true value, is always lower than 15% for all the analytes. The method can successfully be applied for screening analyses in many fields of forensic toxicology.	[Strano-Rossi, Sabina; de la Torre, Xavier; Botre, Francesco] FMSI, Lab Antidoping, I-00197 Rome, Italy; [Maria Bermejo, Ana] Inst Legal Med, Forens Toxicol Serv, Fac Med, Santiago De Compostela 15782, Spain; [Botre, Francesco] Univ Roma La Sapienza, Dipartimento Tecnol & Management, I-00161 Rome, Italy	Strano-Rossi, S (reprint author), FMSI, Lab Antidoping, Lgo G Onesti 1, I-00197 Rome, Italy.	Sabina.stranorossi@gmail.com	Strano Rossi, Sabina/G-6866-2012; Bermejo, Ana/H-3221-2015; Rossi, Sabina Strano/P-4848-2019; de la Torre, Xavier/AAO-3059-2020	Rossi, Sabina Strano/0000-0001-7530-2968; de la Torre, Xavier/0000-0001-8037-6750			Adamowicz P, 2010, FORENSIC SCI INT, V198, P39, DOI 10.1016/j.forsciint.2010.02.012; Bush DM, 2008, FORENSIC SCI INT, V174, P111, DOI 10.1016/j.forsciint.2007.03.008; DEGIOVANNI N, 1994, J CHROMATOGR B, V658, P69, DOI 10.1016/0378-4347(94)00209-6; Eichhorst JC, 2009, CLIN BIOCHEM, V42, P1531, DOI 10.1016/j.clinbiochem.2009.07.019; European Workplace Drug Testing Society, 2002, EUR LAB GUID LEG DEF; FERRARA SD, 1994, J ANAL TOXICOL, V18, P278, DOI 10.1093/jat/18.5.278; Fraser AD, 2002, THER DRUG MONIT, V24, P187, DOI 10.1097/00007691-200202000-00030; Gallardo E, 2009, DRUG TEST ANAL, V1, P109, DOI 10.1002/dta.26; Garcia-Jimenez S, 2008, ANN NY ACAD SCI, V1139, P422, DOI 10.1196/annals.1432.018; Huskova R, 2009, J CHROMATOGR A, V1216, P6326, DOI 10.1016/j.chroma.2009.07.013; Jonsson AK, 2007, FORENSIC SCI INT, V169, P101, DOI 10.1016/j.forsciint.2006.08.002; Kyle PB, 2003, J TOXICOL-CLIN TOXIC, V41, P919, DOI 10.1081/CLT-120026511; Langman LJ, 2009, J ANAL TOXICOL, V33, P447, DOI 10.1093/jat/33.8.447; Lehrmann E, 2008, ADDICT BIOL, V13, P105, DOI 10.1111/j.1369-1600.2007.00085.x; Lillsunde P, 2008, FORENSIC SCI INT, V174, P99, DOI 10.1016/j.forsciint.2007.03.006; Lopez P, 2009, J ANAL TOXICOL, V33, P351, DOI 10.1093/jat/33.7.351; Marquet P, 1998, J FORENSIC SCI, V43, P806; Mazzarino M, 2007, RAPID COMMUN MASS SP, V21, P4117, DOI 10.1002/rcm.3326; Morra V, 2006, J CHROMATOGR A, V1135, P219, DOI 10.1016/j.chroma.2006.09.034; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Rittner M, 2001, J ANAL TOXICOL, V25, P115, DOI 10.1093/jat/25.2.115; Rohrig TP, 2003, J ANAL TOXICOL, V27, P449, DOI 10.1093/jat/27.7.449; Rossi SS, 2010, RAPID COMMUN MASS SP, V24, P1475, DOI 10.1002/rcm.4542; ROSSI SS, 2005, J ANAL TOXICOL, V29, P217; Strano-Rossi S, 2005, RAPID COMMUN MASS SP, V19, P1529, DOI 10.1002/rcm.1942; Thevis M, 2007, ANAL BIOANAL CHEM, V388, P1351, DOI 10.1007/s00216-007-1131-4; U.S. Substance Abuse and Mental Health Services Administration, 2004, MAND GUID FED WORKPL; US. FDA, 2001, BIOAN METH VAL; Van Thuyne W, 2008, J CHROMATOGR A, V1210, P193, DOI 10.1016/j.chroma.2008.09.049; Verstraete AG, 2001, FORENSIC SCI INT, V121, P2, DOI 10.1016/S0379-0738(01)00445-5; von Mach MA, 2007, THER DRUG MONIT, V29, P27, DOI 10.1097/FTD.0b013e31802bb2aa; WADA, 2010, TD2010MRPL WADA; Walsh J Michael, 2004, Traffic Inj Prev, V5, P241; *WORLD ANT AG, 2010, TD2010DCR WADA; *WORLD ANT AG, 2009, INT ST LAB; *WORLD ANT AG MONT, 2010, WORLD ANT COD 2010 P	36	27	28	2	60	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642			ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	FEB	2011	399	4					1623	1630		10.1007/s00216-010-4471-4			8	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	711NR	WOS:000286599200023	21153585				2020-06-30	J	Williams, BS; Wong, D; Amin, S				Williams, Bryan S.; Wong, David; Amin, Sandeep			Case Scenario: Self-extraction of Intrathecal Pump Medication with a Concomitant Intrathecal Granulomatous Mass	ANESTHESIOLOGY			English	Article							CHRONIC NONMALIGNANT PAIN; TIP INFLAMMATORY MASS; DRUG INFUSION; CANCER PAIN; SHEEP MODEL; MORPHINE; CATHETER; MANAGEMENT; HYDROMORPHONE; BACLOFEN		[Williams, Bryan S.] Rush Univ, Med Ctr, Div Pain Med, Dept Anesthesiol & Crit Care Med,Rush Med Coll, Chicago, IL 60612 USA	Williams, BS (reprint author), Rush Univ, Med Ctr, Div Pain Med, Dept Anesthesiol & Crit Care Med,Rush Med Coll, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	bryan.williams@yahoo.com					Allen JW, 2006, ANESTHESIOLOGY, V105, P581, DOI 10.1097/00000542-200609000-00024; Anderson VC, 2001, PAIN MED, V2, P287, DOI 10.1046/j.1526-4637.2001.01052.x; Anderson VC, 1999, NEUROSURGERY, V44, P289, DOI 10.1097/00006123-199902000-00026; Angel IF, 1998, SURG NEUROL, V49, P92, DOI 10.1016/S0090-3019(97)00287-5; Aprili D, 2009, ANESTHESIOLOGY, V111, P1346, DOI 10.1097/ALN.0b013e3181bfab9a; Blount JP, 1996, J NEUROSURG, V84, P272, DOI 10.3171/jns.1996.84.2.0272; Burton AW, 1998, ANESTHESIOLOGY, V89, P1264, DOI 10.1097/00000542-199811000-00032; Coffey RJ, 2002, NEUROSURGERY, V50, P78, DOI 10.1097/00006123-200201000-00014; Coffey RJ, 2009, ANESTHESIOLOGY, V111, P881, DOI 10.1097/ALN.0b013e3181b64ab8; Dario A, 2005, NEUROMODULATION, V8, P36, DOI 10.1111/j.1094-7159.2005.05218.x; Deer TR, 2008, PAIN MED, V9, P391, DOI 10.1111/j.1526-4637.2008.00468.x; Deer T, 2007, NEUROMODULATION, V10, P300, DOI 10.1111/j.1525-1403.2007.00128.x; Deer Timothy R, 2004, Pain Physician, V7, P225; Deer TR, 2007, PAIN MED, V8, P259, DOI 10.1111/j.1526-4637.2006.00150.x; Follett KA, 2003, ANESTHESIOLOGY, V99, P5, DOI 10.1097/00000542-200307000-00004; Gradert TL, 2003, ANESTHESIOLOGY, V99, P188, DOI 10.1097/00000542-200307000-00029; Hassenbusch S, 2002, PAIN MED, V3, P313, DOI 10.1046/j.1526-4637.2002.02055.x; Johansen MJ, 2004, PAIN MED, V5, P14, DOI 10.1111/j.1526-4637.2004.04010.x; Kittelberger KP, 2004, ANESTHESIOLOGY, V101, P807, DOI 10.1097/00000542-200409000-00044; Kongkam P, 2009, AM J GASTROENTEROL, V104, P1249, DOI 10.1038/ajg.2009.54; Kumar K, 2001, SURG NEUROL, V55, P79, DOI 10.1016/S0090-3019(01)00353-6; Kumar K, 2009, PAIN MED, V10, P819, DOI 10.1111/j.1526-4637.2009.00640.x; Kumar V, 2010, ROBBINS COTRAN PATHO, P73; Miele VJ, 2006, EUR J PAIN, V10, P251, DOI 10.1016/j.ejpain.2005.05.002; NORTH RB, 1991, NEUROSURGERY, V29, P778, DOI 10.1227/00006123-199111000-00025; ONOFRIO BM, 1981, MAYO CLIN PROC, V56, P516; Phillips JA, 2007, AM J ROENTGENOL, V189, pW375, DOI 10.2214/AJR.07.2225; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Toombs JD, 2005, ANESTHESIOLOGY, V102, P687, DOI 10.1097/00000542-200503000-00031; Waara-Wolleat KL, 2006, PAIN MED, V7, P251, DOI 10.1111/j.1526-4637.2006.00155.x; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013; Yaksh TL, 2002, PAIN MED, V3, P300, DOI 10.1046/j.1526-4637.2002.02048.x; Yaksh TL, 2003, ANESTHESIOLOGY, V99, P174, DOI 10.1097/00000542-200307000-00028	33	7	7	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	FEB	2011	114	2					424	430		10.1097/ALN.0b013e3181f7dafa			7	Anesthesiology	Anesthesiology	711JE	WOS:000286586200024	21245738	Bronze			2020-06-30	J	Black, AS; Newcombe, GN; Plummer, JL; McLeod, DH; Martin, DK				Black, A. S.; Newcombe, G. N.; Plummer, J. L.; McLeod, D. H.; Martin, D. K.			Spinal anaesthesia for ambulatory arthroscopic surgery of the knee: a comparison of low-dose prilocaine and fentanyl with bupivacaine and fentanyl	BRITISH JOURNAL OF ANAESTHESIA			English	Article						ambulatory; prilocaine; spinal anaesthesia; TNS	TRANSIENT NEUROLOGIC SYMPTOMS; MINIDOSE LIDOCAINE-FENTANYL; INTRATHECAL FENTANYL; PROLONGING RECOVERY; PLAIN ARTICAINE; 5-PERCENT; PROCAINE; VOLUNTEERS; TRIAL	Background. Prospective data on the use of prilocaine for ambulatory spinal anaesthesia remain limited. We compared the behaviour and characteristics of subarachnoid block using prilocaine and fentanyl with that of bupivacaine and fentanyl. Methods. In a prospective, double-blind, randomized controlled trial, 50 patients undergoing elective ambulatory arthroscopic knee surgery received subarachnoid anaesthesia, with either prilocaine 20 mg and fentanyl 20 mg (Group P) or plain bupivacaine 7.5 mg and fentanyl 20 mg (Group B). Primary endpoints included times for onset of maximum sensory block level and regression of sensory block to L4, and also motor block at 1 and 2 h, and levels of haemodynamic stability. Comparisons between the groups were made by chi(2) test for proportions and the Mann-Whitney test for ordinal data. Time-to-event data were analysed by the Mann-Whitney test for uncensored data or the logrank test for censored data. Results. At 2 h, motor block in Group P had fully resolved in 86% of patients, compared with 27% in Group B (P<0.001). Median time to regression of sensory block to L4 was significantly shorter in Group P (97 min) than in Group B (280 min) (P<0.001). A clinically significant decrease in arterial pressure was more common in Group B (73%) than in Group P (32%) (P=0.004). Two patients in Group P required conversion to general anaesthesia, but for reasons unrelated to prilocaine itself. Conclusions. The combination of prilocaine and fentanyl is a better alternative to that of low-dose bupivacaine and fentanyl, for spinal anaesthesia in ambulatory arthroscopic knee surgery.	[Black, A. S.; Newcombe, G. N.; Plummer, J. L.; McLeod, D. H.] Flinders Med Ctr, Dept Anaesthesia & Pain Med, Bedford Pk, SA 5042, Australia; [Martin, D. K.] Sportsmed SA, Stepney, SA 5069, Australia	Black, AS (reprint author), Flinders Med Ctr, Dept Anaesthesia & Pain Med, Bedford Pk, SA 5042, Australia.	Adam.Black@health.sa.gov.au			Department of Anaesthesia and Pain Medicine, Flinders Medical Centre, Adelaide, South Australia	Financial support was provided by the Department of Anaesthesia and Pain Medicine, Flinders Medical Centre, Adelaide, South Australia. There was no external funding.	Bachmann M, 2008, BRIT J ANAESTH, V101, P848, DOI 10.1093/bja/aen294; Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; Ben-David B, 2001, ANESTH ANALG, V93, P319, DOI 10.1097/00000539-200108000-00016; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; Boucher C, 2001, CAN J ANAESTH, V48, P466, DOI 10.1007/BF03028310; de Weert K, 2000, ANAESTHESIA, V55, P1020, DOI 10.1046/j.1365-2044.2000.01618-4.x; Dijkstra T, 2008, BRIT J ANAESTH, V100, P104, DOI 10.1093/bja/aem332; Drasner K, 2005, ANESTH ANALG, V100, P549, DOI 10.1213/01.ANE.0000143382.89888.C3; Gaiser RR, 2000, J CLIN ANESTH, V12, P476, DOI 10.1016/S0952-8180(00)00186-0; Hampl KF, 1998, ANESTHESIOLOGY, V88, P629, DOI 10.1097/00000542-199803000-00012; Hendriks MP, 2009, BRIT J ANAESTH, V102, P259, DOI 10.1093/bja/aen357; Hodgson PS, 2000, REGION ANESTH PAIN M, V25, P218, DOI 10.1016/S1098-7339(00)90001-4; Kallio H, 2006, BRIT J ANAESTH, V97, P704, DOI 10.1093/bja/ael222; Konig W, 1997, ANAESTHESIA, V52, P182; Kouri ME, 2004, ANESTH ANALG, V98, P75, DOI 10.1213/01.ANE.0000093228.61443.EE; Le Truong HH, 2001, CAN J ANAESTH, V48, P470, DOI 10.1007/BF03028311; LIU S, 1995, ANESTH ANALG, V81, P697, DOI 10.1097/00000539-199510000-00007; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Liu SS, 2005, ANESTH ANALG, V101, P1634, DOI 10.1213/01.ANE.0000180829.70036.4F; Martinez-Bourio R, 1998, ANESTHESIOLOGY, V88, P624, DOI 10.1097/00000542-199803000-00011; MOORE DC, 1982, ANESTH ANALG, V61, P155; Nair GS, 2009, BRIT J ANAESTH, V102, P307, DOI 10.1093/bja/aen389; Ostgaard G, 2000, ACTA ANAESTH SCAND, V44, P436, DOI 10.1034/j.1399-6576.2000.440413.x; Pollock JE, 2002, REGION ANESTH PAIN M, V27, P581, DOI 10.1053/rapm.2002.36457; Severinghaus JW, 1998, ACTA ANAESTH SCAND, V42, P3, DOI 10.1111/j.1399-6576.1998.tb04978.x; Zaric D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003006.pub3	27	19	19	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2011	106	2					183	188		10.1093/bja/aeq272			6	Anesthesiology	Anesthesiology	706JY	WOS:000286215900005	20947591	Bronze			2020-06-30	J	Belso, N; Kui, R; Szegesdi, I; Kakuja, M; Kapitany, K; Kemeny, L; Bata-Csorgo, Z				Belsoe, N.; Kui, R.; Szegesdi, I.; Kakuja, M.; Kapitany, K.; Kemeny, L.; Bata-Csoergoe, Z.			Propofol and fentanyl induced perioperative anaphylaxis	BRITISH JOURNAL OF ANAESTHESIA			English	Letter											noribels@mail.derma.szote.u-szeged.hu		Kemeny, Lajos/0000-0002-2119-9501			Cummings KC, 2007, CAN J ANAESTH, V54, P301, DOI 10.1007/BF03022776; Hepner DL, 2003, ANESTH ANALG, V97, P1381, DOI 10.1213/01.ANE.0000082993.84883.7D; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; Mertes PM, 2002, EUR J ANAESTH, V19, P240, DOI 10.1017/S0265021502000418; Societe Francaises d'Anesthesie et de Reanimation, 2002, ANN FR ANESTH S, V21, p7s; Whittington T, 1998, BAILLIERE CLIN ANAES, V12, P301	6	7	10	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2011	106	2					283	284		10.1093/bja/aeq384			2	Anesthesiology	Anesthesiology	706JY	WOS:000286215900031	21233125	Bronze			2020-06-30	J	Krauss, WC; Shah, S; Shah, S; Thomas, SH				Krauss, William C.; Shah, Sachita; Shah, Sachin; Thomas, Stephen H.			FENTANYL IN THE OUT-OF-HOSPITAL SETTING: VARIABLES ASSOCIATED WITH HYPOTENSION AND HYPOXEMIA	JOURNAL OF EMERGENCY MEDICINE			English	Article						analgesia; Emergency Medical Services; pain control; fentanyl	PAIN MANAGEMENT; TRAUMA PATIENTS; EMERGENCY-DEPARTMENT; INTRANASAL FENTANYL; PEDIATRIC TRAUMA; ANALGESIA; MORPHINE; PROGRAM; RELIEF; SAFETY	Background: Previous out-of-hospital fentanyl analgesia studies are limited by retrospective nature or low numbers. Study Objectives: This study sought to prospectively assess fentanyl safety in a large out-of-hospital group, to identify variables associated with post-fentanyl hypotension (HN; systolic blood pressure [SBP] < 90) or hypoxemia (HX; Spo(2) < 90%). Methods: As part of a new protocol requiring documentation of pen-dose vital signs and adverse effects associated with fentanyl bolus doses, our Emergency Medical Services helicopter service assessed 500 consecutive patients receiving fentanyl from July through September 2006. By a priori plan, we assessed HN and HX descriptively (median with interquartile range, exact confidence intervals [CIs]) and with multivariate regression. Results: In 1055 patients, post-fentanyl HN was noted 52 times (4.9%), being a continuation of pre-fentanyl HN in 24 patients (46.2%); HN was new in 28 patients (2.7% of 1055, 95% CI 1.8-3.8%). Regression showed no association between dependent variables HN (assessed for 1055 doses) or HX (528 doses in non-intubated) and independent variables age, diagnosis, gender, scene/inter-facility mission, dose, or total transport dose. Pre-and post-fentanyl SpO(2) means were unchanged: 98.8% (95% CI 98.5-98.9) vs. 98.6% (95% CI 98.3-99.0), respectively. Post-fentanyl HN was seen in patients with pre-fentanyl intubation (odds ratio [OR] 5.3, p = 0.002) and with pre-fentanyl low SBP (OR 40, p < 0.001). Conclusion: In a closely monitored out-of-hospital population, fentanyl incurs a low risk of significant hypoxemia. The risk of fentanyl-associated hypotension is also very low, but difficult to predict in the absence of acuity markers such as preexisting hypotension. (C) 2011 Elsevier Inc.	[Krauss, William C.; Shah, Sachita; Thomas, Stephen H.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Shah, Sachin] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Krauss, WC (reprint author), Brigham & Womens Hosp, Massachusetts Gen Hosp, 75 Francis St, Boston, MA 02115 USA.						Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Beliakov V A, 1993, Anesteziol Reanimatol, P24; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P77, DOI 10.1046/j.1442-2026.2002.00288.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Braude Darren, 2004, Prehosp Emerg Care, V8, P441, DOI 10.1016/j.prehos.2004.07.001; CHAMBERS JA, 1994, RESUSCITATION, V27, P153, DOI 10.1016/0300-9572(94)90008-6; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P635, DOI 10.1016/S0196-0644(89)80517-7; Curtis KM, 2007, J TRAUMA, V63, P819, DOI 10.1097/01.ta.0000240979.31046.98; Danilevich E Ia, 1987, Anesteziol Reanimatol, P46; DANILEVICH EY, 1990, VESTN KHIR IM GREKOV, V145, P104; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; DeVellis P, 1998, Prehosp Emerg Care, V2, P293, DOI 10.1080/10903129808958883; Devellis P, 1998, PEDIATR EMERG CARE, V14, P321; DICKINSON ET, 2004, PREHOSP EMERG CARE, V8, P103; Fullerton-Gleason Lynne, 2002, Prehosp Emerg Care, V6, P411, DOI 10.1080/10903120290938049; Galinski M, 2005, AM J EMERG MED, V23, P114, DOI 10.1016/j.ajem.2004.03.010; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Helm M, 1996, ANAESTHESIST, V45, P1196, DOI 10.1007/s001010050358; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Lucas CE, 2007, J AM COLL SURGEONS, V205, P101, DOI 10.1016/j.jamcollsurg.2007.01.062; Poirier MP, 2004, PEDIATR EMERG CARE, V20, P412, DOI 10.1097/01.pec.0000125666.81431.d2; Ricard-Hibon A, 1999, ANN EMERG MED, V34, P738, DOI 10.1016/S0196-0644(99)70099-5; Silfvast T, 2001, Eur J Emerg Med, V8, P275, DOI 10.1097/00063110-200112000-00005; Thomas SH, 2005, J EMERG MED, V29, P179, DOI 10.1016/j.jemermed.2005.02.007; THOMAS SH, 1996, AIR MED J, V15, P57; Thomas SH, 2008, J EMERG MED, V35, P47, DOI 10.1016/j.jemermed.2007.05.041; Thomas SH, 2007, AM J EMERG MED, V25, P842, DOI 10.1016/j.ajem.2007.02.010; Vergnion M, 2001, ANESTH ANALG, V92, P1543; Zohar Z, 2001, J TRAUMA, V51, P767, DOI 10.1097/00005373-200110000-00024	31	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679			J EMERG MED	J. Emerg. Med.	FEB	2011	40	2					182	187		10.1016/j.jemermed.2009.02.009			6	Emergency Medicine	Emergency Medicine	722XO	WOS:000287468800012	19327928				2020-06-30	J	De Santiago, J; Santos-Yglesias, J; Giron, J; Jimenez, A; Errando, CL				De Santiago, Jesus; Santos-Yglesias, Javier; Giron, Jorge; Jimenez, Alejandro; Errando, Carlos L.			Low-Dose, Low-Concentration Levobupivacaine Plus Fentanyl Selective Spinal Anesthesia for Knee Arthroscopy: A Dose Finding Study	ANESTHESIA AND ANALGESIA			English	Article							AMBULATORY SURGERY; OUTPATIENT LAPAROSCOPY; BUPIVACAINE; STAY	BACKGROUND: Selective sensory spinal anesthesia preserves lower limb motor function and thus facilitates postanesthesia care unit (PACU) bypass and reduces ambulation recovery time. METHODS: We compared the ambulation time and PACU bypass rate after using 3 low-dose, low-concentration levobupivacaine-fentanyl spinal solutions (5, 4, and 3 mg + 10 mu g) in a double-blind study consisting of 90 patients (ASA physical status I and II) scheduled to undergo knee arthroscopy. RESULTS: The 3-mg dose was halted because of a large number of inadequate blocks (50%). Twenty-three percent and 80% of patients from groups 5 mg and 4 mg, respectively, bypassed the PACU (P = 0001). Ambulation took place after 70 minutes (30-130 minutes) (median [range]) in group 5 mg and 45 minutes (23-120 minutes) in group 4 mg (P = 0006). CONCLUSION: Four milligrams levobupivacaine plus 10 mu g fentanyl produced adequate surgical anesthesia with the shortest time to ambulation and the highest PACU bypass rate. (Anesth Analg 2011;112:477-80)	[De Santiago, Jesus; Santos-Yglesias, Javier; Giron, Jorge] Hosp USP La Colina, Dept Anesthesiol, Tenerife 38006, Spain; [Jimenez, Alejandro] HUC Univ La Laguna, Res Unit, Tenerife, Spain; [Errando, Carlos L.] Consorcio Hosp Gen Univ Valencia, Dept Anesthesiol, Valencia, Spain	De Santiago, J (reprint author), Hosp USP La Colina, Dept Anesthesiol, Tenerife 38006, Spain.	jdesantiagom@gmail.com	Errando, Carlos Luis L/J-1172-2016	Errando, Carlos Luis L/0000-0001-8882-081X; Jimenez-Sosa, Alejandro/0000-0001-8732-2616			Alley EA, 2002, ANESTH ANALG, V94, P188, DOI 10.1097/00000539-200201000-00036; Cappelleri G, 2005, ANESTH ANALG, V101, P77, DOI 10.1213/01.ANE.0000155265.79673.56; Chung F, 1999, ANESTH ANALG, V89, P1352, DOI 10.1097/00000539-199912000-00004; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; de Santiago J, 2009, ANESTH ANALG, V109, P1456, DOI 10.1213/ANE.0b013e3181ba792e; Kuusniemi KS, 1999, EUR J ANAESTH, V16, P2, DOI 10.1046/j.1365-2346.1999.00414.x; Nair GS, 2009, BRIT J ANAESTH, V102, P307, DOI 10.1093/bja/aen389; PHILIP BK, 1992, J CLIN ANESTH, V4, P355, DOI 10.1016/0952-8180(92)90155-T; Vaghadia H, 2001, CAN J ANAESTH, V48, P261, DOI 10.1007/BF03019756; Williams BA, 2004, ANESTHESIOLOGY, V101, P3, DOI 10.1097/00000542-200407000-00003	10	6	7	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2011	112	2					477	480		10.1213/ANE.0b013e318202cd03			4	Anesthesiology	Anesthesiology	711GV	WOS:000286576000031	21127284				2020-06-30	J	Tempe, DK; Dutta, D; Garg, M; Minhas, H; Tomar, A; Virmani, S				Tempe, Deepak K.; Dutta, Devesh; Garg, Mukesh; Minhas, Harpreet; Tomar, Akhlesh; Virmani, Sanjula			Myocardial Protection with Isoflurane During Off-Pump Coronary Artery Bypass Grafting: A Randomized Trial	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						anesthetic preconditioning; pharmacological preconditioning; off-pump surgery; coronary artery bypass grafting; myocardial protection	VOLATILE ANESTHETICS; RABBIT MYOCARDIUM; INFARCT SIZE; ON-PUMP; SURGERY; SEVOFLURANE; PROPOFOL; INJURY; ISCHEMIA; RECOVERY	Objectives: To analyze the hemodynamic effects and myocardial injury using troponin-T and creatine phosphokinase (CPK-MB) with isoflurane and compare it with a control group in patients undergoing off-pump coronary artery bypass (OPCAB) surgery. Design: This prospective, randomized study was performed in patients scheduled for elective OPCAB surgery during February 2007 to February 2009. Setting: Tertiary care, university teaching hospital. Participants: Forty-five patients undergoing elective OPCAB surgery. Interventions: Patients were randomly allotted to receive either isoflurane (inspired concentration between 1.0% and 2.5%) or propofol (1.5 to 3.5 mg/kg/h) during OPCAB surgery. The concentration of these agents was titrated such that the BIS value was maintained between 50 and 60. Measurements and Main Results: The hemodynamic data were measured and recorded after induction of anesthesia (baseline), during the distal anastomosis of each coronary artery, and 5 and 30 minutes after giving protamine. In addition, blood samples for troponin-T and CPK-MB were obtained after induction (baseline), after 6 hours and 24 hours postoperatively. The cardiac index was significantly higher in the isoflurane group at all stages, except during distal anastomosis of the diagonal branch of the left anterior descending artery (p < 0.05). There was a significant increase in troponin-T levels at 6 and 24 hours after surgery in the propofol group (from 0.037 +/- 0.013 ng/mL to 0.098 +/- 0.045 ng/mL and 0.081 +/- 0.025 ng/mL, respectively, p < 0.05). Significant increases in the troponin-T levels were observed at 6 hours (from 0.033 +/- 0.011 ng/mL. to 0.052 +/- 0.025 ng/mL, (p < 0.05) in the isoflurane group, and the levels in the propofol group were significantly higher than the isoflurane group at 6 and 24 hours after surgery (p < 0.05). The CPK-MB levels increased in both groups, but were not statistically different. Conclusions: Isoflurane provides protection against myocardial damage in a clinically used dosage as documented by lower levels of troponin-T in patients undergoing OPCAB surgery. (C) 2011 Elsevier Inc. All rights reserved.	[Tempe, Deepak K.; Dutta, Devesh; Garg, Mukesh; Tomar, Akhlesh; Virmani, Sanjula] GB Pant Hosp, Dept Anaesthesiol & Intens Care, New Delhi 110002, India; [Minhas, Harpreet] GB Pant Hosp, Dept Cardiothorac Surg, New Delhi 110002, India	Tempe, DK (reprint author), GB Pant Hosp, Dept Anaesthesiol & Intens Care, New Delhi 110002, India.	tempedeepak@hotmail.com					ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; Bein B, 2005, ANESTH ANALG, V100, P610, DOI 10.1213/01.ANE.0000145012.27484.A7; Belhomme D, 1999, CIRCULATION, V100, P340; Bignami E, 2009, J CARDIOTHOR VASC AN, V23, P594, DOI 10.1053/j.jvca.2009.01.022; Cason BA, 1997, ANESTHESIOLOGY, V87, P1182, DOI 10.1097/00000542-199711000-00023; Cheng DC, 2005, ANESTHESIOLOGY, V102, P188, DOI 10.1097/00000542-200501000-00028; Cohen G, 1998, CIRCULATION, V98, pII184; Conzen PF, 2003, ANESTHESIOLOGY, V99, P826, DOI 10.1097/00000542-200310000-00013; Cope DK, 1997, ANESTHESIOLOGY, V86, P699, DOI 10.1097/00000542-199703000-00023; De Hert SG, 2003, ANESTHESIOLOGY, V99, P314, DOI 10.1097/00000542-200308000-00013; De Hert SG, 2002, ANESTHESIOLOGY, V97, P42, DOI 10.1097/00000542-200207000-00007; Drenger B, 2008, J CARDIOTHOR VASC AN, V22, P369, DOI 10.1053/j.jvca.2007.12.023; FREEDMAN BM, 1985, ANESTHESIOLOGY, V62, P29, DOI 10.1097/00000542-198501000-00006; Guarracino F, 2006, J CARDIOTHOR VASC AN, V20, P477, DOI 10.1053/j.jvca.2006.05.012; Haroun-Bizri S, 2001, J CARDIOTHOR VASC AN, V15, P418, DOI 10.1053/jcan.2001.24954; Hemmerling T, 2008, EUR J ANAESTH, V25, P230, DOI 10.1017/S0265021507002608; Kato R, 2002, CAN J ANAESTH, V49, P777, DOI 10.1007/BF03017409; Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024; Law-Koune JD, 2006, J CARDIOTHOR VASC AN, V20, P484, DOI 10.1053/j.jvca.2005.08.001; Lee MC, 2006, EUR J ANAESTH, V23, P841, DOI 10.1017/S0265021506000354; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Okuda K, 1996, Ann Nucl Med, V10, P201; Piriou V, 2002, BRIT J ANAESTH, V89, P486, DOI 10.1093/bja/aef206; Puskas JD, 2003, J THORAC CARDIOV SUR, V125, P797, DOI 10.1067/mtc.2003.324; Riess ML, 2004, AM J PHYSIOL-HEART C, V286, pH1603, DOI 10.1152/ajpheart.00963.2003; Sellke FW, 2005, CIRCULATION, V111, P2858, DOI 10.1161/CIRCULATIONAHA.105.165030; Shroyer AL, 2009, NEW ENGL J MED, V361, P1827, DOI 10.1056/NEJMoa0902905; Symons JA, 2006, BRIT J ANAESTH, V97, P127, DOI 10.1093/bja/ael149; Tomai F, 1999, G Ital Cardiol, V29, P1007; WARLTIER DC, 1988, ANESTHESIOLOGY, V69, P552, DOI 10.1097/00000542-198810000-00016; Zaugg M, 2004, BRIT J ANAESTH, V93, P21, DOI 10.1093/bja/aeh150	31	22	26	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	FEB	2011	25	1					59	65		10.1053/j.jvca.2010.03.002			7	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	717RN	WOS:000287065200011	20580572				2020-06-30	J	Lowhagen, K; Lindgren, S; Odenstedt, H; Stenqvist, O; Lundin, S				Lowhagen, K.; Lindgren, S.; Odenstedt, H.; Stenqvist, O.; Lundin, S.			Prolonged moderate pressure recruitment manoeuvre results in lower optimal positive end-expiratory pressure and plateau pressure	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; VOLUME-DEPENDENT COMPLIANCE; RANDOMIZED CONTROLLED-TRIAL; RABBIT LUNGS; MECHANICS; SYSTEM	Background In acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), recruitment manoeuvres (RMs) are used frequently. In pigs with induced ALI, superior effects have been found using a slow moderate-pressure recruitment manoeuvre (SLRM) compared with a vital capacity recruitment manoeuvre (VICM). We hypothesized that the positive recruitment effects of SLRM could also be achieved in ALI/ARDS patients. Our primary research question was whether the same compliance could be obtained using lower RM pressure and subsequent positive end-expiratory pressure (PEEP). Secondly, optimal PEEP levels following the RMs were compared, and the use of volume-dependent compliance (VDC) to identify successful lung recruitment and optimal PEEP was evaluated. Patients and methods We performed a prospective randomised cross-over study where 16 ventilated patients with early ALI/ARDS each were subjected to the two RMs, followed by decremental PEEP titration. Volume-dependent initial, middle and final compliance (C(ini), C(mid) and C(fin)) were determined. Electric impedance tomography and end-expiratory lung volume measurements were used to follow lung volume changes. Results The maximum response in compliance, PaO(2)/FIO(2), venous admixture and C(ini)/C(fin) after recruitment, during decremental PEEP, was at significantly lower PEEP and plateau pressure after SLRM than VICM. Fewer patients responded in gas exchange after the SLRM, which was not the case for lung mechanics. The response in C(ini) was more pronounced than in conventional compliance. Conclusions The same compliance increase is achieved with SLRM as with VICM, and lower PEEP can be used, with correspondingly lower plateau pressures. VDC seems promising to identify successful recruitment and optimal PEEP.	[Lowhagen, K.; Lindgren, S.; Odenstedt, H.; Stenqvist, O.; Lundin, S.] Sahlgrens Univ Hosp, Dept Anaesthesia & Intens Care Med, S-41345 Gothenburg, Sweden	Lowhagen, K (reprint author), Sahlgrens Univ Hosp, Dept Anaesthesia & Intens Care Med, S-41345 Gothenburg, Sweden.	karin.lowhagen@vgregion.se			Medical Faculty of University of Gothenburg; Gothenburg Medical Society; GE HealthcareGE Healthcare; Drager Medical	This study was supported by grants from the Medical Faculty of University of Gothenburg and the Gothenburg Medical Society. The EIT equipment was supplied by Drager Medical AG, Germany, and the authors are grateful for valuable advice from Mr Eckhard Teschner, Drager Medical.; Conflict of interest: Ola Stenqvist has received lecture fees and royalty for a trademark from GE Healthcare. Ola Stenqvist has also received lecture fees and has a patent application in collaboration with Drager Medical.	Caramez MP, 2009, INTENS CARE MED, V35, P740, DOI 10.1007/s00134-009-1412-9; Guttmann J, 1994, Technol Health Care, V2, P175, DOI 10.3233/THC-1994-2302; Hermle G, 2002, CRIT CARE MED, V30, P1589, DOI 10.1097/00003246-200207000-00032; Karason S, 2000, ACTA ANAESTH SCAND, V44, P571, DOI 10.1034/j.1399-6576.2000.00515.x; Karason S, 2001, INTENS CARE MED, V27, P1328, DOI 10.1007/s001340101024; Karason S, 2001, ACTA ANAESTH SCAND, V45, P173, DOI 10.1034/j.1399-6576.2001.450207.x; Lichtwarck-Aschoff M, 2000, AM J RESP CRIT CARE, V162, P2125, DOI 10.1164/ajrccm.162.6.9910018; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Mols G, 1999, INTENS CARE MED, V25, P1084, DOI 10.1007/s001340051016; Mols G, 2001, CRIT CARE MED, V29, P144, DOI 10.1097/00003246-200101000-00029; Odenstedt H, 2005, INTENS CARE MED, V31, P1706, DOI 10.1007/s00134-005-2799-6; Olegard C, 2005, ANESTH ANALG, V101, P206, DOI 10.1213/01.ANE.0000165823.90368.55; Sondergaard S, 2003, INTENS CARE MED, V29, P955, DOI 10.1007/s00134-003-1730-2; Stahl CA, 2006, CRIT CARE MED, V34, P2090, DOI 10.1097/01.CCM.0000227220.67613.0D; Stenqvist O, 2008, CURR OPIN CRIT CARE, V14, P87, DOI 10.1097/MCC.0b013e3282f3a166; Suarez-Sipmann F, 2007, CRIT CARE MED, V35, P214, DOI 10.1097/01.CCM.0000251131.40301.E2; Valtier B, 1998, AM J RESP CRIT CARE, V158, P77, DOI 10.1164/ajrccm.158.1.9707031; Wolf Gerhard K, 2005, Crit Care Med, V33, pS163, DOI 10.1097/01.CCM.0000155917.39056.97	19	13	14	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2011	55	2					175	184		10.1111/j.1399-6576.2010.02366.x			10	Anesthesiology	Anesthesiology	706HK	WOS:000286208600006	21226859				2020-06-30	J	Oliver, WC; Nuttall, GA; Murari, T; Bauer, LK; Johnsrud, KH; Long, KJH; Orszulak, TA; Schaff, HV; Hanson, AC; Schroeder, DR; Ereth, MH; Abel, MD				Oliver, William C., Jr.; Nuttall, Gregory A.; Murari, Terri; Bauer, Lori K.; Johnsrud, Kelly H.; Long, Kirsten J. Hall; Orszulak, Thomas A.; Schaff, Hartzell V.; Hanson, Andrew C.; Schroeder, Darrell R.; Ereth, Mark H.; Abel, Martin D.			A Prospective, Randomized, Double-Blind Trial of 3 Regimens for Sedation and Analgesia After Cardiac Surgery	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						cardiac surgery; sedation; analgesia; mechanical ventilation; intensive care unit; propofol; fentanyl; midazolam	INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; PROPOFOL INFUSION SYNDROME; BYPASS GRAFT-SURGERY; TRACHEAL EXTUBATION; MECHANICAL VENTILATION; POSTOPERATIVE PAIN; MIDAZOLAM; MORBIDITY; PATIENT	Objective: The aim of this study was to evaluate cardiac risk as a consideration for selecting postoperative sedation and analgesia regimens used for cardiac surgical patients requiring cardiopulmonary bypass and early extubation. Design: An observer-blind, randomized, controlled trial. Setting: A tertiary referral medical center involving an intensive care unit. Participants: One hundred forty-five adults requiring elective cardiac surgery. Interventions: Patients were stratified preoperatively as low, moderate, or high cardiac risk based on established criteria and then assigned to 1 of 3 postoperative regimens: propofol infusion beginning at 25 mu g/kg/min and morphine boluses (P), fentanyl infusion beginning at 2 mu g/kg/h and midazolam boluses (F), or propofol and fentanyl infusions beginning at 25 mu g/kg/min and 0.5 mu g/kg/h (PF), respectively. Measurements and Main Results: Postoperative regimen P was associated with a significantly reduced time to extubation (median value, 264 minutes; p = 0.05) compared with F (295 minutes) but not PF (278 minutes) in patients characterized as low cardiac risk. The time to extubation did not differ among regimens in patients of moderate/high cardiac risk. Conclusion: Patients with low cardiac risk undergoing cardiac surgery had statistically significantly shorter times to extubation with propofol infusion and intermittent morphine than a fentanyl infusion and intermittent midazolam. These differences were not sustained in patients considered at higher cardiac risk. The time to extubation after cardiac surgery may further improve if postoperative sedation and analgesia are not administered uniformly to all patients but selected based on individual characteristics. (C) 2011 Elsevier Inc. All rights reserved.	[Oliver, William C., Jr.; Johnsrud, Kelly H.; Orszulak, Thomas A.; Schaff, Hartzell V.] Mayo Clin, Dept Surg, Div Cardiovasc Surg, Rochester, MN 55905 USA; [Oliver, William C., Jr.; Nuttall, Gregory A.; Bauer, Lori K.; Ereth, Mark H.; Abel, Martin D.] Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Anesthesiol, Rochester, MN 55905 USA; [Murari, Terri] Lower Columbia Coll, Longview, WA USA; [Long, Kirsten J. Hall] Mayo Clin, Dept Hlth Serv Res, Div Hlth Care Policy & Res, Rochester, MN 55905 USA; [Hanson, Andrew C.; Schroeder, Darrell R.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA	Oliver, WC (reprint author), Mayo Clin, Dept Surg, Div Cardiovasc Surg, 200 1st St SW, Rochester, MN 55905 USA.	oliver.william@mayo.edu		Schaff, Hartzell/0000-0003-0994-027X			Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; BARR J, 1995, CRIT CARE CLIN, V11, P827; Burow BK, 2004, ANESTHESIOLOGY, V101, P239, DOI 10.1097/00000542-200407000-00035; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Carrasco G, 1998, CRIT CARE MED, V26, P844, DOI 10.1097/00003246-199805000-00015; Cheng DCH, 1996, J THORAC CARDIOV SUR, V112, P755, DOI 10.1016/S0022-5223(96)70062-4; Cheng DCH, 1996, ANESTHESIOLOGY, V85, P1300, DOI 10.1097/00000542-199612000-00011; Chong J L, 1993, J Cardiothorac Vasc Anesth, V7, P137; Corbett SM, 2008, PHARMACOTHERAPY, V28, P250, DOI 10.1592/phco.28.2.250; Coyle J P, 1991, Semin Thorac Cardiovasc Surg, V3, P81; Cravens GT, 2007, ANESTHESIOLOGY, V106, P1134, DOI 10.1097/01.anes.0000265421.40477.a3; DUGGLEBY W, 1994, J PAIN SYMPTOM MANAG, V9, P19, DOI 10.1016/0885-3924(94)90142-2; ENGELMAN RM, 1994, ANN THORAC SURG, V58, P1742, DOI 10.1016/0003-4975(94)91674-8; Fraser GL, 2007, CURR OPIN ANESTHESIO, V20, P119, DOI 10.1097/ACO.0b013e32808255b4; Guldbrand P, 2004, ACTA ANAESTH SCAND, V48, P944, DOI 10.1111/j.1399-6576.2004.00445.x; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; Hogarth D Kyle, 2004, Curr Opin Crit Care, V10, P40, DOI 10.1097/00075198-200402000-00007; Howie MB, 2001, ANESTH ANALG, V92, P1084; HUNT BJ, 1991, BRIT MED J, V303, P1401, DOI 10.1136/bmj.303.6814.1401-a; Izurieta R, 2002, CRIT CARE MED, V30, P2644, DOI 10.1097/00003246-200212000-00006; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KROHN BG, 1990, J THORAC CARDIOV SUR, V100, P194; LAVE JR, 1994, MED CARE, V32, pJS77; Maddali MM, 2006, J CLIN ANESTH, V18, P605, DOI 10.1016/j.jclinane.2006.03.022; Martin J, 2006, INTENS CARE MED, V32, P1137, DOI 10.1007/s00134-006-0214-6; Muellejans B, 2006, CRIT CARE, V10, DOI 10.1186/cc4939; Myles PS, 2003, ANESTHESIOLOGY, V99, P982; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; MYLES PS, 1994, ANAESTH INTENS CARE, V22, P672, DOI 10.1177/0310057X9402200605; Nashef SAM, 2002, EUR J CARDIO-THORAC, V22, P101, DOI 10.1016/S1010-7940(02)00208-7; Oliver WC, 2004, ANESTHESIOLOGY, V101, P327, DOI 10.1097/00000542-200408000-00013; Ostermann ME, 2000, JAMA-J AM MED ASSOC, V283, P1451, DOI 10.1001/jama.283.11.1451; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Rady MY, 1998, CRIT CARE MED, V26, P225, DOI 10.1097/00003246-199802000-00016; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Ranucci M, 1999, Minerva Anestesiol, V65, P859; Richman PS, 2006, CRIT CARE MED, V34, P1395, DOI 10.1097/01.CCM.0000215454.50964.F8; Rockemann MG, 1997, ANESTH ANALG, V84, P600, DOI 10.1097/00000539-199703000-00025; Roekaerts P M, 1993, J Cardiothorac Vasc Anesth, V7, P142, DOI 10.1016/1053-0770(93)90206-Z; Roth-Isigkeit A, 1998, J ENDOCRINOL INVEST, V21, P12, DOI 10.1007/BF03347280; Sanjay OP, 2004, ANESTH ANALG, V99, P339; Searle NR, 1997, CAN J ANAESTH, V44, P629, DOI 10.1007/BF03015447; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Shroyer ALW, 2003, ANN THORAC SURG, V75, P1856, DOI 10.1016/S0003-4975(03)00179-6; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Stadler M, 2003, ANESTHESIOLOGY, V98, P46, DOI 10.1097/00000542-200301000-00011; TUMAN KJ, 1992, CHEST, V102, P36, DOI 10.1378/chest.102.1.36; United States Department of Labor Bureau of Labor Statistics, 2007, CONS PRIC IND ALL UR; Walder B, 2002, ANAESTH INTENS CARE, V30, P171, DOI 10.1177/0310057X0203000208; Walder B, 2001, ANESTH ANALG, V92, P975, DOI 10.1097/00000539-200104000-00033; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041	54	10	11	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	FEB	2011	25	1					110	119		10.1053/j.jvca.2010.07.008			10	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	717RN	WOS:000287065200019	20850348				2020-06-30	J	Lust, EB; Barthold, C; Malesker, MA; Wichman, TO				Lust, Elaine Blythe; Barthold, Claudia; Malesker, Mark A.; Wichman, Tammy O.			HUMAN HEALTH HAZARDS OF VETERINARY MEDICATIONS: INFORMATION FOR EMERGENCY DEPARTMENTS	JOURNAL OF EMERGENCY MEDICINE			English	Article						Veterinary Medications; Human health hazards; emergency department; One Medicine; carfentanil; clenbuterol (Ventipulmin); ketamine; tilmicosin (Micotil); testosterone/estradiol (Component E-H and Synovex H); dinoprost (Lutalyse/Prostamate); cloprostenol (Estromate/EstroPlan)	ANABOLIC-STEROIDS; HUMAN EXPOSURE; PROSTAGLANDIN-F2-ALPHA; CLENBUTEROL; MANAGEMENT; CENTERS	Background: There are over 5000 approved prescription and over-the-counter medications, as well as vaccines, with labeled indications for veterinary patients. Of these, there are several products that have significant human health hazards upon accidental or intentional exposure or ingestion in humans: carfentanil, clenbuterol (Ventipulmin), ketamine, tilmicosin (Micotil), testosterone/estradiol (Component E-H and Synovex H), dinoprost (Lutalyse/Prostamate), and cloprostenol (Estromate/EstroPlan). The hazards range from mild to life-threatening in terms of severity, and include bronchospasm, central nervous system stimulation, induction of miscarriage, and sudden death. Objective: To report medication descriptions, human toxicity information, and medical management for the emergent care of patients who may have had exposure to veterinary medications when they present to an emergency department (ED). Discussion: The intended use of this article is to inform and support ED personnel, drug information centers, and poison control centers on veterinary medication hazards. Conclusion: There is a need for increased awareness of the potential hazards of veterinary medications within human medicine circles. Timely reporting of veterinary medication hazards and their medical management may help to prepare the human medical community to deal with such exposures or abuses when time is of the essence. (C) 2011 Elsevier Inc.	[Lust, Elaine Blythe; Malesker, Mark A.] Creighton Univ, Dept Pharm Practice, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA; [Lust, Elaine Blythe] Profess Vet Prod Ltd, Regulatory Affairs, Omaha, NE USA; [Barthold, Claudia] Univ Nebraska Med Ctr, Nebraska Reg Poison Ctr, Dept Emergency Med, Omaha, NE USA; [Malesker, Mark A.; Wichman, Tammy O.] Creighton Univ, Med Ctr, Div Pulm Crit Care & Sleep Med, Omaha, NE 68178 USA	Lust, EB (reprint author), Creighton Univ, Dept Pharm Practice, Sch Pharm & Hlth Profess, 2500 Calif Plaza, Omaha, NE 68178 USA.	elaine.lust@pvpl.com					Alfaidy N, 2001, J CLIN ENDOCR METAB, V86, P5585, DOI 10.1210/jc.86.11.5585; *AM VET MED ASS, STAT REG RUM MIS VET; [Anonymous], 2008, THOMPSON MICROMEDEX; [Anonymous], 2008, WIKIPEDIA; Babigian A, 2001, PLAST RECONSTR SURG, V107, P240, DOI 10.1097/00006534-200101000-00039; Brent J., 2005, CRITICAL CARE TOXICO; BUSKO M, 2007, [No title captured]; Clark BM, 2005, PHARMACOTHERAPY, V25, P756, DOI 10.1592/phco.25.5.756.63592; Dart RC, 2000, ANN EMERG MED, V36, P126, DOI 10.1067/mem.2000.108182; Daubert GP, 2007, J MED TOXICOL, V3, P56, DOI 10.1007/BF03160909; *DEP HLTH HUM SAF, PREV WORK DEATHS INJ; Fineschi V, 2007, INT J LEGAL MED, V121, P48, DOI 10.1007/s00414-005-0055-9; Forrester MB, 2005, HUM EXP TOXICOL, V24, P275, DOI 10.1191/0960327105ht516oa; Griffiths AL, 2006, J ENDOCRINOL, V188, P569, DOI 10.1677/joe.1.06466; HAYES CM, CLUB DRUGS FOCUS KET; Hislop MS, 2001, ATHEROSCLEROSIS, V159, P425, DOI 10.1016/S0021-9150(01)00519-6; Hoffman RS, 2008, ANN EMERG MED, V52, P548, DOI 10.1016/j.annemergmed.2008.04.026; KLAASSEN CD, 2001, CASARETT DOULLS TOXI; Kreeger TJ, 1999, HDB WILDLIFE CHEM IM, p[36, 125]; Kutscher EC, 2002, SPORTS MED, V32, P285, DOI 10.2165/00007256-200232050-00001; Lasseter R. H., 2007, MATLAB SIMPOWERSYSTE, V1, P305; LAUDERDALE J, FACTS BEEF CATTLE GR; Meziani F, 2006, AM J PATHOL, V169, P1473, DOI 10.2353/ajpath.2006.051304; Mueller A, 2006, HUM REPROD, V21, P2000, DOI 10.1093/humrep/del118; *N AM COMP, ONL COMP VET PROD VE; Oakes JA, 2008, J MED TOXICOL, V4, P225, DOI 10.1007/BF03161205; Parkinson AB, 2006, MED SCI SPORT EXER, V38, P644, DOI 10.1249/01.mss.0000210194.56834.5d; Perry PJ, 2005, CLIN J SPORT MED, V15, P326, DOI 10.1097/01.jsm.0000180872.22426.bb; PLUMB DC, 2005, VET DRUG HDB, P19193; Ricaurte GA, 2005, LANCET, V365, P2137, DOI 10.1016/S0140-6736(05)66737-2; ROSSOFF IS, 2002, ENCY CLIN TOXICOLOGY, P5897; Sader MA, 2001, J AM COLL CARDIOL, V37, P224, DOI 10.1016/S0735-1097(00)01083-4; SCHULTZ K, 2007, DVM NEWSMAGAZINE, V24, P10; Shahidi NT, 2001, CLIN THER, V23, P1355, DOI 10.1016/S0149-2918(01)80114-4; Sherry T, 2006, CLIN TOXICOL, V44, P739; Stimac D, 2002, J CLIN GASTROENTEROL, V35, P350, DOI 10.1097/00004836-200210000-00013; STOBBS LA, DRUG WARNING MED INF; Tazzeo T, 2003, BRIT J PHARMACOL, V140, P759, DOI 10.1038/sj.bjp.0705482; Trenton AJ, 2005, CNS DRUGS, V19, P571, DOI 10.2165/00023210-200519070-00002; Veenhuizen MF, 2006, JAVMA-J AM VET MED A, V229, P1737, DOI 10.2460/javma.229.11.1737; Von Essen S, 2003, J TOXICOL-CLIN TOXIC, V41, P229, DOI 10.1081/CLT-120021103; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Wildlife Pharmaceuticals Incorporated, MAT SAF DAT SHEET; Wilkins JR, 1997, OCCUP MED-OXFORD, V47, P451, DOI 10.1093/occmed/47.8.451; Wingert WE, 2008, J ANAL TOXICOL, V32, P522, DOI 10.1093/jat/32.7.522; WISLICKI L, 1982, INT J BIOL RES PREG, V3, P158; Ziganshin AU, 2005, OBSTET GYNECOL, V105, P1429, DOI 10.1097/01.AOG.0000161314.50808.dd; *ZOOPHARM, DRUG INF SHEET CARF; ESTRUMATE PACKAGE IN; EXEMPT ANABOLIC STER; THOMSON MICROMEDEX H; VETAKET PACKAGE INSE; MICOTIL 300 MAT SAFE; MICOTIL PACKAGE INSE; LUTALYSE PACKAGE INS; NAT AG SAFETY DATABA; DRUGS CHEM CONCERN C; DRUGS CHEM CONCERN; FREEDOM INFORM SUMMA	59	41	41	1	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	FEB	2011	40	2					198	207		10.1016/j.jemermed.2009.09.026			10	Emergency Medicine	Emergency Medicine	722XO	WOS:000287468800015	20045604				2020-06-30	J	Davies, A; Sitte, T; Elsner, F; Reale, C; Espinosa, J; Brooks, D; Fallon, M				Davies, Andrew; Sitte, Thomas; Elsner, Frank; Reale, Carlo; Espinosa, Jose; Brooks, David; Fallon, Marie			Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate in Breakthrough Cancer Pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Fentanyl; intranasal; breakthrough pain; cancer; pain management; patient acceptability	PALLIATIVE-CARE; DRUG-DELIVERY; ORAL MORPHINE; MANAGEMENT; PREVALENCE; OPIOIDS; RECOMMENDATIONS; ASSOCIATION; XEROSTOMIA; ADMISSION	Context. We recently reported that fentanyl pectin nasal spray (FPNS) provides superior pain relief from breakthrough cancer pain (BTCP) compared with immediate-release morphine sulfate (IRMS), with significant effects by five minutes and clinically meaningful pain relief from 10 minutes postdose. Objectives. To report the consistency of efficacy, tolerability, and patient acceptability of FPNS vs. IRMS. Methods. Patients (n=110) experiencing one to four BTCP episodes/day while taking >= 60 mg/day oral morphine (or equivalent) for background pain entered a double-blind, double-dummy (DB/DD), multiple-crossover study. Those who completed an open-label titration phase (n=84) continued to a DB/DD phase; 10 episodes were randomly treated with FPNS and overencapsulated placebo or IRMS and nasal spray placebo (five episodes each). Pain intensity (PI) and pain relief scores were assessed. Patient acceptability scores were assessed at 30 and 60 minutes. Safety and tolerability were assessed by adverse events (AEs) and nasal assessments. Results. Per-episode analysis revealed that FPNS consistently provided relief from pain more rapidly than IRMS; by 10 minutes, there were significant differences in PI difference scores and in the percentages of episodes showing clinically meaningful pain relief (P < 0.05). Overall acceptability scores were significantly greater for FPNS than for IRMS at 30 (P < 0.01) and 60 (P < 0.05) minutes. Patients were "satisfied/very satisfied'' with the convenience (79.8%) and ease of use (77.2%) of FPNS. Only 4.7% of patients withdrew from titration because of AEs; no significant nasal effects were reported. Conclusion. This study demonstrates that FPNS is efficacious, well accepted, and well tolerated by patients with BTCP. J Pain Symptom Manage 2011; 41: 358-366. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	[Davies, Andrew] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England; [Sitte, Thomas] Palliat Netz Osthessen, Fulda, Germany; [Elsner, Frank] Rhein Westfal TH Aachen, Aachen, Germany; [Reale, Carlo] Univ Roma La Sapienza, Rome, Italy; [Espinosa, Jose] Inst Catala Oncol, Barcelona, Spain; [Brooks, David] Chesterfield & N Derbyshire Royal Hosp NHS Trust, Chesterfield, England; [Fallon, Marie] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland	Davies, A (reprint author), Royal Surrey Cty Hosp, St Lukes Canc Ctr, Egerton Rd, Surrey GU2 7XX, England.	andavies@doctors.org.uk	Tuluc, Petronel/C-2527-2011	Espinosa Rojas, Jose Armando/0000-0003-2908-8846; Fallon, Marie/0000-0001-9214-0091			Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Dahl June L, 2004, J Natl Cancer Inst Monogr, P124; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; DAVIES A, 2010, PALLIATIVE MED, V24, pS121; DAVIES A, 2010, EUR ASS PALL CAR EAP; Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006; Davies AN, 2001, J PAIN SYMPTOM MANAG, V22, P820, DOI 10.1016/S0885-3924(01)00318-9; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Davies AN, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2689; Fallon M., 2010, PALLIATIVE MED, V24, pS24; Fisch MJ, 2007, CANC PAIN MANAGEMENT; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Jacobsen R, 2009, SCAND J CARING SCI, V23, P190, DOI 10.1111/j.1471-6712.2008.00601.x; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Miaskowski C, 2001, J CLIN ONCOL, V19, P4275, DOI 10.1200/JCO.2001.19.23.4275; Petzke F, 1999, J PAIN SYMPTOM MANAG, V17, P391, DOI 10.1016/S0885-3924(99)00023-8; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Portenoy Russell K, 2010, J Opioid Manag, V6, P97; Ruiz-Garcia V, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a3104; Swanwick M, 2001, PALLIATIVE MED, V15, P9, DOI 10.1191/026921601668030190; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Wiffen Philip J, 2008, J Pain Palliat Care Pharmacother, V22, P239; Zeppetella G, 2009, EUR J CANCER CARE, V18, P331, DOI 10.1111/j.1365-2354.2008.01009.x; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	35	59	63	1	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	FEB	2011	41	2					358	366		10.1016/j.jpainsymman.2010.11.004			9	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	736ZW	WOS:000288536300005	21334555	Bronze			2020-06-30	J	Kim, DY; Song, HS; Ahn, JS; Ryoo, BY; Shin, DB; Yim, CY; Kim, SY				Kim, Do-Yeun; Song, Hong-Suk; Ahn, Jin-Seok; Ryoo, Baek-Yeol; Shin, Dong-Bok; Yim, Chang-Yeol; Kim, Si-Young			The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study	SUPPORTIVE CARE IN CANCER			English	Article						Opioid analgesics; Cancer; Pain		End-of-dose failure is commonly observed as therapeutic levels of sustained-release opioids fall. However, little is known about using these medications for cancer pain control. To determine the dosing frequency of sustained-release opioids (morphine, oxycodone, and transdermal fentanyl) and the prevalence of end-of-dose failure in clinical practice, a patient-reported survey was performed. A multicenter survey was conducted in 56 hospitals in Korea between June and November 2008. The study enrolled 1,097 cancer outpatients who were prescribed oral sustained-release opioids (morphine or oxycodone) or transdermal fentanyl. Of the oral sustained-release opioid patients, 67.0% took oral sustained-release oral opioids twice daily, while 26.2% took them more than twice daily. Of the transdermal fentanyl patients, 88.8% wore the patch for 72 h. Of the enrolled patients, 48.3% experienced worsening pain just before the next sustained-release opioid dose, and 36.8% of these patients took medication earlier than the prescribed dosing schedule. Patients felt that oral sustained-release opioids gave adequate pain control lasting an average of 9.6 h, versus an average of 62.9 h for transdermal fentanyl. This survey demonstrated that sustained-release opioids are used by patients in a manner that is inconsistent with standard recommendations. End-of-dose failure is suggested to explain increased dosing frequency, and patients reported that adequate pain relief lasted for less time than was stated in the manufacturers' prescription recommendation.	[Kim, Si-Young] Kyung Hee Univ, Med Ctr, Div Med Oncol, Seoul, South Korea; [Kim, Do-Yeun] Dongguk Univ, Ilsan Hosp, Div Med Oncol, Seoul, South Korea; [Song, Hong-Suk] Keimyung Univ, Dongsan Med Ctr, Div Med Oncol, Seoul, South Korea; [Ahn, Jin-Seok] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Med Oncol, Seoul, South Korea; [Ryoo, Baek-Yeol] Korea Canc Ctr Hosp, Div Med Oncol, Seoul, South Korea; [Shin, Dong-Bok] Gachon Univ, Gil Hosp, Div Med Oncol, Seoul, South Korea; [Yim, Chang-Yeol] Chonbuk Natl Univ Hosp, Div Med Oncol, Seoul, South Korea	Kim, SY (reprint author), Kyung Hee Univ, Med Ctr, Div Med Oncol, Seoul, South Korea.	sykim55@chol.com					Adams D, 2002, PAIN MED, V3, P185; Gallagher RM, 2007, PAIN MED, V8, P71, DOI 10.1111/j.1526-4637.2007.00260.x; Genf World Health Organization, 1986, CANC PAIN REL; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Kaiko RF, 1997, ACTA ANAESTH SCAND, V41, P166, DOI 10.1111/j.1399-6576.1997.tb04633.x; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; KHOJASTEH A, 1987, J CLIN ONCOL, V5, P956, DOI 10.1200/JCO.1987.5.6.956; Lugo Ralph A, 2002, J Pain Palliat Care Pharmacother, V16, P5; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; MIGNAULT GG, 1995, J PAIN SYMPTOM MANAG, V10, P416, DOI 10.1016/0885-3924(95)00063-5; Olkkola KT, 2009, CURR OPIN ANESTHESIO, V22, P459, DOI 10.1097/ACO.0b013e32832bc818	12	9	9	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	FEB	2011	19	2					297	301		10.1007/s00520-010-0825-x			5	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	702DY	WOS:000285876000014	20213238				2020-06-30	J	Jo, YY; Hong, JY; Choi, EK; Kil, HK				Jo, Y. Y.; Hong, J. Y.; Choi, E. K.; Kil, H. K.			Ketorolac or fentanyl continuous infusion for post-operative analgesia in children undergoing ureteroneocystostomy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							CAUDAL ANALGESIA; INTRAVESICAL URETERONEOCYSTOSTOMY; URINARY-TRACT; PAIN; MORPHINE; CLONIDINE; INCREASE; BLADDER	Background Children undergoing ureteroneocystostomy suffer from post-operative pain due to the surgical incision and bladder spasm. A single-shot caudal block is a common technique for paediatric analgesia, but a disadvantage is the limitation of a short duration in spite of the additives co-administered. A few clinical trials have shown that ketorolac provides an effective post-operative analgesia and reduces the bladder spasms after ureteral implantation in children. We compared the efficacy of a continuous infusion of ketorolac and fentanyl in post-operative analgesia and bladder spasm in children who underwent ureteroneocystostomy. Methods Fifty-two children were allocated to the ketorolac group (Group K, n=26) and fentanyl group (Group F, n=26). After general anaesthesia, a caudal block was performed with 1.5 ml/kg of 0.15% ropivacaine. At the beginning of surgery, an infusion was started after the bolus injection of ketorolac 0.5 mg/kg or fentanyl 1 mu g/kg. An infusion device was programmed to deliver ketorolac 83.3 mu g/kg/h or fentanyl 0.17 mu g/kg/h for 48 h. Results Two of Group F and three of Group K were excluded from the study. Post-operative pain scores were similar between the two groups. One of Group K (4%) and seven of Group F (30.4%) experienced bladder spasms. The rescue analgesic requirements were significantly less in Group K. Conclusions A Continuous infusion of ketorolac provided effective analgesia after operation in children who underwent ureteroneocystostomy as well as a low dosage of fentanyl. Ketorolac was more effective in reducing the frequency of bladder spasms and rescue analgesic requirements.	[Kil, H. K.] Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Anaesthesia & Pain Res Inst, Seoul 120752, South Korea	Kil, HK (reprint author), Yonsei Univ, Coll Med, Dept Anaesthesiol & Pain Med, Anaesthesia & Pain Res Inst, 250 Seongsan No, Seoul 120752, South Korea.	hkkil@yuhs.ac	Choi, Eue-Keun/J-5968-2014; Choi, Eue-Keun/K-3752-2019	Choi, Eue-Keun/0000-0002-0411-6372; 			ABRAMS PH, 1975, BRIT J UROL, V47, P909, DOI 10.1111/j.1464-410X.1975.tb04075.x; Bringuier S, 2009, PAIN, V145, P60, DOI 10.1016/j.pain.2009.05.012; BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495-199039010-00008; Cepeda MS, 2005, ANESTHESIOLOGY, V103, P1225, DOI 10.1097/00000542-200512010-00018; Chauhan RD, 2001, J UROLOGY, V166, P1873, DOI 10.1016/S0022-5347(05)65710-2; Dasgupta P, 1998, J UROLOGY, V159, P1857, DOI 10.1016/S0022-5347(01)63176-8; DEGROAT WC, 1993, UROL CLIN N AM, V20, P383; El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159; Engelhardt T, 2008, ANESTH ANALG, V107, P1170, DOI 10.1213/ane.0b013e318183919e; Forrest JB, 1997, DRUG SAFETY, V16, P309, DOI 10.2165/00002018-199716050-00003; Gold MS, 1996, P NATL ACAD SCI USA, V93, P1108, DOI 10.1073/pnas.93.3.1108; Harper L, 2007, J Pediatr Urol, V3, P301, DOI 10.1016/j.jpurol.2006.11.003; Hong JY, 2009, ANESTH ANALG, V109, P1073, DOI 10.1213/ane.0b013e3181b20c52; Karsenty G, 2005, UROLOGY, V66, P763, DOI 10.1016/j.urology.2005.04.061; Keidan I, 2004, PEDIATR ANESTH, V14, P318, DOI 10.1046/j.1460-9592.2003.01212.x; MAGGI CA, 1985, J UROLOGY, V134, P800, DOI 10.1016/S0022-5347(17)47442-8; Matsuda Yoshifumi, 2009, Masui, V58, P609; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; Merguerian PA, 2004, J UROLOGY, V172, P1621, DOI 10.1097/01.ju.0000139953.04938.07; Miller OF, 2002, J UROLOGY, V167, P2556, DOI 10.1016/S0022-5347(05)65036-7; Park JM, 2000, ANESTH ANALG, V91, P11, DOI 10.1097/00000539-200007000-00003; Routh JC, 2010, UROLOGY, V76, P9, DOI 10.1016/j.urology.2009.10.062; Shin SK, 2009, ANESTHESIOLOGY, V111, P1135, DOI 10.1097/ALN.0b013e3181bc6dd4; Silvani P, 2006, MINERVA ANESTESIOL, V72, P453; Tripi PA, 2005, J UROLOGY, V174, P1081, DOI 10.1097/01.ju.0000169138.90628.b9; VETTER TR, 1994, J CLIN ANESTH, V6, P110, DOI 10.1016/0952-8180(94)90006-X	26	7	8	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2011	55	1					54	59		10.1111/j.1399-6576.2010.02354.x			6	Anesthesiology	Anesthesiology	689AD	WOS:000284898500009	21083540				2020-06-30	J	Park, JH; Kim, JH; Yun, SC; Roh, SW; Rhim, SC; Kim, CJ; Jeon, SR				Park, Jin Hoon; Kim, Jeoung Hee; Yun, Sung Cheol; Roh, Sung Woo; Rhim, Seung Chul; Kim, Chang Jin; Jeon, Sang Ryong			Evaluation of efficacy and safety of fentanyl transdermal patch (Durogesic(A (R))D-TRANS) in chronic pain	ACTA NEUROCHIRURGICA			English	Article						Fentanyl patch; Chronic pain; Neuropathic pain; Nociceptive pain	RELEASE ORAL MORPHINE; LONG-TERM TREATMENT; QUALITY-OF-LIFE; CANCER PAIN; RANDOMIZED CROSSOVER; IDIOPATHIC FORMS; NONCANCER PAIN; OPIOIDS; TRIAL; SUPPRESSION	Opioids are used in controlling several types of pain. This study was designed to evaluate the efficacy and safety of the fentanyl transdermal patch-type system (DurogesicA (R) D-TRANS). Patients who complained of chronic moderate to severe pain were enrolled. Administration dosages of fentanyl patch started from 12.5 mu g/h and could be increased by 12.5 mu g/h or 25 mu g/h, if the average pain score of 4 or higher occurred within 72 h. The total administration period was 12 weeks. The type, location, characteristics, and duration of pain were evaluated. Also, on day 0, weeks of 4, 8, and 12, the physician's assessment of pain intensity, the patient's assessment of pain intensity, the assessment of impact of pain on functions, and the assessment of the impact of pain on sleep were assessed. In addition, side effects were evaluated during the study duration. A total of 65 cases were enrolled, and the final evaluated cases were 41. Before treatment, the average physician's assessment of pain intensity was 6.70 +/- 1.41, and the average patient's assessment of pain intensity was 7.02 +/- 1.63. In the final visit, the average physician's assessment of pain intensity was 2.58 +/- 1.72, and the average patient's assessment of pain intensity was 2.86 +/- 1.78. This prospective study shows that the fentanyl patch is effective in alleviating moderate to severe chronic noncancer pain including neuropathic pain down to mild pain. Therefore, the fentanyl patch should be considered before other invasive intervention procedures in chronic moderate to severe noncancer pain.	[Park, Jin Hoon; Kim, Jeoung Hee; Roh, Sung Woo; Rhim, Seung Chul; Kim, Chang Jin; Jeon, Sang Ryong] Univ Ulsan, Coll Med, ASAN Med Ctr, Dept Neurol Surg, Seoul 138736, South Korea; [Yun, Sung Cheol] Univ Ulsan, Coll Med, Dept Prevent Med, ASAN Med Ctr, Seoul 138736, South Korea	Jeon, SR (reprint author), Univ Ulsan, Coll Med, ASAN Med Ctr, Dept Neurol Surg, 388-1 Pungnap 2 Dong, Seoul 138736, South Korea.	srjeon@amc.seoul.kr			Janssen Korea, Seoul, South Korea [FEN-KOR-10]	The authors express their gratitude to Sun Keun Huh for his assistance in the collection of data. This research was financially supported by a grant (protocol number FEN-KOR-10) from Janssen Korea, Seoul, South Korea, whose role was restricted to providing assistance to the investigators in the conception, conduct, and analysis of this study.	Agarwal S, 2007, PAIN MED, V8, P554, DOI 10.1111/j.1526-4637.2006.00246.x; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; ASBURY AK, 1984, NEUROLOGY, V34, P1587, DOI 10.1212/WNL.34.12.1587; Bolay H, 2002, NEUROLOGY, V59, pS2, DOI 10.1212/WNL.59.5_suppl_2.S2; Brown R L, 1996, J Am Board Fam Pract, V9, P191; Cummings-Ajemian I, 1993, CANC PAIN; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Graziotti PJ, 1997, MED J AUSTRALIA, V167, P30, DOI 10.5694/j.1326-5377.1997.tb138760.x; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Haddox JD, 1997, PAIN FORUM, V6, P77; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; KOLTZENBURG M, 1994, BRAIN, V117, P579, DOI 10.1093/brain/117.3.579; Kosinski MR, 2005, CURR MED RES OPIN, V21, P849, DOI 10.1185/030079905X46377; KUPERS RC, 1991, PAIN, V47, P5, DOI 10.1016/0304-3959(91)90004-H; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Ozaki S, 2004, J NEUROCHEM, V88, P1389, DOI 10.1046/j.1471-4159.2003.02272.x; Ozaki S, 2003, NEUROSCIENCE, V116, P89, DOI 10.1016/S0306-4522(02)00699-1; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Portenoy R.K., 1990, J PAIN SYMPTOM MANAG, V5, P46; PORTER J, 1980, NEW ENGL J MED, V302, P123; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; Suzuki T, 1999, LIFE SCI, V64, pPL151, DOI 10.1016/S0024-3205(99)00036-3	33	10	11	1	8	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2011	153	1					181	190		10.1007/s00701-010-0785-4			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	700YD	WOS:000285780600029	20821238				2020-06-30	J	Yamdeu, RS; Shaqura, M; Mousa, SA; Schafer, M; Droese, J				Yamdeu, Reine-Solange; Shaqura, Mohammed; Mousa, Shaaban A.; Schaefer, Michael; Droese, Jana			p38 Mitogen-activated Protein Kinase Activation by Nerve Growth Factor in Primary Sensory Neurons Upregulates mu-Opioid Receptors to Enhance Opioid Responsiveness Toward Better Pain Control	ANESTHESIOLOGY			English	Article							DORSAL-ROOT GANGLIA; PRIMARY AFFERENT NEURONS; INFLAMMATION-INDUCED INCREASE; GENE-RELATED PEPTIDE; MESSENGER-RNA; SPINAL-CORD; PERIPHERAL INFLAMMATION; AXONAL-TRANSPORT; SUBSTANCE-P; MAP KINASE	Background: Sensory neuron opioid receptors are targets for spinal, epidural, and peripheral opioid application. Although local nerve growth factor (NGF) has been identified as a mediator of sensory neuron mu-opioid receptor (MOR) up-regulation, the signaling pathways involved have not been yet identified. Methods: Wistar rats were treated with intraplantar vehicle, Freund's complete adjuvant, NGF, NGF plus intrathecal p38 mitogen-activated protein kinase (MAPK) inhibitors, or NGF plus extracellular signal-regulated kinase-1/2 MAPK inhibitors. After 4 days of treatment, paw pressure thresholds of an intraplantar full (fentanyl) or partial (buprenorphine) opioid agonist were determined by algesiometry. Tissue samples from rat dorsal root ganglia were subjected to radiolabeled ligand binding, Western blot analysis, and confocal immunofluorescence. Results: Exogenous and endogenous NGF resulting from Freund's complete adjuvant inflammation produced significant potentiation and enhanced efficacy in fentanyl- and buprenorphine-induced dose-dependent antinociception, respectively. Furthermore, in the ipsilateral dorsal root ganglia, NGF produced a significant increase in MOR binding sites, proteins, and immunoreactive neurons. In parallel, phosphorylated p38-MAPK protein, the number of phosphorylated p38-MAPK immunoreactive neurons expressing MOR in dorsal root ganglia, and the peripherally directed axonal transport of MOR significantly increased. Finally, NGF-induced effects occurring in dorsal root ganglia, on axonal transport, and on the potentiation or enhanced efficacy of opioid antinociception were abrogated by inhibition of p38, but not extracellular signal-regulated kinase-1/2, MAPK. Conclusions: Local NGF through activation of the p38-MAPK pathway leads to adaptive changes in sensory neuron MOR toward enhanced susceptibility to local opioids. This effect may act as a counter-regulatory response to p38-MAPK-induced pain (e. g., inflammatory pain) to facilitate opioid-mediated antinociception.	[Yamdeu, Reine-Solange; Shaqura, Mohammed; Mousa, Shaaban A.; Schaefer, Michael; Droese, Jana] Charite, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany	Mousa, SA (reprint author), Charite, Dept Anesthesiol & Intens Care Med, Campus Virchow Klinikum,Augustenburgerpl 1, D-13353 Berlin, Germany.	shaaban.mousa@charite.de	Schafer, Michael/AAB-1395-2020		Deutsche Forschungsgemeinschaft (Bonn, Germany)German Research Foundation (DFG) [KFO100, MOU 1006/1-4, SCHA 820/3-2]	Supported by the Deutsche Forschungsgemeinschaft (Bonn, Germany) Grant nos. KFO100, MOU 1006/1-4, and SCHA 820/3-2 (to Drs. Mousa and Schafer). Drs. Schafer and Droese contributed equally to this work.	Amann R, 1996, PAIN, V64, P323, DOI 10.1016/0304-3959(95)00120-4; Borner C, 2004, MOL PHARMACOL, V66, P1719, DOI 10.1124/mol.104.003806; Bron R, 2003, MOL CELL NEUROSCI, V22, P118, DOI 10.1016/S1044-7431(02)00022-2; Cahill CM, 2003, NEUROPHARMACOLOGY, V45, P543, DOI 10.1016/S0028-3908(03)00192-8; Coggeshall RE, 1997, BRAIN RES, V764, P126, DOI 10.1016/S0006-8993(97)00446-0; de Leon-Casasola OA, 2008, CLIN J PAIN, V24, pS3, DOI 10.1097/AJP.0b013e31816b589f; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; DONNERER J, 1993, REGUL PEPTIDES, V46, P150; Frank AJ, 2003, EXP CELL RES, V283, P127, DOI 10.1016/S0014-4827(02)00026-5; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; Ide Takeshi, 2005, Mod Rheumatol, V15, P454, DOI 10.1007/s10165-005-0441-7; Igwe OJ, 2003, EUR J NEUROSCI, V18, P1719, DOI 10.1046/j.1460-9568.2003.02878.x; JEANJEAN AP, 1994, NEUROSCI LETT, V177, P75, DOI 10.1016/0304-3940(94)90048-5; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002; Ji RR, 1997, J NEUROSCI, V17, P1776; Ji RR, 1995, J NEUROSCI, V15, P8156; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Ji Ru-Rong, 2004, Curr Opin Investig Drugs, V5, P71; Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Kasai S, 2008, N-S ARCH PHARMACOL, V377, P269, DOI 10.1007/s00210-007-0205-3; Kenakin T. P, 1997, PHARM ANAL DRUG RECE, P78; LINDSAY RM, 1989, NEUROSCIENCE, V33, P53, DOI 10.1016/0306-4522(89)90310-2; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; Mamet J, 2002, J NEUROSCI, V22, P10662; Molliver DC, 2005, PAIN, V113, P277, DOI 10.1016/j.pain.2004.10.025; Mousa SA, 2007, NEUROPSYCHOPHARMACOL, V32, P2530, DOI 10.1038/sj.npp.1301393; Mousa SA, 2007, BRAIN, V130, P502, DOI 10.1093/brain/awl330; Mu TW, 2008, CELL, V134, P769, DOI 10.1016/j.cell.2008.06.037; NINKOVIC M, 1982, BRAIN RES, V241, P197, DOI 10.1016/0006-8993(82)91056-3; Obata K, 2004, NEUROSCIENCE, V126, P1011, DOI 10.1016/j.neuroscience.2004.04.036; Puehler W, 2006, NEUROSCIENCE, V141, P989, DOI 10.1016/j.neuroscience.2006.03.078; Puehler W, 2004, NEUROSCIENCE, V129, P473, DOI 10.1016/j.neuroscience.2004.06.086; Rajasingh J, 2006, FASEB J, V20, P2112, DOI 10.1096/fj.06-6084fje; Ramer MS, 2001, J NEUROCHEM, V77, P864, DOI 10.1046/j.1471-4159.2001.00288.x; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; SCHAFER M, 1995, EUR J PHARMACOL, V279, P165, DOI 10.1016/0014-2999(95)00150-J; Schmitt TK, 2003, ANESTHESIOLOGY, V98, P195, DOI 10.1097/00000542-200301000-00030; Shaqura MA, 2004, J PHARMACOL EXP THER, V308, P712, DOI 10.1124/jpet.103.057257; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Sully G, 2004, BIOCHEM J, V377, P629, DOI 10.1042/BJ20031484; Svensson CI, 2003, NEUROREPORT, V14, P1153, DOI 10.1097/00001756-200306110-00010; Tamura S, 2005, NEUROSCIENCE, V133, P797, DOI 10.1016/j.neuroscience.2005.02.046; Walsh GS, 1999, J NEUROSCI, V19, P258; White PF, 2010, ANESTHESIOLOGY, V112, P220, DOI 10.1097/ALN.0b013e3181c6316e; Widmann C, 1999, PHYSIOL REV, V79, P143; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Woolf CJ, 1998, NEURON, V20, P1063, DOI 10.1016/S0896-6273(00)80487-0; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yaksh TL, 2003, ANESTHESIOLOGY, V99, P174, DOI 10.1097/00000542-200307000-00028; Yassen A, 2005, J PHARMACOL EXP THER, V313, P1136, DOI 10.1124/jpet.104.082560; Zhang JQ, 1998, ANAT REC, V251, P214, DOI 10.1002/(SICI)1097-0185(199806)251:2<214::AID-AR9>3.0.CO;2-Y; Zhong HY, 2000, MOL PHARMACOL, V57, P961; Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893-04.2004; Zollner C, 2000, MOL BRAIN RES, V79, P159, DOI 10.1016/S0169-328X(00)00100-5; Zollner C, 2003, MOL PHARMACOL, V64, P202, DOI 10.1124/mol.64.2.202; Zwick M, 2003, PAIN, V106, P491, DOI 10.1016/j.pain.2003.09.016	60	8	12	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JAN	2011	114	1					150	161		10.1097/ALN.0b013e318201c88c			12	Anesthesiology	Anesthesiology	697UB	WOS:000285542700025	21169793	Bronze			2020-06-30	J	Ouerghi, S; Fnaeich, F; Frikha, N; Mestiri, T; Merghli, A; Mebazaa, MS; Kilani, T; Ben Ammar, MS				Ouerghi, S.; Fnaeich, F.; Frikha, N.; Mestiri, T.; Merghli, A.; Mebazaa, M. S.; Kilani, T.; Ben Ammar, M. S.			The effect of adding intrathecal magnesium sulphate to morphine-fentanyl spinal analgesia after thoracic surgery. A prospective, double-blind, placebo-controlled research study	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			English	Article						Intrathecal analgesia; Magnesium; Adjuvant; Thoracic surgery; Morphine	POSTOPERATIVE PAIN; POSTTHORACOTOMY PAIN; BUPIVACAINE-FENTANYL; CONTROLLED-TRIAL; LABOR ANALGESIA; ANESTHESIA; SUFENTANIL; COMBINATION; EXPERIENCE; CLONIDINE	Background. - We investigated whether intrathecally magnesium sulphate added to morphine and fentanyl reduces patients' postoperative analgesia requirements and prolongs spinal opioid analgesia after thoracotomy. Methods. - In a single-center, prospective, placebo-controlled, double-blind trial, we enrolled 58 adult patients undergoing elective posterolateral thoracotomy. Patients were randomized to receive either 25 mu g of fentanyl citrate (0.5 mL) + 300 mu g of morphine + 1.0 mL of preservative-free 0.9% sodium chloride (Group S) or 25 mu g of fentanyl citrate (0.5 mL) + 300 mu g of morphine + 50 mg of magnesium sulphate 5% (1.0 mL) (Group MgSO4) for intrathecal analgesia. Opioid consumption and postoperative pain were assessed for 36 hours. Results. - VAS pain scores at rest and on coughing were similar in all groups. The total 36-h intravenous morphine requirements were significantly lower in group MgSO4 (14[9.50-26.50] mg vs. 33 [30-41] mg, p < 0.001); i.e. 57% less for the group MgSO4. The total dose of intravenous morphine administered during titration was significantly lower in this group (4 [2-8] mg vs. 8 [6-10] mg, p = 0.001). Morphine consumption was significantly lower in the group MgSO4 at intervals 0-12, 12-24 and 24-36 h. The number of patients requiring titration was significantly lower in group MgSO4 (68% vs. 96%, p = 0.001). There is no difference in opioid side effects. No patient experienced side effects resulting from lumbar puncture, or neurological deficit or signs of systemic magnesium toxicity. Conclusion. - We found that in patients undergoing pulmonary resection with elective posterolateral thoracotomy, magnesium sulphate (50 mg), when added to spinal morphine analgesia reduces postoperative morphine requirements, the number of patients requiring morphine titration without increasing opioid side effects. (C) 2010 Elsevier Masson SAS. All rights reserved.	[Mebazaa, M. S.; Ben Ammar, M. S.] Mongi Slim Univ Hosp, Dept Anesthesiol Intens Care & Emergency Med, La Marsa 2046, Sidi Daoud, Tunisia; [Ouerghi, S.; Fnaeich, F.; Mestiri, T.; Merghli, A.; Kilani, T.] Abderrahmen Mami Hosp, Dept Thorac Surg, Ariana, Tunisia	Ben Ammar, MS (reprint author), Mongi Slim Univ Hosp, Dept Anesthesiol Intens Care & Emergency Med, La Marsa 2046, Sidi Daoud, Tunisia.	msbenammar@gmail.com					Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 1976, Lancet, V1, P576; Arcioni R, 2007, ACTA ANAESTH SCAND, V51, P482, DOI 10.1111/j.1399-6576.2007.01263.x; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; Askar FZ, 2007, J INT MED RES, V35, P314, DOI 10.1177/147323000703500305; Bilir A, 2007, BRIT J ANAESTH, V98, P519, DOI 10.1093/bja/aem029; Birbicer H, 2007, PEDIATR SURG INT, V23, P195, DOI 10.1007/s00383-006-1779-4; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Chaney MA, 1997, ANESTH ANALG, V84, P241, DOI 10.1097/00000539-199702000-00002; Chanimov M, 1997, ANAESTHESIA, V52, P223, DOI 10.1111/j.1365-2044.1997.034-az0057.x; D'Angelo R, 1999, ANESTH ANALG, V88, P573, DOI 10.1097/00000539-199903000-00020; DELEONCASASOLA OA, 1994, ANESTHESIOLOGY, V81, P368, DOI 10.1097/00000542-199408000-00015; Ghrab BE, 2009, ANN FR ANESTH, V28, P454, DOI 10.1016/j.annfar.2009.03.004; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Jellish WS, 2008, ANESTHESIOLOGY, V108, P78, DOI 10.1097/01.anes.0000296109.04010.82; KAVANAGH BP, 1994, ANESTHESIOLOGY, V81, P737, DOI 10.1097/00000542-199409000-00028; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; Liu N, 2001, ANESTH ANALG, V92, P31; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Mason N, 2001, BRIT J ANAESTH, V86, P236, DOI 10.1093/bja/86.2.236; McCarthy RJ, 1998, ANESTH ANALG, V86, P830, DOI 10.1097/00000539-199804000-00028; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI [10.1097/01.CCM.0000156293.35868.B2, 10.1097/01.ccm.0000156293.35868.b2]; Neustein S M, 1993, J Cardiothorac Vasc Anesth, V7, P157, DOI 10.1016/1053-0770(93)90209-4; Owen MD, 2000, ANESTHESIOLOGY, V92, P361, DOI 10.1097/00000542-200002000-00016; Ozalevli M, 2005, ACTA ANAESTH SCAND, V49, P1514, DOI 10.1111/j.1399-6576.2005.00793.x; PARKHOUSE J, 1961, BRIT J ANAESTH, V33, P345, DOI 10.1093/bja/33.7.345; REUBEN SS, 1994, ANESTHESIOLOGY, V81, P1371, DOI 10.1097/00000542-199412000-00011; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; SLINGER P, 1995, CAN J ANAESTH, V42, pR77, DOI 10.1007/BF03011022; Unlugenc H, 2009, ACTA ANAESTH SCAND, V53, P346, DOI 10.1111/j.1399-6576.2008.01864.x; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	32	16	16	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0750-7658	1769-6623		ANN FR ANESTH	Ann. Fr. Anest. Reanim.	JAN	2011	30	1					25	30		10.1016/j.annfar.2010.10.018			6	Anesthesiology	Anesthesiology	725BM	WOS:000287620200007	21145193				2020-06-30	J	McNaught, A; Shastri, U; Carmichael, N; Awad, IT; Columb, M; Cheung, J; Holtby, RM; McCartney, CJL				McNaught, A.; Shastri, U.; Carmichael, N.; Awad, I. T.; Columb, M.; Cheung, J.; Holtby, R. M.; McCartney, C. J. L.			Ultrasound reduces the minimum effective local anaesthetic volume compared with peripheral nerve stimulation for interscalene block	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques, regional, brachial plexus; analgesics, postoperative	BRACHIAL-PLEXUS BLOCK; LOW-DOSE BUPIVACAINE	Background. Previous studies have demonstrated that lower local anaesthetic (LA) volumes can be used for ultrasound (US)-guided interscalene brachial plexus block (ISB). However, no study has examined whether US can reduce the volume required when compared with nerve stimulation (NS) for ISB. Our aim was to do this by comparing the minimum effective analgesic volumes (MEAVs). Methods. After ethics approval and informed consent, patients undergoing shoulder surgery were recruited to this randomized, double-blind, up-down sequential allocation study. The volume used for both US and NS was dependent upon the success or failure of the previous block. Success was defined as a verbal rating score of 0/10, 30 min after surgery. Ten needle passes were allowed before defaulting to the opposite group. Patients received general anaesthesia. Pain scores and analgesic consumption were assessed by a blinded observer. Statistical comparisons of continuous variables were performed using Student's t-test and Mann-Whitney U-test as appropriate. Categorical variables were analysed using chi(2) test. MEAV values were estimated using log-transformed up-down independent pairs analysis and probit regression. Significance was assumed at P < 0.05 (two-sided). Results. The MEAV required to provide effective analgesia was significantly (P=0.034) reduced to 0.9 ml [95% confidence interval (CI) 0.3-2.8] in the US group from 5.4 ml (95% CI 3.4-8.6) in the NS group. Fewer needle passes were needed to identify the brachial plexus with US (1 vs 3; P < 0.0001) and patients had less pain at 30 min after surgery (P=0.03). Conclusions. US reduces the number of attempts, LA volume, and postoperative pain when compared with NS for ISB.	[McNaught, A.; Shastri, U.; Carmichael, N.; Awad, I. T.; Cheung, J.; McCartney, C. J. L.] Univ Toronto, Dept Anaesthesia, Toronto, ON M4N 3M5, Canada; [Holtby, R. M.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Orthopaed Surg, Toronto, ON M4N 3M5, Canada; [Columb, M.] Univ S Manchester Hosp, Dept Anaesthesia, Manchester M20 8LR, Lancs, England	McCartney, CJL (reprint author), Univ Toronto, Dept Anaesthesia, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	colin.mccartney@utoronto.ca	Columb, Malachy/F-9588-2016; Cheung, Jeffrey J. H./B-2710-2013	Columb, Malachy/0000-0001-7837-4262; Cheung, Jeffrey J. H./0000-0002-6037-5811	Physicians Services Incorporated Foundation	The study was supported by a grant from the Physicians Services Incorporated Foundation to U.S. and C.J.L.M.	Al-Kaisy A, 1998, REGION ANESTH PAIN M, V23, P469, DOI 10.1016/S1098-7339(98)90029-3; Al-Kaisy AA, 1999, BRIT J ANAESTH, V82, P217, DOI 10.1093/bja/82.2.217; BRULL R, 2004, ACUTE PAIN, V6, P57; Eichenberger U, 2009, REGION ANESTH PAIN M, V34, P242, DOI 10.1097/AAP.0b013e31819a7225; Ilfeld BM, 2003, ANESTH ANALG, V96, P1089, DOI 10.1213/01.ANE.0000049824.51036.EF; Marhofer P, 2010, ANAESTHESIA, V65, P266, DOI 10.1111/j.1365-2044.2010.06247.x; McCartney CJL, 2010, REGION ANESTH PAIN M, V35, pS10, DOI 10.1097/AAP.0b013e3181d25675; Moayeri Nizar, 2008, Anesthesiology, V108, P299, DOI 10.1097/01.anes.0000299433.25179.70; O'Donnell BD, 2009, ANESTHESIOLOGY, V111, P25, DOI 10.1097/ALN.0b013e3181a915c7; Perlas A, 2006, REGION ANESTH PAIN M, V31, P445, DOI 10.1016/j.rapm.2006.05.017; Renes SH, 2009, REGION ANESTH PAIN M, V34, P498, DOI 10.1097/AAP.0b013e3181b49256; Riazi S, 2008, BRIT J ANAESTH, V101, P549, DOI 10.1093/bja/aen229; Watt-Watson Judy, 2004, J Nurs Manag, V12, P153; WINNIE AP, 1970, ANESTH ANAL CURR RES, V49, P455	14	83	91	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JAN	2011	106	1					124	130		10.1093/bja/aeq306			7	Anesthesiology	Anesthesiology	692YX	WOS:000285192900020	21059701	Bronze			2020-06-30	J	Davies, A; Finn, A; Tagarro, I				Davies, Andrew; Finn, Andrew; Tagarro, Ignacio			Intra- and Interindividual Variabilities in the Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects A Cross-Study Analysis	CLINICAL DRUG INVESTIGATION			English	Article							DOSE PHARMACOKINETICS; BREAKTHROUGH PAIN; CITRATE; BIOAVAILABILITY; MANAGEMENT; CANCER	Background and Objective: Breakthrough pain describes transient exacerbations of pain that occur in cancer patients with adequately controlled background pain. Transmucosal fentanyl administration produces rapid-onset and short-duration analgesia that is effective for treating patients with breakthrough pain. Although a significant amount of research has been devoted to the study of speed of analgesia onset of transmucosal fentanyl products, few data exist on their variability in absorption, particularly within the same individual, despite the importance of this characteristic to the dose-to-dose reliability of their analgesic effect. This cross-study analysis aimed to evaluate the intra- and interindividual pharmacolcinetic differences of fentanyl administered via fentanyl buccal soluble film in healthy subjects. Methods: Data were evaluated from 24 subjects in two pharmacolcinetic studies of fentanyl administered via fentanyl buccal soluble film (Breakyl (R)/Onsolis (TM); BEMA (R) [BioErodible MucoAdhesive] technology). In one study, 12 healthy subjects received 600 jig doses of fentanyl as single film on two separate occasions; in the second study, 12 different healthy subjects received 800 mu g doses of fentanyl on two separate occasions, one as a single 800 mu g film and the other as four 200 mu g films. Results: The analysis showed a minimal intraindividual variability and a relatively higher interindividual variability in pharmacokinetic parameters (i.e. maximum plasma concentration, area under the plasma concentration-time curve from time zero to infinity). The coefficient of variation for intraindividual exposure to fentanyl variability was 7-10%, and for interindividual variability was 23-39%. Conclusion: The minimal intraindividual variability in fentanyl absorption from the buccal soluble film demonstrates a predictable dose-to-dose exposure, which is a very desirable attribute for a medicine that is intended to treat breakthrough cancer pain, suggesting that this product would be expected to produce consistent effects in clinical practice. The greater inter-individual variability highlights the need for individual titration of this product (as occurs with similar transmucosal fentanyl products), and for the availability of an adequately wide dose range.	[Tagarro, Ignacio] Meda Pharma, Madrid 28830, Spain; [Davies, Andrew] St Lukes Canc Ctr, Guildford, Surrey, England; [Finn, Andrew] BioDelivery Sci Int, Raleigh, NC USA	Tagarro, I (reprint author), Meda Pharma, Avda Castilla 2,Parque Empresarial San Fernando, Madrid 28830, Spain.	ignacio.tagarro@meda.es			Meda Pharma	Funding for the design and conduct of this study and for the collection, management and analysis of the resulting data was provided by BioDelivery Sciences International. Funding for the manuscript preparation was provided by Meda Pharma. We thank Dr David Blum for his valuable contribution and Bill Wargin (PK-PM Associates LLC) for his assistance and input into this manuscript. We also thank Ray Hill of inScience Communications, a Wolters Kluwer business, who provided editing assistance and journal styling prior to submission. This assistance was funded by Meda Pharma.	*BIODELIVERY SCI I, 2007, FEN110 BIODELIVERY S; *BIODELIVERY SCI I, 2007, FEN202 BIODELIVERY S; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Madhav NVS, 2009, J CONTROL RELEASE, V140, P2, DOI 10.1016/j.jconrel.2009.07.016; *MED PHARM INC, 2009, ONS PRESCR INF 2 1 D; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Skinner C, 2006, CANC RELATED BREAKTH; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Twycross R, 2007, PALLIATIVE CARE FORM; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2010, J CLIN PHARMACOL, V50, P785, DOI 10.1177/0091270010361354; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; ZEPPETELLA G, 2005, EUR J PALLIATIVE C S, V12, P4; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658	16	11	11	0	4	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1173-2563			CLIN DRUG INVEST	Clin. Drug Invest.		2011	31	5					317	324		10.1007/BF03256930			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	761AT	WOS:000290367600004	21294598				2020-06-30	J	Elsner, F; Zeppetella, G; Porta-Sales, J; Tagarro, I				Elsner, Frank; Zeppetella, Giovambattista; Porta-Sales, Josep; Tagarro, Ignacio			Newer Generation Fentanyl Transmucosal Products for Breakthrough Pain in Opioid-Tolerant Cancer Patients	CLINICAL DRUG INVESTIGATION			English	Review							BUCCAL SOLUBLE FILM; 800 MU-G; OPEN-LABEL; DOUBLE-BLIND; CITRATE; PREVALENCE; MANAGEMENT; CROSSOVER; SPRAY; TRIAL	Oral normal-release morphine has long been considered the gold-standard treatment for cancer breakthrough pain. However, its relatively long time to analgesic onset, delay in maximal analgesic effect and prolonged duration of action make it unsuitable for the management of breakthrough pain episodes. These limitations led to the development of an oral transmucosal formulation of the fast-acting opioid fentanyl (oral transmucosal fentanyl citrate [OTFC] lozenge on a plastic handle; Actiq (R)), which has been shown to produce more rapid and effective pain relief than oral morphine. However, the formulation itself has some limitations. Consequently, investigators have continued to develop other, newer generation, transmucosal formulations of fentanyl to further improve the management of breakthrough pain. Recently, five such compounds (Effentora (R)/Fentora (R), Abstral (R), Instanyl (R), Breakyl (R)/Onsolis (TM) and PecFent (R)) have been concurrently approved in Europe and/or the US, and have documented efficacy in quickly relieving breakthrough pain episodes. All of the available pivotal efficacy trials of these agents are randomized, double-blind comparisons with placebo. There are no head-to-head trials comparing any of the newer transmucosal formulations with each other. Only one non-pivotal study of intranasal fentanyl spray used a transmucosal preparation as an active comparator. However, that comparator was OTFC, not one of the newer transmucosal products. Close examination of the existing trials assessing these newer transmucosal preparations reveals significant variation in many study parameters, such as patient selection criteria, severity of breakthrough pain episodes, proportions of patients with a neuropathic pain component, titration protocols, choice of the primary endpoints, protocols for repeat dosing and rescue medication, the separation of treated episodes and the extent of the placebo response, all of which may have affected efficacy results. It is therefore difficult to evaluate the relative efficacies of these treatments on the basis of the available trials. Furthermore, given the differences in design between studies, the value of any potential meta-analyses including these trials would likely be limited. Blinded head-to-head comparisons of new transmucosal fentanyl preparations would be the only way to conclusively determine comparative effectiveness, but given the impracticalities of conducting such studies, these are unlikely.	[Tagarro, Ignacio] Meda Pharmaceut, Madrid 28830, Spain; [Elsner, Frank] Rhein Westfal TH Aachen, Univ Klinikum Aachen, Klin Palliat Med, Aachen, Germany; [Zeppetella, Giovambattista] St Clare Hosp, Hastingwood, Essex, England; [Porta-Sales, Josep] Inst Catala Oncol, Serv Cuidados Paliat, Barcelona, Spain	Tagarro, I (reprint author), Meda Pharmaceut, Av Castilla 2, Madrid 28830, Spain.	ignacio.tagarro@meda.es			Meda Pharmaceuticals, San Fernando de Henares, Madrid, Spain	Editorial assistance was provided by inScience Communications, a Wolters Kluwer business. This assistance was funded by Meda Pharmaceuticals, San Fernando de Henares, Madrid, Spain. Giovambattista Zeppetella has received honoraria for participation on advisory boards and/or at symposia from Archimedes, Cephalon, Dompe, Flynn, Janssen-Cilag, Meda, Napp, Nycomed, ProStrakan, Pfizer and Wyeth. Josep Porta-Sales has participated on an advisory board for Meda. Frank Elsner has received honoraria for participation on advisory boards and/or at symposia from Archimedes, Cephalon, Nycomed, ProStrakan, Janssen-Cilag, Meda, Wyeth, Shire, Grunenthal and Mundipharma. Ignacio Tagarro is an employee of Meda.	Barden J, 2004, PAIN, V109, P351, DOI 10.1016/j.pain.2004.01.032; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; *BIODELIVERY SCI I, 2007, [No title captured]; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; *CEPH INC, [No title captured]; *CEPH INC, [No title captured]; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Darwish M, 2006, CLIN THER, V28, P707, DOI 10.1016/j.clinthera.2006.05.015; DAVIES A, 2005, EUR J PALLIAT CARE S, P4; DAVIES A, 2006, [No title captured]; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; *EUR MED AG, EUR PUBL ASS REP EPA; *EUR MED AG, [No title captured]; *EUR MED AG, ACT 200 400 600 800; *EUR MED AG, [No title captured]; *EUR MED AG, [No title captured]; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Fine PG, 1998, J PAIN SYMPTOM MANAG, V16, P179, DOI 10.1016/S0885-3924(98)00045-1; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Gordon D, 2008, J PALLIAT MED, V11, P633, DOI 10.1089/jpm.2008.9922; Hagen NA, 2008, J PAIN SYMPTOM MANAG, V35, P136, DOI 10.1016/j.jpainsymman.2007.03.016; Hanks GW, 2004, PALLIATIVE MED, V18, P698, DOI 10.1191/0269216304pm966oa; Jacobsen Ramune, 2008, J Opioid Manag, V4, P383; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Laverty Diane, 2007, Br J Community Nurs, V12, P313; Laverty D, 2007, INT J PALLIAT NURS, V13, P326, DOI 10.12968/ijpn.2007.13.7.24344; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; *MED PHARM LTD, [No title captured]; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mystakidou K, 2007, INT J NANOMED, V2, P49, DOI 10.2147/nano.2007.2.1.49; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Ruiz-Garcia V, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a3104; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; Taylor Donald, 2010, J Support Oncol, V8, P184; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Vasisht N, 2009, CLIN DRUG INVEST, V29, P647, DOI 10.2165/11315300-000000000-00000; William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003; Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/14656566.4.4.493; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658	52	24	24	0	11	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.		2011	31	9					605	618		10.2165/11592910-000000000-00000			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	817TX	WOS:000294700600001	21819159				2020-06-30	J	Lyseng-Williamson, KA				Lyseng-Williamson, Katherine A.			Fentanyl Pectin Nasal Spray In Breakthrough Pain in Opioid-Tolerant Adults with Cancer	CNS DRUGS			English	Article							RELEASE MORPHINE-SULFATE; PATIENT ACCEPTABILITY; MULTIPLE-CROSSOVER; DOUBLE-BLIND; MANAGEMENT; EFFICACY; PHARMACOKINETICS; FORMULATIONS; MULTICENTER; RECEPTORS	Fentanyl pectin nasal spray (PecFent (R)) uses a novel pectin-based delivery system that turns from an aqueous solution into a gel when applied to mucosal surfaces. Fentanyl is absorbed in a controlled manner from the pectin gel formed in the nasal cavity, and has a rapid onset of pain relief and duration of action that matches the time course of a typical episode of breakthrough pain in cancer (BTPc). Relative to administration as oral transmucosal fentanyl, fentanyl administered as fentanyl pectin nasal spray is more rapidly absorbed, reaches higher maximum plasma concentrations and has greater bioavailability. In the treatment of BTPc in two randomized, double-blind, crossover trials in opioid-tolerant adults, fentanyl pectin nasal spray (100-800 mu g titrated doses) was significantly more effective than placebo in reducing pain intensity and provided a significantly faster onset of pain relief than oral immediate-release morphine. During long-term treatment of BTPc episodes, fentanyl pectin nasal spray consistently provided effective pain relief in an open-label, 16-week trial. Most patients were satisfied or very satisfied with the ease of use and convenience of the nasal spray. Fentanyl pectin nasal spray 100-800 mu g was generally well tolerated and was not associated with nasal tolerability problems.	Adis Int Ltd, Auckland 0754, New Zealand	Lyseng-Williamson, KA (reprint author), Adis Int Ltd, 41 Centorian Dr,Private Bag 65901, Auckland 0754, New Zealand.	demail@adis.co.nz		Lyseng-Williamson, Katherine/0000-0002-5104-1158			BENNETT D, 2005, [No title captured], V30, P296; BENNETT D, 2005, [No title captured], V30, P354; BILFINGER TV, 1998, INT J CARDIOL, V64, P61; Brooks D, 2010, ANN ONCOL, V21, P385; Dale O., 2010, EUR J PAIN S, V4, P187; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; DAVIS G, 2007, 10 C EUR ASS PALL CA, P175; Fallon M, 2009, EJC SUPPL, V7, P15, DOI 10.1016/S1359-6349(09)72064-6; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; PORTENOY RK, 2010, J OPIOID MANAG, V6, P407; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Prommer E, 2009, J PALLIAT MED, V12, P947, DOI 10.1089/jpm.2009.0051; Radbruch L, SUPPORT CARE CANC; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Taylor Donald, 2010, J Support Oncol, V8, P184; Torres LM, 2010, ANN ONCOL, V21, P377; Veldhorst-Janssen NML, 2009, CLIN THER, V31, P2954, DOI 10.1016/j.clinthera.2009.12.015; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658; 2011, PECFENT 100 400 MICR	29	11	13	0	7	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1172-7047			CNS DRUGS	CNS Drugs		2011	25	6					511	522		10.2165/11207470-000000000-00000			12	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	789QN	WOS:000292531500006	21649451				2020-06-30	J	Qadeer, MA; Lopez, AR; Dumot, JA; Vargo, JJ				Qadeer, Mohammed A.; Lopez, A. Rocio; Dumot, John A.; Vargo, John J.			Hypoxemia during Moderate Sedation for Gastrointestinal Endoscopy: Causes and Associations	DIGESTION			English	Article						Hypoxemia; Moderate sedation; Endoscopy; Causes and associations	SUPPLEMENTAL OXYGEN; RETROGRADE CHOLANGIOPANCREATOGRAPHY; CARDIOPULMONARY COMPLICATIONS; MYOCARDIAL-ISCHEMIA; GI ENDOSCOPY; ROUTINE USE; ERCP; DESATURATION; COLONOSCOPY; EVENTS	Background/Aims: Although prolonged hypoxemia (henceforth referred to as hypoxemia) is not uncommon during moderate sedation for endoscopy, there are only sparse data regarding its relationship with medications, endoscopic intubations and ventilation patterns. We aimed to study these relationships. Methods: 123 patients enrolled in the control arm of a randomized trial of ventilation monitoring during endoscopy were analyzed. Hypoxemia was defined as oxygen saturation of <90% for >= 15 s, and apnea as lack of respiratory activity for >= 15 s. Results: There were 132 hypoxemic events; 46 (35%) and 112 (85%) events occurred within 1 and 5 min of medication administration/endoscopic intubations, and conversely, 46/638 (7%) and 112/638 (18%) of all medication administration/endoscopic intubations led to hypoxemia in 1 and 5 min, respectively. Apnea, abnormal ventilation and normal ventilation were associated with 36, 30 and 34% of all hypoxemia events, respectively. However, only 101/268 (38%) apnea/abnormal ventilation events led to hypoxemia. Significant predictors of apnea were total dose of meperidine/fentanyl 1.3 (1.02- 1.6) and total dose of midazolam 0.84 (0.71-0.99). Conclusions: Hypoxemia occurs typically within 5 min of medication administration or endoscope intubation and only one third of all apnea/abnormal ventilation events eventually lead to hypoxemia. Copyright (C) 2011 S. Karger AG, Basel	[Qadeer, Mohammed A.; Lopez, A. Rocio; Dumot, John A.; Vargo, John J.] Cleveland Clin, Inst Digest Dis, Dept Gastroenterol & Hepatol, Cleveland, OH 44106 USA	Vargo, JJ (reprint author), Cleveland Clin Fdn, Dept Gastroenterol & Hepatol, Inst Digest Dis, 9500 Euclid Ave,A 30, Cleveland, OH 44195 USA.	vargoj@ccf.org		Vargo, John/0000-0001-7638-5283			BARKIN JS, 1989, GASTROINTEST ENDOSC, V35, P526, DOI 10.1016/S0016-5107(89)72904-7; Cohen LB, 2007, GASTROINTEST ENDOSC, V65, pAB103, DOI 10.1016/j.gie.2007.03.076; Cote CJ, 2000, PEDIATRICS, V105, P805, DOI 10.1542/peds.105.4.805; de Sousa AGP, 2008, OBES REV, V9, P340, DOI 10.1111/j.1467-789X.2008.00478.x; Ferreira LEVVC, 2008, GASTROINTEST ENDOSC, V67, P1037, DOI 10.1016/j.gie.2007.10.029; Fisher L, 2006, GASTROINTEST ENDOSC, V63, P948, DOI 10.1016/j.gie.2005.09.020; FREEMAN ML, 1993, GASTROENTEROLOGY, V105, P331, DOI 10.1016/0016-5085(93)90705-H; GRIFFIN MS, 1990, BRIT MED J, V300, P83; Holm C, 1998, SCAND J GASTROENTERO, V33, P769; Johnston SD, 2003, ENDOSCOPY, V35, P1039, DOI 10.1055/s-2003-44597; JURELL KR, 1994, GASTROINTEST ENDOSC, V40, P665, DOI 10.1016/S0016-5107(94)70106-7; KOHN LT, 1999, ERR IS HUMAN BUILDIN; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P205, DOI 10.1016/j.gie.2008.06.002; LIPPER B, 1991, CRIT CARE MED, V19, P330, DOI 10.1097/00003246-199103000-00008; Papachristou GI, 2007, AM J GASTROENTEROL, V102, P738, DOI 10.1111/j.1572-0241.2007.01093.x; Qadeer MA, 2008, CLIN GASTROENTEROL H, V6, P102, DOI 10.1016/j.cgh.2007.10.005; Qadeer MA, 2009, GASTROENTEROLOGY, V136, P1568, DOI 10.1053/j.gastro.2009.02.004; RIMMER KP, 1989, J CLIN GASTROENTEROL, V11, P17, DOI 10.1097/00004836-198902000-00005; ROZEN P, 1981, SCAND J GASTROENTERO, V16, P299, DOI 10.3109/00365528109181972; Seeff LC, 2004, GASTROENTEROLOGY, V127, P1670, DOI 10.1053/j.gastro.2004.09.051; Sharma VK, 2007, GASTROINTEST ENDOSC, V66, P27, DOI 10.1016/j.gie.2006.12.040; WOODS SDS, 1989, GASTROINTEST ENDOSC, V35, P523, DOI 10.1016/S0016-5107(89)72903-5; Zuccaro G, 2000, GASTROINTEST ENDOSC, V51, pAB141, DOI 10.1016/S0016-5107(00)14310-X	23	32	32	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0012-2823			DIGESTION	Digestion		2011	84	1					37	45		10.1159/000321621			9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	797NK	WOS:000293134400008	21304242				2020-06-30	